PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Massimi, P; Pim, D; Bertoli, C; Bouvard, V; Banks, L				Massimi, P; Pim, D; Bertoli, C; Bouvard, V; Banks, L			Interaction between the HPV-16 E2 transcriptional activator and p53	ONCOGENE			English	Article						HPV; E2; p53	HUMAN-PAPILLOMAVIRUS TYPE-16; ONCOGENIC HUMAN PAPILLOMAVIRUSES; ADENOVIRUS-INFECTED CELLS; DNA-REPLICATION; ESTROGEN-RECEPTOR; VIRAL REPLICATION; PROTEIN; BINDING; TRANSACTIVATION; EXPRESSION	The HPV-16 E2 protein is a major regulator of viral DNA replication and gene expression. Through interactions with the viral origin binding protein, El, it localizes El to the origin of replication and stimulates the initiation of viral DNA replication. However, several recent reports have described a number of diverse activities of E2 relating to the induction of apoptosis through both p53 dependent and independent mechanisms, and to induction of growth arrest in both the G1 and G2M phases of the cell cycle. Recent studies have also shown that p53 can specifically inhibit HPV DNA replication, albeit through an unknown mechanism. Since p53 has been described in the replication centres of Herpes Viruses, Adenovirus and SV40 we decided to investigate whether any of the above activities of E2 may be related to an association with p53. We show, in a series of in vitro assays, specific interaction between p53 and HPV-16 E2 via residues in the carboxy terminal half of the E2 protein. Mutational analysis of p53 indicates that sequences in both the DIVA binding and oligomerization domains are essential for the interaction, and a mutant of p53 which is unable to bind E2 is also unable to inhibit HPV DNA replication. Finally, using an inducible system of p53 expression we also show that E2 will complex with p53 in vivo. These results raise the intriguing possibility that p53 may also be involved in HPV DNA replication centres, and also provides explanations for some of the diverse activities reported for the HPV E2 proteins.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; CEA, Ctr Etude Nucl, DSV, DRR,UMR 217 CNRS,Lab Cancerogenese Mol, F-92265 Fontenay Aux Roses, France	International Center for Genetic Engineering & Biotechnology (ICGEB); CEA	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.							ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BOUVARD V, 1994, EMBO J, V13, P5451, DOI 10.1002/j.1460-2075.1994.tb06880.x; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CRIPE TP, 1987, EMBO J, V6, P3745, DOI 10.1002/j.1460-2075.1987.tb02709.x; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; Desaintes C, 1997, EMBO J, V16, P504, DOI 10.1093/emboj/16.3.504; Fortunato EA, 1998, J VIROL, V72, P2033, DOI 10.1128/JVI.72.3.2033-2039.1998; Frattini MG, 1997, EMBO J, V16, P318, DOI 10.1093/emboj/16.2.318; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GIRI I, 1988, EMBO J, V7, P2823, DOI 10.1002/j.1460-2075.1988.tb03138.x; Goodwin EC, 1998, J VIROL, V72, P3925, DOI 10.1128/JVI.72.5.3925-3934.1998; HEDGE RS, 1992, NATURE, V359, P505; Hwang ES, 1996, ONCOGENE, V12, P795; Konig C, 1999, J VIROL, V73, P2253; Kovelman R, 1996, J VIROL, V70, P7549, DOI 10.1128/JVI.70.11.7549-7560.1996; Lepik D, 1998, J VIROL, V72, P6822, DOI 10.1128/JVI.72.8.6822-6831.1998; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LU JZJ, 1993, J VIROL, V67, P7131, DOI 10.1128/JVI.67.12.7131-7139.1993; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Piccini A, 1997, J GEN VIROL, V78, P1963, DOI 10.1099/0022-1317-78-8-1963; PICCINI A, 1995, J GEN VIROL, V61, P1630; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; PRAKASH SS, 1992, GENE DEV, V6, P105, DOI 10.1101/gad.6.1.105; PRATT WB, 1990, MOL CELL ENDOCRINOL, V74, P69; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; REMM M, 1992, NUCLEIC ACIDS RES, V20, P6015, DOI 10.1093/nar/20.22.6015; Sakai H, 1996, J VIROL, V70, P1602, DOI 10.1128/JVI.70.3.1602-1611.1996; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Sedman J, 1996, EMBO J, V15, P5085, DOI 10.1002/j.1460-2075.1996.tb00889.x; Sedman J, 1995, EMBO J, V14, P6218, DOI 10.1002/j.1460-2075.1995.tb00312.x; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Steger G, 1997, J VIROL, V71, P50, DOI 10.1128/JVI.71.1.50-58.1997; Swindle CS, 1999, J VIROL, V73, P1001, DOI 10.1128/JVI.73.2.1001-1009.1999; TARUNINA M, 1993, ONCOGENE, V8, P3165; Thomas M, 1996, ONCOGENE, V13, P471; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Zhong L, 1997, J VIROL, V71, P3146, DOI 10.1128/JVI.71.4.3146-3160.1997	43	66	68	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 16	1999	18	54					7748	7754		10.1038/sj.onc.1203208	http://dx.doi.org/10.1038/sj.onc.1203208			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618715				2022-12-17	WOS:000084256900004
J	Sabourin, LA; Rudnicki, MA				Sabourin, LA; Rudnicki, MA			Induction of apoptosis by SLK, a Ste20-related kinase	ONCOGENE			English	Article						Ste20 kinase; apoptosis; JNK1	STE20-LIKE PROTEIN-KINASE; SIGNAL-TRANSDUCTION; BINDING PROTEIN; CELL-DEATH; CLONING; DOMAIN; SAPK/JNK; CDC42P; SYSTEM; YEAST	We have cloned and characterized a novel murine Ste20-related kinase designated SLK, SLK displays high homology to the Ste20-related kinase LOK, and is more distantly related to MST1 and 2, both Ste20-like kinases, In addition, SLK displays high homology to microtubule and nuclear associated protein (M-NAP) and AT1-46, both of unknown function. SLK is ubiquitously expressed as multiple mRNAs in tissues and cell lines and is downregulated by mitogen depletion in differentiating myoblasts, Biochemical characterization showed that SLK overexpression activates c-Jun amino-terminal kinase 1 (JNK1), However, in vitro kinase assays indicated that SLK was not activated in response to various growth factors or stress-inducing agents. Immunofluorescence studies revealed that SLK colocalized to distinct cytosolic domains, preferentially at the periphery of the cells. In addition, prolonged overexpression of SLK in cultured fibroblasts resulted in apoptosis as demonstrated by annexin-V and TUNEL staining. Our results suggest that SLK belongs to a new family of protein kinases, mediating activation of the stress response pathway through a novel signaling cascade.	McMaster Univ, MOBIX, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada	McMaster University	Rudnicki, MA (corresponding author), McMaster Univ, MOBIX, Inst Mol Biol & Biotechnol, Life Sci Bldg,Room 437,1280 Main St W, Hamilton, ON L8S 4K1, Canada.							Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HUGHES DA, 1995, SEMIN CELL BIOL, V6, P89, DOI 10.1016/1043-4682(95)90005-5; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Itoh S, 1997, ARCH BIOCHEM BIOPHYS, V340, P201, DOI 10.1006/abbi.1997.9893; KATOH M, 1995, ONCOGENE, V10, P1447; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; Sambrook J, 1989, MOL CLONING LAB MANU; Schaar DG, 1996, BRAIN RES, V721, P217, DOI 10.1016/0006-8993(96)00176-X; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246	27	66	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7566	7575		10.1038/sj.onc.1203119	http://dx.doi.org/10.1038/sj.onc.1203119			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602516				2022-12-17	WOS:000084119600018
J	Zhan, Y; van de Water, B; Wang, YP; Stevens, JL				Zhan, Y; van de Water, B; Wang, YP; Stevens, JL			The roles of caspase-3 and bcl-2 in chemically-induced apoptosis but not necrosis of renal epithelial cells	ONCOGENE			English	Article						kidney; bcl-2; apoptosis; caspase; glutathione	C-MYC; OXIDATIVE STRESS; CATHEPSIN-B; GRANZYME-B; DEATH; PROTEASE; ACTIVATION; EXPRESSION; MECHANISM; CA2+	The kidney is a target for toxicants including cisplatin and S-(1,2-dichlorovinyl)-L-cysteine (DCVC), a metabolite of the environmental contaminant, trichloroethylene. Necrosis is well characterized in kidney cells, but pathways leading to apoptosis are less clear. Cysteine conjugates are useful toxicants because they induce either necrosis or apoptosis depending on chemical structure or antioxidant status. Herein, we show that in the renal epithelial cell line LLC-PK1, activation of caspase3 (CPP32/Yama/apopain) is crucial for apoptosis, but not necrosis. Apoptosis was blocked by zVAD.fmk, and partially by a cathepsin inhibitor. Caspase-3 activity and cleavage of poly(ADP-ribose) polymerase (PARP) was detected only during apoptosis. S-(1,1,2,2-Tetrafluoroethyl)-1-cysteine (TFEC), a metabolite of tetrafluoroethylene, kills cells only by necrosis, and did not activate caspases under any conditions. Apoptosis and activation of caspase3 by cisplatin, but not DCVC, was prevented by bcl-2. Thus, caspase-3 activation by bcl-2-dependent and -independent mechanisms is a terminal event in chemical-apoptosis of renal epithelial cells.	Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA; Adirondack Biomed Res Inst, New York, NY 12946 USA	University of Vermont	Stevens, JL (corresponding author), Univ Vermont, Coll Med, Dept Pathol, A249 Med Alumni Bldg, Burlington, VT 05405 USA.				NIDDK NIH HHS [DK46267] Funding Source: Medline; NIEHS NIH HHS [ES07847] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007847] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antoku K, 1997, LEUKEMIA, V11, P1665, DOI 10.1038/sj.leu.2400805; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Brunk UT, 1997, FREE RADICAL BIO MED, V23, P616, DOI 10.1016/S0891-5849(97)00007-5; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CHEN Q, 1990, J BIOL CHEM, V265, P21603; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CRONIN RE, 1995, KIDNEY, P1680; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Distelhorst CW, 1996, ONCOGENE, V12, P2051; Edelstein CL, 1997, KIDNEY INT, V51, P1341, DOI 10.1038/ki.1997.183; Eguchi Y, 1997, CANCER RES, V57, P1835; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GOLDSTEIN RS, 1996, TOXICOLOGY, P417; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gregoli PA, 1999, J CELL PHYSIOL, V178, P133, DOI 10.1002/(SICI)1097-4652(199902)178:2<133::AID-JCP2>3.3.CO;2-X; GUENETTE RS, 1994, EUR J BIOCHEM, V226, P311, DOI 10.1111/j.1432-1033.1994.tb20055.x; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Kagaya S, 1997, MOL CELL BIOL, V17, P6736, DOI 10.1128/MCB.17.11.6736; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lieberthal W, 1996, AM J PHYSIOL-RENAL, V271, pF477, DOI 10.1152/ajprenal.1996.271.3.F477; LOCK EA, 1989, TOXICOL LETT, V46, P93, DOI 10.1016/0378-4274(89)90120-3; Lotem J, 1996, P NATL ACAD SCI USA, V93, P12507, DOI 10.1073/pnas.93.22.12507; MAJNO G, 1995, AM J PATHOL, V146, P3; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; McGowan AJ, 1996, FEBS LETT, V392, P299, DOI 10.1016/0014-5793(96)00838-1; MOALLEM SA, 1995, TERATOLOGY, V52, P3, DOI 10.1002/tera.1420520103; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Roberts LR, 1997, GASTROENTEROLOGY, V113, P1714, DOI 10.1053/gast.1997.v113.pm9352877; Shimizu S, 1996, ONCOGENE, V12, P2251; SimboliCampbell M, 1997, BREAST CANCER RES TR, V42, P31, DOI 10.1023/A:1005772432465; STEVENS JL, 1986, J BIOL CHEM, V261, P5529; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Trudel M, 1997, J EXP MED, V186, P1873, DOI 10.1084/jem.186.11.1873; VAMVAKAS S, 1989, MUTAT RES, V222, P329, DOI 10.1016/0165-1218(89)90108-0; van de Water B, 1999, J BIOL CHEM, V274, P13328, DOI 10.1074/jbc.274.19.13328; VANDEWATER B, 1994, J BIOL CHEM, V269, P14546; VanDeWater B, 1996, AM J PHYSIOL-RENAL, V270, pF593, DOI 10.1152/ajprenal.1996.270.4.F593; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhan Y, 1997, MOL CELL BIOL, V17, P6755, DOI 10.1128/MCB.17.11.6755; ZORNIG M, 1995, ONCOGENE, V11, P2165	56	66	74	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	1999	18	47					6505	6512		10.1038/sj.onc.1203060	http://dx.doi.org/10.1038/sj.onc.1203060			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597253				2022-12-17	WOS:000083709200013
J	Bin, OY; Li, WQ; Pan, HQ; Meadows, J; Hoffmann, I; Dai, W				Bin, OY; Li, WQ; Pan, HQ; Meadows, J; Hoffmann, I; Dai, W			The physical association and phosphorylation of Cdc25C protein phosphatase by Prk	ONCOGENE			English	Article						Cdc25C; Prk; protein kinase; protein phosphatase; cell cycle	XENOPUS EGG EXTRACTS; SERINE/THREONINE KINASE; DNA-DAMAGE; DROSOPHILA; SERINE-216; CHECKPOINT; HOMOLOG; GENE; CDC5; IDENTIFICATION	prk encodes a protein serine/threonine kinase involved in regulating M phase functions during the cell cycle. We have expressed His6-Prk and His6-Cdc25C proteins using the baculoviral vector expression system. Purified recombinant His6-Prk, but not a kinase-defective mutant His6-Prk(K52R), is capable of strongly phosphorylating His6-Cdc25C in vitro. Co-immunoprecipitation and affinity column chromatography experiments demonstrate that GST-Prk and native Cdc25C interact. When co-infected with His6-Prk and His6-Cdc25C recombinant baculoviruses, sf-9 cells produce His6-Cdc25C antigen with an additional slower mobility band on denaturing polyacrylamide gels compared with cells infected with His6-Cdc25C baculovirus alone. In addition, His6-Cdc25C immunoprecipitated from sf-9 cells co-infected with His6-Prk and His6-Cdc25C baculoviruses, but not with His6-Prk(K52R) and His6-Cdc25C baculoviruses, contains a greatly enhanced kinase activity that phosphorylates His6-Cdc25C in vitro. Moreover, phosphopeptide mapping shows that His6-Prk phosphorylates His6-Cdc25C at two sites in vitro and that the major phosphorylation site co-migrates with the one that is phosphorylated in vivo in asynchonized cells. Further studies reveal that His6-Prk phosphorylates Cdc25C on serine(216), a residue also phosphorylated by Chk1 and Chk2. Together, these observations strongly suggest that Prk's role in mitosis is at least partly mediated through direct regulation of Cdc25C.	Univ Cincinnati, Coll Med, Dept Internal Med, Div Hematol Oncol, Cincinnati, OH 45267 USA; German Canc Res Ctr, D-6900 Heidelberg, Germany	University System of Ohio; University of Cincinnati; Helmholtz Association; German Cancer Research Center (DKFZ)	Dai, W (corresponding author), Univ Cincinnati, Coll Med, Dept Internal Med, Div Hematol Oncol, ML-508,K-pavilion,231 Bethesda Ave, Cincinnati, OH 45267 USA.				PHS HHS [R01-74229] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; FEILOTTER H, 1992, BIOCHEM CELL BIOL, V70, P954, DOI 10.1139/o92-140; FENTON B, 1993, NATURE, V363, P637, DOI 10.1038/363637a0; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lammer C, 1998, J CELL SCI, V111, P2445; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OGG S, 1994, J BIOL CHEM, V269, P30461; OUYANG B, 1997, J BIOL CHEM, V274, P28646; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X	29	66	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	1999	18	44					6029	6036		10.1038/sj.onc.1202983	http://dx.doi.org/10.1038/sj.onc.1202983			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557092				2022-12-17	WOS:000083359100009
J	Waikel, RL; Wang, XJ; Roop, DR				Waikel, RL; Wang, XJ; Roop, DR			Targeted expression of c-Myc in the epidermis alters normal proliferation, differentiation and UV-B induced apoptosis	ONCOGENE			English	Article						c-Myc; epidermis; differentiation; keratinocyte; apoptosis and transgenic	TRANSCRIPTION FACTOR NETWORK; TRANSGENIC MICE; GENE-TRANSCRIPTION; INDUCTION; GROWTH; CELLS; MAD; TUMORIGENESIS; ONCOGENE; PROTEIN	c-Myc overexpression has been associated with several types of human cancers. To study the role of c-myc in epidermal differentiation and carcinogenesis, a transgenic mouse model was created to overexpress c-myc in the epidermis, Human c-myc 2 cDNA was subcloned into a 6.5 kb mouse loricrin expression vector, ML.myc2. This loricrin promoter primarily directs expression in the epidermis in both proliferating and differentiated keratinocytes. On day 4, ML.myc2 transgenic pups develop a hyperkeratotic phenotype, which progressively worsens until day 7. Upon histological analysis, both hyperplasia and hyperkeratosis were evident. Bromodeoxyuridine (BrdU) incorporation revealed that transgenic mice had a threefold increase in the number of proliferating cells as compared with a normal littermate, Proliferative cells in the ML.myc2 epidermis were also found to be suprabasal, suggesting an inhibition of terminal differentiation in keratinocytes, Inhibition of terminal differentiation by c-Myc overexpression was further suggested by aberrant expression of differentiation markers, keratin 1, keratin 6, loricrin, and filaggrin in ML.myc2 transgenic mice, Interestingly, ML.myc2 keratinocytes exhibit a reduced sensitivity to UV-B induced apoptosis, in vivo. In vitro studies reveal the reduced sensitivity of ML.myc2 keratinocytcs to UV-B irradiation is growth factor dependent. These findings provide evidence that overexpression of c-Myc in the epidermis induces proliferation, inhibits terminal differentiation and decreases the sensitivity of keratinocytes to UV-B induced apoptosis.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Roop, DR (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA052607] Funding Source: NIH RePORTER; NCI NIH HHS [CA09197, CA52607] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; Ariizumi K, 1996, J DERMATOL SCI, V12, P147, DOI 10.1016/0923-1811(95)00474-2; ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; Berns K, 1997, ONCOGENE, V15, P1347, DOI 10.1038/sj.onc.1201280; BERTSCH S, 1982, CELL TISSUE KINET, V15, P81, DOI 10.1111/j.1365-2184.1982.tb01026.x; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; COTTER FE, 1993, CANCER SURV, V16, P157; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; GARMYN M, 1992, J INVEST DERMATOL, V99, P743, DOI 10.1111/1523-1747.ep12614470; GAZDAR AF, 1994, ANTICANCER RES, V14, P261; GREENHALG DA, 1995, SKIN CANC MECHANISMS, P317; GREENHALGH DA, 1993, ONCOGENE, V8, P2145; Hogan B., 1986, MANIPULATING MOUSE E; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1995, ONCOGENE, V11, P2487; HURLIN PJ, 1994, COLD SPRING HARB SYM, V59, P109, DOI 10.1101/SQB.1994.059.01.014; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; JIN Y, 1992, RADIAT RES, V132, P193, DOI 10.2307/3578526; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KOPAN R, 1989, GENE DEV, V5, P1; KOPNIN B, 1993, TUMORI, V79, P235, DOI 10.1177/030089169307900401; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; Nass SJ, 1997, BREAST CANCER RES TR, V44, P1, DOI 10.1023/A:1005858611585; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; Pusch O, 1997, ONCOGENE, V15, P649, DOI 10.1038/sj.onc.1201236; Rodriguez-Puebla ML, 1998, CELL GROWTH DIFFER, V9, P31; ROOP DR, 1987, DIFFERENTIATION, V35, P143, DOI 10.1111/j.1432-0436.1987.tb00162.x; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Rothnagel J A, 1995, J Invest Dermatol, V104, p42S; ROTHNAGEL JA, 1987, J BIOL CHEM, V262, P15643; Sato H, 1997, PHOTOCHEM PHOTOBIOL, V65, P908, DOI 10.1111/j.1751-1097.1997.tb01942.x; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Trudel M, 1998, AM J PATHOL, V152, P219; WANG XJ, 1994, MOL CARCINOGEN, V10, P15, DOI 10.1002/mc.2940100104; Wang XJ, 1997, P NATL ACAD SCI USA, V94, P2386, DOI 10.1073/pnas.94.6.2386; Wu M, 1996, MOL CELL BIOL, V16, P5015; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	52	66	67	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4870	4878		10.1038/sj.onc.1203040	http://dx.doi.org/10.1038/sj.onc.1203040			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490820				2022-12-17	WOS:000082184800011
J	Souza, RF; Wang, SN; Thakar, M; Smolinski, KN; Yin, J; Zou, TT; Kong, DH; Abraham, JM; Toretsky, JA; Meltzer, SJ				Souza, RF; Wang, SN; Thakar, M; Smolinski, KN; Yin, J; Zou, TT; Kong, DH; Abraham, JM; Toretsky, JA; Meltzer, SJ			Expression of the wild-type insulin-like growth factor II receptor gene suppresses growth and causes death in colorectal carcinoma cells	ONCOGENE			English	Article						insulin-like growth factor II receptor; colon cancer; microsatellite instability; growth; apoptosis	MANNOSE 6-PHOSPHATE RECEPTOR; BREAST-CANCER CELLS; MICROSATELLITE INSTABILITY; IGF-II; BINDING-PROTEIN; FREQUENT LOSS; FACTOR-BETA; LONG ARM; HETEROZYGOSITY; CHROMOSOME-6	The insulin-like growth factor II receptor (IGFIIR) has been implicated as a tumor suppressor gene in human malignancy. Frequent mutation, loss of heterozygosity, and microsatellite instability (MSI) directly affecting the IGFIIR gene have been reported in several primary human tumor types. However, to our knowledge, dynamic functional evidence of a growth-suppressive role for IGFIIR has not yet been provided. We identified one MSI-positive colorectal carcinoma cell line, SW48, with monoallelic mutation in IGFIIR identical to that seen in primary colorectal carcinomas. A zinc-inducible construct containing the wild-type IGFIIR cDNA was stably transfected into SW48 cells. Growth rate and apoptosis mere compared between zinc-treated, untreated, and untransfected cells. A twofold increase in IGFIIR protein expression was detected after zinc treatment in discrete clonal isolates of transfected SW48 cells. Moreover, zinc induction of exogenous wild-type IGFIIR expression reproducibly decreased growth rate and increased apoptosis. These data prove that wild-type IGFIIR functions as a growth suppressor gene in colorectal cancer cells and provide dynamic in vitro functional support for the hypothesis that IGFIIR is a human growth suppressor gene.	Univ Texas, SW Med Sch, Dallas, TX 75216 USA; Dallas VA Med Ctr, Dept Med, GI Div, Dallas, TX 75216 USA; VA Maryland Healthcare Syst, Baltimore, MD USA; Univ Maryland, Sch Med, Dept Med, GI Div, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Mol & Cell Biol, Grad Program, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pediat Hematol Oncol, Baltimore, MD 21201 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Souza, RF (corresponding author), Univ Texas, SW Dallas VA Med Ctr, Dept Gastroenterol, 111B1,4500 S Lancaster Rd, Dallas, TX 75216 USA.				NCI NIH HHS [CA67497, CA77057, CA78843] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078843, R01CA077057, R01CA067497] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOYNTON RF, 1991, CANCER RES, V51, P5766; BRANCH P, 1995, CANCER RES, V55, P2304; CULOUSCOU JM, 1990, J CELL PHYSIOL, V143, P405, DOI 10.1002/jcp.1041430302; DAHMS NM, 1995, ARCH BIOCHEM BIOPHYS, V317, P497, DOI 10.1006/abbi.1995.1193; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DESOUZA AT, 1995, ONCOGENE, V10, P1725; DEVILEE P, 1991, ONCOGENE, V6, P1705; Ellis MJC, 1996, MOL ENDOCRINOL, V10, P286, DOI 10.1210/me.10.3.286; GUO YS, 1995, J AM COLL SURGEONS, V181, P145; Hankins GR, 1996, ONCOGENE, V12, P2003; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOJIMA S, 1993, J CELL BIOL, V121, P439, DOI 10.1083/jcb.121.2.439; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KYLE JW, 1988, J BIOL CHEM, V263, P16230; LAMONERIE T, 1995, INT J CANCER, V61, P587, DOI 10.1002/ijc.2910610425; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LAUREYS G, 1988, GENOMICS, V3, P224, DOI 10.1016/0888-7543(88)90083-3; MANNI A, 1994, CANCER RES, V54, P2934; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILLIKIN D, 1991, CANCER RES, V51, P5449; MINNITI CP, 1994, AM J CLIN PATHOL, V101, P198, DOI 10.1093/ajcp/101.2.198; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; OKA Y, 1985, J BIOL CHEM, V260, P9435; Ouyang H, 1997, CANCER RES, V57, P1851; Parrizas M, 1997, J BIOL CHEM, V272, P154; PARSONS R, 1995, CANCER RES, V55, P5548; RAINIER S, 1995, CANCER RES, V55, P1836; RESNICOFF M, 1995, CANCER RES, V55, P3739; Robertson GP, 1996, CANCER RES, V56, P1635; SAITO S, 1992, CANCER RES, V52, P5815; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Souza RF, 1997, GASTROENTEROLOGY, V112, P40, DOI 10.1016/S0016-5085(97)70217-8; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; Wang SN, 1997, CANCER RES, V57, P2543; YUN K, 1993, LAB INVEST, V69, P603	39	66	69	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4063	4068		10.1038/sj.onc.1202768	http://dx.doi.org/10.1038/sj.onc.1202768			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435587				2022-12-17	WOS:000081431000003
J	Butz, K; Whitaker, N; Denk, C; Ullmann, A; Geisen, C; Hoppe-Seyler, F				Butz, K; Whitaker, N; Denk, C; Ullmann, A; Geisen, C; Hoppe-Seyler, F			Induction of the p53-target gene GADD45 in HPV-positive cancer cells	ONCOGENE			English	Article						cervical cancer; HPV; p53; gadd45; tumor virus	HUMAN ORAL KERATINOCYTES; P53 PROTEIN; TRANSCRIPTIONAL ACTIVITY; P53-INDEPENDENT PATHWAY; ANTICANCER AGENTS; GENOTOXIC STRESS; MESSENGER-RNA; DNA-BINDING; E6; EXPRESSION	The E6 oncoprotein of human papillomaviruses (HPVs) has the potential to functionally antagonize p53. In several experimental model systems, ectopic expression of E6 can block the genotoxic induction of the growth inhibitory p53 target gene gadd45, suggesting that the inactivation of this pathway may play a major role for HPV-associated cell transformation. Here, we investigated whether this reflects the regulation of gadd45 expression in carcinoma-derived HPV-positive cells, We found that the gadd45 gene is efficiently induced by mitomycin C, cisplatin, and UV irradiation in a series of HPV-positive cervical cancer cell lines. Moreover, clear induction of gadd45 gene expression was also observed following treatment with gamma-irradiation, a pathway that is strictly dependent on functional p53, This contrasted with findings in human foreskin keratinocytes experimentally immortalized by expressing the HPV16 E6, E7, or E6/E7 oncogenes from the heterologous CMV promoter, where expression of the E6 gene was linked to a lack of gadd45 induction following gamma-irradiation. These results indicate (I) that the tumorigenic phenotype of HPV-positive cancer cells is not Linked to an inability to induce the gadd45 gene following DNA damage, (2) that experimental model systems in which the E6 gene is expressed ectopically and/or in a different cellular context do not necessarily reflect the regulation of p53-associated pathways in HPV-positive cancer cells and (3) that a pathway strictly depending on functional p53 is inducible in HPV-positive cancer cells, providing direct evidence that the endogenous p53 protein in these cells is competent to activate a cellular target gene, despite coexpression of the viral E6 oncogene.	Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Hoppe-Seyler, F (corresponding author), Deutsch Krebsforschungszentrum, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.			Hoppe-Seyler, Felix/0000-0002-1864-300X				Butz K, 1998, ONCOGENE, V17, P781, DOI 10.1038/sj.onc.1201995; BUTZ K, 1995, ONCOGENE, V10, P927; Butz K, 1996, INT J CANCER, V68, P506, DOI 10.1002/(SICI)1097-0215(19961115)68:4<506::AID-IJC17>3.0.CO;2-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HOPPESEYLER F, 1997, PAPILLOMAVIRUSES HUM, P71; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKMAN J, 1994, CANCER RES, V54, P5656; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KEARSEY JM, 1995, SCIENCE, V270, P1003; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Liu X, 1997, ONCOGENE, V14, P2347, DOI 10.1038/sj.onc.1201078; Loignon M, 1997, CANCER RES, V57, P3390; Lu X, 1996, ONCOGENE, V13, P413; MITSUDOMI T, 1992, NATURE, V358, P80; OConnor PM, 1997, CANCER RES, V57, P4285; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shin KH, 1996, ONCOGENE, V12, P1089; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WHITAKER SJ, 1992, EUR J CANCER, V28A, P273, DOI 10.1016/0959-8049(92)90432-2; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	35	66	67	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 8	1999	18	14					2381	2386		10.1038/sj.onc.1202557	http://dx.doi.org/10.1038/sj.onc.1202557			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184DT	10327059				2022-12-17	WOS:000079595500011
J	Murakami, H; Iwashita, T; Asai, N; Iwata, Y; Narumiya, S; Takahashi, M				Murakami, H; Iwashita, T; Asai, N; Iwata, Y; Narumiya, S; Takahashi, M			Rho-dependent and -independent tyrosine phosphorylation of focal adhesion kinase, paxillin and p130(Cas) mediated by Ret kinase	ONCOGENE			English	Article						Ret; GDNF; focal adhesion kinase; paxillin; p130(Cas)	MEN 2B MUTATIONS; NEUROTROPHIC FACTOR; GROWTH-FACTOR; TRANSFORMING ACTIVITY; BIOLOGICAL PROPERTIES; DOPAMINERGIC-NEURONS; CELL-ADHESION; MOTOR-NEURONS; IN-VIVO; GDNF	Glial cell line-derived neurotrophic factor (GDNF) signals through a unique receptor system that includes Ret receptor tyrosine kinase and a glycosyl-phosphatidylinositol-linked cell surface protein. In the present study, we have identified several proteins in neuroblastoma cells that are phosphorylated on tyrosine in response to GDNF, The phosphorylated proteins include focal adhesion kinase (FAK), paxillin and Crk-associated substrate, p130(Cas), all of which are known to be associated with focal adhesions. Of these, paxillin and p130(Cas) interacted with Crk proteins in GDNF-treated neuroblastoma cells. GDNF also induced reorganization of the actin cytoskelton, Tyrosine phosphorylation of FAK, paxillin and p130(Cas) was inhibited by cytochalasin D or two specific inhibitors of phosphatidylinositol-3' kinase (PI-3' kinase), wortmannin and LY294002, indicating that their tyrosine phosphorylation depends on the formation of actin stress fiber and activation of PI-3' kinase. In addition, phosphorylation of FAK but not of paxillin and p130(Cas) was markedly impaired by the Clostridium botulinum C3 exoenzyme that specifically ADP-ribosylates and inactivates Rho, These results suggested the presence of Rho-dependent and -independent signaling pathways downstream of PI-3' kinase that mediate tyrosine phosphorylation of FAK, paxillin and p130(Cas) through Pet kinase.	Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 466, Japan; Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 606, Japan	Nagoya University; Kyoto University	Takahashi, M (corresponding author), Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 466, Japan.		TAKAHASHI, Masahide/I-7244-2014; ASAI, Naoya/I-7377-2014; Takahashi, Masahide/AAN-4770-2020	Takahashi, Masahide/0000-0002-2803-2683				Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; ASAI N, 1995, MOL CELL BIOL, V15, P1613; Baloh RH, 1997, NEURON, V18, P793, DOI 10.1016/S0896-6273(00)80318-9; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; Bocciardi R, 1997, ONCOGENE, V15, P2257, DOI 10.1038/sj.onc.1201413; BORELLO MG, 1995, ONCOGENE, V11, P2419; BORRELLO MA, 1993, ONCOGENE, V9, P1661; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; BujBello A, 1997, NATURE, V387, P721, DOI 10.1038/42729; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945-053X(97)90008-1; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; Ito S, 1997, CANCER RES, V57, P2870; Iwashita T, 1996, ONCOGENE, V12, P481; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JIAN X, 1991, NATURE, V352, P73; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Nozaki C, 1998, ONCOGENE, V16, P293, DOI 10.1038/sj.onc.1201548; Ohiwa M, 1997, BIOCHEM BIOPH RES CO, V237, P747, DOI 10.1006/bbrc.1997.7225; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Rossel M, 1997, ONCOGENE, V14, P265, DOI 10.1038/sj.onc.1200831; Sanicola M, 1997, P NATL ACAD SCI USA, V94, P6238, DOI 10.1073/pnas.94.12.6238; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Sasaki T, 1996, BIOCHEM J, V315, P1035, DOI 10.1042/bj3151035; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	45	66	67	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	1999	18	11					1975	1982		10.1038/sj.onc.1202514	http://dx.doi.org/10.1038/sj.onc.1202514			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208419				2022-12-17	WOS:000079191300007
J	Walter, AO; Peng, ZY; Cartwright, CA				Walter, AO; Peng, ZY; Cartwright, CA			The Shp-2 tyrosine phosphatase activates the Src tyrosine kinase by a non-enzymatic mechanism	ONCOGENE			English	Article						Src; Shp-2; tyrosine kinase; tyrosine phosphatase	SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; FACTOR RECEPTOR-BETA; PROTEIN-KINASE; SH3 DOMAIN; C-SRC; CELL-TRANSFORMATION; BINDING-SITE; 3T3 CELLS; FAMILY; PHOSPHORYLATION	Previously, we demonstrated that the Src tyrosine kinase interacts with the Shp-2 tyrosine phosphatase. To determine whether Shp-2 regulates Src kinase activity, we measured Src activity in cells overexpressing wild-type or catalytically-inactive C463S Shp-2, We observed a 2-3-fold increase in the specific activity of Src in both cell types and the increase did not appear to be due to dephosphorylation of Tyr 527 or phosphorylation of Tyr 416 on Src. Conversely, we observed a 2-3-fold decrease in the specific activity of Src when Shp-2 expression was inhibited. Using glutathione S-transferase-fusion proteins, we demonstrated that Shp-2 binds to the SH3 domain of Src, Our findings reveal that the Shp-2 tyrosine phosphatase can regulate the Src tyrosine kinase by a non-enzymatic mechanism. We also found that the phosphatase activity of Shp-2 immunoprecipitates is downregulated in cells transformed by Src or other proteins, and that Shp-2, preferentially associates with the membrane fraction of transformed cells. We suggest that membrane-association of Shp-2 is important for regulating Shp-2 activity.	Stanford Univ, Dept Med, Sch Med, Med Sch Lab, Stanford, CA 94305 USA	Stanford University	Cartwright, CA (corresponding author), Stanford Univ, Dept Med, Sch Med, Med Sch Lab, Surge Bldg,P304, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007056, R01DK043743] Funding Source: NIH RePORTER; NIDDK NIH HHS [2R01 DK43743-07, T32 DK07056] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; Cossette LJ, 1996, EXP CELL RES, V223, P459, DOI 10.1006/excr.1996.0102; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FANG KS, 1994, J BIOL CHEM, V269, P20194; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOONG AC, 1994, CANCER RES, V54, P5273; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; PARK J, 1995, MOL CELL BIOL, V15, P2374; PENG ZY, 1995, ONCOGENE, V11, P1955; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wong L, 1996, J BIOL CHEM, V271, P20981, DOI 10.1074/jbc.271.35.20981; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	48	66	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	1999	18	11					1911	1920		10.1038/sj.onc.1202513	http://dx.doi.org/10.1038/sj.onc.1202513			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208413				2022-12-17	WOS:000079191300001
J	Biswas, T; Ramana, CV; Srinivasan, G; Boldogh, I; Hazra, TK; Chen, ZP; Tano, K; Thompson, EB; Mitra, S				Biswas, T; Ramana, CV; Srinivasan, G; Boldogh, I; Hazra, TK; Chen, ZP; Tano, K; Thompson, EB; Mitra, S			Activation of human O-6-methylguanine-DNA methyltransferase gene by glucocorticoid hormone	ONCOGENE			English	Article						CNU; DNA damage; DNA repair; glucocorticoid; gene regulation	O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE ACTIVITY; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; PROGESTERONE-RECEPTOR; NEGATIVE REGULATION; NUCLEAR RECEPTORS; MAMMALIAN-CELLS; CROSS-LINKING; TUMOR CELLS; CPG ISLAND; DNA	O-6-methylguanine-DNA methyltransferase (MGMT), a ubiquitous DNA repair protein, removes the mutagenic DNA adduct O-6-alkylguanine, which is synthesized both endogenously and after exposure to alkylnitrosamines and alkylating antitumor drugs such as 2-chloroethyl-N-nitrosourea (CNU), The MGMT gene is highly regulated in mammalian cells and its overexpression, observed in many types of tumor cells, is often associated with cellular resistance to CNU, Dexamethasone, a synthetic glucocorticoid hormone, was found to increase MGMT expression in HeLa S3 cells, concomitant with their increased resistance to CNU, Two putative glucocorticoid responsive elements (GREs) were identified in the human MGMT (hMGMT) promoter. Transient expression of the luciferase reporter gene driven by an hMGMT promoter fragment containing these GREs was activated by dexamethasone. DNase I footprinting assays demonstrated the binding of glucocorticoid receptor to these sequences. In vitro transcription experiment showed that these DNA sequences are functional in glucocorticoid receptor signal-mediated activation of transcription. These results suggest glucocorticoid-mediated induction of the MGMT gene contributes to high level expression of MGMT.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Immunol & Microbiol, Galveston, TX 77555 USA; Kyoto Univ, Reactor Inst, Osaka 59004, Japan	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Kyoto University	Mitra, S (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA.			chilakamarti, ramana/0000-0002-5153-8252	NATIONAL CANCER INSTITUTE [R01CA031721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007572] Funding Source: NIH RePORTER; NCI NIH HHS [CA 31721] Funding Source: Medline; NIEHS NIH HHS [ES 07572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAGCHI MK, 1990, J BIOL CHEM, V265, P5129; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOWMAN LH, 1981, NUCLEIC ACIDS RES, V9, P4951, DOI 10.1093/nar/9.19.4951; BRENT TP, 1985, P NATL ACAD SCI USA, V82, P2985, DOI 10.1073/pnas.82.9.2985; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAMBROSIO SM, 1987, CANCER RES, V47, P51; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EADIE JS, 1984, NATURE, V308, P201, DOI 10.1038/308201a0; ERICKSON LC, 1980, NATURE, V288, P727, DOI 10.1038/288727a0; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; FRITZ G, 1991, MOL CELL BIOL, V11, P4660, DOI 10.1128/MCB.11.9.4660; Grombacher T, 1996, CARCINOGENESIS, V17, P2329, DOI 10.1093/carcin/17.11.2329; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163; Heiss JD, 1996, J CLIN INVEST, V98, P1400, DOI 10.1172/JCI118927; Izumi T, 1996, BIOCHEMISTRY-US, V35, P14679, DOI 10.1021/bi961995u; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; Kokkinakis DM, 1997, CANCER RES, V57, P5360; LEBLANC B, 1994, DNA PROTEIN INTERACT, P1; Levin Victor A., 1997, P2022; Liu LL, 1996, CANCER RES, V56, P1880; LUDLUM DB, 1990, MUTAT RES, V233, P117, DOI 10.1016/0027-5107(90)90156-X; McEwan IJ, 1995, MUTAT RES-FUND MOL M, V333, P15, DOI 10.1016/0027-5107(95)00126-3; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; MYRNES B, 1984, CARCINOGENESIS, V5, P1061, DOI 10.1093/carcin/5.8.1061; NAKATSU Y, 1993, MUTAT RES, V293, P119, DOI 10.1016/0921-8777(93)90063-M; Patel SA, 1997, MOL CELL BIOL, V17, P5813, DOI 10.1128/MCB.17.10.5813; PEGG AE, 1995, BIOCHEM PHARMACOL, V50, P1141, DOI 10.1016/0006-2952(95)00249-Y; PEGG AE, 1990, CANCER RES, V50, P6119; PIEPER RO, 1990, CANCER COMMUN, V2, P13, DOI 10.3727/095535490820874812; ROBINS P, 1983, NUCLEIC ACIDS RES, V11, P7743, DOI 10.1093/nar/11.22.7743; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SAGHER D, 1989, CANCER RES, V49, P5339; SALMON SE, 1989, CANC PRINCIPLES PRAC, P2344; SCHOLD SC, 1989, J NEUROSURG, V70, P573, DOI 10.3171/jns.1989.70.4.0573; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Singer B., 1983, MOL BIOL MUTAGENS CA; SNOW ET, 1984, J BIOL CHEM, V259, P8095; TANO K, 1990, P NATL ACAD SCI USA, V87, P686, DOI 10.1073/pnas.87.2.686; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TSAI SY, 1990, J BIOL CHEM, V265, P17055; WASHINGTON WJ, 1989, MECH AGEING DEV, V48, P43, DOI 10.1016/0047-6374(89)90024-9; Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612; YAROSH DB, 1984, MUTAT RES, V131, P27, DOI 10.1016/0167-8817(84)90044-0; YUNG W K A, 1990, Current Opinion in Oncology, V2, P673	46	66	69	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					525	532		10.1038/sj.onc.1202320	http://dx.doi.org/10.1038/sj.onc.1202320			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927209				2022-12-17	WOS:000078166500025
J	Salvucci, M; Lemoine, A; Saffroy, R; Azoulay, D; Lepere, B; Gaillard, S; Bismuth, H; Reynes, R; Debuire, B				Salvucci, M; Lemoine, A; Saffroy, R; Azoulay, D; Lepere, B; Gaillard, S; Bismuth, H; Reynes, R; Debuire, B			Microsatellite instability in European hepatocellular carcinoma	ONCOGENE			English	Article						transforming growth factor (TGF beta) type II; receptor (RII) gene; cirrhosis; clinicopathological characteristics; recurrent disease; prognostic factor	II RECEPTOR GENE; GENOMIC INSTABILITY; COLORECTAL-CANCER; LIVER-TRANSPLANTATION; ULCERATIVE-COLITIS; MUTATION COMMON; BREAST-CANCER; HEPATITIS; REPEATS; ADENOCARCINOMA	Genetic instability has been detected in many types of cancers but poorly investigated in hepatocellular carcinoma (HCC). We have studied the incidence of microsatellite instability (MI) at eight highly polymorphic microsatellite markers and the poly A tract BAT26 and tested for mutations at two sites of repetitive sequence (poly-A nucleotides 709-718 and GT repeat-nucleotides 1931-1936) in the Transforming Growth Factor beta (TGF beta) type II receptor (RII) gene, in a group of 46 European HCCs and the surrounding nontumour tissue. This analysis showed that 63% of HCCs exhibit MI in at least one chromosome locus and 41% in two or more loci. No mutations of the TGF beta RII gene were found in the MI positive tumours. No correlation was found with clinicopathological characteristics of the tumours such as cirrhosis, etiology, number of nodules, Edmondson's grade and vascular invasion. However, in patients who had a rearranged D16S402 microsatellite in their tumour, the recurrent disease and the number of nodules were significantly higher than in the others (P<0.005 and P<0.02, respectively). We propose to consider D16S402 rearrangement in HCC as a prognostic factor to identify patients presenting a higher risk of recurrence.	Hop Paul Brousse, Dept Biochem, F-94804 Villejuif, France; Hop Paul Brousse, Hepatobiliary Surg & Liver Transplant Res Unit, F-94804 Villejuif, France; Hop Paul Brousse, Dept Pathol, F-94804 Villejuif, France; Fac Med Paris Sud, CEA, CNRS, UMR 217, Fontenay Aux Roses, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Debuire, B (corresponding author), Hop Paul Brousse, Dept Biochem, 14 Ave Paul Vaillant Couturier, F-94804 Villejuif, France.		Azoulay, Daniel/Q-7887-2018	SAFFROY, RAPHAEL/0000-0002-9878-3669				Abe T, 1996, EUR J SURG ONCOL, V22, P474, DOI 10.1016/S0748-7983(96)92824-3; AKASHI Y, 1991, HEPATOLOGY, V14, P262, DOI 10.1016/0270-9139(91)91413-U; ARZIMANOGLOU IA, 1996, CARCINOGENESIS, V47, P1799; BISMUTH H, 1993, ANN SURG, V218, P145, DOI 10.1097/00000658-199308000-00005; Boige V, 1997, CANCER RES, V57, P1986; BOURDON JC, 1995, GASTROENTEROLOGY, V108, P1176, DOI 10.1016/0016-5085(95)90217-1; BRENTNALL TA, 1995, CANCER RES, V55, P4264; Brentnall TA, 1996, CANCER RES, V56, P1237; Chung YJ, 1996, CANCER RES, V56, P4662; DeMarchis L, 1997, CLIN CANCER RES, V3, P241; DUGGAN BD, 1994, J NATL CANCER I, V86, P1216, DOI 10.1093/jnci/86.16.1216; FERAY C, 1994, HEPATOLOGY, V20, P1137, DOI 10.1016/0270-9139(94)90748-X; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; HANN HJ, 1993, CANCER RES, V53, P5087; HOANG JM, 1996, CANCER RES, V53, P300; HONCHEL R, 1994, CANCER RES, V54, P1159; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kaneko H, 1996, LEUKEMIA, V10, P1696; Kaplanski C, 1997, INT J CANCER, V72, P248, DOI 10.1002/(SICI)1097-0215(19970717)72:2<248::AID-IJC8>3.0.CO;2-R; Lemoine A, 1997, ANN SURG, V226, P43, DOI 10.1097/00000658-199707000-00006; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOTHE RA, 1993, CANCER RES, V53, P5849; LU SL, 1995, BIOCHEM BIOPH RES CO, V216, P452, DOI 10.1006/bbrc.1995.2644; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MELTZER SJ, 1994, CANCER RES, V54, P3379; MERLO A, 1994, CANCER RES, V54, P2098; MYEROFF LL, 1995, CANCER RES, V55, P5545; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; PARSONS R, 1995, CANCER RES, V55, P5548; Paulson TG, 1996, CANCER RES, V56, P4021; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; RHYU MG, 1994, ONCOGENE, V9, P29; Salvucci M, 1996, ONCOGENE, V13, P2681; SAMUEL D, 1995, HEPATOLOGY, V21, P333, DOI 10.1016/0270-9139(95)90089-6; SHRIDHAR V, 1994, CANCER RES, V54, P2084; Souza RF, 1997, GASTROENTEROLOGY, V112, P40, DOI 10.1016/S0016-5085(97)70217-8; Takenoshita S, 1997, CARCINOGENESIS, V18, P1427, DOI 10.1093/carcin/18.7.1427; TAMURA G, 1995, CANCER RES, V55, P1933; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Togo G, 1996, CANCER RES, V56, P5620; UCHIDA T, 1994, CANCER RES, V54, P3682; Vincent F, 1996, BIOCHEM BIOPH RES CO, V223, P561, DOI 10.1006/bbrc.1996.0934; WADA C, 1994, BLOOD, V83, P3449, DOI 10.1182/blood.V83.12.3449.bloodjournal83123449; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; Yeh SH, 1996, GASTROENTEROLOGY, V110, P184, DOI 10.1053/gast.1996.v110.pm8536855; Zhu JG, 1996, ONCOGENE, V12, P1417	46	66	72	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					181	187		10.1038/sj.onc.1202279	http://dx.doi.org/10.1038/sj.onc.1202279			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926933				2022-12-17	WOS:000078166000020
J	Timmermann, S; Hinds, PW; Munger, K				Timmermann, S; Hinds, PW; Munger, K			Re-expression of endogenous p16(ink4a) in oral squamous cell carcinoma lines by 5-aza-2 '-deoxycytidine treatment induces a senescence-like state	ONCOGENE			English	Article						cdk inhibitor; retinoblastoma protein; promoter methylation	CYCLIN-DEPENDENT KINASE-6; TUMOR-SUPPRESSOR GENE; RETINOBLASTOMA PROTEIN; CDKN2 GENE; DNA METHYLTRANSFERASE; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; HEAD; NECK; AMPLIFICATION	We have previously reported that a set of oral squamous cell carcinoma lines express specifically elevated cdk6 activity. One of the cell lines, SCC4, contains a cdk6 amplification and expresses functional p16(ink4a), the other cell lines express undetectable levels of p16(ink4a), despite a lack of coding-region mutations. Two of the cell lines, SCC15 and SCC40 have a hypermethylated p16(ink4A) promoter and a third cell line, SCC9, has a mutation in the p16(ink4a) promoter. Using the demethylation agent 5-aza-2'-deoxycytidine, we showed that the p16(ink4a) protein was re-expressed after a 5-day treatment with this chemical, One cell line, SCC15 espressed high levels of p16(ink4a). In this line, cdk6 activity was decreased after 5-aza-2'deoxycytidine treatment, and the hypophosphorylated, growth suppressive form of the retinoblastoma tumor suppressor protein PRE was detected. Expression of p16(ink4a) persisted, even after the drug was removed and the cells espressed senescence-associated beta-galactosidase activity. Ectopic expression of p16(ink4a) with a recombinant retrovirus in this cell line also induced a similar senescence-like phenotype, Hence, it was possible to restore a functional pRB pathway in an oral squamous cell carcinoma line by inducing re-expression of endogenous p16(ink4a) in response to treatment with a demethylating agent.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Canc Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.			Munger, Karl/0000-0003-3288-9935	NIDCR NIH HHS [1 PO1 DE12467-01] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012467] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABELE R, 1987, EUR J CANCER CLIN ON, V23, P1921, DOI 10.1016/0277-5379(87)90060-5; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bender CM, 1998, CANCER RES, V58, P95; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; Costello JF, 1997, CANCER RES, V57, P1250; CREUSOT F, 1982, J BIOL CHEM, V257, P2041; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Fernandez-Martinez J A, 1995, Bull Group Int Rech Sci Stomatol Odontol, V38, P11; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Gonzalez MV, 1997, J CLIN PATHOL, V50, P509, DOI 10.1136/jcp.50.6.509; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HE J, 1995, CANCER RES, V55, P4833; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KATO J, 1993, GENE DEV, V7, P331; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197; Loughran D, 1996, J MANAGE ENG, V12, P13; LYDIATT WM, 1995, GENE CHROMOSOME CANC, V13, P94, DOI 10.1002/gcc.2870130204; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MICHALOWSKY LA, 1987, MOL CELL BIOL, V7, P3076, DOI 10.1128/MCB.7.9.3076; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIN BM, 1994, ORAL ONCOL, V30B, P338, DOI 10.1016/0964-1955(94)90036-1; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; OTTERSON GA, 1995, ONCOGENE, V11, P1211; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; Reed AL, 1996, CANCER RES, V56, P3630; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Schwoebel A, 1997, J PERINAT NEONAT NUR, V11, P78, DOI 10.1097/00005237-199712000-00009; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SONODA Y, 1995, ONCOGENE, V11, P2145; STEIN GH, 1995, BIOESSAYS, V17, P537, DOI 10.1002/bies.950170610; Timmermann S, 1997, CELL GROWTH DIFFER, V8, P361; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Willemze R, 1997, LEUKEMIA S1, V11, P24; ZHANG SY, 1994, CANCER RES, V54, P5050	55	66	69	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 31	1998	17	26					3445	3453		10.1038/sj.onc.1202244	http://dx.doi.org/10.1038/sj.onc.1202244			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157XD	10030668				2022-12-17	WOS:000078086200005
J	Kim, JJ; Trivedi, NN; Wilson, DM; Mahalingam, S; Morrison, L; Tsai, A; Chattergoon, MA; Dang, KS; Patel, M; Ahn, L; Boyer, JD; Chalian, AA; Shoemaker, H; Kieber-Emmons, T; Agadjanyan, MA; Weiner, DB				Kim, JJ; Trivedi, NN; Wilson, DM; Mahalingam, S; Morrison, L; Tsai, A; Chattergoon, MA; Dang, KS; Patel, M; Ahn, L; Boyer, JD; Chalian, AA; Shoemaker, H; Kieber-Emmons, T; Agadjanyan, MA; Weiner, DB			Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine	ONCOGENE			English	Article						PSA; epitope mapping; DNA vaccination; immune responses; prostate cancer; immunotherapy	IMMUNODEFICIENCY-VIRUS TYPE-1; T-CELL PROLIFERATION; IMMUNE-RESPONSES; ANTITUMOR IMMUNITY; ACTIVATION ANTIGEN; CANCER STATISTICS; DNA IMMUNIZATION; MESSENGER-RNA; PROTEIN; PROTECTION	Nucleic acid immunization has been investigated as immunotherapy for infectious diseases as well as for treating specific types of cancers. In this approach, nucleic acid expression cassettes are directly inoculated into the host, whose transfected cells become the production source of novel and possibly immunologically foreign protein, We have developed a DNA vaccine construct which encodes for PSA by cloning a cDNA for PSA into a mammalian expression vector under control of a CMV promoter, We investigated and characterized the immunogenicity of PSA DNA expression cassettes in mice, PSA-specific immune responses induced in vivo by immunization were characterized by enzyme-linked immunosorbent assay (ELISA), T helper proliferation cytotoxic T lymphocyte (CTL), and flow cytometry assays, We observed a strong and persistent antibody response against PSA for at least 180 days following immunization. In addition, a significant T helper cell proliferation was observed against PSA protein, Using synthetic peptides spanning the PSA open frame, we identified four dominant T helper epitopes of PSA, Furthermore, immunization with PSA plasmid induced MHC Class I CD8+ T cell-restricted cytotoxic T lymphocyte response against tumor cell targets expressing PSA, The prostate represents a very specific functional organ critical for reproduction but not for the health and survival of the individual. Understanding the immunogenicity of PSA DNA immunization cassettes offers insight into the possible use of this tumor-associated antigen as a target for immunotherapy, These results demonstrate the ability of the genetic PSA to serve as a specific immune target capable of generating both humoral and cellular immune responses in vivo.	Univ Penn, Dept Chem Engn, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA; Centocor Inc, Malvern, PA 19355 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc	Weiner, DB (corresponding author), Univ Penn, Dept Chem Engn, Philadelphia, PA 19104 USA.		Weiner, David B/H-8579-2014	Mahalingam, Sundarasamy/0000-0003-4460-3949				AGADJANYAN MG, 1997, IN PRESS CURR TOP IM; ARMBRUSTER DA, 1993, CLIN CHEM, V39, P181; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; Boyer JD, 1997, NAT MED, V3, P526, DOI 10.1038/nm0597-526; BRIDON DP, 1995, UROLOGY, V45, P801, DOI 10.1016/S0090-4295(99)80087-9; Bright RK, 1996, CANCER RES, V56, P1126; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CONRY RM, 1994, CANCER RES, V54, P1164; COUGHLIN CM, 1995, CANCER RES, V55, P4980; DAVIS HL, 1993, HUM MOL GENET, V2, P1847, DOI 10.1093/hmg/2.11.1847; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; GARRICK MB, 1996, ANN INTERN MED, V125, P118; Geissler M, 1997, J IMMUNOL, V158, P1231; GILLILAND FD, 1995, CANCER, V75, P295, DOI 10.1002/1097-0142(19950101)75:1+<295::AID-CNCR2820751313>3.0.CO;2-U; HODGE JW, 1995, INT J CANCER, V63, P231, DOI 10.1002/ijc.2910630215; Kim JJ, 1997, J IMMUNOL, V158, P816; Kim JJ, 1997, NAT BIOTECHNOL, V15, P641; KIM JJ, 1998, SPRINGER SEMIN IMMUN, V19, P174; LABRIE F, 1993, CLIN INVEST MED, V16, P475; LABRIE F, 1992, J UROLOGY, V151, P1283; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LU S, 1995, VIROLOGY, V209, P147, DOI 10.1006/viro.1995.1238; MACGREGOR RR, 1998, IN PRESS J INF DIS; MAHALINGAM S, 1995, P NATL ACAD SCI USA, V92, P3794, DOI 10.1073/pnas.92.9.3794; Mogensen S C, 1987, Interferon, V8, P55; ODONNELL PD, 1989, J UROLOGY, V142, P1227, DOI 10.1016/S0022-5347(17)39038-9; PIENTA KJ, 1993, ANN INTERN MED, V118, P793, DOI 10.7326/0003-4819-118-10-199305150-00007; PLAUTZ GE, 1993, P NATL ACAD SCI USA, V90, P4645, DOI 10.1073/pnas.90.10.4645; RAY R, 1989, ONCOGENE, V4, P593; SANDA MG, 1994, J UROLOGY, V151, P622, DOI 10.1016/S0022-5347(17)35032-2; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SOBEL ES, 1993, J IMMUNOL, V150, P673; STACK RM, 1994, J IMMUNOL, V152, P5723; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; Tjoa B, 1996, PROSTATE, V28, P65; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; VIEWEG J, 1994, CANCER RES, V54, P1760; VIHINEN M, 1994, BIOCHEM BIOPH RES CO, V204, P1251, DOI 10.1006/bbrc.1994.2597; VILLOUTREIX BO, 1994, PROTEIN SCI, V3, P2033, DOI 10.1002/pro.5560031116; WANG B, 1993, P NATL ACAD SCI USA, V90, P4156, DOI 10.1073/pnas.90.9.4156; WANG B, 1995, HUM GENE THER, V6, P407, DOI 10.1089/hum.1995.6.4-407; WANG MC, 1982, METHOD CANCER RES, V19, P179; WATT KWK, 1986, P NATL ACAD SCI USA, V83, P3166, DOI 10.1073/pnas.83.10.3166; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; ZAGARS GK, 1995, UROLOGY, V45, P476, DOI 10.1016/S0090-4295(99)80019-3	51	66	73	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	1998	17	24					3125	3135		10.1038/sj.onc.1201736	http://dx.doi.org/10.1038/sj.onc.1201736			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872328	Bronze			2022-12-17	WOS:000077517400006
J	Webb, CP; Taylor, GA; Jeffers, M; Fiscella, M; Oskarsson, M; Resau, JH; Woude, GFV				Webb, CP; Taylor, GA; Jeffers, M; Fiscella, M; Oskarsson, M; Resau, JH; Woude, GFV			Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis	ONCOGENE			English	Article						Ras; Met; HGF/SF; tumorigenesis; metastasis	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; PROTOONCOGENE PRODUCT; ONCOGENE ACTIVATION; FACTOR RECEPTOR; NIH/3T3 CELLS; HUMAN CANCER; EXPRESSION; TRANSFORMATION; TUMORIGENICITY	Aberrations in Met-hepatocyte growth factor/scatter factor (HGF/SF) signaling have been implicated in the acquisition of tumorigenic and metastatic phenotypes, Here we show that murine NIH3T3 and C127 cells transformed by the Ras oncogene overexpress the Met receptor, resulting in enhanced HGF/SF-mediated responses in vitro including invasion through basement membrane. Accompanying the increase in Met in ras-transformed NIH3T3 cells, there is a decrease in endogenous HGF/SF expression as previously observed in cells exogenously overexpressing Met. However, subcutaneously grown tumors and experimental lung metastases derived from these cells express significantly higher levels of endogenous HGF/SF together with high levels of Met, These results suggest Met-HGF/SF signaling enhances tumor growth and metastasis of Ras-transformed NIH3T3 cells.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Woude, GFV (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, POB B, Frederick, MD 21702 USA.		Webb, Craig/I-8123-2012		NCI NIH HHS [N01-CO-46000] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO046000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLAIR DG, 1980, P NATL ACAD SCI-BIOL, V77, P3504, DOI 10.1073/pnas.77.6.3504; BONDY GP, 1985, CANCER RES, V45, P6005; BOS JL, 1989, CANCER RES, V49, P4682; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; GALANG CK, 1994, ONCOGENE, V9, P2913; Gambarotta G, 1996, ONCOGENE, V13, P1911; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GREIG RG, 1985, P NATL ACAD SCI USA, V82, P3698, DOI 10.1073/pnas.82.11.3698; GUNNING P, 1983, MOL CELL BIOL, V3, P1985, DOI 10.1128/MCB.3.11.1985; Ivan M, 1997, ONCOGENE, V14, P2417, DOI 10.1038/sj.onc.1201083; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jeffers M, 1996, ONCOGENE, V13, P853; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NAKAMURA T, 1991, Progress in Growth Factor Research, V3, P67, DOI 10.1016/0955-2235(91)90014-U; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1995, CANCER RES, V55, P1963; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; THORGEIRSSON UP, 1985, MOL CELL BIOL, V5, P259, DOI 10.1128/MCB.5.1.259; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	31	66	70	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 22	1998	17	16					2019	2025		10.1038/sj.onc.1202135	http://dx.doi.org/10.1038/sj.onc.1202135			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130VK	9798673				2022-12-17	WOS:000076540900001
J	Naumann, U; Durka, S; Weller, M				Naumann, U; Durka, S; Weller, M			Dexamethasone-mediated protection from drug cytotoxicity: association with p21(WAF1/CIP1) protein accumulation?	ONCOGENE			English	Article						steroid; chemotherapy; cell cycle; apoptosis; glioma	HUMAN-MALIGNANT GLIOMA; CELL-CYCLE ARREST; HUMAN NEUTROPHILS; INDUCED APOPTOSIS; BCL-2 EXPRESSION; CARCINOMA CELLS; IMMUNE-SYSTEM; GENE-TRANSFER; P53; P21	Dexamethasone (DEX)-mediated inhibition of drug-induced, but not CD95 ligand-induced, apoptosis in malignant glioma cells correlates with wild-type p53 status. Here, we examined mechanisms underlying DEX-mediated protection from apoptosis, DEX did not induce p53 expression in two p53 wild-type cell lines (U87MG, LN-229) and did not alter drug-induced p53 accumulation. Forced expression of temperature-sensitive p53val(135) in mutant conformation failed to prevent accumulation of endogenous wild-type p53 but acted in a transdominant negative manner to inhibit p53-mediated, camptothecin-induced p21(WAF1/CIF1) expression, p53val(135)-transfected cells retained responsiveness to DEX at restrictive temperature, suggesting that p53 activity is not required for cytoprotection, Forced expression of wild-type p53val(135) abrogated the protective effect of DEX, suggesting redundant cytoprotective effects of DEX and p53, Indeed, DEX induced moderate accumulation of p21(WAF1/CIP1) in U87MG, LN-229 and p53 mutant LN-18 cells, but not in p53 mutant LN-308 or T98G cells. LN-18 is also the p53 mutant cell line with the best cytoprotective response to DEX, p21(WAF1/CIP1) accumulation occurred in the absence of changes in p21(WAF1\CIP1) mRNA expression, Wild-type p53 was not required for this DEX effect since DEX induced p21(WAF1/CIP1) accumulation in p53val(135)-transfected LN-229 cells, too. DEX failed to induce p21(WAF1/CIP1) expression or cytoprotection in untransformed rat astrocytes, The same lack of modulation of p21(WAF1/CIP1) expression and drug toxicity was observed in p21(+/+), p21(+/-) and p21(-/-) human colon carcinoma cells. Paradoxically, while only p21(+/+) and p21(+/-) mouse embryonic fibroblasts showed enhance p21(WAF1/CIP1) levels after exposure to DEX, only p21(-/-) fibroblasts were protected from drug toxicity by DEX, The present study links DEX-mediated protection from cancer chemotherapy to a p53-independent pathway of regulating p21(WAF1/CIP1) expression in glioma cells but this effect appears to cell type-specific.	Univ Tubingen, Sch Med, Dept Neurol, Lab Mol Neurooncol, Tubingen, Germany	Eberhard Karls University of Tubingen	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Lab Mol Neurooncol, Tubingen, Germany.			Weller, Michael/0000-0002-1748-174X				BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chang TC, 1997, FEBS LETT, V415, P11, DOI 10.1016/S0014-5793(97)01083-1; Chen J, 1996, ONCOGENE, V13, P1395; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COX G, 1995, J IMMUNOL, V154, P4719; Cox G, 1997, J LEUKOCYTE BIOL, V61, P224, DOI 10.1002/jlb.61.2.224; EASTHAM JA, 1995, CANCER RES, V55, P5151; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; GOLSTEIN P, 1991, IMMUNOL REV, V121, P29, DOI 10.1111/j.1600-065X.1991.tb00822.x; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; Kondo S, 1996, ONCOGENE, V13, P1279; Li XS, 1996, CANCER RES, V56, P5055; NAUMANN U, 1998, IN PRESS INT J CANC; Roth W, 1997, CANCER IMMUNOL IMMUN, V44, P55, DOI 10.1007/s002620050355; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; TREPEL M, 1998, IN PRESS J NEUROONCO; VAN MEIR EG, 1994, CANCER RES, V54, P649; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Weller M, 1997, NEUROL RES, V19, P459; Weller M, 1997, INT J CANCER, V73, P707, DOI 10.1002/(SICI)1097-0215(19971127)73:5<707::AID-IJC16>3.3.CO;2-5; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Weller M, 1997, NEUROLOGY, V48, P1704, DOI 10.1212/WNL.48.6.1704; WELLER M, 1994, EUR J IMMUNOL, V24, P1293, DOI 10.1002/eji.1830240608; WELLER M, 1995, CANCER RES, V55, P2936; WELLER M, 1995, J CLIN INVEST, V95, P2633, DOI 10.1172/JCI117965; Wolff JEA, 1996, ANTICANCER RES, V16, P805; Wullner U, 1996, NEUROREPORT, V7, P921; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	34	66	66	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1567	1575		10.1038/sj.onc.1202071	http://dx.doi.org/10.1038/sj.onc.1202071			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794234				2022-12-17	WOS:000076089900009
J	White, A; Lamb, PW; Barrett, JC				White, A; Lamb, PW; Barrett, JC			Frequent downregulation of the KAI1(CD82) metastasis suppressor protein in human cancer cell lines	ONCOGENE			English	Article						KAI1 (CD82); metastasis suppressor gene; prostate cancer; transmembrane four superfamily	LEUKEMIA-VIRUS TYPE-1; ANTIPROLIFERATIVE ANTIBODY; MONOCLONAL-ANTIBODY; SYNCYTIUM FORMATION; PROSTATE-CANCER; C33 ANTIGEN; T-CELLS; EXPRESSION; SURFACE; MOTILITY	KAI1 is a metastasis suppressor gene on human chromosome 11p11.2 that encodes a glycoprotein of the transmembrane four superfamily, Reduced KAI1 expression associates with malignant progression of human prostatic, lung and pancreatic cancers, but the role of KAI1 protein in the malignant progression of other human cancers remains to be elucidated. We analysed KAI1 protein in normal and cancer cells of the prostate, ovary, bladder, endometrium, lung and melanocytes by Western blot to determine if KAI1 may be involved in multiple cancers. We also investigated the relationship of KAI1 expression and two other transmembrane four superfamily proteins, CD81 and CD9, in the cells. We found that KAI1 protein was downregulated in 31/42 of the cancer cell lines analysed. Alternatively, some ovarian, bladder and endometrial cells had distinct, heterogeneous KAI1 protein band patterns in Western blots that were due primarily to N-linked glycosylation. Most of the cancer cells expressed two other transmembrane four superfamily proteins, CD81 and CD9, Downregulation of KAI1 protein may be an indicator of metastatic potential in cancers of urogenital, gynecological, and pulmonary origin and in melanomas, KAI1 may also have post-translational modifications specific to tissue type or malignant progression.	NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Barrett, JC (corresponding author), NIEHS, Mol Carcinogenesis Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.							Adachi M, 1996, CANCER RES, V56, P1751; ANGELISOVA P, 1994, IMMUNOGENETICS, V39, P249; ATKINSON B, 1985, HYBRIDOMA, V4, P243, DOI 10.1089/hyb.1985.4.243; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; DEAR TN, 1990, MOL ASPECTS MED, V11, P243, DOI 10.1016/0098-2997(90)90005-M; Dennis J W, 1991, Semin Cancer Biol, V2, P411; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1996, CANCER RES, V56, P4387; ENGEL P, 1994, LEUKEMIA LYMPHOMA, V13, P61, DOI 10.3109/10428199409052677; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; FUSENIG NE, 1991, HUMAN CANC PRIMARY C, P55; GAUGITSCH HW, 1991, EUR J IMMUNOL, V21, P377, DOI 10.1002/eji.1830210219; Guo XZ, 1996, CANCER RES, V56, P4876; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; IMAI T, 1993, J IMMUNOL, V151, P6470; Kakizoe T, 1995, Int J Urol, V2 Suppl 2, P58, DOI 10.1111/j.1442-2042.1995.tb00480.x; KOHN EC, 1993, ANTICANCER RES, V13, P2553; Lagaudriere-Gesbert C, 1997, J IMMUNOL, V158, P2790; LEBELBINAY S, 1994, CELL IMMUNOL, V154, P468, DOI 10.1006/cimm.1994.1092; MIYAKE M, 1995, CANCER RES, V55, P4127; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; NOJIMA Y, 1993, CELL IMMUNOL, V152, P249, DOI 10.1006/cimm.1993.1285; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; SHARKEY FE, 1979, INT J CANCER, V24, P733, DOI 10.1002/ijc.2910240605; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; Ueda T, 1996, AM J PATHOL, V149, P1435	27	66	76	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3143	3149		10.1038/sj.onc.1201852	http://dx.doi.org/10.1038/sj.onc.1201852			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671393	Bronze			2022-12-17	WOS:000074261300007
J	Wurl, P; Meye, A; Schmidt, H; Lautenschlager, C; Kalthoff, H; Rath, FW; Taubert, H				Wurl, P; Meye, A; Schmidt, H; Lautenschlager, C; Kalthoff, H; Rath, FW; Taubert, H			High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities	ONCOGENE			English	Article						soft tissue sarcoma; Mdm2; p53; immunohistochemistry; multivariate prognostic analysis	P53 MUTATION; ONCOPROTEIN MDM2; AMPLIFICATION; DOMAIN	Soft tissue sarcomas are a heterogenous group of neoplasms with various histological subtypes, Up to now, no individual causal molecular markers; for prognosis and therapeutic success have been identified, A tumorigenic connection between the oncogene product Mdm2 and tumor suppressor p53 is generally accepted, but their possible clinical relevance has not yet been investigated sufficiently in soft tissue sarcoma, In 86 primary soft tissue sarcoma of the extremities (RO-resected, T1/2 N0 M0), Mdm2 and p53 overexpression were investigated by immunohistochemistry. The results were adjusted to clinico-pathological characteristics and evaluated for their prognostic relevance by multivariate analysis, In Cox's multivariate analysis with stratification of Mdm2 to p53 results, we determined four groups which had different prognostic values for relapse-free and overall survival (Mdm2-/p53-<Mdm2-/p53+<Mdm2+/p53-<Mdm2+/p53+). The most striking finding was a relative risk (rr) for overall survival of 18.77 (P=0.006) for patients with Mdm2/p53 co-overexpression (n=40). It is noticeably higher than the additive risk from both factors. Coincident Mdm2/p53 overexpression is an independent molecular marker with the highest prognostic relevance described for soft tissue sarcoma, Thus, a high risk sarcoma group has been defined which we believe requires alternative therapeutic approaches.	Univ Halle Wittenberg, Clin Gen Surg, D-4010 Halle, Germany; Univ Halle Wittenberg, Inst Pathol, D-4010 Halle, Germany; Univ Halle Wittenberg, Inst Med Biometry & Informat, D-4010 Halle, Germany; Univ Kiel, Clin Gen Surg, Kiel, Germany	Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; University of Kiel	Taubert, H (corresponding author), Univ Halle Wittenberg, Clin Gen Surg, D-4010 Halle, Germany.		Kalthoff, Holger/B-1618-2010	Taubert, Helge/0000-0002-9077-1727				Chen JD, 1996, MOL CELL BIOL, V16, P2445; CORDONCARDO C, 1994, CANCER RES, V54, P794; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEACH FS, 1993, CANCER RES, V53, P2231; LIN J, 1995, COLD SPRING HARB SYM, V49, P215; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OTTO A, 1993, ONCOGENE, V8, P2591; Reid AH, 1996, DIAGN MOL PATHOL, V5, P65, DOI 10.1097/00019606-199603000-00010; Taubert H, 1996, CANCER RES, V56, P4134; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Wurl P, 1997, J CANCER RES CLIN, V123, P502, DOI 10.1007/s004320050095; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0	18	66	78	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	1998	16	9					1183	1185		10.1038/sj.onc.1201646	http://dx.doi.org/10.1038/sj.onc.1201646			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528860				2022-12-17	WOS:000072336000009
J	Miyaki, M; Nishio, J; Konishi, M; KikuchiYanoshita, R; Tanaka, K; Muraoka, M; Nagato, M; Chong, JM; Koike, M; Terada, T; Kawahara, Y; Fukutome, A; Tomiyama, J; Chuganji, Y; Momoi, M; Utsunomiya, J				Miyaki, M; Nishio, J; Konishi, M; KikuchiYanoshita, R; Tanaka, K; Muraoka, M; Nagato, M; Chong, JM; Koike, M; Terada, T; Kawahara, Y; Fukutome, A; Tomiyama, J; Chuganji, Y; Momoi, M; Utsunomiya, J			Drastic genetic instability of tumors and normal tissues in Turcot syndrome	ONCOGENE			English	Article						Turcot syndrome; genetic instability; colon tumor; brain tumor; RER in normal tissue	NONPOLYPOSIS COLON-CANCER; FAMILIAL ADENOMATOUS POLYPOSIS; MISMATCH REPAIR DEFICIENCY; COLORECTAL-CANCER; GERM-LINE; MUTATIONS; HOMOLOG; HMLH1; MSH2	Turcot syndrome is characterized by an association of malignant brain tumors and colon cancer developing in the patient's teens, Since the mechanism of carcinogenesis in Turcot syndrome is still unclear, we analysed genetic changes in tumors from a Turcot patient with no family history of the condition, All tumors, including one astrocytoma, three colon carcinomas, and two colon adenomas, exhibited severe replication error (RER), and all colon tumors showed somatic mutations at repeated regions of TGF beta RII, E2F-4, hMSH3, and/or hMSH6 genes, Somatic APC mutations were detected in three of three colon carcinomas, and somatic p53 mutations were detected in the astrocytoma and two of three colon carcinomas, both of which showed two mutations without allele loss, We also found that normal colon mucosa, normal skin fibroblasts and normal brain tissue from this patient showed respective high frequencies of RER, in contrast to usual HNPCC patients in which RER was very rare in normal tissues, These results suggest that extreme DNA instability in normal tissues causes the early development of multiple cancer in Turcot syndrome, A missense mutation (GAG to AAG) at codon 705 of hPMS2 gene was detected in one allele of this patient, which was inherited from his mother without tumors, Additional unknown germline mutation may contribute to the genetic instability in normal tissues.	TOKYO METROPOLITAN KOMAGOME HOSP,DEPT PATHOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN BOKUTOU HOSP,DEPT PATHOL,SUMIDA KU,TOKYO 130,JAPAN; TOKYO METROPOLITAN BOKUTOU HOSP,DEPT SURG,SUMIDA KU,TOKYO 130,JAPAN; TOKYO METROPOLITAN BOKUTOU HOSP,DEPT INTERNAL MED,SUMIDA KU,TOKYO 130,JAPAN; HYOGO MED UNIV,DEPT SURG 2,NISHINOMIYA,HYOGO 663,JAPAN; TOKYO MED & DENT UNIV,DEPT INTERNAL MED 1,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Hyogo College of Medicine; University of Hyogo; Tokyo Medical & Dental University (TMDU)	Miyaki, M (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM,BUNKYO KU,3-18-22 HONKOMAGOME,TOKYO 113,JAPAN.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; ITOH H, 1985, DIS COLON RECTUM, V28, P399, DOI 10.1007/BF02560221; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARCOWITZ S, 1995, SCIENCE, V268, P1336; MIYAKI M, 1995, J MOL MED-JMM, V73, P515; MIYAKI M, 1994, CANCER RES, V54, P3011; MORI T, 1994, GENE CHROMOSOME CANC, V9, P168, DOI 10.1002/gcc.2870090304; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; NICOLAIDES NC, 1995, GENOMICS, V29, P329, DOI 10.1006/geno.1995.9997; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; ROCHLITZ CF, 1993, BRIT J CANCER, V68, P519, DOI 10.1038/bjc.1993.379; TURCOT J, 1959, Dis Colon Rectum, V2, P465, DOI 10.1007/BF02616938; Yoshitaka T, 1996, BIOCHEM BIOPH RES CO, V227, P553, DOI 10.1006/bbrc.1996.1544	26	66	73	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2877	2881		10.1038/sj.onc.1201668	http://dx.doi.org/10.1038/sj.onc.1201668			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419979				2022-12-17	WOS:A1997YJ80300014
J	Hamdane, M; DavidCordonnier, MH; DHalluin, JC				Hamdane, M; DavidCordonnier, MH; DHalluin, JC			Activation of p65 NF-kappa B protein by p210(BCR-ABL) in myeloid cell line (p210(BCR-ABL) activates p65 NF-kappa B)	ONCOGENE			English	Article						p210(BCR-ABL); tyrosine kinase; signal transduction; NF-kappa B activity; p65 NF-kappa B (RelA); myeloid cells	CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL ONCOGENE; TYROSINE KINASE-ACTIVITY; CHRONIC MYELOCYTIC-LEUKEMIA; C-ABL; TRANSCRIPTIONAL ACTIVATION; PHILADELPHIA-CHROMOSOME; V-ABL; ANTISENSE INHIBITION; IMMUNOGLOBULIN GENES	The chimeric tyrosine kinase p210(BCR-ABL) is involved in the pathogenesis of chronic myelogenous leukemia. It transforms immature hematopoietic cells in vitro and abrogates IL-3-dependent growth. The mechanisms by which p210(BCR-ABL) mediates its oncogenicity are not well elucidated. Identifying transcription factors targeted by the chimeric protein may help to clarify these mechanisms. We have analysed the effect of p210(BCR-ABL) expression on NF-kappa B activity in DA1 cells (an IL-3-dependent murine myeloid progenitor cell line). A specific stimulation of NF-kappa B activity by kinase-active wild-type p210(BCR-ABL) has been evidenced by transcriptional activation assays. Electrophoretic mobility supershift assays revealed the presence of p65 protein (RelA) DNA binding activity in p210(BCR-ABL) transformed DA1 cells but not in parental DA1 cells. Activation of RelA in transformed DA1 cells may occur by protein stabilization. Experiments using oligonucleotides antisense to RelA showed that p210(BCR-ABL) transfected cells failed to survive after IL-3 removal. Moreover, inhibition of cellular growth was shown following treatment of p210(BCR-ABL) transformed DA1 cells by p65 antisense oligonucleotides. This study suggests that p65 NF-kappa B may be an effector for p210(BCR-ABL) and probably contributes to its induced transformation process.	INSERM U124,INST RECH CANC LILLE,F-59045 LILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			David-Cordonnier, Marie-Helene/M-3725-2018; DAVID-CORDONNIER, Marie-Helene/P-9909-2019	David-Cordonnier, Marie-Helene/0000-0001-9831-5577; DAVID-CORDONNIER, Marie-Helene/0000-0001-9831-5577; Hamdane, Malika/0000-0001-7971-8696				AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; Bazzoni G, 1996, J CLIN INVEST, V98, P521, DOI 10.1172/JCI118820; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BROWN AM, 1994, MOL CELL BIOL, V14, P2926, DOI 10.1128/MCB.14.5.2926; CARLESSO N, 1994, ONCOGENE, V9, P149; COOK WD, 1982, P NATL ACAD SCI USA, V72, P2917; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Galieque-Zouitina S, 1996, LEUKEMIA, V10, P579; Gilmore TD, 1996, ONCOGENE, V13, P1367; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IHLE JN, 1985, CONTEMP TOP MOLEC IM, V10, P93; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KERR LD, 1994, BIOESSAYS, V16, P453, DOI 10.1002/bies.950160702; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KLUG CA, 1994, GENE DEV, V8, P678, DOI 10.1101/gad.8.6.678; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LI WJ, 1988, ONCOGENE, V2, P559; LIFSHITZ B, 1988, ONCOGENE, V2, P113; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MANDANAS RA, 1992, LEUKEMIA, V6, P796; MANDANAS RA, 1993, BLOOD, V82, P1838; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; NARAYANAN R, 1992, ONCOGENE, V7, P553; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NEUMANN M, 1992, ONCOGENE, V7, P2095; Neumann M, 1996, ANTICANCER RES, V16, P1075; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PEREZ JR, 1994, MOL CELL BIOL, V14, P5326, DOI 10.1128/MCB.14.8.5326; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SALGIA R, 1995, ONCOGENE, V11, P1149; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sattler M, 1996, ONCOGENE, V12, P839; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHMITZ ML, 1995, IMMUNOBIOLOGY, V193, P116, DOI 10.1016/S0171-2985(11)80534-6; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHU HB, 1993, MOL CELL BIOL, V13, P6283, DOI 10.1128/MCB.13.10.6283; Shuai K, 1996, ONCOGENE, V13, P247; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SOKOLOSKI JA, 1993, BLOOD, V82, P625; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107	75	66	69	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2267	2275		10.1038/sj.onc.1201411	http://dx.doi.org/10.1038/sj.onc.1201411			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393872				2022-12-17	WOS:A1997YE15700002
J	Choubey, D; Gutterman, JU				Choubey, D; Gutterman, JU			Inhibition of E2F-4/DP-1-stimulated transcription by p202	ONCOGENE			English	Article						E2F-4-mediated transcription; interferon inducible p202; cell growth inhibition; p107; p130	CELL-CYCLE REGULATION; RETINOBLASTOMA PROTEIN; FACTOR E2F; INTERFERON ACTION; FACTOR DRTF1/E2F; FAMILY MEMBERS; DP FAMILY; GENE; BINDING; P107	The interferon (IFN)-inducible proteins mediate activities of the interferons including the cell growth-regulatory activity. We have shown that p202, an IFN-inducible 52kDa primarily nuclear phosphoprotein whose expression in transfected cells inhibits cell proliferation, interacts with the retinoblastoma tumor suppressor protein (pRb) and the transcription factor E2F (E2F-1/DP-1) in vitro and in vivo. p202 was shown to inhibit E2F-1/DP-1-stimulated transcription of a reporter gene and of endogenous genes. Here we report that expression of p202 inhibited E2F-4/DP-1-stimulated transcription of a reporter gene in transfected cells. Furthermore, this inhibition was associated with the inhibition of the sequence-specific DNA-binding of E2F-4 both in complex with the pocket proteins p107 or p130 and in its 'free' form in vitro. p202 bound to p107 and p130 in vitro and in vivo and also associated with E2F-4, supporting the notion that complexes containing p107/E2F-4 or p130/E2F-4 and p202 exist in vivo. Moreover, cotransfection of E2F-4-encoding plasmid in AKR-2B cells overcame p202-mediated inhibition of cell growth, raising the possibility that p202 contributes to cell growth inhibition by the interferons, at least in part, by modulating E2F-4-mediated transcription.			Choubey, D (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MED ONCOL,BOX 41,HOUSTON,TX 77030, USA.		Choubey, Divaker/A-4771-2008		NCI NIH HHS [CA69031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA069031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Choubey D, 1996, BIOCHEM BIOPH RES CO, V221, P396, DOI 10.1006/bbrc.1996.0607; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DAGNINO L, 1995, CELL GROWTH DIFFER, V6, P191; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEMAEYER EM, 1988, INTERFERONS REGULATO; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOOSS K, 1995, ONCOGENE, V10, P1529; JORDAN KL, 1994, ONCOGENE, V9, P1177; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lembo D, 1995, J BIOL REG HOMEOS AG, V9, P42; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; Min W, 1996, MOL CELL BIOL, V16, P359; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; Sambrook J, 1989, MOL CLONING LAB MANU; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; SMITH EJ, 1995, MOL CELL BIOL, V15, P338, DOI 10.1128/MCB.15.1.338; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; ZHU L, 1993, GENE DEV, V7, P111; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1	59	66	69	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 17	1997	15	3					291	301		10.1038/sj.onc.1201184	http://dx.doi.org/10.1038/sj.onc.1201184			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XK999	9233764				2022-12-17	WOS:A1997XK99900006
J	Yayon, A; Ma, YS; Safran, M; Klagsbrun, M; Halaban, R				Yayon, A; Ma, YS; Safran, M; Klagsbrun, M; Halaban, R			Suppression of autocrine cell proliferation and tumorigenesis of human melanoma cells and fibroblast growth factor transformed fibroblasts by a kinase-deficient FGF receptor 1: Evidence for the involvement of Src-family kinases	ONCOGENE			English	Article						FGF2; dominant-negative receptor; receptor tyrosine kinase; melanocytes	ACTIVATED PROTEIN-KINASE; HUMAN-MALIGNANT MELANOMA; MULTIPLE HUMAN CANCERS; TYROSINE KINASES; HUMAN MELANOCYTES; SIGNAL-TRANSDUCTION; C-SRC; FACTORS STIMULATE; CYCLE REGULATOR; EXPRESSION	Basic Fibroblast Growth Factor (bFGF/FGF2) is thought to play a decisive role in malignant progression. Aberrant expression of bFGF causes constitutive autocrine activation of its cognate receptor and autonomous growth of human melanoma cells or bFGF transformed fibroblasts in culture, It remains to be determined, however, whether the endogenous bFGF confers growth advantage to tumors and what are the downstream targets of the activated FGF receptor critical for its transforming capacity, We therefore transfected metastatic melanoma cells and bFGF transformed mouse fibroblasts with a dominant-negative mutant of the murine FGF receptor 1 (fgfr1/flg), comprising the extracellular and transmembrane domains but lacking the intracellular kinase domain (dnflg), Reverse transcriptase-PCR, I-125-bFGF binding and affinity labeling analyses show that the truncated receptor is targeted to the membrane and is expressed at much higher levels than the endogenous receptor in all of the selected clones, Expression of the dnflg dramatically reduces the basal as well as bFGF induced growth of these cells in vitro and also suppresses their tumorigenic potential in nude mice, The expression of the dnflg does not significantly alter the general level of tyrosyl-phosphorylated proteins in the transduced melanoma cells. Rather, a major downstream affected target is a Src-family kinase, whose activity, determined by an in vitro immune kinase assay, is stimulated in normal melanocytes by exogenous bFGF, and is markedly reduced in the dnflg-expressing melanoma cells, The present study demonstrates that direct interference with the activity of FGF receptors has a deleterious effect on cell proliferation and survival in vitro and in vivo leading to the suppression of melanoma tumor progression possibly through the inactivation of a Src-family kinase.	YALE UNIV,SCH MED,DEPT DERMATOL,NEW HAVEN,CT 06510; HARVARD UNIV,SCH MED,BOSTON,MA 02115; CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115; CHILDRENS HOSP,DEPT PATHOL,BOSTON,MA 02115	Yale University; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	Yayon, A (corresponding author), WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL.		Fu, Da/GXF-2656-2022		NCI NIH HHS [CA44542] Funding Source: Medline; NIAMS NIH HHS [AR39848, AR41942] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044542, R29CA044542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041942, R01AR039848] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBINO AP, 1991, CANCER RES, V51, P4815; AMAYA E, 1993, DEVELOPMENT, V118, P477; BALENTIEN E, 1991, ONCOGENE, V6, P1115; BECKER D, 1992, ONCOGENE, V7, P2303; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P1110; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; CannonAlbright LA, 1996, SEMIN ONCOL, V23, P667; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; COWAN JM, 1988, J NATL CANCER I, V80, P1159, DOI 10.1093/jnci/80.14.1159; COWAN JM, 1991, MELANOMA RES GENETIC, V3; CREUZET C, 1995, J NEUROCHEM, V64, P1541; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; EASTY DJ, 1993, J INVEST DERMATOL, V101, P679, DOI 10.1111/1523-1747.ep12371675; EASTY DJ, 1995, CANCER RES, V55, P2528; Estival A, 1996, J BIOL CHEM, V271, P5663, DOI 10.1074/jbc.271.10.5663; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; Grano M, 1996, P NATL ACAD SCI USA, V93, P7644, DOI 10.1073/pnas.93.15.7644; HALABAN R, 1993, SEMIN CANCER BIOL, V4, P171; Halaban R, 1996, J INVEST DERMATOL, V106, P1266, DOI 10.1111/1523-1747.ep12348972; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HALABAN R, 1992, BIOLOGY OF THE EPIDERMIS : MOLECULAR AND FUNCTIONAL ASPECTS, P133; Halaban R, 1996, SEMIN ONCOL, V23, P673; HALABAN R, 1988, ONCOGENE RES, V3, P177; HALABAN R, 1991, ANN NY ACAD SCI, V638, P232, DOI 10.1111/j.1749-6632.1991.tb49034.x; HALABAN R, 1993, EPIDERMAL GROWTH FAC, P273; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; HOLLAND EA, 1994, ONCOGENE, V9, P1361; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KAMB A, 1994, COLD SPRING HARB SYM, V59, P39, DOI 10.1101/SQB.1994.059.01.007; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LANDGREN E, 1995, ONCOGENE, V10, P2027; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LI LY, 1994, BIOCHEMISTRY-US, V33, P10999, DOI 10.1021/bi00202a020; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; LIU L, 1995, ONCOGENE, V11, P405; LOGANZO F, 1993, ONCOGENE, V8, P2637; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; REED JA, 1994, AM J PATHOL, V144, P329; REYMOND A, 1995, ONCOGENE, V11, P1173; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; SCOTT G, 1991, J INVEST DERMATOL, V96, P318, DOI 10.1111/1523-1747.ep12465203; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; UENO H, 1993, J BIOL CHEM, V268, P22814; UENO H, 1992, J BIOL CHEM, V267, P1470; WALKER GJ, 1994, ONCOGENE, V9, P819; WELLBROCK C, 1995, ONCOGENE, V10, P2135; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YAYON A, 1993, P NATL ACAD SCI USA, V90, P10643, DOI 10.1073/pnas.90.22.10643; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; YAYON A, 1990, CANCER METAST REV, V9, P191, DOI 10.1007/BF00046360; ZAKUT R, 1993, ONCOGENE, V8, P2221; ZHAN X, 1994, J BIOL CHEM, V269, P20221	65	66	70	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					2999	3009		10.1038/sj.onc.1201159	http://dx.doi.org/10.1038/sj.onc.1201159			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223663				2022-12-17	WOS:A1997XG10000002
J	Ivanov, VN; Lee, RK; Podack, ER; Malek, TR				Ivanov, VN; Lee, RK; Podack, ER; Malek, TR			Regulation of Fas-dependent activation-induced T cell apoptosis by cAMP signaling: A potential role for transcription factor NF-kappa B	ONCOGENE			English	Article						apoptosis; T lymphocyte; NF-kappa B; Fas ligand	PROTEIN-KINASE-A; IMMUNE-SYSTEM; REL FAMILY; C-MYC; DEATH; INHIBITION; EXPRESSION; BCL-2; HYBRIDOMAS; LIGAND	TCR-mediated activation of T cell hybridomas induces programmed cell death by a Fas-dependent pathway. We now show that costimulation of 2B4 cells, in the absence or presence of transgenic Bcl-2, with anti-CD3 epsilon and forskolin, an activator of cAMP signaling, resulted in antagonism of Fas-dependent activation-induced cell death that was always accompanied by selective down-regulation of the nuclear levels of NF-kappa B p65-p50 (RelA-p50) transcription factor. Forskolin not only inhibited activation-induced cell death and NF-kappa B activation, but also suppressed expression of Fas and Fas ligand (Fast). Furthermore, NF-kappa B p65 antisense oligonucleotide down-regulated nuclear levels of NF-kappa B, inhibited cell surface expression of Fas-L and apoptosis of 2B4. Collectively, these finding demonstrate a potential role of NF-kappa B in the regulation of activation-induced apoptosis in T lymphocytes.	UNIV MIAMI, SCH MED, DEPT MICROBIOL & IMMUNOL, MIAMI, FL 33101 USA; RUSSIAN ACAD SCI, INST GENE BIOL, MOSCOW, RUSSIA	University of Miami; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences			Ivanov, Vladimir N/A-3081-2008	Ivanov, Vladimir N/0000-0003-3091-9774	NCI NIH HHS [R01-CA4609] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDERSON MR, 1995, J EXP MED, V181, P71, DOI 10.1084/jem.181.1.71; ASHWELL JD, 1994, HDB B T LYMPHOCYTES, P63; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BRIDLE PK, 1992, CURR OPIN GENET DEV, V2, P199; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CASOLARO V, 1995, P NATL ACAD SCI USA, V92, P11623, DOI 10.1073/pnas.92.25.11623; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; CODIAS EK, 1990, J IMMUNOL, V145, P1407; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; GOETZL EJ, 1995, J IMMUNOL, V154, P1041; GREEN DR, 1994, IMMUNOL REV, V142, P321, DOI 10.1111/j.1600-065X.1994.tb00895.x; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; IVANOV V, 1994, J IMMUNOL, V153, P2394; IVANOV V, 1993, J IMMUNOL, V151, P4694; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; JONDAL M, 1995, APOPTOSIS IMMUNOLOGY, P67; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LEE MR, 1993, J IMMUNOL, V151, P5208; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MCCAFFREY PG, 1992, J BIOL CHEM, V267, P1864; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OWAKI H, 1993, EMBO J, V12, P4367, DOI 10.1002/j.1460-2075.1993.tb06121.x; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PENNINGER JM, 1994, IMMUNOL REV, V142, P231, DOI 10.1111/j.1600-065X.1994.tb00892.x; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Williams MS, 1996, J IMMUNOL, V157, P2395; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; WU HY, 1994, J BIOL CHEM, V269, P20067; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037	59	66	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	1997	14	20					2455	2464		10.1038/sj.onc.1201088	http://dx.doi.org/10.1038/sj.onc.1201088			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188860	Green Published			2022-12-17	WOS:A1997WZ68000009
J	Li, Y; Mangasarian, K; Mansukhani, A; Basilico, C				Li, Y; Mangasarian, K; Mansukhani, A; Basilico, C			Activation of FGF receptors by mutations in the transmembrane domain	ONCOGENE			English	Article						achondroplasia; differentiation; cell transformation; receptor phosphorylation	FIBROBLAST-GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; MYOGENIC DIFFERENTIATION; TARGETED EXPRESSION; POINT MUTATION; ACHONDROPLASIA; FAMILY; GENE; PHOSPHORYLATION; PROLIFERATION	Signaling through FGF receptors, which constitute a family of membrane-spanning tyrosine kinases, can stimulate cell proliferation, induce or inhibit cell differentiation and plays an important role in development. Recently, mutations in FGF receptors have been shown to be associated with a number of genetically dominant human skeletal disorders. A remarkably conserved mutation (Gly 380-->Arg) in the transmembrane region of FGFR-3 has been shown to be responsible for achondroplasia (ACH) but it was not clear whether such mutations result in loss of receptor function or constitutive activation. We have therefore made mutations in the transmembrane regions of murine FGFR-2 and FGFR-3 and studied their effect on receptor activity. We show here that the ACH mutation in FGFR-3 as well as two similar mutations in FGFR-2 result in constitutive activation of these receptors. This is manifested in their ability to become autophosphorylated in the absence of ligand in L6 cells, transforming activity on NIH3T3 fibroblasts, and the ability to inhibit myogenic differentiation in the absence of growth factor. Thus the transmembrane region of FGFR-2 and FGFR-3 plays a regulatory role in receptor function and the ACH mutation produces a dominant oversignaling receptor which is no longer regulated by FGF binding. These findings also support the newly identified role of FGF signaling as a negative regulator of bone growth.	NYU, SCH MED, DEPT MICROBIOL, NEW YORK, NY 10016 USA; NYU, SCH MED, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	New York University; New York University				Mansukhani, Alka/0000-0003-1020-3242	NCI NIH HHS [CA42568] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042568] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Campochiaro PA, 1996, J NEUROSCI, V16, P1679; CHEATHAM B, 1993, P NATL ACAD SCI USA, V90, P7336, DOI 10.1073/pnas.90.15.7336; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; FOX JC, 1994, MOL CELL BIOL, V14, P4244, DOI 10.1128/MCB.14.6.4244; IANNOTTI JP, 1994, GROWTH PLATE BONE DE, P185; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KATO Y, 1990, J BIOL CHEM, V265, P5903; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; LONARDO F, 1990, New Biologist, V2, P992; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MATHEWS LS, 1993, J BIOL CHEM, V268, P19013; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; MIMA T, 1995, P NATL ACAD SCI USA, V92, P467, DOI 10.1073/pnas.92.2.467; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; STANESCU R, 1990, AM J MED GENET, V37, P412, DOI 10.1002/ajmg.1320370323; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WIDES RJ, 1990, EUR J BIOCHEM, V189, P637, DOI 10.1111/j.1432-1033.1990.tb15532.x; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032	45	66	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	1997	14	12					1397	1406		10.1038/sj.onc.1200983	http://dx.doi.org/10.1038/sj.onc.1200983			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136983				2022-12-17	WOS:A1997WT58400002
J	Pershouse, MA; ElNaggar, AK; Hurr, K; Lin, H; Yung, WKA; Steck, PA				Pershouse, MA; ElNaggar, AK; Hurr, K; Lin, H; Yung, WKA; Steck, PA			Deletion mapping of chromosome 4 in head and neck squamous cell carcinoma	ONCOGENE			English	Article						chromosome 4; loss of heterozygosity; carcinoma	CANCER; ALLELOTYPE; HETEROZYGOSITY; MARKERS	Genomic deletions involving chromosome 4 have recently been implicated in several human cancers. To identify and characterize genetic events associated with the development of head and neck squamous cell carinoma (HNSCC), a fine mapping of allelic losses associated with chromosome 4 was performed on DNA isolated from 27 matched primary tumor specimens and normal tissues. Loss of heterozygosity (LOH) of at least one chromosome 4 polymorphic allele was seen in the majority of tumors (92%). Alleic deletions were confined to short arm loci in four tumors and to the long arm loci in 12 tumors, suggesting the presence of two regions of common deletion. One region of frequent deletion was centered at D4S405 on 4p and included the loci D4S1546 to D4S428 in similar to 41% of the tumors. The common region of deletion on 4q was more complex and extended from D4S1571 to D4S1573, Frequent genetic alterations were observed within this region (4q25) and one marker, D4S407, exhibited a high frequency of LOH (>75%). These results indicate that alterations of chromosome 4 regions are associated with HNSCC tumorigenesis and further localizes the regions that may harbor tumor suppressor genes.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,BRAIN TUMOR CTR,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA056041, R01CA051148] Funding Source: NIH RePORTER; NCI NIH HHS [CA 51148, R01 CA 56041] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHSEE KW, 1994, CANCER RES, V54, P1617; BRACHMAN DG, 1992, CANCER RES, V52, P4832; BUETOW KH, 1989, P NATL ACAD SCI USA, V86, P8852, DOI 10.1073/pnas.86.22.8852; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; DEVESA SS, 1995, JNCI-J NATL CANCER I, V87, P175, DOI 10.1093/jnci/87.3.175; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; FAN JB, 1994, HUM MOL GENET, V3, P243, DOI 10.1093/hmg/3.2.243; FUJIMOTO Y, 1994, CANCER RES, V54, P281; GRANDIS JR, 1993, CANCER RES, V53, P3579; GYAPAY G, 1994, NAT GENET, V7, P268; Hong WK, 1995, CLIN CANCER RES, V1, P677; JIN YS, 1993, CANCER RES, V53, P2140; MCGOWANJORDAN IJ, 1994, CANCER RES, V54, P2568; MITRA AB, 1994, CANCER RES, V54, P4481; MURRAY JC, 1992, NAT GENET, V2, P46, DOI 10.1038/ng0992-46; NAWROZ H, 1994, CANCER RES, V54, P1152; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; POLASCIK TJ, 1995, CANCER RES, V55, P5396; SATO T, 1991, CANCER RES, V51, P5118; SHIN DM, 1994, CANCER RES, V54, P321; Sidransky David, 1995, Current Opinion in Oncology, V7, P229, DOI 10.1097/00001622-199505000-00007; SPITZ MR, 1993, CANCER EPIDEM BIOMAR, V2, P329; SREEKANTAIAH C, 1994, GENE CHROMOSOME CANC, V11, P29, DOI 10.1002/gcc.2870110106; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEINBERG RA, 1991, SCIENCE, V254, P706	27	66	69	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					369	373		10.1038/sj.onc.1200836	http://dx.doi.org/10.1038/sj.onc.1200836			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018123				2022-12-17	WOS:A1997WD51600013
J	Billon, N; vanGrunsven, LA; Rudkin, BB				Billon, N; vanGrunsven, LA; Rudkin, BB			The CDK inhibitor p21(WAF1/Cip1) is induced through a p300-dependent mechanism during NGF-mediated neuronal differentiation of PC12 cells	ONCOGENE			English	Article						NGF; PC12; p21(WAF1/Cip1); p300; E1A; cell cycle; differentiation	NERVE GROWTH-FACTOR; SIGNAL-REGULATED KINASE; TERMINAL DIFFERENTIATION; TRANSCRIPTIONAL ADAPTER; REQUIRES BINDING; CYCLE ARREST; P21; PROTEIN; EXPRESSION; INDUCTION	The block of cell proliferation elicited by the addition of nerve growth factor (NGF) to exponentially-growing PC12 cells results, in part, from the inhibition of cyclin D1-associated kinase activity by p2l(WAF1/ClP1). NGF treatment of PC12 cells provokes the accumulation of p21 mRNA, due to transcriptional activation of the p21 promoter in a p53-independent manner. Transient expression of a mutated form of the adenovirus E1A protein (E1A dCR2), which retains its capacity to bind the transcriptional co-activator p300, completely abolishes the NGF-mediated stimulation of p21 promoter activity. This phenomenon can be reversed by ectopic expression of p300, suggesting that p300 is necessary for the induction of p21 by NGF. In addition, stable expression of E1A dCR2 in PC12 cells results in the inhibition of the NGF response, i.e. it prevents activation of the p21 promoter, cell cycle arrest, and neuronal differentiation. The signalling pathway from the TrkA receptor via the MAP kinase pathway is not altered in these cells. Together, these data indicate that p300 could play a pivotal role in the triggering of the anti-mitogenic effect of NGF and of neuronal differentiation.	ECOLE NORMALE SUPER LYON,BIOL CELLULAIRE & MOL LAB,DIFFERENTIAT & CELL CYCLE GRP,UMR 49 CNRS,F-69364 LYON 07,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON)			van Grunsven, Leo/E-5839-2010	van Grunsven, Leo/0000-0002-0990-7034; RUDKIN, Brian B./0000-0003-3700-1982				ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; BANNISTER AJ, 1995, EMBO J, V14, P4790; BOULUKOS KE, 1993, ONCOGENE, V8, P237; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Decker SJ, 1995, J BIOL CHEM, V270, P30841, DOI 10.1074/jbc.270.52.30841; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; Dubois PM, 1996, J IMMUNOL, V156, P1356; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HEASLEY LE, 1991, CELL REGUL, V2, P479, DOI 10.1091/mbc.2.6.479; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LUNDBLAD JR, 1995, NATURE, V374, P83; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; Savatier P, 1996, ONCOGENE, V12, P309; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SIMPSON DL, 1991, J NEUROSCI RES, V28, P486, DOI 10.1002/jnr.490280405; SLACK RS, 1995, ONCOGENE, V10, P19; Smits PHM, 1996, ONCOGENE, V12, P1529; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; vanGrunsven LA, 1996, ONCOGENE, V12, P855; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAN GZ, 1995, J NEUROSCI, V15, P6200; ZENG X, 1996, ONCOGENE, V12, P1557	53	66	67	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2047	2054						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950971				2022-12-17	WOS:A1996VV14500001
J	SeppLorenzino, L; Eberhard, I; Ma, ZP; Cho, C; Serve, H; Liu, F; Rosen, N; Lupu, R				SeppLorenzino, L; Eberhard, I; Ma, ZP; Cho, C; Serve, H; Liu, F; Rosen, N; Lupu, R			Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells	ONCOGENE			English	Article						signaling; erbB receptors; heregulin	GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; TYROSINE KINASE; CARCINOMA-CELLS; EGF RECEPTOR; TUMOR-CELLS; ACTIVATING FACTOR; ONCOGENE PRODUCT; NEU RECEPTOR; PROTEIN	Heregulins (HRGs) induce tyrosine phosphorylation of several members of the erb-B family of receptors. Although originally isolated as the ligands for p185(c-erbB-2), recent evidence suggests that other receptors of the erb B family, including p180(erbB-3) and p180(erbB-4), are their true cognate receptors. Stimulation of MDA MB-453 cells with HRG beta 2 resulted in the tyrosine phosphorylation of p185(c-erbB-2) and p180(erbB-4) in a time- and dose-dependent fashion, This event was accompanied by the formation of multimeric complexes between the activated receptors and SH2-containing proteins. Ligand caused p120-rasGTPase activating protein (GAP), SHC and the p85 subunit of phosphatidylinositol-3'-kinase (PI3K) to be associated with both p185(c-erbB-2) and p180(erbB-4). In addition, tyrosine phosphorylation of p85-PI3K and SHC, but not of GAP or of its associated p62 and p190 proteins, was also detected, HRG also induced the association of GRB2 with tyrosine phosphorylated p185(c-erbB-2)) p180(crbB-4) and SHC. Activation of mitogen-activated protein kinase (MAPK) (> 30-fold over untreated controls) was observed upon receptor(s) activation, as it was the induction of the immediate early gene c-fos (> 200-fold). These observations suggest that p21(ras) activation plays a role in the HRG pathway. Furthermore, comparative anlaysis of the binding of p85-PI3K to 185(c-crbB-2) and p180(crbB-4), revealed a preferential association with activated p180(erbB-4). These findings might suggest a model of HRG action in which the relative expression of the various erb-B family members and the partitioning of signal transduction molecules between each type of receptor might determine the nature of the signal elicited by the ligand and the biological response attained.	MEM SLOAN KETTERING CANC CTR, PROGRAM MOLEC BIOL, PROGRAM CELL BIOLOG & GENET, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, PROGRAM MOLEC BIOL, DEPT MED, NEW YORK, NY 10021 USA; GEORGETOWN UNIV, VINCENT T LOMBARDI CANC RES CTR, WASHINGTON, DC 20007 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Georgetown University			Rosen, Neal/ABF-2677-2020		NCI NIH HHS [R01 CA 55406-01, R01 CA 58706-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058706, R01CA055406] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; DAVIS JG, 1991, BIOCHEM BIOPH RES CO, V179, P1536, DOI 10.1016/0006-291X(91)91747-Z; DECORTE V, 1994, J CELL SCI, V107, P405; DIFIORE PP, 1990, MOL CELL BIOL, V10, P2749, DOI 10.1128/MCB.10.6.2749; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; DOUGALL WC, 1994, ONCOGENE, V9, P2109; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG SS, 1992, J BIOL CHEM, V267, P11508; JALLAL B, 1992, J BIOL CHEM, V267, P4357; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Lehtola L, 1989, GROWTH FACTORS, V1, DOI 10.3109/08977198909000256; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LIN YZJ, 1991, ONCOGENE, V6, P639; LUPU R, 1995, SEMIN CANCER BIOL, V6, P135, DOI 10.1006/scbi.1995.0016; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; LUPU R, 1993, BREAST CANCER RES TR, V27, P83, DOI 10.1007/BF00683195; LUPU R, 1991, INT S PRINC TAK CANC, V22, P49; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; NORMANNO N, 1994, BREAST CANCER RES TR, V29, P11, DOI 10.1007/BF00666178; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PANDIELLA A, 1989, ONCOGENE, V4, P1299; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SANGHERA JS, 1990, FEBS LETT, V273, P223, DOI 10.1016/0014-5793(90)81090-B; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; SEGATTO O, 1993, ONCOGENE, V8, P2105; SEGATTO O, 1992, ONCOGENE, V7, P1339; SEPPLORENZINO L, 1994, CELL GROWTH DIFFER, V5, P1077; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STAEBLER A, 1994, BREAST CANCER RES TR, V31, P175, DOI 10.1007/BF00666151; TANG C, 1994, P AM ASSOC CANC RES, V35, pA214; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANDEVIJVER MJ, 1991, BIOCHIM BIOPHYS ACTA, V1072, P33, DOI 10.1016/0304-419X(91)90005-6; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	74	66	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1679	1687						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622888				2022-12-17	WOS:A1996UG45800010
J	ANGUS, J; THOMSON, F; MURPHY, K; BAKER, E; SUTHERLAND, GR; PARSONS, PG; STURM, RA				ANGUS, J; THOMSON, F; MURPHY, K; BAKER, E; SUTHERLAND, GR; PARSONS, PG; STURM, RA			THE BRN-2 GENE REGULATES THE MELANOCYTIC PHENOTYPE AND TUMORIGENIC POTENTIAL OF HUMAN-MELANOMA CELLS	ONCOGENE			English	Article						BRN-2; POU DOMAIN; MELANOMA; ANTISENSE RNA; MICROPHTHALMIA; ICAM-1	HUMAN-MALIGNANT MELANOMA; OCTAMER-BINDING-PROTEINS; CENTRAL-NERVOUS-SYSTEM; POU-DOMAIN; DIFFERENTIATING AGENTS; TRANSCRIPTION FACTORS; ADHESION MOLECULES; DNA-BINDING; SCID MOUSE; EXPRESSION	The Oct transcription factors N-Oct-3 and N-Oct-5 are differentially expressed in normal melanocytes, melanoma tumors and cell lines. We have cloned the human brn-2 gene and have shown that it encodes both the N-Oct-3 and N-Oct-5 octamer binding activities detected in melanoma cells. The brn-2 genomic locus has been mapped to chromosome 6q16 and although chromosomal aberrations are common in this region in melanoma, no deletion or rearrangement of the brn-2 gene in melanoma cell lines was observed. Sequencing of the entire gene showed that there are no intervening sequences within the open reading frame. Antisense RNA-mediated inhibition of brn-2 gene expression in melanoma cells was associated with a change in morphology and loss of melanocytic and neural crest markers, including the melanocyte transcription factor microphthalmia and the TYRP pigmentation genes. In addition, loss of brn-2 in these cells resulted in the complete loss of ability to form tumors in SCID and nu/nu mice. These results suggest roles for brn-2 in the determination of the melanocytic lineage and in the tumorigenic phenotype of melanoma.	UNIV QUEENSLAND, CTR MOLEC & CELLULAR BIOL, ST LUCIA, QLD 4072, AUSTRALIA; QUEENSLAND INST MED RES, QUEENSLAND CANC FUND RES UNIT, HERSTON, QLD 4029, AUSTRALIA; WOMENS & CHILDRENS HOSP, DEPT CYTOGENET & MOLEC GENET, ADELAIDE, SA 5006, AUSTRALIA	University of Queensland; QIMR Berghofer Medical Research Institute; Womens & Childrens Hospital Australia			Sturm, Richard A/C-9943-2009; Parsons, Peter G/H-8163-2015; Sutherland, Grant Robert/D-2606-2012	Sturm, Richard A/0000-0003-1301-0294; Parsons, Peter G/0000-0002-0473-3346; 				AVRAHAM KB, 1993, GENOMICS, V18, P131, DOI 10.1006/geno.1993.1436; BALABAN GB, 1986, CANCER GENET CYTOGEN, V19, P113, DOI 10.1016/0165-4608(86)90378-X; BENDALL AJ, 1993, EUR J BIOCHEM, V217, P799, DOI 10.1111/j.1432-1033.1993.tb18308.x; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; BHAT KM, 1994, DEVELOPMENT, V120, P1483; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; CHAR BR, 1994, DEVELOPMENT, V120, P1929; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FUJII H, 1993, NEURON, V11, P1197, DOI 10.1016/0896-6273(93)90231-F; GREENSTEIN D, 1994, GENE DEV, V8, P1935, DOI 10.1101/gad.8.16.1935; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HENDRICKSON EA, 1993, AM J PATHOL, V143, P1511; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; JOHNSON JP, 1991, CANCER METAST REV, V10, P11, DOI 10.1007/BF00046840; JOHNSON JP, 1989, P NATL ACAD SCI USA, V86, P641, DOI 10.1073/pnas.86.2.641; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; KRIEG AM, 1993, P NATL ACAD SCI USA, V90, P1048, DOI 10.1073/pnas.90.3.1048; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MATHIS JM, 1992, EMBO J, V11, P2551, DOI 10.1002/j.1460-2075.1992.tb05320.x; MILLIKIN D, 1991, CANCER RES, V51, P5449; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; NAKAJIMA T, 1982, CANCER, V50, P912, DOI 10.1002/1097-0142(19820901)50:5<912::AID-CNCR2820500519>3.0.CO;2-U; PARMITER AH, 1993, J INVEST DERMATOL, V100, pS254, DOI 10.1038/jid.1993.46; QIN XF, 1994, EMBO J, V13, P5967, DOI 10.1002/j.1460-2075.1994.tb06942.x; RESNICOFF M, 1994, CANCER RES, V54, P4848; RON D, 1992, BIOTECHNIQUES, V13, P866; Sambrook J., 1989, MOL CLONING LAB MANU; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHREIBER E, 1990, NUCLEIC ACIDS RES, V18, P5495, DOI 10.1093/nar/18.18.5495; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; SCHREIBER E, 1994, NEUROSURGERY, V34, P129; SCHREIBER E, 1992, CANCER RES, V52, P6121; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STOYKOVA AS, 1992, NEURON, V8, P541, DOI 10.1016/0896-6273(92)90282-I; STURM RA, 1991, CELL GROWTH DIFFER, V2, P519; STURM RA, 1994, PIGM CELL RES, V7, P235, DOI 10.1111/j.1600-0749.1994.tb00055.x; TAKAHASHI H, 1990, PIGM CELL RES, V3, P223, DOI 10.1111/j.1600-0749.1990.tb00294.x; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; THOMSON JAF, 1993, PIGM CELL RES, V6, P13, DOI 10.1111/j.1600-0749.1993.tb00576.x; THOMSON JAF, 1994, INT J CANCER, V58, P285, DOI 10.1002/ijc.2910580223; TREACY MN, 1992, ANNU REV NEUROSCI, V15, P139, DOI 10.1146/annurev.ne.15.030192.001035; TRENT JM, 1989, CANCER RES, V49, P420; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; VANDUINEN CM, 1994, CANCER-AM CANCER SOC, V73, P2131, DOI 10.1002/1097-0142(19940415)73:8<2131::AID-CNCR2820730818>3.0.CO;2-1; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; WANG SL, 1993, P NATL ACAD SCI USA, V90, P10385, DOI 10.1073/pnas.90.21.10385; WELCH DR, 1994, ONCOGENE, V9, P255; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; XIA YR, 1993, GENOMICS, V18, P126, DOI 10.1006/geno.1993.1435; YANG XH, 1993, GENE DEV, V7, P504, DOI 10.1101/gad.7.3.504; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058	61	66	67	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	1995	11	4					691	700						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651733				2022-12-17	WOS:A1995RQ46900011
J	LI, YJ; HOANGXUAN, K; DELATTRE, JY; POISSON, M; THOMAS, G; HAMELIN, R				LI, YJ; HOANGXUAN, K; DELATTRE, JY; POISSON, M; THOMAS, G; HAMELIN, R			FREQUENT LOSS OF HETEROZYGOSITY ON CHROMOSOME-9, AND LOW INCIDENCE OF MUTATIONS OF CYCLIN-DEPENDENT KINASE INHIBITORS P15 (MTS2) AND P16 (MTS1) GENES IN GLIOMAS	ONCOGENE			English	Note						GLIOMAS; CKIS; P16 GENE; P15 GENE	DELETIONS; P21	Four cyclin-dependent kinase inhibitors called p15, p16, p21 and p27 have been identified in mammals. Because these proteins participate in the control of cell cycle, they are potential targets for somatic mutations during carcinogenesis. In order to document the prevalence of p15 and p16 alterations in gliomas, we looked for loss of heterozygosity of chromosome 9p where these genes are localized. Allelic losses were observed in 31 of 44 investigated cases. In all cases they involved the p15/ p16 locus. We then looked for mutations in the p16 and p15 genes in 46 gliomas. A total of three DNA variants were observed which were all present in the matched constitutional DNA. They may be unrelated to tumor development. A single somatic mutation was detected. It involved a C to G substitution in codon 93 of p16 and is predicted to change a threonine into an arginine. Taken together, these data indicate that inactivation by point mutation of these two cyclin-dependent kinase inhibitors is uncommon in glial tumor carcinogenesis, but that there may be a tumor suppressor gene on 9p in the vicinity of pld and p15 genes.	INST CURIE,INSERM,U434,F-75231 PARIS 05,FRANCE; HOP LA PITIE SALPETRIERE,NEUROL CLIN,F-75013 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite			Hoang-Xuan, Khe/O-7527-2017					CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHENG JQ, 1994, CANCER RES, V54, P5547; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GIANI C, 1994, CANCER RES, V54, P6338; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HAYASHI N, 1994, BIOCHEM BIOPH RES CO, V202, P1426, DOI 10.1006/bbrc.1994.2090; HOANGXUAN K, 1994, INT J CANCER, V60, P478; HUGOT JP, 1994, AM J MED GENET, V52, P207, DOI 10.1002/ajmg.1320520216; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JAMES CD, 1993, CANCER RES, V53, P3674; JEGO N, 1993, ONCOGENE, V8, P209; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OHTA M, 1994, CANCER RES, V54, P5269; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OLOPADE OI, 1992, CANCER RES, V52, P2523; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; SCHMIDT EE, 1994, CANCER RES, V54, P321; SERRANO M, 1994, NATURE, V366, P704; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU L, 1994, CANCER RES, V54, P5262; YEUDALL WA, 1994, CARCINOGENESIS, V15, P2683, DOI 10.1093/carcin/15.12.2683; ZHANG SY, 1994, CANCER RES, V54, P5050; ZHOU XL, 1994, ONCOGENE, V9, P3737	35	66	71	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					597	600						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630644				2022-12-17	WOS:A1995RN53000021
J	SOANS, C; HOLASH, JA; PASQUALE, EB				SOANS, C; HOLASH, JA; PASQUALE, EB			CHARACTERIZATION OF THE EXPRESSION OF THE CEK8 RECEPTOR-TYPE TYROSINE KINASE DURING DEVELOPMENT AND IN TUMOR-CELL LINES	ONCOGENE			English	Article							NERVOUS-SYSTEM; EPH GENE; PROTEIN; FAMILY; CHICKEN; IDENTIFICATION; HINDBRAIN; MEMBERS; ENCODES; CLONING	Cek8 is a receptor-type tyrosine kinase gene that was identified by screening a 10 day chicken embryo library with a DNA probe corresponding to the related kinase Cek4 (Sajjadi and Pasquale, 1993). Here we report the characterization of the Cek8 protein and its expression in embryonic tissues and tumor cell lines. The 120 kd Cek8 protein is detected early in embryogenesis, is developmentally regulated and preferentially, but not exclusively, expressed in neural tissues. In the stage 24 chick embryo, Cek8 immunoreactivity is prominent in the spinal cord and spinal nerves. At embryonic day 6, Cek8 expression becomes concentrated to the ventral portion of the spinal nerves, suggesting a role in axonogenesis of specific subsets of neurons. Cek8 is expressed in nearly all of the tumor cell lines examined, including cell lines derived from tumors of the central nervous system. Although the phosphorylation on tyrosine of Cek8 during development is moderate or undetectable, Cek8 is substantially phosphorylated on tyrosine (and thus presumably activated) in many of the transformed cell lines. Because of its high frequency of expression in tumor cell lines, Cek8 differs from previously investigated Eph-related kinases. However, as we show, Cek8 is not unique among the Eph-related kinases: another member of the Eph subclass, Cek5, has similar patterns of expression and phosphorylation in tumor cells. Based on its binding to a variety of lectin columns, Cek8 contains complex N-linked oligosaccharides. Cross-linking of Cek8 molecules on the cell surface with wheat germ agglutinin caused their rapid phosphorylation on tyrosine. Autophosphorylation on tyrosine is typically the first step in the activation of a receptor tyrosine kinase by a ligand.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD026351, R01HD026351] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA056721] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56721] Funding Source: Medline; NICHD NIH HHS [HD-26351] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDRES AC, 1994, ONCOGENE, V9, P1461; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BISHOP JM, 1991, CELL, V64, P234; BOHME B, 1993, ONCOGENE, V8, P2857; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOYD AW, 1992, J BIOL CHEM, V267, P3262; CHAN J, 1991, ONCOGENE, V6, P1057; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HARLOW E, 1988, ANTIBODIES LABORATOR; Hazan R., 1993, Molecular Biology of the Cell, V4, p9A; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; KAWAGUCHI T, 1987, CANCER RES, V47, P4460; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; NIETO MA, 1992, DEVELOPMENT, V116, P1137; OSAWA T, 1987, ANNU REV BIOCHEM, V56, P21, DOI 10.1146/annurev.biochem.56.1.21; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SUGII S, 1982, CARBOHYD RES, V99, P99, DOI 10.1016/S0008-6215(00)80982-9; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	34	66	66	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3353	3361						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936661				2022-12-17	WOS:A1994PM65800030
J	DEVLIN, J; KEEN, AJ; KNOWLES, MA				DEVLIN, J; KEEN, AJ; KNOWLES, MA			HOMOZYGOUS DELETION MAPPING AT 9P21 IN BLADDER-CARCINOMA DEFINES A CRITICAL REGION WITHIN 2CM OF IFNA	ONCOGENE			English	Note							ALLELIC LOSSES; SHORT ARM; CHROMOSOME-9; CANCER; MELANOMA	We have screened 165 cases of primary transitional cell carcinoma of the bladder for loss of heterozygosity of markers on chromosome 9. High density deletion mapping was then carried out on a panel of 16 tumours with partial deletions of 9p using 15 microsatellite markers. Seven tumours had hemizygous deletions which included small interstitial losses and large terminal deletions. Homozygous deletions of one or more markers were identified in the remaining 9 tumours. By comparing the limits of hemi- and homozygous deletions in these tumours we have defined a single common region of 2cM flanked by IFNA and D9S171.	MARIE CURIE RES INST,GENET MOLEC LAB,OXTED,SURREY RH8 0TL,ENGLAND					Knowles, Margaret/0000-0002-9363-8657				CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1993, ONCOGENE, V8, P1083; CAIRNS P, 1993, CANCER RES, V53, P1230; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CENTER R, 1993, GENE CHROMOSOME CANC, V7, P47, DOI 10.1002/gcc.2870070108; CHENG JQ, 1993, CANCER RES, V53, P4761; COLEMAN A, 1994, CANCER RES, V54, P344; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; HABUCHI T, 1993, INT J CANCER, V53, P579, DOI 10.1002/ijc.2910530409; HOLLAND EA, 1994, ONCOGENE, V9, P1361; JAMES CD, 1993, CANCER RES, V53, P3674; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KEEN AJ, 1994, ONCOGENE, V9, P2083; KNOWLES MA, 1994, CANCER RES, V54, P1; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; MERLO A, 1994, CANCER RES, V54, P2322; MIYAO N, 1993, CANCER RES, V53, P4066; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OLOPADE OI, 1993, CANCER RES, V53, P2410; OLOPADE OI, 1992, CANCER RES, V52, P2523; POVEY S, 1994, IN PRESS ANN HUM GEN; PROCTOR AJ, 1991, ONCOGENE, V6, P789; RUPPERT JM, 1993, CANCER RES, V53, P5093; STADLER WM, 1994, CANCER RES, V54, P2060; TSAI YC, 1990, CANCER RES, V50, P44; VANDERRIET P, 1994, CANCER RES, V54, P1156	27	66	67	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2757	2760						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058343				2022-12-17	WOS:A1994PC05400041
J	GUPTA, K; CHEVRETTE, M; GRAY, DA				GUPTA, K; CHEVRETTE, M; GRAY, DA			THE UNP PROTOONCOGENE ENCODES A NUCLEAR-PROTEIN	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; LARGE T-ANTIGEN; TRE ONCOGENE; NUCLEOTIDE-SEQUENCES; CELLULAR PROTEINS; BINDING; ADENOVIRUS-E1A; CLONING; RECOMBINATION; EXPRESSION	The mouse Unp gene is related to TRE17, a human oncogene, but is not its mouse homolog. Unp is a ubiquitously expressed gene producing two related mRNAs. The protein product of Unp is localized in the nucleus. Expression of Unp from a highly active promoter results in tumorigenic transformation of NIH3T3 cells injected into athymic mice. Unp therefore encodes a novel nuclear oncoprotein.	UNIV OTTAWA,DEPT BIOCHEM,OTTAWA K1H 8M5,ON,CANADA; UNIV OTTAWA,DEPT MED,OTTAWA K1H 8M5,ON,CANADA	University of Ottawa; University of Ottawa			/U-3554-2018	/0000-0002-8634-4984				CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DARNELL J, 1986, MOL CELL BIOL, P319; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GALLIONE CJ, 1981, J VIROL, V39, P529, DOI 10.1128/JVI.39.2.529-535.1981; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUPTA K, 1993, ONCOGENE, V8, P2307; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUEBNER K, 1988, ONCOGENE, V3, P449; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; NEVINS JR, 1992, SCIENCE, V258, P424; ONNO M, 1992, ONCOGENE, V7, P2519; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Sambrook J., 1989, MOL CLONING LAB MANU; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993	24	66	69	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1729	1731						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183569				2022-12-17	WOS:A1994NL81500026
J	WELSH, M; MARES, J; KARLSSON, T; LAVERGNE, C; BREANT, B; CLAESSONWELSH, L				WELSH, M; MARES, J; KARLSSON, T; LAVERGNE, C; BREANT, B; CLAESSONWELSH, L			SHB IS A UBIQUITOUSLY EXPRESSED SRC HOMOLOGY-2 PROTEIN	ONCOGENE			English	Article							TYROSINE KINASE; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; PDGF RECEPTOR; CDNA CLONING; ACTIVATION; ONCOGENE; INSULIN; DOMAIN; SEQUENCES	To identify serum-inducible genes in the insulin-producing cell line beta TC-1, a library subtraction screening procedure was performed on serum-deprived (G(0)) and serum-restimulated (G(1)) insulin-producing beta TC-1 cells. A cDNA containing a motif with strong homology to Src homology 2 (SH2) domains was found using this procedure and called Shb. The Shb cDNA contains two methionine codons in its N-terminus and thus may code for two proteins of 67 and 56 kDa, each with one SH2 domain in its C-terminus. No other structural similarity to proteins with catalytic activity could be detected, suggesting that Shb is a so called adaptor. Shb contains the proline-rich sequence PPPGPGR between the two proposed initiator methionines which resembles a sequence for binding to Src homology 3 (SH3) domains. A second proline-rich sequence was detected after the second methionine codon. The Shb cDNA hybridized to a similar or identical mRNA of 3.1 kb expressed in mouse brain, liver, kidney, heart, NIH3T3 fibroblasts and beta TC-1 cells. Western blot analysis of the same tissues using an antiserum directed against a synthetic peptide corresponding to a part of the SH2 domain of Shb, revealed reactivity with two proteins of 56 and 67 kDa. In addition, a third reactive component of 40 kDa was detected in most tissues. Transfection and transient expression of the Shb cDNA in COS-1 cells yielded increased expression of the 67, 56 and 40 kDa proteins. Transfection and stable expression of the Shb cDNA in pig aortic endothelial cells showed increased expression primarily of the 67 kDa protein. A fusion protein consisting of the SH2 domain of Shb linked to glutathione S-transferase showed increased binding to glycoproteins of cells stimulated with platelet-derived growth factor (PDGF-BB). Furthermore, the autophosphorylated PDGF beta-receptor but not the autophosphorylated epidermal growth factor (EGF) receptor bound specifically to immobilized fusion protein. It is concluded that Shb is a novel SH2-containing protein with proline-rich domains and therefore probably involved in the signal-transduction of some ligand-activated tyrosine kinase receptors.	CHARLES UNIV, INST BIOL & MED GENET, PRAGUE, CZECH REPUBLIC; HOP ST ANTOINE, INSERM, U55, F-75571 PARIS, FRANCE; UPPSALA UNIV, LUDWIG INST CANC RES, UPPSALA, SWEDEN	Charles University Prague; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ludwig Institute for Cancer Research; Uppsala University	WELSH, M (corresponding author), UPPSALA UNIV, DEPT MED CELL BIOL, UPPSALA, SWEDEN.		Welsh, Michael/AAF-8564-2020	Welsh, Michael/0000-0002-5467-9755; Claesson-Welsh, Lena/0000-0003-4275-2000				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BREANT B, 1990, DIABETOLOGIA, V33, P586, DOI 10.1007/BF00400201; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1993, IN PRESS PROG GROWTH; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Hellerstrom C, 1985, DIABETIC PANCREAS, P53; KNORR R, 1989, TETRAHEDRON LETT, V30, P1927, DOI 10.1016/S0040-4039(00)99616-3; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MANIATIS T, 1982, MOL CLONING LABORATO, P187; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; OIE HK, 1983, ENDOCRINOLOGY, V112, P1070, DOI 10.1210/endo-112-3-1070; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Sambrook J., 1989, MOL CLONING LAB MANU; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG JYJ, 1984, CELL, V36, P349; WELSH M, 1993, DIABETES METAB REV, V9, P25, DOI 10.1002/dmr.5610090104; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	38	66	69	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					19	27						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302579				2022-12-17	WOS:A1994MW24700003
J	FAUST, M; EBENSPERGER, C; SCHULZ, AS; SCHLEITHOFF, L; HAMEISTER, H; BARTRAM, CR; JANSSEN, JWG				FAUST, M; EBENSPERGER, C; SCHULZ, AS; SCHLEITHOFF, L; HAMEISTER, H; BARTRAM, CR; JANSSEN, JWG			THE MURINE UFO RECEPTOR - MOLECULAR-CLONING, CHROMOSOMAL LOCALIZATION AND INSITU EXPRESSION ANALYSIS	ONCOGENE			English	Article							TYROSINE KINASES; PROTEIN-KINASE; HYBRIDIZATION; DOMAINS; FAMILY; SIGNAL; AMPLIFICATION; FIBRONECTIN; RECOGNITION; HOMOLOGY	We have cloned the mouse homologue of the ufo oncogene. It encodes a novel tyrosine kinase receptor characterized by a unique extracellular domain containing two immunoglobulin-like and two fibronectin type III repeats. Comparison of the predicted ufo amino acid sequences of mouse and man revealed an overall identity of 87.6%. The ufo locus maps to mouse chromosome 7A3-B1 and thereby extends the known conserved linkage group between mouse chromosome 7 and human chromosome 19. RNA in situ hyrbridization analysis established the onset of specific ufo expression in the late embryogenesis at day 12.5 post coitum (p.c.) and localized ufo transcription to distinct substructures of a broad spectrum of developing tissues (e.g. subepidermal cells of the skin, mesenchymal cells of the periosteum). In adult animals ufo is expressed in cells forming organ capsules as well as in connective tissue structures. ufo may function as a signal transducer between specific cell types of mesodermal origin.	UNIV ULM,DEPT PEDIAT 2,MOLEC BIOL SECT,PRITTWITZSTR 43,W-7900 ULM,GERMANY; UNIV ULM,DEPT CLIN GENET,W-7900 ULM,GERMANY	Ulm University; Ulm University								ADOLPH S, 1987, CYTOGENET CELL GENET, V44, P65, DOI 10.1159/000132345; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRNING U, 1991, MECH DEVELOP, V33, P119, DOI 10.1016/0925-4773(91)90078-K; HUNTER T, 1982, J BIOL CHEM, V257, P4843; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; Lyon M., 1989, GENETIC VARIANTS STR; LYON MF, 1987, MOUSE NEWS LETT, V787, P12; Maniatis T., 1982, MOL CLONING; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; RENTROP M, 1986, HISTOCHEM J, V18, P271, DOI 10.1007/BF01676237; RESCIGNO J, 1991, ONCOGENE, V6, P1909; Rinchik E M, 1991, Mamm Genome, V1 Spec No, pS97, DOI 10.1007/BF00656488; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SEALEY PG, 1985, NUCLEIC ACIDS RES, V13, P1905, DOI 10.1093/nar/13.6.1905; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SONNENBERG E, 1991, EMBO J, V10, P3693, DOI 10.1002/j.1460-2075.1991.tb04937.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	35	66	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1287	1293						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1320243				2022-12-17	WOS:A1992HZ97100006
J	DRAGANI, TA; MANENTI, G; COLOMBO, BM; FALVELLA, FS; GARIBOLDI, M; PIEROTTI, MA; DELLAPORTA, G				DRAGANI, TA; MANENTI, G; COLOMBO, BM; FALVELLA, FS; GARIBOLDI, M; PIEROTTI, MA; DELLAPORTA, G			INCIDENCE OF MUTATIONS AT CODON-61 OF THE HA-RAS GENE IN LIVER-TUMORS OF MICE GENETICALLY SUSCEPTIBLE AND RESISTANT TO HEPATOCARCINOGENESIS	ONCOGENE			English	Article							TRANSGENIC MICE; B6C3F1 MOUSE; DIETHYLNITROSAMINE HEPATOCARCINOGENESIS; HEPATOCELLULAR-CARCINOMA; N-NITROSODIETHYLAMINE; ACTIVATED ONCOGENES; INFANT MOUSE; KI-RAS; EXPRESSION; LESIONS	By selective oligonucleotide hybridization of polymerase chain reaction (PCR) amplified tumor DNAs we have analysed the incidence of mutations at codon 61 of the Ha-ras gene in 42 liver tumors spontaneously developed in Balb/c, C3Hf and B6C3 male mice, and in 79 liver tumors induced by the chemical carcinogens diethylnitrosamine (NDEA) and urethan in B6C3 and B6C male and female mice. The incidence of Ha-ras gene mutations in both spontaneously developed and urethan-induced liver tumors was 50%-63% in mice genetically susceptible to hepatocarcinogenesis (C3Hf, B6C3) and 7%-9% in mice genetically resistant (Balb/c, B6C). Urethan-induced tumors showed about the same incidence of ras mutations in male and in female B6C3 mice. NDEA-induced tumors showed a low incidence of Ha-ras mutations in both the hybrid mice (3/18 and 1/13 in B6C3 and B6C male mice, respectively). The most frequently found mutations were a C --> A transversion at the 1st base of codon 61 in spontaneous tumors, and an A --> T transversion at the 2nd base in urethan-induced tumors. Our results indicate that liver tumors induced by NDEA or urethan or spontaneously arisen have a different pattern of Ha-ras mutations at codon 61 and that these mutations constitute a rare molecular alteration in the pathogenesis of liver tumors in genetically resistant mice.			DRAGANI, TA (corresponding author), IST NAZL TUMORI,DIV EXPTL ONCOL A,VIA G VENEZIAN 1,I-20133 MILAN,ITALY.		Manenti, Giacomo/J-3339-2017; Gariboldi, Manuela/K-4744-2016; Dragani, Tommaso A./K-4493-2016	Manenti, Giacomo/0000-0002-4887-4482; Pierotti, Marco Alessandro/0000-0002-7431-8332; Gariboldi, Manuela/0000-0001-8406-165X; Dragani, Tommaso A./0000-0001-5915-4598				ALBINO AP, 1984, NATURE, V308, P69, DOI 10.1038/308069a0; BACHMANN B, 1990, NUCLEIC ACIDS RES, V18, P1309, DOI 10.1093/nar/18.5.1309; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECKER FF, 1982, CANCER RES, V42, P3918; BECKER FF, 1985, CANCER RES, V45, P768; BONHAM K, 1989, MOL CARCINOGEN, V2, P34, DOI 10.1002/mc.2940020106; BUCHMANN A, 1989, MOL CARCINOGEN, V2, P121, DOI 10.1002/mc.2940020303; DELLAPORTA G, 1978, TOXICOL APPL PHARM, V43, P293, DOI 10.1016/0041-008X(78)90009-1; DELLAPORTA G, 1990, TERATOGEN CARCIN MUT, V10, P137; DELLAPORTA G, 1984, J CANCER RES CLIN, V108, P308; DELLAPORTA G, 1982, CARCINOGENESIS, V3, P647; DIWAN BA, 1986, CARCINOGENESIS, V7, P215, DOI 10.1093/carcin/7.2.215; DRAGANI TA, 1990, CARCINOGENESIS, V11, P953, DOI 10.1093/carcin/11.6.953; DRAGANI TA, 1987, J CANCER RES CLIN, V113, P223, DOI 10.1007/BF00396377; DRAGANI TA, 1986, CANCER RES, V46, P1915; DRAGANI TA, 1984, TUMORI J, V70, P485, DOI 10.1177/030089168407000603; DRINKWATER NR, 1986, CARCINOGENESIS, V7, P1701, DOI 10.1093/carcin/7.10.1701; FARBER E, 1984, CANCER RES, V44, P5463; FRITH CH, 1984, MOUSE LIVER NEOPLASI, P85; FRITH CH, 1980, J ENVIRON PATHOL TOX, V3, P329; GOLDFARB S, 1983, ENVIRON HEALTH PERSP, V50, P149, DOI 10.2307/3429545; GOLDFARB S, 1985, CANCER RES, V45, P909; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HANIGAN MH, 1988, CARCINOGENESIS, V9, P885, DOI 10.1093/carcin/9.6.885; HELD WA, 1989, EMBO J, V8, P183, DOI 10.1002/j.1460-2075.1989.tb03363.x; ISHIKAWA F, 1985, JPN J CANCER RES, V76, P425; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; MARONPOT RR, 1987, ARCH TOXICOL S, V10, P10; MULDER MP, 1989, ONCOGENE, V4, P1345; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; SANDGREN EP, 1989, ONCOGENE, V4, P715; STOWERS SJ, 1988, CARCINOGENESIS, V9, P271, DOI 10.1093/carcin/9.2.271; TADA M, 1990, CANCER RES, V50, P1121; TAKADA S, 1989, ONCOGENE, V4, P189; TSUDA H, 1989, JPN J CANCER RES, V80, P196, DOI 10.1111/j.1349-7006.1989.tb02290.x; Vesselinovitch S D, 1982, Carcinog Compr Surv, V7, P127; VESSELINOVITCH SD, 1985, CANCER RES, V45, P910; VESSELINOVITCH SD, 1983, CANCER RES, V43, P4253; WARD JM, 1979, J NATL CANCER I, V63, P849, DOI 10.1093/jnci/63.3.849; WISEMAN RW, 1986, P NATL ACAD SCI USA, V83, P5825, DOI 10.1073/pnas.83.16.5825; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070	43	66	66	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					333	338						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	2000226				2022-12-17	WOS:A1991FZ13400021
J	NARANJO, JR; MELLSTROM, B; ACHAVAL, M; LUCAS, JJ; DELRIO, J; SASSONECORSI, P				NARANJO, JR; MELLSTROM, B; ACHAVAL, M; LUCAS, JJ; DELRIO, J; SASSONECORSI, P			COINDUCTION OF JUN B AND C-FOS IN A SUBSET OF NEURONS IN THE SPINAL-CORD	ONCOGENE			English	Article							DNA-BINDING DOMAINS; GENE-EXPRESSION; PROTO-ONCOGENE; GROWTH-FACTORS; LEUCINE ZIPPERS; RAT; STIMULATION; TRANSCRIPTION; HYBRIDIZATION; HYPERALGESIA	Noxious stimulation in vivo provokes the transcriptional activation of several genes which are though to play an important role in the phenomena of stress and pain. In the rat, the expression of the c-fos proto-oncogene is rapidly induced upon noxious stimulation in defined neurons in the dorsal horn of the spinal cord. Interestingly, expression of the prodynorphin gene, which is thought to be involved in the endogenous mechanisms for pain/stress control, also localizes in the same anatomical area. Fos proteins are known to associate in transcriptional complexes with the products of the jun family constituting nuclear factor AP-1. These considerations prompted us to analyse the expression of the jun gene family members c-jun, jun B and jun D in rats subjected to noxious stimulation. We present data indicating that in unstimulated animals the transcripts of the three genes are differentially expressed and abundant within the various laminas of the lumbar spinal cord. Surprisingly, upon stimulation only the jun B transcript is augmented, being co-localized with Fos in a subset of neurons of the medial dorsal horn.	FAC MED STRASBOURG,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE; CSIC,INST CAJAL NEUROCIENCIA,E-28002 MADRID,SPAIN	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Consejo Superior de Investigaciones Cientificas (CSIC)			NARANJO, Jose R/K-1950-2014; Lucas, Jose J./U-6543-2019; Sassone-Corsi, Paolo/H-6182-2011	NARANJO, Jose R/0000-0002-0270-3469; Lucas, Jose J./0000-0003-1597-3916				ALHO H, 1988, P NATL ACAD SCI USA, V85, P7018, DOI 10.1073/pnas.85.18.7018; ANGERER LM, 1987, IN SITU HYBRIDIZATIO, P42; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BULLITT E, 1989, BRAIN RES, V493, P391, DOI 10.1016/0006-8993(89)91177-3; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CECCATELLI S, 1989, P NATL ACAD SCI USA, V86, P9569, DOI 10.1073/pnas.86.23.9569; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COMB M, 1988, EUR MOL BIOL ORG J, V7, P3795; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DRAISCI G, 1989, MOL BRAIN RES, V6, P31, DOI 10.1016/0169-328X(89)90025-9; DUBNER R, 1984, ADV PAIN RES THER, V6, P151; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GOELET P, 1986, NATURE, V311, P433; HALEZONETIS TD, 1988, CELL, V55, P917; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; HERDEGEN T, 1990, 6TH P WORLD C PAIN; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; IADAROLA MJ, 1988, BRAIN RES, V455, P205, DOI 10.1016/0006-8993(88)90078-9; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; MENETREY D, 1989, J COMP NEUROL, V285, P177, DOI 10.1002/cne.902850203; MINAMI M, 1989, NEUROSCI LETT, V98, P105, DOI 10.1016/0304-3940(89)90382-0; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NARANJO JR, 1990, NUCLEIC ACIDS RES, V18, P3605, DOI 10.1093/nar/18.12.3605; NOGUCHI K, 1989, MOL BRAIN RES, V5, P227, DOI 10.1016/0169-328X(89)90039-9; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RUDA MA, 1988, P NATL ACAD SCI USA, V85, P622, DOI 10.1073/pnas.85.2.622; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; STERNBERGER LA, 1986, IMMUNOCYTOCHEMISTRY; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y	44	66	66	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					223	227						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1900356				2022-12-17	WOS:A1991FZ13400007
J	AGHIB, DF; BISHOP, JM; OTTOLENGHI, S; GUERRASIO, A; SERRA, A; SAGLIO, G				AGHIB, DF; BISHOP, JM; OTTOLENGHI, S; GUERRASIO, A; SERRA, A; SAGLIO, G			A 3' TRUNCATION OF MYC CAUSED BY CHROMOSOMAL TRANSLOCATION IN A HUMAN T-CELL LEUKEMIA INCREASES MESSENGER-RNA STABILITY	ONCOGENE			English	Article									UNIV MILAN, DIPARTIMENTO GENET BIOL MICROORGANISMI, I-20133 MILAN, ITALY; DIPARTIMENTO SCI BIOMED & ONCOL UMANA, I-10126 TURIN, ITALY; CTR STUDIO PATOL CELLULARE, I-20133 MILAN, ITALY; UNIV TURIN, IST MICROBIOL, I-10126 TURIN, ITALY	University of Milan; University of Turin				Saglio, Giuseppe/0000-0002-1046-3514				AGHIB D, 1987, ANN NY ACAD SCI, V511, P338, DOI 10.1111/j.1749-6632.1987.tb36262.x; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHEN SJ, 1989, NUCLEIC ACIDS RES, V17, P7631, DOI 10.1093/nar/17.19.7631; COLE MD, 1985, NATURE, V318, P510, DOI 10.1038/318510a0; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; CROCE CM, 1985, BLOOD, V65, P1; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; ERIKSON J, 1986, SCIENCE, V232, P884, DOI 10.1126/science.3486470; FINGER LR, 1986, SCIENCE, V234, P982, DOI 10.1126/science.3490692; FINGER LR, 1988, P NATL ACAD SCI USA, V85, P9158, DOI 10.1073/pnas.85.23.9158; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; HOLLIS GF, 1988, MOL CELL BIOL, V8, P124, DOI 10.1128/MCB.8.1.124; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; Maxam A M, 1980, Methods Enzymol, V65, P499; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; SAGLIO G, 1986, CANCER RES, V46, P1413; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	26	66	66	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1990	5	5					707	711						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	2189107				2022-12-17	WOS:A1990DG37400011
J	LEMOINE, NR; MAYALL, ES; WILLIAMS, ED; THURSTON, V; WYNFORDTHOMAS, D				LEMOINE, NR; MAYALL, ES; WILLIAMS, ED; THURSTON, V; WYNFORDTHOMAS, D			AGENT-SPECIFIC RAS ONCOGENE ACTIVATION IN RAT-THYROID TUMORS	ONCOGENE			English	Article											LEMOINE, NR (corresponding author), UNIV WALES COLL MED,DEPT PATHOL,CANC RES CTR,THYROID TUMOUR BIOL RES GRP,CARDIFF CF4 4XN,S GLAM,WALES.							BALMAIN A, 1986, J PATHOL, V149, P3, DOI 10.1002/path.1711490103; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; DONIACH I, 1950, BRIT J CANCER, V4, P223, DOI 10.1038/bjc.1950.22; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; GUERRERO I, 1986, LEUKEMIA RES, V10, P851, DOI 10.1016/0145-2126(86)90306-1; GUERRERO I, 1984, P NATL ACAD SCI-BIOL, V81, P202, DOI 10.1073/pnas.81.1.202; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; KNOWLES MA, 1987, ONCOGENE, V1, P143; LEMOINE NR, 1988, CANCER RES, V48, P4459; MCMAHON G, 1986, P NATL ACAD SCI USA, V83, P9418, DOI 10.1073/pnas.83.24.9418; REYNOLDS SH, 1986, P NATL ACAD SCI USA, V83, P33, DOI 10.1073/pnas.83.1.33; SAWEY MJ, 1987, MOL CELL BIOL, V7, P932, DOI 10.1128/MCB.7.2.932; SCHAFFER R, 1980, J CANCER RES CLIN, V96, P281, DOI 10.1007/BF00408100; STEINHOFF D, 1983, TOXICOL APPL PHARM, V60, P161; STOWERS SJ, 1987, CANCER RES, V47, P3212; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; SUKUMAR S, 1986, MOL CELL BIOL, V6, P2716, DOI 10.1128/MCB.6.7.2716; TSUDA H, 1976, J NATL CANCER I, V46, P81; WILLIAMS ED, 1980, RECENT RES CANCER, P47; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	22	66	67	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1988	3	5					541	544						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R5163	3078959				2022-12-17	WOS:A1988R516300009
J	Schaefer, T; Lengerke, C				Schaefer, Thorsten; Lengerke, Claudia			SOX2 protein biochemistry in stemness, reprogramming, and cancer: the PI3K/AKT/SOX2 axis and beyond	ONCOGENE			English	Review							INHIBITS CELL-PROLIFERATION; CYCLIN-DEPENDENT KINASES; MOBILITY-GROUP DOMAIN; DNA-BINDING; HELICOBACTER-PYLORI; S6 PHOSPHORYLATION; SIGNALING PATHWAY; NUCLEAR EXPORT; MOUSE; AKT	Research of the past view years expanded our understanding of the various physiological functions the cell-fate determining transcription factor SOX2 exerts in ontogenesis, reprogramming, and cancer. However, while scientific reports featuring novel and exciting aspects of SOX2-driven biology are published in near weekly routine, investigations in the underlying protein-biochemical processes that transiently tailor SOX2 activity to situational demand are underrepresented and have not yet been comprehensively summarized. Largely unrecognizable to modern array or sequencing-based technology, various protein secondary modifications and concomitant function modulations have been reported for SOX2. The chemical modifications imposed onto SOX2 are inherently heterogeneous, comprising singular or clustered events of phosphorylation, methylation, acetylation, ubiquitination, SUMOylation, PARPylation, and O-glycosylation that reciprocally affect each other and critically impact SOX2 functionality, often in a tissue and species-specific manner. One recurring regulatory principle though is the canonical PI3K/AKT signaling axis to which SOX2 relates in various entangled, albeit not exclusive ways. Here we provide a comprehensive review of the current knowledge on SOX2 protein modifications, their proposed relationship to the PI3K/AKT pathway, and regulatory influence on SOX2 with regards to stemness, reprogramming, and cancer.	[Schaefer, Thorsten; Lengerke, Claudia] Univ Basel, Basel, Switzerland; [Schaefer, Thorsten; Lengerke, Claudia] Univ Hosp Basel, Dept Biomed, Basel, Switzerland; [Lengerke, Claudia] Univ Hosp Basel, Div Hematol, Basel, Switzerland	University of Basel; University of Basel; University of Basel	Schaefer, T (corresponding author), Univ Basel, Basel, Switzerland.; Schaefer, T (corresponding author), Univ Hosp Basel, Dept Biomed, Basel, Switzerland.	thorsten.schaefer@unibas.ch	Lengerke, Claudia/AAV-8745-2021	Lengerke, Claudia/0000-0001-5442-2805; Schaefer, Thorsten/0000-0003-4867-8374	University of Basel Forschungsfonds [DMS-2351]	University of Basel Forschungsfonds	We acknowledge funding assigned to TS through the University of Basel Forschungsfonds (Grant No. DMS-2351) and apologize to authors whose work could not be cited or laid out in further detail due to reference or space limitations.	Arnold K, 2011, CELL STEM CELL, V9, P317, DOI 10.1016/j.stem.2011.09.001; Asanuma K, 2016, GUT, V65, P1416, DOI 10.1136/gutjnl-2015-309272; Asonuma S, 2009, AM J PHYSIOL-GASTR L, V297, pG312, DOI 10.1152/ajpgi.00518.2007; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Baltus GA, 2009, STEM CELLS, V27, P2175, DOI 10.1002/stem.168; Bareiss PM, 2013, CANCER RES, V73, P5544, DOI 10.1158/0008-5472.CAN-12-4177; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Biernaskie J, 2009, CELL STEM CELL, V5, P610, DOI 10.1016/j.stem.2009.10.019; Blanco S, 2016, NATURE, V534, P335, DOI 10.1038/nature18282; Boucher J, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a009191; Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305; Bowles J, 2000, DEV BIOL, V227, P239, DOI 10.1006/dbio.2000.9883; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Carrasco-Garcia E, 2016, AM J CANCER RES, V6, P701; Driskell RR, 2009, DEVELOPMENT, V136, P2815, DOI 10.1242/dev.038620; Fang L, 2014, MOL CELL, V55, P537, DOI 10.1016/j.molcel.2014.06.018; Fang XF, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-11; Fang XF, 2011, PROTEOMICS, V11, P921, DOI 10.1002/pmic.201000419; Feng RP, 2015, BIOL CHEM, V396, P883, DOI 10.1515/hsz-2014-0317; Fernandes KJL, 2004, NAT CELL BIOL, V6, P1082, DOI 10.1038/ncb1181; Foulk R A, 2001, Early Pregnancy, V5, P61; Gao FR, 2009, J BIOL CHEM, V284, P22263, DOI 10.1074/jbc.M109.033118; Gargini R, 2015, STEM CELLS, V33, P646, DOI 10.1002/stem.1904; Garros-Regulez L, 2016, EXPERT OPIN THER TAR, V20, P393, DOI 10.1517/14728222.2016.1151002; Gasca S, 2002, P NATL ACAD SCI USA, V99, P11199, DOI 10.1073/pnas.172383099; Gaullier G, 2017, MOL CELL, V65, P581, DOI 10.1016/j.molcel.2017.02.001; Gen Y, 2013, CANCER SCI, V104, P810, DOI 10.1111/cas.12155; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Golden BDO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076345; GRANA X, 1995, ONCOGENE, V11, P211; Grimm D, 2020, SEMIN CANCER BIOL, V67, P122, DOI 10.1016/j.semcancer.2019.03.004; Gunawardena J, 2010, SCIENCE, V328, P581, DOI 10.1126/science.1188974; Guth SIE, 2008, CELL MOL LIFE SCI, V65, P3000, DOI 10.1007/s00018-008-8138-7; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hietakangas V, 2006, P NATL ACAD SCI USA, V103, P45, DOI 10.1073/pnas.0503698102; Hori N, 2012, J BIOL CHEM, V287, P44006, DOI 10.1074/jbc.M112.424580; Hossini AM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154770; Hou LL, 2017, SEMIN CELL DEV BIOL, V63, P2, DOI 10.1016/j.semcdb.2016.08.005; Ikushima H, 2011, J BIOL CHEM, V286, P41434, DOI 10.1074/jbc.M111.300863; Jang H, 2012, CELL STEM CELL, V11, P62, DOI 10.1016/j.stem.2012.03.001; Jeong CH, 2010, STEM CELLS, V28, P2141, DOI 10.1002/stem.540; Jeong HC, 2017, STEM CELLS, V35, P2037, DOI 10.1002/stem.2642; Josse L, 2016, BIOCHEM J, V473, P4651, DOI 10.1042/BCJ20160845; Juuri E, 2013, DEVELOPMENT, V140, P1424, DOI 10.1242/dev.089599; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Kamachi Y, 2001, GENE DEV, V15, P1272, DOI 10.1101/gad.887101; Kamachi Y, 2013, DEVELOPMENT, V140, P4129, DOI 10.1242/dev.091793; Kim BR, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002581; Knauss JL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0840-2; Kopp JL, 2008, STEM CELLS, V26, P903, DOI 10.1634/stemcells.2007-0951; Koren S, 2015, NATURE, V525, P114, DOI 10.1038/nature14669; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; Krol I, 2018, BRIT J CANCER, V119, P487, DOI 10.1038/s41416-018-0186-7; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Lengerke C, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-42; Li J, 2007, J BIOL CHEM, V282, P19481, DOI 10.1074/jbc.M702056200; Liao CH, 2018, STEM CELLS, V36, P1514, DOI 10.1002/stem.2862; Liao XH, 2008, AMINO ACIDS, V35, P761, DOI 10.1007/s00726-008-0100-3; Liu TH, 2016, SCI REP-UK, V6, DOI 10.1038/srep28946; Liu ZY, 2017, MOL CELL, V65, P589, DOI 10.1016/j.molcel.2017.01.017; Luo JF, 2018, AM J TRANSL RES, V10, P639; Mackenzie RWA, 2014, DIABETES METAB SYNDR, V7, P55, DOI 10.2147/DMSO.S48260; Maier S, 2011, HUM PATHOL, V42, P1078, DOI 10.1016/j.humpath.2010.11.010; Malak PN, 2015, CELL CYCLE, V14, P3748, DOI 10.1080/15384101.2015.1104444; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Mansouri Sheila, 2016, CNS Oncol, V5, P159, DOI 10.2217/cns-2016-0001; Mao J, 2014, STEM CELLS DEV, V23, P779, DOI 10.1089/scd.2013.0325; Martelli AM, 2011, CURR MED CHEM, V18, P2715; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Matsuda K, 2008, SCAND J GASTROENTERO, V43, P25, DOI 10.1080/00365520701579795; Matsushima D, 2011, DEVELOPMENT, V138, P443, DOI 10.1242/dev.055178; Mehta GA, 2017, BREAST CANCER RES TR, V162, P439, DOI 10.1007/s10549-017-4139-2; Meyuhas O, 2015, INT REV CEL MOL BIO, V320, P41, DOI 10.1016/bs.ircmb.2015.07.006; Miinea CP, 2005, BIOCHEM J, V391, P87, DOI 10.1042/BJ20050887; Myers SA, 2016, ELIFE, V5, DOI 10.7554/eLife.10647; Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374; Nicoletti F, 2007, TRENDS PHARMACOL SCI, V28, P206, DOI 10.1016/j.tips.2007.03.008; Nowling TK, 2000, J BIOL CHEM, V275, P3810, DOI 10.1074/jbc.275.6.3810; Otsubo T, 2008, BRIT J CANCER, V98, P824, DOI 10.1038/sj.bjc.6604193; Pham DL, 2013, INT J GYNECOL PATHOL, V32, P358, DOI 10.1097/PGP.0b013e31826a642b; Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064; Qin J, 2015, ONCOTARGET, V6, P6944, DOI 10.18632/oncotarget.3128; Que J, 2007, DEVELOPMENT, V134, P2521, DOI 10.1242/dev.003855; Ren CM, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0321-3; Rigbolt KTG, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001570; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Sarkar A, 2016, CELL REP, V16, P1929, DOI 10.1016/j.celrep.2016.07.034; Schaefer T, 2019, BRAIN PATHOL, V29, P336, DOI 10.1111/bpa.12670; Schaefer T, 2015, ONCOTARGET, V6, P43540, DOI 10.18632/oncotarget.6183; Schaefer T, 2015, CELL CYCLE, V14, P3784, DOI 10.1080/15384101.2015.1115642; Schepers GE, 2002, DEV CELL, V3, P167, DOI 10.1016/S1534-5807(02)00223-X; Schneider A, 2009, AM J MED GENET A, V149A, P2706, DOI 10.1002/ajmg.a.33098; Schrock A, 2014, CARCINOGENESIS, V35, P1636, DOI 10.1093/carcin/bgu094; Schrock A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059201; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Sendoel A, 2017, NATURE, V541, P494, DOI 10.1038/nature21036; Sharma NS, O GLCNAC MODIFICATIO, DOI 10.1101/345223; Siddle K, 2011, J MOL ENDOCRINOL, V47, pR1, DOI 10.1530/JME-11-0022; Signer RAJ, 2014, NATURE, V509, P49, DOI 10.1038/nature13035; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tang JM, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0074-2; Taranova OV, 2006, GENE DEV, V20, P1187, DOI 10.1101/gad.1407906; Thevenet L, 2004, EMBO J, V23, P3336, DOI 10.1038/sj.emboj.7600352; Tripathi SC, 2017, CANCER RES, V77, P4414, DOI 10.1158/0008-5472.CAN-16-2874; Tsuruzoe S, 2006, BIOCHEM BIOPH RES CO, V351, P920, DOI 10.1016/j.bbrc.2006.10.130; Van Hoof D, 2009, CELL STEM CELL, V5, P214, DOI 10.1016/j.stem.2009.05.021; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Velcheti V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061427; Wahl GM, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0012-z; Wang K, 2018, ORGANOMETALLICS, V37, P1, DOI 10.1021/acs.organomet.7b00657; Wang SM, 2015, CANCER LETT, V358, P210, DOI 10.1016/j.canlet.2014.12.045; Wang Z, 2019, ONCOGENE, V38, P5250, DOI 10.1038/s41388-019-0790-x; Wilbertz T, 2011, MODERN PATHOL, V24, P944, DOI 10.1038/modpathol.2011.49; Williamson KA, 2006, HUM MOL GENET, V15, P1413, DOI 10.1093/hmg/ddl064; Wilson M, 2002, CURR OPIN GENET DEV, V12, P441, DOI 10.1016/S0959-437X(02)00323-4; Wissmuller S, 2006, NUCLEIC ACIDS RES, V34, P1735, DOI 10.1093/nar/gkl105; Wuebben EL, 2017, ONCOTARGET, V8, P44917, DOI 10.18632/oncotarget.16570; Yesudhas D, 2017, FEBS OPEN BIO, V7, P1750, DOI 10.1002/2211-5463.12316; Zhang JC, 2012, CANCER RES, V72, P4597, DOI 10.1158/0008-5472.CAN-12-1045; Zhang J, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0207-y; Zhao HY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027026; Zhao SL, 2004, MOL CELL NEUROSCI, V27, P332, DOI 10.1016/j.mcn.2004.08.002	124	65	67	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					278	292		10.1038/s41388-019-0997-x	http://dx.doi.org/10.1038/s41388-019-0997-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477842	Green Published, hybrid			2022-12-17	WOS:000507766400003
J	Kong, FY; Deng, X; Kong, XY; Du, YQ; Li, L; Zhu, HY; Wang, YX; Xie, DC; Guha, S; Li, ZS; Guan, M; Xie, KP				Kong, Fanyang; Deng, Xuan; Kong, Xiangyu; Du, Yiqi; Li, Lei; Zhu, Huiyun; Wang, Yuxin; Xie, Dacheng; Guha, Shivani; Li, Zhaoshen; Guan, Ming; Xie, Keping			ZFPM2-AS1, a novel IncRNA, attenuates the p53 pathway and promotes gastric carcinogenesis by stabilizing MIF	ONCOGENE			English	Article							MIGRATION-INHIBITORY FACTOR; LONG NONCODING RNAS; MOLECULAR-MECHANISMS; PANCREATIC-CANCER; CELL-PROLIFERATION; ANTISENSE LNCRNA; EXPRESSION; PROGRESSION; GROWTH; ADENOCARCINOMA	Long non-coding RNAs (lncRNAs) are implicated to be involved in the pathogenesis of many cancers. Herein we report on our discovery of a novel lncRNA, ZFPM2 antisense RNA 1 (ZFPM2-AS1), and its critical role in gastric carcinogenesis. ZFPM2-AS1 expression in gastric cancer specimens was analyzed using Gene Expression Omnibus data set and validated in 73 paired gastric tumor and normal adjacent gastric tissue specimens using qRT-PCR. The effect of ZFPM2-AS1 expression on proliferation and apoptosis in gastric cancer cells was assessed by altering its expression in vitro and in vivo. Mechanistic investigation was carried out using cell and molecular biological approaches. ZFPM2-AS1 expression was higher in gastric tumors than in normal gastric tissue. Also, increased ZFPM2-AS1 expression in gastric cancer specimens was associated with tumor size, depth of tumor invasion, differentiation grade, and TNM stage. High ZFPM2-AS1 expression predicted markedly reduced overall and disease-free survival in gastric cancer patients. Functional experiments demonstrated that ZFPM2-AS1 expression promoted proliferation and suppressed apoptosis of gastric cancer cells in vitro and promoted tumor growth in vivo. This effect is associated with attenuated nuclear translocation of p53. Mechanistic experiments demonstrated that tumor-activated ZFPM2-AS1 could bind to and protect the degradation of macrophage migration inhibitory factor (MIF), a potent destabilizer of p53. Knockdown of MIF expression diminished ZFPM2-AS1's impact on p53 expression in gastric cancer cells. Our findings demonstrated that ZFPM2-AS1 regulates gastric cancer progression and revealed a novel ZFPM2-AS1/MIF/p53 signaling axis, shedding light on the molecular mechanisms underlying the tumorigenicity of certain malignant gastric cells.	[Kong, Fanyang; Kong, Xiangyu; Du, Yiqi; Li, Lei; Zhu, Huiyun; Wang, Yuxin; Li, Zhaoshen] Second Mil Med Univ, Changhai Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Kong, Fanyang; Kong, Xiangyu; Xie, Dacheng; Guha, Shivani; Xie, Keping] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA; [Deng, Xuan; Guan, Ming] Fudan Univ, Huashan Hosp, Shanghai Med Coll, Dept Lab Med, Shanghai, Peoples R China	Naval Medical University; University of Texas System; UTMD Anderson Cancer Center; Fudan University	Li, ZS (corresponding author), Second Mil Med Univ, Changhai Hosp, Dept Gastroenterol, Shanghai, Peoples R China.; Xie, KP (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA.; Guan, M (corresponding author), Fudan Univ, Huashan Hosp, Shanghai Med Coll, Dept Lab Med, Shanghai, Peoples R China.	zhaoshenli5610@hotmail.com; guanminghsyy@hotmail.com; kepxie@mdanderson.org	Zhu, Huiyun/S-8032-2019		National Cancer Institute, National Institutes of Health [R01CA172233, R01CA195651, R01CA198090]; National Natural Science Foundation of China [81772640]; NATIONAL CANCER INSTITUTE [R01CA198090, R01CA195651, R01CA172233, R01CA220236, R21CA140999] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants R01CA172233, R01CA195651, and R01CA198090 from the National Cancer Institute, National Institutes of Health (to K.X.) and grant 81772640 from the National Natural Science Foundation of China (to X.K.).	Amit-Avraham I, 2015, P NATL ACAD SCI USA, V112, pE982, DOI 10.1073/pnas.1420855112; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Beermann J, 2016, PHYSIOL REV, V96, P1297, DOI 10.1152/physrev.00041.2015; Bellini MF, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/891961; Brock SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099795; Conroy H, 2010, QJM-INT J MED, V103, P831, DOI 10.1093/qjmed/hcq148; Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663; Dessein AF, 2010, CANCER RES, V70, P4644, DOI 10.1158/0008-5472.CAN-09-3828; Dimitrova N, 2014, MOL CELL, V54, P777, DOI 10.1016/j.molcel.2014.04.025; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Fu M, 2016, ONCOL REP, V36, P1207, DOI 10.3892/or.2016.4929; Fukaya R, 2016, CANCER RES, V76, P2813, DOI 10.1158/0008-5472.CAN-15-1011; GABBERT HE, 1995, CANCER, V76, P720, DOI 10.1002/1097-0142(19950901)76:5<720::AID-CNCR2820760503>3.0.CO;2-E; Guo K, 2017, CLIN CANCER RES, V23, P687, DOI 10.1158/1078-0432.CCR-16-1064; He XX, 2006, GUT, V55, P797, DOI 10.1136/gut.2005.078113; Huang B, 2016, ONCOGENE, V35, P4927, DOI 10.1038/onc.2016.25; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040; Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848; IMAZEKI F, 1992, GASTROENTEROLOGY, V103, P892, DOI 10.1016/0016-5085(92)90022-Q; Jung H, 2008, J BIOL CHEM, V283, P32669, DOI 10.1074/jbc.M806225200; Jung HY, 2008, J BIOL CHEM, V283, P20383, DOI 10.1074/jbc.M800050200; Katayama S, 2005, SCIENCE, V309, P1564, DOI 10.1126/science.1112009; Kong FY, 2017, CANCER RES, V77, P6851, DOI 10.1158/0008-5472.CAN-17-0067; Larsen M, 2008, CANCER LETT, V265, P239, DOI 10.1016/j.canlet.2008.02.012; Li TW, 2016, ONCOTARGET, V7, P8601, DOI 10.18632/oncotarget.6926; Lin YS, 2011, WORLD J GASTROENTERO, V17, P4421, DOI 10.3748/wjg.v17.i39.4421; Lopez-Saez JF, 1998, HISTOL HISTOPATHOL, V13, P1197, DOI 10.14670/HH-13.1197; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Oda S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002215; Pardal R, 2005, COLD SH Q B, V70, P177, DOI 10.1101/sqb.2005.70.057; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Salminen A, 2011, CELL SIGNAL, V23, P747, DOI 10.1016/j.cellsig.2010.10.012; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Schulz R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.508; Schulz R, 2012, J EXP MED, V209, P275, DOI 10.1084/jem.20111117; Shi XF, 2015, TUMOR BIOL, V36, P503, DOI 10.1007/s13277-015-3106-y; Shun CT, 2005, WORLD J GASTROENTERO, V11, P3767, DOI 10.3748/wjg.v11.i24.3767; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sugano K, 2015, BEST PRACT RES CL GA, V29, P895, DOI 10.1016/j.bpg.2015.09.013; Sun BL, 2003, INT J MOL MED, V12, P633; Tan P, 2015, GASTROENTEROLOGY, V149, P1153, DOI 10.1053/j.gastro.2015.05.059; Tripathi V, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003368; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Villegas VE, 2015, INT J MOL SCI, V16, P3251, DOI 10.3390/ijms16023251; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wei N, 2015, ANIM GENET, V46, P133, DOI 10.1111/age.12275; Werner A, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-31; Wight M, 2013, ESSAYS BIOCHEM, V54, P91, DOI [10.1042/bse0540091, 10.1042/BSE0540091]; Winner M, 2007, CANCER RES, V67, P186, DOI 10.1158/0008-5472.CAN-06-3292; Yang SH, 2016, CANCER RES, V76, P3838, DOI 10.1158/0008-5472.CAN-15-2841; Zhang CL, 2017, CANCER LETT, V396, P66, DOI 10.1016/j.canlet.2017.03.018	52	65	68	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2018	37	45					5982	5996		10.1038/s41388-018-0387-9	http://dx.doi.org/10.1038/s41388-018-0387-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GZ6PQ	29985481	Green Accepted			2022-12-17	WOS:000449562500006
J	Gala, K; Li, Q; Sinha, A; Razavi, P; Dorso, M; Sanchez-Vega, F; Chung, YR; Hendrickson, R; Hsieh, JJ; Berger, M; Schultz, N; Pastore, A; Abdel-Wahab, O; Chandarlapaty, S				Gala, Kinisha; Li, Qing; Sinha, Amit; Razavi, Pedram; Dorso, Madeline; Sanchez-Vega, Francisco; Chung, Young Rock; Hendrickson, Ronald; Hsieh, James J.; Berger, Michael; Schultz, Nikolaus; Pastore, Alessandro; Abdel-Wahab, Omar; Chandarlapaty, Sarat			KMT2C mediates the estrogen dependence of breast cancer through regulation of ER alpha enhancer function	ONCOGENE			English	Article							ACTIVATING SIGNAL COINTEGRATOR-2; METHYLTRANSFERASE MLL3; GENE-EXPRESSION; CRUCIAL ROLES; DNA-BINDING; RECEPTOR; COMPLEX; TUMORS; BRAF(V600E); MACROPHAGE	Estrogen receptor alpha (ER alpha) is a ligand-activated nuclear receptor that directs proliferation and differentiation in selected cancer cell types including mammary-derived carcinomas. These master-regulatory functions of ER alpha require trans-acting elements such as the pioneer factor FOXA1 to establish a genomic landscape conducive to ER alpha control. Here, we identify the H3K4 methyltransferase KMT2C as necessary for hormone-driven ER alpha activity and breast cancer proliferation. KMT2C knockdown suppresses estrogen-dependent gene expression and causes H3K4me1 and H3K27ac loss selectively at ER alpha enhancers. Correspondingly, KMT2C loss impairs estrogen-driven breast cancer proliferation but has no effect on ER- breast cells. Whereas KMT2C loss disrupts estrogen-driven proliferation, it conversely promotes tumor outgrowth under hormone-depleted conditions. In accordance, KMT2C is one of the most frequently mutated genes in ER-positive breast cancer with KMT2C deletion correlating with significantly shorter progression-free survival on anti-estrogen therapy. From a therapeutic standpoint, KMT2C-depleted cells that develop hormone-independence retain their dependence on ER alpha, displaying ongoing sensitivity to ER alpha antagonists. We conclude that KMT2C is a key regulator of ER alpha activity whose loss uncouples breast cancer proliferation from hormone abundance.	[Gala, Kinisha; Chandarlapaty, Sarat] Mem Sloan Kettering Canc Ctr, Louis V Gerstner Jr Grad Sch Biomed Sci, Sloan Kettering Inst, 1275 York Ave, New York, NY 10021 USA; [Gala, Kinisha; Li, Qing; Razavi, Pedram; Dorso, Madeline; Chung, Young Rock; Berger, Michael; Abdel-Wahab, Omar; Chandarlapaty, Sarat] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA; [Sinha, Amit] Basepair Inc, New York, NY USA; [Sanchez-Vega, Francisco; Hsieh, James J.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; [Hendrickson, Ronald] Mem Sloan Kettering Canc Ctr, Microchem & Prote Core Facil, 1275 York Ave, New York, NY 10021 USA; [Schultz, Nikolaus; Pastore, Alessandro] Mem Sloan Kettering Canc Ctr, Computat Biol Program, 1275 York Ave, New York, NY 10021 USA; [Chandarlapaty, Sarat] Weill Cornell Med Coll, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Washington University (WUSTL); Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Chandarlapaty, S (corresponding author), Mem Sloan Kettering Canc Ctr, Louis V Gerstner Jr Grad Sch Biomed Sci, Sloan Kettering Inst, 1275 York Ave, New York, NY 10021 USA.; Chandarlapaty, S (corresponding author), Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA.; Chandarlapaty, S (corresponding author), Weill Cornell Med Coll, New York, NY 10065 USA.	chandars@mskcc.org	Schultz, Nikolaus/ABE-6347-2020	Chung, Young Rock/0000-0001-5752-8322; Sanchez-Vega, Francisco/0000-0002-2990-4893; Razavi, Pedram/0000-0003-4236-0576	Anna Fuller Foundation; Cancer Couch Foundation; NCI Cancer Center Support Grant (CCSG) [P30 CA08748]; Susan G. Komen Foundation; Geoffrey Beene Cancer Research Center; Grayer Fellowship; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	Anna Fuller Foundation; Cancer Couch Foundation; NCI Cancer Center Support Grant (CCSG); Susan G. Komen Foundation(Susan G. Komen Breast Cancer Foundation); Geoffrey Beene Cancer Research Center; Grayer Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank P. Chi for plasmids and cells, C. Sawyers for plasmids, M. Jasin and S. Lowe for mice and S. Monette for assistance with mouse pathology. We would like to thank J. Reis-Filho, W. Toy, Z. Li, A. Smith, R. Levine, N. Rosen and P. Chi for their helpful discussions. This work was funded by generous support of the Anna Fuller Foundation, the Cancer Couch Foundation, and the NCI Cancer Center Support Grant (CCSG, P30 CA08748). SC is funded by the Susan G. Komen Foundation. KG is funded by the Geoffrey Beene Cancer Research Center and a Grayer Fellowship. AP is a Mildred-Scheel Postdoctoral Research Fellow of the Deutsche Krebshilfe e.V.	Ananthanarayanan M, 2011, AM J PHYSIOL-GASTR L, V300, pG771, DOI 10.1152/ajpgi.00499.2010; Ansari KI, 2012, J MOL ENDOCRINOL, V48, P61, DOI 10.1530/JME-11-0078; Ansari KI, 2011, J MOL BIOL, V411, P334, DOI 10.1016/j.jmb.2011.05.050; Ansari KI, 2011, BIOCHEMISTRY-US, V50, P3517, DOI 10.1021/bi102037t; Bhan A, 2013, J MOL BIOL, V425, P3707, DOI 10.1016/j.jmb.2013.01.022; Calo E, 2013, MOL CELL, V49, P825, DOI 10.1016/j.molcel.2013.01.038; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chen C, 2014, CANCER CELL, V25, P652, DOI 10.1016/j.ccr.2014.03.016; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143; Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dumont JA, 1996, CELL GROWTH DIFFER, V7, P351; Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143; Fellmann C, 2013, CELL REP, V5, P1704, DOI 10.1016/j.celrep.2013.11.020; Feng Y, 2007, P NATL ACAD SCI USA, V104, P14718, DOI 10.1073/pnas.0706933104; Flockhart RJ, 2012, GENOME RES, V22, P1006, DOI 10.1101/gr.140061.112; Goo YH, 2003, MOL CELL BIOL, V23, P140, DOI 10.1128/MCB.23.1.140-149.2003; Guo XY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0328-y; Gutierrez MC, 2005, J CLIN ONCOL, V23, P2469, DOI 10.1200/JCO.2005.01.172; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Hsu PD, 2013, NAT BIOTECHNOL, V31, P827, DOI 10.1038/nbt.2647; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Jeng MH, 1998, ENDOCRINOLOGY, V139, P4164, DOI 10.1210/en.139.10.4164; Johnston SRD, 1999, CLIN CANCER RES, V5, P251; Joseph R, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.109; Kaikkonen MU, 2013, MOL CELL, V51, P310, DOI 10.1016/j.molcel.2013.07.010; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kannengiesser C, 2008, MOL ONCOL, V1, P425, DOI 10.1016/j.molonc.2008.01.002; Kim DH, 2015, HEPATOLOGY, V61, P1012, DOI 10.1002/hep.27578; Kim DH, 2009, MOL ENDOCRINOL, V23, P1556, DOI 10.1210/me.2009-0099; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Lee J, 2009, P NATL ACAD SCI USA, V106, P8513, DOI 10.1073/pnas.0902873106; Lee JE, 2013, ELIFE, V2, DOI 10.7554/eLife.01503; Lee S, 2008, MOL ENDOCRINOL, V22, P1312, DOI 10.1210/me.2008-0012; Lee S, 2009, MOL ENDOCRINOL, V23, P610, DOI 10.1210/me.2008-0455; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Malorni L, 2016, MOL CANCER RES, V14, P470, DOI 10.1158/1541-7786.MCR-15-0423; MASAMURA S, 1995, J CLIN ENDOCR METAB, V80, P2918, DOI 10.1210/jc.80.10.2918; Mohammed H, 2016, NAT PROTOC, V11, P316, DOI 10.1038/nprot.2016.020; Mohammed H, 2015, NATURE, V523, P313, DOI 10.1038/nature14583; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Razavi P, 2016, CANC RES; Richart L, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2016.1152346; Richart L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10153; Sato K, 2016, CLIN BREAST CANCER, V17, pe135; Schiff R, 2000, J NATL CANCER I, V92, P1926, DOI 10.1093/jnci/92.23.1926; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Valekunja UK, 2013, P NATL ACAD SCI USA, V110, P1554, DOI 10.1073/pnas.1214168110; Wang CY, 2011, MOL ENDOCRINOL, V25, P1527, DOI 10.1210/me.2011-1037; Wellbrock C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002734; Won HH, 2013, JOVE-J VIS EXP, V80, P50710; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zhang Z, 2016, CELL REP, V16, P3146, DOI 10.1016/j.celrep.2016.08.048; Zhou YM, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-59	60	65	67	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2018	37	34					4692	4710		10.1038/s41388-018-0273-5	http://dx.doi.org/10.1038/s41388-018-0273-5			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GR3SE	29755131	Green Accepted, hybrid, Green Published			2022-12-17	WOS:000442514400005
J	Tran, DDH; Kessler, C; Niehus, SE; Mahnkopf, M; Koch, A; Tamura, T				Tran, D. D. H.; Kessler, C.; Niehus, S. E.; Mahnkopf, M.; Koch, A.; Tamura, T.			Myc target gene, long intergenic noncoding RNA, Linc00176 in hepatocellular carcinoma regulates cell cycle and cell survival by titrating tumor suppressor microRNAs	ONCOGENE			English	Article							GENOME; GROWTH; IDENTIFICATION; PROLIFERATION; EXPRESSION; PROGNOSIS; APOPTOSIS; PROTEIN	Hepatocellular carcinoma (HCC) is a frequent form of cancer with a poor prognosis and with limited possibilities for medical intervention. Recent evidence has accumulated that long noncoding RNAs (lncRNAs) are important regulators of disease processes including cancer. Chromatin remodeling in cancer cells may result in an unusual expression of lncRNAs and indeed it has been shown that more than 7000 unannotated lncRNAs are expressed in HCCs. We identified a novel long intergenic noncoding RNA, Linc00176, that plays a role in proliferation and survival of HCC. Linc00176 regulates expression of more than 200 genes by the sponge function for tumor suppressor miRNAs, miR-9 and miR-185. Linc00176 is expressed at a high level only in HCC, and is activated by Myc, Max and AP-4 transcription regulators. Myc also upregulates miR-9 and miR-185. In Linc00176-depleted HCC, these miRNAs were released from Linc00176 and downregulated their target mRNAs. Thus, depletion of Linc00176 disrupted the cell cycle and induced necroptosis in HCC via released tumor suppressor miRNAs. These data indicate that atypically expressed lncRNAs may be useful targets for cancer therapy.	[Tran, D. D. H.; Kessler, C.; Niehus, S. E.; Mahnkopf, M.; Koch, A.; Tamura, T.] Hannover Med Sch, Inst Biochem, OE4310,Carl Neuberg Str 1, D-30623 Hannover, Germany	Hannover Medical School	Tamura, T (corresponding author), Hannover Med Sch, Inst Biochem, OE4310,Carl Neuberg Str 1, D-30623 Hannover, Germany.	Tamura.Teruko@MH-Hannover.de	Tran, Doan Duy Hai/AGU-7573-2022	Tran, Doan Duy Hai/0000-0003-2392-0259	Deutsche Krebshilfe [111153]; DFG [Ta-111/13-3]; Niedersachsische Krebsgesellschaft; DDHT, PhD program Molecular Medicine and Structure Medicine in HBRS; Leistungsorientierte Mittelvergabe; Frauenfaktor from MHH	Deutsche Krebshilfe(Deutsche Krebshilfe); DFG(German Research Foundation (DFG)); Niedersachsische Krebsgesellschaft; DDHT, PhD program Molecular Medicine and Structure Medicine in HBRS; Leistungsorientierte Mittelvergabe; Frauenfaktor from MHH	We thank C Bruce Boschek for critically reading the manuscript. This work is a part of thesis of CK. This research was supported by Deutsche Krebshilfe (111153), DFG Ta-111/13-3, Niedersachsische Krebsgesellschaft to AK and DDHT, PhD program Molecular Medicine and Structure Medicine in HBRS and Leistungsorientierte Mittelvergabe with Frauenfaktor from MHH.	Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90; Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; Cai L, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0228-2; Chen LL, 2016, TRENDS BIOCHEM SCI, V41, P761, DOI 10.1016/j.tibs.2016.07.003; Dang YW, 2014, ASIAN PAC J CANCER P, V15, P4969, DOI 10.7314/APJCP.2014.15.12.4969; Deng HX, 2011, CANCER BIOL THER, V11, P401, DOI 10.4161/cbt.11.4.14178; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Tran DDH, 2016, CELL SIGNAL, V28, P1872, DOI 10.1016/j.cellsig.2016.09.002; Drakaki A, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1562-9; Evans JR, 2016, J CLIN INVEST, V126, P2775, DOI 10.1172/JCI84421; Ferrin G, 2015, HEPATIC MED-EVID RES, V7, P1, DOI 10.2147/HMER.S50161; Guria A, 2011, RNA, V17, P1048, DOI 10.1261/rna.2607011; Higashi T, 2015, BRIT J CANCER, V113, P252, DOI 10.1038/bjc.2015.170; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jung P, 2009, CELL CYCLE, V8, P982, DOI 10.4161/cc.8.7.7949; Kim HS, 2015, ONCOTARGET, V6, P8089, DOI 10.18632/oncotarget.3512; Levens David, 2008, J Natl Cancer Inst Monogr, P41, DOI 10.1093/jncimonographs/lgn004; Liu SJ, 2017, SCIENCE, V355, DOI 10.1126/science.aah7111; Luscher B, 2012, GENE, V494, P145, DOI 10.1016/j.gene.2011.12.027; Martin G, 2012, CELL REP, V1, P753, DOI 10.1016/j.celrep.2012.05.003; Padgett RA, 2012, TRENDS GENET, V28, P147, DOI 10.1016/j.tig.2012.01.001; Qadir XV, 2014, AM J PATHOL, V184, P2355, DOI 10.1016/j.ajpath.2014.05.004; Remijsen Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.531; Saran S, 2016, ONCOGENE, V35, P3872, DOI 10.1038/onc.2015.433; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Steitz JA, 2009, BIOCHEM SOC T, V37, P931, DOI 10.1042/BST0370931; Sun JC, 2015, INT J CLIN EXP MED, V8, P17748; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Wu WL, 2015, INT J MOL MED, V36, P1713, DOI 10.3892/ijmm.2015.2379; Yang JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023525; Yang Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14421; Yoon JH, 2012, METHODS, V58, P81, DOI 10.1016/j.ymeth.2012.07.004; Zhang JB, 2015, ONCOTARGET, V6, P42040, DOI 10.18632/oncotarget.5969; Zhu SY, 2016, NAT BIOTECHNOL, V34, P1279, DOI 10.1038/nbt.3715; Zhu XC, 2012, INT J MOL MED, V30, P1321, DOI 10.3892/ijmm.2012.1140	38	65	69	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2018	37	1					75	85		10.1038/onc.2017.312	http://dx.doi.org/10.1038/onc.2017.312			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS7YF	28869604				2022-12-17	WOS:000422625000008
J	Castro, BA; Flanigan, P; Jahangiri, A; Hoffman, D; Chen, W; Kuang, R; De Lay, M; Yagnik, G; Wagner, JR; Mascharak, S; Sidorov, M; Shrivastav, S; Kohanbash, G; Okada, H; Aghi, MK				Castro, B. A.; Flanigan, P.; Jahangiri, A.; Hoffman, D.; Chen, W.; Kuang, R.; De Lay, M.; Yagnik, G.; Wagner, J. R.; Mascharak, S.; Sidorov, M.; Shrivastav, S.; Kohanbash, G.; Okada, H.; Aghi, M. K.			Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy	ONCOGENE			English	Article							ANTIANGIOGENIC THERAPY; VEGF THERAPY; MESENCHYMAL TRANSITION; RECURRENT GLIOBLASTOMA; MEDIATES RESISTANCE; RECEPTOR CD74; CELL INVASION; POLARIZATION; SURVIVAL; CANCER	Anti-angiogenic therapies for cancer such as VEGF neutralizing antibody bevacizumab have limited durability. While mechanisms of resistance remain undefined, it is likely that acquired resistance to anti-angiogenic therapy will involve alterations of the tumor microenvironment. We confirmed increased tumor-associated macrophages in bevacizumab-resistant glioblastoma patient specimens and two novel glioblastoma xenograft models of bevacizumab resistance. Microarray analysis suggested downregulated macrophage migration inhibitory factor (MIF) to be the most pertinent mediator of increased macrophages. Bevacizumab-resistant patient glioblastomas and both novel xenograft models of resistance had less MIF than bevacizumab-naive tumors, and harbored more M2/protumoral macrophages that specifically localized to the tumor edge. Xenografts expressing MIF-shRNA grew more rapidly with greater angiogenesis and had macrophages localizing to the tumor edge which were more prevalent and proliferative, and displayed M2 polarization, whereas bevacizumab-resistant xenografts transduced to upregulate MIF exhibited the opposite changes. Bone marrow-derived macrophage were polarized to an M2 phenotype in the presence of condition-media derived from bevacizumab-resistant xenograft-derived cells, while recombinant MIF drove M1 polarization. Media from macrophages exposed to bevacizumab-resistant tumor cell conditioned media increased glioma cell proliferation compared with media from macrophages exposed to bevacizumab-responsive tumor cell media, suggesting that macrophage polarization in bevacizumab-resistant xenografts is the source of their aggressive biology and results from a secreted factor. Two mechanisms of bevacizumab-induced MIF reduction were identified: (1) bevacizumab bound MIF and blocked MIF-induced M1 polarization of macrophages; and (2) VEGF increased glioma MIF production in a VEGFR2-dependent manner, suggesting that bevacizumab-induced VEGF depletion would downregulate MIF. Site-directed biopsies revealed enriched MIF and VEGF at the enhancing edge in bevacizumab-naive patients. This MIF enrichment was lost in bevacizumab-resistant glioblastomas, driving a tumor edge M1-to-M2 transition. Thus, bevacizumab resistance is driven by reduced MIF at the tumor edge causing proliferative expansion of M2 macrophages, which in turn promotes tumor growth.	[Castro, B. A.; Flanigan, P.; Jahangiri, A.; Hoffman, D.; Chen, W.; Kuang, R.; De Lay, M.; Yagnik, G.; Wagner, J. R.; Mascharak, S.; Sidorov, M.; Shrivastav, S.; Kohanbash, G.; Okada, H.; Aghi, M. K.] Univ Calif San Francisco, Dept Neurol Surg, Diller Canc Res Bldg,1450 Third St Room HD-465, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Aghi, MK (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, Diller Canc Res Bldg,1450 Third St Room HD-465, San Francisco, CA 94158 USA.	aghim@neurosurg.ucsf.edu		Hoffman, Daniel/0000-0002-2302-6786; Chen, William/0000-0001-8924-5853; Flanigan, Patrick/0000-0002-3611-8575	American Brain Tumor Association (ABTA); James S. McDonnell Foundation; American Cancer Society (ACS); University of California Cancer Research Coordinating Committee; NIH [5K02NS64167, 1R01NS079697]; Howard Hughes Medical Institute (HHMI) fellowship; American Association of Neurological Surgeons (AANS); ABTA; UCSF School of Medicine (SOM) Pathways Explore Summer Grant; NATIONAL CANCER INSTITUTE [T32CA151022] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K02NS064167, R01NS079697] Funding Source: NIH RePORTER	American Brain Tumor Association (ABTA); James S. McDonnell Foundation; American Cancer Society (ACS)(American Cancer Society); University of California Cancer Research Coordinating Committee(University of California System); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Howard Hughes Medical Institute (HHMI) fellowship; American Association of Neurological Surgeons (AANS); ABTA; UCSF School of Medicine (SOM) Pathways Explore Summer Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	MKA was supported by the American Brain Tumor Association (ABTA), the James S. McDonnell Foundation, American Cancer Society (ACS), University of California Cancer Research Coordinating Committee and the NIH (5K02NS64167 and 1R01NS079697). BC was supported by the Howard Hughes Medical Institute (HHMI) fellowship, the American Association of Neurological Surgeons (AANS) and ABTA. DH was supported by the Howard Hughes Medical Institute (HHMI) fellowship. WC was supported by the UCSF School of Medicine (SOM) Pathways Explore Summer Grant.	Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Carbonell WS, 2013, CANCER RES, V73, P3145, DOI 10.1158/0008-5472.CAN-13-0011; Casazza A, 2013, CANCER CELL, V24, P695, DOI 10.1016/j.ccr.2013.11.007; Cho HR, 2016, ONCOTARGET, V7, P69606, DOI 10.18632/oncotarget.11901; Choudhary S, 2013, CARCINOGENESIS, V34, P2891, DOI 10.1093/carcin/bgt239; Clark AJ, 2012, NEUROSURGERY, V70, P361, DOI 10.1227/NEU.0b013e3182314f9d; de Groot JF, 2011, CLIN CANCER RES, V17, P6109, DOI 10.1158/1078-0432.CCR-11-1853; Delay M, 2012, CLIN CANCER RES, V18, P2930, DOI 10.1158/1078-0432.CCR-11-2390; Frentzas S, 2016, NAT MED, V22, P1294, DOI 10.1038/nm.4197; Gabrusiewicz K, 2014, ONCOTARGET, V5, P2208, DOI 10.18632/oncotarget.1893; Ghoochani A, 2016, ONCOGENE, V35, P6246, DOI 10.1038/onc.2016.160; Girard E, 2012, BRIT J CANCER, V107, P1498, DOI 10.1038/bjc.2012.392; Gupta Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146482; Hodi FS, 2014, CANCER IMMUNOL RES, V2, P632, DOI 10.1158/2326-6066.CIR-14-0053; Hoppstadter J, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00055; Hu YL, 2012, AUTOPHAGY, V8, P979, DOI 10.4161/auto.20232; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Jahangiri A, 2013, CLIN CANCER RES, V19, P1773, DOI 10.1158/1078-0432.CCR-12-1281; Jenkins SJ, 2011, SCIENCE, V332, P1284, DOI 10.1126/science.1204351; Kessler T, 2015, ONCOTARGET, V6, P31050, DOI 10.18632/oncotarget.2910; Kreisl TN, 2009, J CLIN ONCOL, V27, P740, DOI 10.1200/JCO.2008.16.3055; Leidi M, 2009, J IMMUNOL, V182, P4415, DOI 10.4049/jimmunol.0713732; Li JL, 2011, CANCER RES, V71, P6073, DOI 10.1158/0008-5472.CAN-11-1704; Li Z, 2004, CHINESE MED J-PEKING, V117, P107; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Lu-Emerson C, 2013, NEURO-ONCOLOGY, V15, P1079, DOI 10.1093/neuonc/not082; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mao XG, 2016, ONCOTARGET, V7, P47808, DOI 10.18632/oncotarget.10029; Martinez FO, 2014, F1000PRIME REP, V6, P13, DOI DOI 10.12703/P6-13; Meyer-Siegler KL, 2006, J IMMUNOL, V177, P8730, DOI 10.4049/jimmunol.177.12.8730; Mittelbronn M, 2011, ACTA NEUROPATHOL, V122, P353, DOI 10.1007/s00401-011-0858-3; Mizutani M, 2012, J IMMUNOL, V188, P29, DOI 10.4049/jimmunol.1100421; Moughon DL, 2015, CANCER RES, V75, P4742, DOI 10.1158/0008-5472.CAN-14-3373; Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6; Piao Y, 2016, NEURO-ONCOLOGY, V18, P1230, DOI 10.1093/neuonc/now030; Piao Y, 2013, CLIN CANCER RES, V19, P4392, DOI 10.1158/1078-0432.CCR-12-1557; Piao YJ, 2012, NEURO-ONCOLOGY, V14, P1379, DOI 10.1093/neuonc/nos158; Piette C, 2009, J BIOL CHEM, V284, P32483, DOI 10.1074/jbc.M109.014589; Rahbari NN, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf5219; Redente EF, 2010, J LEUKOCYTE BIOL, V88, P159, DOI 10.1189/jlb.0609378; Rubenstein JL, 2000, NEOPLASIA, V2, P306, DOI 10.1038/sj.neo.7900102; Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693; Scholz A, 2016, EMBO MOL MED, V8, P39, DOI 10.15252/emmm.201505505; Sun B, 2005, CLIN CANCER RES, V11, P1050; Thiele M, 2015, J IMMUNOL, V195, P2343, DOI 10.4049/jimmunol.1500572; Ueno T, 2000, CLIN CANCER RES, V6, P3282; Verschuren L, 2009, CIRC RES, V105, P99, DOI 10.1161/CIRCRESAHA.109.199166; Wang X, 2012, CANCER RES, V72, P2867, DOI 10.1158/0008-5472.CAN-11-3247; Wei J, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/285246; Yaddanapudi K, 2013, J IMMUNOL, V190, P2984, DOI 10.4049/jimmunol.1201650; Zeiner PS, 2015, BRAIN PATHOL, V25, P491, DOI 10.1111/bpa.12194	53	65	68	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3749	3759		10.1038/onc.2017.1	http://dx.doi.org/10.1038/onc.2017.1			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28218903	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000404349700010
J	Varga, MG; Shaffer, CL; Sierra, JC; Suarez, G; Piazuelo, MB; Whitaker, ME; Romero-Gallo, J; Krishna, US; Delgado, A; Gomez, MA; Good, JAD; Almqvist, F; Skaar, EP; Correa, P; Wilson, KT; Hadjifrangiskou, M; Peek, RM				Varga, M. G.; Shaffer, C. L.; Sierra, J. C.; Suarez, G.; Piazuelo, M. B.; Whitaker, M. E.; Romero-Gallo, J.; Krishna, U. S.; Delgado, A.; Gomez, M. A.; Good, J. A. D.; Almqvist, F.; Skaar, E. P.; Correa, P.; Wilson, K. T.; Hadjifrangiskou, M.; Peek, R. M.			Pathogenic Helicobacter pylori strains translocate DNA and activate TLR9 via the cancer-associated cag type IV secretion system	ONCOGENE			English	Article							GASTRIC EPITHELIAL-CELLS; PATTERN-RECOGNITION RECEPTORS; IN-VITRO; BACTERIAL; INDUCTION; RISK; INFECTION; ISLAND; GENES; CONJUGATION	Helicobacter pylori (H. pylori) is the strongest identified risk factor for gastric cancer, the third most common cause of cancer-related death worldwide. An H. pylori constituent that augments cancer risk is the strain-specific cag pathogenicity island, which encodes a type IV secretion system (T4SS) that translocates a pro-inflammatory and oncogenic protein, CagA, into epithelial cells. However, the majority of persons colonized with CagA+ H. pylori strains do not develop cancer, suggesting that other microbial effectors also have a role in carcinogenesis. Toll-like receptor 9 (TLR9) is an endosome bound, innate immune receptor that detects and responds to hypo-methylated CpG DNA motifs that are most commonly found in microbial genomes. High-expression tlr9 polymorphisms have been linked to the development of premalignant lesions in the stomach. We now demonstrate that levels of H. pylorimediated TLR9 activation and expression are directly related to gastric cancer risk in human populations. Mechanistically, we show for the first time that the H. pylori cancer-associated cag T4SS is required for TLR9 activation and that H. pylori DNA is actively translocated by the cag T4SS to engage this host receptor. Activation of TLR9 occurs through a contact-dependent mechanism between pathogen and host, and involves transfer of microbial DNA that is both protected as well as exposed during transport. These results indicate that TLR9 activation via the cag island may modify the risk for malignancy within the context of H. pylori infection and provide an important framework for future studies investigating the microbial-epithelial interface in gastric carcinogenesis.	[Varga, M. G.; Wilson, K. T.; Peek, R. M.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37212 USA; [Shaffer, C. L.; Skaar, E. P.; Wilson, K. T.; Hadjifrangiskou, M.; Peek, R. M.] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA; [Sierra, J. C.; Suarez, G.; Piazuelo, M. B.; Whitaker, M. E.; Romero-Gallo, J.; Krishna, U. S.; Delgado, A.; Correa, P.; Wilson, K. T.; Peek, R. M.] Vanderbilt Univ, Sch Med, Dept Med, Div Gastroenterol Hepatol & Nutr, Nashville, TN 37212 USA; [Gomez, M. A.] Univ Nacl Colombia, Dept Internal Med, Gastroenterol Unit, Sch Med, Bogota, Colombia; [Good, J. A. D.; Almqvist, F.] Umea Univ, Dept Chem, Umea, Sweden; [Good, J. A. D.; Almqvist, F.] Umea Univ, Umea Ctr Microbial Res, Umea, Sweden; [Skaar, E. P.; Wilson, K. T.] Vet Affairs Tennessee Valley Healthcare Syst, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Universidad Nacional de Colombia; Umea University; Umea University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Peek, RM (corresponding author), Vanderbilt Univ, Sch Med, Div Gastroenterol Hepatol & Nutr, Dept Med, 2215 Garland Ave 1030C Med Res Bldg 4, Nashville, TN 37232 USA.	richard.peek@vanderbilt.edu	Varga, Matthew Gordon/I-5056-2019; Shaffer, Carrie/X-6106-2019	Varga, Matthew Gordon/0000-0002-2075-3224; Wilson, Keith/0000-0003-4421-1830; Shaffer, Carrie L./0000-0002-7457-7422; Good, James/0000-0003-2377-030X; Almqvist, Fredrik/0000-0002-0504-4446; Gomez, Martin/0000-0002-2377-6544	NIH [R01-DK58587, R01-CA77955, P01-CA116087, P30-DK058404]; Vanderbilt CTSA grant from NCATS/NIH (VICTR award) [UL1 TR000445, VR7227]; Department of Veterans Affairs Merit Review grant [I01BX001453];  [APS 1-04-520-9211];  [R01-DK053620];  [R01-CA190612];  [P01-CA028842]; NATIONAL CANCER INSTITUTE [R01CA077955, P01CA028842, R01CA190612, P01CA116087] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000445] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT004821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058587, T35DK007383, P30DK058404, R01DK053620] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001453] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Vanderbilt CTSA grant from NCATS/NIH (VICTR award); Department of Veterans Affairs Merit Review grant(US Department of Veterans Affairs); ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	We acknowledge the following core laboratories and personnel at Vanderbilt University for their contributions to these studies: Tissue Acquisition and Pathology Core; Division of Animal Care; Cell Imaging Shared Resource Core (CISR) and the Digestive Disease Research Center. This work was supported by NIH R01-DK58587, R01-CA77955, P01-CA116087 and P30-DK058404 (RMP); Vanderbilt CTSA grant UL1 TR000445 from NCATS/NIH (VICTR award VR7227), APS 1-04-520-9211 and institutional funds (MH); R01-DK053620, R01-CA190612, and a Department of Veterans Affairs Merit Review grant I01BX001453 (KTW); and P01-CA028842 (KTW and PC).	Akopyants NS, 1998, MOL MICROBIOL, V28, P37, DOI 10.1046/j.1365-2958.1998.00770.x; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Alvarez-Arellano L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101342; Amieva M, 2016, GASTROENTEROLOGY, V150, P64, DOI 10.1053/j.gastro.2015.09.004; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; Barrozo RM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003189; Barton GM, 2008, J CLIN INVEST, V118, P413, DOI 10.1172/JCI34431; Basso D, 2008, GASTROENTEROLOGY, V135, P91, DOI 10.1053/j.gastro.2008.03.041; Bates S, 1998, J BACTERIOL, V180, P6538, DOI 10.1128/JB.180.24.6538-6543.1998; BLASER MJ, 1995, CANCER RES, V55, P2111; Bravo LE, 2002, AM J GASTROENTEROL, V97, P2839, DOI 10.1111/j.1572-0241.2002.07031.x; Cascales E, 2004, SCIENCE, V304, P1170, DOI 10.1126/science.1095211; Castano-Rodriguez N, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00336; Castano-Rodriguez N, 2014, HUM IMMUNOL, V75, P808, DOI 10.1016/j.humimm.2014.06.001; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Chang YJ, 2005, J IMMUNOL, V175, P8242, DOI 10.4049/jimmunol.175.12.8242; Chang YJ, 2004, MOL PHARMACOL, V66, P1465, DOI 10.1124/mol.104.005199; Chaturvedi R, 2015, ONCOGENE, V34, P3429, DOI 10.1038/onc.2014.273; CHILTON MD, 1977, CELL, V11, P263, DOI 10.1016/0092-8674(77)90043-5; Christie PJ, 2014, BBA-MOL CELL RES, V1843, P1578, DOI 10.1016/j.bbamcr.2013.12.019; Christie PJ, 1997, J BACTERIOL, V179, P3085, DOI 10.1128/jb.179.10.3085-3094.1997; CORREA P, 1976, JNCI-J NATL CANCER I, V57, P1027, DOI 10.1093/jnci/57.5.1027; CRABTREE JE, 1993, GUT, V34, P1339, DOI 10.1136/gut.34.10.1339; Crawford HC, 2003, GASTROENTEROLOGY, V125, P1125, DOI 10.1016/S0016-5085(03)01206-X; CUELLO C, 1976, JNCI-J NATL CANCER I, V57, P1015, DOI 10.1093/jnci/57.5.1015; Ernst PB, 2006, GASTROENTEROLOGY, V130, P188, DOI 10.1053/j.gastro.2005.06.032; Fernandez-Gonzalez E, 2014, J GASTROENTEROL, V49, P594, DOI 10.1007/s00535-014-0938-y; Fernandez-Gonzalez E, 2011, J BACTERIOL, V193, P6257, DOI 10.1128/JB.05905-11; Figueiredo C, 2002, J NATL CANCER I, V94, P1680, DOI 10.1093/jnci/94.22.1680; Fischer W, 2010, NUCLEIC ACIDS RES, V38, P6089, DOI 10.1093/nar/gkq378; Franco AT, 2005, P NATL ACAD SCI USA, V102, P10646, DOI 10.1073/pnas.0504927102; Hamilton HL, 2005, MOL MICROBIOL, V55, P1704, DOI 10.1111/j.1365-2958.2005.04521.x; HEINEMANN JA, 1989, NATURE, V340, P205, DOI 10.1038/340205a0; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Ilvesaro JM, 2008, MOL CANCER RES, V6, P1534, DOI 10.1158/1541-7786.MCR-07-2005; Johnson EM, 2014, INFECT IMMUN, V82, P3457, DOI 10.1128/IAI.01640-14; Kauppila JH, 2013, APMIS, V121, P511, DOI 10.1111/apm.12016; Kersulyte D, 2003, J BACTERIOL, V185, P3764, DOI 10.1128/JB.185.13.3764-3772.2003; KUIPERS EJ, 1995, J NATL CANCER I, V87, P1777, DOI 10.1093/jnci/87.23.1777; Kunik T, 2001, P NATL ACAD SCI USA, V98, P1871, DOI 10.1073/pnas.041327598; Linz B, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5165; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Otani K, 2012, BIOCHEM BIOPH RES CO, V426, P342, DOI 10.1016/j.bbrc.2012.08.080; Pachathundikandi SK, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/192420; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Polk DB, 2010, NAT REV CANCER, V10, P403, DOI 10.1038/nrc2857; Rad R, 2009, GASTROENTEROLOGY, V136, P2247, DOI 10.1053/j.gastro.2009.02.066; Schmausser B, 2004, CLIN EXP IMMUNOL, V136, P521, DOI 10.1111/j.1365-2249.2004.02464.x; Schroder G, 2011, P NATL ACAD SCI USA, V108, P14643, DOI 10.1073/pnas.1019074108; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Selbach M, 2002, J BIOL CHEM, V277, P6775, DOI 10.1074/jbc.C100754200; Shaffer CL, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002237; Sierra JC, 2013, AM J PHYSIOL-GASTR L, V305, pG196, DOI 10.1152/ajpgi.00495.2012; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Suarez G, 2015, CANCER RES, V75, P1749, DOI 10.1158/0008-5472.CAN-14-2291; Tammer I, 2007, GASTROENTEROLOGY, V132, P1309, DOI 10.1053/j.gastro.2007.01.050; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Torres J, 2005, CANCER EPIDEM BIOMAR, V14, P1874, DOI 10.1158/1055-9965.EPI-05-0113; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Wang TR, 2014, INT J CLIN EXP PATHO, V7, P6950; Waters VL, 2001, NAT GENET, V29, P375, DOI 10.1038/ng779	62	65	67	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6262	6269		10.1038/onc.2016.158	http://dx.doi.org/10.1038/onc.2016.158			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27157617	Green Accepted			2022-12-17	WOS:000388857700010
J	Mandal, R; Becker, S; Strebhardt, K				Mandal, R.; Becker, S.; Strebhardt, K.			Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy	ONCOGENE			English	Review							RECEPTOR TYROSINE KINASES; ACTIVATED PROTEIN-KINASES; I DOSE-ESCALATION; PHASE-I; ACQUIRED-RESISTANCE; ANTITUMOR-ACTIVITY; B-RAF; FEEDBACK PHOSPHORYLATION; CONSTITUTIVE ACTIVATION; PI3K/MTOR INHIBITORS	The RAS-RAF-MEK1/2-ERK1/2 pathway is a key signal transduction pathway in the cells. Critically, it remains constitutively active in approximately 30% of human cancers, having key roles in cancer development, maintenance and progression, while being responsible for poorer prognosis and drug resistance. Consequently, the inhibition of this pathway has been the subject of intense research for >25 years. The advent of better patient screening techniques has increasingly shown that upstream regulators like RAS and RAF remain persistently mutated in many cancer types. These gain-of-function mutations, such as KRAS-4BG(12V/G13D/Q61K), NRAS(Q61L/Q61R) or BRAF(V600E), lead to tremendous increase in their activities, resulting in constitutively active extracellular signalregulated kinase 1/2 (ERK1/2). They were not efficiently targeted by the first-generation inhibitors such as Lonafarnib or Sorafenib, which were essentially broad spectrum inhibitors targeting pan-RAS and pan-RAF, respectively. This triggered the development of the second-generation inhibitors selective against the mutated proteins. Second generation inhibitors such as Vemurafenib (Zelboraf) and Dabrafenib (Tafinlar) targeting BRAF(V600E), Trametinib (Mekinist) targeting MEK1/2 and the first generation pan-RAF inhibitor Sorafenib (Nexavar) have already been approved for treating renal, hepatocellular, thyroid cancers and BRAF(V600E/K) harboring metastatic melanoma. Others against RAF and MEK1/2 are presently undergoing clinical trials. Their success would depend on the better understanding of the acquired resistance mechanisms to these drugs in the cancer cells and the identification of predictive biomarkers for the proper administration of suitable inhibitor(s).	[Mandal, R.; Becker, S.; Strebhardt, K.] German Canc Consortium DKTK, Heidelberg, Germany; [Mandal, R.; Strebhardt, K.] Goethe Univ Frankfurt, Dept Obstet & Gynaecol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany; [Mandal, R.; Strebhardt, K.] German Canc Res Ctr, Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ)	Strebhardt, K (corresponding author), Goethe Univ Frankfurt, Dept Obstet & Gynaecol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	strebhardt@em.uni-frankfurt.de	Strebhardt, Klaus/E-8765-2011	Mandal, Ranadip/0000-0003-2861-9545; Strebhardt, Klaus/0000-0003-2173-9763				Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Adjei AA, 2013, ASCO M ABSTR S15, V31, P2528; Adjei AA, 2008, J CLIN ONCOL, V26, P2139, DOI 10.1200/JCO.2007.14.4956; Akinleye A, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-27; Ascierto PA, 2013, LANCET ONCOL, V14, P249, DOI 10.1016/S1470-2045(13)70024-X; Ascierto PA, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-38; Azijli K, 2014, ANTICANCER RES, V34, P1493; Baker NM, 2013, NATURE, V497, P577, DOI 10.1038/nature12248; Bollag G, 2012, NAT REV DRUG DISCOV, V11, P873, DOI 10.1038/nrd3847; Britten C, 2012, EUR J CANCER, V48, P109, DOI 10.1016/S0959-8049(12)72156-1; Cantwell-Dorris ER, 2011, MOL CANCER THER, V10, P385, DOI 10.1158/1535-7163.MCT-10-0799; Caponigro G, 2013, CANC RES S8, V73, P2337; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Chintala L, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.3593; Cohen RB, 2013, EUR J CANCER, V49, P1521, DOI 10.1016/j.ejca.2013.01.013; Collins S, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-3738; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; Corcoran RB, 2011, ONCOTARGET, V2, P336; Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148; Cox AD, 2010, CANCER CELL, V17, P221, DOI 10.1016/j.ccr.2010.02.029; Dai BJ, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1404; Davies BR, 2007, MOL CANCER THER, V6, P2209, DOI 10.1158/1535-7163.MCT-07-0231; Descot A, 2009, MOL CELL, V35, P291, DOI 10.1016/j.molcel.2009.07.015; Dickson MA, 2015, INVEST NEW DRUG, V33, P349, DOI 10.1007/s10637-014-0191-5; Dougherty MK, 2005, MOL CELL, V17, P215, DOI 10.1016/j.molcel.2004.11.055; Eblen ST, 2004, MOL CELL BIOL, V24, P2308, DOI 10.1128/MCB.24.6.2308-2317.2004; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Fabrey R, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-3739; Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084; Finn RS, 2012, J CLIN ONCOL, V30, DOI 10.1200/jco.2012.30.4_suppl.220; Fisher Rosalie, 2012, Cancer Manag Res, V4, P243, DOI 10.2147/CMAR.S25284; Fremin C, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-8; Friday BB, 2008, CLIN CANCER RES, V14, P342, DOI 10.1158/1078-0432.CCR-07-4790; Geest CR, 2009, J LEUKOCYTE BIOL, V86, P237, DOI 10.1189/jlb.0209097; Gilmartin AG, 2011, CLIN CANCER RES, V17, P989, DOI 10.1158/1078-0432.CCR-10-2200; Girotti MR, 2015, CANCER CELL, V27, P85, DOI 10.1016/j.ccell.2014.11.006; Gollob JA, 2007, J CLIN ONCOL, V25, P3288, DOI 10.1200/JCO.2007.10.8613; Gollob JA, 2006, SEMIN ONCOL, V33, P392, DOI 10.1053/j.seminoncol.2006.04.002; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Hatzivassiliou G, 2013, NATURE, V501, P232, DOI 10.1038/nature12441; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hocker HJ, 2013, P NATL ACAD SCI USA, V110, P10201, DOI 10.1073/pnas.1300016110; Hoeflich KP, 2009, CANCER RES, V69, P3042, DOI 10.1158/0008-5472.CAN-08-3563; Hoh C, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.3591; Holderfield M, 2014, NAT REV CANCER, V14, P455, DOI 10.1038/nrc3760; Honda K, 2013, CANCER CHEMOTH PHARM, V72, P577, DOI 10.1007/s00280-013-2228-4; Hong D, 2007, P AN M AM SOC CLIN, V25, P3549; Huang TG, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-30; Jing JP, 2012, MOL CANCER THER, V11, P720, DOI 10.1158/1535-7163.MCT-11-0505; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Johansson CH, 2014, PHARMACOL THERAPEUT, V142, P176, DOI 10.1016/j.pharmthera.2013.11.011; Juric D, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.9051; Khazak V, 2007, EXPERT OPIN THER TAR, V11, P1587, DOI 10.1517/14728222.11.12.1587; Kirkwood JM, 2012, CLIN CANCER RES, V18, P555, DOI 10.1158/1078-0432.CCR-11-1491; Lam ET, 2010, J CLIN ONCOL, V28, P2323, DOI 10.1200/JCO.2009.25.0068; Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979; Leijen S, 2012, CLIN CANCER RES, V18, P4794, DOI 10.1158/1078-0432.CCR-12-0868; Leow CCY, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.1; Lim HY, 2012, ASCO MEETING ABSTRAC, V30, P4103; Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011; Little AS, 2013, ONCOGENE, V32, P1207, DOI 10.1038/onc.2012.160; Little AS, 2012, BIOCHEM SOC T, V40, P73, DOI 10.1042/BST20110647; Little AS, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001752; Liu X, 2004, ONCOGENE, V23, P763, DOI 10.1038/sj.onc.1207188; Lo RS, 2012, CELL RES, V22, P945, DOI 10.1038/cr.2012.78; Long GV, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.9011; Luke JJ, 2012, CLIN CANCER RES, V18, P9, DOI 10.1158/1078-0432.CCR-11-2197; Mandal R, 2014, MOL ONCOL, V8, P232, DOI 10.1016/j.molonc.2013.11.003; Martinelli E, 2013, INT J CANCER, V133, P2089, DOI 10.1002/ijc.28236; Martinez-Garcia M, 2012, CLIN CANCER RES, V18, P4806, DOI 10.1158/1078-0432.CCR-12-0742; Maurer T, 2012, P NATL ACAD SCI USA, V109, P5299, DOI 10.1073/pnas.1116510109; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Menzies AM, 2014, CLIN CANCER RES, V20, P2035, DOI 10.1158/1078-0432.CCR-13-2054; Menzies AM, 2012, DRUG DES DEV THER, V6, P391, DOI 10.2147/DDDT.S38998; Narita Y, 2014, MOL CANCER THER, V13, P823, DOI 10.1158/1535-7163.MCT-13-0667; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2011, CANCER CELL, V19, P11, DOI 10.1016/j.ccr.2011.01.008; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Pucci B, 2009, J CELL BIOCHEM, V108, P1166, DOI 10.1002/jcb.22345; Ramos JW, 2008, INT J BIOCHEM CELL B, V40, P2707, DOI 10.1016/j.biocel.2008.04.009; Riess H, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.4129; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Rizos H, 2014, CLIN CANCER RES, V20, P1965, DOI 10.1158/1078-0432.CCR-13-3122; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Rudd CE, 2005, NAT IMMUNOL, V6, P368, DOI 10.1038/ni0405-368; Sale MJ, 2014, BIOCHEM SOC T, V42, P776, DOI 10.1042/BST20140129; Sanada M, 2007, CARCINOGENESIS, V28, P2657, DOI 10.1093/carcin/bgm188; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schafer B, 2004, ONCOGENE, V23, P991, DOI 10.1038/sj.onc.1207278; Schneider H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001718; Schwartz GK, 2009, J CLIN ONCOL, V27; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Sourvinos G, 1999, ONCOGENE, V18, P4968, DOI 10.1038/sj.onc.1202891; Steinmetz R, 2004, MOL ENDOCRINOL, V18, P2570, DOI 10.1210/me.2004-0082; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Strebhardt K, 2008, NAT REV CANCER, V8, P473, DOI 10.1038/nrc2394; Stuart D., 2008, AACR M, V68, P4876; Stuart DD, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-3790; Su YJ, 2012, CLIN CANCER RES, V18, P2184, DOI 10.1158/1078-0432.CCR-11-1122; Tentler JJ, 2010, MOL CANCER THER, V9, P3351, DOI 10.1158/1535-7163.MCT-10-0376; Towatari M, 1997, LEUKEMIA, V11, P479, DOI 10.1038/sj.leu.2400617; Trunzer K, 2013, J CLIN ONCOL, V31, P1767, DOI 10.1200/JCO.2012.44.7888; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Van Laethem J-L., 2014, J CLIN ONCOL, V32, P4025; Villanueva J, 2013, CELL REP, V4, P1090, DOI 10.1016/j.celrep.2013.08.023; Villanueva J, 2011, CANCER RES, V71, P7137, DOI 10.1158/0008-5472.CAN-11-1243; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Wang D, 2007, BBA-MOL CELL RES, V1773, P1248, DOI 10.1016/j.bbamcr.2006.11.009; Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Xiao Z, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.213; Yang H, 2010, CANCER RES, V70, P5518, DOI 10.1158/0008-5472.CAN-10-0646; Yeh JJ, 2009, MOL CANCER THER, V8, P834, DOI 10.1158/1535-7163.MCT-08-0972; Zhao YJ, 2014, NAT REV CLIN ONCOL, V11, P385, DOI 10.1038/nrclinonc.2014.83; Zimmermann G, 2013, NATURE, V497, P638, DOI 10.1038/nature12205	119	65	67	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2016	35	20					2547	2561		10.1038/onc.2015.329	http://dx.doi.org/10.1038/onc.2015.329			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GS	26364606				2022-12-17	WOS:000376165700001
J	Cui, YM; Jiao, HL; Ye, YP; Chen, CM; Wang, JX; Tang, N; Li, TT; Lin, J; Qi, L; Wu, P; Wang, SY; He, MR; Liang, L; Bian, XW; Liao, WT; Ding, YQ				Cui, Y-M; Jiao, H-L; Ye, Y-P; Chen, C-M; Wang, J-X; Tang, N.; Li, T-T; Lin, J.; Qi, L.; Wu, P.; Wang, S-Y; He, M-R; Liang, L.; Bian, X-W; Liao, W-T; Ding, Y-Q			RETRACTED: FOXC2 promotes colorectal cancer metastasis by directly targeting MET (Retracted article. See vol. 41, pg. 2529, 2022)	ONCOGENE			English	Article; Retracted Publication							HEPATOCYTE GROWTH-FACTOR; PRIMARY COLON-CANCER; CELL LUNG-CANCER; C-MET; FACTOR RECEPTOR; REGULATES EXPRESSION; STAGE; GENE; OVEREXPRESSION; PROTOONCOGENE	Metastasis is the major cause of death in colorectal cancer (CRC). Although multiple genes have been identified to be responsible for the development of CRC, the molecular changes that enable CRC cells to undergo early local invasion and to form distant metastatic colonies still remain largely unknown. Herein, we investigated the role of Forkhead box protein C2 (FOXC2) and explored the underlying mechanisms in invasion and metastasis of CRC. We show that both high FOXC2 expression and nuclear localization of FOXC2 are significantly correlated with advanced TNM (T = primary tumor; N = regional lymph nodes; M= distant metastasis) stages. FOXC2 enhanced the invasive abilities of CRC cells in vitro and promoted local invasion and distant metastasis in an orthotopic mouse metastatic model of CRC. Microarray analysis revealed that overexpression of FOXC2 increased the proto-oncogene MET tyrosine kinase expression and activated the hepatocyte growth factor (HGF)-MET signaling pathway. Furthermore, luciferase reporter assays and chromatin immunoprecipitation assays revealed that FOXC2 directly associated with MET promoter to increase the transcriptional activity of MET. Inhibition of MET attenuates the invasive phenotype and metastatic potential of FOXC2-overexpressing CRC cells, indicating that MET is a major mediator of FOXC2-promoted metastasis. In addition, FOXC2 expression was positively correlated with MET expression in CRC tissue samples. Our findings suggest that FOXC2 has a crucial role in CRC metastasis by regulating HGF-MET signaling via inducing MET expression, highlighting FOXC2 as a potential therapeutic target for preventing or reducing metastasis in CRC.	[Cui, Y-M; Jiao, H-L; Ye, Y-P; Chen, C-M; Wang, J-X; Tang, N.; Li, T-T; Lin, J.; Qi, L.; Wu, P.; Wang, S-Y; Liang, L.; Liao, W-T; Ding, Y-Q] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China; [Cui, Y-M; Jiao, H-L; Ye, Y-P; Chen, C-M; Wang, J-X; Tang, N.; Li, T-T; Lin, J.; Qi, L.; Wu, P.; Wang, S-Y; Liang, L.; Liao, W-T; Ding, Y-Q] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China; [Cui, Y-M; Jiao, H-L; Ye, Y-P; Chen, C-M; Wang, J-X; Tang, N.; Li, T-T; Lin, J.; Qi, L.; Wu, P.; Wang, S-Y; Liang, L.; Liao, W-T; Ding, Y-Q] Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou, Guangdong, Peoples R China; [He, M-R] Southern Med Univ, Nanfang Hosp, Guangdong Prov Key Lab Gastroenterol, Guangzhou 510515, Guangdong, Peoples R China; [He, M-R] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangzhou 510515, Guangdong, Peoples R China; [Bian, X-W] Third Mil Med Univ, Southwest Hosp, Inst Pathol, Chongqing, Peoples R China; [Bian, X-W] Third Mil Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Army Medical University; Army Medical University	Liao, WT (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China.	liaowt2002@gmail.com; dyqgz@126.com	Bian, Xiu-Wu/D-4736-2017; liang, li/AAB-9126-2022	Bian, Xiu-Wu/0000-0003-4383-0197; 	National Basic Research Program of China (973 program) [2015CB554002, 2010CB529403]; National Natural Science Foundation of China (NSFC)-Guangdong Joint Fund [U1201226]; National Natural Science Foundation of China [81090422, 30901791, 81172055, 81472313, 81472710, 81071735]; Guangdong Provincial Natural Science Foundation of China [S2012010009643]; Zhu Jiang Science & Technology New Star Foundation in Guangzhou city [2012J2200052, 2012J2200044]; Science and Technology Innovation Foundation of Guangdong Higher Education [CXZD1016]; Key Program of the National Natural Science Foundation of Guangdong, China [2010B031500012]; Guangzhou Science & Technology Plan Project [201300000056]	National Basic Research Program of China (973 program)(National Basic Research Program of China); National Natural Science Foundation of China (NSFC)-Guangdong Joint Fund(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Provincial Natural Science Foundation of China(National Natural Science Foundation of Guangdong Province); Zhu Jiang Science & Technology New Star Foundation in Guangzhou city; Science and Technology Innovation Foundation of Guangdong Higher Education; Key Program of the National Natural Science Foundation of Guangdong, China; Guangzhou Science & Technology Plan Project	This work was supported by the National Basic Research Program of China (973 program, nos. 2015CB554002 and 2010CB529403), the National Natural Science Foundation of China (NSFC)-Guangdong Joint Fund (U1201226), the Major Projects of the National Natural Science Foundation of China (no. 81090422), the National Natural Science Foundation of China (nos. 30901791, 81172055, 81472313, 81472710 and 81071735), Guangdong Provincial Natural Science Foundation of China (no. S2012010009643), Zhu Jiang Science & Technology New Star Foundation in Guangzhou city (2012J2200052 and 2012J2200044), the Science and Technology Innovation Foundation of Guangdong Higher Education (CXZD1016), the Key Program of the National Natural Science Foundation of Guangdong, China (2010B031500012), and Guangzhou Science & Technology Plan Project (201300000056).	Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boon EMJ, 2002, CANCER RES, V62, P5126; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Chmielowiec J, 2007, J CELL BIOL, V177, P151, DOI 10.1083/jcb.200701086; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Duffy MJ, 2007, EUR J CANCER, V43, P1348, DOI 10.1016/j.ejca.2007.03.021; Hayashi H, 2008, J BIOL CHEM, V283, P23791, DOI 10.1074/jbc.M800190200; Hollier BG, 2013, CANCER RES, V73, P1981, DOI 10.1158/0008-5472.CAN-12-2962; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jiang W, 2012, CLIN LUNG CANCER, V13, P280, DOI 10.1016/j.cllc.2011.11.005; Kammula US, 2007, CANCER LETT, V248, P219, DOI 10.1016/j.canlet.2006.07.007; Kume T, 2012, J ONCOL, V2012, DOI 10.1155/2012/204593; Liang HY, 2004, INT J ONCOL, V24, P1057; Liao WT, 2011, CLIN CANCER RES, V17, P3569, DOI 10.1158/1078-0432.CCR-10-2533; Lin YZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079299; LIU C, 1992, ONCOGENE, V7, P181; Liu XD, 2008, EXPERT OPIN INV DRUG, V17, P997, DOI [10.1517/13543784.17.7.997, 10.1517/13543784.17.7.997 ]; Liu YH, 1998, GENE, V215, P159, DOI 10.1016/S0378-1119(98)00264-9; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Mazzone M, 2006, FASEB J, V20, P1611, DOI 10.1096/fj.06-5947rev; Mortazavi F, 2010, MOL CANCER RES, V8, P762, DOI 10.1158/1541-7786.MCR-10-0004; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Nishida N, 2011, ANN SURG ONCOL, V18, P535, DOI 10.1245/s10434-010-1274-y; Park SJ, 2011, BONE, V49, P428, DOI 10.1016/j.bone.2011.05.012; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Rasola A, 2007, ONCOGENE, V26, P1078, DOI 10.1038/sj.onc.1209859; Sano H, 2010, BIOCHEM BIOPH RES CO, V392, P201, DOI 10.1016/j.bbrc.2010.01.015; Sattler Martin, 2007, Curr Oncol Rep, V9, P102, DOI 10.1007/s11912-007-0005-4; Shibue T, 2012, CANCER DISCOV, V2, P706, DOI 10.1158/2159-8290.CD-11-0239; Song LB, 2006, CANCER RES, V66, P6225, DOI 10.1158/0008-5472.CAN-06-0094; Stein Ulrike, 2007, V176, P61; Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889; Takeuchi H, 2003, CLIN CANCER RES, V9, P1480; De Oliveira ATT, 2009, ANTICANCER RES, V29, P4807; Tseng William, 2007, J Vis Exp, P484, DOI 10.3791/484; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Van Cutsem E, 2013, LANCET, V381, P1538, DOI 10.1016/S0140-6736(13)60978-2; Xue Y, 2008, P NATL ACAD SCI USA, V105, P10167, DOI 10.1073/pnas.0802486105; Yu YH, 2013, ONCOGENE, V32, P431, DOI 10.1038/onc.2012.74; Zeng ZS, 2008, CANCER LETT, V265, P258, DOI 10.1016/j.canlet.2008.02.049; Zhu JL, 2013, HISTOPATHOLOGY, V62, P1038, DOI 10.1111/his.12132	43	65	66	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2015	34	33					4379	4390		10.1038/onc.2014.368	http://dx.doi.org/10.1038/onc.2014.368			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO9KK	25381815				2022-12-17	WOS:000359494400009
J	Patel, A; Burton, DGA; Halvorsen, K; Balkan, W; Reiner, T; Perez-Stable, C; Cohen, A; Munoz, A; Giribaldi, MG; Singh, S; Robbins, DJ; Nguyen, DM; Rai, P				Patel, A.; Burton, D. G. A.; Halvorsen, K.; Balkan, W.; Reiner, T.; Perez-Stable, C.; Cohen, A.; Munoz, A.; Giribaldi, M. G.; Singh, S.; Robbins, D. J.; Nguyen, D. M.; Rai, P.			MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways	ONCOGENE			English	Article							ONCOGENIC RAS; CANCER-CELLS; TUMOR-CELLS; DNA; SENESCENCE; P53; INHIBITION; APOPTOSIS; PROTEIN; GROWTH	Oncogenic RAS promotes production of reactive oxygen species (ROS), which mediate pro-malignant signaling but can also trigger DNA damage-induced tumor suppression. Thus RAS-driven tumor cells require redox-protective mechanisms to mitigate the damaging aspects of ROS. Here, we show that MutT Homolog 1 (MTH1), the mammalian 8-oxodGTPase that sanitizes oxidative damage in the nucleotide pool, is important for maintaining several KRAS-driven pro-malignant traits in a nonsmall cell lung carcinoma (NSCLC) model. MTH1 suppression in KRAS-mutant NSCLC cells impairs proliferation and xenograft tumor formation. Furthermore, MTH1 levels modulate KRAS-induced transformation of immortalized lung epithelial cells. MTH1 expression is upregulated by oncogenic KRAS and correlates positively with high KRAS levels in NSCLC human tumors. At a molecular level, in p53-competent KRAS-mutant cells, MTH1 loss provokes DNA damage and induction of oncogene-induced senescence. In p53-nonfunctional KRAS-mutant cells, MTH1 suppression does not produce DNA damage but reduces proliferation and leads to an adaptive decrease in KRAS expression levels. Thus, MTH1 not only enables evasion of oxidative DNA damage and its consequences, but can also function as a molecular rheostat for maintaining oncogene expression at optimal levels. Accordingly, our results indicate MTH1 is a novel and critical component of oncogenic KRAS-associated malignancy and its inhibition is likely to yield significant tumor-suppressive outcomes in KRAS-driven tumors.	[Patel, A.; Burton, D. G. A.; Halvorsen, K.; Perez-Stable, C.; Cohen, A.; Munoz, A.; Giribaldi, M. G.; Rai, P.] Univ Miami, Leonard M Miller Sch Med, Dept Med, Miami, FL 33136 USA; [Reiner, T.; Perez-Stable, C.] Bruce W Carter Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Miami, FL USA; [Perez-Stable, C.; Robbins, D. J.; Nguyen, D. M.; Rai, P.] Univ Miami, Leonard M Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; [Cohen, A.] Univ Miami, Leonard M Miller Sch Med, David & Sheila Fuente Grad Program Canc Biol, Miami, FL 33136 USA; [Singh, S.; Robbins, D. J.; Nguyen, D. M.] Univ Miami, Leonard M Miller Sch Med, Dept Surg, Miami, FL 33136 USA	University of Miami; Geriatric Research Education & Clinical Center; University of Miami; University of Miami; University of Miami	Rai, P (corresponding author), Univ Miami, Leonard M Miller Sch Med, Dept Med, RMSB 7094,D-503,1600 North West 10th Ave, Miami, FL 33136 USA.	prai@med.miami.edu	Singh, Samer/H-8468-2013	Singh, Samer/0000-0002-0921-1686; Rai, Priyamvada/0000-0001-7822-7553	James and Esther King Florida Biomedical New Investigator Research grant, a University of Miami Dean's Bridge Fund award; NIH/NCI grant [R01CA175086]; NATIONAL CANCER INSTITUTE [R01CA175086] Funding Source: NIH RePORTER	James and Esther King Florida Biomedical New Investigator Research grant, a University of Miami Dean's Bridge Fund award; NIH/NCI grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Ramiro Verdun for helpful discussions, and Karen Alvarez Delfin for technical assistance. This work was supported by a James and Esther King Florida Biomedical New Investigator Research grant, a University of Miami Dean's Bridge Fund award and an NIH/NCI grant (R01CA175086) to PR.	Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Burton DGA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068003; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Cao JX, 2009, EMBO J, V28, P1505, DOI 10.1038/emboj.2009.101; Chen CY, 1998, CELL DEATH DIFFER, V5, P984, DOI 10.1038/sj.cdd.4400448; Cho WCS, 2011, RNA BIOL, V8, P125, DOI 10.4161/rna.8.1.14259; Clark DW, 2012, FREE RADICAL BIO MED, V53, P51, DOI 10.1016/j.freeradbiomed.2012.04.024; Cogoi S, 2006, NUCLEIC ACIDS RES, V34, P2536, DOI 10.1093/nar/gkl286; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dobbs TA, 2008, DNA REPAIR, V7, P1372, DOI 10.1016/j.dnarep.2008.05.001; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; FAN SJ, 1994, CANCER RES, V54, P5824; Fei DL, 2010, CANCER RES, V70, P1981, DOI 10.1158/0008-5472.CAN-09-2898; Finkel T, 2006, ANTIOXID REDOX SIGN, V8, P1857, DOI 10.1089/ars.2006.8.1857; Gad H, 2014, NATURE, V508, P215, DOI 10.1038/nature13181; Ghosh A, 2009, J BIOL CHEM, V284, P31074, DOI 10.1074/jbc.M109.027532; Hommura F, 2000, CLIN CANCER RES, V6, P4073; Hu CM, 2012, CANCER CELL, V22, P36, DOI 10.1016/j.ccr.2012.04.038; Huber KVM, 2014, NATURE, V508, P222, DOI 10.1038/nature13194; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Janik J, 2011, MUTAT RES-FUND MOL M, V709-10, P21, DOI 10.1016/j.mrfmmm.2011.02.009; Kennedy CH, 2003, FREE RADICAL BIO MED, V34, P1447, DOI 10.1016/S0891-5849(03)00176-X; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Liou JS, 2000, J BIOL CHEM, V275, P39001, DOI 10.1074/jbc.M007154200; Liu B, 2008, FREE RADICAL BIO MED, V44, P1529, DOI 10.1016/j.freeradbiomed.2008.01.011; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Mitsushita J, 2004, CANCER RES, V64, P3580, DOI 10.1158/0008-5472.CAN-03-3909; Moiseeva O, 2009, MOL CELL BIOL, V29, P4495, DOI 10.1128/MCB.01868-08; MUKHOPADHYAY T, 1991, CANCER RES, V51, P1744; Nakabeppu Y, 2001, MUTAT RES-FUND MOL M, V477, P59, DOI 10.1016/S0027-5107(01)00096-3; Nogueira V, 2013, CLIN CANCER RES, V19, P4309, DOI 10.1158/1078-0432.CCR-12-1424; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Patel A, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-3; Rai P, 2011, ONCOGENE, V30, P1489, DOI 10.1038/onc.2010.520; Rai P, 2009, P NATL ACAD SCI USA, V106, P169, DOI 10.1073/pnas.0809834106; Rajalingam K, 2007, BBA-MOL CELL RES, V1773, P1177, DOI 10.1016/j.bbamcr.2007.01.012; Reiner T, 2006, PROSTATE, V66, P1487, DOI 10.1002/pros.20478; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Speina E, 2005, JNCI-J NATL CANCER I, V97, P384, DOI 10.1093/jnci/dji058; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Sunaga N, 2011, MOL CANCER THER, V10, P336, DOI 10.1158/1535-7163.MCT-10-0750; Szalai VA, 2002, J AM CHEM SOC, V124, P1625, DOI 10.1021/ja0119651; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Wiederschain D, 2009, CELL CYCLE, V8, P498, DOI 10.4161/cc.8.3.7701; Wikman H, 2000, INT J CANCER, V88, P932, DOI 10.1002/1097-0215(20001215)88:6<932::AID-IJC15>3.0.CO;2-P; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	53	65	67	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2586	2596		10.1038/onc.2014.195	http://dx.doi.org/10.1038/onc.2014.195			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25023700	Green Accepted			2022-12-17	WOS:000354541300005
J	Tuominen, I; Heliovaara, E; Raitila, A; Rautiainen, MR; Mehine, M; Katainen, R; Donner, I; Aittomaki, V; Lehtonen, HJ; Ahlsten, M; Kivipelto, L; Schalin-Jantti, C; Arola, J; Hautaniemi, S; Karhu, A				Tuominen, I.; Heliovaara, E.; Raitila, A.; Rautiainen, M-R; Mehine, M.; Katainen, R.; Donner, I.; Aittomaki, V.; Lehtonen, H. J.; Ahlsten, M.; Kivipelto, L.; Schalin-Jantti, C.; Arola, J.; Hautaniemi, S.; Karhu, A.			AIP inactivation leads to pituitary tumorigenesis through defective G alpha(i)-cAMP signaling	ONCOGENE			English	Article							INTERACTING PROTEIN GENE; STIMULATORY G-PROTEIN; ADENOMA PREDISPOSITION; ADENYLYL-CYCLASE; CELL-PROLIFERATION; MUTATIONS; CAMP; EXPRESSION; SUBUNIT; XAP2	The aryl hydrocarbon receptor interacting protein (AIP) is a tumor-suppressor gene underlying the pituitary adenoma predisposition. Thus far, the exact molecular mechanisms by which inactivated AIP exerts its tumor-promoting action have been unclear. To better understand the role of AIP in pituitary tumorigenesis, we performed gene expression microarray analysis to examine changes between Aip wild-type and knockout mouse embryonic fibroblast (MEF) cell lines. Transcriptional analyses implied that Aip deficiency causes a dysfunction in cyclic adenosine monophosphate (cAMP) signaling, as well as impairments in signaling cascades associated with developmental and immune-inflammatory responses. In vitro experiments showed that AIP deficiency increases intracellular cAMP concentrations in both MEF and murine pituitary adenoma cell lines. Based on knockdown of various G protein a subunits, we concluded that AIP deficiency leads to elevated cAMP concentrations through defective G alpha(i)-2 and G alpha(i)-3 proteins that normally inhibit cAMP synthesis. Furthermore, immunostaining of G alpha(i)-2 revealed that AIP deficiency is associated with a clear reduction in G alpha(i)-2 protein expression levels in human and mouse growth hormone (GH)-secreting pituitary adenomas, thus indicating defective Gai signaling in these tumors. By contrast, all prolactin-secreting tumors showed prominent G alpha(i)-2 protein levels, irrespective of Aip mutation status. We additionally observed reduced expression of phosphorylated extracellular signal-regulated kinases 1/2 and cAMP response element-binding protein levels in mouse and human AIP-deficient somatotropinomas. This study implies for the first time that a failure to inhibit cAMP synthesis through dysfunctional G alpha(i) signaling underlies the development of GH-secreting pituitary adenomas in AIP mutation carriers.	[Tuominen, I.; Heliovaara, E.; Raitila, A.; Rautiainen, M-R; Mehine, M.; Katainen, R.; Donner, I.; Lehtonen, H. J.; Ahlsten, M.; Karhu, A.] Univ Helsinki, Inst Biomed Biomed Helsinki, Genome Scale Biol Res Program, Dept Med Genet, Helsinki 00014, Finland; [Aittomaki, V.; Hautaniemi, S.] Univ Helsinki, Inst Biomed Biomed Helsinki, Genome Scale Biol Res Program, Syst Biol Lab, Helsinki 00014, Finland; [Kivipelto, L.] Univ Helsinki, Dept Neurosurg, Helsinki 00014, Finland; [Kivipelto, L.; Schalin-Jantti, C.] Helsinki Univ Hosp, Helsinki, Finland; [Schalin-Jantti, C.] Univ Helsinki, Dept Med, Div Endocrinol, Helsinki 00014, Finland; [Tuominen, I.; Heliovaara, E.; Arola, J.] Univ Helsinki, Cent Hosp, HUSLAB, Dept Pathol, Helsinki 00014, Finland; [Arola, J.] Univ Helsinki, Haartman Inst, Helsinki 00014, Finland	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki	Karhu, A (corresponding author), Univ Helsinki, Inst Biomed Biomed Helsinki, Genome Scale Biol Res Program, Dept Med Genet, Helsinki 00014, Finland.	auli.karhu@helsinki.fi	Hautaniemi, Sampsa/A-3122-2009; Katainen, Riku/GYR-0921-2022; Hautaniemi, Sampsa/CAG-0362-2022	Hautaniemi, Sampsa/0000-0002-7749-2694; Hautaniemi, Sampsa/0000-0002-7749-2694; Karhu, Auli/0000-0002-7927-0796; Katainen, Riku/0000-0003-4575-4239	Academy of Finland [250345]; Cancer Society of Finland [4700325]; Novo Nordisk Foundation [A14582]; Association for International Cancer Research [13-1075]	Academy of Finland(Academy of Finland); Cancer Society of Finland; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Association for International Cancer Research	We thank Inga-Lill Svedberg, Mairi Kuris, Alison Ollikainen and Iina Vuoristo for technical assistance. The Biomedicum Imaging Unit is acknowledged for the microscopy service and the Biomedicum Functional Genomics Unit (FuGU) for expression array and virus core services. This study was supported by the Academy of Finland (250345), the Cancer Society of Finland (4700325), the Novo Nordisk Foundation (A14582) and the Association for International Cancer Research (13-1075). This work was supported in part by the Novo Nordisk Foundation (AK).	Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; Beckers A, 2013, ENDOCR REV, V34, P239, DOI 10.1210/er.2012-1013; Ben-Shlomo A, 2007, MOL ENDOCRINOL, V21, P2565, DOI 10.1210/me.2007-0081; Ben-Shlomo A, 2010, TRENDS ENDOCRIN MET, V21, P123, DOI 10.1016/j.tem.2009.12.003; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BERTHERAT J, 1995, MOL ENDOCRINOL, V9, P777, DOI 10.1210/me.9.7.777; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; Boikos SA, 2007, HUM MOL GENET, V16, pR80, DOI 10.1093/hmg/ddm019; Bolger GB, 2003, J BIOL CHEM, V278, P33351, DOI 10.1074/jbc.M303269200; Caunt CJ, 2006, TRENDS ENDOCRIN MET, V17, P276, DOI 10.1016/j.tem.2006.07.008; Chahal HS, 2012, J CLIN ENDOCR METAB, V97, pE1411, DOI 10.1210/jc.2012-1111; Daly AF, 2007, J CLIN ENDOCR METAB, V92, P1891, DOI 10.1210/jc.2006-2513; Daly AF, 2010, J CLIN ENDOCR METAB, V95, pE373, DOI 10.1210/jc.2009-2556; de Oliveira SK, 2007, J BIOL CHEM, V282, P13656, DOI 10.1074/jbc.M610942200; Formosa R, 2013, ENDOCR-RELAT CANCER, V20, P495, DOI 10.1530/ERC-13-0043; Georgitsi M, 2007, P NATL ACAD SCI USA, V104, P4101, DOI 10.1073/pnas.0700004104; Gohla A, 2007, P NATL ACAD SCI USA, V104, P3003, DOI 10.1073/pnas.0611434104; Grant M, 2008, MOL ENDOCRINOL, V22, P2278, DOI 10.1210/me.2007-0334; Gueorguiev M, 2011, NAT REV ENDOCRINOL, V7, P71, DOI 10.1038/nrendo.2010.233; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; Hayward BE, 2001, J CLIN INVEST, V107, pR31, DOI 10.1172/JCI11887; Heliovaara E, 2009, AM J PATHOL, V175, P2501, DOI 10.2353/ajpath.2009.081131; Jiang LI, 2008, J BIOL CHEM, V283, P23429, DOI 10.1074/jbc.M803281200; Jiang LI, 2007, J BIOL CHEM, V282, P10576, DOI 10.1074/jbc.M609695200; Kazlauskas A, 2000, J BIOL CHEM, V275, P41317, DOI 10.1074/jbc.M007765200; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; Lahlou H, 2003, J BIOL CHEM, V278, P39356, DOI 10.1074/jbc.M304524200; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Lania A, 2003, J CLIN ENDOCR METAB, V88, P1692, DOI 10.1210/jc.2002-021207; Lappano R, 2011, NAT REV DRUG DISCOV, V10, P47, DOI 10.1038/nrd3320; Leontiou CA, 2008, J CLIN ENDOCR METAB, V93, P2390, DOI 10.1210/jc.2007-2611; Liu YF, 1999, J BIOL CHEM, V274, P16444, DOI 10.1074/jbc.274.23.16444; LIU YF, 1994, J BIOL CHEM, V269, P13880; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Malbon CC, 2005, NAT REV MOL CELL BIO, V6, P689, DOI 10.1038/nrm1716; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; Moran TB, 2012, TOXICOL APPL PHARM, V265, P139, DOI 10.1016/j.taap.2012.08.026; Nakata A, 2009, EMBO REP, V10, P622, DOI 10.1038/embor.2009.35; Nesbit MA, 2013, NEW ENGL J MED, V368, P2476, DOI 10.1056/NEJMoa1300253; Nurnberg B, 2004, NAT REV DRUG DISCOV, V575, P577; Omori K, 2007, CIRC RES, V100, P309, DOI 10.1161/01.RES.0000256354.95791.f1; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Peri A, 2001, J CLIN ENDOCR METAB, V86, P2111, DOI 10.1210/jc.86.5.2111; Raitila A, 2010, AM J PATHOL, V177, P1969, DOI 10.2353/ajpath.2010.100138; Sandrini Fabiano, 2004, Arq Bras Endocrinol Metab, V48, P637, DOI 10.1590/S0004-27302004000500007; SCHWINDINGER WF, 1992, P NATL ACAD SCI USA, V89, P5152, DOI 10.1073/pnas.89.11.5152; Stefan E, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1605; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Trivellin G, 2011, J ENDOCRINOL, V210, P137, DOI 10.1530/JOE-11-0054; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vierimaa O, 2006, SCIENCE, V312, P1228, DOI 10.1126/science.1126100; Vlotides G, 2008, CANCER RES, V68, P6377, DOI 10.1158/0008-5472.CAN-08-0508; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; Wettschureck N, 2004, PHARMACOL THERAPEUT, V101, P75, DOI 10.1016/j.pharmthera.2003.10.005; Zatelli MC, 2003, J CLIN ENDOCR METAB, V88, P2797, DOI 10.1210/jc.2002-021825	61	65	68	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2015	34	9					1174	1184		10.1038/onc.2014.50	http://dx.doi.org/10.1038/onc.2014.50			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC1RY	24662816				2022-12-17	WOS:000350122100010
J	De Saedeleer, CJ; Porporato, PE; Copetti, T; Perez-Escuredo, J; Payen, VL; Brisson, L; Feron, O; Sonveaux, P				De Saedeleer, C. J.; Porporato, P. E.; Copetti, T.; Perez-Escuredo, J.; Payen, V. L.; Brisson, L.; Feron, O.; Sonveaux, P.			Glucose deprivation increases monocarboxylate transporter 1 (MCT1) expression and MCT1-dependent tumor cell migration	ONCOGENE			English	Article						monocarboxylate transporter 1 (MCT1); basigin; glucose metabolism; mitochondrial dysfunction; reactive oxygen species (ROS); tumor cell migration	MITOCHONDRIAL SUPEROXIDE; GLYCOLYTIC TUMORS; LACTIC-ACID; HYPOXIA; LACTATE; CD147; CANCER; METASTASIS; METABOLISM; PROGRESSION	The glycolytic end-product lactate is a pleiotropic tumor growth-promoting factor. Its activities primarily depend on its uptake, a process facilitated by the lactate-proton symporter monocarboxylate transporter 1 (MCT1). Therefore, targeting the transporter or its chaperon protein CD147/basigin, itself involved in the aggressive malignant phenotype, is an attractive therapeutic option for cancer, but basic information is still lacking regarding the regulation of the expression, interaction and activities of both proteins. In this study, we found that glucose deprivation dose-dependently upregulates MCT1 and CD147 protein expression and their interaction in oxidative tumor cells. While this posttranslational induction could be recapitulated using glycolysis inhibition, hypoxia, oxidative phosphorylation (OXPHOS) inhibitor rotenone or hydrogen peroxide, it was blocked with alternative oxidative substrates and specific antioxidants, pointing out at a mitochondrial control. Indeed, we found that the stabilization of MCT1 and CD147 proteins upon glucose removal depends on mitochondrial impairment and the associated generation of reactive oxygen species. When glucose was a limited resource (a situation occurring naturally or during the treatment of many tumors), MCT1-CD147 heterocomplexes accumulated, including in cell protrusions of the plasma membrane. It endowed oxidative tumor cells with increased migratory capacities towards glucose. Migration increased in cells overexpressing MCT1 and CD147, but it was inhibited in glucose-starved cells provided with an alternative oxidative fuel, treated with an antioxidant, lacking MCT1 expression, or submitted to pharmacological MCT1 inhibition. While our study identifies the mitochondrion as a glucose sensor promoting tumor cell migration, MCT1 is also revealed as a transducer of this response, providing a new rationale for the use of MCT1 inhibitors in cancer.	[De Saedeleer, C. J.; Porporato, P. E.; Copetti, T.; Perez-Escuredo, J.; Payen, V. L.; Brisson, L.; Feron, O.; Sonveaux, P.] Catholic Univ Louvain, Inst Rech Expt & Clin, Pole Pharmacol, B-1200 Brussels, Belgium	Universite Catholique Louvain	Sonveaux, P (corresponding author), Catholic Univ Louvain, Inst Rech Expt & Clin, Pole Pharmacol, Ave Emmanuel Mounier 53 Box B1-53-09, B-1200 Brussels, Belgium.	pierre.sonveaux@uclouvain.be	Brisson, Lucie/R-1179-2016; FERON, Olivier/AAM-6395-2020; Porporato, Paolo E./A-9932-2018	Brisson, Lucie/0000-0001-7811-1382; FERON, Olivier/0000-0001-5360-0286; Porporato, Paolo E./0000-0001-8519-1552; Sonveaux, Pierre/0000-0001-6484-8834	European Research Council (FP7); European Research Council Independent Researcher Starting Grant [243188]; Belgian Science Policy Office (Belspo) [UP7-03]; Communaute Francaise de Belgique [ARC 09/14-020]; Fondation Belge contre le Cancer; Fonds National de la Recherche Scientifique (FRS-FNRS); Fonds National de la Recherche Scientifique Medicale; Televie	European Research Council (FP7); European Research Council Independent Researcher Starting Grant; Belgian Science Policy Office (Belspo)(Belgian Federal Science Policy Office); Communaute Francaise de Belgique(Australian Research Council); Fondation Belge contre le Cancer; Fonds National de la Recherche Scientifique (FRS-FNRS)(Fonds de la Recherche Scientifique - FNRS); Fonds National de la Recherche Scientifique Medicale(Fonds de la Recherche Scientifique - FNRS); Televie	This work was supported by the European Research Council (FP7/2007-2013 European Research Council Independent Researcher Starting Grant No. 243188 TUMETABO to PS), Interuniversity Attraction Pole grant #UP7-03 from the Belgian Science Policy Office (Belspo), an Action de Recherche Concertee from the Communaute Francaise de Belgique (ARC 09/14-020 to PS and OF), the Fondation Belge contre le Cancer, the Fonds National de la Recherche Scientifique (FRS-FNRS), the Fonds National de la Recherche Scientifique Medicale, and the Televie. OF is a Honorary Research Director and PS is a Research Associate of the FRS-FNRS. CJD is a Televie Research Fellow. Funding bodies had no role in the design of the study, collection and analysis of data and decision to publish. The authors thank Prof Jacques Pouyssegur (University of Nice Sophia Antipolis, France) for the kind gift of the CD147 vector, and Elise Beneteau, Morgane Tardy, Fabien Rodriguez, Thibaut Vazeille and Floriane Ribeiro for excellent technical assistance. This paper is dedicated to the loving memory of Mrs Anne-Sophie Brouckaert, PharmD.	Asada K, 2003, ONCOLOGY-BASEL, V64, P380, DOI 10.1159/000070297; Birsoy K, 2013, NAT GENET, V45, P104, DOI 10.1038/ng.2471; Boidot R, 2012, CANCER RES, V72, P939, DOI 10.1158/0008-5472.CAN-11-2474; Cardaci S, 2012, CANCER RES, V72, P4526, DOI 10.1158/0008-5472.CAN-12-1741; Cheng C, 2012, CELL ONCOL, V35, P217, DOI 10.1007/s13402-012-0081-9; Dang CV, 2011, J MOL MED, V89, P205, DOI 10.1007/s00109-011-0730-x; De Bock K, 2011, NAT REV CLIN ONCOL, V8, P393, DOI 10.1038/nrclinonc.2011.83; De Saedeleer CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046571; Dhup S, 2012, CURR PHARM DESIGN, V18, P1319, DOI 10.2174/138161212799504902; Dikalova AE, 2010, CIRC RES, V107, P106, DOI 10.1161/CIRCRESAHA.109.214601; Dimmer KS, 2000, BIOCHEM J, V350, P219, DOI 10.1042/0264-6021:3500219; Eyster CA, 2009, TRAFFIC, V10, P590, DOI 10.1111/j.1600-0854.2009.00894.x; Ferretti AC, 2012, MOL GENET METAB, V105, P186, DOI 10.1016/j.ymgme.2011.11.007; Fox JEM, 2000, J PHYSIOL-LONDON, V529, P285, DOI 10.1111/j.1469-7793.2000.00285.x; Gallagher SM, 2009, AM J PHYSIOL-CELL PH, V296, pC414, DOI 10.1152/ajpcell.00430.2008; Halestrap AP, 2012, IUBMB LIFE, V64, P109, DOI 10.1002/iub.572; Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806; Iacono KT, 2007, EXP MOL PATHOL, V83, P283, DOI 10.1016/j.yexmp.2007.08.014; Izumi H, 2011, CANCER SCI, V102, P1007, DOI 10.1111/j.1349-7006.2011.01908.x; Jia L, 2008, CANCER INVEST, V26, P977, DOI 10.1080/07357900802072723; Ke X, 2012, CARCINOGENESIS, V33, P1598, DOI 10.1093/carcin/bgs196; Kennedy KM, 2010, FUTURE ONCOL, V6, P127, DOI 10.2217/FON.09.145; Kirk P, 2000, EMBO J, V19, P3896, DOI 10.1093/emboj/19.15.3896; Le Floch R, 2011, P NATL ACAD SCI USA, V108, P16663, DOI 10.1073/pnas.1106123108; Lee GH, 2011, ONCOL LETT, V2, P831, DOI 10.3892/ol.2011.353; Li J, 2010, J DERMATOL SCI, V58, P204, DOI 10.1016/j.jdermsci.2010.03.022; Lu HS, 2002, J BIOL CHEM, V277, P23111, DOI 10.1074/jbc.M202487200; Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406; Merezhinskaya N, 2009, HISTOL HISTOPATHOL, V24, P243, DOI 10.14670/HH-24.243; Moon EJ, 2010, P NATL ACAD SCI USA, V107, P20477, DOI 10.1073/pnas.1006646107; Mukhopadhyay P, 2007, NAT PROTOC, V2, P2295, DOI 10.1038/nprot.2007.327; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Porporato PE, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00049; Rademakers SE, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-167; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; SCHEWE T, 1995, GEN PHARMACOL-VASC S, V26, P1153, DOI 10.1016/0306-3623(95)00003-J; Smith JK, 2012, PSYCHOL AESTHET CREA, V6, P1, DOI 10.1037/a0027241; Sonveaux P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033418; Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843; Stock C, 2009, PFLUG ARCH EUR J PHY, V458, P981, DOI 10.1007/s00424-009-0677-8; Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200; Vegran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008-5472.CAN-10-2828; Walenta S, 2004, SEMIN RADIAT ONCOL, V14, P267, DOI 10.1016/j.semradonc.2004.04.004; Walenta S, 2001, INT J RADIAT ONCOL, V51, P840, DOI 10.1016/S0360-3016(01)01700-X; Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365; Webb BA, 2011, NAT REV CANCER, V11, P671, DOI 10.1038/nrc3110; WU R, 1959, J BIOL CHEM, V234, P1036; Xu DS, 2005, MOL CELL PROTEOMICS, V4, P1061, DOI 10.1074/mcp.M400207-MCP200; Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229	49	65	66	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2014	33	31					4060	4068		10.1038/onc.2013.454	http://dx.doi.org/10.1038/onc.2013.454			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YG	24166504	hybrid			2022-12-17	WOS:000340595300005
J	Chew, TW; Liu, XJ; Liu, L; Spitsbergen, J; Gong, Z; Low, BC				Chew, T. W.; Liu, X. J.; Liu, L.; Spitsbergen, J. M.; Gong, Z.; Low, B. C.			Crosstalk of Ras and Rho: activation of RhoA abates Kras-induced liver tumorigenesis in transgenic zebrafish models	ONCOGENE			English	Article						hepatocellular carcinoma; zebrafish; RhoA; Ras; signaling crosstalk; Akt	CELL-PROLIFERATION; SIGNALING PATHWAYS; IN-VIVO; DEPENDENT PHOSPHORYLATION; HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION; DOWN-REGULATION; KINASE PATHWAY; TET-ON; AKT	RAS and Rho small GTPases are key molecular switches that control cell dynamics, cell growth and tissue development through their distinct signaling pathways. Although much has been learnt about their individual functions in both cell and animal models, the physiological and pathophysiological consequences of their signaling crosstalk in multi-cellular context in vivo remain largely unknown, especially in liver development and liver tumorigenesis. Furthermore, the roles of RhoA in RAS-mediated transformation and their crosstalk in vitro remain highly controversial. When challenged with carcinogens, zebrafish developed liver cancer that resembles the human liver cancer both molecularly and histopathologically. Capitalizing on the growing importance and relevance of zebrafish ( Danio rerio) as an alternate cancer model, we have generated liver-specific, Tet-on-inducible transgenic lines expressing oncogenic Kras(G12V), RhoA, constitutively active RhoA(G14V) or dominant-negative Rho(AT19N). Double-transgenic lines expressing Kras(G12V) with one of the three RhoA genes were also generated. Based on quantitative bioimaging and molecular markers for genetic and signaling aberrations, we showed that the induced expression of oncogenic Kras during early development led to liver enlargement and hepatocyte proliferation, associated with elevated Erk phosphorylation, activation of Akt2 and modulation of its two downstream targets, p21Cip and S6 kinase. Such an increase in liver size and Akt2 expression was augmented by dominant-negative Rho(AT19N), but was abrogated by the constitutive-active Rho(AG14V). Consequently, induced expression of the oncogenic Kras in adult transgenic fish led to the development of hepatocellular carcinomas. Survival studies further revealed that the co-expression of dominant-negative Rho(AT19N) with oncogenic Kras increased the mortality rate compared with the other single or double-transgenic lines. This study provides evidence of the previously unappreciated signaling crosstalk between Kras and RhoA in regulating liver overgrowth and liver tumorigenesis. Our results also implicate that activating Rho could be beneficial to suppress the Kras-induced liver malignancies.	[Chew, T. W.; Liu, L.; Low, B. C.] Natl Univ Singapore, Dept Biol Sci, Cell Signaling & Dev Biol Lab, Singapore 117548, Singapore; [Chew, T. W.; Low, B. C.] Natl Univ Singapore, Mechanobiol Inst, T Lab Level 10,5A Engn Dr, Singapore 117411, Singapore; [Liu, X. J.; Gong, Z.] Natl Univ Singapore, Dept Biol Sci, Mol Biol Lab, Singapore 117548, Singapore; [Spitsbergen, J. M.] Oregon State Univ, Dept Microbiol & Marine, Corvallis, OR 97331 USA; [Spitsbergen, J. M.] Oregon State Univ, Freshwater Biomed Sci Ctr, Corvallis, OR 97331 USA	National University of Singapore; National University of Singapore; National University of Singapore; Oregon State University; Oregon State University	Low, BC (corresponding author), Natl Univ Singapore, Mechanobiol Inst, T Lab Level 10,5A Engn Dr, Singapore 117411, Singapore.	dbslowbc@nus.edu.sg	Low, Boon Chuan/AAU-7685-2021; Low, Boon Chuan/H-8049-2012; Gong, Zhiyuan/H-8794-2012	Low, Boon Chuan/0000-0003-0756-096X; Low, Boon Chuan/0000-0003-0756-096X; Gong, Zhiyuan/0000-0002-9660-5260	NUS graduate research scholarship; Biomedical Research Council of Singapore; National Medical Research Council; Mechanobiology Institute of Singapore; National Research Foundation; Ministry of Education, Singapore	NUS graduate research scholarship; Biomedical Research Council of Singapore(Agency for Science Technology & Research (A*STAR)); National Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Mechanobiology Institute of Singapore; National Research Foundation; Ministry of Education, Singapore(Ministry of Education, Singapore)	This work was supported by the NUS graduate research scholarship awarded to TWC and in part by grants from the Biomedical Research Council of Singapore (ZG and BCL), National Medical Research Council (ZG and BCL) and the Mechanobiology Institute of Singapore (BCL), which is co-funded through the National Research Foundation and the Ministry of Education, Singapore.	Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Amatruda JF, 2002, CANCER CELL, V1, P229, DOI 10.1016/S1535-6108(02)00052-1; Nguyen AT, 2012, DIS MODEL MECH, V5, P63, DOI 10.1242/dmm.008367; Nguyen AT, 2011, DIS MODEL MECH, V4, P801, DOI 10.1242/dmm.007831; Beis D, 2006, TRENDS CELL BIOL, V16, P105, DOI 10.1016/j.tcb.2005.12.001; Boorman GA, 1997, TOXICOL PATHOL, V25, P202, DOI 10.1177/019262339702500210; Chen JC, 2003, J BIOL CHEM, V278, P2807, DOI 10.1074/jbc.M207943200; Cox Adrienne D, 2010, Small GTPases, V1, P2; del Pulgar TG, 2005, BIOESSAYS, V27, P602, DOI 10.1002/bies.20238; Dreissigacker U, 2006, CELL SIGNAL, V18, P1156, DOI 10.1016/j.cellsig.2005.09.004; Emelyanov A, 2006, GENETICS, V174, P1095, DOI 10.1534/genetics.106.061184; Feitsma H, 2008, MOL CANCER RES, V6, P685, DOI 10.1158/1541-7786.MCR-07-2167; Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084; Fleming YM, 2009, ONCOGENE, V28, P983, DOI 10.1038/onc.2008.449; Forti FL, 2007, ENDOCR-RELAT CANCER, V14, P1117, DOI 10.1677/ERC-07-0154; Frau M, 2010, MOL ASPECTS MED, V31, P179, DOI 10.1016/j.mam.2010.02.007; Fukui K, 2006, J CANCER RES CLIN, V132, P627, DOI 10.1007/s00432-006-0107-7; Gedaly R, 2012, J SURG RES, V176, P542, DOI 10.1016/j.jss.2011.10.045; Ghosh PM, 2002, CANCER RES, V62, P2630; Gomaa AI, 2008, WORLD J GASTROENTERO, V14, P4300, DOI 10.3748/wjg.14.4300; Gupta S, 2000, MOL CELL BIOL, V20, P9294, DOI 10.1128/MCB.20.24.9294-9306.2000; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Harada N, 2004, CANCER RES, V64, P48, DOI 10.1158/0008-5472.CAN-03-2123; Her GM, 2003, FEBS LETT, V538, P125, DOI 10.1016/S0014-5793(03)00157-1; Izawa I, 1998, ONCOGENE, V17, P2863, DOI 10.1038/sj.onc.1202213; Jackson LN, 2008, AM J PHYSIOL-GASTR L, V294, pG1401, DOI 10.1152/ajpgi.00062.2008; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Karaguni IM, 2002, CANCER RES, V62, P1718; Karreth FA, 2009, CURR OPIN GENET DEV, V19, P4, DOI 10.1016/j.gde.2008.12.006; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kim JH, 2009, P NATL ACAD SCI USA, V106, P11149, DOI 10.1073/pnas.0812651106; Korzh S, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-84; Kumar MS, 2012, CELL, V149, P642, DOI 10.1016/j.cell.2012.02.059; Lam SH, 2006, NAT BIOTECHNOL, V24, P73, DOI 10.1038/nbt1169; Lam SH, 2006, CELL CYCLE, V5, P573, DOI 10.4161/cc.5.6.2550; Li XR, 2006, EJSO-EUR J SURG ONC, V32, P1130, DOI 10.1016/j.ejso.2006.05.012; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Li Z, 2012, J HEPATOL, V56, P419, DOI 10.1016/j.jhep.2011.07.025; Liu LH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002850; Man JH, 2010, J CLIN INVEST, V120, P2829, DOI 10.1172/JCI42542; Mebratu Y, 2009, CELL CYCLE, V8, P1168, DOI 10.4161/cc.8.8.8147; Ming XF, 2002, MOL CELL BIOL, V22, P8467, DOI 10.1128/MCB.22.24.8467-8477.2002; Morin P, 2009, EUR J CELL BIOL, V88, P495, DOI 10.1016/j.ejcb.2009.04.005; Mullany LK, 2007, J BIOL CHEM, V282, P21244, DOI 10.1074/jbc.M702110200; Mure H, 2010, NEURO-ONCOLOGY, V12, P221, DOI 10.1093/neuonc/nop026; O'Shaughnessy RFL, 2007, CANCER RES, V67, P8207, DOI 10.1158/0008-5472.CAN-07-0755; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Pal I, 2012, ACTA PHARMACOL SIN, V33, P1441, DOI 10.1038/aps.2012.72; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-06-0302; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Ravichandran A, 2012, MOL BIOL CELL, V23; Reboredo M, 2008, HUM GENE THER, V19, P1233, DOI 10.1089/hum.2008.057; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Roy HK, 2002, CARCINOGENESIS, V23, P201, DOI 10.1093/carcin/23.1.201; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Shah V, 2001, ONCOGENE, V20, P2112, DOI 10.1038/sj.onc.1204291; Skinner J, 2004, ONCOGENE, V23, P5994, DOI 10.1038/sj.onc.1207798; Spitsbergen JM, 2012, ILAR J, V53, P114, DOI 10.1093/ilar.53.2.114; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Vidal A, 2002, J BIOL CHEM, V277, P16433, DOI 10.1074/jbc.M112090200; Wang DS, 2007, J GASTROEN HEPATOL, V22, P1916, DOI 10.1111/j.1440-1746.2006.04534.x; Westerfield M., 2000, ZEBRAFISH BOOK GUIDE; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Xia MX, 2007, NAT STRUCT MOL BIOL, V14, P215, DOI 10.1038/nsmb1208; Xu XD, 2004, ONCOL REP, V11, P25; Yang S, 2011, BIOMATERIALS, V32, P2851, DOI 10.1016/j.biomaterials.2011.01.015; Zhang YD, 2007, MOL CANCER RES, V5, P909, DOI 10.1158/1541-7786.MCR-06-0388; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou Q, 2011, FUTURE ONCOL, V7, P1149, DOI [10.2217/FON.11.95, 10.2217/fon.11.95]; Zhu S, 2008, ONCOGENE, V27, P1580, DOI 10.1038/sj.onc.1210790; Zhu SZ, 2012, METHODS MOL BIOL, V827, P321, DOI 10.1007/978-1-61779-442-1_21; Zhu SZ, 2006, CELL SIGNAL, V18, P359, DOI 10.1016/j.cellsig.2005.05.019; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	76	65	67	1	32	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2717	2727		10.1038/onc.2013.240	http://dx.doi.org/10.1038/onc.2013.240			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23812423				2022-12-17	WOS:000337231700005
J	Kurokawa, K; Akaike, Y; Masuda, K; Kuwano, Y; Nishida, K; Yamagishi, N; Kajita, K; Tanahashi, T; Rokutan, K				Kurokawa, K.; Akaike, Y.; Masuda, K.; Kuwano, Y.; Nishida, K.; Yamagishi, N.; Kajita, K.; Tanahashi, T.; Rokutan, K.			Downregulation of serine/arginine-rich splicing factor 3 induces G1 cell cycle arrest and apoptosis in colon cancer cells	ONCOGENE			English	Article						SRSF3 (SRp20); G1 arrest; apoptosis; alternative splicing; HIPK2	INTERACTING PROTEIN KINASE-2; SR PROTEINS; OVARIAN-CANCER; FACTOR SRP20; P53 ACTIVITY; DNA-DAMAGE; HIPK2; TRANSCRIPTION; EXPRESSION; PHOSPHORYLATION	Serine/arginine-rich splicing factor 3 (SRSF3) likely has wide-ranging roles in gene expression and facilitation of tumor cell growth. SRSF3 knockdown induced G1 arrest and apoptosis in colon cancer cells (HCT116) in association with altered expression of 833 genes. Pathway analysis revealed 'G1/S Checkpoint Regulation' as the most highly enriched category in the affected genes. SRSF3 knockdown did not induce p53 or stimulate phosphorylation of p53 or histone H2A. X in wild-type HCT116 cells. Furthermore, the knockdown induced G1 arrest in p53-null HCT116 cells, suggesting that p53-dependent DNA damage responses did not mediate the G1 arrest. Real-time reverse transcription-polymerase chain reaction and western blotting confirmed that SRSF3 knockdown reduced mRNA and protein levels of cyclins (D1, D3 and E1), E2F1 and E2F7. The decreased expression of cyclin D and E2F1 likely impaired the G1-to-S-phase progression. Consequently, retinoblastoma protein remained hypophosphorylated in SRSF3 knockdown cells. The knockdown also induced apoptosis in association with reduction of BCL2 protein levels. We also found that SRSF3 knockdown facilitated skipping of 81 5'-nucleotides (27 amino acids) from exon 8 of homeodomain-interacting protein kinase-2 (HIPK2) and produced a HIPK2 Delta e8 isoform. Full-length HIPK2 (HIPK2 FL) is constantly degraded through association with an E3 ubiquitin ligase (Siah-1), whereas HIPK2 Delta e8, lacking the 27 amino acids, lost Siah-1-binding ability and became resistant to proteasome digestion. Interestingly, selective knockdown of HIPK2 FL induced apoptosis in various colon cancer cells expressing wild-type or mutated p53. Thus, these findings disclose an important role of SRSF3 in the regulation of the G1-to-S-phase progression and alternative splicing of HIPK2 in tumor growth.	[Kurokawa, K.; Akaike, Y.; Masuda, K.; Kuwano, Y.; Nishida, K.; Yamagishi, N.; Kajita, K.; Tanahashi, T.; Rokutan, K.] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Stress Sci, Tokushima 7708503, Japan	Tokushima University	Kurokawa, K (corresponding author), Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Stress Sci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	kurokawa178@basic.med.tokushima-u.ac.jp	Nishida, Kensei/AAF-2829-2020	Nishida, Kensei/0000-0003-2314-785X	Japan Society for the Promotion of Science	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was funded by the Grants-in-Aid for Scientific Research from Japan Society for the Promotion of Science (to KR).	Anko ML, 2010, NAT STRUCT MOL BIOL, V17, P962, DOI 10.1038/nsmb.1862; Ahn EY, 2011, MOL CELL, V42, P185, DOI 10.1016/j.molcel.2011.03.014; Aikawa Y, 2006, EMBO J, V25, P3955, DOI 10.1038/sj.emboj.7601273; Anczukow O, 2012, NAT STRUCT MOL BIOL, V19, P220, DOI 10.1038/nsmb.2207; Calzado MA, 2009, NAT CELL BIOL, V11, P85, DOI 10.1038/ncb1816; Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777; Choi DW, 2008, J BIOL CHEM, V283, P4682, DOI 10.1074/jbc.M708873200; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; D'Orazi G, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-63; Ghigna C, 1998, CANCER RES, V58, P5818; Giraud S, 2004, J VIROL, V78, P2984, DOI 10.1128/JVI.78.6.2984-2993.2004; Hailemariam K, 2010, J CELL SCI, V123, P3863, DOI 10.1242/jcs.073627; He X, 2011, ONCOGENE, V30, P356, DOI 10.1038/onc.2010.426; He XL, 2004, CLIN CANCER RES, V10, P4652, DOI 10.1158/1078-0432.CCR-03-0439; Hikasa H, 2010, DEV CELL, V19, P521, DOI 10.1016/j.devcel.2010.09.005; Hofmann TG, 2003, CANCER RES, V63, P8271; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Jumaa H, 1999, CURR BIOL, V9, P899, DOI 10.1016/S0960-9822(99)80394-7; Kim SY, 2009, CANCER LETT, V279, P177, DOI 10.1016/j.canlet.2009.01.036; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kurokawa K, 2010, NEUROSCI LETT, V484, P128, DOI 10.1016/j.neulet.2010.08.031; Kuwano Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024723; Lazzari C, 2011, ONCOGENE, V30, P4802, DOI 10.1038/onc.2011.182; Li XL, 2005, GENE DEV, V19, P2705, DOI 10.1101/gad.1359305; Li XL, 2005, CELL, V122, P365, DOI 10.1016/j.cell.2005.06.008; Lin SR, 2008, NAT STRUCT MOL BIOL, V15, P819, DOI 10.1038/nsmb.1461; Loomis RJ, 2009, MOL CELL, V33, P450, DOI 10.1016/j.molcel.2009.02.003; Lou H, 1998, MOL CELL BIOL, V18, P4977, DOI 10.1128/MCB.18.9.4977; Manley JL, 2010, GENE DEV, V24, P1073, DOI 10.1101/gad.1934910; Moore MJ, 2010, CELL, V142, P625, DOI 10.1016/j.cell.2010.07.019; Puca R, 2010, ONCOGENE, V29, P4378, DOI 10.1038/onc.2010.183; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Sanford JR, 2004, GENE DEV, V18, P755, DOI 10.1101/gad.286404; Sapra AK, 2009, MOL CELL, V34, P179, DOI 10.1016/j.molcel.2009.02.031; Schwerk C, 2005, MOL CELL, V19, P1, DOI 10.1016/j.molcel.2005.05.026; Sombroek D, 2009, CELL DEATH DIFFER, V16, P187, DOI 10.1038/cdd.2008.154; Srebrow A, 2006, J CELL SCI, V119, P2635, DOI 10.1242/jcs.03053; Stickeler E, 1999, ONCOGENE, V18, P3574, DOI 10.1038/sj.onc.1202671; Wei GW, 2007, P NATL ACAD SCI USA, V104, P13040, DOI 10.1073/pnas.0703213104; Winter M, 2008, NAT CELL BIOL, V10, P812, DOI 10.1038/ncb1743; Xiao R, 2007, MOL CELL BIOL, V27, P5393, DOI 10.1128/MCB.00288-07; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhang Z, 2004, MOL CELL, V16, P597, DOI 10.1016/j.molcel.2004.10.031; Zhong XY, 2009, MOL CELL, V35, P1, DOI 10.1016/j.molcel.2009.06.016	44	65	68	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1407	1417		10.1038/onc.2013.86	http://dx.doi.org/10.1038/onc.2013.86			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23503458				2022-12-17	WOS:000332943500008
J	Postel-Vinay, S; Bajrami, I; Friboulet, L; Elliott, R; Fontebasso, Y; Dorvault, N; Olaussen, KA; Andre, F; Soria, JC; Lord, CJ; Ashworth, A				Postel-Vinay, S.; Bajrami, I.; Friboulet, L.; Elliott, R.; Fontebasso, Y.; Dorvault, N.; Olaussen, K. A.; Andre, F.; Soria, J-C; Lord, C. J.; Ashworth, A.			A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer	ONCOGENE			English	Article						non-small cell lung cancer; ERCC1; PARP1; synthetic lethality; DNA repair	NUCLEOTIDE EXCISION-REPAIR; DNA-REPAIR; OVARIAN-CANCER; ERCC1; EXPRESSION; RESISTANCE; CISPLATIN; ENDONUCLEASE; CHEMOTHERAPY; SENSITIVITY	Excision repair cross-complementation group 1 (ERCC1) is a DNA repair enzyme that is frequently defective in non-small cell lung cancer (NSCLC). Although low ERCC1 expression correlates with platinum sensitivity, the clinical effectiveness of platinum therapy is limited, highlighting the need for alternative treatment strategies. To discover new mechanism-based therapeutic strategies for ERCC1-defective tumours, we performed high-throughput drug screens in an isogenic NSCLC model of ERCC1 deficiency and dissected the mechanism underlying ERCC1-selective effects by studying molecular biomarkers of tumour cell response. The high-throughput screens identified multiple clinical poly (ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitors, such as olaparib (AZD-2281), niraparib (MK-4827) and BMN 673, as being selective for ERCC1 deficiency. We observed that ERCC1-deficient cells displayed a significant delay in double-strand break repair associated with a profound and prolonged G2/M arrest following PARP1/2 inhibitor treatment. Importantly, we found that ERCC1 isoform 202, which has recently been shown to mediate platinum sensitivity, also modulated PARP1/2 sensitivity. A PARP1/2 inhibitor-synthetic lethal siRNA screen revealed that ERCC1 deficiency was epistatic with homologous recombination deficiency. However, ERCC1-deficient cells did not display a defect in RAD51 foci formation, suggesting that ERCC1 might be required to process PARP1/2 inhibitor-induced DNA lesions before DNA strand invasion. PARP1 silencing restored PARP1/2 inhibitor resistance in ERCC1-deficient cells but had no effect in ERCC1-proficient cells, supporting the hypothesis that PARP1 might be required for the ERCC1 selectivity of PARP1/2 inhibitors. This study suggests that PARP1/2 inhibitors as a monotherapy could represent a novel therapeutic strategy for NSCLC patients with ERCC1-deficient tumours.	[Postel-Vinay, S.; Bajrami, I.; Elliott, R.; Fontebasso, Y.; Lord, C. J.; Ashworth, A.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Postel-Vinay, S.; Bajrami, I.; Elliott, R.; Fontebasso, Y.; Lord, C. J.; Ashworth, A.] Inst Canc Res, CRUK Gene Funct Lab, London SW3 6JB, England; [Postel-Vinay, S.; Friboulet, L.; Dorvault, N.; Olaussen, K. A.; Andre, F.; Soria, J-C] Inst Gustave Roussy, Dept Med Unite INSERM 981, Villejuif, France; [Olaussen, K. A.; Andre, F.; Soria, J-C] Univ Paris 11, Paris, France	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Lord, CJ (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	chris.lord@icr.ac.uk; alan.ashworth@icr.ac.uk	Soria, Jean-Charles/F-3619-2014; Lord, Christopher J/B-3295-2012; Lord, Christopher/AAX-7130-2021; ANDRE, Fabrice/AAL-2683-2020; friboulet, luc/N-7276-2015	Lord, Christopher J/0000-0002-3226-0515; ANDRE, Fabrice/0000-0001-5795-8357; friboulet, luc/0000-0002-1129-4978; Olaussen, Ken/0000-0002-3115-8914	NHS; Cancer Research UK; European Union; European Society of Medical Oncology; Institut National du Cancer: Bourse pour la Formation a la Recherche Translationnelle; Cancer Research UK [14276] Funding Source: researchfish	NHS; Cancer Research UK(Cancer Research UK); European Union(European Commission); European Society of Medical Oncology; Institut National du Cancer: Bourse pour la Formation a la Recherche Translationnelle; Cancer Research UK(Cancer Research UK)	We thank David Roberston and Marieke Aarts for assistance with confocal microscopy and FACS analysis, and Jerry Shen and Len Post at Biomarin for the provision of BMN 673. We also acknowledge NHS funding to the NIHR Royal Marsden Hospital BRC. This work was supported by grants from Cancer Research UK and The European Union as part of the FP7 teams 'DDResponse' and 'Eurocan'. SPV is supported by a Translational Research Fellowship from the European Society of Medical Oncology (2011 and 2012) and by funding from the Institut National du Cancer: Bourse pour la Formation a la Recherche Translationnelle (2011)	Andre F, 2011, NAT REV CLIN ONCOL, V8, P171, DOI 10.1038/nrclinonc.2011.4; Bajrami I, 2012, EMBO MOL MED, V4, P1087, DOI 10.1002/emmm.201201250; Bergstralh DT, 2008, TRENDS GENET, V24, P70, DOI 10.1016/j.tig.2007.11.003; Camidge DR, 2012, LANCET ONCOL, V13, P1011, DOI 10.1016/S1470-2045(12)70344-3; Chen SF, 2010, LUNG CANCER, V70, P63, DOI 10.1016/j.lungcan.2010.05.010; Cheng HY, 2013, CARCINOGENESIS, V34, P739, DOI 10.1093/carcin/bgs393; Curtin NJ, 2012, NAT REV CANCER, V12, P801, DOI 10.1038/nrc3399; DABHOLKAR M, 1995, ONCOL REP, V2, P209; Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548; Fagbemi AF, 2011, DNA REPAIR, V10, P722, DOI 10.1016/j.dnarep.2011.04.022; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Friboulet L, 2013, NEW ENGL J MED, V368, P1101, DOI 10.1056/NEJMoa1214271; Graeser M, 2010, CLIN CANCER RES, V16, P6159, DOI 10.1158/1078-0432.CCR-10-1027; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Johnson N, 2011, NAT MED, V17, P875, DOI 10.1038/nm.2377; Kedar PS, 2012, MOL CANCER RES, V10, P360, DOI 10.1158/1541-7786.MCR-11-0477; Kirschner K, 2010, ANTICANCER RES, V30, P3223; Langelier MF, 2012, SCIENCE, V336, P728, DOI 10.1126/science.1216338; Langelier MF, 2011, J BIOL CHEM, V286, P10690, DOI 10.1074/jbc.M110.202507; Langer CJ, 2012, CANCER-AM CANCER SOC, V118, P3882, DOI 10.1002/cncr.26718; Lord CJ, 2009, J CLIN PATHOL, V62, P195, DOI 10.1136/jcp.2008.058735; Lord RVN, 2002, CLIN CANCER RES, V8, P2286; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Metzger R, 2010, FUTURE ONCOL, V6, P1735, DOI [10.2217/fon.10.140, 10.2217/FON.10.140]; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Niedernhofer LJ, 2001, EMBO J, V20, P6540, DOI 10.1093/emboj/20.22.6540; Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570; Patterson MJ, 2012, EUR J CANCER, V48, P106, DOI 10.1016/S0959-8049(12)72146-9; Postel-Vinay S, 2012, NAT REV CLIN ONCOL, V9, P144, DOI 10.1038/nrclinonc.2012.3; Rehman FL, 2010, NAT REV CLIN ONCOL, V7, P718, DOI 10.1038/nrclinonc.2010.172; Sijbers AM, 1996, NUCLEIC ACIDS RES, V24, P3370, DOI 10.1093/nar/24.17.3370; Simon GR, 2012, CANCER-AM CANCER SOC, V118, P2525, DOI 10.1002/cncr.26522; Steffensen KD, 2009, INT J GYNECOL CANCER, V19, P820, DOI 10.1111/IGC.0b013e3181a12e09; Sun YH, 2009, CANCER INVEST, V27, P891, DOI 10.3109/07357900902744536; Tripsianes K, 2005, STRUCTURE, V13, P1849, DOI 10.1016/j.str.2005.08.014; Turner NC, 2008, EMBO J, V27, P1368, DOI 10.1038/emboj.2008.61; Vilmar AC, 2011, EUR RESPIR REV, V20, P45, DOI 10.1183/09059180.00007310; Vilmar AC, 2010, ANN ONCOL, V21, P1817, DOI 10.1093/annonc/mdq053; Wang B, 2009, MOL CANCER THER, V8, DOI 10.1158/1535-7163.TARG-09-A121; Yin M, 2011, CLIN CANCER RES, V17, P1632, DOI 10.1158/1078-0432.CCR-10-2169; Zhang YW, 2011, NUCLEIC ACIDS RES, V39, P3607, DOI 10.1093/nar/gkq1304	41	65	67	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2013	32	47					5377	5387		10.1038/onc.2013.311	http://dx.doi.org/10.1038/onc.2013.311			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	254PM	23934192				2022-12-17	WOS:000327177600001
J	Das, S; Bryan, K; Buckley, PG; Piskareva, O; Bray, IM; Foley, N; Ryan, J; Lynch, J; Creevey, L; Fay, J; Prenter, S; Koster, J; van Sluis, P; Versteeg, R; Eggert, A; Schulte, JH; Schramm, A; Mestdagh, P; Vandesompele, J; Speleman, F; Stallings, RL				Das, S.; Bryan, K.; Buckley, P. G.; Piskareva, O.; Bray, I. M.; Foley, N.; Ryan, J.; Lynch, J.; Creevey, L.; Fay, J.; Prenter, S.; Koster, J.; van Sluis, P.; Versteeg, R.; Eggert, A.; Schulte, J. H.; Schramm, A.; Mestdagh, P.; Vandesompele, J.; Speleman, F.; Stallings, R. L.			Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs	ONCOGENE			English	Article						miRNA; methylation; tumor suppressor; neuroblastoma; SOX2	TUMOR-SUPPRESSOR; PROMOTES TRANSFORMATION; TRANSCRIPTION FACTOR; CELL-PROLIFERATION; RETINOIC ACID; EXPRESSION; METHYLATION; GENE; DIFFERENTIATION; PATTERNS	MicroRNAs (miRNAs) contribute to the pathogenesis of many forms of cancer, including the pediatric cancer neuroblastoma, but the underlying mechanisms leading to altered miRNA expression are often unknown. Here, a novel integrated approach for analyzing DNA methylation coupled with miRNA and mRNA expression data sets identified 67 epigenetically regulated miRNA in neuroblastoma. A large proportion (42%) of these miRNAs was associated with poor patient survival when underexpressed in tumors. Moreover, we demonstrate that this panel of epigenetically silenced miRNAs targets a large set of genes that are overexpressed in tumors from patients with poor survival in a highly redundant manner. The genes targeted by the epigenetically regulated miRNAs are enriched for a number of biological processes, including regulation of cell differentiation. Functional studies involving ectopic overexpression of several of the epigenetically silenced miRNAs had a negative impact on neuroblastoma cell viability, providing further support to the concept that inactivation of these miRNAs is important for neuroblastoma disease pathogenesis. One locus, miR-340, induced either differentiation or apoptosis in a cell context dependent manner, indicating a tumor suppressive function for this miRNA. Intriguingly, it was determined that miR-340 is upregulated by demethylation of an upstream genomic region that occurs during the process of neuroblastoma cell differentiation induced by all-trans retinoic acid (ATRA). Further biological studies of miR-340 revealed that it directly represses the SOX2 transcription factor by targeting of its 30-untranslated region, explaining the mechanism by which SOX2 is downregulated by ATRA. Although SOX2 contributes to the maintenance of stem cells in an undifferentiated state, we demonstrate that miR-340-mediated downregulation of SOX2 is not required for ATRA induced differentiation to occur. In summary, our results exemplify the dynamic nature of the miRNA epigenome and identify a remarkable network of miRNA/mRNA interactions that significantly contribute to neuroblastoma disease pathogenesis.	[Das, S.; Bryan, K.; Buckley, P. G.; Piskareva, O.; Bray, I. M.; Foley, N.; Ryan, J.; Lynch, J.; Creevey, L.; Fay, J.; Prenter, S.; Stallings, R. L.] Royal Coll Surgeons Ireland, Dept Mol & Cellular Therapeut, Dublin 2, Ireland; [Das, S.; Bryan, K.; Buckley, P. G.; Piskareva, O.; Bray, I. M.; Foley, N.; Ryan, J.; Lynch, J.; Creevey, L.; Fay, J.; Prenter, S.; Stallings, R. L.] Our Ladys Childrens Hosp, Natl Childrens Res Ctr, Dublin, Ireland; [Koster, J.; van Sluis, P.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Eggert, A.; Schulte, J. H.; Schramm, A.] Univ Childrens Hosp, Essen, Germany; [Mestdagh, P.; Vandesompele, J.; Speleman, F.] Ghent Univ Hosp, Ctr Med Genet, Ghent, Belgium	Royal College of Surgeons - Ireland; National Children's Research Centre (NCRC); Our Ladys Children Hospital Crumlin; Trinity College Dublin; University of Amsterdam; Academic Medical Center Amsterdam; University of Duisburg Essen; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ghent University; Ghent University Hospital	Stallings, RL (corresponding author), Royal Coll Surgeons Ireland, Dept Mol & Cellular Therapeut, York House,York St, Dublin 2, Ireland.	rstallings@rcsi.ie	Versteeg, Rogier/AAQ-1765-2020; Vandesompele, Jo/W-3411-2018; Eggert, Angelika/AAE-6907-2022; Schulte, Johannes H/G-3981-2010; Schulte, Johannes H./V-2474-2018; Koster, Jan/C-5934-2008; Schramm, Alexander/G-5688-2010; Stallings, Raymond/A-7213-2008; speleman, frank/AAR-5184-2020	Vandesompele, Jo/0000-0001-6274-0184; Eggert, Angelika/0000-0003-3476-8184; Koster, Jan/0000-0002-0890-7585; Schramm, Alexander/0000-0001-7670-7529; speleman, frank/0000-0002-6628-8559; Versteeg, Rogier/0000-0001-7172-0388; Fay, Joanna/0000-0001-6294-2886; Mestdagh, Pieter/0000-0001-7821-9684; Schulte, Johannes Hubertus/0000-0003-0671-1201; Bryan, Kenneth/0000-0002-9550-8354	Science Foundation Ireland [07/IN.1/B1776]; Children's Medical and Research Foundation; NIH [5R01CA127496]; NATIONAL CANCER INSTITUTE [R01CA127496] Funding Source: NIH RePORTER	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Children's Medical and Research Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from Science Foundation Ireland (07/IN.1/B1776), Children's Medical and Research Foundation and NIH (5R01CA127496).	Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bray I, 2011, CANCER LETT, V303, P56, DOI 10.1016/j.canlet.2011.01.016; Bray I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007850; Buckley PG, 2011, INT J CANCER, V128, P2296, DOI 10.1002/ijc.25584; Buckley PG, 2010, CLIN CANCER RES, V16, P2971, DOI 10.1158/1078-0432.CCR-09-3215; Buechner J, 2011, BRIT J CANCER, V105, P296, DOI 10.1038/bjc.2011.220; Chen YX, 2007, CANCER RES, V67, P976, DOI 10.1158/0008-5472.CAN-06-3667; Chim CS, 2010, CARCINOGENESIS, V31, P745, DOI 10.1093/carcin/bgq033; Corcoran DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005279; Das S, 2010, CANCER RES, V70, P7874, DOI 10.1158/0008-5472.CAN-10-1534; Decock A, 2011, EPIGENETICS-US, V6, P962, DOI 10.4161/epi.6.8.16516; Gomez-Mateo MD, 2011, GENE CHROMOSOME CANC, V50, P374, DOI 10.1002/gcc.20859; Dudziec E, 2011, CLIN CANCER RES, V17, P1287, DOI 10.1158/1078-0432.CCR-10-2017; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Foley NH, 2011, CELL DEATH DIFFER, V18, P1089, DOI 10.1038/cdd.2010.172; Foley NH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-83; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Fujita S, 2008, BIOINFORMATICS, V24, P303, DOI 10.1093/bioinformatics/btm589; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Garzon R, 2009, BLOOD, V114, P5331, DOI 10.1182/blood-2009-03-211938; Girgert R, 1997, J NEURO-ONCOL, V31, P93, DOI 10.1023/A:1005789516322; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hoebeeck J, 2009, CANCER LETT, V273, P336, DOI 10.1016/j.canlet.2008.08.019; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Jankowski MP, 2006, NEUROSCIENCE, V143, P501, DOI 10.1016/j.neuroscience.2006.09.010; Johnson CD, 2007, CANCER RES, V67, P7713, DOI 10.1158/0008-5472.CAN-07-1083; Kunej T, 2011, MUTAT RES-FUND MOL M, V717, P77, DOI 10.1016/j.mrfmmm.2011.03.008; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Lopez-Serra P., 2011, ONCOGENE; Lynch J, 2012, CARCINOGENESIS, V33, P976, DOI 10.1093/carcin/bgs114; Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020; Mestdagh P, 2010, ONCOGENE, V29, P1394, DOI 10.1038/onc.2009.429; Mestdagh P, 2010, MOL CELL, V40, P762, DOI 10.1016/j.molcel.2010.11.038; Murphy DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008154; Ozsolak F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508; Patel M, 2010, STEM CELL REV REP, V6, P367, DOI 10.1007/s12015-010-9123-8; Saetrom P, 2007, NUCLEIC ACIDS RES, V35, P2333, DOI 10.1093/nar/gkm133; Saini HK, 2007, P NATL ACAD SCI USA, V104, P17719, DOI 10.1073/pnas.0703890104; Schulte JH, 2010, INT J CANCER, V127, P2374, DOI 10.1002/ijc.25436; SIDELL N, 1982, J NATL CANCER I, V68, P589; Stallings RL, 2010, EXPERT OPIN THER TAR, V14, P951, DOI 10.1517/14728222.2010.510136; Stallings RL, 2011, SEMIN CANC BIOL; Stevanovic M, 2003, MOL BIOL REP, V30, P127, DOI 10.1023/A:1023961009869; Tivnan A, 2010, ANTICANCER RES, V30, P4391; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Vogt M, 2011, VIRCHOWS ARCH, V458, P313, DOI 10.1007/s00428-010-1030-5; Wang YC, 2010, CARCINOGENESIS, V31, P1516, DOI 10.1093/carcin/bgq107; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Wu ZS, 2011, CANCER-AM CANCER SOC, V117, P2842, DOI 10.1002/cncr.25860; Xu T, 2009, HEPATOLOGY, V50, P113, DOI 10.1002/hep.22919; Yang QW, 2007, CLIN CANCER RES, V13, P3191, DOI 10.1158/1078-0432.CCR-06-2846; Yang QW, 2004, CANCER RES, V64, P4531, DOI 10.1158/0008-5472.CAN-04-0956; Zhao JJ, 2010, BLOOD, V115, P2630, DOI 10.1182/blood-2009-09-243147	56	65	68	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2013	32	24					2927	2936		10.1038/onc.2012.311	http://dx.doi.org/10.1038/onc.2012.311			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WV	22797059	Green Accepted			2022-12-17	WOS:000320369700003
J	Wu, CL; Qiang, L; Han, W; Ming, M; Viollet, B; He, YY				Wu, C. L.; Qiang, L.; Han, W.; Ming, M.; Viollet, B.; He, Y. Y.			Role of AMPK in UVB-induced DNA damage repair and growth control	ONCOGENE			English	Article							NUCLEOTIDE EXCISION-REPAIR; CYCLOBUTANE PYRIMIDINE DIMERS; ACTIVATED PROTEIN-KINASE; NONMELANOMA SKIN-CANCER; XERODERMA-PIGMENTOSUM; HUMAN KERATINOCYTES; ULTRAVIOLET-B; CELL-GROWTH; PATHWAY; IRRADIATION	Skin cancer is the most common cancer in the United States, while DNA-damaging ultraviolet B (UVB) radiation from the sun remains the major environmental risk factor. Reducing skin cancer incidence is becoming an urgent issue. The energy-sensing enzyme 50-AMP-activated protein kinase (AMPK) has a key role in the regulation of cellular lipid and protein metabolism in response to stimuli such as exercise and changes in fuel availability. However, the role of AMPK in the response of skin cells to UVB damage and in skin cancer prevention remains unknown. Here we show that AMPK activation is reduced in human and mouse squamous cell carcinoma as compared with normal skin, and by UVB irradiation, suggesting that AMPK is a tumor suppressor. At the molecular level, AMPK deletion reduced the expression of the DNA repair protein xeroderma pigmentosum C (XPC) and UVB-induced DNA repair. AMPK activation by its activators AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) and metformin (N', N'-dimethylbiguanide), the most widely used antidiabetic drug, increased the expression of XPC and UVB-induced DNA repair in mouse skin, normal human epidermal keratinocytes, and AMPK wild-type (WT) cells but not in AMPK-deficient cells, indicating an AMPK-dependent mechanism. Topical treatment with AICAR and metformin not only delayed onset of UVB-induced skin tumorigenesis but also reduced tumor multiplicity. Furthermore, AMPK deletion increased extracellular signal-regulated kinase (ERK) activation and cell proliferation, whereas AICAR and metformin inhibited ERK activation and cell proliferation in keratinocytes, mouse skin, AMPK WT and AMPK-deficient cells, suggesting an AMPK-independent mechanism. Finally, in UVB-damaged tumorbearing mice, both topical and systemic metformin prevented the formation of new tumors and suppressed growth of established tumors. Our findings not only suggest that AMPK is a tumor suppressor in the skin by promoting DNA repair and controlling cell proliferation, but also demonstrate previously unknown mechanisms by which the AMPK activators prevent UVB-induced skin tumorigenesis.	[Wu, C. L.] China Med Univ, Dept Radiat Oncol, Affiliated Hosp 4, Shenyang, Peoples R China; [Wu, C. L.; Qiang, L.; Han, W.; Ming, M.; He, Y. Y.] Univ Chicago, Dept Med, Dermatol Sect, Chicago, IL 60637 USA; [Viollet, B.] Inst Cochin, INSERM, U1016, Paris, France; [Viollet, B.] CNRS, UMR8104, Paris, France; [Viollet, B.] Univ Paris 05, Sorbonne Paris Cite, Paris, France	China Medical University; University of Chicago; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	He, YY (corresponding author), Univ Chicago, Dept Med, Dermatol Sect, 5841 S Maryland Ave,MC5067, Chicago, IL 60637 USA.	yyhe@medicine.bsd.uchicago.edu	Qiang, Lei/B-2763-2012; Viollet, Benoit/N-2397-2019; Viollet, Benoit/O-6927-2017	Qiang, Lei/0000-0002-7164-3164; Viollet, Benoit/0000-0002-0121-0224; Viollet, Benoit/0000-0002-0121-0224	NIH [ES016936]; University of Chicago Comprehensive Cancer Center Pilot program [P30 CA014599]; CTSA [NIH UL1RR024999]; UC Friends of Dermatology Research Funds; NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016936] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Chicago Comprehensive Cancer Center Pilot program; CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); UC Friends of Dermatology Research Funds; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by NIH grant ES016936 (YYH), the University of Chicago Comprehensive Cancer Center Pilot program (P30 CA014599), the CTSA (NIH UL1RR024999) and UC Friends of Dermatology Research Funds. We thank Terri Li for the Ki67 immunohistochemistry, Dr Pradip Raychaudhuri (University of Illinois at Chicago, Chicago, IL, USA) for kindly providing the XPC promoter luciferase construct, and Dr Ann Motten for critical reading of the manuscript.	Ben Sahra I, 2011, CANCER RES, V71, P4366, DOI 10.1158/0008-5472.CAN-10-1769; Ben Sahra I, 2010, MOL CANCER THER, V9, P1092, DOI 10.1158/1535-7163.MCT-09-1186; Bode Ann M, 2003, Sci STKE, V2003, pRE2, DOI 10.1126/stke.2003.167.re2; Bowden GT, 2004, NAT REV CANCER, V4, P23, DOI 10.1038/nrc1253; Cleaver JE, 2009, NAT REV GENET, V10, P756, DOI 10.1038/nrg2663; Cleaver JE, 2005, NAT REV CANCER, V5, P564, DOI 10.1038/nrc1652; Drakos E, 2009, LEUKEMIA, V23, P784, DOI 10.1038/leu.2008.348; Du JH, 2008, BIOCHEM BIOPH RES CO, V368, P402, DOI 10.1016/j.bbrc.2008.01.099; Foretz M, 2010, J CLIN INVEST, V120, P2355, DOI 10.1172/JCI40671; Fu XA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002009; Garinis GA, 2005, EMBO J, V24, P3952, DOI 10.1038/sj.emboj.7600849; Green AS, 2010, BLOOD, V116, P4262, DOI 10.1182/blood-2010-02-269837; Guo DL, 2009, P NATL ACAD SCI USA, V106, P12932, DOI 10.1073/pnas.0906606106; Han WN, 2011, J BIOL CHEM, V286, P22825, DOI 10.1074/jbc.M111.222349; He YY, 2006, ONCOGENE, V25, P3680, DOI 10.1038/sj.onc.1209384; Jans J, 2005, CURR BIOL, V15, P105, DOI 10.1016/j.cub.2005.01.001; Johnson TM, 1998, J AM ACAD DERMATOL, V38, P681, DOI 10.1016/S0190-9622(98)70196-3; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kim J, 2001, J BIOL CHEM, V276, P19102, DOI 10.1074/jbc.M011579200; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; KRAEMER KH, 1984, CARCINOGENESIS, V5, P511, DOI 10.1093/carcin/5.4.511; KRAEMER KH, 1994, ARCH DERMATOL, V130, P1018, DOI 10.1001/archderm.130.8.1018; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Luo ZJ, 2010, FUTURE ONCOL, V6, P457, DOI [10.2217/fon.09.174, 10.2217/FON.09.174]; Luo ZJ, 2005, TRENDS PHARMACOL SCI, V26, P69, DOI 10.1016/j.tips.2004.12.011; Maeda T, 2001, J INVEST DERMATOL, V117, P1490, DOI 10.1046/j.0022-202x.2001.01562.x; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Miller RA, 2010, J CLIN INVEST, V120, P2267, DOI 10.1172/JCI43661; Ming M, 2010, ONCOGENE, V29, P492, DOI 10.1038/onc.2009.357; Ming M, 2011, CANCER RES, V71, P5287, DOI 10.1158/0008-5472.CAN-10-4614; Ming M, 2010, P NATL ACAD SCI USA, V107, P22623, DOI 10.1073/pnas.1010377108; Nathan DM, 2009, DIABETES CARE, V32, P193, DOI 10.2337/dc08-9025; NIGGLI HJ, 1988, J INVEST DERMATOL, V91, P579, DOI 10.1111/1523-1747.ep12477095; Pollak M, 2010, CANCER PREV RES, V3, P1060, DOI 10.1158/1940-6207.CAPR-10-0175; Ries G, 2000, NATURE, V406, P98, DOI 10.1038/35017595; Saha AK, 2006, BIOCHEM BIOPH RES CO, V349, P519, DOI 10.1016/j.bbrc.2006.08.107; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Sugasawa K, 2006, J MOL HISTOL, V37, P189, DOI 10.1007/s10735-006-9044-7; VINK AA, 1991, CARCINOGENESIS, V12, P861, DOI 10.1093/carcin/12.5.861; Wang JR, 2009, J BIOL CHEM, V284, P21412, DOI 10.1074/jbc.M109.026013; Wischermann K, 2008, ONCOGENE, V27, P4269, DOI 10.1038/onc.2008.70; Woodard J, 2010, BIOCHEM BIOPH RES CO, V398, P135, DOI 10.1016/j.bbrc.2010.06.052; You YH, 2001, J BIOL CHEM, V276, P44688, DOI 10.1074/jbc.M107696200; Zhang J, 2008, MOL CARCINOGEN, V47, P974, DOI 10.1002/mc.20450	45	65	68	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 23	2013	32	21					2682	2689		10.1038/onc.2012.279	http://dx.doi.org/10.1038/onc.2012.279			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FH	22751115	Green Accepted			2022-12-17	WOS:000319806700009
J	Cai, Q; Lin, T; Kamarajugadda, S; Lu, J				Cai, Q.; Lin, T.; Kamarajugadda, S.; Lu, J.			Regulation of glycolysis and the Warburg effect by estrogen-related receptors	ONCOGENE			English	Article						aerobic glycolysis; Warburg effect; nuclear receptor; Randle cycle	PYRUVATE-DEHYDROGENASE KINASE; CANCER-CELL METABOLISM; PDK4 GENE-EXPRESSION; TRANSCRIPTIONAL CONTROL; ERR-ALPHA; HYPOXIA; MYC; SWITCH; PGC-1-ALPHA; ADAPTATION	Cancer cells typically display altered glucose metabolism characterized by a preference of aerobic glycolysis, known as the Warburg effect, which facilitates cell proliferation. Hypoxia-inducible factor (HIF) and oncoprotein Myc are two prominent transcription factors that drive glycolysis. Previously, we reported that the estrogen-related receptors (ERRs) act as cofactors of HIF and enhance HIF-dependent transcription of glycolytic genes under hypoxia. ERRs are orphan nuclear receptors and key regulators of energy metabolism by orchestrating mitochondrial biogenesis, fatty acid oxidation (FAO) and oxidative phosphorylation. Here, we show that ERRs also stimulate glycolysis under normoxia. ERRs directly bind to and activate promoters of many genes encoding glycolytic enzymes, and the ERR-binding sites in such promoters are essential for ERR-mediated transcriptional activation. ERRs interact with Myc, and the two factors synergistically activate transcription of glycolytic genes. Furthermore, overexpression of ERRs increases glycolytic gene expression and lactate production. Conversely, depletion of ERRs in cancer cells reduces expression of glycolytic genes and glucose uptake, resulting in decreased aerobic glycolysis and cell growth. Taken together, these results suggest that ERRs are important transcriptional activators of the glycolytic pathway and contribute to the Warburg effect in cancer cells. Oncogene (2013) 32, 2079-2086; doi:10.1038/onc.2012.221; published online 4 June 2012	[Cai, Q.; Lin, T.; Kamarajugadda, S.; Lu, J.] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Lu, J (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, POB 103633, Gainesville, FL 32610 USA.	jrlu@ufl.edu	Cai, Qingsong/J-6428-2012; Lu, Jianrong/F-5240-2013	Lu, Jianrong/0000-0002-4969-6040	National Cancer Institute [R01CA137021]; Florida Bankhead-Coley Cancer Research Program [09BN-12-23092, 2BT01]; NATIONAL CANCER INSTITUTE [R01CA137021] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Florida Bankhead-Coley Cancer Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Cancer Institute (R01CA137021) and Florida Bankhead-Coley Cancer Research Program (09BN-12-23092 and 2BT01).	Ao A, 2008, P NATL ACAD SCI USA, V105, P7821, DOI 10.1073/pnas.0711677105; Araki M, 2006, FEBS J, V273, P1669, DOI 10.1111/j.1742-4658.2006.05183.x; Ariazi EA, 2006, CURR TOP MED CHEM, V6, P203, DOI 10.2174/1568026610606030203; Chang CY, 2011, CANCER CELL, V20, P500, DOI 10.1016/j.ccr.2011.08.023; Charest-Marcotte A, 2010, GENE DEV, V24, P537, DOI 10.1101/gad.1871610; Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Deblois G, 2009, CANCER RES, V69, P6149, DOI 10.1158/0008-5472.CAN-09-1251; Dufour CR, 2007, CELL METAB, V5, P345, DOI 10.1016/j.cmet.2007.03.007; Eichner LJ, 2010, CELL METAB, V12, P352, DOI 10.1016/j.cmet.2010.09.002; Giguere V, 2008, ENDOCR REV, V29, P677, DOI 10.1210/er.2008-0017; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hock MB, 2009, ANNU REV PHYSIOL, V71, P177, DOI 10.1146/annurev.physiol.010908.163119; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Hue L, 2009, AM J PHYSIOL-ENDOC M, V297, pE578, DOI 10.1152/ajpendo.00093.2009; Jose C, 2011, BBA-BIOENERGETICS, V1807, P552, DOI 10.1016/j.bbabio.2010.10.012; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kim JW, 2004, MOL CELL BIOL, V24, P5923, DOI 10.1128/MCB.24.13.5923-5936.2004; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Semenza GL, 2011, BBA-MOL CELL RES, V1813, P1263, DOI 10.1016/j.bbamcr.2010.08.006; Semenza GL, 2009, SEMIN CANCER BIOL, V19, P12, DOI 10.1016/j.semcancer.2008.11.009; Stein RA, 2008, CANCER RES, V68, P8805, DOI 10.1158/0008-5472.CAN-08-1594; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Tennessen JM, 2011, CELL METAB, V13, P139, DOI 10.1016/j.cmet.2011.01.005; Wende AR, 2005, MOL CELL BIOL, V25, P10684, DOI 10.1128/MCB.25.24.10684-10694.2005; Wu M, 2007, AM J PHYSIOL-CELL PH, V292, pC125, DOI 10.1152/ajpcell.00247.2006; Zhang Y, 2006, J BIOL CHEM, V281, P39897, DOI 10.1074/jbc.M608657200	34	65	66	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2013	32	16					2079	2086		10.1038/onc.2012.221	http://dx.doi.org/10.1038/onc.2012.221			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	130LY	22665055	Green Accepted			2022-12-17	WOS:000317919900009
J	Wei, S; Chen, X; McGraw, K; Zhang, L; Komrokji, R; Clark, J; Caceres, G; Billingsley, D; Sokol, L; Lancet, J; Fortenbery, N; Zhou, J; Eksioglu, EA; Sallman, D; Wang, H; Epling-Burnettel, PK; Djeu, J; Sekeres, M; Maciejewski, JP; List, A				Wei, S.; Chen, X.; McGraw, K.; Zhang, L.; Komrokji, R.; Clark, J.; Caceres, G.; Billingsley, D.; Sokol, L.; Lancet, J.; Fortenbery, N.; Zhou, J.; Eksioglu, E. A.; Sallman, D.; Wang, H.; Epling-Burnettel, P. K.; Djeu, J.; Sekeres, M.; Maciejewski, J. P.; List, A.			Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion	ONCOGENE			English	Article						myelodysplastic syndrome; drug resistance; MDM2	RIBOSOMAL-PROTEIN L11; CANCER; PP2A; PHOSPHORYLATION; UBIQUITINATION; IDENTIFICATION; 5Q-SYNDROME; MUTATIONS; MECHANISM; PATHWAY	Allelic deletion of the RPS14 gene is a key effector of the hypoplastic anemia in patients with myelodysplastic syndrome (MDS) and chromosome 5q deletion (del(5q)). Disruption of ribosome integrity liberates free ribosomal proteins to bind to and trigger degradation of mouse double minute 2 protein (MDM2), with consequent p53 transactivation. Herein we show that p53 is overexpressed in erythroid precursors of primary bone marrow del(5q) MDS specimens accompanied by reduced cellular MDM2. More importantly, we show that lenalidonnide (Len) acts to stabilize MDM2, thereby accelerating p53 degradation. Biochemical and molecular analyses showed that Len inhibits the haplodeficient protein phosphatase 2A catalytic domain alpha (PP2Ac alpha) phosphatase resulting in hyperphosphorylation of inhibitory serine-166 and serine-186 residues on MDM2, and displaces binding of RPS14 to suppress MDM2 autoubiquitination whereas PP2Ac alpha overexpression promotes drug resistance. Bone marrow specimens from del(5q) MDS patients resistant to Len overexpressed PP2Ac alpha accompanied by restored accumulation of p53 in erythroid precursors. Our findings indicate that Len restores MDM2 functionality in the 5q-syndrome to overcome p53 activation in response to nucleolar stress, and therefore may warrant investigation in other disorders of ribosomal biogenesis. Oncogene (2013) 32, 1110-1120; doi:10.1038/onc.2012.139; published online 23 April 2012	[Wei, S.; Chen, X.; McGraw, K.; Zhang, L.; Komrokji, R.; Clark, J.; Caceres, G.; Billingsley, D.; Sokol, L.; Lancet, J.; Fortenbery, N.; Zhou, J.; Eksioglu, E. A.; Sallman, D.; Wang, H.; Epling-Burnettel, P. K.; Djeu, J.; List, A.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33647 USA; [Sekeres, M.; Maciejewski, J. P.] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA	H Lee Moffitt Cancer Center & Research Institute; Cleveland Clinic Foundation	Wei, S (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, MRC 4072,12902 Magnolia Dr, Tampa, FL 33647 USA.	sheng.wei@moffitt.org	Eksioglu, Erika/E-6315-2015	Eksioglu, Erika/0000-0003-4458-7192; LIST, ALAN/0000-0002-1647-2972; Sekeres, Mikkael/0000-0003-2009-6524	NIH [1R01CA131076, AI056213]; NATIONAL CANCER INSTITUTE [R01CA131076, P30CA076292] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056213] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by NIH Grants 1R01CA131076 and AI056213.	Barlow JL, 2010, NAT MED, V16, P59, DOI 10.1038/nm.2063; Dai MS, 2006, J BIOL CHEM, V281, P24304, DOI 10.1074/jbc.M602596200; Danilova N, 2008, BLOOD, V112, P5228, DOI 10.1182/blood-2008-01-132290; Dutt S, 2011, BLOOD, V117, P2567, DOI 10.1182/blood-2010-07-295238; Ebert BL, 2009, LEUKEMIA, V23, P1252, DOI 10.1038/leu.2009.53; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Ebert BL, 2011, SEMIN ONCOL, V38, P621, DOI 10.1053/j.seminoncol.2011.04.010; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Gandhi AK, 2006, LEUKEMIA RES, V30, P849, DOI 10.1016/j.leukres.2006.01.010; Ginzinger DG, 2000, CANCER RES, V60, P5405; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Ito T, 2010, SCIENCE, V327, P1345, DOI 10.1126/science.1177319; Jadersten M, 2011, J CLIN ONCOL, V29, P1971, DOI 10.1200/JCO.2010.31.8576; Jones NC, 2008, NAT MED, V14, P125, DOI 10.1038/nm1725; Joslin JM, 2007, BLOOD, V110, P719, DOI 10.1182/blood-2007-01-068809; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Lehmann S, 2007, LEUKEMIA, V21, P1931, DOI 10.1038/sj.leu.2404852; Li HH, 2004, MOL CELL, V13, P867, DOI 10.1016/S1097-2765(04)00123-6; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; List A, 2005, NEW ENGL J MED, V352, P549, DOI 10.1056/NEJMoa041668; List A, 2006, NEW ENGL J MED, V355, P1456, DOI 10.1056/NEJMoa061292; List A, 2009, CLIN LYMPHOMA MYELOM, V9, pS302, DOI 10.3816/CLM.2009.s.028; Liu G, 2007, J PATHOL, V213, P360, DOI 10.1002/path.2238; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Look A Thomas, 2005, Hematology Am Soc Hematol Educ Program, P156; McGowan KA, 2008, NAT GENET, V40, P963, DOI 10.1038/ng.188; Meek DW, 2010, SEMIN CANCER BIOL, V20, P19, DOI 10.1016/j.semcancer.2009.10.005; Meek DW, 2003, MOL CANCER RES, V1, P1017; Mi J, 2009, MOL CANCER THER, V8, P135, DOI 10.1158/1535-7163.MCT-08-0457; Nimer SD, 2008, BLOOD, V111, P4841, DOI 10.1182/blood-2007-08-078139; OCONNOR PM, 1993, CANCER RES, V53, P4776; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Quarello P, 2010, HAEMATOL-HEMATOL J, V95, P206, DOI 10.3324/haematol.2009.011783; Starczynowski DT, 2010, NAT MED, V16, P49, DOI 10.1038/nm.2054; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Volonte D, 2009, AGING-US, V1, P831, DOI 10.18632/aging.100079; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wei S, 2009, P NATL ACAD SCI USA, V106, P12974, DOI 10.1073/pnas.0811267106; Westermarck J, 2008, TRENDS MOL MED, V14, P152, DOI 10.1016/j.molmed.2008.02.001; Whelan JA, 2003, J IMMUNOL METHODS, V278, P261, DOI 10.1016/S0022-1759(03)00223-0; Yokobori T, 2009, CANCER RES, V69, P3788, DOI 10.1158/0008-5472.CAN-08-2846; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	48	65	71	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2013	32	9					1110	1120		10.1038/onc.2012.139	http://dx.doi.org/10.1038/onc.2012.139			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110FU	22525275	Green Accepted			2022-12-17	WOS:000316428800005
J	Brooks, K; Oakes, V; Edwards, B; Ranall, M; Leo, P; Pavey, S; Pinder, A; Beamish, H; Mukhopadhyay, P; Lambie, D; Gabrielli, B				Brooks, K.; Oakes, V.; Edwards, B.; Ranall, M.; Leo, P.; Pavey, S.; Pinder, A.; Beamish, H.; Mukhopadhyay, P.; Lambie, D.; Gabrielli, B.			A potent Chkl inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress	ONCOGENE			English	Article						Chk1; replicative stress; melanoma	DNA-DAMAGE CHECKPOINT; MITOTIC CATASTROPHE; ANTICANCER THERAPY; G(2) CHECKPOINT; CELL-DEATH; KINASE 1; ATR; CANCER; ACCUMULATION; PHOSPHATASE	There are few effective treatments for metastatic melanoma. Checkpoint kinase 1 (Chk1) inhibitors are being trialled for their efficacy in enhancing conventional chemotherapeutic agents, but their effectiveness as single agents is not known. We have examined the effectiveness of two novel Chk1 selective inhibitors, AR323 and AR678, in a panel of melanoma cell lines and normal cell types. We demonstrate that these drugs display single-agent activity, with IC50s in the low nanomolar range. The drugs produce cytotoxic effects in cell lines that are most sensitive to these drugs, whereas normal cells are only sensitive to these drugs at the higher concentrations where they have cytostatic activity. The cytotoxic effect is the consequence of inhibition of S-phase Chk1, which drives cells prematurely from late S phase into an aberrant mitosis and results in either failure of cytokinesis or cell death through an apoptotic mechanism. The sensitivity to the Chk1 inhibitors was correlated with the level of endogenous DNA damage indicating replicative stress. Chk1 inhibitors are viable single-agent therapies that target melanoma cells with high levels of endogenous DNA damage. This sensitivity suggests that Chk1 is a critical component of an adaptation to replicative stress in these cells. It also suggests that markers of DNA damage may be useful in identifying the melanomas and potentially other tumour types that are more likely to be sensitive to Chk1 inhibitors as single agents. Oncogene (2013) 32, 788-796; doi:10.1038/onc.2012.72; published online 5 March 2012	[Brooks, K.; Oakes, V.; Edwards, B.; Ranall, M.; Leo, P.; Pavey, S.; Pinder, A.; Beamish, H.; Mukhopadhyay, P.; Gabrielli, B.] Univ Queensland, Princess Alexandra Hosp, Diamantina Inst, Brisbane, Qld 4102, Australia; [Lambie, D.] Princess Alexandra Hosp, Dept Pathol, Brisbane, Qld 4102, Australia	University of Queensland	Gabrielli, B (corresponding author), Univ Queensland, Princess Alexandra Hosp, Diamantina Inst, Brisbane, Qld 4102, Australia.	brianG@uq.edu.au	Brooks, Kelly M/F-8248-2017; Leo, Paul/R-4464-2019; Lambie, Duncan/C-1863-2018; Mukhopadhyay, Pamela/I-6373-2015; Leo, Paul J/B-3470-2011; Gabrielli, Brian G/B-3655-2011; Pavey, Sandra/B-3662-2011	Brooks, Kelly M/0000-0002-9751-5961; Lambie, Duncan/0000-0002-0102-6638; Mukhopadhyay, Pamela/0000-0002-5905-1350; Leo, Paul J/0000-0001-8325-4134; Gabrielli, Brian G/0000-0003-3933-1651; Pavey, Sandra/0000-0003-4519-5932	Cancer Council Queensland; National Health and Medical Research Council (NHMRC Australia); Australia Research Council	Cancer Council Queensland(Cancer Council Queensland); National Health and Medical Research Council (NHMRC Australia)(National Health and Medical Research Council (NHMRC) of Australia); Australia Research Council(Australian Research Council)	We wish to acknowledge Drs Kurt Davies and Cheryl Napier (Array Biopharma), and KeeMing Chia for their technical assistance, A/Professor Grant McArthur and Dr Petranel Ferrao for their helpful comments, Prof. Penny Jeggo (University of Sussex) for her gift of the FO2 cells, and the Australasian Biospecimen Network (Oncology) for the melanoma cell lines. This work was supported by funding from Cancer Council Queensland, the National Health and Medical Research Council (NHMRC Australia) and the Australia Research Council. Brian Gabrielli is an NHMRC senior research fellow.	Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Brown EJ, 2000, GENE DEV, V14, P397; Burgess A, 2004, ONCOGENE, V23, P6693, DOI 10.1038/sj.onc.1207893; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chen MS, 2003, MOL CELL BIOL, V23, P7488, DOI 10.1128/MCB.23.21.7488-7497.2003; Dai Y, 2010, CLIN CANCER RES, V16, P376, DOI 10.1158/1078-0432.CCR-09-1029; Davies KD, 2011, ONCOL RES, V19, P349, DOI 10.3727/096504011X13079697132961; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gabrielli B, 2007, J BIOL CHEM, V282, P6954, DOI 10.1074/jbc.M610104200; Ge XQ, 2010, J CELL BIOL, V191, P1285, DOI 10.1083/jcb.201007074; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Kuntz K, 2009, CANCER BIOL THER, V8, P1433, DOI 10.4161/cbt.8.15.9081; Lainchbury M, 2011, EXPERT OPIN THER PAT, V21, P1191, DOI 10.1517/13543776.2011.586632; Lazzaro F, 2009, DNA REPAIR, V8, P1055, DOI 10.1016/j.dnarep.2009.04.022; Liu QH, 2000, GENE DEV, V14, P1448; Loffler H, 2006, CELL CYCLE, V5, P2543, DOI 10.4161/cc.5.21.3435; Ma CX, 2011, TRENDS MOL MED, V17, P88, DOI 10.1016/j.molmed.2010.10.009; McDonald ER, 2001, ANN MED, V33, P113, DOI 10.3109/07853890109002066; McNeely S, 2010, CELL CYCLE, V9, P995, DOI 10.4161/cc.9.5.10935; Morgan MA, 2010, CANCER RES, V70, P4972, DOI 10.1158/0008-5472.CAN-09-3573; Myers K, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000324; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Niida H, 2005, J BIOL CHEM, V280, P39246, DOI 10.1074/jbc.M505009200; Nitta M, 2004, ONCOGENE, V23, P6548, DOI 10.1038/sj.onc.1207873; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Peddibhotla S, 2009, P NATL ACAD SCI USA, V106, P5159, DOI 10.1073/pnas.0806671106; Petermann E, 2010, P NATL ACAD SCI USA, V107, P16090, DOI 10.1073/pnas.1005031107; Ranall MV, 2010, BIOTECHNIQUES, V48, P379, DOI 10.2144/000113410; Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Stevens FE, 2008, ONCOGENE, V27, P1345, DOI 10.1038/sj.onc.1210779; Stewart ZA, 2003, TRENDS PHARMACOL SCI, V24, P139, DOI 10.1016/S0165-6147(03)00026-9; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Takai H, 2000, GENE DEV, V14, P1439; Tang JB, 2006, P NATL ACAD SCI USA, V103, P11964, DOI 10.1073/pnas.0604987103; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vogel C, 2007, CANCER RES, V67, P339, DOI 10.1158/0008-5472.CAN-06-2548; Wang WD, 2007, NAT REV GENET, V8, P735, DOI 10.1038/nrg2159; Wang XQ, 1996, CANCER RES, V56, P2510; Wasco MJ, 2008, HUM PATHOL, V39, P1614, DOI 10.1016/j.humpath.2008.03.007	41	65	68	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 7	2013	32	6					788	796		10.1038/onc.2012.72	http://dx.doi.org/10.1038/onc.2012.72			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101AF	22391562				2022-12-17	WOS:000315746700012
J	Piskunov, A; Rochette-Egly, C				Piskunov, A.; Rochette-Egly, C.			A retinoic acid receptor RAR alpha pool present in membrane lipid rafts forms complexes with G protein alpha Q to activate p38MAPK	ONCOGENE			English	Article						retinoic acid; RAR; p38MAPK; G alpha Q; lipid rafts	BREAST-CANCER; F9 CELLS; SIGNAL-TRANSDUCTION; NONGENOMIC ACTIONS; ESTROGEN-RECEPTOR; TARGET GENES; IN-VIVO; PHOSPHORYLATION; DIFFERENTIATION; PATHWAY	Retinoic acid (RA) regulates several gene programs by nuclear RA receptors (RARs) that are ligand-dependent transcriptional transregulators. The basic mechanism for switching on transcription of cognate-target genes involves RAR binding at specific response elements and a network of interactions with coregulatory protein complexes. In addition to these classical genomic effects, we recently demonstrated that RA also induces the rapid activation of the p38MAPK/MSK1 pathway, with characteristic downstream consequences on the phosphorylation of RARs and the expression of their target genes. Here, we aimed at deciphering the underlying mechanism of the rapid nongenomic effects of RA. We highlighted a novel paradigm in which a fraction of the cellular RAR alpha pool is present in membrane lipid rafts, where it forms complexes with G protein alpha Q (G alpha q) in response to RA. This rapid RA-induced formation of RAR alpha/G alpha q complexes in lipid rafts is required for the activation of p38MAPK that occurs in response to RA. Accordingly, in RA-resistant cancer cells, characterized by the absence of p38MAPK activation, RAR alpha present in membrane lipid rafts does not associate with Gaq, pointing out the essential contribution of RAR alpha/G alpha q complexes in RA signaling. Oncogene (2012) 31, 3333-3345; doi: 10.1038/onc.2011.499; published online 7 November 2011	[Rochette-Egly, C.] Univ Strasbourg, Dept Funct Genom & Canc, INSERM, U964,IGBMC, F-67404 Illkirch Graffenstaden, Bas Rhin, France; Univ Strasbourg, CNRS, UMR7104, F-67404 Illkirch Graffenstaden, Bas Rhin, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Rochette-Egly, C (corresponding author), Univ Strasbourg, Dept Funct Genom & Canc, INSERM, U964,IGBMC, 1 Rue Laurent Fries, F-67404 Illkirch Graffenstaden, Bas Rhin, France.	cegly@igbmc.fr	Piskunov, Aleksandr/H-9871-2014	Piskunov, Aleksandr/0000-0001-5552-5419	CNRS; INSERM; Agence Nationale pour la Recherche [ANR-05-BLAN-0390-02, ANR-09-BLAN-0297-01]; Association pour la Recherche sur le Cancer [ARC-07-1-3169]; Fondation pour la Recherche Medicale [DEQ20090515423]; Institut National du Cancer [INCa-PL09-194, PL07-96099]; Fondation pour la Recherche Medicale; Lady TATA Memorial Trust	CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Agence Nationale pour la Recherche(French National Research Agency (ANR)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Institut National du Cancer(Institut National du Cancer (INCA) France); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Lady TATA Memorial Trust	We are grateful to the members of the cell culture facilities for their help and to all the members of the team for their helpful discussions and suggestions. Special thanks to Nathalie Bruck for GTPases analysis and to Regis Lutzing for generating the RAR gamma WT MEF rescue line. This work was supported by funds from CNRS, INSERM, the Agence Nationale pour la Recherche (ANR-05-BLAN-0390-02 and ANR-09-BLAN-0297-01), the Association pour la Recherche sur le Cancer (ARC-07-1-3169), the Fondation pour la Recherche Medicale (DEQ20090515423) and the Institut National du Cancer (INCa-PL09-194 and PL07-96099). AP was supported by the Fondation pour la Recherche Medicale and by the Lady TATA Memorial Trust.	Alsayed Y, 2001, J BIOL CHEM, V276, P4012, DOI 10.1074/jbc.M007431200; Altucci L, 2007, NAT REV DRUG DISCOV, V6, P793, DOI 10.1038/nrd2397; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Bour G, 2005, P NATL ACAD SCI USA, V102, P16608, DOI 10.1073/pnas.0505556102; Bruck N, 2009, EMBO J, V28, P34, DOI 10.1038/emboj.2008.256; Chen N, 2008, FASEB J, V22, P236, DOI 10.1096/fj.07-8739com; Clagett-Dame M, 2011, NUTRIENTS, V3, P385, DOI 10.3390/nu3040385; de Laurentiis Angela, 2007, Open Biochem J, V1, P12, DOI 10.2174/1874091X00701010012; Dey N, 2007, MOL CELL BIOL, V27, P4179, DOI 10.1128/MCB.01352-06; Duong V, 2011, BBA-MOL BASIS DIS, V1812, P1023, DOI 10.1016/j.bbadis.2010.10.007; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; Germain P, 2006, PHARMACOL REV, V58, P685, DOI 10.1124/pr.58.4.2; Germain P, 2006, PHARMACOL REV, V58, P712, DOI 10.1124/pr.58.4.4; Gianni M, 2006, EMBO J, V25, P739, DOI 10.1038/sj.emboj.7600981; Gianni M, 2002, EMBO J, V21, P3760, DOI 10.1093/emboj/cdf374; Huhtakangas JA, 2004, MOL ENDOCRINOL, V18, P2660, DOI 10.1210/me.2004-0116; Lai L, 2008, J PINEAL RES, V45, P476, DOI 10.1111/j.1600-079X.2008.00620.x; Laudet V., 2001, NUCL RECEPTOR FACTSB; Le Romancer M, 2008, MOL CELL, V31, P212, DOI 10.1016/j.molcel.2008.05.025; Lefebvre P, 2005, VITAM HORM, V70, P199, DOI 10.1016/S0083-6729(05)70007-8; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Luoma JI, 2008, MOL CELL ENDOCRINOL, V290, P8, DOI 10.1016/j.mce.2008.04.005; Marquez DC, 2006, MOL CELL ENDOCRINOL, V246, P91, DOI 10.1016/j.mce.2005.11.020; Masia S, 2007, MOL ENDOCRINOL, V21, P2391, DOI 10.1210/me.2007-0062; Matthews L, 2008, MOL ENDOCRINOL, V22, P1320, DOI 10.1210/me.2007-0154; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Mizuno N, 2009, NEUROSIGNALS, V17, P42, DOI 10.1159/000186689; Norman AW, 2001, STEROIDS, V66, P147, DOI 10.1016/S0039-128X(00)00165-3; Norman AW, 2004, NAT REV DRUG DISCOV, V3, P27, DOI 10.1038/nrd1283; Ordonez-Moran P, 2008, J CELL BIOL, V183, P697, DOI 10.1083/jcb.200803020; Ostrom Rennolds S., 2006, V332, P181; Pan J, 2005, J NEUROCHEM, V93, P571, DOI 10.1111/j.1471-4159.2005.03106.x; Park SS, 2005, HISTOPATHOLOGY, V47, P625, DOI 10.1111/j.1365-2559.2005.02303.x; Pedram A, 2007, J BIOL CHEM, V282, P22278, DOI 10.1074/jbc.M611877200; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Piskunov A., 2011, MSKS; Qiu J, 2003, J NEUROSCI, V23, P9529; Rochette-Egly C, 2000, MOL ENDOCRINOL, V14, P1398, DOI 10.1210/me.14.9.1398; Rochette-Egly Cecile, 2009, Nucl Recept Signal, V7, pe005, DOI 10.1621/nrs.07005; Samarut E, 2011, MOL CELL ENDOCRINOL; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Staubach S, 2011, EXPERT REV PROTEOMIC, V8, P263, DOI [10.1586/EPR.11.2, 10.1586/epr.11.2]; Stuermer CAO, 2011, J NEUROCHEM, V116, P708, DOI 10.1111/j.1471-4159.2010.07007.x; Sugawara Y, 2007, CELL SIGNAL, V19, P1301, DOI 10.1016/j.cellsig.2007.01.012; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Tari AM, 2002, ONCOGENE, V21, P5224, DOI 10.1038/sj.onc.1205660; Vasudevan N, 2008, FRONT NEUROENDOCRIN, V29, P238, DOI 10.1016/j.yfrne.2007.08.003; Waugh Mark G., 2009, V462, P403, DOI 10.1007/978-1-60327-115-8_26; White CD, 2008, MOL ENDOCRINOL, V22, P2520, DOI 10.1210/me.2008-0122; Yao Y, 2009, CELL RES, V19, P497, DOI 10.1038/cr.2009.27; Zanotto A, 2008, TOXICOL IN VITRO, V22, P1205, DOI 10.1016/j.tiv.2008.04.001	53	65	66	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2012	31	28					3333	3345		10.1038/onc.2011.499	http://dx.doi.org/10.1038/onc.2011.499			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973NT	22056876				2022-12-17	WOS:000306367600003
J	Mackintosh, C; Ordonez, JL; Garcia-Dominguez, DJ; Sevillano, V; Llombart-Bosch, A; Szuhai, K; Scotlandi, K; Alberghini, M; Sciot, R; Sinnaeve, F; Hogendoorn, PCW; Picci, P; Knuutila, S; Dirksen, U; Debiec-Rychter, M; Schaefer, KL; de Alava, E				Mackintosh, C.; Ordonez, J. L.; Garcia-Dominguez, D. J.; Sevillano, V.; Llombart-Bosch, A.; Szuhai, K.; Scotlandi, K.; Alberghini, M.; Sciot, R.; Sinnaeve, F.; Hogendoorn, P. C. W.; Picci, P.; Knuutila, S.; Dirksen, U.; Debiec-Rychter, M.; Schaefer, K-L; de Alava, E.			1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma	ONCOGENE			English	Article						Ewing sarcoma; 1q Gain; CDT2; clinical outcome; microarrays	COMPARATIVE GENOMIC HYBRIDIZATION; CHROMOSOME-TRANSLOCATION; GENETIC CHANGES; DNA-DAMAGE; CELL-LINES; ARRAY CGH; S-PHASE; TUMORS; DEGRADATION; ABERRATIONS	Despite extensive characterization of the role of the EWS-ETS fusions, little is known about secondary genetic alterations and their clinical contribution to Ewing sarcoma (ES). It has been demonstrated that the molecular structure of EWS-ETS lacks prognostic value. Moreover, CDKN2A deletion and TP53 mutation, despite carrying a poor prognosis, are infrequent. In this scenario identifying secondary genetic alterations with a significant prevalence could contribute to understand the molecular mechanisms underlying the most aggressive forms of ES. We screened a 67 ES tumor set for copy number alterations by array comparative genomic hybridization. 1q gain (1qG), detected in 31% of tumor samples, was found markedly associated with relapse and poor overall and disease-free survival and demonstrated a prognostic value independent of classical clinical parameters. Reanalysis of an expression dataset belonging to an independent tumor set (n = 37) not only validated this finding but also led us to identify a transcriptomic profile of severe cell cycle deregulation in 1qG ES tumors. Consistently, a higher proliferation rate was detected in this tumor subset by Ki-67 immunohistochemistry. CDT2, a 1q-located candidate gene encoding a protein involved in ubiquitin ligase activity and significantly overexpressed in 1qG ES tumors, was validated in vitro and in vivo proving its major contribution to this molecular and clinical phenotype. This integrative genomic study of 105 ES tumors in overall renders the potential value of 1qG and CDT2 overexpression as prognostic biomarkers and also affords a rationale for the application of already available new therapeutic compounds selectively targeting the protein-ubiquitin machinery. Oncogene (2012) 31, 1287-1298; doi: 10.1038/onc.2011.317; published online 8 August 2011	[Mackintosh, C.; Ordonez, J. L.; Garcia-Dominguez, D. J.; Sevillano, V.; de Alava, E.] Ctr Invest Canc IBMCC USAL CSIC, Mol Pathol Program, Salamanca 37007, Spain; [Llombart-Bosch, A.] Univ Valencia, Dept Pathol, Valencia, Spain; [Szuhai, K.] Leiden Univ, Med Ctr, Dept Mol Cell Biol, Leiden, Netherlands; [Scotlandi, K.; Picci, P.] Ist Ortoped Rizzoli, Lab Oncol Res, Bologna, Italy; [Alberghini, M.] Ist Ortoped Rizzoli, Dept Pathol, Bologna, Italy; [Sciot, R.] Catholic Univ Louvain, Dept Pathol, B-3000 Louvain, Belgium; [Sinnaeve, F.] Catholic Univ Louvain, Dept Orthoped Surg, B-3000 Louvain, Belgium; [Hogendoorn, P. C. W.] Leiden Univ, Dept Pathol, Med Ctr, Leiden, Netherlands; [Knuutila, S.] Univ Helsinki, Dept Pathol, Helsinki, Finland; [Knuutila, S.] Helsinki Univ Cent Hosp, Helsinki, Finland; [Dirksen, U.] Univ Childrens Hosp Muenster, Dept Pediat Hematol & Oncol, Munster, Germany; [Debiec-Rychter, M.] Catholic Univ Louvain, Ctr Human Genet, B-3000 Louvain, Belgium; [Schaefer, K-L] Univ Dusseldorf, Inst Pathol, Dusseldorf, Germany; [de Alava, E.] Univ Hosp Salamanca, Dept Pathol, Salamanca, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Valencia; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; IRCCS Istituto Ortopedico Rizzoli; IRCCS Istituto Ortopedico Rizzoli; Universite Catholique Louvain; Universite Catholique Louvain; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Munster; Universite Catholique Louvain; Heinrich Heine University Dusseldorf; University of Salamanca	Mackintosh, C (corresponding author), Ctr Invest Canc IBMCC USAL CSIC, Mol Pathol Program, Campus Miguel de Unamuno S-N, Salamanca 37007, Spain.	cmackintosh@usal.es; edealava@usal.es	Dirksen, Uta/AGX-8472-2022; Garcia, Daniel Jose/B-5366-2016; Hogendoorn, Pancras/O-6494-2019; Ordóñez, José Luis/B-6069-2017; IBIS, SARCOMAS/O-1893-2015; Scotlandi, Katia/J-9009-2016; de Alava, Enrique/GOH-0368-2022; Garcia, Daniel Jose/X-6857-2019; Szuhai, Karoly/A-1100-2008; Hogendoorn, Pancras C.W./H-5859-2015; Picci, Piero/J-5979-2016	Garcia, Daniel Jose/0000-0001-8150-2747; Hogendoorn, Pancras/0000-0002-1513-8104; Ordóñez, José Luis/0000-0002-3791-4215; Scotlandi, Katia/0000-0001-6114-9499; de Alava, Enrique/0000-0001-8400-046X; Szuhai, Karoly/0000-0002-1228-4245; Hogendoorn, Pancras C.W./0000-0002-1513-8104; Sinnaeve, Friedl/0000-0003-4321-7771; sciot, raf/0000-0003-2244-5839; Picci, Piero/0000-0002-8519-4101; Mackintosh, Carlos/0000-0002-6786-9558	European Commission; Maria Garcia-Estrada Foundation; Ministry of Science and Innovation of Spain [PI081828, RD06/0020/0059]; Deutsche Krebshilfe [50-2551 Ju3, 50-2551-Ju4]; Federal Ministry of Education and Research Germany, BMBF (TranSaRNet) [01GM0869]; Deutsches Zentrum fur Luft- und Raumfahrt e.V.	European Commission(European CommissionEuropean Commission Joint Research Centre); Maria Garcia-Estrada Foundation; Ministry of Science and Innovation of Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Deutsche Krebshilfe(Deutsche Krebshilfe); Federal Ministry of Education and Research Germany, BMBF (TranSaRNet)(Federal Ministry of Education & Research (BMBF)); Deutsches Zentrum fur Luft- und Raumfahrt e.V.(Helmholtz AssociationGerman Aerospace Centre (DLR))	Centro de Investigacion del Cancer-IBMCC, Heinrich-Heine-University Duesseldorf, Catholic University of Leuven, University of Valencia, Istituti Ortopedici Rizzoli, University of Helsinki, Leiden University Medical Center and University Children's Hospital Muenster are partners of the EuroBoNeT consortium, a network of excellence granted by the European Commission for studying the pathology and genetics of bone tumors. Daniel J Garcia-Dominguez is supported by a grant from the Maria Garcia-Estrada Foundation. Research in Enrique de Alava's lab is also supported by the Ministry of Science and Innovation of Spain-FEDER (PI081828, RD06/0020/0059). Trial center Muenster is supported by grants from Deutsche Krebshilfe, 50-2551 Ju3 und 50-2551-Ju4 and Federal Ministry of Education and Research Germany, BMBF (TranSaRNet) 01GM0869, Deutsches Zentrum fur Luft- und Raumfahrt e.V. We thank Dr Hung-Wei Pan and Dr Hey-Chi Hsu (Department of Pathology, College of Medicine, National Taiwan University, Taipei, Taiwan) for the anti-CDT2 antibody and pBABE-CDT2 construction. Thanks are due to Cristina Teodosio and Martin Perez de Andres for their kind help with the flow cytometer, to Andreas Ranft for helping with the clinical data, to Agustin Mayo Iscar for his help with statistics, and to Antonella Chiechi, Alicia Ginel and Alberto de Luis for their advice.	Abbas T, 2008, GENE DEV, V22, P2496, DOI 10.1101/gad.1676108; AURIAS A, 1984, CANCER GENET CYTOGEN, V12, P21, DOI 10.1016/0165-4608(84)90003-7; Balcarkova J, 2009, CANCER GENET CYTOGEN, V192, P68, DOI 10.1016/j.cancergencyto.2009.02.020; Banks D, 2006, CELL CYCLE, V5, P1719, DOI 10.4161/cc.5.15.3150; Brisset S, 2001, CANCER GENET CYTOGEN, V130, P57, DOI 10.1016/S0165-4608(01)00454-X; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Ferreira BI, 2008, ONCOGENE, V27, P2084, DOI 10.1038/sj.onc.1210845; Friedrichs N, 2006, DIAGN MOL PATHOL, V15, P83, DOI 10.1097/00019606-200606000-00004; HAAS AL, 1982, J BIOL CHEM, V257, P329; Haeusler J, 2010, CANCER-AM CANCER SOC, V116, P443, DOI 10.1002/cncr.24740; Hattinger CM, 1996, GENE CHROMOSOME CANC, V17, P141, DOI 10.1002/(SICI)1098-2264(199611)17:3<141::AID-GCC1>3.0.CO;2-4; Hattinger CM, 2002, BRIT J CANCER, V86, P1763, DOI 10.1038/sj.bjc.6600332; Higa LA, 2006, CELL CYCLE, V5, P71, DOI 10.4161/cc.5.1.2266; Higa LA, 2006, NAT CELL BIOL, V8, P1277, DOI 10.1038/ncb1490; Higa LA, 2006, CELL CYCLE, V5, P1675, DOI 10.4161/cc.5.15.3149; Hing S, 2001, AM J PATHOL, V158, P393, DOI 10.1016/S0002-9440(10)63982-X; Huang HY, 2005, J CLIN ONCOL, V23, P548, DOI 10.1200/JCO.2005.02.081; Jin JP, 2006, MOL CELL, V23, P709, DOI 10.1016/j.molcel.2006.08.010; Kauer M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005415; Kim Y, 2008, GENE DEV, V22, P2507, DOI 10.1101/gad.1703708; Kjellman P, 2001, GENE CHROMOSOME CANC, V32, P43, DOI 10.1002/gcc.1165; Knuutila S, 1998, CANCER GENET CYTOGEN, V100, P25, DOI 10.1016/S0165-4608(97)00001-0; Kullendorff CM, 1999, MED PEDIATR ONCOL, V32, P79, DOI 10.1002/(SICI)1096-911X(199902)32:2<79::AID-MPO1>3.0.CO;2-R; Le Deley MC, 2010, J CLIN ONCOL, V28, P1982, DOI 10.1200/JCO.2009.23.3585; Liu CL, 2007, J BIOL CHEM, V282, P1109, DOI 10.1074/jbc.M606535200; Lo KC, 2007, CLIN CANCER RES, V13, P7022, DOI 10.1158/1078-0432.CCR-07-1420; Ordonez JL, 2009, CANCER RES, V69, P7140, DOI 10.1158/0008-5472.CAN-08-4041; Nishitani H, 2008, J BIOL CHEM, V283, P29045, DOI 10.1074/jbc.M806045200; Ottaviano L, 2010, GENE CHROMOSOME CANC, V49, P40, DOI 10.1002/gcc.20717; Ozaki T, 2001, GENE CHROMOSOME CANC, V32, P164, DOI 10.1002/gcc.1178; Pezzolo A, 2009, NEURO-ONCOLOGY, V11, P192, DOI 10.1215/15228517-2008-086; Ralph E, 2006, EMBO REP, V7, P1134, DOI 10.1038/sj.embor.7400827; Roberts P, 2008, GENE CHROMOSOME CANC, V47, P207, DOI 10.1002/gcc.20523; Sansam CL, 2006, GENE DEV, V20, P3117, DOI 10.1101/gad.1482106; Savola S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-17; Scotlandi K, 2009, J CLIN ONCOL, V27, P2209, DOI 10.1200/JCO.2008.19.2542; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tarkkanen M, 1999, CANCER GENET CYTOGEN, V114, P35, DOI 10.1016/S0165-4608(99)00031-X; TURCCAREL C, 1984, CANCER GENET CYTOGEN, V12, P1, DOI 10.1016/0165-4608(84)90002-5; van de Wiel MA, 2005, BIOINFORMATICS, V21, P3193, DOI 10.1093/bioinformatics/bti489; van de Wiel MA, 2007, CANCER INFORM, V3, P55; van de Wiel MA, 2007, BIOINFORMATICS, V23, P892, DOI 10.1093/bioinformatics/btm030; van Doorninck JA, 2010, J CLIN ONCOL, V28, P1989, DOI 10.1200/JCO.2009.24.5845; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907	45	65	65	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	10					1287	1298		10.1038/onc.2011.317	http://dx.doi.org/10.1038/onc.2011.317			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21822310	Green Published			2022-12-17	WOS:000301344600008
J	Vaira, V; Faversani, A; Dohi, T; Montorsi, M; Augello, C; Gatti, S; Coggi, G; Altieri, DC; Bosari, S				Vaira, V.; Faversani, A.; Dohi, T.; Montorsi, M.; Augello, C.; Gatti, S.; Coggi, G.; Altieri, D. C.; Bosari, S.			miR-296 regulation of a cell polarity-cell plasticity module controls tumor progression	ONCOGENE			English	Article						miR-296; Scribble; cell plasticity; tumor progression; metastases	COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN CANCERS; LEADING-EDGE; MICRORNAS; CARCINOMA; TUMORIGENESIS; EXPRESSION; MIGRATION; PROTEINS; INVASION	The expression of small, non-coding RNA or microRNAs (miR), is frequently deregulated in human cancer, but how these pathways affect disease progression is still largely elusive. Here, we report on a miR, miR-296, which is progressively lost during tumor progression and correlates with metastatic disease in colorectal, breast, lung, gastric, parathyroid, liver and bile ducts cancers. Functionally, miR-296 controls a global cell motility gene signature in epithelial cells by transcriptionally repressing the cell polarity-cell plasticity module, Scribble (Scrib). In turn, loss of miR-296 causes aberrantly increased and mislocalized Scrib in human tumors, resulting in exaggerated random cell migration and tumor cell invasiveness. Re-expression of miR-296 in MDA-MB231 cells inhibits tumor growth in vivo. Finally, miR-296 or Scrib levels predict tumor relapse in hepatocellular carcinoma patients. These data identify miR-296 as a global repressor of tumorigenicity and uncover a previously unexplored exploitation of Scrib in tumor progression in humans. Oncogene (2012) 31, 27-38; doi: 10.1038/onc.2011.209; published online 6 June 2011	[Vaira, V.; Faversani, A.; Augello, C.; Coggi, G.; Bosari, S.] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Pathol, I-20132 Milan, Italy; [Faversani, A.; Augello, C.; Coggi, G.; Bosari, S.] Univ Milan, Sch Med, Div Pathol, Dept Med Surg & Dent, Milan, Italy; [Dohi, T.; Altieri, D. C.] Wistar Inst Canc Ctr, Prostate Canc Discovery & Dev Program, Philadelphia, PA USA; [Montorsi, M.] Univ Milan, Sch Med, Ist Clin Humanitas IRCCS, Div Gen Surg 3, Rozzano, Italy; [Gatti, S.] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Surg Res Ctr, I-20132 Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; The Wistar Institute; IRCCS Humanitas Research Hospital; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico	Bosari, S (corresponding author), Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Pathol, Via F Sforza 35, I-20132 Milan, Italy.	silvano.bosari@unimi.it	Bosari, Silvano/K-7744-2016; Vaira, Valentina/K-6499-2016; Faversani, Alice/K-6509-2016; Gatti, Stefano/AAE-3281-2022; Gatti, Stefano/M-1780-2015; Montorsi, Marco/GYD-3896-2022	Bosari, Silvano/0000-0002-9744-6951; Vaira, Valentina/0000-0003-4416-6216; Faversani, Alice/0000-0002-0970-6208; Gatti, Stefano/0000-0003-2209-4338; Gatti, Stefano/0000-0003-2209-4338; Montorsi, Marco/0000-0002-3887-3451	Doctorate School of Molecular Medicine at Universita degli Studi di Milano; Fondazione Invernizzi; Fondazione Berlucchi; National Institutes of Health [HL54131, CA140043, CA78810, CA118005]; NATIONAL CANCER INSTITUTE [R01CA078810, R01CA118005, P01CA140043] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL054131, R01HL054131] Funding Source: NIH RePORTER	Doctorate School of Molecular Medicine at Universita degli Studi di Milano; Fondazione Invernizzi; Fondazione Berlucchi; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Riccardo Ghidoni, Michele Samaja and Massimo Locati for availability of laboratory equipment and reagents, Patrizia Doi and Delfina Tosi for technical help. AF is supported by a fellowship of the Doctorate School of Molecular Medicine at Universita degli Studi di Milano. This work was supported by grants from the Fondazione Invernizzi (to GC), Fondazione Berlucchi (to SB), and from National Institutes of Health grants HL54131, CA140043, CA78810 and CA118005 (to DCA).	Assemat E, 2008, BBA-BIOMEMBRANES, V1778, P614, DOI 10.1016/j.bbamem.2007.08.029; Augello C, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-125; Bahri S, 2010, DEVELOPMENT, V137, P2023, DOI 10.1242/dev.045088; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bauer M, 2010, ONCOGENE, V29, P1732, DOI 10.1038/onc.2009.463; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Dow LE, 2008, ONCOGENE, V27, P5988, DOI 10.1038/onc.2008.219; Dow LE, 2007, ONCOGENE, V26, P2272, DOI 10.1038/sj.onc.1210016; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; Hong L, 2010, ANN SURG, V251, P1056, DOI 10.1097/SLA.0b013e3181dd4ea9; Houbaviy HB, 2003, DEV CELL, V5, P351, DOI 10.1016/S1534-5807(03)00227-2; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Kamei Y, 2007, HUM PATHOL, V38, P1273, DOI 10.1016/j.humpath.2007.01.026; Kim SW, 2007, GENE CHROMOSOME CANC, V46, P1, DOI 10.1002/gcc.20384; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Nagasaka K, 2010, ONCOGENE, V29, P5311, DOI 10.1038/onc.2010.265; Naylor TL, 2005, BREAST CANCER RES, V7, pR1186, DOI 10.1186/bcr1356; Olson P, 2009, GENE DEV, V23, P2152, DOI 10.1101/gad.1820109; Osmani N, 2006, CURR BIOL, V16, P2395, DOI 10.1016/j.cub.2006.10.026; Pedersen IM, 2007, NATURE, V449, P919, DOI 10.1038/nature06205; Petrie RJ, 2009, NAT REV MOL CELL BIO, V10, P538, DOI 10.1038/nrm2729; Phua DCY, 2009, MOL BIOL CELL, V20, P2841, DOI 10.1091/mbc.E08-02-0199; Romagnoli S, 2009, AM J PATHOL, V174, P762, DOI 10.2353/ajpath.2009.080721; Seike M, 2009, P NATL ACAD SCI USA, V106, P12085, DOI 10.1073/pnas.0905234106; Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Wei JJ, 2011, CLIN CANCER RES, V17, P1297, DOI 10.1158/1078-0432.CCR-10-0993; Woo HG, 2009, CANCER RES, V69, P4059, DOI 10.1158/0008-5472.CAN-09-0164; Wu M, 2010, NATURE, V463, P545, DOI 10.1038/nature08702; Wurdinger T, 2008, CANCER CELL, V14, P382, DOI 10.1016/j.ccr.2008.10.005; Yang HS, 2009, CLIN CANCER RES, V15, P5744, DOI 10.1158/1078-0432.CCR-09-0385; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045; Zhang H, 2010, ONCOGENE, V29, P937, DOI 10.1038/onc.2009.406; Zhuo OY, 2010, ONCOL RES, V18, P593, DOI 10.3727/096504010X12767359114045	39	65	68	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	1					27	38		10.1038/onc.2011.209	http://dx.doi.org/10.1038/onc.2011.209			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	877JT	21643016	Green Accepted			2022-12-17	WOS:000299176200003
J	Anania, MC; Sensi, M; Radaelli, E; Miranda, C; Vizioli, MG; Pagliardini, S; Favini, E; Cleris, L; Supino, R; Formelli, F; Borrello, MG; Pierotti, MA; Greco, A				Anania, M. C.; Sensi, M.; Radaelli, E.; Miranda, C.; Vizioli, M. G.; Pagliardini, S.; Favini, E.; Cleris, L.; Supino, R.; Formelli, F.; Borrello, M. G.; Pierotti, M. A.; Greco, A.			TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells	ONCOGENE			English	Article						TIMP3; thyroid tumors; PTC	TISSUE INHIBITOR; GENE-EXPRESSION; DOWN-REGULATION; CARCINOMA; CANCER; GROWTH; METALLOPROTEINASE-3; ANGIOGENESIS; METHYLATION; LINE	Papillary thyroid carcinoma (PTC) arises from the thyroid follicular epithelium and represents the most frequent thyroid malignancy. PTC is associated with gene rearrangements generating RET/PTC and TRK oncogenes, and to the BRAFV600E activating point mutation. A role of tumor-suppressor genes in the pathogenesis of PTC has not been assessed yet. The tissue inhibitor of metalloproteinase-3 (TIMP3) gene, encoding a metalloproteinases inhibitor and capable of inhibiting growth, angiogenesis, invasion and metastasis of several cancers, was found to be silenced by promoter methylation in a consistent fraction of PTCs, in association with tumor aggressiveness and BRAFV600E mutation, thus suggesting an oncosuppressor role. To explore this possibility, in this study we performed gene expression and functional studies. Analysis of gene expression data produced in our laboratory as well as meta-analysis of publicly available data sets confirmed the downregulation of TIMP3 gene expression in PTC with respect to normal thyroid. The functional consequences of TIMP3 downregulation were investigated in the PTC-derived NIM1 cell line, in which the expression of TIMP3 is silenced. Restoration of TIMP3 expression by exposure to soluble TIMP3 protein or by complementary DNA transfection had no effect on the growth rate of NIM1 cells. Instead, it affected the adhesive, migratory and invasive capabilities of NIM1 cells by modulating several proteins involved in these processes. A striking effect was observed in vivo, as TIMP3 reduced the tumorigenicity of NIM1 cells by repressing angiogenesis and macrophage infiltration. Our data indicate that the loss of TIMP3 expression exerts a functional role in the pathogenesis of PTC. Oncogene (2011) 30, 3011-3023; doi:10.1038/onc.2011.18; published online 21 February 2011	[Anania, M. C.; Miranda, C.; Vizioli, M. G.; Pagliardini, S.; Borrello, M. G.; Greco, A.] IRCCS Fdn Ist Nazl Tumori, Mol Mechanisms Unit, I-20133 Milan, Italy; [Sensi, M.] IRCCS Fdn Ist Nazl Tumori, Funct Genom Core Facil, I-20133 Milan, Italy; [Sensi, M.] IRCCS Fdn Ist Nazl Tumori, Human Tumors Immunobiol Unit, I-20133 Milan, Italy; [Radaelli, E.] Univ Milan, Fac Vet Med, Dept Vet Pathol, Milan, Italy; [Radaelli, E.] Fdn Filarete, Mouse & Anim Pathol Lab, Milan, Italy; [Favini, E.; Supino, R.] IRCCS Fdn Ist Nazl Tumori, Mol Pharmacol Unit, I-20133 Milan, Italy; [Cleris, L.; Formelli, F.] IRCCS Fdn Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Chemoprevent Unit, I-20133 Milan, Italy; [Pierotti, M. A.] IRCCS Fdn Ist Nazl Tumori, Sci Directorate, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Greco, A (corresponding author), IRCCS Fdn Ist Nazl Tumori, Mol Mechanisms Unit, Via GA Amadeo 42, I-20133 Milan, Italy.	angela.greco@istitutotumori.mi.it	Cleris, Loredana/T-3144-2018; Pierotti, Marco Alessandro/AAC-4728-2022; Greco, Angela/C-1953-2017; Anania, Maria Chiara/N-4853-2019; Sensi, Marialuisa/K-5631-2014; Anania, Maria Chiara/B-9339-2017; Borrello, Maria Grazia/C-3161-2017; Oliveira Ribeiro, Ciro Alberto de/A-5199-2008	Cleris, Loredana/0000-0001-8778-7931; Pierotti, Marco Alessandro/0000-0002-7431-8332; Greco, Angela/0000-0003-2994-0349; Anania, Maria Chiara/0000-0003-4012-1870; Sensi, Marialuisa/0000-0002-7643-0248; Anania, Maria Chiara/0000-0003-4012-1870; Borrello, Maria Grazia/0000-0002-6854-2848; Oliveira Ribeiro, Ciro Alberto de/0000-0002-3168-9272	AIRC, ACC [4472]; Ministry of Health and Progetto Strategico Istituzionale (PSI) 5xmille	AIRC, ACC(Fondazione AIRC per la ricerca sul cancro); Ministry of Health and Progetto Strategico Istituzionale (PSI) 5xmille	We thank Drs Daniele Lecis, Francesca Micciche and Anna De Filippo for providing reagents and advice for the detection of soluble TNF alpha and ALCAM, and Mrs Cristina Mazzadi for secretarial help. This work was supported by AIRC grant N. 4472, ACC, Ministry of Health and Progetto Strategico Istituzionale (PSI) 5xmille, 2008.	Ahonen M, 2003, ONCOGENE, V22, P2121, DOI 10.1038/sj.onc.1206292; Akslen LA, 2000, HUM PATHOL, V31, P439, DOI 10.1053/1-ip.2000.6548; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; [Anonymous], 1988, BRIT J CANCER, V58, P109, DOI 10.1038/bjc.1988.174; Bachman KE, 1999, CANCER RES, V59, P798; Barski D, 2010, BRAIN PATHOL, V20, P623, DOI 10.1111/j.1750-3639.2009.00340.x; Bordeleau F, 2010, MOL BIOL CELL, V21, P1698, DOI 10.1091/mbc.E09-05-0373; Borrello MG, 2005, P NATL ACAD SCI USA, V102, P14825, DOI 10.1073/pnas.0503039102; Calabro V, 1996, INT J CANCER, V67, P29, DOI 10.1002/(SICI)1097-0215(19960703)67:1<29::AID-IJC7>3.3.CO;2-P; Degl'Innocenti D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012701; Detoraki A, 2009, J ALLERGY CLIN IMMUN, V123, P1142, DOI 10.1016/j.jaci.2009.01.044; Dineen SP, 2008, CANCER RES, V68, P4340, DOI 10.1158/0008-5472.CAN-07-6705; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI200113171; Ferrario C, 2008, LAB INVEST, V88, P474, DOI 10.1038/labinvest.2008.17; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Giordano TJ, 2005, ONCOGENE, V24, P6646, DOI 10.1038/sj.onc.1208822; Greco A, 2009, Q J NUCL MED MOL IM, V53, P440; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; Hedinger C, 1988, HISTOLOGICAL TYPING; Hu SY, 2006, INT J CANCER, V119, P2322, DOI 10.1002/ijc.22110; Jarzab B, 2005, CANCER RES, V65, P1587, DOI 10.1158/0008-5472.CAN-04-3078; Latini FRM, 2008, ENDOCR-RELAT CANCER, V15, P787, DOI 10.1677/ERC-08-0079; Mahller YY, 2008, CANCER RES, V68, P1170, DOI 10.1158/0008-5472.CAN-07-2734; Margineanu Eliana, 2008, Rev Med Chir Soc Med Nat Iasi, V112, P432; Masson D, 2010, EUR J CANCER, V46, P1430, DOI 10.1016/j.ejca.2010.01.009; Melillo RM, 2010, ONCOGENE, V29, P6203, DOI 10.1038/onc.2010.348; Mohammed FF, 2004, NAT GENET, V36, P969, DOI 10.1038/ng1413; Nakamura M, 2005, LAB INVEST, V85, P165, DOI 10.1038/labinvest.3700223; Pallante P, 2008, CANCER RES, V68, P6770, DOI 10.1158/0008-5472.CAN-08-0695; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Roland CL, 2009, MOL CANCER THER, V8, P1761, DOI 10.1158/1535-7163.MCT-09-0280; Rosso O, 2007, MOL CANCER RES, V5, P1246, DOI 10.1158/1541-7786.MCR-07-0060; Russell JP, 2003, ONCOGENE, V22, P4569, DOI 10.1038/sj.onc.1206759; Ryder M, 2008, ENDOCR-RELAT CANCER, V15, P1069, DOI 10.1677/ERC-08-0036; Schweppe RE, 2008, J CLIN ENDOCR METAB, V93, P4331, DOI 10.1210/jc.2008-1102; Spurbeck WW, 2002, BLOOD, V100, P3361, DOI 10.1182/blood.V100.9.3361; TOHYAMA K, 1992, JPN J CANCER RES, V83, P153, DOI 10.1111/j.1349-7006.1992.tb00080.x; Vasko V, 2007, P NATL ACAD SCI USA, V104, P2803, DOI 10.1073/pnas.0610733104; Vizioli MG, 2010, ONCOGENE, V29, P3835, DOI 10.1038/onc.2010.136; Wang B, 2010, ONCOGENE, V29, P1787, DOI 10.1038/onc.2009.468; Xing MZ, 2007, ENDOCRINOLOGY, V148, P948, DOI 10.1210/en.2006-0927; Xing MZ, 2008, OTOLARYNG CLIN N AM, V41, P1135, DOI 10.1016/j.otc.2008.07.001; ZEKI K, 1993, J CLIN ENDOCR METAB, V76, P127, DOI 10.1210/jc.76.1.127; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; Zuo H, 2010, CANCER RES, V70, P1389, DOI 10.1158/0008-5472.CAN-09-2812	46	65	66	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	27					3011	3023		10.1038/onc.2011.18	http://dx.doi.org/10.1038/onc.2011.18			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	789IW	21339735				2022-12-17	WOS:000292510100002
J	Sidler, D; Renzulli, P; Schnoz, C; Berger, B; Schneider-Jakob, S; Fluck, C; Inderbitzin, D; Corazza, N; Candinas, D; Brunner, T				Sidler, D.; Renzulli, P.; Schnoz, C.; Berger, B.; Schneider-Jakob, S.; Flueck, C.; Inderbitzin, D.; Corazza, N.; Candinas, D.; Brunner, T.			Colon cancer cells produce immunoregulatory glucocorticoids	ONCOGENE			English	Article						extra-adrenal steroidogenesis; colon cancer; immune escape; nuclear receptors	INTESTINAL EPITHELIAL-CELLS; COLORECTAL-CANCER; TUMOR SURVEILLANCE; IMMUNE PRIVILEGE; LRH-1; LYMPHOCYTES; ACTIVATION; EXPRESSION; APOPTOSIS; SURVIVAL	Glucocorticoids (GC) have important anti-inflammatory and pro-apoptotic activities. Initially thought to be exclusively produced by the adrenal glands, there is now increasing evidence for extra-adrenal sources of GCs. We have previously shown that the intestinal epithelium produces immunoregulatory GCs and that intestinal steroidogenesis is regulated by the nuclear receptor liver receptor homolog-1 (LRH-1). As LRH-1 has been implicated in the development of colon cancer, we here investigated whether LRH-1 regulates GC synthesis in colorectal tumors and whether tumor-produced GCs suppress T-cell activation. Colorectal cancer cell lines and primary tumors were found to express steroidogenic enzymes and regulatory factors required for the de novo synthesis of cortisol. Both cell lines and primary tumors constitutively produced readily detectable levels of cortisol, as measured by radioimmunoassay, thin-layer chromatography and bioassay. Whereas overexpression of LRH-1 significantly increased the expression of steroidogenic enzymes and the synthesis of cortisol, downregulation or inhibition of LRH-1 effectively suppressed these processes, indicating an important role of LRH-1 in colorectal tumor GC synthesis. An immunoregulatory role of tumor-derived GCs could be further confirmed by demonstrating a suppression of T-cell activation. This study describes for the first time cortisol synthesis in a non-endocrine tumor in humans, and suggests that the synthesis of bioactive GCs in colon cancer cells may account as a novel mechanism of tumor immune escape. Oncogene (2011) 30, 2411-2419; doi:10.1038/onc.2010.629; published online 24 January 2011	[Brunner, T.] Univ Konstanz, Dept Biol, Div Biochem Pharmacol, D-78457 Constance, Germany; [Sidler, D.; Schnoz, C.; Berger, B.; Schneider-Jakob, S.; Corazza, N.] Univ Bern, Inst Pathol, Div Expt Pathol, Bern, Switzerland; [Renzulli, P.; Inderbitzin, D.; Candinas, D.] Univ Bern, Insel Univ Hosp, Dept Visceral Surg & Med, Bern, Switzerland; [Flueck, C.] Univ Bern, Univ Childrens Hosp, Div Pediat Endocrinol, Bern, Switzerland	University of Konstanz; University of Bern; University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	Brunner, T (corresponding author), Univ Konstanz, Dept Biol, Div Biochem Pharmacol, Box 660,Univ Str 10, D-78457 Constance, Germany.	thomas.brunner@uni-konstanz.de	Sidler, Daniel/G-2447-2019; Renzulli, Pietro/GQH-9366-2022	Renzulli, Pietro/0000-0001-5557-5512; Flueck, Christa/0000-0002-4568-5504	Oncosuisse [OCS-02025-02-2007]; Swiss National Science Foundation [310000-121854]	Oncosuisse; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	We thank Mario Noti, Pamela Bianchi, Andrea Hirsch, Gabi Hofer and Andreas Kappeler for technical help and advice, the members of the Division of Clinical Histopathology for preparation of tissue sections, and Sam Okret and Kristina Schoonjans for reagents. This work was supported by research grants from Oncosuisse (OCS-02025-02-2007) and the Swiss National Science Foundation (310000-121854) to TB. DS was supported by an MD-PhD fellowship from the Swiss National Science Foundation.	Atanasov AG, 2008, FASEB J, V22, P4117, DOI 10.1096/fj.08-114157; Botrugno OA, 2004, MOL CELL, V15, P499, DOI 10.1016/j.molcel.2004.07.009; Brunner T, 2001, CELL DEATH DIFFER, V8, P706, DOI 10.1038/sj.cdd.4400854; Camus M, 2009, CANCER RES, V69, P2685, DOI 10.1158/0008-5472.CAN-08-2654; Chen J, 1998, SCIENCE, V282, P95, DOI 10.1126/science.282.5386.95; Cima I, 2004, J EXP MED, V200, P1635, DOI 10.1084/jem.20031958; Cima I, 2006, IMMUNOL LETT, V106, P99, DOI 10.1016/j.imlet.2006.04.005; Coste A, 2007, P NATL ACAD SCI USA, V104, P13098, DOI 10.1073/pnas.0702440104; Dardis A, 2003, J ENDOCRINOL, V179, P131, DOI 10.1677/joe.0.1790131; Davies E, 2003, CLIN EXP PHARMACOL P, V30, P437, DOI 10.1046/j.1440-1681.2003.03867.x; Davies RJ, 2005, NAT REV CANCER, V5, P199, DOI 10.1038/nrc1569; Finn OJ, 2008, NEW ENGL J MED, V358, P2704, DOI 10.1056/NEJMra072739; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Griffith TS, 1997, IMMUNOL TODAY, V18, P240, DOI 10.1016/S0167-5699(97)81663-5; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He N, 2008, GASTROENTEROLOGY, V134, P793, DOI 10.1053/j.gastro.2008.01.006; Igney FH, 2002, J LEUKOCYTE BIOL, V71, P907; Kempna P, 2007, MOL PHARMACOL, V71, P787, DOI 10.1124/mol.106.028902; Lee YK, 2006, J BIOL CHEM, V281, P7850, DOI 10.1074/jbc.M509115200; MacKenzie SM, 2000, J MOL ENDOCRINOL, V24, P321, DOI 10.1677/jme.0.0240321; Miller Walter L., 2008, V13, P1, DOI 10.1159/000134751; Mueller M, 2007, ENDOCRINOLOGY, V148, P1445, DOI 10.1210/en.2006-0591; Mueller M, 2006, J EXP MED, V203, P2057, DOI 10.1084/jem.20060357; Noti M, 2009, SEMIN IMMUNOPATHOL, V31, P237, DOI 10.1007/s00281-009-0159-2; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Parker KL, 2002, RECENT PROG HORM RES, V57, P19, DOI 10.1210/rp.57.1.19; Pazirandeh A, 1999, FASEB J, V13, P893, DOI 10.1096/fasebj.13.8.893; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Schoonjans K, 2005, P NATL ACAD SCI USA, V102, P2058, DOI 10.1073/pnas.0409756102; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Smyth MJ, 2000, J EXP MED, V191, P661, DOI 10.1084/jem.191.4.661; TAKEDA Y, 1994, ENDOCRINOLOGY, V135, P2283, DOI 10.1210/en.135.5.2283; VACCHIO MS, 1994, J EXP MED, V179, P1835, DOI 10.1084/jem.179.6.1835; vandenBroek MF, 1996, J EXP MED, V184, P1781, DOI 10.1084/jem.184.5.1781; Wahl SM, 2006, IMMUNOL REV, V213, P213, DOI 10.1111/j.1600-065X.2006.00437.x	35	65	65	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2011	30	21					2411	2419		10.1038/onc.2010.629	http://dx.doi.org/10.1038/onc.2010.629			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	769JF	21258413	Green Submitted			2022-12-17	WOS:000291008000003
J	Fielding, AB; Lim, S; Montgomery, K; Dobreva, I; Dedhar, S				Fielding, A. B.; Lim, S.; Montgomery, K.; Dobreva, I.; Dedhar, S.			A critical role of integrin-linked kinase, ch-TOG and TACC3 in centrosome clustering in cancer cells	ONCOGENE			English	Article						integrin-linked kinase; centrosome clustering; multipolar mitosis; TACC3; ch-TOG/XMAP215; cancer	SPINDLE POLE ORGANIZATION; AURORA-A; CHROMOSOMAL INSTABILITY; EXTRA CENTROSOMES; IN-VITRO; PROTEIN; MICROTUBULES; AMPLIFICATION; ABERRATIONS; PROGRESSION	Many cancer cells contain more than two centrosomes, which imposes a potential for multipolar mitoses, leading to cell death. To circumvent this, cancer cells develop mechanisms to cluster supernumerary centrosomes to form bipolar spindles, enabling successful mitosis. Disruption of centrosome clustering thus provides a selective means of killing supernumerary centrosome-harboring cancer cells. Although the mechanisms of centrosome clustering are poorly understood, recent genetic analyses have identified requirements for both actin and tubulin regulating proteins. In this study, we demonstrate that the integrin-linked kinase (ILK), a protein critically involved in actin and mitotic microtubule organization, is required for centrosome clustering. Inhibition of ILK expression or activity inhibits centrosome clustering in several breast and prostate cancer cell lines that have centrosome amplification. Furthermore, cancer cells with supernumerary centrosomes are significantly more sensitive to ILK inhibition than cells with two centrosomes, demonstrating that inhibiting ILK offers a selective means of targeting cancer cells. Live cell analysis shows ILK perturbation leads cancer cells to undergo multipolar anaphases, mitotic arrest and cell death in mitosis. We also show that ILK performs its centrosome clustering activity in a focal adhesion-independent, but centrosome-dependent, manner through the microtubule regulating proteins TACC3 and ch-TOG. In addition, we identify a specific TACC3 phosphorylation site that is required for centrosome clustering and demonstrate that ILK regulates this phosphorylation in an Aurora-A-dependent manner. Oncogene (2011) 30, 521-534; doi: 10.1038/onc.2010.431; published online 13 September 2010	[Fielding, A. B.; Lim, S.; Montgomery, K.; Dobreva, I.; Dedhar, S.] BC Canc Agcy, Dept Integrat Oncol, British Columbia Canc Res Ctr, Vancouver, BC, Canada; [Dedhar, S.] Univ British Columbia, Dept Biochem & Mol Biol, Inst Life Sci, Vancouver, BC V5Z 1L3, Canada	British Columbia Cancer Agency; University of British Columbia	Dedhar, S (corresponding author), Univ British Columbia, Dept Biochem, BC Canc Res Ctr, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	sdedhar@interchange.ubc.ca		Dedhar, Shoukat/0000-0003-4355-1657; Fielding, Andrew/0000-0002-3170-9966	Canadian Institute of Health Research (CIHR); Canadian Cancer Society Research Institute; Canadian Cancer Society	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Canadian Cancer Society(Canadian Cancer Society (CCS))	This work was supported by grants to SD from the Canadian Institute of Health Research (CIHR) and the Canadian Cancer Society Research Institute, with funds raised by the Canadian Cancer Society. We thank Quadra Logic Technology Inc (QLT Inc), Vancouver, BC for supplying QLT-0267. We thank Dr Kazuhisa Kinoshita for the kind gift of anti-phospho-Ser558 TACC3 antibody and Dr Peter Lansdorp for the Aurora-A plasmid.	Albee AJ, 2008, MOL BIOL CELL, V19, P3347, DOI 10.1091/mbc.E07-11-1204; Barr AR, 2008, MOL CELL BIOL, V28, P7199, DOI 10.1128/MCB.01040-08; Barros TP, 2005, J CELL BIOL, V170, P1039, DOI 10.1083/jcb.200504097; Basto R, 2008, CELL, V133, P1032, DOI 10.1016/j.cell.2008.05.039; Bettencourt-Dias M, 2004, NATURE, V432, P980, DOI 10.1038/nature03160; Boveri T., 1914, FRAGE ENTSTEHUNG MAL; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Cassimeris L, 2004, MOL BIOL CELL, V15, P1580, DOI 10.1091/mbc.E03-07-0544; Dobreva I, 2008, J PROTEOME RES, V7, P1740, DOI 10.1021/pr700852r; Edwards LA, 2008, MOL CANCER THER, V7, P59, DOI 10.1158/1535-7163.MCT-07-0329; Fielding AB, 2008, J CELL BIOL, V180, P681, DOI 10.1083/jcb.200710074; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Gkretsi V, 2007, HEPATOLOGY, V45, P1025, DOI 10.1002/hep.21540; Guidotti JE, 2003, J BIOL CHEM, V278, P19095, DOI 10.1074/jbc.M300982200; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Kinoshita K, 2005, J CELL BIOL, V170, P1047, DOI 10.1083/jcb.200503023; Koul D, 2005, MOL CANCER THER, V4, P1681, DOI 10.1158/1535-7163.MCT-05-0258; Kramer A, 2002, LEUKEMIA, V16, P767, DOI 10.1038/sj.leu.2402454; Kwon M, 2008, GENE DEV, V22, P2189, DOI 10.1101/gad.1700908; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; LeRoy PJ, 2007, CANCER RES, V67, P5362, DOI 10.1158/0008-5472.CAN-07-0122; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Margall-Ducos G, 2007, J CELL SCI, V120, P3633, DOI 10.1242/jcs.016907; McDonald PC, 2008, J CELL SCI, V121, P3121, DOI 10.1242/jcs.017996; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nigg EA, 2006, INT J CANCER, V119, P2717, DOI 10.1002/ijc.22245; Peset I, 2005, J CELL BIOL, V170, P1057, DOI 10.1083/jcb.200504037; Pihan GA, 2003, CANCER RES, V63, P1398; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; Rebacz B, 2007, CANCER RES, V67, P6342, DOI 10.1158/0008-5472.CAN-07-0663; RING D, 1982, J CELL BIOL, V94, P549, DOI 10.1083/jcb.94.3.549; Silkworth WT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006564; Tien AC, 2004, MOL CELL PROTEOMICS, V3, P93, DOI 10.1074/mcp.M300072-MCP200; Troussard AA, 2006, CANCER RES, V66, P393, DOI 10.1158/0008-5472.CAN-05-2304; Tu YZ, 2003, CELL, V113, P37, DOI 10.1016/S0092-8674(03)00163-6; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; Xu FL, 2008, CANCER CELL, V14, P197, DOI 10.1016/j.ccr.2008.08.007; You FL, 2004, ONCOGENE, V23, P5792, DOI 10.1038/sj.onc.1207739; Zyss D, 2009, TRENDS CELL BIOL, V19, P334, DOI 10.1016/j.tcb.2009.04.001	44	65	66	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	5					521	534		10.1038/onc.2010.431	http://dx.doi.org/10.1038/onc.2010.431			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	20838383				2022-12-17	WOS:000286922300002
J	Marshall, GM; Gherardi, S; Xu, N; Neiron, Z; Trahair, T; Scarlett, CJ; Chang, DK; Liu, PY; Jankowski, K; Iraci, N; Haber, M; Norris, MD; Keating, J; Sekyere, E; Jonquieres, G; Stossi, F; Katzenellenbogen, BS; Biankin, AV; Perini, G; Liu, T				Marshall, G. M.; Gherardi, S.; Xu, N.; Neiron, Z.; Trahair, T.; Scarlett, C. J.; Chang, D. K.; Liu, P. Y.; Jankowski, K.; Iraci, N.; Haber, M.; Norris, M. D.; Keating, J.; Sekyere, E.; Jonquieres, G.; Stossi, F.; Katzenellenbogen, B. S.; Biankin, A. V.; Perini, G.; Liu, T.			Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects	ONCOGENE			English	Article						N-Myc; c-Myc; histone deacetylase 2; cyclin G2; cell proliferation	C-MYC; CYCLIN G2; PANCREATIC-CANCER; GENOMIC TARGETS; IN-VIVO; EXPRESSION; INHIBITION; PROTEIN; CELLS; IDENTIFICATION	Myc oncoproteins and histone deacetylases (HDACs) modulate gene transcription and enhance cancer cell proliferation, and HDAC inhibitors are among the most promising new classes of anticancer drugs. Here, we show that N-Myc and c-Myc upregulated HDAC2 gene expression in neuroblastoma and pancreatic cancer cells, respectively, which contributed to N-Myc- and c-Myc-induced cell proliferation. Cyclin G2 (CCNG2) was commonly repressed by N-Myc and HDAC2 in neuroblastoma cells and by c-Myc and HDAC2 in pancreatic cancer cells, and could be reactivated by HDAC inhibitors. 5-bromo-2'-deoxyuridine incorporation assays showed that transcriptional repression of CCNG2 was, in part, responsible for N-Myc-, c-Myc- and HDAC2-induced cell proliferation. Dual crosslinking chromatin immunoprecipitation assay demonstrated that N-Myc acted as a transrepressor by recruiting the HDAC2 protein to Sp1-binding sites at the CCNG2 gene core promoter. Moreover, HDAC2 was upregulated, and CCNG2 downregulated, in pre-cancerous and neuroblastoma tissues from N-Myc transgenic mice, and c-Myc overexpression correlated with upregulation of HDAC2 and repression of CCNG2 in tumour tissues from pancreatic cancer patients. Taken together, our data indicate the critical roles of upregulation of HDAC2 and suppression of CCNG2 in Myc-induced oncogenesis, and have significant implications for the application of HDAC inhibitors in the prevention and treatment of Myc-driven cancers. Oncogene (2010) 29, 5957-5968; doi:10.1038/onc.2010.332; published online 9 August 2010	[Marshall, G. M.; Xu, N.; Neiron, Z.; Trahair, T.; Liu, P. Y.; Jankowski, K.; Haber, M.; Norris, M. D.; Keating, J.; Sekyere, E.; Jonquieres, G.; Liu, T.] Univ New S Wales, Childrens Canc Inst Australia Med Res, Lowy Canc Res Ctr, Sydney, NSW 2052, Australia; [Marshall, G. M.] Univ New S Wales, Ctr Childrens Canc & Blood Disorders, Sydney Childrens Hosp, Sydney, NSW 2052, Australia; [Gherardi, S.; Iraci, N.; Perini, G.] Univ Bologna, Dept Biol, I-40126 Bologna, Italy; [Scarlett, C. J.; Chang, D. K.; Biankin, A. V.] St Vincents Hosp, Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia; [Stossi, F.; Katzenellenbogen, B. S.] Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA	Children's Cancer Institute; Children's Medical Research Institute - Australia; University of New South Wales Sydney; University of New South Wales Sydney; University of Sydney; University of Bologna; Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of Illinois System; University of Illinois Urbana-Champaign	Liu, T (corresponding author), Univ New S Wales, Childrens Canc Inst Australia Med Res, Lowy Canc Res Ctr C25, POB 81, Sydney, NSW 2052, Australia.	g.marshall@unsw.edu.au; tliu@ccia.unsw.edu.au	Liu, Tao/A-3922-2015; Iraci, Nunzio/M-7451-2016; von Jonquieres, Georg/W-1781-2019	Iraci, Nunzio/0000-0003-2146-9329; von Jonquieres, Georg/0000-0002-7423-3355; Scarlett, Christopher/0000-0002-4140-7785; Chang, David/0000-0002-4821-3078; Haber, Michelle/0000-0003-2036-8817; Norris, Murray/0000-0002-0632-4589; Liu, Tao/0000-0001-6244-7316; Trahair, Toby/0000-0002-3295-228X; Biankin, Andrew/0000-0002-0362-5597	NIH; Cancer Institute NSW; NHMRC; Cancer Council NSW; Italian Association for Research on Cancer	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Institute NSW; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council NSW(Cancer Council New South Wales); Italian Association for Research on Cancer(Fondazione AIRC per la ricerca sul cancro)	The authors are supported by an NIH project grant (T L), a Career Development and Support Fellowship from Cancer Institute NSW (T L and AVB), NHMRC (TL and GMM) and Cancer Council NSW (TL, AVB and CJS) project grants, NHMRC, Cancer Institute NSW and Cancer Council NSW programme grants (GMM, MH and MDN), Italian Association for Research on Cancer (GP), NHMRC Postdoctoral Training Fellowships (CJS and TT). Children's Cancer Institute Australia is affiliated with University of New South Wales and Sydney Children's Hospital.	Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Biankin AV, 2009, GASTROENTEROLOGY, V137, P558, DOI 10.1053/j.gastro.2009.04.009; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Fritsche P, 2009, GUT, V58, P1399, DOI 10.1136/gut.2009.180711; Hansford LM, 2004, P NATL ACAD SCI USA, V101, P12664, DOI 10.1073/pnas.0401083101; Hrzenjak A, 2006, MOL CANCER THER, V5, P2203, DOI 10.1158/1535-7163.MCT-05-0480; Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567; Kim Y, 2004, CANCER RES, V64, P8980, DOI 10.1158/0008-5472.CAN-04-1926; Kurland JF, 2008, CANCER RES, V68, P3624, DOI 10.1158/0008-5472.CAN-07-6552; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Liu T, 2007, P NATL ACAD SCI USA, V104, P18682, DOI 10.1073/pnas.0705524104; Mahlamaki EH, 2002, GENE CHROMOSOME CANC, V35, P353, DOI 10.1002/gcc.10122; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Nowak DE, 2005, BIOTECHNIQUES, V39, P715, DOI 10.2144/000112014; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Raetz EA, 2003, CANCER, V98, P841, DOI 10.1002/cncr.11584; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; Schleger C, 2002, MODERN PATHOL, V15, P462, DOI 10.1038/modpathol.3880547; Stossi F, 2006, J BIOL CHEM, V281, P16272, DOI 10.1074/jbc.M513405200; Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Xu GX, 2008, MOL BIOL CELL, V19, P4968, DOI 10.1091/mbc.E08-03-0259; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X; Zimmermann S, 2007, CANCER RES, V67, P9047, DOI 10.1158/0008-5472.CAN-07-0312	29	65	70	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2010	29	44					5957	5968		10.1038/onc.2010.332	http://dx.doi.org/10.1038/onc.2010.332			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	675PS	20697349				2022-12-17	WOS:000283843400009
J	Lee, SH; Bahn, JH; Whitlock, NC; Baek, SJ				Lee, S-H; Bahn, J. H.; Whitlock, N. C.; Baek, S. J.			Activating transcription factor 2 (ATF2) controls tolfenamic acid-induced ATF3 expression via MAP kinase pathways	ONCOGENE			English	Article						Tolfenamic acid; ATF2; ATF3; apoptosis; colorectal cancer	COLORECTAL-CANCER CELLS; STRESS-INDUCIBLE GENE; RESPONSE GENE; SIGNALING PATHWAYS; ENDOTHELIAL-CELLS; MAMMARY-TUMORS; BREAST-CANCER; APOPTOSIS; GROWTH; NAG-1	Tolfenamic acid (TA) is a non-steroidal anti-inflammatory drug associated with anti-tumorigenic and pro-apoptotic properties in animal and in vitro models of cancer. However, the underlying cellular mechanisms by which TA exerts its effects are only partially understood. Activating transcription factor 3 (ATF3) is a member of the ATF/CREB subfamily of the basic region-leucine zipper family and has been known as a tumor suppressor in human colorectal cancer cells. The present study was performed to observe whether ATF3 mediates TA-induced apoptosis and to elucidate the molecular mechanism of ATF3 transcription induced by TA. TA treatment and ectopic expression of ATF3 increased apoptosis, whereas knockdown of ATF3 resulted in significant repression of TA-activated apoptosis. The TA treatment also induced ATF3 promoter activity. Internal deletion and point mutation of the predicted ATF/C/EBP binding site in ATF3 promoter abolished luciferase activation by TA. Overexpression of ATF2 resulted in significant increase in ATF3 promoter activity, and electrophoretic mobility shift assay identified this region as a core sequence to which ATF2 binds. TA treatment resulted in an increase in ATF2 phosphorylation, which was followed by a subsequent increase in ATF3 transcription. Knock down of ATF2 abolished TA-induced ATF3 expression. We further provide evidence that TA leads to increases in phospho-p38 MAPK, JNK and ERK levels. Inhibition of these pathways using selective inhibitors and dominant negative constructs ameliorated TA-induced ATF3 expression and promoter activities. The current study shows that TA stimulates ATF3 expression and subsequently induces apoptosis. These pathways are mediated through phosphorylation of ATF2, which is mediated by p38 MAPK-, JNK- and ERK-dependent pathways. Oncogene (2010) 29, 5182-5192; doi:10.1038/onc.2010.251; published online 28 June 2010	[Lee, S-H; Bahn, J. H.; Whitlock, N. C.; Baek, S. J.] Univ Tennessee, Dept Pathobiol, Lab Environm Carcinogenesis, Coll Vet Med, Knoxville, TN 37996 USA	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	Baek, SJ (corresponding author), Univ Tennessee, Dept Pathobiol, Lab Environm Carcinogenesis, Coll Vet Med, 2407 River Dr, Knoxville, TN 37996 USA.	sbaek2@utk.edu	Bahn, Jae Hoon/G-7686-2016; Bahn, Jae Hoon/AAP-2672-2020; Bahn, Jae Hoon/AAA-9612-2019	Bahn, Jae Hoon/0000-0002-0365-1728; 	National Institutes of Health [R01CA108975]; University of Tennessee, Center of Excellence in Livestock Diseases and Human Health; American Cancer Society [CNE-111611]; NATIONAL CANCER INSTITUTE [R01CA108975] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Tennessee, Center of Excellence in Livestock Diseases and Human Health; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr T Hai (Ohio State University, Columbus, OH, USA) and Dr S Kitajima (Tokyo Medical and Dental University, Tokyo, Japan) for providing the pCG-ATF3 construct and ATF3 promoter, respectively. We thank Dr Philip Cohen (University of Dundee, Scotland, UK) and Dr Joo-Heon Yoon (Yonsei University, Seoul, Korea) for providing pEBG2T-GST-ATF2-6His- and CREB-expression vector, respectively. We thank Dr Melanie Cobb (University of Texas Southwestern Medical Center, Dallas, TX, USA) for providing wild type and dominant negative ERK2-expression vector. We also thank Misty Bailey for her critical reading of the paper. This work was supported by Grants from the American Cancer Society (CNE-111611), National Institutes of Health (R01CA108975) and the University of Tennessee, Center of Excellence in Livestock Diseases and Human Health to SJB.	Abdelrahim M, 2007, CANCER RES, V67, P3286, DOI 10.1158/0008-5472.CAN-06-3831; Abdelrahim M, 2006, J NATL CANCER I, V98, P855, DOI 10.1093/jnci/djj232; Allan AL, 2001, J BIOL CHEM, V276, P27272, DOI 10.1074/jbc.M103196200; Baek SJ, 2004, CARCINOGENESIS, V25, P2425, DOI 10.1093/carcin/bgh255; Bhoumik A, 2008, CELL CYCLE, V7, P2341, DOI 10.4161/cc.6388; Bhoumik A, 2008, P NATL ACAD SCI USA, V105, P1674, DOI 10.1073/pnas.0706057105; Bottone FG, 2005, MOL CANCER THER, V4, P693, DOI 10.1158/1535-7163.MCT-04-0337; Bottone FG, 2004, CARCINOGENESIS, V25, P349, DOI 10.1093/carcin/bgh016; Brown SL, 2008, CANCER RES, V68, P364, DOI 10.1158/0008-5472.CAN-07-2170; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; Chen HH, 2004, MOL PHARMACOL, V65, P1130, DOI 10.1124/mol.65.5.1130; Cho KN, 2007, EUR J CANCER, V43, P2404, DOI 10.1016/j.ejca.2007.07.020; Deng XH, 2008, CANCER RES, V68, P9663, DOI 10.1158/0008-5472.CAN-08-2229; Fan FY, 2002, ONCOGENE, V21, P7488, DOI 10.1038/sj.onc.1205896; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; HANSEN PE, 1994, PHARMACOL TOXICOL, V75, P81, DOI 10.1111/j.1600-0773.1994.tb02005.x; Hao F, 2007, BBA-MOL CELL BIOL L, V1771, P883, DOI 10.1016/j.bbalip.2007.04.010; Huang XW, 2008, J BIOL CHEM, V283, P29795, DOI 10.1074/jbc.M802515200; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kashiwakura Y, 2008, CANCER RES, V68, P8333, DOI 10.1158/0008-5472.CAN-08-0080; Lee SH, 2008, MOL CANCER THER, V7, P3739, DOI 10.1158/1535-7163.MCT-08-0548; Lee SH, 2006, CARCINOGENESIS, V27, P972, DOI 10.1093/carcin/bgi268; Lee SH, 2005, BIOCHEM BIOPH RES CO, V328, P63, DOI 10.1016/j.bbrc.2004.12.138; Lu D, 2006, J BIOL CHEM, V281, P10473, DOI 10.1074/jbc.M509278200; Maekawa T, 2008, ONCOGENE, V27, P1045, DOI 10.1038/sj.onc.1210727; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Maekawa T, 2007, MOL CELL BIOL, V27, P1730, DOI 10.1128/MCB.01579-06; Miyazaki K, 2009, NUCLEIC ACIDS RES, V37, P1438, DOI 10.1093/nar/gkn1082; Oh YK, 2008, MOL CANCER RES, V6, P1232, DOI 10.1158/1541-7786.MCR-07-0297; Ouwens DM, 2002, EMBO J, V21, P3782, DOI 10.1093/emboj/cdf361; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Piyanuch R, 2007, CANCER LETT, V258, P230, DOI 10.1016/j.canlet.2007.09.007; Tamura K, 2005, EMBO J, V24, P2590, DOI 10.1038/sj.emboj.7600742; Whitmore MM, 2007, J IMMUNOL, V179, P3622, DOI 10.4049/jimmunol.179.6.3622; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Woo IS, 2002, INT J ONCOL, V20, P527; Xue L, 2005, ONCOGENE, V24, P2343, DOI 10.1038/sj.onc.1208434; Yamaguchi K, 2006, CANCER RES, V66, P2376, DOI 10.1158/0008-5472.CAN-05-1987; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712; Yan CH, 2006, CELL CYCLE, V5, P926, DOI 10.4161/cc.5.9.2714; Yin X, 2008, ONCOGENE, V27, P2118, DOI 10.1038/sj.onc.1210861	45	65	68	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	37					5182	5192		10.1038/onc.2010.251	http://dx.doi.org/10.1038/onc.2010.251			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650QZ	20581861	Green Accepted			2022-12-17	WOS:000281867200007
J	Vizioli, MG; Sensi, M; Miranda, C; Cleris, L; Formelli, F; Anania, MC; Pierotti, MA; Greco, A				Vizioli, M. G.; Sensi, M.; Miranda, C.; Cleris, L.; Formelli, F.; Anania, M. C.; Pierotti, M. A.; Greco, A.			IGFBP7: an oncosuppressor gene in thyroid carcinogenesis	ONCOGENE			English	Article						IGFBP7; thyroid tumors; PTC	EXPRESSION PROFILES; COLORECTAL-CANCER; TUMOR-GROWTH; PAPILLARY; PROTEIN; CARCINOMA; SENESCENCE; BRAF	Insulin-like growth factor-binding protein 7 (IGFBP7) is a secreted protein involved in several cellular processes, including proliferation, senescence and apoptosis. Loss of IGFBP7 expression is a critical step in the development of human tumors, including melanoma and colon cancer. By microarray gene expression studies, we have detected downregulation of IGFBP7 gene expression in follicular and papillary thyroid tumors in comparison with normal thyroid tissue. Evaluation of publicly available PTC microarray gene expression data sets confirmed, in a consistent fraction of tumors, the downregulation of IGFBP7 transcript levels. The functional consequence of IGFBP7 downregulation was addressed in the PTC-derived NIM1 cell line in which IGFBP7 expression is repressed by promoter hypermethylation. Exposure to soluble IGFBP7 protein or restoration of IGFBP7 expression by complementary DNA transfection reduced growth rate, migration, anchorage-independent growth and tumorigenicity of NIM1 cells. We show that the effects of IGFBP7 are related to apoptosis. Our data suggest that loss of IGFBP7 expression has a functional role in thyroid carcinogenesis, and it may represent a possible basis for therapeutic strategies. Oncogene (2010) 29, 3835-3844; doi: 10.1038/onc.2010.136; published online 3 May 2010	[Vizioli, M. G.; Miranda, C.; Anania, M. C.; Greco, A.] Ist Nazl Tumori, IRCCS Fdn, Dept Expt Oncol & Mol Med, Mol Mech Unit, I-20133 Milan, Italy; [Sensi, M.] Ist Nazl Tumori, IRCCS Fdn, Dept Expt Oncol & Mol Med, Human Tumors Immunobiol Unit, I-20133 Milan, Italy; [Cleris, L.; Formelli, F.] Ist Nazl Tumori, IRCCS Fdn, Dept Expt Oncol & Mol Med, Chemoprevent Unit, I-20133 Milan, Italy; [Pierotti, M. A.] Ist Nazl Tumori, IRCCS Fdn, Dept Expt Oncol & Mol Med, Sci Directorate, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico	Greco, A (corresponding author), Ist Nazl Tumori, IRCCS Fdn, Dept Expt Oncol & Mol Med, Mol Mech Unit, Via Venezian 1, I-20133 Milan, Italy.	angela.greco@istitutotumori.mi.it	Anania, Maria Chiara/N-4853-2019; Cleris, Loredana/T-3144-2018; Greco, Angela/C-1953-2017; Sensi, Marialuisa/K-5631-2014; Anania, Maria Chiara/B-9339-2017; Pierotti, Marco Alessandro/AAC-4728-2022	Anania, Maria Chiara/0000-0003-4012-1870; Cleris, Loredana/0000-0001-8778-7931; Greco, Angela/0000-0003-2994-0349; Sensi, Marialuisa/0000-0002-7643-0248; Anania, Maria Chiara/0000-0003-4012-1870; Pierotti, Marco Alessandro/0000-0002-7431-8332	AIRC [4472]; ACC; Ministry of Health	AIRC(Fondazione AIRC per la ricerca sul cancro); ACC; Ministry of Health	The authors thank Mrs Sonia Pagliardini for technical assistance and Mrs Cristina Mazzadi for editing and secretarial help. This work was supported by AIRC grant N. 4472, ACC and Ministry of Health.	Ahmed S, 2003, BIOCHEM BIOPH RES CO, V310, P612, DOI 10.1016/j.bbrc.2003.09.058; Akaogi K, 1996, P NATL ACAD SCI USA, V93, P8384, DOI 10.1073/pnas.93.16.8384; Aldred MA, 2004, J CLIN ONCOL, V22, P3531, DOI 10.1200/JCO.2004.08.127; [Anonymous], 1988, BRIT J CANCER, V58, P109, DOI 10.1038/bjc.1988.174; Burger AM, 2005, EUR J CANCER, V41, P1515, DOI 10.1016/j.ejca.2005.04.023; Chen Y, 2007, J PATHOL, V211, P431, DOI 10.1002/path.2132; Davies L, 2006, JAMA-J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164; Ferrario C, 2008, LAB INVEST, V88, P474, DOI 10.1038/labinvest.2008.17; Giordano TJ, 2005, ONCOGENE, V24, P6646, DOI 10.1038/sj.onc.1208822; Greco A, 2009, Q J NUCL MED MOL IM, V53, P440; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; Hinoue T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008357; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Jarzab B, 2005, CANCER RES, V65, P1587, DOI 10.1158/0008-5472.CAN-04-3078; Kanemitsu N, 2000, BIOCHEM BIOPH RES CO, V279, P251, DOI 10.1006/bbrc.2000.3944; Latini FRM, 2008, ENDOCR-RELAT CANCER, V15, P787, DOI 10.1677/ERC-08-0079; Lin J, 2007, J PATHOL, V212, P83, DOI 10.1002/path.2144; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Pallante P, 2008, CANCER RES, V68, P6770, DOI 10.1158/0008-5472.CAN-08-0695; Ruan Wen-jing, 2006, J Zhejiang Univ Sci B, V7, P929, DOI 10.1631/jzus.2006.B0929; Ruan WJ, 2007, CANCER BIOL THER, V6, P354, DOI 10.4161/cbt.6.3.3702; Sato Y, 2007, CANCER SCI, V98, P1055, DOI 10.1111/j.1349-7006.2007.00502.x; Schrama D, 2010, J INVEST DERMATOL, V130, P897, DOI 10.1038/jid.2009.304; Sprenger CC, 1999, CANCER RES, V59, P2370; Suzuki H, 2010, CARCINOGENESIS, V31, P342, DOI 10.1093/carcin/bgp179; Vasko V, 2007, P NATL ACAD SCI USA, V104, P2803, DOI 10.1073/pnas.0610733104; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Wajapeyee N, 2009, MOL CANCER THER, V8, P3009, DOI 10.1158/1535-7163.MCT-09-0470; Wilson HMP, 2002, CELL GROWTH DIFFER, V13, P205; Yamanaka Y, 1997, J BIOL CHEM, V272, P30729, DOI 10.1074/jbc.272.49.30729; ZEKI K, 1993, J CLIN ENDOCR METAB, V76, P127, DOI 10.1210/jc.76.1.127	31	65	66	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2010	29	26					3835	3844		10.1038/onc.2010.136	http://dx.doi.org/10.1038/onc.2010.136			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	618VW	20440262				2022-12-17	WOS:000279385200011
J	Xu, Y; Lee, SH; Kim, HS; Kim, NH; Piao, S; Park, SH; Jung, YS; Yook, JI; Park, BJ; Ha, NC				Xu, Y.; Lee, S-H; Kim, H. S.; Kim, N. H.; Piao, S.; Park, S-H; Jung, Y. S.; Yook, J. I.; Park, B-J; Ha, N-C			Role of CK1 in GSK3 beta-mediated phosphorylation and degradation of Snail	ONCOGENE			English	Article						snail; casein kinase 1; EMT; GSK3 beta; metastasis	CASEIN KINASE-I; EPITHELIAL-MESENCHYMAL TRANSITIONS; BETA-CATENIN; TRANSCRIPTION FACTOR; SIGNALING PATHWAY; GENE-EXPRESSION; BREAST-CANCER; WNT; EPSILON; PROTEIN	The epithelial to mesenchymal transition (EMT) that occurs during embryonic development has begun to attract attention as a potential mechanism for tumor cell metastasis. Snail is a well-known Zn-finger transcription factor that promotes EMT by repressing E-cadherin expression. It is known that Snail is phosphorylated by GSK3 beta and degraded by beta-TrCP-mediated ubiquitination. Here we described another protein kinase, CK1, whose phosphorylation of Snail is required for the subsequent GSK3 beta phosphorylation. Specific inhibition or depletion of CK1 epsilon inhibits the phosphorylation and degradation of Snail and promotes cell migration, suggesting a central role of CK1 epsilon in the EMT process. Furthermore, our study uncovered distinct roles and steps of Snail phosphorylation by CK1 epsilon and GSK3 beta. Taken together, we identified CK1 epsilon as a new component of the Snail-mediated EMT process, providing insight into the mechanism of human cancer metastasis. Oncogene (2010) 29, 3124-3133; doi: 10.1038/onc.2010.77; published online 22 March 2010	[Xu, Y.; Piao, S.; Park, S-H; Ha, N-C] Pusan Natl Univ, Coll Pharm, Dept Mfg Pharm, Pusan 609735, South Korea; [Xu, Y.; Piao, S.; Park, S-H; Ha, N-C] Pusan Natl Univ, Res Inst Drug Dev, Pusan 609735, South Korea; [Lee, S-H; Jung, Y. S.; Park, B-J] Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Pusan 609735, South Korea; [Kim, H. S.; Kim, N. H.; Yook, J. I.] Yonsei Univ, Coll Dent, Oral Canc Res Inst, Dept Oral Pathol, Seoul 120749, South Korea	Pusan National University; Pusan National University; Pusan National University; Yonsei University; Yonsei University Health System	Ha, NC (corresponding author), Pusan Natl Univ, Coll Pharm, Dept Mfg Pharm, 30 Jangjeon Dong, Pusan 609735, South Korea.	hnc@pusan.ac.kr		Kim, Nam Hee/0000-0002-3087-5276; Kim, Hyun Sil/0000-0003-3614-1764; Yook, Jong In/0000-0002-7318-6112	Ministry for Health, Welfare and Family affairs, Republic of Korea [0920140]	Ministry for Health, Welfare and Family affairs, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	We thank Xiao Ling Jin for assisting in DNA construction and protein purification. This study was supported by a grant from the National R&D Program for Cancer Control, Ministry for Health, Welfare and Family affairs, Republic of Korea (0920140).	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Birchmeier W, 1991, CURR OPIN CELL BIOL, V3, P832, DOI 10.1016/0955-0674(91)90057-6; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Chu EY, 2004, DEVELOPMENT, V131, P4819, DOI 10.1242/dev.01347; COBB MH, 1983, J BIOL CHEM, V258, P2472; Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014; Dahlberg CL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004766; Dominguez D, 2003, MOL CELL BIOL, V23, P5078, DOI 10.1128/MCB.23.14.5078-5089.2003; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Kim MJ, 2003, NAT GENET, V34, P330, DOI 10.1038/ng1182; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lee SH, 2009, NEOPLASIA, V11, P22, DOI 10.1593/neo.81006; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Piao S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004046; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Santos JA, 1996, J CELL SCI, V109, P1847; Schwarz-Romond T, 2007, J CELL SCI, V120, P2402, DOI 10.1242/jcs.002956; Swiatek W, 2004, J BIOL CHEM, V279, P13011, DOI 10.1074/jbc.M304682200; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tuazon P. T., 1991, ADV 2 MESSENGER PHOS, V23, P123; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zhou BHP, 2005, CELL CYCLE, V4, P772, DOI 10.4161/cc.4.6.1744; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	44	65	70	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2010	29	21					3124	3133		10.1038/onc.2010.77	http://dx.doi.org/10.1038/onc.2010.77			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602IQ	20305697				2022-12-17	WOS:000278133100009
J	Muller, T; Stein, U; Poletti, A; Garzia, L; Rothley, M; Plaumann, D; Thiele, W; Bauer, M; Galasso, A; Schlag, P; Pankratz, M; Zollo, M; Sleeman, JP				Mueller, T.; Stein, U.; Poletti, A.; Garzia, L.; Rothley, M.; Plaumann, D.; Thiele, W.; Bauer, M.; Galasso, A.; Schlag, P.; Pankratz, M.; Zollo, M.; Sleeman, J. P.			ASAP1 promotes tumor cell motility and invasiveness, stimulates metastasis formation in vivo, and correlates with poor survival in colorectal cancer patients	ONCOGENE			English	Article						ASAP1; metastasis; ARF-GAP; motility; invasion	GTPASE-ACTIVATING PROTEIN; SMOOTH-MUSCLE-CELLS; PODOSOME FORMATION; BINDING-PROTEIN; EXPRESSION; SRC; PHOSPHORYLATION; INVASION; ARF1; GAP	We have previously performed an unbiased screen to identify genes whose expression is associated with the metastatic phenotype. Secondary screening of these genes using custom microarray chips identified ASAP1, a multidomain adaptor protein with ADP-ribosylation factor-GAP activity, as being potentially involved in tumor progression. Here, we show that at least three different splice forms of ASAP1 are upregulated in rodent tumor models in a manner that correlates with metastatic potential. In human cancers, we found that ASAP1 expression is strongly upregulated in a variety of tumors in comparison with normal tissue and that this expression correlates with poor metastasis-free survival and prognosis in colorectal cancer patients. Using loss and gain of function approaches, we were able to show that ASAP1 promotes metastasis formation in vivo and stimulates tumor cell motility, invasiveness, and adhesiveness in vitro. Furthermore, we show that ASAP1 interacts with the metastasis-promoting protein h-prune and stimulates its phosphodiesterase activity. In addition, ASAP1 binds to the SH3 domains of several proteins, including SLK with which it co-immunoprecipitates. These data support the notion that ASAP1 can contribute to the dissemination of a variety of tumor types and represent a potential target for cancer therapy. Oncogene (2010) 29, 2393-2403; doi:10.1038/onc.2010.6; published online 15 February 2010	[Poletti, A.; Rothley, M.; Thiele, W.; Sleeman, J. P.] Univ Heidelberg, Univ Med Mannheim, D-68167 Mannheim, Germany; [Mueller, T.; Rothley, M.; Plaumann, D.; Thiele, W.; Bauer, M.; Pankratz, M.; Sleeman, J. P.] Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; [Stein, U.] Max Delbruck Ctr Mol Med, Charite Univ Med Berlin, Expt & Clin Res Ctr, Berlin, Germany; [Garzia, L.; Galasso, A.; Zollo, M.] Ctr Ingn Genet & Biotecnol Avanzate CEINGE, Naples, Italy; [Schlag, P.] Charite Comprehens Canc Ctr, Berlin, Germany; [Zollo, M.] Univ Naples Federico 2, Fac Biotechnol Sci, Dipartimento Biochim & Biotecnol Med, Naples, Italy	Ruprecht Karls University Heidelberg; Helmholtz Association; Karlsruhe Institute of Technology; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; CEINGE Biotecnologie Avanzate; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Naples Federico II	Sleeman, JP (corresponding author), Univ Heidelberg, Univ Med Mannheim, Ludolf Krehl Str 13-17, D-68167 Mannheim, Germany.	sleeman@medma.uni-heidelberg.de	Thiele, Wilko/AAF-7856-2020; Sleeman, Jonathan P/H-2515-2013	Thiele, Wilko/0000-0002-8978-4192; Sleeman, Jonathan P/0000-0003-1718-7687; Galasso, Alessia/0000-0001-7110-9925; Stein, Ulrike/0000-0001-7006-282X	BMBF; European Union [LSHC-CT-2004-503224]; AIRC [2007-2010]; Association for International Cancer Research (AICR) [08-0015]	BMBF(Federal Ministry of Education & Research (BMBF)); European Union(European Commission); AIRC(Fondazione AIRC per la ricerca sul cancro); Association for International Cancer Research (AICR)	This work was supported by grants to JPS and US from the BMBF NGFN2 CancerNet Program, to JPS from the European Union (FP6 STREP project BRECOSM, contract no. LSHC-CT-2004-503224), to MZ from AIRC 2007-2010 and to JPS and MZ from the Association for International Cancer Research (AICR, grant no. 08-0015). We thank Norma Howells and Selma Huber for animal care and Paul Randazzo, Craig Furman, and Margaret Frame for providing expression contructs. The contribution of Franziska Arlt Pia Hermann and Markus Niederstrasser is also gratefully acknowledged.	Andreev J, 1999, MOL CELL BIOL, V19, P2338; Bharti S, 2007, MOL CELL BIOL, V27, P8271, DOI 10.1128/MCB.01781-06; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Buffart TE, 2005, CELL ONCOL, V27, P57; Cougoule C, 2005, TRAFFIC, V6, P682, DOI 10.1111/j.1600-0854.2005.00307.x; D'Angelo A, 2004, CANCER CELL, V5, P137, DOI 10.1016/S1535-6108(04)00021-2; Ehlers JP, 2005, CLIN CANCER RES, V11, P3609, DOI 10.1158/1078-0432.CCR-04-1941; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Furman C, 2002, J BIOL CHEM, V277, P7962, DOI 10.1074/jbc.M109149200; Harlow E LD, 1988, ANTIBODIES LAB MANUA; Hashimoto S, 2006, P NATL ACAD SCI USA, V103, P7036, DOI 10.1073/pnas.0509166103; Hofmann M, 1998, J CELL SCI, V111, P1673; ISAACS JT, 1986, PROSTATE, V9, P261, DOI 10.1002/pros.2990090306; Jackson TR, 2000, TRENDS BIOCHEM SCI, V25, P489, DOI 10.1016/S0968-0004(00)01644-3; Kowanetz K, 2004, MOL BIOL CELL, V15, P3155, DOI 10.1091/mbc.E03-09-0683; Kruljac-Letunic A, 2003, J BIOL CHEM, V278, P29560, DOI 10.1074/jbc.M302278200; Lin D, 2008, CANCER RES, V68, P4352, DOI 10.1158/0008-5472.CAN-07-5237; Liu YH, 2005, J BIOL CHEM, V280, P8884, DOI 10.1074/jbc.M412200200; Liu YH, 2002, MOL BIOL CELL, V13, P2147, DOI 10.1091/mbc.E02-01-0018; Marino N, 2007, CLIN EXP METASTAS, V24, P637, DOI 10.1007/s10585-007-9109-3; Mengwasser J, 2004, ONCOGENE, V23, P7430, DOI 10.1038/sj.onc.1207987; Nam JM, 2007, EMBO J, V26, P647, DOI 10.1038/sj.emboj.7601534; Nestl A, 2001, CANCER RES, V61, P1569; Nie ZZ, 2006, CURR BIOL, V16, P130, DOI 10.1016/j.cub.2005.11.069; Niebuhr K, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P398; Oda A, 2003, J BIOL CHEM, V278, P6456, DOI 10.1074/jbc.M210817200; Onodera Y, 2005, EMBO J, V24, P963, DOI 10.1038/sj.emboj.7600588; Oshiro T, 2002, J BIOL CHEM, V277, P38618, DOI 10.1074/jbc.M203453200; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Randazzo PA, 2000, P NATL ACAD SCI USA, V97, P4011, DOI 10.1073/pnas.070552297; Randazzo PA, 2004, CELL SIGNAL, V16, P401, DOI 10.1016/j.cellsig.2003.09.012; Sabe H, 2009, TRAFFIC, V10, P982, DOI 10.1111/j.1600-0854.2009.00917.x; Stein U, 2002, J CLIN ONCOL, V20, P3282, DOI 10.1200/JCO.2002.01.003; Wagner S, 2002, J BIOL CHEM, V277, P37685, DOI 10.1074/jbc.M205899200; Webb BA, 2005, AM J PHYSIOL-CELL PH, V289, pC898, DOI 10.1152/ajpcell.00095.2005; Zhou ST, 2006, AM J PHYSIOL-CELL PH, V290, pC463, DOI 10.1152/ajpcell.00350.2005	37	65	68	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	16					2393	2403		10.1038/onc.2010.6	http://dx.doi.org/10.1038/onc.2010.6			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	586YK	20154719				2022-12-17	WOS:000276951500008
J	Atkinson, GP; Nozell, SE; Harrison, DK; Stonecypher, MS; Chen, D; Benveniste, EN				Atkinson, G. P.; Nozell, S. E.; Harrison, D. K.; Stonecypher, M. S.; Chen, D.; Benveniste, E. N.			The prolyl isomerase Pin1 regulates the NF-kappa B signaling pathway and interleukin-8 expression in glioblastoma	ONCOGENE			English	Article						glioblastoma; gene expression; signal transduction; NF-kappa B; Pin1	NECROSIS-FACTOR-ALPHA; TRANSCRIPTIONAL ACTIVITY; CANCER; PHOSPHORYLATION; TARGET; ACTIVATION; APOPTOSIS; TUMORS; GROWTH; STAT3	The brain tumor glioblastoma (GBM) remains one of the most aggressive and devastating tumors despite decades of effort to find more effective treatments. A hallmark of GBM is the constitutive activation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B) signaling pathway, which regulates cell proliferation, in. ammation, migration and apoptosis. The prolyl isomerase, Pin1, has been found to bind directly to the NF-kappa B protein, p65, and cause increases in NF-kappa B promoter activity in a breast cancer model. We now present evidence that this interaction occurs in GBM and that it has important consequences on NF-kappa B signaling. We demonstrate that Pin1 levels are enhanced in primary GBM tissues compared with controls, and that this difference in Pin1 expression affects the migratory capacity of GBM-derived cells. Pin1 knockdown decreases the amount of activated, phosphorylated p65 in the nucleus, resulting in inhibition of the transcriptional program of the IL-8 gene. Through the use of microarray, we also observed changes in the expression levels of other NF-kappa B regulated genes due to Pin1 knockdown. Taken together, these data suggest that Pin1 is an important regulator of NF-kappa B in GBM, and support the notion of using Pin1 as a therapeutic target in the future. Oncogene (2009) 28, 3735-3745; doi: 10.1038/onc.2009.232; published online 10 August 2009	[Atkinson, G. P.; Nozell, S. E.; Stonecypher, M. S.; Benveniste, E. N.] Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; [Harrison, D. K.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Chen, D.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Benveniste, EN (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, THT Room 926A,1900 Univ Blvd, Birmingham, AL 35294 USA.	tika@uab.edu			National Institutes of Health [CA97247, NS-54158, IRG-60-001-47]; American Cancer Society [CA-13148-31]; NCI (SEN); UAB Medical Scientist Training Program; NIH [T32AI0705]; NATIONAL CANCER INSTITUTE [P30CA013148, R01CA158534, R01CA194414, P50CA097247] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000705, T32AI007051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS054158, R01NS045290] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NCI (SEN)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UAB Medical Scientist Training Program; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr Michael Crowley in the UAB Comprehensive Cancer Center Gene Expression Shared Facility for his assistance with microarray processing, and Dr Cheryl Ann Palmer (University of Alabama at Birmingham) for providing the brain tumor resections. We also thank Dr Yancey Gillespie, UAB Brain Tumor Tissue Core, for glioma and control tissue samples, and express our appreciation to the laboratory of Dr Dale Benos for assistance with the scratch assay. Finally, many thanks to Dr Rafal Bartoszewski for assistance with the qPCR and to Dr Gerald Fuller for reading the paper. This work was supported in part by National Institutes of Health grants CA97247 (ENB), NS-54158 (ENB and SEN) and IRG-60-001-47 from the American Cancer Society and CA-13148-31 from the NCI (SEN). GPA was supported by the UAB Medical Scientist Training Program, and is currently supported by NIH T32AI0705.	Afra D, 2002, LANCET, V359, P1011; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Ayala G, 2003, CANCER RES, V63, P6244; Baker BJ, 2008, GLIA, V56, P1250, DOI 10.1002/glia.20694; Bao L, 2004, AM J PATHOL, V164, P1727, DOI 10.1016/S0002-9440(10)63731-5; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Brandes AA, 2008, CRIT REV ONCOL HEMAT, V67, P139, DOI 10.1016/j.critrevonc.2008.02.005; Brantley EC, 2008, CLIN CANCER RES, V14, P4694, DOI 10.1158/1078-0432.CCR-08-0618; Brat DJ, 2005, NEURO-ONCOLOGY, V7, P122, DOI 10.1215/S1152851704001061; Chandana SR, 2008, AM FAM PHYSICIAN, V77, P1423; Choi C, 2002, MOL CELL BIOL, V22, P724, DOI 10.1128/MCB.22.3.724-736.2002; Choi YH, 2006, P NATL ACAD SCI USA, V103, P18715, DOI 10.1073/pnas.0604800103; Finn G, 2008, CURR CANCER DRUG TAR, V8, P223, DOI 10.2174/156800908784293622; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Harant H, 1996, J BIOL CHEM, V271, P26954, DOI 10.1074/jbc.271.43.26954; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hoffmann A, 2003, EMBO J, V22, P5530, DOI 10.1093/emboj/cdg534; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Jang HD, 2004, J BIOL CHEM, V279, P24873, DOI 10.1074/jbc.M313018200; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Li ST, 2006, MOL CELL, V24, P497, DOI 10.1016/j.molcel.2006.10.015; Lu KP, 2003, CANCER CELL, V4, P175, DOI 10.1016/S1535-6108(03)00218-6; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Lufei C, 2007, ONCOGENE, V26, P7656, DOI 10.1038/sj.onc.1210567; Nagai S, 2002, J NEUROSURG, V96, P909, DOI 10.3171/jns.2002.96.5.0909; Nozell S, 2004, J BIOL CHEM, V279, P38577, DOI 10.1074/jbc.M403738200; Nozell S, 2008, MOL CELL BIOL, V28, P6632, DOI 10.1128/MCB.00697-08; Nozell S, 2006, J IMMUNOL, V177, P822, DOI 10.4049/jimmunol.177.2.822; Pang RW, 2006, J PATHOL, V210, P19, DOI 10.1002/path.2024; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Raychaudhuri B, 2007, J NEURO-ONCOL, V85, P39, DOI 10.1007/s11060-007-9390-7; Ryo A, 2005, CLIN CANCER RES, V11, P7523, DOI 10.1158/1078-0432.CCR-05-0457; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Ryo A, 2002, MOL CELL BIOL, V22, P5281, DOI 10.1128/MCB.22.15.5281-5295.2002; Ryo A, 2007, J BIOL CHEM, V282, P36671, DOI 10.1074/jbc.M704145200; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Smith D, 2008, MOL CELL BIOCHEM, V307, P141, DOI 10.1007/s11010-007-9593-4; Strieter RM, 2006, EUR J CANCER, V42, P768, DOI 10.1016/j.ejca.2006.01.006; Stupp R, 2002, J CLIN ONCOL, V20, P1375, DOI 10.1200/JCO.20.5.1375; Vila-Carriles WH, 2006, J BIOL CHEM, V281, P19220, DOI 10.1074/jbc.M603100200; Wakabayashi K, 2004, ONCOGENE, V23, P6924, DOI 10.1038/sj.onc.1207778; Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Xu YX, 2007, GENE DEV, V21, P2950, DOI 10.1101/gad.1592807; Yamamoto M, 2000, ANTICANCER RES, V20, P611; Yeh ES, 2007, NAT REV CANCER, V7, P381, DOI 10.1038/nrc2107; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	54	65	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2009	28	42					3735	3745		10.1038/onc.2009.232	http://dx.doi.org/10.1038/onc.2009.232			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	509MY	19668231	Green Accepted			2022-12-17	WOS:000271023200006
J	Malecka, KA; Ho, WC; Marmorstein, R				Malecka, K. A.; Ho, W. C.; Marmorstein, R.			Crystal structure of a p53 core tetramer bound to DNA	ONCOGENE			English	Article						p53; tumor suppressor; protein/DNA complex; crystal structure	BINDING DOMAIN PEPTIDES; TUMOR-SUPPRESSOR; SEQUENCE; RECOGNITION; COMPLEX; MULTIPLE; ELEMENTS; LOOP	The tumor suppressor p53 regulates downstream genes in response to many cellular stresses and is frequently mutated in human cancers. Here, we report the use of a crosslinking strategy to trap a tetrameric p53 DNA-binding domain (p53DBD) bound to DNA and the X-ray crystal structure of the protein/DNA complex. The structure reveals that two p53DBD dimers bind to B form DNA with no relative twist and that a p53 tetramer can bind to DNA without introducing significant DNA bending. The numerous dimer-dimer interactions involve several strictly conserved residues, thus suggesting a molecular basis for p53DBD-DNA binding cooperativity. Surface residue conservation of the p53DBD tetramer bound to DNA highlights possible regions of other p53 domain or p53 cofactor interactions.	[Malecka, K. A.; Ho, W. C.; Marmorstein, R.] Wistar Inst Anat & Biol, Program Gene Express & Regulat, Philadelphia, PA 19104 USA; [Malecka, K. A.; Ho, W. C.; Marmorstein, R.] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania	Marmorstein, R (corresponding author), Wistar Inst Anat & Biol, Program Gene Express & Regulat, 3601 Spruce St, Philadelphia, PA 19104 USA.	marmor@wistar.org			NIGMS NIH HHS [R01 GM052880, R01 GM052880-11, T32 GM008275] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052880, T32GM008275] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALAGURUMOORTHY P, 1995, P NATL ACAD SCI USA, V92, P8591, DOI 10.1073/pnas.92.19.8591; Banerjee A, 2006, SCIENCE, V311, P1153, DOI 10.1126/science.1120288; Banerjee A, 2005, NATURE, V434, P612, DOI 10.1038/nature03458; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DeLano WL, 2002, PYMOL USERS MANUAL; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gasteiger E, 2003, NUCLEIC ACIDS RES, V31, P3784, DOI 10.1093/nar/gkg563; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; He CA, 2002, CHEM BIOL, V9, P1297, DOI 10.1016/S1074-5521(02)00283-1; Ho WC, 2006, J BIOL CHEM, V281, P20494, DOI 10.1074/jbc.M603634200; Horn HF, 2007, ONCOGENE, V26, P1306, DOI 10.1038/sj.onc.1210263; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Klein C, 2001, J BIOL CHEM, V276, P37390, DOI 10.1074/jbc.M103801200; Lu XJ, 2003, NUCLEIC ACIDS RES, V31, P5108, DOI 10.1093/nar/gkg680; MACMILLAN AM, 1991, TETRAHEDRON, V47, P2603, DOI 10.1016/S0040-4020(01)81793-2; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MCNAMARA PT, 1990, J BIOMOL STRUCT DYN, V8, P529, DOI 10.1080/07391102.1990.10507827; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; NAGAICH AK, 1994, J BIOL CHEM, V269, P7824; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan YP, 2007, J BIOL CHEM, V282, P691, DOI 10.1074/jbc.M605908200; Pan YP, 2008, J PHYS CHEM B, V112, P6716, DOI 10.1021/jp800680w; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Verdine GL, 2003, ANNU REV BIOCHEM, V72, P337, DOI 10.1146/annurev.biochem.72.121801.161447; Wang Y, 2007, ACTA CRYSTALLOGR D, V63, P276, DOI 10.1107/S0907444906048499; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; Zhao KH, 2001, J BIOL CHEM, V276, P12120, DOI 10.1074/jbc.M011644200; ZHURKIN VB, 1991, P NATL ACAD SCI USA, V88, P7046, DOI 10.1073/pnas.88.16.7046; Zupnick A, 2006, J BIOL CHEM, V281, P20464, DOI 10.1074/jbc.M603387200	34	65	67	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					325	333		10.1038/onc.2008.400	http://dx.doi.org/10.1038/onc.2008.400			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18978813	Green Accepted			2022-12-17	WOS:000262550300002
J	Januschke, J; Gonzalez, C				Januschke, J.; Gonzalez, C.			Drosophila asymmetric division, polarity and cancer	ONCOGENE			English	Review						stem cells; asymmetric division; centrosomes; cell-of-origin; neuroblasts; cancer	NEURAL STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; NEUROBLAST SELF-RENEWAL; REGULATES SPINDLE ORIENTATION; TUMOR-SUPPRESSOR GENES; BRAIN-TUMOR; POSTEMBRYONIC NEUROBLASTS; TRANSCRIPTION FACTORS; PROTEIN LOCALIZATION; EPITHELIAL POLARITY	A limited number of adult stem cells (SCs) maintain the homoestasis of different tissues through the lifetime of the individual by generating differentiating daughters and renewing themselves. Errors in the SC division rate or in the. ne balance between self-renewal and differentiation might result in tissue overgrowth or depletion, two potentially lethal conditions. A few types of SCs have been identified in Drosophila. These include the SCs of the adult intestine and malpighian tubes, (Micchelli and Perrimon, 2006; Ohlstein and Spradling, 2006; Singh et al., 2007), the prohematocytes that maintain the population of cells involved in the immunoresponse (Lanot et al., 2001; Lemaitre and Hoffmann, 2007), the SC of the follicle epithelia in the ovary (Nystul and Spradling, 2007), germ line SCs (GSCs) of both sexes (Fuller and Spradling, 2007) and neuroblasts (NBs), the fly neural SCs (Yu et al., 2006; Chia et al., 2008; Knoblich, 2008). Drosophila SCs have proved a fruitful model system to unveil some aspects of the molecular logic that sustains SC function. This review focuses on results obtained in the last few years from the study of NBs, particularly from the standpoint of the possible functional connection between asymmetric SC division and cancer.	[Januschke, J.; Gonzalez, C.] IRB Barcelona, Cell Div Grp, PCB, Barcelona 08028, Spain; [Gonzalez, C.] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain	Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona; ICREA	Gonzalez, C (corresponding author), IRB Barcelona, Cell Div Grp, PCB, C Baldiri Reixac 10-12, Barcelona 08028, Spain.	gonzalez@irbbarcelona.org	Gonzalez, Cayetano/K-3055-2019; Gonzalez, Cayetano/K-3933-2019	Gonzalez, Cayetano/0000-0002-5259-3608; Januschke, Jens/0000-0001-8985-2717	EU and Spanish [ONCASYM-037398 FP6, BFU2006-05813]; ICREA Funding Source: Custom	EU and Spanish; ICREA(ICREA)	This study was supported by EU and Spanish Grants: ONCASYM-037398 FP6, BFU2006-05813, SGR2005 Generalitatde Catalunya and Consolider-Ingenio2010 CENTRO-SOME_3DCSD2006-23.	Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; Almeida MS, 2005, MECH DEVELOP, V122, P1282, DOI 10.1016/j.mod.2005.08.004; Atwood SX, 2007, J CELL SCI, V120, P3200, DOI 10.1242/jcs.014902; Basto R, 2008, CELL, V133, P1032, DOI 10.1016/j.cell.2008.05.039; Basto R, 2006, CELL, V125, P1375, DOI 10.1016/j.cell.2006.05.025; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Bello B, 2006, DEVELOPMENT, V133, P2639, DOI 10.1242/dev.02429; Bello BC, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-5; Betschinger J, 2006, CELL, V124, P1241, DOI 10.1016/j.cell.2006.01.038; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Boone JQ, 2008, DEV NEUROBIOL, V68, P1185, DOI 10.1002/dneu.20648; Bowman SK, 2008, DEV CELL, V14, P535, DOI 10.1016/j.devcel.2008.03.004; Bowman SK, 2006, DEV CELL, V10, P731, DOI 10.1016/j.devcel.2006.05.005; Brawley C, 2004, SCIENCE, V304, P1331, DOI 10.1126/science.1097676; Broadus J, 1997, CURR BIOL, V7, P827, DOI 10.1016/S0960-9822(06)00370-8; Broadus J, 1998, NATURE, V391, P792, DOI 10.1038/35861; Castellanos E, 2008, CURR BIOL, V18, P1209, DOI 10.1016/j.cub.2008.07.029; Caussinus E, 2005, NAT GENET, V37, P1125, DOI 10.1038/ng1632; Caussinus Emmanuel, 2007, Prog Mol Subcell Biol, V45, P205; Ceron J, 2006, EUR J CELL BIOL, V85, P567, DOI 10.1016/j.ejcb.2006.02.006; Chabu C, 2008, DEVELOPMENT, V135, P2739, DOI 10.1242/dev.024059; Chia W, 2008, J CELL BIOL, V180, P267, DOI 10.1083/jcb.200708159; Choksi SP, 2006, DEV CELL, V11, P775, DOI 10.1016/j.devcel.2006.09.015; Doe CQ, 2008, DEVELOPMENT, V135, P1575, DOI 10.1242/dev.014977; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; Duensing S, 2005, CELL BIOL INT, V29, P352, DOI 10.1016/j.cellbi.2005.03.005; Dumstrei K, 2003, J NEUROSCI, V23, P3325; EBENS AJ, 1993, CELL, V74, P15, DOI 10.1016/0092-8674(93)90291-W; Feiguin F, 1998, CURR TOP DEV BIOL, V36, P279; Frank DJ, 2002, DEVELOPMENT, V129, P399; Fuller MT, 2007, SCIENCE, V316, P402, DOI 10.1126/science.1140861; GATEFF E, 1978, SCIENCE, V200, P1448, DOI 10.1126/science.96525; GATEFF E, 1967, AM ZOOL, V7, P760; Gonczy P, 2008, NAT REV MOL CELL BIO, V9, P355, DOI 10.1038/nrm2388; Golubovsky MD, 2006, EXP GERONTOL, V41, P819, DOI 10.1016/j.exger.2006.06.035; Gonzalez C, 2007, NAT REV GENET, V8, P462, DOI 10.1038/nrg2103; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris H, 2005, BIOESSAYS, V27, P833, DOI 10.1002/bies.20263; Harris H, 2008, J CELL SCI, V121, P3, DOI [10.1242/jcs.017483, 10.1242/jcs.025742]; HARSHBAR.JC, 1968, ANNU REV ENTOMOL, V13, P159, DOI 10.1146/annurev.en.13.010168.001111; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Huntly BJP, 2005, NAT REV CANCER, V5, P311, DOI 10.1038/nrc1592; IkeshimaKataoka H, 1997, NATURE, V390, P625, DOI 10.1038/37641; Isshiki T, 2001, CELL, V106, P511, DOI 10.1016/S0092-8674(01)00465-2; ITO K, 1992, DEV BIOL, V149, P134, DOI 10.1016/0012-1606(92)90270-Q; Izumi Y, 2004, J CELL BIOL, V164, P729, DOI 10.1083/jcb.200309162; Izumi Y, 2006, NAT CELL BIOL, V8, P586, DOI 10.1038/ncb1409; Kai T, 2004, NATURE, V428, P564, DOI 10.1038/nature02436; Kaltschmidt JA, 2000, NAT CELL BIOL, V2, P7, DOI 10.1038/71323; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Lanot R, 2001, DEV BIOL, V230, P243, DOI 10.1006/dbio.2000.0123; Le Borgne R, 2005, DEVELOPMENT, V132, P1751, DOI 10.1242/dev.01789; Lee CY, 2006, GENE DEV, V20, P3464, DOI 10.1101/gad.1489406; Lee CY, 2006, DEV CELL, V10, P441, DOI 10.1016/j.devcel.2006.01.017; Lee CY, 2006, NATURE, V439, P594, DOI 10.1038/nature04299; Lemaitre B, 2007, ANNU REV IMMUNOL, V25, P697, DOI 10.1146/annurev.immunol.25.022106.141615; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li L, 2000, GENE DEV, V14, P147; Li P, 1997, CELL, V90, P437, DOI 10.1016/S0092-8674(00)80504-8; Loop T, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-24; Lu BW, 1998, CELL, V95, P225, DOI 10.1016/S0092-8674(00)81753-5; Lucas EP, 2007, J CELL BIOL, V178, P725, DOI 10.1083/jcb.200704081; Maurange C, 2008, CELL, V133, P891, DOI 10.1016/j.cell.2008.03.034; MECHLER BM, 1991, ENVIRON HEALTH PERSP, V93, P63, DOI 10.2307/3431171; Micchelli CA, 2006, NATURE, V439, P475, DOI 10.1038/nature04371; Nigg EA, 2006, INT J CANCER, V119, P2717, DOI 10.1002/ijc.22245; Nystul T, 2007, CELL STEM CELL, V1, P277, DOI 10.1016/j.stem.2007.07.009; Ohlstein B, 2006, NATURE, V439, P470, DOI 10.1038/nature04333; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Park Y, 2003, DEV BIOL, V253, P247, DOI 10.1016/S0012-1606(02)00019-2; Parmentier ML, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-14-j0003.2000; Pearson BJ, 2003, NATURE, V425, P624, DOI 10.1038/nature01910; Peng CY, 2000, NATURE, V408, P596, DOI 10.1038/35046094; Petronczki M, 2001, NAT CELL BIOL, V3, P43, DOI 10.1038/35050550; Potter CJ, 2000, TRENDS GENET, V16, P33, DOI 10.1016/S0168-9525(99)01878-8; Rebollo E, 2007, DEV CELL, V12, P467, DOI 10.1016/j.devcel.2007.01.021; REMENSBERGER P, 1968, CHROMOSOMA, V23, P386, DOI 10.1007/BF00625286; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rolls MM, 2003, J CELL BIOL, V163, P1089, DOI 10.1083/jcb.200306079; Rolls MM, 2004, NAT NEUROSCI, V7, P1293, DOI 10.1038/nn1346; Rusan NM, 2007, J CELL BIOL, V177, P13, DOI 10.1083/jcb.200612140; Scadden DT, 2006, NATURE, V441, P1075, DOI 10.1038/nature04957; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Schober M, 1999, NATURE, V402, P548, DOI 10.1038/990135; Schweisguth F, 2004, CURR BIOL, V14, pR129, DOI 10.1016/j.cub.2004.01.023; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; Siegrist SE, 2005, CELL, V123, P1323, DOI 10.1016/j.cell.2005.09.043; Siller KH, 2006, NAT CELL BIOL, V8, P594, DOI 10.1038/ncb1412; Singh SR, 2007, CELL STEM CELL, V1, P191, DOI 10.1016/j.stem.2007.07.003; Smith CA, 2007, EMBO J, V26, P468, DOI 10.1038/sj.emboj.7601495; Sonoda J, 2001, GENE DEV, V15, P762, DOI 10.1101/gad.870801; Speicher S, 2008, CURR BIOL, V18, P831, DOI 10.1016/j.cub.2008.04.072; Tio M, 2001, NATURE, V409, P1063, DOI 10.1038/35059124; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; Wang H, 2006, GENE DEV, V20, P3453, DOI 10.1101/gad.1487506; Wang HY, 2007, NATURE, V449, P96, DOI 10.1038/nature06056; WATSON KL, 1994, J CELL SCI, P19; Wodarz A, 1999, NATURE, V402, P544, DOI 10.1038/990128; Wodarz A, 2005, CURR OPIN CELL BIOL, V17, P475, DOI 10.1016/j.ceb.2005.08.005; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; WU CF, 1983, J NEUROSCI, V3, P1888; Yu FW, 2006, NEURON, V51, P13, DOI 10.1016/j.neuron.2006.06.016; Yu FW, 2003, J CELL BIOL, V162, P623, DOI 10.1083/jcb.200303174; Zhu CC, 2008, DEVELOPMENT, V135, P513, DOI 10.1242/dev.010876	107	65	66	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					6994	7002		10.1038/onc.2008.349	http://dx.doi.org/10.1038/onc.2008.349			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029940				2022-12-17	WOS:000261108200011
J	Bessard, A; Fremin, C; Ezan, F; Fautrel, A; Gailhouste, L; Baffet, G				Bessard, A.; Fremin, C.; Ezan, F.; Fautrel, A.; Gailhouste, L.; Baffet, G.			RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo	ONCOGENE			English	Article						MEK/ERK pathway; MEK inhibitor; U0126; RNAi; tumor growth; in vivo	HUMAN HEPATOCELLULAR-CARCINOMA; SMALL INTERFERING RNAS; MAP KINASE PATHWAY; S-PHASE ENTRY; PROTEIN-KINASES; MEK INHIBITOR; HUMAN LIVER; SUPPRESSES GROWTH; MAMMALIAN-CELLS; EXPRESSION	The MAPK MEK/ERK pathway is often upregulated in cancer cells and represents an attractive target for development of anticancer drugs. Only few data concerning the specific functions of ERK1 and 2 are reported in the literature. In this report, we investigated the specific role of ERK1 and 2 in liver tumor growth both in vitro and in vivo. DNA synthesis and cells in S phase analysed by flow cytometry, correlated with strong inhibition of Cdk1 and cyclin E levels, are strongly reduced after exposure to MEK inhibitor, U0126. We obtained a significant reduction of colony formation in soft agar assays and a reduction in the size of tumor xenografts in nude mice treated with U0126. Then, we could specifically abolished ERK1 or 2 expression by small-interfering RNA (siRNA) and demonstrated that ERK2 knockdown but not ERK1 interferes with the process of replication. Moreover, we found that colony formation and tumor growth in vivo were significantly inhibited by targeting ERK2 using stable chemically modified siRNA. Taken together, our results emphasize the importance of the MEK/ERK pathway in liver cancer cell growth in vitro and in vivo and argue for a crucial role of ERK2 in this regulation.	[Bessard, A.; Fremin, C.; Ezan, F.; Gailhouste, L.; Baffet, G.] Univ Rennes 1, Hop Pontchaillou, IFR 140, INSERM U522, F-35033 Rennes, France; [Fautrel, A.] Univ Rennes 1, CHU Rennes, IFR140, F-35033 Rennes, France	CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes 1; CHU Rennes; Universite de Rennes 1	Baffet, G (corresponding author), Univ Rennes 1, Rue H Guillou, F-35033 Rennes, France.	georges.baffet@rennes.inserm.fr	Bessard, Anne/K-2396-2015; Fautrel, Alain/AAL-7391-2020; Baffet, Georges/I-2574-2015; Baffet, Georges/M-1583-2016	FAUTREL, Alain/0000-0002-3449-0779	Institut National de la Sante et de la Recherche Medicale; Association pour la Recherche sur le Cancer (ARC)	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer)	We thank Dr P Loyer for flow cytometry advices, Sigma-Aldrich and Dr Heike Lehrmann for giving us the LNA ERK2 oligonucleotides, and C Ribault for technical assistance. This research was supported by the Institut National de la Sante et de la Recherche Medicale and the Association pour la Recherche sur le Cancer (ARC). A Bessard and C Fremin are a recipient of fellowship from the Region Bretagne/INSERM and the Ministere de l'Education Nationale et de la Technologie, respectively, and the ARC.	Aharinejad S, 2004, CANCER RES, V64, P5378, DOI 10.1158/0008-5472.CAN-04-0961; ALBRECHT JH, 1995, BIOCHEM BIOPH RES CO, V209, P648, DOI 10.1006/bbrc.1995.1548; ALBRECHT JH, 1993, AM J PHYSIOL, V265, pG857, DOI 10.1152/ajpgi.1993.265.5.G857; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Andrieux LO, 2007, CANCER RES, V67, P2114, DOI 10.1158/0008-5472.CAN-06-3821; Arslan MA, 2006, CURR CANCER DRUG TAR, V6, P623, DOI 10.2174/156800906778742479; Behlke MA, 2006, MOL THER, V13, P644, DOI 10.1016/j.ymthe.2006.01.001; Bessard A, 2007, J CELL PHYSIOL, V212, P526, DOI 10.1002/jcp.21049; Braasch DA, 2003, BIOCHEMISTRY-US, V42, P7967, DOI 10.1021/bi0343774; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Dahlgren C, 2006, BIOCHEM BIOPH RES CO, V341, P1211, DOI 10.1016/j.bbrc.2006.01.085; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7689; Duesbery NS, 2001, P NATL ACAD SCI USA, V98, P4089, DOI 10.1073/pnas.061031898; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Elmen J, 2005, NUCLEIC ACIDS RES, V33, P439, DOI 10.1093/nar/gki193; Fischer AM, 2005, IMMUNITY, V23, P431, DOI 10.1016/j.immuni.2005.08.013; Fremin C, 2007, HEPATOLOGY, V45, P1035, DOI 10.1002/hep.21551; Gysin S, 2005, CANCER RES, V65, P4870, DOI 10.1158/0008-5472.CAN-04-2848; Haass NK, 2008, CLIN CANCER RES, V14, P230, DOI 10.1158/1078-0432.CCR-07-1440; Hilger RA, 2002, ONKOLOGIE, V25, P511, DOI 10.1159/000068621; Huynh H, 2003, BMC GASTROENTEROL, V3, DOI 10.1186/1471-230X-3-19; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Klein PJ, 2006, NEOPLASIA, V8, P1, DOI 10.1593/neo.05373; Lefloch R, 2008, MOL CELL BIOL, V28, P511, DOI 10.1128/MCB.00800-07; Leung RKM, 2005, PHARMACOL THERAPEUT, V107, P222, DOI 10.1016/j.pharmthera.2005.03.004; Liu L, 2006, CANCER RES, V66, P11851, DOI 10.1158/0008-5472.CAN-06-1377; Liu X, 2004, ONCOGENE, V23, P763, DOI 10.1038/sj.onc.1207188; LoRusso PM, 2005, J CLIN ONCOL, V23, P5281, DOI 10.1200/JCO.2005.14.415; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; Mook OR, 2007, MOL CANCER THER, V6, P833, DOI 10.1158/1535-7163.MCT-06-0195; MORELCHANY E, 1978, EUR J CANCER, V14, P1341, DOI 10.1016/0014-2964(78)90116-0; Normanno N, 2006, J CELL PHYSIOL, V207, P420, DOI 10.1002/jcp.20588; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Rescan C, 2001, MOL BIOL CELL, V12, P725, DOI 10.1091/mbc.12.3.725; REUBER MD, 1961, J NATL CANCER I, V26, P891; Saba-El-Leil MK, 2003, EMBO REP, V4, P964, DOI 10.1038/sj.embor.embor939; Sanjo H, 2007, MOL CELL BIOL, V27, P1236, DOI 10.1128/MCB.01530-06; Schmidt CM, 1997, BIOCHEM BIOPH RES CO, V236, P54, DOI 10.1006/bbrc.1997.6840; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Sebolt-Leopold JS, 2006, NATURE, V441, P457, DOI 10.1038/nature04874; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Takei Y, 2004, CANCER RES, V64, P3365, DOI 10.1158/0008-5472.CAN-03-2682; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Vantaggiato Chiara, 2006, J Biol, V5, P14, DOI 10.1186/jbiol38; Wabnitz PA, 2004, PHARM RES, V21, P1670, DOI 10.1023/B:PHAM.0000041464.27579.d0; Wang D, 2007, BBA-MOL CELL RES, V1773, P1248, DOI 10.1016/j.bbamcr.2006.11.009; Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150	50	65	71	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2008	27	40					5315	5325		10.1038/onc.2008.163	http://dx.doi.org/10.1038/onc.2008.163			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	346UW	18521085				2022-12-17	WOS:000259096100004
J	Wischermann, K; Popp, S; Moshir, S; Scharfetter-Kochanek, K; Wlaschek, M; de Gruijl, F; Hartschuh, W; Greinert, R; Volkmer, B; Faust, A; Rapp, A; Schmezer, P; Boukamp, P				Wischermann, K.; Popp, S.; Moshir, S.; Scharfetter-Kochanek, K.; Wlaschek, M.; de Gruijl, F.; Hartschuh, W.; Greinert, R.; Volkmer, B.; Faust, A.; Rapp, A.; Schmezer, P.; Boukamp, P.			UVA radiation causes DNA strand breaks, chromosomal aberrations and tumorigenic transformation in HaCaT skin keratinocytes	ONCOGENE			English	Article						DNA double strand breaks; tumor formation; chromosomal aberrations; telomere length; radiation regimes	OXIDATIVE STRESS; IN-VITRO; H2AX PHOSPHORYLATION; COMET ASSAY; HUMAN-CELLS; DAMAGE; PROGRESSION; REPAIR; TUMOR; OVEREXPRESSION	The role of UVA-radiation-the major fraction in sunlight-in human skin carcinogenesis is still elusive. We here report that different UVA exposure regime (4 x 5 J/cm(2) per week or 1 x 20 J/cm(2) per week) caused tumorigenic conversion (tumors in nude mice) of the HaCaT skin keratinocytes. While tumorigenicity was not associated with general telomere shortening, we found new chromosomal changes characteristic for each recultivated tumor. Since this suggested a nontelomere-dependent relationship between UVA irradiation and chromosomal aberrations, we investigated for alternate mechanisms of UVA-dependent genomic instability. Using the alkaline and neutral comet assay as well as gamma-H2AX foci formation on irradiated HaCaT cells (20-60 J/cm(2)), we show a dosedependent and long lasting induction of DNA single and double (ds) strand breaks. Extending this to normal human skin keratinocytes, we demonstrate a comparable damage response and, additionally, a significant induction and maintenance of micronuclei (MN) with more acentric fragments (indicative of ds breaks) than entire chromosomes particularly 5 days post irradiation. Thus, physiologically relevant UVA doses cause long-lasting DNA strand breaks, a prerequisite for chromosomal aberration that most likely contribute to tumorigenic conversion of the HaCaT cells. Since normal keratinocytes responded similarly, UVA may likewise contribute to the complex karyotype characteristic for human skin carcinomas.	[Wischermann, K.; Popp, S.; Moshir, S.; Boukamp, P.] German Canc Res Ctr, Div Genet Skin Carcinogenesis, D-69120 Heidelberg, Germany; [Scharfetter-Kochanek, K.; Wlaschek, M.] Univ Ulm, Dept Dermatol & Allerg Dis, Ulm, Germany; [de Gruijl, F.] Leiden Univ, Med Ctr, Dept Dermatol, Leiden, Netherlands; [Hartschuh, W.] Heidelberg Univ, Dept Dermatol, D-6900 Heidelberg, Germany; [Greinert, R.; Volkmer, B.; Faust, A.] Dermatol Ctr, Mol Cell Biol Div, Buxtehude, Germany; [Rapp, A.] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; [Schmezer, P.] German Canc Res Ctr, Div Toxicol & Canc Risk Factors, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ulm University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Ruprecht Karls University Heidelberg; University of Oxford; Helmholtz Association; German Cancer Research Center (DKFZ)	Boukamp, P (corresponding author), German Canc Res Ctr, Div Genet Skin Carcinogenesis, Neuenheimer Feld 280,Postfach 101949, D-69120 Heidelberg, Germany.	P.Boukamp@DKFZ-Heidelberg.de	Rapp, Alexander/F-5327-2012	Rapp, Alexander/0000-0001-9108-3929				ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Bleuel K, 1999, P NATL ACAD SCI USA, V96, P2065, DOI 10.1073/pnas.96.5.2065; Boukamp P, 1997, GENE CHROMOSOME CANC, V19, P201, DOI 10.1002/(SICI)1098-2264(199708)19:4<201::AID-GCC1>3.0.CO;2-0; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOUKAMP P, 1995, ONCOGENE, V11, P961; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOUKAMP P, 1990, DIFFERENTIATION, V44, P150, DOI 10.1111/j.1432-0436.1990.tb00548.x; Boukamp P, 1999, ONCOGENE, V18, P5638, DOI 10.1038/sj.onc.1202934; Boukamp Petra, 2005, J Dtsch Dermatol Ges, V3, P493, DOI 10.1111/j.1610-0387.2005.05037.x; Burnworth B, 2006, ONCOGENE, V25, P4399, DOI 10.1038/sj.onc.1209474; Cadet J, 2005, MUTAT RES-FUND MOL M, V571, P3, DOI 10.1016/j.mrfmmm.2004.09.012; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; de Gruijl FR, 2002, SKIN PHARMACOL APPL, V15, P316, DOI 10.1159/000064535; Emri G, 2000, J INVEST DERMATOL, V115, P435, DOI 10.1046/j.1523-1747.2000.00057.x; *FED OFF RAD PROT, 2006, CONT SOL UV MON GERM; Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8; Fenech M, 2002, TOXICOLOGY, V181, P411, DOI 10.1016/S0300-483X(02)00480-8; Figueroa R, 2000, CANCER RES, V60, P2770; Folkman J, 1991, Princess Takamatsu Symp, V22, P339; Garinis GA, 2005, EMBO J, V24, P3952, DOI 10.1038/sj.emboj.7600849; He YY, 2006, ONCOGENE, V25, P3680, DOI 10.1038/sj.onc.1209384; Ikehata H, 2004, MUTAT RES-FUND MOL M, V556, P11, DOI 10.1016/j.mrfmmm.2004.06.038; Ikehata H, 2003, MUTAGENESIS, V18, P511, DOI 10.1093/mutage/geg030; Ikehata H, 2007, PHOTOCHEM PHOTOBIOL, V83, P196, DOI 10.1562/2006-02-28-IR-822; Kielbassa C, 1997, CARCINOGENESIS, V18, P811, DOI 10.1093/carcin/18.4.811; Krude T, 1999, EXP CELL RES, V247, P148, DOI 10.1006/excr.1998.4342; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Marti TM, 2006, P NATL ACAD SCI USA, V103, P9891, DOI 10.1073/pnas.0603779103; Murnane JP, 2004, BIOESSAYS, V26, P1164, DOI 10.1002/bies.20125; MUTZHAS MF, 1981, J INVEST DERMATOL, V76, P42, DOI 10.1111/1523-1747.ep12524813; Obermueller E, 2004, CANCER RES, V64, P7801, DOI 10.1158/0008-5472.CAN-03-3301; Oikawa S, 1999, FEBS LETT, V453, P365, DOI 10.1016/S0014-5793(99)00748-6; Olive PL, 1999, INT J RADIAT BIOL, V75, P395, DOI 10.1080/095530099140311; OLIVE PL, 1993, RADIAT RES, V136, P130, DOI 10.2307/3578650; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; Phillipson RP, 2002, FREE RADICAL BIO MED, V32, P474, DOI 10.1016/S0891-5849(01)00829-2; Popp S, 2002, INT J CANCER, V99, P352, DOI 10.1002/ijc.10321; Popp S, 2000, J INVEST DERMATOL, V115, P1095, DOI 10.1046/j.1523-1747.2000.00173.x; Rapp A, 2000, J PHOTOCH PHOTOBIO B, V56, P109, DOI 10.1016/S1011-1344(00)00052-X; Rapp A, 2004, J CELL SCI, V117, P4935, DOI 10.1242/jcs.01355; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Sedelnikova OA, 2002, RADIAT RES, V158, P486, DOI 10.1667/0033-7587(2002)158[0486:QDOIID]2.0.CO;2; Skobe M, 1998, P NATL ACAD SCI USA, V95, P1050, DOI 10.1073/pnas.95.3.1050; Tefferi A, 2005, MAYO CLIN PROC, V80, P390, DOI 10.4065/80.3.390; Thompson LH, 2004, MOL B INT U, P107; Von Zglinicki T, 2000, FREE RADICAL BIO MED, V28, P64, DOI 10.1016/S0891-5849(99)00207-5; Wischermann K, 2007, MUTAT RES-GEN TOX EN, V630, P122, DOI 10.1016/j.mrgentox.2007.02.009; Wondrak GT, 2006, PHOTOCH PHOTOBIO SCI, V5, P215, DOI 10.1039/b504573h	52	65	69	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4269	4280		10.1038/onc.2008.70	http://dx.doi.org/10.1038/onc.2008.70			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18372922				2022-12-17	WOS:000257691100002
J	Asim, M; Siddiqui, IA; Hafeez, BB; Baniahmad, A; Mukhtar, H				Asim, M.; Siddiqui, I. A.; Hafeez, B. B.; Baniahmad, A.; Mukhtar, H.			Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells	ONCOGENE			English	Article						androgen receptor; casodex; invasion; prostate cancer; PP2; Src kinase	GROWTH-FACTOR-I; MOUSE MODEL; INHIBITION; ACTIVATION; RNA; PHOSPHORYLATION; COACTIVATOR-1; PROGRESSION; METASTASIS; EXPRESSION	Prostate cancer is one of the most prominent malignancies of elderly men in many Western countries including Europe and the United States with increasing trend worldwide. The growth of normal prostate as well as of prostate carcinoma cells depends on functional androgen receptor (AR) signaling. AR manifests the biological actions of androgens and its transcriptional activity is known to be influenced by signal transduction pathways. Here we show that Src, a nonreceptor tyrosine kinase, is overexpressed in androgen-independent prostate carcinoma C4-2 cells. Interestingly, the expression of Src was found to progressively increase (up to threefold) in transgenic adenocarcinoma of mouse prostate mice as a function of age and cancer progression. Blocking Src kinase function by a specific inhibitor, PP2, resulted in decreased AR transactivation function on two different reporters, mouse mammary tumor virus (MMTV) and prostate-specific antigen (PSA). Consistent with this, overexpression of a functional Src mutant also led to a dramatic decrease in AR transactivation potential in a hormone-dependent manner. Interference with Src function in C4-2 cells led to decreased recruitment of AR on the target gene PSA enhancer and also resulted in the abrogation of hormone-dependent PSA transcript induction. Src inhibition also led to a dramatic decrease in the cell invasion in addition to decreasing the cellular growth. We suggest that targeting Src kinase could be an effective strategy to inhibit prostate cancer growth and metastasis.	[Mukhtar, H.] Univ Wisconsin, Dept Dermatol, Med Sci Ctr, Madison, WI 53706 USA; [Asim, M.; Baniahmad, A.] Univ Jena, Fac Med, Inst Human Genet & Anthropol, Jena, Germany; [Baniahmad, A.] Univ Kuopio, Dept Biosci, FIN-70211 Kuopio, Finland	University of Wisconsin System; University of Wisconsin Madison; Friedrich Schiller University of Jena; University of Eastern Finland	Mukhtar, H (corresponding author), Univ Wisconsin, Dept Dermatol, Med Sci Ctr, 1300 Univ Ave,Med Sci Ctr 25B, Madison, WI 53706 USA.	aban@mti.uni-jena.de; hmukhtar@wisc.edu	Siddiqui, Imtiaz/B-6587-2009		NCI NIH HHS [R01 CA101039, R01CA101039, R01 CA120451, R01CA78809, R01 CA078809, R01CA120451] Funding Source: Medline; NIDDK NIH HHS [P50 DK065303, P50DK065303-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA120451, R01CA078809, R01CA101039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK065303] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Adhami VM, 2004, CANCER RES, V64, P8715, DOI 10.1158/0008-5472.CAN-04-2840; Baniahmad A, 2005, J STEROID BIOCHEM, V93, P89, DOI 10.1016/j.jsbmb.2004.12.012; BRINKMANN AO, 1992, J STEROID BIOCHEM, V41, P361, DOI 10.1016/0960-0760(92)90362-M; Castoria G, 2003, J CELL BIOL, V161, P547, DOI 10.1083/jcb.200211099; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Chen S, 1998, MOL ENDOCRINOL, V12, P1558, DOI 10.1210/me.12.10.1558; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; Dehm SM, 2007, MOL ENDOCRINOL, V21, P2855, DOI 10.1210/me.2007-0223; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Haag P, 2005, J STEROID BIOCHEM, V96, P251, DOI 10.1016/j.jsbmb.2005.04.029; Isaacs JT, 2000, JNCI-J NATL CANCER I, V92, P1367, DOI 10.1093/jnci/92.17.1367; Jenster G, 2000, J PATHOL, V191, P227; Jia L, 2005, CANCER RES, V65, P8003, DOI 10.1158/0008-5472.CAN-04-3679; Liao XB, 2005, MOL CANCER THER, V4, P505, DOI 10.1158/1535-7163.MCT-04-0313; Moehren U, 2007, MOL ENDOCRINOL, V21, P1039, DOI 10.1210/me.2006-0468; Notini AJ, 2005, J MOL ENDOCRINOL, V35, P547, DOI 10.1677/jme.1.01884; Perry JE, 1996, PROSTATE, P79; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Shah YM, 2005, MOL ENDOCRINOL, V19, P732, DOI 10.1210/me.2004-0298; Siddiqui IA, 2006, CARCINOGENESIS, V27, P833, DOI 10.1093/carcin/bgi323; THALMANN GN, 1994, CANCER RES, V54, P2577; Thalmann GN, 2000, PROSTATE, V44, P91; Ueda T, 2002, J BIOL CHEM, V277, P38087, DOI 10.1074/jbc.M203313200; Wang L, 2004, MOL CELL BIOL, V24, P2202, DOI 10.1128/MCB.24.5.2202-2213.2004; YOUNG CYF, 1992, BIOCHEMISTRY-US, V31, P818, DOI 10.1021/bi00118a026	30	65	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3596	3604		10.1038/sj.onc.1211016	http://dx.doi.org/10.1038/sj.onc.1211016			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223692	Green Accepted			2022-12-17	WOS:000256468500011
J	Richard, S; Vogel, G; Huot, ME; Guo, T; Muller, WJ; Lukong, KE				Richard, S.; Vogel, G.; Huot, M-E; Guo, T.; Muller, W. J.; Lukong, K. E.			Sam68 haploinsufficiency delays onset of mammary tumorigenesis and metastasis	ONCOGENE			English	Article						Sam68; RNA binding; mammary tumorigenesis; Src; metastasis; signaling	MESENCHYMAL TRANSITION; TYROSINE KINASE; TARGETED DISRUPTION; SIGNAL-TRANSDUCTION; BREAST-CANCER; CELL-LINES; C-CBL; SRC; PROTEIN; GROWTH	The Src-associated substrate in mitosis Sam68 is a KH type RNA-binding protein known to be a substrate of numerous tyrosine kinases, and often referred to as a STAR ( signal transduction activator of RNA) protein. Herein, we observed that Sam68-null mice display mammary gland and the uterine development defects. Moreover, we report that Sam68 haploinsufficiency impedes mammary tumor onset in vivo driven by the potent mammary-targeted polyoma middle T-antigen (MMTV-PyMT) oncogene. The effect was cell autonomous as the Sam68 knockdown in PyMT-transformed cell lines also delayed tumorigenesis and metastasis formation in nude mice. Interestingly, tumor extracts isolated from PyMT/Sam68(+/-) mice compared with PyMT/Sam68(+/+) mice contained activated Src and FAK kinases. These findings suggest that Sam68 may be a modulator of tyrosine kinase activity in vivo and a signaling requirement for mammary tumorigenesis and metastasis.	[Richard, S.; Vogel, G.; Huot, M-E; Guo, T.; Lukong, K. E.] Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; [Richard, S.; Vogel, G.; Huot, M-E; Guo, T.; Lukong, K. E.] Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; [Richard, S.; Vogel, G.; Huot, M-E; Guo, T.; Muller, W. J.; Lukong, K. E.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Richard, S.; Vogel, G.; Huot, M-E; Guo, T.; Lukong, K. E.] McGill Univ, Dept Oncol, Montreal, PQ, Canada; [Muller, W. J.] McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ, Canada; [Muller, W. J.] McGill Univ, Dept Biochem, Montreal, PQ, Canada	Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; McGill University; McGill University; McGill University; McGill University	Richard, S (corresponding author), Lady Davis Inst Med Res, Segal Canc Ctr, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.	stephane.richard@mcgill.ca						Andrechek ER, 2000, BREAST CANCER RES, V2, P211, DOI 10.1186/bcr56; Babic I, 2004, ONCOGENE, V23, P3781, DOI 10.1038/sj.onc.1207484; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Borowsky AD, 2005, CLIN EXP METASTAS, V22, P47, DOI 10.1007/s10585-005-2908-5; BUSA R, 2007, ONCOGENE; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Cheng CH, 2006, MOL CELL BIOL, V26, P362, DOI 10.1128/MCB.26.1.362-370.2006; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Cohen LA, 2005, CURR CANCER DRUG TAR, V5, P629, DOI 10.2174/156800905774932798; COURTNEIDGE SA, 1991, J VIROL, V65, P3301, DOI 10.1128/JVI.65.6.3301-3308.1991; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Dilworth SM, 2002, NAT REV CANCER, V2, P951, DOI 10.1038/nrc946; Fendrick JL, 1998, J MAMMARY GLAND BIOL, V3, P7, DOI 10.1023/A:1018766000275; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hovey RC, 2002, J MAMMARY GLAND BIOL, V7, P17, DOI 10.1023/A:1015766322258; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; Kim H, 2005, ONCOGENE, V24, P5629, DOI 10.1038/sj.onc.1208718; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu K, 2000, J BIOL CHEM, V275, P40195, DOI 10.1074/jbc.M006194200; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LUCCHINI F, 1992, CANCER LETT, V64, P203, DOI 10.1016/0304-3835(92)90044-V; Lukong KE, 2005, J BIOL CHEM, V280, P38639, DOI 10.1074/jbc.M505802200; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Mamidipudi V, 2007, ONCOGENE, V26, P2914, DOI 10.1038/sj.onc.1210091; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, ADV CANCER RES, V64, P111, DOI 10.1016/S0065-230X(08)60836-2; Richard S, 2005, PLOS GENET, V1, P676, DOI 10.1371/journal.pgen.0010074; Schomberg DW, 1999, ENDOCRINOLOGY, V140, P2733, DOI 10.1210/en.140.6.2733; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344	36	65	69	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2008	27	4					548	556		10.1038/sj.onc.1210652	http://dx.doi.org/10.1038/sj.onc.1210652			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17621265				2022-12-17	WOS:000252426100015
J	Tomioka, N; Oba, S; Ohira, M; Misra, A; Fridlyand, J; Ishii, S; Nakamura, Y; Isogai, E; Hirata, T; Yoshida, Y; Todo, S; Kaneko, Y; Albertson, DG; Pinkel, D; Feuerstein, BG; Nakagawara, A				Tomioka, N.; Oba, S.; Ohira, M.; Misra, A.; Fridlyand, J.; Ishii, S.; Nakamura, Y.; Isogai, E.; Hirata, T.; Yoshida, Y.; Todo, S.; Kaneko, Y.; Albertson, D. G.; Pinkel, D.; Feuerstein, B. G.; Nakagawara, A.			Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature	ONCOGENE			English	Article						neuroblastoma; array-CGH; molecular signature; risk stratification; microarray	NEURO-BLASTOMA; EXPRESSION; INFANTS; TUMORS; GENE; AMPLIFICATION; HYBRIDIZATION; CHEMOTHERAPY; MICROARRAYS; SURVIVAL	Human neuroblastoma remains enigmatic because it often shows spontaneous regression and aggressive growth. The prognosis of advanced stage of sporadic neuroblastomas is still poor. Here, we investigated whether genomic and molecular signatures could categorize new therapeutic risk groups in primary neuroblastomas. We conducted microarray-based comparative genomic hybridization (array-CGH) with a DNA chip carrying 2464 BAC clones to examine genomic aberrations of 236 neuroblastomas and used in-house cDNA microarrays for gene-expression pro. ling. Array-CGH demonstrated three major genomic groups of chromosomal aberrations: silent (GGS), partial gains and/or losses (GGP) and whole gains and/or losses (GGW), which well corresponded with the patterns of chromosome 17 abnormalities. They were further classifi ed into subgroups with different outcomes. In 112 sporadic neuroblastomas, MYCN amplification was frequent in GGS (22%) and GGP (53%) and caused serious outcomes in patients. Sporadic tumors with a single copy of MYCN showed the 5-year cumulative survival rates of 89% in GGS, 53% in GGP and 85% in GGW. Molecular signatures also segregated patients into the favorable and unfavorable prognosis groups (P = 0.001). Both univariate and multivariate analyses revealed that genomic and molecular signatures were mutually independent, powerful prognostic indicators. Thus, combined genomic and molecular signatures may categorize novel risk groups and confer new clues for allowing tailored or even individualized medicine to patients with neuroblastoma.	[Tomioka, N.; Ohira, M.; Nakamura, Y.; Isogai, E.; Nakagawara, A.] Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; [Tomioka, N.; Misra, A.; Feuerstein, B. G.] Univ Calif San Francisco, Brain Tumor Res Ctr, Dept Neurol Surg, San Francisco, CA USA; [Tomioka, N.; Todo, S.] Hokkaido Univ, Sch Med, Dept Surg, Sapporo, Hokkaido 060, Japan; [Oba, S.; Ishii, S.] Nara Inst Sci & Technol, Grad Sch Informat Sci, Ikoma, Japan; [Fridlyand, J.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Hirata, T.] Hisamitsu Pharmaceut Co Inc, Tokyo, Japan; [Yoshida, Y.] NGK Insulators Ltd, R&D Ctr, GENESHOT Project, Nagoya, Aichi, Japan; [Kaneko, Y.] Saitama Canc Ctr, Res Inst, Saitama, Japan; [Albertson, D. G.; Pinkel, D.; Feuerstein, B. G.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Albertson, D. G.; Pinkel, D.; Feuerstein, B. G.] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA USA	Chiba Cancer Center; University of California System; University of California San Francisco; Hokkaido University; Nara Institute of Science & Technology; University of California System; University of California San Francisco; Hisamitsu Pharmaceutical Co Ltd; NGK Insulators Ltd; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp	Feuerstein, Burt G/A-5186-2015	Feuerstein, Burt G/0000-0001-7276-8842; Ishii, Shin/0000-0001-9385-8230				Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; Bagchi A, 2007, CELL, V128, P459, DOI 10.1016/j.cell.2006.11.052; BECKWITH JB, 1963, AM J PATHOL, V43, P1089; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brodeur GM, 2001, MED PEDIATR ONCOL, V36, P157, DOI 10.1002/1096-911X(20010101)36:1<157::AID-MPO1038>3.0.CO;2-F; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Iehara T, 2006, BRIT J CANCER, V94, P1510, DOI 10.1038/sj.bjc.6603149; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; Kaneko M, 2002, J PEDIAT HEMATOL ONC, V24, P613, DOI 10.1097/00043426-200211000-00004; Levy IG, 2005, J NATL CANCER I, V97, P1105, DOI 10.1093/jnci/dji243; LOOK AT, 1984, NEW ENGL J MED, V311, P231, DOI 10.1056/NEJM198407263110405; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Nakagawara A, 2004, PROG BRAIN RES, V146, P233, DOI 10.1016/S0079-6123(03)46015-9; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Nakagawara A, 1998, MED PEDIATR ONCOL, V31, P113, DOI 10.1002/(SICI)1096-911X(199808)31:2<113::AID-MPO14>3.0.CO;2-O; OBA S, 2006, IPSJ T BIOINFORMATIC, V47, P73; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Ohira M, 2003, ONCOGENE, V22, P5525, DOI 10.1038/sj.onc.1206853; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; SAWADA T, 1984, LANCET, V2, P271; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; SRIVATSAN ES, 1993, GENE CHROMOSOME CANC, V7, P32, DOI 10.1002/gcc.2870070106; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Tomioka N, 2003, GENE CHROMOSOME CANC, V36, P139, DOI 10.1002/gcc.10151; TONINI GP, 1993, STEM CELLS, V11, P276, DOI 10.1002/stem.5530110404; Vandesompele J, 1998, GENE CHROMOSOME CANC, V23, P141, DOI 10.1002/(SICI)1098-2264(199810)23:2<141::AID-GCC7>3.0.CO;2-2; Wei JS, 2004, CANCER RES, V64, P6883, DOI 10.1158/0008-5472.CAN-04-0695; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; Woods WG, 2002, NEW ENGL J MED, V346, P1041, DOI 10.1056/NEJMoa012387	32	65	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2008	27	4					441	449		10.1038/sj.onc.1210661	http://dx.doi.org/10.1038/sj.onc.1210661			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637744				2022-12-17	WOS:000252426100004
J	Rong, R; Jiang, LY; Sheikh, MS; Huang, Y				Rong, R.; Jiang, L. Y.; Sheikh, M. S.; Huang, Y.			Mitotic kinase Aurora-A phosphorylates RASSF1A and modulates RASSF1A-mediated microtubule interaction and M-phase cell cycle regulation	ONCOGENE			English	Article						tumor suppressor; mitotic kinase; RASSF1A; Aurora-A; cell cycle; microtubules	TUMOR-SUPPRESSOR RASSF1A; CENTROSOME AMPLIFICATION; CDC2 KINASE; PROTEIN; OVEREXPRESSION; SITES; MAP4	RASSF1A (RAS-association domain family 1, isoform A) is a newer tumor suppressor that binds to and stabilizes microtubules as well as induces M-phase cell cycle arrest. Several other proteins that interact with and stabilize microtubules also undergo mitotic phase phosphorylation to regulate microtubule dynamics and M-phase cell cycle progression. Currently, however, there is a paucity of information regarding the phosphorylation status of RASSF1A and its regulation during mitosis. In this study, for the first time, we demonstrate that Aurora-A is a RASSF1A kinase and, to the best of our knowledge, this is also the first study reporting the identification of a kinase for RASSF1A. We show that the mitotic kinase Aurora-A directly interacts with and phosphorylates RASSF1 and that RASSF1A is phosphorylated by Aurora-A during mitosis. These findings therefore link an important oncogenic mitotic kinase to regulate RASSF1A tumor suppressor. Aurora-A appears to phosphorylate RASSF1A at Threonine202 and/or Serine203 that reside within the known microtubule-binding domain of RASSF1A. Substitutions of these residues with glutamic acid at both positions, mimicking constitutive phosphorylation of RASSF1A, disrupt RASSF1A interactions with microtubules and abolish its ability to induce M-phase cell cycle arrest. Our results further demonstrate that Aurora-A overexpression also interferes with RASSF1A-mediated growth suppression. In view of our results, we propose that Aurora-A-mediated phosphorylation of RASSF1A is a novel mechanism that regulates the ability of this tumor suppressor to interact with microtubules and modulate M-phase cell cycle progression.	[Rong, R.; Jiang, L. Y.; Sheikh, M. S.; Huang, Y.] SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Huang, Y (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	huangy@upstate.edu			NATIONAL CANCER INSTITUTE [R01CA086945, R21CA113868] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK067271] Funding Source: NIH RePORTER; NCI NIH HHS [CA86945, CA113868] Funding Source: Medline; NIDDK NIH HHS [DK067271] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; FARUKI S, 1992, J CELL SCI, V101, P69; Illenberger S, 1996, J BIOL CHEM, V271, P10834, DOI 10.1074/jbc.271.18.10834; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Ookata K, 1997, BIOCHEMISTRY-US, V36, P15873, DOI 10.1021/bi971251w; Rong R, 2004, ONCOGENE, V23, P8216, DOI 10.1038/sj.onc.1207901; Shiina N, 1999, MOL BIOL CELL, V10, P597, DOI 10.1091/mbc.10.3.597; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Trzepacz C, 1997, J BIOL CHEM, V272, P21681, DOI 10.1074/jbc.272.35.21681; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Wang XX, 2006, CELL RES, V16, P356, DOI 10.1038/sj.cr.7310046; Wittmann T, 2001, NAT CELL BIOL, V3, pE28, DOI 10.1038/35050669; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	19	65	67	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7700	7708		10.1038/sj.onc.1210575	http://dx.doi.org/10.1038/sj.onc.1210575			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17563743				2022-12-17	WOS:000251537800012
J	Lastowska, M; Viprey, V; Santibanez-Koref, M; Wappler, I; Peters, H; Cullinane, C; Roberts, P; Hall, AG; Tweddle, DA; Pearson, ADJ; Lewis, I; Burchill, SA; Jackson, MS				Lastowska, M.; Viprey, V.; Santibanez-Koref, M.; Wappler, I.; Peters, H.; Cullinane, C.; Roberts, P.; Hall, A. G.; Tweddle, D. A.; Pearson, A. D. J.; Lewis, I.; Burchill, S. A.; Jackson, M. S.			Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data	ONCOGENE			English	Article						neuroblastoma; expression arrays; SNP arrays; candidate genes	HIGH-RESOLUTION ANALYSIS; TUMOR-SUPPRESSOR GENE; N-MYC ONCOGENE; COPY NUMBER; CHROMOSOME 1P; ALLELIC LOSS; 17Q; AMPLIFICATION; CGH; ABNORMALITIES	Identifying genes, whose expression is consistently altered by chromosomal gains or losses, is an important step in defining genes of biological relevance in a wide variety of tumour types. However, additional criteria are needed to discriminate further among the large number of candidate genes identified. This is particularly true for neuroblastoma, where multiple genomic copy number changes of proven prognostic value exist. We have used Affymetrix microarrays and a combination of. fluorescentin situ hybridization and single nucleotide polymorphism (SNP) microarrays to establish expression profiles and delineate copy number alterations in 30 primary neuroblastomas. Correlation of microarray data with patient survival and analysis of expression within rodent neuroblastoma cell lines were then used to define further genes likely to be involved in the disease process. Using this approach, we identify > 1000 genes within eight recurrent genomic alterations (loss of 1p, 3p, 4p, 10q and 11q, 2p gain, 17q gain, and the MYCN amplicon) whose expression is consistently altered by copy number change. Of these, 84 correlate with patient survival, with the minimal regions of 17q gain and 4p loss being enriched significantly for such genes. These include genes involved in RNA and DNA metabolism, and apoptosis. Orthologues of all but one of these genes on 17q are overexpressed in rodent neuroblastoma cell lines. A significant excess of SNPs whose copy number correlates with survival is also observed on proximal 4p in stage 4 tumours, and we find that deletion of 4p is associated with improved outcome in an extended cohort of tumours. These results de. ne the major impact of genomic copy number alterations upon transcription within neuroblastoma, and highlight genes on distal 17q and proximal 4p for downstream analyses. They also suggest that integration of discriminators, such as survival and comparative gene expression, with microarray data be useful in the identification of critical genes within regions of loss or gain in many human cancers.	Int Ctr Life, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England; St James Univ Hosp, Canc Res UK Clin Ctr, Childrens Canc Res Lab, Leeds, W Yorkshire, England; St James Univ Hosp, Dept Pathol, Leeds LS9 7TF, W Yorkshire, England; St James Univ Hosp, Dept Cytogenet, Leeds LS9 7TF, W Yorkshire, England; Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Inst Canc Res, Sutton, Surrey, England; St James Univ Hosp, Dept Paediat Oncol & Haematol, Leeds LS9 7TF, W Yorkshire, England	Newcastle University - UK; Cancer Research UK; Saint James's University Hospital; University of Leeds; Saint James's University Hospital; Saint James's University Hospital; Newcastle University - UK; University of London; Institute of Cancer Research - UK; Saint James's University Hospital	Jackson, MS (corresponding author), Int Ctr Life, Inst Human Genet, Central Parkway, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.	m.s.jackson@ncl.ac.uk	Hall, Andrew G/B-3485-2009	Viprey, Virginie/0000-0001-6463-7092; Jackson, Michael/0000-0001-7179-1354; Lastowska, Maria/0000-0003-0632-6995				Ambros PF, 2001, MED PEDIATR ONCOL, V37, P492, DOI 10.1002/mpo.1242; Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; BOWN NP, 1994, MED PEDIATR ONCOL, V23, P124, DOI 10.1002/mpo.2950230210; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Bussey KJ, 2006, MOL CANCER THER, V5, P853, DOI 10.1158/1535-7163.MCT-05-0155; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; Caron H, 1996, HUM GENET, V97, P834; Chen QR, 2006, GENE CHROMOSOME CANC, V45, P856, DOI 10.1002/gcc.20349; Chen QR, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-70; De Preter K, 2005, J CLIN ONCOL, V23, P3167, DOI 10.1200/JCO.2005.05.346; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Fischer M, 2005, J MOL DIAGN, V7, P89, DOI 10.1016/S1525-1578(10)60013-X; Hackett CS, 2003, CANCER RES, V63, P5266; Henrich KO, 2006, CLIN CANCER RES, V12, P131, DOI 10.1158/1078-0432.CCR-05-1431; Huang Jing, 2004, Human Genomics, V1, P287; Janoueix-Lerosey I, 2004, ONCOGENE, V23, P5912, DOI 10.1038/sj.onc.1207784; Lastowska M, 1997, GENE CHROMOSOME CANC, V18, P162; Lastowska M, 2004, GENE CHROMOSOME CANC, V40, P158, DOI 10.1002/gcc.20031; Lastowska M, 2002, GENE CHROMOSOME CANC, V34, P428, DOI 10.1002/gcc.10089; Lastowska M, 2001, J CLIN ONCOL, V19, P3080; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Miller MA, 2006, J PEDIAT HEMATOL ONC, V28, P412, DOI 10.1097/01.mph.0000212937.00287.e5; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; Nigro JM, 2005, CANCER RES, V65, P1678, DOI 10.1158/0008-5472.CAN-04-2921; NISEN PD, 1988, J NATL CANCER I, V80, P1633, DOI 10.1093/jnci/80.20.1633; Perri P, 2002, ONCOGENE, V21, P8356, DOI 10.1038/sj.onc.1206009; Popescu NC, 1997, CANCER GENET CYTOGEN, V93, P10, DOI 10.1016/S0165-4608(96)00262-2; Rao CR, 1973, LINEAR STAT INTERFER; Schleiermacher G, 2005, ONCOGENE, V24, P3377, DOI 10.1038/sj.onc.1208486; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SELTZER R, 2005, GENE CHROMOSOME CANC, V44, P305; SLAVC I, 1990, CANCER RES, V50, P1459; Stallings RL, 2006, CANCER RES, V66, P3673, DOI 10.1158/0008-5472.CAN-05-4154; Tsafrir D, 2006, CANCER RES, V66, P2129, DOI 10.1158/0008-5472.CAN-05-2569; Vandesompele J, 2005, J CLIN ONCOL, V23, P2280, DOI 10.1200/JCO.2005.06.104; Walker BA, 2006, BLOOD, V108, P1733, DOI 10.1182/blood-2006-02-005496; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Weber A, 2004, J CLIN ONCOL, V22, P2681, DOI 10.1200/JCO.2004.07.192	41	65	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2007	26	53					7432	7444		10.1038/sj.onc.1210552	http://dx.doi.org/10.1038/sj.onc.1210552			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17533364				2022-12-17	WOS:000251282000005
J	Wang, Y; Kreisberg, JI; Bedolla, RG; Mikhailova, M; White, RWD; Ghosh, PM				Wang, Y.; Kreisberg, J. I.; Bedolla, R. G.; Mikhailova, M.; White, R. W. deVere; Ghosh, P. M.			A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells	ONCOGENE			English	Article						proliferation; prostate cancer; androgen receptor; Akt; bicalutamide	ACTIN-BINDING PROTEIN; C-TERMINAL REGION; PHOSPHORYLATION SITE; MEMBRANE ANTIGEN; CROSS-LINKING; AKT; PROLIFERATION; BICALUTAMIDE; PROGRESSION; EXPRESSION	Prostate tumors are initially dependent on androgens for growth, but the majority of patients treated with antiandrogen therapy progress to androgen- independence characterized by resistance to such treatment. This study investigates a novel role for. lamin A ( FlnA), a 280 kDa cytoskeletal protein ( consisting of an actin- binding domain ( ABD) followed by 24 sequential repeats), in androgen- independent ( AI) growth. Full- length FlnA is cleaved to 170 kDa ( ABD+FlnA1 - 15) and 110 kDa fragments ( FlnA16 - 24); the latter is further cleaved to a 90 kDa fragment ( repeats 16 - 23) capable of nuclear translocation and androgen receptor ( AR) binding. Here, we demonstrate that in androgen- dependent LNCaP prostate cancer cells, the cleaved 90 kDa fragment is localized to the nucleus, whereas in its AI subline C4 - 2, FlnA failed to cleave and remained cytoplasmic. Transfection of FlnA16 - 24 cDNA in C4 - 2 cells restored expression and nuclear localization of 90 kDa FlnA. Unlike LNCaP, C4 - 2 cells proliferate in androgen-reduced medium and in the presence of the AR- antagonist Casodex. They also exhibit increased Akt phosphorylation compared to LNCaP, which may contribute to their AI phenotype. Nuclear expression of 90 kDa FlnA in C4 - 2 cells decreased Akt phosphorylation, prevented proliferation in androgen- reduced medium and restored Casodex sensitivity. This effect was inhibited by constitutive activation of Akt indicating that FlnA restored Casodex sensitivity in C4 - 2 cells by decreasing Akt phosphorylation. In addition, FlnA-specific siRNA which depleted FlnA levels, but not control siRNA, induced resistance to Casodex in LNCaP cells. Our results demonstrate that expression of nuclear FlnA is necessary for androgen dependence in these cells.	VA No California Hlth Care Syst, Res Serv, Mather, CA 95655 USA; Univ Calif Davis, Sch Med, Dept Urol, Sacramento, CA 95817 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX 78285 USA	University of California System; University of California Davis; University of Texas System; University of Texas Health San Antonio	Ghosh, PM (corresponding author), VA No California Hlth Care Syst, Res Serv, 10535 Hosp Way, Mather, CA 95655 USA.	paramita.ghosh@ucdmc.ucdavis.edu	WANG, YU/E-4655-2013		NCI NIH HHS [CA109057, R21 CA109057] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA109057] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anilkumar G, 2003, CANCER RES, V63, P2645; BARRY CP, 1993, J BIOL CHEM, V268, P25577; Browne KA, 2000, J BIOL CHEM, V275, P39262, DOI 10.1074/jbc.C000622200; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; Culig ZR, 2003, J UROLOGY, V170, P1363, DOI 10.1097/01.ju.0000075099.20662.7f; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Ghosh A, 2005, CANCER RES, V65, P727; Ghosh PM, 2005, ENDOCR-RELAT CANCER, V12, P119, DOI 10.1677/erc.1.00835; Ghosh PM, 2003, CURR DRUG METAB, V4, P487, DOI 10.2174/1389200033489226; Ghosh PM, 2002, CANCER RES, V62, P2630; Ghosh PM, 2001, AM J PHYSIOL-RENAL, V280, pF972, DOI 10.1152/ajprenal.2001.280.6.F972; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Hara T, 2003, CANCER RES, V63, P149; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; HSIEH JT, 1993, CANCER RES, V53, P2852; Isaacs JT, 2000, JNCI-J NATL CANCER I, V92, P1367, DOI 10.1093/jnci/92.17.1367; Jay D, 2000, ARCH BIOCHEM BIOPHYS, V377, P80, DOI 10.1006/abbi.2000.1762; Jay D, 2004, MOL CELL BIOCHEM, V260, P49, DOI 10.1023/B:MCBI.0000026052.76418.55; JENSTER G, 1992, J STEROID BIOCHEM, V41, P671, DOI 10.1016/0960-0760(92)90402-5; Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272; Loy CJ, 2003, P NATL ACAD SCI USA, V100, P4562, DOI 10.1073/pnas.0736237100; Malik SN, 2002, CLIN CANCER RES, V8, P1168; Manin M, 2002, BIOCHEM J, V366, P729, DOI 10.1042/BJ20020585; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; Murray JT, 2004, BIOCHEM J, V384, P489, DOI 10.1042/BJ20041058; Ozanne DM, 2000, MOL ENDOCRINOL, V14, P1618, DOI 10.1210/me.14.10.1618; Robertson SP, 2003, NAT GENET, V33, P487, DOI 10.1038/ng1119; Shi XB, 2004, PROSTATE, V60, P257, DOI 10.1002/pros.20039; Tepper CG, 2002, CANCER RES, V62, P6606; Thomas P, 1996, NEUROLOGY, V46, P1165, DOI 10.1212/WNL.46.4.1165; Tigges U, 2003, J BIOL CHEM, V278, P23561, DOI 10.1074/jbc.M302302200; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; Wen Y, 2000, CANCER RES, V60, P6841; Woo MS, 2004, MOL CELL BIOL, V24, P3025, DOI 10.1128/MCB.24.7.3025-3035.2004; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319	37	65	68	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2007	26	41					6061	6070		10.1038/sj.onc.1210435	http://dx.doi.org/10.1038/sj.onc.1210435			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17420725				2022-12-17	WOS:000249277200009
J	Tong, WM; Yang, YG; Cao, WH; Galendo, D; Frappart, L; Shen, Y; Wang, ZQ				Tong, W. M.; Yang, Y. G.; Cao, W. H.; Galendo, D.; Frappart, L.; Shen, Y.; Wang, Z. Q.			Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice	ONCOGENE			English	Article						breast cancer; DNA damage response; PARP-1; p53; BRCA1	DNA-DAMAGE RESPONSE; HUMAN BREAST-CANCER; TUMOR-FORMATION; HISTONE H2AX; P53; BRCA1; PARP-1; PHOSPHORYLATION; SUSCEPTIBILITY; DEFICIENT	The DNA strand break-binding molecule, poly(ADPribose) polymerase-1 (PARP-1), plays a role in DNA repair, chromosomal stability, transcription and cell death. Accumulating evidence suggests that dysfunction of PARP-1 contributes to tumorigenesis. Here, we report that PARP-1 deficiency causes mammary carcinoma formation in female mice, and that the introduction of Trp53 mutations accelerates the onset and shortens the latency of mammary tumorigenesis. We show that PARP1 deficiency results in chromosomal aneuploidy and centrosome amplification, which are substantiated by the inactivation of Trp53 in primary mammary epithelial (PME) cells. In addition, PARP-1 deficiency compromises p53 activation and impairs BRCA1 recruitment to the sites of DNA damage in PME cells. PARP-1 complementation partly rescues the defective DNA damage response mediated by p53 and BRCA1. The present study thus identifies a role of PARP-1 in suppressing mammary tumorigenesis in vivo and suggests that dysfunction of PARP-1 may be a risk factor for breast cancer in humans.	IARC, Pathol Grp, F-69008 Lyon, France; Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100037, Peoples R China; Peking Union Med Coll, Beijing, Peoples R China; Hosp Edouard Herriot, Dept Pathol, Lyon, France	World Health Organization; International Agency for Research on Cancer (IARC); Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; bioMerieux; CHU Lyon	Tong, WM (corresponding author), IARC, Pathol Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.	tong@iarc.fr						Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Beneke R, 2001, ONCOGENE, V20, P8136, DOI 10.1038/sj.onc.1205056; Bieche I, 1996, CLIN CANCER RES, V2, P1163; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; De Soto Joseph A, 2006, Int J Med Sci, V3, P117; De Soto JA, 2006, INT J BIOL SCI, V2, P179; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Edwards PAW, 1996, J MAMMARY GLAND BIOL, V1, P75, DOI 10.1007/BF02096304; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hao BT, 2004, CANCER RES, V64, P4378, DOI 10.1158/0008-5472.CAN-04-0372; Helleday T, 2005, CELL CYCLE, V4, P1176, DOI 10.4161/cc.4.9.2031; Herceg Z, 1999, MOL CELL BIOL, V19, P5124; Hu JJ, 1997, PHARMACOGENETICS, V7, P309, DOI 10.1097/00008571-199708000-00006; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kanai M, 2003, MOL CELL BIOL, V23, P2451, DOI 10.1128/MCB.23.7.2451-2462.2003; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Lebel M, 2003, AM J PATHOL, V162, P1559, DOI 10.1016/S0002-9440(10)64290-3; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Lockett KL, 2004, CANCER RES, V64, P6344, DOI 10.1158/0008-5472.CAN-04-0338; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; MALKIN D, 1998, LI FRAUMENI SYNDROME, P393; Masutani M, 2003, GENE CHROMOSOME CANC, V38, P339, DOI 10.1002/gcc.10250; McCabe N, 2005, CANCER BIOL THER, V4, P934, DOI 10.4161/cbt.4.9.2141; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Nozaki T, 2003, CANCER SCI, V94, P497, DOI 10.1111/j.1349-7006.2003.tb01472.x; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rajaee-Behbahani N, 2002, INT J CANCER, V98, P780, DOI 10.1002/ijc.10234; Shibata A, 2005, ONCOGENE, V24, P1328, DOI 10.1038/sj.onc.1208289; Shiokawa M, 2005, JPN J CLIN ONCOL, V35, P97, DOI 10.1093/jjco/hyi028; STEWART BW, 2003, BREAST CANC WORLD CA; Tong WM, 2001, MOL CELL BIOL, V21, P4046, DOI 10.1128/MCB.21.12.4046-4054.2001; Tong WM, 2003, AM J PATHOL, V162, P343, DOI 10.1016/S0002-9440(10)63825-4; Tong WM, 2001, BBA-REV CANCER, V1552, P27, DOI 10.1016/S0304-419X(01)00035-X; Tong WM, 2002, CANCER RES, V62, P6990; Tsutsumi M, 2001, CARCINOGENESIS, V22, P1, DOI 10.1093/carcin/22.1.1; Turner JMA, 2004, CURR BIOL, V14, P2135, DOI 10.1016/j.cub.2004.11.032; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Zhang XM, 2005, CANCER RES, V65, P722	48	65	70	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2007	26	26					3857	3867		10.1038/sj.onc.1210156	http://dx.doi.org/10.1038/sj.onc.1210156			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17160013				2022-12-17	WOS:000247026400009
J	Huang, W; Chang, HY; Fei, T; Wu, H; Chen, YG				Huang, W.; Chang, H. Y.; Fei, T.; Wu, H.; Chen, Y-G			GSK3 beta mediates suppression of cyclin D2 expression by tumor suppressor PTEN	ONCOGENE			English	Article						PTEN; cyclin D2; gene expression; GSK3 beta; beta-catenin; TCF	GERM-CELL TUMORS; PROTEIN-KINASE-A; BETA-CATENIN; COWDEN-DISEASE; TRANSCRIPTIONAL ACTIVATION; INDUCED PROLIFERATION; COLON-CARCINOMA; GENE; PATHWAY; SURVIVAL	PTEN, encoding a lipid phosphatase, is a tumor suppressor gene and is mutated in various types of cancers. It is reported to regulate G1 to S phase transition of the cell cycle by influencing the expression, protein stability and subcellular location of cyclin D1. Here, we provide evidence that PTEN modulates the transcription and protein stability of cyclin D2. Targeted deletion of Pten in mouse embryonic fibroblasts (MEFs) endowed cells with greater potential to overcome G1 arrest than wild-type MEFs and led to the elevated expression of cyclin D2, which was suppressed by the introduction of PTEN. We further de fined a pathway involving GSK3 beta and beta-catenin/TCF in PTEN-mediated suppression of cyclin D2 transcription. LiCl, an inhibitor of GSK3b, abolished inhibitory effect of PTEN on cyclin D2 expression, and TCF members could directly bind to the promoter of cyclin D2 and regulate its transcription in a CREB-dependent manner. Our results indicate that the downregulation of cyclin D2 expression by PTEN is mediated by the GSK3 beta/beta-catenin/TCF pathway in cooperation with CREB, and suggest a convergence from the PI-3 kinase/PTEN pathway and the Wnt pathway in modulation of cyclin D2 expression.	Tsing Hua Univ, Dept Mol Biol & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China; Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA	Tsinghua University; Stanford University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Chen, YG (corresponding author), Tsing Hua Univ, Dept Mol Biol & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China.	ygchen@tsinghua.edu.cn	Chen, Ye-Guang/L-6998-2019; Fei, Teng/A-5963-2010; Fei, Teng/G-5324-2015	Fei, Teng/0000-0001-5707-0673; FEI, TENG/0000-0001-9620-0450				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Anzelon AN, 2003, NAT IMMUNOL, V4, P287, DOI 10.1038/ni892; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; Carthon BC, 2005, MOL CELL BIOL, V25, P1081, DOI 10.1128/MCB.25.3.1081-1088.2005; Chaganti RSK, 2000, CANCER RES, V60, P1475; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Vizio D, 2005, ONCOGENE, V24, P1882, DOI 10.1038/sj.onc.1208368; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huard JMT, 1999, DEVELOPMENT, V126, P1927; Jena N, 2002, CANCER RES, V62, P535; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, GENE CHROMOSOME CANC, V21, P61, DOI 10.1002/(SICI)1098-2264(199801)21:1<61::AID-GCC8>3.0.CO;2-6; Mohamedali A, 2003, J LEUKOCYTE BIOL, V74, P1139, DOI 10.1189/jlb.0803363; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Piatelli MJ, 2004, J IMMUNOL, V172, P2753, DOI 10.4049/jimmunol.172.5.2753; Pradeep A, 2004, ONCOGENE, V23, P3689, DOI 10.1038/sj.onc.1207454; Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003; RAVNIK SE, 1995, DEV GENET, V16, P171, DOI 10.1002/dvg.1020160209; Robker RL, 1998, MOL ENDOCRINOL, V12, P924, DOI 10.1210/me.12.7.924; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stiles B, 2002, MOL CELL BIOL, V22, P3842, DOI 10.1128/MCB.22.11.3842-3851.2002; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; White PC, 2006, ONCOGENE, V25, P2170, DOI 10.1038/sj.onc.1209255; Wianny F, 1998, DEV DYNAM, V212, P49, DOI 10.1002/(SICI)1097-0177(199805)212:1<49::AID-AJA5>3.0.CO;2-2; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; Xu LF, 2000, GENE DEV, V14, P585; Zhu XY, 2001, CANCER RES, V61, P4569	52	65	69	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2007	26	17					2471	2482		10.1038/sj.onc.1210033	http://dx.doi.org/10.1038/sj.onc.1210033			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17043650				2022-12-17	WOS:000245831000007
J	Wang, F; Liu, R; Lee, SW; Sloss, CM; Couget, J; Cusack, JC				Wang, F.; Liu, R.; Lee, S. W.; Sloss, C. M.; Couget, J.; Cusack, J. C.			Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance	ONCOGENE			English	Article						HB-EGF; EGFR; NF-kappa B; c-fos; chemotherapy resistance	NF-KAPPA-B; HB-EGF; PROHB-EGF; METALLOPROTEINASE-CLEAVAGE; CELL-PROLIFERATION; SIGNALING CASCADES; CARCINOMA-CELLS; INHIBITION; CHEMORESISTANCE; ACTIVATION	We have shown that one of the principle mechanisms of chemotherapy resistance involves the activation of nuclear factor kappa-B (NF-kappa B). In an effort to identify NF- kappa-B-regulated chemotherapy response genes, we performed a microarray assay and observed that heparin-binding EGF-like growth factor (HB-EGF) was significantly upregulated by SN38 (a strong inducer of NF-kappa B activity) in colon cancer cells. Further studies revealed that HB-EGF was rapidly induced following a variety of chemotherapy treatments. Using RNA interference, we demonstrated that the chemotherapy-induced HB-EGF was largely dependent on activator protein-1 (AP-1) and NF-kappa B activation. Constitutive HB-EGF expression rescued AP-1/NF-kappa B small interfering RNA (siRNA) cells from chemotherapy-induced apoptosis. Meanwhile, we found that the enzymatic shedding of HB-EGF was also regulated by chemotherapy treatment, resulting in the elevated release of soluble HB-EGF from the cellular membrane. Induction of HB-EGF expression and ectodomain shedding synergistically led to robust epidermal growth factor receptor (EGFR) phosphorylation, whereas inhibition of HB-EGF expression by use of the HB-EGF inhibitor (CRM197) or siRNA resulted in the suppression of chemotherapyinduced EGFR phosphorylation. These results suggest that the chemotherapy-induced EGFR activation is regulated by HB-EGF. Finally, we demonstrated that overexpression of HB-EGF led to apoptotic resistance to chemotherapy, whereas suppression of HB-EGF expression by siRNA resulted in a dramatic increase in cell death. In summary, our study suggests that chemotherapy-induced HB-EGF activation represents a critical mechanism of inducible chemotherapy resistance. Therefore, therapeutic intervention aimed at inhibiting HB-EGF activity may be useful in cancer prevention and treatments.	Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Boston, MA 02114 USA; Harvard Univ, Bauer Ctr Genom Res, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University	Cusack, JC (corresponding author), Massachusetts Gen Hosp, Div Surg Oncol, 55 Fruit St,7th Floor, Boston, MA 02114 USA.	jcusack@partners.org			NATIONAL CANCER INSTITUTE [K08CA077278, R01CA098871] Funding Source: NIH RePORTER; NCI NIH HHS [CA98871-01, CA77278-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armant DR, 2006, DEVELOPMENT, V133, P751, DOI 10.1242/dev.02237; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bode AM, 2004, MUTAT RES-FUND MOL M, V555, P33, DOI 10.1016/j.mrfmmm.2004.05.018; Cusack JC, 2001, CANCER RES, V61, P3535; Cusack JC, 1999, DRUG RESIST UPDATE, V2, P271, DOI 10.1054/drup.1999.0094; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Higashiyama S, 2005, BBA-PROTEINS PROTEOM, V1751, P110, DOI 10.1016/j.bbapap.2004.11.009; Hirata M, 2001, BIOCHEM BIOPH RES CO, V283, P915, DOI 10.1006/bbrc.2001.4879; Ito Y, 2001, INT J PANCREATOL, V29, P47, DOI 10.1385/IJGC:29:1:47; Ito Y, 2001, ONCOL REP, V8, P903; Itoh Y, 2005, CYTOKINE, V29, P275, DOI 10.1016/j.cyto.2004.11.005; Kanda N, 2005, AM J PHYSIOL-CELL PH, V288, pC813, DOI 10.1152/ajpcell.00483.2004; Kishida O, 2005, CANCER CHEMOTH PHARM, V55, P393, DOI 10.1007/s00280-004-0904-0; Miyamoto S, 2004, CANCER RES, V64, P5720, DOI 10.1158/0008-5472.CAN-04-0811; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; Nishi E, 2004, GROWTH FACTORS, V22, P253, DOI 10.1080/08977190400008448; Ongusaha PP, 2004, CANCER RES, V64, P5283, DOI 10.1158/0008-5472.CAN-04-0925; Park JM, 1999, AM J PHYSIOL-CELL PH, V277, pC294, DOI 10.1152/ajpcell.1999.277.2.C294; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; Suganuma K, 2003, CANCER SCI, V94, P355, DOI 10.1111/j.1349-7006.2003.tb01446.x; Takenobu H, 2003, J BIOL CHEM, V278, P17255, DOI 10.1074/jbc.M211835200; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Xu KP, 2004, INVEST OPHTH VIS SCI, V45, P813, DOI 10.1167/iovs.03-0851; Yang XP, 2005, MOL CELLS, V20, P263; Yemelyanov A, 2006, ONCOGENE, V25, P387, DOI 10.1038/sj.onc.1209066	26	65	67	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2006	2016		10.1038/sj.onc.1209999	http://dx.doi.org/10.1038/sj.onc.1209999			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17001310				2022-12-17	WOS:000245313400003
J	Lo, PHY; Leung, ACC; Kwok, CYC; Cheung, WSY; Ko, JMY; Yang, LC; Law, S; Wang, LD; Li, J; Stanbridge, EJ; Srivastava, G; Tang, JCO; Tsao, SW; Lung, ML				Lo, P. H. Y.; Leung, A. C. C.; Kwok, C. Y. C.; Cheung, W. S. Y.; Ko, J. M. Y.; Yang, L. C.; Law, S.; Wang, L. D.; Li, J.; Stanbridge, E. J.; Srivastava, G.; Tang, J. C. O.; Tsao, S. W.; Lung, M. L.			Identification of a tumor suppressive critical region mapping to 3p14.2 in esophageal squamous cell carcinoma and studies of a candidate tumor suppressor gene, ADAMTS9	ONCOGENE			English	Article						esophageal carcinoma; tumor suppressor gene; chromosome 3; microcell-mediated chromosome transfer; ADAMTS9	NASOPHARYNGEAL CARCINOMA; EPIGENETIC INACTIVATION; FUNCTIONAL EVIDENCE; CHROMOSOME 3P21.3; CANCER; LINES; EXPRESSION; HUMAN-CHROMOSOME-3; TUMORIGENICITY; ESTABLISHMENT	A gene critical to esophageal cancer has been identified. Functional studies using microcell-mediated chromosome transfer of intact and truncated donor chromosomes 3 into an esophageal cancer cell line and nude mouse tumorigenicity assays were used to identify a 1.61Mb tumor suppressive critical region (CR) mapping to chromosome 3p14.2. This CR is bounded by D3S1600 and D3S1285 microsatellite markers. One candidate tumor suppressor gene, ADAMTS9, maps to this CR. Further studies showed normal expression levels of this gene in tumor-suppressed microcell hybrids, levels that were much higher than observed in the recipient cells. Complete loss or downregulation of ADAMTS9 gene expression was found in 15 out of 16 esophageal carcinoma cell lines. Promoter hypermethylation was detected in the cell lines that do not express this gene. Re-expression of ADAMTS9 was observed after demethylation drug treatment, confirming that hypermethylation is involved in gene downregulation. Downregulation of ADAMTS9 was also found in 43.5 and 47.6% of primary esophageal tumor tissues from Hong Kong and from the high-risk region of Henan, respectively. Thus, this study identifies and provides functional evidence for a CR associated with tumor suppression on 3p14.2 and provides the first evidence that ADAMTS9, mapping to this region, may contribute to esophageal cancer development.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Ctr Canc Res, Kowloon, Hong Kong, Peoples R China; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Zhengzhou Univ, Ctr Med Expt, Canc Res Lab, Henan Key Lab Esophageal Canc, Zhengzhou 450052, Henan, Peoples R China; Yaocun Esophageal Canc Hosp, Dept Pathol, Linzhou, Henan, Peoples R China; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; University of Hong Kong; Zhengzhou University; University of California System; University of California Irvine; University of Hong Kong; Hong Kong Polytechnic University; University of Hong Kong	Lung, ML (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China.	bomaria@ust.hk	Tang, Johnny C. O./M-9639-2014; Ko, Josephine/U-2972-2019; Law, Simon/C-4324-2009; Tang, Johnny Cheuk-on/W-7214-2019; Lung, Maria Li/C-4495-2009	Tang, Johnny C. O./0000-0002-4261-3206; Ko, Josephine/0000-0002-7997-331X; Law, Simon/0000-0002-6518-5806; Tang, Johnny Cheuk-on/0000-0002-4261-3206; Lung, Maria Li/0000-0003-2559-3626				Chen WY, 2005, CELL CYCLE, V4, P10, DOI 10.4161/cc.4.1.1361; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; CHEUNG AL, 2005, IN PRESS CANC LETT; Clark ME, 2000, GENOMICS, V67, P343, DOI 10.1006/geno.2000.6246; Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; Hesson L, 2004, ONCOGENE, V23, P2408, DOI 10.1038/sj.onc.1207407; Horiguchi K, 2003, ONCOGENE, V22, P7862, DOI 10.1038/sj.onc.1207082; HU CP, 1984, J NATL CANCER I, V72, P577; Hu YC, 2002, CANCER GENET CYTOGEN, V135, P120, DOI 10.1016/S0165-4608(01)00580-5; Ko JMY, 2005, GENE CHROMOSOME CANC, V43, P284, DOI 10.1002/gcc.20190; Ko JMY, 2001, CANCER LETT, V170, P131, DOI 10.1016/S0304-3835(01)00577-8; Li J Y, 1982, Natl Cancer Inst Monogr, V62, P113; Lo PHY, 2006, CANCER LETT, V234, P184, DOI 10.1016/j.canlet.2005.03.036; Lung HL, 2005, ONCOGENE, V24, P6525, DOI 10.1038/sj.onc.1208812; Lung HL, 2004, INT J CANCER, V112, P628, DOI 10.1002/ijc.20454; MOK CH, 1987, ANTICANCER RES, V7, P409; PAN Q, 1989, Proceedings of the Chinese Academy of Medical Sciences and the Peking Union Medical College, V4, P52; Porter S, 2004, CLIN CANCER RES, V10, P2429, DOI 10.1158/1078-0432.CCR-0398-3; Qin Yan-Ru, 2005, Zhonghua Bing Li Xue Za Zhi, V34, P80; RIMESSI P, 1994, ONCOGENE, V9, P3467; Rooney D E, 1986, HUMAN CYTOGENETICS P, VFirst; Sambrook J., 1989, MOL CLONING; SAXON PJ, 1985, MOL CELL BIOL, V5, P140, DOI 10.1128/MCB.5.1.140; Sekine I, 2005, ONCOGENE, V24, P2735, DOI 10.1038/sj.onc.1207694; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Shiomi H, 2003, CANCER GENET CYTOGEN, V147, P50, DOI 10.1016/S0165-4608(03)00159-6; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Takahashi K., 1990, JPN J ORAL MAXILLOFA, V36, P307; Tanaka H, 1998, GENE CHROMOSOME CANC, V23, P123, DOI 10.1002/(SICI)1098-2264(199810)23:2<123::AID-GCC5>3.0.CO;2-4; Tang JCO, 2001, CANCER GENET CYTOGEN, V124, P36, DOI 10.1016/S0165-4608(00)00317-4; Tischoff I, 2005, INT J CANCER, V115, P684, DOI 10.1002/ijc.20944; Uzawa N, 1998, CANCER GENET CYTOGEN, V107, P125, DOI 10.1016/S0165-4608(98)00097-1; Wang L, 1996, ONCOGENE, V12, P699; Xiong W, 2004, CANCER RES, V64, P1972, DOI 10.1158/0008-5472.CAN-03-3253; Yang LC, 2005, ONCOGENE, V24, P697, DOI 10.1038/sj.onc.1208179; Yang Y, 2001, P NATL ACAD SCI USA, V98, P1136, DOI 10.1073/pnas.98.3.1136	37	65	68	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					148	157		10.1038/sj.onc.1209767	http://dx.doi.org/10.1038/sj.onc.1209767			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799631				2022-12-17	WOS:000243236500015
J	Balavenkatraman, KK; Jandt, E; Friedrich, K; Kautenburger, T; Pool-Zobel, B; Ostman, A; Bohmer, FD				Balavenkatraman, K. K.; Jandt, E.; Friedrich, K.; Kautenburger, T.; Pool-Zobel, B. L.; Ostman, A.; Boehmer, F. D.			DEP-1 protein tyrosine phosphatase inhibits proliferation and migration of colon carcinoma cells and is upregulated by protective nutrients	ONCOGENE			English	Article						protein-tyrosine phosphatase; colon cancer; DEP-1; cell migration; cell proliferation	GLUTATHIONE S-TRANSFERASES; GROWTH-FACTOR RECEPTOR; IN-VITRO; ETA SUPPRESSES; CANCER CELLS; EXPRESSION; DEPHOSPHORYLATION; CARCINOGENESIS; ACTIVATION; ADHESION	The transmembrane protein-tyrosine phosphatase (PTP) DEP-1 (density-enhanced phosphatase) is a candidate tumor suppressor in the colon epithelium. We have explored the function of DEP-1 in colon epithelial cells by inducible re-expression in a DEP-1- deficient human colon cancer cell line. Density-enhanced phosphatase-1 re-expression led to profound inhibition of cell proliferation and cell migration, and was associated with cytoskeletal rearrangements. These effects were dependent on the PTP activity of DEP-1 as they were not observed with cells expressing the catalytically inactive DEP-1 C1239S variant. shRNA-mediated suppression of DEP-1 in a colon epithelial cell line with high endogenous DEP-1 levels enhanced proliferation, further supporting the antiproliferative function of DEP-1. Nutrients, which are considered to be chemoprotective with respect to colon cancer development, including butyrate, green tea and apple polyphenols, had the capacity to elevate transcription of endogenous DEP-1 mRNA and expression of DEP-1 protein. Upregulation of DEP-1 expression, and in turn inhibition of cell growth and migration may present a previously unrecognized mechanism of chemoprevention by nutrients.	Univ Jena, Fac Med, Inst Mol Cell Biol, D-07747 Jena, Germany; Univ Jena, Fac Med, Inst Biochem 1, D-6900 Jena, Germany; Univ Jena, Inst Nutr, Dept Nutr Toxicol, D-6900 Jena, Germany; Karolinska Inst, Ctr Canc, Stockholm, Sweden	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Karolinska Institutet	Bohmer, FD (corresponding author), Univ Jena, Fac Med, Inst Mol Cell Biol, Drackendorfer Str 1, D-07747 Jena, Germany.	i5frbo@rz.uni-jena.de						Barth SW, 2005, CARCINOGENESIS, V26, P1414, DOI 10.1093/carcin/bgi082; Glei M, 2003, TOXICOL IN VITRO, V17, P723, DOI 10.1016/S0887-2333(03)00099-7; Gosse F, 2005, CARCINOGENESIS, V26, P1291, DOI 10.1093/carcin/bgi074; Iuliano R, 2003, CANCER RES, V63, P882; Jandt E, 2003, ONCOGENE, V22, P4175, DOI 10.1038/sj.onc.1206652; KAUTENBURGER T, 2006, IN PRESS INT J CANC; Keane MM, 1996, CANCER RES, V56, P4236; Kellie S, 2004, J CELL SCI, V117, P609, DOI 10.1242/jcs.00879; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Le Pera I, 2005, ONCOGENE, V24, P3187, DOI 10.1038/sj.onc.1208510; Massa A, 2004, J BIOL CHEM, V279, P29004, DOI 10.1074/jbc.M403573200; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Pool-Zobel B, 2005, MUTAT RES-FUND MOL M, V591, P74, DOI 10.1016/j.mrfmmm.2005.04.020; Pool-Zobel BL, 2005, CARCINOGENESIS, V26, P1064, DOI 10.1093/carcin/bgi059; Richter M, 2002, EUR J CANCER, V38, P1937, DOI 10.1016/S0959-8049(02)00158-2; Ruivenkamp C, 2003, ONCOGENE, V22, P3472, DOI 10.1038/sj.onc.1206246; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Shimizu M, 2005, CLIN CANCER RES, V11, P2735, DOI 10.1158/1078-0432.CCR-04-2014; Takahashi T, 2003, MOL CELL BIOL, V23, P1817, DOI 10.1128/MCB.23.5.1817-1831.2003; Tenev T, 2000, EUR J CELL BIOL, V79, P261, DOI 10.1078/S0171-9335(04)70029-1; Trapasso F, 2004, CARCINOGENESIS, V25, P2107, DOI 10.1093/carcin/bgh224; Trapasso F, 2000, MOL CELL BIOL, V20, P9236, DOI 10.1128/MCB.20.24.9236-9246.2000	24	65	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2006	25	47					6319	6324		10.1038/sj.onc.1209647	http://dx.doi.org/10.1038/sj.onc.1209647			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16682945				2022-12-17	WOS:000241218200008
J	Difeo, A; Narla, G; Camacho-Vanegas, O; Nishio, H; Rose, SL; Buller, RE; Friedman, SL; Walsh, MJ; Martignetti, JA				DiFeo, A.; Narla, G.; Camacho-Vanegas, O.; Nishio, H.; Rose, S. L.; Buller, R. E.; Friedman, S. L.; Walsh, M. J.; Martignetti, J. A.			E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor	ONCOGENE			English	Article						KLF6; KLF6-SV1; E-cadherin; alternative splicing; ovarian cancer	KRUPPEL-LIKE FACTOR-6; CELL LUNG-CANCER; PROSTATE-CANCER; GENE-EXPRESSION; OVARIAN-CANCER; GROWTH; ACTIVATION; PROTEIN; INHIBITION; CARCINOMA	The tumor suppressor KLF6 is a member of the Kruppel-like family of transcription factors, which has been implicated in the pathogenesis of several human carcinomas. Uncovering the transcriptional targets relevant for its tumorigenic properties, including cellular proliferation and invasion, will be essential to understanding possible mechanisms by which KLF6 and its antagonistic splice form, KLF6-SV1, regulate this development. To begin de. ning possible metastatic-related pathways, we analysed the effect of KLF6 dysregulation on a recognized suppressor of cellular invasion, E-cadherin. Targeted KLF6 reduction in an ovarian cancer cell line, SKOV-3, resulted in a 50% reduction of E-cadherin expression (P < 0.01) and conversely, KLF6-SV1 silencing upregulated E-cadherin approximately fivefold (P < 0.0001). These changes resulted from KLF6 directly transactivating the E-cadherin promoter as demonstrated by luciferase promoter assay and chromatin immunoprecipitation (ChIP). KLF6-mediated changes in E-cadherin levels were accompanied by downstream changes in both the subcellular localization of beta-catenin and c-myc expression levels. Moreover, and consistent with these experimental findings, patient-derived epithelial ovarian tumors with low KLF6 and high KLF6-SV1 expression ratios had significantly decreased E-cadherin expression (P < 0.0001). These combined findings highlight the E-cadherin pathway as a novel and functionally important mediator by which changes in KLF6 and KLF6-SV1 can directly alter ovarian tumor invasion and metastasis.	Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Univ Iowa Hosp & Clin, Div Gynecol Oncol, Iowa City, IA 52242 USA; Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Iowa; Icahn School of Medicine at Mount Sinai	Martignetti, JA (corresponding author), Mt Sinai Sch Med, Dept Human Genet, 1425 Madison Ave,Box 1498, New York, NY 10029 USA.	john.martignetti@mssm.edu	Narla, Goutham/AAZ-5710-2020	Narla, Goutham/0000-0003-4098-4203; DiFeo, Analisa/0000-0001-8319-6763				Ananthanarayanan M, 2004, J BIOL CHEM, V279, P54348, DOI 10.1074/jbc.M410021200; Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; Berchuck A, 1997, BIOCHEM PHARMACOL, V54, P541, DOI 10.1016/S0006-2952(97)00061-0; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Chen Han-kui, 2002, Ai Zheng, V21, P1047; Cho YG, 2005, ONCOGENE, V24, P4588, DOI 10.1038/sj.onc.1208670; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; DIFEO A, 2006, IN PRESS CLIN CANC R; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Gabbert HE, 1996, INT J CANCER, V69, P184, DOI 10.1002/(SICI)1097-0215(19960621)69:3<184::AID-IJC6>3.0.CO;2-W; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Jeng YM, 2003, INT J CANCER, V105, P625, DOI 10.1002/ijc.11123; Kaczynski J, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-206; Kettunen E, 2004, CANCER GENET CYTOGEN, V149, P98, DOI 10.1016/s0165-4608(03)00300-5; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Kremer-Tal S, 2004, HEPATOLOGY, V40, P1047, DOI 10.1002/hep.20460; Macleod K, 2005, CANCER RES, V65, P6789, DOI 10.1158/0008-5472.CAN-04-2684; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Narla G, 2005, CANCER RES, V65, P5761, DOI 10.1158/0008-5472.CAN-05-0217; Narla G, 2005, CANCER RES, V65, P1213, DOI 10.1158/0008-5472.CAN-04-4249; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; Rubinstein M, 2004, ENDOCRINOLOGY, V145, P3769, DOI 10.1210/en.2004-0173; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Slavin DA, 2004, ONCOGENE, V23, P8196, DOI 10.1038/sj.onc.1208020; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; TALKREMER S, 2004, HEPATOLOGY, V40, P1047; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M	33	65	68	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2006	25	44					6026	6031		10.1038/sj.onc.1209611	http://dx.doi.org/10.1038/sj.onc.1209611			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16702959				2022-12-17	WOS:000240826300011
J	Fraser, M; Chan, SL; Chan, SSL; Fiscus, RR; Tsang, BK				Fraser, M; Chan, SL; Chan, SSL; Fiscus, RR; Tsang, BK			Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells	ONCOGENE			English	Article						ovarian cancer; apoptosis; soluble guanylyl cyclase; cGMP; p53	X-LINKED INHIBITOR; INSULIN-RECEPTOR SUBSTRATE-1; CISPLATIN-INDUCED APOPTOSIS; ACTIVATED PROTEIN-KINASE; ENDOGENOUS NITRIC-OXIDE; CYCLIC-GMP; DNA-DAMAGE; PC12 CELLS; GUANOSINE-MONOPHOSPHATE; NATRIURETIC PEPTIDES	Dysregulated apoptosis plays a critical role in the development of a number of aberrant cellular processes, including tumorigenesis and chemoresistance. However, the mechanisms that govern the normal apoptotic program are not completely understood. Soluble guanylyl cyclase (sGC) and cyclic guanosine monophosphate ( cGMP) promote mammalian cell viability via an unknown mechanism and p53 status is a key determinant of cell fate in human ovarian cancer cells. Whether an interaction exists between these two determinants of cell fate is unknown. We hypothesized that basal sGC activity reduces p53 content and attenuates p53-dependent apoptosis in human ovarian cancer cells. Suppression of sGC activity with the specific inhibitor 1H-[1,2,4] oxadiazolo[ 4,3-a] quinoxalin-1-one (ODQ) lowered cGMP content, and increased p53 protein content and induced apoptosis in three ovarian cancer cell lines, effects which were attenuated by the cGMP analog 8-Br-cGMP and by Atrial Natriuretic Factor, an activator of particulate guanylyl cyclase, which circumvent the inhibition of sGC. ODQ prolonged p53 half-life, induced phosphorylation of p53 on Ser15, and upregulated the p53- dependent gene products p21, murine double minute-2, and the proapoptotic, p53- responsive gene product Bax. ODQ activated caspase-3, and ODQ-induced apoptosis was inhibited by overexpression of X-linked inhibitor of apoptosis Protein. Pretreatment with the specific p53 inhibitor pifithrin or downregulation of p53 using a specific small inhibitory RNA significantly attenuated ODQ-induced apoptosis. Moreover, ODQ-induced upregulation of p21 and Bax and ODQ-induced apoptosis were significantly reduced in a p53 mutant cell line relative to the wild-type parental cell line. Thus, the current study establishes that basal sGC/cGMP activity regulates p53 protein stability, content, and function, possibly by altering p53 phosphorylation and stabilization, and promotes cell survival in part through regulation of caspase-3 and p53.	Univ Ottawa, Reprod Biol Unit, Ottawa, ON, Canada; Univ Ottawa, Dept Obstet & Gynecol, Div Gynecol Oncol, Ottawa, ON, Canada; Univ Ottawa, Dept Cellular & Mol Biol, Ottawa, ON, Canada; Ottawa Hosp, Hlth Res Inst, Hormones Growth & Dev Program, Ottawa, ON, Canada; Chinese Univ Hong Kong, Fac Med, Dept Physiol, Epithelial Cell Biol Res Ctr, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Ctr Gerontol & Geriatr, Shatin, Hong Kong, Peoples R China	University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; Chinese University of Hong Kong; Chinese University of Hong Kong	Tsang, BK (corresponding author), Ottawa Hlth Res Inst, 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.	btsang@ohri.ca		Tsang, Benjamin K./0000-0003-1213-3946				Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Asselin E, 2001, CANCER RES, V61, P1862; Chan SL, 2003, MOL HUM REPROD, V9, P775, DOI 10.1093/molehr/gag094; Chen HW, 2001, FERTIL STERIL, V75, P1163, DOI 10.1016/S0015-0282(01)01780-0; Ciani E, 2002, J NEUROCHEM, V81, P218, DOI 10.1046/j.1471-4159.2002.00857.x; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Estevez AG, 1998, PROG BRAIN RES, V118, P269; Falcone S, 2002, BIOCHEM J, V366, P165, DOI 10.1042/bj20020017; Fiscus RR, 2002, J CARDIAC SURG, V17, P336; Fiscus RR, 2002, NEUROSIGNALS, V11, P175, DOI 10.1159/000065431; Fiscus RR, 2001, NEUROREPORT, V12, P185, DOI 10.1097/00001756-200102120-00003; Flamigni F, 2001, BIOCHEM PHARMACOL, V62, P319, DOI 10.1016/S0006-2952(01)00646-3; Fraser M, 2003, CANCER RES, V63, P7081; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; Ha KS, 2003, FASEB J, V17, P1036, DOI 10.1096/fj.02-0738com; Havrilesky L, 2003, J CLIN ONCOL, V21, P3814, DOI 10.1200/JCO.2003.11.052; Heinloth A, 2002, ATHEROSCLEROSIS, V162, P93, DOI 10.1016/S0021-9150(01)00687-6; Jadeski LC, 2000, INT J CANCER, V86, P30, DOI 10.1002/(SICI)1097-0215(20000401)86:1<30::AID-IJC5>3.0.CO;2-I; Jadeski LC, 2003, INT J CANCER, V106, P496, DOI 10.1002/ijc.11268; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Kim YM, 1999, J NEUROSCI, V19, P6740, DOI 10.1523/JNEUROSCI.19-16-06740.1999; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Leitao MM, 2004, GYNECOL ONCOL, V93, P301, DOI 10.1016/j.ygyno.2004.01.043; LEVINE EL, 1995, RADIOTHER ONCOL, V37, P1, DOI 10.1016/0167-8140(95)01622-N; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LUESLEY DM, 1987, BRIT J OBSTET GYNAEC, V94, P461, DOI 10.1111/j.1471-0528.1987.tb03126.x; LUESLEY DM, 1986, BRIT J OBSTET GYNAEC, V93, P380; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moro MA, 1996, P NATL ACAD SCI USA, V93, P1480, DOI 10.1073/pnas.93.4.1480; Mulsch A, 1997, BRIT J PHARMACOL, V120, P681, DOI 10.1038/sj.bjp.0700982; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Olesen SP, 1998, BRIT J PHARMACOL, V123, P299, DOI 10.1038/sj.bjp.0701603; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Orucevic A, 1999, INT J CANCER, V81, P889, DOI 10.1002/(SICI)1097-0215(19990611)81:6<889::AID-IJC9>3.0.CO;2-2; Panahian N, 2001, J NEUROCHEM, V76, P539, DOI 10.1046/j.1471-4159.2001.00023.x; Panahian N, 1999, J NEUROCHEM, V72, P1187; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; REAP EA, 1995, J IMMUNOL, V154, P936; Sasaki H, 2000, CANCER RES, V60, P5659; Sasaki H, 2002, GYNECOL ONCOL, V85, P339, DOI 10.1006/gyno.2002.6632; Sheets EE, 1997, ANN MED, V29, P121, DOI 10.3109/07853899709113697; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Suenobu N, 1999, ARTERIOSCL THROM VAS, V19, P140, DOI 10.1161/01.ATV.19.1.140; Tang CH, 2004, J BIOL CHEM, V279, P288, DOI 10.1074/jbc.M310821200; Tejedo JR, 2004, ENDOCRINOLOGY, V145, P2319, DOI 10.1210/en.2003-1489; TURNER GA, 1982, BRIT J OBSTET GYNAEC, V89, P760, DOI 10.1111/j.1471-0528.1982.tb05105.x; TURNER GA, 1982, J CLIN PATHOL, V35, P800, DOI 10.1136/jcp.35.8.800; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; WALDMAN SA, 1987, PHARMACOL REV, V39, P163; Xiao CW, 2003, ENDOCRINOLOGY, V144, P623, DOI 10.1210/en.2001-211024; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	55	65	68	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2203	2212		10.1038/sj.onc.1209251	http://dx.doi.org/10.1038/sj.onc.1209251			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288207				2022-12-17	WOS:000236581200007
J	Ladiges, WC				Ladiges, WC			Mouse models of XRCC1 DNA repair polymorphisms and cancer	ONCOGENE			English	Review						DNA repair; polymorphisms; XRCC1; cancer; mouse models	STRAND BREAK REPAIR; BASE EXCISION-REPAIR; GENETIC POLYMORPHISMS; PROTEIN; RISK; DOMAIN; DAMAGE; REQUIREMENT; PHENOTYPE	DNA damage plays a major role in mutagenesis, carcinogenesis and aging. A gene that is emerging as an essential element in the repair of both damaged bases and single-strand breaks (SSB) is XRCC1. XRCC1 has been shown to have a large number of single-nucleotide polymorphisms ( SNPs), several of which are being increasingly studied in cancer epidemiology investigations, in part because of their relative high frequency in the population. Although association trends with specific cancer types have occasionally been shown in a variety of ethnic backgrounds, there are often conflicting reports that weaken any substantial conclusions. The functional significance of these SNPs is still largely unknown. XRCC1 is an excellent prototype to provide a forum for determining how epidemiological cancer association studies with DNA repair gene polymorphisms can be validated or refuted. The focus is on the utilization of in silico data and biochemical studies in cell lines and existing mouse models to help provide a framework for the development of new mutant mouse lines that mimic human polymorphisms. These mouse lines will provide the next generation of mammalian tools for carcinogen exposure studies relevant to human cancer and variations in XRCC1, and provide the basis for investigating groups of genes and polymorphisms in an animal model.	Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Ladiges, WC (corresponding author), Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA.	wladiges@u.washington.edu			NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033, U01ES011045] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES07033, U01 ES11045] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aka P, 2004, MUTAT RES-FUND MOL M, V556, P169, DOI 10.1016/j.mrfmmm.2004.08.002; Au WW, 2003, ENVIRON HEALTH PERSP, V111, P1843, DOI 10.1289/ehp.6632; Beernink PT, 2005, J BIOL CHEM, V280, P30206, DOI 10.1074/jbc.M502155200; Brem R, 2005, NUCLEIC ACIDS RES, V33, P2512, DOI 10.1093/nar/gki543; Caldecott KW, 2003, DNA REPAIR, V2, P955, DOI 10.1016/S1568-7864(03)00118-6; De Bont R, 2004, MUTAGENESIS, V19, P169, DOI 10.1093/mutage/geh025; Dianova II, 2004, NUCLEIC ACIDS RES, V32, P2550, DOI 10.1093/nar/gkh567; El-Khamisy SF, 2003, NUCLEIC ACIDS RES, V31, P5526, DOI 10.1093/nar/gkg761; Fan JS, 2004, NUCLEIC ACIDS RES, V32, P2193, DOI 10.1093/nar/gkh556; Geisler SA, 2005, HEAD NECK-J SCI SPEC, V27, P232, DOI 10.1002/hed.20141; Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513; Hu ZB, 2005, CANCER EPIDEM BIOMAR, V14, P1810, DOI 10.1158/1055-9965.EPI-04-0793; Hung RJ, 2005, JNCI-J NATL CANCER I, V97, P567, DOI 10.1093/jnci/dji101; Kelada SN, 2003, ENVIRON HEALTH PERSP, V111, P1055, DOI 10.1289/ehp.6065; Kirk GD, 2005, CANCER EPIDEM BIOMAR, V14, P373, DOI 10.1158/1055-9965.EPI-04-0161; Loizou JI, 2004, CELL, V117, P17, DOI 10.1016/S0092-8674(04)00206-5; Marintchev A, 1999, NAT STRUCT BIOL, V6, P884; Marsin S, 2003, J BIOL CHEM, V278, P44068, DOI 10.1074/jbc.M306160200; Moullan N, 2003, CANCER EPIDEM BIOMAR, V12, P1168; Ron E, 1998, RADIAT RES, V150, pS30, DOI 10.2307/3579806; Shen NR, 1998, NUCLEIC ACIDS RES, V26, P1032, DOI 10.1093/nar/26.4.1032; Takanami T, 2005, MUTAT RES-GEN TOX EN, V582, P135, DOI 10.1016/j.mrgentox.2005.01.007; Taylor RM, 2002, MOL CELL BIOL, V22, P2556, DOI 10.1128/MCB.22.8.2556-2563.2002; Tebbs RS, 2003, DNA REPAIR, V2, P1405, DOI 10.1016/j.dnarep.2003.08.007; Tebbs RS, 1999, DEV BIOL, V208, P513, DOI 10.1006/dbio.1999.9232; Thomas M C, 2000, BMC Nephrol, V1, P1, DOI 10.1186/1471-2369-1-1; WALLACE SS, 1994, INT J RADIAT BIOL, V66, P579, DOI 10.1080/09553009414551661; Wang YF, 2003, DNA REPAIR, V2, P901, DOI 10.1016/S1568-7864(03)00085-5; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404	29	65	66	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	11					1612	1619		10.1038/sj.onc.1209370	http://dx.doi.org/10.1038/sj.onc.1209370			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020JL	16550161				2022-12-17	WOS:000235904700003
J	Heller, G; Fong, KM; Girard, L; Seidl, S; End-Pfutzenreuter, A; Lang, G; Gazdar, AF; Minna, JD; Zielinski, CC; Zochbauer-Muller, S				Heller, G; Fong, KM; Girard, L; Seidl, S; End-Pfutzenreuter, A; Lang, G; Gazdar, AF; Minna, JD; Zielinski, CC; Zochbauer-Muller, S			Expression and methylation pattern of TSLC1 cascade genes in lung carcinomas	ONCOGENE			English	Article						tumor suppressor gene; TSLC1; DAL-1; MPP3; methylation; lung cancer	TUMOR-SUPPRESSOR TSLC1; CANCER-CELL-LINES; PROMOTER METHYLATION; BREAST-CANCER; ASSOCIATION; PROFILES; ADHESION; ABSENCE; GROWTH; DAL-1	TSLC1 (tumor suppressor in lung cancer-1, IGSF4) encodes a member of the immunoglobulin superfamily molecules, which is involved in cell-cell adhesion. TSLC1 is connected to the actin cytoskeleton by DAL-1 (differentially expressed in adenocarcinoma of the lung-1, EPB41L3) and it directly associates with MPP3, one of the human homologues of a Drosophila tumor suppressor gene, Discs large. Recent data suggest that aberrant promoter methylation is important for TSLC1 inactivation in lung carcinomas. However, little is known about the other two genes in this cascade, DAL-1 and MPP3. Thus, we investigated the expression and methylation patterns of these genes in lung cancer cell lines, primary lung carcinomas and nonmalignant lung tissue samples. By reverse transcription-polymerase chain reaction, loss of TSLC1 expression was observed in seven of 16 (44%) non-small-cell lung cancer (NSCLC) cell lines and in one of 11 (9%) small-cell lung cancer (SCLC) cell lines, while loss of DAL- 1 expression was seen in 14 of 16 (87%) NSCLC cell lines and in four of 11 (36%) SCLC cell lines. By contrast, MPP3 expression was found in all tumor cell lines analysed. Similar results were obtained by microarray analysis. TSLC1 methylation was seen in 13 of 39 (33%) NSC LC cell lines, in one of 11 (9%) SCLC cell lines and in 100 of 268 (37%) primary NSCLCs. DAL-1 methylation was observed in 17 of 39 (44%) NSCLC cell lines, in three of 11 (27%) SCLC cell lines and in 147 of 268 (55%) primary NSCLCs. In tumors of NSCLC patients with stage II-III disease, DAL-1 methylation was seen at a statistically significant higher frequency compared to tumors of patients with stage I disease. A significant correlation between loss of expression and methylation of the genes in lung cancer cell lines was found. Overall, 65% of primary NSCLCs had either TSLC1 or DAL-1 methylated. Methylation of one of these genes was detected in 59% of NSCLC cell lines; however, in SCLC cell lines, methylation was much less frequently observed. The majority of nonmalignant lung tissue samples was not TSLC1 and DAL-1 methylated. Re-expression of TSLC1 and DAL-1 was seen after treatment of lung cancer cell lines with 5-aza-2$-deoxy-cytidine. Our results suggest that methylation of TSLC1 and/or DAL-1, leading to loss of their expression, is an important event in the pathogenesis of NSCLC.	Univ Hosp Vienna, Div Clin Oncol, Dept Med 1, A-1090 Vienna, Austria; Univ Hosp Vienna, Ctr Excellence Clin & Expt Oncol, A-1090 Vienna, Austria; Prince Charles Hosp, Brisbane, Qld 4032, Australia; Univ Texas, SW Med Ctr, Hamon Ctr Theapeut Oncol Res, Dallas, TX USA; Univ Hosp Vienna, Dept Thorac Surg, Vienna, Austria; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX USA	University Hospital Vienna; University Hospital Vienna; Prince Charles Hospital; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University Hospital Vienna; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Zochbauer-Muller, S (corresponding author), Univ Hosp Vienna, Div Clin Oncol, Dept Med 1, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	sabine.zoechbauer-mueller@meduniwien.ac.at	Zöchbauer-Müller, Sabine/B-8399-2012; heller, gerwin/E-6521-2011; Fong, Kwun M/G-6369-2010; Lang, György/O-5256-2017	Zöchbauer-Müller, Sabine/0000-0002-6777-1729; heller, gerwin/0000-0001-8742-5631; Lang, György/0000-0002-8839-6649; Fong, Kwun/0000-0002-6507-1403	NCI NIH HHS [P50 CA 70907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson JM, 1996, CURR BIOL, V6, P382, DOI 10.1016/S0960-9822(02)00501-8; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Charboneau AL, 2002, INT J CANCER, V100, P181, DOI 10.1002/ijc.10470; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Esteller M, 2001, CANCER RES, V61, P3225; Fukami T, 2003, INT J CANCER, V107, P53, DOI 10.1002/ijc.11348; Fukuhara H, 2003, ONCOGENE, V22, P6160, DOI 10.1038/sj.onc.1206744; Fukuhara H, 2001, ONCOGENE, V20, P5401, DOI 10.1038/sj.onc.1204696; GIRARD L, 2005, UNPUB; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ito T, 2003, CANCER RES, V63, P6320; Kikuchi S, 2005, CLIN CANCER RES, V11, P2954, DOI 10.1158/1078-0432.CCR-04-2206; Kittiniyom K, 2004, GENE CHROMOSOME CANC, V40, P190, DOI 10.1002/gcc.20034; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; LAM CL, 2005, UNPUB; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; MAO X, 2004, ONCOGENE, V7, P7; Masuda M, 2002, J BIOL CHEM, V277, P31014, DOI 10.1074/jbc.M203620200; Murakami Y, 1998, P NATL ACAD SCI USA, V95, P8153, DOI 10.1073/pnas.95.14.8153; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Toyooka S, 2001, MOL CANCER THER, V1, P61; Toyooka S, 2003, INT J CANCER, V103, P153, DOI 10.1002/ijc.10787; Tran Y, 1998, ONCOGENE, V17, P3499, DOI 10.1038/sj.onc.1202258; Tran YK, 1999, CANCER RES, V59, P35; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Virmani AK, 2002, CANCER EPIDEM BIOMAR, V11, P291; Xiong YN, 2005, CANCER RES, V65, P2684, DOI 10.1158/0008-5472.CAN-04-2843; Yageta M, 2002, CANCER RES, V62, P5129; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	33	65	81	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	6					959	968		10.1038/sj.onc.1209115	http://dx.doi.org/10.1038/sj.onc.1209115			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	010RK	16205641				2022-12-17	WOS:000235212700015
J	Sun, Y; Gao, D; Liu, Y; Huang, J; Lessnick, S; Tanaka, S				Sun, Y; Gao, D; Liu, Y; Huang, J; Lessnick, S; Tanaka, S			IGF2 is critical for tumorigenesis by synovial sarcoma oncoprotein SYT-SSX1	ONCOGENE			English	Article						SYT-SSX1; IGF2; apoptosis; synovial sarcoma	FACTOR-II GENE; CTCF-BINDING SITES; GROWTH-FACTORS; HUMAN CANCER; WILMS-TUMOR; SSX GENES; COLORECTAL-CANCER; TARGET GENE; SYT; EXPRESSION	Synovial sarcoma is an aggressive soft tissue tumor characterized by a specific chromosomal translocation between chromosome 18 and X. This translocation can generate a fusion transcript encoding SYT-SSX1, a transforming oncoprotein. We present evidence that SYT-SSX1 induces insulin-like growth factor II expression in fibroblast cells. SYT-SSX2, a fusion also frequently found in synovial sarcoma, is necessary for maintaining Igf2 expression in the synovial sarcoma cell line, and the increased IGF2 synthesis protects cells from anoikis and is required for tumor formation in vivo. We also found a loss of imprinting ( LOI) for Igf2 in a limited number of primary synovial sarcomas despite demethylation of CpG dinucleotides critical for maintaining imprinting. These findings suggest that inhibition of the IGF2/IGF1-R signaling pathway may represent a significant therapeutic modality for treating synovial sarcoma.	Univ Rochester, Sch Med & Dent, Dept Biomed Genet, Rochester, NY 14642 USA; Univ Rochester, Dept Pathol, Sch Med & Dent, Rochester, NY USA; Huntsman Canc Inst, Salt Lake City, UT USA; Hokkaido Univ, Grad Sch Med, Lab Mol & Cellular Pathol, Sapporo, Hokkaido, Japan	University of Rochester; University of Rochester; Huntsman Cancer Institute; Hokkaido University	Sun, Y (corresponding author), Univ Rochester, Sch Med & Dent, Dept Biomed Genet, 601 Elmwood Ave, Rochester, NY 14642 USA.	yin_sun@urmc.rochester.edu	Gao, Dingcheng/P-5889-2019; Tanaka, Shinya/D-3586-2011					Allander SV, 2002, AM J PATHOL, V161, P1587, DOI 10.1016/S0002-9440(10)64437-9; ASSOIAN RK, 1984, NATURE, V309, P804, DOI 10.1038/309804a0; Bartolomei MS, 1997, ANNU REV GENET, V31, P493, DOI 10.1146/annurev.genet.31.1.493; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; Cui HM, 2002, CANCER RES, V62, P6442; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Frevel MAE, 1999, TRENDS GENET, V15, P216, DOI 10.1016/S0168-9525(99)01752-7; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Garcia-Echeverria C, 2004, CANCER CELL, V5, P231, DOI 10.1016/S1535-6108(04)00051-0; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Holmgren C, 2001, CURR BIOL, V11, P1128, DOI 10.1016/S0960-9822(01)00314-1; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kato H, 2002, J BIOL CHEM, V277, P5498, DOI 10.1074/jbc.M108702200; Ladanyi M, 2002, CANCER RES, V62, P135; Ladanyi M, 2001, ONCOGENE, V20, P5755, DOI 10.1038/sj.onc.1204601; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Liu QQ, 1996, CIRC RES, V79, P716, DOI 10.1161/01.RES.79.4.716; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Miyagishi M, 2002, NAT BIOTECHNOL, V20, P497, DOI 10.1038/nbt0502-497; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698; NIELSEN FC, 1994, CANCER, V73, P1312, DOI 10.1002/1097-0142(19940215)73:4<1312::AID-CNCR2820730429>3.0.CO;2-D; O'Dell SD, 1998, INT J BIOCHEM CELL B, V30, P767, DOI 10.1016/S1357-2725(98)00048-X; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; PAL N, 1990, ONCOGENE, V5, P1665; PEDONE PV, 1994, HUM MOL GENET, V3, P1117, DOI 10.1093/hmg/3.7.1117; Qi CF, 2003, P NATL ACAD SCI USA, V100, P633, DOI 10.1073/pnas.0237127100; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; SCHMID C, 1995, CELL BIOL INT, V19, P445, DOI 10.1006/cbir.1995.1088; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; Stadnick MP, 1999, DEV GENES EVOL, V209, P239, DOI 10.1007/s004270050248; Takai D, 2001, HUM MOL GENET, V10, P2619, DOI 10.1093/hmg/10.23.2619; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; Tureci O, 1998, INT J CANCER, V77, P19, DOI 10.1002/(SICI)1097-0215(19980703)77:1<19::AID-IJC4>3.0.CO;2-2; Wong S, 2001, ONCOGENE, V20, P5644, DOI 10.1038/sj.onc.1204638; Xie YT, 1999, CANCER RES, V59, P3588; Xie YT, 2003, ONCOGENE, V22, P7628, DOI 10.1038/sj.onc.1207153; Zhang LJ, 1996, CANCER RES, V56, P1367	53	65	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1042	1052		10.1038/sj.onc.1209143	http://dx.doi.org/10.1038/sj.onc.1209143			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16247461				2022-12-17	WOS:000235361000009
J	Seo, J; Chung, YS; Sharma, GG; Moon, E; Burack, WR; Pandita, TK; Choi, K				Seo, J; Chung, YS; Sharma, GG; Moon, E; Burack, WR; Pandita, TK; Choi, K			Cdt1 transgenic mice develop lymphoblastic lymphoma in the absence of p53	ONCOGENE			English	Article						Cdt1; genomic instability; p53; cancer	DNA-REPLICATION; CELL-CYCLE; CANCER; GEMININ; GENE; EXPRESSION; REREPLICATION; INHIBITION; PROTEIN; MARKER	The exact duplication of chromosomal DNA during each cell cycle ensures the correct inheritance of genetic material from mother to daughter cells. In eukaryotic cells, DNA replication can occur only when the origin of DNA replication is accurately marked by a group of proteins termed licensing proteins. One such protein is Cdt1, which is recruited first to the origin of DNA replication followed by cell division cycle 6 (Cdc6) and mini-chromosome maintenance proteins (Mcms). We previously reported that NIH3T3 cells overexpressing Cdt1 readily formed tumors in mice. To further investigate its oncogenic mechanism, we generated transgenic mice expressing Cdt1 in thymocytes. Our studies demonstrated that T-cell-directed Cdt1 transgenic mice showed normal T-cell development. However, such transgenic mice developed thymic lymphoblastic lymphoma when crossed with p53 null mice. Furthermore, tumor cells derived from NIH3T3 cells overexpressing Cdt1 displayed numerical and structural chromosomal aberrations in the form of ploidy, double minutes, translocation, inversion, chromosome end-to-end fusion and robertsonian mutation. Collectively, our studies suggest that Cdt1 overexpression most likely contributes to tumorigenecity by causing genomic instability.	Washington Univ, Sch Med, Dept Pathol & Immunol, Suwon, South Korea; Ajou Univ, Dept Biol Sci, Suwon 441749, South Korea; Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO 63110 USA	Ajou University; Washington University (WUSTL)	Choi, K (corresponding author), Dept Pathol & Immunol, 660 S Euclid Ave,Campus Box 8118, St Louis, MO 63110 USA.	kchoi@pathology.wustl.edu	Pandita, Tej K/AAM-9188-2020		NCI NIH HHS [CA10445] Funding Source: Medline; NINDS NIH HHS [NS34746] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arentson E, 2002, ONCOGENE, V21, P1150, DOI 10.1038/sj.onc.1205175; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Blow JJ, 2000, NATURE, V404, P560, DOI 10.1038/35007187; Bond L, 2002, ARCH PATHOL LAB MED, V126, P1163; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUJITA M, 1999, FRONT BIOSCI, V4, P816; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HIRAMA T, 1995, BLOOD, V86, P841; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; Hunt CR, 2004, MOL CELL BIOL, V24, P899, DOI 10.1128/MCB.24.2.899-911.2004; KAMB A, 1994, SCIENCE, V264, P440; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; MAINE GT, 1984, GENETICS, V106, P365; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Melixetian M, 2004, J CELL BIOL, V165, P473, DOI 10.1083/jcb.200403106; MOIR D, 1982, GENETICS, V100, P547; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Ohta S, 2001, ONCOL REP, V8, P1063; QUINTANA DG, 1999, FRONT BIOSCI, V4, P805, DOI DOI 10.2741/QUINTANA; Saxena S, 2003, CELL CYCLE, V2, P283, DOI 10.4161/cc.2.4.443; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shreeram S, 2003, Prog Cell Cycle Res, V5, P287; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tan DF, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-6; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Wharton SB, 2004, BRIT J CANCER, V91, P262, DOI 10.1038/sj.bjc.6601949; Whittaker AJ, 2000, GENE DEV, V14, P1765; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; Wohlschlegel JA, 2002, AM J PATHOL, V161, P267, DOI 10.1016/S0002-9440(10)64178-8; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Xouri G, 2004, EUR J BIOCHEM, V271, P3368, DOI 10.1111/j.1432-1033.2004.04271.x; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004	46	65	66	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8176	8186		10.1038/sj.onc.1208881	http://dx.doi.org/10.1038/sj.onc.1208881			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16261166				2022-12-17	WOS:000233809400009
J	Ko, D; Hawkins, L; Yu, DC				Ko, D; Hawkins, L; Yu, DC			Development of transcriptionally regulated oncolytic adenoviruses	ONCOGENE			English	Review						cancer virotherapy; transcriptionally regulated; oncolytic adenovirus	REPLICATION-COMPETENT ADENOVIRUS; VESICULAR STOMATITIS-VIRUS; CANCER-SPECIFIC ADENOVIRUS; POLYMER-COATED ADENOVIRUS; RECURRENT PROSTATE-CANCER; TUMOR-NECROSIS-FACTOR; HERPES-SIMPLEX-VIRUS; SUICIDE GENE-THERAPY; IN-VIVO; TRANSGENE EXPRESSION	Changes initiated at the cellular and systemic levels as a result of viral infection or neoplastic transformation share significant overlap. Therefore, the use of replicating viruses to treat tumors has long been postulated as a promising avenue for oncolytic therapy. Over the last 10 years, transcriptionally regulated adenoviruses have become a popular platform for the development of such oncolytic viruses. Placement of heterologous promoters in front of key adenoviral transcription units to achieve tumor- or tissue-specific viral replication is well documented. Various derivatives of this general strategy have led to considerable insight into its limitations, pitfalls, and potential. Although a general process can be described by which to develop transcriptionally regulated adenoviruses, it is apparent that few set rules can yet be defined as to what constitutes a safe, stable, and therapeutically effective vector. Clinical experiences to date suggest the short-term potential for this class of therapeutics lies in combination therapy regimens. Such lessons from the clinic suggest the next generation of transcriptionally regulated oncolytic adenoviruses take advantage of the ability of the platform to carry transgenes in order to deliver a multimodal therapy from a single agent. Beyond this 'arming' of the vectors lies the detargeting, retargeting, and coating of adenoviruses to improve the delivery of the agent to the treatment site( s). As a therapeutic platform, transcriptionally regulated adenoviruses are at an early stage of development with considerable opportunities for advancement.	Cell Genesys Inc, San Francisco, CA 94080 USA	Cell Genesys Inc	Yu, DC (corresponding author), Cell Genesys Inc, San Francisco, CA 94080 USA.	mich204@yahoo.com						ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; Aghi M, 2005, ONCOGENE, V24, P7802, DOI 10.1038/sj.onc.1209037; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BELL JA, 1956, AM J PUBLIC HEALTH N, V46, P1130, DOI 10.2105/AJPH.46.9.1130; BERGET SM, 1977, P NATL ACAD SCI USA, V74, P3171, DOI 10.1073/pnas.74.8.3171; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BETT AJ, 1993, J VIROL, V67, P5911, DOI 10.1128/JVI.67.10.5911-5921.1993; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Bristol JA, 2003, MOL THER, V7, P755, DOI 10.1016/S1525-0016(03)00103-5; Chen Y, 2001, CANCER RES, V61, P5453; Cripe TP, 2001, CANCER RES, V61, P2953; DEWEESE T, 2003, MOL THER S1, V7; DeWeese TL, 2001, CANCER RES, V61, P7464; Dilley J, 2005, CANCER GENE THER, V12, P715, DOI 10.1038/sj.cgt.7700835; Dmitriev I, 1998, J VIROL, V72, P9706, DOI 10.1128/JVI.72.12.9706-9713.1998; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; Douglas JT, 2001, CANCER RES, V61, P813; Fisher KD, 2001, GENE THER, V8, P341, DOI 10.1038/sj.gt.3301389; Freytag SO, 2002, CANCER RES, V62, P4968; Freytag SO, 2003, CANCER RES, V63, P7497; Giedlin MA, 2003, CANCER CELL, V4, P241, DOI 10.1016/S1535-6108(03)00251-4; GOODING LR, 1991, J VIROL, V65, P4114, DOI 10.1128/JVI.65.8.4114-4123.1991; GOODING LR, 1988, CELL, V53, P341, DOI 10.1016/0092-8674(88)90154-7; Green NK, 2004, GENE THER, V11, P1256, DOI 10.1038/sj.gt.3302295; Han JH, 1998, ONCOGENE, V17, P2993, DOI 10.1038/sj.onc.1202215; Hemminki A, 2001, CANCER RES, V61, P6377; Henderson D.R., 2002, ADENOVIRAL VECTORS G, P287; HENTTU P, 1992, ENDOCRINOLOGY, V130, P766, DOI 10.1210/en.130.2.766; HERMISTON TW, 1993, J VIROL, V67, P5289, DOI 10.1128/JVI.67.9.5289-5298.1993; HITT MM, 1990, VIROLOGY, V179, P667, DOI 10.1016/0042-6822(90)90134-D; HOFFMANN D, 2005, J GENE MED      0609; HUNEYCUTT BS, 1993, J VIROL, V67, P6698, DOI 10.1128/JVI.67.11.6698-6706.1993; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; Ilan Y, 1997, P NATL ACAD SCI USA, V94, P2587, DOI 10.1073/pnas.94.6.2587; Jakubczak JL, 2003, CANCER RES, V63, P1490; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; Johnson L, 2002, CANCER CELL, V1, P325, DOI 10.1016/S1535-6108(02)00060-0; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kirn D, 2000, ONCOGENE, V19, P6660, DOI 10.1038/sj.onc.1204094; KRAJCSI P, 1992, VIROLOGY, V187, P492, DOI 10.1016/0042-6822(92)90451-T; Li YH, 2001, CANCER RES, V61, P6428; Lichtenstein DL, 2004, J VIROL, V78, P12297, DOI 10.1128/JVI.78.22.12297-12307.2004; Lichtenstein DL, 2002, J VIROL, V76, P11329, DOI 10.1128/JVI.76.22.11329-11342.2002; Lipinski KS, 2001, MOL THER, V4, P365, DOI 10.1006/mthe.2001.0468; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MITSUI Y, 1957, AM J OPHTHALMOL, V43, P84, DOI 10.1016/0002-9394(57)91484-8; NEVINS JR, 1981, CELL, V26, P213, DOI 10.1016/0092-8674(81)90304-4; O'Shea C, 2005, EMBO J, V24, P1211, DOI 10.1038/sj.emboj.7600597; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; OBERT S, 1994, MOL CELL BIOL, V14, P1333, DOI 10.1128/MCB.14.2.1333; OSBORNE TF, 1983, J VIROL, V45, P594, DOI 10.1128/JVI.45.2.594-599.1983; Parr MJ, 1997, NAT MED, V3, P1145, DOI 10.1038/nm1097-1145; Polakis P, 2000, GENE DEV, V14, P1837; RAMESH N, 2005, UNPUB CLIN CANC RES; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Reid T, 2002, CANCER GENE THER, V9, P979, DOI 10.1038/sj.cgt.7700539; Rodriguez R, 1997, CANCER RES, V57, P2559; Rubinchik S, 2001, GENE THER, V8, P247, DOI 10.1038/sj.gt.3301364; Ryan PC, 2004, CANCER GENE THER, V11, P555, DOI 10.1038/sj.cgt.7700735; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Shayakhmetov DM, 2005, J VIROL, V79, P1053, DOI 10.1128/JVI.79.2.1053-1061.2005; SHEN Y, 2003, 12 INT C GEN THER CA; SMALL EM, 2002, 5 ANN M AM SCOIET GE; Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000; Tollefson AE, 1996, J VIROL, V70, P2296, DOI 10.1128/JVI.70.4.2296-2306.1996; Toth K, 2004, CANCER RES, V64, P3638, DOI 10.1158/0008-5472.CAN-03-3882; Varghese S, 2002, CANCER GENE THER, V9, P967, DOI 10.1038/sj.cgt.7700537; Wakimoto H, 2003, GENE THER, V10, P983, DOI 10.1038/sj.gt.3302038; WARD TG, 1955, SCIENCE, V122, P1086, DOI 10.1126/science.122.3179.1086; Worgall S, 1997, HUM GENE THER, V8, P37, DOI 10.1089/hum.1997.8.1-37; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YOUNG CYF, 1992, BIOCHEMISTRY-US, V31, P818, DOI 10.1021/bi00118a026; YOUNG CYF, 1991, CANCER RES, V51, P3748; Yu DC, 1999, CANCER RES, V59, P4200; Yu DC, 2001, CANCER RES, V61, P517; Yu DC, 1999, CANCER RES, V59, P1498; Zhu MZ, 2005, J VIROL, V79, P5455, DOI 10.1128/JVI.79.9.5455-5465.2005	82	65	72	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2005	24	52					7763	7774		10.1038/sj.onc.1209048	http://dx.doi.org/10.1038/sj.onc.1209048			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299536				2022-12-17	WOS:000233372600012
J	Hamdi, M; Kool, J; Cornelissen-Steijger, P; Carlotti, F; Popeijus, HE; van der Burgt, C; Janssen, JM; Yasui, A; Hoeben, RC; Terleth, C; Mullenders, LH; van Dam, H				Hamdi, M; Kool, J; Cornelissen-Steijger, P; Carlotti, F; Popeijus, HE; van der Burgt, C; Janssen, JM; Yasui, A; Hoeben, RC; Terleth, C; Mullenders, LH; van Dam, H			DNA damage in transcribed genes induces apoptosis via the JNK pathway and the JNK-phosphatase MKP-1	ONCOGENE			English	Article						AP-1; DNA damage; MKP-1; JNK; transcription-coupled repair	ACTIVATED PROTEIN-KINASE; NUCLEOTIDE EXCISION-REPAIR; SIGNAL-TRANSDUCTION PATHWAY; JUN NH2-TERMINAL KINASE; CANCER-PRONE SYNDROMES; HERPES-SIMPLEX VIRUS; C-JUN; MAP KINASE; COUPLED REPAIR; XERODERMA-PIGMENTOSUM	The nucleotide excision repair (NER) system consists of two subpathways, global genome repair (GGR) and transcription-coupled repair (TCR), which exhibit distinct functions in the cellular response to genotoxic stress. Defects in TCR result in prolonged UV light-induced stalling of RNA polymerase II and hypersensitivity to apoptosis induced by UV and certain chemotherapeutic drugs. Here, we show that low doses of UV trigger delayed activation of the stress-induced MAPkinase JNK and its proapoptotic targets c-Jun and ATF-3 in TCR-deficient primary human fibroblasts from Xeroderma Pigmentosum (XP) and Cockayne syndrome (CS) patients. This delayed activation of the JNK pathway is not observed in GGR-deficient TCR-proficient XP cells, is independent of functional p53, and is established through repression of the JNK-phosphatase MKP-1 rather than by activation of the JNK kinases MKK4 and 7. Enzymatic reversal of UV-induced cyclobutane pyrimidine dimers (CPDs) by CPD photolyase abrogated JNK activation, MKP-1 repression, and apoptosis in TCR-deficient XPA cells. Ectopic expression of MKP-1 inhibited DNA-damage-induced JNK activity and apoptosis. These results identify both MKP-1 and JNK as sensors and downstream effectors of persistent DNA damage in transcribed genes and suggest a link between the JNK pathway and UV-induced stalling of RNApol II.	Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2333 AL Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Toxicogenet, NL-2333 AL Leiden, Netherlands; Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 9808575, Japan	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Tohoku University	van Dam, H (corresponding author), Leiden Univ, Med Ctr, Dept Mol Cell Biol, Wasswnaarseweg 72, NL-2333 AL Leiden, Netherlands.	vdam@lumc.nl	Hoeben, Rob C./A-5771-2008; Carlotti, Françoise/H-1060-2014; Carlotti, Françoise/AAN-5018-2021	Hoeben, Rob C./0000-0001-9443-8377; Carlotti, Françoise/0000-0001-7929-8468; Carlotti, Françoise/0000-0001-7929-8468; van Dam, Hans/0000-0002-8307-4325; Janssen, Josephine Martine/0000-0002-3430-7014				Abrahams PJ, 1998, MUTAT RES-DNA REPAIR, V407, P189, DOI 10.1016/S0921-8777(98)00009-3; ABRAHAMS PJ, 1992, CANCER RES, V52, P53; ABRAHAMS PJ, 1988, CANCER RES, V48, P6054; ALESSI DR, 1993, ONCOGENE, V8, P2015; Bazuine M, 2004, MOL ENDOCRINOL, V18, P1697, DOI 10.1210/me.2003-0213; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; Blattner C, 1998, ONCOGENE, V16, P2827, DOI 10.1038/sj.onc.1201827; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Carlotti F, 2004, MOL THER, V9, P209, DOI 10.1016/j.ymthe.2003.11.021; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; Desbois-Mouthon C, 2000, ENDOCRINOLOGY, V141, P922, DOI 10.1210/en.141.3.922; Engelbrecht Y, 2003, ENDOCRINOLOGY, V144, P412, DOI 10.1210/en.2002-220769; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Franklin CC, 1998, P NATL ACAD SCI USA, V95, P3014, DOI 10.1073/pnas.95.6.3014; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Guo YL, 1998, J BIOL CHEM, V273, P10362, DOI 10.1074/jbc.273.17.10362; Hai T, 1999, GENE EXPRESSION, V7, P321; Hayakawa J, 2004, MOL CELL, V16, P521, DOI 10.1016/j.molcel.2004.10.024; Hayakawa J, 2003, J BIOL CHEM, V278, P20582, DOI 10.1074/jbc.M210992200; Herrlich P, 1999, CR ACAD SCI III-VIE, V322, P121, DOI 10.1016/S0764-4469(99)80033-X; Jaspers NGJ, 2002, DNA REPAIR, V1, P1027, DOI 10.1016/S1568-7864(02)00166-0; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KLEIN B, 1990, EXP CELL RES, V191, P256, DOI 10.1016/0014-4827(90)90012-Y; Kool J, 2003, ONCOGENE, V22, P4235, DOI 10.1038/sj.onc.1206611; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Li CH, 1999, J BIOL CHEM, V274, P25273, DOI 10.1074/jbc.274.36.25273; Li J, 2001, MOL CELL BIOL, V21, P8213, DOI 10.1128/MCB.21.23.8213-8224.2001; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MacLaren A, 2004, MOL CELL BIOL, V24, P9006, DOI 10.1128/MCB.24.20.9006-9018.2004; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mashima T, 2001, J CELL PHYSIOL, V188, P352, DOI 10.1002/jcp.1130; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; McKay BC, 2001, ONCOGENE, V20, P6805, DOI 10.1038/sj.onc.1204901; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Mitchell JR, 2003, CURR OPIN CELL BIOL, V15, P232, DOI 10.1016/S0955-0674(03)00018-8; Mizuno R, 2004, J UROLOGY, V172, P723, DOI 10.1097/01.ju.0000124990.37563.00; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Nakajima S, 2004, J BIOL CHEM, V279, P46674, DOI 10.1074/jbc.M406070200; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Queille S, 2001, J INVEST DERMATOL, V117, P1162, DOI 10.1046/j.0022-202x.2001.01533.x; Rockx DAP, 2000, P NATL ACAD SCI USA, V97, P10503, DOI 10.1073/pnas.180169797; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Spivak G, 2002, DNA REPAIR, V1, P629, DOI 10.1016/S1568-7864(02)00056-3; Svejstrup JQ, 2002, MOL CELL, V9, P1151, DOI 10.1016/S1097-2765(02)00553-1; Todd DE, 2004, ONCOGENE, V23, P3284, DOI 10.1038/sj.onc.1207467; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; van Oosten M, 2000, P NATL ACAD SCI USA, V97, P11268, DOI 10.1073/pnas.200226697; van Steeg H, 1999, MOL MED TODAY, V5, P86, DOI 10.1016/S1357-4310(98)01394-X; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1989, ONCOGENE, V4, P1207; Wada T, 2004, NAT CELL BIOL, V6, P215, DOI 10.1038/ncb1098; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Xu QH, 2004, FREE RADICAL BIO MED, V36, P985, DOI 10.1016/j.freeradbiomed.2004.01.009; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200	75	65	68	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 3	2005	24	48					7135	7144		10.1038/sj.onc.1208875	http://dx.doi.org/10.1038/sj.onc.1208875			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	980BY	16044158				2022-12-17	WOS:000232990100003
J	Wittmann, BM; Fujinaga, K; Deng, HY; Ogba, N; Montano, MM				Wittmann, BM; Fujinaga, K; Deng, HY; Ogba, N; Montano, MM			The breast cell growth inhibitor, estrogen down regulated gene 1, modulates a novel functional interaction between estrogen receptor alpha and transcriptional elongation factor cyclin T1	ONCOGENE			English	Article						estrogen receptor; breast cancer; cyclin T1	POLYMERASE-II TRANSCRIPTION; SMOOTH-MUSCLE-CELLS; P-TEFB; RNA; EXPRESSION; MECHANISMS; PROMOTER; KINASE; HEXIM1; CDK9	Estrogen receptor alpha (ER alpha) regulates transcription of specific genes and is believed to play a major role in breast tumorigenesis. We previously identified estrogen down regulated gene 1 (EDG1 (also known as HEXIM1)) using the C-terminus of ER alpha (E/F domain) as bait in yeast two-hybrid screenings. Here we report on the role of EDG1 as a coregulator of ER alpha transcriptional activity. We observe an interaction between EDG1 and ER alpha. EDG1 inhibits the transcriptional activity of ER alpha and this is dependent upon the C-terminus of EDG1. The C-terminus of EDG1/ HEXIM1 was recently shown to inhibit the positive transcription elongation factor b (P-TEFb) by interacting with the cyclin T1 subunit. Here we show that ER alpha interacts with cyclin T1, cyclin T1 and ER co-occupancy on the promoter region of an ER target gene, and that this interaction plays an important role in ER alpha-induced gene expression. The interaction of ER alpha with cyclin T1 also allows ER alpha to compete with EDG1 for cyclin T1, and may release cyclin T1 from EDG1 repression. Conversely, increased EDG1 expression results in inhibition of cyclin T1 recruitment and ER alpha DNA binding. Our results support a novel functional interaction between ER alpha and cyclin T1 that is modulated by EDG1.	Case Western Reserve Univ, Dept Pharmacol, Sch Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Div Infect Dis, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Montano, MM (corresponding author), Case Western Reserve Univ, Dept Pharmacol, Sch Med, HG Wood Bldg,W307,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mxm126@po.cwru.edu	Ogba, Ndiya/K-8429-2014	Ogba, Ndiya/0000-0003-0453-3763	NATIONAL CANCER INSTITUTE [R01CA092440] Funding Source: NIH RePORTER; NCI NIH HHS [CA92440] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Bianco NR, 2005, BIOCHEM J, V385, P279, DOI 10.1042/BJ20040959; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carlson B, 1999, CANCER RES, V59, P4634; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Flototto T, 2001, HORM METAB RES, V33, P451, DOI 10.1055/s-2001-16936; Fong YW, 2000, MOL CELL BIOL, V20, P5897, DOI 10.1128/MCB.20.16.5897-5907.2000; Fujinaga K, 1999, P NATL ACAD SCI USA, V96, P1285, DOI 10.1073/pnas.96.4.1285; Glass CK, 2000, GENE DEV, V14, P121; HENDERSON BE, 1982, CANCER RES, V42, P3232; Huang FC, 2002, GENE, V292, P245, DOI 10.1016/S0378-1119(02)00596-6; Kanazawa S, 2003, ONCOGENE, V22, P5707, DOI 10.1038/sj.onc.1206800; Kim JB, 2001, J BIOL CHEM, V276, P12317, DOI 10.1074/jbc.M010908200; Kino T, 2002, J BIOL CHEM, V277, P2396, DOI 10.1074/jbc.M106312200; Kusuhara M, 1999, BIOMED RES-TOKYO, V20, P273, DOI 10.2220/biomedres.20.273; Lee DK, 2001, J BIOL CHEM, V276, P9978, DOI 10.1074/jbc.M002285200; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Michels AA, 2003, MOL CELL BIOL, V23, P4859, DOI 10.1128/MCB.23.14.4859-4869.2003; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Nahta R, 2003, CANCER RES, V63, P3626; Napolitano G, 2003, ONCOGENE, V22, P4882, DOI 10.1038/sj.onc.1206785; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Orphanides G, 2002, CELL, V108, P439, DOI 10.1016/S0092-8674(02)00655-4; Ouchida R, 2003, GENES CELLS, V8, P95, DOI 10.1046/j.1365-2443.2003.00618.x; Sano M, 2004, EMBO J, V23, P3559, DOI 10.1038/sj.emboj.7600351; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wittmann BM, 2003, CANCER RES, V63, P5151; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5	33	65	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 25	2005	24	36					5576	5588		10.1038/sj.onc.1208728	http://dx.doi.org/10.1038/sj.onc.1208728			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	15940264				2022-12-17	WOS:000231296100005
J	Azuma, K; Tanaka, M; Uekita, T; Inoue, S; Yokota, J; Ouchi, Y; Sakai, R				Azuma, K; Tanaka, M; Uekita, T; Inoue, S; Yokota, J; Ouchi, Y; Sakai, R			Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcoma	ONCOGENE			English	Article						osteosarcoma; pulmonary metastasis; paxillin; tyrosine phosphorylation; Src family kinase; motility	FOCAL ADHESION KINASE; CELL-MIGRATION; C-SRC; PULMONARY METASTASES; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; CRK; BINDING; PROTEIN; ASSOCIATION	To acquire information on signal alteration corresponding to the changes in metastatic potential, we analysed protein tyrosine phosphorylation of low- and high-metastatic human osteosarcoma HuO9 sublines, which were recently established as the first metastatic model of human osteosarcoma. Tyrosine phosphorylation of proteins around 60, 70, and 120 - 130 kDa was enhanced in high-metastatic sublines. Among these proteins, the protein around 70kDa, which was most remarkably phosphorylated, was identified as paxillin, a scaffold protein in integrin signaling. Activity of Src family kinase correlated well with metastatic potential, and a Src family kinase inhibitor, PP2, not only abolished tyrosine phosphorylation of paxillin but also impaired the motility of high-metastatic sublines. The expression of paxillin was also elevated in high-metastatic sublines, and knocking down of paxillin expression by RNAi method resulted in attenuated motility of high-metastatic cells. We also demonstrated that the phosphorylated form of paxillin is essential for the migration-promoting effect in human osteosarcoma. These findings suggest that enhanced activity of Src family kinases and overexpression of paxillin synergistically contribute to the high metastatic potential of human osteosarcoma through the hyperphosphorylation of paxillin.	Natl Canc Ctr, Inst Res, Div Growth Factor, Chuo Ku, Tokyo 1040045, Japan; Univ Tokyo, Grad Sch Med, Dept Geriatr Med, Bunkyo Ku, Tokyo 1138655, Japan; Natl Canc Ctr, Inst Res, Div Biol, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan; University of Tokyo; National Cancer Center - Japan	Sakai, R (corresponding author), Natl Canc Ctr, Inst Res, Div Growth Factor, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	rsakai@gan2.res.ncc.go.jp		Sakai, Ryuichi/0000-0001-6833-1103				Batanian JR, 2002, J CLIN PATHOL-MOL PA, V55, P389, DOI 10.1136/mp.55.6.389; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Huang JH, 2003, J BIOL CHEM, V278, P48367, DOI 10.1074/jbc.M308213200; HUTH JF, 1989, ARCH SURG-CHICAGO, V124, P122; Iwaya K, 2003, CLIN EXP METASTAS, V20, P525, DOI 10.1023/A:1025821229013; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Khanna C, 2001, CANCER RES, V61, P3750; Kimura K, 2002, CLIN EXP METASTAS, V19, P477, DOI 10.1023/A:1020395816633; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Lau CC, 2004, GENE CHROMOSOME CANC, V39, P11, DOI 10.1002/gcc.10291; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Marchetti D, 1998, ONCOGENE, V16, P3253, DOI 10.1038/sj.onc.1201877; MEYERS PA, 1993, J CLIN ONCOL, V11, P449, DOI 10.1200/JCO.1993.11.3.449; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Nakano T, 2003, CLIN EXP METASTAS, V20, P665, DOI 10.1023/A:1027355610603; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Squire JA, 2003, GENE CHROMOSOME CANC, V38, P215, DOI 10.1002/gcc.10273; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117; Tsuchiya H, 2002, J CLIN ONCOL, V20, P3470, DOI 10.1200/JCO.2002.11.028; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; WARD WG, 1994, J CLIN ONCOL, V12, P1849, DOI 10.1200/JCO.1994.12.9.1849; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366	32	65	68	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2005	24	30					4754	4764		10.1038/sj.onc.1208654	http://dx.doi.org/10.1038/sj.onc.1208654			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	945CC	15870699				2022-12-17	WOS:000230477900002
J	Yoon, HS; Ghaleb, AM; Nandan, MO; Hisamuddin, IM; Dalton, WB; Yang, VW				Yoon, HS; Ghaleb, AM; Nandan, MO; Hisamuddin, IM; Dalton, WB; Yang, VW			Kruppel-like factor 4 prevents centrosome amplification following gamma-irradiation-induced DNA damage	ONCOGENE			English	Article						cell cycle; GKLF; p53; cyclin E; Cdk2; small hairpin RNA (shRNA)	CYCLIN-E OVEREXPRESSION; HUMAN BREAST-TUMORS; CHROMOSOME INSTABILITY; GENOMIC INSTABILITY; CANCER-CELLS; COLORECTAL-CANCER; P53 MUTATION; E GENE; ABNORMALITIES; ARREST	Centrosome duplication is a carefully controlled process in the cell cycle. Previous studies indicate that the tumor suppressor, p53, regulates centrosome duplication. Here, we present evidence for the involvement of the mammalian Kruppel-like transcription factor, KLF4, in preventing centrosome amplification following DNA damage caused by gamma-irradiation. The colon cancer cell line HCT116, which contains wild-type p53 alleles ( HCT116 p53 +/+), displayed stable centrosome numbers following gamma-irradiation. In contrast, HCT116 cells null for the p53 alleles (HCT116 p53-/-) exhibited centrosome amplification after irradiation. In the latter cell line, KLF4 was not activated following gamma-irradiation due to the absence of p53. However, centrosome amplification could be suppressed in irradiated HCT116 p53 -/- cells by conditional induction of exogenous KLF4. Conversely, in a HCT116 p53+/+ cell line stably transfected with small hairpin RNA (shRNA) designed to specifically inhibit KLF4, gamma-irradiation induced centrosome amplification. In these cells, the inability of KLF4 to become activated in response to DNA damage was directly associated with an increase in cyclin E level and Cdk2 activity, both essential for regulating centrosome duplication. Cotransfection experiments showed that KLF4 overexpression suppressed the promoter activity of the cyclin E gene. The results of this study demonstrated that KLF4 is both necessary and sufficient in preventing centrosome amplification following gamma-radiation-induced DNA damage and does so by transcriptionally suppressing cyclin E expression.	Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Oncol, Atlanta, GA 30322 USA	Emory University; Emory University	Yang, VW (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 201 Whitehead Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	vyang@emory.edu	; Dalton, William/M-7944-2017	Mandayam, Nandan/0000-0002-4061-9348; Dalton, William/0000-0002-1314-0534	NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052230, R24DK064399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169] Funding Source: NIH RePORTER; NCI NIH HHS [CA84197, R01 CA084197] Funding Source: Medline; NIDDK NIH HHS [R24 DK064399, DK64399, DK52230, R01 DK052230] Funding Source: Medline; NIGMS NIH HHS [T32 GM008169] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Romaih K, 2003, CANCER GENET CYTOGEN, V144, P91, DOI 10.1016/S0165-4608(02)00929-9; Bennett RA, 2004, ONCOGENE, V23, P6823, DOI 10.1038/sj.onc.1207561; Botz J, 1996, MOL CELL BIOL, V16, P3401; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bunz F, 2002, CANCER RES, V62, P1129; CARDER P, 1993, ONCOGENE, V8, P1397; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; Donehower LA, 1996, PROG CLIN BIOL RES, V395, P1; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Ekholm SV, 2001, MOL CELL BIOL, V21, P3256, DOI 10.1128/MCB.21.9.3256-3265.2001; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Geng Y, 1996, ONCOGENE, V12, P1173; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; HARVEY M, 1993, ONCOGENE, V8, P2457; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hinchcliffe EH, 2002, ONCOGENE, V21, P6154, DOI 10.1038/sj.onc.1205826; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; KELLOGG DR, 1989, NATURE, V340, P99, DOI 10.1038/340099a0; KIRSCHNER MW, 1986, NATURE, V324, P621, DOI 10.1038/324621a0; Kuo KK, 2000, HEPATOLOGY, V31, P59, DOI 10.1002/hep.510310112; LEE JM, 1994, ONCOGENE, V9, P3731; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Mayer F, 2003, ONCOGENE, V22, P3859, DOI 10.1038/sj.onc.1206469; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ouyang XS, 2001, BBA-MOL CELL RES, V1541, P212, DOI 10.1016/S0167-4889(01)00157-4; Pihan GA, 2001, CANCER RES, V61, P2212; Pihan GA, 2003, CANCER RES, V63, P1398; Pihan GA, 1998, CANCER RES, V58, P3974; Sato N, 1999, CLIN CANCER RES, V5, P963; Sato N, 2001, CANCER GENET CYTOGEN, V126, P13, DOI 10.1016/S0165-4608(00)00384-8; Schatten H, 2000, BIOL CELL, V92, P331, DOI 10.1016/S0248-4900(00)01079-0; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Sluder G, 1997, J CELL SCI, V110, P421; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2002, CELL CYCLE, V1, P75, DOI 10.4161/cc.1.1.103; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; Yoon HS, 2004, J BIOL CHEM, V279, P5035, DOI 10.1074/jbc.M307631200; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	58	65	66	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4017	4025		10.1038/sj.onc.1208576	http://dx.doi.org/10.1038/sj.onc.1208576			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15806166	Green Accepted			2022-12-17	WOS:000229680300002
J	Minami, M; Daimon, Y; Mori, K; Takashima, H; Nakajima, T; Itoh, Y; Okanoue, T				Minami, M; Daimon, Y; Mori, K; Takashima, H; Nakajima, T; Itoh, Y; Okanoue, T			Hepatitis B virus-related insertional mutagenesis in chronic hepatitis B patients as an early drastic genetic change leading to hepatocarcinogenesis	ONCOGENE			English	Article						viral integration; Alu repeat; viral carcinogenesis; DNA tumor virus; liver cancer	COMMON FRAGILE SITES; HEPATOCELLULAR-CARCINOMA; HEPADNAVIRUS INSERTION; DELTA-CATENIN; C-MYC; INTEGRATION; ACTIVATION; CANCER; DNA; IDENTIFICATION	Growing evidence demonstrates that hepatitis B virus (HBV) integration and resulting insertional mutagenesis play an important role in cell growth or maintenance in hepatocellular carcinomas (HCCs). To determine if HBV integration occurs and affects cellular genes at such a stage of infection, we analysed viral-host junctions in chronic hepatitis tissues without HCC using PCR amplification with primers specific to human Alu-repeat and HBV. We obtained 42 independent viral-host junctions from six patients examined and identified chromosomal locations for 20 of the 42 junctions. In six clones, each integration apparently affected a single gene. These six candidate genes included one known tumor suppressor gene, three human homologs of drosophila genes that are critical for organ development, one putative oncogene and one recently found chemokine. Our data, together with previously reported HBV integrants in HCCs, suggested preferential HBV integration into chromosome 3 (P = 0.022). Our virus-tagging approach provided (a) firm evidence of HBV integration in hepatocytes at an early stage of chronic infection and (b) revealed cellular genes possibly affected by HBV integration and potentially involved in early steps of the process leading to carcinogenesis.	Kyoto Prefectural Univ Med, Grad Sch Med Sci, Kamigyo Ku, Kyoto 6028566, Japan	Kyoto Prefectural University of Medicine	Minami, M (corresponding author), Kyoto Prefectural Univ Med, Grad Sch Med Sci, Kamigyo Ku, Kyoto 6028566, Japan.	minami@koto.kpu-m.ac.jp						Bagutti C, 2003, J CELL SCI, V116, P2957, DOI 10.1242/jcs.00603; BEASLEY RP, 1981, LANCET, V2, P1129; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; Burger MJ, 2002, INT J CANCER, V100, P228, DOI 10.1002/ijc.10468; Daub H, 2002, J VIROL, V76, P8124, DOI 10.1128/JVI.76.16.8124-8137.2002; Ferber MJ, 2003, ONCOGENE, V22, P7233, DOI 10.1038/sj.onc.1207006; Ferber MJ, 2003, ONCOGENE, V22, P3813, DOI 10.1038/sj.onc.1206528; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; Gozuacik D, 2001, ONCOGENE, V20, P6233, DOI 10.1038/sj.onc.1204835; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Horikawa I, 2001, J NATL CANCER I, V93, P1171, DOI 10.1093/jnci/93.15.1171; HSU TY, 1988, CELL, V55, P627, DOI 10.1016/0092-8674(88)90221-8; Lettice LA, 2002, P NATL ACAD SCI USA, V99, P7548, DOI 10.1073/pnas.112212199; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; Luo LY, 2001, BIOCHEM BIOPH RES CO, V280, P401, DOI 10.1006/bbrc.2000.4126; Maleszka R, 1998, P NATL ACAD SCI USA, V95, P3731, DOI 10.1073/pnas.95.7.3731; MINAMI M, 1995, GENOMICS, V29, P403, DOI 10.1006/geno.1995.9004; Murakami Y, 2004, J MED VIROL, V72, P203, DOI 10.1002/jmv.10547; NEVINS JR, 1996, FIELDS VIROLOGY, P301; Nobrega MA, 2003, SCIENCE, V302, P413, DOI 10.1126/science.1088328; Paffenholz R, 1997, DIFFERENTIATION, V61, P293, DOI 10.1046/j.1432-0436.1997.6150293.x; Paterlini-Brechot P, 2003, ONCOGENE, V22, P3911, DOI 10.1038/sj.onc.1206492; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shen HF, 2003, J VIROL, V77, P1584, DOI 10.1128/JVI.77.2.1584-1588.2003; Smith DI, 1998, INT J ONCOL, V12, P187; TAKADA S, 1990, J VIROL, V64, P822, DOI 10.1128/JVI.64.2.822-828.1990; Tang YT, 2004, GENOMICS, V83, P727, DOI 10.1016/j.ygeno.2003.10.006; Thorland EC, 2003, ONCOGENE, V22, P1225, DOI 10.1038/sj.onc.1206170; TOKINO T, 1991, J VIROL, V65, P6761, DOI 10.1128/JVI.65.12.6761-6764.1991; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wang Y, 2004, ONCOGENE, V23, P142, DOI 10.1038/sj.onc.1206889; YAGINUMA K, 1987, J VIROL, V61, P1808, DOI 10.1128/JVI.61.6.1808-1813.1987; Yu MW, 2000, J NATL CANCER I, V92, P1159, DOI 10.1093/jnci/92.14.1159; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	36	65	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2005	24	27					4340	4348		10.1038/sj.onc.1208628	http://dx.doi.org/10.1038/sj.onc.1208628			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806150				2022-12-17	WOS:000229976900003
J	Woerner, SM; Kloor, M; Mueller, A; Rueschoff, J; Friedrichs, N; Buettner, R; Buzello, M; Kienle, P; Knaebel, HP; Kunstmann, E; Pagenstecher, C; Schackert, HK; Moslein, G; Vogelsang, H; Doeberitz, MV; Gebert, JF				Woerner, SM; Kloor, M; Mueller, A; Rueschoff, J; Friedrichs, N; Buettner, R; Buzello, M; Kienle, P; Knaebel, HP; Kunstmann, E; Pagenstecher, C; Schackert, HK; Moslein, G; Vogelsang, H; Doeberitz, MV; Gebert, JF		German HNPCC Consort	Microsatellite instability of selective target genes in HNPCC-associated colon adenomas	ONCOGENE			English	Article						colon adenoma; DNA mismatch repair; coding microsatellites; microsatellite instability; Selective Target genes	NONPOLYPOSIS COLORECTAL-CANCER; II RECEPTOR GENE; REPAIR-DEFICIENT CANCERS; FACTOR-BETA RECEPTOR; FRAMESHIFT MUTATIONS; GENOMIC INSTABILITY; REPEATED SEQUENCES; MUTATOR PHENOTYPE; PROXIMAL COLON; CARCINOMAS	Microsatellite instability (MSI) occurs in most hereditary nonpolyposis colorectal cancers (HNPCC) and less frequently in sporadic tumors as the result of DNA mismatch repair (MMR) deficiency. Instability at coding microsatellites (cMS) in specific target genes causes frameshift mutations and functional inactivation of affected proteins, thereby providing a selective growth advantage to MMR deficient cells. At present, little is known about Selective Target Gene frameshift mutations in preneoplastic lesions. In this study, we examined 30 HNPCC-associated MSI-H colorectal adenomas of different grades of dysplasia for frameshift mutations in 26 cMS-bearing genes, which, according to our previous model, represent Selective Target genes of MSI. About 30% (8/26) of these genes showed a high mutation frequency (>= 50%) in colorectal adenomas, similar to the frequencies reported for colorectal carcinomas. Mutations in one gene (PTHL3) occurred significantly less frequently in MSI adenomas compared to published mutation rates in MSI carcinomas (36.0 vs 85.7%, P = 0.023). Biallelic inactivation was observed in nine genes, thus emphasizing the functional impact of cMS instability on MSI tumorigenesis. Some genes showed a high frequency of frameshift mutations already at early stages of MSI colorectal tumorigenesis that increased with grade of dysplasia and transition to carcinoma. These include known Target Genes like BAX and TGFBR2, as well as three novel candidates, MACS, NDUFC2, and TAF1B. Overall, we have identified genes of potential relevance for the initiation and progression of MSI tumorigenesis, thus representing promising candidates for novel diagnostic and therapeutic approaches directed towards MMR deficient tumors.	Univ Heidelberg, Inst Mol Pathol, D-69120 Heidelberg, Germany; Univ Gottingen, Dept Gen Surg, D-3400 Gottingen, Germany; Klinikum Kassel, Dept Pathol, Kassel, Germany; Univ Hosp Bonn, Inst Pathol, Bonn, Germany; Univ Heidelberg, Inst Pathol, Heidelberg, Germany; Univ Heidelberg, Dept Surg, D-6900 Heidelberg, Germany; Ruhr Univ Bochum, Knappschaftskrankenhaus, Dept Internal Med, D-4630 Bochum, Germany; Ruhr Univ Bochum, D-4630 Bochum, Germany; Univ Hosp Bonn, Inst Human Genet, Bonn, Germany; Dresden Univ Technol, Dept Surg Res, D-8027 Dresden, Germany; Univ Dusseldorf, Dept Surg, D-4000 Dusseldorf, Germany; Univ Technol, Dept Surg, Munich, Germany	Ruprecht Karls University Heidelberg; University of Gottingen; Klinikum Kassel; University of Bonn; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruhr University Bochum; Ruhr University Bochum; University of Bonn; Technische Universitat Dresden; Heinrich Heine University Dusseldorf; Technical University of Munich	Gebert, JF (corresponding author), Univ Heidelberg, Inst Mol Pathol, Neuenheimer Feld 220-221, D-69120 Heidelberg, Germany.	johannes.gebert@med.uni-heidelberg.de	Vogelsang, Holger/AAB-1244-2020; Woerner, Stefan/A-2187-2010; von Knebel Doeberitz, Magnus/D-2372-2016	von Knebel Doeberitz, Magnus/0000-0002-0498-6781				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Akiyama Y, 1997, GASTROENTEROLOGY, V112, P33, DOI 10.1016/S0016-5085(97)70216-6; Alazzouzi H, 2005, HUM MOL GENET, V14, P235, DOI 10.1093/hmg/ddi021; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Boland CR, 1998, CANCER RES, V58, P5248; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; Duval A, 2002, ANN GENET-PARIS, V45, P71, DOI 10.1016/S0003-3995(02)01115-2; Duval A, 1999, CANCER RES, V59, P4213; Duval A, 2001, HUM MOL GENET, V10, P513, DOI 10.1093/hmg/10.5.513; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Furlan D, 2002, J PATHOL, V197, P603, DOI 10.1002/path.1162; Goel A, 2003, CANCER RES, V63, P1608; Grady WM, 1998, CANCER RES, V58, P3101; HOLM S, 1979, SCAND J STAT, V6, P65; Iino H, 2000, GUT, V47, P37, DOI 10.1136/gut.47.1.37; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kim NG, 2002, ONCOGENE, V21, P5081, DOI 10.1038/sj.onc.1205703; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Li LS, 2003, AM J PATHOL, V163, P1429, DOI 10.1016/S0002-9440(10)63500-6; Li YH, 2001, J BIOL CHEM, V276, P40982, DOI 10.1074/jbc.M105614200; Loeffen JLCM, 1998, BIOCHEM BIOPH RES CO, V253, P415, DOI 10.1006/bbrc.1998.9786; Lothe RA, 1997, MOL MED TODAY, V3, P61, DOI 10.1016/S1357-4310(96)10055-1; Loukola A, 1999, AM J PATHOL, V155, P1849, DOI 10.1016/S0002-9440(10)65503-4; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Miyakura Y, 2001, GASTROENTEROLOGY, V121, P1300, DOI 10.1053/gast.2001.29616; Mori Y, 2001, CANCER RES, V61, P6046; MYEROFF LL, 1995, CANCER RES, V55, P5545; PARSONS R, 1995, CANCER RES, V55, P5548; Percesepe A, 2000, GENE CHROMOSOME CANC, V27, P424, DOI 10.1002/(SICI)1098-2264(200004)27:4<424::AID-GCC13>3.0.CO;2-M; *R DEV COR TEAM, 2004, LANG ENV STAT COMP; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Samowitz WS, 1999, AM J PATHOL, V154, P1637, DOI 10.1016/S0002-9440(10)65418-1; Samowitz WS, 1997, GASTROENTEROLOGY, V112, P1515, DOI 10.1016/S0016-5085(97)70032-5; Schwartz S, 1999, CANCER RES, V59, P2995; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Sugai T, 2003, J PATHOL, V200, P168, DOI 10.1002/path.1340; Sutter C, 1999, MOL CELL PROBE, V13, P157, DOI 10.1006/mcpr.1999.0231; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421; Woerner SM, 2001, INT J CANCER, V93, P12, DOI 10.1002/ijc.1299; Yagi OK, 1998, GASTROENTEROLOGY, V114, P268, DOI 10.1016/S0016-5085(98)70477-9	48	65	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2525	2535		10.1038/sj.onc.1208456	http://dx.doi.org/10.1038/sj.onc.1208456			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735733				2022-12-17	WOS:000228180600010
J	Sithanandam, G; Fornwald, LW; Fields, J; Anderson, LM				Sithanandam, G; Fornwald, LW; Fields, J; Anderson, LM			Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549	ONCOGENE			English	Article						lung adenocarcinoma; ErbB3; siRNA; Akt; apoptosis; invasion	BREAST-CANCER CELLS; NF-KAPPA-B; C-ERBB-3 PROTEIN EXPRESSION; FACTOR RECEPTOR; KINASE-B; ENHANCES MOTILITY; AKT ACTIVATION; IN-VITRO; HEREGULIN; OVEREXPRESSION	The ErbB3 receptor and the downstream signaling kinase Akt are implicated in proliferation of lung adenocarcinoma cells. Inhibition by siRNAs to ErbB3 and Akt isoforms 1, 2 and 3 was utilized to investigate the contribution of these molecules to tumor survival, spreading and invasiveness, and the roles of specific Akt isoforms. ErbB3 siRNA stably and dose-dependently suppressed ErbB3 protein for 2 days or more, and reduced cell numbers, by both suppressing cell cycle and causing apoptosis and necrosis. It also inhibited soft agar growth, cell motility and migration, and invasiveness. Akt1, 2 and 3 siRNAs had similar suppressive effects on cell number, apoptosis/ necrosis and soft agar growth. However, although Akt1 siRNA had no effect on cell migration or invasion, Akt2 siRNA effectively suppressed both activities, and Akt3 siRNA had moderate effectiveness. In A549 cells, ErbB3 is indicated as having major effects on cell division, survival, motility, migration and invasiveness. All three Akt isoforms are to varying degrees involved in these cell behaviors, with Akt2 especially implicated in migration and invasion. ErbB3 and the Akts are promising targets for therapy, and siRNAs may be useful for this purpose.	NCI, SAIC Frederick, Basic Res Program, Frederick, MD 21702 USA; NCI, Comparat Carcinogenesis Lab, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sithanandam, G (corresponding author), NCI, SAIC Frederick, Basic Res Program, Frederick, MD 21702 USA.	sithanan@mail.ncifcrf.gov			NCI NIH HHS [N01-CO-12400] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arboleda MJ, 2003, CANCER RES, V63, P196; Balsara BR, 2004, CARCINOGENESIS, V25, P2053, DOI 10.1093/carcin/bgh226; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Bellacosa A, 2004, CANCER BIOL THER, V3, P268, DOI 10.4161/cbt.3.3.703; Britsch S, 1998, GENE DEV, V12, P1825, DOI 10.1101/gad.12.12.1825; Brognard J, 2001, CANCER RES, V61, P3986; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Cho HJ, 2003, AM J PHYSIOL-GASTR L, V284, pG996, DOI 10.1152/ajpgi.00347.2002; Chun KH, 2003, JNCI-J NATL CANCER I, V95, P291, DOI 10.1093/jnci/95.4.291; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Conus NM, 2002, J BIOL CHEM, V277, P38021, DOI 10.1074/jbc.M203387200; David O, 2004, CHEST, V125, p152S, DOI 10.1378/chest.125.5_suppl.152S; Gilmour LMR, 2002, CLIN CANCER RES, V8, P3933; Gollamudi M, 2004, LUNG CANCER, V43, P135, DOI 10.1016/j.lungcan.2003.08.027; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Hauck CR, 2001, CANCER RES, V61, P7079; Hijazi MM, 2000, INT J ONCOL, V17, P629; Hilbe W, 2003, J CLIN PATHOL, V56, P736, DOI 10.1136/jcp.56.10.736; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Hutchinson JN, 2004, CANCER RES, V64, P3171, DOI 10.1158/0008-5472.CAN-03-3465; Jackson JG, 2004, CANCER RES, V64, P2601, DOI 10.1158/0008-5472.CAN-03-3106; Krystal GW, 2002, MOL CANCER THER, V1, P913; Lai WW, 2001, ANN THORAC SURG, V72, P1868, DOI 10.1016/S0003-4975(01)03207-6; Lee KY, 2002, EXP MOL MED, V34, P462, DOI 10.1038/emm.2002.64; Liu XS, 2001, NEOPLASIA, V3, P278, DOI 10.1038/sj.neo.7900163; Luo J, 2000, BREAST CANCER RES TR, V63, P61, DOI 10.1023/A:1006436315284; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mukohara T, 2004, ANTICANCER RES, V24, P11; Munster PN, 2002, CANCER RES, V62, P3132; Natale RB, 2004, INT J RADIAT ONCOL, V59, P39, DOI 10.1016/j.ijrobp.2004.02.037; Noguchi H, 1999, GASTROENTEROLOGY, V117, P1119, DOI 10.1016/S0016-5085(99)70397-5; Okudela K, 2004, AM J PATHOL, V164, P91, DOI 10.1016/S0002-9440(10)63100-8; Ono M, 2004, MOL CANCER THER, V3, P465; Ozes ON, 1999, NATURE, V401, P82; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Patel NV, 2000, AM J RESP CELL MOL, V22, P432, DOI 10.1165/ajrcmb.22.4.3854; POLLER DN, 1992, J PATHOL, V168, P275, DOI 10.1002/path.1711680306; Raben D, 2004, INT J RADIAT ONCOL, V59, P27, DOI 10.1016/j.ijrobp.2004.01.054; Ritch PA, 2003, J BIOL CHEM, V278, P20971, DOI 10.1074/jbc.M213074200; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Roy HK, 2002, CARCINOGENESIS, V23, P201, DOI 10.1093/carcin/23.1.201; Sandirasegarane L, 2001, BIOCHEM BIOPH RES CO, V283, P158, DOI 10.1006/bbrc.2001.4739; Shishodia S, 2004, BIOCHEM PHARMACOL, V68, P1071, DOI 10.1016/j.bcp.2004.04.026; Sithanandam G, 2003, CARCINOGENESIS, V24, P1581, DOI 10.1093/carcin/bgg125; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Sundaresan S, 1998, ENDOCRINOLOGY, V139, P4756, DOI 10.1210/en.139.12.4756; TATEISHI M, 1991, EUR J CANCER, V27, P1372, DOI 10.1016/0277-5379(91)90012-3; Taylor JM, 2004, EXP CELL RES, V300, P463, DOI 10.1016/j.yexcr.2004.07.018; Tsao AS, 2003, CANCER EPIDEM BIOMAR, V12, P660; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; VAN AD, 1996, SCIENCE, V274, P787; VEALE D, 1987, BRIT J CANCER, V55, P513, DOI 10.1038/bjc.1987.104; Venkateswarlu S, 2002, ONCOGENE, V21, P78, DOI 10.1038/sj.onc.1205011; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Vijapurkar U, 2003, EXP CELL RES, V284, P291, DOI 10.1016/S0014-4827(02)00040-X; Way TD, 2004, J BIOL CHEM, V279, P4479, DOI 10.1074/jbc.M305529200; West KA, 2004, CANCER RES, V64, P446, DOI 10.1158/0008-5472.CAN-03-3241; Xu FJ, 1997, CLIN CANCER RES, V3, P1629; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yi ES, 1997, MODERN PATHOL, V10, P142; Zhou H, 2002, ONCOGENE, V21, P8732, DOI 10.1038/sj.onc.1205984; Zinda MJ, 2001, CLIN CANCER RES, V7, P2475	62	65	78	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1847	1859		10.1038/sj.onc.1208381	http://dx.doi.org/10.1038/sj.onc.1208381			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688028				2022-12-17	WOS:000227542000004
J	Demuth, I; Digweed, M; Concannon, P				Demuth, I; Digweed, M; Concannon, P			Human SNM1B is required for normal cellular response to both DNA interstrand crosslink-inducing agents and ionizing radiation	ONCOGENE			English	Article						hSNM1B; DNA doublestrand break; Fanconi anemia; DNA interstrand crosslinks; PSO2; DCLRE1B	FANCONI-ANEMIA GENE; SACCHAROMYCES-CEREVISIAE; POSITIONAL CLONING; GENOME INSTABILITY; MAMMALIAN-CELLS; REPAIR GENE; MITOMYCIN-C; PSO GENES; PATHWAY; PROTEIN	DNA interstrand crosslinks (ICLs) are critical lesions for the mammalian cell since they affect both DNA strands and block transcription and replication. The repair of ICLs in the mammalian cell involves components of different repair pathways such as nucleotide-excision repair and the double-strand break/homologous recombination repair pathways. However, the mechanistic details of mammalian ICL repair have not been fully delineated. We describe here the complete coding sequence and the genomic organization of hSNM1B, one of at least three human homologs of the Saccharomyces cerevisiae PSO2 gene. Depletion of hSNM1B by RNA interference rendered cells hypersensitive to ICL-inducing agents. This requirement for hSNM1B in the cellular response to ICL has been hypothesized before but never experimentally verified. In addition, siRNA knockdown of hSNM1B rendered cells sensitive to ionizing radiation, suggesting the possibility of hSNM1B involvement in homologous recombination repair of double-strand breaks arising as intermediates of ICL repair. Monoubiquitination of FANCD2, a key step in the FANG/BRCA pathway, is not affected in hSNM1B-depleted HeLa cells, indicating that hSNM1B is probably not a part of the Fanconi anemia core complex. Nonetheless, similarities in the phenotype of hSNM1B-depleted cells and cultured cells from patients suffering from Fanconi anemia make hSNM1B a candidate for one of the as yet unidentified Fanconi anemia genes not involved in monoubiquitination of FANCD2.	Benaroya Res Inst, Mol Genet Program, Seattle, WA 98101 USA; Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98195 USA; Humboldt Univ, Inst Humangenet, D-13353 Berlin, Germany	Benaroya Research Institute; University of Washington; University of Washington Seattle; Humboldt University of Berlin	Concannon, P (corresponding author), Benaroya Res Inst, Mol Genet Program, 1201 9th Ave, Seattle, WA 98101 USA.	patcon@benaroyaresearch.org	Demuth, Ilja/ABD-5352-2021	Demuth, Ilja/0000-0002-4340-2523; Concannon, Patrick/0000-0002-5801-1859	NCI NIH HHS [CA57569] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057569] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; Brendel M, 2003, MUTAT RES-REV MUTAT, V544, P179, DOI 10.1016/j.mrrev.2003.06.018; Bruun D, 2003, DNA REPAIR, V2, P1007, DOI 10.1016/S1568-7864(03)00112-5; CALDECOTT K, 1991, MUTAT RES, V255, P111, DOI 10.1016/0921-8777(91)90046-R; Callebaut I, 2002, NUCLEIC ACIDS RES, V30, P3592, DOI 10.1093/nar/gkf470; Carreau M, 1999, MUTAT RES-DNA REPAIR, V435, P103, DOI 10.1016/S0921-8777(99)00041-5; CASSIER C, 1980, GENETICS, V96, P841; CASSIERCHAUVAT C, 1988, CURR GENET, V13, P37, DOI 10.1007/BF00365754; Cerosaletti KM, 2003, J BIOL CHEM, V278, P21944, DOI 10.1074/jbc.M211689200; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; Demuth I, 1998, MUTAT RES-DNA REPAIR, V409, P11, DOI 10.1016/S0921-8777(98)00037-8; Digweed M, 2002, ONCOGENE, V21, P4873, DOI 10.1038/sj.onc.1205616; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Dronkert MLG, 2000, MOL CELL BIOL, V20, P4553, DOI 10.1128/MCB.20.13.4553-4561.2000; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Foe J R, 1996, Nat Genet, V14, P488; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Gatti RA, 2001, ACTA ONCOL, V40, P702, DOI 10.1080/02841860152619115; HENRIQUES JAP, 1980, GENETICS, V95, P273; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; JACHYMCZYK WJ, 1981, MOL GEN GENET, V182, P196, DOI 10.1007/BF00269658; Jenny A, 1996, SCIENCE, V274, P1514, DOI 10.1126/science.274.5292.1514; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; LEVITUS M, 2003, BLOOD, V103, P298; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; MAGANASCHWENCKE N, 1982, P NATL ACAD SCI-BIOL, V79, P1722, DOI 10.1073/pnas.79.6.1722; McHugh PJ, 2001, LANCET ONCOL, V2, P483, DOI 10.1016/S1470-2045(01)00454-5; McHugh PJ, 2000, MOL CELL BIOL, V20, P3425, DOI 10.1128/MCB.20.10.3425-3433.2000; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moynahan ME, 2001, CANCER RES, V61, P4842; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Richie CT, 2002, MOL CELL BIOL, V22, P8635, DOI 10.1128/MCB.22.24.8635-8647.2002; RICHTER D, 1992, MOL GEN GENET, V231, P194, DOI 10.1007/BF00279791; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Rothfuss A, 2004, MOL CELL BIOL, V24, P123, DOI 10.1128/MCB.24.1.123-134.2004; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; WILBORN F, 1989, CURR GENET, V16, P331, DOI 10.1007/BF00340711	47	65	66	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 11	2004	23	53					8611	8618		10.1038/sj.onc.1207895	http://dx.doi.org/10.1038/sj.onc.1207895			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	869MR	15467758				2022-12-17	WOS:000224988800007
J	Dudognon, C; Pendino, F; Hillion, J; Saumet, A; Lanotte, M; Segal-Bendirdjian, E				Dudognon, C; Pendino, F; Hillion, J; Saumet, A; Lanotte, M; Segal-Bendirdjian, E			Death receptor signaling regulatory function for telomerase: hTERT abolishes TRAIL-induced apoptosis, independently of telomere maintenance	ONCOGENE			English	Article						telomerase; TRAIL; apoptosis; ATRA; APL	LEUKEMIA-CELL LINE; CATALYTIC SUBUNIT; CANCER-CELLS; EXPRESSION; LENGTH; SENESCENCE; INHIBITION; MATURATION; RESISTANCE; MECHANISM	Human telomerase has been implicated in cell immortalization and cancer. Recent works suggest that telomerase confers additional function required for tumorigenesis that does not depend on its ability to maintain telomeres. This new action may influence tumor therapy outcomes by yet unraveled mechanisms. Here, we show that overexpression of the catalytic subunit of telomerase (hTERT) protects a maturation-resistant acute promyelocytic leukemia (APL) cell line from apoptosis induced by the tumor necrosis factor (TNF) or TNF-related apoptosis- inducing ligand (TRAIL) and not from apoptosis induced by chemotherapeutic drugs such as etoposide or cisplatin. Conversely, in these cells, TRAIL-induced cell death is magnified by all-trans retinoic acid ( ATRA) treatment, independently of telomerase activity on telomeres. Of note, this response is subordinated neither to maturation nor to telomere shortening. This work underlines that retinoids and death receptor signaling cross-talks offer new perspectives for antitumor therapy.	Hop St Louis, Inst Hematol, INSERM, U496, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Segal-Bendirdjian, E (corresponding author), Hop St Louis, Inst Hematol, INSERM, U496, 1 Ave Claude Vellefaux, F-75010 Paris, France.	Evelyne.Segal-Bendirdjian@stlouis.inserm.fr	PENDINO, Frederic/G-6630-2017	Segal-Bendirdjian, Evelyne/0000-0001-9813-4880				Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; DUPREZ E, 1992, LEUKEMIA, V6, P1281; Folini M, 2000, EUR J CANCER, V36, P2137, DOI 10.1016/S0959-8049(00)00295-1; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Fu WM, 2000, J MOL NEUROSCI, V14, P3, DOI 10.1385/JMN:14:1-2:003; GOLSTEIN P, 1997, CURR BIOL, V7, P750; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Helder MN, 2002, CANCER INVEST, V20, P82, DOI 10.1081/CNV-120000370; Kondo Y, 1998, ONCOGENE, V16, P2243, DOI 10.1038/sj.onc.1201754; Kushner DM, 2000, GYNECOL ONCOL, V76, P183, DOI 10.1006/gyno.1999.5668; LANOTTE M, 1991, BLOOD, V77, P1080; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; Lu CB, 2001, DEV BRAIN RES, V131, P167, DOI 10.1016/S0165-3806(01)00237-1; Ludwig A, 2001, CANCER RES, V61, P3053; Mergny JL, 2002, NUCLEIC ACIDS RES, V30, P839, DOI 10.1093/nar/30.4.839; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pendino F, 2002, LEUKEMIA, V16, P826, DOI 10.1038/sj.leu.2402470; Pendino F, 2001, P NATL ACAD SCI USA, V98, P6662, DOI 10.1073/pnas.111464998; Rubio MA, 2002, J BIOL CHEM, V277, P28609, DOI 10.1074/jbc.M203747200; RUBIO MA, 2004, IN PRESS EXP CELL RE; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Yuan Zhang, 2002, Hematol J, V3, P201, DOI 10.1038/sj.thj.6200177	32	65	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7469	7474		10.1038/sj.onc.1208029	http://dx.doi.org/10.1038/sj.onc.1208029			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326479				2022-12-17	WOS:000224176500003
J	Dominguez-Caceres, MA; Garcia-Martinez, JM; Calcabrini, A; Gonzalez, L; Porque, PG; Leon, J; Martin-Perez, J				Dominguez-Caceres, MA; Garcia-Martinez, JM; Calcabrini, A; Gonzalez, L; Porque, PG; Leon, J; Martin-Perez, J			Prolactin induces c-Myc expression and cell survival through activation of Src/Akt pathway in lymphoid cells	ONCOGENE			English	Article						prolactin; cell proliferation and survival; Src kinases; Akt; FKHRL1; GSK3; Myc	GLYCOGEN-SYNTHASE KINASE-3; FORKHEAD TRANSCRIPTION FACTORS; SIGNALING PATHWAYS; S6 KINASE; PROTEIN STABILITY; GENE-EXPRESSION; TARGET GENES; IN-VIVO; APOPTOSIS; PROLIFERATION	Stimulation of resting W53 cells ( lymphoid murine cells expressing prolactin (PRL) receptor) by PRL induced expression of growth-related immediate-early genes (IEG), and proliferation through activation of the Src kinases. Since IEG are essential for cell cycle progression, we have studied how PRL controls expression of c-Myc mRNA and c-Fos. Stimulation of W53 cell proliferation by PRL required activation of MAPK, as the Mek1/2 inhibitor PD184352 eliminated Erk1/2 stimulation, cell proliferation, and expression of c-Fos mRNA. In contrast, PD184352 did not alter PRL activation of c-Myc mRNA expression or stimulation of p70S6K, Akt, and the Jak2/ Stat5 pathway. Activation of the PI3K by PRL was necessary for the expression of c-Myc mRNA and W53 cell proliferation, as the PI3K inhibitor LY294002 abolished them. However, it did not modify PRL stimulation of c-Fos mRNA expression or activation of Erk1/2 and Stat5. Furthermore, rapamycin, an inhibitor of mTOR and consequently of p70S6K, did not alter PRL stimulation of c-Myc and c-Fos mRNA expression and it had a very minor inhibitory effect on PRL stimulation of W53 cell proliferation. In addition, rapamycin did not affect PRL stimulation of Akt or Stat5. However, it reinforced PRL activation of Erk1/2. Overexpression of a constitutively activated Akt ( myristoylated Akt) in W53 cells overcame the inhibitory effect of LY294002 on c-Myc expression, as well as cell death upon PRL deprivation. Consistently, inducible expression of Akt-CAAX Box in W53 cells caused inhibition of c-Myc expression. PRL stimulation of W53 cells resulted in Akt translocation to the nucleus, phosphorylation of FKHRL1 transcription factor, and its nuclear exclusion. In contrast, induced expression of Akt-CAAX Box caused inhibition of FKHRL1 phosphorylation. Furthermore, transient expression of nonphosphorylatable FKHRL1-A3 mutant impaired PRL-induced activation of the c-Myc promoter. Akt activation also resulted in phosphorylation and inhibition of glycogen synthetase kinase 3 (GSK3), which in turn promoted c-Myc stability. Consistently, treatment of W53 with selective inhibitors of GSK3 such as SB415286 and lithium salts resulted in increased levels of c-Myc. Also, overexpression of c-Myc in W53 cells overcame the decrease in cell proliferation induced by LY294002. These findings defined a PRL-signalling cascade in W53 cells, involving Src kinases/PI3K/Akt/ FKHRL1-GSK3, that mediates stimulation of c-Myc expression.	CSIC, Inst Invest Biomed, Madrid 28029, Spain; Ist Super Sanita, I-00161 Rome, Italy; Hosp Univ Ramon & Cajal, Serv Inmunol, Madrid, Spain; Univ Cantabria, Fac Med, Dept Mol Biol, Unidad Biomed,CSIC, E-39005 Santander, Spain; Univ Cantabria, Grp Biol Mol Canc, E-39005 Santander, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Istituto Superiore di Sanita (ISS); Hospital Universitario Ramon y Cajal; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria (IBBTEC); Universidad de Cantabria	Martin-Perez, J (corresponding author), CSIC, Inst Invest Biomed, Calle Arturo Duperier 4, Madrid 28029, Spain.	jmartin@iib.uam.es	Martin-Perez, Jorge/A-3522-2008; Leon, Javier/K-4615-2014; Calcabrini, Annarica/C-9897-2015; Martínez, José Manuel García/AAB-5909-2019	Martin-Perez, Jorge/0000-0002-2292-0057; Calcabrini, Annarica/0000-0002-9600-1117; Martínez, José Manuel García/0000-0002-6498-5174; Gonzalez, Lorena/0000-0002-0575-7833; Leon, Javier/0000-0001-5803-0112				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Barre B, 2003, J BIOL CHEM, V278, P2990, DOI 10.1074/jbc.M210422200; Barry FA, 2003, FEBS LETT, V553, P173, DOI 10.1016/S0014-5793(03)01015-9; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CALVO V, 1994, EUR J IMMUNOL, V24, P2664, DOI 10.1002/eji.1830241115; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen CM, 2001, J BIOL CHEM, V276, P38518, DOI 10.1074/jbc.M105702200; Cheriyath V, 2002, J BIOL CHEM, V277, P22798, DOI 10.1074/jbc.M202956200; Dang CV, 1999, MOL CELL BIOL, V19, P1; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dufner A, 1999, MOL CELL BIOL, V19, P4525; FERRARI S, 1993, J BIOL CHEM, V268, P16091; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Hoffman B, 1998, ONCOGENE, V17, P3351, DOI 10.1038/sj.onc.1202592; Iavarone C, 2003, J BIOL CHEM, V278, P50024, DOI 10.1074/jbc.M308617200; Jeay S, 2001, ENDOCRINOLOGY, V142, P147, DOI 10.1210/en.142.1.147; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Lee TC, 1999, J BIOL CHEM, V274, P595, DOI 10.1074/jbc.274.2.595; LUTZ W, 2002, BIOCHIM BIOPHYS ACTA, V14, P61; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Mauleon I, 2004, MOL CARCINOGEN, V39, P85, DOI 10.1002/mc.20000; Medh RD, 2001, ONCOGENE, V20, P4629, DOI 10.1038/sj.onc.1204680; Morales P, 1999, CELL GROWTH DIFFER, V10, P583; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Orme MH, 2003, MOL CELL NEUROSCI, V24, P673, DOI 10.1016/S1044-7431(03)00229-X; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rohn JL, 1998, ONCOGENE, V17, P2811, DOI 10.1038/sj.onc.1202393; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Sanchez-Beato M, 2003, BLOOD, V101, P1220, DOI 10.1182/blood-2002-07-2009; Sayas CL, 1999, J BIOL CHEM, V274, P37046, DOI 10.1074/jbc.274.52.37046; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Vara JAF, 2001, MOL BIOL CELL, V12, P2171, DOI 10.1091/mbc.12.7.2171; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Wu M, 1996, MOL CELL BIOL, V16, P5015; Xie SH, 2002, ONCOGENE, V21, P7137, DOI 10.1038/sj.onc.1205942	58	65	67	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7378	7390		10.1038/sj.onc.1208002	http://dx.doi.org/10.1038/sj.onc.1208002			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15286700				2022-12-17	WOS:000224021400008
J	Gildea, JJ; Herlevsen, M; Harding, MA; Gulding, KM; Moskaluk, CA; Frierson, HF; Theodorescu, D				Gildea, JJ; Herlevsen, M; Harding, MA; Gulding, KM; Moskaluk, CA; Frierson, HF; Theodorescu, D			PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity	ONCOGENE			English	Article						PTEN; bladder neoplasms; tumor motility; tumor invasion; tumor-suppressor genes	GROWTH-FACTOR RECEPTOR; TUMOR-SUPPRESSOR PTEN; FOCAL ADHESION KINASE; GLIOMA-CELLS; RADICAL CYSTECTOMY; CARCINOMA; METASTASIS; MOTILITY; ARREST; GENE	Recent studies have found a higher frequency of the PTEN tumor-suppressor gene alterations in invasive bladder carcinoma than in superficial disease, suggesting that PTEN is important in this process. A role of PTEN in bladder cancer invasion is further suggested by the fact that PTEN is a regulator of cell motility, a necessary component of tumor invasion. However, it is unknown whether PTEN is mechanistically involved in 'in vivo' tumor invasion or merely an epiphenomenon and, if the former is true, whether this process is dependent on its protein or lipid phosphatase activities. To address these issues, we stably transfected several commonly used human bladder cancer cell lines with known invasive phenotypes with either wild-type PTEN constructs or those deficient in the lipid phosphatase (G129E) or both protein and lipid phosphatase (G129R) activities. Here we show that chemotaxis was inhibited by both the wild-type and G129E mutant of PTEN but not by G129R-transfected cells. Using a novel organotypic in vitro invasion assay, we evaluated the impact of wild-type and mutant PTEN transgene expression on the invasive ability of T24T, a human bladder cancer cell line with a functionally impaired PTEN. Results indicate that the G129E mutant blocks invasion as efficiently as wild-type PTEN transfection. In contrast to the wild-type gene, this mutant has no effect on cell clonogenicity in agar. To further establish the role of PTEN in tumor invasion, we evaluated vector- and PTEN-transfected T24T cells in an orthotopic in vivo assay that faithfully reproduces human disease. Microscopic examination of murine bladders at the completion of this experiment parallels the results obtained with the organotypic assay. Our results are the first demonstration: ( 1) that the inhibitory effects of PTEN on cell motility translate into suppression of in vivo invasion; ( 2) that PTEN can inhibit tumor invasion even in the absence of its lipid phosphatase activity; ( 3) how organotypic in vitro approaches can be used as surrogates of in vivo invasion allowing rapid dissection of molecular processes leading to this phenotype while reducing the number of animals used in research.	Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Theodorescu, D (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Box 422, Charlottesville, VA 22908 USA.	dt9d@virginia.edu	Harding, Michael/C-3438-2013	Harding, Michael/0000-0001-8636-067X	NCI NIH HHS [R01CA085329] Funding Source: Medline; NIDDK NIH HHS [DK007766] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085329] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHLERING TE, 1987, CANCER RES, V47, P6660; Aveyard JS, 1999, BRIT J CANCER, V80, P904, DOI 10.1038/sj.bjc.6690439; Cairns P, 1998, ONCOGENE, V16, P3215, DOI 10.1038/sj.onc.1201855; Cappellen D, 1997, ONCOGENE, V14, P3059, DOI 10.1038/sj.onc.1201154; Fontana D, 1996, EUR UROL, V29, P470; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Gildea JJ, 2002, CANCER RES, V62, P6418; Gildea JJ, 2000, BIOTECHNIQUES, V29, P81, DOI 10.2144/00291st02; Gildea JJ, 2002, CANCER RES, V62, P982; Gildea JJ, 2000, GENE CHROMOSOME CANC, V27, P252, DOI 10.1002/(SICI)1098-2264(200003)27:3<252::AID-GCC5>3.0.CO;2-9; HENEY NM, 1983, J UROLOGY, V130, P1083, DOI 10.1016/S0022-5347(17)51695-X; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lianes P, 1998, CLIN CANCER RES, V4, P1267; LIPPONEN P, 1994, BRIT J CANCER, V69, P1120, DOI 10.1038/bjc.1994.220; Liu JH, 2000, MOL CARCINOGEN, V29, P143, DOI 10.1002/1098-2744(200011)29:3<143::AID-MC3>3.0.CO;2-A; Ludbrook J, 1998, CLIN EXP PHARMACOL P, V25, P1032, DOI 10.1111/j.1440-1681.1998.tb02179.x; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Maier D, 1999, CANCER RES, V59, P5479; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Seraj MJ, 2001, CLIN CANCER RES, V7, P1516; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Skinner DG, 1998, EUR UROL, V33, P25, DOI 10.1159/000052260; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tamura M, 1999, CANCER RES, V59, P442; Tanaka M, 2000, ONCOGENE, V19, P5406, DOI 10.1038/sj.onc.1203918; Theodorescu D, 1998, CELL GROWTH DIFFER, V9, P919; THEODORESCU D, 1990, P NATL ACAD SCI USA, V87, P9047, DOI 10.1073/pnas.87.22.9047; Upchurch GR, 1997, J BIOL CHEM, V272, P17012, DOI 10.1074/jbc.272.27.17012; Vazquez F, 2000, BBA-REV CANCER, V1470, pM21, DOI 10.1016/S0304-419X(99)00032-3; Wang DS, 2000, INT J CANCER, V88, P620, DOI 10.1002/1097-0215(20001115)88:4<620::AID-IJC16>3.0.CO;2-Z; Weng LP, 1999, CANCER RES, V59, P5808; Wolf JS, 1996, UROLOGY, V47, P2, DOI 10.1016/S0090-4295(99)80374-4	38	65	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6788	6797		10.1038/sj.onc.1207599	http://dx.doi.org/10.1038/sj.onc.1207599			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273733				2022-12-17	WOS:000223653600010
J	Riesterer, O; Zingg, D; Hummerjohann, J; Bodis, S; Pruschy, M				Riesterer, O; Zingg, D; Hummerjohann, J; Bodis, S; Pruschy, M			Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells	ONCOGENE			English	Article						PKB/Akt; VEGF receptor; rapamycin; PTK787/ZK222584; protein degradation	AKT/PROTEIN KINASE-B; SIGNAL-TRANSDUCTION PATHWAY; TUMOR RADIATION RESPONSE; PROSTATE-CANCER CELLS; GROWTH-FACTOR; IONIZING-RADIATION; PANCREATIC-CANCER; COLON-CANCER; ANGIOGENESIS; EXPRESSION	An intact VEGF receptor/PI3K/PKB/Akt signaling cascade protects endothelial cells from apoptotic stress-stimuli and mediates the formation of new blood vessels in pathological conditions such as cancer. Therefore, downregulation of this signaling cascade is of clinical interest for antiangiogenic cancer therapy. In this report, we demonstrate that VEGF controls the protein stability of the serine-threonine kinase PKB/Akt via inhibition of PKB/Akt protein degradation. VEGF deprivation or blockage of the VEGF signal transduction cascade with the VEGF receptor tyrosine kinase inhibitor PTK787/ZK222584 resulted in a specific decrease of the PKB/Akt protein level and subsequent cellular restimulation with VEGF rescued its stability. Real-time quantitative RTPCR analysis demonstrated that VEGF does not regulate PKB/Akt gene expression. On the other hand, broad range inhibitors of caspases and the proteasome complex prevented VEGF-dependent downregulation of the PKB/Akt protein level indicating that PKB/Akt protein stability is regulated by VEGF-controlled proteolysis. Inhibition of the VEGF receptor and PKB/Akt-downstream PIK-related mTOR-kinase by rapamycin also neutralized the VEGF-protective effect in an PKB/Akt gene expression-independent way but results in proteolysis-dependent reduction of PKB/Akt protein stability. These results demonstrate a novel regulatory mechanism of the activated VEGF receptor/mTOR-signal transduction pathway to control the protein stability of PKB/Akt and survival threshold in endothelial cells.	Univ Zurich Hosp, Dept Radiat Oncol, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Med Oncol, CH-8091 Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	Pruschy, M (corresponding author), Univ Zurich Hosp, Dept Radiat Oncol, CH-8091 Zurich, Switzerland.	martin.pruschy@usz.ch		Bodis, Stephan/0000-0003-1078-8711; Riesterer, Oliver/0000-0002-9508-0546; Pruschy, Martin/0000-0002-3124-9015				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1999, MOL CELL BIOL, V19, P5061; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Bachelder RE, 2001, J BIOL CHEM, V276, P34702, DOI 10.1074/jbc.M102806200; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; BROWN LF, 1993, AM J PATHOL, V143, P1255; BROWN LF, 1993, CANCER RES, V53, P4727; Bruns CJ, 2000, CANCER, V89, P488, DOI 10.1002/1097-0142(20000801)89:3<488::AID-CNCR3>3.3.CO;2-O; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chan J, 2002, CANCER CELL, V1, P257, DOI 10.1016/S1535-6108(02)00042-9; Chaudhry IH, 2001, HISTOPATHOLOGY, V39, P409, DOI 10.1046/j.1365-2559.2001.01230.x; Decker T, 2003, BLOOD, V101, P278, DOI 10.1182/blood-2002-01-0189; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Eshleman JS, 2002, CANCER RES, V62, P7291; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Geng L, 2001, CANCER RES, V61, P2413; Geoerger B, 2001, CANCER RES, V61, P1527; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gorski DH, 1999, CANCER RES, V59, P3374; Griffin RJ, 2002, CANCER RES, V62, P1702; Grunwald V, 2002, CANCER RES, V62, P6141; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Gupta VK, 2002, CANCER J, V8, P47, DOI 10.1097/00130404-200201000-00009; Hashemolhosseini S, 1998, J BIOL CHEM, V273, P14424, DOI 10.1074/jbc.273.23.14424; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hess C, 2001, BRIT J CANCER, V85, P2010, DOI 10.1054/bjoc.2001.2166; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com; Ikeda N, 1999, BRIT J CANCER, V79, P1553, DOI 10.1038/sj.bjc.6690248; Itakura J, 2000, INT J CANCER, V85, P27; Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265; Joukov V, 1997, J CELL PHYSIOL, V173, P211, DOI 10.1002/(SICI)1097-4652(199711)173:2<211::AID-JCP23>3.0.CO;2-H; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kozin SV, 2001, CANCER RES, V61, P39; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Law BK, 2002, MOL CELL BIOL, V22, P8184, DOI 10.1128/MCB.22.23.8184-8198.2002; Lee CG, 2000, CANCER RES, V60, P5565; Li JR, 2000, J BIOL CHEM, V275, P13026, DOI 10.1074/jbc.275.17.13026; Madhusudan S, 2002, CURR OPIN PHARMACOL, V2, P403, DOI 10.1016/S1471-4892(02)00184-4; Manley PW, 2002, EXPERT OPIN INV DRUG, V11, P1715, DOI 10.1517/13543784.11.12.1715; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Matter A, 2001, DRUG DISCOV TODAY, V6, P1005, DOI 10.1016/S1359-6446(01)01939-0; Nelsen CJ, 2003, J BIOL CHEM, V278, P3656, DOI 10.1074/jbc.M209374200; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Scappaticci FA, 2002, J CLIN ONCOL, V20, P3906, DOI 10.1200/JCO.2002.01.033; Shaheen RM, 1999, CANCER RES, V59, P5412; Shi YJ, 2002, CANCER RES, V62, P5027; Solit DB, 2003, CANCER RES, V63, P2139; Sun L, 2000, DRUG DISCOV TODAY, V5, P344, DOI 10.1016/S1359-6446(00)01534-8; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; Takahashi Y, 1996, CLIN CANCER RES, V2, P1679; Tenzer A, 2001, CANCER RES, V61, P8203; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Weidner Noel, 1996, P167; Wood JM, 2000, CANCER RES, V60, P2178; Xu J, 2002, J BIOL CHEM, V277, P35561, DOI 10.1074/jbc.M203805200; Yao Y, 2001, ACTA NEUROCHIR, V143, P159, DOI 10.1007/s007010170122; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J; Zhong H, 2000, CANCER RES, V60, P1541	68	65	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 3	2004	23	26					4624	4635		10.1038/sj.onc.1207596	http://dx.doi.org/10.1038/sj.onc.1207596			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15064712				2022-12-17	WOS:000221799000012
J	Yeh, PY; Chuang, SE; Yeh, KH; Song, YC; Chang, LLY; Cheng, AL				Yeh, PY; Chuang, SE; Yeh, KH; Song, YC; Chang, LLY; Cheng, AL			Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death	ONCOGENE			English	Article						ERK2; p53; p53Thr55; doxorubicin; Bcl-2	TUMOR-SUPPRESSOR P53; IN-VITRO; PROTEIN-KINASE; TARGET GENES; CISPLATIN; CANCER; APOPTOSIS; BCL-2; VIVO; INHIBITION	We recently reported that exposure of human cervical carcinoma cells to doxorubicin results in extracellular signal-regulated kinase (ERK) 2 activation, which in turn phosphorylates p53 on a previously uncharacterized site, Thr55. This study sought to clarify the biological significance of doxorubicin-induced Thr55 phosphorylation. In breast carcinoma MCF7 cells, doxorubicin (300 nM) activated ERK2 and induced phosphorylation of p53 on Thr55 residues. Pretreatment of MCF7 cells with an ERK2 chemical inhibitor, PD98059 or U0126, blocked doxorubicin-induced p53 activation and suppressed phosphorylation of p53Thr55. MCF55a cells were established by transfection of full-length p53 carrying Thr55 mutation (Thr to Ala) into MCF7 cells. Doxorubicin ( 500 nM) could not induce p53 activation in MCF55a cells, which showed significantly increased drug resistance toward doxorubicin. While the expression of the apoptotic protein, Bax, showed no difference between MCF7 and MCF55a cells, Bcl-2, an antiapoptotic protein, was constitutively expressed in MCF55a cells. The increase of Bcl-2 protein and/or Bcl-2/Bax ratio might at least partly contribute to the drug resistance of MCF55a cells. In summary, our results suggest that phosphorylation of p53Thr55 by ERK2 is important for doxorubicin-induced p53 activation and cell death.	Natl Taiwan Univ Hosp, Dept Oncol, Taipei 10016, Taiwan; Natl Taiwan Univ, Coll Med, Ctr Canc Res, Taipei 10018, Taiwan; Natl Hlth Res Inst, Div Canc Res, Taipei, Taiwan; Far Eastern Mem Hosp, Dept Med Res, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 10016, Taiwan; Natl Taiwan Univ, Coll Med, Inst Toxicol, Taipei 10018, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Health Research Institutes - Taiwan; Far Eastern Memorial Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Cheng, AL (corresponding author), Natl Taiwan Univ Hosp, Dept Oncol, Taipei 10016, Taiwan.	andrew@ha.mc.ntu.edu.tw	Chuang, Shuang-En/D-2080-2010; Yeh, Kun-Huei/HGD-3316-2022	Cheng, Ann-Lii/0000-0002-9152-6512; Song, Ying-Chyi/0000-0003-0279-4652; YEH, Kun-Huei/0000-0002-7306-174X				Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; de Almodovar CR, 2001, ONCOGENE, V20, P7128, DOI 10.1038/sj.onc.1204887; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FAN SJ, 1995, CANCER RES, V55, P1649; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HALDAR S, 1994, CANCER RES, V54, P2095; Hayakawa J, 1999, J BIOL CHEM, V274, P31648, DOI 10.1074/jbc.274.44.31648; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Liu L, 1999, MOL CELL BIOL, V19, P1202; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Persons DL, 1999, CLIN CANCER RES, V5, P1007; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Woessmann W, 2002, CANCER CHEMOTH PHARM, V50, P397, DOI 10.1007/s00280-002-0502-y; Yeh PY, 2002, BIOCHEM PHARMACOL, V63, P1423, DOI 10.1016/S0006-2952(02)00908-5; Yeh PY, 2001, BIOCHEM BIOPH RES CO, V284, P880, DOI 10.1006/bbrc.2001.5043; Zhao RB, 2000, GENE DEV, V14, P981	48	65	66	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3580	3588		10.1038/sj.onc.1207426	http://dx.doi.org/10.1038/sj.onc.1207426			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116093				2022-12-17	WOS:000221101700009
J	Hideshima, T; Hayashi, T; Chauhan, D; Akiyama, M; Richardson, P; Anderson, K				Hideshima, T; Hayashi, T; Chauhan, D; Akiyama, M; Richardson, P; Anderson, K			Biologic sequelae of c-Jun NH2-terminal kinase (JNK) activation in multiple myeloma cell lines	ONCOGENE			English	Article						multiple myeloma; JNK; growth arrest; p21; NF-kappa B	N-TERMINAL KINASE; PROTEASOME INHIBITOR PS-341; MARROW STROMAL CELLS; KAPPA-B; THERAPEUTIC APPLICATIONS; MOLECULAR-MECHANISMS; INDUCED APOPTOSIS; DRUG-RESISTANCE; PLASMA-CELLS; INTERLEUKIN-6	Although c-Jun NH2-terminal kinase (JNK) is activated by treatment with therapeutic agents, the biologic sequelae of inhibiting constitutive activation of JNK has not yet been clarified. In this study, we examine the biologic effect of JNK inhibition in multiple myeloma (MM) cell lines. JNK-specific inhibitor SP600125 induces growth inhibition via induction of G1 or G2/M arrest in U266 and MM.1S multiple myeloma cell lines, respectively. Neither exogenous IL-6 nor insulin-like growth factor-1 (IGF-1) overcome SP600125-induced growth inhibition, and IL-6 enhances SP600125-induced G2/M phase in MM.1S cells. Induction of growth arrest is mediated by upregulation of p27(Kip1), without alteration of p53 and JNK protein expression. Importantly, SP600125 inhibits growth of MM cells adherent to bone marrow stromal cells (BMSCs). SP600125 induces NF-kappaB activation in a dose-dependent fashion, associated with phosphorylation of IkappaB kinase alpha (IKKalpha) and degradation of IkappaBalpha. In contrast, SP600125 does not affect phosphorylation of STAT3, Akt, and/or ERK. IKK-specific inhibitor PS-1145 inhibits SP600125-induced NF-kappaB activation and blocks the protective effect of SP600125 against apoptosis. Our data therefore demonstrate for the first time that inhibiting JNK activity induces growth arrest and activates NF-kappaB in MM cells.	Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Anderson, K (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Mayer 557,44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA050947, P01CA078378] Funding Source: NIH RePORTER; NCI NIH HHS [P0-1 CA78378, R0-1 CA50947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chen Y, 2001, J BIOL CHEM, V276, P8350, DOI 10.1074/jbc.M008431200; FREUND GG, 1993, J IMMUNOL, V151, P1811; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI200112466; Herr I, 1999, CELL DEATH DIFFER, V6, P130, DOI 10.1038/sj.cdd.4400467; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; HIDESHIMA T, 2003, UNPUB CANC RES; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Mitsiades CS, 2002, BLOOD, V100, p170A; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; Ogata A, 1997, J IMMUNOL, V159, P2212; Pearce AK, 2001, TRENDS CELL BIOL, V11, P426, DOI 10.1016/S0962-8924(01)02119-5; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Tu YP, 2000, CANCER RES, V60, P6763; UCHIYAMA H, 1993, BLOOD, V82, P3712; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1	29	65	67	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8797	8801		10.1038/sj.onc.1206919	http://dx.doi.org/10.1038/sj.onc.1206919			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647474				2022-12-17	WOS:000186844900017
J	Agazie, YM; Movilla, N; Ischenko, I; Hayman, MJ				Agazie, YM; Movilla, N; Ischenko, I; Hayman, MJ			The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3	ONCOGENE			English	Article						SHP2; FGFR3; transformation; Ras-ERK; PI3K-Akt	TYROSINE-PHOSPHATASE; MULTIPLE-MYELOMA; ACTIVATING MUTATIONS; SIGNAL-TRANSDUCTION; ECTOPIC EXPRESSION; SKELETAL DISORDERS; TUMOR PROGRESSION; KINASE ACTIVATION; STAT ACTIVATION; FGFR3 MUTATIONS	Receptor tyrosine kinases (RTKs) such as the fibroblast growth factor receptor (FGFR) and the epidermal growth factor receptor are overexpressed in a variety of cancers. In addition to overexpression, the FGFRs are found mutated in some cancers. The Src homology 2 domain-containing phosphotyrosine phosphatase (SHP2) is a critical mediator of RTK signaling, but its role in oncogenic RTK-induced cell transformation and cancer development is largely unknown. In the current report, we demonstrate that constitutively activated FGFR3 (K/E-FR3) transforms NIH-3T3 cells, and that SHP2 is a critical mediator of this transformation. Infection of K/E-FR3-transformed 3T3 cells with a retrovirus carrying a dominant-negative mutant of SHP2 (C/S-SHP2) retarded cell growth, reversed the transformation phenotype and inhibited focus-forming ability. Furthermore, treatment of K/E-FR3-transformed NIH-3T3 cells with PD98059 or LY294002, specific inhibitors of MEK and PI3K, respectively, inhibited focus formation. Biochemical analysis showed that K/E-FR3 activates the Ras-ERK and the PI3K signaling pathways, and that the C/SSHP2 mutant suppressed this effect via competitive displacement of interaction of the endogenous SHP2 with FRS2. However, the C/SSHP2 protein did not show any effect on receptor autophosphorylation, FRS2 tyrosine phosphorylation or interaction of Grb2 with K/E-FR3 or FRS2. Together, the results show that K/E-FR3 is transforming and that the Ras-ERK and the PI3K-Akt signaling pathways, which are positively regulated by SHP2, are important for K/E-FR3-induced transformation.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hayman, MJ (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NCI NIH HHS [CA42573, CA28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146, R01CA042573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agazie Y, 2002, ONCOGENE, V21, P697, DOI 10.1038/sj.onc.1205115; Agazie YM, 2003, J BIOL CHEM, V278, P13952, DOI 10.1074/jbc.M210670200; Anderson J, 1998, HUM MOL GENET, V7, P1475, DOI 10.1093/hmg/7.9.1475; Bellus GA, 2000, AM J HUM GENET, V67, P1411, DOI 10.1086/316892; Chesi M, 2002, CURR OPIN HEMATOL, V9, P288, DOI 10.1097/00062752-200207000-00005; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Deb TB, 1998, J BIOL CHEM, V273, P16643, DOI 10.1074/jbc.273.27.16643; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Dickson C, 2000, BREAST CANCER RES, V2, P191, DOI 10.1186/bcr53; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1611; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Hakak Y, 2000, ONCOGENE, V19, P3164, DOI 10.1038/sj.onc.1203655; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; Hart KC, 2001, MOL BIOL CELL, V12, P931, DOI 10.1091/mbc.12.4.931; Iseki S, 1997, DEVELOPMENT, V124, P3375; Jang JH, 2001, CANCER RES, V61, P3541; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; Legeai-Mallet L, 1998, J BIOL CHEM, V273, P13007, DOI 10.1074/jbc.273.21.13007; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Li Y, 1997, ONCOGENE, V14, P1397, DOI 10.1038/sj.onc.1200983; Lin HY, 1996, J NEUROSCI, V16, P4579; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Monsonego-Ornan E, 2000, MOL CELL BIOL, V20, P516, DOI 10.1128/MCB.20.2.516-522.2000; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; O'Reilly AM, 2000, MOL CELL BIOL, V20, P299, DOI 10.1128/MCB.20.1.299-311.2000; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Park CY, 1999, J BIOL CHEM, V274, P7583, DOI 10.1074/jbc.274.11.7583; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Robertson SC, 1998, P NATL ACAD SCI USA, V95, P4567, DOI 10.1073/pnas.95.8.4567; Rousseau F, 1996, HUM MOL GENET, V5, P509, DOI 10.1093/hmg/5.4.509; Saxton TM, 2000, NAT GENET, V24, P420, DOI 10.1038/74279; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Tavormina PL, 1999, AM J HUM GENET, V64, P722, DOI 10.1086/302275; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; UEKI T, 1995, J PATHOL, V177, P353, DOI 10.1002/path.1711770405; van Rhijn BWG, 2002, EUR J HUM GENET, V10, P819, DOI 10.1038/sj.ejhg.5200883; Van Vactor D, 1998, CURR OPIN GENET DEV, V8, P112, DOI 10.1016/S0959-437X(98)80070-1; Webster MK, 1997, MOL CELL BIOL, V17, P5739, DOI 10.1128/MCB.17.10.5739; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Wilkie AOM, 1996, CURR OPIN NEUROL, V9, P146, DOI 10.1097/00019052-199604000-00016; Wilkie AOM, 1997, AM J MED GENET, V69, P433, DOI 10.1002/(SICI)1096-8628(19970414)69:4<433::AID-AJMG21>3.0.CO;2-N; WILKIE AOM, 1995, J MED GENET, V32, P174, DOI 10.1136/jmg.32.3.174; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; Wilkie AOM, 2001, NAT REV GENET, V2, P458, DOI 10.1038/35076601; Winterpacht A, 2000, PHYSIOL GENOMICS, V2, P9, DOI 10.1152/physiolgenomics.2000.2.1.9; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987	57	65	74	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2003	22	44					6909	6918		10.1038/sj.onc.1206798	http://dx.doi.org/10.1038/sj.onc.1206798			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534538				2022-12-17	WOS:000185843400012
J	Li, G; Kalabis, J; Xu, XW; Meier, F; Oka, M; Bogenrieder, T; Herlyn, M				Li, G; Kalabis, J; Xu, XW; Meier, F; Oka, M; Bogenrieder, T; Herlyn, M			Reciprocal regulation of MelCAM and AKT in human melanoma	ONCOGENE			English	Article						AKT; MelCAM; melanoma; survival; signaling	PROTEIN-KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE-AKT PATHWAY; CELL-ADHESION MOLECULES; GROWTH-FACTOR; TUMOR-GROWTH; TYROSINE PHOSPHORYLATION; VASCULOGENIC MIMICRY; MALIGNANT-MELANOMA; ESTROGEN-RECEPTOR; E-CADHERIN	Alteration in the expression of invasion/ metastasis-related melanoma cell adhesion molecule (MelCAM) is strongly associated with the acquisition of malignancy by human melanoma. However, little is known about the molecular and biochemical mechanisms that regulate the expression and function of MelCAM, or its downstream signaling transduction. In this study, we show that there is a reciprocal regulation loop between AKT and MelCAM. Pharmacological inhibition of AKT in human melanoma cell lines substantially reduced the expression of MelCAM. Overexpression of constitutively active AKT upregulated the levels of MelCAM in melanoma cell lines, whereas expression of a dominant-negative PI-3 kinase downregulated MelCAM. On the other hand, overexpression of MelCAM activated endogenous AKT and inhibited proapoptotic protein BAD in melanoma cells, leading to increased survival under stress conditions. Constitutive activation of AKT was observed in most melanoma cell lines and tumor samples of different progression stages. These data link AKT activation with MelCAM expression, and implicate that intervention of MelCAM-AKT signaling axis in melanoma is a potential therapeutical approach.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Hosp Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA; Kobe Univ, Sch Med, Dept Dermatol, Kobe, Hyogo 6500017, Japan	The Wistar Institute; University of Pennsylvania; Pennsylvania Medicine; Kobe University	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	herlynm@wistar.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA080999, R01CA076674, R01CA047159, P30CA010815, P01CA025874] Funding Source: NIH RePORTER; NCI NIH HHS [CA-80999, CA-76674, CA-47159, CA-25874, CA-10815] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1990, CANCER RES, V50, P6757; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Anfosso F, 1998, J BIOL CHEM, V273, P26852, DOI 10.1074/jbc.273.41.26852; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; ARMSTRONG PB, 1989, CRIT REV BIOCHEM MOL, V24, P119, DOI 10.3109/10409238909086396; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Berking C, 2001, HISTOL HISTOPATHOL, V16, P669, DOI 10.14670/HH-16.669; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Folberg R, 2000, AM J PATHOL, V156, P361, DOI 10.1016/S0002-9440(10)64739-6; Hendrix MJC, 2001, P NATL ACAD SCI USA, V98, P8018, DOI 10.1073/pnas.131209798; Hess AR, 2001, CANCER RES, V61, P3250; Hsu MY, 1999, HUMAN CELL CULTURE, V1, P259; Hsu MY, 2000, J CELL SCI, V113, P1535; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; Johnson JP, 1999, CANCER METAST REV, V18, P345, DOI 10.1023/A:1006304806799; Johnson JP, 1997, INT J CANCER, V73, P769; JOHNSON JP, 1992, INT J CLIN LAB RES, V22, P69, DOI 10.1007/BF02591399; JOHNSON JP, 1993, MELANOMA RES, V3, P337, DOI 10.1097/00008390-199310000-00006; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; LEHMANN JM, 1987, CANCER RES, V47, P841; Li G, 2000, MOL MED TODAY, V6, P163, DOI 10.1016/S1357-4310(00)01692-0; Li G, 2002, CRIT REV ORAL BIOL M, V13, P62, DOI 10.1177/154411130201300107; Li G, 2001, CANCER RES, V61, P3819; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Mills L, 2002, CANCER RES, V62, P5106; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Oka M, 2000, J INVEST DERMATOL, V115, P699, DOI 10.1046/j.1523-1747.2000.00095.x; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Poetsch M, 2001, CANCER GENET CYTOGEN, V125, P21, DOI 10.1016/S0165-4608(00)00353-8; Pollock PM, 2000, CLIN LAB MED, V20, P667; Ries LAG, 2000, CANCER-AM CANCER SOC, V88, P2398, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2398::AID-CNCR26>3.0.CO;2-I; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Rummel MM, 1996, CANCER RES, V56, P2218; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Satyamoorthy K, 2003, CANCER RES, V63, P756; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; Satyamoorthy K, 2001, CANCER RES, V61, P7318; Satyamoorthy K, 2001, ONCOGENE, V20, P4676, DOI 10.1038/sj.onc.1204616; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; Shi IM, 1999, J PATHOL, V189, P4, DOI 10.1002/(SICI)1096-9896(199909)189:1<4::AID-PATH332>3.0.CO;2-P; Shih IM, 1997, CANCER RES, V57, P3835; SHIH IM, 1994, AM J PATHOL, V145, P837; SHIH IM, 1994, CANCER RES, V54, P2514; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Sun M, 2001, CANCER RES, V61, P5985; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Waldmann V, 2002, MELANOMA RES, V12, P45, DOI 10.1097/00008390-200202000-00007; Waldmann V, 2001, ARCH DERMATOL RES, V293, P368, DOI 10.1007/s004030100236; WHITE MF, 1994, J BIOL CHEM, V269, P1; Woods D, 2001, MOL CELL BIOL, V21, P3192, DOI 10.1128/MCB.21.9.3192-3205.2001; Xie SH, 1997, CANCER RES, V57, P2295	67	65	72	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2003	22	44					6891	6899		10.1038/sj.onc.1206819	http://dx.doi.org/10.1038/sj.onc.1206819			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534536				2022-12-17	WOS:000185843400010
J	Miller, CT; Chen, G; Gharib, TG; Wang, H; Thomas, DG; Misek, DE; Giordano, TJ; Yee, J; Orringer, MB; Hanash, SM; Beer, DG				Miller, CT; Chen, G; Gharib, TG; Wang, H; Thomas, DG; Misek, DE; Giordano, TJ; Yee, J; Orringer, MB; Hanash, SM; Beer, DG			Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas	ONCOGENE			English	Article						CRK; lung adenocarcinomas; differentiation; quantitative 2-D protein	ADAPTER PROTEIN CRK; CELL-MIGRATION; PROTEOMIC ANALYSIS; SIGNALING PATHWAY; KINASE ACTIVATION; GROWTH-FACTOR; SURVIVAL; CANCER; PHOSPHORYLATION; MEMBRANE	The C-CRK gene, cellular homolog of the avian v-crk oncogene, encodes two alternatively spliced adaptor signaling proteins, CRKI (28kDa) and CRKII (40kDa). Both CRKI and CRKII have been shown to activate kinase signaling and anchorage-independent growth in vitro and CRKI transformed cells readily form tumors in nude mice. Affymetrix oligonucleotide arrays were used to analyse 86 lung adenocarcinomas and 10 uninvolved lung tissues. C-CRK mRNA expression was increased in more advanced (stage III versus stage I), larger (T2-4 versus T-1), and poorly differentiated tumors and in tumors from patients demonstrating poor survival (P = 0.00034). An overlapping series of 93 lung adenocarcinomas (64 stage I and 29 stage III) and 10 uninvolved lung specimens were measured for quantitative differences in CRKI and CRKII protein levels using 2-D PAGE. CRK protein spots were identified using mass spectrometry and 2-D Western blotting. A significant increase in levels of the CRKI oncoprotein and the phosphorylated isoform of CRKII was observed in tumors (P < 0.05). No difference in protein level was evident between stages. Concordant with mRNA expression, CRKI and CRKII were increased in poorly differentiated tumors (P < 0.05). CRK immunohistochemical analysis of tumor tissue arrays using the same tumor series also demonstrated increased abundance of nuclear and cytoplasmic CRK in more proliferative tumors (P < 0.05). This study provides the first quantitative analysis of discrete CRKI and CRKII protein isoforms in human lung tumors and provides evidence that the C-CRK proto-oncogene may foment a more aggressive phenotype in lung cancers.	Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Beer, DG (corresponding author), Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA.		Chen, Guoan/J-9140-2018	Chen, Guoan/0000-0001-5608-6761; Giordano, Thomas/0000-0003-0641-8873	NATIONAL CANCER INSTITUTE [R01CA085953] Funding Source: NIH RePORTER; NCI NIH HHS [U19 CA-85953] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; Chen GA, 2002, CLIN CANCER RES, V8, P2298; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; Colby TV, 1995, AFIP ATLAS TUMOR PAT, V13; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; EDELMAN GM, 1983, P NATL ACAD SCI-BIOL, V80, P4384, DOI 10.1073/pnas.80.14.4384; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fry WA, 1999, CANCER, V86, P1867, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1867::AID-CNCR31>3.0.CO;2-9; Gharib TG, 2002, NEOPLASIA, V4, P440, DOI 10.1038/sj.neo.7900257; Giordano TJ, 2001, AM J PATHOL, V159, P1231, DOI 10.1016/S0002-9440(10)62509-6; Girardin SE, 2001, EMBO J, V20, P3437, DOI 10.1093/emboj/20.13.3437; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; Hughes SJ, 1997, CANCER RES, V57, P5571; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; KUICK RD, 1987, ELECTROPHORESIS, V8, P199, DOI 10.1002/elps.1150080405; KUICK RD, 1991, ELECTROPHORESIS, V12, P736, DOI 10.1002/elps.1150121007; Lamorte L, 2002, MOL BIOL CELL, V13, P1449, DOI 10.1091/mbc.01-10-0477; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Miller JR, 1997, DEV BIOL, V192, P310, DOI 10.1006/dbio.1997.8739; Morali OG, 2000, DEV BIOL, V227, P133, DOI 10.1006/dbio.2000.9875; NARUKE T, 1988, J THORAC CARDIOV SUR, V96, P440; Nishihara H, 2002, CANCER LETT, V180, P55, DOI 10.1016/S0304-3835(01)00763-7; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; WILLIAMS DE, 1981, J THORAC CARDIOV SUR, V82, P70; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	37	65	72	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7950	7957		10.1038/sj.onc.1206529	http://dx.doi.org/10.1038/sj.onc.1206529			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970743				2022-12-17	WOS:000185388200010
J	Suriano, G; Mulholland, D; de Wever, O; Ferreira, P; Mateus, AR; Bruyneel, E; Nelson, CC; Mareel, MM; Yokota, J; Huntsman, D; Seruca, R				Suriano, G; Mulholland, D; de Wever, O; Ferreira, P; Mateus, AR; Bruyneel, E; Nelson, CC; Mareel, MM; Yokota, J; Huntsman, D; Seruca, R			The intracellular E-cadherin germline mutation V832 M lacks the ability to mediate cell-cell adhesion and to suppress invasion	ONCOGENE			English	Article						E-cadherin; hereditary diffuse gastric cancer; mutations; cell-cell adhesion; invasion; TCF-LEF	GASTRIC-CANCER FAMILIES	E-cadherin germline missense mutations have been shown to be responsible for significant loss of protein activity. A new cytoplasmic E-cadherin germline missense mutation (V832 M) was recently identified in a hereditary diffuse gastric cancer (HDGC) Japanese family. This E-cadherin mutant was cloned in a Chinese hamster ovary cell model system and functionally characterized, in terms of aggregation and invasion. Cells expressing the germline V832M mutant fail to aggregate and invade into collagen, supporting the pathogenic role of this germline missense mutation in gastric cancer. We also tested the ability of this mutation to activate the TCF-LEF trascriptional activity, in comparison with three other E-cadherin missense mutations (T340A, A634V and A617T), associated to loss of E-cadherin function. All the E-cadherin mutants reduced TCF-LEF activation to a similar extent as the wild-type protein, suggesting that the oncogenic effect of the E-cadherin mutants is unlikely to be transmitted through a beta-catenin-dependent activation of the WNT pathway.	Univ Porto IPATIMUP, Inst Patol & Imunol Mol, P-4200 Oporto, Portugal; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; UZG, Expt Cancerol Lab, B-9000 Ghent, Belgium; Natl Canc Ctr, Res Inst, Tokyo 104, Japan; Hosp Sao Joao, Fac Med, P-4200 Oporto, Portugal	Universidade do Porto; University of British Columbia; National Cancer Center - Japan; Sao Joao Hospital; Universidade do Porto	Seruca, R (corresponding author), Univ Porto IPATIMUP, Inst Patol & Imunol Mol, P-4200 Oporto, Portugal.	rseruca@ipatimup.pt	Huntsman, David/ABE-6082-2020; de wever, olivier/J-3094-2013; seruca, raquel/F-8187-2011	de wever, olivier/0000-0002-5453-760X; Seruca, Raquel/0000-0002-8851-4166				Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; BECKER KF, 1994, CANCER RES, V54, P3845; Becker KF, 1999, AM J PATHOL, V155, P1803, DOI 10.1016/S0002-9440(10)65497-1; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BOTERBERG T, 2000, METASTASIS RES PROTO, P35; BRACKE ME, 2000, METASTASIS RES PROTO, P81; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cavallaro U, 2002, CANCER LETT, V176, P123, DOI 10.1016/S0304-3835(01)00759-5; Chausovsky A, 2000, NAT CELL BIOL, V2, P797, DOI 10.1038/35041037; Chen HY, 1997, J CELL SCI, V110, P345; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Gayther SA, 1998, CANCER RES, V58, P4086; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Handschuh G, 2001, J MOL BIOL, V314, P445, DOI 10.1006/jmbi.2001.5143; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Machado JC, 2001, ONCOGENE, V20, P1525, DOI 10.1038/sj.onc.1204234; Oliveira C, 2003, EXPERT REV MOL DIAGN, V3, P201; Oliveira C, 2002, HUM MUTAT, V19, P510, DOI 10.1002/humu.10068; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; Polakis P, 2000, GENE DEV, V14, P1837; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHORE EM, 1991, J BIOL CHEM, V266, P19672; Suriano G, 2003, HUM MOL GENET, V12, P575, DOI 10.1093/hmg/ddg048; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Van Aken E, 2001, VIRCHOWS ARCH, V439, P725, DOI 10.1007/S004280100516; van de Wetering M, 2001, CANCER RES, V61, P278; Vecsey-Semjen B, 2002, ONCOGENE, V21, P4646, DOI 10.1038/sj.onc.1205577; Yabuta T, 2002, INT J CANCER, V101, P434, DOI 10.1002/ijc.10633	31	65	69	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2003	22	36					5716	5719		10.1038/sj.onc.1206672	http://dx.doi.org/10.1038/sj.onc.1206672			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944922				2022-12-17	WOS:000184865900023
J	Vukovic, B; Park, PC; Al-Maghrabi, J; Beheshti, B; Sweet, J; Evans, A; Trachtenberg, J; Squire, J				Vukovic, B; Park, PC; Al-Maghrabi, J; Beheshti, B; Sweet, J; Evans, A; Trachtenberg, J; Squire, J			Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma	ONCOGENE			English	Article						prostate; telomere; heterogeneity	IN-SITU HYBRIDIZATION; ATYPICAL ADENOMATOUS HYPERPLASIA; NUMERICAL CHROMOSOMAL CHANGES; INDEPENDENT ORIGIN; TUMOR PROGRESSION; ALLELIC LOSS; INSTABILITY; CANCER; IMMUNOHISTOCHEMISTRY; EPIDEMIOLOGY	Mechanisms underlying prostate cancer (CaP) initiation and progression are poorly understood. A chromosomal instability mechanism leading to the generation of numerical and structural chromosomal changes has been implicated in the preneoplastic and neoplastic stages of CaP. Telomere dysfunction is one potential mechanism associated with the onset of such instability. To determine whether there was alteration in telomere length and chromosome number, 15 paraffin-embedded prostatectomy specimens were investigated using quantitative peptide nucleic acid (PNA) FISH analysis of representative foci of carcinoma, putative precancerous lesions (high-grade prostatic intraepithelial neoplasia, HPIN) and nondysplastic prostate epithelium. A significant decrease in telomere length was shown in both HPIN and CaP in comparison with normal epithelium. In addition, elevated rates of aneusomy suggested that increased levels of chromosomal aberrations were associated with decreased telomere length. Moreover, multiple foci of HPIN were shown to have a heterogeneous overall reduction of telomere length. This reduction was more evident in the histologic regions of the prostate containing CaP. Such observations lend support to the hypothesis that telomere erosion may be a consistent feature of CaP oncogenesis and may also be associated with the generation of chromosomal instability that characterizes this malignancy.	Univ Toronto, Princess Margaret Hosp, Ontario Canc Inst, Hlth Network, Toronto, ON M5G 2M9, Canada; Univ Toronto, Fac Med, Dept Med Biophys, Hlth Network, Toronto, ON M5G 2M9, Canada; Univ Toronto, Fac Med, Lab Med & Pathobiol, Hlth Network, Toronto, ON M5G 2M9, Canada; Univ Toronto, Fac Med, Div Pathol, Hlth Network, Toronto, ON M5G 2M9, Canada; Univ Toronto, Fac Med, Div Urol, Hlth Network, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Squire, J (corresponding author), Univ Toronto, Hlth Network, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	jeremy.squire@utoronto.ca	Squire, Jeremy A/A-9352-2012; Al-Maghrabi, Jaudah/L-4367-2013	Squire, Jeremy A/0000-0002-9863-468X; Al-Maghrabi, Jaudah/0000-0002-0812-9592; Sweet, Joan/0000-0002-6791-4929				Al-Maghrabi J, 2002, ARCH PATHOL LAB MED, V126, P165; Al-Maghrabi J, 2001, MODERN PATHOL, V14, P1252, DOI 10.1038/modpathol.3880471; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; BAAS IO, 1994, J PATHOL, V172, P5, DOI 10.1002/path.1711720104; BASTACKY SI, 1995, J UROLOGY, V153, P987, DOI 10.1016/S0022-5347(01)67619-5; Beheshti B, 2001, NEOPLASIA, V3, P62, DOI 10.1038/sj.neo.7900125; Bohr V, 1998, TOXICOL LETT, V103, P47; BONKHOFF H, 1994, PROSTATE, V24, P114, DOI 10.1002/pros.2990240303; Bonsing BA, 1997, CYTOMETRY, V28, P11, DOI 10.1002/(SICI)1097-0320(19970501)28:1<11::AID-CYTO2>3.3.CO;2-H; Bostwick DG, 1998, CANCER, V83, P1995, DOI 10.1002/(SICI)1097-0142(19981101)83:9<1995::AID-CNCR16>3.0.CO;2-2; CAMPBELL C, 1993, BRIT J DERMATOL, V129, P235, DOI 10.1111/j.1365-2133.1993.tb11840.x; Cheng L, 1998, J NATL CANCER I, V90, P233, DOI 10.1093/jnci/90.3.233; COLEMAN WB, 1995, CLIN CHEM, V41, P644; Counter CM, 1996, MUTAT RES-REV GENET, V366, P45, DOI 10.1016/S0165-1110(96)90006-8; Cunningham JM, 1996, CANCER RES, V56, P4475; Dong Jin-Tang, 1997, Current Opinion in Oncology, V9, P101; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; EMMERTBUCK MR, 1995, CANCER RES, V55, P2959; Erbersdobler A, 1996, PATHOL RES PRACT, V192, P418, DOI 10.1016/S0344-0338(96)80003-3; Erbersdobler A, 1999, PROSTATE, V38, P92, DOI 10.1002/(SICI)1097-0045(19990201)38:2<92::AID-PROS2>3.0.CO;2-6; Foster CS, 2000, SCAND J UROL NEPHROL, V34, P19, DOI 10.1080/003655900750169284; GIARETTI W, 1990, INT J CANCER, V45, P597, DOI 10.1002/ijc.2910450404; Goyns MH, 2000, MECH AGEING DEV, V114, P69, DOI 10.1016/S0047-6374(00)00095-6; GRAHAM SD, 1992, CANCER, V70, P359, DOI 10.1002/1097-0142(19920701)70:1+<359::AID-CNCR2820701329>3.0.CO;2-B; Grobelny JV, 2001, HUM MOL GENET, V10, P1953, DOI 10.1093/hmg/10.18.1953; Haas GP, 1997, CA-CANCER J CLIN, V47, P273, DOI 10.3322/canjclin.47.5.273; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; Harding MA, 2000, UROL ONCOL, V5, P258, DOI 10.1016/S1078-1439(00)00073-9; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Hixon ML, 2000, FRONT BIOSCI, V5, pD50, DOI 10.2741/Hixon; ISAACS WB, 1994, SEMIN ONCOL, V21, P514; Kallakury BVS, 1997, DIAGN MOL PATHOL, V6, P192, DOI 10.1097/00019606-199708000-00003; Koeneman KS, 1998, J UROLOGY, V160, P1533, DOI 10.1016/S0022-5347(01)62608-9; Lin Y, 1997, J UROLOGY, V157, P1161, DOI 10.1016/S0022-5347(01)65160-7; MACOSKA JA, 1994, CANCER RES, V54, P3824; McClintock B, 1941, GENETICS, V26, P234; MCNEAL J, 1986, HUM PATHOL, V17; Meeker AK, 2002, AM J PATHOL, V160, P1259, DOI 10.1016/S0002-9440(10)62553-9; Morgan WF, 1998, MUTAT RES-FUND MOL M, V404, P125, DOI 10.1016/S0027-5107(98)00104-3; MUIR CS, 1991, ACTA ONCOL, V30, P133, DOI 10.3109/02841869109092336; MULLER HJ, 1938, COLLECTING NET, V13, P183; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Poon SSS, 1999, CYTOMETRY, V36, P267, DOI 10.1002/(SICI)1097-0320(19990801)36:4<267::AID-CYTO1>3.0.CO;2-O; Qian JQ, 1999, EUR UROL, V35, P479, DOI 10.1159/000019883; QIAN JQ, 1995, UROLOGY, V46, P837, DOI 10.1016/S0090-4295(99)80354-9; Rasnick D, 1999, BIOCHEM J, V340, P621, DOI 10.1042/0264-6021:3400621; Sakr WA, 1998, ANAL QUANT CYTOL, V20, P417; Sakr WA, 1996, EUR UROL, V30, P138; SAKR WA, 1993, J UROLOGY, V150, P379, DOI 10.1016/S0022-5347(17)35487-3; Sakr WA, 2001, UROLOGY, V57, P115, DOI 10.1016/S0090-4295(00)00953-5; SAKR WA, 1995, PATHOL RES PRACT, V191, P838, DOI 10.1016/S0344-0338(11)80965-9; Scates DK, 1997, BRIT J UROL, V80, P263, DOI 10.1046/j.1464-410X.1997.00248.x; Shackney SE, 1995, CYTOMETRY, V22, P307, DOI 10.1002/cyto.990220407; Takahashi C, 1997, EUR UROL, V32, P494, DOI 10.1159/000480814; Takahashi S, 1996, CLIN CANCER RES, V2, P137; van der Kwast TH, 1999, EUR UROL, V35, P508, DOI 10.1159/000019889; Wen JP, 1998, HUM MOL GENET, V7, P1137, DOI 10.1093/hmg/7.7.1137; Wullich B, 1999, J UROLOGY, V161, P1997, DOI 10.1016/S0022-5347(05)68872-6; Zhang WB, 1998, CANCER RES, V58, P619	59	65	69	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2003	22	13					1978	1987		10.1038/sj.onc.1206227	http://dx.doi.org/10.1038/sj.onc.1206227			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673203				2022-12-17	WOS:000181967700008
J	Greenblatt, MS; Beaudet, JG; Gump, JR; Godin, KS; Trombley, L; Koh, J; Bond, JP				Greenblatt, MS; Beaudet, JG; Gump, JR; Godin, KS; Trombley, L; Koh, J; Bond, JP			Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants	ONCOGENE			English	Article						missense mutation; database; cell cycle; structural biology; SNP	MISSENSE MUTATIONS; HUMAN CANCERS; GENE; SUBSTITUTION; CONSERVATION; SPECTRUM	Deciding whether a missense allelic variant affects protein function is important in many contexts. We previously demonstrated that a detailed analysis of p53 intragenic conservation correlates with somatic mutation hotspots. Here we refine these evolutionary studies and expand them to the p16/Ink4a gene. We calculated that in order for 'absolute conservation' of a codon across multiple species to achieve P < 0.05, the evolutionary substitution database must contain at least 3(M) variants, where M equals the number of codons in the gene. Codons in p53 were divided into high (73% of codons), intermediate (29% of codons), and low (0 codons) likelihood of being mutation hotspots. From a database of 263 somatic missense p16 mutations, we identified only four codons that are mutational hotspots at P < 0.05 ( > 8 mutations). However, data on function, structure, and disease association support the conclusion that 11 other codons with greater than or equal to5 somatic mutations also likely indicate functionally critical residues, even though P > 0.05. We calculated p16 evolution using amino acid substitution matrices and nucleotide substitution distances. We looked for evolutionary parameters at each codon that would predict whether missense mutations were disease associated or disrupted function. The current p16 evolutionary substitution database is too small to determine whether observations of 'absolute conservation' are statistically significant. Increasing the number of sequences from three to seven significantly improved the predictive value of evolutionary computations. The sensitivity and specificity for conservation scores in predicting disease association of P16 codons is 70-80%. Despite the small p16 sequence database, our calculations of high conservation correctly predicted loss of cell cycle arrest function in 75% of tested codons, and low conservation correctly predicted wild-type function in 80-90% of codons. These data validate our hypothesis that detailed evolutionary analyses help predict the consequences of missense amino-acid variants.	Univ Vermont, Vermont Canc Ctr, Dept Med, Burlington, VT 05401 USA; Univ Vermont, Vermont Canc Ctr, Dept Pathol, Burlington, VT 05401 USA; Univ Vermont, Vermont Canc Ctr, Dept Microbiol & Med Genet, Burlington, VT 05401 USA	University of Vermont; University of Vermont; University of Vermont	Greenblatt, MS (corresponding author), IV VT, Hematol Oncol Unit, UHC Campus,St Joseph 3210, Burlington, VT 05401 USA.	marc.greenblatt@vtmednet.org			NATIONAL CANCER INSTITUTE [P30CA022435] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA22435] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOTTEMA CDK, 1991, AM J HUM GENET, V49, P820; Ciotti P, 2000, AM J HUM GENET, V67, P311, DOI 10.1086/303001; FITCH WM, 1971, SYST ZOOL, V20, P406, DOI 10.2307/2412116; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Greenblatt MS, 2001, CANCER RES, V61, P4092; Greenblatt MS, 1996, CANCER RES, V56, P2130; HENIKOFF S, 1993, PROTEINS, V17, P49, DOI 10.1002/prot.340170108; INA Y, 1995, J MOL EVOL, V40, P190, DOI 10.1007/BF00167113; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li W.H., 1997, MOL EVOLUTION; Makalowski W, 1998, P NATL ACAD SCI USA, V95, P9407, DOI 10.1073/pnas.95.16.9407; Miller MP, 2001, HUM MOL GENET, V10, P2319, DOI 10.1093/hmg/10.21.2319; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; Ruas M, 1999, ONCOGENE, V18, P5423, DOI 10.1038/sj.onc.1202918; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; WACEY AI, 1994, HUM GENET, V94, P594; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; Walker GJ, 1999, INT J CANCER, V82, P305, DOI 10.1002/(SICI)1097-0215(19990719)82:2<305::AID-IJC24>3.0.CO;2-Z; Yang ZH, 1996, MOL BIOL EVOL, V13, P650, DOI 10.1093/oxfordjournals.molbev.a025625; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Yarbrough WG, 1999, J NATL CANCER I, V91, P1569, DOI 10.1093/jnci/91.18.1569	25	65	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1150	1163		10.1038/sj.onc.1206101	http://dx.doi.org/10.1038/sj.onc.1206101			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606942				2022-12-17	WOS:000181249700004
J	van Wely, KHM; Molijn, AC; Buijs, A; Meester-Smoor, MA; Aarnoudse, AJ; Hellemons, A; den Besten, P; Grosveld, GC; Zwarthoff, EC				van Wely, KHM; Molijn, AC; Buijs, A; Meester-Smoor, MA; Aarnoudse, AJ; Hellemons, A; den Besten, P; Grosveld, GC; Zwarthoff, EC			The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription	ONCOGENE			English	Article						translocation; leukemia; retinoic acid; hormone receptor; coactivator	ACUTE PROMYELOCYTIC LEUKEMIA; FUSION PROTEIN; DNA-BINDING; PROGESTERONE-RECEPTOR; RESPONSE ELEMENTS; MYELOID-LEUKEMIA; CELL-GROWTH; GENE; TEL; DOMAINS	The t(12;22) creates an MN1-TEL fusion gene leading to acute myeloid leukemia. The fusion partner TEL (ETV6) is a member of the ETS family of transcription factors. The nature of the other fusion partner, MAII, has not been investigated in detail until now. We recently described that MN1 activates the transcription activity of the moloney sarcoma virus long terminal repeat, indicating that this protein itself may act as a transcription factor. We show here that MN1 comprises multiple transcription activating domains. A search for a bound DNA sequence revealed that MN1 has affinity for retinoic acid responsive elements. A DR5 retinoic acid responsive element was observed in the LTR. The combination of MN1 and ligand-activated retinoic acid receptor leads to a synergistic induction of expression directed by the LTR. Cotransfection of MN1 with RAC3 or p300, known coactivators of retinoic acid receptors, leads to a further synergistic induction of transcription. In addition, the effect of MN1 can be inhibited by the wild-type adenovirus E1A protein that inhibits p300 function, but not by an E1A mutant lacking the p300-binding site. GAL4-MN1-mediated transcription can be enhanced directly by RAC3 and p300. Taken together, our results indicate that MN1 is a transcription coactivator rather than a sequence-specific transcription factor, and that it may stimulate RAR/RXR-mediated transcription through interaction with p160 and p300.	Erasmus Univ, Dept Pathol, NL-3000 DR Rotterdam, Netherlands; Univ Utrecht Hosp, Dept Hematol, NL-3584 CX Utrecht, Netherlands; St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38101 USA	Erasmus University Rotterdam; Utrecht University; Utrecht University Medical Center; St Jude Children's Research Hospital	Zwarthoff, EC (corresponding author), Erasmus Univ, Dept Pathol, POB 1738, NL-3000 DR Rotterdam, Netherlands.	zwarthoff@path.fgg.eur.nl		van Wely, Karel Hermanus Martinus/0000-0001-8431-8072	NCI NIH HHS [CA72996-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072996] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Beverloo HB, 2001, CANCER RES, V61, P5374; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; Buijs A, 2000, MOL CELL BIOL, V20, P9281, DOI 10.1128/MCB.20.24.9281-9293.2000; Cazzaniga G, 2001, CANCER RES, V61, P4666; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; DENBAKKER MA, 1995, AM J PATHOL, V147, P1339; DEPREZ RHL, 1995, ONCOGENE, V10, P1521; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; DORSMAN JC, 1995, J VIROL, V69, P2962, DOI 10.1128/JVI.69.5.2962-2967.1995; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Goodman RH, 2000, GENE DEV, V14, P1553; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li H, 1998, J BIOL CHEM, V273, P5948, DOI 10.1074/jbc.273.10.5948; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Nakshatri H, 1998, NUCLEIC ACIDS RES, V26, P2491, DOI 10.1093/nar/26.10.2491; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Shao WL, 2000, BLOOD, V96, P2233; SHEMSHEDINI L, 1992, J BIOL CHEM, V267, P1834; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Wang ZG, 1998, SCIENCE, V279, P1547; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Xu Y, 2000, MOL CELL BIOL, V20, P2138, DOI 10.1128/MCB.20.6.2138-2146.2000; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x	38	65	66	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2003	22	5					699	709		10.1038/sj.onc.1206124	http://dx.doi.org/10.1038/sj.onc.1206124			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569362				2022-12-17	WOS:000180642100007
J	Afonja, O; Raaka, BM; Huang, A; Das, S; Zhao, XY; Helmer, E; Juste, D; Samuels, HH				Afonja, O; Raaka, BM; Huang, A; Das, S; Zhao, XY; Helmer, E; Juste, D; Samuels, HH			RAR agonists stimulate SOX9 gene expression in breast cancer cell lines: evidence for a role in retinoid-mediated growth inhibition	ONCOGENE			English	Article						SOX9; retinoids; retinoic acid receptor; breast cancer; cell cycle; growth inhibition	ACUTE PROMYELOCYTIC LEUKEMIA; MAMMARY EPITHELIAL-CELLS; ACID RECEPTOR-ALPHA; MAMMALIAN SEX DETERMINATION; II COLLAGEN GENE; CARCINOMA CELLS; SELECTIVE RETINOIDS; APOPTOSIS INDUCTION; G(1) ARREST; VITAMIN-A	Retinoic acid receptors (RARs) are ligand-dependent transcription factors which are members of the steroid/thyroid hormone receptor gene family. RAR-agonists inhibit the proliferation of many human breast cancer cell lines, particularly those whose growth is stimulated by estradiol (E2) or growth factors. PCR-amplified subtractive hybridization was used to identify candidate retinoid-regulated genes that may be involved in growth inhibition. One candidate gene identified was SOX9, a member of the high mobility group (HMG) box gene family of transcription factors. SOX9 gene expression is rapidly stimulated by RAR-agonists in T-47D cells and other retinoid-inhibited breast cancer cell lines. In support of this finding, a database search indicates that SOX9 is expressed as an EST in breast tumor cells. SOX9 is known to be expressed in chondrocytes where it regulates the transcription of type 11 collagen and in testes where it plays a role in male sexual differentiation. RAR pan-agonists and the RARalpha-selective agonist Am580, but not RXR agonists, stimulate the expression of SOX9 in a wide variety of retinoid-inhibited breast cancer cell lines. RAR-agonists did not stimulate SOX9 in breast cancer cell lines which were not growth inhibited by retinoids. Expression of SOX9 in T-47D cells leads to cycle changes similar to those found with RAR-agonists while expression of a dominant negative form of SOX9 blocks RA-mediated cell cycle changes, suggesting a role for SOX9 in retinoid-mediated growth inhibition.	NYU, Sch Med, Dept Pediat, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; Long Isl Univ, Dept Biol, Brooklyn, NY 11201 USA	New York University; New York University; Long Island University-Brooklyn Campus	Samuels, HH (corresponding author), NYU, Sch Med, Dept Pediat, 550 1st Ave, New York, NY 10016 USA.	herbert.samuels@med.nyu.edu			NCI NIH HHS [K12CA01713, CO15710] Funding Source: Medline; PHS HHS [D16636] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA001713] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO015710] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGADIR A, 1994, CELL MOL BIOL, V40, P263; AMOS B, 1990, METHOD ENZYMOL, V190, P217; Arafa HMM, 1996, J CHROMATOGR A, V729, P125, DOI 10.1016/0021-9673(95)00980-9; Arafa HMM, 2000, ARCH TOXICOL, V73, P547, DOI 10.1007/s002040050007; Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; Brooks SC, 1996, BLOOD, V87, P227; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAWSON MI, 1995, CANCER RES, V55, P4446; Desai SH, 2000, BIOCHEM PHARMACOL, V59, P1265, DOI 10.1016/S0006-2952(00)00269-0; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Fanjul AN, 1996, CANCER RES, V56, P1571; FENAUX P, 1993, ACTA HAEMATOL-BASEL, V89, P22; Fitzgerald P, 1997, CANCER RES, V57, P2642; FONTANA JA, 1990, CANCER RES, V50, P1977; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; Gianni M, 1996, BLOOD, V87, P1520, DOI 10.1182/blood.V87.4.1520.bloodjournal8741520; Giese K, 1997, P NATL ACAD SCI USA, V94, P12845, DOI 10.1073/pnas.94.24.12845; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Graham JD, 1999, J MOL ENDOCRINOL, V22, P295, DOI 10.1677/jme.0.0220295; Graves JAM, 1998, BIOESSAYS, V20, P264, DOI 10.1002/(SICI)1521-1878(199803)20:3&lt;264::AID-BIES10&gt;3.0.CO;2-1; Grunt TW, 1998, BRIT J CANCER, V78, P79, DOI 10.1038/bjc.1998.446; Hanley NA, 2000, MECH DEVELOP, V91, P403, DOI 10.1016/S0925-4773(99)00307-X; HAWKINS JR, 1995, J ENDOCRINOL, V147, P183, DOI 10.1677/joe.0.1470183; Healy C, 1999, DEV DYNAM, V215, P69, DOI 10.1002/(SICI)1097-0177(199905)215:1<69::AID-DVDY8>3.0.CO;2-N; Hong W K, 1995, J Natl Cancer Inst Monogr, P49; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; Jinno H, 1999, CARCINOGENESIS, V20, P229, DOI 10.1093/carcin/20.2.229; KAGECHIKA H, 1988, J MED CHEM, V31, P2182, DOI 10.1021/jm00119a021; Kent J, 1996, DEVELOPMENT, V122, P2813; Koopman P, 1999, CELL MOL LIFE SCI, V55, P839; Koopman P, 2001, EXS, V91, P25; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LACROIX A, 1980, J CLIN INVEST, V65, P586, DOI 10.1172/JCI109703; Langenfeld J, 1996, ONCOGENE, V13, P1983; Lefebvre V, 1998, MATRIX BIOL, V16, P529; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MANGELSDORF DJ, 1993, RECENT PROG HORM RES, V48, P99; MANGELSDORF DJ, 1994, NUTR REV, V52, P32; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Mangiarotti R, 1998, BRIT J CANCER, V77, P186, DOI 10.1038/bjc.1998.32; MARTH C, 1984, BIOCHEM PHARMACOL, V33, P2217, DOI 10.1016/0006-2952(84)90657-9; Nagai K, 2001, GENE, V270, P161, DOI 10.1016/S0378-1119(01)00479-6; Offterdinger M, 1998, BIOCHEM BIOPH RES CO, V251, P907, DOI 10.1006/bbrc.1998.9570; Olney PN, 1999, AM J MED GENET, V84, P20, DOI 10.1002/(SICI)1096-8628(19990507)84:1<20::AID-AJMG5>3.3.CO;2-E; Panda DK, 2001, J BIOL CHEM, V276, P41229, DOI 10.1074/jbc.M104231200; Raffo P, 2000, ANTICANCER RES, V20, P1535; Schafer AJ, 1996, ANN NY ACAD SCI, V785, P137, DOI 10.1111/j.1749-6632.1996.tb56252.x; Schneider SM, 2000, CANCER RES, V60, P5479; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Seewaldt VL, 1999, CELL GROWTH DIFFER, V10, P49; Seewaldt VL, 1997, CELL GROWTH DIFFER, V8, P631; Seewaldt VL, 1997, EXP CELL RES, V236, P16, DOI 10.1006/excr.1997.3694; Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738; Sekiya I, 2001, J CELL BIOCHEM, P71, DOI 10.1002/jcb.1077; SHAO ZM, 1995, ONCOGENE, V11, P493; SHEIKH MS, 1993, J CELL BIOCHEM, V53, P394, DOI 10.1002/jcb.240530417; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; SPORN MB, 1983, CANCER RES, V43, P3034; Sudbeck P, 1997, J BIOL CHEM, V272, P27848, DOI 10.1074/jbc.272.44.27848; Teixeira C, 1997, MOL ENDOCRINOL, V11, P1191, DOI 10.1210/me.11.9.1191; Toma S, 1997, INT J CANCER, V70, P619, DOI 10.1002/(SICI)1097-0215(19970304)70:5<619::AID-IJC21>3.0.CO;2-6; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; VANDERLEEDE BJM, 1995, MOL CELL ENDOCRINOL, V109, P77, DOI 10.1016/0303-7207(95)03487-R; Watanabe K, 2000, P NATL ACAD SCI USA, V97, P1624, DOI 10.1073/pnas.97.4.1624; Willhite CC, 1996, DRUG METAB REV, V28, P105, DOI 10.3109/03602539608993994; Zhou Q, 1997, ONCOGENE, V15, P107, DOI 10.1038/sj.onc.1201142	75	65	72	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2002	21	51					7850	7860		10.1038/sj.onc.1205985	http://dx.doi.org/10.1038/sj.onc.1205985			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	610DT	12420222				2022-12-17	WOS:000178946000010
J	Morelli, C; Karayianni, E; Magnanini, C; Mungall, AJ; Thorland, E; Negrini, M; Smith, DI; Barbanti-Brodano, G				Morelli, C; Karayianni, E; Magnanini, C; Mungall, AJ; Thorland, E; Negrini, M; Smith, DI; Barbanti-Brodano, G			Cloning and characterization of the common fragile site FRA6F harboring a replicative senescence gene and frequently deleted in human tumors	ONCOGENE			English	Article						FRA6F; fragile sites; chromosome 6q21; senescence; human tumors; schizophrenia	IMMORTAL HUMAN FIBROBLASTS; EPITHELIAL OVARIAN-CANCER; 2 DISTINCT REGIONS; CHROMOSOME 6Q; HOMOZYGOUS DELETIONS; MULTIPLE REGIONS; INTEGRATION SITE; HUMAN HOMOLOG; BROAD REGION; ALLELIC LOSS	The common fragile site FRA6GF, located at 6q21, is an extended region of about 1200 kb, with two hot spots of breakage each spanning about 200 kb. Transcription mapping of the FRA6F region identified 19 known genes, 10 within the FRA6F interval and nine in a proximal or distal position. The nucleotide sequence of FRA6F is rich in repetitive elements (LINE1 and LINE2, Alu, MIR, MER and endogenous retroviral sequences) as well as in matrix attachment regions (MARs), and shows several DNA segments with increased helix flexibility. We found that tight clusters of stem-loop structures were localized exclusively in the two regions with greater frequency of breakage. Chromosomal instability at FRA6F probably depends on a complex interaction of different factors, involving regions of greater DNA flexibility and MARs. We propose an additional mechanism of fragility at FRA6F, based on stem-loop structures which may cause delay or arrest in DNA replication. A senescence gene likely maps within FRA6F, as suggested by detection of deletion and translocation breakpoints involving this fragile site in immortal human-mouse cell hybrids and in SV40-immortalized human fibroblasts containing a human chromosome 6 deleted at q21. Deletion breakpoints within FRA6F are common in several types of human leukemias and solid tumors, suggesting the presence of a tumor suppressor gene in the region. Moreover, a gene associated to hereditary schizophrenia maps within FRA6F. Therefore, FRA6F may represent a landmark for the identification and cloning of genes involved in senescence, leukemia, cancer and schizophrenia.	Univ Ferrara, Microbiol Sect, Dept Exptl & Diagnost Med, I-44100 Ferrara, Italy; Univ Ferrara, Ctr Biotechnol, I-44100 Ferrara, Italy; Sanger Ctr, Hinxton CB10 1SA, Cambs, England; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Med, Rochester, MN 55905 USA	University of Ferrara; University of Ferrara; Wellcome Trust Sanger Institute; Mayo Clinic	Barbanti-Brodano, G (corresponding author), Univ Ferrara, Microbiol Sect, Dept Exptl & Diagnost Med, Via Luigi Borsari 46, I-44100 Ferrara, Italy.		Negrini, Massimo/J-2377-2016; Mungall, Andrew J./U-7067-2018	Negrini, Massimo/0000-0002-0007-1920; Mungall, Andrew J./0000-0002-0905-2742				Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Bell DW, 1997, CANCER RES, V57, P4057; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; BRUKNER I, 1995, EMBO J, V14, P1812, DOI 10.1002/j.1460-2075.1995.tb07169.x; Cao QH, 1997, GENOMICS, V43, P1, DOI 10.1006/geno.1997.4815; Chen CH, 1998, HUM GENET, V103, P702, DOI 10.1007/s004390050894; Cooney KA, 1996, CANCER RES, V56, P4150; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Egeli U, 2000, HEAD NECK-J SCI SPEC, V22, P591, DOI 10.1002/1097-0347(200009)22:6<591::AID-HED8>3.0.CO;2-C; Gabrielian A, 1996, FEBS LETT, V393, P65, DOI 10.1016/0014-5793(96)00855-1; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; GUALANDI F, 1994, GENE CHROMOSOME CANC, V10, P77, DOI 10.1002/gcc.2870100202; Hellman A, 2000, MOL CELL BIOL, V20, P4420, DOI 10.1128/MCB.20.12.4420-4427.2000; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Huang HJ, 1998, ONCOGENE, V16, P2311, DOI 10.1038/sj.onc.1200202; Huang HJ, 1999, GENE CHROMOSOME CANC, V24, P48, DOI 10.1002/(SICI)1098-2264(199901)24:1<48::AID-GCC7>3.3.CO;2-M; Huang NN, 1998, J CHIN INST ENG, V21, P159, DOI 10.1080/02533839.1998.9670381; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; Inoue H, 1997, P NATL ACAD SCI USA, V94, P14584, DOI 10.1073/pnas.94.26.14584; Jackson A, 1998, GENOMICS, V50, P34, DOI 10.1006/geno.1998.5270; Karayianni E, 1999, CYTOGENET CELL GENET, V86, P263, DOI 10.1159/000015356; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; Le Beau MM, 1998, HUM MOL GENET, V7, P755, DOI 10.1093/hmg/7.4.755; LEBEAU MM, 1984, NATURE, V308, P607, DOI 10.1038/308607a0; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; Mangelsdorf M, 2000, CANCER RES, V60, P1683; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; Miele ME, 2000, INT J CANCER, V86, P524, DOI 10.1002/(SICI)1097-0215(20000515)86:4<524::AID-IJC13>3.0.CO;2-W; Mimori K, 1999, P NATL ACAD SCI USA, V96, P7456, DOI 10.1073/pnas.96.13.7456; Mishmar D, 1999, AM J HUM GENET, V64, P908, DOI 10.1086/302299; Mishmar D, 1998, P NATL ACAD SCI USA, V95, P8141, DOI 10.1073/pnas.95.14.8141; Morelli C, 2000, GENE, V252, P217, DOI 10.1016/S0378-1119(00)00231-6; Morelli C, 1997, CANCER RES, V57, P4153; Morelli C, 1998, CYTOGENET CELL GENET, V83, P18, DOI 10.1159/000015157; Morelli C, 1997, CYTOGENET CELL GENET, V79, P97, DOI 10.1159/000134691; Paige AJW, 2000, CANCER RES, V60, P1690; PAPPAS GJ, 1995, GENOMICS, V25, P124, DOI 10.1016/0888-7543(95)80117-5; QUEIMADO L, 1995, GENE CHROMOSOME CANC, V14, P28, DOI 10.1002/gcc.2870140106; Queimado L, 1998, ONCOGENE, V16, P83, DOI 10.1038/sj.onc.1201480; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; RAY FA, 1992, CANCER GENET CYTOGEN, V59, P39, DOI 10.1016/0165-4608(92)90155-2; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; Shridhar V, 1999, ONCOGENE, V18, P3913, DOI 10.1038/sj.onc.1202756; Simonic I, 1996, HUM GENET, V97, P524; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; Smith DI, 1998, INT J ONCOL, V12, P187; Starostik P, 2000, BLOOD, V95, P1180, DOI 10.1182/blood.V95.4.1180.004k14_1180_1187; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; Talwalkar VR, 1998, CANCER GENET CYTOGEN, V104, P111, DOI 10.1016/S0165-4608(97)00452-4; Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272; Tunca B, 2000, CANCER GENET CYTOGEN, V119, P139, DOI 10.1016/S0165-4608(99)00228-9; Tunca B, 2000, CANCER LETT, V152, P201, DOI 10.1016/S0304-3835(00)00334-7; Utada Y, 2000, JPN J CANCER RES, V91, P293, DOI 10.1111/j.1349-7006.2000.tb00944.x; Wang L, 1997, GENOMICS, V41, P485, DOI 10.1006/geno.1997.4690; Wang L, 1999, HUM MOL GENET, V8, P431, DOI 10.1093/hmg/8.3.431; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375	66	65	65	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7266	7276		10.1038/sj.onc.1205573	http://dx.doi.org/10.1038/sj.onc.1205573			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370818				2022-12-17	WOS:000178504600016
J	Jiang, XH; Lam, SK; Lin, MC; Jiang, SH; Kung, HF; Slosberg, ED; Soh, JW; Weinstein, B; Wong, BCY				Jiang, XH; Lam, SK; Lin, MC; Jiang, SH; Kung, HF; Slosberg, ED; Soh, JW; Weinstein, B; Wong, BCY			Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-beta(1)-dependent pathway	ONCOGENE			English	Article						gastric cancer; apoptosis; protein kinase C; cyclo-oxygenase-2; cancer prevention	COLON-CANCER CELLS; NONSTEROIDAL ANTIINFLAMMATORY DRUG; KAPPA-B ACTIVITY; CYCLOOXYGENASE-2 INHIBITOR; EPITHELIAL-CELLS; COLORECTAL-CANCER; PROSTAGLANDIN E-2; SULINDAC SULFIDE; CARCINOMA CELLS; PHORBOL ESTER	Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the risk of gastrointestinal cancers. Recently, a similar protective effect has been demonstrated by the specific cyclo-oxygenase-2 (COX-2) inhibitors. However, the exact mechanism that accounts for the anti-proliferative effect of specific COX-2 inhibitors is still not fully understood, and it is still controversial whether these protective effects are predominantly mediated through the inhibition of COX-2 activity and prostaglandin synthesis. Identification of molecular targets regulated by COX-2 inhibitors could lead to a better understanding of their pro-apoptotic and anti-neoplastic activities. In the present study, we investigated the effect and the possible molecular target of a COX-2-specific inhibitor SC-236 on gastric cancer. We showed that SC-236 induced apoptosis in gastric cancer cells. However, this effect was not dependent on COX-2 inhibition. SC-236 down-regulated the protein expression and kinase activity of PKC-beta(1), increased the expression of PKCdelta and PKCeta, but did not alter the expression of other PKC isoforms in AGS cells. Moreover, exogenous prostaglandins or PGE(2) receptor antagonists could not reverse the inhibition effect on PKCbeta(1) by SC-236, which suggested that this effect occurred through a mechanism independent of cyclo-oxygenase activity and prostaglandin synthesis. Overexpression of PKCbeta(1) attenuated the apoptotic response of AGS cells to SC-236 and was associated with overexpression of p21(wafl/cip1). Inhibition of PKQ1-mediated overexpression of p21(wafl/cip1) partially reduced the anti-apoptotic effect of PKCbeta(1). The down-regulation of PKCbeta(1) provides an explanation for COX-independent apoptotic effects of specific COX-2 inhibitor in cultured gastric cancer cells. We also suggest that PKCbeta(1) act as survival mediator in gastric cancer, and its down-regulation by COX-2 inhibitor SC-236 may provide new target for future treatment of gastric cancer.	Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China; Rui Jin Hosp, Dept Gastroenterol, Shanghai, Peoples R China; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China; Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	University of Hong Kong; University of Hong Kong; Columbia University	Wong, BCY (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China.		Wong, Benjamin Chun Yu/C-4436-2009; Wong, Benjamin Chun Yu/ABB-1962-2020; jiang, cynthia xiaohua/F-7580-2017	jiang, cynthia xiaohua/0000-0002-7372-4961				Akashi M, 1999, BIOCHEM J, V337, P607, DOI 10.1042/0264-6021:3370607; Barnes CJ, 1998, BRIT J CANCER, V77, P573, DOI 10.1038/bjc.1998.93; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Cesaro P, 2001, INT J CANCER, V93, P179, DOI 10.1002/ijc.1314; Das D, 2000, FEBS LETT, V472, P50, DOI 10.1016/S0014-5793(00)01416-2; Deacon EM, 1997, J CLIN PATHOL-MOL PA, V50, P124, DOI 10.1136/mp.50.3.124; DuBois RN, 1996, J GASTROENTEROL, V31, P898, DOI 10.1007/BF02358623; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Frey MR, 1997, J BIOL CHEM, V272, P9424; Goldberg Y, 1996, ONCOGENE, V12, P893; Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje; Gupta RA, 1998, GASTROENTEROLOGY, V114, P1095, DOI 10.1016/S0016-5085(98)70330-0; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; JONES DA, 1993, J BIOL CHEM, V268, P9049; Jones MK, 1999, NAT MED, V5, P1418; JUN C, 1997, J IMMUNOL, V162, P3395; KARGMAN SL, 1995, CANCER RES, V55, P3785; Kawamori T, 1998, CANCER RES, V58, P409; Kinoshita T, 1999, BBA-MOL CELL BIOL L, V1438, P120, DOI 10.1016/S1388-1981(99)00034-7; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kunikata T, 2001, J PHYSIOLOGY-PARIS, V95, P157, DOI 10.1016/S0928-4257(01)00021-3; Li M, 2001, CLIN CANCER RES, V7, P1010; LI Y, 1999, J BIOL CHEM, V271, P27025; Livneh E, 1996, ONCOGENE, V12, P1545; Mitchell JA, 1999, BRIT J PHARMACOL, V128, P1121, DOI 10.1038/sj.bjp.0702897; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Reddy BS, 1996, CANCER RES, V56, P4566; Richter M, 2001, CARCINOGENESIS, V22, P17, DOI 10.1093/carcin/22.1.17; Ristimaki A, 1997, CANCER RES, V57, P1276; Sawaoka H, 1998, AM J PHYSIOL-GASTR L, V274, pG1061, DOI 10.1152/ajpgi.1998.274.6.G1061; SCHWARTZ GK, 1995, J NATL CANCER I, V87, P1394, DOI 10.1093/jnci/87.18.1394; SCHWARTZ GK, 1993, J NATL CANCER I, V85, P402, DOI 10.1093/jnci/85.5.402; Shao J, 2000, ONCOGENE, V19, P726, DOI 10.1038/sj.onc.1203383; Sheng HM, 1998, CANCER RES, V58, P362; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Shureiqi I, 2000, J NATL CANCER I, V92, P1136, DOI 10.1093/jnci/92.14.1136; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Sugibayashi R, 2001, ONCOGENE, V20, P1220, DOI 10.1038/sj.onc.1204206; Teicher BA, 2001, ANTICANCER RES, V21, P3175; Teicher BA, 2001, CANCER CHEMOTH PHARM, V48, P473, DOI 10.1007/s002800100372; Teicher BA, 2001, IN VIVO, V15, P185; Thun MJ, 1996, GASTROENTEROL CLIN N, V25, P333, DOI 10.1016/S0889-8553(05)70250-8; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Tucker ON, 1999, CANCER RES, V59, P987; Weber CK, 2000, GASTROENTEROLOGY, V119, P1209, DOI 10.1053/gast.2000.19458; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Wilson KT, 1998, CANCER RES, V58, P2929; Won JS, 1998, MOL BRAIN RES, V60, P203, DOI 10.1016/S0169-328X(98)00182-X; YASUI W, 1985, JPN J CANCER RES, V76, P1168; Zeng YX, 1996, ONCOGENE, V12, P1557; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451; Zhu GH, 2000, GASTROENTEROLOGY, V118, P507, DOI 10.1016/S0016-5085(00)70256-3; Zhu GH, 1999, BRIT J CANCER, V79, P393, DOI 10.1038/sj.bjc.6690062; Zhu GH, 1999, DIGEST DIS SCI, V44, P2020, DOI 10.1023/A:1026670301787	66	65	68	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2002	21	39					6113	6122		10.1038/sj.onc.1205778	http://dx.doi.org/10.1038/sj.onc.1205778			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	587YF	12203123				2022-12-17	WOS:000177671300014
J	Bernard, D; Monte, D; Vandenbunder, B; Abbadie, C				Bernard, D; Monte, D; Vandenbunder, B; Abbadie, C			The c-Rel transcription factor can both induce and inhibit apoptosis in the same cells via the upregulation of MnSOD	ONCOGENE			English	Article						NF-kappaB; apoptosis; MnSOD; reactive oxygen species	NF-KAPPA-B; MANGANESE SUPEROXIDE-DISMUTASE; SEVERE LIVER DEGENERATION; PROSTATE CARCINOMA-CELLS; ALPHA-INDUCED APOPTOSIS; MICE LACKING; DIHYDRORHODAMINE 123; HYDROGEN-PEROXIDE; DEFICIENT MICE; T-LYMPHOCYTES	Rel/NF-kappaB transcription factors are involved in several physiological processes, including the regulation of apoptosis. These factors were shown to exhibit pro- or anti-apoptotic activities in different cellular models, but at present, the mechanisms underlying these opposite effects are poorly understood. In this study, we show that the constitutive expression of a transcriptionally active member of the Rel/NF-kappaB family, c-Rel, first induces a resistance against TNFalpha-induced apoptosis and later increases the level of spontaneous apoptosis of HeLa cells. Both the anti- and pro-apoptotic effects increase with the level of c-Rel overexpression. The up-regulation by c-Rel of the manganese superoxide dismutase (MnSOD) could explain both the rapid anti-apoptotic effect and the delayed pro-apoptotic one. Indeed, the enzymatic activity of MnSOD is to transform the toxic O-2(.-) in H2O2. Hence, on one hand, its induction helps cells to resist against the apoptogenic burst of O-2 produced upon TNFalpha stimulation, but on the other hand, it leads to a progressive H2O2 accumulation that ultimately results in apoptosis. These results indicate that the anti- and pro-apoptotic effects of Rel/NF-kappaB factors are not necessarily alternative but can occur successively in the same cell, via the up-regulation of the same target gene.	Univ Lille 2, IPL, CNRS, FRE 2353,Inst Biol Lille, F-59021 Lille, France; Univ Lille 2, IPL, CNRS, UMR 8526,Inst Biol Lille, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille	Abbadie, C (corresponding author), Univ Lille 2, IPL, CNRS, FRE 2353,Inst Biol Lille, 1 Rue Calmette,BP 447, F-59021 Lille, France.	corinne.abbadie@ibl.fr	ABBADIE, Corinne/F-4949-2018; Bernard, David/D-6265-2018	ABBADIE, Corinne/0000-0002-8174-2393; monte, didier/0000-0002-0613-6203				ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bernard D, 2001, J BIOL CHEM, V276, P27322, DOI 10.1074/jbc.M011183200; Bernard D, 2001, CANCER RES, V61, P2656; Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Cusack JC, 2000, CANCER RES, V60, P2323; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Dumont A, 1999, ONCOGENE, V18, P747, DOI 10.1038/sj.onc.1202325; Gorman A, 1997, FEBS LETT, V404, P27, DOI 10.1016/S0014-5793(97)00069-0; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200; Gugasyan R, 2000, IMMUNOL REV, V176, P134; HENDERSON LM, 1993, EUR J BIOCHEM, V217, P973, DOI 10.1111/j.1432-1033.1993.tb18328.x; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang Y, 2000, CANCER RES, V60, P4426; Huguet C, 1997, CELL DEATH DIFFER, V4, P413, DOI 10.1038/sj.cdd.4400259; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kaufman CK, 2000, J CELL BIOL, V149, P999, DOI 10.1083/jcb.149.5.999; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; Leo E, 2001, J BIOL CHEM, V276, P8087, DOI 10.1074/jbc.M009450200; Li N, 1998, J CELL PHYSIOL, V175, P359, DOI 10.1002/(SICI)1097-4652(199806)175:3<359::AID-JCP14>3.0.CO;2-0; Li N, 1999, FREE RADICAL BIO MED, V26, P1554, DOI 10.1016/S0891-5849(99)00024-6; Li N, 1998, PROSTATE, V35, P221, DOI 10.1002/(SICI)1097-0045(19980515)35:3<221::AID-PROS8>3.0.CO;2-J; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Moreno-Manzano V, 2000, J BIOL CHEM, V275, P12684, DOI 10.1074/jbc.275.17.12684; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; OBERLEY TD, 1995, FREE RADICAL BIO MED, V19, P53, DOI 10.1016/0891-5849(95)00012-M; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Qin ZH, 1999, J NEUROSCI, V19, P4023; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Rudolph D, 2000, GENE DEV, V14, P854; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Sohur US, 2000, CANCER RES, V60, P1202; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Zong WX, 1998, CELL DEATH DIFFER, V5, P963, DOI 10.1038/sj.cdd.4400441	57	65	73	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2002	21	28					4392	4402		10.1038/sj.onc.1205536	http://dx.doi.org/10.1038/sj.onc.1205536			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	564MA	12080470				2022-12-17	WOS:000176317100005
J	Kahana, O; Micksche, M; Witz, IP; Yron, I				Kahana, O; Micksche, M; Witz, IP; Yron, I			The focal adhesion kinase (P125(FAK)) is constitutively active in human malignant melanoma	ONCOGENE			English	Article						melanoma; anchorage independence; integrins; FAK; phosphorylation; cytoskeleton	DEPENDENT TYROSINE PHOSPHORYLATION; C-TERMINAL DOMAIN; PROTEIN-KINASE; CELL-LINES; SIGNAL-TRANSDUCTION; T-CELLS; EXPRESSION; GENE; SRC; OVEREXPRESSION	Malignant melanoma cells show high aggressiveness and metastatic potential. Tumor cells as they become more metastatic, gradually lose their dependence on both adhesion and serum. Thus, in the process of tumor progression cells undergo series of changes that allow them to adapt to different tissue milieu. This implies that during this process, points on the integrin pathway may become constitutively activated. In the present study we investigated the possible role of FAK, being one of the key members of the integrin-signaling pathway, in the multi-step progression towards a malignant phenotype in human melanoma. In our study we show that in melanoma cells there is neither an increase in the amount of FAK nor in its phosphorylation capacity, but rather in its levels of constitutive activation. Indeed, in all melanoma cells tested and not in nevus and neuroblastoma cells, we observed various degrees of constitutive activation of FAK. Our results also suggest that FAK constitutive activation is regulated at least in part by the cytoskeleton, implying that steps along the integrin signaling pathway involving FAK could be among the oncogenic mechanisms that operate in melanoma and may account for the highly aggressive, anchorage independent phenotype of this tumor.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Ela Kodesz Inst Res Canc Dev & Prevent, IL-69978 Tel Aviv, Israel; Univ Vienna, Inst Canc Res, Dept Appl & Expt Oncol, Vienna, Austria	Tel Aviv University; Tel Aviv University; University of Vienna	Yron, I (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel.							Agochiya M, 1999, ONCOGENE, V18, P5646, DOI 10.1038/sj.onc.1202957; AKASAKA T, 1995, J INVEST DERMATOL, V105, P104, DOI 10.1111/1523-1747.ep12313396; Berger W, 1997, INT J CANCER, V71, P108, DOI 10.1002/(SICI)1097-0215(19970328)71:1<108::AID-IJC18>3.0.CO;2-E; BERGER W, 1994, INT J CANCER, V59, P717, DOI 10.1002/ijc.2910590522; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; CHEN HC, 1994, J BIOL CHEM, V269, P31229; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Flinn HM, 1996, J CELL SCI, V109, P1133; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HEMLER ME, 1983, J IMMUNOL, V131, P334; HYNES RO, 1992, CELL, V69, P1; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; LEWIS JM, 1995, MOL BIOL CELL, V6, P151, DOI 10.1091/mbc.6.2.151; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Maung K, 1999, ONCOGENE, V18, P6824, DOI 10.1038/sj.onc.1203094; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; Nolan K, 1999, MOL CELL BIOL, V19, P6120; OWENS LV, 1995, CANCER RES, V55, P2752; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Ren XD, 2000, J CELL SCI, V113, P3673; Richardson A, 1997, BIOCHEM J, V324, P141, DOI 10.1042/bj3240141; Ridley A, 2000, J CELL BIOL, V150, pF107, DOI 10.1083/jcb.150.4.F107; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; Yron I, 1999, CELL ADHES COMMUN, V7, P1, DOI 10.3109/15419069909034388	44	65	68	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 6	2002	21	25					3969	3977		10.1038/sj.onc.1205472	http://dx.doi.org/10.1038/sj.onc.1205472			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037679				2022-12-17	WOS:000175869900003
J	Lein, M; Jung, K; Ortel, B; Stephan, C; Rothaug, W; Juchem, R; Johannsen, M; Deger, S; Schnorr, D; Loening, S; Krell, HW				Lein, M; Jung, K; Ortel, B; Stephan, C; Rothaug, W; Juchem, R; Johannsen, M; Deger, S; Schnorr, D; Loening, S; Krell, HW			The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model	ONCOGENE			English	Article						prostate cancer; Dunning tumor; metalloproteinases; synthetic inhibitor; animal model	TISSUE INHIBITOR; BATIMASTAT BB-94; TIMP-2; ANGIOGENESIS; PROGRESSION; EXPRESSION; CARCINOMA; SECRETION; CULTURES; BENIGN	The therapeutic efficacy of synthetic inhibitors of matrix-metalloproteinases (MMPs) in various cancers has been demonstrated. A novel inhibitor, Ro 28-2653, with high selectivity for MMP2, MMP9 and membrane type 1-MMP was evaluated in an orthotopic prostate cancer rat model. Efficacy was determined by recording tumor growth and survival endpoints. Prostate cancer was induced by inoculating R3327 Dunning tumor cells (MatLyLu) into the ventral lobe of the prostates of 148 Copenhagen rats. Daily oral treatment with Ro 282653 (10-300 mg/kg per day) was started on day 1 or on day 6 after tumor cell injection. Animals were sacrificed on day 20 for determination of tumor weights. For survival studies, rats received daily oral Ro 28-2653 (100 mg/kg per day) or vehicle for up to 30 days. Tumor induction was successful in 100% of the animals. Ro 282653 reproducibly reduced the tumor weights by up to 90% in a dose-dependent manner. In addition, an inhibitory effect in rats with established tumors (treatment start at day 6) was shown. A significantly prolonged survival of Ro 28-2653-treated rats was also demonstrated. Selective inhibition of MMP activity is a novel therapeutic approach, which bears promise for studies in patients with prostate cancer.	Humboldt Univ, Univ Hosp Charite, Dept Urol, D-10098 Berlin, Germany; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Labs Photomed, Boston, MA USA; Roche Diagnost GmbH, Pharma Res Penzberg, Penzberg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Harvard University; Harvard Medical School; Massachusetts General Hospital; Roche Holding	Lein, M (corresponding author), Humboldt Univ, Univ Hosp Charite, Dept Urol, D-10098 Berlin, Germany.	Michael.Lein@charite.de	Ortel, Bernhard/AAF-7658-2019; Deger, Serpil Muge/ABG-5774-2021; Jung, Klaus/Z-2122-2018	Jung, Klaus/0000-0001-9797-5362; Stephan, Carsten/0000-0002-3270-258X				ANDERSON IC, 1995, CANCER RES, V55, P4120; BOASBERG P, 1997, P AN M AM SOC CLIN, V16, pA316; Brown PD, 1995, ANN ONCOL, V6, P967, DOI 10.1093/oxfordjournals.annonc.a059091; CRAWFORD HC, 1994, INVAS METAST, V14, P234; DAVIES B, 1993, BRIT J CANCER, V67, P1126, DOI 10.1038/bjc.1993.207; Eccles SA, 1996, CANCER RES, V56, P2815; Festuccia C, 1996, INT J CANCER, V69, P386, DOI 10.1002/(SICI)1097-0215(19961021)69:5<386::AID-IJC6>3.0.CO;2-1; FIELDING J, 2000, P AN M AM SOC CLIN, V19, pA240; Grams F, 2001, BIOL CHEM, V382, P1277, DOI 10.1515/BC.2001.159; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hidalgo M, 2001, JNCI-J NATL CANCER I, V93, P178, DOI 10.1093/jnci/93.3.178; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Lein M, 2000, INT J CANCER, V85, P801, DOI 10.1002/(SICI)1097-0215(20000315)85:6<801::AID-IJC11>3.0.CO;2-C; Lein M, 2000, UROLOGY, V56, P167, DOI 10.1016/S0090-4295(00)00553-7; Lein M, 2000, PROSTATE, V43, P77; LIOTTA LA, 1991, CANCER RES, V51, pS5054; LOKESHWAR BL, 1993, CANCER RES, V53, P4493; Lubaroff D M, 1980, Prog Clin Biol Res, V37, P243; Lucia MS, 1998, PROSTATE, V36, P49, DOI 10.1002/(SICI)1097-0045(19980615)36:1<49::AID-PROS9>3.0.CO;2-6; Macaulay VM, 1999, CLIN CANCER RES, V5, P513; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; Oh WK, 1998, J UROLOGY, V160, P1220, DOI 10.1016/S0022-5347(01)62501-1; Price A, 1999, CLIN CANCER RES, V5, P845; Rabbani SA, 1998, IN VIVO, V12, P135; Rothenberg ML, 1999, STEM CELLS, V17, P237, DOI 10.1002/stem.170237; Shalinsky DR, 1999, CLIN CANCER RES, V5, P1905; Shalinsky DR, 2000, CANC DRUG DISC DEV, P143; Smith DC, 1999, J CLIN ONCOL, V17, P1664, DOI 10.1200/JCO.1999.17.6.1664; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; Steward WP, 1999, CANCER CHEMOTH PHARM, V43, pS56, DOI 10.1007/s002800051099; Still K, 2000, PROSTATE, V42, P18; Thomas AL, 2000, EXPERT OPIN INV DRUG, V9, P2913, DOI 10.1517/13543784.9.12.2913; Tierney GM, 1999, EUR J CANCER, V35, P563, DOI 10.1016/S0959-8049(99)00007-6; Walsh PC, 2000, J UROLOGY, V163, P1802, DOI 10.1016/S0022-5347(05)67547-7; Wood M, 1997, CLIN EXP METASTAS, V15, P246, DOI 10.1023/A:1018421431388; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	36	65	69	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2089	2096		10.1038/sj.onc.1205267	http://dx.doi.org/10.1038/sj.onc.1205267			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960381				2022-12-17	WOS:000174827000015
J	Williams, KJ; Telfer, BA; Airley, RE; Peters, HPW; Sheridan, MR; van der Kogel, AJ; Harris, AL; Stratford, IJ				Williams, KJ; Telfer, BA; Airley, RE; Peters, HPW; Sheridan, MR; van der Kogel, AJ; Harris, AL; Stratford, IJ			A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis	ONCOGENE			English	Article						HIF-1; glucose; redox; tumorigenesis; cyanide; Glut-1	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; GENE-EXPRESSION; OXIDATIVE-PHOSPHORYLATION; FACTOR 1-ALPHA; FACTOR-I; TRANSCRIPTION; CELLS; HIF-1-ALPHA; OVEREXPRESSION; PROLIFERATION	We have investigated the role of HIF-1 in the cellular response to redox modulation via the inhibition of oxidative phosphorylation. We demonstrate that manipulation of redox in air, achieved by inhibiting cytochrome oxidase with cyanide, induces HIF-1 mediated transcription in wild-type CHO and HT1080 human tumour cells but not in CHO cells deficient in the oxygen responsive, HIF-1 alpha sub-unit of HIF-1. Hypoglycaemia attenuates cyanide-mediated transcription in nontransformed HIF-1 wild-type CHO cells but not the human tumour derived cell line. Cells lacking either HIF-1 alpha, or the second composite sub-unit of HIF-1, HIF-1 beta, were markedly more sensitive to the combined stress of perturbed redox and hypoglycaemia than wild-type cells. As such conditions together with hypoxia are prevalent in tumours, these data suggest that HIF-1 may have a protective role in adaptation to the tumour microenvironment. In support of this we demonstrate that HIF-1 alpha deficient cells are less tumorigenic than wild-type cells. They showed a reduced growth rate when grown as xenografts in nude mice. This was not related to vascular parameters that were identical to those found in HIF-1 wild-type tumours. The HIF-1 deficient tumours lacked focal expression of Glut-1 in hypoxic tumour regions. Compromized glucose uptake and metabolic adaptation to the tumour micro-environment may form the basis of the reduced tumorigenecity associated with these cells.	Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England; Christie Hosp NHS Trust, Paterson Inst, Expt Radiat Oncol Grp, Manchester M20 4BX, Lancs, England; Univ Nijmegen, Inst Radiotherapy, Nijmegen, Netherlands; John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England	University of Manchester; Christie NHS Foundation Trust; Christie Hospital; Radboud University Nijmegen; University of Oxford	Williams, KJ (corresponding author), Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England.		Harris, Adrian L/ABA-3343-2020; van der Kogel, A.J./L-4441-2015	Harris, Adrian L/0000-0003-1376-8409; stratford, ian/0000-0002-5222-4765; Telfer, Brian/0000-0003-1857-5120	Medical Research Council [G0500366] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Agani FH, 2000, J BIOL CHEM, V275, P35863, DOI 10.1074/jbc.M005643200; Airley R, 2001, CLIN CANCER RES, V7, P928; Behrooz A, 1997, J BIOL CHEM, V272, P5555, DOI 10.1074/jbc.272.9.5555; Birner P, 2000, CANCER RES, V60, P4693; Blancher C, 2000, CANCER RES, V60, P7106; Brown RS, 1996, J NUCL MED, V37, P1042; Bussink J, 1998, BRIT J CANCER, V77, P57, DOI 10.1038/bjc.1998.9; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chung JK, 1999, J NUCL MED, V40, P339; Dachs GU, 1997, NAT MED, V3, P515, DOI 10.1038/nm0597-515; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; GRIFFITHS JR, IN PRESS CANC RES; HODGKISS RJ, 1991, BRIT J CANCER, V63, P119, DOI 10.1038/bjc.1991.24; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1997, CANCER RES, V57, P5328; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; NECAS E, 1972, AM J PHYSIOL, V222, P1187, DOI 10.1152/ajplegacy.1972.222.5.1187; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; Raleigh JA, 1999, RADIAT RES, V151, P580, DOI 10.2307/3580034; Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Srinivas V, 2001, J BIOL CHEM, V276, P21995, DOI 10.1074/jbc.C100177200; Stratford IJ, 1999, TUMOR HYPOXIA, P107; TAN CC, 1991, AM J PHYSIOL, V261, pF982, DOI 10.1152/ajprenal.1991.261.6.F982; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 1998, CANCER RES, V58, P5280; Zhong H, 1999, CANCER RES, V59, P5830	35	65	66	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					282	290		10.1038/sj.onc.1205047	http://dx.doi.org/10.1038/sj.onc.1205047			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803471				2022-12-17	WOS:000173026200012
J	Venkateswarlu, S; Dawson, DM; St Clair, P; Gupta, A; Willson, JKV; Brattain, MG				Venkateswarlu, S; Dawson, DM; St Clair, P; Gupta, A; Willson, JKV; Brattain, MG			Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells	ONCOGENE			English	Article						ErbB2; constitutive activation; heregulin	NEU DIFFERENTIATION FACTOR; FACTOR-RELATED PEPTIDES; FACTOR-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; HUMAN-BREAST; CONSTITUTIVE ACTIVATION; SIGNALING NETWORK; OVARIAN-CANCER; FACTOR-ALPHA; EPITHELIAL-CELLS	The aim of this study was to determine whether constitutive ErbB2 activation controls growth and apoptosis in colon cancer cells. Growth arrested GEO cells showed constitutive activation of ErbB2 in the absence of exogenous growth factors or serum supplementation. Higher levels of heregulin and ErbB2 activation were observed in the growth-arrested state and cell cycle re-entry was independent of exogenous growth factors. Blockade of ErbB2 activation by heregulin neutralizing antibodies and by AG879 resulted in prevention of cell cycle re-entry. This indicated that autocrine heregulin activity was responsible for growth factor independence and for cell cycle re-entry. Activation of ErbB2 was the result of heregulin mediated interaction with ErbB3 and generated downstream activation of the ERK and the PI3K/AKT pathways. Heregulin neutralizing antibody treatment of growth arrested GEO cells also generated apoptosis as reflected by PARP cleavage and DNA fragmentation indicating a cell survival signal was also induced by the constitutively activated ErbB2. The activation of AKT but not the MAPK pathway was responsible for cell survival in these cells.	Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78284 USA; Case Western Reserve Univ, Ireland Canc Ctr, Dept Med, Cleveland, OH 44106 USA	University of Texas System; University of Texas Health San Antonio; Case Western Reserve University	Brattain, MG (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.				NATIONAL CANCER INSTITUTE [R01CA054807, R01CA034432, K08CA084337, R01CA068316] Funding Source: NIH RePORTER; NCI NIH HHS [CA 68316, CA 34432, CA 54807, CA84337-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Coffer PJ, 1998, BIOCHEM J, V335, P1; COFFEY RJ, 1988, CANCER RES, V48, P1596; Daly JM, 1997, CANCER RES, V57, P3804; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; GOLDIE JH, 1979, CANCER TREAT REP, V63, P1727; Grammer TC, 1996, CANCER SURV, V27, P271; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Gullick WJ, 1996, CANCER SURV, V27, P339; Howell GM, 1998, J BIOL CHEM, V273, P9214, DOI 10.1074/jbc.273.15.9214; HSU SM, 1981, AM J CLIN PATHOL, V75, P816, DOI 10.1093/ajcp/75.6.816; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; Jiang DH, 1998, J BIOL CHEM, V273, P31471, DOI 10.1074/jbc.273.47.31471; Kapitanovic S, 1997, GASTROENTEROLOGY, V112, P1103, DOI 10.1016/S0016-5085(97)70120-3; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Klapper LN, 2000, ADV CANCER RES, V77, P25; Kristt DA, 1996, CANCER-AM CANCER SOC, V78, P1272, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1272::AID-CNCR16>3.0.CO;2-Y; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Lewis GD, 1996, CANCER RES, V56, P1457; MARKOWITZ SD, 1990, J CLIN INVEST, V86, P356, DOI 10.1172/JCI114709; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MORALI F, 1993, ANN ONCOL, V4, P775, DOI 10.1093/oxfordjournals.annonc.a058663; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; MULDER KM, 1989, J CELL PHYSIOL, V138, P450, DOI 10.1002/jcp.1041380303; Noguchi H, 1999, GASTROENTEROLOGY, V117, P1119, DOI 10.1016/S0016-5085(99)70397-5; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PITTELKOW MR, 1993, CELL GROWTH DIFFER, V4, P513; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Ram TG, 1996, CELL GROWTH DIFFER, V7, P551; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Saeki T, 1995, JPN J CLIN ONCOL, V25, P240; Scoccia B, 1998, J SOC GYNECOL INVEST, V5, P161, DOI 10.1016/S1071-5576(98)00006-9; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; VANDEVIJVER MJ, 1988, ONCOGENE, V2, P175; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Worthylake R, 1997, J BIOL CHEM, V272, P8594, DOI 10.1074/jbc.272.13.8594	55	65	71	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2002	21	1					78	86		10.1038/sj.onc.1205011	http://dx.doi.org/10.1038/sj.onc.1205011			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	505AD	11791178				2022-12-17	WOS:000172887800008
J	Wang, RH; Liu, CWY; Avramis, VI; Berndt, N				Wang, RH; Liu, CWY; Avramis, VI; Berndt, N			Protein phosphatase 1 alpha-mediated stimulation of apoptosis is associated with dephosphorylation of the retinoblastoma protein	ONCOGENE			English	Article						protein phosphatase 1; retinoblastoma protein; caspase; protein phosphorylation; cell cycle; apoptosis	CELL-CYCLE PROGRESSION; INHIBITOR OKADAIC ACID; CATALYTIC SUBUNIT; GENE-PRODUCT; MAMMALIAN-CELLS; PHOSPHORYLATION; DEATH; ACTIVATION; CLEAVAGE; ARREST	Protein phosphatase I (PPI) plays important roles in many different aspects of cellular activities including cell cycle control. One important function of PP1 is to activate the retinoblastoma protein pRB. Here we show that pRB is one of PPI's downstream targets during apoptosis. When HL-60 cells synchronized at the G1/S boundary were treated with pro-apoptotic cytosine arabinoside (araC), PP1 alpha protein increased twofold and PP1 activity about 30% within I h. This was followed by pRB dephosphorylation, pRB cleavage by caspases, DNA fragmentation, the appearance of cells with < 2n DNA content and finally, dying and dead cells. In vitro, pRB was protected from caspase-3 digestion by prior Cdk-mediated phosphorylation, whereas PP1 alpha converted phospho-pRB into an efficient substrate for caspase-3. Introduction of active PP1 alpha into HL-60 cells by electroporation was sufficient to induce characteristics of apoptosis. Similarly, araC-resistant cells, normally unable to die in response to araC, initiated apoptosis when electroporated with active PP1 alpha. This was also accompanied by pRB cleavage. In contrast, introduction of inhibitor-2 delayed the onset of araC-induced apoptosis, whereas concomitant introduction of PP1 alpha and inhibitor-2 completely prevented PP1 alpha -induced apoptosis. These results suggest that dephosphorylation of key proteins by PP1 alpha may be crucial for the initiation of apoptosis and further support the concept of PPI serving as a potential target for anti-cancer therapy.	Univ So Calif, Childrens Hosp Los Angeles, Sch Med, Div Hematol Oncol, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California	Berndt, N (corresponding author), Univ So Calif, Childrens Hosp Los Angeles, Sch Med, Div Hematol Oncol, 4650 Sunset Blvd, Los Angeles, CA 90027 USA.				NCI NIH HHS [CA 54167] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054167] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; Ayllon V, 2000, EMBO J, V19, P2237, DOI 10.1093/emboj/19.10.2237; BAXTER GD, 1992, J IMMUNOL, V148, P1949; Berndt N, 1997, CURR BIOL, V7, P375, DOI 10.1016/S0960-9822(06)00185-0; Berndt N., 2000, EMERGING THER TARGET, V4, P581; BERNDT N, 1995, ADV PROTEIN PHOSPHAT, V9, P63; Berndt N., 1999, FRONT BIOSCI, V4, pD22, DOI DOI 10.2741/BERNDT;PMID:9872729; Berry DE, 1996, ONCOGENE, V12, P1809; BOOHER R, 1989, CELL, V57, P1009, DOI 10.1016/0092-8674(89)90339-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; Cheng AY, 2000, J BIOL CHEM, V275, P1846, DOI 10.1074/jbc.275.3.1846; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Damer CK, 1998, J BIOL CHEM, V273, P24396, DOI 10.1074/jbc.273.38.24396; Dohadwala M, 1998, METH MOL B, V93, P191; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUNIGAN DD, 1995, VIROLOGY, V207, P460, DOI 10.1006/viro.1995.1105; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fan GS, 1996, ONCOGENE, V12, P1909; FERNANDEZ A, 1992, J CELL BIOL, V116, P1421, DOI 10.1083/jcb.116.6.1421; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HOTZ MA, 1994, CYTOMETRY, V15, P237, DOI 10.1002/cyto.990150309; INOMATA M, 1995, J CANCER RES CLIN, V121, P729, DOI 10.1007/BF01213319; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Liu CWY, 1999, J BIOL CHEM, V274, P29470, DOI 10.1074/jbc.274.41.29470; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martin-Aragon S, 2000, ANTICANCER RES, V20, P139; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; Morimoto Y, 1997, EXP CELL RES, V230, P181, DOI 10.1006/excr.1996.3404; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; Puntoni F, 1999, BIOCHEM BIOPH RES CO, V266, P279, DOI 10.1006/bbrc.1999.1800; SCHONTHAL A, 1993, ONCOGENE, V8, P433; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Spector D. L., 1998, CELLS LAB MANUAL; Takemura M, 1997, ONCOGENE, V15, P2483, DOI 10.1038/sj.onc.1201431; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Taylor BK, 2000, AM J PHYSIOL-LUNG C, V278, pL1062, DOI 10.1152/ajplung.2000.278.5.L1062; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; Yi HK, 1997, ONCOGENE, V14, P1259, DOI 10.1038/sj.onc.1201099; ZHENG B, 1991, J BIOL CHEM, V266, P10031	55	65	66	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 27	2001	20	43					6111	6122		10.1038/sj.onc.1204829	http://dx.doi.org/10.1038/sj.onc.1204829			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593419				2022-12-17	WOS:000171206300002
J	Satyamoorthy, K; Muyrers, J; Meier, F; Patel, D; Herlyn, M				Satyamoorthy, K; Muyrers, J; Meier, F; Patel, D; Herlyn, M			Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication	ONCOGENE			English	Article						melanoma; cell-cell adhesion; antisense MEL-CAM; MUC1	CELL-ADHESION MOLECULE; INTERCELLULAR COMMUNICATION; IMMUNOGLOBULIN SUPERFAMILY; RETROVIRAL VECTORS; MAMMALIAN-CELLS; POTENTIAL ROLE; HIGH-TITER; PROGRESSION; ANTIGEN; EXPRESSION	Normal human melanocytes are interspersed singly among keratinocytes along the basement membrane of the epidermis, whereas melanoma cells readily adhere to each other during invasion of the dermis or distant organs. The tumorigenic and metastatic phenotype of melanoma cells often correlates with increased expression of cell-cell and cell-matrix adhesion receptors. Mel-CAM (MCAM, MUC 18, CD146) is a cell-cell adhesion receptor highly expressed by melanoma cells but not normal melanocytes. We show here that inhibition of Mel-CAM expression in metastatic melanoma cells using genetic suppressor elements of Mel-CAM cDNA leads to inhibition of adhesion between melanoma cells and to downregulation of the tumorigenic phenotype. Growth was not inhibited in genetic suppressor elements-transduced melanoma cells cultured in monolayers but was inhibited when cells were maintained anchorage-independently in soft agar and greatly reduced in immunodeficient mice. A three-dimensional epidermal skin equivalent model demonstrated that Mel-CANT allows melanoma cells to separate from the epidermis and invade the basement membrane zone and dermis. However, melanoma cells with little or no Mel-CAM were poorly invasive, possibly due to their loss of gap junctional communication. These results suggest the multifunctional role of a melanoma-associated cell-cell adhesion receptor in tumor progression.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	HerlynM@wistar.upenn.edu	Satyamoorthy, Kapaettu/H-3254-2015	Satyamoorthy, Kapaettu/0000-0002-2368-5490	NCI NIH HHS [CA25874, CA74294, CA76674, CA10815, CA47159] Funding Source: Medline; NIDDK NIH HHS [DK50306] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076674, R01CA047159, P30CA010815, P01CA025874, P01CA074294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anfosso F, 1998, J BIOL CHEM, V273, P26852, DOI 10.1074/jbc.273.41.26852; Bardin N, 1996, TISSUE ANTIGENS, V48, P531, DOI 10.1111/j.1399-0039.1996.tb02666.x; Bryant PJ, 1997, DEV GENET, V20, P75, DOI 10.1002/(SICI)1520-6408(1997)20:2<75::AID-DVG1>3.3.CO;2-G; Cochlovius B, 1998, ADV EXP MED BIOL, V451, P345; Degen WGJ, 1998, AM J PATHOL, V152, P805; GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HERLYN D, 1990, CANCER RES, V50, P2296; HERLYN M, 1996, MOL CELLULAR BIOL ME, P1; HOLNESS CL, 1994, J CELL SCI, V107, P2065; Hsu MY, 2000, J CELL SCI, V113, P1535; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; JOHNS DR, 1994, J NEURO-OPHTHALMOL, V14, P130; Johnson JP, 1999, CANCER METAST REV, V18, P345, DOI 10.1023/A:1006304806799; Johnson JP, 1997, INT J CANCER, V73, P769; Johnson JP, 1996, CURR TOP MICROBIOL, V213, P95; KATH R, 1991, CANCER RES, V51, P2205; Kraus A, 1997, MELANOMA RES, V7, pS75; Krutovskikh V, 1997, HISTOL HISTOPATHOL, V12, P761; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; Levenson VV, 1999, SOMAT CELL MOLEC GEN, V25, P9; Li G, 2000, MOL MED TODAY, V6, P163, DOI 10.1016/S1357-4310(00)01692-0; LYNCH CM, 1991, J VIROL, V65, P3887, DOI 10.1128/JVI.65.7.3887-3890.1991; Marcusson EG, 1999, MOL BIOTECHNOL, V12, P1, DOI 10.1385/MB:12:1:1; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; MORGAN RA, 1992, NUCLEIC ACIDS RES, V20, P1293, DOI 10.1093/nar/20.6.1293; Morimoto C, 1996, Hum Cell, V9, P163; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; NESBIT M, 1994, INVAS METAST, V14, P131; PESTOV DG, 1994, P NATL ACAD SCI USA, V91, P12549, DOI 10.1073/pnas.91.26.12549; Pickl WF, 1997, J IMMUNOL, V158, P2107; RONINSON IB, 1995, CANCER RES, V55, P4023; Rummel MM, 1996, CANCER RES, V56, P2218; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; SERS C, 1994, CANCER RES, V54, P5689; Shi IM, 1999, J PATHOL, V189, P4, DOI 10.1002/(SICI)1096-9896(199909)189:1<4::AID-PATH332>3.0.CO;2-P; Shih IM, 1997, CANCER RES, V57, P3835; SHIH IM, 1994, CANCER RES, V54, P2514; St Croix B, 2000, SCIENCE, V289, P1197; Xie SH, 1997, CANCER RES, V57, P2295; Yagi T, 2000, GENE DEV, V14, P1169; Yamasaki H, 1996, MUTAT RES-REV GENET, V365, P91, DOI 10.1016/S0165-1110(96)90014-7	46	65	70	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4676	4684		10.1038/sj.onc.1204616	http://dx.doi.org/10.1038/sj.onc.1204616			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498790				2022-12-17	WOS:000170208600008
J	Jimenez, B; Volpert, OV; Reiher, F; Chang, LF; Munoz, A; Karin, M; Bouck, N				Jimenez, B; Volpert, OV; Reiher, F; Chang, LF; Munoz, A; Karin, M; Bouck, N			c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1	ONCOGENE			English	Article						thrombospondin; anti-angiogenic signalling; CD36; tumor angiogenesis; JNK	ENDOTHELIAL GROWTH-FACTOR; PROTEIN-KINASE; IN-VITRO; ANGIOGENESIS; APOPTOSIS; CELLS; JNK2; MECHANISMS; INDUCTION; SURVIVIN	Thrombospondin-1 (TSP-1) is a potent inhibitor of angiogenesis that acts directly on endothelial cells via the CD36 surface receptor molecule to halt their migration, proliferation, and morphogenesis in vitro and to block neovascularization in vivo. Here we show that inhibitory signals elicited by TSP-1 did not alter the ability of inducers of angiogenesis to activate p42 and p44 mitogen-activated protein kinase (MAPK). Rather, TSP-1 induced a rapid and transient activation of c-Jun N-terminal kinases (JNK). JNK activation by TSP-1 required engagement of CD36, as it was blocked by antagonistic CD36 antibodies and stimulated by short anti-angiogenic peptides derived from TSP-1 that act exclusively via CD36. TSP-1 inhibition of corneal neovascularization induced by bFGF was severely impaired in mice null for JNK-1, pointing to a critical role for this stress-activated kinase in the inhibition of neovascularization by TSP-1.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Madrid 28029, Spain; Northwestern Univ, Sch Med, Dept Immunol Microbiol, Chicago, IL USA; Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA; Univ Autonoma Madrid, Fac Med, Dept Bioquim, Madrid, Spain; Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Autonomous University of Madrid; University of California System; University of California San Diego	Jimenez, B (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Arturo Duperier 4, Madrid 28029, Spain.		Munoz, Alberto/O-6393-2014; Cuenca, Benilde Jimenez/K-9959-2014	Munoz, Alberto/0000-0003-3890-4251; Volpert, Olga/0000-0003-1381-5543; Jimenez Cuenca, Benilde/0000-0002-1806-6636	NCI NIH HHS [CA52750, CA64239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; LOO D, 1994, CELL BIOL LAB HDB, P45; Lucas R, 1998, BLOOD, V92, P4730; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yang DD, 1998, IMMUNITY, V9, P575, DOI 10.1016/S1074-7613(00)80640-8; Yeh CH, 1998, BLOOD, V92, P3268, DOI 10.1182/blood.V92.9.3268.421k41_3268_3276; Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951	33	65	72	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3443	3448		10.1038/sj.onc.1204464	http://dx.doi.org/10.1038/sj.onc.1204464			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423995				2022-12-17	WOS:000169248800015
J	Luo, JC; Shibuya, M				Luo, JC; Shibuya, M			A variant of nuclear localization signal of bipartite-type is required for the nuclear translocation of hypoxia inducible factors (1 alpha, 2 alpha and 3 alpha)	ONCOGENE			English	Article						nuclear localization signal; hypoxia inducible factor; ubiquitin-proteasome system; von hippellindau tumor suppressor; protein stability	TUMOR-SUPPRESSOR PROTEIN; ARYL-HYDROCARBON RECEPTOR; HIPPEL-LINDAU PROTEIN; EXPORT SIGNALS; EXPRESSION; BINDING; DOMAIN; ALPHA; FACTOR-1-ALPHA; STABILIZATION	Hypoxia inducible factors (HTF1, 2 and 3), consisting of alpha and beta subunits, play an essential role in various responses to hypoxia. Nuclear entry of alpha subunits is a necessary step for the formation of DNA-binding complex with beta subunit, which is constitutively localized in the nucleus. We show here that the nuclear accumulation of HIF2 alpha induced by hypoxia is mediated through a novel variant of bipartite-type nuclear localization signal (NLS) in the C-terminus of the protein, which has an unusual length of spacer sequence between two adjacent basic domains. We further show that when the ubiquitin-proteasome system was deficient or inhibited, HIF2a accumulated in the nucleus even under normoxia, also mediated through the bipartite NLS, These findings indicate that the protein stability is critical for the nuclear localization of HIF2a and hypoxia is not a necessary factor for the process. Importantly, the NLS of HIF2a is also conserved in the other HIF family members, HIF1 alpha and HIF3 alpha. Mutational analyses proved that the NLS mediating the nuclear localization of HIF1 alpha is indeed bipartite-, but not monopartite-type as thought before, Our results suggest that the newly identified NLS is crucial for the functional regulation of HIF family.	Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 1088639, Japan	University of Tokyo	Shibuya, M (corresponding author), Univ Tokyo, Inst Med Sci, Dept Genet, Minato Ku, Tokyo 1088639, Japan.		Jin Cai, Luo/A-7900-2011					ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bear J, 1999, MOL CELL BIOL, V19, P6306; BURGLIN TR, 1987, GENE DEV, V1, P97, DOI 10.1101/gad.1.1.97; Chilov D, 1999, J CELL SCI, V112, P1203; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Eguchi H, 1997, J BIOL CHEM, V272, P17640, DOI 10.1074/jbc.272.28.17640; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; IMAI Y, 1991, NUCLEIC ACIDS RES, V19, P2785, DOI 10.1093/nar/19.10.2785; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Luo JC, 1998, CANCER RES, V58, P2652; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268	28	65	68	2	8	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2001	20	12					1435	1444		10.1038/sj.onc.1204228	http://dx.doi.org/10.1038/sj.onc.1204228			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	413DT	11313887				2022-12-17	WOS:000167595200004
J	Wong, AST; Pelech, SL; Woo, MMM; Yim, G; Rosen, B; Ehlen, T; Leung, PCK; Auersperg, N				Wong, AST; Pelech, SL; Woo, MMM; Yim, G; Rosen, B; Ehlen, T; Leung, PCK; Auersperg, N			Coexpression of hepatocyte growth factor-Met: an early step in ovarian carcinogenesis?	ONCOGENE			English	Article						hepatocyte growth factor; Met; ovarian surface epithelial cells; cell signaling; familial ovarian cancer; ovarian cancer	FACTOR SCATTER FACTOR; SURFACE EPITHELIAL-CELLS; C-MET; EXTRACELLULAR-MATRIX; CARCINOMA CELLS; FAMILY HISTORY; HGF RECEPTOR; CANCER; EXPRESSION; KINASE	Since autocrine regulation of HGF-Met is implicated in many forms of human cancer, we investigated whether the predisposition to develop ovarian cancer in women with hereditary ovarian cancer syndromes involves changes in the expression of HGF-Met by the tissue of origin of epithelial ovarian cancers, the ovarian surface epithelium (OSE), We compared cultures of normal OSE from women with (FH-OSE) (n = 20) and with no (NFH-OSE) (n = 48) family histories of ovarian cancer, SV40 Tag immortalized OSE lines (IOSE, n = 5) and ovarian cancer cell lines (n = 3), Cultures derived from 21/22 women with NFH-OSE and 13/13 women with FH-OSE expressed Met mRNA initially. After two to three passages, Met was downregulated in 37% of NFH-OSE cultures but persisted in 100% of FH-OSE cultures and ovarian cancer lines, like other epithelial differentiation markers that are stabilized in FH-OSE and neoplasia, HGF and Met mRNA were concomitantly expressed by NFH-OSE from only three of 32 women but in FH-OSE from eight of 13 women, and also in five of five IOSE and two of three ovarian cancer lines. Conditioned media from FH-OSE, but not NFH-OSE, contained immunoreactive HGF and induced cohort migration which was inhibited by neutralizing HGF antibody. Several signaling molecules of the PI3K pathway, including Akt2 and p70 S6K, were constitutively activated in FH-OSE from six of six women but in NFH-OSE from only four of eight women. Exogenous HGF was mitogenic in OSE, and that effect was regulated through the MAP kinase (ERK1/ERK2) and FRAP/p70 S6K pathways. The proliferative response to HGF was greater in NFH-OSE than in FH-OSE cultures. The results show that FH-OSE cultures differ from NFH-OSE by increased stability of Met expression and by HGF secretion. Constitutive phosphorylation of kinases and a diminished growth response to HGF suggest the presence of autocrine regulation in FH-OSE. In analogy with other cell types where an autocrine HGF-R let loop has been implicated in tumorigenic transformation, this change in FH-OSE may play a role in the enhanced susceptibility to ovarian carcinogenesis in women with hereditary ovarian cancer syndromes.	Univ British Columbia, Dept Obstet & Gynaecol, Vancouver, BC V6H 3V5, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6H 3V5, Canada; Toronto Hosp, Toronto, ON M5T 2S8, Canada	University of British Columbia; University of British Columbia; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Auersperg, N (corresponding author), Univ British Columbia, British Columbia Childrens Hosp, Dept Obstet & Gynecol, 2H30,4490 Oak St, Vancouver, BC V6H 3V5, Canada.		Wong, Alice/AFJ-4595-2022	Wong, Alice/0000-0002-0676-6475; Leung, Peter/0000-0003-3152-3800				AUERSPERG N, 1994, LAB INVEST, V71, P510; Auersperg N, 1998, SEMIN ONCOL, V25, P281; AUERSPERG N, 1995, AM J OBSTET GYNECOL, V173, P558, DOI 10.1016/0002-9378(95)90282-1; Aunoble B, 2000, INT J ONCOL, V16, P567; Balkovetz DF, 1999, LIFE SCI, V64, P1393, DOI 10.1016/S0024-3205(99)00073-9; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; Corps AN, 1997, INT J CANCER, V73, P151, DOI 10.1002/(SICI)1097-0215(19970926)73:1<151::AID-IJC23>3.0.CO;2-I; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; Dyck HG, 1996, INT J CANCER, V69, P429, DOI 10.1002/(SICI)1097-0215(19961220)69:6<429::AID-IJC1>3.0.CO;2-6; ELLIOTT WM, 1993, BIOTECH HISTOCHEM, V68, P29, DOI 10.3109/10520299309105573; Gulati R, 1997, ENDOCRINOLOGY, V138, P1847, DOI 10.1210/en.138.5.1847; Hess S, 1999, ENDOCRINOLOGY, V140, P2908, DOI 10.1210/en.140.6.2908; Hulleman E, 1999, J CELL PHYSIOL, V180, P325, DOI 10.1002/(SICI)1097-4652(199909)180:3<325::AID-JCP3>3.0.CO;2-R; Huntsman D, 1999, AM J PATHOL, V155, P343, DOI 10.1016/S0002-9440(10)65130-9; Jiang W, 1999, CRIT REV ONCOL HEMAT, V29, P209, DOI 10.1016/S1040-8428(98)00019-5; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim SO, 1998, J CELL BIOCHEM, V71, P328, DOI 10.1002/(SICI)1097-4644(19981201)71:3<328::AID-JCB2>3.0.CO;2-U; Klominek J, 1998, INT J CANCER, V76, P240, DOI 10.1002/(SICI)1097-0215(19980413)76:2<240::AID-IJC12>3.0.CO;2-G; KRUK PA, 1994, EXP CELL RES, V215, P97, DOI 10.1006/excr.1994.1320; MAINESBANDIERA SL, 1992, AM J OBSTET GYNECOL, V167, P729, DOI 10.1016/S0002-9378(11)91579-8; Miyazawa K, 1996, J BIOL CHEM, V271, P3615; MOGHUL A, 1994, ONCOGENE, V9, P2045; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Nabeshima K, 1998, INT J CANCER, V78, P750, DOI 10.1002/(SICI)1097-0215(19981209)78:6<750::AID-IJC13>3.0.CO;2-#; Ong A, 2000, INT J CANCER, V85, P430, DOI 10.1002/(SICI)1097-0215(20000201)85:3<430::AID-IJC21>3.0.CO;2-Q; Parrott JA, 2000, BIOL REPROD, V62, P491, DOI 10.1095/biolreprod62.3.491; PARROTT JA, 1994, ENDOCRINOLOGY, V135, P569, DOI 10.1210/en.135.2.569; Parrott LA, 1999, J BIOL CHEM, V274, P24731, DOI 10.1074/jbc.274.35.24731; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Sato N, 1997, Respirology, V2, P185, DOI 10.1111/j.1440-1843.1997.tb00077.x; Scully RE, 1995, J CELL BIOCHEM, P208; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; Sowter HM, 1999, INT J CANCER, V83, P476, DOI 10.1002/(SICI)1097-0215(19991112)83:4<476::AID-IJC7>3.0.CO;2-V; STOKER M, 1985, J CELL SCI, V77, P209; To CTT, 1998, ONCOL REP, V5, P1013; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Wong AST, 1999, INT J CANCER, V81, P180; Wong AST, 2000, GYNECOL ONCOL, V78, P158, DOI 10.1006/gyno.2000.5877; ZILTENER HJ, 1993, BIOL REPROD, V49, P635, DOI 10.1095/biolreprod49.3.635	44	65	71	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1318	1328		10.1038/sj.onc.1204253	http://dx.doi.org/10.1038/sj.onc.1204253			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313876				2022-12-17	WOS:000167495000006
J	Pritchard, DM; Print, C; O'Reilly, L; Adams, JM; Potten, CS; Hickman, JA				Pritchard, DM; Print, C; O'Reilly, L; Adams, JM; Potten, CS; Hickman, JA			Bcl-w is an important determinant of damage-induced apoptosis in epithelia of small and large intestine	ONCOGENE			English	Article						apoptosis; bcl-w; 5-fluorouracil; gamma-radiation; intestinal epithelia	RADIATION-INDUCED APOPTOSIS; GASTROINTESTINAL-TRACT; CELL-SURVIVAL; MICE; EXPRESSION; P53; PROLIFERATION; INHIBITION; FAMILY; CRYPTS	The potential role of the bcl-2 relative bcl-w as a physiological regulator of apoptosis in intestinal epithelia has been investigated, Immunoblots for bcl-w with new monoclonal antibodies revealed that it was expressed in the small intestine and colon, among other murine tissues, as well as in six: human tumour cell lines of epithelial origin, including two colon carcinoma lines, To assess whether bcl-w regulates either spontaneous or damage-induced apoptosis in the small intestine or colon, apoptosis in intestinal crypts of bcl-w -/- and wild-type mice,vas quantified microscopically on a cell positional basis. Spontaneous apoptosis within crypt epithelia was not significantly increased by loss of bcl-w, in either the small intestine or midcolon. However, after treatment with the cytotoxic drug 5-fluorouracil or with gamma-radiation, the bcl-w-null animals exhibited substantially more apoptosis than their wild-type counterparts in both tissues. The greatest enhancement of apoptosis attributable to the absence of bcl-w (up to sixfold) occurred in the small intestine, Hence, bcl-w is an important determinant of damage-induced apoptosis in intestinal epithelia, and unlike bcl-2, which regulates only colonic apoptosis, plays a major role In small intestinal epithelium.	Christie Hosp NHS Trust, Paterson Inst, CRC, Dept Epithelial Biol, Manchester M20 9BX, Lancs, England; Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Grp, Manchester M13 9PT, Lancs, England; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia	Christie NHS Foundation Trust; Christie Hospital; University of Manchester; Walter & Eliza Hall Institute	Pritchard, DM (corresponding author), Univ Liverpool, Dept Med, 5th Floor UCD Bldg,Duncan Bldg,Daulby St, Liverpool L69 3GA, Merseyside, England.		Adams, Jerry M/E-1199-2013	Print, Cristin/0000-0001-8345-7812; Pritchard, David Mark/0000-0001-7971-3561; Adams, Jerry/0000-0002-4360-8628	NCI NIH HHS [CA 43540, CA80188] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540, R01CA080188] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; Gibson L, 1996, ONCOGENE, V13, P665; Manne U, 1997, INT J CANCER, V74, P346, DOI 10.1002/(SICI)1097-0215(19970620)74:3<346::AID-IJC19>3.0.CO;2-9; MERRITT AJ, 1995, J CELL SCI, V108, P2261; MERRITT AJ, 1994, CANCER RES, V54, P614; Merritt Anita J., 1996, P269; POTTEN CS, 1977, NATURE, V269, P518, DOI 10.1038/269518a0; POTTEN CS, 1990, INT J RADIAT BIOL, V57, P185, DOI 10.1080/09553009014550431; Potten CS, 1998, BRIT J CANCER, V78, P993, DOI 10.1038/bjc.1998.618; POTTEN CS, 1992, CANCER METAST REV, V11, P179, DOI 10.1007/BF00048063; Print CG, 1998, P NATL ACAD SCI USA, V95, P12424, DOI 10.1073/pnas.95.21.12424; Pritchard DM, 1999, ONCOGENE, V18, P7287, DOI 10.1038/sj.onc.1203150; Pritchard DM, 1997, P NATL ACAD SCI USA, V94, P1795, DOI 10.1073/pnas.94.5.1795; Pritchard DM, 1998, CANCER RES, V58, P5453; Reed JC, 1999, CANC DRUG DISC DEV, V5, P99; Ross AJ, 1998, NAT GENET, V18, P251, DOI 10.1038/ng0398-251; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Watson AJM, 1996, BRIT J CANCER, V73, P889, DOI 10.1038/bjc.1996.178	19	65	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2000	19	34					3955	3959		10.1038/sj.onc.1203729	http://dx.doi.org/10.1038/sj.onc.1203729			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951589				2022-12-17	WOS:000088614300015
J	O'Connor, DJ; Lu, X				O'Connor, DJ; Lu, X			Stress signals induce transcriptionally inactive E2F-1 independently of p53 and Rb	ONCOGENE			English	Article						E2F1; p53; transcription; DNA damage; hypoxia; stress response	RETINOBLASTOMA GENE-PRODUCT; S-PHASE ENTRY; DNA-DAMAGE; CELL-CYCLE; P53-INDEPENDENT APOPTOSIS; DEREGULATED EXPRESSION; PROTEIN; FAMILY; DEGRADATION; LEADS	One of the common features of cellular response to stress is cell cycle arrest or apoptosis, E2F is one of the key factors which controls cell cycle progression. Overexpression of E2F-1 can also induce apoptosis, In order to understand the role of E2F-1 in cellular response to stress, we studied the E2F-1 response in various cell lines to different types of stress signals including UV irradiation, cisplatin, etoposide and hypoxia, We showed here that the expression level of E2F-1 can be up regulated by the treatment of DNA damage agents as well as hypoxia, The kinetics of E2F-1 increase was dependent on the types of inducer and was similar to that of p53, However, stress signals can induce E2F-1 expression independently of p53 and Rb, Furthermore, the induced E2F-1 was transcriptionally inactive, All these results suggested that E2F-1 may play a very important role in cellular response to stress and this novel role of E2F-1 is independent of its transactivation function.	Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, London W2 1PG, England	Imperial College London; Ludwig Institute for Cancer Research	Lu, X (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ludwig Inst Canc Res, St Marys Campus,Norfolk Pl, London W2 1PG, England.			Lu, Xin/0000-0002-6587-1152				Amellem O, 1996, EXP CELL RES, V227, P106, DOI 10.1006/excr.1996.0255; Blattner C, 1999, MOL CELL BIOL, V19, P3704; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Holmberg C, 1998, ONCOGENE, V17, P143, DOI 10.1038/sj.onc.1201915; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Huang YY, 1997, CANCER RES, V57, P3640; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Krtolica A, 1998, ONCOGENE, V17, P2295, DOI 10.1038/sj.onc.1202159; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Vandel L, 1999, EMBO J, V18, P4280, DOI 10.1093/emboj/18.15.4280; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHANG YH, 1995, ONCOGENE, V10, P2085	35	65	68	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2369	2376		10.1038/sj.onc.1203540	http://dx.doi.org/10.1038/sj.onc.1203540			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828878				2022-12-17	WOS:000087018400001
J	Strobeck, MW; Fribourg, AF; Puga, A; Knudsen, ES				Strobeck, MW; Fribourg, AF; Puga, A; Knudsen, ES			Restoration of retinoblastoma mediated signaling to Cdk2 results in cell cycle arrest	ONCOGENE			English	Article						AHR; BRG-1; Cdk; cyclins; G1	FAMILY PROTEINS; HISTONE DEACETYLASE; GROWTH SUPPRESSION; G(1)/S TRANSITION; PHASE-TRANSITION; HUMAN CANCER; PRB-FAMILY; S-PHASE; ACTIVATION; INHIBITION	Phosphorylation/inactivation of RB is typically required for cell cycle progression. However, we have identified a tumor cell line, C33A, which progresses through the cell cycle in the presence of an active allele of RB (PSM-RB), To determine how C33A cells evade RB-mediated arrest, we compared RB signaling to downstream effecters in this resistant cell line to that of the RB-sensitive SAOS-2 cell line. Although introduction of PSM-RB repressed E2F-mediated transcription in both C33A and SAOS-2 cells, PSM-RB failed to repress Cyclin A promoter activity in C33A, Ectopic expression of PSM-RB in SAOS-2 cells resulted in a decrease in both Cyclin A and Cdk2 protein levels without affecting Cyclin E or Cdk4, In contrast, over-expression of PSM-RB in C33A cells did not alter endogenous Cyclin A, Cyclin E, or Cdk2 protein levels or impact Cdk2 kinase activity, indicating that signaling from RB to downstream targets is abrogated in this cell line. The importance of Cdk2 activity was demonstrated by p27Kip1, which attenuated Cdk2 activity and inhibited cell cycle progression in C33A cells, Since RB signaling to Cdk2 is disrupted in these tumor cells, we coexpressed two proteins that cooperate with RB transcriptional repression, AHR and BRG-1, in an attempt to correct this signaling dysfunction, Coexpression of AHR/BRG-1 with PSM-RB attenuated Cyclin A and Cdk2 expression as well as Cdk2-associated kinase activity, resulting in cell cycle inhibition of C33A cells. Importantly, ectopic expression of Cyclin A was able to reverse the arrest mediated by co-expression of AHR/BRG-1 with PSM-RB, These results indicate that down-regulation of Cdk2 activity is requisite for RB-mediated cell cycle arrest. Thus, this study reveals a new mechanism through which tumor cells evade anti-proliferative signals, and provides insight into how RB-signaling is mediated.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Knudsen, ES (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA.		Puga, Alvaro/B-7676-2008		NATIONAL CANCER INSTITUTE [R01CA082525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006273, R56ES006273] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA82525-01] Funding Source: Medline; NIEHS NIH HHS [ES06273] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bartkova J, 1997, Prog Cell Cycle Res, V3, P211; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Ciaparrone M, 1998, CANCER RES, V58, P114; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DePinho RA, 1998, NATURE, V391, P533, DOI 10.1038/35257; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kaelin WG, 1997, CANCER INVEST, V15, P243, DOI 10.3109/07357909709039722; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 1999, J BIOL CHEM, V274, P27632, DOI 10.1074/jbc.274.39.27632; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Philips A, 1998, ONCOGENE, V16, P1373, DOI 10.1038/sj.onc.1201655; Puga A, 2000, J BIOL CHEM, V275, P2943, DOI 10.1074/jbc.275.4.2943; Reed SI, 1997, CANCER SURV, V29, P7; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Schulze A, 1996, MOL CELL BIOL, V16, P4632; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	51	65	66	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2000	19	15					1857	1867		10.1038/sj.onc.1203510	http://dx.doi.org/10.1038/sj.onc.1203510			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773875				2022-12-17	WOS:000086424300001
J	Johnson, BA; Geha, M; Blackwell, TK				Johnson, BA; Geha, M; Blackwell, TK			Similar but distinct effects of the tristetraprolin/TIS11 immediate-early proteins on cell survival	ONCOGENE			English	Article						immediate-early; apoptosis; zinc finger; TNF-alpha; mRNA; growth factor	PRIMARY RESPONSE GENE; FINGER TRANSCRIPTION FACTOR; MESSENGER-RNA DEGRADATION; NECROSIS-FACTOR-ALPHA; C-MYC; YEAST HOMOLOG; DNA-SYNTHESIS; TNF-ALPHA; IN-VIVO; APOPTOSIS	The immediate early protein tristetraprolin (TTP) is required to prevent inappropriate production of the cytokine TNF-alpha, and is a member of a zinc finger protein family that is associated with RNA binding. TTP expression is induced by TNF-alpha, and evidence indicates that TTP can bind and destabilize the TNF-alpha mRNA, TTP and the closely related TIS11b and TIS11d proteins are evolutionarily conserved, however, and induced transiently in various cell types by numerous diverse stimuli, suggesting that they have additional functions. Supporting this idea, continuous expression of each TTP/TIS11 protein at physiological levels causes apoptotic cell death. By various criteria, this cell death appears analogous to apoptosis induced by certain oncoproteins. It is also dependent upon the zinc fingers, suggesting that it involves action on appropriate cellular targets. TTP but not TIS11b or TIS11d also sensitizes cells to induction of apoptosis by TNF-alpha. The data suggest that the TTP and TIS11 immediate early proteins have similar but distinct effects on growth or survival pathways, and that TTP might influence TNF-alpha regulation at multiple levels.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Blackwell, TK (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, 200 Longwood Ave, Boston, MA 02115 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD017461] Funding Source: NIH RePORTER; NICHD NIH HHS [P01 HD17461] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Barabino SML, 1997, GENE DEV, V11, P1703, DOI 10.1101/gad.11.13.1703; Batchelder C, 1999, GENE DEV, V13, P202, DOI 10.1101/gad.13.2.202; BEUTLER B, 1992, TUMOR NECROSIS FACTO, P561; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; Carballo E, 1997, J CLIN INVEST, V100, P986, DOI 10.1172/JCI119649; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CORPS AN, 1995, FEBS LETT, V368, P160, DOI 10.1016/0014-5793(95)00635-M; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GOMPERTS M, 1992, FEBS LETT, V306, P1, DOI 10.1016/0014-5793(92)80825-2; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guedes S, 1997, DEVELOPMENT, V124, P731; Hafezi F, 1997, NAT MED, V3, P346, DOI 10.1038/nm0397-346; Han JH, 1998, MOL CELL BIOL, V18, P6052, DOI 10.1128/MCB.18.10.6052; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KANOH J, 1995, MOL BIOL CELL, V6, P1185, DOI 10.1091/mbc.6.9.1185; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; MA QF, 1995, ONCOGENE, V10, P487; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; MESNER PW, 1995, J NEUROSCI, V15, P7357; Murray MV, 1997, MOL CELL BIOL, V17, P2291, DOI 10.1128/MCB.17.4.2291; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Rudner DZ, 1998, GENE DEV, V12, P1010, DOI 10.1101/gad.12.7.1010; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Tabara H, 1999, DEVELOPMENT, V126, P1; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TAYLOR GA, 1995, J BIOL CHEM, V270, P13341, DOI 10.1074/jbc.270.22.13341; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; Thompson MJ, 1996, GENE, V174, P225, DOI 10.1016/0378-1119(96)00084-4; Tronchere H, 1997, NATURE, V388, P397, DOI 10.1038/41137; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; VARNUM BC, 1989, ONCOGENE, V4, P119; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WARBRICK E, 1994, GENE, V151, P243, DOI 10.1016/0378-1119(94)90664-5; Worthington MT, 1996, P NATL ACAD SCI USA, V93, P13754, DOI 10.1073/pnas.93.24.13754; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Zhan Y, 1997, MOL CELL BIOL, V17, P6755, DOI 10.1128/MCB.17.11.6755; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	56	65	67	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1657	1664		10.1038/sj.onc.1203474	http://dx.doi.org/10.1038/sj.onc.1203474			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763822				2022-12-17	WOS:000086083800005
J	Noel, A; Boulay, A; Kebers, F; Kannan, R; Hajitou, A; Calberg-Bacq, CM; Basset, P; Rio, MC; Foidart, JM				Noel, A; Boulay, A; Kebers, F; Kannan, R; Hajitou, A; Calberg-Bacq, CM; Basset, P; Rio, MC; Foidart, JM			Demonstration in vivo that stromelysin-3 functions through its proteolytic activity	ONCOGENE			English	Article						metalloproteases; tumor growth; stromelysin-3; MMP inhibitors	BREAST-CANCER; GELATINASE-A; STRUCTURAL DETERMINANTS; MOUSE STROMELYSIN-3; GENE-EXPRESSION; GROWTH-FACTOR; CELLS; METALLOPROTEINASE; CARCINOMA; TUMOR	Stromelysin-3 (ST3), a matrix metalloproteinase (MMP) expressed in aggressive carcinomas, has been shown to promote tumor development in different in vivo experimental models. However, the inability of its mature form to degrade extracellular matrix components casts doubt on whether ST3 functions in vivo as protease, In this study, we evaluated whether the ST3 tumor-promoting effect could be ascribed to its proteolytic activity and whether this putative protease could be targeted with MMP inhibitors. Catalytically inactive mutant cDNA of human (h) ST3 or mouse (m) ST3 were generated and transfected into MCF7 cells, When injected into nude mice in the presence of matrigel, the mutant-bearing cells did not exhibit the enhanced tumorigenicity elicited by MCF7 cells transfected with wild-type ST3 cDNA, In a second approach, TIMP2 overproduction in MCF7 cells expressing hST3 was induced by retroviral infection. The co-expression of ST3 and TIMP2 failed to enhance the tumorigenicity of MCF7 cells. Notably, matrigel depleted of low-molecuiar-weight proteins and growth factors failed to promote the tumorigenicity of ST3-expressing MCF7 cells. These findings provide the first in vivo evidence that ST3 is indeed a protease that can modulate cancer progression by remodeling extracellular matrix and probably by inducing it to release the necessary microenvironmental factors. Thus, ST3 represents an interesting target for specific MMP inhibition.	Univ Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, France; Univ Liege, Virol Lab, B-4000 Liege, Belgium	University of Liege; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Liege	Noel, A (corresponding author), Univ Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium.			Noel, Agnes/0000-0002-7670-6179				Ahmad A, 1998, AM J PATHOL, V152, P721; Ahmad A, 1997, INT J CANCER, V73, P290, DOI 10.1002/(SICI)1097-0215(19971009)73:2<290::AID-IJC21>3.0.CO;2-I; ANGLARD P, 1995, J BIOL CHEM, V270, P20337, DOI 10.1074/jbc.270.35.20337; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75; Chenard MP, 1996, INT J CANCER, V69, P448, DOI 10.1002/(SICI)1097-0215(19961220)69:6<448::AID-IJC5>3.3.CO;2-4; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; DECLERCK YA, 1998, CHEM BIOL SERPINS, P89; GARTNER MFRM, 1992, INT J CANCER, V51, P788, DOI 10.1002/ijc.2910510520; Gill LJ, 1997, BRIT J HEALTH PSYCH, V2, P131, DOI 10.1111/j.2044-8287.1997.tb00529.x; Guerin E, 1997, J BIOL CHEM, V272, P11088; Kannan R, 1999, PROTEIN EXPRES PURIF, V16, P76, DOI 10.1006/prep.1999.1068; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Manes S, 1997, J BIOL CHEM, V272, P25706, DOI 10.1074/jbc.272.41.25706; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; MURPHY G, 1993, J BIOL CHEM, V268, P15435; NOEL A, 1995, J BIOL CHEM, V270, P22866, DOI 10.1074/jbc.270.39.22866; NOEL A, 1992, BIOCHEM PHARMACOL, V43, P1263, DOI 10.1016/0006-2952(92)90501-9; Noel A, 1998, INT J CANCER, V76, P267, DOI 10.1002/(SICI)1097-0215(19980413)76:2<267::AID-IJC15>3.3.CO;2-Y; NOEL AC, 1994, INT J CANCER, V56, P331, DOI 10.1002/ijc.2910560306; Noel AC, 1996, J CLIN INVEST, V97, P1924, DOI 10.1172/JCI118624; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PEI DQ, 1994, J BIOL CHEM, V269, P25849; Price JE, 1996, BREAST CANCER RES TR, V39, P93, DOI 10.1007/BF01806081; ROUYER N, 1994, INVAS METAST, V14, P269; Rudolph-Owen LA, 1998, J MAMMARY GLAND BIOL, V3, P177, DOI 10.1023/A:1018746923474; Santavicca M, 1996, BIOCHEM J, V315, P953, DOI 10.1042/bj3150953; TAUB M, 1990, P NATL ACAD SCI USA, V87, P4002, DOI 10.1073/pnas.87.10.4002; Tetu B, 1998, HUM PATHOL, V29, P979, DOI 10.1016/S0046-8177(98)90204-0; WINDSOR LJ, 1994, J BIOL CHEM, V269, P26201	30	65	68	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 16	2000	19	12					1605	1612		10.1038/sj.onc.1203465	http://dx.doi.org/10.1038/sj.onc.1203465			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297XN	10734321	Green Submitted			2022-12-17	WOS:000086108100014
J	Porter, AC; Fanger, GR; Vaillancourt, RR				Porter, AC; Fanger, GR; Vaillancourt, RR			Signal transduction pathways regulated by arsenate and arsenite	ONCOGENE			English	Article						arsenic; Rac; Rho; PAK; MEKK3; MEKK4	ACTIVATED-PROTEIN-KINASE; HEAT-SHOCK; DIFFERENTIAL ACTIVATION; JUN KINASE; STRESS; CELLS; RAC; RHO; PHOSPHORYLATION; DOMAIN	Arsenate and arsenite activate c-Jun N-terminal kinase (JNK), however, the mechanism by which this occurs is not known, By expressing inhibitory mutant small GTP-binding proteins, p21-activated kinase (PAK) and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinases (MEKKs), we have identified specific proteins that are involved in arsenate-and arsenite-mediated activation of JNK, We observe a distinct difference between arsenate and arsenite signaling, which demonstrates that arsenate and arsenite are capable of activating unique proteins. Both arsenate and arsenite activation of JNK requires Rac and Rho. Neither arsenate nor arsenite signaling was inhibited by a dominant-negative mutant of Cdc42 or Ras. Arsenite stimulation of JNK requires PAK, whereas arsenate-mediated activation of JNK was unaffected by inhibitory mutant PAK. Of the four MEKKs tested, only MEKK3 and MEKK4 are involved in arsenate-mediated activation of JNK. In contrast, arsenite-mediated JNK activation requires MEKK2, MEKK3 and MEKK4. These results better define the mechanisms by which arsenate and arsenite activate JNK and demonstrate differences in the regulation of signal transduction pathways by these inorganic arsenic species.	Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA; Natl Jewish Med & Res Ctr, Div Basic Sci, Program Mol Signal Transduct, Denver, CO 80206 USA	University of Arizona; National Jewish Health	Vaillancourt, RR (corresponding author), Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 06694] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; BOS JL, 1989, CANCER RES, V49, P4682; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMAN RS, 1973, SCIENCE, V182, P1247, DOI 10.1126/science.182.4118.1247; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; JACOBSONKRAM D, 1985, ENVIRON MUTAGEN, V7, P787, DOI 10.1002/em.2860070515; Joneson T, 1998, J BIOL CHEM, V273, P17991, DOI 10.1074/jbc.273.29.17991; KENNEY LJ, 1988, J BIOL CHEM, V263, P7954; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE TC, 1985, CARCINOGENESIS, V6, P1421, DOI 10.1093/carcin/6.10.1421; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Mikami K, 1998, PLANT J, V15, P563, DOI 10.1046/j.1365-313X.1998.00227.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Ren XD, 1998, CURR OPIN GENET DEV, V8, P63, DOI 10.1016/S0959-437X(98)80063-4; ROSSMAN TG, 1980, ENVIRON MUTAGEN, V2, P371, DOI 10.1002/em.2860020307; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sakurai T, 1998, CHEM RES TOXICOL, V11, P273, DOI 10.1021/tx9701384; Smith AH, 1998, AM J EPIDEMIOL, V147, P660, DOI 10.1093/oxfordjournals.aje.a009507; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TRIGON S, 1995, J BIOL CHEM, V270, P13091, DOI 10.1074/jbc.270.22.13091; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; WHANGER PD, 1977, ENVIRON HEALTH PERSP, V19, P139, DOI 10.2307/3428465; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; YAN MH, 1994, NATURE, V372, P798; YEH S, 1968, CANCER, V21, P312, DOI 10.1002/1097-0142(196802)21:2<312::AID-CNCR2820210222>3.0.CO;2-K; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao CQ, 1997, P NATL ACAD SCI USA, V94, P10907, DOI 10.1073/pnas.94.20.10907	54	65	67	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 16	1999	18	54					7794	7802		10.1038/sj.onc.1203214	http://dx.doi.org/10.1038/sj.onc.1203214			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	265RJ	10618720				2022-12-17	WOS:000084256900009
J	Adams, JM; Harris, AW; Strasser, A; Ogilvy, S; Cory, S				Adams, JM; Harris, AW; Strasser, A; Ogilvy, S; Cory, S			Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector	ONCOGENE			English	Review						lymphoma; leukemia; oncogene; transgenic vectors; hematopoiesis	E-MU-MYC; CHRONIC MYELOGENOUS LEUKEMIA; POSITION-EFFECT VARIEGATION; PROGRAMMED CELL-DEATH; PRE-B-CELLS; C-MYC; T-CELL; V-ABL; N-MYC; VAV PROTOONCOGENE	The pathways to lymphoid neoplasia have been explored in a number of transgenic models. Because B lymphoid malignancies often involve translocation of an oncogene (e.g, myc, bcl-2, cyclin D1) to an immunoglobulin locus, resulting in its deregulated expression, the consequences of oncogene overexpression in lymphocytes can be evaluated with transgenes driven by an immunoglobulin regulatory element, such as an enhancer from the IgH locus. Mice bearing such transgenes have provided insight into the preneoplastic state, including alterations in the control of cellular proliferation, differentiation or apoptosis. They have also allowed studies on oncogene cooperation in,tiro and the modulating effect of genetic background. Briefly reviewed here are the models studied in the authors' Laboratories. Mice bearing myc and bcl-2 transgenes have received most attention but others studied include abl, ras, cyclin D1 and bmi-1 oncogenes. Also discussed is a new transgenic vector that should facilitate transgenic approaches to non-lymphoid leukemias, The vector bears elements from the promoter region of the vav gene, which is expressed almost exclusively in hematopoietic cells. It has proven capable of driving transgene expression throughout the hematopoietic compartment, including progenitor cells and their precursors. This novel vector should aid studies on many aspects of hematopoiesis, including the modeling of leukemogenesis.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute	Adams, JM (corresponding author), Walter & Eliza Hall Inst Med Res, PO Royal Melbourne Hosp, Melbourne, Vic 3050, Australia.		Cory, Suzanne/E-1642-2013; Strasser, Andreas/C-7581-2013; Adams, Jerry M/E-1199-2013	Cory, Suzanne/0000-0002-6818-3451; Strasser, Andreas/0000-0002-5020-4891; Adams, Jerry/0000-0002-4360-8628	NCI NIH HHS [CA43540, CA80188] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540, R01CA080188] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1992, CANCER SURV, V15, P119; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ADAMS JM, 1992, ONCOGENE, V7, P611; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; ADAMS JM, 1991, ORIGINS HUMAN CANC C; ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; ALEXANDER WS, 1989, ONCOGENE, V4, P575; ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Alkema MJ, 1997, ONCOGENE, V15, P899, DOI 10.1038/sj.onc.1201262; Amati Bruno, 1998, Frontiers in Bioscience, V3, pD250; ASKEW DS, 1991, ONCOGENE, V6, P1915; BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOS JL, 1989, CANCER RES, V49, P4682; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; CORY S, 1994, PHILOS T R SOC B, V345, P289, DOI 10.1098/rstb.1994.0108; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CORY S, 1994, COLD SPRING HARB SYM, V59, P365, DOI 10.1101/SQB.1994.059.01.041; Cory S, 1999, CANCER RES, V59, p1685S; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; CUI CQ, 1994, TRANSGENIC RES, V3, P182, DOI 10.1007/BF01973986; DALEY GQ, 1991, ADV CANCER RES, V57, P151; Davidson WF, 1998, J EXP MED, V187, P1825, DOI 10.1084/jem.187.11.1825; DePinho RA, 1999, ONCOGENE, V18, P5248, DOI 10.1038/sj.onc.1203108; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; Domen J, 1998, BLOOD, V91, P2272, DOI 10.1182/blood.V91.7.2272.2272_2272_2282; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Festenstein R, 1996, SCIENCE, V271, P1123, DOI 10.1126/science.271.5252.1123; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; HARIHARAN JK, 1988, ONCOGENE RES, V3, P1; HARRIS A, 1991, MECHANISMS B CELL NE, P367; Harris AW, 1997, CURR TOP MICROBIOL, V224, P221; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HARRIS AW, 1998, CURR TOP MICROBIOL I, V141, P82; HAUPT Y, 1993, ONCOGENE, V8, P3161; HAUPT Y, 1992, ONCOGENE, V7, P981; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HAUPT Y, 1993, INT J CANCER, V55, P623, DOI 10.1002/ijc.2910550418; Higgs DR, 1998, CELL, V95, P299, DOI 10.1016/S0092-8674(00)81761-4; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; HURLIN PJ, 1994, COLD SPRING HARB SYM, V59, P109, DOI 10.1101/SQB.1994.059.01.014; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kioussis D, 1997, CURR OPIN GENET DEV, V7, P614, DOI 10.1016/S0959-437X(97)80008-1; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; LANGDON WY, 1988, ONCOGENE RES, V3, P271; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LINDEMAN GJ, 1995, ONCOGENE, V10, P1013; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Martin David I. K., 1996, Bioessays, V18, P919, DOI 10.1002/bies.950181111; Matolcsy A, 1996, BLOOD, V88, P3937, DOI 10.1182/blood.V88.10.3937.bloodjournal88103937; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Ogilvy S, 1998, BLOOD, V91, P419, DOI 10.1182/blood.V91.2.419.419_419_430; OGILVY S, 1999, IN PRESS BLOOD; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Peng SL, 1996, J EXP MED, V184, P1149, DOI 10.1084/jem.184.3.1149; Raitano AB, 1997, BBA-REV CANCER, V1333, pF201, DOI 10.1016/S0304-419X(97)00023-1; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1990, CURR TOP MICROBIOL, V166, P175; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1995, NATURE, V373, P385, DOI 10.1038/373385a0; Strasser A, 1999, INT J CANCER, V81, P505, DOI 10.1002/(SICI)1097-0215(19990517)81:4<505::AID-IJC1>3.0.CO;2-J; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 1996, EMBO J, V15, P3823, DOI 10.1002/j.1460-2075.1996.tb00756.x; Strasser A, 1996, Behring Inst Mitt, P101; STRASSER A, 1995, CURR OPIN IMMUNOL, V7, P228, DOI 10.1016/0952-7915(95)80007-7; Strasser A, 1997, BBA-REV CANCER, V1333, pF151, DOI 10.1016/S0304-419X(97)00019-X; STRASSER A, 1994, P NATL ACAD SCI USA, V91, P1376, DOI 10.1073/pnas.91.4.1376; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; STRASSER A, 1997, 5 EUR AP BING GERM; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA S, 1992, BLOOD, V79, P229; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; Vairo G, 1996, ONCOGENE, V13, P1511; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1987, J IMMUNOL, V139, P3854; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; Vooijs M, 1999, ONCOGENE, V18, P5293, DOI 10.1038/sj.onc.1202999; Walters MC, 1996, GENE DEV, V10, P185, DOI 10.1101/gad.10.2.185; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WARNER BJ, 1998, THESIS U MELBOURNE; Westervelt P, 1999, BLOOD, V93, P2143, DOI 10.1182/blood.V93.7.2143.407a32_2143_2148; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829; ZORNIG M, 1995, ONCOGENE, V10, P2397	127	65	66	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	1999	18	38					5268	5277		10.1038/sj.onc.1202997	http://dx.doi.org/10.1038/sj.onc.1202997			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498879				2022-12-17	WOS:000082808400005
J	Bieche, I; Nogues, C; Lidereau, R				Bieche, I; Nogues, C; Lidereau, R			Overexpression of BRCA2 gene in sporadic breast tumours	ONCOGENE			English	Article						breast carcinoma; BRCA2; quantitative RT-PCR	CANCER SUSCEPTIBILITY GENE; CHROMOSOME 13Q12-Q13; MUTATION ANALYSIS; OVARIAN CANCERS; RT-PCR; HETEROZYGOSITY; EXPRESSION; CELLS; DIFFERENTIATION; PROLIFERATION	The breast cancer susceptibility gene BRCA2 is expressed in a wide range of tissues as an Il-lib mRNA transcript that encodes a 3418-amino acid protein involved in the response to DNA damage. To obtain better a molecular characterization of BRCA2 expression in sporadic breast cancer, we quantified BRCA2 mRNA by means of RT- PCR in a large series of human primary breast tumours, BRCA2 expression showed wide variations in tumour tissues, being underexpressed in 14/127 (11%) and overexpressed in 25/127 (20%), BRCA2 overexpression (but not underexpression) correlated significantly with Scarff, Bloom and Richardson (SBR) histopathological grade III (P=0.007) and was mainly attributed to nuclear polymorphism (P=0.005) and mitotic index (P=0.048), suggesting that the BRCA2 gene contributes to the proliferation rate in breast tumours, BRCA2 status (under and/or overexpression versus normal expression) was not associated with subsequent relapse and with significantly shorter disease-free survival. The observed disruption of BRCA2 expression is not due to allelic loss, because the latter did not correlate with altered BRCA2 mRNA expression in our tumour series. Taken together, these data suggest the involvement, especially by overexpression, of the BRCA2 gene in sporadic breast tumours, and the existence of another important tumour-suppressor gene in breast cancer, in the 13q12-q13 region.	Ctr Rene Huguenin, Lab Oncogenet, F-92211 St Cloud, France; Ctr Rene Huguenin, Dept Stat Med, F-92211 St Cloud, France; Fac Sci Pharmaceut & Biol Paris, Genet Mol Lab, F-75006 Paris, France	Rene Huguenin Hospital; Rene Huguenin Hospital; UDICE-French Research Universities; Universite Paris Cite	Lidereau, R (corresponding author), Ctr Rene Huguenin, Lab Oncogenet, 35 Rue Dailly, F-92211 St Cloud, France.		Bièche, Ivan/O-7399-2017	Bièche, Ivan/0000-0002-2430-5429				Beckmann MW, 1996, BRIT J CANCER, V73, P1220, DOI 10.1038/bjc.1996.234; Bieche I, 1997, BRIT J CANCER, V76, P1416, DOI 10.1038/bjc.1997.572; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLETONJANSEN AM, 1995, BRIT J CANCER, V72, P1241, DOI 10.1038/bjc.1995.493; Collins N, 1997, BRIT J CANCER, V76, P1150, DOI 10.1038/bjc.1997.526; COLLINS N, 1995, ONCOGENE, V10, P1673; Couch FJ, 1996, NAT GENET, V13, P123, DOI 10.1038/ng0596-123; DIRNHOFER S, 1995, TRENDS GENET, V11, P380, DOI 10.1016/S0168-9525(00)89115-5; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; Hamann U, 1996, CANCER RES, V56, P1988; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kelsell DP, 1996, LANCET, V347, P1554, DOI 10.1016/S0140-6736(96)90707-2; KERANGUEVEN F, 1995, GENE CHROMOSOME CANC, V13, P291, DOI 10.1002/gcc.2870130410; Lancaster JM, 1996, NAT GENET, V13, P238, DOI 10.1038/ng0696-238; LAZAR V, 1995, CANCER RES, V55, P3735; MANIATIS T, 1982, MOL CLONING LABORATO, P458; Miki Y, 1996, NAT GENET, V13, P245, DOI 10.1038/ng0696-245; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mullen CA, 1998, AM J REPROD IMMUNOL, V39, P41; PANNETIER C, 1993, NUCLEIC ACIDS RES, V21, P577, DOI 10.1093/nar/21.3.577; PERSYN JP, 1980, EUR J CANCER, V16, P1513; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; SARKAR G, 1994, BIOTECHNIQUES, V17, P864; Sellner LN, 1996, MOL CELL PROBE, V10, P481, DOI 10.1006/mcpr.1996.0068; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; Spillman MA, 1996, ONCOGENE, V13, P1639; Teng DHF, 1996, NAT GENET, V13, P241, DOI 10.1038/ng0696-241; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; vandenBerg J, 1996, BRIT J CANCER, V74, P1615, DOI 10.1038/bjc.1996.597; Vaughn JP, 1996, CANCER RES, V56, P4590; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zhang HB, 1998, CELL, V92, P433, DOI 10.1016/S0092-8674(00)80936-8	37	65	69	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5232	5238		10.1038/sj.onc.1202903	http://dx.doi.org/10.1038/sj.onc.1202903			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498873				2022-12-17	WOS:000082555700012
J	Nagao, M; Kaziro, Y; Itoh, H				Nagao, M; Kaziro, Y; Itoh, H			The Src family tyrosine kinase is involved in Rho-dependent activation of c-Jun N-terminal kinase by G alpha(12)	ONCOGENE			English	Article						G alpha(12); Src; Rho; JNK	SERUM RESPONSE FACTOR; GTP-BINDING PROTEIN; CELL-SHAPE CHANGES; ALPHA-SUBUNIT; DROSOPHILA GASTRULATION; TRANSFORMING ACTIVITY; SIGNALING PATHWAY; G13 PROTEINS; GENE-PRODUCT; P115 RHOGEF	G alpha(12), a member of alpha subunit of heterotrimeric G protein G(12) subfamily, has been shown to stimulate c-Jun N-terminal kinase (JNK) activity through the low molecular weight GTP-binding proteins Ras, Rac, and Cdc42. In this study using the transient expression of a constitutively activated mutant of G alpha(12) (G alpha(12)Q229L) in human embryonic kidney (HEK) 293 cells, we found that Rho and Src family kinase are also involved in the Gu,,induced activation of JNK. The activation of JNK by G alpha(12)Q229L was inhibited by dominant-negative RhoA(T19N), and botulinum C3 exoenzyme which specifically inactivates Rho. In addition, the expression of activated RhoA(G14V) elevated JNK activity in HEK 293 cells. The G alpha(12)Q229L-stimulated activation of JNK was blocked by a specific inhibitor of protein tyrosine kinases (PP2), and C-terminal Src kinase (Csk). Moreover, we observed that G alpha(12)Q229L stimulated Src family kinase activity and v-Src induced JNK activation. Interestingly, the v-Src-induced activation of JNK was inhibited by dominant-negative RhoA(T19N). In contrast, Csk did not inhibit the JNK activation by activated RhoA(G14V). These results suggest that Rho and Src family kinase are required for the G alpha(12)-induced JNK activation, and that Src family kinase acts upstream of Rho activation in the JNK pathway.	Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Itoh, H (corresponding author), Tokyo Inst Technol, Fac Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.							Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; Barr AJ, 1997, J BIOL CHEM, V272, P2223; Barrett K, 1997, CELL, V91, P905, DOI 10.1016/S0092-8674(00)80482-1; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Hacker U, 1998, GENE DEV, V12, P274, DOI 10.1101/gad.12.2.274; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; Jiang Y, 1998, NATURE, V395, P808, DOI 10.1038/27454; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; Mao JH, 1998, J BIOL CHEM, V273, P27118, DOI 10.1074/jbc.273.42.27118; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nagao M, 1998, J BIOL CHEM, V273, P22892, DOI 10.1074/jbc.273.36.22892; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; SEKINE A, 1989, J BIOL CHEM, V264, P8602; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wadsworth SJ, 1997, J BIOL CHEM, V272, P28829, DOI 10.1074/jbc.272.46.28829; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744	52	65	66	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4425	4434		10.1038/sj.onc.1202832	http://dx.doi.org/10.1038/sj.onc.1202832			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442633				2022-12-17	WOS:000081813500004
J	Wolff, B; Naumann, M				Wolff, B; Naumann, M			INK4 cell cycle inhibitors direct transcriptional inactivation of NF-kappa B	ONCOGENE			English	Article						NF-kappa B; ankyrin; INK4 cell cycle inhibitors; p27	DEPENDENT KINASES; PRECURSOR P105; DNA-BINDING; PROTEIN; BCL-3; IDENTIFICATION; ONCOGENESIS; COACTIVATOR; TRANSITION; P16(INK4A)	The nuclear factor kappa B, a transcription factor regulating the expression of multiple genes including genes essential for cell cycle control, is found in most cells in a dormant state in the cytoplasm bound to the inhibitory family I kappa B via an ankyrin repeat domain. Stimulation of cells with a variety of inducers inactivates I kappa B proteins. The active dimeric NF-kappa B complex, often composed of 50- and 65-kilodalton subunits of the Rel family, translocates into the nucleus, where the NF-kappa Bp65 subunit stimulates transcription. Here me report that a family of proteins containing ankyrin repeats, the inhibitors of Cdk4 (INK4) is able to bind NF-kappa Bp65, The association of p161NK4 with NF-kappa Bp65 is considerable in HeLa- or 293 cells, if the NF-kappa B inhibitor I kappa B alpha is degraded in response to TNF alpha stimulation. Overexpression of INK4 molecules suppresses the transactivational ability of NF-kappa B significantly, In contrast to INK4 proteins, the cell cycle inhibitor p27 enhances NF-kappa B transactivation activity. Thus, the effect of INK4 proteins on NF-kappa B function possibly modifies NF-kappa B mediated transcriptional activation of cell cycle associated factors.	Max Planck Inst Infekt Biol, Mol Biol Abt, D-10117 Berlin, Germany	Max Planck Society	Naumann, M (corresponding author), Max Planck Inst Infekt Biol, Mol Biol Abt, Monbijoustr 2, D-10117 Berlin, Germany.		Naumann, Michael/B-5285-2011	Naumann, Michael/0000-0002-8060-2313				Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; DellaRagione F, 1996, J BIOL CHEM, V271, P15942, DOI 10.1074/jbc.271.27.15942; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HIRST K, 1994, EMBO J, V13, P5410, DOI 10.1002/j.1460-2075.1994.tb06876.x; KAMB A, 1994, SCIENCE, V264, P440; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Mosialos G, 1997, SEMIN CANCER BIOL, V8, P121, DOI 10.1006/scbi.1997.0063; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; Naumann M, 1996, GASTROENTEROLOGY, V110, P1215, DOI 10.1053/gast.1996.v110.pm8613012; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Paal K, 1997, NUCLEIC ACIDS RES, V25, P1050, DOI 10.1093/nar/25.5.1050; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078	30	65	65	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	1999	18	16					2663	2666		10.1038/sj.onc.1202617	http://dx.doi.org/10.1038/sj.onc.1202617			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353611				2022-12-17	WOS:000079907100015
J	Corbet, SW; Clarke, AR; Gledhill, S; Wyllie, AH				Corbet, SW; Clarke, AR; Gledhill, S; Wyllie, AH			P53-dependent and -independent links between DNA-damage, apoptosis and mutation frequency in ES cells	ONCOGENE			English	Article						p53; apoptosis; mutation; DNA-damage; tissue specificity	WILD-TYPE P53; RADIATION-INDUCED APOPTOSIS; P53-DEFICIENT MICE; IONIZING-RADIATION; GAMMA-IRRADIATION; TUMOR-SUPPRESSOR; NUCLEAR ACCUMULATION; GENE AMPLIFICATION; TRANSGENIC MICE; GROWTH ARREST	The hypothesis that p53 deficiency enhances the survival of DNA-damage bearing cells was investigated in wildtype and p53 mutant embryonic stem (ES) cells. Following UV-C irradiation, p53 is rapidly induced in wild-type cells and p53-dependent apoptosis follows within 8 h, resulting in the death of the majority of cells within 36 h. Increasing doses of UV-irradiation resulted in enhanced clonogenic survival of null cells as compared to wild-type. Amongst surviving clones, the Hprt mutation frequency was found to be dependent upon UV dose and influenced by p53 status. Treatment with ionizing radiation led to enhanced expression of p53 but resulted in little induction of apoptosis irrespective of p53 status. However, clonogenic potential was considerably reduced, particularly in wild-type cells which showed a tenfold lower survival than null cells. In contrast to the effects of UV-irradiation, the incidence of Hprt mutation did not differ significantly between wild-type and p53 null survivors. The data confirm that p53 restricts the numbers of cells bearing mutations that survive DNA damage induced by either agent, albeit by different mechanisms.	Univ Edinburgh, Sch Med, Dept Pathol, CRC Labs, Edinburgh, Midlothian, Scotland	University of Edinburgh	Corbet, SW (corresponding author), Univ Edinburgh, Sch Med, Dept Pathol, CRC Labs, Teviot Pl, Edinburgh, Midlothian, Scotland.		Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X				Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BRAIN R, 1994, ONCOGENE, V9, P1775; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARDER P, 1993, ONCOGENE, V8, P1397; CLARKE AR, 1995, ONCOGENE, V11, P1913; CLARKE AR, 1994, ONCOGENE, V9, P1767; Clarke AR, 1997, ONCOGENE, V14, P2015, DOI 10.1038/sj.onc.1201040; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Clutton SM, 1996, CELL DEATH DIFFER, V3, P141; CROLLA JA, 1990, GENET RES, V55, P107, DOI 10.1017/S0016672300025349; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; FANTES JA, 1992, AM J HUM GENET, V51, P1286; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HARVEY M, 1993, ONCOGENE, V8, P2457; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANGLEY RE, 1994, INT J RADIAT BIOL, V65, P605, DOI 10.1080/09553009414550691; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Li G, 1996, AM J PATHOL, V148, P1113; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Linke SP, 1997, CANCER RES, V57, P1171; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MAHMUD KKS, 1992, CELL, V69, P367; MALCOMSON RDG, 1995, BRIT J CANCER, V72, P952, DOI 10.1038/bjc.1995.440; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1976, J CELL PHYSIOL, V89, P441, DOI 10.1002/jcp.1040890310; MELING GI, 1993, BRIT J CANCER, V67, P93, DOI 10.1038/bjc.1993.15; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NISHINO H, 1995, ONCOGENE, V11, P263; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PURDIE CA, 1994, ONCOGENE, V9, P603; Rafferty JA, 1996, ONCOGENE, V12, P693; RENZING J, 1995, ONCOGENE, V10, P1865; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROBERTSON EJ, 1986, EXPT APPROACHES MAMM, P475; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; Scherer SJ, 1996, BIOCHEM BIOPH RES CO, V221, P722, DOI 10.1006/bbrc.1996.0663; SEYMOUR C, 1992, MUTAT RES, V267, P19, DOI 10.1016/0027-5107(92)90107-D; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUGANO T, 1995, JPN J CANCER RES, V86, P415, DOI 10.1111/j.1349-7006.1995.tb03072.x; TSUKADA T, 1993, ONCOGENE, V8, P3313; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	71	65	66	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1537	1544		10.1038/sj.onc.1202436	http://dx.doi.org/10.1038/sj.onc.1202436			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102623				2022-12-17	WOS:000078770700003
J	Vermeulen, SJ; Nollet, F; Teugels, E; Vennekens, KM; Malfait, F; Philippe, J; Speleman, F; Bracke, ME; van Roy, FM; Mareel, MM				Vermeulen, SJ; Nollet, F; Teugels, E; Vennekens, KM; Malfait, F; Philippe, J; Speleman, F; Bracke, ME; van Roy, FM; Mareel, MM			The alpha E-catenin gene (CTNNA1) acts as an invasion-suppressor gene in human colon cancer cells	ONCOGENE			English	Article						colon cancer; invasion; alpha E-catenin; genetic instability	NONPOLYPOSIS COLORECTAL-CARCINOMA; II RECEPTOR GENE; E-CADHERIN; MICROSATELLITE INSTABILITY; GROWTH-FACTOR; LYNCH SYNDROME; RETINOIC ACID; BETA-CATENIN; TUMOR-CELLS; MUTATIONS	The acquisition of invasiveness is a crucial step in the malignant progression of cancer. In cancers of the colon and of other organs the E-cadherin/catenin complex, which is implicated in homotypic cell-cell adhesion as well as in signal transduction, serves as a powerful inhibitor of invasion. We show here that one allele of the alpha E-catenin (CTNNA1) gene is mutated in the human colon cancer cell family HCT-8, which is identical to HCT-15, DLD-1 and HRT-18. Genetic instability, due to mutations in the HMSH6 (also called GTBP) mismatch repair gene, results in the spontaneous occurrence of invasive variants, all carrying either a mutation or exon skipping in the second alpha E-catenin allele, The alpha E-catenin gene is therefore, an invasion-suppressor gene in accordance with the two-hit model of Knudsen for tumour-suppressor genes.	State Univ Ghent Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium; State Univ Ghent, Dept Mol Biol, Mol Cell Biol Lab, B-9000 Ghent, Belgium; VIB, B-9000 Ghent, Belgium; Univ Hosp Brussels, Lab Med Oncol, B-1010 Jette, Belgium; State Univ Ghent Hosp, Dept Clin Chem Microbiol & Immunol, B-9000 Ghent, Belgium; State Univ Ghent Hosp, Dept Med Genet, B-9000 Ghent, Belgium	Ghent University; Ghent University Hospital; Ghent University; Flanders Institute for Biotechnology (VIB); University Hospital Brussels; Ghent University; Ghent University Hospital; Ghent University; Ghent University Hospital	Mareel, MM (corresponding author), State Univ Ghent Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, Pintelaan 185, B-9000 Ghent, Belgium.		van Roy, Frans M/C-6123-2009; philippé, jan/AAG-8964-2019; speleman, frank/AAR-5184-2020; Malfait, Fransiska/K-7897-2014; Philippé, Jan/A-1027-2008	van Roy, Frans M/0000-0003-4358-1039; philippé, jan/0000-0003-4857-5746; speleman, frank/0000-0002-6628-8559; Philippé, Jan/0000-0003-4857-5746; Malfait, Fransiska/0000-0002-5010-0304; Vermeulen, Stefan/0000-0003-3710-800X				BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BHATTACHARYYA NP, 1995, HUM MOL GENET, V4, P2057, DOI 10.1093/hmg/4.11.2057; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; BRACKE ME, 1993, BRIT J CANCER, V68, P282, DOI 10.1038/bjc.1993.329; BRACKE ME, 1991, BRIT J CANCER, V63, P867, DOI 10.1038/bjc.1991.191; BREEN E, 1993, CELL ADHES COMMUN, V1, P239, DOI 10.3109/15419069309097257; BRUSSEMAKERS MJG, 1996, CLIN EXP METASTAS S1, V14, P15; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; Casares S, 1995, ONCOGENE, V11, P2303; CHEN TR, 1995, CANCER GENET CYTOGEN, V81, P103, DOI 10.1016/0165-4608(94)00225-Z; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; Eshleman JR, 1996, ONCOGENE, V12, P1425; EWING CM, 1995, CANCER RES, V55, P4813; FREI JV, 1992, CANCER, V69, P1108; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KNUDSON AG, 1985, CANCER RES, V45, P1437; KOI M, 1994, CANCER RES, V54, P4308; KOURI M, 1990, CANCER, V65, P1825, DOI 10.1002/1097-0142(19900415)65:8<1825::AID-CNCR2820650827>3.0.CO;2-H; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; Luria SE, 1943, GENETICS, V28, P491; Lynch HT, 1996, CANCER, V78, P1149, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1149::AID-CNCR1>3.0.CO;2-5; Mareel M, 1996, J CELL BIOCHEM, V61, P524; MAREEL M, 1997, HDB CLIN NEUROLOGY 3, V25, P105; Mareel M. M., 1991, MECH INVASION METAST; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MORTON RA, 1993, CANCER RES, V53, P3585; NOLLET F, 1995, GENOMICS, V26, P410, DOI 10.1016/0888-7543(95)80231-A; ODA T, 1993, BIOCHEM BIOPH RES CO, V193, P897, DOI 10.1006/bbrc.1993.1710; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1995, CANCER RES, V55, P5548; Rhyu MS, 1996, J NATL CANCER I, V88, P240, DOI 10.1093/jnci/88.5.240; ROEST PAM, 1993, HUM MOL GENET, V2, P1719, DOI 10.1093/hmg/2.10.1719; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SHIOZAKI H, 1994, AM J PATHOL, V144, P667; SHIOZAKI H, 1995, BRIT J CANCER, V71, P250, DOI 10.1038/bjc.1995.52; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; SPELEMAN F, 1992, CANCER GENET CYTOGEN, V58, P176; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TOMPKINS WA, 1974, J NATL CANCER I, V52, P1101, DOI 10.1093/jnci/52.4.1101; Vermeulen S, 1996, PATHOL RES PRACT, V192, P694, DOI 10.1016/S0344-0338(96)80091-4; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VERMEULEN SJ, 1995, BRIT J CANCER, V72, P1447, DOI 10.1038/bjc.1995.528; VERMEULEN SJ, 1998, IN PRESS CANC GENET; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M	51	65	67	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					905	915		10.1038/sj.onc.1202348	http://dx.doi.org/10.1038/sj.onc.1202348			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023666				2022-12-17	WOS:000078510600007
J	de Fromentel, CC; Gruel, N; Venot, C; Debussche, L; Conseiller, E; Dureuil, C; Teillaud, JL; Tocque, B; Bracco, L				de Fromentel, CC; Gruel, N; Venot, C; Debussche, L; Conseiller, E; Dureuil, C; Teillaud, JL; Tocque, B; Bracco, L			Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments	ONCOGENE			English	Article						p53; scFv; intracellular immunization; gene therapy	DNA-BINDING FUNCTION; C-TERMINAL DOMAIN; ACTIVATION FUNCTION; GROWTH SUPPRESSION; INDUCED APOPTOSIS; PROTEIN; INDUCTION; DAMAGE; INVOLVEMENT; SEQUENCE	We report here the production and the properties of single chain Fv fragments (scFvs) derived from the anti-p53 monoclonal antibodies PAb421 and 11D3, 11D3 is a newly generated monoclonal antibody which exhibits properties very comparable to those of PAb421, The scFvs PAb421 and 11D3 are able to stably associate with p53 and to restore the DNA binding activity of some p53 mutants in vitro. When expressed in p53(-/-) human tumour cells, the scFv421 is essentially localized in the cytoplasm in the absence of p53, and in the nucleus when exogenous p53 is present, Thus, p53 is also able to stably associate with an anti-p53 scFv in cells. Cotransfection of p53(-/-) human tumour cells with expression vectors encoding the His273 p53 mutant and either scFv leads to restoration of the p53 mutant deficient transcriptional activity. These data demonstrate that, in human tumour cells, these scFvs are able to restore a function essential for the tumour suppressor activity of p53 and may represent a novel class of molecules for p53-based cancer therapy.	Rhone Poulenc Rorer SA, Gene Med Dept, F-94403 Vitry, France; Inst Curie, Lab Biotechnol Anticorps, F-75005 Paris, France; Inst Curie, U255, INSERM, F-75005 Paris, France	Sanofi-Aventis; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	de Fromentel, CC (corresponding author), Inst Cochin Genet Mol, INSERM, U380, 22 Rue Mechain, F-75014 Paris, France.		de Fromentel, Claude Caron/Y-9715-2019	de Fromentel, Claude Caron/0000-0001-7566-3958; Teillaud, Jean-Luc/0000-0003-4442-9565				ABARZUA P, 1995, CANCER RES, V55, P3490; Abarzua P, 1996, ONCOGENE, V13, P2477; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; BYK G, 1995, Patent No. 01865; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cochet O, 1998, CANCER RES, V58, P1170; EIZENBERG O, 1995, EMBO J, V14, P1136, DOI 10.1002/j.1460-2075.1995.tb07097.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GUILLOUF C, 1995, ONCOGENE, V10, P2263; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jannot CB, 1997, BIOCHEM BIOPH RES CO, V230, P242, DOI 10.1006/bbrc.1996.5930; Kabat EA, 1991, SEQUENCES PROTEINS I; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEGROS Y, 1994, ONCOGENE, V9, P2071; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Marasco WA, 1997, GENE THER, V4, P11, DOI 10.1038/sj.gt.3300346; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MIYASHITA T, 1995, CELL, V80, P293; Nieba L, 1997, PROTEIN ENG, V10, P435, DOI 10.1093/protein/10.4.435; NIEWOLIK D, 1995, ONCOGENE, V10, P881; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PARK DJ, 1994, ONCOGENE, V9, P1899; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RICHARDSON JH, 1995, P NATL ACAD SCI USA, V92, P3137, DOI 10.1073/pnas.92.8.3137; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SMITH ML, 1995, ONCOGENE, V10, P1053; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	49	65	71	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					551	557		10.1038/sj.onc.1202338	http://dx.doi.org/10.1038/sj.onc.1202338			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927212				2022-12-17	WOS:000078166500028
J	Rohn, JL; Hueber, AO; McCarthy, NJ; Lyon, D; Navarro, P; Burgering, BMT; Evan, GI				Rohn, JL; Hueber, AO; McCarthy, NJ; Lyon, D; Navarro, P; Burgering, BMT; Evan, GI			The opposing roles of the Akt and c-Myc signalling pathways in survival from CD95-mediated apoptosis	ONCOGENE			English	Article						proto-oncogene c-myc; Akt protein kinase B; apoptosis; CD95/APO-1/Fas	DOMAIN-CONTAINING PROTEIN; CELL-DEATH; MOLECULAR-CLONING; GENE-TRANSFER; FAS; KINASE; INTERACTS; BAD; PHOSPHORYLATION; ACTIVATION	Expression of the proto-oncogene c-myc stimulates cell proliferation in the presence of the appropriate survival factors and triggers apoptosis in their absence; this dual capacity ensures that cell growth is restricted to the correct paracrine environment and is thereby strictly controlled. Recently our laboratory demonstrated that c-Myc-induced apoptosis requires the CD95 death receptor pathway and that insulin-like growth factor (IGF-1) signalling suppresses this killing. To investigate further the links between c-Myc and IGF-1 pathways in CD95-induced apoptosis, we examined the effects of c-Myc and a downstream IGF-I survival kinase, Akt, on killing mediated by CD95 and its recruited effector proteins (FADD and caspase-8). Here, we show that c-Myc activation does not exacerbate killing induced by FADD or pro-caspase-8, which narrows the point at which c-Myc exerts its action downstream of the interaction of CD95 with its ligand and upstream of FADD. We show further that activated Akt suppresses CD95-induced apoptosis and that Akt exerts its activity at a point downstream of FADD but upstream of caspase-8. These results restrict the possible mechanisms by which CD95-induced apoptosis is modulated by death signals and survival factors.	Imperial Canc Res Fund, Biochem Cell Nucleus Lab, London WC2A 3PX, England; Univ Complutense, Fac Pharm, Dept Biochem & Mol Biol, E-28040 Madrid, Spain; Univ Utrecht, Physiol Chem Lab, NL-3521 GG Utrecht, Netherlands	Cancer Research UK; Complutense University of Madrid; Utrecht University	Evan, GI (corresponding author), Imperial Canc Res Fund, Biochem Cell Nucleus Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Anne-Odile, Hueber/P-9860-2019; Anne-Odile, Hueber/G-4352-2013	Anne-Odile, Hueber/0000-0003-3816-2446; Anne-Odile, Hueber/0000-0003-3816-2446; Rohn, Jennifer/0000-0001-8766-6056; McCarthy, Nicola/0000-0001-6990-3943				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FIELD JK, 1990, ANTICANCER RES, V10, P1; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; HUEBER AO, 1998, IN PRESS TRENDS GENE; ITOH N, 1993, J IMMUNOL, V151, P621; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; WANTANABEFUKUNA.R, 1992, NATURE, V356, P314; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zornig M, 1998, CURR BIOL, V8, P467, DOI 10.1016/S0960-9822(98)70182-4	52	65	67	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	1998	17	22					2811	2818		10.1038/sj.onc.1202393	http://dx.doi.org/10.1038/sj.onc.1202393			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879987				2022-12-17	WOS:000077286400001
J	Shivji, MKK; Ferrari, E; Ball, K; Hubscher, U; Wood, RD				Shivji, MKK; Ferrari, E; Ball, K; Hubscher, U; Wood, RD			Resistance of human nucleotide excision repair synthesis in vitro to p21(Cdn1)	ONCOGENE			English	Article						PCNA; DNA polymerase; nucleotide excision repair; cip1/waf1/sdi1	CELL NUCLEAR ANTIGEN; DEPENDENT KINASE INHIBITOR; DNA-POLYMERASE-EPSILON; SINGLE-STRANDED-DNA; CALF THYMUS; SACCHAROMYCES-CEREVISIAE; REPLICATION COMPLEX; PURIFIED PROTEINS; DELTA HOLOENZYME; BINDING DOMAINS	The p21(Cdn1) protein (cipl/waf1/sdi1) plays an important role as an inhibitor of mammalian cell proliferation in response to DNA damage. By interacting with and inhibiting the function of cyclin-Cdk complexes, p21 can block entry into S phase. p21 can also directly inhibit replicative DNA synthesis by binding to the DNA polymerase sliding clamp factor PCNA. When cells are damaged and p21 is induced, DNA nucleotide excision repair (NER) continues, even though this pathway is PCNA-dependent. We investigated features of p21-resistant NER using human cell extracts. A direct end-labelling approach was used to measure the excision of damaged oligonucleotides by NER and no inhibition by p21 was found. By contrast, filling of the similar to 30 nt gaps created by NER could be inhibited by pre-binding p21 to PCNA, but only when gap filling was uncoupled from incision. Binding p21 to PCNA could also inhibit filling of model similar to 30 nt gaps by both purified DNA polymerases delta and epsilon. When p21 was incubated in a cell extract before addition of PCNA, inhibition of repair synthesis was gradually relieved with time. This incubation gives p21 the opportunity to associate with other targets. As p21 blocks association of DNA polymerases with PCNA but does not prevent loading of PCNA onto DNA, repair gap filling can occur rapidly as soon as p21 dissociates from PCNA. A synthetic PCNA-binding p21 peptide was an efficient inhibitor of NER synthesis in cell extracts.	Imperial Canc Res Fund, Clare Hall Labs, Potters Bar EN6 3LD, Herts, England; Univ Zurich Irchel, Dept Vet Biochem, CH-8057 Zurich, Switzerland; Univ Dundee, Dept Biochem, CRC Labs, Dundee DD1 4HN, Scotland	University of Zurich; University of Dundee	Wood, RD (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, Potters Bar EN6 3LD, Herts, England.		Wood, Richard D/M-6319-2018	Wood, Richard D/0000-0002-9495-6892				Adams PD, 1996, MOL CELL BIOL, V16, P6623; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; BIGGERSTAFF M, 1998, IN PRESS DNA REPAIR; Budd ME, 1997, MUTAT RES-DNA REPAIR, V384, P157, DOI 10.1016/S0921-8777(97)00024-4; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gibbs E, 1997, J BIOL CHEM, V272, P2373; GOUBIN F, 1995, ONCOGENE, V10, P2281; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HARPER JW, 1993, CELL, V75, P805; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Hess MT, 1997, MOL CELL BIOL, V17, P7069, DOI 10.1128/MCB.17.12.7069; Hindges R, 1997, BIOL CHEM, V378, P345; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; LEE SH, 1991, J BIOL CHEM, V266, P22707; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MAGA G, 1995, BIOCHEMISTRY-US, V34, P891, DOI 10.1021/bi00003a023; McDonald E, 1996, CANCER RES, V56, P2250; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P5003, DOI 10.1021/bi00015a011; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; PODUST VN, 1993, NUCLEIC ACIDS RES, V21, P841, DOI 10.1093/nar/21.4.841; Savio M, 1996, ONCOGENE, V13, P1591; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; SHIVJI MKK, 1998, IN PRESS DNA REPAIR; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WEINBERG DH, 1990, P NATL ACAD SCI USA, V87, P8692, DOI 10.1073/pnas.87.22.8692; WEISER T, 1991, J BIOL CHEM, V266, P10420; Wood RD, 1997, CARCINOGENESIS, V18, P605, DOI 10.1093/carcin/18.4.605; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Wood Richard D., 1995, Methods (Orlando), V7, P163, DOI 10.1006/meth.1995.1022; Zlotkin T, 1996, EMBO J, V15, P2298, DOI 10.1002/j.1460-2075.1996.tb00583.x	56	65	66	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 3	1998	17	22					2827	2838		10.1038/sj.onc.1202352	http://dx.doi.org/10.1038/sj.onc.1202352			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	143ZA	9879989				2022-12-17	WOS:000077286400003
J	Grutz, G; Forster, A; Rabbitts, TH				Grutz, G; Forster, A; Rabbitts, TH			Identification of the LMO4 gene encoding an interaction partner of the LIM-binding protein LDB1/NLI1: a candidate for displacement by LMO proteins in T cell acute leukaemia	ONCOGENE			English	Article						LIM domains; T cell; leukaemia; chromosomal translocations; protein interactions	TRANSGENIC MICE; DOMAIN PROTEINS; HOMEODOMAIN PROTEINS; RBTN2; RHOMBOTIN; LEUKEMIA; FAMILY; EXPRESSION; MOTIF; TAL1	The T cell oncogenes LMO2 and LMO2 are activated by distinct chromosomal translocations in childhood T cell acute leukaemias. Transgenic mouse models of this disease demonstrate that enforced expression of Lmo1 and Lmo2 cause T cell leukaemias with long latency and that Lmo2 expression leads to an inhibition of the T cell differentiation programme, prior to overt disease. These functions appear to be partly mediated by interaction of LMO1 or LMO2 with the LIM-binding protein LDB1/NLI1. We have now identified a new member of the Lmo family, designated Lmo4, via its interaction with Ldb1. Lmo4 is widely expressed in mouse tissues, including adult thymus (mainly CD4, CDS-double positive T cells) and embryonic thymus (mainly CD4, CD8-double negative T cells). These characteristics imply that Ldb1-Lmo4 interaction may function in the T cell developmental programme and that enforced expression of LMO1 or LMO2 by chromosomal translocations or transgenesis may displace Lmo4 from this complex and thereby influence T cell differentiation prior to T cell tumour occurrence.	MRC, Mol Biol Lab, Div Protein & Nucle Acid Chem, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Rabbitts, TH (corresponding author), MRC, Mol Biol Lab, Div Protein & Nucle Acid Chem, Hills Rd, Cambridge CB2 2QH, England.		Rabbitts, Terence/D-6262-2016	Rabbitts, Terence/0000-0002-4982-2609				Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1991, ONCOGENE, V6, P695; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISCH P, 1992, ONCOGENE, V7, P2389; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; Grutz GG, 1998, EMBO J, V17, P4594, DOI 10.1093/emboj/17.16.4594; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Kenny DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/pnas.95.19.11257; LARSON RC, 1995, ONCOGENE, V11, P853; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LARSON RC, 1994, ONCOGENE, V9, P3675; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MCGUIRE EA, 1991, BLOOD, V77, P599; NEALE GAM, 1995, BLOOD, V86, P3060; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; RABBITTS TH, 1998, IN PRESS CANC RES; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; SANCHEZGARCIA I, 1995, ONCOGENE, V10, P1301; SANCHEZGARCIA I, 1993, SEMIN CANCER BIOL, V4, P349; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VALGEARCHER V, 1998, IN PRESS ONCOGENE; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; ZHU TH, 1995, ONCOGENE, V11, P1283	39	65	69	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2799	2803		10.1038/sj.onc.1202502	http://dx.doi.org/10.1038/sj.onc.1202502			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840944				2022-12-17	WOS:000077146700013
J	Barnard, D; Diaz, B; Clawson, D; Marshall, M				Barnard, D; Diaz, B; Clawson, D; Marshall, M			Oncogenes, growth factors and phorbol esters regulate Raf-1 through common mechanisms	ONCOGENE			English	Article						oncogene; Ras; Raf; PKC; Src; EGF	ACTIVATED PROTEIN-KINASE; CELL-CYCLE ARREST; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; IN-VITRO; RAS; C-RAF-1; DOMAIN; IDENTIFICATION; ASSOCIATION	We have uniformly examined the regulatory steps required by oncogenic Ras, Src, EGF and phorbol 12-myristate 13-acetate (PMA) to activate Raf-1. Specifically, we determined the role of Ras binding and the phosphorylation of serines 338/339, tyrosines 340/341 and the activation loop (491-508) in response to these stimuli in COS-7 cells. An intact Ras binding domain was found to be essential for Raf-1 kinase activation by each stimulus, including PMA, Brief treatment of COS-7 cells with PMA was found to rapidly promote accumulation of the active, GTP-bound form of Ras. Furthermore, loss of the serine 338/339 and tyrosine 340/341 phosphorylation sites also blocked Raf-1 activation by all stimuli tested. Loss of the serine 497 and serine 499 PKC alpha phosphorylation sites failed to significantly reduce Raf-1 activation by any stimulus including PMA. Alanine substitution of all other potential phosphorylation sites within the Raf-1 activation loop had little or no effect on kinase regulation by Ras[V12] or vSrc although some mutants were less responsive to PMA. These results suggest that in mammalian cells, Raf-1 can be regulated by a variety of different stimuli through a common mechanism involving association with Ras-GTP and multiple phosphorylations of the amino-terminal region of the catalytic domain. Phosphorylation of the activation loop does not appear to be a significant mechanism of Raf-1 kinase regulation in COS-7 cells.	Indiana Univ, Sch Med, Dept Med, Div Hematol & Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Marshall, M (corresponding author), Indiana Univ, Sch Med, Dept Med, Div Hematol & Oncol, 1044 W Walnut St, Indianapolis, IN 46202 USA.							Arai H, 1996, MOL PHARMACOL, V50, P522; Barnard D, 1995, ONCOGENE, V10, P1283; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CAI H, 1993, MOL CELL BIOL, V13, P7645, DOI 10.1128/MCB.13.12.7645; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Ferrier AF, 1997, J BIOL CHEM, V272, P2136; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MORRISON DK, 1995, MOL REPROD DEV, V42, P507, DOI 10.1002/mrd.1080420420; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Rommel C, 1996, ONCOGENE, V12, P609; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; TRAVERSE S, 1993, ONCOGENE, V8, P3175; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	45	65	67	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1539	1547		10.1038/sj.onc.1202061	http://dx.doi.org/10.1038/sj.onc.1202061			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794231				2022-12-17	WOS:000076089900006
J	Fiddes, RJ; Janes, PW; Sivertsen, SP; Sutherland, RL; Musgrove, EA; Daly, RJ				Fiddes, RJ; Janes, PW; Sivertsen, SP; Sutherland, RL; Musgrove, EA; Daly, RJ			Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells	ONCOGENE			English	Article						heregulin; MAP kinase; erbB; cell cycle; breast cancer	EPIDERMAL-GROWTH-FACTOR; GTPASE-ACTIVATING PROTEIN; MAMMARY EPITHELIAL-CELLS; SIGNAL-REGULATED KINASE; FACTOR RECEPTOR FAMILY; PHOSPHOLIPASE-C-GAMMA; ERBB3 GENE-PRODUCT; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; DIFFERENTIATION	Members of the erbB family of receptor tyrosine kinases are commonly overexpressed in human breast cancer. However, the relative contribution of particular signalling pathways activated downstream of these receptors to the mitogenic response of transformed breast epithelial cells remains poorly characterized. Administration of heregulin-beta 2 (HRG), a ligand for erbB3 and erbB4, to growth arrested T-47D human breast cancer cells leads to activation of both the PI3-kinase and MAP kinase signalling pathways and potent stimulation of cell cycle progression. Specific inhibitors were used to assess the role of these pathways in HRG-induced mitogenesis and to identify underlying mechanisms in terms of regulation of gene expression. Treatment with the MEK inhibitor PD98059 led to a complete block of HRG-induced entry into S-phase, whilst administration of the PI3-kinase inhibitor wortmannin resulted in only modest inhibition. In addition, administration of PD98059 8 h after HRG was equipotent with simultaneous administration in inhibiting entry into S-phase, However, delaying addition for 14-16 h after HRG, when the cells were entering S-phase, was without effect. HRG stimulation led to sequential induction of c-myc, cyclin D1, cyclin E and cyclin A. gene expression and hyperphosphorylation of the retinoblastoma protein pRB, p21 (WAF1/CIP1/ SDI1) gene expression was rapidly induced by HRG, but significant changes in p27 (KIP1) protein levels were not detected. Preincubation with PD98059 blocked the HRG-dependent induction of cyclin DI mRNA, p21 and c-Myc protein and pRB phosphorylation, These findings demonstrate that MEK activation is critical to HRG-induced S-phase entry in these cells whilst PI3-kinase plays a minor role. Moreover, these data are compatible with HRG-induced activation of MEK being critical for a mid-G1 transition point and implicate c-myc and cyclin D1 as key targets of the MAP kinase pathway involved in this response.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; St Vincents Hosp, Garvan Inst Med Res, CRC Biopharmaceut Res, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Daly, RJ (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia.		Daly, Roger J/C-8179-2009; Sutherland, Robert L/A-8378-2008	Daly, Roger/0000-0002-5739-8027; Janes, Peter/0000-0002-9039-1097				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALEXANDER IE, 1989, MOL ENDOCRINOL, V3, P1377, DOI 10.1210/mend-3-9-1377; Bacus SS, 1996, ONCOGENE, V12, P2535; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARRAWAY KL, 1997, NATURE, V387, P52; CHAN YL, 1984, J BIOL CHEM, V259, P224; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COBB MH, 1994, CELL MOL BIOL RES, V40, P253; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FIDDES RJ, 1995, CELL GROWTH DIFFER, V6, P1567; FILMUS J, 1994, ONCOGENE, V9, P3627; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IVARAMAN VS, 1997, J CLIN INVEST, V99, P1478; JANES PW, 1994, ONCOGENE, V9, P3601; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KIM HH, 1994, J BIOL CHEM, V269, P24747; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; LIU JJ, 1995, MOL CELL BIOL, V15, P364; Liu Y, 1996, CANCER RES, V56, P31; MARRA F, 1995, FEBS LETT, V376, P141, DOI 10.1016/0014-5793(95)01261-0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MARTE BM, 1995, ONCOGENE, V10, P167; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUSGROVE EA, 1989, CANCER RES, V49, P2398; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Musgrove EA, 1997, MOL ENDOCRINOL, V11, P54, DOI 10.1210/me.11.1.54; MUSGROVE EA, 1993, EUR J CANCER, V29, P21273; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; POWIS G, 1994, CANCER RES, V54, P2419; PRALL OWJ, 1998, UNPUB; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Ram TG, 1996, CELL GROWTH DIFFER, V7, P551; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SAINSBURY JRC, 1987, LANCET, V1, P1398; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; TZAHAR E, 1994, J BIOL CHEM, V269, P26226; VASTRIK I, 1994, CRIT REV ONCOGENESIS, V5, P59, DOI 10.1615/CritRevOncog.v5.i1.30; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Winston JT, 1996, ONCOGENE, V12, P127; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	82	65	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2803	2813		10.1038/sj.onc.1201815	http://dx.doi.org/10.1038/sj.onc.1201815			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652748				2022-12-17	WOS:000073812200013
J	Sattler, M; Salgia, R; Shrikhande, G; Verma, S; Choi, JL; Rohrschneider, LR; Griffin, JD				Sattler, M; Salgia, R; Shrikhande, G; Verma, S; Choi, JL; Rohrschneider, LR; Griffin, JD			The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors	ONCOGENE			English	Article						BCR/ABL; SHIP; SHP-2; CBL	SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; MULTIPLE CYTOKINES; RECEPTOR; ACTIVATION; BINDING; KINASE; SHC; PHOSPHORYLATION; P210(BCR/ABL); GRB2	We report here that interleukin-3 (IL-3) and erythropoietin (EPO) induce formation of a complex composed of two SH2-containing phosphatases, the tyrosine phosphatase SHP-2 and the SH2 containing inositol 5-phosphatase (SHIP), Both SHP-2 and SHIP are known to be involved in growth factor signal transduction, but their potential interaction in the same pathway is novel, SHIP has previously been shown to associate with SHC, and potentially to be involved in regulating apoptosis, In contrast, in some model systems, SHP-2 has been demonstrated to positively regulate cell growth, Both phosphatases in the complex were tyrosine phosphorylated, and the amount of SHIP coprecipitating with SHP-2 was inversely related to the amount of SHIP coprecipitating with SHC, In hematopoietic cells transformed by the BCR/ABL oncogene, this phosphatase complex was found to be constitutively present with both components heavily tyrosine phosphorylated, Also, other proteins were detected in the complex, including BCR/ABL itself and c-CBL, However, transformation by BCR/ABL was associated with a reduced SHIP protein expression, which could further affect the accumulation of various inositol polyphosphates in these leukemic cells, These data suggest that the function of SHIP and SHP-2 in normal cells are linked and that BCR/ABL alters the function of this signaling complex.	CHILDRENS HOSP,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,DPET ADULT ONCOL,BOSTON,MA 02115; FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98125	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Fred Hutchinson Cancer Center					NCI NIH HHS [CA01730] Funding Source: Medline; NIDDK NIH HHS [DK50654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA001730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bazenet CE, 1996, MOL CELL BIOL, V16, P6926; BEDI A, 1994, BLOOD, V83, P2038; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Liu L, 1997, J BIOL CHEM, V272, P10998; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; Liu L, 1997, J BIOL CHEM, V272, P8983; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Perkins LA, 1996, DEV BIOL, V180, P63, DOI 10.1006/dbio.1996.0285; Salgia R, 1996, EXP HEMATOL, V24, P310; Sattler M, 1996, ONCOGENE, V12, P839; SATTLER M, 1995, EXP HEMATOL, V23, P1040; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217	22	65	70	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 6	1997	15	19					2379	2384		10.1038/sj.onc.1201422	http://dx.doi.org/10.1038/sj.onc.1201422			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE157	9393882				2022-12-17	WOS:A1997YE15700012
J	Pu, MY; Akhand, AA; Kato, M; Hamaguchi, M; Koike, T; Iwata, H; Sabe, H; Suzuki, H; Nakashima, I				Pu, MY; Akhand, AA; Kato, M; Hamaguchi, M; Koike, T; Iwata, H; Sabe, H; Suzuki, H; Nakashima, I			Evidence of a novel redox-linked activation mechanism for the Src kinase which is independent of tyrosine 527-mediated regulation	ONCOGENE			English	Article						Src kinase; redox regulation; Hg2+ (Mercuric ions)	HERBIMYCIN-A; T-CELLS; V-SRC; PHOSPHORYLATION; PP60C-SRC; BINDING; SITE; IDENTIFICATION; AUTOIMMUNITY; ASSOCIATION	The kinase activity of p60(c-src) has been shown to be basically regulated through phosphorylation and dephosphorylation of Y527. We found that catalytic activity of the immunoprecipitated c-Src kinase from NIH3T3 cells was elevated several folds by exposure to 0.5-50 mu M of sulfhydryl-reactive Hg2+. V-max of the kinase was increased whereas K-m was decreased. N-acetylcysteine neutralized this Hg2+ effect, suggesting a critical role of the Hg2+-mediated sulfhydryl modification of the kinase in the mechanism. Addition of protein tyrosine phosphatase inhibitor Na3VO4 into the reaction mixture did not inhibit the Hg2+-mediated activation. Further study revealed that Hg2+ was capable of activating the v-Src kinase lacking Y527 and the c-Src kinase from mutant cells defective of the Y527-phosphorylating Csk kinase. Cyanogen bromide cleavage maps of radiolabeled Src proteins showed that Hg2+ selectively promoted the autophosphorylation at Y416 and that the previously in vivo radiolabeled phosphorous on Y527 was not deleted during the promotion of Y416 autophosphorylation by Hg2+, Phosphoamino acid analysis demonstrated selective promotion of phosphorylation at tyrosine but not at serine/threonine. Not like bivalent Hg2+, monovalent p-chloromercuribenzenesulfonic acid was incapable of activating c-Src kinase. These results suggest a novel Y416 phosphorylation-linked activation pathway for Src kinases which is initially triggered independent of Y527-mediated or serine/threonine phosphorylation-linked regulation, possibly through sulfhydryl-based protein structural modification for functional alteration.	NAGOYA UNIV, SCH MED, DEPT IMMUNOL, SHOWA KU, NAGOYA, AICHI 466, JAPAN; NAGOYA UNIV, SCH MED, DIS MECHANISM & CONTROL RES INST, SHOWA KU, NAGOYA, AICHI 466, JAPAN; NAGOYA UNIV, SCH MED, DIV MED, RADIOISOTOPE CTR, SHOWA KU, NAGOYA, AICHI 466, JAPAN; KYOTO UNIV, JRDC, PRESTO, INST VIRUS RES, KYOTO 60601, JAPAN	Nagoya University; Nagoya University; Nagoya University; Japan Science & Technology Agency (JST); Kyoto University			KATO, Masashi/I-7250-2014; Sabe, Hisataka/GPF-4385-2022; Sabe, Hisataka/A-4066-2012					ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ATEN J, 1991, EUR J IMMUNOL, V21, P611, DOI 10.1002/eji.1830210312; ATKINSON TP, 1993, J IMMUNOL, V151, P1448; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAWSON DC, 1995, HANDB EXP PHARMACOL, V115, P53; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FUKAZAWA H, 1994, FEBS LETT, V340, P155, DOI 10.1016/0014-5793(94)80127-4; GEORGE RJ, 1990, J CELL BIOCHEM, V42, P71, DOI 10.1002/jcb.240420203; GOLDMAN M, 1991, IMMUNOL TODAY, V12, P223, DOI 10.1016/0167-5699(91)90034-Q; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HAMAGUCHI M, 1993, ONCOGENE, V8, P559; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; LANDER HM, 1992, CELL IMMUNOL, V145, P146, DOI 10.1016/0008-8749(92)90319-K; LANDER HM, 1993, J IMMUNOL, V150, P1509; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; NAKAMURA K, 1993, ONCOGENE, V8, P3133; NAKASHIMA I, 1994, J IMMUNOL, V152, P1064; OKADA M, 1989, J BIOL CHEM, V264, P20886; RAHMAN SMJ, 1993, FEBS LETT, V317, P35, DOI 10.1016/0014-5793(93)81486-J; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SCHUHMANN D, 1990, J IMMUNOL, V145, P2132; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIMPSON RB, 1961, J AM CHEM SOC, V83, P4711, DOI 10.1021/ja01484a005; SPERLING R, 1969, BIOCHEMISTRY-US, V8, P3810, DOI 10.1021/bi00837a047; STEER ML, 1974, BIOCHIM BIOPHYS ACTA, V334, P389, DOI 10.1016/0005-2744(74)90182-X; STRICKS W, 1953, J AM CHEM SOC, V75, P5673, DOI 10.1021/ja01118a060; TAKAFUJI S, 1989, CIBA F SYMP, V147, P188; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; UTSCHIG LM, 1995, SCIENCE, V268, P380, DOI 10.1126/science.7716541; VEILLETTE A, 1993, J BIOL CHEM, V268, P17547; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B	42	65	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 19	1996	13	12					2615	2622						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000135				2022-12-17	WOS:A1996VZ65400011
J	Sitzmann, J; NobenTrauth, K; Kamano, H; Klempnauer, KH				Sitzmann, J; NobenTrauth, K; Kamano, H; Klempnauer, KH			Expression of B-Myb during mouse embryogenesis	ONCOGENE			English	Article						B-myb; histone H4; mouse development; cell proliferation; spermatogenesis	C-MYB; A-MYB; HEMATOPOIETIC-CELLS; GENE; PROLIFERATION; TRANSCRIPTION; ACTIVATION; XENOPUS	B-myb is a member of the myb family of nuclear sequence-specific DNA-binding proteins which has been highly conserved among vertebrates. B-myb has been implicated in the control of cell proliferation, particularly at the G1/S transition of the cell cycle. So far, most of the work on B-myb has been performed in immortalized cell lines. Since these cells might show aberrant behavior of genes involved in proliferation control we have begun to investigate the role of B-myb in normal cells. As a first step, we have studied the expression of B-myb during mouse development. Here, we show the B-myb is expressed at similar levels during all stages of embryogenesis. In situ hybridization reveals a tight linkage between B-myb expression and proliferative activity (as assessed by the expression of the S-phase specific histone H4 gene) in most tissues and throughout embryonic development. However, B-myb and histone H4 expression are uncoupled during spermatogenesis in the adult mouse. Histone H4 is expressed at high levels in the early spermatogenic progenitor cells but not in successive stages of sperm cell development. By contrast, the highest levels of B-myb expression are found during the intermediate stages of spermatogenesis. Furthermore, we have found that B-myb mRNA isolated from the testis differs in size from that of other tissues. The data presented here strongly support the notion that B-myb plays a general role during proliferation of most cells. Furthermore, our results raise the possibility that the function of B-myb in cells undergoing meiosis may be different from its role in cells dividing mitotically.	MAX PLANCK INST IMMUNBIOL,HANS SPEMANN LAB,D-79108 FREIBURG,GERMANY	Max Planck Society								ARSURA M, 1992, BLOOD, V79, P2708; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DZIERZAK E, 1995, TRENDS GENET, V11, P359, DOI 10.1016/S0168-9525(00)89107-6; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GOLAY J, 1991, BLOOD, V77, P149; GOLAY J, 1994, ONCOGENE, V9, P2469; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; KAMANO H, 1996, ONCOGENE, V11, P2575; KLEMPNAUER KH, 1983, J VIROL, V48, P565, DOI 10.1128/JVI.48.3.565-572.1983; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1992, ONCOGENE, V7, P1185; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; METTUS RV, 1994, ONCOGENE, V9, P3077; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.bi.60.070191.004143; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SEILERTUYNS A, 1981, J MOL BIOL, V151, P607, DOI 10.1016/0022-2836(81)90426-5; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; Sitzmann J, 1995, ONCOGENE, V11, P2273; SITZMANN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P773, DOI 10.1177/41.5.7682230; SITZMANN JH, 1995, BRIT J DERMATOL, V133, P241, DOI 10.1111/j.1365-2133.1995.tb02622.x; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WILKINSON DG, 1987, DEVELOPMENT, V99, P493	31	65	66	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1889	1894						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649849				2022-12-17	WOS:A1996UK49800007
J	Beretta, L; Gabbay, M; Berger, R; Hanash, SM; Sonenberg, N				Beretta, L; Gabbay, M; Berger, R; Hanash, SM; Sonenberg, N			Expression of the protein kinase PKR is modulated by IRF-1 and is reduced in 5q-associated leukemias	ONCOGENE			English	Article						tumor suppressor; translation	REGULATORY FACTOR-I; IFN-INDUCIBLE GENES; TRANSCRIPTION FACTOR; CELL-GROWTH; BETA GENES; INDUCTION; CHROMOSOME; ELEMENTS; DELETION; SYSTEM	The transcription factor IRF-1 (interferon regulatory factor 1) is an activator of type I interferon and interferon-inducible genes. IRF-1 manifests tumor suppresser activity. Its overexpression results in inhibition of cell growth, and gene were demonstrated in leukemias and myelodysplasias. Although the mechanism by which IRF-1 affects cell growth is unknown, it is believed that IRF-1 activates a Set of genes that negatively regulate cell growth. The double-stranded RNA-dependent protein kinase (PKR), which is an interferon-inducible gene, contains a promoter element for the binding of IRF-1 and exhibits antiproliferative properties. Consequently, we investigated the role of IRF-1 in PKR expression. Here, we show that in IRF-1-deficient embryonic fibroblasts, PKR expression is reduced relative to wildtype cells. This result predicts diminished expression of PKR as a potential consequence of deletion of the IRF-1 gene in human leukemias. We show that cells of the human leukemic U937 cell line contain a deletion of one IRF-1 gene and express low levels of PKR. We demonstrate that upregulation of IRF-1 expression in U937 cells by transfection is sufficient to induce PKR expression. We also found a marked reduction in the expression of PKR in blood samples from two patients with myelodysplasias, carrying a deletion of chromosome 5q, a locus to which IRF-1 was mapped. These results show that IRF-1 activates PKR expression and suggest that loss of one allele of the IRF-1 gene is sufficient to affect PKR expression. Therefore, PKR is a strong candidate for a mediator of the tumor suppressor activity of IRF-1.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA; HOP ST LOUIS,INST MOLEC GENET,INSERM U301,F-75010 PARIS,FRANCE; UNIV MICHIGAN,DEPT PEDIAT,ANN ARBOR,MI 48109	McGill University; McGill University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Michigan System; University of Michigan				Laura, Beretta/0000-0002-2054-684X				CHANG CH, 1992, IMMUNOGENETICS, V35, P378; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; ITOH S, 1991, GENOMICS, V10, P1097, DOI 10.1016/0888-7543(91)90208-V; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; KIRCHHOFF S, 1995, NUCLEIC ACIDS RES, V11, P439; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MITELMAN F, 1994, HUMAN GENE MAPPING 1, P773; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RUFFNER H, 1993, P NATL ACAD SCI USA, V90, P11503, DOI 10.1073/pnas.90.24.11503; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; VANDENBERGHE H, 1974, NATURE, V251, P437, DOI 10.1038/251437a0; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YAMADA G, 1991, P NATL ACAD SCI USA, V88, P532, DOI 10.1073/pnas.88.2.532	28	65	70	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1593	1596						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622878				2022-12-17	WOS:A1996UF07600026
J	MOODIE, SA; PARIS, M; VILLAFRANCA, E; KIRSHMEIER, P; WILLUMSEN, BM; WOLFMAN, A				MOODIE, SA; PARIS, M; VILLAFRANCA, E; KIRSHMEIER, P; WILLUMSEN, BM; WOLFMAN, A			DIFFERENT STRUCTURAL REQUIREMENTS WITHIN THE SWITCH-II REGION OF THE RAS PROTEIN FOR INTERACTIONS WITH SPECIFIC DOWNSTREAM TARGETS	ONCOGENE			English	Article						RAS; PI-3 KINASE; DOWNSTREAM TARGETS	NUCLEOTIDE-FREE; GTP HYDROLYSIS; P21; DOMAIN; GAP; NEUROFIBROMATOSIS; IDENTIFICATION; ACTIVATION; EXPRESSION; MUTATIONS	Ras proteins function through the formation of specific complexes with Raf-1, B-raf, PI-3 kinase and RalGDS. These interactions all require Ras-GTP with an intact effector binding domain (Switch I region). We have examined the requirements of the Switch II region (amino acids 60-72) for the production of stable interactions between Ras and its downstream effecters. A point mutation at position 65 or 64 combined with additional mutations at either position 65 or 71 rendered nucleotide-free Ras protein unable to stably interact with Ras specific guanine nucleotide exchange factors. Ha-Ras containing point mutations at positions 65 and 71 possessed a twofold higher affinity for B-raf and consequently MEK1. The point mutation at 64, in combination with additional point mutations at either position 65 or 71, resulted in a protein which failed to interact with either PI-3 kinase or neurofibromin, though these Ras mutants effectively bound both Raf-1 and B-raf. An activated form of Ras, Q61L-Ras, associated with all effector proteins independent of the bound guanine nucleotide. Q61L-Ras-GDP was almost as effective as wild type Ras-GMPPNP in the in vitro activation of MEK1 and MAP kinase. Competitive studies with the catalytic domain of neurofibromin, NF1-GRD, demonstrated that its interaction with Ras-GMPPNP is mutually exclusive with both Raf-1 and B-raf. These data suggest that rasGAP and neurofibromin are unable to downregulate Ras-GTP complexed to Raf-1 or B-raf.	CLEVELAND CLIN FDN,DEPT CELL BIOL,CLEVELAND,OH 44195; BRISTOL MYERS & SQUIBB RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543; CLEVELAND CLIN FDN,DEPT CANC BIOL,CLEVELAND,OH 44195; AGOURON PHARMACEUT,SAN DIEGO,CA 92191; SCHERING PLOUGH CORP,RES INST,KENILWORTH,NJ 07033; UNIV COPENHAGEN,DEPT MOLEC CELL BIOL,DK-1353 COPENHAGEN,DENMARK	Cleveland Clinic Foundation; Bristol-Myers Squibb; Cleveland Clinic Foundation; Pfizer; Merck & Company; Schering Plough Corporation; University of Copenhagen			Willumsen, Berthe M/H-1903-2012	Willumsen, Berthe M/0000-0002-2277-6999	NIGMS NIH HHS [GM49652] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM049652, R01GM049652] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BAZENET CE, 1994, ONCOGENE, V9, P517; BUSS JE, 1989, BIOCHEM SOC T, V17, P867, DOI 10.1042/bst0170867; CATLING AD, 1994, J BIOL CHEM, V269, P30014; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DIBATTISTE D, 1993, ONCOGENE, V8, P637; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GUTMANN DH, 1992, ANN NEUROL, V31, P555, DOI 10.1002/ana.410310515; HALL A, 1986, J BIOL CHEM, V261, P963; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HOWE LR, 1993, ONCOGENE, V8, P2583; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8693; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; KURODA S, 1995, J BIOL CHEM, V270, P2460, DOI 10.1074/jbc.270.6.2460; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; McCormick Frank, 1994, Trends in Cell Biology, V4, P347, DOI 10.1016/0962-8924(94)90075-2; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOODIE SA, 1994, MOL CELL BIOL, V14, P6944; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sambrook J., 1989, MOL CLONING LAB MANU; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SHIROUZU M, 1994, ONCOGENE, V9, P2153; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P206; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1989, GUANINE NUCLEOTIDE B, P165; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	58	65	65	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					447	454						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630628				2022-12-17	WOS:A1995RN53000004
J	SUBLETT, JE; JEON, IS; SHAPIRO, DN				SUBLETT, JE; JEON, IS; SHAPIRO, DN			THE ALVEOLAR RHABDOMYOSARCOMA PAX3/FKHR FUSION PROTEIN IS A TRANSCRIPTIONAL ACTIVATOR	ONCOGENE			English	Article						RHABDOMYOSARCOMA; TRANSCRIPTION FACTORS; DNA BINDING; PAIRED BOX; HOMEOBOX	DNA-BINDING-DOMAIN; FORK HEAD DOMAIN; PAIRED BOX; MAMMALIAN-CELLS; GENE FUSION; PAX3; DROSOPHILA; FAMILY; IDENTIFICATION; TRANSLOCATION	Chimeric transcription factors, created by gene fusions as the result of chromosomal translocations, have been implicated in the pathogenesis of several pathologically disparate solid tumors. The PAX3/FKHR fusion gene, formed by a t(2;13)(q35;q14) in alveolar rhabdomyosarcoma, encodes a hybrid protein that contains both PAX3 DNA binding domains, the paired box and homeodomain, linked to the bisected DNA binding domain of FKHR, a member of the forkhead family of transcription factors: Here we report that PAX3 and PAX3/FKHR display similar, but not identical transactivation activities when tested with model Pax recognition sequences. No functional role could be ascribed solely to the residual FKHR binding domain present in the fusion protein, but FKHR was found to contribute a strong carboxyl terminal activation domain replacing the one located in the unrearranged PAX3 gene. We show that the native PAX3/FKHR protein present in tumor cells with this translocation has transcriptional characteristics similar to the in vitro expressed protein. The ability of the PAX3/FKHR hybrid protein to bind DNA in a sequence specific manner and to transactivate the expression of artificial reporter genes suggests that its aberrant expression could subvert the transcriptional programs that normally control the growth, differentiation, and survival of primitive myogenic precursors in vivo.	ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center					NCI NIH HHS [CA-23099, CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, P01CA023099] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUERSPERG N, 1969, JNCI-J NATL CANCER I, V43, P151; BALLING R, 1988, CELL, V55, P531, DOI 10.1016/0092-8674(88)90039-6; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P3685, DOI 10.1073/pnas.91.9.3685; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DAVIS RJ, 1994, CANCER RES, V54, P2869; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOEY T, 1988, NATURE, V332, P858, DOI 10.1038/332858a0; HOTH CF, 1993, AM J HUM GENET, V52, P455; KASTURY K, 1994, P NATL ACAD SCI USA, V91, P3616, DOI 10.1073/pnas.91.9.3616; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LI C, 1993, P NATL ACAD SCI USA, V90, P11583, DOI 10.1073/pnas.90.24.11583; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SCHAFER BW, 1994, NUCLEIC ACIDS RES, V22, P4574, DOI 10.1093/nar/22.22.4574; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; TREMBLAY P, 1994, PHARMACOL THERAPEUT, V61, P205, DOI 10.1016/0163-7258(94)90063-9; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	44	65	67	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					545	552						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630639				2022-12-17	WOS:A1995RN53000015
J	STURZL, M; BRANDSTETTER, H; ZIETZ, C; EISENBURG, B; RAIVICH, G; GEARING, DP; BROCKMEYER, NH; HOFSCHNEIDER, PH				STURZL, M; BRANDSTETTER, H; ZIETZ, C; EISENBURG, B; RAIVICH, G; GEARING, DP; BROCKMEYER, NH; HOFSCHNEIDER, PH			IDENTIFICATION OF INTERLEUKIN-1 AND PLATELET-DERIVED GROWTH FACTOR-B AS MAJOR MITOGENS FOR THE SPINDLE CELLS OF KAPOSIS-SARCOMA - A COMBINED IN-VITRO AND IN-VIVO ANALYSIS	ONCOGENE			English	Article						KAPOSIS SARCOMA; PDGF; INTERLEUKIN ONCOSTATIN; IN SITU HYBRIDIZATION; GP130	IL-6 SIGNAL TRANSDUCER; YOUNG HOMOSEXUAL MEN; ONCOSTATIN-M; EXPRESSION; RECEPTOR; AUTOCRINE; CULTURE; INVITRO; GP130; HYBRIDIZATION	By means of a combined in vitro and in vivo analysis we provide evidence that IL-1 beta and PDGF-B, but not OSM (oncostatin M) or IL-6, are major mitogens for the spindle cells of Kaposi's sarcoma (KS) in vivo. PDGF-B and IL-1 beta stimulated proliferation of cultivated KS spindle cells in vitro. Analysis of gene expression in vivo revealed that both factors as well as the PDGF beta-receptor are present in KS lesions, By contrast, IL-6 had no effect and OSM inhibited proliferation of cultivated KS spindle cells. Again, the effect of these factors on cultivated KS spindle cells in vitro was reflected by the gene expression observed in KS lesions in vivo. Neither the expression of IL-6 receptor nor of OSM could be detected in KS lesions by in situ hybridization, Moreover, in situ hybridization revealed an identical pattern of gene expression in cultivated KS spindle cells and KS spindle cells in vivo with respect to the above-mentioned cytokines [PDGF-B, IL-1 beta, IL-1 alpha, IL-6, OSM] and their receptors [PDGF beta-receptor, gp130, IL-6 receptor, leukemia inhibitory factor (LII;) receptor]. This further supported the suitability of cultivated KS spindle cells as an in vitro model in order to determine which cytokines may activate proliferation of KS spindle cells in vivo.	UNIV MUNICH, INST PATHOL, D-80337 MUNICH, GERMANY; MAX PLANCK INST PSYCHIAT, NEUROMORPHOL ABT, D-82152 MARTINSRIED, GERMANY; IMMUNEX RES & DEV CORP, SEATTLE, WA 98101 USA; UNIV ESSEN GESAMTHSCH KLIN, HAUTKLIN, ESSEN, GERMANY	University of Munich; Max Planck Society; University of Duisburg Essen	STURZL, M (corresponding author), MAX PLANCK INST BIOCHEM, VIRUSFORSCH ABT, KLOPFERSPITZ 18A, D-82152 MARTINSRIED, GERMANY.		Stürzl, Michael/B-3019-2015; Raivich, Gennadij/AAL-7229-2021; Raivich, Gennadij/A-6770-2011	Stürzl, Michael/0000-0002-9276-2824; 				ALBINI A, 1988, J CELL BIOCHEM, V36, P369, DOI 10.1002/jcb.240360406; ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARILLARI G, 1992, J IMMUNOL, V149, P3727; BOVI PD, 1986, CANCER RES, V46, P6333; CAI J, 1994, AM J PATHOL, V145, P74; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORBEIL J, 1991, J IMMUNOL, V146, P2972; COZZOLINO F, 1990, P NATL ACAD SCI USA, V87, P6487, DOI 10.1073/pnas.87.17.6487; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FRIEDMANKIEN AE, 1981, J AM ACAD DERMATOL, V5, P468, DOI 10.1016/S0190-9622(81)80010-2; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GOTTLIEB GJ, 1982, HUM PATHOL, V13, P882, DOI 10.1016/S0046-8177(82)80047-6; GROVE RI, 1993, P NATL ACAD SCI USA, V90, P823, DOI 10.1073/pnas.90.3.823; HAMILTON AS, 1994, J ACQ IMMUN DEF SYND, V7, P410; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; KAAYA EE, 1992, EUR J CANCER, V28A, P1890, DOI 10.1016/0959-8049(92)90030-6; KAPOSI M, 1872, ARCH DERMATOL SYPHIL, V4, P742; LEPEZUNIGA JL, 1987, J CLIN MICROBIOL, V25, P1695, DOI 10.1128/JCM.25.9.1695-1700.1987; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; MILES SA, 1990, P NATL ACAD SCI USA, V87, P4068, DOI 10.1073/pnas.87.11.4068; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; NAKAMURA S, 1988, SCIENCE, V242, P426, DOI 10.1126/science.3262925; REGEZI JA, 1993, AM J PATHOL, V143, P240; ROTH WK, 1988, INT J CANCER, V42, P767, DOI 10.1002/ijc.2910420523; ROTH WK, 1989, ONCOGENE, V4, P483; SCHIRREN CG, 1990, BRIT J DERMATOL, V123, P313, DOI 10.1111/j.1365-2133.1990.tb06290.x; SCHULZEOSTHOFF K, 1990, J INVEST DERMATOL, V95, P238, DOI 10.1111/1523-1747.ep12478105; SNOVER DC, 1985, CLIN BIOCH ANAL, P181; STURZL M, 1990, ANAL BIOCHEM, V185, P164, DOI 10.1016/0003-2697(90)90274-D; STURZL M, 1992, AIDS RES HUM RETROV, V8, P1753, DOI 10.1089/aid.1992.8.1753; STURZL M, 1992, P NATL ACAD SCI USA, V89, P7046, DOI 10.1073/pnas.89.15.7046; WERNER S, 1989, INT J CANCER, V43, P1137, DOI 10.1002/ijc.2910430629; XERRI L, 1991, AM J PATHOL, V138, P9; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YANG J, 1994, J IMMUNOL, V152, P943	41	65	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	1995	10	10					2007	2016						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761101				2022-12-17	WOS:A1995QZ92600015
J	DOBRZANSKI, P; RYSECK, RP; BRAVO, R				DOBRZANSKI, P; RYSECK, RP; BRAVO, R			SPECIFIC-INHIBITION OF RELB/P52 TRANSCRIPTIONAL ACTIVITY BY THE C-TERMINAL DOMAIN OF P100	ONCOGENE			English	Note						RELB-P52 COMPLEX; P100 C-TERMINUS; TRANSCRIPTIONAL INHIBITION	NF-KAPPA-B; REL-ASSOCIATED PP40; DNA-BINDING; ACTIVATION; PROTEIN; ALPHA; PHOSPHORYLATION; PRECURSOR; ENCODES; FAMILY	The Rel/NF-kappa B family transcriptional factors plays an important role in the regulation of immune and acute phase responses. The activity of Rel/NF-kappa B complexes is regulated by their interactions with members of the I kappa B family of inhibitors. We have previously shown that the RelB/p52 heterodimer is not effectively inhibited by any of the known I kappa B molecules: I kappa B alpha, I kappa B gamma and Bcl3. Here we report that the C-terminal domain of p100 (the putative I kappa B delta) functions as a strong inhibitor of RelB/p52 transcriptional activity. In vivo interaction with I kappa B delta leads to the cytoplasmic retention and decreased DNA binding activity of RelB/p52 complexes. Thus, I kappa B delta is the only I kappa B molecule able to efficiently modulate the activity of RelB/p52 heterodimer, In Daudi cells, a 46 kD protein, probably representing the C-terminal product of the proteolytic processing of p100, remains associated,vith Rel/NF-kappa B complexes and might have a transient regulatory function. Our results indicate a specific role for the putative I kappa B delta and suggest a possible mechanism of how the truncation of the ankyrin domain of p100, found in a number of lymphoid neoplasias, might contribute to tumorigenesis.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543	Bristol-Myers Squibb								BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1992, MOL CELL BIOL, V12, P343; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GRILLI M, 1993, INT REV CYTOL, V143, P1; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0	44	65	66	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					1003	1007						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898917				2022-12-17	WOS:A1995QL03800022
J	ROSSELLI, F; RIDET, A; SOUSSI, T; DUCHAUD, E; ALAPETITE, C; MOUSTACCHI, E				ROSSELLI, F; RIDET, A; SOUSSI, T; DUCHAUD, E; ALAPETITE, C; MOUSTACCHI, E			P53-DEPENDENT PATHWAY OF RADIO-INDUCED APOPTOSIS IS ALTERED IN FANCONI-ANEMIA	ONCOGENE			English	Article						P53; APOPTOSIS; FANCONI ANEMIA; RADIATIONS	WILD-TYPE P53; RADIATION-INDUCED APOPTOSIS; DNA-DAMAGING AGENTS; CELL-CYCLE CONTROL; ATAXIA-TELANGIECTASIA; GROWTH-ARREST; GENE AMPLIFICATION; MICE DEFICIENT; LEUKEMIC-CELLS; G2 PHASE	Fanconi anemia belongs to a group of human genetic diseases characterized by chromosomal instability, sensitivity to genotoxic agents associated to impaired processing of DNA lesions, cell cycle anomalies and cancer predisposition. We recently added to this list of distinctive features reduced production of interleukin 6 and overproduction of tumor necrosis factor alpha. Since growth factor deprivation, TNF alpha treatment or DNA damage can trigger apoptosis, we monitored the apoptotic response of FA cell lines. We show here that, although the spontaneous rate of apoptosis is slightly more elevated in FA than in normal cell cultures, the apoptosis induced by gamma-irradiation is drastically reduced in FA. Since the induction of apoptosis by radiation is a p53-dependent mechanism, the induction of this protein in FA cells was also examined. We found that the p53 protein is not radio-induced in FA cells belonging to the two genetic complementation groups examined (C and D), in contrast to normal cells. Moreover, the same impairment in p53 induction is observed after exposure to mitomycin C, a chemical agent for which FA cells demonstrate a specific cellular and chromosomal hypersensitivity, as well as after u.v.-B irradiation, an agent known to cause oxidative stress. These observations are in line with recent reports showing that at least certain cell lines from other chromosome breakage syndromes, such as ataxia telangiectasia and Bloom syndrome, may be also defective for radiation-induced increase of p53 protein. As the p53 tumor suppressor gene encodes a transcriptional activator whose targets include genes that regulate genomic stability, cellular response to DNA damage and cell cycle progression, we suggest that altered expression of p53 may be relevant to the FA phenotype.	INST GENET MOLEC, INSERM, U301, F-75010 PARIS, FRANCE; INST CURIE, DEPT RADIOTHERAPIE, MED SECT, F-75231 PARIS 05, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	ROSSELLI, F (corresponding author), INST CURIE, CNRS, URA 1292, 26 RUE ULM, F-75231 PARIS 05, FRANCE.		Filippo, Rosselli/AAO-6393-2020	Filippo, Rosselli/0000-0003-1080-5745; soussi, thierry/0000-0001-8184-3293				ALTER BP, 1993, BRIT J HAEMATOL, V85, P9, DOI 10.1111/j.1365-2141.1993.tb08638.x; BAGNARA GP, 1993, STEM CELLS, V11, P137; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BEUTLER B, 1990, Critical Reviews in Oncogenesis, V2, P9; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COOHILL TP, 1987, PHOTOCHEM PHOTOBIOL, V46, P1043, DOI 10.1111/j.1751-1097.1987.tb04891.x; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FRITSCHE M, 1993, ONCOGENE, V8, P307; GHOSH R, 1993, MOL CELL BIOL, V13, P6992, DOI 10.1128/MCB.13.11.6992; GLUCKMAN E, 1990, RADIOTHER ONCOL S, V1, P88; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HEIM RA, 1992, MUTAT RES, V284, P25, DOI 10.1016/0027-5107(92)90022-T; JENSEN PO, 1994, CYTOMETRY, V15, P154, DOI 10.1002/cyto.990150209; JONVEAUX P, 1991, NOUV REV FR HEMATOL, V33, P343; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MERCER WE, 1990, ONCOGENE, V5, P973; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OLIVE PL, 1993, RADIAT RES, V136, P130, DOI 10.2307/3578650; PAPADOPOULO D, 1990, P NATL ACAD SCI USA, V87, P8383, DOI 10.1073/pnas.87.21.8383; PARSHAD R, 1983, P NATL ACAD SCI-BIOL, V80, P5612, DOI 10.1073/pnas.80.18.5612; PERDAHL EB, 1994, BLOOD, V83, P645; ROSSELLI F, 1994, BLOOD, V83, P1216; ROSSELLI F, 1992, HUM GENET, V89, P42, DOI 10.1007/BF00207040; SACHS L, 1993, BLOOD, V82, P15, DOI 10.1182/blood.V82.1.15.bloodjournal82115; SCHULTZ JC, 1993, AM J HEMATOL, V42, P196, DOI 10.1002/ajh.2830420211; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; STRATHDEE CA, 1992, NAT GENET, V1, P196, DOI 10.1038/ng0692-196; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; STRATHDEE CA, 1992, AM J PEDIAT HEMATOL, V14, P177; VANLAAR T, 1994, ONCOGENE, V9, P981; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WEGNER RD, 1991, ADV MUTAGENESIS RES, V3, P81; WEICHSELBAUM RR, 1980, CANCER RES, V40, P920; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEKSBERG R, 1979, J CELL PHYSIOL, V101, P311, DOI 10.1002/jcp.1041010211; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P345; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	55	65	65	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					9	17						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824283				2022-12-17	WOS:A1995QA98000002
J	MARTINERIE, C; HUFF, V; JOUBERT, I; BADZIOCH, M; SAUNDERS, G; STRONG, L; PERBAL, B				MARTINERIE, C; HUFF, V; JOUBERT, I; BADZIOCH, M; SAUNDERS, G; STRONG, L; PERBAL, B			STRUCTURAL-ANALYSIS OF THE HUMAN NOV PROTOONCOGENE AND EXPRESSION IN WILMS-TUMORS	ONCOGENE			English	Note							FACTOR-II GENE; PLASMODIUM-FALCIPARUM; WT1	We have cloned and sequenced the nov gene (novH) which is the homolog of the chicken nov proto-oncogene overexpressed in avian nephroblastomas. The novH gene is highly conserved and encodes a putative IGF-binding protein similar to that of chicken. We report that relative to autologous normal kidney expression of novH is elevated in Wilms tumors containing predominantly stromal elements and is inversely correlated in these tumors to the expression of WT1. Our results suggest that the regulation of IGFII expression by WT1 and increase of novH in Wilms tumors might be interrelated and represent a key element in tumor development in human.	INST CURIE,ONCOL VIRALE & MOLEC LAB,F-91405 ORSAY,FRANCE; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPTL PEDIAT,HOUSTON,TX; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030; UNIV PARIS 07,UFR BIOCHIM,DENIS DIDEROT,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; UDICE-French Research Universities; Universite Paris Cite								ALEY SB, 1986, J EXP MED, V164, P1915, DOI 10.1084/jem.164.6.1915; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BECKWITH JB, 1986, J UROLOGY, V136, P320, DOI 10.1016/S0022-5347(17)44854-3; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GANSLER T, 1989, AM J PATHOL, V135, P961; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GONZALEZCRUSSI F, 1984, WILMS TUMOR NEPHROBL, P207; HEINE U, 1962, JNCI-J NATL CANCER I, V29, P41; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HUFF V, 1990, HUM GENET, V84, P253; ISHIGURO H, 1962, J NATL CANCER I, V29, P1; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; MARTINERIE C, 1992, ONCOGENE, V7, P2529; MATSUNAGA E, 1981, HUM GENET, V57, P231; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; PRITCHARDJONES K, 1991, ONCOGENE, V6, P2211; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; SORET J, 1989, J VIROL, V63, P1803, DOI 10.1128/JVI.63.4.1803-1807.1989; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828	28	65	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2729	2732						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	7520150				2022-12-17	WOS:A1994PC05400035
J	SIYANOVA, EY; SERFAS, MS; MAZO, IA; TYNER, AL				SIYANOVA, EY; SERFAS, MS; MAZO, IA; TYNER, AL			TYROSINE KINASE GENE-EXPRESSION IN THE MOUSE SMALL-INTESTINE	ONCOGENE			English	Note							POLYMERASE CHAIN-REACTION; HEMATOPOIETIC-CELLS; PROTEIN-KINASE; DIFFERENTIATED ENTEROCYTES; CATALYTIC DOMAIN; CARCINOMA-CELLS; STEM-CELLS; RECEPTOR; FAMILY; CRYPT	To identify tyrosine kinases that may regulate regeneration of the mammalian intestinal epithelium, we amplified portions of the catalytic domains of protein kinases expressed in intestinal crypt cells, using the polymerase chain reaction technique with primers directed against two invariant amino acid sequence motifs found in all kinases. These fragments were cloned and a library of kinase catalytic domains was generated, Sequence analysis of unique clones resulted in the identification of the catalytic domains of several characterized tyrosine kinases, including lyn, hck, c-fgr, tec, JAK2, itk, and the putative receptor kinase ryk, and expression of these kinases has not previously been described in the intestine. We compared the levels of mRNA encoding these kinases in multiple tissues using RNase protection assays, and we localized the expression of hck, lyn, and JAK2 in the intestine using in situ hybridization. In addition, we identified two novel putative catalytic domain sequences. One of these, which we have named sik (src-related intestinal kinase), is expressed at high levels in the gastrointestinal tract and may play a specific role in signal transduction in epithelial tissues.	UNIV ILLINOIS, COLL MED, DEPT GENET, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Mazo, Ilya A/G-6549-2014	Mazo, Ilya A/0000-0002-8587-4895; Tyner, Angela/0000-0001-7448-8625	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK044525, R01DK044525] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK044525, DK44525, R01 DK044525-06] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BJERKNES M, 1981, ANAT REC, V199, P565, DOI 10.1002/ar.1091990412; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOULTER CA, 1988, EXP CELL RES, V179, P214, DOI 10.1016/0014-4827(88)90360-6; BURGESS DR, 1989, J CELL BIOL, V109, P2139, DOI 10.1083/jcb.109.5.2139; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CERFBENSUSSAN N, 1991, GASTROENTEROL CLIN N, V20, P549; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FOSS FM, 1989, ONCOGENE RES, V5, P13; GILMAN M, 1987, CURRENT PROTOCOLS MO; GORDON JI, 1993, GASTROENTEROLOGY, V104, P315; GUYGRAND D, 1993, CURR OPIN IMMUNOL, V5, P247, DOI 10.1016/0952-7915(93)90012-H; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARPUR AG, 1992, ONCOGENE, V7, P1347; HOEKSTRA MF, 1991, TRENDS GENET, V7, P256, DOI 10.1016/0168-9525(91)90161-I; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; KLEMSZ MJ, 1987, NUCLEIC ACIDS RES, V15, P9600, DOI 10.1093/nar/15.22.9600; LEE J, 1994, GENE, V138, P247, DOI 10.1016/0378-1119(94)90817-6; LEGUEN L, 1992, GENE, V120, P249, DOI 10.1016/0378-1119(92)90100-4; MAHER PA, 1988, J CELL BIOL, V106, P1747, DOI 10.1083/jcb.106.5.1747; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1993, ONCOGENE, V8, P417; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; NEUTRA MR, 1988, CELL TISSUE BIOL, P642; OTTILIE S, 1992, ONCOGENE, V7, P1625; PAUL SR, 1992, INT J CELL CLONING, V10, P309, DOI 10.1002/stem.5530100509; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; SERFAS MS, 1993, AM J PHYSIOL, V265, pG506, DOI 10.1152/ajpgi.1993.265.3.G506; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TRIER JS, 1991, GASTROENTEROL CLIN N, V20, P531; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILKS AF, 1991, METHOD ENZYMOL, V200, P533; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	38	65	68	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1994	9	7					2053	2057						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208550				2022-12-17	WOS:A1994NR68500030
J	YAMAMOTO, H; LAMPHIER, MS; FUJITA, T; TANIGUCHI, T; HARADA, H				YAMAMOTO, H; LAMPHIER, MS; FUJITA, T; TANIGUCHI, T; HARADA, H			THE ONCOGENIC TRANSCRIPTION FACTOR IRF-2 POSSESSES A TRANSCRIPTIONAL REPRESSION AND A LATENT ACTIVATION DOMAIN	ONCOGENE			English	Article							INTERFERON-BETA GENE; NF-KAPPA-B; IFN-INDUCIBLE GENES; REGULATORY ELEMENTS; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; VIRUS INDUCTION; ALPHA PROMOTER; LEXA GENE; EXPRESSION	IRF-1 and IRF-2 are two structurally related transcription factors originally identified as regulators of the type I interferon (IFN) system. IRF-1 functions as an activator whereas IRF-2 binds to the same cis-elements and can repress IRF-1 action. More recently these two factors have been shown to act in a mutually antagonistic manner to regulate cell growth; overexpression of the repressor IRF-2 leads to cell transformation, whereas concomitant overexpression of IRF-1 leads to reversion. Previous studies have identified DNA-binding domains in IRF-1 and IRF-2 and an activation domain in IRF-1. In the present study we show that IRF-2 also possesses a transcriptional repression domain in its carboxyl terminal region. We further observe that a LexA-IRF2 fusion can inhibit the function of an activator positioned nearby in the promoter. Thus, repression by IRF-2 may involve both competition with IRF-1 for binding to the promoter as well as the 'silencing' of nearby activators. Furthermore, we demonstrate the presence of a latent activation domain in the central region of IRF-2 and speculate that IRF-2 may contribute to gene activation under certain conditions.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN	Osaka University			Harada, Hisashi/H-2815-2019	Harada, Hisashi/0000-0001-5993-1289				AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; CLEMENS MJ, 1985, BIOCHEM J, V226, P345, DOI 10.1042/bj2260345; COHEN L, 1991, CELL GROWTH DIFFER, V2, P323; Demaeyer E., 1988, INTERFERONS OTHER RE; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1985, CELL, V41, P489, DOI 10.1016/S0092-8674(85)80022-2; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; HAGGARTY A, 1991, CELL GROWTH DIFFER, V2, P503; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HORII T, 1981, CELL, V23, P689, DOI 10.1016/0092-8674(81)90432-3; ITOH S, 1989, NUCLEIC ACIDS RES, V17, P8372, DOI 10.1093/nar/17.20.8372; ITOH S, 1991, GENOMICS, V10, P1097, DOI 10.1016/0888-7543(91)90208-V; JAYNES J, 1988, EMBO J, V10, P1427; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KELLER AD, 1991, GENE DEV, V5, P868, DOI 10.1101/gad.5.5.868; KUHL D, 1987, CELL, V50, P1057, DOI 10.1016/0092-8674(87)90172-3; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MACDONALD NJ, 1990, CELL, V60, P767, DOI 10.1016/0092-8674(90)90091-R; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MARKHAM BE, 1981, NUCLEIC ACIDS RES, V9, P4149, DOI 10.1093/nar/9.16.4149; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SALTMAN DL, 1993, GENOMICS, V16, P726, DOI 10.1006/geno.1993.1254; SEN GC, 1992, J BIOL CHEM, V267, P5017; TAMM I, 1987, INTERFERON, V9, P14; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VILCEK J, 1990, PEPTIDE GROWTH FACTO, V2, P3; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156	48	65	67	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1423	1428						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152803				2022-12-17	WOS:A1994NH40100014
J	KOUHARA, H; KOGA, M; KASAYAMA, S; TANAKA, A; KISHIMOTO, T; SATO, B				KOUHARA, H; KOGA, M; KASAYAMA, S; TANAKA, A; KISHIMOTO, T; SATO, B			TRANSFORMING ACTIVITY OF A NEWLY CLONED ANDROGEN-INDUCED GROWTH-FACTOR	ONCOGENE			English	Article							FACTOR FGF RECEPTOR; SHIONOGI CARCINOMA-115 CELLS; EXPRESSION CDNA CLONING; BREAST-CANCER-CELLS; SERUM-FREE CULTURE; POINT MUTATION; FACTOR-ALPHA; BASIC FGF; FIBROBLAST; PROLIFERATION	Our previous study demonstrated that androgen-dependent growth of mouse mammary carcinoma cells (SC-3) was mediated through an induction of heparin-binding growth factor, termed as androgen-induced growth factor (AIGF). Here, we report that NIH3T3 cells stably transfected with AIGF expression vector exhibit the abilities of tumor formation in nude mice, focus formation in monolayer culture and colony formation in soft agar. Thus, this newly cloned growth factor can be categorized as an oncogene. In addition, androgen-induced enhancement of DNA synthesis in SC-3 cells can be blocked by simultaneous incubation with AIGF antisense oligonucleotides. The possibility is also addressed that AIGF exerts its biological activity through an interaction with fibroblast growth factor (FGF) receptor. Transfection of expression vector encoding a variant form of FGF receptor-1 cloned from SC-3 cells into FGF receptor-negative L6 cells results in AIGF-dependent inhibition of differentiation. These results demonstrate that the ability of androgen to elicit transformed phenotype of SC-3 cells is mediated through AIGF induction and its interaction with FGF receptor-1,	OSAKA UNIV,SCH MED,DEPT MED 3,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT PATHOL,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University			Kishimoto, Tadamitsu/C-8470-2009					ABLAHAM JA, 1986, EMBO J, V5, P2523; ARTEAGA CL, 1988, MOL ENDOCRINOL, V2, P1064, DOI 10.1210/mend-2-11-1064; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE R, 1989, MOL ENDOCRINOL, V3, P372, DOI 10.1210/mend-3-2-372; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; HAGGINS C, 1952, CANCER RES, V12, P134; HARRIS SE, 1989, MOL ENDOCRINOL, V3, P1839, DOI 10.1210/mend-3-11-1839; HIGASHI T, 1990, P NATL ACAD SCI USA, V87, P2409, DOI 10.1073/pnas.87.7.2409; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; KASAYAMA S, 1991, J CELL PHYSIOL, V148, P260, DOI 10.1002/jcp.1041480211; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KOUHARA H, 1991, BIOCHEM BIOPH RES CO, V176, P31, DOI 10.1016/0006-291X(91)90885-B; LU J, 1989, CANCER RES, V49, P4963; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MARICS I, 1989, ONCOGENE, V4, P335; MATSUO Y, 1987, CANCER RES, V47, P188; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NISHII K, 1991, CANCER RES, V51, P5573; NISHIZAWA Y, 1990, CANCER RES, V50, P3866; NOGUCHI S, 1987, CANCER RES, V47, P263; NONOMURA N, 1990, CANCER RES, V50, P2316; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; SAITO H, 1991, BIOCHEM BIOPH RES CO, V174, P136, DOI 10.1016/0006-291X(91)90496-T; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; SATO B, 1988, PROGR ENDOCRINOLOGY, P99; STORY MT, 1987, BIOCHEM BIOPH RES CO, V142, P702, DOI 10.1016/0006-291X(87)91471-9; SUMITANI S, 1993, ENDOCRINOLOGY, V132, P1199, DOI 10.1210/en.132.3.1199; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487	35	65	67	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					455	462						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290257				2022-12-17	WOS:A1994MW24800012
J	GUPTA, K; COPELAND, NG; GILBERT, DJ; JENKINS, NA; GRAY, DA				GUPTA, K; COPELAND, NG; GILBERT, DJ; JENKINS, NA; GRAY, DA			UNP, A MOUSE GENE-RELATED TO THE TRE ONCOGENE	ONCOGENE			English	Note							LINKAGE MAP; CLONING; SEQUENCES; REGION; CDNA; ADENOVIRUS-E1A; TRANSLATION; CARCINOMA; DELETION; PROTEIN	We have cloned cDNAs from a novel gene designated Unp. Unp cDNAs contain a large open reading frame that would encode a protein of 89 kDa. The predicted protein contains a putative nuclear localization signal, as well as consensus sequences for binding to the retinoblastoma gene product. The latter elements are contained within a region having strong similarity to the human tre oncogene. We have localized the Unp gene to mouse chromosome 9 in a region of homology with human chromosome 3p. This region has been implicated in a number of human malignancies.	UNIV OTTAWA,DEPT BIOCHEM,451 SMYTH RD,OTTAWA K1H 8M5,ONTARIO,CANADA; NCI,FREDERICK CANC RES & DEV CTR,ABL,BASIC RES PROGRAM,FREDERICK,MD 21702; UNIV OTTAWA,DEPT MED,OTTAWA K1H 8M5,ONTARIO,CANADA	University of Ottawa; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of Ottawa			/U-3554-2018	/0000-0002-8634-4984	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1989, J NATL CANCER I, V81, P1815, DOI 10.1093/jnci/81.23.1815; ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; COLLINS T, 1985, NATURE, V316, P748, DOI 10.1038/316748a0; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; Green EL, 1981, GENETICS PROBABILITY, P77; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUEBNER K, 1988, ONCOGENE, V3, P449; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KINGSLEY DM, 1989, GENETICS, V123, P165; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	24	65	70	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2307	2310						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336951				2022-12-17	WOS:A1993LP17100035
J	CHEN, XR; AZIZKHAN, JC; LEE, DC				CHEN, XR; AZIZKHAN, JC; LEE, DC			THE BINDING OF TRANSCRIPTION FACTOR SP1 TO MULTIPLE SITES IS REQUIRED FOR MAXIMAL EXPRESSION FROM THE RAT TRANSFORMING GROWTH-FACTOR ALPHA-PROMOTER	ONCOGENE			English	Article							SPECIFICALLY STIMULATES TRANSCRIPTION; REDUCTASE GENE PROMOTER; EPITHELIAL-CELL LINE; FACTOR RECEPTOR GENE; RNA POLYMERASE-II; C-FOS GENE; TGF-ALPHA; TRANSGENIC MICE; MESSENGER-RNA; HEPATOCELLULAR-CARCINOMA	Transcription from the rat transforming growth factor-alpha (TGF-alpha) promoter initiates at multiple sites within a 200-bp G+C-rich region that lacks TATA and CAAT motifs but contains multiple potential binding sites for the transcription factor Sp1. In the present study, we used deletion analysis to establish the 5' boundary of sequences required for efficient transcription from the predominant - 58 start site. We then examined the functional activity of several putative Spl binding sites that occur within the transcriptionally important region downstream from - 155. In the presence of either crude HeLa cell extract or purified Sp1 protein, two double-stranded oligonucleotides from this region, each of which contains three Spl elements, both displayed gel mobility shifts that were specifically inhibited in the presence of excess bona fide Spl-binding sequence from the hamster dihydrofolate reductase (DHFR) gene. Methylation interference analysis of the major gel-shift complex produced with one of these oligonucleotides revealed a series of critical guanine residues located in, or adjacent to, one of the putative Sp1 recognition elements. rhe functional importance of Sp1 binding was confirmed by these findings that transcription in vitro from the - 58 start site was inhibited in the presence of excess consensus Sp1-binding sequence and that coexpression of Spl dramatically induced TGF-alpha promoter-directed chloramphenicol acetyl transferase (CAT) expression in transfected Drostophila Schneider cells that otherwise lack functional Sp1. Additionally, the introduction of mutations into any of several putative Spl elements inhibited transcription in vitro from the - 58 site, with the most proximal element tested having the largest effect. Sequential mutation of more distal elements produced a synergistic inhibition of transcription, suggesting that cooperative interactions between Spl sites are necessary for full expression from the TGF-alpha promoter.	UNIV N CAROLINA, DEPT MICROBIOL & IMMUNOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PEDIAT, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NCI NIH HHS [CA-43793] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043793] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTEAGA CL, 1988, CANCER RES, V48, P5023; AZIZKHAN JC, 1986, BIOCHEMISTRY-US, V25, P6228, DOI 10.1021/bi00368a059; BARRANDON Y, 1987, CELL, V50, P1131, DOI 10.1016/0092-8674(87)90179-6; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1984, CELL, V38, P287, DOI 10.1016/0092-8674(84)90550-6; DERYNCK R, 1987, CANCER RES, V47, P707; DERYNCK R, 1986, J CELL BIOCHEM, V32, P293, DOI 10.1002/jcb.240320406; DICKSON RB, 1986, CANCER RES, V46, P1707; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GODWIN AK, 1990, ONCOGENE, V5, P1231; HAN VKM, 1987, MOL CELL BIOL, V7, P2335, DOI 10.1128/MCB.7.7.2335; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENNINGHAUSEN L, 1987, METHOD ENZYMOL, V152, P725; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KADONAGA JT, 1987, NEW FRONTIERS STUDY, P87; KAGEYAMA R, 1988, P NATL ACAD SCI USA, V85, P5016, DOI 10.1073/pnas.85.14.5016; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KINGSTON RE, 1989, CURRENT PROTOCOLS MO, P481; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KUDLOW JE, 1989, J BIOL CHEM, V264, P3880; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LIU C, 1988, CANCER RES, V48, P850; LIU SC, 1987, MOL ENDOCRINOL, V1, P683, DOI 10.1210/mend-1-10-683; LOBB DK, 1989, BIOL REPROD, V40, P1087, DOI 10.1095/biolreprod40.5.1087; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MARCO ED, 1989, ONCOGENE, V4, P831; MASSAGUE J, 1983, J BIOL CHEM, V258, P3614; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; Maxam A M, 1980, Methods Enzymol, V65, P499; MITCHELL PJ, 1986, MOL CELL BIOL, V6, P425, DOI 10.1128/MCB.6.2.425; MUELLER SG, 1989, MOL ENDOCRINOL, V3, P976, DOI 10.1210/mend-3-6-976; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; OZANNE B, 1980, J CELL PHYSIOL, V105, P163, DOI 10.1002/jcp.1041050118; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; RAJA RH, 1991, MOL ENDOCRINOL, V5, P514, DOI 10.1210/mend-5-4-514; RAYMOND VW, 1989, CANCER RES, V49, P3608; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SAMSOONDAR J, 1986, J BIOL CHEM, V261, P4408; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SKINNER MK, 1989, ENDOCRINOLOGY, V124, P845, DOI 10.1210/endo-124-2-845; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; TEIXIDO J, 1988, J BIOL CHEM, V263, P3924; TSAO MS, 1984, EXP CELL RES, V154, P38, DOI 10.1016/0014-4827(84)90666-9; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; WILCOX JN, 1988, J NEUROSCI, V8, P1901; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; YEH YC, 1987, CANCER RES, V47, P896; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	79	65	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1992	7	9					1805	1815						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501890				2022-12-17	WOS:A1992JJ37600017
J	SRIVASTAVA, S; TONG, YA; DEVADAS, K; ZOU, ZQ; SYKES, VW; CHEN, Y; BLATTNER, WA; PIROLLO, K; CHANG, EH				SRIVASTAVA, S; TONG, YA; DEVADAS, K; ZOU, ZQ; SYKES, VW; CHEN, Y; BLATTNER, WA; PIROLLO, K; CHANG, EH			DETECTION OF BOTH MUTANT AND WILD-TYPE P53-PROTEIN IN NORMAL SKIN FIBROBLASTS AND DEMONSTRATION OF A SHARED 2ND HIT ON P53 IN DIVERSE TUMORS FROM A CANCER-PRONE FAMILY WITH LI-FRAUMENI SYNDROME	ONCOGENE			English	Note							ONCOGENE; GENE; SUPPRESSION; MUTATIONS; PROTEIN; GROWTH	Germline transmission of mutant p53 gene in cancerprone families with Li-Fraumeni syndrome has revealed a new role for p53 in the genetic predisposition to cancer. The studies reported here focus on the analysis of the expression of normal and mutant p53 RNA and protein in germline configuration and demonstrate that normal skin fibroblasts derived from members of a family with Li-Fraumeni syndrome express mutant p53Gly --> Asp(245) protein and RNA at levels similar to the wild-type p53. Thus, these fibroblasts represent a unique biological system in which endogenous promoters are utilized for the expression of both mutant and normal p53. We have further extended the earlier observations on the analysis of mutant p53 with a limited number of tumors derived from individuals with Li-Fraumeni syndrome. Tumors arising from two different germ layers in four individuals in a single family clearly exhibited the loss of the wild-type allele and the retention of the mutant allele observed in the normal skin fibroblasts derived from the same individuals. These observations further support the notion that germline p53 mutation plays a key role in the tumorigenesis of individuals with Li-Fraumeni syndrome.	UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL,BETHESDA,MD 20814; UNIFORMED SERV UNIV HLTH SCI,DEPT SURG,BETHESDA,MD 20814; NCI,ENVIRONM EPIDEMIOL BRANCH,BETHESDA,MD 20892	Uniformed Services University of the Health Sciences - USA; Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARKER D, 1987, SCIENCE, V236, P1100, DOI 10.1126/science.3107130; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DEMARS R, 1970, 23RD ANN S FUND CANC, P105; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PONDER BAJ, 1990, TRENDS GENET, V6, P213, DOI 10.1016/0168-9525(90)90181-5; Scrable H J, 1990, Adv Cancer Res, V54, P25, DOI 10.1016/S0065-230X(08)60807-6; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0	25	65	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1992	7	5					987	991						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1373881				2022-12-17	WOS:A1992HP64200019
J	BLASBAND, A; SCHRYVER, B; PAPKOFF, J				BLASBAND, A; SCHRYVER, B; PAPKOFF, J			THE BIOCHEMICAL-PROPERTIES AND TRANSFORMING POTENTIAL OF HUMAN WNT-2 ARE SIMILAR TO WNT-1	ONCOGENE			English	Article							PROTO-ONCOGENE INT-1; MOUSE MAMMARY ONCOGENE; EPITHELIAL-CELL LINE; NUCLEOTIDE-SEQUENCE; SARCOMA VIRUS; MURINE INT-1; EXPRESSION; GENE; DROSOPHILA; WINGLESS	Wnt-2 is a member of the Wnt gene family that includes the proto-oncogene Wnt-1 (formerly Int-1). Although the predicted protein product of the Wnt-2 gene has only 38% amino acid identity with Wnt-1, it exhibits significant conservation of structural properties, including a hydrophobic signal sequence and invariant spacing and conservation of 22 cysteine residues. We have sought to characterize the biological and biochemical properties of Wnt family members and here present a characterization of Wnt-2 protein and a comparison with Wnt-1. We demonstrate, using both CHO and AtT-20 cells transfected with human Wnt-2 cDNA, that Wnt-2 encodes a 33 kl)a protein that is modified by N-linked glycosylation to a 35 kDa species. Secreted Wnt-2 protein was detected in the culture medium only after cells were treated with suramin indicating that, like Wnt-1 protein, Wnt-2 is tightly associated with the cell surface. Expression of Wnt-2 cDNA in the mammary epithelial cell line C57 mg results in loss of density-inhibited growth and induces a transformed phenotype in monolayer culture similar to the effects produced by Wnt-1. These results indicate that Wnt-2 shares several biochemical and biological characteristics with Wnt-1 and suggests that other Wnt family members, by virtue of conserved structural features, may also exhibit similar properties.	SYNTEX INC,S3-1,3401 HILLVIEW AVE,PALO ALTO,CA 94304	Syntex Corporation								BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; DAVIS CA, 1988, GENE DEV, V2, P361, DOI 10.1101/gad.2.3.361; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GILMAN M, 1989, CURRENT PROTOCOLS MO; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MCMAHON JA, 1989, DEVELOPMENT, V107, P643; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; NOORDERMEER J, 1989, NUCLEIC ACIDS RES, V17, P11, DOI 10.1093/nar/17.1.11; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1991, CELL, V64, P231, DOI 10.1016/0092-8674(91)90633-A; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PETCU DJ, 1988, VIROLOGY, V167, P385, DOI 10.1016/0042-6822(88)90099-2; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VAIDYA AB, 1978, VIROLOGY, V90, P12, DOI 10.1016/0042-6822(78)90328-8; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILLIAMS LT, 1984, J BIOL CHEM, V259, P5287	39	65	66	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					153	161						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1371336				2022-12-17	WOS:A1992HC22700021
J	GARCIA, R; PARIKH, NU; SAYA, H; GALLICK, GE				GARCIA, R; PARIKH, NU; SAYA, H; GALLICK, GE			EFFECT OF HERBIMYCIN-A ON GROWTH AND PP60C-SRC ACTIVITY IN HUMAN COLON-TUMOR CELL-LINES	ONCOGENE			English	Article							TYROSINE PROTEIN-KINASES; ROUS-SARCOMA VIRUS; SRC GENE-PRODUCT; RAT-KIDNEY CELLS; C-SRC; MITOGENIC RESPONSIVENESS; SIGNAL TRANSDUCTION; MUCOSAL CELLS; PHOSPHORYLATION; CARCINOMA	The effect of herbimycin A, an ansamycin antibiotic which inhibits cellular transformation by retroviral tyrosine kinases, on the monolayer growth of seven colon tumor cell lines and one cell line established from normal colonic mucosa, CCL239, was examined. Each colon tumor cell line tested showed dose-dependent growth inhibition in response to herbimycin A. A 125 ng ml-1 dose of the antibiotic caused > 40% growth inhibition in all colon tumor cell lines after two cell doublings. In contrast, at similar herbimycin A concentrations only 12% inhibition was observed in 'normal' CCL239 cells. No major morphologic changes were observed at the light microscopic level in any of the tumor cell lines or CCL239 cells in response to treatment with herbimycin A. Studies using the HT29 colon adenocarcinoma cell line showed dose-dependent inactivation of pp60c-src by herbimycin A, resulting in decreased autophosphorylation, enolase phosphorylation and steady-state levels, which correlated with cellular growth inhibition. Herbimycin A-induced reductions in pp60c-src kinase activity preceded changes in pp60c-src steady-state levels. Growth and pp60c-src inhibition were reversible following removal of herbimycin A from cell culture media. Our results suggest that regulation of pp60c-src tyrosine kinase activity may be important in growth control of colon tumor cells.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT NEUROONCOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Saya, Hideyuki/J-4325-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM013005] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM13005-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON SM, 1990, ONCOGENE, V5, P317; BARNEKOW A, 1987, CANCER RES, V47, P235; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; COURTNEIDGE SA, 1980, P NATL ACAD SCI-BIOL, V77, P3783, DOI 10.1073/pnas.77.7.3783; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; DESEAU V, 1987, J CELL BIOCHEM, V35, P113, DOI 10.1002/jcb.240350205; EDWARDS AM, 1988, MOL CELL BIOL, V8, P2655, DOI 10.1128/MCB.8.6.2655; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FOSS FM, 1989, ONCOGENE RES, V5, P13; GALLICK GE, 1984, VIROLOGY, V139, P366, DOI 10.1016/0042-6822(84)90382-9; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HONMA Y, 1989, CANCER RES, V49, P331; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1984, ADV CYCLIC NUCL PROT, V17, P443; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAMPS MP, 1988, ONCOGENE RES, V3, P105; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOH SWM, 1991, BIOCHEM BIOPH RES CO, V174, P452, DOI 10.1016/0006-291X(91)91437-H; KONDO K, 1989, J CELL BIOL, V109, P285, DOI 10.1083/jcb.109.1.285; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; LUTTRELL LM, 1989, ONCOGENE, V4, P317; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; MAXWELL SA, 1987, CANCER RES, V47, P1731; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MURAKAMI Y, 1988, CANCER RES, V48, P1587; MUSER J, 1989, ONCOGENE, V4, P1433; OMURA S, 1979, TETRAHEDRON LETT, P4323; OMURA S, 1979, J ANTIBIOT, V32, P255, DOI 10.7164/antibiotics.32.255; PAWSON T, 1988, ONCOGENE, V3, P491; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PREIS PN, 1988, CANCER RES, V48, P6530; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; ROHRSCHNEIDER LR, 1984, J VIROL, V51, P547, DOI 10.1128/JVI.51.2.547-552.1984; ROSEN N, 1986, J BIOL CHEM, V261, P3754; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAYA H, 1989, J CELL BIOCH UCL B S, V13, P111; SEFTON BM, 1986, CURR TOP MICROBIOL, V123, P39; SEFTON BM, 1984, ADV CYCLIC NUCL PROT, V18, P195; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUZUKAKETSUCHIYA K, 1989, J ANTIBIOT, V42, P1831, DOI 10.7164/antibiotics.42.1831; UEHARA Y, 1989, CANCER RES, V49, P780; UEHARA Y, 1988, VIROLOGY, V164, P294, DOI 10.1016/0042-6822(88)90649-6; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1985, JPN J CANCER RES, V76, P672; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; UEHARA Y, 1988, J ANTIBIOT, V41, P831, DOI 10.7164/antibiotics.41.831; UMEZAWA K, 1987, EXPERIENTIA, V43, P614, DOI 10.1007/BF02126351; WASILENKO WJ, 1987, J CELL PHYSIOL, V131, P450, DOI 10.1002/jcp.1041310318; WASILENKO WJ, 1990, MOL CELL BIOL, V10, P1254, DOI 10.1128/MCB.10.3.1254; WASILENKO WJ, 1991, MOL CELL BIOL, V11, P309, DOI 10.1128/MCB.11.1.309; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YU KT, 1985, J BIOL CHEM, V260, P5838	64	65	67	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1991	6	11					1983	1989						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1719464				2022-12-17	WOS:A1991GX11900007
J	CARTER, R; COSENZA, SC; PENA, A; LIPSON, K; SOPRANO, DR; SOPRANO, KJ				CARTER, R; COSENZA, SC; PENA, A; LIPSON, K; SOPRANO, DR; SOPRANO, KJ			A POTENTIAL ROLE FOR C-JUN IN CELL-CYCLE PROGRESSION THROUGH LATE G1 AND S	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; HUMAN-DIPLOID FIBROBLASTS; TUMOR NECROSIS FACTOR; PROTO-ONCOGENE; GROWTH-FACTOR; G0/G1 TRANSITION; FOS; BINDING; GENE; EXPRESSION	When the level of c-jun mRNA was analyzed in WI-38 human fibroblasts exciting short- and long-term quiescence, two peaks of c-jun mRNA accumulation were found. The first occurred one hour after stimulation and lasted three to five hours, whereas the second occurred at the G1/S border and was coupled to the time of entry to S phase rather than to the time of stimulation. The early peak is well documented and in agreement with the proposed role of c-Jun/AP-1 in mediating cellular responses to receptor-generated signals. The later peak, however, has not been previously reported. Additional follow-up studies showed that late G1/S expression was not solely a phenomenon of cells exiting a quiescent state, nor was it restricted only to human cells. Gel retardation studies confirmed that there is AP-1 specific DNA binding activity in nuclear extracts isolated in late G1 and S phase, and that this AP-1 binding activity is due to the presence of Jun protein. An anti-Fos antibody was able to significantly decrease AB-1 binding activity in early G1 extracts, but had no effect on extracts isolated in late G1 and S phase, indicating that the complexes observed in late G1 and S phase are clearly different from those seen in early G1. These studies are among the first to suggest a functional dissociation of c-Jun from c-Fos. Our results identify a new, previously unreported role for c-Jun/AP-1 in regulation of cell cycle progression and mammalian cell growth.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,3400 N BROAD ST,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University				Borghaei, Ruth/0000-0003-4206-0231; Lipson, Kenneth/0000-0001-8847-6051				ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AUGENLICHT LH, 1974, EXP CELL RES, V89, P255, DOI 10.1016/0014-4827(74)90789-7; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COSENZA SC, 1988, J BIOL CHEM, V263, P12751; CRESS AE, 1977, EXP CELL RES, V110, P347, DOI 10.1016/0014-4827(77)90301-9; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; FLOROS J, 1978, CELL BIOL INT REP, V2, P259, DOI 10.1016/0309-1651(78)90006-1; GLENN GM, 1990, J VIROL, V64, P2193, DOI 10.1128/JVI.64.5.2193-2201.1990; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OWEN TA, 1987, J BIOL CHEM, V262, P15111; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAO PN, 1984, J CELL PHYSIOL, V119, P77, DOI 10.1002/jcp.1041190113; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SAUVE G, IN PRESS; SCHUTTE J, 1989, CELL, V59, P989; SHARMA A, 1989, P NATL ACAD SCI USA, V86, P491, DOI 10.1073/pnas.86.2.491; SOPRANO KJ, 1987, MOL CELL BIOCHEM, V75, P61, DOI 10.1007/BF00231609; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; THOMAS P, 1980, P NATL ACAD SCI USA, V77, P54201; TOBEY RA, 1988, EXP CELL RES, V179, P400, DOI 10.1016/0014-4827(88)90279-0; TOLMACH LJ, 1988, CELL TISSUE KINET, V23, P125; TOSCANI A, 1987, ANAL BIOCHEM, V165, P309, DOI 10.1016/0003-2697(87)90274-0; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; TUSCHINSKI R, 1977, P NATL ACAD SCI USA, V74, P2357; WASYLYK C, 1990, ONCOGENE, V5, P1055; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	43	65	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					229	235						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1900357				2022-12-17	WOS:A1991FZ13400008
J	LEMOINE, NR; STADDON, S; BOND, J; WYLLIE, FS; SHAW, JJ; WYNFORDTHOMAS, D				LEMOINE, NR; STADDON, S; BOND, J; WYLLIE, FS; SHAW, JJ; WYNFORDTHOMAS, D			PARTIAL TRANSFORMATION OF HUMAN THYROID EPITHELIAL-CELLS BY MUTANT HA-RAS ONCOGENE	ONCOGENE			English	Note							EMBRYO FIBROBLASTS; GENE-PRODUCT; HARVEY; CARCINOGENESIS; ACTIVATION; INVITRO; TUMORS; VIRUS; MYC	We have previously shown that activation of ras oncogenes by mutation is a frequent early event in human thyroid neoplasia. Using amphotropic retroviral vectors to achieve gene transfer, we demonstrate here that human primary thyroid epithelial cells can be partially transformed by an activated cellular or viral Ha-ras oncogene, in the absence of a cooperating oncogene. The transformation event induced by ras involves temporary rescue from senescence for up to 20 rounds of cell division together with morphological alteration, growth factor independence and anchorage independence. It has therefore been possible to reconstruct in vitro a key early event in the genesis of human epithelial neoplasia.	UNIV COLL CARDIFF,CANC RES CTR,THYROID TUMOUR BIOL RES GRP,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University	LEMOINE, NR (corresponding author), HAMMERSMITH HOSP,IMPERIAL CANC RES FUND,MOLEC ONCOL GRP,DUCANE RD,LONDON W12 0HS,ENGLAND.							BARTEK J, 1989, MONOCLONAL ANTIBODIE; BOS JL, 1989, CANCER RES, V49, P4682; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; COMPERE SJ, 1989, MOL CELL BIOL, V9, P6, DOI 10.1128/MCB.9.1.6; DOTTO GP, 1988, P NATL ACAD SCI USA, V85, P6389, DOI 10.1073/pnas.85.17.6389; DOTTO GP, 1985, NATURE, V318, P472; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; HARLOW E, 1988, ANTIBODIES LABORATOR; HUBER BE, 1988, ONCOGENE, V3, P245; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LANE EB, 1982, J CELL BIOL, V92, P665, DOI 10.1083/jcb.92.3.665; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1989, BRIT J CANCER, V60, P897, DOI 10.1038/bjc.1989.387; LEMOINE NR, 1988, ONCOGENE, V3, P541; LEMOINE NR, 1990, MOL BIOL CANCER GENE, P82; LEMOINE NR, 1990, GENES CANCER, P19; REDMOND SMS, 1988, ONCOGENE, V2, P259; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; SEYAMA T, 1988, MOL CARCINOGEN, V1, P89, DOI 10.1002/mc.2940010204; SUAREZ HG, 1990, ONCOGENE, V5, P565; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEINBERG RA, 1989, CANCER RES, V49, P3713; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607	27	65	66	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1990	5	12					1833	1837						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET436	1704496				2022-12-17	WOS:A1990ET43600014
J	DRAETTA, G; BEACH, D; MORAN, E				DRAETTA, G; BEACH, D; MORAN, E			SYNTHESIS OF P34, THE MAMMALIAN HOMOLOG OF THE YEAST CDC2+/CDC28 PROTEIN-KINASE, IS STIMULATED DURING ADENOVIRUS-INDUCED PROLIFERATION OF PRIMARY BABY RAT-KIDNEY CELLS	ONCOGENE			English	Article											DRAETTA, G (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.				NATIONAL CANCER INSTITUTE [P30CA045508, P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034607] Funding Source: NIH RePORTER; NCI NIH HHS [CA-13106, CA-45508] Funding Source: Medline; NIGMS NIH HHS [GM 34607] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS RLP, 1967, J BIOL CHEM, V242, P1314; ANDERSON CW, 1974, P NATL ACAD SCI USA, V71, P2756, DOI 10.1073/pnas.71.7.2756; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; DOEFLER W, 1984, CURR TOP MICROBIOL I, V109; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; FERRARI S, 1987, BIOESSAYS, V7, P9, DOI 10.1002/bies.950070103; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARTWELL LH, 1974, BACTERIOL REV, V38, P164, DOI 10.1128/MMBR.38.2.164-198.1974; HAYLES J, 1986, J CELL SCI, P155; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEWIS JB, 1980, CELL, V21, P303, DOI 10.1016/0092-8674(80)90138-5; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1980, GENETICS, V96, P627; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLNICK D, 1982, J VIROL, V42, P106, DOI 10.1128/JVI.42.1.106-113.1982; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEREB AJ, 1977, GENE, V2, P115, DOI 10.1016/0378-1119(77)90012-9; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	37	65	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1988	2	6					553	557						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	2838787				2022-12-17	WOS:A1988N841500004
J	ERISMAN, MD; SCOTT, JK; WATT, RA; ASTRIN, SM				ERISMAN, MD; SCOTT, JK; WATT, RA; ASTRIN, SM			THE C-MYC PROTEIN IS CONSTITUTIVELY EXPRESSED AT ELEVATED LEVELS IN COLORECTAL-CARCINOMA CELL-LINES	ONCOGENE			English	Article									SK&F LABS, SWEDELAND, PA 19479 USA		ERISMAN, MD (corresponding author), FOX CHASE CANC CTR, INST CANC RES, PHILADELPHIA, PA 19111 USA.				NATIONAL CANCER INSTITUTE [P30CA006927, R01CA040636] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927, CA-40636] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; BEIMLING P, 1985, BIOCHEMISTRY-US, V24, P6349, DOI 10.1021/bi00344a005; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; BRAVO R, 1985, EXP CELL RES, V160, P540, DOI 10.1016/0014-4827(85)90200-9; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CALABRETTA B, 1985, CANCER RES, V45, P6000; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CERNI C, 1987, EXP CELL RES, V168, P439, DOI 10.1016/0014-4827(87)90016-4; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DENHARDT DT, 1986, BIOCHIM BIOPHYS ACTA, V865, P83, DOI 10.1016/0304-419X(86)90024-7; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DREWINKO B, 1984, CANCER RES, V44, P4241; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; ERISMAN MD, 1988, IN PRESS ONCOGENE HD; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GUILLEM JG, 1987, CANCER RES, V47, P2036; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; JOHNSON BE, 1987, J CLIN INVEST, V79, P1629, DOI 10.1172/JCI112999; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MAKOWSKI DR, 1985, PHARMACOL THERAPEUT, V27, P63, DOI 10.1016/0163-7258(85)90065-8; MOORE JP, 1987, ONCOGENE RES, V2, P65; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; ROTHBERG PG, 1984, MOL CELL BIOL, V4, P1096, DOI 10.1128/MCB.4.6.1096; ROTHBERG PG, 1985, BRIT J CANCER, V52, P629, DOI 10.1038/bjc.1985.237; SCHWAB M, 1986, MOL CELL BIOL, V6, P2752, DOI 10.1128/MCB.6.7.2752; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHUIN T, 1986, CANCER RES, V46, P5302; SIKORA K, 1987, CANCER-AM CANCER SOC, V59, P1289, DOI 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O; SORRENTINO V, 1986, P NATL ACAD SCI USA, V83, P8167, DOI 10.1073/pnas.83.21.8167; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPECTOR DL, 1987, ONCOGENE, V1, P5; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; STEWART J, 1986, BRIT J CANCER, V53, P1, DOI 10.1038/bjc.1986.1; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; VOGT M, 1986, MOL CELL BIOL, V6, P3545, DOI 10.1128/MCB.6.10.3545; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	64	65	66	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1988	2	4					367	378						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	M9472	3283655				2022-12-17	WOS:A1988M947200009
J	Zhu, PP; He, F; Hou, YX; Tu, G; Li, Q; Jin, T; Zeng, H; Qin, YL; Wan, XY; Qiao, YN; Qiu, YX; Teng, Y; Liu, MR				Zhu, Pengpeng; He, Fang; Hou, Yixuan; Tu, Gang; Li, Qiao; Jin, Ting; Zeng, Huan; Qin, Yilu; Wan, Xueying; Qiao, Yina; Qiu, Yuxiang; Teng, Yong; Liu, Manran			A novel hypoxic long noncoding RNA KB-1980E6.3 maintains breast cancer stem cell stemness via interacting with IGF2BP1 to facilitate c-Myc mRNA stability	ONCOGENE			English	Article							LNCRNA THOR INCREASES; TUMOR HYPOXIA; PROLIFERATION; METASTASIS; HIF-1-ALPHA; EXPRESSION; BINDING; RECOGNITION; INVASION; FEEDBACK	The hostile hypoxic microenvironment takes primary responsibility for the rapid expansion of breast cancer tumors. However, the underlying mechanism is not fully understood. Here, using RNA sequencing (RNA-seq) analysis, we identified a hypoxia-induced long noncoding RNA (lncRNA) KB-1980E6.3, which is aberrantly upregulated in clinical breast cancer tissues and closely correlated with poor prognosis of breast cancer patients. The enhanced lncRNA KB-1980E6.3 facilitates breast cancer stem cells (BCSCs) self-renewal and tumorigenesis under hypoxic microenvironment both in vitro and in vivo. Mechanistically, lncRNA KB-1980E6.3 recruited insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) to form a lncRNA KB-1980E6.3/IGF2BP1/c-Myc signaling axis that retained the stability of c-Myc mRNA through increasing binding of IGF2BP1 with m6A-modified c-Myc coding region instability determinant (CRD) mRNA. In conclusion, we confirm that lncRNA KB-1980E6.3 maintains the stemness of BCSCs through lncRNA KB-1980E6.3/IGF2BP1/c-Myc axis and suggest that disrupting this axis might provide a new therapeutic target for refractory hypoxic tumors.	[Zhu, Pengpeng; Li, Qiao; Jin, Ting; Zeng, Huan; Qin, Yilu; Wan, Xueying; Qiao, Yina; Qiu, Yuxiang; Liu, Manran] Chongqing Med Univ, Key Lab Lab Med Diagnost, Chinese Minist Educ, Chongqing 400016, Peoples R China; [He, Fang] Chongqing Med Univ, Affiliated Hosp 1, Dept Pharm, Chongqing 400016, Peoples R China; [Hou, Yixuan] Chongqing Med Univ, Expt Teaching Ctr Basic Med Sci, Chongqing 400016, Peoples R China; [Tu, Gang] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, Chongqing 400016, Peoples R China; [Teng, Yong] Dent Coll Georgia, Dept Oral Biol & Dx Sci, Augusta, GA 30907 USA; [Teng, Yong] Augusta Univ, Georgia Canc Ctr, Augusta, GA 30907 USA	Chongqing Medical University; Chongqing Medical University; Chongqing Medical University; Chongqing Medical University; University System of Georgia; Augusta University	Liu, MR (corresponding author), Chongqing Med Univ, Key Lab Lab Med Diagnost, Chinese Minist Educ, Chongqing 400016, Peoples R China.	manranliu@cqmu.edu.cn	Teng, Yong/AAK-4160-2020	Teng, Yong/0000-0002-1856-7289	National Natural Science Foundation of China (NSFC) [81874199, 31671481, 81472476]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This work was supported in part by National Natural Science Foundation of China (NSFC 81874199, NSFC 31671481, and NSFC 81472476). We would like to thank Reid Loveless for his help in English language editing.	Adinolfi E, 2012, CANCER RES, V72, P2957, DOI 10.1158/0008-5472.CAN-11-1947; Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409; Bell JL, 2013, CELL MOL LIFE SCI, V70, P2657, DOI 10.1007/s00018-012-1186-z; Bhandari V, 2019, NAT GENET, V51, P308, DOI 10.1038/s41588-018-0318-2; Bueno MJ, 2011, BLOOD, V117, P6255, DOI 10.1182/blood-2010-10-315432; Chen X, 2018, CLIN CANCER RES, V24, P2002, DOI 10.1158/1078-0432.CCR-17-2376; Chen Y, 2018, J CLIN INVEST, V128, P1937, DOI 10.1172/JCI95089; Cho SW, 2018, CELL, V173, P1398, DOI 10.1016/j.cell.2018.03.068; Choudhry H, 2016, MOL ASPECTS MED, V47-48, P35, DOI 10.1016/j.mam.2016.01.003; De Los Angeles A, 2015, NATURE, V525, P469, DOI 10.1038/nature15515; Deng SJ, 2018, ONCOGENE, V37, P5811, DOI 10.1038/s41388-018-0382-1; Han DL, 2019, NATURE, V566, P270, DOI 10.1038/s41586-019-0916-x; Hua Q, 2020, THERANOSTICS, V10, P4762, DOI 10.7150/thno.43839; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Huang JG, 2016, NUCLEIC ACIDS RES, V44, P3059, DOI 10.1093/nar/gkv1353; Huang XW, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0628-y; Huttelmaier S, 2005, NATURE, V438, P512, DOI 10.1038/nature04115; Jing XM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1089-9; Jung HM, 2013, MOL BIOL CELL, V24, P1638, DOI 10.1091/mbc.E12-12-0891; Kalimutho M, 2019, TRENDS PHARMACOL SCI, V40, P198, DOI 10.1016/j.tips.2019.01.005; Kang CL, 2019, THERANOSTICS, V9, P4421, DOI 10.7150/thno.32854; Kapinova A, 2018, BIOMED PHARMACOTHER, V99, P51, DOI 10.1016/j.biopha.2017.12.104; Kuo TC, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00654-x; Lal A, 2009, MOL CELL, V35, P610, DOI 10.1016/j.molcel.2009.08.020; Lan J, 2018, P NATL ACAD SCI USA, V115, pE9640, DOI 10.1073/pnas.1809695115; Lee H, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0226-3; Lee JT, 2012, SCIENCE, V338, P1435, DOI 10.1126/science.1231776; Li HZ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0738-0; Lin F, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-58; Liu DL, 2016, TUMOR BIOL, V37, P5039, DOI 10.1007/s13277-015-4355-5; Liu L, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00420; Liu ML, 2019, THERANOSTICS, V9, P4795, DOI 10.7150/thno.30988; Liu N, 2015, NATURE, V518, P560, DOI 10.1038/nature14234; Liu YB, 2017, BIOMED PHARMACOTHER, V91, P731, DOI 10.1016/j.biopha.2017.05.007; Luo LY, 2018, ONCOGENE, V37, P6166, DOI 10.1038/s41388-018-0396-8; Luo ML, 2020, JNCI-J NATL CANCER I, V112, P356, DOI 10.1093/jnci/djz134; Marchese FP, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1348-2; Muller S, 2019, NUCLEIC ACIDS RES, V47, P375, DOI 10.1093/nar/gky1012; Niu YL, 2020, CANCER RES, V80, P964, DOI 10.1158/0008-5472.CAN-19-1532; Peng WX, 2020, MOL THER, V28, P9, DOI 10.1016/j.ymthe.2019.09.024; Prasetyanti PR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0600-4; Prensner JR, 2014, NEOPLASIA, V16, P900, DOI 10.1016/j.neo.2014.09.001; Shang YM, 2018, BIOMED PHARMACOTHER, V106, P1243, DOI 10.1016/j.biopha.2018.07.052; Shih JW, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0358-4; Shih JW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15874; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Song H, 2018, BIOMED PHARMACOTHER, V108, P338, DOI 10.1016/j.biopha.2018.09.057; Tong J, 2020, HAEMATOLOGICA, V105, P1630, DOI 10.3324/haematol.2019.218289; Wang C, 2019, ONCOGENE, V38, P1611, DOI 10.1038/s41388-018-0548-x; Wang YF, 2014, NEOPLASIA, V16, P1094, DOI 10.1016/j.neo.2014.10.008; Wang YR, 2020, J EXP MED, V217, DOI 10.1084/jem.20190950; Weidensdorfer D, 2009, RNA, V15, P104, DOI 10.1261/rna.1175909; Wen X, 2018, THERANOSTICS, V8, P5676, DOI 10.7150/thno.28538; Wu HJ, 2019, FEBS OPEN BIO, V9, P781, DOI 10.1002/2211-5463.12620; Wu JY, 2019, J HEPATOL, V70, P918, DOI 10.1016/j.jhep.2018.12.015; Xiao ZD, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00902-z; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Yang F, 2014, FEBS J, V281, P802, DOI 10.1111/febs.12625; Yang HJ, 2019, BIOCHIMIE, V165, P9, DOI 10.1016/j.biochi.2019.06.012; Yang J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0954-x; Yang XC, 2018, BIOCHEM BIOPH RES CO, V498, P207, DOI 10.1016/j.bbrc.2018.02.211; Yang ZC, 2018, EXP CELL RES, V368, P194, DOI 10.1016/j.yexcr.2018.04.030; Zhang CZ, 2016, P NATL ACAD SCI USA, V113, pE2047, DOI 10.1073/pnas.1602883113; Zhang X, 2017, NAT COMMUN, V8, P1, DOI [10.1038/ncomms14542, 10.1038/s41467-017-01968-5, 10.1038/s41467-017-00321-0]; Zhang XZ, 2020, CANCERS, V12, DOI 10.3390/cancers12051245; Zheng ZQ, 2019, CANCER RES, V79, P4612, DOI 10.1158/0008-5472.CAN-19-0799; Zhou ML, 2016, STEM CELLS, V34, P55, DOI 10.1002/stem.2219; Zou ZG, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0758-8	68	64	65	6	38	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1609	1627		10.1038/s41388-020-01638-9	http://dx.doi.org/10.1038/s41388-020-01638-9		JAN 2021	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33469161	hybrid, Green Published			2022-12-17	WOS:000608959500001
J	Choi, EJ; Jung, BJ; Lee, SH; Yoo, HS; Shin, EA; Ko, HJ; Chang, S; Kim, SY; Jeon, SM				Choi, E-J; Jung, B-J; Lee, S-H; Yoo, H-S; Shin, E-A; Ko, H-J; Chang, S.; Kim, S-Y; Jeon, S-M			A clinical drug library screen identifies clobetasol propionate as an NRF2 inhibitor with potential therapeutic efficacy in KEAP1 mutant lung cancer	ONCOGENE			English	Article							TRANSCRIPTION FACTOR NRF2; CARDIAC-GLYCOSIDES; OXIDATIVE STRESS; GENE-EXPRESSION; RETINOIC ACID; CELLS; LKB1; PATHWAY; ACTIVATION; ASSAY	The Kelch-like ECH-associated protein 1 (KEAP1)-nuclear factor E2-related factor 2 (NRF2) pathway has a central role in cellular antioxidant defense. NRF2 activation due to KEAP1 or NRF2 mutations occurs frequently in many cancers, suggesting that NRF2 inhibition could be a promising therapeutic strategy. However, no potent NRF2 inhibitors are clinically available to date. To develop potent NRF2 inhibitors for therapeutic purpose, we screened similar to 4000 clinical compounds and determined clobetasol propionate (CP) as the most potent NRF2 inhibitor. Mechanistically, CP prevented nuclear accumulation and promoted beta-TrCP-dependent degradation of NRF2 in a glucocorticoid receptor-and a glycogen synthase kinase 3 (GSK3)-dependent manner. As a result, CP induced oxidative stress and strongly suppressed the anchorage-independent growth of tumors with KEAP1 mutation, but not with the wild-type KEAP1. Further, CP alone or in combination with rapamycin strongly inhibited the in vitro and in vivo growth of tumors harboring mutations in KEAP1 or both KEAP1 and LKB1 that are frequently observed in lung cancer. Thus, CP could be a repurposed therapeutic agent for cancers with high NRF2 activity. We also proposed that the use CP and rapamycin in combination could be a potential therapeutic strategy for tumors harboring both KEAP1 and LKB1 mutations.	[Choi, E-J; Jung, B-J; Yoo, H-S; Shin, E-A; Jeon, S-M] Ajou Univ, Coll Pharm, 206 World Cup Ro,Room 207, Suwon 16499, Gyeonggi Do, South Korea; [Lee, S-H; Kim, S-Y] Natl Canc Ctr, Res Inst, Canc Cell & Mol Biol Branch, Goyang, South Korea; [Ko, H-J] Kangwon Natl Univ, Coll Pharm, Chunchon, South Korea; [Ko, H-J] Adv Inst Convergence Technol, Convergence Res Ctr Funct Plant Prod, Suwon, South Korea; [Chang, S.] Univ Ulsan, Dept Biomed Sci, Asan Med Ctr, Sch Med, Seoul, South Korea; [Jeon, S-M] Ajou Univ, Inst Pharmaceut Sci & Technol, Suwon, South Korea	Ajou University; National Cancer Center - Korea (NCC); Kangwon National University; University of Ulsan; Asan Medical Center; Ajou University	Jeon, SM (corresponding author), Ajou Univ, Coll Pharm, 206 World Cup Ro,Room 207, Suwon 16499, Gyeonggi Do, South Korea.	smjeon@ajou.ac.kr	Jeon, Sang-Min/I-7917-2018	Jeon, Sang-Min/0000-0002-0132-925X; Chang, Suhwan/0000-0002-0282-0120; Ko, Hyun-Jeong/0000-0002-3844-928X	National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea [S2014-A0251-00001]; National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [S2014-A0403-00067]; National Cancer Center of Korea [NCC1410670]	National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea); National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning(National Research Foundation of Korea); National Cancer Center of Korea	We thank Y-GL and S-HP for the technical assistance provided. The clinical compound library (with 1887 compounds) was provided by the Korea Chemical Bank (KCB) from the Korea Research Institute of Chemical Technology (KRICT). This work was supported by grants from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (S2014-A0251-00001) and Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (S2014-A0403-00067) to S-MJ and the National Cancer Center of Korea (NCC1410670) to S-YK.	Arlt A, 2013, ONCOGENE, V32, P4825, DOI 10.1038/onc.2012.493; Calderon-Montano JM, 2014, ONCOGENE, V33, P2947, DOI 10.1038/onc.2013.229; Chowdhry S, 2013, ONCOGENE, V32, P3765, DOI 10.1038/onc.2012.388; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Cuadrado A, 2015, FREE RADICAL BIO MED, V88, P147, DOI 10.1016/j.freeradbiomed.2015.04.029; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Faubert B, 2014, P NATL ACAD SCI USA, V111, P2554, DOI 10.1073/pnas.1312570111; Ference JD, 2009, AM FAM PHYSICIAN, V79, P135; Gao YJ, 2010, P NATL ACAD SCI USA, V107, P18892, DOI 10.1073/pnas.1004952107; Gluschnaider U, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009060; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Guo Y, 2015, FREE RADICAL BIO MED, V88, P337, DOI 10.1016/j.freeradbiomed.2015.06.013; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hast BE, 2014, CANCER RES, V74, P808, DOI 10.1158/0008-5472.CAN-13-1655; Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031; Jacob SE, 2006, J AM ACAD DERMATOL, V54, P723, DOI 10.1016/j.jaad.2005.12.028; Jaramillo MC, 2013, GENE DEV, V27, P2179, DOI 10.1101/gad.225680.113; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Kadmiel M, 2013, TRENDS PHARMACOL SCI, V34, P518, DOI 10.1016/j.tips.2013.07.003; Kaufman JM, 2014, J THORAC ONCOL, V9, P794, DOI 10.1097/JTO.0000000000000173; Ki SH, 2005, MOL CELL BIOL, V25, P4150, DOI 10.1128/MCB.25.10.4150-4165.2005; KIM N, 2016, SCI REP UK, V6; Kratschmar DV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036774; Leinonen HM, 2015, BIOCHEM SOC T, V43, P645, DOI 10.1042/BST20150048; Lin KT, 2016, STEROIDS, V111, P84, DOI 10.1016/j.steroids.2016.02.019; Lu MC, 2016, MED RES REV, V36, P924, DOI 10.1002/med.21396; Calderon-Montano JM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/794930; Meijsing SH, 2009, SCIENCE, V324, P407, DOI 10.1126/science.1164265; Menegon S, 2016, TRENDS MOL MED, V22, P578, DOI 10.1016/j.molmed.2016.05.002; Moghadam-Kia S, 2010, INT J DERMATOL, V49, P239, DOI 10.1111/j.1365-4632.2009.04322.x; Olayanju A, 2015, FREE RADICAL BIO MED, V78, P202, DOI 10.1016/j.freeradbiomed.2014.11.003; Rada P, 2011, MOL CELL BIOL, V31, P1121, DOI 10.1128/MCB.01204-10; Ramos-Gomez M, 2003, CARCINOGENESIS, V24, P461, DOI 10.1093/carcin/24.3.461; Ren DM, 2011, P NATL ACAD SCI USA, V108, P1433, DOI 10.1073/pnas.1014275108; Salazar M, 2006, J BIOL CHEM, V281, P14841, DOI 10.1074/jbc.M513737200; Sanchez-Cespedes M, 2007, ONCOGENE, V26, P7825, DOI 10.1038/sj.onc.1210594; Scagliotti GV, 2006, EXPERT OPIN THER PAT, V16, P189, DOI 10.1517/13543776.16.2.189; Sharma S, 2006, CARCINOGENESIS, V27, P1721, DOI 10.1093/carcin/bgl052; Shaw RJ, 2009, ACTA PHYSIOL, V196, P65, DOI 10.1111/j.1748-1716.2009.01972.x; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Skoulidis F, 2015, CANCER DISCOV, V5, P860, DOI 10.1158/2159-8290.CD-14-1236; Slingerland M, 2013, INVEST NEW DRUG, V31, P1087, DOI 10.1007/s10637-013-9984-1; Spokoini R, 2010, MOL ENDOCRINOL, V24, P1136, DOI 10.1210/me.2009-0466; Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278; Sundahl N, 2015, PHARMACOL THERAPEUT, V152, P28, DOI 10.1016/j.pharmthera.2015.05.001; Suzuki T, 2015, FREE RADICAL BIO MED, V88, P93, DOI 10.1016/j.freeradbiomed.2015.06.006; Tan KP, 2008, FREE RADICAL BIO MED, V45, P1663, DOI 10.1016/j.freeradbiomed.2008.09.010; Tang XW, 2011, FREE RADICAL BIO MED, V50, P1599, DOI 10.1016/j.freeradbiomed.2011.03.008; Tao S, 2014, CANCER RES, V74, P7430, DOI 10.1158/0008-5472.CAN-14-1439; Umemura A, 2016, CANCER CELL, V29, P935, DOI 10.1016/j.ccell.2016.04.006; van Meerloo J, 2011, METHODS MOL BIOL, V731, P237, DOI 10.1007/978-1-61779-080-5_20; Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179; Wang G, 2008, FREE RADICAL RES, V42, P435, DOI 10.1080/10715760802074462; Wang XJ, 2007, P NATL ACAD SCI USA, V104, P19589, DOI 10.1073/pnas.0709483104; Zhang YC, 2013, FOOD CHEM TOXICOL, V59, P272, DOI 10.1016/j.fct.2013.05.058; Zhong D, LUNG CANC, V53, P285	57	64	66	3	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2017	36	37					5285	5295		10.1038/onc.2017.153	http://dx.doi.org/10.1038/onc.2017.153			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FG8HT	28504720				2022-12-17	WOS:000410671700007
J	Geng, C; Kaochar, S; Li, M; Rajapakshe, K; Fiskus, W; Dong, J; Foley, C; Dong, B; Zhang, L; Kwon, OJ; Shah, SS; Bolaki, M; Xin, L; Ittmann, M; O'Malley, BW; Coarfa, C; Mitsiades, N				Geng, C.; Kaochar, S.; Li, M.; Rajapakshe, K.; Fiskus, W.; Dong, J.; Foley, C.; Dong, B.; Zhang, L.; Kwon, O-J; Shah, S. S.; Bolaki, M.; Xin, L.; Ittmann, M.; O'Malley, B. W.; Coarfa, C.; Mitsiades, N.			SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein	ONCOGENE			English	Article							CANCER-ASSOCIATED MUTANTS; WILD-TYPE SPOP; POZ PROTEIN; ANDROGEN RECEPTOR; TUMOR-SUPPRESSOR; COLORECTAL-CANCER; SIGNALING PATHWAY; DEGRADATION; EXPRESSION; MUTATIONS	The E3 ubiquitin ligase adaptor speckle-type POZ protein (SPOP) is frequently dysregulated in prostate adenocarcinoma (PC), via either somatic mutations or mRNA downregulation, suggesting an important tumour suppressor function. To examine its physiologic role in the prostate epithelium in vivo, we generated mice with prostate-specific biallelic ablation of Spop. These mice exhibited increased prostate mass, prostate epithelial cell proliferation, and expression of c-MYC protein compared to littermate controls, and eventually developed prostatic intraepithelial neoplasia (PIN). We found that SPOPWT can physically interact with c-MYC protein and, upon exogenous expression in vitro, can promote c-MYC ubiquitination and degradation. This effect was attenuated in PC cells by introducing PC-associated SPOP mutants or upon knockdown of SPOP via short-hairpin-RNA, suggesting that SPOP inactivation directly increases c-MYC protein levels. Gene Set Enrichment Analysis revealed enrichment of Myc-induced genes in transcriptomic signatures associated with SPOPMT. Likewise, we observed strong inverse correlation between c-MYC activity and SPOP mRNA levels in two independent PC patient cohorts. The core SPOPMT; MYCHigh transcriptomic response, defined by the overlap between the SPOPMT and c-MYC transcriptomic programmes, was also associated with inferior clinical outcome in human PCs. Finally, the organoid-forming capacity of Spop-null murine prostate cells was more sensitive to c-MYC inhibition than that of Spop-WT cells, suggesting that c-MYC upregulation functionally contributes to the proliferative phenotype of Spop knockout prostates. Taken together, our data highlight SPOP as an important regulator of luminal epithelial cell proliferation and c-MYC expression in prostate physiology, identify c-MYC as a novel bona fide SPOP substrate, and help explain the frequent inactivation of SPOP in human PC. We propose SPOPMT-induced stabilization of c-MYC protein as a novel mechanism that can increase total c-MYC levels in PC cells, in addition to amplification of c-MYC locus.	[Geng, C.; Kaochar, S.; Li, M.; Fiskus, W.; Foley, C.; Dong, B.; Shah, S. S.; Bolaki, M.; Mitsiades, N.] Baylor Coll Med, Dept Med, One Baylor Plaza,Suite R407, Houston, TX 77030 USA; [Geng, C.; Kaochar, S.; Li, M.; Rajapakshe, K.; Fiskus, W.; Dong, J.; Foley, C.; Dong, B.; Zhang, L.; Kwon, O-J; Shah, S. S.; Bolaki, M.; Xin, L.; O'Malley, B. W.; Coarfa, C.; Mitsiades, N.] Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza,Suite R407, Houston, TX 77030 USA; [Xin, L.; Ittmann, M.; Coarfa, C.; Mitsiades, N.] Dan L Duncan Canc Ctr, Houston, TX USA; [Ittmann, M.] Dept Pathol & Immunol, Houston, TX USA; [Ittmann, M.] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Mitsiades, N.] Baylor Coll Med, Ctr Drug Discovery, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Mitsiades, N (corresponding author), Baylor Coll Med, Dept Med, One Baylor Plaza,Suite R407, Houston, TX 77030 USA.; Coarfa, C; Mitsiades, N (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, One Baylor Plaza,Suite R407, Houston, TX 77030 USA.	coarfa@bcm.edu; mitsiade@bcm.edu			American Cancer Society [RSG-14-218-01-TBG]; Prostate Cancer Foundation; Conquer Cancer Foundation of the American Society of Clinical Oncology [SPORE P50CA58183]; Pilot/Feasibility Program of the Diabetes and Endocrinology Research Center at Baylor College of Medicine [P30-DK079638]; CPRIT [RP170295, RP170005, RP150578]; NIH [R01CA190378, 5T32CA174647-03, DK56338, CA125123]; NICHD [8818]; Department of Defense Breast Cancer Research Program Innovator Award; John S Dunn Gulf Coast Consortium for Chemical Genomics (NCI Cancer Center Support Grant) [P30CA125123]; Dan L Duncan Cancer Center (NCI Cancer Center Support) [P30CA125123]; Alkek Foundation for Molecular Discovery Pilot grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD008188] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA174647, R01CA190378, P30CA125123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK079638] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); Prostate Cancer Foundation; Conquer Cancer Foundation of the American Society of Clinical Oncology; Pilot/Feasibility Program of the Diabetes and Endocrinology Research Center at Baylor College of Medicine; CPRIT; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Department of Defense Breast Cancer Research Program Innovator Award; John S Dunn Gulf Coast Consortium for Chemical Genomics (NCI Cancer Center Support Grant); Dan L Duncan Cancer Center (NCI Cancer Center Support); Alkek Foundation for Molecular Discovery Pilot grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The authors acknowledge the joint participation by Adrienne Helis Malvin Medical Research Foundation through its direct engagement in the continuous active conduct of medical research in conjunction with Baylor College of Medicine. This work was also supported by the American Cancer Society RSG-14-218-01-TBG (to NM), the Prostate Cancer Foundation (to BWO and NM); the Conquer Cancer Foundation of the American Society of Clinical Oncology Young Investigator and Career Development Awards (both to NM) and a Developmental Project from SPORE P50CA58183 (NM); the Pilot/Feasibility Program of the Diabetes and Endocrinology Research Center (P30-DK079638) at Baylor College of Medicine (NM), an Alkek Foundation for Molecular Discovery Pilot grant (CC), CPRIT awards RP170295 and RP170005 (CC); NIH R01CA190378 (LX); NIH 5T32CA174647-03 (SK); and NICHD 8818 and Department of Defense Breast Cancer Research Program Innovator Award (BWO). NM is a Dan L Duncan Scholar, a Caroline Wiess Law Scholar and member of the Center for Drug Discovery at Baylor College of Medicine. The authors also acknowledge the assistance of the BCM Genetically Engineered Mouse and Human Tissue Acquisition and Pathology Core, Human Tissue Acquisition and Pathology Core, Integrated Microscopy Core funded via the NIH (DK56338, and CA125123), CPRIT (RP150578), and John S Dunn Gulf Coast Consortium for Chemical Genomics and the Dan L Duncan Cancer Center (supported by the NCI Cancer Center Support Grant P30CA125123).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320; Amati B, 2004, P NATL ACAD SCI USA, V101, P8843, DOI 10.1073/pnas.0403046101; An J, 2015, MOL CELL, V59, P904, DOI 10.1016/j.molcel.2015.07.025; An J, 2014, CELL REP, V6, P657, DOI 10.1016/j.celrep.2014.01.013; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Barfeld SJ, 2015, ONCOTARGET, V6, P12587, DOI 10.18632/oncotarget.3494; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Blattner M, 2014, NEOPLASIA, V16, P14, DOI 10.1593/neo.131704; Bredel M, 2005, CANCER RES, V65, P8679, DOI 10.1158/0008-5472.CAN-05-1204; Brown SDM, 2012, MAMM GENOME, V23, P632, DOI 10.1007/s00335-012-9427-x; Chen H, 2010, PROSTATE CANCER P D, V13, P238, DOI 10.1038/pcan.2010.20; Choi N, 2012, CANCER CELL, V21, P253, DOI 10.1016/j.ccr.2012.01.005; Claiborn KC, 2010, J CLIN INVEST, V120, P3713, DOI 10.1172/JCI40440; Coarfa C, 2016, ONCOGENE, V35, P2345, DOI 10.1038/onc.2015.295; Ding DC, 2015, INT J ONCOL, V46, P333, DOI 10.3892/ijo.2014.2729; Fan L, 2016, ONCOGENE, V35, P2441, DOI 10.1038/onc.2015.309; Farrell A.S., 2014, COLD SPRING HARB PER, V4; FLEMING WH, 1986, CANCER RES, V46, P1535; Fromont G, 2013, HUM PATHOL, V44, P1617, DOI 10.1016/j.humpath.2013.01.012; Gan WJ, 2015, MOL CELL, V59, P917, DOI 10.1016/j.molcel.2015.07.026; Garcia-Flores M, 2014, EUR J CANCER, V50, P2994, DOI 10.1016/j.ejca.2014.08.009; Geng C, 2014, CANCER RES, V74, P5631, DOI 10.1158/0008-5472.CAN-14-0476; Geng C, 2013, P NATL ACAD SCI USA, V110, P6997, DOI 10.1073/pnas.1304502110; Groner AC, 2016, CANCER CELL, V29, P846, DOI 10.1016/j.ccell.2016.04.012; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; Haffner MC, 2013, J CLIN INVEST, V123, P4918, DOI 10.1172/JCI70354; He B, 2014, P NATL ACAD SCI USA, V111, P18261, DOI 10.1073/pnas.1421415111; Hubbard GK, 2016, CANCER RES, V76, P283, DOI 10.1158/0008-5472.CAN-14-3280; Iwata T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009427; Jenkins RB, 1997, CANCER RES, V57, P524; Jin CL, 2003, PROSTATE, V57, P160, DOI 10.1002/pros.10283; Ju XM, 2013, CANCER RES, V73, P978, DOI 10.1158/0008-5472.CAN-12-2133; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Kemp Z, 2005, CANCER RES, V65, P11361, DOI 10.1158/0008-5472.CAN-05-2565; Kessler JD, 2012, SCIENCE, V335, P348, DOI 10.1126/science.1212728; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Koh CM, 2011, AM J PATHOL, V178, P1824, DOI 10.1016/j.ajpath.2010.12.040; Koh Cheryl M, 2010, Genes Cancer, V1, P617, DOI 10.1177/1947601910379132; Kwon JE, 2006, J BIOL CHEM, V281, P12664, DOI 10.1074/jbc.M600204200; Li C, 2011, ONCOGENE, V30, P4350, DOI 10.1038/onc.2011.151; Mei ZC, 2015, J BIOL CHEM, V290, P16202, DOI 10.1074/jbc.M115.645978; Nelson WG, 2012, CANCER DISCOV, V2, P206, DOI 10.1158/2159-8290.CD-12-0027; Pellakuru LG, 2012, AM J PATHOL, V181, P560, DOI 10.1016/j.ajpath.2012.04.021; Pomerantz MM, 2009, CANCER RES, V69, P5568, DOI 10.1158/0008-5472.CAN-09-0387; Priolo C, 2014, CANCER RES, V74, P7198, DOI 10.1158/0008-5472.CAN-14-1490; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Sun C, 2008, ONCOGENE, V27, P5348, DOI 10.1038/onc.2008.183; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Theurillat JPP, 2014, SCIENCE, V346, P85, DOI 10.1126/science.1250255; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wu F, 2017, CANCER LETT, V385, P207, DOI 10.1016/j.canlet.2016.10.021; Xu JF, 2015, J GASTROINTEST SURG, V19, P1484, DOI 10.1007/s11605-015-2767-6; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Zeng CY, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0075-8; Zhang C, 2014, ONCOGENE, V33, P5582, DOI 10.1038/onc.2013.505; Zhang PZ, 2014, HUM MUTAT, V35, P1142, DOI 10.1002/humu.22614; Zhang Q, 2009, P NATL ACAD SCI USA, V106, P21191, DOI 10.1073/pnas.0912008106; Zhi XF, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.435; Zhu HR, 2015, CELL REP, V13, P1183, DOI 10.1016/j.celrep.2015.09.083; Zhuang M, 2009, MOL CELL, V36, P39, DOI 10.1016/j.molcel.2009.09.022	61	64	70	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4767	4777		10.1038/onc.2017.80	http://dx.doi.org/10.1038/onc.2017.80			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28414305	Green Accepted			2022-12-17	WOS:000407702400009
J	Po, A; Silvano, M; Miele, E; Capalbo, C; Eramo, A; Salvati, V; Todaro, M; Besharat, ZM; Catanzaro, G; Cucchi, D; Coni, S; Di Marcotullio, L; Canettieri, G; Vacca, A; Stassi, G; De Smaele, E; Tartaglia, M; Screpanti, I; De Maria, R; Ferretti, E				Po, A.; Silvano, M.; Miele, E.; Capalbo, C.; Eramo, A.; Salvati, V.; Todaro, M.; Besharat, Z. M.; Catanzaro, G.; Cucchi, D.; Coni, S.; Di Marcotullio, L.; Canettieri, G.; Vacca, A.; Stassi, G.; De Smaele, E.; Tartaglia, M.; Screpanti, I.; De Maria, R.; Ferretti, E.			Noncanonical GLI1 signaling promotes stemness features and in vivo growth in lung adenocarcinoma	ONCOGENE			English	Article							HEDGEHOG PATHWAY; ABC TRANSPORTERS; SONIC HEDGEHOG; CELL-SURVIVAL; CANCER-CELLS; EXPRESSION; IDENTIFICATION; NEUROPILIN-2; ACTIVATION; TARGET	Aberrant Hedgehog/GLIsignaling has been implicated in a diverse spectrum of human cancers, but its role in lung adenocarcinoma (LAC) is still under debate. We show that the downstream effector of the Hedgehog pathway, GLI1, is expressed in 76% of LACs, but in roughly half of these tumors, the canonical pathway activator, Smoothened, is expressed at low levels, possibly owing to epigenetic silencing. In LAC cells including the cancer stem cell compartment, we show that GLI1 is activated noncanonically by MAPK/ERK signaling. Different mechanisms can trigger the MAPK/ERK/GLI1 cascade including KRAS mutation and stimulation of NRP2 by VEGF produced by the cancer cells themselves in an autocrine loop or by stromal cells as paracrine cross talk. Suppression of GLI1, by silencing or drug-mediated, inhibits LAC cells proliferation, attenuates their stemness and increases their susceptibility to apoptosis in vitro and in vivo. These findings provide insight into the growth of LACs and point to GLI1 as a downstream effector for oncogenic pathways. Thus, strategies involving direct inhibition of GLI1 may be useful in the treatment of LACs.published online 3 April 2017	[Po, A.; Silvano, M.; Capalbo, C.; Besharat, Z. M.; Cucchi, D.; Coni, S.; Di Marcotullio, L.; Canettieri, G.; Screpanti, I.] Sapienza Univ, Dept Mol Med, Rome, Italy; [Miele, E.; Screpanti, I.] IIT, Ctr Life NanoSci Sapienza, Rome, Italy; [Eramo, A.; Salvati, V.; De Maria, R.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, Rome, Italy; [Todaro, M.; Stassi, G.] Univ Palermo, Surg & Oncol Sci, Palermo, Italy; [Todaro, M.] Univ Palermo, Cent Lab Adv Diag & Biomed Res CLADIBIOR, Palermo, Italy; [Catanzaro, G.; Vacca, A.; De Smaele, E.; Ferretti, E.] Sapienza Univ, Dept Expt Med, Viale Regina Elena,291, I-00161 Rome, Italy; [Tartaglia, M.] Osped Pediat Bambino Gesu, Genet & Rare Dis Res Div, Rome, Italy; [De Maria, R.] Univ Cattolica Sacro Cuore, Inst Gen Pathol, Largo Francesco Vito,1, I-00168 Rome, Italy; [Ferretti, E.] IRCCS Neuromed, Pozzilli, Italy; [Miele, E.] IRCCS, Bambino Gesu Childrens Hosp, Dept Hematol Oncol & Stem Cell Transplantat, I-00165 Rome, Italy	Sapienza University Rome; Istituto Italiano di Tecnologia - IIT; Istituto Superiore di Sanita (ISS); University of Palermo; University of Palermo; Sapienza University Rome; IRCCS Bambino Gesu; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; IRCCS Neuromed; IRCCS Bambino Gesu	Ferretti, E (corresponding author), Sapienza Univ, Dept Expt Med, Viale Regina Elena,291, I-00161 Rome, Italy.; De Maria, R (corresponding author), Univ Cattolica Sacro Cuore, Inst Gen Pathol, Largo Francesco Vito,1, I-00168 Rome, Italy.	ruggero.demaria@unicatt.it; elisabetta.ferretti@uniroma1.it	Miele, Evelina/AAK-1963-2021; Miele, Evelina/M-4611-2013; catanzaro, giuseppina/AGZ-8080-2022; todaro, matilde/AAC-1003-2022; Stassi, Giorgio/AAC-1175-2022; Eramo, Adriana/K-6694-2016; salvati, Valentina/J-1264-2018; De Maria, Ruggero/S-6385-2019; Tartaglia, Marco/K-2955-2018; Po, Agnese/G-8754-2015; Po, Agnese/AEQ-0192-2022; Besharat, Zein Mersini/G-5413-2013; Miele, Evelina/ABB-7545-2021; De Smaele, Enrico/C-1124-2013; Ferretti, Elisabetta/G-5413-2013	Miele, Evelina/0000-0002-4747-1032; catanzaro, giuseppina/0000-0001-8427-9691; todaro, matilde/0000-0001-8686-8043; Eramo, Adriana/0000-0002-0814-6683; salvati, Valentina/0000-0002-0322-3504; De Maria, Ruggero/0000-0003-2255-0583; Tartaglia, Marco/0000-0001-7736-9672; Po, Agnese/0000-0002-9346-8782; Po, Agnese/0000-0002-9346-8782; Besharat, Zein Mersini/0000-0003-0317-9854; Miele, Evelina/0000-0002-4747-1032; De Smaele, Enrico/0000-0003-4524-4423; VACCA, Alessandra/0000-0002-0006-5379; Ferretti, Elisabetta/0000-0001-7265-6429; Cucchi, Danilo/0000-0002-9934-510X; DI MARCOTULLIO, LUCIA/0000-0003-0274-7178; CANETTIERI, Gianluca/0000-0001-6694-2613	Associazione Italiana Ricerca Cancro (AIRC); Ministry of University and Research (FIRB); Ministry of University and Research (PRIN); Ministry of University and Research (PON); Sapienza University of Rome (Ateneo); Pasteur Institute/Cenci Bolognetti Foundation; Umberto Di Mario ONLUS Foundation; Italian Institute of Technology (IIT) projects; Societa Italiana Articoli Laboratorio S.r.l (Rome, Italy)	Associazione Italiana Ricerca Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministry of University and Research (FIRB)(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); Ministry of University and Research (PRIN)(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Ministry of University and Research (PON); Sapienza University of Rome (Ateneo); Pasteur Institute/Cenci Bolognetti Foundation(Istituto Pasteur Italia Fondazione Cenci Bolognetti); Umberto Di Mario ONLUS Foundation; Italian Institute of Technology (IIT) projects; Societa Italiana Articoli Laboratorio S.r.l (Rome, Italy)	We thank Alberto Gulino, friend, mentor and colleague, who passed away while the manuscript was in preparation, for his inspiring vision and continued support. This work was supported by Associazione Italiana Ricerca Cancro (AIRC and AIRC 5XMILLE), Ministry of University and Research (FIRB, PRIN and PON), Sapienza University of Rome (Ateneo), Pasteur Institute/Cenci Bolognetti Foundation, Umberto Di Mario ONLUS Foundation, Italian Institute of Technology (IIT) projects. Medical writing support was provided by ME Kent (EMWA) and funded by the Societa Italiana Articoli Laboratorio S.r.l (Rome, Italy).	Agyeman A, 2014, ONCOTARGET, V5, P4492, DOI 10.18632/oncotarget.2046; Amakye D, 2013, NAT MED, V19, P1410, DOI 10.1038/nm.3389; Atwood SX, 2013, NATURE, V494, P484, DOI 10.1038/nature11889; Beauchamp EM, 2011, J CLIN INVEST, V121, P148, DOI 10.1172/JCI42874; Beck B, 2011, NATURE, V478, P399, DOI 10.1038/nature10525; Belani CP, 2016, CANCER-AM CANCER SOC, V122, P2371, DOI 10.1002/cncr.30062; Bermudez O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063226; Canettieri G, 2010, NAT CELL BIOL, V12, P132, DOI 10.1038/ncb2013; Cao X, 2012, ONCOGENE, V31, P104, DOI 10.1038/onc.2011.219; Caunt M, 2008, CANCER CELL, V13, P331, DOI 10.1016/j.ccr.2008.01.029; Chen X, 2008, STEM CELLS, V26, P2759, DOI 10.1634/stemcells.2008-0398; Chen Y, 2014, MOL CARCINOGEN, V53, P625, DOI 10.1002/mc.22015; Chenge J, 2016, SCI REP-UK, V6, DOI 10.1038/srep26628; Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; D'Amico D, 2015, DEV CELL, V35, P21, DOI 10.1016/j.devcel.2015.09.008; Davidson MR, 2013, J THORAC DIS, V5, pS463, DOI 10.3978/j.issn.2072-1439.2013.08.43; De Smaele E, 2010, CURR OPIN INVEST DR, V11, P707; Di Marcotullio L, 2004, P NATL ACAD SCI USA, V101, P10833, DOI 10.1073/pnas.0400690101; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Favier B, 2006, BLOOD, V108, P1243, DOI 10.1182/blood-2005-11-4447; Fletcher JI, 2010, NAT REV CANCER, V10, P147, DOI 10.1038/nrc2789; Garvalov BK, 2011, J MOL MED, V89, P95, DOI 10.1007/s00109-010-0685-3; Glinka Y, 2012, BIOCHEM BIOPH RES CO, V425, P775, DOI 10.1016/j.bbrc.2012.07.151; Goel HL, 2013, EMBO MOL MED, V5, P488, DOI 10.1002/emmm.201202078; Gonnissen A, 2015, ONCOTARGET, V6, P13899, DOI 10.18632/oncotarget.4224; Hamerlik P, 2012, J EXP MED, V209, P507, DOI 10.1084/jem.20111424; Huang LL, 2014, CLIN CANCER RES, V20, P1566, DOI 10.1158/1078-0432.CCR-13-2195; Huang W-Y, 2014, NUCLEIC ACIDS RES, V43; Hwang J, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-268; Infante P, 2015, EMBO J, V34, P200, DOI 10.15252/embj.201489213; Ingram WJ, 2013, EXP HEMATOL ONCOL, V2, DOI 10.1186/2162-3619-2-26; Ingram WJ, 2002, ONCOGENE, V21, P8196, DOI 10.1038/sj.onc.1205975; Jiang F, 2009, MOL CANCER RES, V7, P330, DOI 10.1158/1541-7786.MCR-08-0393; Johnson DH, 2014, J CLIN ONCOL, V32, P1389, DOI 10.1200/JCO.2014.55.1929; Justilien V, 2015, CLIN CANCER RES, V21, P505, DOI 10.1158/1078-0432.CCR-14-0507; Justilien V, 2014, CANCER CELL, V25, P139, DOI 10.1016/j.ccr.2014.01.008; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Katoh Y, 2009, CURR MOL MED, V9, P873, DOI 10.2174/156652409789105570; Kawakami T, 2002, CANCER, V95, P2196, DOI 10.1002/cncr.10936; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Kober P, 2011, MOL CARCINOGEN, V50, P846, DOI 10.1002/mc.20763; Lantuejoul S, 2003, J PATHOL, V200, P336, DOI 10.1002/path.1367; Lauth M, 2007, CELL CYCLE, V6, P2458, DOI 10.4161/cc.6.20.4808; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Lee RTH, 2016, DEVELOPMENT, V143, P367, DOI 10.1242/dev.120154; Matchett KB, 2014, STEM CELLS, V32, P2563, DOI 10.1002/stem.1798; Mills LD, 2013, J BIOL CHEM, V288, P11786, DOI 10.1074/jbc.M112.438846; Nasarre P, 2013, CANCER RES, V73, P7111, DOI 10.1158/0008-5472.CAN-13-1755; Nolan-Stevaux O, 2009, GENE DEV, V23, P24, DOI 10.1101/gad.1753809; Park JT, 2015, ONCOGENE, V34, P2801, DOI 10.1038/onc.2014.223; Park KS, 2011, NAT MED, V17, P1504, DOI 10.1038/nm.2473; Pinato DJ, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1213934; Po A, 2010, EMBO J, V29, P2646, DOI 10.1038/emboj.2010.131; Raz G, 2012, LUNG CANCER, V76, P191, DOI 10.1016/j.lungcan.2011.10.015; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Riobo NA, 2006, CANCER RES, V66, P839, DOI 10.1158/0008-5472.CAN-05-2539; Rodriguez-Blanco J, 2013, ONCOGENE, V32, P2335, DOI 10.1038/onc.2012.243; Ronci M, 2015, MOL BIOSYST, V11, P1603, DOI 10.1039/c5mb00034c; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; Seluanov Andrei, 2010, J Vis Exp, DOI 10.3791/2033; Seto M, 2009, MOL CARCINOGEN, V48, P703, DOI 10.1002/mc.20516; Sette G, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.217; Silvano M, 2015, J STEM CELL RES THER, V5, P2; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Singh RR, 2011, ONCOGENE, V30, P4874, DOI 10.1038/onc.2011.195; Singh S, 2011, CANCER RES, V71, P4454, DOI 10.1158/0008-5472.CAN-10-2313; Sinha S, 2006, NAT CHEM BIOL, V2, P29, DOI 10.1038/nchembio753; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Sullivan JP, 2010, CANCER RES, V70, P9937, DOI 10.1158/0008-5472.CAN-10-0881; Theunissen JW, 2009, CANCER RES, V69, P6007, DOI 10.1158/0008-5472.CAN-09-0756; Thomas A, 2015, NAT REV CLIN ONCOL, V12, P511, DOI 10.1038/nrclinonc.2015.90; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608; Varnat F, 2010, EMBO MOL MED, V2, P440, DOI 10.1002/emmm.201000098; Wang Y, 2012, CANCER CELL, V21, P374, DOI 10.1016/j.ccr.2011.12.028; Yuan Z, 2007, ONCOGENE, V26, P1046, DOI 10.1038/sj.onc.1209860; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137; Zhu YH, 2004, CANCER LETT, V207, P205, DOI 10.1016/j.canlet.2003.10.025; Zinzi L, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00163	83	64	66	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2017	36	32					4641	4652		10.1038/onc.2017.91	http://dx.doi.org/10.1038/onc.2017.91			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD0RK	28368412	Green Published, hybrid			2022-12-17	WOS:000407246200011
J	Stojanovic, N; Hassan, Z; Wirth, M; Wenzel, P; Beyer, M; Schafer, C; Brand, P; Kroemer, A; Stauber, RH; Schmid, RM; Arlt, A; Sellmer, A; Mahboobi, S; Rad, R; Reichert, M; Saur, D; Kramer, OH; Schneider, G				Stojanovic, N.; Hassan, Z.; Wirth, M.; Wenzel, P.; Beyer, M.; Schaefer, C.; Brand, P.; Kroemer, A.; Stauber, R. H.; Schmid, R. M.; Arlt, A.; Sellmer, A.; Mahboobi, S.; Rad, R.; Reichert, M.; Saur, D.; Kraemer, O. H.; Schneider, G.			HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer	ONCOGENE			English	Article							HISTONE DEACETYLASE INHIBITORS; NF-KAPPA-B; TUMOR-SUPPRESSOR GENE; MULTIPLE-MYELOMA; TRICHOSTATIN-A; BREAST-CANCER; MOUSE MODELS; CELL-LINES; STEM-CELLS; IN-VIVO	Mutation of p53 is a frequent genetic lesion in pancreatic cancer being an unmet clinical challenge. Mutants of p53 have lost the tumour-suppressive functions of wild type p53. In addition, p53 mutants exert tumour-promoting functions, qualifying them as important therapeutic targets. Here, we show that the class I histone deacetylases HDAC1 and HDAC2 contribute to maintain the expression of p53 mutants in human and genetically defined murine pancreatic cancer cells. Our data reveal that the inhibition of these HDACs with small molecule HDAC inhibitors (HDACi), as well as the specific genetic elimination of HDAC1 and HDAC2, reduce the expression of mutant p53 mRNA and protein levels. We further show that HDAC1, HDAC2 and MYC directly bind to the TP53 gene and that MYC recruitment drops upon HDAC inhibitor treatment. Therefore, our results illustrate a previously unrecognized class I HDAC-dependent control of the TP53 gene and provide evidence for a contribution of MYC. A combined approach targeting HDAC1/HDAC2 and MYC may present a novel and molecularly defined strategy to target mutant p53 in pancreatic cancer.	[Stojanovic, N.; Hassan, Z.; Wirth, M.; Wenzel, P.; Kroemer, A.; Schmid, R. M.; Rad, R.; Reichert, M.; Saur, D.; Schneider, G.] Tech Univ Munich, Med Klin 2, Ismaninger Str 22, D-81675 Munich, Bavaria, Germany; [Beyer, M.; Kraemer, O. H.] Johannes Gutenberg Univ Mainz, Med Ctr, Dept Toxicol, Mainz, Germany; [Schaefer, C.; Brand, P.] Friedrich Schiller Univ Jena, CMB, Inst Biochem & Biophys, Jena, Germany; [Stauber, R. H.] Univ Med Ctr Mainz, Mol & Cellular Oncol ENT, Mainz, Germany; [Arlt, A.] Univ Hosp Schleswig Holstein, Lab Mol Gastroenterol & Hepatol, Dept Internal Med 1 1, Kiel, Germany; [Sellmer, A.; Mahboobi, S.] Univ Regensburg, Inst Pharm, Fac Chem & Pharm, Dept Pharmaceut Chem 1, Regensburg, Germany; [Rad, R.; Saur, D.] German Canc Res Ctr, Heidelberg, Germany; [Rad, R.; Saur, D.] German Canc Consortium DKTK, Heidelberg, Germany; [Reichert, M.] Univ Penn, Perelman Sch Med, Div Gastroenterol, Philadelphia, PA 19104 USA	Technical University of Munich; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; Johannes Gutenberg University of Mainz; Friedrich Schiller University of Jena; Johannes Gutenberg University of Mainz; University of Kiel; Schleswig Holstein University Hospital; University of Regensburg; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Pennsylvania; Pennsylvania Medicine	Kramer, OH; Schneider, G (corresponding author), Tech Univ Munich, Med Klin 2, Ismaninger Str 22, D-81675 Munich, Bavaria, Germany.	okraemer@uni-mainz.de; guenter.schneider@tum.de	Arlt, Alexander/G-7308-2019; Saur, Dieter/O-8355-2015; Wirth, Matthias/AEG-6333-2022; Reichert, Maximilian/GOH-1246-2022; Krämer, Oliver H/L-9266-2015	Arlt, Alexander/0000-0002-6160-1059; Saur, Dieter/0000-0001-5874-0210; Krämer, Oliver H/0000-0003-3973-045X; Wirth, Matthias/0000-0002-8340-0872	Deutsche Krebshilfe [110908, 110909, 111273]; Wilhelm-Sander Stiftung [2016.004.1, 2010.078.1]; Else Kroner-Fresenius-Stiftung [2016_A43]; Deutsche Forschungsgemeinschaft (DFG) [SCHN 959/2-1 t, SFB824/C9, KR 2291/4-1/MA, 2183/1-1, KR 2291/5-1]; DKTK Joint Funding	Deutsche Krebshilfe(Deutsche Krebshilfe); Wilhelm-Sander Stiftung; Else Kroner-Fresenius-Stiftung; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); DKTK Joint Funding	We thank Dr E. Olson, Dr T. Jacks, Dr A. Lowy, Dr P. Soriano, and Dr D. Tuveson for providing mouse lines. We thank Dr A. Bradley for support and help during the transfer of mouse lines. This work was supported by: Deutsche Krebshilfe [110908 to G.S., 110909 to O.H.K., and 111273 to M.R.], Wilhelm-Sander Stiftung [2016.004.1 to S.M. and G.S., 2010.078.1 to O.H.K], Else Kroner-Fresenius-Stiftung (2016_A43 to M.W.), Deutsche Forschungsgemeinschaft (DFG) [SCHN 959/2-1 to G.S.; SFB824/C9 to G.S. and D.S.; KR 2291/4-1/MA; 2183/1-1 to O.H.K. and S.M., and KR 2291/5-1 to O.H.K.], and DKTK Joint Funding [to R.R., D.S., and G.S.].	Aghdassi A, 2012, GUT, V61, P439, DOI 10.1136/gutjnl-2011-300060; Alexandrova EM, 2015, NATURE, V523, P352, DOI 10.1038/nature14430; Azmi AS, 2010, EUR J CANCER, V46, P1122, DOI 10.1016/j.ejca.2010.01.015; Bantscheff M, 2011, NAT BIOTECHNOL, V29, P255, DOI 10.1038/nbt.1759; Bhadury J, 2014, P NATL ACAD SCI USA, V111, pE2721, DOI 10.1073/pnas.1406722111; Bradner JE, 2010, P NATL ACAD SCI USA, V107, P12617, DOI 10.1073/pnas.1006774107; Bradner JE, 2010, NAT CHEM BIOL, V6, P238, DOI 10.1038/NCHEMBIO.313; Buchwald M, 2009, CANCER LETT, V280, P160, DOI 10.1016/j.canlet.2009.02.028; Chang DK, 2014, CURR OPIN GENET DEV, V24, P74, DOI 10.1016/j.gde.2013.12.001; Conradt L, 2013, INT J CANCER, V132, P2248, DOI 10.1002/ijc.27916; Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022; Diersch S, 2016, ONCOGENE, V35, P3880, DOI 10.1038/onc.2015.437; Donadelli M, 2007, BBA-MOL CELL RES, V1773, P1095, DOI 10.1016/j.bbamcr.2007.05.002; Dovey OM, 2010, CELL CYCLE, V9, P2700, DOI 10.4161/cc.9.14.12626; Doyle B, 2010, J PATHOL, V222, P129, DOI 10.1002/path.2748; Fiorini C, 2015, BBA-MOL CELL RES, V1853, P89, DOI 10.1016/j.bbamcr.2014.10.003; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Fritsche P, 2009, GUT, V58, P1399, DOI 10.1136/gut.2009.180711; Geismann C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.417; Greer CB, 2015, CELL REP, V13, P1444, DOI 10.1016/j.celrep.2015.10.013; Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100; Hamilton G, 2014, ONCOTARGET, V5, P6142, DOI 10.18632/oncotarget.2178; Hanel W, 2013, CELL DEATH DIFFER, V20, P898, DOI 10.1038/cdd.2013.17; Heller G, 2008, CANCER RES, V68, P44, DOI 10.1158/0008-5472.CAN-07-2531; Hessmann E, 2016, ONCOGENE, V35, P1609, DOI 10.1038/onc.2015.216; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Jamaladdin S, 2014, P NATL ACAD SCI USA, V111, P9840, DOI 10.1073/pnas.1321330111; Kidder BL, 2012, NUCLEIC ACIDS RES, V40, P2925, DOI 10.1093/nar/gkr1151; Kim YJ, 2013, ONCOGENE, V32, P2828, DOI 10.1038/onc.2013.32; Kubicek S, 2012, P NATL ACAD SCI USA, V109, P5364, DOI 10.1073/pnas.1201079109; Kumagai T, 2007, INT J CANCER, V121, P656, DOI 10.1002/ijc.22558; Labisso WL, 2012, CELL CYCLE, V11, P1593, DOI 10.4161/cc.20008; Lauffer BEL, 2013, J BIOL CHEM, V288, P26926, DOI 10.1074/jbc.M113.490706; Lehmann A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-395; Li D, 2011, CELL DEATH DIFFER, V18, P1904, DOI 10.1038/cdd.2011.71; Li YQ, 2008, CANCER RES, V68, P1723, DOI 10.1158/0008-5472.CAN-07-1963; Lukashchuk N, 2007, MOL CELL BIOL, V27, P8284, DOI 10.1128/MCB.00050-07; Mahboobi S., 2016, PCT Int. Appl., Patent No. [WO 2016020369 A1, 2016020369, WO2016020369A1]; Marshall GM, 2010, ONCOGENE, V29, P5957, DOI 10.1038/onc.2010.332; Matthews GM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.306; Mazur PK, 2015, NAT MED, V21, P1163, DOI 10.1038/nm.3952; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Murakami J, 2005, CANCER CHEMOTH PHARM, V56, P22, DOI 10.1007/s00280-004-0976-x; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107; Ossewaarde JM, 1996, APPL ENVIRON MICROB, V62, P328, DOI 10.1128/AEM.62.2.328-331.1996; Ouaissi M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108520; Pei YX, 2016, CANCER CELL, V29, P311, DOI 10.1016/j.ccell.2016.02.011; Peltonen K, 2005, PIGM CELL RES, V18, P196, DOI 10.1111/j.1600-0749.2005.00225.x; Peulen O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075102; Piacentini P, 2006, VIRCHOWS ARCH, V448, P797, DOI 10.1007/s00428-006-0173-x; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Reed SM, 2015, CANCERS, V7, P30, DOI 10.3390/cancers7010030; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; Saborowski M, 2014, GENE DEV, V28, P85, DOI 10.1101/gad.232082.113; Sachweh MCC, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.61; Saldana-Meyer R, 2011, EPIGENETICS-US, V6, P1068, DOI 10.4161/epi.6.9.16683; Schneider G, 2010, ONCOGENE, V29, P2795, DOI 10.1038/onc.2010.46; Schneider G, 2011, BBA-REV CANCER, V1815, P90, DOI 10.1016/j.bbcan.2010.10.003; Schonhuber N, 2014, NAT MED, V20, P1340, DOI 10.1038/nm.3646; Scholz C, 2015, NAT BIOTECHNOL, V33, P415, DOI 10.1038/nbt.3130; Schuler S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-80; Shortt J, 2014, CELL REP, V7, P1009, DOI 10.1016/j.celrep.2014.04.008; Sonnemann J, 2014, BRIT J CANCER, V110, P656, DOI 10.1038/bjc.2013.742; Sui X, 2009, ONCOGENE, V28, P709, DOI 10.1038/onc.2008.423; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; Timpson P, 2011, CANCER RES, V71, P747, DOI 10.1158/0008-5472.CAN-10-2267; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Wagner T, 2014, BBA-REV CANCER, V1846, P524, DOI 10.1016/j.bbcan.2014.07.010; Walz S, 2014, NATURE, V511, P483, DOI 10.1038/nature13473; Wang ZT, 2016, CELL SIGNAL, V28, P506, DOI 10.1016/j.cellsig.2016.02.006; Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049; Weissmueller S, 2014, CELL, V157, P382, DOI 10.1016/j.cell.2014.01.066; Wirth M, 2016, TRENDS CANCER, V2, P1, DOI 10.1016/j.trecan.2015.12.002; Wirth M, 2016, MOL CANCER THER, V15, P1792, DOI 10.1158/1535-7163.MCT-16-0050; Wirth M, 2014, NUCLEIC ACIDS RES, V42, P10433, DOI 10.1093/nar/gku763; Wirth M, 2011, PANCREAS, V40, P144, DOI 10.1097/MPA.0b013e3181f7e41c; Yan W, 2013, ONCOGENE, V32, P599, DOI 10.1038/onc.2012.81; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Yu XD, 2002, J NATL CANCER I, V94, P504; Zappasodi R, 2014, INT J CANCER, V135, P2034, DOI 10.1002/ijc.28852; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	86	64	65	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 30	2017	36	13					1804	1815		10.1038/onc.2016.344	http://dx.doi.org/10.1038/onc.2016.344			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EQ5NF	27721407				2022-12-17	WOS:000398128900006
J	Sun, Y; Zhu, D; Chen, F; Qian, M; Wei, H; Chen, W; Xu, J				Sun, Y.; Zhu, D.; Chen, F.; Qian, M.; Wei, H.; Chen, W.; Xu, J.			SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironment	ONCOGENE			English	Article							SECRETORY PHENOTYPE; DRIVEN RESISTANCE; DRUG-RESISTANCE; SENESCENCE; FIBROBLASTS; EXPRESSION; INHIBITORS; PATHWAYS; PROTEINS; COMPLEX	Most tumors initially respond to cytotoxic treatments, but acquired resistance often follows. The tumor microenvironment (TME) is a major barrier to clinical success by compromising therapeutic efficacy, and pathological relevance of multiple soluble factors released by a therapeutically remodeled TME remains largely unexplored. Here we show that the secreted frizzled-related protein 2 (SFRP2), a Wnt pathway modulator, is produced by human primary fibroblasts after genotoxic treatments. SFRP2 induction is remarkable in tumor stroma, with transcription mainly modulated by the nuclear factor-kappa B (NF-kappa B) complex, a property shared by several effectors of the DNA damage secretory program. Instead of directly altering canonical Wnt signaling, SFRP2 augments beta-catenin activities initiated by WNT16B, another soluble factor from DNA-damaged stroma. WNT16B recognizes cancer cell surface receptors including frizzled (FZD) 3/4/6, a process enhanced by SFRP2, coordinated by the co-receptor LRP6 but subject to abrogation by DKK1. Importantly, we found WNT16B plays a central role in promoting advanced malignancies particularly acquired resistance by counteracting cell death, an effect that can be minimized by a neutralizing antibody co-administered with classical chemotherapy. Furthermore, DNA damage-triggered expression of WNT16B is systemic, imaged by significant induction among diverse solid organs and circulation in peripheral blood, thereby holding promise as not only a TME-derived anticancer target but also a novel biomarker for clinical evaluation of treatment efficacy. Overall, our study substantiates the biological complexity and pathological implication of a therapy-activated TME, and provides the proof of principle of co-targeting tumor and the TME to prevent acquired resistance, with the aim of improving intervention outcome in an era of precision medicine.	[Sun, Y.; Chen, F.; Qian, M.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, 320 Yueyang Rd, Shanghai 200031, Peoples R China; [Sun, Y.; Chen, F.; Qian, M.] Shanghai Jiao Tong Univ, Sch Med SJTUSM, 320 Yueyang Rd, Shanghai 200031, Peoples R China; [Sun, Y.] Shanghai Jiao Tong Univ, Sch Med, Collaborat Innovat Ctr Syst Biomed, Shanghai, Peoples R China; [Sun, Y.] Univ Washington, Dept Med, Seattle, WA 98195 USA; [Sun, Y.] Univ Washington, VAPSHCS, Seattle, WA 98195 USA; [Zhu, D.; Xu, J.] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China; [Wei, H.; Chen, W.] Second Mil Med Univ, Changzheng Hosp, Dept Pharmacol, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Shanghai Jiao Tong University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fudan University; Naval Medical University	Sun, Y (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	sunyu@sibs.ac.cn		sun, yu/0000-0001-7121-9112	US DoD PCRP Idea Development Award [PC111703]; National Natural Science Foundation of China [81472709, 81272390, 81472228]; National 1000 Youth Elites Research Program of China	US DoD PCRP Idea Development Award; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National 1000 Youth Elites Research Program of China	We thank Dr Peter Nelson (Fred Hutchinson Cancer Research Center) for kindly providing fibroblast cell lines, essential reagents and conferring critical comments. This work was supported by a US DoD PCRP Idea Development Award (PC111703 to YS), the National Natural Science Foundation of China (81472709 to YS, 81272390 and 81472228 to JX) and the National 1000 Youth Elites Research Program of China (to YS).	Alspach E, 2014, CANCER DISCOV, V4, P716, DOI 10.1158/2159-8290.CD-13-0743; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229; Bao J, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003028; Basch E, 2014, J CLIN ONCOL, V32, P3436, DOI 10.1200/JCO.2013.54.8404; Binet R, 2009, CANCER RES, V69, P9183, DOI 10.1158/0008-5472.CAN-09-1016; Borriello L, 2014, M S-MED SCI, V30, P445, DOI 10.1051/medsci/20143004021; Chen F, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0278-7; Chen F, 2014, PROTEIN CELL, V5, P816, DOI 10.1007/s13238-014-0097-1; Cheng ZH, 2011, NAT STRUCT MOL BIOL, V18, P1204, DOI 10.1038/nsmb.2139; Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Corso S, 2013, CANCER DISCOV, V3, P978, DOI 10.1158/2159-8290.CD-13-0040; Courtwright A, 2009, CANCER RES, V69, P4621, DOI 10.1158/0008-5472.CAN-08-3402; Halabi S, 2013, JNCI-J NATL CANCER I, V105, P1729, DOI 10.1093/jnci/djt280; Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599; Huber RM, 2015, ONCOTARGET, V6, P2134, DOI 10.18632/oncotarget.3040; Kinugasa Y, 2014, STEM CELLS, V32, P145, DOI 10.1002/stem.1556; Klemm F, 2015, TRENDS CELL BIOL, V25, P198, DOI 10.1016/j.tcb.2014.11.006; Kongkham PN, 2010, ONCOGENE, V29, P3017, DOI 10.1038/onc.2010.32; Laberge RM, 2015, NAT CELL BIOL, V17, P1049, DOI 10.1038/ncb3195; Laberge RM, 2012, AGING CELL, V11, P569, DOI 10.1111/j.1474-9726.2012.00818.x; Mii Y, 2009, DEVELOPMENT, V136, P4083, DOI 10.1242/dev.032524; O'Hurley G, 2011, HISTOPATHOLOGY, V59, P1240, DOI 10.1111/j.1365-2559.2011.04073.x; Orjalo AV, 2009, P NATL ACAD SCI USA, V106, P17031, DOI 10.1073/pnas.0905299106; Ostman A, 2012, NAT MED, V18, P1332, DOI 10.1038/nm.2938; PAGET S, 1989, CANCER METAST REV, V8, P98; Pazolli E, 2012, CANCER RES, V72, P2251, DOI 10.1158/0008-5472.CAN-11-3386; Perry AS, 2013, INT J CANCER, V132, P1771, DOI 10.1002/ijc.27798; Ren SY, 2013, P NATL ACAD SCI USA, V110, P1440, DOI 10.1073/pnas.1211179110; Ries CH, 2014, CANCER CELL, V25, P846, DOI 10.1016/j.ccr.2014.05.016; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Saini S, 2011, NAT REV UROL, V8, P690, DOI 10.1038/nrurol.2011.146; Seruga B, 2011, NAT REV CLIN ONCOL, V8, P12, DOI 10.1038/nrclinonc.2010.136; Siamakpour-Reihani S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020412; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Sun Y, 2016, CANCER LETT, V380, P205, DOI 10.1016/j.canlet.2015.07.044; Sun Y, 2015, MED RES REV, V35, P408, DOI 10.1002/med.21338; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Sun Y, 2012, CLIN CANCER RES, V18, P4019, DOI 10.1158/1078-0432.CCR-11-0768; Tsuchimochi K, 2010, J BIOL CHEM, V285, P8395, DOI 10.1074/jbc.M109.038638; Vidal SJ, 2014, ONCOGENE, V33, P4451, DOI 10.1038/onc.2013.411; von Marschall Z, 2010, BIOCHEM BIOPH RES CO, V400, P299, DOI 10.1016/j.bbrc.2010.08.043; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Xu J, 2007, ANN SURG, V245, P583, DOI 10.1097/01.sla.0000250453.34507.d3; Yang XM, 2014, CANCER CELL, V25, P37, DOI 10.1016/j.ccr.2013.12.004; Yang Y, 2015, CANCER RES, V75, P594, DOI 10.1158/0008-5472.CAN-14-2362; Zhang Shengting, 2014, Zhonghua Xue Ye Xue Za Zhi, V35, P466, DOI 10.3760/cma.j.issn.0253-2727.2014.05.022	49	64	65	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4321	4334		10.1038/onc.2015.494	http://dx.doi.org/10.1038/onc.2015.494			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26751775	Green Published, hybrid			2022-12-17	WOS:000382152100004
J	Cai, Q; Yan, L; Xu, Y				Cai, Q.; Yan, L.; Xu, Y.			Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells	ONCOGENE			English	Article							MOUSE MODEL; CARCINOMA; GROWTH; TUMOR	High-grade serous ovarian cancer is an aggressive form of epithelial ovarian cancer (EOC), and accounts for the majority of deaths due to EOC. The critical cellular processes and underlying molecular mechanisms that define this malignancy remain poorly understood. Using a syngeneic murine model, we investigated the changes that accompanied the progression to increased aggressiveness induced by in vivo passage of mouse EOC cells. We found that enhanced anoikis resistance was a key cellular process associated with greater aggressiveness and tumorigenicity in vivo. Biochemical studies revealed that the enhanced anoikis resistance was associated with the activation of the Src/Akt/Erk signaling pathway. A higher rate of metabolism and autophagy were also associated with increased anoikis resistance. Blocking these pathways with specific inhibitors and/or genetic modifications significantly increased anoikis in vitro and inhibited tumor development in vivo. In addition, we demonstrated that similar signaling pathways were also involved in a human EOC cell line model. Collectively, our data suggest that anoikis resistance represents a critical and a distinguishing feature underlying the aggressiveness of ovarian cancer cells.	[Cai, Q.; Yan, L.; Xu, Y.] Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University Bloomington	Xu, Y (corresponding author), Indiana Univ Sch Med, Dept Obstet & Gynecol, 975 W Walnut St IB355A, Indianapolis, IN 46202 USA.	xu2@iupui.edu			National Institutes of Health [RO1 155145]; Mary Fendrich-Hulman Charitable Trust Fund; NATIONAL CANCER INSTITUTE [R01CA155145] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mary Fendrich-Hulman Charitable Trust Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Caryl Antalis and Christy A Tidwell for their critical reading and editing of this manuscript. This work is supported in part by the National Institutes of Health (RO1 155145 to YX) and the Mary Fendrich-Hulman Charitable Trust Fund to YX.	Ahmed N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00256; BAUMAL R, 1986, CANCER RES, V46, P3994; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Chiarugi P, 2008, BIOCHEM PHARMACOL, V76, P1352, DOI 10.1016/j.bcp.2008.07.023; Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165; Janat-Amsbury MM, 2006, ANTICANCER RES, V26, P3223; Li H, 2009, MOL CANCER THER, V8, P1692, DOI 10.1158/1535-7163.MCT-08-1106; Miskimins WK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085576; Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585; Said NA, 2007, NEOPLASIA, V9, P23, DOI 10.1593/neo.06658; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Sher I, 2009, INT J CANCER, V124, P553, DOI 10.1002/ijc.23963; Ward KK, 2013, CLIN EXP METASTAS, V30, P579, DOI 10.1007/s10585-012-9562-5; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; YU DH, 1993, CANCER RES, V53, P891	15	64	67	3	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3315	3324		10.1038/onc.2014.264	http://dx.doi.org/10.1038/onc.2014.264			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25132267	Green Accepted, Green Submitted			2022-12-17	WOS:000356592300010
J	Trautmann, M; Sievers, E; Aretz, S; Kindler, D; Michels, S; Friedrichs, N; Renner, M; Kirfel, J; Steiner, S; Huss, S; Koch, A; Penzel, R; Larsson, O; Kawai, A; Tanaka, S; Sonobe, H; Waha, A; Schirmacher, P; Mechtersheimer, G; Wardelmann, E; Buttner, R; Hartmann, W				Trautmann, M.; Sievers, E.; Aretz, S.; Kindler, D.; Michels, S.; Friedrichs, N.; Renner, M.; Kirfel, J.; Steiner, S.; Huss, S.; Koch, A.; Penzel, R.; Larsson, O.; Kawai, A.; Tanaka, S.; Sonobe, H.; Waha, A.; Schirmacher, P.; Mechtersheimer, G.; Wardelmann, E.; Buettner, R.; Hartmann, W.			SS18-SSX fusion protein-induced Wnt/beta-catenin signaling is a therapeutic target in synovial sarcoma	ONCOGENE			English	Article						Synovial sarcoma; SYT-SSX; beta-catenin; Wnt signaling pathway; PKF115-584; CGP049090; PKF118-310	SMALL-MOLECULE ANTAGONISTS; SOFT-TISSUE SARCOMA; CELLS IN-VITRO; BETA-CATENIN; GENE-EXPRESSION; BREAST-CANCER; COMPLEX; TRANSLOCATION; INHIBITORS; MUTATIONS	Synovial sarcoma is a high-grade soft tissue malignancy characterized by a specific reciprocal translocation t(X; 18), which leads to the fusion of the SS18 (SYT) gene to one of three SSX genes (SSX1, SSX2 or SSX4). The resulting chimeric SS18-SSX protein is suggested to act as an oncogenic transcriptional regulator. Despite multimodal therapeutic approaches, metastatic disease is often lethal and the development of novel targeted therapeutic strategies is required. Several expression-profiling studies identified distinct gene expression signatures, implying a consistent role of Wnt/beta-catenin signaling in synovial sarcoma tumorigenesis. Here we investigate the functional and therapeutic relevance of Wnt/beta-catenin pathway activation in vitro and in vivo. Immunohistochemical analyses of nuclear beta-catenin and Wnt downstream targets revealed activation of canonical Wnt signaling in a significant subset of 30 primary synovial sarcoma specimens. Functional aspects of Wnt signaling including dependence of Tcf/beta-catenin complex activity on the SS18-SSX fusion proteins were analyzed. Efficient SS18-SSX-dependent activation of the Tcf/beta-catenin transcriptional complex was confirmed by TOPflash reporter luciferase assays and immunoblotting. In five human synovial sarcoma cell lines, inhibition of the Tcf/beta-catenin protein-protein interaction significantly blocked the canonical Wnt/beta-catenin signaling cascade, accompanied by the effective downregulation of Wnt targets (AXIN2, CDC25A, c-MYC, DKK1, CyclinD1 and Survivin) and the specific suppression of cell viability associated with the induction of apoptosis. In SYO-1 synovial sarcoma xenografts, administration of small molecule Tcf/beta-catenin complex inhibitors significantly reduced tumor growth, associated with diminished AXIN2 protein levels. In summary, SS18-SSX-induced Wnt/beta-catenin signaling appears to be of crucial biological importance in synovial sarcoma tumorigenesis and progression, representing a potential molecular target for the development of novel therapeutic strategies.	[Trautmann, M.; Sievers, E.; Kindler, D.; Michels, S.; Friedrichs, N.; Huss, S.; Wardelmann, E.; Buettner, R.; Hartmann, W.] Univ Hosp Cologne, Dept Pathol, D-50937 Cologne, Germany; [Trautmann, M.; Kirfel, J.; Steiner, S.] Univ Hosp Bonn, Dept Pathol, Bonn, Germany; [Aretz, S.] Univ Bonn, Inst Human Genet, Bonn, Germany; [Renner, M.; Penzel, R.; Schirmacher, P.; Mechtersheimer, G.] Univ Heidelberg Hosp, Dept Pathol, Heidelberg, Germany; [Koch, A.] Charite, Dept Neuropathol, D-13353 Berlin, Germany; [Larsson, O.] Karolinska Inst, Dept Oncol & Pathol, Stockholm, Sweden; [Kawai, A.] Natl Canc Ctr, Div Orthopaed Surg, Tokyo, Japan; [Tanaka, S.] Hokkaido Univ, Grad Sch Med, Lab Mol & Cellular Pathol, Sapporo, Hokkaido, Japan; [Sonobe, H.] Chungoku Cent Hosp, Dept Lab Med, Fukuyama, Hiroshima, Japan; [Waha, A.] Univ Hosp Bonn, Dept Neuropathol, Bonn, Germany	University of Cologne; University of Bonn; University of Bonn; Ruprecht Karls University Heidelberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Karolinska Institutet; National Cancer Center - Japan; Hokkaido University; University of Bonn	Hartmann, W (corresponding author), Univ Hosp Cologne, Dept Pathol, Kerpener Str 62, D-50937 Cologne, Germany.	wolfgang.hartmann@uk-koeln.de	Trautmann, Marcel/B-4627-2015; Aretz, Stefan/C-1241-2008; Hartmann, Wolfgang/G-1893-2017; Tanaka, Shinya/D-3586-2011	Trautmann, Marcel/0000-0002-5842-1196; Aretz, Stefan/0000-0002-5228-1890; Hartmann, Wolfgang/0000-0002-7609-5021; 	Wilhelm Sander-Stiftung; Dr Eberhard und Hilde Rudiger Stiftung; Deutsche Krebshilfe (KoSar sarcoma competence network); BONFOR (Medical Faculty, University Hospital Bonn, Bonn); Fortune program (Medical Faculty, University of Cologne, Cologne)	Wilhelm Sander-Stiftung; Dr Eberhard und Hilde Rudiger Stiftung; Deutsche Krebshilfe (KoSar sarcoma competence network); BONFOR (Medical Faculty, University Hospital Bonn, Bonn); Fortune program (Medical Faculty, University of Cologne, Cologne)	PKF115-584, CGP049090 and PKF118-310 were generously provided by A Wood (Novartis Pharma AG, Basel, Switzerland). This study was supported by Wilhelm Sander-Stiftung, Dr Eberhard und Hilde Rudiger Stiftung, Deutsche Krebshilfe (KoSar sarcoma competence network), BONFOR (Medical Faculty, University Hospital Bonn, Bonn) and Fortune program (Medical Faculty, University of Cologne, Cologne).	Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Baird K, 2005, CANCER RES, V65, P9226, DOI 10.1158/0008-5472.CAN-05-1699; Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154; Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; de Bruijn DRH, 2006, CANCER RES, V66, P9474, DOI 10.1158/0008-5472.CAN-05-3726; Francis P, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-73; Friedrichs N, 2006, DIAGN MOL PATHOL, V15, P83, DOI 10.1097/00019606-200606000-00004; Friedrichs N, 2008, J PATHOL, V216, P428, DOI 10.1002/path.2438; Gandhirajan RK, 2010, NEOPLASIA, V12, P326, DOI 10.1593/neo.91972; Garcia CB, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-189; Haldar M, 2008, CLIN ORTHOP RELAT R, V466, P2156, DOI 10.1007/s11999-008-0340-2; Haldar M, 2007, CANCER CELL, V11, P375, DOI 10.1016/j.ccr.2007.01.016; Haldar M, 2009, CANCER RES, V69, P3657, DOI 10.1158/0008-5472.CAN-08-4127; Hasegawa T, 2001, HUM PATHOL, V32, P257, DOI 10.1053/hupa.2001.22764; Kadoch C, 2013, CELL, V153, P71, DOI 10.1016/j.cell.2013.02.036; Kawai A, 2004, CANCER LETT, V204, P105, DOI 10.1016/j.canlet.2003.09.031; Kim SY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008979; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Lubieniecka JM, 2008, CANCER RES, V68, P4303, DOI 10.1158/0008-5472.CAN-08-0092; Michels S, 2013, CANCER RES, V73, P2518, DOI 10.1158/0008-5472.CAN-12-3023; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nagayama S, 2002, CANCER RES, V62, P5859; Naka N, 2010, STEM CELLS, V28, P1119, DOI 10.1002/stem.452; Ng TL, 2005, MODERN PATHOL, V18, P68, DOI 10.1038/modpathol.3800272; Nguyen Anne, 2009, Sarcoma, V2009, P794901, DOI 10.1155/2009/794901; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; NOJIMA T, 1990, ACTA PATHOL JAPON, V40, P486; Pretto D, 2006, ONCOGENE, V25, P3661, DOI 10.1038/sj.onc.1209413; Provost E, 2005, ONCOGENE, V24, P2667, DOI 10.1038/sj.onc.1208346; Romagnolo B, 1999, CANCER RES, V59, P3875; Saito T, 2000, J PATHOL, V192, P342, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH705>3.0.CO;2-R; Saito T, 2002, J PATHOL, V196, P445, DOI 10.1002/path.1066; Sato H, 2001, VIRCHOWS ARCH, V438, P23; Segal NH, 2003, AM J PATHOL, V163, P691, DOI 10.1016/S0002-9440(10)63696-6; SONOBE H, 1992, LAB INVEST, V67, P498; Soulez M, 1999, ONCOGENE, V18, P2739, DOI 10.1038/sj.onc.1202613; Su L, 2012, CANCER CELL, V21, P333, DOI 10.1016/j.ccr.2012.01.010; Taurin S, 2006, J BIOL CHEM, V281, P9971, DOI 10.1074/jbc.M508778200; Trosset JY, 2006, PROTEINS, V64, P60, DOI 10.1002/prot.20955; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V23, P93, DOI 10.1016/0165-4608(86)90153-6; Vijayakumar S, 2011, CANCER CELL, V19, P601, DOI 10.1016/j.ccr.2011.03.010; Webb J.L., 1966, ENZYME METABOLIC INH; Wei W, 2010, INT J CANCER, V126, P2426, DOI 10.1002/ijc.24810; Weiss SW, 2007, ENZINGER, DOI DOI 10.3109/02844319209035195; Zhang M, 2013, ACS MED CHEM LETT, V4, P306, DOI 10.1021/ml300367f	52	64	69	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2014	33	42					5006	5016		10.1038/onc.2013.443	http://dx.doi.org/10.1038/onc.2013.443			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OB	24166495				2022-12-17	WOS:000343768000005
J	Fahraeus, R; Olivares-Illana, V				Fahraeus, R.; Olivares-Illana, V.			MDM2's social network	ONCOGENE			English	Review						MDM2; interactome; interactions; p53	MESSENGER-RNA STABILIZATION; DNA-DAMAGE; E3 LIGASE; UBIQUITIN LIGASE; REGULATES P53; TRANSCRIPTIONAL ACTIVITY; PROTEASOMAL DEGRADATION; ANDROGEN RECEPTOR; INDUCED APOPTOSIS; INHIBITING MDM2	MDM2 is considered a hub protein due to its capacity to interact with a large number of different partners of which p53 is most well described. MDM2 is an E3 ubiquitin ligase, and many, but not all, of its interactions relate directly to this activity, such as substrates, adaptors or bridges, promoters, inhibitors or complementary factors. Some interactions serve regulatory functions that in response to cellular stresses control the localisation and functions of MDM2 including protein kinases, ribosomal proteins and proteases. Moreover, interactions with nucleotides serve other functions such as mRNA to regulate protein synthesis and DNA to control transcription. To perform such a pleiotropic panorama of different functions, MDM2 is subjected to a multitude of post-translational modifications and is expressed in different isoforms. The large and diverse interactome is made possible due to the plasticity of MDM2 and in this review we have listed the MDM2 interactions until now and we will discuss how this multifaceted protein can interact with such a variety of substrates to provide a key intermediary role in different signalling pathways.	[Fahraeus, R.] Univ Paris 07, Hop St Louis, INSERM Unite 940, Equipe Labellisee Ligue Canc,Inst Genet Mol, Paris, France; [Olivares-Illana, V.] Univ Autonoma San Luis Potosi, Inst Fis, San Luis Potosi 78290, Mexico	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universidad Autonoma de San Luis Potosi	Olivares-Illana, V (corresponding author), Univ Autonoma San Luis Potosi, Inst Fis, Av Manuel Nava 6 Zona Univ, San Luis Potosi 78290, Mexico.	vanesa@ifisica.uaslp.mx	Olivares-Illana, Vanesa/AAF-9710-2021; fahraeus, robin/K-8726-2014	Olivares-Illana, Vanesa/0000-0001-6949-5986	CONACyT [CB-166233]; Fondo de Apoyo a la Investigacion [C13-FAI-03-57.57]; La Ligue Contre le Cancer, Inserm; European Regional Development Fund; State Budget of the Czech Republic (RECAMO) [CZ.1.05/2.1.00/03.0101];  [PROMEP/103.5/12/3953]	CONACyT(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Fondo de Apoyo a la Investigacion; La Ligue Contre le Cancer, Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)); European Regional Development Fund(European Commission); State Budget of the Czech Republic (RECAMO); 	We apologise to those whose works have not been cited in this article owing to lack of space. This article is supported by CONACyT CB-166233; PROMEP/103.5/12/3953 and Fondo de Apoyo a la Investigacion (C13-FAI-03-57.57). RF is funded by La Ligue Contre le Cancer, Inserm and the European Regional Development Fund and the State Budget of the Czech Republic (RECAMO, CZ.1.05/2.1.00/03.0101). The authors thank Dr Gomez-Puyou for revision of the manuscript.	Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; Asahara H, 2003, NUCLEIC ACIDS RES, V31, P2451, DOI 10.1093/nar/gkg342; Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; Bae S, 2012, ONCOL REP, V28, P1924, DOI 10.3892/or.2012.2005; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Banks D, 2006, CELL CYCLE, V5, P1719, DOI 10.4161/cc.5.15.3150; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Biderman Lynn, 2012, Genes Cancer, V3, P264, DOI 10.1177/1947601912455331; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Boyd MT, 2000, J BIOL CHEM, V275, P31883, DOI 10.1074/jbc.M004252200; Brenkman AB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002819; Busso CS, 2009, ONCOGENE, V28, P1616, DOI 10.1038/onc.2009.5; Calabro V, 2002, J BIOL CHEM, V277, P2674, DOI 10.1074/jbc.M107173200; Candeias MM, 2008, NAT CELL BIOL, V10, P1098, DOI 10.1038/ncb1770; Challen C, 2012, INT J ONCOL, V40, P851, DOI 10.3892/ijo.2011.1267; Chen D, 2007, ONCOGENE, V26, P5029, DOI 10.1038/sj.onc.1210327; Chen D, 2009, EMBO REP, V10, P166, DOI 10.1038/embor.2008.231; Chen LH, 2010, EMBO J, V29, P2538, DOI 10.1038/emboj.2010.140; Chen S, 2004, NATURE, V432, P640; Cheng TH, 2007, MOL CELL BIOL, V27, P111, DOI 10.1128/MCB.00235-06; Chi XZ, 2009, CANCER RES, V69, P8111, DOI 10.1158/0008-5472.CAN-09-1057; Daftuar L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068667; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Dohmesen C, 2008, CELL CYCLE, V7, P222, DOI 10.4161/cc.7.2.5185; Elenbaas B, 1996, MOL MED, V2, P439, DOI 10.1007/BF03401903; Embade N, 2012, HEPATOLOGY, V55, P1237, DOI 10.1002/hep.24795; Fu XY, 2010, P NATL ACAD SCI USA, V107, P4579, DOI 10.1073/pnas.0912094107; Gajjar M, 2012, CANCER CELL, V21, P25, DOI 10.1016/j.ccr.2011.11.016; Gama V, 2009, CELL DEATH DIFFER, V16, P758, DOI 10.1038/cdd.2009.6; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu L, 2012, ONCOGENE, V31, P1342, DOI 10.1038/onc.2011.343; Gu LB, 2002, BLOOD, V99, P3367, DOI 10.1182/blood.V99.9.3367; Gu LB, 2009, CANCER CELL, V15, P363, DOI 10.1016/j.ccr.2009.03.002; Hara MR, 2011, NATURE, V477, P349, DOI 10.1038/nature10368; Hew HC, 2011, MOL CARCINOGEN, V50, P719, DOI 10.1002/mc.20748; Higashitsuji H, 2005, CANCER CELL, V8, P75, DOI 10.1016/j.ccr.2005.06.006; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Huart AS, 2009, J BIOL CHEM, V284, P32384, DOI 10.1074/jbc.M109.052647; Inuzuka H, 2010, CANCER CELL, V18, P147, DOI 10.1016/j.ccr.2010.06.015; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Jeong MH, 2006, J BIOL CHEM, V281, P8707, DOI 10.1074/jbc.M513853200; Jin YT, 2002, J BIOL CHEM, V277, P30838, DOI 10.1074/jbc.M204078200; Jung CH, 2013, CANCER LETT, V335, P270, DOI 10.1016/j.canlet.2013.02.035; Jung CR, 2010, J CLIN INVEST, V120, P4493, DOI 10.1172/JCI42674; Jung YS, 2012, DNA REPAIR, V11, P177, DOI 10.1016/j.dnarep.2011.10.017; Kadakia M, 2001, DNA CELL BIOL, V20, P321, DOI 10.1089/10445490152122433; Kass EM, 2009, CELL CYCLE, V8, P430, DOI 10.4161/cc.8.3.7624; Kawai H, 2007, CANCER RES, V67, P6026, DOI 10.1158/0008-5472.CAN-07-1313; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kim MM, 2007, ONCOGENE, V26, P4209, DOI 10.1038/sj.onc.1210212; Knappskog S, 2011, TRANSCR-AUSTIN, V2, P207, DOI 10.4161/trns.2.5.16813; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Kostic M, 2006, J MOL BIOL, V363, P433, DOI 10.1016/j.jmb.2006.08.027; Kurki S, 2003, J CELL SCI, V116, P3917, DOI 10.1242/jcs.00714; Lai KP, 2010, EMBO J, V29, P2994, DOI 10.1038/emboj.2010.166; Lane David P, 2012, Genes Cancer, V3, P320, DOI 10.1177/1947601912458285; Lau R, 2012, CELL CYCLE, V11, P4009, DOI 10.4161/cc.22223; Lee D, 2012, EMBO REP, V13, P163, DOI 10.1038/embor.2011.235; Lee M. H., 2011, CELL CYCLE, V10, P3057, DOI [DOI 10.4161/CC.10.18, 10.4161/cc.10.18.17320, DOI 10.4161/CC.10.18.17320]; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; Lehman JA, 2012, INT J MOL SCI, V13, P16373, DOI 10.3390/ijms131216373; Lessard F, 2012, NUCLEIC ACIDS RES, V40, P5357, DOI 10.1093/nar/gks198; Leveillard T, 1997, J BIOL CHEM, V272, P30651, DOI 10.1074/jbc.272.49.30651; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; Liu T, 2013, J BIOL CHEM, V288, P3359, DOI 10.1074/jbc.M112.384289; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; Maguire M, 2008, CANCER RES, V68, P3232, DOI 10.1158/0008-5472.CAN-07-5271; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Mayo LD, 1997, CANCER RES, V57, P5013; Meek DW, 2010, SEMIN CANCER BIOL, V20, P19, DOI 10.1016/j.semcancer.2009.10.005; Minsky N, 2004, MOL CELL, V16, P631, DOI 10.1016/j.molcel.2004.10.016; Miyauchi Y, 2002, J BIOL CHEM, V277, P50131, DOI 10.1074/jbc.M208319200; Mo PL, 2010, J BIOL CHEM, V285, P26908, DOI 10.1074/jbc.M110.132597; Moumen A, 2005, CELL, V123, P1065, DOI 10.1016/j.cell.2005.09.032; Nicholson J, 2012, J PROTEOME RES, V11, P5464, DOI 10.1021/pr300698d; Nicholson J, 2010, CELL CYCLE, V9, P1878, DOI 10.4161/cc.9.10.11597; Ochocka AM, 2002, EMBO J, V7, P1704; Ofir-Rosenfeld Y, 2008, MOL CELL, V32, P180, DOI 10.1016/j.molcel.2008.08.031; Oh W, 2010, ONCOGENE, V29, P4101, DOI 10.1038/onc.2010.160; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Okoro Danielle R, 2012, Genes Cancer, V3, P311, DOI 10.1177/1947601912455323; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Oliver TG, 2011, MOL CELL, V43, P57, DOI 10.1016/j.molcel.2011.06.012; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Perry ME, 2004, MOL CANCER RES, V2, P9; Pettersson S, 2013, BIOCHEM J, V450, P523, DOI 10.1042/BJ20121249; Pettersson S, 2009, BIOCHEM J, V418, P575, DOI 10.1042/BJ20082087; Polanski R, 2011, CARCINOGENESIS, V32, P1133, DOI 10.1093/carcin/bgr070; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Riemenschneider MJ, 1999, CANCER RES, V59, P6091; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sczaniecka M, 2012, J BIOL CHEM, V287, P14052, DOI 10.1074/jbc.M111.303875; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Sheng Y, 2006, NAT STRUCT MOL BIOL, V13, P285, DOI 10.1038/nsmb1067; Shouse GP, 2011, ONCOGENE, V30, P3755, DOI 10.1038/onc.2011.95; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Singh S, 2013, CELL DEATH DIFFER, V20, P558, DOI 10.1038/cdd.2012.153; Song MS, 2008, EMBO J, V27, P1863, DOI 10.1038/emboj.2008.115; Sood R, 2013, BEHAV BRAIN RES, V240, P26, DOI 10.1016/j.bbr.2012.11.009; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Sun NK, 2012, BIOCHEM J, V444, P303, DOI 10.1042/BJ20112223; Sun XX, 2011, J BIOL CHEM, V286, P22730, DOI 10.1074/jbc.M111.223651; Sun Y, 2011, J CELL SCI, V124, P1067, DOI 10.1242/jcs.068965; Taira N, 2010, J BIOL CHEM, V285, P4909, DOI 10.1074/jbc.M109.042341; Tang J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Thotala DK, 2012, CELL DEATH DIFFER, V19, P387, DOI 10.1038/cdd.2011.94; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Uldrijan S, 2007, EMBO J, V26, P102, DOI 10.1038/sj.emboj.7601469; Vlatkovic N, 2000, NUCLEIC ACIDS RES, V28, P3581, DOI 10.1093/nar/28.18.3581; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wallace M, 2006, AM BOOK REV, V27, P3, DOI 10.1353/abr.2006.0081; Wang KS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023571; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Wang XJ, 2004, FEBS LETT, V561, P195, DOI 10.1016/S0014-5793(04)00168-1; Wang YV, 2007, P NATL ACAD SCI USA, V104, P12365, DOI 10.1073/pnas.0701497104; Wang YYV, 2009, CELL CYCLE, V8, P3443, DOI 10.4161/cc.8.21.9744; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wei XL, 2003, J BIOL CHEM, V278, P29288, DOI 10.1074/jbc.M212215200; Wen W, 2014, ONCOGENE, V33, P421, DOI 10.1038/onc.2012.605; Winter M, 2004, BIOCHEMISTRY-US, V43, P16356, DOI 10.1021/bi0489255; Wu CW, 2004, NATURE, V432, P640, DOI 10.1038/nature03173; Wu H, 2011, NAT MED, V17, P347, DOI 10.1038/nm.2283; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Xiong X, 2011, ONCOGENE, V30, P1798, DOI 10.1038/onc.2010.569; Xirodimas DP, 2002, FEBS LETT, V528, P207, DOI 10.1016/S0014-5793(02)03310-0; Xu HX, 2010, J BIOL CHEM, V285, P18407, DOI 10.1074/jbc.M109.059568; Xue Y, PAIL PREDICTION ACET; Yang HY, 2007, ONCOGENE, V26, P7355, DOI 10.1038/sj.onc.1210540; Yap DBS, 1999, ONCOGENE, V18, P7681, DOI 10.1038/sj.onc.1202954; Yogosawa S, 2003, BIOCHEM BIOPH RES CO, V302, P869, DOI 10.1016/S0006-291X(03)00282-1; Zdzalik M, 2010, CELL CYCLE, V9, P4584, DOI 10.4161/cc.9.22.13871; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhang Q, 2011, J BIOL CHEM, V286, P38264, DOI 10.1074/jbc.M111.277012; Zhang X, 2013, ONCOGENE, V32, P2782, DOI 10.1038/onc.2012.289; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhao RY, 2011, J CLIN INVEST, V121, P851, DOI 10.1172/JCI44111; Zheng M, 2010, J MOL CELL BIOL, V2, P96, DOI 10.1093/jmcb/mjp038; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou S, 2011, MOL CELL BIOL, V31, P4928, DOI 10.1128/MCB.06085-11; Zhou X, 2013, ONCOGENE, V32, P388, DOI 10.1038/onc.2012.63; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014	156	64	67	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2014	33	35					4365	4376		10.1038/onc.2013.410	http://dx.doi.org/10.1038/onc.2013.410			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MR	24096477				2022-12-17	WOS:000341157800001
J	Nair, R; Roden, DL; Teo, WS; McFarland, A; Junankar, S; Ye, S; Nguyen, A; Yang, J; Nikolic, I; Hui, M; Morey, A; Shah, J; Pfefferle, AD; Usary, J; Selinger, C; Baker, LA; Armstrong, N; Cowley, MJ; Naylor, MJ; Ormandy, CJ; Lakhani, SR; Herschkowitz, JI; Perou, CM; Kaplan, W; O'Toole, SA; Swarbrick, A				Nair, R.; Roden, D. L.; Teo, W. S.; McFarland, A.; Junankar, S.; Ye, S.; Nguyen, A.; Yang, J.; Nikolic, I.; Hui, M.; Morey, A.; Shah, J.; Pfefferle, A. D.; Usary, J.; Selinger, C.; Baker, L. A.; Armstrong, N.; Cowley, M. J.; Naylor, M. J.; Ormandy, C. J.; Lakhani, S. R.; Herschkowitz, J. I.; Perou, C. M.; Kaplan, W.; O'Toole, S. A.; Swarbrick, A.			c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer	ONCOGENE			English	Article						Her2; ERBB2; Myc; cancer stem cell; transcriptomics; oncogene cooperation	EPITHELIAL-MESENCHYMAL TRANSITION; BASAL-LIKE PHENOTYPE; LIPOPROTEIN-LIPASE; TRANSGENIC MICE; CELL-PROLIFERATION; MAMMARY-CARCINOMA; EXPRESSION; IDENTIFICATION; AMPLIFICATION; ONCOGENE	The HER2 (ERBB2) and MYC genes are commonly amplified in breast cancer, yet little is known about their molecular and clinical interaction. Using a novel chimeric mammary transgenic approach and in vitro models, we demonstrate markedly increased self-renewal and tumour-propagating capability of cells transformed with Her2 and c-Myc. Coexpression of both oncoproteins in cultured cells led to the activation of a c-Myc transcriptional signature and acquisition of a self-renewing phenotype independent of an epithelial-mesenchymal transition programme or regulation of conventional cancer stem cell markers. Instead, Her2 and c-Myc cooperated to induce the expression of lipoprotein lipase, which was required for proliferation and self-renewal in vitro. HER2 and MYC were frequently coamplified in breast cancer, associated with aggressive clinical behaviour and poor outcome. Lastly, we show that in HER2(+) breast cancer patients receiving adjuvant chemotherapy (but not targeted anti-Her2 therapy), MYC amplification is associated with a poor outcome. These findings demonstrate the importance of molecular and cellular context in oncogenic transformation and acquisition of a malignant stem-like phenotype and have diagnostic and therapeutic consequences for the clinical management of HER2(+) breast cancer.	[Nair, R.; Roden, D. L.; Teo, W. S.; McFarland, A.; Junankar, S.; Ye, S.; Nguyen, A.; Yang, J.; Nikolic, I.; Hui, M.; Cowley, M. J.; Naylor, M. J.; Ormandy, C. J.; O'Toole, S. A.; Swarbrick, A.] Garvan Inst Med Res, Kinghorn Canc Ctr, Canc Res Div, Darlinghurst, NSW 2010, Australia; [Nair, R.; Roden, D. L.; Teo, W. S.; McFarland, A.; Junankar, S.; Ye, S.; Nguyen, A.; Yang, J.; Nikolic, I.; Hui, M.; Cowley, M. J.; Naylor, M. J.; Ormandy, C. J.; O'Toole, S. A.; Swarbrick, A.] Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; [Teo, W. S.; Junankar, S.; Ye, S.; Morey, A.; Naylor, M. J.; Ormandy, C. J.; Kaplan, W.; O'Toole, S. A.; Swarbrick, A.] Univ New S Wales, Fac Med, St Vincents Clin Sch, Sydney, NSW, Australia; [Morey, A.] St Vincents Hosp, Dept Anat Pathol, Darlinghurst, NSW 2010, Australia; [Shah, J.] Univ New S Wales, Sch Med Sci, Camperdown, NSW, Australia; [Pfefferle, A. D.; Perou, C. M.] Dept Pathol & Lab Med, Chapel Hill, NC USA; [Pfefferle, A. D.; Usary, J.; Perou, C. M.] Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA; [Shah, J.; Perou, C. M.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA; [Selinger, C.; O'Toole, S. A.] Royal Prince Alfred Hosp, Deptt Tissue Pathol & Diagnost Oncol, Camperdown, NSW 2050, Australia; [Baker, L. A.] Univ New S Wales, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia; [Armstrong, N.] Univ Sydney, Sch Math & Stat, Sydney, NSW 2006, Australia; [Cowley, M. J.; Kaplan, W.] Garvan Inst Med Res, Peter Wills Bioinformat Ctr, Darlinghurst, NSW 2010, Australia; [Naylor, M. J.] Univ Sydney, Sch Med Sci, Discipline Physiol, Sydney, NSW 2006, Australia; [Naylor, M. J.] Univ Sydney, Sch Med Sci, Bosch Inst, Sydney, NSW 2006, Australia; [Lakhani, S. R.] Univ Queensland, UQ Ctr Clin Res, Sch Med & Pathol Queensland, Royal Brisbane & Womens Hosp, Herston, Qld, Australia; [Herschkowitz, J. I.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [O'Toole, S. A.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia	Garvan Institute of Medical Research; Garvan Institute of Medical Research; University of New South Wales Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney; University of North Carolina; University of North Carolina Chapel Hill; University of Sydney; University of New South Wales Sydney; University of Sydney; Garvan Institute of Medical Research; University of Sydney; University of Sydney; Royal Brisbane & Women's Hospital; University of Queensland; Baylor College of Medicine; University of Sydney	Swarbrick, A (corresponding author), Garvan Inst Med Res, Kinghorn Canc Ctr, Canc Res Div, 370 Victoria St, Darlinghurst, NSW 2010, Australia.	a.swarbrick@garvan.org.au	Cowley, Mark/K-8731-2019; Swarbrick, Alexander/E-6107-2010; Lakhani, Sunil R/I-1970-2018; Armstrong, Nicola J./AAF-3045-2021; Junankar, Simon/O-2009-2019; Perou, Charles M/H-9934-2014; Junankar, Simon/B-7677-2019; Yang, Jean/D-2920-2015	Cowley, Mark/0000-0002-9519-5714; Swarbrick, Alexander/0000-0002-3051-5676; Lakhani, Sunil R/0000-0003-4067-2760; Armstrong, Nicola J./0000-0002-4477-293X; Junankar, Simon/0000-0002-3965-8278; Perou, Charles M/0000-0001-9827-2247; Nair, Radhika/0000-0002-6585-3384; Ormandy, Christopher/0000-0002-2504-7919; Shah, Jaynish/0000-0002-1089-7355; Yang, Jean/0000-0002-5271-2603; Nikolic, Iva/0000-0002-0141-5975; Morey, Adrienne/0000-0002-7823-8276	International Postgraduate Research Scholarship (IPRS); Beth Yarrow Memorial Award in Medical Science; Victoria Taylor, Sydney Breast Cancer Foundation; CCNSW; Colin Biggers & Paisley, Sydney; Early Career Fellowship from the National Breast Cancer Foundation Australia; Cancer Institute NSW Clinical Research Fellowship [10-CRF 1-07]	International Postgraduate Research Scholarship (IPRS)(Australian Government); Beth Yarrow Memorial Award in Medical Science; Victoria Taylor, Sydney Breast Cancer Foundation; CCNSW; Colin Biggers & Paisley, Sydney; Early Career Fellowship from the National Breast Cancer Foundation Australia; Cancer Institute NSW Clinical Research Fellowship	We thank Professor JM Bishop and The GW Hooper Foundation (UCSF); Nikki Ailing and Alice Boulghourjian for technical assistance with Flow cytometry and Immunohistochemistry, respectively; and Aurelie Cazet for proof reading the manuscript. WST is a recipient of an International Postgraduate Research Scholarship (IPRS) and the Beth Yarrow Memorial Award in Medical Science. We would like to acknowledge funding from Victoria Taylor, Sydney Breast Cancer Foundation, CCNSW and Colin Biggers & Paisley, Sydney. This research was supported by an Early Career Fellowship from the National Breast Cancer Foundation Australia. AS is a Career Development Fellow of the National Health and Medical Research Council of Australia. SOT is funded by the Cancer Institute NSW Clinical Research Fellowship 10-CRF 1-07.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alonso SR, 2007, CANCER RES, V67, P3450, DOI 10.1158/0008-5472.CAN-06-3481; Axelrod R, 2006, P NATL ACAD SCI USA, V103, P13474, DOI 10.1073/pnas.0606053103; Bagaria SP, 2012, ANN SURG ONCOL, V19, P935, DOI 10.1245/s10434-011-2032-5; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; Bilban M, 2006, LEUKEMIA, V20, P1080, DOI 10.1038/sj.leu.2404220; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Carter SA, 2012, BRIT J CANCER, V107, P739, DOI 10.1038/bjc.2012.301; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Danilo C, 2012, CURR OPIN PHARMACOL, V12, P677, DOI 10.1016/j.coph.2012.07.009; Deming SL, 2000, BRIT J CANCER, V83, P1688, DOI 10.1054/bjoc.2000.1522; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hardy KM, 2010, J MAMMARY GLAND BIOL, V15, P191, DOI 10.1007/s10911-010-9172-2; Heintel D, 2005, LEUKEMIA, V19, P1216, DOI 10.1038/sj.leu.2403748; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hynes NE, 2001, J MAMMARY GLAND BIOL, V6, P141, DOI 10.1023/A:1009528918064; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Kim YH, 2006, ONCOGENE, V25, P130, DOI 10.1038/sj.onc.1208997; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Laudadio J, 2007, EXPERT REV MOL DIAGN, V7, P53, DOI 10.1586/14737159.7.1.53; Lee T, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000013; Liu H, 2008, HUM PATHOL, V39, P167, DOI 10.1016/j.humpath.2007.06.012; Liu JC, 2007, CANCER RES, V67, P8671, DOI 10.1158/0008-5472.CAN-07-1486; Llaverias G, 2011, AM J PATHOL, V178, P402, DOI 10.1016/j.ajpath.2010.11.005; Lo PK, 2012, ONCOGENE, V31, P2614, DOI [10.1038/onc.2012.147, 10.1038/onc.2011.439]; Lopez-Knowles E, 2010, INT J CANCER, V126, P1121, DOI 10.1002/ijc.24831; Lopez-Knowles E, 2010, CANCER EPIDEM BIOMAR, V19, P301, DOI 10.1158/1055-9965.EPI-09-0741; Magnifico A, TUMOR INITIATING CEL; Matthews L, 2009, NUCLEIC ACIDS RES, V37, pD619, DOI 10.1093/nar/gkn863; Mead JR, 2002, J MOL MED, V80, P753, DOI 10.1007/s00109-002-0384-9; Millar EKA, 2009, BRIT J CANCER, V100, P123, DOI 10.1038/sj.bjc.6604809; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; O'Toole SA, 2011, CANCER RES, V71, P4002, DOI 10.1158/0008-5472.CAN-10-3738; Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008; Park K, 2005, HUM PATHOL, V36, P634, DOI 10.1016/j.humpath.2005.04.016; Perez E, 2009, CANC RES S, V69, P56; Perez EA, 2011, J CLIN ONCOL, V29, P651, DOI 10.1200/JCO.2010.30.2125; Persons DL, 1997, MODERN PATHOL, V10, P720; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Roberts PJ, 2012, CLIN CANCER RES, V18, P5290, DOI 10.1158/1078-0432.CCR-12-0563; Rosenbloom KR, 2013, NUCLEIC ACIDS RES, V41, pD56, DOI 10.1093/nar/gks1172; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shachaf CM, 2008, CANCER RES, V68, P5132, DOI 10.1158/0008-5472.CAN-07-6192; Singh SK, 2003, CANCER RES, V63, P5821; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Stoelzle Tina, 2009, BMC Biol, V7, P63, DOI 10.1186/1741-7007-7-63; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Swarbrick A, 2008, P NATL ACAD SCI USA, V105, P5402, DOI 10.1073/pnas.0801505105; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Welm AL, 2005, P NATL ACAD SCI USA, V102, P4324, DOI 10.1073/pnas.0500470102; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Wolfer A, 2010, P NATL ACAD SCI USA, V107, P3698, DOI 10.1073/pnas.0914203107; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Zhang WZ, 2010, P NATL ACAD SCI USA, V107, P18956, DOI 10.1073/pnas.1013420107	82	64	68	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2014	33	30					3992	4002		10.1038/onc.2013.368	http://dx.doi.org/10.1038/onc.2013.368			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8NA	24056965				2022-12-17	WOS:000339394700011
J	Lin, S; Tian, L; Shen, H; Gu, Y; Li, JL; Chen, Z; Sun, X; You, MJ; Wu, L				Lin, S.; Tian, L.; Shen, H.; Gu, Y.; Li, J-L; Chen, Z.; Sun, X.; You, M. James; Wu, L.			DDX5 is a positive regulator of oncogenic NOTCH1 signaling in T cell acute lymphoblastic leukemia	ONCOGENE			English	Article						NOTCH; MAML1; DDX5; T-ALL; leukemia	RNA HELICASES P68; TRANSCRIPTIONAL COACTIVATOR; SOLID TUMORS; MASTERMIND; PROTEINS; CANCER; IDENTIFICATION; ACTIVATION; DIFFERENTIATION; COREGULATORS	Notch signaling is a highly conserved cell-cell communication pathway regulating normal development and tissue homeostasis. Aberrant Notch signaling represents an important oncogenic mechanism for T cell acute lymphoblastic leukemia (T-ALL), an aggressive subset of the most common malignant childhood cancer ALL. Therefore, understanding the molecular regulation of Notch signaling is critical to identify new approaches to block aberrant Notch oncogenic activity. The family of three MAML transcriptional coactivators is crucial for Notch signaling activation. The prototypic member MAML1 is the major coactivator that regulates Notch oncogenic activities in leukemic cells. However, the molecular basis underlying MAML1 coactivator function that contributes to Notch signaling remains unclear. In this study, we performed proteomic studies and identified DDX5, an ATP-dependent DEAD-box RNA helicase, as a component of the MAML1 protein complex. DDX5 interacts with MAML1 in vitro and in vivo, and is associated with the endogenous NOTCH1 transcription activation complex in human T-ALL leukemic cells. Lentivirus-mediated short-hairpin RNA knock-down of DDX5 resulted in decreased expression of Notch target genes, reduced cell proliferation and increased apoptosis in cultured human leukemic cells with constitutive activation of Notch signaling. Also, DDX5 depletion inhibited the growth of human leukemia xenograft in nude mice. Moreover, DDX5 is highly expressed in primary human T-ALL leukemic cells based on the analyses of Oncomine and GEO databases, and Immunohistochemical staining. Our overall findings revealed a critical role of DDX5 in promoting efficient Notch-mediated transcription in leukemic cells, suggesting that DDX5 might be critical for NOTCH1-mediated T-ALL pathogenesis and thus is a potential new target for modulating the Notch signaling in leukemia.	[Lin, S.; Tian, L.; Shen, H.; Gu, Y.; Chen, Z.; Wu, L.] Univ Florida, Dept Mol Genet & Microbiol, Shands Canc Ctr, Gainesville, FL 32610 USA; [Tian, L.; Shen, H.] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China; [Li, J-L] Sanford Burnham Med Res Inst Lake Nona, Orlando, FL USA; [Sun, X.; You, M. James] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	State University System of Florida; University of Florida; Sun Yat Sen University; Sanford Burnham Prebys Medical Discovery Institute; University of Texas System; UTMD Anderson Cancer Center	Wu, L (corresponding author), Univ Florida, Dept Mol Genet & Microbiol, Shands Canc Ctr, 2033 Mowry Rd, Gainesville, FL 32610 USA.	lzwu@ufl.edu	Li, J L/E-6100-2018; chen, zirong/S-4042-2016; Li, Jian-Liang/AAE-9315-2019	Li, J L/0000-0002-6487-081X; chen, zirong/0000-0002-0589-4619; Li, Jian-Liang/0000-0002-6487-081X	University of Florida Shands Cancer Center Startup fund; STOP! Children's Cancer, Inc.; Florida Bankhead Coley Cancer Research Program [2BB11, 1BF04]; National Natural Science Foundation of China [81170891]; NIH/NCI [RO1 CA164346]; Developmental Research Awards in Leukemia SPORE [CA100632]; UT MDACC Physician Scientist Award; American Cancer Society IRG; UT MDACC IRG; Ladies Leukemia League; NATIONAL CANCER INSTITUTE [R01CA164346, P30CA016672, P50CA100632] Funding Source: NIH RePORTER	University of Florida Shands Cancer Center Startup fund; STOP! Children's Cancer, Inc.; Florida Bankhead Coley Cancer Research Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Developmental Research Awards in Leukemia SPORE; UT MDACC Physician Scientist Award; American Cancer Society IRG(American Cancer Society); UT MDACC IRG; Ladies Leukemia League; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Vittorio Sartorelli for kindly providing us with DDX5 expression constructs, Marda Jorgensen for helping with immunohistochemical staining and Jameson Kuang for careful reading of the manuscript. This work was supported by the University of Florida Shands Cancer Center Startup fund, STOP! Children's Cancer, Inc., and Florida Bankhead Coley Cancer Research Program (2BB11 and 1BF04 to LW). HS was supported by the National Natural Science Foundation of China (81170891). MJY was supported by NIH/NCI RO1 CA164346, Developmental Research Awards in Leukemia SPORE CA100632, UT MDACC Physician Scientist Award, American Cancer Society IRG, UT MDACC IRG and Ladies Leukemia League.	Artayanis-Tsakonas S, 2010, CURR TOP DEV BIOL, V92, P1, DOI 10.1016/S0070-2153(10)92001-2; Aster JC, 2011, J PATHOL, V223, P262, DOI 10.1002/path.2789; Caretti G, 2007, CELL CYCLE, V6, P1172, DOI 10.4161/cc.6.10.4228; Caretti G, 2006, DEV CELL, V11, P547, DOI 10.1016/j.devcel.2006.08.003; Chiang MY, 2008, J CLIN INVEST, V118, P3181, DOI 10.1172/JCI35090; Clark EL, 2008, CANCER RES, V68, P7938, DOI 10.1158/0008-5472.CAN-08-0932; Cohen AA, 2008, SCIENCE, V322, P1511, DOI 10.1126/science.1160165; Endoh H, 1999, MOL CELL BIOL, V19, P5363; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Fuller-Pace FV, 2008, BIOCHEM SOC T, V36, P609, DOI 10.1042/BST0360609; Fuller-Pace FV, 2011, FUTURE ONCOL, V7, P239, DOI 10.2217/FON.11.1; Germann S, 2012, ONCOGENE, V31, P4536, DOI 10.1038/onc.2011.618; Gu Y, 2012, ONCOGENE, V31, P469, DOI 10.1038/onc.2011.247; Guo DM, 2009, LEUKEMIA RES, V33, P678, DOI 10.1016/j.leukres.2008.10.026; Haferlach T, 2010, J CLIN ONCOL, V28, P2529, DOI 10.1200/JCO.2009.23.4732; Hansson ML, 2009, NUCLEIC ACIDS RES, V37, P2996, DOI 10.1093/nar/gkp163; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; Homminga I, 2011, CANCER CELL, V19, P484, DOI 10.1016/j.ccr.2011.02.008; Janknecht R, 2010, AM J TRANSL RES, V2, P223; Jensen ED, 2008, J CELL BIOCHEM, V103, P1438, DOI 10.1002/jcb.21526; Koch U, 2010, CURR TOP DEV BIOL, V92, P411, DOI 10.1016/S0070-2153(10)92013-9; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Lin SE, 2002, J BIOL CHEM, V277, P50612, DOI 10.1074/jbc.M209529200; McElhinny AS, 2008, ONCOGENE, V27, P5138, DOI 10.1038/onc.2008.228; Moellering RE, 2009, NATURE, V462, P182, DOI 10.1038/nature08543; Nicol SM, 2010, METHODS MOL BIOL, V587, P265, DOI 10.1007/978-1-60327-355-8_19; Paganin M, 2011, BLOOD REV, V25, P83, DOI 10.1016/j.blre.2010.09.004; Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035; Ribeiro MSJ, 2009, NUCLEIC ACIDS RES, V37, P6691, DOI 10.1093/nar/gkp724; Van Vlierberghe P, 2011, J EXP MED, V208, P2571, DOI 10.1084/jem.20112239; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Yang L, 2007, ONCOGENE, V26, P6082, DOI 10.1038/sj.onc.1210427	37	64	71	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2013	32	40					4845	4853		10.1038/onc.2012.482	http://dx.doi.org/10.1038/onc.2012.482			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23108395	Green Accepted			2022-12-17	WOS:000325274700013
J	Bernard, H; Garmy-Susini, B; Ainaoui, N; Van Den Berghe, L; Peurichard, A; Javerzat, S; Bikfalvi, A; Lane, DP; Bourdon, JC; Prats, AC				Bernard, H.; Garmy-Susini, B.; Ainaoui, N.; Van Den Berghe, L.; Peurichard, A.; Javerzat, S.; Bikfalvi, A.; Lane, D. P.; Bourdon, J. C.; Prats, A-C			The p53 isoform, Delta 133p53 alpha, stimulates angiogenesis and tumour progression	ONCOGENE			English	Article						angiogenesis; p53; isoform; cancer; glioblastoma	EXPRESSION; DELTA-113P53; SURVIVAL; CANCER; GENE	The tumour suppressor p53, involved in DNA repair, cell cycle arrest and apoptosis, also inhibits blood vessel formation, that is, angiogenesis, a process strongly contributing to tumour development. The p53 gene expresses 12 different proteins (isoforms), including TAp53 (p53 (or p53 alpha), p53 beta and p53 gamma) and Delta 133p53 isoforms (Delta 133p53 alpha, Delta 133p53 beta and Delta 133p53 gamma). The Delta 133p53 alpha isoform was shown to modulate p53 transcriptional activity and is overexpressed in various human tumours. However, its role in tumour progression is still unexplored. In the present study, we examined the involvement of Delta 133p53 isoforms in tumoural angiogenesis and tumour growth in the highly angiogenic human glioblastoma U87. Our data show that conditioned media from U87 cells depleted for Delta 133p53 isoforms block endothelial cell migration and tubulogenesis without affecting endothelial cell proliferation in vitro. The Delta 133p53 depletion in U2OS osteosarcoma cells resulted in a similar angiogenesis blockade. Furthermore, using conditioned media from U87 cells ectopically expressing each Delta 133p53 isoform, we determined that Delta 133p53 alpha and Delta 133p53 gamma but not Delta 133p53 beta, stimulate angiogenesis. Our in vivo data using the chicken chorio-allantoic membrane and mice xenografts establish that angiogenesis and growth of glioblastoma U87 tumours are inhibited upon depletion of Delta 133p53 isoforms. By TaqMan low-density array, we show that alteration of expression ratio of Delta 133p53 and TAp53 isoforms differentially regulates angiogenic gene expression with Delta 133p53 isoforms inducing pro-angiogenic gene expression and repressing anti-angiogenic gene expression. Oncogene (2013) 32, 2150-2160; doi:10.1038/onc.2012.242; published online 25 June 2012	[Bernard, H.; Garmy-Susini, B.; Ainaoui, N.; Van Den Berghe, L.; Peurichard, A.; Prats, A-C] Univ Toulouse, Lab Translat Control & Gene Therapy Vasc Dis, Inst Malad Metab & Cardiovasc, UPS,TRADGENE,EA4554, Toulouse, France; [Bernard, H.; Lane, D. P.; Bourdon, J. C.] Univ Dundee, Dept Surg & Mol Oncol, Dundee, Scotland; [Garmy-Susini, B.] Fac Med Toulouse, INSERM, U1037, F-31073 Toulouse, France; [Van Den Berghe, L.] INSERM, U1048, F-31432 Toulouse, France; [Javerzat, S.; Bikfalvi, A.] INSERM, U920, Talence, France; [Javerzat, S.; Bikfalvi, A.] Univ Bordeaux 1, Angiogenesis & Canc Microenvironm Lab, F-33405 Talence, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Dundee; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Prats, AC (corresponding author), Univ Toulouse 3, Inst Malad Metab & Cardiovasc, Lab Translat Control & Gene Therapy Vasc Dis, TRADGENE,EA 4554, 1 Ave Jean Poulhes,BP 84225, F-31432 Toulouse 4, France.	Anne-Catherine.Prats@inserm.fr	VAN DEN BERGHE, Loïc/X-6705-2019; Prats, Anne-Catherine/E-5051-2016; Garmy-Susini, Barbara/B-9735-2014; Petibois, Cyril/L-9049-2014; JC, Bourdon/A-4439-2008	Prats, Anne-Catherine/0000-0002-5282-3776; Petibois, Cyril/0000-0001-9027-4192; JC, Bourdon/0000-0003-4623-9386; Lane, David/0000-0003-0551-3545; GARMY-SUSINI, Barbara/0000-0001-6100-2294	Association pour la Recherche sur le Cancer; Canceropole GSO; INCA; Fondation de l'Avenir; Association Francaise contre les Myopathies (AFM); Ligue Nationale Contre Le Cancer; ARC; Fondation pour la Recherche Medicale; AFM; Cancer Research UK [C8/A6613]	Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Canceropole GSO; INCA(Institut National du Cancer (INCA) France); Fondation de l'Avenir; Association Francaise contre les Myopathies (AFM)(Association Francaise contre les Myopathies); Ligue Nationale Contre Le Cancer(Ligue nationale contre le cancer); ARC(Australian Research Council); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); AFM(Association Francaise contre les Myopathies); Cancer Research UK(Cancer Research UK)	We thank A Delluc-Clavieres and F Pujol for technical assistance, Y Barreira, S Legonidec (animal production and phenotyping facilities of ANEXPLO platform, Inserm US006), F Gross (Vector facility), J-J Maoret (GeT TQ plateau of the Genotoul Genome-Transcriptome platform), M Pucelle (CAM facility) and C Touriol (ABAE and HUVEC cells). This work was supported by grants from Association pour la Recherche sur le Cancer, Canceropole GSO, INCA, Fondation de l'Avenir, Association Francaise contre les Myopathies (AFM). HB had a fellowship from the Ligue Nationale Contre Le Cancer, then from the ARC. BGS had a postdoc fellowship from the Fondation pour la Recherche Medicale, NA had a thesis fellowship from AFM. DPL and JCB were supported by Cancer Research UK (grant number: C8/A6613).	Aoubala M, 2011, CELL DEATH DIFFER, V18, P248, DOI 10.1038/cdd.2010.91; Bossard C, 2004, CANCER RES, V64, P7507, DOI 10.1158/0008-5472.CAN-04-0287; Bourdon JC, 2007, BRIT J CANCER, V97, P277, DOI 10.1038/sj.bjc.6603886; Bourdon JC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2811; Chen J, 2009, GENE DEV, V23, P278, DOI 10.1101/gad.1761609; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Davidson WR, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-102; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Folkman Judah, 2006, Sci STKE, V2006, ppe35, DOI 10.1126/stke.3542006pe35; Fraisl P, 2009, DEV CELL, V16, P167, DOI 10.1016/j.devcel.2009.01.003; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; Giuriato S, 2006, P NATL ACAD SCI USA, V103, P16266, DOI 10.1073/pnas.0608017103; Hagedorn M, 2005, P NATL ACAD SCI USA, V102, P1643, DOI 10.1073/pnas.0408622102; Jensen Mette Munk, 2008, BMC Med Imaging, V8, P16, DOI 10.1186/1471-2342-8-16; Khoury Marie P, 2011, Genes Cancer, V2, P453, DOI 10.1177/1947601911408893; Marcel V, 2010, ONCOGENE, V29, P2691, DOI 10.1038/onc.2010.26; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Naumov GN, 2006, CELL CYCLE, V5, P1779, DOI 10.4161/cc.5.16.3018; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Pal S, 2001, CANCER RES, V61, P6952; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Ravi R, 2000, GENE DEV, V14, P34; Saidi A, 2008, INT J CANCER, V122, P2187, DOI 10.1002/ijc.23313; Sirven A, 2001, MOL THER, V3, P438, DOI 10.1006/mthe.2001.0282; Teodoro JG, 2007, J MOL MED-JMM, V85, P1175, DOI 10.1007/s00109-007-0221-2; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; Wong MLH, 2009, J CLIN NEUROSCI, V16, P1119, DOI 10.1016/j.jocn.2009.02.009	29	64	67	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2013	32	17					2150	2160		10.1038/onc.2012.242	http://dx.doi.org/10.1038/onc.2012.242			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	132JD	22733133	Green Submitted			2022-12-17	WOS:000318062800004
J	Pareja, F; Ferraro, DA; Rubin, C; Cohen-Dvashi, H; Zhang, F; Aulmann, S; Ben-Chetrit, N; Pines, G; Navon, R; Crosetto, N; Kostler, W; Carvalho, S; Lavi, S; Schmitt, F; Dikic, I; Yakhini, Z; Sinn, P; Mills, GB; Yarden, Y				Pareja, F.; Ferraro, D. A.; Rubin, C.; Cohen-Dvashi, H.; Zhang, F.; Aulmann, S.; Ben-Chetrit, N.; Pines, G.; Navon, R.; Crosetto, N.; Koestler, W.; Carvalho, S.; Lavi, S.; Schmitt, F.; Dikic, I.; Yakhini, Z.; Sinn, P.; Mills, G. B.; Yarden, Y.			Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression	ONCOGENE			English	Article						gene amplification; deubiquitination; endocytosis; growth factor	EPIDERMAL-GROWTH-FACTOR; FACTOR RECEPTOR; UBIQUITIN RECOGNITION; BINDING DOMAINS; BREAST-CANCER; ENDOCYTOSIS; DEGRADATION; PROTEIN; AMSH; MONOUBIQUITINATION	Once stimulated, the epidermal growth factor receptor (EGFR) undergoes self-phosphorylation, which, on the one hand, instigates signaling cascades, and on the other hand, recruits CBL ubiquitin ligases, which mark EGFRs for degradation. Using RNA interference screens, we identified a deubiquitinating enzyme, Cezanne-1, that opposes receptor degradation and enhances EGFR signaling. These functions require the catalytic-and ubiquitin-binding domains of Cezanne-1, and they involve physical interactions and transphosphorylation of Cezanne-1 by EGFR. In line with the ability of Cezanne-1 to augment EGF-induced growth and migration signals, the enzyme is overexpressed in breast cancer. Congruently, the corresponding gene is amplified in approximately one third of mammary tumors, and high transcript levels predict an aggressive disease course. In conclusion, deubiquitination by Cezanne-1 curtails degradation of growth factor receptors, thereby promotes oncogenic growth signals.	[Pareja, F.; Ferraro, D. A.; Rubin, C.; Cohen-Dvashi, H.; Ben-Chetrit, N.; Pines, G.; Koestler, W.; Carvalho, S.; Lavi, S.; Yarden, Y.] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; [Zhang, F.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Aulmann, S.; Sinn, P.] Heidelberg Univ, Inst Pathol, D-6900 Heidelberg, Germany; [Navon, R.; Yakhini, Z.] Agilent Labs, Tel Aviv, Israel; [Crosetto, N.; Dikic, I.] Goethe Univ Frankfurt, Frankfurt Inst Mol Life Sci, Frankfurt, Germany; [Crosetto, N.; Dikic, I.] Goethe Univ Frankfurt, Inst Biochem 2, Frankfurt, Germany; [Carvalho, S.; Schmitt, F.] Univ Porto, IPATIMUP Inst Mol Pathol & Immunol, P-4100 Oporto, Portugal; [Carvalho, S.; Schmitt, F.] Univ Porto, Fac Med, P-4100 Oporto, Portugal; [Yakhini, Z.] Technion Israel Inst Technol, Dept Comp Sci, IL-32000 Haifa, Israel	Weizmann Institute of Science; University of Texas System; UTMD Anderson Cancer Center; Ruprecht Karls University Heidelberg; Agilent Technologies; Goethe University Frankfurt; Goethe University Frankfurt; Universidade do Porto; Universidade do Porto; Technion Israel Institute of Technology	Yarden, Y (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, Max & Lillian Candiotty Bldg,Room 312,Herzl St 1, IL-76100 Rehovot, Israel.	yosef.yarden@weizmann.ac.il	Sinn, Hans-Peter/C-5661-2008; YARDEN, YOSEF/K-1467-2012; Dikic, Ivan/O-4650-2015; Pines, Gur/X-7501-2019; Schmitt, Fernando/A-5270-2008	Sinn, Hans-Peter/0000-0003-2836-6699; Dikic, Ivan/0000-0001-8156-9511; Pines, Gur/0000-0002-1757-6722; Schmitt, Fernando/0000-0002-3711-8681; Yakhini, Zohar/0000-0002-0420-5412; Schmitt, Fernando/0000-0003-1006-6946	National Cancer Institute [5R37CA072981, CCSG, P30 CA16672]; European Commission; German-Israeli Project Cooperation; Israel Cancer Research Fund; Dr Miriam and Sheldon G Adelson Medical Research Foundation; MD Moross Institute for Cancer Research; NATIONAL CANCER INSTITUTE [R01CA123219, R37CA072981, P30CA016672, P01CA099031, P50CA098258] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); European Commission(European CommissionEuropean Commission Joint Research Centre); German-Israeli Project Cooperation; Israel Cancer Research Fund; Dr Miriam and Sheldon G Adelson Medical Research Foundation; MD Moross Institute for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Tissue Bank of the National Center for Tumor Diseases, Heidelberg University Hospital (Heidelberg, Germany). Our research is supported by grants from the National Cancer Institute (5R37CA072981, CCSG and P30 CA16672), the European Commission, the German-Israeli Project Cooperation, the Israel Cancer Research Fund, the Dr Miriam and Sheldon G Adelson Medical Research Foundation and the MD Moross Institute for Cancer Research. YY is the incumbent of the Harold and Zelda Goldenberg Professorial Chair.	Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Bowers K, 2006, J BIOL CHEM, V281, P5094, DOI 10.1074/jbc.M508632200; Caswell PT, 2008, J CELL BIOL, V183, P143, DOI 10.1083/jcb.200804140; Cheng KW, 2004, NAT MED, V10, P1251, DOI 10.1038/nm1125; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; Courjal F, 1997, CANCER RES, V57, P4368; Crosetto N, 2008, J BIOL CHEM, V283, P35173, DOI 10.1074/jbc.M803219200; Dikic I, 2009, NAT REV MOL CELL BIO, V10, P659, DOI 10.1038/nrm2767; Duex JE, 2009, MOL BIOL CELL, V20, P1833, DOI 10.1091/mbc.E08-08-0880; Enesa K, 2008, J BIOL CHEM, V283, P7036, DOI 10.1074/jbc.M708690200; Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200; Fehrenbacher N, 2009, MOL ONCOL, V3, P297, DOI 10.1016/j.molonc.2009.06.004; Frosi Y, 2010, J CELL BIOL, V189, P557, DOI 10.1083/jcb.201002032; Goh LK, 2010, J CELL BIOL, V189, P871, DOI 10.1083/jcb.201001008; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hawthorn L, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-460; Hou QS, 2008, CANCER RES, V68, P4623, DOI 10.1158/0008-5472.CAN-07-5870; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Katz M, 2002, TRAFFIC, V3, P740, DOI 10.1034/j.1600-0854.2002.31006.x; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Lee S, 2006, NAT STRUCT MOL BIOL, V13, P264, DOI 10.1038/nsmb1064; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Ma YM, 2007, J BIOL CHEM, V282, P9805, DOI 10.1074/jbc.M611635200; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; McCullough J, 2004, J CELL BIOL, V166, P487, DOI 10.1083/jcb.200401141; Mills GB, 2009, J CLIN INVEST, V119, P2123, DOI 10.1172/JCI40256; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Nakamura M, 2006, GENES CELLS, V11, P593, DOI 10.1111/j.1365-2443.2006.00963.x; Orsetti B, 2006, BRIT J CANCER, V95, P1439, DOI 10.1038/sj.bjc.6603433; Palmieri D, 2006, BREAST CANCER RES TR, V100, P127, DOI 10.1007/s10549-006-9244-6; Penengo L, 2006, CELL, V124, P1183, DOI 10.1016/j.cell.2006.02.020; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Row PE, 2006, J BIOL CHEM, V281, P12618, DOI 10.1074/jbc.M512615200; Sacco JJ, 2010, IUBMB LIFE, V62, P140, DOI 10.1002/iub.300; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Tarcic G, 2009, CURR BIOL, V19, P1788, DOI 10.1016/j.cub.2009.09.048; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Zhang JQ, 2009, J CLIN INVEST, V119, P2171, DOI 10.1172/JCI37622	40	64	72	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	43					4599	4608		10.1038/onc.2011.587	http://dx.doi.org/10.1038/onc.2011.587			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029WP	22179831	Bronze, Green Accepted			2022-12-17	WOS:000310528200003
J	Schepeler, T; Holm, A; Halvey, P; Nordentoft, I; Lamy, P; Riising, EM; Christensen, LL; Thorsen, K; Liebler, DC; Helin, K; Orntoft, TF; Andersen, CL				Schepeler, T.; Holm, A.; Halvey, P.; Nordentoft, I.; Lamy, P.; Riising, E. M.; Christensen, L. L.; Thorsen, K.; Liebler, D. C.; Helin, K.; Orntoft, T. F.; Andersen, C. L.			Attenuation of the beta-catenin/TCF4 complex in colorectal cancer cells induces several growth-suppressive microRNAs that target cancer promoting genes	ONCOGENE			English	Article						microRNA; Wnt; cancer; miR-30e-3p; PIK3C2A; TCF4	ADENOMATOUS POLYPOSIS-COLI; BETA-CATENIN; PROSTATE-CANCER; EXPRESSION; PROLIFERATION; BLADDER; CONTRIBUTES; OSTEOBLASTS; DOWNSTREAM; TRANSITION	Aberrant activation of the Wnt signaling pathway is causally involved in the formation of most colorectal cancers (CRCs). Although detailed knowledge exists regarding Wnt-regulated protein-coding genes, much less is known about the possible involvement of non-coding RNAs. Here we used TaqMan Array MicroRNA Cards, capable of detecting 664 unique human microRNAs (miRNAs), to describe changes of the miRNA transcriptome following disruption of beta-catenin/TCF4 activity in DLD1 CRC cells. Most miRNAs appeared to respond independent of host gene regulation and proximal TCF4 chromatin occupancy as inferred from expression microarray and ChIP-chip data. A module of miRNAs induced by abrogated Wnt signaling in vitro was downregulated in two independent series of human primary CRCs (n = 76) relative to normal adjacent mucosa (n = 34). Several of these miRNAs (miR-145, miR-126, miR-30e-3p and miR-139-5p) markedly inhibited CRC cell growth in vitro when ectopically expressed. By using an integrative approach of proteomics and expression microarrays, we found numerous mRNAs and proteins to be affected by ectopic miR-30e-3p levels. This included HELZ and PIK3C2A that were directly repressed by several miRNA binding sites as confirmed by luciferase reporter assays in combination with mutational analyses. Finally, small interfering RNA-mediated downregulation of PIK3C2A, but not HELZ, was sufficient on its own to restrict CRC cell growth. Collectively, our study demonstrates that multiple miRNAs are upregulated as a consequence of forced attenuation of Wnt signaling in CRC cells, and some of these miRNAs inhibit cell growth with concomitant suppression of several growth-stimulatory cancer-related genes. Oncogene (2012) 31, 2750-2760; doi: 10.1038/onc.2011.453; published online 3 October 2011	[Schepeler, T.; Holm, A.; Nordentoft, I.; Lamy, P.; Christensen, L. L.; Thorsen, K.; Orntoft, T. F.; Andersen, C. L.] Aarhus Univ Hosp, Dept Mol Med MOMA, DK-8200 Aarhus N, Denmark; [Halvey, P.; Liebler, D. C.] Vanderbilt Univ, Sch Med, Dept Biochem, Jim Ayers Inst Precanc Detect & Diag, Nashville, TN 37212 USA; [Riising, E. M.; Helin, K.] Univ Copenhagen, BRIC, Copenhagen, Denmark	Aarhus University; Vanderbilt University; University of Copenhagen	Andersen, CL (corresponding author), Aarhus Univ Hosp, Dept Mol Med MOMA, Brendstrupgaardsvej 100, DK-8200 Aarhus N, Denmark.	cla@ki.au.dk	Nordentoft, Iver/C-6345-2017; Holm, Anja/AAN-7702-2020; Helin, Kristian/K-2526-2019; Andersen, Claus L/C-1477-2017; Helin, Kristian/HDM-8306-2022; Andersen, Claus Lindbjerg/A-9217-2012	Helin, Kristian/0000-0003-1975-6097; Liebler, Daniel/0000-0002-7873-3031; Andersen, Claus Lindbjerg/0000-0002-7406-2103; Holm, Anja/0000-0001-8796-1872; Madi Riising, Eva/0000-0003-3152-5769; Nordentoft, Iver Kristiansen/0000-0003-4856-4086	Desiree and Niels Yde's Foundation; John and Birthe Meyer Foundation; Lundbeck Foundation; Danish Council for Independent Research Medical Sciences; Danish Council for Strategic Research; Danish Agency for Science, Technology and Innovation; Danish Ministry of the Interior and Health	Desiree and Niels Yde's Foundation; John and Birthe Meyer Foundation; Lundbeck Foundation(Lundbeckfonden); Danish Council for Independent Research Medical Sciences(Det Frie Forskningsrad (DFF)); Danish Council for Strategic Research(Danske Strategiske Forskningsrad (DSF)); Danish Agency for Science, Technology and Innovation; Danish Ministry of the Interior and Health	We thank Misti Martinez, Hanne Steen, Inge-Lis Thorsen and Pamela Celis for technical assistance. TOPflash/FOPflash plasmids were kindly provided by Philippe Blache, and the CLINT1 luciferase reporter plasmid was generously provided by Jesper B Bramsen. This work was supported by the Desiree and Niels Yde's Foundation, the John and Birthe Meyer Foundation, the Lundbeck Foundation, the Danish Council for Independent Research Medical Sciences, the Danish Council for Strategic Research, the Danish Agency for Science, Technology and Innovation, and the Danish Ministry of the Interior and Health.	Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Blauwkamp TA, 2008, EMBO J, V27, P1436, DOI 10.1038/emboj.2008.80; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Chen F, 2010, ONCOL REP, V23, P1457, DOI 10.3892/or_00000784; Chi SW, 2009, NATURE, V460, P479, DOI 10.1038/nature08170; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Cselenyi CS, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.18pe10; Dehner M, 2008, J BIOL CHEM, V283, P19201, DOI 10.1074/jbc.M710366200; Ding L, 2010, CELL RES, V20, P784, DOI 10.1038/cr.2010.79; Elis W, 2008, MOL CANCER RES, V6, P614, DOI 10.1158/1541-7786.MCR-07-0262; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497; Gregorieff A, 2005, GASTROENTEROLOGY, V129, P626, DOI 10.1053/j.gastro.2005.06.007; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Guo CG, 2008, GENE CHROMOSOME CANC, V47, P939, DOI 10.1002/gcc.20596; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Hatzis P, 2008, MOL CELL BIOL, V28, P2732, DOI 10.1128/MCB.02175-07; Heintzman ND, 2009, CURR OPIN GENET DEV, V19, P541, DOI 10.1016/j.gde.2009.09.006; Henson BJ, 2009, GENE CHROMOSOME CANC, V48, P569, DOI 10.1002/gcc.20666; Herranz H, 2008, EMBO J, V27, P1633, DOI 10.1038/emboj.2008.84; Ichimi T, 2009, INT J CANCER, V125, P345, DOI 10.1002/ijc.24390; Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137; Kapinas K, 2009, J CELL BIOCHEM, V108, P216, DOI 10.1002/jcb.22243; Kato M, 2009, NAT CELL BIOL, V11, P881, DOI 10.1038/ncb1897; Labbe E, 2007, CANCER RES, V67, P75, DOI 10.1158/0008-5472.CAN-06-2559; Li HB, 2009, J BIOL CHEM, V284, P2012, DOI 10.1074/jbc.M805612200; Liao Y, 2010, CELL MOL LIFE SCI, V67, P2969, DOI 10.1007/s00018-010-0366-y; Martello G, 2007, NATURE, V449, P183, DOI 10.1038/nature06100; Medici D, 2008, MOL BIOL CELL, V19, P4875, DOI 10.1091/mbc.E08-05-0506; Nagel R, 2008, CANCER RES, V68, P5795, DOI 10.1158/0008-5472.CAN-08-0951; Ng SKL, 2009, BIOCHEM BIOPH RES CO, V387, P310, DOI 10.1016/j.bbrc.2009.07.013; Noonan EJ, 2009, ONCOGENE, V28, P1714, DOI 10.1038/onc.2009.19; Ostenfeld MS, 2010, ONCOGENE, V29, P1073, DOI 10.1038/onc.2009.395; Railo A, 2009, EXP CELL RES, V315, P2690, DOI 10.1016/j.yexcr.2009.06.021; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Saydam O, 2009, MOL CELL BIOL, V29, P5923, DOI 10.1128/MCB.00332-09; Schepeler T, 2008, CANCER RES, V68, P6416, DOI 10.1158/0008-5472.CAN-07-6110; Schneikert J, 2007, GUT, V56, P417, DOI 10.1136/gut.2006.093310; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Slaby O, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-102; Small EM, 2010, P NATL ACAD SCI USA, V107, P4218, DOI 10.1073/pnas.1000300107; Theisen H, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000142; Thorsen K, 2008, MOL CELL PROTEOMICS, V7, P1214, DOI 10.1074/mcp.M700590-MCP200; Tsuchiya K, 2007, GASTROENTEROLOGY, V132, P208, DOI 10.1053/j.gastro.2006.10.031; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039; Vlad A, 2008, CELL SIGNAL, V20, P795, DOI 10.1016/j.cellsig.2007.10.031; Wang X, 2009, BIOCHEM BIOPH RES CO, V387, P376, DOI 10.1016/j.bbrc.2009.07.034; Waterman ML, 2004, CANCER METAST REV, V23, P41, DOI 10.1023/A:1025858928620; Weitz J, 2005, LANCET, V365, P153, DOI 10.1016/S0140-6736(05)17706-X; Wu FT, 2009, CLIN CANCER RES, V15, P1550, DOI 10.1158/1078-0432.CCR-08-0820; Yochum GS, 2008, MOL CELL BIOL, V28, P7368, DOI 10.1128/MCB.00744-08	52	64	68	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	22					2750	2760		10.1038/onc.2011.453	http://dx.doi.org/10.1038/onc.2011.453			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	952DB	21963845				2022-12-17	WOS:000304769000005
J	Morinaka, A; Funato, Y; Uesugi, K; Miki, H				Morinaka, A.; Funato, Y.; Uesugi, K.; Miki, H.			Oligomeric peroxiredoxin-I is an essential intermediate for p53 to activate MST1 kinase and apoptosis	ONCOGENE			English	Article						MST1; PRX-I; reactive oxygen species (ROS); p53; cisplatin	OXIDATIVE-STRESS; HYDROGEN-PEROXIDE; HIPPO PATHWAY; P53-DEPENDENT APOPTOSIS; TUMOR SUPPRESSION; PROTEIN-KINASE; CANCER-CELLS; DNA-DAMAGE; C-MYC; PHOSPHORYLATION	Mammalian Ste20-like kinase-1 (MST1) kinase mediates H(2)O(2)-induced cell death by anticancer drugs such as cisplatin in a p53-dependent manner. However, the mechanism underlying MST1 activation by H(2)O(2) remains unknown. Here we show that peroxiredoxin-I (PRX-I) is an essential intermediate in H(2)O(2)-induced MST1 activation and cisplatin-induced cell death through p53. Cell stimulation with H(2)O(2) resulted in PRX-I oxidation to form homo-oligomers and interaction with MST1, leading to MST1 autophosphorylation and augmentation of kinase activity. In addition, RNA interference knockdown experiments indicated that endogenous PRX-I is required for H(2)O(2)-induced MST1 activation. Live-cell imaging showed H(2)O(2) generation by cisplatin treatment, which likewise caused PRX-I oligomer formation, MST1 activation and cell death. Cisplatin-induced PRX-I oligomer formation was not observed in embryonic fibroblasts obtained from p53-knockout mice, confirming the importance of p53. Indeed, ectopic expression of p53 induced PRX-I oligomer formation and cell death, both of which were cancelled by the antioxidant NAC. Moreover, we succeeded in reconstituting H(2)O(2)-induced MST1 activation in vitro, using purified PRX-I and MST1 proteins. Collectively, our results show a novel PRX-I function to cause cell death in response to high levels of oxidative stress by activating MST1, which underlies the p53-dependent cytotoxicity caused by anticancer agents. Oncogene (2011) 30, 4208-4218; doi:10.1038/onc.2011.139; published online 25 April 2011	[Morinaka, A.; Funato, Y.; Uesugi, K.; Miki, H.] Osaka Univ, Inst Prot Res, Lab Intracellular Signaling, Osaka 5650871, Japan	Osaka University	Miki, H (corresponding author), Osaka Univ, Inst Prot Res, Lab Intracellular Signaling, 3-2 Yamadaoka, Osaka 5650871, Japan.	hmiki@protein.osaka-u.ac.jp			Japan Society for the Promotion of Science (JSPS); Ministry of Education, Culture, Sports, Science and Technology (MEXT)-Japan; Grants-in-Aid for Scientific Research [22770195] Funding Source: KAKEN	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science and Technology (MEXT)-Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Yoshiaki Kise (Flanders Institute for Biotechnology, Belgium) for technical assistance in preparing the expression constructs. This study was supported in part by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS) and Ministry of Education, Culture, Sports, Science and Technology (MEXT)-Japan.	Ahn SH, 2005, CELL, V120, P25, DOI 10.1016/j.cell.2004.11.016; Belousov VV, 2006, NAT METHODS, V3, P281, DOI 10.1038/NMETH866; Choi MH, 2005, NATURE, V435, P347, DOI 10.1038/nature03587; Colombani J, 2006, CURR BIOL, V16, P1453, DOI 10.1016/j.cub.2006.05.059; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; de Souza PM, 2004, BIOCHEM SOC T, V32, P485, DOI 10.1042/BST0320485; Egler RA, 2005, ONCOGENE, V24, P8038, DOI 10.1038/sj.onc.1208821; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Graves JA, 2009, J BIOL CHEM, V284, P6520, DOI 10.1074/jbc.M807564200; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Iwamura T, 2001, GENES CELLS, V6, P375, DOI 10.1046/j.1365-2443.2001.00426.x; Jang HH, 2004, CELL, V117, P625, DOI 10.1016/j.cell.2004.05.002; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Konig J, 2002, P NATL ACAD SCI USA, V99, P5738, DOI 10.1073/pnas.072644999; Lee WS, 2007, J BIOL CHEM, V282, P22011, DOI 10.1074/jbc.M610330200; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Moon JC, 2005, J BIOL CHEM, V280, P28775, DOI 10.1074/jbc.M505362200; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; O'Neill EE, 2005, CANCER RES, V65, P5485, DOI 10.1158/0008-5472.CAN-05-1453; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; Praskova M, 2008, CURR BIOL, V18, P311, DOI 10.1016/j.cub.2008.02.006; Ren AX, 2008, CANCER RES, V68, P2266, DOI 10.1158/0008-5472.CAN-07-6248; Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; TSUKADA T, 1993, ONCOGENE, V8, P3313; Veal EA, 2004, MOL CELL, V15, P129, DOI 10.1016/j.molcel.2004.06.021; Veal EA, 2007, MOL CELL, V26, P1, DOI 10.1016/j.molcel.2007.03.016; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011	37	64	67	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	40					4208	4218		10.1038/onc.2011.139	http://dx.doi.org/10.1038/onc.2011.139			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	833ZK	21516123				2022-12-17	WOS:000295924600007
J	Durie, D; Lewis, SM; Liwak, U; Kisilewicz, M; Gorospe, M; Holcik, M				Durie, D.; Lewis, S. M.; Liwak, U.; Kisilewicz, M.; Gorospe, M.; Holcik, M.			RNA-binding protein HuR mediates cytoprotection through stimulation of XIAP translation	ONCOGENE			English	Article						translation; internal initiation; ITAF; HuR; XIAP; cancer	X-LINKED INHIBITOR; RIBOSOME-ENTRY-SITE; TRANS-ACTING FACTOR; MESSENGER-RNA; APOPTOSIS PROTEIN; PROGNOSTIC-FACTOR; HIGH EXPRESSION; UP-REGULATION; ELEMENT; OVEREXPRESSION	Expression of the intrinsic cellular caspase inhibitor XIAP is regulated primarily at the level of protein synthesis. The 50 untranslated region harbours an Internal Ribosome Entry Site (IRES) motif that supports cap-independent translation of XIAP mRNA during conditions of cellular stress. In this study, we show that the RNA-binding protein HuR, which is known to orchestrate an antiapoptotic cellular program, stimulates translation of XIAP mRNA through XIAP IRES. We further show that HuR binds to XIAP IRES in vitro and in vivo, and stimulates recruitment of the XIAP mRNA into polysomes. Importantly, protection from the apoptosis-inducing agent etoposide by overexpression of HuR requires the presence of XIAP, suggesting that HuR-mediated cytoprotection is partially executed through enhanced XIAP translation. Our data suggest that XIAP belongs to the HuR-regulated RNA operon of antiapoptotic genes, which, along with Bcl-2, Mcl-1 and ProT alpha, contributes to the regulation of cell survival. Oncogene (2011) 30, 1460-1469; doi:10.1038/onc.2010.527; published online 22 November 2010	[Durie, D.; Lewis, S. M.; Liwak, U.; Kisilewicz, M.; Holcik, M.] Childrens Hosp Eastern Ontario, Res Inst, Apoptosis Res Ctr, Ottawa, ON K1H 8L1, Canada; [Durie, D.; Liwak, U.; Kisilewicz, M.] Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada; [Holcik, M.] Univ Ottawa, Dept Paediat, Ottawa, ON, Canada; [Gorospe, M.] NIA, Cellular & Mol Biol Lab, Intramural Res Program, NIH, Baltimore, MD 21224 USA	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; University of Ottawa; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Holcik, M (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, Apoptosis Res Ctr, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	martin@mgcheo.med.uottawa.ca	Holcik, Martin/E-5372-2011; Lewis, Stephen/E-5533-2010; Holcik, Martin/AAC-6660-2019	Lewis, Stephen/0000-0001-9537-5822; Holcik, Martin/0000-0002-1922-5299	Canadian Institutes of Health Research (CIHR) [MOP 89737]; National Institute on Aging, National Institutes of Health; NATIONAL INSTITUTE ON AGING [Z01AG000511, ZIAAG000511] Funding Source: NIH RePORTER	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); National Institute on Aging, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Drs Nehal Thakor and Stephen Baird for critical discussions. We are grateful to Drs P Anderson and R Screaton for the gift of anti-TIA-1/TIAR and anti-GST antibodies, respectively, and to Dr I Gallouzi for the GFP-HuR, GFP-HuR(CP1), GFP-HuR(CP2), AP-HuR-GST, AP-HuR(CP1)-GST and AP-HuR(CP2)-GST overexpression constructs. This work was supported by an operating grant from the Canadian Institutes of Health Research to MH (CIHR; MOP 89737); MG was supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health. MH is the CHEO Volunteer Association Endowed Scholar.	Abdelmohsen K, 2007, CELL CYCLE, V6, P1288, DOI 10.4161/cc.6.11.4299; Baird SD, 2007, NUCLEIC ACIDS RES, V35, P4664, DOI 10.1093/nar/gkm483; Braunstein S, 2007, MOL CELL, V28, P501, DOI 10.1016/j.molcel.2007.10.019; Coleman J, 2009, RNA BIOL, V6, P84, DOI 10.4161/rna.6.1.7572; Dean E, 2009, J CLIN ONCOL, V27, P1660, DOI 10.1200/JCO.2008.19.5677; Dean EJ, 2007, EXPERT OPIN THER TAR, V11, P1459, DOI 10.1517/14728222.11.11.1459; Denkert C, 2004, CLIN CANCER RES, V10, P5580, DOI 10.1158/1078-0432.CCR-04-0070; Denkert C, 2004, CANCER RES, V64, P189, DOI 10.1158/0008-5472.CAN-03-1987; DENKERT C, 2006, MODERN PATHOL, V23, P23; Dormoy-Raclet V, 2007, MOL CELL BIOL, V27, P5365, DOI 10.1128/MCB.00113-07; Dubrez-Daloz L, 2008, CELL CYCLE, V7, P1036, DOI 10.4161/cc.7.8.5783; ERKINHEIMO TL, 2005, GYNECOL ONCOL, V26, P26; Fialcowitz-White EJ, 2007, J BIOL CHEM, V282, P20948, DOI 10.1074/jbc.M701751200; Galban S, 2008, MOL CELL BIOL, V28, P93, DOI 10.1128/MCB.00973-07; Graber TE, 2010, CELL DEATH DIFFER, V17, P719, DOI 10.1038/cdd.2009.164; Gu LB, 2009, CANCER CELL, V15, P363, DOI 10.1016/j.ccr.2009.03.002; Heinonen M, 2005, CANCER RES, V65, P2157, DOI 10.1158/0008-5472.CAN-04-3765; Heinonen M, 2007, CLIN CANCER RES, V13, P6959, DOI 10.1158/1078-0432.CCR-07-1432; Hinman MN, 2008, CELL MOL LIFE SCI, V65, P3168, DOI 10.1007/s00018-008-8252-6; Holcik M, 2003, MOL CELL BIOL, V23, P280, DOI 10.1128/MCB.23.1.280-288.2003; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Holcik M, 2005, RNA, V11, P1605, DOI 10.1261/rna.2158605; Holcik M, 2003, ANN NY ACAD SCI, V1010, P249, DOI 10.1196/annals.1299.043; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; Lal A, 2005, EMBO J, V24, P1852, DOI 10.1038/sj.emboj.7600661; Lewis SM, 2007, MOL BIOL CELL, V18, P1302, DOI 10.1091/mbc.E06-06-0515; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Macgregor G R, 1991, Methods Mol Biol, V7, P217, DOI 10.1385/0-89603-178-0:217; Mazroui R, 2008, J CELL BIOL, V180, P113, DOI 10.1083/jcb.200709030; Meisner NC, 2004, CHEMBIOCHEM, V5, P1432, DOI 10.1002/cbic.200400219; Meng Z, 2005, NUCLEIC ACIDS RES, V33, P2962, DOI 10.1093/nar/gki603; Myer VE, 1997, EMBO J, V16, P2130, DOI 10.1093/emboj/16.8.2130; Pardo OE, 2003, MOL CELL BIOL, V23, P7600, DOI 10.1128/MCB.23.21.7600-7610.2003; Rivas-Aravena A, 2009, VIROLOGY, V392, P178, DOI 10.1016/j.virol.2009.06.050; Schimmer AD, 2009, J CLIN ONCOL, V27, P4741, DOI 10.1200/JCO.2009.21.8172; Schimmer AD, 2006, CELL DEATH DIFFER, V13, P179, DOI 10.1038/sj.cdd.4401826; Silvera D, 2009, NAT CELL BIOL, V11, P903, DOI 10.1038/ncb1900; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tamm I, 2004, HEMATOL J, V5, P489, DOI 10.1038/sj.thj.6200549; Tamm I, 2004, CLIN CANCER RES, V10, P3737, DOI 10.1158/1078-0432.CCR-03-0642; Wilkinson JC, 2004, MOL CELL BIOL, V24, P7003, DOI 10.1128/MCB.24.16.7003-7014.2004; Yeh CH, 2008, MOL BIOL CELL, V25, P25; Yoo PS, 2009, ANN SURG ONCOL, V16, P200, DOI 10.1245/s10434-008-0209-3; Yoon A, 2006, SCIENCE, V312, P902, DOI 10.1126/science.1123835; Zhang X, 2009, NUCLEIC ACIDS RES, V37, P7623, DOI 10.1093/nar/gkp755	50	64	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	12					1460	1469		10.1038/onc.2010.527	http://dx.doi.org/10.1038/onc.2010.527			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	739UM	21102524	Green Accepted			2022-12-17	WOS:000288743800008
J	Fukunaga-Kalabis, M; Martinez, G; Nguyen, TK; Kim, D; Santiago-Walker, A; Roesch, A; Herlyn, M				Fukunaga-Kalabis, M.; Martinez, G.; Nguyen, T. K.; Kim, D.; Santiago-Walker, A.; Roesch, A.; Herlyn, M.			Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population	ONCOGENE			English	Article						tenascin; ABCB5; side population	STEM-CELLS; MATRICELLULAR PROTEINS; GENE-EXPRESSION; CANCER CELLS; GROWTH; RESISTANCE; SURVIVAL; IDENTIFICATION; SUBPOPULATION; ACTIVATION	Tenascin-C (TNC) is highly expressed in melanoma; however, little is known about its functions. Recent studies indicate that TNC has a role within the stem cell niche. We hypothesized that TNC creates a specific environment for melanoma cells to show a stem cell-like phenotype, promoting tumor growth and evading conventional therapies. TNC expression was strongly upregulated in melanoma cells grown as 3D spheres (enriched for stem-like cells) when compared to adherent cells. Down-modulation of TNC by shRNA lentiviruses significantly decreased the growth of melanoma spheres. The incidence of pulmonary metastases after intravenous injection of TNC knockdown cells was significantly lower in NOD/SCID IL2R gamma(null) mice compared with control cells. Melanoma spheres contain an increased number of side population (SP) cells, which show stem cell characteristics, and have the potential for drug resistance due to their high efflux capacity. Knockdown of TNC dramatically decreased the SP fraction in melanoma spheres and lowered their resistance to doxorubicin treatment, likely because of the downregulation of multiple ATP-binding cassette (ABC) transporters, including ABCB5. These data suggest that TNC is critical in melanoma progression as it mediates protective signals in the therapy-resistant population of melanoma. Oncogene (2010) 29, 6115-6124; doi:10.1038/onc.2010.350; published online 23 August 2010	[Fukunaga-Kalabis, M.; Martinez, G.; Nguyen, T. K.; Kim, D.; Santiago-Walker, A.; Roesch, A.; Herlyn, M.] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Div Mol & Cellular Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Div Mol & Cellular Biol, 3601 Spruce St,489 WISTAR, Philadelphia, PA 19104 USA.	herlynm@wistar.org			NCI [CA25874, CA47159, CA93372, CA10815]; NATIONAL CANCER INSTITUTE [R01CA225874, P01CA025874, P50CA093372, R01CA076674, R01CA047159, P30CA010815] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the NCI (CA25874, CA47159, CA93372, CA10815). We thank Angela Cipolla, Sarah Telson and Kate M Belser for technical assistance. This work was also supported by Ellen Heber-Katz, James Hayden and Frederick Keeney (The Wistar Microscopy Facility), Russell Delgiacco (The Wistar Histotechnology Facility), Jonni Moore and Hank Fletcher (University of Pennsylvania, Flow Cytometry Core Facility) and The Wistar Animal Facility.	Bidard FC, 2008, CANCER METAST REV, V27, P5, DOI 10.1007/s10555-007-9103-x; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Chiquet-Ehrismann R, 2003, J PATHOL, V200, P488, DOI 10.1002/path.1415; Cohen ED, 2009, J CLIN INVEST, V119, P2538, DOI 10.1172/JCI38079; Dick JE, 2008, BLOOD, V112, P4793, DOI 10.1182/blood-2008-08-077941; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Frank NY, 2005, CANCER RES, V65, P4320, DOI 10.1158/0008-5472.CAN-04-3327; Fukunaga-Kalabis M, 2006, J CELL BIOL, V175, P563, DOI 10.1083/jcb.200602132; Garcion E, 2004, DEVELOPMENT, V131, P3423, DOI 10.1242/dev.01202; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Grichnik JM, 2006, J INVEST DERMATOL, V126, P142, DOI 10.1038/sj.jid.5700017; Helleman J, 2008, CLIN CANCER RES, V14, P5555, DOI 10.1158/1078-0432.CCR-08-0555; HERLYN M, 1991, CANCER RES, V51, P4853; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; Jang JH, 2005, CANCER LETT, V229, P101, DOI 10.1016/j.canlet.2004.12.012; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Jonker JW, 2005, STEM CELLS, V23, P1059, DOI 10.1634/stemcells.2005-0150; Kabashima A, 2009, INT J CANCER, V124, P2771, DOI 10.1002/ijc.24349; Katoh SY, 2008, J BIOCHEM, V143, P517, DOI 10.1093/jb/mvm242; Kloepper JE, 2008, EXP DERMATOL, V17, P592, DOI 10.1111/j.1600-0625.2008.00720.x; Kuo MT, 2002, ONCOGENE, V21, P1945, DOI 10.1038/sj.onc.1205117; Marchionini DM, 2003, J COMP NEUROL, V464, P172, DOI 10.1002/cne.10785; Matsuzaki Y, 2008, AM J RESP CELL MOL, V38, P551, DOI 10.1165/rcmb.2007-0311OC; Mouthon MA, 2006, J NEUROCHEM, V99, P807, DOI 10.1111/j.1471-4159.2006.04118.x; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; Nakanishi T, 2006, BLOOD, V108, P678, DOI 10.1182/blood-2005-10-4020; Nilsson SK, 2005, BLOOD, V106, P1232, DOI 10.1182/blood-2004-11-4422; Nishii T, 2009, CANCER SCI, V100, P1397, DOI 10.1111/j.1349-7006.2009.01211.x; Orend G, 2006, CANCER LETT, V244, P143, DOI 10.1016/j.canlet.2006.02.017; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Qin XF, 2003, P NATL ACAD SCI USA, V100, P183, DOI 10.1073/pnas.232688199; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Refaeli Y, 2009, EMBO REP, V10, P965, DOI 10.1038/embor.2009.184; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Susanto J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004023; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; TUOMINEN H, 1994, J CUTAN PATHOL, V21, P424, DOI 10.1111/j.1600-0560.1994.tb00284.x; Villuendas R, 2006, LEUKEMIA, V20, P1047, DOI 10.1038/sj.leu.2404197; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Zhang HB, 2007, J CLIN INVEST, V117, P730, DOI 10.1172/JCI28984	46	64	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	46					6115	6124		10.1038/onc.2010.350	http://dx.doi.org/10.1038/onc.2010.350			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681XD	20729912	Green Accepted			2022-12-17	WOS:000284356500004
J	Kong, B; Michalski, CW; Hong, X; Valkovskaya, N; Rieder, S; Abiatari, I; Streit, S; Erkan, M; Esposito, I; Friess, H; Kleeff, J				Kong, B.; Michalski, C. W.; Hong, X.; Valkovskaya, N.; Rieder, S.; Abiatari, I.; Streit, S.; Erkan, M.; Esposito, I.; Friess, H.; Kleeff, J.			AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGF-beta-mediated ERK signaling	ONCOGENE			English	Article						pancreatic cancer; AZGP1; EMT; MET; transdifferentiation; transforming growth factor-beta	GROWTH-FACTOR-BETA; K-RAS; CELL-LINE; CONFERS RESISTANCE; GENE-EXPRESSION; STELLATE CELLS; INDUCTION; ZN-ALPHA-2-GLYCOPROTEIN; PROGRESSION; ACTIVATION	Epithelial-to-mesenchymal transdifferentiation (EMT) mediated by transforming growth factor-beta (TGF-beta) signaling leads to aggressive cancer progression. In this study, we identified zinc-alpha 2-glycoprotein (AZGP1, ZAG) as a tumor suppressor in pancreatic ductal adenocarcinoma whose expression is lost due to histone deacetylation. In vitro, ZAG silencing strikingly increased invasiveness of pancreatic cancer cells accompanied by the induction of a mesenchymal phenotype. Expression analysis of a set of EMT markers showed an increase in the expression of mesenchymal markers (vimentin (VIM) and integrin-alpha 5) and a concomitant reduction in the expression of epithelial markers (cadherin 1 (CDH1), desmoplakin and keratin-19). Blockade of endogenous TGF-beta signaling inhibited these morphological changes and the downregulation of CDH1, as elicited by ZAG silencing. In a ZAG-negative cell line, human recombinant ZAG (rZAG) specifically inhibited exogenous TGF-beta-mediated tumor cell invasion and VIM expression. Furthermore, rZAG blocked TGF-beta-mediated ERK2 phosphorylation. PCR array analysis revealed that ZAG-induced epithelial transdifferentiation was accompanied by a series of concerted cellular events including a shift in the energy metabolism and prosurvival signals. Thus, epigenetically regulated ZAG is a novel tumor suppressor essential for maintaining an epithelial phenotype. Oncogene (2010) 29, 5146-5158; doi:10.1038/onc.2010.258; published online 28 June 2010	[Kong, B.; Michalski, C. W.; Hong, X.; Valkovskaya, N.; Rieder, S.; Abiatari, I.; Streit, S.; Erkan, M.; Friess, H.; Kleeff, J.] Tech Univ Munich, Dept Surg, D-81675 Munich, Germany; [Esposito, I.] Tech Univ Munich, Inst Pathol, D-81675 Munich, Germany	Technical University of Munich; Technical University of Munich	Kleeff, J (corresponding author), Tech Univ Munich, Dept Surg, Ismaningerstr 22, D-81675 Munich, Germany.	kleeff@chir.med.tu-muenchen.de	Kleeff, Jorg/B-2124-2009; Michalski, Christoph/U-9167-2019; Abiatari, Ivane/ABC-6247-2021	Kleeff, Jorg/0000-0003-3432-6669; Abiatari, Ivane/0000-0002-1118-3477	European Union; Commission for Clinical Research of the TU Munich; Ministry of Education of China	European Union(European Commission); Commission for Clinical Research of the TU Munich; Ministry of Education of China(Ministry of Education, China)	We thank Felicitas Altmayr, Tanja Rossmann-Bloeck, Manja Thorwirth and Carmen Marthen for excellent technical support. This study was in part supported by the European Union (within the framework of the 'MolDiagPaca' project; to JK, CWM and HF) and by the commission for clinical research of the TU Munich (KKF). BK received a fellowship from the Scholarship Council of the Ministry of Education of China.	Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Benfield AP, 2007, ARCH BIOCHEM BIOPHYS, V462, P47, DOI 10.1016/j.abb.2007.03.010; Biliran H, 2005, CLIN CANCER RES, V11, P6075, DOI 10.1158/1078-0432.CCR-04-2419; Bing C, 2004, P NATL ACAD SCI USA, V101, P2500, DOI 10.1073/pnas.0308647100; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; BUERGI W, 1961, J BIOL CHEM, V236, P1066; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Dembinski JL, 2009, CLIN EXP METASTAS, V26, P611, DOI 10.1007/s10585-009-9260-0; DIEZITZA I, 1993, EUR J CANCER, V29A, P1256, DOI 10.1016/0959-8049(93)90068-Q; Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105; Ellenrieder V, 2001, CANCER RES, V61, P4222; Esposito I, 2007, J CLIN PATHOL, V60, P885, DOI 10.1136/jcp.2006.038257; Evdokimova V, 2009, CELL CYCLE, V8, P2901, DOI 10.4161/cc.8.18.9537; Finkel E, 1996, LANCET, V347, P1034, DOI 10.1016/S0140-6736(96)90163-4; Freemantle SJ, 2007, J CELL BIOCHEM, V102, P869, DOI 10.1002/jcb.21519; FRENETTE G, 1987, PROSTATE, V11, P257, DOI 10.1002/pros.2990110306; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Fritsche P, 2009, GUT, V58, P1399, DOI 10.1136/gut.2009.180711; Giehl K, 2000, ONCOGENE, V19, P2930, DOI 10.1038/sj.onc.1203612; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115; Hale LP, 2001, CLIN CANCER RES, V7, P846; Hamada S, 2007, J CELL PHYSIOL, V213, P768, DOI 10.1002/jcp.21148; Horiguchi K, 2009, J BIOL CHEM, V284, P245, DOI 10.1074/jbc.M804777200; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Ketterer K, 2009, CANCER LETT, V277, P72, DOI 10.1016/j.canlet.2008.11.028; Khasawneh J, 2009, P NATL ACAD SCI USA, V106, P3354, DOI 10.1073/pnas.0802864106; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lecanda J, 2009, CELL CYCLE, V8, P742, DOI 10.4161/cc.8.5.7871; LEMOINE NR, 1992, GASTROENTEROLOGY, V102, P230, DOI 10.1016/0016-5085(92)91805-E; Lim JH, 2008, J CELL BIOCHEM, V105, P1117, DOI 10.1002/jcb.21914; Longnecker DS, 1998, PANCREAS, V17, P323, DOI 10.1097/00006676-199811000-00001; Lung FDT, 2003, BIOPOLYMERS, V71, P132, DOI 10.1002/bip.10396; Marrades MP, 2008, J PHYSIOL BIOCHEM, V64, P61, DOI 10.1007/BF03168235; Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603; Michalski CW, 2007, ANN SURG, V246, P786, DOI 10.1097/SLA.0b013e318070d56e; Michalski CW, 2007, GASTROENTEROLOGY, V132, P1968, DOI 10.1053/j.gastro.2007.02.035; Michalski CW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001701; Michaud DS, 2001, JAMA-J AM MED ASSOC, V286, P921, DOI 10.1001/jama.286.8.921; OHKUBO I, 1990, BIOCHIM BIOPHYS ACTA, V1034, P152, DOI 10.1016/0304-4165(90)90069-9; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Robson EJD, 2006, DIFFERENTIATION, V74, P254, DOI 10.1111/j.1432-0436.2006.00075.x; Rolli V, 2007, FEBS LETT, V581, P394, DOI 10.1016/j.febslet.2006.12.047; Russell ST, 2004, BBA-MOL CELL BIOL L, V1636, P59, DOI 10.1016/j.bbalip.2003.12.004; Russell ST, 2010, ENDOCRINOLOGY, V151, P948, DOI 10.1210/en.2009-0827; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Subramanian G, 2004, CANCER RES, V64, P5200, DOI 10.1158/0008-5472.CAN-04-0018; TADA T, 1991, J HISTOCHEM CYTOCHEM, V39, P1221, DOI 10.1177/39.9.1918940; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Wan M, 2005, AM J PATHOL, V166, P1379, DOI 10.1016/S0002-9440(10)62356-5; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Zhang WW, 2007, CANCER BIOL THER, V6, P218, DOI 10.4161/cbt.6.2.3623	55	64	69	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	37					5146	5158		10.1038/onc.2010.258	http://dx.doi.org/10.1038/onc.2010.258			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650QZ	20581862				2022-12-17	WOS:000281867200004
J	Nagasaka, K; Pim, D; Massimi, P; Thomas, M; Tomaic, V; Subbaiah, VK; Kranjec, C; Nakagawa, S; Yano, T; Taketani, Y; Myers, M; Banks, L				Nagasaka, K.; Pim, D.; Massimi, P.; Thomas, M.; Tomaic, V.; Subbaiah, V. K.; Kranjec, C.; Nakagawa, S.; Yano, T.; Taketani, Y.; Myers, M.; Banks, L.			The cell polarity regulator hScrib controls ERK activation through a KIM site-dependent interaction	ONCOGENE			English	Article						hScrib; phosphorylation; ERK; protein kinase A	LARGE TUMOR-SUPPRESSOR; PAPILLOMAVIRUS E6 PROTEINS; MAP KINASE KINASE; DISCS LARGE; HUMAN SCRIBBLE; NUCLEAR TRANSLOCATION; MEDIATED DEGRADATION; CYCLE PROGRESSION; DOCKING SITES; HUMAN HOMOLOG	The cell polarity regulator, human Scribble (hScrib), is a potential tumour suppressor whose loss is a frequent event in late-stage cancer development. Little is yet known about the mode of action of hScrib, although recent reports suggest its role in the regulation of cell signalling. In this study we show that hScrib is a direct regulator of extracellular signal-regulated kinase (ERK). In human keratinocytes, loss of hScrib results in elevated phospho-ERK levels and concomitant increased nuclear translocation of phospho-ERK. We also show that hScrib interacts with ERK through two well-conserved kinase interaction motif (KIM) docking sites, both of which are also required for ERK-induced phosphorylation of hScrib on two distinct residues. Although wild-type hScrib can downregulate activation of ERK and oncogenic Ras co-transforming activity, an hScrib mutant that lacks the carboxy terminal KIM docking site has no such effects. These results provide a clear mechanistic explanation of how hScrib can regulate ERK signalling and begin to explain how loss of hScrib during cancer development can contribute to disease progression. Oncogene (2010) 29, 5311-5321; doi:10.1038/onc.2010.265; published online 12 July 2010	[Nagasaka, K.; Pim, D.; Massimi, P.; Thomas, M.; Tomaic, V.; Subbaiah, V. K.; Kranjec, C.; Myers, M.; Banks, L.] Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; [Nagasaka, K.; Nakagawa, S.; Yano, T.; Taketani, Y.] Univ Tokyo, Dept Obstet & Gynecol, Grad Sch Med, Tokyo, Japan	International Center for Genetic Engineering & Biotechnology (ICGEB); University of Tokyo	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Area Sci Pk,Padriciano 99, I-34012 Trieste, Italy.	nagasaka@icgeb.org; banks@icgeb.org	Nagasaka, Kazunori/AAM-4311-2020; Kranjec, Christian/ABA-9194-2021; , Subbaiah/AAB-9747-2021	Nagasaka, Kazunori/0000-0002-0696-5175; Kranjec, Christian/0000-0001-9713-7406; Krishna, Vanitha/0000-0002-0444-531X	Yoshida (YKK) Scholarship Foundation; Associazione Italiana per la Ricerca sul Cancro	Yoshida (YKK) Scholarship Foundation; Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the Yoshida (YKK) Scholarship Foundation (to KN) and by a research grant from the Associazione Italiana per la Ricerca sul Cancro (to LB). We are also very grateful to David Allen (Nextgen Sciences) for his kind support and advice on the phospho-mapping analyses.	Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Dow LE, 2008, ONCOGENE, V27, P5988, DOI 10.1038/onc.2008.219; Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Garnett MJ, 2005, MOL CELL, V20, P963, DOI 10.1016/j.molcel.2005.10.022; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Houslay MD, 2000, MOL PHARMACOL, V58, P659, DOI 10.1124/mol.58.4.659; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Massimi P, 2006, ONCOGENE, V25, P4276, DOI 10.1038/sj.onc.1209457; Massimi P, 2008, EXP CELL RES, V314, P3306, DOI 10.1016/j.yexcr.2008.08.016; Nagasaka K, 2006, CANCER SCI, V97, P1217, DOI 10.1111/j.1349-7006.2006.00315.x; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Nola S, 2008, HUM MOL GENET, V17, P3552, DOI 10.1093/hmg/ddn248; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Sabio G, 2005, EMBO J, V24, P1134, DOI 10.1038/sj.emboj.7600578; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; Torii S, 2004, DEV CELL, V7, P33, DOI 10.1016/j.devcel.2004.05.019; Torii S, 2006, CANCER SCI, V97, P697, DOI 10.1111/j.1349-7006.2006.00244.x; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Zeitler J, 2004, J CELL BIOL, V167, P1137, DOI 10.1083/jcb.200407158; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045; Zhou TJ, 2006, STRUCTURE, V14, P1011, DOI 10.1016/j.str.2006.04.006	41	64	65	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	38					5311	5321		10.1038/onc.2010.265	http://dx.doi.org/10.1038/onc.2010.265			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	653KE	20622900				2022-12-17	WOS:000282089100009
J	Bower, JJ; Karaca, GF; Zhou, Y; Simpson, DA; Cordeiro-Stone, M; Kaufmann, WK				Bower, J. J.; Karaca, G. F.; Zhou, Y.; Simpson, D. A.; Cordeiro-Stone, M.; Kaufmann, W. K.			Topoisomerase II alpha maintains genomic stability through decatenation G(2) checkpoint signaling	ONCOGENE			English	Article						decatenation; G(2) checkpoint; topoisomerase II alpha; topoisomerase II beta; chromosomal instability	CELL-CYCLE; DNA TOPOISOMERASES; BREAST-CANCER; CHROMOSOME SEGREGATION; IONIZING-RADIATION; GENE-EXPRESSION; BETA; POISONS; ROLES; BISDIOXOPIPERAZINES	Topoisomerase II alpha (topoII alpha) is an essential mammalian enzyme that topologically modifies DNA and is required for chromosome segregation during mitosis. Previous research suggests that inhibition of topoII decatenatory activity triggers a G(2) checkpoint response, which delays mitotic entry because of insufficient decatenation of daughter chromatids. Here we examine the effects of both topoII alpha and topoII beta on decatenatory activity in cell extracts, DNA damage and decatenation G(2) checkpoint function, and the frequencies of p16(INK4A) allele loss and gain. In diploid human fibroblast lines, depletion of topoII alpha by small-interfering RNA was associated with severely reduced decatenatory activity, delayed progression from G(2) into mitosis and insensitivity to G(2) arrest induced by the topoII catalytic inhibitor ICRF-193. Furthermore, interphase nuclei of topoII alpha-depleted cells showed increased frequencies of losses and gains of the tumor suppressor genetic locus p16(INK4A). This study shows that the topoII alpha protein is required for decatenation G(2) checkpoint function, and inactivation of decatenation and the decatenation G(2) checkpoint leads to abnormal chromosome segregation and genomic instability. Oncogene (2010) 29, 4787-4799; doi:10.1038/onc.2010.232; published online 21 June 2010	[Bower, J. J.; Karaca, G. F.; Zhou, Y.; Simpson, D. A.; Cordeiro-Stone, M.; Kaufmann, W. K.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; [Bower, J. J.; Cordeiro-Stone, M.; Kaufmann, W. K.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Cordeiro-Stone, M.; Kaufmann, W. K.] Univ N Carolina, Ctr Environm Hlth & Susceptibil, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Kaufmann, WK (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, Rm 31-345 Lineberger Comprehens Canc Ctr,CB 7295, Chapel Hill, NC 27599 USA.	bill_kaufmann@med.unc.edu	, UNC Flow Cytometry Core/AGU-9839-2022; Ariel, Pablo/AGJ-4118-2022		NIH-NCI Ruth L. Kirschstein National Research Service [1F32CA134155-01]; PHS [CA81343, P30-ES10126]; NATIONAL CANCER INSTITUTE [R01CA081343, F32CA134155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES010126] Funding Source: NIH RePORTER	NIH-NCI Ruth L. Kirschstein National Research Service(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); PHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Financial Support: This work was supported by an NIH-NCI Ruth L. Kirschstein National Research Service Award Grant # 1F32CA134155-01 (JJ Bower) and PHS grants CA81343 and P30-ES10126 (WK Kaufmann).	Akimitsu N, 2003, GENES CELLS, V8, P393, DOI 10.1046/j.1365-2443.2003.00643.x; Austin CA, 1998, BIOESSAYS, V20, P215, DOI 10.1002/(SICI)1521-1878(199803)20:3<215::AID-BIES5>3.0.CO;2-Q; Bandele OJ, 2008, CHEM RES TOXICOL, V21, P936, DOI 10.1021/tx700434v; Bandele OJ, 2007, BIOCHEMISTRY-US, V46, P6097, DOI 10.1021/bi7000664; Baxter J, 2008, MOL CELL, V30, P790, DOI 10.1016/j.molcel.2008.04.019; Beser AR, 2007, PATHOL ONCOL RES, V13, P180, DOI 10.1007/BF02893497; Biersack H, 1996, P NATL ACAD SCI USA, V93, P8288, DOI 10.1073/pnas.93.16.8288; Bower JJ, 2010, CELL CYCLE, V9, P1617, DOI 10.4161/cc.9.8.11470; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; CAPRANICO G, 1992, BIOCHIM BIOPHYS ACTA, V1132, P43, DOI 10.1016/0167-4781(92)90050-A; Carpenter AJ, 2004, MOL BIOL CELL, V15, P5700, DOI 10.1091/mbc.E04-08-0732; Coelho PA, 2008, PLOS BIOL, V6, P1758, DOI 10.1371/journal.pbio.0060207; Cortes F, 2003, MUTAT RES-REV MUTAT, V543, P59, DOI 10.1016/S1383-5742(02)00070-4; Damelin M, 2005, CANCER CELL, V8, P479, DOI 10.1016/j.ccr.2005.11.004; Dawlaty MM, 2008, CELL, V133, P103, DOI 10.1016/j.cell.2008.01.045; Deming PB, 2002, J BIOL CHEM, V277, P36832, DOI 10.1074/jbc.M206109200; Deming PB, 2001, P NATL ACAD SCI USA, V98, P12044, DOI 10.1073/pnas.221430898; Diaz-Martinez LA, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000053; Doherty SC, 2003, J NATL CANCER I, V95, P1859, DOI 10.1093/jnci/djg120; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; Emmons M, 2006, BIOCHEM PHARMACOL, V72, P11, DOI 10.1016/j.bcp.2006.03.017; Franchitto A, 2003, CANCER RES, V63, P3289; Goswami PC, 1996, MOL CELL BIOL, V16, P1500; Gromova I, 1998, BIOCHEMISTRY-US, V37, P16645, DOI 10.1021/bi981391l; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; Jarvinen TAH, 1996, AM J PATHOL, V148, P2073; Jensen LH, 2000, J BIOL CHEM, V275, P2137, DOI 10.1074/jbc.275.3.2137; Johnson M, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp480; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Kaufmann WK, 1997, CELL GROWTH DIFFER, V8, P1105; Larsen A K, 1996, Prog Cell Cycle Res, V2, P229; Li H, 2008, J BIOL CHEM, V283, P6209, DOI 10.1074/jbc.M709007200; Lorusso V, 2007, ANN ONCOL, V18, P70, DOI 10.1093/annonc/mdm229; Lou ZK, 2005, NAT STRUCT MOL BIOL, V12, P589, DOI 10.1038/nsmb953; Luo KT, 2009, NAT CELL BIOL, V11, P204, DOI 10.1038/ncb1828; Lyu YL, 2007, CANCER RES, V67, P8839, DOI 10.1158/0008-5472.CAN-07-1649; Maeshima K, 2005, CHROMOSOMA, V114, P365, DOI 10.1007/s00412-005-0023-7; Mao Y, 2001, J BIOL CHEM, V276, P40652, DOI 10.1074/jbc.M104009200; Nakagawa T, 2004, CANCER RES, V64, P4826, DOI 10.1158/0008-5472.CAN-04-0871; Park I, 2006, EXP CELL RES, V312, P1996, DOI 10.1016/j.yexcr.2006.02.029; Robinson HMR, 2007, CELL CYCLE, V6, P1265, DOI 10.4161/cc.6.10.4225; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Santamaria A, 2007, MOL BIOL CELL, V18, P4024, DOI 10.1091/mbc.E07-05-0517; Sehested M, 1996, BIOCHEM PHARMACOL, V51, P879, DOI 10.1016/0006-2952(95)02241-4; Simpson Dennis A, 2005, J Carcinog, V4, P18, DOI 10.1186/1477-3163-4-18; van Doorn-Khosrovani SBV, 2007, CARCINOGENESIS, V28, P1703, DOI 10.1093/carcin/bgm102; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wang LHC, 2008, CHROMOSOMA, V117, P123, DOI 10.1007/s00412-007-0131-7; Xiao H, 2003, P NATL ACAD SCI USA, V100, P3239, DOI 10.1073/pnas.0736401100; Zhou T, 2006, ENVIRON HEALTH PERSP, V114, P553, DOI 10.1289/ehp.8026	51	64	65	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2010	29	34					4787	4799		10.1038/onc.2010.232	http://dx.doi.org/10.1038/onc.2010.232			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643VB	20562910	Green Accepted, Green Submitted			2022-12-17	WOS:000281326400005
J	Shrestha-Bhattarai, T; Rangnekar, VM				Shrestha-Bhattarai, T.; Rangnekar, V. M.			Cancer-selective apoptotic effects of extracellular and intracellular Par-4	ONCOGENE			English	Review						Par-4; cell surface GRP78; apoptosis	TUMOR-SUPPRESSOR PAR-4; NECROSIS-FACTOR-ALPHA; PROTEIN PAR-4; ENDOPLASMIC-RETICULUM; PROSTATIC-CANCER; DOWN-REGULATION; ONCOGENIC RAS; CELLS; GENE; KINASE	Selectivity toward cancer cells is the most desirable element in cancer therapeutics. Par-4 is a cancer cell-selective proapoptotic protein that functions intracellularly in the cytoplasmic and nuclear compartments as a tumor suppressor. Moreover, recent findings indicate that the Par-4 protein is secreted by cells, and extracellular Par-4 induces cancer cell-specific apoptosis by interaction with the cell-surface receptor GRP78. This review describes the mechanisms underlying the apoptotic effects of both extracellular and intracellular Par-4 acting through its effector domain SAC. Oncogene (2010) 29, 3873-3880; doi:10.1038/onc.2010.141; published online 3 May 2010	[Rangnekar, V. M.] Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA; [Shrestha-Bhattarai, T.; Rangnekar, V. M.] Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; [Rangnekar, V. M.] Univ Kentucky, Dept Microbiol Immunol & Mol Genet, Lexington, KY 40536 USA; [Rangnekar, V. M.] Univ Kentucky, LP Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky	Rangnekar, VM (corresponding author), Univ Kentucky, Dept Radiat Med, Combs Res Bldg,Room 309,800 Rose St, Lexington, KY 40536 USA.	vmrang01@email.uky.edu			NIH/NCI [CA60872, CA105453, CA84511]; NATIONAL CANCER INSTITUTE [R01CA105453, R01CA060872, R01CA116658, R01CA084511] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the NIH/NCI grants CA60872, CA105453 and CA84511 (to VMR).	Ahmed MM, 2008, INT J CANCER, V122, P63, DOI 10.1002/ijc.23019; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barradas M, 1999, EMBO J, V18, P6362, DOI 10.1093/emboj/18.22.6362; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; Boosen M, 2009, MOL BIOL CELL, V20, P4010, DOI 10.1091/mbc.E09-02-0173; BOS JL, 1989, CANCER RES, V49, P4682; Burikhanov R, 2009, CELL, V138, P377, DOI 10.1016/j.cell.2009.05.022; Chakraborty M, 2001, CANCER RES, V61, P7255; Cook J, 1999, ONCOGENE, V18, P1205, DOI 10.1038/sj.onc.1202416; Davidson DJ, 2005, CANCER RES, V65, P4663, DOI 10.1158/0008-5472.CAN-04-3426; Diaz-Meco MT, 1999, J BIOL CHEM, V274, P19606, DOI 10.1074/jbc.274.28.19606; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; El-Guendy N, 2003, MOL CELL BIOL, V23, P5516, DOI 10.1128/MCB.23.16.5516-5525.2003; El-Guendy N, 2003, EXP CELL RES, V283, P51, DOI 10.1016/S0014-4827(02)00016-2; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Garcia-Cao I, 2005, EMBO REP, V6, P577, DOI 10.1038/sj.embor.7400421; Goswami A, 2005, MOL CELL, V20, P33, DOI 10.1016/j.molcel.2005.08.016; Gurumurthy S, 2005, MOL CELL BIOL, V25, P1146, DOI 10.1128/MCB.25.3.1146-1161.2005; Inesi G, 1998, ANN NY ACAD SCI, V853, P195, DOI 10.1111/j.1749-6632.1998.tb08267.x; ISAACS JT, 1981, CANCER RES, V41, P5070; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Johnstone RW, 1998, GENOMICS, V53, P241, DOI 10.1006/geno.1998.5494; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kelber JA, 2009, ONCOGENE, V28, P2324, DOI 10.1038/onc.2009.97; Kimura M, 1998, CANCER RES, V58, P2456; Kogel D, 2001, BRIT J CANCER, V85, P1801, DOI 10.1054/bjoc.2001.2158; Kukoc-Zivojnov N, 2004, EXP HEMATOL, V32, P649, DOI 10.1016/j.exphem.2004.04.004; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Lucas T, 2001, MELANOMA RES, V11, P379, DOI 10.1097/00008390-200108000-00008; MARTIKAINEN P, 1991, CANCER RES, V51, P4693; Misra UK, 2005, J BIOL CHEM, V280, P26278, DOI 10.1074/jbc.M414467200; Moreno-Bueno G, 2007, CANCER RES, V67, P1927, DOI 10.1158/0008-5472.CAN-06-2687; Nalca A, 1999, J BIOL CHEM, V274, P29976, DOI 10.1074/jbc.274.42.29976; Page G, 1999, ONCOGENE, V18, P7265, DOI 10.1038/sj.onc.1203170; Paige AJW, 2003, CELL MOL LIFE SCI, V60, P2147, DOI 10.1007/s00018-003-3027-6; Park MA, 2008, CANCER BIOL THER, V7, P1648, DOI 10.4161/cbt.7.10.6623; Pruitt K, 2005, J BIOL CHEM, V280, P23363, DOI 10.1074/jbc.M503083200; Qiu SG, 1999, ONCOGENE, V18, P7115, DOI 10.1038/sj.onc.1203199; Schneider BG, 2003, J CLIN PATHOL-MOL PA, V56, P141, DOI 10.1136/mp.56.3.141; Schwarze S, 2010, CANCER BIOL THER, V9, P153, DOI 10.4161/cbt.9.2.10760; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; Shareef MM, 2007, CANCER RES, V67, P11811, DOI 10.1158/0008-5472.CAN-07-0722; Zapata-Benavides P, 2009, ARCH MED RES, V40, P595, DOI 10.1016/j.arcmed.2009.08.007; Zhao YM, 2007, CANCER RES, V67, P9276, DOI 10.1158/0008-5472.CAN-07-2124; Zhao YM, 2008, CANCER BIOL THER, V7, P1867, DOI 10.4161/cbt.7.12.6945; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	48	64	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2010	29	27					3873	3880		10.1038/onc.2010.141	http://dx.doi.org/10.1038/onc.2010.141			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	621SL	20440265	Green Accepted			2022-12-17	WOS:000279603200001
J	Lock, FE; Underhill-Day, N; Dunwell, T; Matallanas, D; Cooper, W; Hesson, L; Recino, A; Ward, A; Pavlova, T; Zabarovsky, E; Grant, MM; Maher, ER; Chalmers, AD; Kolch, W; Latif, F				Lock, F. E.; Underhill-Day, N.; Dunwell, T.; Matallanas, D.; Cooper, W.; Hesson, L.; Recino, A.; Ward, A.; Pavlova, T.; Zabarovsky, E.; Grant, M. M.; Maher, E. R.; Chalmers, A. D.; Kolch, W.; Latif, F.			The RASSF8 candidate tumor suppressor inhibits cell growth and regulates the Wnt and NF-kappa B signaling pathways	ONCOGENE			English	Article						RASSF8; adherens junctions; lung cancer	BETA-CATENIN; GENE; INTERACTS; ADHESION; PROTEINS; DOMAIN; FAMILY	The Ras-assocation domain family (RASSF) of tumor suppressor proteins until recently contained six proteins named RASSF1-6. Recently, four novel family members, RASSF7-10, have been identified by homology searches for RA-domain-containing proteins. These additional RASSF members are divergent and structurally distinct from RASSF1-6, containing an N-terminal RA domain and lacking the Sav/RASSF/Hpo (SARAH) domain. Here, we show that RASSF8 is ubiquitously expressed throughout the murine embryo and in normal human adult tissues. Functionally, RNAi-mediated knockdown of RASSF8 in non-small-cell lung cancer (NSCLC) cell lines, increased anchorage-independent growth in soft agar and enhanced tumor growth in severe combined immunodeficiency (SCID) mice. Furthermore, EdU staining of RASSF8-depleted cells showed growth suppression in a manner dependent on contact inhibition. We show that endogenous RASSF8 is not only found in the nucleus, but is also membrane associated at sites of cell-cell adhesion, co-localizing with the adherens junction (AJ) component beta-catenin and binding to E-cadherin. Following RASSF8 depletion in two different lung cancer cell lines using alternative small interfering RNA (siRNA) sequences, we show that AJs are destabilized and E-cadherin is lost from the cell membrane. The AJ components beta-catenin and p65 are also lost from sites of cell-cell contact and are relocalized to the nucleus with a concomitant increase in beta-catenin-dependent and nuclear factor-kappa B (NF-kappa B)-dependent signaling following RASSF8 depletion. RASSF8 may also be required to maintain actin -cytoskeletal organization since immunofluorescence analysis shows a striking disorganization of the actincytoskeleton following RASSF8 depletion. Accordingly, scratch wound healing studies show increased cellular migration in RASSF8-deficient cells. These results implicate RASSF8 as a tumor suppressor gene that is essential for maintaining AJs function in epithelial cells and have a role in epithelial cell migration. Oncogene (2010) 29, 4307-4316; doi: 10.1038/onc.2010.192; published online 31 May 2010	[Lock, F. E.; Underhill-Day, N.; Dunwell, T.; Cooper, W.; Hesson, L.; Maher, E. R.; Latif, F.] Univ Birmingham, Dept Med & Mol Genet, Inst Biomed Res, Birmingham B15 2TT, W Midlands, England; [Matallanas, D.; Kolch, W.] Univ Coll Dublin, Dublin 2, Ireland; [Recino, A.; Ward, A.; Chalmers, A. D.] Univ Bath, Dept Biol & Biochem, Ctr Regenerat Med, Bath BA2 7AY, Avon, England; [Pavlova, T.; Zabarovsky, E.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Grant, M. M.] Univ Birmingham, Sch Dent, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University College Dublin; University of Bath; Karolinska Institutet; University of Birmingham	Latif, F (corresponding author), Univ Birmingham, Dept Med & Mol Genet, Inst Biomed Res, Birmingham B15 2TT, W Midlands, England.	f.latif@bham.ac.uk	Admin, SBI/HGB-2738-2022; Zabarovsky, Eugene R/A-6645-2010; Grant, Melissa/A-5590-2010; Kolch, Walter/ABF-2102-2021; Chalmers, Andrew/D-4103-2009; MAHER, EAMONN R/A-9507-2008; Hesson, Luke/HDM-0311-2022; gomez, david/U-9465-2019	Grant, Melissa/0000-0003-1154-7266; Chalmers, Andrew/0000-0003-4182-6717; MAHER, EAMONN R/0000-0002-6226-6918; gomez, david/0000-0002-2360-3141; Ward, Andrew/0000-0001-8311-5695; Dunwell, Thomas/0000-0001-9985-3828; Kolch, Walter/0000-0001-5777-5016; Pavlova, Tatiana/0000-0002-2857-5696	Cancer Research UK; Breast Cancer Campaign; Sport Aiding Medical Research for Kids (SPARKS); MRC; Swedish Cancer Society; Swedish Research Council; Swedish Foundation for International Cooperation in Research and Higher Education (STINT); Swedish Instituteand Karolinska Institute	Cancer Research UK(Cancer Research UK); Breast Cancer Campaign; Sport Aiding Medical Research for Kids (SPARKS); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Foundation for International Cooperation in Research and Higher Education (STINT); Swedish Instituteand Karolinska Institute(Karolinska Institutet)	Work in FL's laboratory is supported by Cancer Research UK, Breast Cancer Campaign and Sport Aiding Medical Research for Kids (SPARKS). Work in ADC's laboratory is funded by MRC and Cancer Research UK, and AR by a Marie Curie PhD studentship. EZ was supported by research grants from the Swedish Cancer Society, the Swedish Research Council and the Swedish Foundation for International Cooperation in Research and Higher Education (STINT), the Swedish Instituteand Karolinska Institute.	Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Charalambous M, 2003, P NATL ACAD SCI USA, V100, P8292, DOI 10.1073/pnas.1532175100; Chen LH, 1998, J BIOL CHEM, V273, P33524, DOI 10.1074/jbc.273.50.33524; Dallol A, 2005, CANCER RES, V65, P7653, DOI 10.1158/0008-5472.CAN-05-0247; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; Dallol A, 2009, CURR BIOL, V19, P1227, DOI 10.1016/j.cub.2009.05.064; Debeer P, 2002, J MED GENET, V39, P98, DOI 10.1136/jmg.39.2.98; Deng J, 2004, MOL CARCINOGEN, V39, P139, DOI 10.1002/mc.10169; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; Downward J, 2009, NATURE, V462, P44, DOI 10.1038/462044a; Falvella FS, 2006, ONCOGENE, V25, P3934, DOI 10.1038/sj.onc.1209422; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hesson LB, 2007, ONCOGENE, V26, P7283, DOI 10.1038/sj.onc.1210547; Hesson LB, 2007, DIS MARKERS, V23, P73, DOI 10.1155/2007/291538; Hesson LB, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-42; Katagiri K, 2003, NAT IMMUNOL, V4, P741, DOI 10.1038/ni950; Langton PF, 2009, CURR BIOL, V19, P1969, DOI 10.1016/j.cub.2009.10.027; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004; Rodriguez-Viciana P, 2004, MOL CELL BIOL, V24, P4943, DOI 10.1128/MCB.24.11.4943-4954.2004; Rudini N, 2008, CURR BIOL, V18, pR1080, DOI 10.1016/j.cub.2008.09.018; Scheel H, 2003, CURR BIOL, V13, pR899, DOI 10.1016/j.cub.2003.11.007; Sherwood V, 2008, MOL BIOL CELL, V19, P1772, DOI 10.1091/mbc.E07-07-0652; Solanas G, 2008, J CELL SCI, V121, P2224, DOI 10.1242/jcs.021667; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Wang FL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003031	26	64	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2010	29	30					4307	4316		10.1038/onc.2010.192	http://dx.doi.org/10.1038/onc.2010.192			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	633ZV	20514026	Green Submitted			2022-12-17	WOS:000280547900007
J	Ochiai, H; Takenobu, H; Nakagawa, A; Yamaguchi, Y; Kimura, M; Ohira, M; Okimoto, Y; Fujimura, Y; Koseki, H; Kohno, Y; Nakagawara, A; Kamijo, T				Ochiai, H.; Takenobu, H.; Nakagawa, A.; Yamaguchi, Y.; Kimura, M.; Ohira, M.; Okimoto, Y.; Fujimura, Y.; Koseki, H.; Kohno, Y.; Nakagawara, A.; Kamijo, T.			Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1B beta and TSLC1 in neuroblastoma	ONCOGENE			English	Article						Bmi1; MYCN; neuroblastoma; TSLC1; KIF1B beta	SELF-RENEWAL; STEM-CELLS; N-MYC; EXPRESSION; CANCER; METHYLATION; PROTEINS; HYPERMETHYLATION; PROLIFERATION; AMPLIFICATION	Recent advances in neuroblastoma (NB) research addressed that epigenetic alterations such as hypermethylation of promoter sequences, with consequent silencing of tumor-suppressor genes, can have significant roles in the tumorigenesis of NB. However, the exact role of epigenetic alterations, except for DNA hypermethylation, remains to be elucidated in NB research. In this paper, we clarified the direct binding of MYCN to Bmi1 promoter and upregulation of Bmi1 transcription by MYCN. Mutation introduction into an MYCN binding site in the Bmi1 promoter suggests that MYCN has more important roles in the transcription of Bmi1 than E2F-related Bmi1 regulation. A correlation between MYCN and polycomb protein Bmi1 expression was observed in primary NB tumors. Expression of Bmi1 resulted in the acceleration of proliferation and colony formation in NB cells. Bmi1-related inhibition of NB cell differentiation was confirmed by neurite extension assay and analysis of differentiation marker molecules. Intriguingly, the above-mentioned Bmi1-related regulation of the NB cell phenotype seems not to be mediated only by p14ARF/p16INK4a in NB cells. Expression profiling analysis using a tumor-specific cDNA microarray addressed the Bmi1-dependent repression of KIF1B beta and TSLC1, which have important roles in predicting the prognosis of NB. Chromatin immunoprecipitation assay showed that KIF1Bb and TSLC1 are direct targets of Bmi1 in NB cells. These findings suggest that MYCN induces Bmi1 expression, resulting in the repression of tumor suppressors through Polycomb group gene-mediated epigenetic chromosome modification. NB cell proliferation and differentiation seem to be partially dependent on the MYCN/Bmi1/tumor-suppressor pathways. Oncogene (2010) 29, 2681-2690; doi:10.1038/onc.2010.22; published online 1 March 2010	[Kamijo, T.] Chiba Canc Ctr, Res Inst, Div Biochem & Mol Carcinogenesis, Chuo Ku, Chiba 2608717, Japan; [Ochiai, H.; Kohno, Y.] Chiba Univ, Dept Pediat, Grad Sch Med, Chiba, Japan; [Nakagawa, A.] Natl Ctr Child Hlth & Dev, Dept Pathol, Tokyo, Japan; [Ohira, M.] Chiba Canc Ctr, Res Inst, Lab Canc Genom, Chiba 2608717, Japan; [Okimoto, Y.] Chiba Childrens Hosp, Dept Hematol & Oncol, Chiba, Japan; [Fujimura, Y.; Koseki, H.] RIKEN, Res Ctr Allergy & Immunol, Dev Genet Grp, Yokohama, Kanagawa, Japan; [Nakagawara, A.] Chiba Canc Ctr, Res Inst, Div Innovat Canc Therapeut, Chiba 2608717, Japan	Chiba Cancer Center; Chiba University; National Center for Child Health & Development - Japan; Chiba Cancer Center; Chiba Children's Hospital; RIKEN; Chiba Cancer Center	Kamijo, T (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem & Mol Carcinogenesis, Chuo Ku, 666-2 Nitona, Chiba 2608717, Japan.	tkamijo@chiba-cc.jp	Koseki, Haruhiko/I-3825-2014	Koseki, Haruhiko/0000-0001-8424-5854; Takenobu, Hisanori/0000-0001-7355-1565	Sankyo Foundation of Life Science; Ministry of Health, Labor, and Welfare; Ministry of Health, Labor, and Welfare of Japan [20-13]; Ministry of Education, Culture, Sports, Science and Technology, Japan; Grants-in-Aid for Scientific Research [21390317] Funding Source: KAKEN	Sankyo Foundation of Life Science; Ministry of Health, Labor, and Welfare(Ministry of Health, Labour and Welfare, Japan); Ministry of Health, Labor, and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank K Sakurai for technical assistance, and Daniel Mrozek, Medical English Service, for editorial assistance. This study was supported in part by a grant-in-aid from the Sankyo Foundation of Life Science, a grant-in-aid from the Ministry of Health, Labor, and Welfare for Third Term Comprehensive Control Research for Cancer, a grant-in-aid for Cancer Research (20-13) from the Ministry of Health, Labor, and Welfare of Japan, and a grant-in-aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Ando K, 2008, INT J CANCER, V123, P2087, DOI 10.1002/ijc.23776; Atsuta T, 2001, HYBRIDOMA, V20, P43, DOI 10.1089/027245701300060427; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Bruggeman SWM, 2007, CANCER CELL, V12, P328, DOI 10.1016/j.ccr.2007.08.032; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Caren H, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-10; CARON H, 1995, MED PEDIATR ONCOL, V24, P215, DOI 10.1002/mpo.2950240402; Cui HJ, 2007, AM J PATHOL, V170, P1370, DOI 10.2353/ajpath.2007.060754; Cui HJ, 2006, J BIOL CHEM, V281, P34696, DOI 10.1074/jbc.M604009200; Easton J, 1998, CANCER RES, V58, P2624; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fujimura Y, 2006, DEVELOPMENT, V133, P2371, DOI 10.1242/dev.02405; Guney I, 2006, P NATL ACAD SCI USA, V103, P3645, DOI 10.1073/pnas.0600069103; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Iwama A, 2004, IMMUNITY, V21, P843, DOI 10.1016/j.immuni.2004.11.004; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kamminga LM, 2006, STEM CELLS, V24, P1143, DOI 10.1634/stemcells.2005-0345; Kamminga LM, 2006, BLOOD, V107, P2170, DOI 10.1182/blood-2005-09-3585; Kramps C, 2004, J BIOL CHEM, V279, P5110, DOI 10.1074/jbc.M304758200; Kurata K, 2008, ONCOGENE, V27, P741, DOI 10.1038/sj.onc.1210672; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Lutz W, 1996, ONCOGENE, V13, P803; Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Munirajan AK, 2008, J BIOL CHEM, V283, P24426, DOI 10.1074/jbc.M802316200; Murakami Y, 2005, CANCER SCI, V96, P543, DOI 10.1111/j.1349-7006.2005.00089.x; Nowak K, 2006, NUCLEIC ACIDS RES, V34, P1745, DOI 10.1093/nar/gkl119; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Pietersen AM, 2008, CURR OPIN CELL BIOL, V20, P201, DOI 10.1016/j.ceb.2008.01.004; Rajasekhar VK, 2007, STEM CELLS, V25, P2498, DOI 10.1634/stemcells.2006-0608; Schwartz YB, 2008, CURR OPIN CELL BIOL, V20, P266, DOI 10.1016/j.ceb.2008.03.002; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Strieder V, 2003, J BIOL CHEM, V278, P2983, DOI 10.1074/jbc.M207596200; Sugino Y, 2007, ONCOGENE, V26, P7401, DOI 10.1038/sj.onc.1210550; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Yan P, 2003, GENE CHROMOSOME CANC, V36, P129, DOI 10.1002/gcc.10150; Yang JC, 2007, P NATL ACAD SCI USA, V104, P10494, DOI 10.1073/pnas.0704001104; Yang QW, 2004, CLIN CANCER RES, V10, P8493, DOI 10.1158/1078-0432.CCR-04-1331; Yang QW, 2003, CANCER RES, V63, P6299	46	64	66	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	2010	29	18					2681	2690		10.1038/onc.2010.22	http://dx.doi.org/10.1038/onc.2010.22			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20190806				2022-12-17	WOS:000277354600008
J	Gandhi, M; Dillon, LW; Pramanik, S; Nikiforov, YE; Wang, YH				Gandhi, M.; Dillon, L. W.; Pramanik, S.; Nikiforov, Y. E.; Wang, Y-H			DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells	ONCOGENE			English	Article						fragile site; RET/PTC rearrangement; FRA10C/FRA10G; papillary thyroid carcinomas	HUMAN-CHROMOSOME 7; IN-VITRO; TRINUCLEOTIDE REPEATS; RET REARRANGEMENTS; LATE REPLICATION; COMMON; CARCINOMAS; INDUCTION; RADIATION; CANCER	Human chromosomal fragile sites are regions of the genome that are prone to DNA breakage, and are classified as common or rare, depending on their frequency in the population. Common fragile sites frequently coincide with the location of genes involved in carcinogenic chromosomal translocations, suggesting their role in cancer formation. However, there has been no direct evidence linking breakage at fragile sites to the formation of a cancer-specific translocation. Here, we studied the involvement of fragile sites in the formation of RET/PTC rearrangements, which are frequently found in papillary thyroid carcinoma (PTC). These rearrangements are commonly associated with radiation exposure; however, most of the tumors found in adults are not linked to radiation. In this study, we provide structural and biochemical evidence that the RET, CCDC6 and NCOA4 genes participating in two major types of RET/PTC rearrangements, are located in common fragile sites FRA10C and FRA10G, and undergo DNA breakage after exposure to fragile site-inducing chemicals. Moreover, exposure of human thyroid cells to these chemicals results in the formation of cancer-specific RET/PTC rearrangements. These results provide the direct evidence for the involvement of chromosomal fragile sites in the generation of cancer-specific rearrangements in human cells. Oncogene (2010) 29, 2272-2280; doi: 10.1038/onc.2009.502; published online 25 January 2010	[Dillon, L. W.; Pramanik, S.; Wang, Y-H] Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; [Gandhi, M.; Nikiforov, Y. E.] Univ Pittsburgh, Dept Pathol & Lab Med, Pittsburgh, PA USA	Wake Forest University; Wake Forest Baptist Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wang, YH (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, 1 Med Ctr Blvd,2051 Hanes Bldg, Winston Salem, NC 27157 USA.	ywang@wfubmc.edu	Pramanik, Sreemanta/E-2800-2013; Pramanik, Sreemanta/AAK-3772-2020	Pramanik, Sreemanta/0000-0003-0448-2118; Pramanik, Sreemanta/0000-0003-0448-2118	National Cancer Institute [CA113863]; NATIONAL CANCER INSTITUTE [R01CA113863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM095440] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by the National Cancer Institute (CA113863 to Y-H Wang and YE Nikiforov).	Arlt MF, 2006, DNA REPAIR, V5, P1126, DOI 10.1016/j.dnarep.2006.05.010; Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; Bongarzone I, 1997, GENOMICS, V42, P252, DOI 10.1006/geno.1997.4685; Burrow AA, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-59; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Casper AM, 2004, AM J HUM GENET, V75, P654, DOI 10.1086/422701; Caudill CM, 2005, J CLIN ENDOCR METAB, V90, P2364, DOI 10.1210/jc.2004-1811; Ciampi R, 2005, ENDOCR PATHOL, V16, P99, DOI 10.1385/EP:16:2:099; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; Corbin S, 2002, CANCER RES, V62, P3477; Durkin SG, 2008, P NATL ACAD SCI USA, V105, P246, DOI 10.1073/pnas.0708097105; Durkin SG, 2007, ANNU REV GENET, V41, P169, DOI 10.1146/annurev.genet.41.042007.165900; Fenton CL, 2000, J CLIN ENDOCR METAB, V85, P1170, DOI 10.1210/jc.85.3.1170; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GACY AM, 1995, CELL, V81, P533; Gasparini P, 2007, J CELL BIOCHEM, V102, P320, DOI 10.1002/jcb.21481; Glover TW, 2006, CANCER LETT, V232, P4, DOI 10.1016/j.canlet.2005.08.032; GLOVER TW, 1987, AM J HUM GENET, V41, P882; GLOVER TW, 1988, AM J HUM GENET, V43, P265; Handt O, 2000, CHROMOSOME RES, V8, P677, DOI 10.1023/A:1026737203447; Hansen RS, 1997, P NATL ACAD SCI USA, V94, P4587, DOI 10.1073/pnas.94.9.4587; Hellman A, 2000, MOL CELL BIOL, V20, P4420, DOI 10.1128/MCB.20.12.4420-4427.2000; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Hewett DR, 1998, MOL CELL, V1, P773, DOI 10.1016/S1097-2765(00)80077-5; Klugbauer S, 2001, GENOMICS, V73, P149, DOI 10.1006/geno.2000.6434; Kong QZ, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.6.e33; KUWANO A, 1987, HUM GENET, V75, P75; Mishmar D, 1998, P NATL ACAD SCI USA, V95, P8141, DOI 10.1073/pnas.95.14.8141; MITELMAN F, 2008, MITELMAN DATABASE CH; Motomura T, 1998, THYROID, V8, P485, DOI 10.1089/thy.1998.8.485; MURANO I, 1989, HUM GENET, V83, P45, DOI 10.1007/BF00274145; Musio A, 1997, ENVIRON MOL MUTAGEN, V29, P250, DOI 10.1002/(SICI)1098-2280(1997)29:3&lt;250::AID-EM4&gt;3.0.CO;2-G; Nikiforov YE, 1999, ONCOGENE, V18, P6330, DOI 10.1038/sj.onc.1203019; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nikiforov YE, 2008, MODERN PATHOL, V21, pS37, DOI 10.1038/modpathol.2008.10; Nikiforova MN, 2008, EXPERT REV MOL DIAGN, V8, P83, DOI 10.1586/14737159.8.1.83; Palakodeti A, 2004, GENE CHROMOSOME CANC, V39, P71, DOI 10.1002/gcc.10290; Pelliccia F, 2008, CYTOGENET GENOME RES, V121, P196, DOI 10.1159/000138885; Popescu NC, 2003, CANCER LETT, V192, P1, DOI 10.1016/S0304-3835(02)00596-7; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Santoro M, 2006, EUR J ENDOCRINOL, V155, P645, DOI 10.1530/eje.1.02289; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; SMANIK PA, 1995, HUM MOL GENET, V4, P2313, DOI 10.1093/hmg/4.12.2313; SUTHERLAND GR, 1985, HUM GENET, V69, P233, DOI 10.1007/BF00293031; SUTHERLAND GR, 1991, GENET ANAL-BIOMOL E, V8, P161, DOI 10.1016/1050-3862(91)90056-W; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; Wang L, 1999, HUM MOL GENET, V8, P431, DOI 10.1093/hmg/8.3.431; Weterings E, 2008, CELL RES, V18, P114, DOI 10.1038/cr.2008.3; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; Zhang H, 2007, MOL CELL, V27, P367, DOI 10.1016/j.molcel.2007.06.012; Zlotorynski E, 2003, MOL CELL BIOL, V23, P7143, DOI 10.1128/MCB.23.20.7143-7151.2003	51	64	66	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	15					2272	2280		10.1038/onc.2009.502	http://dx.doi.org/10.1038/onc.2009.502			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583NT	20101222	Green Accepted			2022-12-17	WOS:000276685200012
J	Janoueix-Lerosey, I; Schleiermacher, G; Delattre, O				Janoueix-Lerosey, I.; Schleiermacher, G.; Delattre, O.			Molecular pathogenesis of peripheral neuroblastic tumors	ONCOGENE			English	Review						neuroblastoma; genetic alterations; susceptibility; ALK mutations; expression profiling; progression	ANAPLASTIC LYMPHOMA KINASE; HIGH-RESOLUTION ANALYSIS; HOMEOBOX GENE PHOX2B; B-CELL LYMPHOMA; N-MYC GENE; NPM-ALK; PROGNOSTIC-SIGNIFICANCE; MALIGNANT PROGRESSION; ACTIVATING MUTATIONS; GENOMIC ALTERATIONS	Neuroblastoma (NB) is an embryonal cancer of the sympathetic nervous system observed in early childhood, characterized by a broad spectrum of clinical behaviors, ranging from spontaneous regression to fatal outcome despite aggressive therapies. NB accounts for 8-10% of pediatric cancers and 15% of the deaths attributable to malignant conditions in children. Interestingly, NB may occur in various contexts, being mostly sporadic but also familial or syndromic. This review focuses on recent advances in the identification of the genes and mechanisms implicated in NB pathogenesis. Although the extensive characterization of the genomic aberrations recurrently observed in sporadic NBs provides important insights into the understanding of the clinical heterogeneity of this neoplasm, analysis of familial and syndromic cases also unravels essential clues on the genetic bases of NB. Recently, the ALK gene emerged as an important NB gene, being implicated both in sporadic and familial cases. The identification of gene expression signatures associated with patient's outcome points out the potential of using gene expression profiling to improve clinical management of patients suffering from NB. Finally, based on recent observations integrating genomic analyses, biological data and clinical information, we discuss possible evolution/progression schemes in NB. Oncogene (2010) 29, 1566-1579; doi:10.1038/onc.2009.518; published online 25 January 2010	[Janoueix-Lerosey, I.; Schleiermacher, G.; Delattre, O.] Inst Curie, INSERM, Lab Genet & Biol Canc, U830, F-75248 Paris 05, France; [Schleiermacher, G.] Inst Curie, Dept Pediat, F-75248 Paris 05, France; [Delattre, O.] Inst Curie, Unite Genet Somat, F-75248 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Janoueix-Lerosey, I (corresponding author), Inst Curie, INSERM, Lab Genet & Biol Canc, U830, 26 Rue Ulm, F-75248 Paris 05, France.	janoueix@curie.fr	Schleiermacher, Gudrun/AAN-4711-2021; Janoueix-Lerosey, Isabelle/G-1758-2018	Schleiermacher, Gudrun/0000-0002-0133-5879; Janoueix-Lerosey, Isabelle/0000-0003-0434-3003; delattre, olivier/0000-0002-8730-2276	Agence Nationale pour la Recherche; Institut National du Cancer; Ligue Nationale contre le Cancer; APAESIC (Association des Parents et des Amis des Enfants Soignes a l'Institut Curie); Association Hubert Gouin; Les Bagouz a Manon; les amis de Claire and Enfance et Sante	Agence Nationale pour la Recherche(French National Research Agency (ANR)); Institut National du Cancer(Institut National du Cancer (INCA) France); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); APAESIC (Association des Parents et des Amis des Enfants Soignes a l'Institut Curie); Association Hubert Gouin; Les Bagouz a Manon; les amis de Claire and Enfance et Sante	We thank V Marty, P Vielh and G Vassal from the Institut Gustave Roussy for providing the image of ALK immunohistochemistry. We are grateful to F Bourdeaut for critical reading of the paper. Our work was supported by grants from the Agence Nationale pour la Recherche, the Institut National du Cancer, the Ligue Nationale contre le Cancer (Equipe labellisee), the APAESIC (Association des Parents et des Amis des Enfants Soignes a l'Institut Curie), the Association Hubert Gouin, Les Bagouz a Manon, les amis de Claire and Enfance et Sante	Adam P, 2003, AM J SURG PATHOL, V27, P1473, DOI 10.1097/00000478-200311000-00012; Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Amiel J, 2003, NAT GENET, V33, P459, DOI 10.1038/ng1130; Asgharzadeh S, 2006, JNCI-J NATL CANCER I, V98, P1193, DOI 10.1093/jnci/djj330; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; Barrette SP, 2006, J CLIN ONCOL, V24, P1542, DOI 10.1200/JCO.2005.04.4602; Bentires-Alj M, 2006, NAT MED, V12, P283, DOI 10.1038/nm0306-283; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Bilsland JG, 2008, NEUROPSYCHOPHARMACOL, V33, P685, DOI 10.1038/sj.npp.1301446; Bourdeaut F, 2008, ONCOGENE, V27, P3066, DOI 10.1038/sj.onc.1210965; Bourdeaut F, 2009, J PATHOL, V219, P463, DOI 10.1002/path.2614; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Capasso M, 2009, NAT GENET, V41, P718, DOI 10.1038/ng.374; Caren H, 2008, BIOCHEM J, V416, P153, DOI 10.1042/BJ20081834; CARON H, 1994, AM J HUM GENET, V55, P341; Caron H, 2001, GENE CHROMOSOME CANC, V30, P168, DOI 10.1002/1098-2264(200102)30:2<168::AID-GCC1072>3.0.CO;2-E; Carr J, 2007, CANCER GENET CYTOGEN, V172, P127, DOI 10.1016/j.cancergencyto.2006.08.012; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; Chen QR, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-70; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chesler L, 2007, CANCER RES, V67, P9435, DOI 10.1158/0008-5472.CAN-07-1316; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; Cole KA, 2008, MOL CANCER RES, V6, P735, DOI 10.1158/1541-7786.MCR-07-2102; Denayer E, 2008, J MED GENET, V45, P695, DOI 10.1136/jmg.2007.055772; Diskin SJ, 2009, NATURE, V459, P987, DOI 10.1038/nature08035; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; Fix A, 2004, GENE CHROMOSOME CANC, V40, P266, DOI 10.1002/gcc.20041; Fix A, 2008, GENE CHROMOSOME CANC, V47, P819, DOI 10.1002/gcc.20583; Fredlund E, 2008, P NATL ACAD SCI USA, V105, P14094, DOI 10.1073/pnas.0804455105; FUKUDA Y, 2005, NUCL ACIDS S SER, V49, P341, DOI DOI 10.1093/NASS/49.1.341; Galkin AV, 2007, P NATL ACAD SCI USA, V104, P270, DOI 10.1073/pnas.0609412103; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; George RE, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000255; George RE, 1997, EUR J CANCER, V33, P2037, DOI 10.1016/S0959-8049(97)00206-2; Griffin CA, 1999, CANCER RES, V59, P2776; Heck JE, 2009, PAEDIATR PERINAT EP, V23, P125, DOI 10.1111/j.1365-3016.2008.00983.x; Hiyama E, 2008, LANCET, V371, P1173, DOI 10.1016/S0140-6736(08)60523-1; Janoueix-Lerosey I, 2005, CELL CYCLE, V4, P1842, DOI 10.4161/cc.4.12.2257; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Janoueix-Lerosey I, 2009, J CLIN ONCOL, V27, P1026, DOI 10.1200/JCO.2008.16.0630; JINBO T, 1989, JPN J CANCER RES, V80, P299, DOI 10.1111/j.1349-7006.1989.tb02309.x; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Krasnoselsky AL, 2005, ONCOGENE, V24, P1533, DOI 10.1038/sj.onc.1208341; Ladenstein R, 2001, MED PEDIATR ONCOL, V36, P83; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Laneve P, 2007, P NATL ACAD SCI USA, V104, P7957, DOI 10.1073/pnas.0700071104; Lastowska M, 2001, J CLIN ONCOL, V19, P3080; Liu X, 2008, ONCOGENE, V27, P1478, DOI 10.1038/sj.onc.1210769; LOOK AT, 1984, NEW ENGL J MED, V311, P231, DOI 10.1056/NEJM198407263110405; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; Marcelis CLM, 2008, HUM MUTAT, V29, P1125, DOI 10.1002/humu.20750; Maris JM, 2008, NEW ENGL J MED, V358, P2585, DOI 10.1056/NEJMoa0708698; Maris JM, 2008, LANCET, V371, P1142, DOI 10.1016/S0140-6736(08)60500-0; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; McConville C, 2006, AM J MED GENET A, V140A, P1297, DOI 10.1002/ajmg.a.31278; McDermott U, 2008, CANCER RES, V68, P3389, DOI 10.1158/0008-5472.CAN-07-6186; Melo JV, 2007, NAT REV CANCER, V7, P441, DOI 10.1038/nrc2147; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Michels E, 2007, GENE CHROMOSOME CANC, V46, P1098, DOI 10.1002/gcc.20496; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; Molenaar JJ, 2003, GENE CHROMOSOME CANC, V36, P242, DOI 10.1002/gcc.10166; Monclair T, 2009, J CLIN ONCOL, V27, P298, DOI 10.1200/JCO.2008.16.6876; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mosse Y, 2003, LANCET ONCOL, V4, P769, DOI 10.1016/S1470-2045(03)01283-X; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mosse YP, 2007, GENE CHROMOSOME CANC, V46, P936, DOI 10.1002/gcc.20477; Mosse YP, 2005, GENE CHROMOSOME CANC, V43, P390, DOI 10.1002/gcc.20198; Mosse YP, 2004, AM J HUM GENET, V75, P727, DOI 10.1086/424530; Mourali J, 2006, MOL CELL BIOL, V26, P6209, DOI 10.1128/MCB.01515-05; Munzer C, 2008, INT J CANCER, V122, P2315, DOI 10.1002/ijc.23301; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Onciu M, 2003, BLOOD, V102, P2642, DOI 10.1182/blood-2003-04-1095; Osajima-Hakomori Y, 2005, AM J PATHOL, V167, P213, DOI 10.1016/S0002-9440(10)62966-5; Palmer RH, 2009, BIOCHEM J, V420, P345, DOI 10.1042/BJ20090387; Passoni L, 2009, CANCER RES, V69, P7338, DOI 10.1158/0008-5472.CAN-08-4419; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Plantaz D, 2001, INT J CANCER, V91, P680, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1114>3.0.CO;2-R; Raabe EH, 2008, ONCOGENE, V27, P469, DOI 10.1038/sj.onc.1210659; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Rothenberg AB, 2009, PEDIATR RADIOL, V39, P155, DOI 10.1007/s00247-008-1062-z; Satge D, 2003, CANCER GENET CYTOGEN, V147, P89, DOI 10.1016/S0165-4608(03)00203-6; Schilling FH, 2002, NEW ENGL J MED, V346, P1047, DOI 10.1056/NEJMoa012277; Schleiermacher G, 2005, ONCOGENE, V24, P3377, DOI 10.1038/sj.onc.1208486; Schleiermacher G, 2004, GENE CHROMOSOME CANC, V39, P143, DOI 10.1002/gcc.10313; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Schleiermacher G, 2003, CANCER GENET CYTOGEN, V141, P32, DOI 10.1016/S0165-4608(02)00644-1; Schneiderman J, 2008, J CLIN ONCOL, V26, P913, DOI 10.1200/JCO.2007.13.9493; Schramm A, 2005, ONCOGENE, V24, P7902, DOI 10.1038/sj.onc.1208936; Schulte JH, 2008, INT J CANCER, V122, P699, DOI 10.1002/ijc.23153; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; Shojaei-Brosseau T, 2004, PEDIATR BLOOD CANCER, V42, P99, DOI 10.1002/pbc.10381; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Soda M, 2008, P NATL ACAD SCI USA, V105, P19893, DOI 10.1073/pnas.0805381105; Spitz R, 2006, GENE CHROMOSOME CANC, V45, P1130, DOI 10.1002/gcc.20376; Stallings RL, 2006, CANCER RES, V66, P3673, DOI 10.1158/0008-5472.CAN-05-4154; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Su WT, 2004, CANCER GENET CYTOGEN, V154, P131, DOI 10.1016/j.cancergencyto.2004.02.009; Tomioka N, 2008, ONCOGENE, V27, P441, DOI 10.1038/sj.onc.1210661; Trochet D, 2005, HUM MOL GENET, V14, P3697, DOI 10.1093/hmg/ddi401; Trochet D, 2005, AM J HUM GENET, V76, P421, DOI 10.1086/428366; Trochet D, 2004, AM J HUM GENET, V74, P761, DOI 10.1086/383253; Trochet D, 2009, HUM MUTAT, V30, pE421, DOI 10.1002/humu.20923; Turner SD, 2003, ONCOGENE, V22, P7750, DOI 10.1038/sj.onc.1207048; van Bokhoven H, 2005, NAT GENET, V37, P465, DOI 10.1038/ng1546; van Limpt V, 2004, ONCOGENE, V23, P9280, DOI 10.1038/sj.onc.1208157; Van Roy N, 2001, GENE CHROMOSOME CANC, V32, P126, DOI 10.1002/gcc.1174; Van Roy N, 2006, GENE CHROMOSOME CANC, V45, P107, DOI 10.1002/gcc.20272; Vandepoele K, 2005, MOL BIOL EVOL, V22, P2265, DOI 10.1093/molbev/msi222; Vandepoele K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002207; Vandesompele J, 2005, J CLIN ONCOL, V23, P2280, DOI 10.1200/JCO.2005.06.104; Vermeulen J, 2009, LANCET ONCOL, V10, P663, DOI 10.1016/S1470-2045(09)70154-8; Vita M, 2006, SEMIN CANCER BIOL, V16, P318, DOI 10.1016/j.semcancer.2006.07.015; Wang Q, 2006, CANCER RES, V66, P6050, DOI 10.1158/0008-5472.CAN-05-4618; Webb TR, 2009, EXPERT REV ANTICANC, V9, P331, DOI 10.1586/14737140.9.3.331; Wei JS, 2008, ONCOGENE, V27, P5204, DOI 10.1038/onc.2008.154; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Weinstein IB, 2008, CANCER RES, V68, P3086; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Westermann F, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r150; Wimmer K, 1999, ONCOGENE, V18, P233, DOI 10.1038/sj.onc.1202287; Yamamoto K, 2002, J CLIN ONCOL, V20, P1209, DOI 10.1200/JCO.2002.20.5.1209; Zou HY, 2007, CANCER RES, V67, P4408, DOI 10.1158/0008-5472.CAN-06-4443	133	64	67	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2010	29	11					1566	1579		10.1038/onc.2009.518	http://dx.doi.org/10.1038/onc.2009.518			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	570RC	20101209				2022-12-17	WOS:000275694700002
J	Bai, J; Zhang, J; Wu, J; Shen, L; Zeng, J; Ding, J; Wu, Y; Gong, Z; Li, A; Xu, S; Zhou, J; Li, G				Bai, J.; Zhang, J.; Wu, J.; Shen, L.; Zeng, J.; Ding, J.; Wu, Y.; Gong, Z.; Li, A.; Xu, S.; Zhou, J.; Li, G.			JWA regulates melanoma metastasis by integrin alpha(V)beta(3) signaling	ONCOGENE			English	Article						JWA; melanoma; metastasis; integrin	V BETA 3; CANCER-CELLS; ALPHA-V-BETA-3 INTEGRIN; VITRONECTIN RECEPTOR; MALIGNANT-MELANOMA; ARSENIC TRIOXIDE; PC12 CELLS; EXPRESSION; PROTEIN; ADHESION	JWA, a newly identified novel microtubule-associated protein (MAP), was recently demonstrated to be indispensable for the rearrangement of actin cytoskeleton and activation of MAPK cascades induced by arsenic trioxide (As2O3) and phorbol ester (PMA). JWA depletion blocked the inhibitory effect of As2O3 on HeLa cell migration, but enhanced cell migration after PMA treatment. As cancer cell migration is a hallmark of tumor metastasis and the functional role of JWA in cancer metastasis is not understood, here we show that JWA has an important role in melanoma metastasis. Our data demonstrated that JWA knockdown increased the adhesion and invasion abilities of melanoma cells. Furthermore, JWA knockdown in B16-F10 and A375 melanoma cells significantly promoted the formation and growth of metastatic colonies in vivo. Moreover, in the tumor biopsies from human melanoma patients, JWA expression was significantly decreased in malignant melanoma compared with normal nevi. In addition, we found that JWA knockdown could intensify tumor integrin alpha(V)beta(3) signaling by regulating nuclear factor Sp1. These findings suggest that JWA suppresses melanoma metastasis and may serve a potential therapeutic target for human melanoma. Oncogene (2010) 29, 1227-1237; doi: 10.1038/onc.2009.408; published online 30 November 2009	[Bai, J.; Zhang, J.; Wu, J.; Shen, L.; Zeng, J.; Ding, J.; Wu, Y.; Gong, Z.; Li, A.; Xu, S.; Zhou, J.] Nanjing Med Univ, Sch Publ Hlth, Dept Mol Cell Biol & Toxicol, Ctr Canc, Nanjing 210029, Peoples R China; [Bai, J.; Li, G.] Univ British Columbia, Dept Dermatol & Skin Sci, Jack Bell Res Ctr, Vancouver Coastal Hlth Res Inst, Vancouver, BC V5Z 1M9, Canada; [Zhang, J.] Nantong Canc Hosp, Dept Pathol, Nantong, Jiangsu Prov, Peoples R China	Nanjing Medical University; University of British Columbia; Vancouver Coastal Health Research Institute	Zhou, J (corresponding author), Nanjing Med Univ, Sch Publ Hlth, Dept Mol Cell Biol & Toxicol, Ctr Canc, Nanjing 210029, Peoples R China.	jwzhou@njmu.edu.cn	Li, Gang/A-8257-2011	gong, zhenghua/0000-0002-4363-1043	Key Basic Research Project of Department of Education, Jiangsu Province [06KJA33023]; National Natural Science Foundation of China [30771829, 30930080]; Doctoral Training Program of Education Ministry [200803120001]; Jiangsu Provincial Graduate Students Innovation Project [CX08B-181Z]; Canadian Institutes of Health Research [MOP-84559, MOP-93810]; Cancer Research Society; Canadian Dermatology Foundation	Key Basic Research Project of Department of Education, Jiangsu Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Doctoral Training Program of Education Ministry; Jiangsu Provincial Graduate Students Innovation Project; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Cancer Research Society; Canadian Dermatology Foundation	This study was partially supported by the grants of Key Basic Research Project of Department of Education, Jiangsu Province (06KJA33023), the National Natural Science Foundation of China (30771829, 30930080), the Doctoral Training Program of Education Ministry (200803120001) to JZ and the Jiangsu Provincial Graduate Students Innovation Project (CX08B-181Z) to JB; and Canadian Institutes of Health Research (MOP-84559 and MOP-93810), Cancer Research Society and Canadian Dermatology Foundation to GL.	ALBELDA SM, 1990, CANCER RES, V50, P6757; Balch CM, 2001, J CLIN ONCOL, V19, P3635, DOI 10.1200/JCO.2001.19.16.3635; Becker JC, 2000, CLIN EXP DERMATOL, V25, P503, DOI 10.1046/j.1365-2230.2000.00690.x; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Butchbach MER, 2002, GENE, V292, P81, DOI 10.1016/S0378-1119(02)00669-8; Cao HX, 2002, CHINESE SCI BULL, V47, P834, DOI 10.1360/02tb9188; Chen HR, 2007, CELL SIGNAL, V19, P1315, DOI 10.1016/j.cellsig.2007.01.007; Chen HR, 2004, CHINESE SCI BULL, V49, P467, DOI 10.1360/03wc0398; Chen R, 2007, FREE RADICAL BIO MED, V42, P1704, DOI 10.1016/j.freeradbiomed.2007.02.018; Cheng CM, 2009, J BIOL CHEM, V284, P8786, DOI 10.1074/jbc.M806144200; Cooper CR, 2002, NEOPLASIA, V4, P191, DOI 10.1038/sj.neo.7900224; Felding-Habermann B, 2003, CLIN EXP METASTAS, V20, P203, DOI 10.1023/A:1022983000355; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; Horton MA, 1997, INT J BIOCHEM CELL B, V29, P721, DOI 10.1016/S1357-2725(96)00155-0; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; Huang S, 2006, BIOCHEM BIOPH RES CO, V341, P440, DOI 10.1016/j.bbrc.2005.12.197; Hynes RO, 2003, CELL, V113, P821, DOI 10.1016/S0092-8674(03)00468-9; Ingley E, 1999, FEBS LETT, V459, P69, DOI 10.1016/S0014-5793(99)01188-6; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Li AQ, 2003, CHINESE SCI BULL, V48, P1828, DOI 10.1360/03wc0032; Li XW, 2001, J CELL SCI, V114, P2665; Lossner D, 2009, J CELL PHYSIOL, V220, P367, DOI 10.1002/jcp.21774; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; Moretti S, 1997, MELANOMA RES, V7, P313, DOI 10.1097/00008390-199708000-00006; NIP J, 1995, CANCER METAST REV, V14, P241, DOI 10.1007/BF00690295; Pechkovsky DV, 2008, J BIOL CHEM, V283, P12898, DOI 10.1074/jbc.M708226200; REMMELE W, 1987, PATHOLOGE, V8, P138; Rothhammer T, 2004, CELL MOL LIFE SCI, V61, P118, DOI 10.1007/s00018-003-3337-8; Sampsel JW, 2004, NEW ENGL J MED, V351, P2770; Schweneker M, 2005, FEBS LETT, V579, P1751, DOI 10.1016/j.febslet.2005.02.037; Seftor REB, 1999, CANCER METAST REV, V18, P359, DOI 10.1023/A:1006317125454; Sinanan ACM, 2008, BIOL CELL, V100, P465, DOI 10.1042/BC20070115; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Tajima A, 2000, BBA-GENE STRUCT EXPR, V1492, P377, DOI 10.1016/S0167-4781(00)00121-4; van Nimwegen MJ, 2007, BIOCHEM PHARMACOL, V73, P597, DOI 10.1016/j.bcp.2006.08.011; Voura EB, 2001, MOL BIOL CELL, V12, P2699, DOI 10.1091/mbc.12.9.2699; Wang SY, 2009, NUCLEIC ACIDS RES, V37, P1936, DOI 10.1093/nar/gkp054; Zhou H, 2005, J BIOL CHEM, V280, P10624, DOI 10.1074/jbc.M411900200; Zhou JH, 2008, TOXICOL APPL PHARM, V230, P33, DOI 10.1016/j.taap.2008.01.041; Zhou JW, 1999, INVESTIGATION CELL M, P110	42	64	66	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	2010	29	8					1227	1237		10.1038/onc.2009.408	http://dx.doi.org/10.1038/onc.2009.408			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19946336				2022-12-17	WOS:000274912100013
J	Hader, C; Marlier, A; Cantley, L				Hader, C.; Marlier, A.; Cantley, L.			Mesenchymal-epithelial transition in epithelial response to injury: the role of Foxc2	ONCOGENE			English	Article						Foxc2; kidney; E-cadherin; vimentin; migration	FORKHEAD TRANSCRIPTION FACTORS; MARROW-DERIVED CELLS; POSTISCHEMIC KIDNEY; NEPHRON SEGMENTS; EXPRESSION; REPAIR; PROLIFERATION; INSULIN; BOX; MECHANISM	Overexpression of the forkhead family transcription factor Foxc2 has been shown to activate epithelial-mesenchymal transition (EMT) and correlate with tumor metastasis. In this study, we show that both mRNA and protein levels of Foxc2 increase 1 day after kidney ischemia/reperfusion in sublethally injured tubular cells and that the protein is located in the cytoplasm rather than the nucleus of these cells. in vitro studies of cultured tubular cells confirm the cytoplasmic location of Foxc2 and show that increased cytoplasmic expression of Foxc2 correlates with epithelial differentiation rather than dedifferentiation. Silencing of Foxc2 by RNAi in these cells led to EMT and increased cell migration. In contrast, Foxc2 is found in both the nucleus and cytoplasm of cultured fibroblasts, with RNAi leading to increased expression of epithelial markers and impaired cell migration. Consistent with a subcellular localization dependence of Foxc2 function, overexpression of Foxc2 in renal epithelial cells resulted in de novo nuclear expression of the protein and promotion of a mesenchymal/fibroblast phenotype. These results suggest that Foxc2 may have regulatory functions independent of its nuclear transcriptional activity and that upregulation of endogenous Foxc2 in the cytoplasm of injured tubular cells activates epithelial cell redifferentiation rather than dedifferentiation during organ repair. Oncogene (2010) 29, 1031-1040; doi:10.1038/onc.2009.397; published online 23 November 2009	[Hader, C.; Marlier, A.; Cantley, L.] Yale Univ, Sch Med, Nephrol Sect, Dept Internal Med, New Haven, CT 06520 USA	Yale University	Cantley, L (corresponding author), Yale Univ, Sch Med, Nephrol Sect, Dept Internal Med, 333 Cedar St,POB 208029, New Haven, CT 06520 USA.	lloyd.cantley@yale.edu			NIH [DK65109, DK66216]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK065109, R01DK066216] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH awards to LGC (DK65109 and DK66216). We thank Dr Robert Weinberg for the generous gift of the plasmids for expression of Foxc2, Insa Schmidt for providing the PTEC cells and Dr Jiankan Guo for his experimental assistance.	Arden KC, 2006, EXP GERONTOL, V41, P709, DOI 10.1016/j.exger.2006.05.015; Bard JBL, 2008, DEV DYNAM, V237, P2748, DOI 10.1002/dvdy.21652; Berry FB, 2005, HUM MOL GENET, V14, P2619, DOI 10.1093/hmg/ddi295; Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292; Bois PRJ, 2003, EMBO J, V22, P1147, DOI 10.1093/emboj/cdg116; Bonventre JV, 2003, J AM SOC NEPHROL, V14, pS55, DOI 10.1097/01.ASN.0000067652.51441.21; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Coffer PJ, 2004, NAT REV IMMUNOL, V4, P889, DOI 10.1038/nri1488; Duffield JS, 2005, KIDNEY INT, V68, P1956, DOI 10.1111/j.1523-1755.2005.00629.x; Fujita H, 2006, CIRC RES, V98, P626, DOI 10.1161/01.RES.0000207407.51752.3c; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Gronning LM, 2002, MOL ENDOCRINOL, V16, P873, DOI 10.1210/me.16.4.873; Hayashi H, 2008, J BIOL CHEM, V283, P23791, DOI 10.1074/jbc.M800190200; Hayashi H, 2008, BIOCHEM BIOPH RES CO, V367, P584, DOI 10.1016/j.bbrc.2007.12.183; Ishibe S, 2008, CURR OPIN NEPHROL HY, V17, P379, DOI 10.1097/MNH.0b013e3283046507; Ishibe S, 2006, MOL CELL BIOL, V26, P9232, DOI 10.1128/MCB.01312-06; Kale S, 2003, J CLIN INVEST, V112, P42, DOI 10.1172/JCI200317856; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Karihaloo A, 2005, MOL CELL BIOL, V25, P7441, DOI 10.1128/MCB.25.17.7441-7448.2005; Lin FM, 2005, J CLIN INVEST, V115, P1756, DOI 10.1172/JCI23015; Liu YH, 2004, J AM SOC NEPHROL, V15, P1, DOI 10.1097/01.ASN.0000106015.29070.E7; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Obsil T, 2008, ONCOGENE, V27, P2263, DOI 10.1038/onc.2008.20; Schafer JA, 1997, AM J PHYSIOL-RENAL, V273, pF650, DOI 10.1152/ajprenal.1997.273.4.F650; Schwab TS, 2005, APOPTOSIS, V10, P831, DOI 10.1007/s10495-005-0429-y; Sinha D, 2003, AM J PHYSIOL-RENAL, V284, pF488, DOI 10.1152/ajprenal.00172.2002; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; WALLIN A, 1992, LAB INVEST, V66, P474; WITZGALL R, 1994, J CLIN INVEST, V93, P2175, DOI 10.1172/JCI117214; Xu L, 2004, NAT REV MOL CELL BIO, V5, P209, DOI 10.1038/nrm1331	31	64	70	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2010	29	7					1031	1040		10.1038/onc.2009.397	http://dx.doi.org/10.1038/onc.2009.397			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556PV	19935708	Green Accepted			2022-12-17	WOS:000274604400009
J	Careccia, S; Mainardi, S; Pelosi, A; Gurtner, A; Diverio, D; Riccioni, R; Testa, U; Pelosi, E; Piaggio, G; Sacchi, A; Lavorgna, S; Lo-Coco, F; Blandino, G; Levrero, M; Rizzo, MG				Careccia, S.; Mainardi, S.; Pelosi, A.; Gurtner, A.; Diverio, D.; Riccioni, R.; Testa, U.; Pelosi, E.; Piaggio, G.; Sacchi, A.; Lavorgna, S.; Lo-Coco, F.; Blandino, G.; Levrero, M.; Rizzo, M. G.			A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes	ONCOGENE			English	Article						microRNAs; acute promyelocytic leukemia; PML/RAR alpha	HEMATOPOIETIC STEM; RETINOIC ACID; RAR-ALPHA; LEUKEMIA; DIFFERENTIATION; MICRORNAS; EXPRESSION; CELLS; RECEPTORS; GENOMICS	MicroRNAs (miRNAs) are small non-coding RNAs involved in the regulation of critical cell processes such as apoptosis, cell proliferation and differentiation. A small set of miRNAs is differentially expressed in hematopoietic cells and seemingly has an important role in granulopoiesis and lineage differentiation. In this study, we analysed, using a quantitative real-time PCR approach, the expression of 12 granulocytic differentiation signature miRNAs in a cohort of acute promyelocytic leukemia (APL) patients. We found nine miRNAs overexpressed and three miRNAs (miR-107, -342 and let-7c) downregulated in APL blasts as compared with normal promyelocytes differentiated in vitro from CD34+ progenitors. Patients successfully treated with all-trans-retinoic acid (ATRA) and chemotherapy showed downregulation of miR-181b and upregulation of miR-15b, -16, -107, -223, -342 and let-7c. We further investigated whether the APL-associated oncogene, promyelocytic leukemia gene (PML)/retinoic acid receptor alpha (RAR alpha), might be involved in the transcriptional repression of miR-107, -342 and let-7c. We found that PML/RAR alpha binds the regulatory sequences of the intragenic miR-342 and let-7c. In addition, we observed, in response to ATRA, the release of PML/RAR alpha paralleled by their transcriptional activation, together with their host genes, EVL and C21orf34 alpha. In conclusion, we show that a small subset of miRNAs is differentially expressed in APL and modulated by ATRA-based treatment. Oncogene (2009) 28, 4034-4040; doi:10.1038/onc.2009.255; published online 14 September 2009	[Careccia, S.; Mainardi, S.; Pelosi, A.; Gurtner, A.; Piaggio, G.; Sacchi, A.; Blandino, G.; Rizzo, M. G.] Regina Elena Inst Canc Res, Dept Expt Oncol, Lab Mol Oncogenesis, I-00158 Rome, Italy; [Diverio, D.] Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy; [Riccioni, R.; Testa, U.; Pelosi, E.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; [Lavorgna, S.; Lo-Coco, F.] Univ Roma Tor Vergata, Dept Biopathol, Rome, Italy; [Lavorgna, S.; Lo-Coco, F.] Fdn Santa Lucia, Lab Neurooncoematol, Rome, Italy; [Blandino, G.; Levrero, M.] ROC, Rome, Italy; [Levrero, M.] Univ Roma La Sapienza, Dept Internal Med, Rome, Italy; [Levrero, M.] Fdn Andrea Cesalpino, Gene Express Lab, Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Sapienza University Rome; Istituto Superiore di Sanita (ISS); University of Rome Tor Vergata; IRCCS Santa Lucia; Sapienza University Rome	Rizzo, MG (corresponding author), Regina Elena Inst Canc Res, Dept Expt Oncol, Lab Mol Oncogenesis, Via Messi dOro 156, I-00158 Rome, Italy.	massimo.levrero@uniroma1.it; rizzo@ifo.it	lavorgna, serena/O-8490-2016; pelosi, elvira/J-7298-2016; riccioni, roberta/AAC-5636-2021; Pelosi, Andrea/J-9690-2018; Piaggio, Giulia/J-7214-2018; Blandino, Giovanni/B-1137-2013; Rizzo, Maria Giulia/B-2107-2018; Gurtner, Aymone/J-7217-2018; Careccia, Silvia/K-6475-2016; gurtner, aymone/AAB-8843-2020; Testa, Ugo/J-6472-2016; Piaggio, Giulia/AAD-7336-2022; Levrero, Massimo/G-5680-2016	lavorgna, serena/0000-0001-8812-2325; pelosi, elvira/0000-0002-3043-6249; riccioni, roberta/0000-0002-5766-7717; Pelosi, Andrea/0000-0003-2308-9215; Piaggio, Giulia/0000-0003-2114-1892; Blandino, Giovanni/0000-0002-6970-2241; Rizzo, Maria Giulia/0000-0002-5009-2412; Gurtner, Aymone/0000-0002-7661-9059; Careccia, Silvia/0000-0001-7221-8170; gurtner, aymone/0000-0002-7661-9059; Testa, Ugo/0000-0001-7900-8942; Levrero, Massimo/0000-0002-4978-0875	Associazione Italiana per la Ricerca sul Cancro (AIRC); Ministero della Salute-Italy; European Community (Eu Active p53 Consortium)	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero della Salute-Italy(Ministry of Health, Italy); European Community (Eu Active p53 Consortium)(European Commission)	We thank Dr WH Miller Jr for kindly providing the NB4 sub-clone MR2 and Dr I Sperduti for his help on statistical analysis. This work was supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC), Ministero della Salute-Italy and European Community (Eu Active p53 Consortium).	Abramovich C, 2005, CURR OPIN HEMATOL, V12, P210, DOI 10.1097/01.moh.0000160737.52349.aa; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; De Marchis ML, 2009, LEUKEMIA, V23, P856, DOI 10.1038/leu.2008.372; Diaz-Blanco E, 2007, LEUKEMIA, V21, P494, DOI 10.1038/sj.leu.2404549; Fabbri M, 2008, LEUKEMIA, V22, P1095, DOI 10.1038/leu.2008.30; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Fontana L, 2007, NAT CELL BIOL, V9, P775, DOI 10.1038/ncb1613; Garzon R, 2007, ONCOGENE, V26, P4148, DOI 10.1038/sj.onc.1210186; Grady WM, 2008, ONCOGENE, V27, P3880, DOI 10.1038/onc.2008.10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kim YK, 2007, EMBO J, V26, P775, DOI 10.1038/sj.emboj.7601512; Kumar AR, 2009, BLOOD, V113, P1756, DOI 10.1182/blood-2008-06-163287; Mainardi S, 2007, CELL DEATH DIFFER, V14, P1968, DOI 10.1038/sj.cdd.4402210; Mallardo M, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-19; Mandelli F, 1997, BLOOD, V90, P1014; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Meltzer PS, 2005, NATURE, V435, P745, DOI 10.1038/435745a; Pasquinelli AE, 2005, CURR OPIN GENET DEV, V15, P200, DOI 10.1016/j.gde.2005.01.002; Peng Y, 2008, MOL CANCER RES, V6, P663, DOI 10.1158/1541-7786.MCR-07-0370; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Rosenauer A, 1996, BLOOD, V88, P2671, DOI 10.1182/blood.V88.7.2671.bloodjournal8872671; Saumet A, 2009, BLOOD, V113, P412, DOI 10.1182/blood-2008-05-158139; Tallman MS, 2002, BLOOD, V99, P759, DOI 10.1182/blood.V99.3.759; Testa U, 1996, BLOOD, V88, P3391, DOI 10.1182/blood.V88.9.3391.bloodjournal8893391	26	64	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2009	28	45					4034	4040		10.1038/onc.2009.255	http://dx.doi.org/10.1038/onc.2009.255			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AC	19749800				2022-12-17	WOS:000272560300008
J	Seckinger, A; Meissner, T; Moreaux, J; Goldschmidt, H; Fuhler, GM; Benner, A; Hundemer, M; Reme, T; Shaughnessy, JD; Barlogie, B; Bertsch, U; Hillengass, J; Ho, AD; Pantesco, V; Jauch, A; De Vos, J; Rossi, JF; Mohler, T; Klein, B; Hose, D				Seckinger, A.; Meissner, T.; Moreaux, J.; Goldschmidt, H.; Fuhler, G. M.; Benner, A.; Hundemer, M.; Reme, T.; Shaughnessy, J. D., Jr.; Barlogie, B.; Bertsch, U.; Hillengass, J.; Ho, A. D.; Pantesco, V.; Jauch, A.; De Vos, J.; Rossi, J. F.; Moehler, T.; Klein, B.; Hose, D.			Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis	ONCOGENE			English	Article						gene expression profiling; multiple myeloma; angiogenesis; proliferation; survival	MESENCHYMAL STEM-CELLS; MULTIPLE-MYELOMA; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; HEPARAN-SULFATE; PROSTATE-CANCER; GROWTH-FACTOR; UP-REGULATION; B-CELLS; BMP-6	Pathogenesis of multiple myeloma is associated with an aberrant expression of pro-proliferative, pro-angiogenic and bone-metabolism-modifying factors by malignant plasma cells. Given the frequently long time span from diagnosis of early-stage plasma cell dyscrasias to overt myeloma and the mostly low proliferation rate of malignant plasma cells, we hypothesize these to similarly express a novel class of inhibitory factors of potential prognostic relevance. Bone morphogenic proteins (BMPs) represent possible candidates as they inhibit proliferation, stimulate bone formation and have an effect on the survival of cancer patients. We assessed the expression of BMPs and their receptors by Affymetrix DNA microarrays (n=779) including CD138-purified primary myeloma cell samples (n=635) of previously untreated patients. BMP6 is the only BMP expressed by malignant and normal plasma cells. Its expression is significantly lower in proliferating myeloma cells, myeloma cell lines or plasmablasts. BMP6 significantly inhibits the proliferation of myeloma cell lines, survival of primary myeloma cells and in vitro angiogenesis. A high BMP6 expression in primary myeloma cell samples delineates significantly superior overall survival for patients undergoing high-dose chemotherapy independent of conventional prognostic factors (International Staging System (ISS) stage, beta(2) microglobulin). Oncogene (2009) 28, 3866-3879; doi:10.1038/onc.2009.257; published online 31 August 2009	[Seckinger, A.; Meissner, T.; Goldschmidt, H.; Hundemer, M.; Bertsch, U.; Hillengass, J.; Ho, A. D.; Moehler, T.; Hose, D.] Univ Klinikum Heidelberg, Med Klin 5, D-69120 Heidelberg, Germany; [Moreaux, J.; Reme, T.; Pantesco, V.; De Vos, J.; Rossi, J. F.; Klein, B.] Hop St Eloi, Inst Res Biotherapy, CHU Montpellier, Montpellier, France; [Moreaux, J.; Reme, T.; Pantesco, V.; De Vos, J.; Rossi, J. F.; Klein, B.] INSERM, U847, Montpellier, France; [Moreaux, J.; Reme, T.; Pantesco, V.; De Vos, J.; Rossi, J. F.; Klein, B.] Univ Montpellier, F-34059 Montpellier, France; [Goldschmidt, H.; Moehler, T.; Hose, D.] Natl Ctr Tumorerkrankungen, Heidelberg, Germany; [Fuhler, G. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Cell Biol, NL-9713 AV Groningen, Netherlands; [Benner, A.] Deutsch Krebsforschungszentrum, Biostat Abt, D-6900 Heidelberg, Germany; [Shaughnessy, J. D., Jr.; Barlogie, B.] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA; [Jauch, A.] Univ Klinikum Heidelberg, Inst Humangenet, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; University of Groningen; Helmholtz Association; German Cancer Research Center (DKFZ); University of Arkansas System; University of Arkansas Medical Sciences; Ruprecht Karls University Heidelberg	Hose, D (corresponding author), Univ Klinikum Heidelberg, Med Klin 5, Neuenheimer Feld 410, D-69120 Heidelberg, Germany.	dirk.hose@med.uni-heidelberg.de	De Vos, John/A-5703-2010; J, Moreaux/ABA-2974-2021; moreaux, jerome/HGA-5649-2022	De Vos, John/0000-0003-1880-4130; J, Moreaux/0000-0002-5717-3207; Ho, Anthony D./0000-0002-1656-0833	Hopp-Foundation (Germany); University of Heidelberg (Germany); National Centre for Tumor Diseases (Heidelberg, Germany); Tumorzentrum Heidelberg/Mannheim (Germany); European Community; Ligue Nationale Contre Le Cancer (equipe labellisee) (Paris, France); Ligue Nationale Contre le Cancer (France)	Hopp-Foundation (Germany); University of Heidelberg (Germany); National Centre for Tumor Diseases (Heidelberg, Germany); Tumorzentrum Heidelberg/Mannheim (Germany); European Community(European Commission); Ligue Nationale Contre Le Cancer (equipe labellisee) (Paris, France); Ligue Nationale Contre le Cancer (France)(Ligue nationale contre le cancer)	We thank Katrin Heimlich, Maria Dorner and Gabriele Hoock for technical assistance. This work was supported in part by grants from the Hopp-Foundation (Germany), the University of Heidelberg (Germany), the National Centre for Tumor Diseases (Heidelberg, Germany), the Tumorzentrum Heidelberg/Mannheim (Germany), the European Myeloma Stem Cell Network (MSCNET) funded within the 6th framework program of the European Community, Novartis Pharma GmbH (Nuremberg, Germany), the Ligue Nationale Contre Le Cancer (equipe labellisee) (Paris, France). It is also part of a national program called 'Carte d'Identite des Tumeurs' (CIT) funded by the Ligue Nationale Contre le Cancer (France).	Barlogie B, 2006, BLOOD, V107, P2633, DOI 10.1182/blood-2005-10-4084; Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x; Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200; Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623-200308000-00017; Clement JH, 1999, INT J CANCER, V80, P250, DOI 10.1002/(SICI)1097-0215(19990118)80:2<250::AID-IJC14>3.0.CO;2-D; Corre J, 2007, LEUKEMIA, V21, P1079, DOI 10.1038/sj.leu.2404621; Cremer FW, 2005, GENE CHROMOSOME CANC, V44, P194, DOI 10.1002/gcc.20231; Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008-5472.CAN-05-1891; De Vos J, 2006, IMMUNOL REV, V210, P86, DOI 10.1111/j.0105-2896.2006.00362.x; De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771; Du J, 2008, J CELL BIOCHEM, V103, P1584, DOI 10.1002/jcb.21547; DURIE BGM, 1986, SEMIN ONCOL, V13, P300; Ebisawa T, 1999, J CELL SCI, V112, P3519; Goldschmidt H, 2003, ANN HEMATOL, V82, P654, DOI 10.1007/s00277-003-0685-2; Greipp PR, 2005, J CLIN ONCOL, V23, P3412, DOI 10.1200/JCO.2005.04.242; Hamdy FC, 1997, CANCER RES, V57, P4427; Haudenschild DR, 2004, CANCER RES, V64, P8276, DOI 10.1158/0008-5472.CAN-04-2251; Hoang B, 2006, BLOOD, V107, P4484, DOI 10.1182/blood-2005-09-3926; Hose D, 2009, BLOOD, V114, P128, DOI 10.1182/blood-2008-10-184226; Hose D, 2009, BLOOD, V113, P4331, DOI 10.1182/blood-2008-09-178350; Irie A, 2003, BIOCHEM BIOPH RES CO, V308, P858, DOI 10.1016/S0006-291X(03)01500-6; Jourdan M, 1998, BRIT J HAEMATOL, V100, P637, DOI 10.1046/j.1365-2141.1998.00623.x; Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359-6101(97)00036-1; Kersten C, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-9; Kersten C, 2006, EXP HEMATOL, V34, P72, DOI 10.1016/j.exphem.2005.09.010; Kim IY, 2003, CLIN CANCER RES, V9, P6046; Klein B, 2003, INT J HEMATOL, V78, P106, DOI 10.1007/BF02983377; Kochanowska I, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471-2474-8-128; Kusu N, 2003, J BIOL CHEM, V278, P24113, DOI 10.1074/jbc.M301716200; Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875; Mahtouk K, 2006, ONCOGENE, V25, P7180, DOI 10.1038/sj.onc.1209699; Mahtouk K, 2005, ONCOGENE, V24, P3512, DOI 10.1038/sj.onc.1208536; Mahtouk K, 2007, BLOOD, V109, P4914, DOI 10.1182/blood-2006-08-043232; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Moreaux J, 2005, BLOOD, V106, P1021, DOI 10.1182/blood-2004-11-4512; Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011; Ren RQ, 2007, BLOOD, V109, P2847, DOI 10.1182/blood-2006-08-039743; Ro TB, 2004, ONCOGENE, V23, P3024, DOI 10.1038/sj.onc.1207386; Tarte K, 2002, BLOOD, V100, P1113, DOI 10.1182/blood.V100.4.1113.h81602001113_1113_1122; Trojan A, 2006, SWISS MED WKLY, V136, P400; VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x; Valdimarsdottir G, 2002, CIRCULATION, V106, P2263, DOI 10.1161/01.CIR.0000033830.36431.46; Witzig TE, 1999, BRIT J HAEMATOL, V104, P131, DOI 10.1046/j.1365-2141.1999.01136.x; Wutzl A, 2006, J BIOMED MATER RES A, V77A, P75, DOI 10.1002/jbm.a.30615; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745; ZHANG XG, 1994, BLOOD, V83, P3654	46	64	65	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2009	28	44					3866	3879		10.1038/onc.2009.257	http://dx.doi.org/10.1038/onc.2009.257			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	515LJ	19718049	Green Accepted, Green Submitted			2022-12-17	WOS:000271471900002
J	Cooper, WN; Hesson, LB; Matallanas, D; Dallol, A; von Kriegsheim, A; Ward, R; Kolch, W; Latif, F				Cooper, W. N.; Hesson, L. B.; Matallanas, D.; Dallol, A.; von Kriegsheim, A.; Ward, R.; Kolch, W.; Latif, F.			RASSF2 associates with and stabilizes the proapoptotic kinase MST2	ONCOGENE			English	Article						RASSF2; MST2; MST1; proteomics; epigenetics	CASPASE-MEDIATED ACTIVATION; POTENTIAL TUMOR-SUPPRESSOR; STE20-LIKE PROTEIN-KINASE; CHROMATIN CONDENSATION; EPIGENETIC INACTIVATION; APOPTOSIS; PHOSPHORYLATION; PATHWAY; EFFECTOR; GENE	RASSF2 is a tumour suppressor that in common with the rest of the RASSF family contains Ras association and SARAH domains. We identified the proapoptotic kinases, MST1 and MST2, as the most significant binding partners of RASSF2, confirmed the interactions at endogenous levels and showed that RASSF2 immunoprecipitates active MST1/2. We then showed that RASSF2 can be phosphorylated by a co-immunoprecipitating kinase that is likely to be MST1/2. Furthermore, we showed that RASSF2 and MST2 do indeed colocalize, but whereas RASSF2 alone is nuclear, the presence of MST1 or MST2 results in colocalization in the cytoplasm. Expression of RASSF2 (stably in MCF7 or transiently in HEK-293) increases MST2 levels and knockdown of RASSF2 in HEK-293 cells reduces MST2 levels, in addition colorectal tumour cell lines and primary tumours with low RASSF2 levels show decreased MST2 protein levels. This is likely to be mediated by RASSF2-dependent protection of MST2 against proteolytic degradation. Our findings suggest that MST2 and RASSF2 form an active complex in vivo, in which RASSF2 is maintained in a phosphorylated state and protects MST2 from degradation and turnover. Thus, we propose that the frequent loss of RASSF2 in tumours results in the destablization of MST2 and thus decreased apoptotic potential. Oncogene (2009) 28, 2988-2998; doi:10.1038/onc.2009.152; published online 15 June 2009	[Cooper, W. N.; Hesson, L. B.; Dallol, A.; Latif, F.] Univ Birmingham, Sect Med & Mol Genet, Inst Biomed Res, Birmingham B15 2TT, W Midlands, England; [Hesson, L. B.] UNSW, Fac Med, Lowy Canc Ctr, Sydney, NSW, Australia; [Hesson, L. B.] UNSW, Fac Med, POW Clin Sch, Sydney, NSW, Australia; [Matallanas, D.; von Kriegsheim, A.; Kolch, W.] Beatson Inst Canc Res, Prote & Signalling Networks Grp, Glasgow G61 1BD, Lanark, Scotland; [Kolch, W.] Univ Glasgow, Inst Biomed & Life Sci, Glasgow, Lanark, Scotland	University of Birmingham; University of New South Wales Sydney; University of New South Wales Sydney; Beatson Institute; University of Glasgow	Latif, F (corresponding author), Univ Birmingham, Sect Med & Mol Genet, Inst Biomed Res, Birmingham B15 2TT, W Midlands, England.	f.latif@bham.ac.uk	Kolch, Walter/ABF-2102-2021; Ward, Robyn L/I-2313-2013; Admin, SBI/HGB-2738-2022; gomez, david/U-9465-2019; Dallol, Ashraf/H-8661-2012; Hesson, Luke/HDM-0311-2022; von Kriegsheim, Alex/C-2371-2016	Ward, Robyn L/0000-0002-6877-8906; gomez, david/0000-0002-2360-3141; Dallol, Ashraf/0000-0002-8803-228X; von Kriegsheim, Alex/0000-0002-4952-8573; Kolch, Walter/0000-0001-5777-5016	Breast Cancer Campaign; Cancer Research UK; Sport Aiding Medical Research for Kids; European Union [LSHG-CT-2003-505520]	Breast Cancer Campaign; Cancer Research UK(Cancer Research UK); Sport Aiding Medical Research for Kids; European Union(European Commission)	We thank David Sumpton and Willy Bienvenut for the mass spectrometry. This work was supported by Breast Cancer Campaign, Cancer Research UK, Sport Aiding Medical Research for Kids (to FL) and The European Union FP6 project 'Interaction Proteome' (LSHG-CT-2003-505520) and Cancer Research UK (to WK).	Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Callus BA, 2006, FEBS J, V273, P4264, DOI 10.1111/j.1742-4658.2006.05427.x; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; Cooper WN, 2008, ONCOGENE, V27, P1805, DOI 10.1038/sj.onc.1210805; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; Deng Y, 2003, J BIOL CHEM, V278, P11760, DOI 10.1074/jbc.M211085200; Durocher Y, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.2.e9; Endoh M, 2005, BRIT J CANCER, V93, P1395, DOI 10.1038/sj.bjc.6602854; Fenton SL, 2004, CANCER RES, V64, P102, DOI 10.1158/0008-5472.CAN-03-2622; Glantschnig H, 2002, J BIOL CHEM, V277, P42987, DOI 10.1074/jbc.M208538200; Graves JD, 2001, J BIOL CHEM, V276, P14909, DOI 10.1074/jbc.M010905200; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Guo C, 2007, CURR BIOL, V17, P700, DOI 10.1016/j.cub.2007.02.055; Hesson LB, 2005, ONCOGENE, V24, P3987, DOI 10.1038/sj.onc.1208566; Hu Y, 2007, CELL DEATH DIFFER, V14, P2035, DOI 10.1038/sj.cdd.4402214; Hwang E, 2007, P NATL ACAD SCI USA, V104, P9236, DOI 10.1073/pnas.0610716104; Imai T, 2008, CANCER SCI, V99, P958, DOI 10.1111/j.1349-7006.2008.00769.x; Kaira K, 2007, INT J ONCOL, V31, P169; Kakeya H, 1998, CANCER RES, V58, P4888; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kurnari G, 2007, J MOL BIOL, V367, P1294, DOI 10.1016/j.jmb.2007.01.026; Kuznetsov S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003997; Lee KK, 2002, J BIOL CHEM, V277, P12351, DOI 10.1074/jbc.M108138200; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Liao XY, 2008, INT J CANCER, V123, P296, DOI 10.1002/ijc.23494; Lin YS, 2002, J BIOL CHEM, V277, P47991, DOI 10.1074/jbc.M202630200; MARUYAMA R, 2008, CARCINOGENESIS; O'Neill E, 2004, SCIENCE, V306, P2267, DOI 10.1126/science.1103233; Oh HJ, 2006, CANCER RES, V66, P2562, DOI 10.1158/0008-5472.CAN-05-2951; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; Rabizadeh S, 2004, J BIOL CHEM, V279, P29247, DOI 10.1074/jbc.M401699200; Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967; Scheel H, 2003, CURR BIOL, V13, pR899, DOI 10.1016/j.cub.2003.11.007; Ura S, 2001, P NATL ACAD SCI USA, V98, P10148, DOI 10.1073/pnas.181161698; Ura S, 2007, MOL CELL BIOL, V27, P5514, DOI 10.1128/MCB.00199-07; von Kriegsheim A, 2006, NAT CELL BIOL, V8, P1011, DOI 10.1038/ncb1465; von Kriegsheim A, 2008, METHODS MOL BIOL, V484, P177, DOI 10.1007/978-1-59745-398-1_12; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200	39	64	69	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2009	28	33					2988	2998		10.1038/onc.2009.152	http://dx.doi.org/10.1038/onc.2009.152			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485SA	19525978	Green Accepted			2022-12-17	WOS:000269142800007
J	Yap, LF; Jenei, V; Robinson, CM; Moutasim, K; Benn, TM; Threadgold, SP; Lopes, V; Wei, W; Thomas, GJ; Paterson, IC				Yap, L. F.; Jenei, V.; Robinson, C. M.; Moutasim, K.; Benn, T. M.; Threadgold, S. P.; Lopes, V.; Wei, W.; Thomas, G. J.; Paterson, I. C.			Upregulation of Eps8 in oral squamous cell carcinoma promotes cell migration and invasion through integrin-dependent Rac1 activation	ONCOGENE			English	Article						Eps8; oral cancer; integrin; migration; Rac1; invasion	EXTRACAPSULAR SPREAD; CANCER; EXPRESSION; IDENTIFICATION; GROWTH; HEAD; INTEGRIN-ALPHA(V)BETA(6); TRANSFORMATION; PROGRESSION; MOTILITY	Oral squamous cell carcinoma (OSCC) is a lethal disease and early death usually occurs as a result of local invasion and regional lymph node metastases. Current treatment regimens are, to a certain degree, inadequate, with a 5-year mortality rate of around 50% and novel therapeutic targets are urgently required. Using expression microarrays, we identified the eps8 gene as being overexpressed in OSCC cell lines relative to normal oral keratinocytes, and confirmed these findings using RT-PCR and western blotting. In human tissues, we found that Eps8 was upregulated in OSCC (32% of primary tumors) compared with normal oral mucosa, and that expression correlated significantly with lymph node metastasis (P = 0.032), suggesting a disease-promoting effect. Using OSCC cell lines, we assessed the functional role of Eps8 in tumor cells. Although suppression of Eps8 produced no effect on cell proliferation, both cell spreading and migration were markedly inhibited. The latter cell functions may be modulated through the small GTP-ase, Rac1 and we used pull-down assays to investigate the role of Eps8 in Rac1 signaling. We found that alpha v beta 6- and alpha 5 beta 1-integrin-dependent activation of Rac1 was mediated through Eps8. Knockdown of either Eps8 or Rac1, inhibited integrin-dependent cell migration similarly and transient expression of constitutively active Rac1 restored migration of cells in which Eps8 expression had been suppressed. We also showed that knockdown of Eps8 inhibited tumor cell invasion in an organotypic model of OSCC. These data suggest that Eps8 and Rac1 are part of an integrated signaling pathway modulating integrin-dependent tumour cell motility and identify Eps8 as a possible therapeutic target. Oncogene ( 2009) 28, 2524-2534; doi: 10.1038/onc.2009.105; published online 18 May 2009	[Jenei, V.; Moutasim, K.; Thomas, G. J.] Univ Southampton, Sch Med, Canc Sci Div, Southampton, Hants, England; [Yap, L. F.; Benn, T. M.; Threadgold, S. P.; Paterson, I. C.] Univ Bristol, Dept Oral & Dent Sci, Bristol, Avon, England; [Yap, L. F.] Canc Res Initiat Fdn, Kuala Lumpur, Malaysia; [Jenei, V.; Moutasim, K.; Thomas, G. J.] Barts & London Queen Marys Sch Med & Dent, Inst Canc, Tumor Biol Ctr, London, England; [Robinson, C. M.] Univ Newcastle, Sch Dent Sci, Newcastle Upon Tyne, Tyne & Wear, England; [Lopes, V.] Univ Edinburgh, Edinburgh Dent Inst, Edinburgh, Midlothian, Scotland; [Wei, W.] Univ Birmingham, Inst Canc Studies, Birmingham, W Midlands, England	University of Southampton; University of Bristol; University of London; Queen Mary University London; Newcastle University - UK; University of Edinburgh; University of Birmingham	Thomas, GJ (corresponding author), Univ Southampton, Sch Med, Canc Sci Div, Tremona Rd, Southampton, Hants, England.	g.thomas@soton.ac.uk	Paterson, Ian/G-8688-2011; Yap, Lee-Fah/M-1065-2016; Robinson, Max/R-5280-2018	Paterson, Ian/0000-0001-9156-401X; Yap, Lee-Fah/0000-0002-6815-3607; Robinson, Max/0000-0003-4491-6865; Wei, Wenbin/0000-0003-1288-6999	Cancer Research Initiatives Foundation, Malaysia; Health Foundation	Cancer Research Initiatives Foundation, Malaysia; Health Foundation	The Cancer Research Initiatives Foundation, Malaysia and The Health Foundation supported the research.	Al Moustafa AE, 2002, ONCOGENE, V21, P2634, DOI 10.1038/sj.onc.1205351; Alevizos I, 2001, ONCOGENE, V20, P6196, DOI 10.1038/sj.onc.1204685; Bates RC, 2005, J CLIN INVEST, V115, P339, DOI 10.1172/JCI200523183; Croce A, 2004, NAT CELL BIOL, V6, P1173, DOI 10.1038/ncb1198; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; del Pozo MA, 2004, SCIENCE, V303, P839, DOI 10.1126/science.1092571; Disanza A, 2004, NAT CELL BIOL, V6, P1180, DOI 10.1038/ncb1199; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; Elayadi AN, 2007, CANCER RES, V67, P5889, DOI 10.1158/0008-5472.CAN-07-0245; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; Funato Y, 2004, CANCER RES, V64, P5237, DOI 10.1158/0008-5472.CAN-04-0327; Innocenti M, 2003, J CELL BIOL, V160, P17, DOI 10.1083/jcb.200206079; Inobe M, 1999, BIOCHEM BIOPH RES CO, V266, P216, DOI 10.1006/bbrc.1999.1782; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jeon GA, 2004, INT J CANCER, V112, P249, DOI 10.1002/ijc.20399; Kim MM, 2004, INT J CANCER, V112, P545, DOI 10.1002/ijc.20379; Maa MC, 2001, ONCOGENE, V20, P106, DOI 10.1038/sj.onc.1204069; Maa MC, 2007, J BIOL CHEM, V282, P19399, DOI 10.1074/jbc.M610280200; Marsh D, 2008, CANCER RES, V68, P3295, DOI 10.1158/0008-5472.CAN-08-0174; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; Miki H, 2000, NATURE, V408, P732, DOI 10.1038/35047107; Myers JN, 2001, CANCER-AM CANCER SOC, V92, P3030, DOI 10.1002/1097-0142(20011215)92:12<3030::AID-CNCR10148>3.0.CO;2-P; Nystrom ML, 2006, CANCER RES, V66, P10833, DOI 10.1158/0008-5472.CAN-06-1640; Nystrom ML, 2005, J PATHOL, V205, P468, DOI 10.1002/path.1716; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; PRIME SS, 1990, J PATHOL, V160, P259, DOI 10.1002/path.1711600313; Ramsay AG, 2007, CANCER RES, V67, P5275, DOI 10.1158/0008-5472.CAN-07-0318; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Scita G, 2001, J CELL BIOL, V154, P1031, DOI 10.1083/jcb.200103146; Thirthagiri E, 2007, CANCER LETT, V258, P276, DOI 10.1016/j.canlet.2007.09.008; Thomas GJ, 2002, BRIT J CANCER, V87, P859, DOI 10.1038/sj.bjc.6600545; Thomas GJ, 2001, INT J CANCER, V92, P641, DOI 10.1002/1097-0215(20010601)92:5<641::AID-IJC1243>3.0.CO;2-P; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Welsch T, 2007, CANCER LETT, V255, P205, DOI 10.1016/j.canlet.2007.04.008; Woolgar JA, 2003, ORAL ONCOL, V39, P130, DOI 10.1016/S1368-8375(02)00030-1; Yao J, 2006, CANCER RES, V66, P4065, DOI 10.1158/0008-5472.CAN-05-4083; Yeudall WA, 2005, ORAL ONCOL, V41, P698, DOI 10.1016/j.oraloncology.2005.03.004	38	64	67	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2009	28	27					2524	2534		10.1038/onc.2009.105	http://dx.doi.org/10.1038/onc.2009.105			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468HD	19448673				2022-12-17	WOS:000267806800005
J	Wang, IC; Meliton, L; Tretiakova, M; Costa, RH; Kalinichenko, VV; Kalin, TV				Wang, I-C; Meliton, L.; Tretiakova, M.; Costa, R. H.; Kalinichenko, V. V.; Kalin, T. V.			Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors	ONCOGENE			English	Article						winged helix DNA-binding domain; forkhead transcription factor; Foxm1; non-small cell lung cancer; lung epithelial cells; cellular proliferation	GENE-EXPRESSION; CYCLOOXYGENASE-2 EXPRESSION; HEPATOCELLULAR-CARCINOMA; FOXM1; PROGRESSION; CELLS; IDENTIFICATION; PROLIFERATION; PATHWAYS; NETWORK	The forkhead box m1 (Foxm1 or Foxm1b) protein (previously called HFH-11B, Trident, Win or MPP2) is abundantly expressed in human non-small cell lung cancers where it transcriptionally induces expression of genes essential for proliferation of tumor cells. In this study, we used Rosa26-Foxm1 transgenic mice, in which the Rosa26 promoter drives ubiquitous expression of Foxm1 transgene, to identify new signaling pathways regulated by Foxm1. Lung tumors were induced in Rosa26-Foxm1 mice using the 3-methylcholanthrene (MCA)/butylated hydroxytoluene (BHT) lung tumor initiation/promotion protocol. Tumors from MCA/BHT-treated Rosa26-Foxm1 mice displayed a significant increase in the number, size and DNA replication compared to wild-type mice. Elevated tumor formation in Rosa26-Foxm1 transgenic lungs was associated with persistent pulmonary inflammation, macrophage infiltration and increased expression of cyclooxygenase-2 (Cox-2), Cdc25C phosphatase, cyclin E2, chemokine ligands CXCL5, CXCL1 and CCL3, cathepsins and matrix metalloprotease-12. Cell culture experiments with A549 human lung adenocarcinoma cells demonstrated that depletion of Foxm1 by either short interfering RNA transfection or treatment with Foxm1-inhibiting ARF 26-44 peptide significantly reduced Cox-2 expression. In co-transfection experiments, Foxm1 protein-induced Cox-2 promoter activity and directly bound to the -2566/- 2580 bp region of human Cox-2 promoter.	[Wang, I-C; Kalinichenko, V. V.; Kalin, T. V.] Cincinnati Childrens Hosp Res Fdn, Div Pulm Biol, Cincinnati, OH 45229 USA; [Meliton, L.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Tretiakova, M.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; [Costa, R. H.] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University of Chicago; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kalin, TV (corresponding author), Cincinnati Childrens Hosp Res Fdn, Div Pulm Biol, 3333 Burnet Ave,MLC 7009, Cincinnati, OH 45229 USA.	kal4ti@cchmc.org	Tretiakova, Maria/U-3320-2019	Wang, I-Ching/0000-0003-4398-2975	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054687] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acuff HB, 2006, CANCER RES, V66, P7968, DOI 10.1158/0008-5472.CAN-05-4279; Blaine SA, 2005, CARCINOGENESIS, V26, P209, DOI 10.1093/carcin/bgh302; Bratt T, 2000, BBA-PROTEIN STRUCT M, V1482, P318, DOI 10.1016/S0167-4838(00)00154-0; Chang MS, 2005, CELL SIGNAL, V17, P299, DOI 10.1016/j.cellsig.2004.07.008; Chun KS, 2004, BIOCHEM PHARMACOL, V68, P1089, DOI 10.1016/j.bcp.2004.05.031; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLEVIDENCE DE, 1993, P NATL ACAD SCI USA, V90, P3948, DOI 10.1073/pnas.90.9.3948; Costa RH, 2005, CURR OPIN GENET DEV, V15, P42, DOI 10.1016/j.gde.2004.12.007; Giaccone G, 1996, CHEST, V109, pS130, DOI 10.1378/chest.109.5_Supplement.130S; Gusarova GA, 2007, J CLIN INVEST, V117, P99, DOI 10.1172/JCI27527; Kalin TV, 2006, CANCER RES, V66, P1712, DOI 10.1158/0008-5472.CAN-05-3138; Kalinichenko VV, 2003, J BIOL CHEM, V278, P37888, DOI 10.1074/jbc.M305555200; Kalinichenko VV, 2001, DEV BIOL, V235, P489, DOI 10.1006/dbio.2001.0322; Kalinichenko VV, 2001, AM J PHYSIOL-LUNG C, V280, pL695, DOI 10.1152/ajplung.2001.280.4.L695; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kim IM, 2006, CANCER RES, V66, P2153, DOI 10.1158/0008-5472.CAN-05-3003; Kim IM, 2005, J BIOL CHEM, V280, P37908, DOI 10.1074/jbc.M506531200; Kim IM, 2005, J BIOL CHEM, V280, P22278, DOI 10.1074/jbc.M500936200; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Krupczak-Hollis K, 2004, DEV BIOL, V276, P74, DOI 10.1016/j.ydbio.2004.08.022; Kulbe H, 2004, INT J DEV BIOL, V48, P489, DOI 10.1387/ijdb.041814hk; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Major ML, 2004, MOL CELL BIOL, V24, P2649, DOI 10.1128/MCB.24.7.2649-2661.2004; Malkinson AM, 1998, EXP LUNG RES, V24, P541, DOI 10.3109/01902149809087385; Malkinson AM, 1997, CANCER RES, V57, P2832; McCormick Frank, 1999, Trends in Cell Biology, V9, pM53, DOI 10.1016/S0962-8924(99)01668-2; Mitsuuchi Y, 2002, AM J MED GENET, V115, P183, DOI 10.1002/ajmg.10692; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Obama K, 2005, HEPATOLOGY, V41, P1339, DOI 10.1002/hep.20718; Park HJ, 2008, ONCOGENE, V27, P1696, DOI 10.1038/sj.onc.1210814; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277; Riedl K, 2004, DRUG RESIST UPDATE, V7, P169, DOI 10.1016/j.drup.2004.04.003; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Teh MT, 2002, CANCER RES, V62, P4773; Toloza EM, 2006, J CELL BIOCHEM, V99, P1, DOI 10.1002/jcb.20851; Tong M, 2006, CARCINOGENESIS, V27, P2170, DOI 10.1093/carcin/bgl053; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Wolters P J, 2000, Respir Res, V1, P170, DOI 10.1186/rr29; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Zhao YY, 2006, J CLIN INVEST, V116, P2333, DOI 10.1172/JCI27154	46	64	70	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2008	27	30					4137	4149		10.1038/onc.2008.60	http://dx.doi.org/10.1038/onc.2008.60			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18345025				2022-12-17	WOS:000257496800001
J	Szabova, L; Chrysovergis, K; Yamada, SS; Holmbeck, K				Szabova, L.; Chrysovergis, K.; Yamada, S. S.; Holmbeck, K.			MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease	ONCOGENE			English	Article						MT1-MMP; PyMT; mammary cancer; metastasis; collagen; proteolysis	MATRIX METALLOPROTEINASES; PERICELLULAR PROTEOLYSIS; EXTRACELLULAR-MATRIX; BREAST CARCINOMAS; CANCER INVASION; DEFICIENT MICE; MEMBRANE; EXPRESSION; CELLS; ANGIOGENESIS	Membrane-type I matrix metalloproteinase (MT1-MMP) is associated with multiple forms of cancer including mammary cancer. To directly evaluate the significance of MT1-MMP expression in tumor progression and metastasis using a genetically induced cancer model, we crossed MT1-MMP-deficient mice to MMTV-polyoma virus middle T-antigen (PyMT) mice. Expression of PyMT in the MT1-MMP-deficient background consistently resulted in hyperplasia of the mammary gland as seen in wild-type PyMT littermates. Following orthotopic transplantation of PyMT + glands into the cleared mammary fat pad of syngeneic recipient mice, MT1-MMP-deficient tumors were palpable earlier than wild-type tumors. Moreover, MT1-MMP-deficient tumors grew to the experimental end point size quicker than control tumors, but demonstrated markedly reduced ability to metastasize to the lungs of recipient mice. Accordingly, MT1-MMP deficient mice displayed an overall reduction in metastasis count of 50%. MT1-MMP was expressed solely in the stroma of PyMT-induced tumors and those metastatic nodules that formed in the lungs were devoid of MT1-MMP expression. Stromal fibbroblasts isolated from MT1-MMP-deficient tumors did not degrade type I collagen suggesting that efficient dissemination of tumor cells is dependent on stromal cell remodeling of the tumor environment. The data demonstrate directly that MT1-MMP-mediated proteolysis by stromal cells is important in the metastatic process.	[Szabova, L.; Chrysovergis, K.; Yamada, S. S.; Holmbeck, K.] Natl Inst Dent & Craniofacial Res, Matrix Metalloproteinase Unit, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Holmbeck, K (corresponding author), Natl Inst Dent & Craniofacial Res, Matrix Metalloproteinase Unit, Craniofacial & Skeletal Dis Branch, NIH, Bldg 30,Room 125,30 Convent Dr,MSC 4380, Bethesda, MD 20892 USA.	kenn.holmbeck@nih.gov		Holmbeck, Kenn/0000-0002-4472-3257	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000676] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Andarawewa KL, 2003, CANCER RES, V63, P5844; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Bisson C, 2003, INT J CANCER, V105, P7, DOI 10.1002/ijc.11012; Blavier L, 2001, MOL BIOL CELL, V12, P1457, DOI 10.1091/mbc.12.5.1457; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Bugge TH, 1998, ONCOGENE, V16, P3097, DOI 10.1038/sj.onc.1201869; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Holmbeck K, 2003, J CELL BIOL, V163, P661, DOI 10.1083/jcb.200307061; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Hotary K, 2006, GENE DEV, V20, P2673, DOI 10.1101/gad.1451806; Itoh T, 1998, CANCER RES, V58, P1048; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; McCawley LJ, 2004, CANCER RES, V64, P6965, DOI 10.1158/0008-5472.CAN-04-0910; Murphy G, 2002, ARTHRITIS RES THER, V4, DOI 10.1186/ar572; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Pedersen TX, 2005, CARCINOGENESIS, V26, P1233, DOI 10.1093/carcin/bgi065; Pendas AM, 2004, MOL CELL BIOL, V24, P5304, DOI 10.1128/MCB.24.12.5304-5313.2004; Polette M, 1996, VIRCHOWS ARCH, V428, P29; Polette M, 1997, CLIN EXP METASTAS, V15, P157, DOI 10.1023/A:1018404927753; Ricard-Blum S, 2005, PATHOL BIOL, V53, P430, DOI 10.1016/j.patbio.2004.12.024; Rosenthal EL, 2004, ARCH OTOLARYNGOL, V130, P943, DOI 10.1001/archotol.130.8.943; Seiki M, 2003, CANCER SCI, V94, P569, DOI 10.1111/j.1349-7006.2003.tb01484.x; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Szabova L, 2005, J CELL PHYSIOL, V205, P123, DOI 10.1002/jcp.20385; Tran KT, 2005, J DERMATOL SCI, V40, P11, DOI 10.1016/j.jdermsci.2005.05.001; Ueno H, 1997, CANCER RES, V57, P2055; Vizoso FJ, 2007, BRIT J CANCER, V96, P903, DOI 10.1038/sj.bjc.6603666; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Winkler MK, 2002, AM J PHYSIOL-LUNG C, V283, pL1, DOI 10.1152/ajplung.00489.2001; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Zatterstrom UK, 2000, CELL STRUCT FUNCT, V25, P97	38	64	66	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	23					3274	3281		10.1038/sj.onc.1210982	http://dx.doi.org/10.1038/sj.onc.1210982			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18071307				2022-12-17	WOS:000256111400006
J	Vasilcanu, R; Vasilcanu, D; Rosengren, L; Natalishvili, N; Sehat, B; Yin, S; Girnita, A; Axelson, M; Girnita, L; Larsson, O				Vasilcanu, R.; Vasilcanu, D.; Rosengren, L.; Natalishvili, N.; Sehat, B.; Yin, S.; Girnita, A.; Axelson, M.; Girnita, L.; Larsson, O.			Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1	ONCOGENE			English	Article						PPP; IGF-1R; MDM2; beta-arrestin1; cancer	GROWTH-FACTOR-I; IGF-1 RECEPTOR; CYCLOLIGNAN PPP; BETA-ARRESTIN; CELL-GROWTH; MULTIPLE-MYELOMA; TYROSINE KINASE; UVEAL MELANOMA; TUMOR-GROWTH; MOUSE MODEL	The insulin-like growth factor 1 receptor (IGF-1R) is crucial for growth and survival of malignant cells. Experience in targeting IGF-1R in cancer models has shown that strategies promoting downregulation of the receptor are much more efficient in inducing apoptosis than those inhibiting the IGF-1R activity. Recently, we found that the cyclolignan picropodophyllin (PPP) inhibits phosphorylation of IGF-1R and activation of downstream signaling without interfering with the highly homologous insulin receptor (IR). Furthermore, PPP treatment caused strong regression of tumor grafts and prolonged survival of animals with systemic tumor disease. Here we demonstrate that PPP also downregulates the IGF-1R, whereas the IR and several other receptors were not affected. PPP-induced IGF-1R downregulation required expression of the MDM2 E3 ligase, which recently was found to ubiquitinate and cause degradation of the IGF-1R. In addition knockdown of beta-arrestin1, the adaptor molecule known to bridges MDM2 and IGF-1R, prevented downregulation of the receptor and significantly decreased PPP-induced cell death. All together these data suggest that PPP downregulates IGF-1R by interfering with the action of beta-arrestin1/MDM2 as well as the achieved receptor downregulation contributes to the apoptotic effect of PPP.	[Vasilcanu, R.; Vasilcanu, D.; Rosengren, L.; Natalishvili, N.; Sehat, B.; Yin, S.; Girnita, A.; Girnita, L.; Larsson, O.] Karolinska Inst, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; [Vasilcanu, R.; Vasilcanu, D.; Rosengren, L.; Natalishvili, N.; Sehat, B.; Yin, S.; Girnita, A.; Girnita, L.; Larsson, O.] Karolinska Univ Hosp, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; [Axelson, M.] Karolinska Univ Hosp, Dept Clin Chem, SE-17176 Stockholm, Sweden; [Axelson, M.] Karolinska Inst, Dept Clin Chem, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Larsson, O (corresponding author), Karolinska Inst, Dept Pathol & Oncol, CCK R8 04, SE-17176 Stockholm, Sweden.	Olle.Larsson@ki.se	Girnita, Leonard/A-4168-2008; Girnita, Ada/AAC-4518-2020	Girnita, Leonard/0000-0003-0280-9500; 				Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; All-Ericsson C, 2002, INVEST OPHTH VIS SCI, V43, P1; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 2005, EXPERT OPIN THER TAR, V9, P753, DOI 10.1517/14728222.9.4.753; Baserga R, 2004, EUR J CANCER, V40, P2013, DOI 10.1016/j.ejca.2004.06.015; Baserga R, 1997, BBA-REV CANCER, V1332, pF105, DOI 10.1016/S0304-419X(97)00007-3; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; BUCHARDT O, 1986, J PHARM SCI, V75, P1076, DOI 10.1002/jps.2600751111; Catrina SB, 2005, BRIT J CANCER, V92, P1467, DOI 10.1038/sj.bjc.6602408; Colon E, 2007, ENDOCRINOLOGY, V148, P128, DOI 10.1210/en.2006-0835; Conti L, 2007, BLOOD, V109, P2496, DOI 10.1182/blood-2006-07-034231; GHOSH RN, 1994, J CELL SCI, V107, P2177; Girnita A, 2004, CANCER RES, V64, P236, DOI 10.1158/0008-5472.CAN-03-2522; Girnita A, 2006, CLIN CANCER RES, V12, P1383, DOI 10.1158/1078-0432.CCR-05-1106; Girnita L, 2000, CANCER RES, V60, P5278; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Girnita L, 2000, ANTI-CANCER DRUG DES, V15, P67; Girnita L, 2005, J BIOL CHEM, V280, P24412, DOI 10.1074/jbc.M501129200; Girnita L, 2007, J BIOL CHEM, V282, P11329, DOI 10.1074/jbc.M611526200; Larsson O, 2005, BRIT J CANCER, V92, P2097, DOI 10.1038/sj.bjc.6602627; Lee CT, 1996, CANCER RES, V56, P3038; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Loughran G, 2005, ONCOGENE, V24, P6185, DOI 10.1038/sj.onc.1208772; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; Menu E, 2006, BLOOD, V107, P655, DOI 10.1182/blood-2005-01-0293; Menu E, 2007, INT J CANCER, V121, P1857, DOI 10.1002/ijc.22845; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Razuvaev A, 2007, J VASC SURG, V46, P108, DOI 10.1016/j.jvs.2007.02.066; RESNICOFF M, 1994, CANCER RES, V54, P4848; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Samani AA, 2007, ENDOCR REV, V28, P20, DOI 10.1210/er.2006-0001; Sehat B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000340; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Stromberg T, 2006, BLOOD, V107, P669, DOI 10.1182/blood-2005-01-0306; Tomizawa M, 2006, WORLD J GASTROENTERO, V12, P6531, DOI 10.3748/wjg.v12.i40.6531; Ulfarsson E, 2005, CLIN CANCER RES, V11, P4674, DOI 10.1158/1078-0432.CCR-05-0129; Vasilcanu D, 2004, ONCOGENE, V23, P7854, DOI 10.1038/sj.onc.1208065; Vasilcanu D, 2006, ONCOGENE, V25, P3186, DOI 10.1038/sj.onc.1209339; Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363-3372.2003; Xie YT, 1999, CANCER RES, V59, P3588; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472	42	64	68	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1629	1638		10.1038/sj.onc.1210797	http://dx.doi.org/10.1038/sj.onc.1210797			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17828296				2022-12-17	WOS:000253815800015
J	Veeck, J; Chorovicer, M; Naami, A; Breuer, E; Zafrakas, M; Bektas, N; Durst, M; Kristiansen, G; Wild, PJ; Hartmann, A; Knuechel, R; Dahl, E				Veeck, J.; Chorovicer, M.; Naami, A.; Breuer, E.; Zafrakas, M.; Bektas, N.; Duerst, M.; Kristiansen, G.; Wild, P. J.; Hartmann, A.; Knuechel, R.; Dahl, E.			The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation	ONCOGENE			English	Article						inter-alpha-trypsin inhibitor heavy chain ( ITIH); breast cancer; prognostic marker; predictive marker; tumour invasion; metastasis	ALPHA-TRYPSIN INHIBITOR; FACTOR-STIMULATED GENE-6; SHAP-HYALURONAN COMPLEX; TUMOR-SUPPRESSOR GENES; DNA METHYLATION; HEAVY-CHAIN; OVARIAN-CANCER; FAMILY; BINDING; TISSUE	Inter-alpha-trypsin inhibitors (ITIs) are protease inhibitors stabilizing the extracellular matrix. ITIs consist of one light (bikunin) and two heavy chains (ITIHs). We have recently characterized ITIH5, a novel member of the ITIH gene family, and showed that its messenger RNA is lost in a high proportion of breast tumours. In the present study, an ITIH5-specific polyclonal antibody was generated, validated with western blot and used for immunohistochemical analysis on a tissue microarray; ITIH5 was strongly expressed in epithelial cells of normal breast (n = 11/15), while it was lost or strongly reduced in 42% (92/217) of invasive breast cancers. ITIH5 expression in invasive carcinomas was associated with positive expression of oestrogen receptor (P = 0.008) and histological grade (P = 0.024). Correlation of ITIH5 expression with clinical outcome revealed that patients with primary tumours retaining abundant ITIH5 expression had longer recurrence-free survival (RFS; P = 0.037) and overall survival (OS; P = 0.044), compared to those with reduced expression (mean RFS: 102 vs 78 months; mean OS: 120 vs 105 months). Methylation-specific PCR analysis frequently showed strong methylation of the ITIH5 promoter in primary breast tumours (41%, n = 109) and breast cancer cell lines (n = 6). Methylation was significantly associated with mRNA loss (P<0.001; n = 39), and ITIH5 expression was induced after treatment of tumour cell lines with the demethylating agent 5-aza-2'-deoxycytidine. Moreover, ITIH5 promoter methylation was significantly associated with reduced OS (P = 0.008). The cellular function of ITIH5 was evaluated by forced expression of a full-length ITIH5 complementary DNA in the breast cancer cell line MDA-MB-231, which does not endogenously express ITIH5. ITIH5-expressing clones showed a 40% reduced proliferation rate compared to mock-transfected cells. Overall, these data show that promoter methylation-mediated loss of ITIH5 expression is associated with unfavourable outcome in breast cancer patients, and thus ITIH5 could be used as a prognostic marker, although this marker is not multivariate independent due to its close association with ER expression. Our data indicate that ITIH5 is a candidate class II tumour suppressor gene and could be involved in tumour progression, invasion and metastasis, as its absence is associated with increased proliferation rates and a prognostic value indicating poor clinical outcome.	[Veeck, J.; Chorovicer, M.; Naami, A.; Breuer, E.; Zafrakas, M.; Bektas, N.; Knuechel, R.; Dahl, E.] Rhein Westfal TH Aachen, Univ Hosp Aachen, Inst Pathol, Mol Oncol Grp, D-52074 Aachen, Germany; [Duerst, M.] Univ Jena, Dept Gynecol & Obstet, Jena, Germany; [Kristiansen, G.] Univ Med Berlin, Inst Pathol, Berlin, Germany; [Wild, P. J.] Univ Zurich, Inst Pathol, Zurich, Switzerland; [Hartmann, A.] Univ Regensburg, Inst Pathol, Regensburg, Germany	RWTH Aachen University; RWTH Aachen University Hospital; Friedrich Schiller University of Jena; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Zurich; University of Regensburg	Dahl, E (corresponding author), Rhein Westfal TH Aachen, Univ Hosp Aachen, Inst Pathol, Mol Oncol Grp, Pauwelsstr 30, D-52074 Aachen, Germany.	edahl@ukaachen.de	Veeck, Jürgen/B-9256-2008; , Zafrakas-M/ABA-8487-2021	Veeck, Jürgen/0000-0002-2952-6159; 				Atmani F, 1999, UROL RES, V27, P57, DOI 10.1007/s002400050089; Bachman KE, 1999, CANCER RES, V59, P798; Balduyck M, 2000, J LAB CLIN MED, V135, P188, DOI 10.1067/mlc.2000.104462; Bost F, 1998, EUR J BIOCHEM, V252, P339, DOI 10.1046/j.1432-1327.1998.2520339.x; Bourguignon J, 1999, J HISTOCHEM CYTOCHEM, V47, P1625, DOI 10.1177/002215549904701214; CHEN L, 1994, J BIOL CHEM, V269, P28282; Dahl E, 2005, J PATHOL, V205, P21, DOI 10.1002/path.1687; Dahl E, 2006, CLIN CANCER RES, V12, P3950, DOI 10.1158/1078-0432.CCR-05-2090; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; DIARRAMEHRPOUR M, 1989, EUR J BIOCHEM, V179, P147, DOI 10.1111/j.1432-1033.1989.tb14532.x; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; Esteller M, 2005, CURR OPIN ONCOL, V17, P55, DOI 10.1097/01.cco.0000147383.04709.10; Esteller M, 1999, CANCER RES, V59, P67; Fujita Y, 2004, J HUM GENET, V49, P24, DOI 10.1007/s10038-003-0101-8; GRAFF JR, 1995, CANCER RES, V55, P5195; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Himmelfarb M, 2004, CANCER LETT, V204, P69, DOI 10.1016/j.canlet.2003.09.011; HUANG L, 1993, J BIOL CHEM, V268, P26725; Janssen U, 2001, KIDNEY INT, V60, P126, DOI 10.1046/j.1523-1755.2001.00779.x; Jessen TE, 2003, REPRODUCTION, V125, P27, DOI 10.1530/rep.0.1250027; KOBAYASHI H, 1995, J BIOL CHEM, V270, P8361, DOI 10.1074/jbc.270.14.8361; Onda H, 1999, J CEREBR BLOOD F MET, V19, P1279, DOI 10.1097/00004647-199911000-00013; Paris S, 2002, INT J CANCER, V97, P615, DOI 10.1002/ijc.10120; Pineiro M, 2004, INFECT IMMUN, V72, P3777, DOI 10.1128/IAI.72.7.3777-3782.2004; REMMELE W, 1987, PATHOLOGE, V8, P138; Rugg MS, 2005, J BIOL CHEM, V280, P25674, DOI 10.1074/jbc.M501332200; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; Sanggaard KW, 2005, J BIOL CHEM, V280, P11936, DOI 10.1074/jbc.M409016200; Shao GZ, 2006, CANCER RES, V66, P4566, DOI 10.1158/0008-5472.CAN-05-2130; Sobin L., 1997, UICC TNM CLASSIFICAT, P184; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386; Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115; Yingsung W, 2003, J BIOL CHEM, V278, P32710, DOI 10.1074/jbc.M303658200; YONEDA M, 1990, J BIOL CHEM, V265, P5247; Zhang Z, 2004, CANCER RES, V64, P5882, DOI 10.1158/0008-5472.CAN-04-0746; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657; Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200	39	64	68	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					865	876		10.1038/sj.onc.1210669	http://dx.doi.org/10.1038/sj.onc.1210669			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17653090				2022-12-17	WOS:000252884500016
J	Broude, EV; Swift, ME; Vivo, C; Chang, BD; Davis, BM; Kalurupalle, S; Blagosklonny, MV; Roninson, IB				Broude, E. V.; Swift, M. E.; Vivo, C.; Chang, B-D; Davis, B. M.; Kalurupalle, S.; Blagosklonny, M. V.; Roninson, I. B.			p21(Waf1/Cip1/Sdi1) mediates retinoblastoma protein degradation	ONCOGENE			English	Article						p21; Rb; p27; damage response	RETROVIRAL VECTORS; TUMOR-CELLS; DNA-DAMAGE; SENESCENCE; ARREST; P21; P53; FIBROBLASTS; REQUIREMENT; SUPPRESSION	Damage-induced G1 checkpoint in mammalian cells involves upregulation of p53, which activates transcription of p21(Waf1) (CDKN1A). Inhibition of cyclin-dependent kinase (CDK)2 and CDK4/6 by p21 leads to dephosphorylation and activation of Rb. We now show that ectopic p21. expression in human HT1080 fibrosarcoma cells causes not only dephosphorylation but also depletion of Rb; this effect was p53-independent and susceptible to a proteasome inhibitor. CDK inhibitor p27 (CDKN1B) also caused Rb dephosphorylation and depletion, but another CDK inhibitor p16 (CDKN2A) induced only dephosphorylation but not depletion of Rb. Rb depletion was observed in both HT1080 and HCT116 colon carcinoma cells, where p21. was induced by DNA-damaging agents. Rb depletion after DNA damage did not occur in the absence of p21, and it was reduced when p21 induction was inhibited by p21-targeting short hairpin RNA or by a transdominant inhibitor of p53. These results indicate that p2l both activates Rb through dephosphorylation and inactivates it through degradation, suggesting negative feedback regulation of damage-induced cell-cycle checkpoint arrest.	Ordway Res Inst, Ctr Canc, Albany, NY 12208 USA; Univ Illinois, Dept Mol Genet, Chicago, IL USA	Ordway Research Institute; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Roninson, IB (corresponding author), Ordway Res Inst, Ctr Canc, 150 New Scotland Ave, Albany, NY 12208 USA.	roninson@ordwayresearch.org	Roninson, Igor/K-1310-2017	Roninson, Igor/0000-0002-9211-1327	NCI NIH HHS [R01 CA95727, R01 CA62099] Funding Source: Medline; NIA NIH HHS [R01 AG17921] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062099, R01CA095727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017921] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Boyer SN, 1996, CANCER RES, V56, P4620; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chang BD, 1996, GENE, V183, P137, DOI 10.1016/S0378-1119(96)00532-X; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; Kandel ES, 1997, SOMAT CELL MOLEC GEN, V23, P325, DOI 10.1007/BF02674280; Kehn K, 2005, ONCOGENE, V24, P525, DOI 10.1038/sj.onc.1208105; Maliyekkel A, 2006, CELL CYCLE, V5, P2390, DOI 10.4161/cc.5.20.3363; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; SMITH ML, 1994, EXP CELL RES, V215, P386, DOI 10.1006/excr.1994.1356; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Ying HQ, 2006, CELL CYCLE, V5, P506, DOI 10.4161/cc.5.5.2515	21	64	65	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 18	2007	26	48					6954	6958		10.1038/sj.onc.1210516	http://dx.doi.org/10.1038/sj.onc.1210516			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17486059				2022-12-17	WOS:000250188400011
J	Moniz, S; Verissimo, F; Matos, P; Brazao, R; Silva, E; Kotevelets, L; Chastre, E; Gespach, C; Jordan, P				Moniz, S.; Verissimo, F.; Matos, P.; Brazao, R.; Silva, E.; Kotevelets, L.; Chastre, E.; Gespach, C.; Jordan, P.			Protein kinase WNK2 inhibits cell proliferation by negatively modulating the activation of MEK1/ERK1/2	ONCOGENE			English	Article						cell cycle progression; EGF; ERK MAP kinase pathway; MEK1; WNK protein kinases	CROSS-CASCADE ACTIVATION; WNK KINASES; CYCLE ARREST; PHOSPHORYLATION; RAS; SPAK; MEK1; IDENTIFICATION; EXPRESSION; MUTATIONS	The recently identified subfamily of WNK protein kinases is characterized by a unique sequence variation in the catalytic domain and four related human WNK genes were identified. Here, we describe the cloning and functional analysis of the human family member WNK2. We show that the depletion of endogenous WNK2 expression by RNA interference in human cervical HeLa cancer cells led to the activation of the extracellular signal - regulated kinase ( ERK) 1/ 2 mitogen- activated protein kinases but, in contrast to the depletion of WNK1, had no effect on ERK5. Furthermore, expression of a kinase-dead WNK2- K207M mutant also activated ERK1/ 2 suggesting that WNK2 catalytic activity is required. Depletion of WNK2 expression increased G1/ S progression and potentiated the cellular response to low epidermal growth factor concentrations. The molecular mechanism of ERK1/ 2 activation in WNK2- depleted cells lies downstream of the Raf kinases and involves MEK1 phosphorylation at serine 298 in both HeLa and HT29 colon cancer cells. This modi. cation is linked to the upregulation of MEK1 activity toward ERK1/2. Together, these results provide evidence that WNK2 is involved in the modulation of growth factor - induced cancer cell proliferation through the MEK1/ERK1/2 pathway. The data identify WNK2 as a candidate tumor suppressor gene and suggest a coordinated activity of WNK kinases in the regulation of cell proliferation. ' in ' ' '	Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, P-1649016 Lisbon, Portugal; INSERM, U773, Ctr Rech Biomed Bichat Bequjon CRB3, Paris, France; Univ Paris 07, Paris, France; INSERM U673, Paris, France; Univ Paris 06, Fac Med, Lab Mol & Clin Oncol Solid Tumors, Paris, France	Instituto Nacional de Saude Dr. Ricardo Jorge; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Jordan, P (corresponding author), Inst Nacl Saude Dr Ricardo Jorge, Ctr Genet Humana, Avenida,Padre Cruz, P-1649016 Lisbon, Portugal.	peter.jordan@insa.min-saude.pt	Jordan, Peter/G-9335-2012; CHASTRE, Eric/L-8446-2018; Matos, Paulo/F-5245-2012; Matos, Paulo/P-3012-2019	Jordan, Peter/0000-0002-1425-9211; CHASTRE, Eric/0000-0002-8993-1228; Matos, Paulo/0000-0002-9379-9696; Matos, Paulo/0000-0002-9379-9696				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Balmanno K, 1999, ONCOGENE, V18, P3085, DOI 10.1038/sj.onc.1202647; Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj.onc.1205302; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; Ebisuya M, 2005, J CELL SCI, V118, P2997, DOI 10.1242/jcs.02505; Eblen ST, 2002, MOL CELL BIOL, V22, P6023, DOI 10.1128/MCB.22.17.6023-6033.2002; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gagnon KBE, 2006, MOL CELL BIOL, V26, P689, DOI 10.1128/MCB.26.2.689-698.2006; Gamba G, 2005, AM J PHYSIOL-RENAL, V288, pF245, DOI 10.1152/ajprenal.00311.2004; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hong CB, 2007, P NATL ACAD SCI USA, V104, P10974, DOI 10.1073/pnas.0700683104; Ito M, 2001, CANCER RES, V61, P2038; Jiang ZY, 2005, J BIOL CHEM, V280, P21622, DOI 10.1074/jbc.m414464200; Kahle KT, 2004, CURR OPIN NEPHROL HY, V13, P557, DOI 10.1097/00041552-200409000-00012; Kerkhoff E, 1998, CANCER RES, V58, P1636; Kostich M, 2002, GENOME BIOL, V3; Lee BH, 2004, MOL CELL, V15, P741, DOI 10.1016/j.molcel.2004.07.018; Lenertz LY, 2005, J BIOL CHEM, V280, P26653, DOI 10.1074/jbc.M502598200; Li WQ, 2000, GENE DEV, V14, P895; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matheny SA, 2004, NATURE, V427, P256, DOI 10.1038/nature02237; Matos P, 2005, EXP CELL RES, V305, P292, DOI 10.1016/j.yexcr.2004.12.029; Min XS, 2004, STRUCTURE, V12, P1303, DOI 10.1016/j.str.2004.04.014; Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Murphy LO, 2004, MOL CELL BIOL, V24, P144, DOI 10.1128/MCB.24.1.144-153.2004; Park ER, 2007, CELL SIGNAL, V19, P1488, DOI 10.1016/j.cellsig.2007.01.018; Rodriguez-Viciana P, 2005, COLD SH Q B, V70, P461, DOI 10.1101/sqb.2005.70.044; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Verissimo F, 2006, ONCOGENE, V25, P4172, DOI 10.1038/sj.onc.1209449; Verissimo F, 2001, ONCOGENE, V20, P5562, DOI 10.1038/sj.onc.1204726; Vitari AC, 2005, BIOCHEM J, V391, P17, DOI 10.1042/BJ20051180; Vitari AC, 2004, BIOCHEM J, V378, P257, DOI 10.1042/BJ20031692; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wilson FH, 2001, SCIENCE, V293, P1107, DOI 10.1126/science.1062844; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xu BE, 2005, P NATL ACAD SCI USA, V102, P10315, DOI 10.1073/pnas.0504422102; Xu BE, 2004, J BIOL CHEM, V279, P7826, DOI 10.1074/jbc.M313465200; Xu BE, 2000, J BIOL CHEM, V275, P16795, DOI 10.1074/jbc.275.22.16795; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	46	64	68	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6071	6081		10.1038/sj.onc.1210706	http://dx.doi.org/10.1038/sj.onc.1210706			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17667937				2022-12-17	WOS:000249277200010
J	Nakaya, K; Yamagata, HD; Arita, N; Nakashiro, K; Nose, M; Miki, T; Hamakawa, H				Nakaya, K.; Yamagata, H. D.; Arita, N.; Nakashiro, K-i; Nose, M.; Miki, T.; Hamakawa, H.			Identification of homozygous deletions of tumor suppressor gene FAT in oral cancer using CGH-array	ONCOGENE			English	Article						oral cancer; CGH-array; tumor suppressor gene; homozygous deletion; FAT	COMPARATIVE GENOMIC HYBRIDIZATION; SQUAMOUS-CELL CARCINOMAS; COPY NUMBER; DROSOPHILA; MUTATIONS; BREAST; HEAD; NECK; AMPLIFICATION; EXPRESSION	Homozygous deletions (HD) provide an important resource for identifying the location of candidate tumor suppressor genes. To identify the tumor suppressor gene in oral cancer, we employed high-resolution comparative genomic hybridization (CGH)-array analysis. We identified a homozygous loss of FAT ( 4q35), a new member of the human cadherin superfamily, from genome-wide screening of copy number alterations in one primary oral cancer. This result was evaluated by genomic polymerase chain reaction in 13 oral cancer cell lines and 20 primary oral cancers and Southern blot in the cell lines. We found frequent exonic HD of FAT in the cell lines (3/13, 23%) and in primary oral cancers (16/20, 80%). FAT expression was absent in these cell lines. Homozygous deletion hot spots were observed in exon 1 (9/20, 45%) and exon 4 (7/20, 35%). Moreover, loss of gene expression was identified in other types of squamous cell carcinoma. The methylation status of the FAT CpG island in squamous cell carcinomas correlated negatively with its expression. Our results identify mutations in FAT as an important factor in the development of oral cancer and indicate the importance of FATs function in some squamous cell carcinomas.	Ehime Univ, Grad Sch Med, Dept Prevent Med, Toon, Ehime 7910295, Japan; Ehime Univ, Grad Sch Med, Dept Oral & Maxillofacial Surg, Organ Funct Regenerat & Reconstruct Surg, Toon, Ehime 7910295, Japan; Ehime Univ, Grad Sch Med, Dept Pathol, Div Pathogenom, Toon, Ehime 7910295, Japan; Ehime Univ, Grad Sch Med, Dept Geriatr Med, Toon, Ehime 7910295, Japan	Ehime University; Ehime University; Ehime University; Ehime University	Yamagata, HD (corresponding author), Ehime Univ, Grad Sch Med, Dept Prevent Med, Toon, Ehime 7910295, Japan.	hideyama@m.ehime-u.ac.jp	Nakashiro, Koichi/AAV-6317-2020	Nakashiro, Koh-ichi/0000-0002-9975-902X				Beder LB, 2003, LAB INVEST, V83, P99, DOI 10.1097/01.LAB.0000047489.26246.E1; BRYANT PJ, 1988, DEV BIOL, V129, P541, DOI 10.1016/0012-1606(88)90399-5; DRYJA TP, 1984, NEW ENGL J MED, V310, P550, DOI 10.1056/NEJM198403013100902; Frijters ACJ, 1997, THEOR APPL GENET, V94, P390, DOI 10.1007/s001220050428; Garoia F, 2000, MECH DEVELOP, V94, P95, DOI 10.1016/S0925-4773(00)00306-3; HAUGHEY BH, 1992, AM J OTOLARYNG, V13, P168, DOI 10.1016/0196-0709(92)90117-C; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; Ishwad CS, 1999, INT J CANCER, V80, P25, DOI 10.1002/(SICI)1097-0215(19990105)80:1<25::AID-IJC6>3.3.CO;2-7; Keller G, 1999, AM J PATHOL, V155, P337, DOI 10.1016/S0002-9440(10)65129-2; KIARIS H, 1995, BRIT J CANCER, V72, P123, DOI 10.1038/bjc.1995.287; LEWIS GJ, 1989, E MIDLANDS GEOGRAPHE, V11, P3; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Loughran O, 1997, ONCOGENE, V14, P1955, DOI 10.1038/sj.onc.1201028; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Ponassi M, 1999, MECH DEVELOP, V80, P207, DOI 10.1016/S0925-4773(98)00217-2; PRIME SS, 1990, J PATHOL, V160, P259, DOI 10.1002/path.1711600313; Rook MS, 2004, AM J PATHOL, V164, P23, DOI 10.1016/S0002-9440(10)63092-1; SAMBROOK J, 1989, MOL CLONING, V2, P9; Siegelmann-Danieli N, 2005, TUMORI J, V91, P346, DOI 10.1177/030089160509100412; Simon R, 2002, ONCOGENE, V21, P2476, DOI 10.1038/sj.onc.1205304; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Tanoue T, 2005, J CELL SCI, V118, P2347, DOI 10.1242/jcs.02398; Teni Tanuja, 2002, Pathology and Oncology Research, V8, P109; Veltman JA, 2002, AM J HUM GENET, V70, P1269, DOI 10.1086/340426; WATSON KL, 1994, J CELL SCI, P19; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	29	64	69	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2007	26	36					5300	5308		10.1038/sj.onc.1210330	http://dx.doi.org/10.1038/sj.onc.1210330			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17325662				2022-12-17	WOS:000248674200013
J	Durkin, ME; Ullmannova, V; Guan, M; Popescu, NC				Durkin, M. E.; Ullmannova, V.; Guan, M.; Popescu, N. C.			Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth	ONCOGENE			English	Article						tumor suppressor gene; Rho GTPase-activating protein; prostate cancer; breast cancer	HEPATOCELLULAR-CARCINOMA; SUPPRESSOR FUNCTION; GENE-EXPRESSION; HUMAN BREAST; IDENTIFICATION; PROLIFERATION; MUTATIONS; ENCODES; PROFILE; KINASE	Two related Rho GTPase-activating proteins, DLC-1 (deleted in liver cancer 1) and DLC-2, are emerging as bona. de tumor suppressor genes that inhibit cancer cell growth. In this report, we characterized a gene on chromosome Xq13 that encodes DLC-3 (also known as KIAA0189 and STARD8), a third member of the DLC family. The DLC-3 gene has transcripts with alternative 50 ends, one of which, DLC-3a, encodes an 1103-amino acid polypeptide highly similar to DLC-1 and DLC-2. A second isoform (DLC-3b) would yield a protein lacking the N-terminal sterile alpha motif domain. The DLC-3 gene is widely expressed in normal tissues, but DLC-3 mRNA levels were low or absent in a significant number of breast, ovarian, liver and prostate cancer cell lines. Using a cancer pro. ling array to compare matched tumor and normal human tissues, downregulation of DLC-3 mRNA was observed in kidney, lung, ovarian, uterine and breast cancer samples. By quantitative reverse transcriptase polymerase chain reaction, DLC-3 expression was reduced in primary prostate carcinomas relative to normal prostate tissue. Transfection of human breast and prostate cancer cells with a DLC-3a expression vector inhibited cell proliferation, colony formation and growth in soft agar. These results indicate that deregulation of DLC-3 may contribute to breast and prostate tumorigenesis.	NCI, Ctr Canc Res, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Popescu, NC (corresponding author), NCI, Ctr Canc Res, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA.	popescun@mail.nih.gov	Benson, Veronika/D-9942-2014	Benson, Veronika/0000-0003-4770-9909	NATIONAL CANCER INSTITUTE [ZIABC010038, Z01BC010038] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Alpy F, 2005, J CELL SCI, V118, P2791, DOI 10.1242/jcs.02485; Avila DM, 2001, J STEROID BIOCHEM, V76, P135, DOI 10.1016/S0960-0760(00)00158-8; Bernards A, 2004, TRENDS CELL BIOL, V14, P377, DOI 10.1016/j.tcb.2004.05.003; Bernards A, 2003, BBA-REV CANCER, V1603, P47, DOI 10.1016/S0304-419X(02)00082-3; Billuart P, 1998, NATURE, V392, P923, DOI 10.1038/31940; Brown MC, 1998, NAT STRUCT BIOL, V5, P677, DOI 10.1038/1370; Carrel L, 2005, NATURE, V434, P400, DOI 10.1038/nature03479; Ching YP, 2003, J BIOL CHEM, V278, P10824, DOI 10.1074/jbc.M208310200; del Pulgar TG, 2005, BIOESSAYS, V27, P602, DOI 10.1002/bies.20238; Denholm B, 2005, DEVELOPMENT, V132, P2389, DOI 10.1242/dev.01829; Durkin ME, 2005, FEBS LETT, V579, P1191, DOI 10.1016/j.febslet.2004.12.090; Durkin ME, 2002, GENE, V288, P119, DOI 10.1016/S0378-1119(02)00462-6; Edelson MI, 1998, ONCOGENE, V16, P197, DOI 10.1038/sj.onc.1201479; Goodison S, 2005, CANCER RES, V65, P6042, DOI 10.1158/0008-5472.CAN-04-3043; Guan M, 2006, CLIN CANCER RES, V12, P1412, DOI 10.1158/1078-0432.CCR-05-1906; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hers I, 2006, J BIOL CHEM, V281, P4762, DOI 10.1074/jbc.M511008200; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Leung THY, 2005, P NATL ACAD SCI USA, V102, P15207, DOI 10.1073/pnas.0504501102; Li SSC, 2005, BIOCHEM J, V390, P641, DOI 10.1042/BJ20050411; McLysaght A, 2002, NAT GENET, V31, P200, DOI 10.1038/ng884; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Murakami T, 2003, J BIOL CHEM, V278, P34364, DOI 10.1074/jbc.M301542200; Nagaraja GM, 2004, BIOCHEM BIOPH RES CO, V313, P654, DOI 10.1016/j.bbrc.2003.12.001; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; Ng IOL, 2000, CANCER RES, V60, P6581; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; QIAO F, 2005, SCI STKE; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; SENG TJ, 2006, ONCOGENE; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Song YF, 2006, J CLIN PATHOL, V59, P947, DOI 10.1136/jcp.2005.031377; Spatz A, 2004, NAT REV CANCER, V4, P617, DOI 10.1038/nrc1413; Syed V, 2005, ONCOGENE, V24, P1774, DOI 10.1038/sj.onc.1207991; Thakur A, 2005, BREAST CANCER RES TR, V93, P135, DOI 10.1007/s10549-005-4516-0; Twigg SRF, 2006, AM J HUM GENET, V78, P999, DOI 10.1086/504440; Ullmannova V, 2006, INT J ONCOL, V29, P1127; VAN AL, 1997, GENE DEV, V11, P2295; Wieland I, 2004, AM J HUM GENET, V74, P1209, DOI 10.1086/421532; Wong CM, 2003, CANCER RES, V63, P7646; Wong CM, 2005, CANCER RES, V65, P8861, DOI 10.1158/0008-5472.CAN-05-1318; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291; Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064; Zhou XL, 2004, ONCOGENE, V23, P1308, DOI 10.1038/sj.onc.1207246	47	64	65	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4580	4589		10.1038/sj.onc.1210244	http://dx.doi.org/10.1038/sj.onc.1210244			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17297465				2022-12-17	WOS:000247836100012
J	Narla, G; Kremer-Tal, S; Matsumoto, N; Zhao, X; Yao, S; Kelley, K; Tarocchi, M; Friedman, SL				Narla, G.; Kremer-Tal, S.; Matsumoto, N.; Zhao, X.; Yao, S.; Kelley, K.; Tarocchi, M.; Friedman, S. L.			In vivo regulation of p21 by the Kruppel-like factor 6 tumor-suppressor gene in mouse liver and human hepatocellular carcinoma	ONCOGENE			English	Article						KLF6; Kruppel-like factor; tumor-suppressor gene; p21; haploinsufficiency	KRUPPEL-LIKE FACTOR-6; TRANSCRIPTION FACTOR KLF6; CELL LUNG-CANCER; PROSTATE-CANCER; EXPRESSION; PROGRESSION; ACTIVATION; HAPLOINSUFFICIENCY; INHIBITOR; PROMOTER	Kruppel-like factor (KLF) 6 is a tumor-suppressor gene functionally inactivated by loss of heterozygosity, somatic mutation and/or alternative splicing that generates a dominant-negative splice form, KLF6-SV1. Wild-type KLF6 (wtKLF6) expression is decreased in many human malignancies, which correlates with reduced patient survival. Additionally, loss of the KLF6 locus in the absence of somatic mutation in the remaining allele occurs in a number of human cancers, raising the possibility that haploinsuffi. ciency of the KLF6 gene alone contributes to cellular growth dysregulation and tumorigenesis. Our earlier studies identified the cyclin-dependent kinase inhibitor p21 as a transcriptional target of the KLF6 gene in cultured cells, but not in vivo. To address this issue, we have generated two genetic mouse models to de. ne the in vivo role of KLF6 in regulating cell proliferation and p21 expression. Transgenic overexpression of KLF6 in the liver resulted in a runted phenotype with decreased body and liver size, with evidence of decreased hepatocyte proliferation, increased p21 and reduced proliferating cell nuclear antigen expression. In contrast, mice with targeted deletion of one KLF6 allele (KLF6+/-) display increased liver mass with reduced p21 expression, compared to wild type littermates. Moreover, in primary hepatocellular carcinoma samples, there is a significant correlation between wtKLF6 and p21 mRNA expression. Combined, these data suggest that haploinsuffi. ciency of the KLF6 gene may regulate cellular proliferation in vivo through decreased transcriptional activation of the cyclin- dependent kinase inhibitor p21.	CUNY Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Div Liver Dis, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Div Hematol Oncol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Brookdale Dept Mol Cell & Dev Biol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Friedman, SL (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Box 1123,1425 Madison Ave,Room 11-70, New York, NY 10029 USA.	scott.friedman@mssm.edu	Narla, Goutham/AAZ-5710-2020	Narla, Goutham/0000-0003-4098-4203; TAROCCHI, MIRKO/0000-0002-7767-5116	NIDDK NIH HHS [DK37340] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberici P, 2006, ONCOGENE, V25, P1841, DOI 10.1038/sj.onc.1209226; Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Bissell D M, 1980, Ann N Y Acad Sci, V349, P85, DOI 10.1111/j.1749-6632.1980.tb29518.x; Botella LM, 2002, BLOOD, V100, P4001, DOI 10.1182/blood.V100.12.4001; Boyault S, 2005, HEPATOLOGY, V41, P681, DOI 10.1002/hep.20588; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Chen Han-kui, 2002, Ai Zheng, V21, P1047; Cho YG, 2005, ONCOGENE, V24, P4588, DOI 10.1038/sj.onc.1208670; Difeo A, 2006, ONCOGENE, V25, P6026, DOI 10.1038/sj.onc.1209611; Difeo A, 2006, CLIN CANCER RES, V12, P3730, DOI 10.1158/1078-0432.CCR-06-0054; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Ito G, 2004, CANCER RES, V64, P3838, DOI 10.1158/0008-5472.CAN-04-0185; Jeng YM, 2003, INT J CANCER, V105, P625, DOI 10.1002/ijc.11123; Kettunen E, 2004, CANCER GENET CYTOGEN, V149, P98, DOI 10.1016/s0165-4608(03)00300-5; Kim Y, 1998, J BIOL CHEM, V273, P33750, DOI 10.1074/jbc.273.50.33750; Kimmelman AC, 2004, ONCOGENE, V23, P5077, DOI 10.1038/sj.onc.1207662; Kremer-Tal S, 2004, HEPATOLOGY, V40, P1047, DOI 10.1002/hep.20460; KREMERTAL S, 2006, J HEPATOL       1127; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; MATSUMOTO N, 2006, HEPATOLOGY, V107, P1357; Narla G, 2005, CANCER RES, V65, P1213, DOI 10.1158/0008-5472.CAN-04-4249; Narla G, 2003, AM J PATHOL, V162, P1047, DOI 10.1016/S0002-9440(10)63901-6; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Pan Xiu-cheng, 2006, J Zhejiang Univ Sci B, V7, P830, DOI 10.1631/jzus.2006.B0830; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Slavin DA, 2004, ONCOGENE, V23, P8196, DOI 10.1038/sj.onc.1208020; Song J, 2006, J GASTROEN HEPATOL, V21, P1286, DOI 10.1111/j.1440-1746.2006.04445.x; Venkatachalam S, 2001, TOXICOL PATHOL, V29, P147, DOI 10.1080/019262301753178555; Walthall K, 2005, BIRTH DEFECTS RES B, V74, P132, DOI 10.1002/bdrb.20040; Wang Shao-ping, 2004, Zhonghua Wai Ke Za Zhi, V42, P1258; Warke VG, 2003, J BIOL CHEM, V278, P14812, DOI 10.1074/jbc.M300787200; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245	36	64	71	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2007	26	30					4428	4434		10.1038/sj.onc.1210223	http://dx.doi.org/10.1038/sj.onc.1210223			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	184CZ	17297474				2022-12-17	WOS:000247620000010
J	Toualbi, K; Guller, MC; Mauriz, JL; Labalette, C; Buendia, MA; Mauviel, A; Bernuau, D				Toualbi, K.; Guller, M. C.; Mauriz, J-L; Labalette, C.; Buendia, M-A; Mauviel, A.; Bernuau, D.			Physical and functional cooperation between AP-1 and beta-catenin for the regulation of TCF-dependent genes	ONCOGENE			English	Article						AP-1; beta-catenin; Fos; Jun; cyclin D1; hepatoma cells	GROWTH-FACTOR-BETA; ONLY PROTEIN FHL2; C-FOS EXPRESSION; NF-KAPPA-B; CYCLIN D1; TRANSCRIPTIONAL COACTIVATOR; SIGNALING PATHWAY; MESENCHYMAL TRANSITION; BINDING PROTEIN; ACTIVATION	Stabilization of cytoplasmic beta-catenin is a hallmark of a variety of cancers. The stabilized beta-catenin is able to translocate to the nucleus, where it acts as a transcriptional activator of T-cell factor (TCF)-regulated genes. beta-Catenin may cross-talk with many signalling cascades to activate target genes. Whether beta-catenin cooperates with AP-1, another transcriptional complex activated during tumorigenesis is not fully clarified. We show that alpha-catenin co-immunoprecipitates with c-Jun and c- os. GST pull-down experiments indicate a physical association of the armadillo repeat domain of b-catenin with the DNA-binding domain of c-Jun and of the C-terminal domain of beta- catenin with the N-terminal domain of c-Fos. Promoter studies indicate that overexpression of AP-1 activates the transcription of two beta-catenin target genes, cyclin D1 and c-myc, by a mechanism independent of the AP-1 site, and fully dependent on the TCF-binding site. We further demonstrate that AP-1/beta-catenin synergism is involved during serum-induced cyclin D1 transcriptional activation. We identify a TCF-binding site on the cyclin D1 promoter which binds in vivo a complex induced by serum, containing beta- catenin, TCF4, c-Fos, c-Jun, JunB and JunD. This novel mechanism of interaction between two signalling cascades might contribute to the potentiation of malignancy.	INSERM, U697, Paris, France; Univ Paris 07, Paris, France; Inst Pasteur, Unite Recombinaison & Express Genet, Paris, France; INSERM, U163, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bernuau, D (corresponding author), Hop St Louis, Unite INSERM, U 697, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.	bernuau@stlouis.inserm.fr	Mauriz, Jose L/G-9970-2014; MAUVIEL, Alain/F-6251-2013	Mauriz, Jose L/0000-0003-3160-8599; Mauviel, Alain/0000-0002-0438-2793				Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Carruba G, 1999, ANN NY ACAD SCI, V886, P212, DOI 10.1111/j.1749-6632.1999.tb09419.x; Chakladar A, 2005, BIOCHEM BIOPH RES CO, V336, P190, DOI 10.1016/j.bbrc.2005.08.061; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eger A, 2004, ONCOGENE, V23, P2672, DOI 10.1038/sj.onc.1207416; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Esufali S, 2004, ONCOGENE, V23, P8260, DOI 10.1038/sj.onc.1208007; Ferrara P, 2003, ONCOGENE, V22, P1461, DOI 10.1038/sj.onc.1206266; Ferrigno O, 2002, ONCOGENE, V21, P4879, DOI 10.1038/sj.onc.1205623; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; Grueneberg DA, 2003, MOL CELL BIOL, V23, P3936, DOI 10.1128/MCB.23.11.3936-3950.2003; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; Harris TJC, 2005, TRENDS CELL BIOL, V15, P234, DOI 10.1016/j.tcb.2005.03.002; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Iavarone C, 2003, J BIOL CHEM, V278, P50024, DOI 10.1074/jbc.M308617200; Ishikawa T, 2000, MOL CELL ENDOCRINOL, V164, P77, DOI 10.1016/S0303-7207(00)00241-0; Iwahashi H, 2000, J IMMUNOL, V164, P5403, DOI 10.4049/jimmunol.164.10.5403; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morlon A, 2003, P NATL ACAD SCI USA, V100, P3977, DOI 10.1073/pnas.0735923100; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Peron P, 2001, J BIOL CHEM, V276, P10524, DOI 10.1074/jbc.M005919200; Rahmani M, 2001, ONCOGENE, V20, P5132, DOI 10.1038/sj.onc.1204678; Rivat C, 2003, FASEB J, V17, P1721, DOI 10.1096/fj.03-0132fje; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Sasaki T, 2003, CANCER RES, V63, P801; Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200; SIMONSON MS, 1994, EXP CELL RES, V215, P137, DOI 10.1006/excr.1994.1325; Sparks AB, 1998, CANCER RES, V58, P1130; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Verrecchia F, 2001, ONCOGENE, V20, P2205, DOI 10.1038/sj.onc.1204347; Wei Y, 2003, J BIOL CHEM, V278, P5188, DOI 10.1074/jbc.M207216200; Zhurinsky J, 2000, J CELL SCI, V113, P3127	52	64	67	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3492	3502		10.1038/sj.onc.1210133	http://dx.doi.org/10.1038/sj.onc.1210133			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17146436				2022-12-17	WOS:000246799200005
J	Kim, KE; Song, H; Kim, TS; Yoon, D; Kim, CW; Bang, SI; Hur, DY; Park, H; Cho, DH				Kim, K-E; Song, H.; Kim, T. S.; Yoon, D.; Kim, C-w; Bang, S. I.; Hur, D. Y.; Park, H.; Cho, D-H			Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines	ONCOGENE			English	Article						ERK1/2; F-actin; IL-18; migration; tensin; VEGF	GAMMA-INDUCING FACTOR; IL-18; EXPRESSION; METASTASIS; PROTEIN; PROLIFERATION; ANGIOGENESIS; IMMUNITY; TENSIN; ACTS	Cell migration and angiogenesis are key steps in tumor metastasis. However, the mechanism of migration regulated by vascular endothelial growth factor ( VEGF), a potent regulator of angiogenesis, is not completely understood. This study examined the relationship between VEGF and migration, along with the mechanism involved in the VEGF-regulated migration of human gastric cancer cells. The level of cell migration was increased by recombinant human (rh) VEGF-165 in the VEGF receptor-2-expressing SNU-601 cells. Interleukin (IL)-18 is associated with the malignant progression of tumors. Accordingly, this study examined the effect of IL-18 on the migration of cancer cells in order to identify the factors involved in VEGF-enhanced migration. Inhibiting IL-18 markedly reduced the level of VEGF-enhanced migration, and IL-18 increased cell migration directly through filamentous-actin polymerization and tensin downregulation. It was confirmed that rhVEGF-165 increased IL-18 production significantly. An antioxidant and an extracellular signal-regulated kinase (ERK) 1/2-specific inhibitor blocked rhVEGF-165-enhanced IL-18 production. Accordingly, rhVEGF-165 increased the generation of region of interest (ROI) and activated the ERK1/2 pathway. These results suggest that rhVEGF-165 enhances IL-18 production via the generation of ROI and ERK1/2 phosphorylation, which results in the increased migration of gastric cancer cells.	Catholic Univ Korea, Dept Dermatol, St Marys Hosp, Coll Med, Seoul, South Korea; Sookmyung Womens Univ, Dept Life Sci, Seoul 140742, South Korea; Inje Univ, Coll Med, Dept Anat, Pusan, South Korea; Korea Univ, Sch Life Sci & Technol, Seoul 136701, South Korea; Konkuk Univ, Grad Sch, Div Biosci & Biotechnol, Seoul, South Korea; Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 151, South Korea; Seoul Natl Univ, Coll Med, Tumor Immun Med Res Ctr, Seoul, South Korea; Sungkyunkwan Univ, Sch Med, Dept Plast Surg, Samsung Med Ctr, Seoul, South Korea	Catholic University of Korea; Catholic University Korea Hospital; Seoul St. Mary's Hospital; Sookmyung Women's University; Inje University; Korea University; Konkuk University; Seoul National University (SNU); Seoul National University (SNU); Sungkyunkwan University (SKKU); Samsung Medical Center	Park, H (corresponding author), Catholic Univ Korea, Dept Dermatol, St Marys Hosp, Coll Med, Seoul, South Korea.	hjpark@catholic.ac.kr; cdhkor@sookmyung.ac.kr	Kim, Chul-Woo/F-7008-2011					Cao RH, 1999, FASEB J, V13, P2195, DOI 10.1096/fasebj.13.15.2195; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carrascal MT, 2003, CANCER RES, V63, P491; Chen JH, 2004, CELL COMMUN ADHES, V11, P1, DOI 10.1080/15419060490471739; Cho D, 2000, CANCER RES, V60, P2703; Cho DH, 2002, BIOCHEM BIOPH RES CO, V298, P289, DOI 10.1016/S0006-291X(02)02433-6; Cumberbatch M, 2001, IMMUNOLOGY, V102, P323, DOI 10.1046/j.1365-2567.2001.01187.x; Gossart S, 1996, J IMMUNOL, V156, P1540; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; Ishida Y, 2004, FEBS LETT, V569, P156, DOI 10.1016/j.febslet.2004.05.039; Ju DW, 2001, CANCER RES, V61, P3735; Lissoni P, 2000, J BIOL REG HOMEOS AG, V14, P275; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; Lo SH, 2004, INT J BIOCHEM CELL B, V36, P31, DOI 10.1016/S1357-2725(03)00171-7; Majima T, 2006, INT J CANCER, V118, P388, DOI 10.1002/ijc.21334; Meili R, 2003, CELL, V114, P153, DOI 10.1016/S0092-8674(03)00553-1; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Park CC, 2001, J IMMUNOL, V167, P1644, DOI 10.4049/jimmunol.167.3.1644; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Stoll S, 1997, J IMMUNOL, V159, P298; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005; Vidal-Vanaclocha F, 2000, P NATL ACAD SCI USA, V97, P734, DOI 10.1073/pnas.97.2.734; Zhang B, 2004, LEUKEMIA RES, V28, P91, DOI 10.1016/S0145-2126(03)00121-8; Zhang H, 2002, WORLD J GASTROENTERO, V8, P994, DOI 10.3748/wjg.v8.i6.994	25	64	68	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1468	1476		10.1038/sj.onc.1209926	http://dx.doi.org/10.1038/sj.onc.1209926			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	17001321				2022-12-17	WOS:000244558800011
J	Letessier, A; Garrido-Urbani, S; Ginestier, C; Fournier, G; Esterni, B; Monville, F; Adelaide, J; Geneix, J; Xerri, L; Dubreuil, P; Viens, P; Charafe-Jauffret, E; Jacquemier, J; Birnbaum, D; Lopez, M; Chaffanet, M				Letessier, A.; Garrido-Urbani, S.; Ginestier, C.; Fournier, G.; Esterni, B.; Monville, F.; Adelaide, J.; Geneix, J.; Xerri, L.; Dubreuil, P.; Viens, P.; Charafe-Jauffret, E.; Jacquemier, J.; Birnbaum, D.; Lopez, M.; Chaffanet, M.			Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer	ONCOGENE			English	Article						Afadin; AF-6 gene; breast cancer; FRA6E; Parkin; PARK2 gene; tissue microarrays	RECESSIVE JUVENILE PARKINSONISM; ACUTE LYMPHOBLASTIC-LEUKEMIA; TUMOR-SUPPRESSOR GENE; COMMON FRAGILE SITES; CELL-CELL JUNCTIONS; LONG ARM; HEPATOCELLULAR-CARCINOMA; TYROSINE KINASE; BINDING PROTEIN; LUNG-CANCER	Common fragile sites (CFSs) are regions of chromosomal break that may play a role in oncogenesis. The most frequent alteration occurs at FRA3B, within the FHIT gene, at chromosomal region 3p14. We studied a series of breast carcinomas for break of a CFS at 6q26, FRA6E, and its associated gene PARK2, using fluorescence in situ hybridization on tissue microarrays (TMA). We found break of PARK2 in 6% of cases. We studied the PARK2-encoded protein Parkin by using immunohistochemistry on the same TMA. Loss of Parkin was found in 13% of samples but was not correlated with PARK2 break. PARK2 break but not Parkin expression was correlated with prognosis. Alteration of PARK2/FRA6E may cause haplo-insufficiency of one or several telomeric potential tumor suppressor genes (TSG). The AF-6/MLLT4 gene, telomeric of PARK2, encodes the Afadin scaffold protein, which is essential for epithelial integrity. Loss of Afadin was found in 14.5% of cases, and 36% of these cases showed PARK2 break. Loss of Afadin had prognostic impact, suggesting that AF-6 may be a TSG. Loss of Afadin was correlated with loss of FHIT expression, suggesting fragility of FRA6E and FRA3B in a certain proportion of breast tumors.	Ctr Rech Cancerol Marseille, UMR599, Dept Mol Oncol, INSERM, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Biostat, F-13009 Marseille, France; INSERM, UMR599, Dept Med Oncol, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept BioPathol, F-13009 Marseille, France; Univ Mediterranee, Fac Med, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite	Birnbaum, D (corresponding author), Ctr Rech Cancerol Marseille, UMR599, Dept Mol Oncol, INSERM, 27 Bd Lei Roure, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	Letessier, Anne/M-3431-2017; CHAFFANET, Max/AAU-5743-2020; ADELAIDE, José JA/O-4390-2017; dubreuil, patrice/F-5346-2011; Ginestier, Christophe/M-8828-2017; Dubreuil, Patrice/V-4816-2019; Charafe-Jauffret, emmanuelle/P-6009-2017	Letessier, Anne/0000-0002-1894-4072; ADELAIDE, José JA/0000-0003-4364-9857; dubreuil, patrice/0000-0003-1155-1150; Ginestier, Christophe/0000-0002-7477-3837; Dubreuil, Patrice/0000-0003-1155-1150; CHAFFANET, Max/0000-0002-2344-1488; Charafe-Jauffret, emmanuelle/0000-0002-0286-1299				Agirre X, 2006, INT J CANCER, V118, P1945, DOI 10.1002/ijc.21584; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Bobinnec Y, 1998, CELL MOTIL CYTOSKEL, V39, P223, DOI 10.1002/(SICI)1097-0169(1998)39:3<223::AID-CM5>3.0.CO;2-5; Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; Bonnet C, 2001, J BIOL CHEM, V276, P12839, DOI 10.1074/jbc.M011380200; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Charafe-Jauffret E, 2005, INT J ONCOL, V27, P1307; Chin SF, 2003, J CLIN PATHOL-MOL PA, V56, P275, DOI 10.1136/mp.56.5.275; Delaval B, 2005, CANCER RES, V65, P7231, DOI 10.1158/0008-5472.CAN-04-4167; Denison SR, 2003, GENE CHROMOSOME CANC, V38, P40, DOI 10.1002/gcc.10236; Denison SR, 2003, ONCOGENE, V22, P8370, DOI 10.1038/sj.onc.1207072; Dhillon VS, 2003, TERATOGEN CARCIN MUT, P35, DOI 10.1002/tcm.10068; Fabbri M, 2005, P NATL ACAD SCI USA, V102, P15611, DOI 10.1073/pnas.0505485102; Ginestier C, 2003, INT J CANCER, V107, P854, DOI 10.1002/ijc.11462; Ginestier C, 2002, AM J PATHOL, V161, P1223, DOI 10.1016/S0002-9440(10)64399-4; Guasch G, 2004, BLOOD, V103, P309, DOI 10.1182/blood-2003-05-1690; Guler G, 2005, PATHOL INT, V55, P471, DOI 10.1111/j.1440-1827.2005.01855.x; HAYASHI Y, 1990, BLOOD, V76, P1626; Huang Tie-Jun, 2004, Hepatobiliary Pancreat Dis Int, V3, P62; Huebner K, 2003, BRIT J CANCER, V88, P1501, DOI 10.1038/sj.bjc.6600937; Huebner K, 1998, RECENT RES CANCER, V154, P200; Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Ishii H, 2003, FASEB J, V17, P1768, DOI 10.1096/fj.03-0241fje; Johnson SAS, 2003, CELL CYCLE, V2, P442, DOI 10.4161/cc.2.5.493; Johnson SAS, 2003, MOL CELL BIOL, V23, P3043, DOI 10.1128/MCB.23.9.3043-3051.2003; Kerangueven F, 1997, CANCER RES, V57, P5469; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Marin I, 2004, PHYSIOL GENOMICS, V17, P253, DOI 10.1152/physiolgenomics.00226.2003; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P26, DOI 10.1002/gcc.2870100105; Miki H, 2005, TRENDS CELL BIOL, V15, P467, DOI 10.1016/j.tcb.2005.07.006; MILLIKIN D, 1991, CANCER RES, V51, P5449; NEGRINI M, 1994, CANCER RES, V54, P1331; Noviello C, 1996, CLIN CANCER RES, V2, P1601; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Park SW, 2004, BRIT J CANCER, V91, P753, DOI 10.1038/sj.bjc.6602023; Picchio MC, 2004, CLIN CANCER RES, V10, P2720, DOI 10.1158/1078-0432.CCR-03-0086; Popescu NC, 2003, CANCER LETT, V192, P1, DOI 10.1016/S0304-3835(02)00596-7; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; PRASAD R, 1993, CANCER RES, V53, P5624; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Rodriguez C, 2000, GENE CHROMOSOME CANC, V27, P76, DOI 10.1002/(SICI)1098-2264(200001)27:1<76::AID-GCC10>3.0.CO;2-E; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; SAITO S, 1992, CANCER RES, V52, P5815; Sato T, 2006, J BIOL CHEM, V281, P5288, DOI 10.1074/jbc.M510070200; Seki N, 2001, INT J ONCOL, V19, P305; Smith DI, 1998, INT J ONCOL, V12, P187; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; Taki T, 1996, ONCOGENE, V13, P2121; Teixeira MR, 2002, GENE CHROMOSOME CANC, V33, P1, DOI 10.1002/gcc.1206; Tibiletti MG, 1996, CANCER RES, V56, P4493; van der Burg M, 2004, LEUKEMIA, V18, P895, DOI 10.1038/sj.leu.2403340; Wang F, 2004, GENE CHROMOSOME CANC, V40, P85, DOI 10.1002/gcc.20020; Whitcomb BP, 2003, CLIN CANCER RES, V9, P2277; Zhadanov AB, 1999, CURR BIOL, V9, P880, DOI 10.1016/S0960-9822(99)80392-3	61	64	65	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					298	307		10.1038/sj.onc.1209772	http://dx.doi.org/10.1038/sj.onc.1209772			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819513				2022-12-17	WOS:000243398300014
J	Fontenay, M; Cathelin, S; Amiot, M; Gyan, E; Solary, E				Fontenay, M.; Cathelin, S.; Amiot, M.; Gyan, E.; Solary, E.			Mitochondria in hematopoiesis and hematological diseases	ONCOGENE			English	Review						mitochondria; sideroblastic anemia; leukemia; myelodysplastic syndromes; apoptosis	LINKED SIDEROBLASTIC ANEMIA; MULTIPLE-MYELOMA CELLS; CYTOCHROME-C RELEASE; BCL-2 ANTISENSE OLIGONUCLEOTIDE; LYMPHOCYTIC-LEUKEMIA CELLS; DEPENDENT KINASE INHIBITOR; FAS-LIGAND EXPRESSION; BONE-MARROW-CELLS; NF-KAPPA-B; MYELODYSPLASTIC SYNDROMES	Mitochondria are involved in hematopoietic cell homeostasis through multiple ways such as oxidative phosphorylation, various metabolic processes and the release of cytochrome c in the cytosol to trigger caspase activation and cell death. In erythroid cells, the mitochondrial steps in heme synthesis, iron (Fe) metabolism and Fe-sulfur (Fe-S) cluster biogenesis are of particular importance. Mutations in the specifc delta-aminolevulinic acid synthase (ALAS) 2 isoform that catalyses the first and rate-limiting step in heme synthesis pathway in the mitochondrial matrix, lead to ineffective erythropoiesis that characterizes X-linked sideroblastic anemia (XLSA), the most common inherited sideroblastic anemia. Mutations in the adenosine triphosphate-binding cassette protein ABCB7, identified in XLSA with ataxia (XLSA-A), disrupt the maturation of cytosolic (Fe-S) clusters, leading to mitochondrial Fe accumulation. In addition, large deletions in mitochondrial DNA, whose integrity depends on a specific DNA polymerase, are the hallmark of Pearson's syndrome, a rare congenital disorder with sideroblastic anemia. In acquired myelodysplastic syndromes at early stage, exacerbation of physiological pathways involving caspases and the mitochondria in erythroid differentiation leads to abnormal activation of a mitochondria-mediated apoptotic cell death pathway. In contrast, oncogenesis-associated changes at the mitochondrial level can alter the apoptotic response of transformed hematopoietic cells to chemotherapeutic agents. Recent findings in mitochondria metabolism and functions open new perspectives in treating hematopoietic cell diseases, for example various compounds currently developed to trigger tumor cell death by directly targeting the mitochondria could prove efficient as either cytotoxic drugs or chemosensitizing agents in treating hematological malignancies.	Fac Med, INSERM, U 517, F-21000 Dijon, France; Inst Biol, INSERM U601, Nantes, France; Inst Cochin, Dept Hematol, INSERM U567, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Solary, E (corresponding author), Fac Med, INSERM, U 517, 7 Blvd Jeanne Arc, F-21000 Dijon, France.	esolary@u-bourgogne.fr		Fontenay, Michaela/0000-0002-5492-6349; GYAN, Emmanuel/0000-0002-7651-9189; Solary, Eric/0000-0002-8629-1341				Aerbajinai W, 2003, BLOOD, V102, P712, DOI 10.1182/blood-2002-11-3324; Astner I, 2005, EMBO J, V24, P3166, DOI 10.1038/sj.emboj.7600792; Azzouz M, 2000, HUM MOL GENET, V9, P803, DOI 10.1093/hmg/9.5.803; Banker DE, 2002, LEUKEMIA RES, V26, P91, DOI 10.1016/S0145-2126(01)00112-6; Becattini B, 2004, CHEM BIOL, V11, P1107, DOI 10.1016/j.chembiol.2004.05.022; Becker EM, 2002, BLOOD, V99, P3813, DOI 10.1182/blood.V99.10.3813; Belzacq AS, 2001, CANCER RES, V61, P1260; Benesch M, 2003, LEUKEMIA, V17, P2460, DOI 10.1038/sj.leu.2403180; Berger G, 2001, Hematol J, V2, P87, DOI 10.1038/sj.thj.6200086; Bombrun A, 2003, J MED CHEM, V46, P4365, DOI 10.1021/jm034107j; Bouchier-Hayes L, 2005, J CLIN INVEST, V115, P2640, DOI 10.1172/JCI26274; Bouscary D, 1997, LEUKEMIA, V11, P839, DOI 10.1038/sj.leu.2400654; Bouscary D, 2000, EXP HEMATOL, V28, P784, DOI 10.1016/S0301-472X(00)00179-X; Bowen D, 2002, BRIT J HAEMATOL, V118, P345, DOI 10.1046/j.1365-2141.2002.03576_2.x; Braun T, 2006, BLOOD, V107, P1156; CAMPOS L, 1993, BLOOD, V81, P3091; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Carlile GW, 2004, BLOOD, V103, P4310, DOI 10.1182/blood-2003-09-3362; Carlsson G, 2004, BLOOD, V103, P3355, DOI 10.1182/blood-2003-04-1011; Cazzola M, 2003, BLOOD, V101, P1996, DOI 10.1182/blood-2002-07-2006; Chandra J, 2002, BLOOD, V99, P655, DOI 10.1182/blood.V99.2.655; Chauhan D, 2004, BLOOD, V103, P3158, DOI 10.1182/blood-2003-08-2873; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9; Chou WC, 2004, P NATL ACAD SCI USA, V101, P4578, DOI 10.1073/pnas.0306687101; Claessens YE, 2005, BLOOD, V105, P4035, DOI 10.1182/blood-2004-08-3166; Claessens YE, 2003, BLOOD, V102, p144A; Claessens YE, 2002, BLOOD, V99, P1594, DOI 10.1182/blood.V99.5.1594; Cotter PD, 1999, BLOOD, V93, P1757, DOI 10.1182/blood.V93.5.1757.405a12_1757_1769; COX TC, 1994, NEW ENGL J MED, V330, P675, DOI 10.1056/NEJM199403103301004; Craven SE, 2005, BLOOD, V105, P3528, DOI 10.1182/blood-2004-03-1089; de Botton S, 2002, BLOOD, V100, P1310, DOI 10.1182/blood-2002-03-0686; De Maria R, 1999, BLOOD, V93, P796, DOI 10.1182/blood.V93.3.796.403k23_796_803; Decaudin D, 2002, CANCER RES, V62, P1388; del Rio G, 2001, FEBS LETT, V494, P213, DOI 10.1016/S0014-5793(01)02348-1; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Fadeel B, 1999, LEUKEMIA, V13, P719, DOI 10.1038/sj.leu.2401411; FELLOUS R, 1988, CANCER RES, V48, P6542; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Fleming MD, 2001, GENE DEV, V15, P652, DOI 10.1101/gad.873001; Friedman JS, 2004, BLOOD, V104, P2565, DOI 10.1182/blood-2003-11-3858; Furuyama K, 1997, BLOOD, V90, P822, DOI 10.1182/blood.V90.2.822.822_822_830; Furuyama K, 2000, J CLIN INVEST, V105, P757, DOI 10.1172/JCI6816; Gattermann N, 2000, LEUKEMIA RES, V24, P141, DOI 10.1016/S0145-2126(99)00160-5; Gattermann N, 2002, BRIT J HAEMATOL, V119, P1139, DOI 10.1046/j.1365-2141.2002.03942_3.x; Gattermann N, 1997, BLOOD, V90, P4961, DOI 10.1182/blood.V90.12.4961.4961_4961_4972; Gattermann N, 1996, BRIT J HAEMATOL, V93, P845, DOI 10.1046/j.1365-2141.1996.d01-1724.x; Genini D, 2000, BLOOD, V96, P3537; Gersuk GM, 1996, BLOOD, V88, P1122, DOI 10.1182/blood.V88.3.1122b.bloodjournal8831122b; Gojo I, 2002, CLIN CANCER RES, V8, P3527; Gomez-Bougie P, 2005, ONCOGENE, V24, P8076, DOI 10.1038/sj.onc.1208949; Gomez-Bougie P, 2004, EUR J IMMUNOL, V34, P3156, DOI 10.1002/eji.200424981; Gomez-Bougie P, 2005, EUR J IMMUNOL, V35, P971, DOI 10.1002/eji.200425878; GRASSO JA, 1980, BRIT J HAEMATOL, V46, P57; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Gupta P, 1999, LEUKEMIA, V13, P44, DOI 10.1038/sj.leu.2401233; Hafid-Medheb K, 2003, BLOOD, V101, P2575, DOI 10.1182/blood-2002-02-0478; Harigae H, 2003, BLOOD, V101, P1188, DOI 10.1182/blood-2002-01-0309; He L, 2003, LEUKEMIA, V17, P2487, DOI 10.1038/sj.leu.2403146; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; Hermine O, 1996, BLOOD, V87, P265, DOI 10.1182/blood.V87.1.265.bloodjournal871265; Hishita T, 2001, CANCER RES, V61, P2878; Houwerzijl EJ, 2005, BLOOD, V105, P3472, DOI 10.1182/blood-2004-06-2108; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Jonasova A, 1998, BRIT J HAEMATOL, V100, P304, DOI 10.1046/j.1365-2141.1998.00551.x; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kerbauy DMB, 2005, BLOOD, V106, P3917, DOI 10.1182/blood-2005-04-1424; Kitagawa M, 1998, LEUKEMIA, V12, P486, DOI 10.1038/sj.leu.2400980; Kolbus A, 2002, J EXP MED, V196, P1347, DOI 10.1084/jem.20020562; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; Kroemer G, 1999, JNCI-J NATL CANCER I, V91, P743, DOI 10.1093/jnci/91.9.743; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Lacour S, 2003, ONCOGENE, V22, P1807, DOI 10.1038/sj.onc.1206127; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Launay S, 2005, ONCOGENE, V24, P5137, DOI 10.1038/sj.onc.1208524; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; Letai A, 2004, CANCER CELL, V6, P241, DOI 10.1016/j.ccr.2004.07.011; Letai A, 2005, J CLIN INVEST, V115, P2648, DOI 10.1172/JCI26250; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lindberg EH, 2001, BRIT J HAEMATOL, V112, P714, DOI 10.1046/j.1365-2141.2001.02581.x; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Logette E, 2005, MOL CELL BIOL, V25, P9621, DOI 10.1128/MCB.25.21.9621-9631.2005; Marchetti P, 1999, CANCER RES, V59, P6257; Marczin N, 2003, ARCH BIOCHEM BIOPHYS, V420, P222, DOI 10.1016/j.abb.2003.08.037; Matthes TW, 2000, BRIT J HAEMATOL, V111, P843, DOI 10.1046/j.1365-2141.2000.02425.x; Matthes TW, 2002, LEUKEMIA, V16, P1319, DOI 10.1038/sj.leu.2402527; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Michels J, 2005, INT J BIOCHEM CELL B, V37, P267, DOI 10.1016/j.biocel.2004.04.007; Moreaux J, 2004, BLOOD, V103, P3148, DOI 10.1182/blood-2003-06-1984; Moshynska O, 2004, JNCI-J NATL CANCER I, V96, P673, DOI 10.1093/jnci/djh122; Motoyama N, 1999, J EXP MED, V189, P1691, DOI 10.1084/jem.189.11.1691; Mufti GJ, 2004, BEST PRACT RES CL HA, V17, P543, DOI 10.1016/j.beha.2004.08.007; Nakajima O, 1999, EMBO J, V18, P6282, DOI 10.1093/emboj/18.22.6282; Napier I, 2005, BLOOD, V105, P1867, DOI 10.1182/blood-2004-10-3856; Nencioni A, 2005, BLOOD, V105, P3255, DOI 10.1182/blood-2004-10-3984; Nie GJ, 2005, BLOOD, V105, P2161, DOI 10.1182/blood-2004-07-2722; Ogasawara Y, 2005, BLOOD, V106, P3271, DOI 10.1182/blood-2005-01-0150; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Oren Z, 2002, EUR J BIOCHEM, V269, P3869, DOI 10.1046/j.1432-1033.2002.03080.x; Oudard S, 2003, J NEURO-ONCOL, V63, P81, DOI 10.1023/A:1023756707900; Pandolfo Massimo, 2003, Semin Pediatr Neurol, V10, P163, DOI 10.1016/S1071-9091(03)00025-1; Parker JE, 2000, BLOOD, V96, P3932, DOI 10.1182/blood.V96.12.3932.h8003932_3932_3938; PASANEN AVO, 1981, SCAND J HAEMATOL, V27, P35; PEARSON HA, 1979, J PEDIATR-US, V95, P976, DOI 10.1016/S0022-3476(79)80286-3; Ponka P, 1999, AM J MED SCI, V318, P241, DOI 10.1097/00000441-199910000-00004; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Raje N, 2005, BLOOD, V106, P1042, DOI 10.1182/blood-2005-01-0320; RAZA A, 1995, BLOOD, V86, P268, DOI 10.1182/blood.V86.1.268.bloodjournal861268; Reddy PL, 2002, BRIT J HAEMATOL, V116, P564, DOI 10.1046/j.0007-1048.2001.03323.x; Richardson DR, 1996, BLOOD, V87, P3477, DOI 10.1182/blood.V87.8.3477.bloodjournal8783477; ROTIG A, 1991, GENOMICS, V10, P502, DOI 10.1016/0888-7543(91)90342-C; Rudin CM, 2004, J CLIN ONCOL, V22, P1110, DOI 10.1200/JCO.2004.10.148; SANDRELLI A, 1992, EUR J CANCER, V28A, P1633, DOI 10.1016/0959-8049(92)90057-9; Sawada M, 2003, NAT CELL BIOL, V5, P352, DOI 10.1038/ncb955; Schiller AB, 2002, CYTOMETRY, V50, P203, DOI 10.1002/cyto.10091; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Serkova N, 2004, MOL INTERV, V4, P97, DOI 10.1124/mi.4.2.7; Shetty V, 2002, BRIT J HAEMATOL, V116, P817, DOI 10.1046/j.0007-1048.2002.03366.x; Shimada Y, 1998, J HUM GENET, V43, P115, DOI 10.1007/s100380050051; Shin MG, 2004, BLOOD, V103, P553, DOI 10.1182/blood-2003-05-1724; Shin MG, 2003, BLOOD, V101, P3118, DOI 10.1182/blood-2002-06-1825; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Shirihai OS, 2000, EMBO J, V19, P2492, DOI 10.1093/emboj/19.11.2492; Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Sordet O, 2001, BLOOD, V97, P3931, DOI 10.1182/blood.V97.12.3931; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; Taketani S, 2003, BLOOD, V101, P3274, DOI 10.1182/blood-2002-04-1212; Tehranchi R, 2005, CLIN CANCER RES, V11, P6291, DOI 10.1158/1078-0432.CCR-04-1850; Tehranchi R, 2003, BLOOD, V101, P1080, DOI 10.1182/blood-2002-06-1774; Testa U, 2004, LEUKEMIA, V18, P1176, DOI 10.1038/sj.leu.2403383; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; TURA S, 1984, ONCOLOGY, V41, P90, DOI 10.1159/000225894; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; Walker A, 1997, CANCER RES, V57, P1939; Walsh M, 2002, BLOOD, V99, P3439, DOI 10.1182/blood.V99.9.3439; Wang JL, 2000, CANCER RES, V60, P1498; Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798; Watabe M, 2000, CANCER RES, V60, P5214; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weisberg EL, 1996, CANCER RES, V56, P551; Weisleder N, 2004, P NATL ACAD SCI USA, V101, P769, DOI 10.1073/pnas.0303202101; Woo M, 2003, NAT IMMUNOL, V4, P1016, DOI 10.1038/ni976; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Yamamoto K, 2004, LEUKEMIA RES, V28, P1203, DOI 10.1016/j.leukres.2004.03.020; Yamamoto M, 2000, INT J HEMATOL, V72, P157; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zhang B, 2003, ONCOGENE, V22, P1848, DOI 10.1038/sj.onc.1206358; Zhivotovsky B, 2005, BIOCHEM BIOPH RES CO, V331, P859, DOI 10.1016/j.bbrc.2005.03.191; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhou Y, 2003, BLOOD, V101, P4098, DOI 10.1182/blood-2002-08-2512; Zinkel SS, 2003, GENE DEV, V17, P229, DOI 10.1101/gad.1045603	163	64	66	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	34					4757	4767		10.1038/sj.onc.1209606	http://dx.doi.org/10.1038/sj.onc.1209606			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892088				2022-12-17	WOS:000239687000012
J	Ohta, S				Ohta, S.			Contribution of somatic mutations in the mitochondrial genome to the development of cancer and tolerance against anticancer drugs	ONCOGENE			English	Review						apoptosis; cybrid; codon; mitochondrial disease; transplantation	CELLS LACKING MTDNA; DNA MUTATIONS; HELA-CELLS; BIOENERGETIC SIGNATURE; PATHOGENIC MUTATIONS; PROTEIN-SYNTHESIS; GENE; APOPTOSIS; DISEASE; STRESS	Mitochondrial defects have long been suspected to play an important role in the development of cancer. Although most cancer cells harbor somatic mutations in mitochondrial DNA (mtDNA), the question of whether such mutations positively contribute to the development of cancer remained unclear. To clarify the role of mutant mtDNA excluding effects by the nuclear background, we focus on a method of transmitochondrial cybrids. Tumors were formed by transplanting cybrids with or without mutant mtDNA into nude mice and compared each size, revealing that mutant cybrids enhanced tumorigenesis. Next, we discuss a method for excluding the possibility of secondary nuclear mutations that may affect tumorigenesis. Mitochondrial genes that had been converted from mitochondrial to nuclear codons and equipped with a mitochondrial-targeting sequence were introduced into the nucleus of mutant cybrids. The gene products complemented the dysfunction, and reduced the promotion of tumors. By these methods, we concluded that mutant mitochondria positively and directly contribute to tumorigenesis. Since apoptosis occurred less frequently in the mutant versus wild-type cybrids in tumors, pathogenic mtDNA mutations contribute to the promotion of tumors by preventing apoptosis. Finally, we discuss the role of mutant mtDNA in conferring tolerance against anticancer drugs.	Nippon Med Sch, Grad Sch Med, Inst Dev & Aging Sci, Dept Biochem & Cell Biol,Nakahara Ku, Kawasaki, Kanagawa 2118533, Japan	Nippon Medical School	Ohta, S (corresponding author), Nippon Med Sch, Grad Sch Med, Inst Dev & Aging Sci, Dept Biochem & Cell Biol,Nakahara Ku, 1-396 Kosugi Cho, Kawasaki, Kanagawa 2118533, Japan.	ohta@nms.ac.jp						Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cb.04.110188.001445; ATTARDI G, 1995, BBA-MOL BASIS DIS, V1271, P241, DOI 10.1016/0925-4439(95)00034-2; Bayona-Bafaluy MP, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng100; Biswas G, 2005, GENE, V354, P132, DOI 10.1016/j.gene.2005.03.028; Carew Jennifer S, 2002, Mol Cancer, V1, P9, DOI 10.1186/1476-4598-1-9; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; Coller HA, 2001, NAT GENET, V28, P147, DOI 10.1038/88859; Cuezva JM, 2004, CARCINOGENESIS, V25, P1157, DOI 10.1093/carcin/bgh113; Cuezva JM, 2002, CANCER RES, V62, P6674; D'Aurelio M, 2004, HUM MOL GENET, V13, P3171, DOI 10.1093/hmg/ddh326; DESJARDINS P, 1986, SOMAT CELL MOLEC GEN, V12, P133, DOI 10.1007/BF01560660; DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602; DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Geromel V, 2001, HUM MOL GENET, V10, P1221, DOI 10.1093/hmg/10.11.1221; Ghelli A, 2003, J BIOL CHEM, V278, P4145, DOI 10.1074/jbc.M210285200; Guy J, 2002, ANN NEUROL, V52, P534, DOI 10.1002/ana.10354; HAYASHI J, 1990, BIOCHEM BIOPH RES CO, V167, P216, DOI 10.1016/0006-291X(90)91753-F; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1993, BIOCHEM BIOPH RES CO, V197, P1049, DOI 10.1006/bbrc.1993.2584; HAYASHI JI, 1992, SOMAT CELL MOLEC GEN, V18, P123, DOI 10.1007/BF01233159; HAYASHI JI, 1991, PROGR NEUROPATHOLOGY, P93; HOLT IJ, 1990, AM J HUM GENET, V46, P428; Inoue K, 1997, J BIOL CHEM, V272, P15510, DOI 10.1074/jbc.272.24.15510; Isidoro A, 2004, BIOCHEM J, V378, P17, DOI 10.1042/BJ20031541; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; Klein Theodore M., 1993, Current Opinion in Biotechnology, V4, P583, DOI 10.1016/0958-1669(93)90081-7; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; Linnartz B, 2004, CANCER RES, V64, P1966, DOI 10.1158/0008-5472.CAN-03-2956; Liu VWS, 2001, CANCER RES, V61, P5998; Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851; Matsuzawa A, 2005, NAT IMMUNOL, V6, P587, DOI 10.1038/ni1200; Maximo V, 2002, AM J PATHOL, V160, P1857, DOI 10.1016/S0002-9440(10)61132-7; McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5; Michiels C, 2002, FREE RADICAL BIO MED, V33, P1231, DOI 10.1016/S0891-5849(02)01045-6; Moraes CT, 2001, METHOD CELL BIOL, V65, P397, DOI 10.1016/S0091-679X(01)65023-4; MORAIS R, 1994, CANCER RES, V54, P3889; Nakano K, 2003, MITOCHONDRION, V3, P21, DOI 10.1016/S1567-7249(03)00056-4; Nakashima-Kamimura N, 2005, J CELL SCI, V118, P5357, DOI 10.1242/jcs.02645; Nishikawa M, 2001, CANCER RES, V61, P1843; Ohta S, 2003, CURR MED CHEM, V10, P2485, DOI 10.2174/0929867033456440; Parrella P, 2001, CANCER RES, V61, P7623; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Qian W, 2005, AM J PHYSIOL-CELL PH, V289, pC1466, DOI 10.1152/ajpcell.00265.2005; Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012; Shin YK, 2005, CANCER RES, V65, P3162, DOI 10.1158/0008-5472.CAN-04-3300; Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056; Takamatsu C, 2002, EMBO REP, V3, P451, DOI 10.1093/embo-reports/kvf099; Tan DJ, 2002, CANCER RES, V62, P972; Tang JT, 1999, ANTICANCER RES, V19, P4959; TATUCH Y, 1992, AM J HUM GENET, V50, P852; Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102; Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WARBURG O, 1930, METABOLISM TUMORS; Wong LJC, 2003, CANCER RES, V63, P3866; Xu RH, 2005, CANCER RES, V65, P613; Yasukawa T, 2005, MOL CELL, V18, P651, DOI 10.1016/j.molcel.2005.05.002; Yeh JJ, 2000, ONCOGENE, V19, P2060, DOI 10.1038/sj.onc.1203537; YONEDA M, 1995, BIOCHEM BIOPH RES CO, V209, P723, DOI 10.1006/bbrc.1995.1559; YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164	67	64	69	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	34					4768	4776		10.1038/sj.onc.1209602	http://dx.doi.org/10.1038/sj.onc.1209602			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892089				2022-12-17	WOS:000239687000013
J	Higuchi, M; Kudo, T; Suzuki, S; Evans, TT; Sasaki, R; Wada, Y; Shirakawa, T; Sawyer, JR; Gotoh, A				Higuchi, M; Kudo, T; Suzuki, S; Evans, TT; Sasaki, R; Wada, Y; Shirakawa, T; Sawyer, JR; Gotoh, A			Mitochondrial DNA determines androgen dependence in prostate cancer cell lines	ONCOGENE			English	Article						mitochondrial DNA; prostate cancer; hormone dependence	FACTOR-KAPPA-B; NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY; SACCHAROMYCES-CEREVISIAE; MULTIPLE DELETIONS; MUTATOR PHENOTYPE; POINT MUTATIONS; MTDNA; ACTIVATION; EXPRESSION; CARCINOMA	Prostate cancer progresses from an androgen-dependent to androgen-independent stage after androgen ablation therapy. Mitochondrial DNA plays a role in cell death and metastatic competence. Further, heteroplasmic large-deletion mitochondrial DNA is very common in prostate cancer. To investigate the role of mitochondrial DNA in androgen dependence of prostate cancers, we tested the changes of normal and deleted mitochondrial DNA in accordance with the progression of prostate cancer. We demonstrated that the androgen-independent cell line C4-2, established by inoculation of the androgen-dependent LNCaP cell line into castrated mice, has a greatly reduced amount of normal mitochondrial DNA and an accumulation of large-deletion DNA. Strikingly, the depletion of mitochondrial DNA from androgen-dependent LNCaP resulted in a loss of androgen dependence. Reconstitution of normal mitochondrial DNA to the mitochondrial DNA-depleted clone restored androgen dependence. These results indicate that mitochondrial DNA determines androgen dependence of prostate cancer cell lines. Further, mitochondrial DNA-deficient cells formed tumors in castrated athymic mice, whereas LNCaP did not. The accumulation of large deletion and depletion of mitochondrial DNA may thus play a role in the development of androgen independence, leading to progression of prostate cancers.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; VA Med Ctr, Houston, TX USA; Dept Neurol, Houston, TX USA; Baylor Coll Med, Houston, TX 77030 USA; Kobe Univ, Sch Med, Dept Radiol, Chuo Ku, Kobe, Hyogo 657, Japan; Kobe Univ, Sch Med, Dept Clin Genet, Chuo Ku, Kobe, Hyogo 657, Japan; Kobe Univ, Sch Med, Dept Urol, Chuo Ku, Kobe, Hyogo 657, Japan; Kobe Univ, Sch Med, Int Ctr Med Res, Chuo Ku, Kobe, Hyogo 657, Japan; Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center; Baylor College of Medicine; Kobe University; Kobe University; Kobe University; Kobe University; University of Arkansas System; University of Arkansas Medical Sciences	Higuchi, M (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, 4301 W Markham Slot 516, Little Rock, AR 72205 USA.	mhiguchi@uams.edu	Suzuki, Seigo/G-5378-2012	Shirakawa, Toshiro/0000-0003-3925-8730	NATIONAL CANCER INSTITUTE [R01CA100846] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100846-06, R01 CA100846-03, R01 CA100846-02, R01 CA100846-01A1, R01 CA100846-04, R01 CA100846, R01 CA100846-05, CA100846] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Arnould T, 2002, EMBO J, V21, P53, DOI 10.1093/emboj/21.1.53; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; BURGART LJ, 1995, AM J PATHOL, V147, P1105; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Chen JJZ, 2002, CANCER RES, V62, P6470; CULIG Z, 1993, PROSTATE, V22, P11, DOI 10.1002/pros.2990220103; DIAMOND DA, 1984, J UROLOGY, V132, P821, DOI 10.1016/S0022-5347(17)49881-8; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Higuchi M, 2002, ANTIOXID REDOX SIGN, V4, P945, DOI 10.1089/152308602762197489; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721; Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jeronimo C, 2001, ONCOGENE, V20, P5195, DOI 10.1038/sj.onc.1204646; Jessie BC, 2001, EXP GERONTOL, V37, P169, DOI 10.1016/S0531-5565(01)00153-X; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; Kawarada Y, 1998, J BIOCHEM-TOKYO, V123, P492; Kimura K, 2001, CANCER RES, V61, P5611; KING MP, 1988, CELL, V52, P811, DOI 10.1016/0092-8674(88)90423-0; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Loeb LA, 2001, CANCER RES, V61, P3230; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774; Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010; Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828; Ozawa T, 1997, PHYSIOL REV, V77, P425, DOI 10.1152/physrev.1997.77.2.425; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Papadimitriou A, 1998, NEUROLOGY, V51, P1086, DOI 10.1212/WNL.51.4.1086; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Rasmussen AK, 2003, NUCLEIC ACIDS RES, V31, P3909, DOI 10.1093/nar/gkg446; Ripple MO, 1997, JNCI-J NATL CANCER I, V89, P40, DOI 10.1093/jnci/89.1.40; Simonnet H, 2002, CARCINOGENESIS, V23, P759, DOI 10.1093/carcin/23.5.759; Singh KK, 2001, NUCLEIC ACIDS RES, V29, P1381, DOI 10.1093/nar/29.6.1381; Sommer A, 2003, CURR OPIN DRUG DISC, V6, P702; Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058; Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0; Zhang DK, 2000, GENOMICS, V69, P151, DOI 10.1006/geno.2000.6333	44	64	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2006	25	10					1437	1445		10.1038/sj.onc.1209190	http://dx.doi.org/10.1038/sj.onc.1209190			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16278679	Green Accepted			2022-12-17	WOS:000235890400001
J	Joshi, S; Guleria, R; Pan, J; DiPette, D; Singh, US				Joshi, S; Guleria, R; Pan, J; DiPette, D; Singh, US			Retinoic acid receptors and tissue-transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells	ONCOGENE			English	Article						neuroblastoma; SH-SY5Y; IMR-32; retinoic acid; RAR; RXR; tissue-transglutaminase	CENTRAL-NERVOUS-SYSTEM; GROWTH IN-VIVO; NEURONAL DIFFERENTIATION; NEURITE OUTGROWTH; UP-REGULATION; TUMOR-GROWTH; MATRIX-METALLOPROTEINASE-9 EXPRESSION; MATRIX-METALLOPROTEINASE; KINASE PATHWAYS; ACTIVATION	Long-term treatment with all trans-retinoic acid ( RA) induces neuronal differentiation and apoptosis. However, the effect of short-term RA treatment on cell proliferation, migration and invasion of neuroblastoma cell lines (SH-SY5Y and IMR-32) remains unclear. RA induces expression of tissue-transglutaminase ( TGase) and promotes migration and invasion after 24 h of treatment in SH-SY5Y cells, but not in IMR-32 cells. RA receptor (RAR) agonist (4-(E-2-[5,6,7,8-tetrahydro-5,5,8,8-tetramethy-2- naphthalenyl]-1-propenyl) benzoic acid) and RAR/retinoid X receptor (RXR) agonist (9-cis-RA) promote expression of TGase, migration and invasion of SH-SY5Y cells, while RXR agonist has no significant effect. RAR antagonist blocks RA effect on migration and invasion, indicating that RAR receptors are required. Retinoid receptors are expressed and activated by RA in both cell lines. However, only transient activation of RAR is observed in IMR-32 cells. These findings suggest that different responses observed in SH-SY5Y and IMR-32 cells could be due to differential activation of retinoid receptors. Overexpression of TGase has no effect on migration or invasion, while overexpression of antisense TGase blocks RA-induced migration and invasion, indicating that other molecules along with TGase mediate RA effects. In addition to the long-term effects of RA that are coupled with cell differentiation, short-term effects involve migration and invasion of neuroblastoma SH-SY5Y cells.	Texas A&M Univ Syst, Hlth Sci Ctr, Inst Cardiovasc Res, Div Mol Cardiol,Dept Internal Med,Coll Med, Temple, TX 76504 USA; Scott & White Mem Hosp & Clin, Temple, TX USA; Cent Texas Vet Hlth Care Syst, Temple, TX USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Scott & White Medical Center	Singh, US (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Inst Cardiovasc Res, Div Mol Cardiol,Dept Internal Med,Coll Med, Bldg 205,1901 S 1st St, Temple, TX 76504 USA.	Usingh@medicine.tamhsc.edu						Abel EL, 2001, J PEDIATR-US, V138, P295, DOI 10.1067/mpd.2001.107612; Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; Akimov SS, 2001, BLOOD, V98, P1567, DOI 10.1182/blood.V98.5.1567; Antonyak MA, 2001, J BIOL CHEM, V276, P33582, DOI 10.1074/jbc.M105318200; Arvidsson Y, 2001, CELL DEATH DIFFER, V8, P1029, DOI 10.1038/sj.cdd.4400922; Biedler J L, 1988, Prog Clin Biol Res, V271, P265; Carpentier A, 1997, ONCOGENE, V15, P1805, DOI 10.1038/sj.onc.1201335; Castleberry RP, 1997, PEDIATR CLIN N AM, V44, P919, DOI 10.1016/S0031-3955(05)70537-X; Chambaut-Guerin AM, 2000, J NEUROCHEM, V74, P508, DOI 10.1046/j.1471-4159.2000.740508.x; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Cianfarani S, 1997, EUR J PEDIATR, V156, P256, DOI 10.1007/s004310050595; CICCARONE V, 1989, CANCER RES, V49, P219; DAVIES PJA, 1992, RETINOIDS NORMAL DEV; DENNING MF, 1991, BIOCHEM BIOPH RES CO, V175, P344, DOI 10.1016/S0006-291X(05)81241-0; Eggert A, 2002, CANCER RES, V62, P1802; Emionite L, 2003, ANTICANCER RES, V23, P13; Farina AR, 1999, CELL GROWTH DIFFER, V10, P353; Farina AR, 2002, CELL GROWTH DIFFER, V13, P343; FESTUCCIA C, 1996, INT J CANC PRED ONCO, V69, P1; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; Frappaz D, 2000, J CLIN ONCOL, V18, P468, DOI 10.1200/JCO.2000.18.3.468; Giannini G, 1997, J BIOL CHEM, V272, P26693, DOI 10.1074/jbc.272.42.26693; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Ishaq M, 2000, J IMMUNOL, V165, P4217, DOI 10.4049/jimmunol.165.8.4217; Isobe T, 1999, EUR J CELL BIOL, V78, P876, DOI 10.1016/S0171-9335(99)80089-2; JULIANO R, 1994, CANCER METAST REV, V13, P25, DOI 10.1007/BF00690416; Kang SK, 2004, J BIOL CHEM, V279, P36593, DOI 10.1074/jbc.M402084200; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Klaassen I, 2001, INT J CANCER, V92, P661, DOI 10.1002/1097-0215(20010601)92:5<661::AID-IJC1251>3.0.CO;2-O; Leelawat K, 2005, CANCER LETT, V224, P303, DOI 10.1016/j.canlet.2004.10.016; Lotan Y, 2000, J CLIN ONCOL, V18, P116, DOI 10.1200/JCO.2000.18.1.116; MACKAY AR, 1992, INVAS METAST, V12, P168; MADEN M, 1992, BIOESSAYS, V14, P431, DOI 10.1002/bies.950140702; Maden M, 2002, NAT REV NEUROSCI, V3, P843, DOI 10.1038/nrn963; Mehta K, 2004, CLIN CANCER RES, V10, P8068, DOI 10.1158/1078-0432.CCR-04-1107; Meyer GE, 2001, ONCOGENE, V20, P7542, DOI 10.1038/sj.onc.1204927; Mohan K, 2003, J IMMUNOL, V171, P3179, DOI 10.4049/jimmunol.171.6.3179; NILES RM, 2004, MUTAT RES, V55, P97; Palm-Leis A, 2004, J BIOL CHEM, V279, P54905, DOI 10.1074/jbc.M407383200; PAN J, 2005, J NEUROCHEM, V10, P1; Phuangsab A, 2001, CANCER LETT, V172, P27, DOI 10.1016/S0304-3835(01)00617-6; Pola S, 2003, J BIOL CHEM, V278, P40601, DOI 10.1074/jbc.M306510200; Ponthan F, 2001, MED PEDIATR ONCOL, V36, P127, DOI 10.1002/1096-911X(20010101)36:1<127::AID-MPO1030>3.0.CO;2-B; Ponthan F, 2003, INT J CANCER, V104, P418, DOI 10.1002/ijc.10954; PRAISE L, 2000, SEMIN CANCER BIOL, V10, P407; Priglinger SG, 2004, INVEST OPHTH VIS SCI, V45, P955, DOI 10.1167/iovs.03-0210; QUI H, 1999, AM J PATHOL, V155, P1519; Reynolds C P, 2000, Curr Oncol Rep, V2, P511, DOI 10.1007/s11912-000-0104-y; Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304-3835(03)00108-3; Reynolds CP, 2001, HEMATOL ONCOL CLIN N, V15, P867, DOI 10.1016/S0889-8588(05)70256-2; Rodolfo C, 2004, J BIOL CHEM, V279, P54783, DOI 10.1074/jbc.M410938200; ROSSINO P, 1991, CELL REGUL, V2, P1021, DOI 10.1091/mbc.2.12.1021; SATO H, 1992, ONCOGENE, V7, P77; Schmidt ML, 2000, J CLIN ONCOL, V18, P1260, DOI 10.1200/JCO.2000.18.6.1260; Singh US, 2003, J BIOL CHEM, V278, P391, DOI 10.1074/jbc.M206361200; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; Soprano KJ, 2002, J NUTR, V132, p3809S, DOI 10.1093/jn/132.12.3809S; SPORN MB, 1994, RETINOIDS BIOL MED; Stahle M, 2003, J CELL SCI, V116, P3835, DOI 10.1242/jcs.00679; Sugiura Y, 1998, CANCER RES, V58, P2209; Tucholski J, 2001, NEUROSCIENCE, V102, P481, DOI 10.1016/S0306-4522(00)00482-6; Voigt A, 2003, MED PEDIATR ONCOL, V40, P205, DOI 10.1002/mpo.10250; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; XU C, 1997, CANCER RES, V57, P4992; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; XU XC, 1994, CANCER RES, V54, P3580; YAO M, 1995, J NEUROSCI RES, V41, P792, DOI 10.1002/jnr.490410610; Zang CB, 2000, J CANCER RES CLIN, V126, P33, DOI 10.1007/PL00008462; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022	71	64	70	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	2					240	247		10.1038/sj.onc.1209027	http://dx.doi.org/10.1038/sj.onc.1209027			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	002AK	16158052				2022-12-17	WOS:000234583600008
J	Wechselberger, C; Strizzi, L; Kenney, N; Hirota, M; Sun, YP; Ebert, A; Orozco, O; Bianco, C; Khan, NI; Wallace-Jones, B; Normanno, N; Adkins, H; Sanicola, M; Salomon, DS				Wechselberger, C; Strizzi, L; Kenney, N; Hirota, M; Sun, YP; Ebert, A; Orozco, O; Bianco, C; Khan, NI; Wallace-Jones, B; Normanno, N; Adkins, H; Sanicola, M; Salomon, DS			Human Cripto-1 overexpression in the mouse mammary gland results in the development of hyperplasia and adenocarcinoma	ONCOGENE			English	Article						Cripto-1; transgenic mice; mammary development; mammary tumorigenesis; MMTV-LTR	INTEGRIN-LINKED KINASE; COLON-CANCER CELLS; HUMAN BREAST CARCINOMAS; FACTOR-RELATED PROTEINS; GROWTH-FACTOR-ALPHA; TRANSGENIC MICE; SIGNALING PATHWAY; EPITHELIAL-CELLS; ANTISENSE OLIGONUCLEOTIDES; BRANCHING MORPHOGENESIS	Human Cripto-1 (CR-1) is overexpressed in approximately 80% of human breast, colon and lung carcinomas. Mouse Cr-1 upregulation is also observed in a number of transgenic (Tg) mouse mammary tumors. To determine whether CR-1 can alter mammary gland development and/or may contribute to tumorigenesis in vivo, we have generated Tg mouse lines that express human CR-1 under the transcriptional control of the mouse mammary tumor virus ( MMTV). Stable Tg MMTV/CR-1 FVB/N lines expressing different levels of CR-1 were analysed. Virgin female MMTV/CR-1 Tg mice exhibited enhanced ductal branching, dilated ducts, intraductal hyperplasia, hyperplastic alveolar nodules and condensation of the mammary stroma. Virgin aged MMTV/CR-1 Tg mice also possessed persistent end buds. In aged multiparous MMTV/ CR-1 mice, the hyperplastic phenotype was most pronounced with multifocal hyperplasias. In the highest CR1-expressing subline, G4,38% (12/31) of the multiparous animals aged 12 - 20 months developed hyperplasias and approximately 33% (11/31) developed papillary adenocarcinomas. The long latency period suggests that additional genetic alterations are required to facilitate mammary tumor formation in conjunction with CR-1. This is the first in vivo study that shows hyperplasia and tumor growth in CR-1-overexpressing animals.	NCI, Tumor Growth Factor Sect, Mammary Biol & Tumorigenesis Lab, Bethesda, MD 20892 USA; Hampton Univ, Dept Biol Sci, Hampton, VA 23668 USA; Free Univ Berlin, Med Ctr Benjamin Franklin, Dept Obstet & Gynecol, D-12200 Berlin, Germany; Biogen Idec Inc, Cambridge, MA 02142 USA; IT Fdn, Div Haematol Oncol, I-80131 Naples, Italy; IT Fdn, Dept Expt Oncol, I-80131 Naples, Italy	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hampton University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Biogen	Salomon, DS (corresponding author), NCI, Tumor Growth Factor Sect, Mammary Biol & Tumorigenesis Lab, Bldg 10,Room 5B39,10 Ctr Dr, Bethesda, MD 20892 USA.	salomond@mail.nih.gov	Normanno, Nicola/AAT-1107-2021; Sun, Youping/AAX-7058-2021	Normanno, Nicola/0000-0002-7158-2605; Wechselberger, Christian/0000-0002-2164-3019; Hirota, Morihisa/0000-0001-5682-0911	NATIONAL CANCER INSTITUTE [ZIABC009003, Z01BC009003] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamson ED, 2002, J CELL PHYSIOL, V190, P267, DOI 10.1002/jcp.10072; Adkins HB, 2003, J CLIN INVEST, V112, P575, DOI 10.1172/JCI200317788; Bhattacharya B, 2004, BLOOD, V103, P2956, DOI 10.1182/blood-2003-09-3314; Bianco C, 2003, CANCER RES, V63, P1192; Bianco C, 2002, MOL CELL BIOL, V22, P2586, DOI 10.1128/MCB.22.8.2586-2597.2002; BOTCHAN M, 1976, CELL, V9, P269, DOI 10.1016/0092-8674(76)90118-5; Brisken C, 2000, GENE DEV, V14, P650; CARDIFF RD, 1995, CANCER LETT, V90, P13, DOI 10.1016/0304-3835(94)03672-6; Carpenter MK, 2004, DEV DYNAM, V229, P243, DOI 10.1002/dvdy.10431; Cheng SK, 2003, GENE DEV, V17, P31, DOI 10.1101/gad.1041203; CIARDIELLO F, 1991, CANCER RES, V51, P1051; CIARDIELLO F, 1994, ONCOGENE, V9, P291; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; Colas JF, 2000, GENE, V255, P205, DOI 10.1016/S0378-1119(00)00337-1; De Luca A, 1999, INT J CANCER, V80, P589, DOI 10.1002/(SICI)1097-0215(19990209)80:4<589::AID-IJC17>3.0.CO;2-D; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DeLuca A, 1997, INT J CANCER, V73, P277, DOI 10.1002/(SICI)1097-0215(19971009)73:2<277::AID-IJC19>3.3.CO;2-J; Ding JX, 1998, NATURE, V395, P702, DOI 10.1038/27215; DONEHOWER LA, 1981, J VIROL, V37, P226, DOI 10.1128/JVI.37.1.226-238.1981; DONO R, 1993, DEVELOPMENT, V118, P1157; Ebert AD, 2000, EXP CELL RES, V257, P223, DOI 10.1006/excr.2000.4881; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Gray PC, 2003, P NATL ACAD SCI USA, V100, P5193, DOI 10.1073/pnas.0531290100; Harms PW, 2003, GENE DEV, V17, P2624, DOI 10.1101/gad.1127703; Herrington EE, 1997, J CELL PHYSIOL, V170, P47; Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Johnson MD, 2003, NAT MED, V9, P1081, DOI 10.1038/nm902; Kenney N., 1997, PATHOGENESIS, V1, P57; Kenney NJ, 1996, MOL CARCINOGEN, V15, P44; KENNEY NJ, 1995, MOL REPROD DEV, V41, P277, DOI 10.1002/mrd.1080410302; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Morkel M, 2003, DEVELOPMENT, V130, P6283, DOI 10.1242/dev.00859; Naylor MJ, 2002, DEV DYNAM, V225, P100, DOI 10.1002/dvdy.10133; Niemeyer CC, 1999, INT J CANCER, V81, P588, DOI 10.1002/(SICI)1097-0215(19990517)81:4<588::AID-IJC14>3.0.CO;2-I; Niemeyer CC, 1998, CELL DEATH DIFFER, V5, P440, DOI 10.1038/sj.cdd.4400368; Normanno N, 1999, ONCOL REP, V6, P1105; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; Normanno N, 1996, CLIN CANCER RES, V2, P601; Oloumi A, 2004, BBA-MOL CELL RES, V1691, P1, DOI 10.1016/j.bbamcr.2003.12.002; Panico L, 1996, INT J CANCER, V65, P51, DOI 10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.3.CO;2-N; POLLARD JW, 2001, BREAST CANCER RES, V3, P320; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; Robinson GW, 1997, DEVELOPMENT, V124, P2701; Robinson GW, 2000, GENE DEV, V14, P889; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Salomon DS, 1999, BIOESSAYS, V21, P61, DOI 10.1002/(SICI)1521-1878(199901)21:1&lt;61::AID-BIES8&gt;3.0.CO;2-H; Salomon DS, 2000, ENDOCR-RELAT CANCER, V7, P199, DOI 10.1677/erc.0.0070199; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Shen MM, 2000, TRENDS GENET, V16, P303, DOI 10.1016/S0168-9525(00)02006-0; Shen MM, 1997, DEVELOPMENT, V124, P429; Silberstein GB, 2001, BREAST CANCER RES, V3, P218, DOI 10.1186/bcr299; Soriano JV, 1998, J MAMMARY GLAND BIOL, V3, P133, DOI 10.1023/A:1018790705727; Srinivasan R, 2000, CANCER RES, V60, P1483; Strizzi L, 2004, J CELL PHYSIOL, V201, P266, DOI 10.1002/jcp.20062; Uyttendaele H, 1998, DEV BIOL, V196, P204, DOI 10.1006/dbio.1998.8863; Webster MA, 1998, ONCOGENE, V16, P1963, DOI 10.1038/sj.onc.1201707; WECHSELBERGER C, 1992, P NATL ACAD SCI USA, V89, P9819, DOI 10.1073/pnas.89.20.9819; Wechselberger C, 2001, EXP CELL RES, V266, P95, DOI 10.1006/excr.2001.5195; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; Xing PX, 2004, CANCER RES, V64, P4018, DOI 10.1158/0008-5472.CAN-03-3888; Xu CH, 1999, DEVELOPMENT, V126, P483; Yan YT, 2002, MOL CELL BIOL, V22, P4439, DOI 10.1128/MCB.22.13.4439-4449.2002; Yeo CY, 2001, MOL CELL, V7, P949, DOI 10.1016/S1097-2765(01)00249-0; Yokota C, 2003, DEVELOPMENT, V130, P2199, DOI 10.1242/dev.00434; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6	71	64	65	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4094	4105		10.1038/sj.onc.1208417	http://dx.doi.org/10.1038/sj.onc.1208417			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15897912				2022-12-17	WOS:000229680300008
J	Li, L; Forman, SJ; Bhatia, R				Li, L; Forman, SJ; Bhatia, R			Expression of DLK1 in hematopoietic cells results in inhibition of differentiation and proliferation	ONCOGENE			English	Article						Delta-like; myelodysplastic syndrome; hematopoietic progenitor cell; cell differentiation; cell proliferation	HOMEOTIC PROTEIN DLK; DELTA-LIKE DLK; ADIPOCYTE DIFFERENTIATION; MYELODYSPLASTIC SYNDROMES; BONE-MARROW; PREF-1; GROWTH; PROGENITORS; ANTIGEN-1; IDENTIFICATION	The Delta-like (DLK1) gene is overexpressed in CD34+ cells from myelodysplastic syndrome (MDS) patients. DLK1 encodes an EGF-like homeotic transmembrane protein homologous to the notch/delta/serrate family. Although exogenous DLK1 promotes maintenance of murine hematopoietic stem cells, the functional effects of DLK1 overexpression in hematopoietic cells are unknown. We show that ectopically expressed DLK1 significantly inhibits differentiation and proliferation of human promyelocytic HL-60 cells. Unlike preadipocytes, where proteolytic processing of membrane-bound protein and release of a soluble form mediates differentiation inhibition, proteolytic release of the extracellular domain was not required for inhibition of hematopoietic cell differentiation. However, intracellular domain interactions were critical to this DLK1 function. We conclude that DLK1 overexpression in hematopoietic cells has important functional consequences. Our studies identify novel molecular mechanisms and indicate that DLK1 has activity both as a soluble and a transmembrane expressed protein. Our results support further investigation of the role of DLK1 in abnormal hematopoiesis in MDS.	City Hope Natl Med Ctr, Div Hematol & Hematopoiet Cell Transplantat, Duarte, CA 91010 USA	City of Hope	Bhatia, R (corresponding author), City Hope Natl Med Ctr, Div Hematol & Hematopoiet Cell Transplantat, 1500 E Duarte Rd, Duarte, CA 91010 USA.	rbhatia@coh.org						Abdallah BM, 2004, J BONE MINER RES, V19, P841, DOI 10.1359/JBMR.040118; Allampallam K, 1999, ANTICANCER RES, V19, P5323; Bachmann E, 1996, J REPROD FERTIL, V107, P279; Baladron V, 2002, BIOCHEM BIOPH RES CO, V291, P193, DOI 10.1006/bbrc.2002.6431; Bauer SR, 1998, MOL CELL BIOL, V18, P5247, DOI 10.1128/MCB.18.9.5247; Bhatia R, 2000, EXP HEMATOL, V28, P1401, DOI 10.1016/S0301-472X(00)00545-2; Costaglioli P, 2001, FEBS LETT, V509, P413, DOI 10.1016/S0014-5793(01)03205-7; Friedrichsen BN, 2003, J ENDOCRINOL, V176, P257, DOI 10.1677/joe.0.1760257; Garces C, 1999, DIFFERENTIATION, V64, P103, DOI 10.1007/s002580050265; Greenberg Peter L, 2002, Hematology Am Soc Hematol Educ Program, P136; Hofmann WK, 2002, BLOOD, V100, P3553, DOI 10.1182/blood.V100.10.3553; JENSEN CH, 1994, EUR J BIOCHEM, V225, P83, DOI 10.1111/j.1432-1033.1994.00083.x; Kaneta M, 2000, J IMMUNOL, V164, P256, DOI 10.4049/jimmunol.164.1.256; LABORDA J, 1993, J BIOL CHEM, V268, P3817; Langer F, 2004, LEUKEMIA RES, V28, P1081, DOI 10.1016/j.leukres.2004.01.020; LEE YL, 1995, BBA-GENE STRUCT EXPR, V1261, P223; Mei BS, 2002, BIOCHEM J, V364, P137, DOI 10.1042/bj3640137; Miyazato A, 2001, BLOOD, V98, P422, DOI 10.1182/blood.V98.2.422; Moore KA, 1997, P NATL ACAD SCI USA, V94, P4011, DOI 10.1073/pnas.94.8.4011; Ramaraj P, 2004, CANCER RES, V64, P5322, DOI 10.1158/0008-5472.CAN-03-3656; Raza A, 1997, LEUKEMIA LYMPHOMA, V27, P111, DOI 10.3109/10428199709068277; Silver RT, 2004, LEUKEMIA RES, V28, P979, DOI 10.1016/j.leukres.2004.01.012; Smas CM, 1997, MOL CELL BIOL, V17, P977, DOI 10.1128/MCB.17.2.977; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; Sul HS, 2000, INT J OBESITY, V24, pS15, DOI 10.1038/sj.ijo.0801494; van Limpt VAE, 2003, INT J CANCER, V105, P61, DOI 10.1002/ijc.11047; Walker L, 1999, STEM CELLS, V17, P162, DOI 10.1002/stem.170162; Ye Q, 2004, LEUKEMIA, V18, P777, DOI 10.1038/sj.leu.2403291	28	64	68	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2005	24	27					4472	4476		10.1038/sj.onc.1208637	http://dx.doi.org/10.1038/sj.onc.1208637			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	938CG	15806146				2022-12-17	WOS:000229976900016
J	Marreiros, A; Dudgeon, K; Dao, V; Grimm, MO; Czolij, R; Crossley, M; Jackson, P				Marreiros, A; Dudgeon, K; Dao, V; Grimm, MO; Czolij, R; Crossley, M; Jackson, P			KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells	ONCOGENE			English	Article						KAI1; transcription factor; metastasis suppressor; prostate cancer	METASTASIS-SUPPRESSOR GENE; FREQUENT DOWN-REGULATION; PROSTATE-CANCER; TRANSCRIPTION FACTOR; BLADDER-CANCER; HUMAN-MELANOMA; MESSENGER-RNA; MUTANT P53; C-JUN; LINES	A molecular mechanism to explain reduced KAI1 expression in invasive and metastatic tumour cells remains elusive. In this report, we extend an earlier study in bladder cells to confirm that a 76 bp region of the KAI1 promoter ( residues - 922 to - 847), with binding motifs for p53, AP1 and AP2, is required for high level activity of a KAI1 reporter in prostate cancer cell lines. Gel shift and supershift experiments supported binding of p53, junB and heterodimers of AP2alpha/AP2gamma or AP2beta/AP2gamma to this sequence. Introduction of mutations into specific motifs demonstrated an essential requirement for p53 and junB to reporter activity, and that functional synergy between these two factors enhanced activity. A further elevation of reporter activity required AP2. Roles of individual p53, junB and AP2 proteins, as well as functional synergy between p53 and junB, were confirmed in transfection experiments. Western blotting analysis showed that an absence of wild-type p53, and/or a loss of junB and AP2 protein expression, correlated with downregulation of KAI1 mRNA levels in a series of prostate cancer cell lines. A loss of p53 function and/or expression of junB, combined with reduced expression of specific AP2 proteins may underly downregulated KAI1 expression in tumour cells.	Prince Wales Hosp, Oncol Res Ctr, Randwick, NSW 2031, Australia; Univ New S Wales, Sch Med, Kensington, NSW 2033, Australia; Univ Dusseldorf, Dept Urol, D-4000 Dusseldorf, Germany; Univ Sydney, Sch Mol & Microbial Sci, Camperdown, NSW, Australia	University of New South Wales Sydney; Heinrich Heine University Dusseldorf; University of Sydney	Jackson, P (corresponding author), Prince Wales Hosp, Oncol Res Ctr, Level 2 Clin Sci Bldg,Barker St, Randwick, NSW 2031, Australia.	paul.jackson@unsw.edu.au	Crossley, Merlin/D-7888-2011	Crossley, Merlin/0000-0003-2057-3642; Grimm, Marc-Oliver/0000-0003-3084-8654				Akita H, 2000, CANCER LETT, V153, P79, DOI 10.1016/S0304-3835(00)00352-9; Bergman MR, 2003, BIOCHEM J, V369, P485, DOI 10.1042/BJ20020707; Bosher JM, 1996, ONCOGENE, V13, P1701; BUTZ K, 1995, ONCOGENE, V10, P927; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1997, GENOMICS, V41, P25, DOI 10.1006/geno.1997.4618; Dong JT, 1996, CANCER RES, V56, P4387; Duriez C, 2000, ONCOGENE, V19, P2461, DOI 10.1038/sj.onc.1203580; Gao AC, 2003, PROSTATE, V57, P256, DOI 10.1002/pros.10309; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Jackson P, 2003, PROSTATE CANCER P D, V6, P174, DOI 10.1038/sj.pcan.4500634; Jackson P, 2002, UROL ONCOL, V7, P99, DOI 10.1016/S1078-1439(01)00175-2; Jackson P, 2000, CANCER LETT, V157, P169, DOI 10.1016/S0304-3835(00)00483-3; Jackson P, 2000, BIOCHEM BIOPH RES CO, V278, P499, DOI 10.1006/bbrc.2000.3799; JACKSON P, 2004, IN PRESS PROGR BLADD; Jean D, 1998, J BIOL CHEM, V273, P16501, DOI 10.1074/jbc.273.26.16501; LI SL, 1992, ORAL ONCOL, V28B, P129, DOI 10.1016/0964-1955(92)90041-X; Lijovic M, 2002, CANCER DETECT PREV, V26, P69, DOI 10.1016/S0361-090X(02)00012-0; Liu FS, 2000, GYNECOL ONCOL, V78, P10, DOI 10.1006/gyno.2000.5801; Lombardi DP, 1999, CANCER RES, V59, P5724; Marreiros A, 2003, GENE, V302, P155, DOI 10.1016/S0378-1119(02)01101-0; Mashimo T, 1998, P NATL ACAD SCI USA, V95, P11307, DOI 10.1073/pnas.95.19.11307; Mashimo T, 2000, BIOCHEM BIOPH RES CO, V274, P370, DOI 10.1006/bbrc.2000.3139; MAY E, 1991, ONCOGENE, V6, P1363; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200; Miyazaki T, 2000, CANCER-AM CANCER SOC, V89, P955, DOI 10.1002/1097-0142(20000901)89:5<955::AID-CNCR3>3.0.CO;2-Z; Ow K, 2000, J PATHOL, V191, P39, DOI 10.1002/(SICI)1096-9896(200005)191:1<39::AID-PATH580>3.0.CO;2-K; Ribeiro JCC, 1997, INT J RADIAT BIOL, V72, P11, DOI 10.1080/095530097143491; Ruiz M, 2004, CANCER RES, V64, P631, DOI 10.1158/0008-5472.CAN-03-2751; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schindl M, 2001, CANCER LETT, V162, P261, DOI 10.1016/S0304-3835(00)00672-8; Sekita N, 2001, JPN J CANCER RES, V92, P947, DOI 10.1111/j.1349-7006.2001.tb01185.x; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shinohara T, 2001, CANCER RES, V61, P673; Tagawa K, 1999, JPN J CANCER RES, V90, P970, DOI 10.1111/j.1349-7006.1999.tb00843.x; Tellez C, 2003, ONCOGENE, V22, P3130, DOI 10.1038/sj.onc.1206453; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; Vandel L, 1996, MOL CELL BIOL, V16, P1881; WEIJERMAN PC, 1994, CANCER RES, V54, P5579; White A, 1998, ONCOGENE, V16, P3143, DOI 10.1038/sj.onc.1201852; Yardley G, 1998, FEBS LETT, V430, P171, DOI 10.1016/S0014-5793(98)00650-4; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200; Zhu CH, 2002, BREAST CANCER RES TR, V71, P47, DOI 10.1023/A:1013378113916	46	64	72	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					637	649		10.1038/sj.onc.1208216	http://dx.doi.org/10.1038/sj.onc.1208216			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580298				2022-12-17	WOS:000226420400011
J	Jandrig, B; Seitz, S; Hinzmann, B; Arnold, W; Micheel, B; Koelble, K; Siebert, R; Schwartz, A; Ruecker, K; Schlag, PM; Scherneck, S; Rosenthal, A				Jandrig, B; Seitz, S; Hinzmann, B; Arnold, W; Micheel, B; Koelble, K; Siebert, R; Schwartz, A; Ruecker, K; Schlag, PM; Scherneck, S; Rosenthal, A			ST18 is a breast cancer tumor suppressor gene at human chromosome 8q11.2	ONCOGENE			English	Article						breast cancer; tumor suppressor genes; ST18; chromosome 8q11	DNA METHYLATION; ZINC-FINGER; REGION; HETEROZYGOSITY; CARCINOGENESIS; IDENTIFICATION; INVOLVEMENT; PARAMETERS; MUTATIONS	We have identified a gene, ST18 ( suppression of tumorigenicity 18, breast carcinoma, zinc-finger protein), within a frequent imbalanced region of chromosome 8q11 as a breast cancer tumor suppressor gene. The ST18 gene encodes a zinc-finger DNA-binding protein with six fingers of the C2HC type ( configuration Cys-X-5-Cys-X-12-His-X-4-Cys) and an SMC domain. ST18 has the potential to act as transcriptional regulator. ST18 is expressed in a number of normal tissues including mammary epithelial cells although the level of expression is quite low. In breast cancer cell lines and the majority of primary breast tumors, ST18 mRNA is significantly downregulated. A 160 bp region within the promoter of the ST18 gene is hypermethylated in about 80% of the breast cancer samples and in the majority of breast cancer cell lines. The strong correlation between ST18 promoter hypermethylation and loss of ST18 expression in tumor cells suggests that this epigenetic mechanism is responsible for tumor-specific downregulation. We further show that ectopic ST18 expression in MCF-7 breast cancer cells strongly inhibits colony formation in soft agar and the formation of tumors in a xenograft mouse model.	Max Delbruck Ctr Mol Med, Dept Tumor Genet, D-13092 Berlin, Germany; Signature Diagnost AG, D-10719 Berlin, Germany; Atugen AG, D-13125 Berlin, Germany; Univ Potsdam, Inst Biochem & Biol, D-14476 Golm, Germany; Humboldt Univ, Charite Hosp, Inst Pathol, D-10117 Berlin, Germany; Robert Rossle Hosp, Clin Surg & Surg Oncol, D-13122 Berlin, Germany; Univ Hosp Schleswig Holstein, Inst Human Genet, D-24105 Kiel, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Potsdam; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Kiel; Schleswig Holstein University Hospital	Jandrig, B (corresponding author), Max Delbruck Ctr Mol Med, Dept Tumor Genet, D-13092 Berlin, Germany.	jandrig@mdc-berlin.de	Siebert, Reiner/A-8049-2010					Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S; Astrom AK, 2000, INT J ONCOL, V16, P1107; Bardet V, 2002, GENE CHROMOSOME CANC, V33, P178, DOI 10.1002/gcc.10014; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; Bottger V, 1999, J MOL RECOGNIT, V12, P191; BURN TC, 1995, GENE, V161, P183, DOI 10.1016/0378-1119(95)00223-S; Chano T, 2002, NAT GENET, V31, P285, DOI 10.1038/ng911; Dahiya R, 1998, INT J ONCOL, V12, P811; Esteller M, 2003, ADV EXP MED BIOL, V532, P39; Gu GQ, 2004, DEVELOPMENT, V131, P165, DOI 10.1242/dev.00921; Haering CH, 2003, BIOESSAYS, V25, P1178, DOI 10.1002/bies.10361; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jandrig B, 1996, INT J CANCER, V68, P188, DOI 10.1002/(SICI)1097-0215(19961009)68:2<188::AID-IJC8>3.0.CO;2-U; Janke J, 2000, J EXP MED, V191, P1675, DOI 10.1084/jem.191.10.1675; Kim JG, 1997, J NEUROSCI RES, V50, P272, DOI 10.1002/(SICI)1097-4547(19971015)50:2<272::AID-JNR16>3.0.CO;2-A; LINDNER W, 1987, INT J PEPT PROT RES, V30, P794; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Osborne RJ, 2000, CANCER RES, V60, P3706; Seitz S, 2000, EUR J CANCER, V36, P1507, DOI 10.1016/S0959-8049(00)00135-0; Seitz S, 1997, BRIT J CANCER, V76, P983, DOI 10.1038/bjc.1997.497; Ueki T, 2002, ONCOGENE, V21, P2114, DOI 10.1038/sj.onc.1205275; Wang JC, 1999, GENOMICS, V60, P1, DOI 10.1006/geno.1999.5905; Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606; Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115; Yee KSY, 1998, J BIOL CHEM, V273, P5366, DOI 10.1074/jbc.273.9.5366; Zhang Y, 1999, CYTOGENET CELL GENET, V87, P115, DOI 10.1159/000015375	26	64	69	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	2004	23	57					9295	9302		10.1038/sj.onc.1208131	http://dx.doi.org/10.1038/sj.onc.1208131			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15489893				2022-12-17	WOS:000225638000015
J	Liu, CA; Wang, MJ; Chi, CW; Wu, CW; Chen, JY				Liu, CA; Wang, MJ; Chi, CW; Wu, CW; Chen, JY			Rho/rhotekin-mediated NF-kappa B activation confers resistance to apoptosis	ONCOGENE			English	Article						Rho GTPases; rhotekin; nuclear factor-kappa B; antiapoptosis; gastric cancer	RHO EFFECTOR RHOTEKIN; ACTIN STRESS FIBERS; LUNG-CANCER CELLS; BREAST-CANCER; PROTEIN-KINASE; CYCLIN D1; EXPRESSION; GTPASES; GENE; BINDING	Rhotekin ( RTKN), the gene coding for the Rho effector, RTKN, was shown to be overexpressed in human gastric cancer ( GC). In this study, we further showed that RTKN is expressed at a low level in normal cells and is overexpressed in many cancer-derived cell lines. The function of RTKN as an effector protein in Rho GTPase-mediated pathways regulating apoptosis was investigated. By transfection and expression of RTKN in cells that expressed endogenous RTKN at a low basal level, we showed that RTKN overexpression conferred cell resistance to apoptosis induced by serum deprivation or treatment with sodium butyrate, and the increased resistance correlated to the level of RTKN. Conversely, reducing RTKN expression by small interfering RNAs greatly sensitized cells to apoptosis. The RTKN-mediated antiapoptotic effect was blocked by the nuclear factor-kappaB (NF-kappaB) inhibitors, curcumin or parthenolide, but not by the phosphatidylinositol 3'-OH-kinase inhibitor, LY294002, or the MAP kinase inhibitor, PD98059. Reporter gene assays and electrophoretic mobility shift assay confirmed that RTKN overexpression led to constitutive activation of NF-kappaB through the phosphorylation of IkappaB by IKKbeta. By using the RTKN truncation mutants, we showed that RTKN mediated Rho activity eliciting signaling pathway to activate NF-kappaB, with a concomitant induction of expression of the NF-kappaB antiapoptotic genes, cIAP-2, BCl-xL, A1, and A20. Consistent with these data, RTKN-expressing cells showed increased chemoresistance to 5-fluorouracil and paclitaxol, and the resistance was greatly attenuated by NF-kappaB inhibitor. In conclusion, overactivated Rho/RTKN/NF-kappaB signaling pathway through overexpression of RTKN may play a key role in gastric tumorigenesis by conferring cells resistance to apoptosis, and this signaling pathway may serve as an important target for novel therapeutic approaches to the treatment of human GC.	Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; Vet Gen Hosp, Dept Surg, Taipei 11217, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center	Chen, JY (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Sect 2 Acad Rd, Taipei 11529, Taiwan.	bmchen@ibms.sinica.edu.tw	Chen, Joanne Jeou-Yuan/S-7022-2018					Arlt A, 2002, CANCER RES, V62, P910; Asin S, 1999, J VIROL, V73, P3893, DOI 10.1128/JVI.73.5.3893-3903.1999; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Cammarano MS, 2001, J BIOL CHEM, V276, P25876, DOI 10.1074/jbc.M011345200; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; CHEN JY, 1993, ONCOGENE, V8, P2159; Chiao PJ, 2002, CANCER, V95, P1696, DOI 10.1002/cncr.10829; Chuang SE, 2002, BIOCHEM PHARMACOL, V63, P1709, DOI 10.1016/S0006-2952(02)00931-0; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Engers R, 2000, INT J CANCER, V88, P369, DOI 10.1002/1097-0215(20001101)88:3<369::AID-IJC8>3.0.CO;2-K; Fritz G, 2002, BRIT J CANCER, V87, P635, DOI 10.1038/sj.bjc.6600510; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Gildea JJ, 2002, CANCER RES, V62, P6418; IKEDA H, 2003, AM J PHYSL GASTROINT; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Kamai T, 2002, BJU INT, V89, P449, DOI 10.1046/j.1464-4096.2001.01920.x; Kanai M, 2001, GASTROENTEROLOGY, V121, P56, DOI 10.1053/gast.2001.25544; Kaneko K, 2002, PANCREAS, V24, P251, DOI 10.1097/00006676-200204000-00007; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kim JY, 2000, BIOCHEM BIOPH RES CO, V273, P140, DOI 10.1006/bbrc.2000.2909; Kleer CG, 2002, AM J PATHOL, V160, P579, DOI 10.1016/S0002-9440(10)64877-8; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lai JM, 2001, BIOCHEM J, V359, P227, DOI 10.1042/0264-6021:3590227; Liu CA, 2004, J BIOMED SCI, V11, P661, DOI 10.1159/000079679; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Maeda S, 2000, GASTROENTEROLOGY, V119, P97, DOI 10.1053/gast.2000.8540; Metzger E, 2003, EMBO J, V22, P270, DOI 10.1093/emboj/cdg023; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Reynaud C, 2000, J BIOL CHEM, V275, P33962, DOI 10.1074/jbc.M000465200; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; ROMERO P, 1995, J VIROL, V69, P301, DOI 10.1128/JVI.69.1.301-307.1995; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Sanlioglu S, 2001, CANCER GENE THER, V8, P897, DOI 10.1038/sj.cgt.7700394; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; Sepulveda VAT, 2002, ENDOCRINOLOGY, V143, P596, DOI 10.1210/en.143.2.596; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Tu H, 1999, MOL CELL BIOL, V19, P602; van Golen KL, 2000, CANCER RES, V60, P5832; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739; Zhou J, 2003, WORLD J GASTROENTERO, V9, P9, DOI 10.3748/wjg.v9.i1.9	56	64	72	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8731	8742		10.1038/sj.onc.1208106	http://dx.doi.org/10.1038/sj.onc.1208106			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480428				2022-12-17	WOS:000225165100003
J	Kim, IY; Lee, DH; Lee, DK; Ahn, HJ; Kim, MM; Kim, SJ; Morton, RA				Kim, IY; Lee, DH; Lee, DK; Ahn, HJ; Kim, MM; Kim, SJ; Morton, RA			Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells	ONCOGENE			English	Article						BMP; BMP receptors; prostate cancer	OSTEOGENIC PROTEIN-1; GROWTH-FACTOR; IB RECEPTOR; PROLIFERATION; DIFFERENTIATION; INSENSITIVITY; PROGRESSION; TISSUES; MOUSE	Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-beta superfamily and signal through a number of membrane receptors. We have previously demonstrated that the loss of expression of BMP receptors (BMPRs) type IA, - IB, and - II (BMP-RIA, - RIB, and - RII) correlates with Gleason score in prostate cancer patients. To evaluate the prognostic value of this observation, we used immunohistochemistry to investigate the expression of BMPRs in association with disease progression in 60 patients. The results demonstrated a significant association between the loss of expression of the three BMPRs and Gleason score and clinical stage. However, only the loss of expression of BMP-RII showed a statistically significant association with 5-year survival rate ( P<0.05) and biochemical recurrence-free rate following radical prostatectomy ( P<0.005). To elucidate the effect of an abnormal BMP signaling in prostate cancer cells, we transfected dominant-negative BMP-RII (BMP-RIIDN) into the human prostate cancer cell line, PC3M. When a stable clone overexpressing BMP-RIIDN was inoculated subcutaneously into nude mice, the tumor growth rate was approximately 10 times that of control and parental cell line. These observations, taken together, indicate that the loss of BMP-RII expression as measured by immunohistochemistry may be a prognostic marker in prostate cancer patients, and that the loss of BMP-RII function may result in increased tumorigenicity in human prostate cancer cells.	Baylor Coll Med, Dept Urol 2, Houston, TX 77030 USA; NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; Ewha Womans Univ, Dept Urol, Seoul, South Korea; Asan Med Ctr, Dept Urol, Seoul, South Korea; Univ Calif Irvine, Dept Urol, Orange, CA 92868 USA	Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ewha Womans University; University of Ulsan; Asan Medical Center; University of California System; University of California Irvine	Morton, RA (corresponding author), Baylor Coll Med, Dept Urol 2, Houston, TX 77030 USA.	mortonra@umdnj.edu			NATIONAL CANCER INSTITUTE [Z01BC005617] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Autzen P, 1998, BRIT J CANCER, V78, P1219, DOI 10.1038/bjc.1998.658; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Brubaker KD, 2004, J CELL BIOCHEM, V91, P151, DOI 10.1002/jcb.10679; Buckley S, 2004, AM J PHYSIOL-LUNG C, V286, pL81, DOI 10.1152/ajplung.00160.2003; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Foletta VC, 2003, J CELL BIOL, V162, P1089, DOI 10.1083/jcb.200212060; Hamdy FC, 1997, CANCER RES, V57, P4427; HARRIS SE, 1994, PROSTATE, V24, P204, DOI 10.1002/pros.2990240406; HOGAN BL, 1996, GENE DEV, V10, P1540; Horvath LG, 2004, PROSTATE, V59, P234, DOI 10.1002/pros.10361; Ide H, 1997, CANCER RES, V57, P5022; Ide H, 1997, ONCOGENE, V14, P1377, DOI 10.1038/sj.onc.1200964; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kawamura C, 2002, LEUKEMIA LYMPHOMA, V43, P635, DOI 10.1080/10428190290012182; Kim IY, 2000, CANCER RES, V60, P2840; Kim IY, 2003, CLIN CANCER RES, V9, P6046; Kim IY, 1996, CANCER RES, V56, P44; Lamm MLG, 2001, DEV BIOL, V232, P301, DOI 10.1006/dbio.2001.0187; LIU F, 1995, MOL CELL BIOL, V15, P3479; Masuda H, 2004, PROSTATE, V59, P101, DOI 10.1002/pros.20030; Masuda H, 2003, PROSTATE, V54, P268, DOI 10.1002/pros.10193; Pouliot F, 2003, CANCER RES, V63, P277; Rudarakanchana N, 2002, HUM MOL GENET, V11, P1517, DOI 10.1093/hmg/11.13.1517; SAMPATH TK, 1992, J BIOL CHEM, V267, P20352; Sintich SM, 1999, ENDOCRINOLOGY, V140, P3411, DOI 10.1210/en.140.8.3411; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Thomas R, 1998, PROSTATE, V37, P236, DOI 10.1002/(SICI)1097-0045(19981201)37:4<236::AID-PROS5>3.0.CO;2-C; Wen XZ, 2004, BIOCHEM BIOPH RES CO, V316, P100, DOI 10.1016/j.bbrc.2004.02.016; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Yamada N, 1996, BRIT J CANCER, V73, P624, DOI 10.1038/bjc.1996.108; Yamashita H, 1996, BONE, V19, P569, DOI 10.1016/S8756-3282(96)00259-1; Yonemori K, 1997, AM J PATHOL, V150, P1335; Zhao GQ, 2003, GENESIS, V35, P43, DOI 10.1002/gene.10167	33	64	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 7	2004	23	46					7651	7659		10.1038/sj.onc.1207924	http://dx.doi.org/10.1038/sj.onc.1207924			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15354178				2022-12-17	WOS:000224306700006
J	Huang, YC; Chen, JY; Hung, WC				Huang, YC; Chen, JY; Hung, WC			Vitamin D-3 receptor/Sp1 complex is required for the induction of p27(Kip1) expression by vitamin D-3	ONCOGENE			English	Article						vitamin D-3; p27(Kip1); Sp1; small interference RNA; NF-Y	TRANSCRIPTIONAL ACTIVATION; PROMOTER ACTIVITY; GENE-EXPRESSION; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; GROWTH-INHIBITION; CANCER CELLS; NF-Y; SP1; DIFFERENTIATION; 17-BETA-ESTRADIOL	1alpha, 25-dihydroxyvitamin D-3 (vitamin D-3) has been shown to upregulate p27(Kip1) expression via Sp1 and NF-Y binding sites in the p27(Kip1) promoter. However, whether vitamin D-3 receptor (VDR) involves in this process is unclear. In this study, we demonstrated that expression of VDR in SW620 cells, which exhibited low level of endogenous VDR, increased vitamin D-3-stimulated p27(Kip1) promoter activity. On the contrary, suppression of Sp1 expression by small interference RNA reduced the stimulation of p27(Kip1) promoter activity by vitamin D-3 in LNCaP cells. DNA affinity precipitation assay and chromatin immunoprecipitation assay showed that VDR bound to the p27(Kip1) promoter in vitro and in vivo. In addition, we also demonstrated that VDR interacted with Sp1 in vitro and in cells. Collectively, our results suggest that VDR is involved in the induction of p27(Kip1) by vitamin D-3 and may interact with Sp1 to modulate the expression of target genes that lack VDR response element (VDRE) in their promoters.	Kaohsiung Med Univ, Sch Technol Med Sci, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Grad Inst Med, Kaohsiung 807, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University	Hung, WC (corresponding author), Kaohsiung Med Univ, Sch Technol Med Sci, Kaohsiung 807, Taiwan.	hung1228@ms10.hinet.net						Boyan BD, 2002, STEROIDS, V67, P421, DOI 10.1016/S0039-128X(01)00178-7; Buitrago C, 2000, J CELL BIOCHEM, V79, P274, DOI 10.1002/1097-4644(20001101)79:2<274::AID-JCB100>3.0.CO;2-R; Christakos S, 2003, J CELL BIOCHEM, V88, P238, DOI 10.1002/jcb.10349; Deluca HF, 2001, FASEB J, V15, P2579, DOI 10.1096/fj.01-0433rev; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; GARETH IO, 1998, J BIOL CHEM, V273, P10696; Ge YB, 2002, BBA-GENE STRUCT EXPR, V1579, P73, DOI 10.1016/S0167-4781(02)00509-2; Gurlek A, 2002, ENDOCR REV, V23, P763, DOI 10.1210/er.2001-0044; Guyton KZ, 2001, ANNU REV PHARMACOL, V41, P421, DOI 10.1146/annurev.pharmtox.41.1.421; Haidweger E, 2001, J MOL BIOL, V306, P201, DOI 10.1006/jmbi.2000.4406; Harper JW, 1997, CANCER SURV, V29, P91; Hengst L, 1998, CURR TOP MICROBIOL, V227, P25; Hewetson A, 2003, J BIOL CHEM, V278, P40177, DOI 10.1074/jbc.M303921200; Huang YC, 2002, MOL PHARMACOL, V62, P1515, DOI 10.1124/mol.62.6.1515; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Johnson CS, 2002, CANCER METAST REV, V21, P147, DOI 10.1023/A:1020836226594; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Khorasanizadeh S, 2001, TRENDS BIOCHEM SCI, V26, P384, DOI 10.1016/S0968-0004(01)01800-X; Kim K, 2003, MOL ENDOCRINOL, V17, P804, DOI 10.1210/me.2002-0406; Kumagai T, 2003, J NATL CANCER I, V95, P896, DOI 10.1093/jnci/95.12.896; Liu LT, 2003, CANCER RES, V63, P3069; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu W, 2002, AM J PATHOL, V160, P511, DOI 10.1016/S0002-9440(10)64870-5; Lok CN, 2002, BIOCHEM J, V368, P741, DOI 10.1042/BJ20020791; Martinez ME, 1996, JNCI-J NATL CANCER I, V88, P1375, DOI 10.1093/jnci/88.19.1375; Minami S, 1997, FEBS LETT, V411, P1, DOI 10.1016/S0014-5793(97)00660-1; Narvaez CJ, 2001, STEROIDS, V66, P301, DOI 10.1016/S0039-128X(00)00202-6; Olefsky JM, 2001, J BIOL CHEM, V276, P36863, DOI 10.1074/jbc.R100047200; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Pan MR, 2002, J BIOL CHEM, V277, P32775, DOI 10.1074/jbc.M202334200; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Schwartz Z, 2003, STEROIDS, V68, P423, DOI 10.1016/S0039-128X(03)00044-8; SHABAHANG M, 1994, CANCER RES, V54, P4057; SHABAHANG M, 1993, CANCER RES, V53, P3712; SHIGEAKI K, 2000, J BIOCH, V127, P717; Sun GL, 1998, MOL ENDOCRINOL, V12, P882, DOI 10.1210/me.12.6.882; TOWERS TL, 1993, P NATL ACAD SCI USA, V90, P6310, DOI 10.1073/pnas.90.13.6310; Valor LM, 2002, J BIOL CHEM, V277, P8866, DOI 10.1074/jbc.M110454200; Vidal M, 2002, MOL CELL BIOL, V22, P2777, DOI 10.1128/MCB.22.8.2777-2787.2002; Wang F, 1998, NUCLEIC ACIDS RES, V26, P3044, DOI 10.1093/nar/26.12.3044; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; Yang ES, 2002, MOL CELL ENDOCRINOL, V186, P69, DOI 10.1016/S0303-7207(01)00671-2; ZHANG DE, 1994, J IMMUNOL, V153, P3276; Zhu Y, 2002, J BIOL CHEM, V277, P6923, DOI 10.1074/jbc.M108075200	45	64	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4856	4861		10.1038/sj.onc.1207621	http://dx.doi.org/10.1038/sj.onc.1207621			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15064717				2022-12-17	WOS:000222104200006
J	Zhang, M; Altuwaijri, S; Yeh, S				Zhang, M; Altuwaijri, S; Yeh, S			RRR-alpha-tocopheryl succinate inhibits human prostate cancer cell invasiveness	ONCOGENE			English	Article						alpha-vitamin E succinate; prostate cancer tumor invasion; matrix metalloproteinases	VITAMIN-E SUCCINATE; TUMOR-CELLS; EXPRESSION; INVASION; GROWTH; METALLOPROTEINASES; PROLIFERATION; METASTASES; SECRETION; RECEPTOR	RRR-alpha-tocopheryl succinate (alpha-vitamin E succinate, VES), one of the vitamin E derivatives, can effectively inhibit the proliferation of human prostate cancer cells. However, little is known about its effect on prostate cancer cell invasive ability. Tumor metastasis is a complex process and the extracellular matrix (ECM) is the first barrier that tumor cells encounter. Therefore, we tested the effect of VES on the invasion of different prostate tumor cells, PC-3, DU-145, and LNCaP, through Matrigel, a reconstituted ECM, using an in vitro cell invasion assay. The invasion of PC-3 and DU-145 cells through Matrigel was inhibited by 20 muM VES after treating for 24 h. The condition did not alter cell survival, cell cycle, cell adhesion or cell motility. We further investigated whether the ability of VES to inhibit prostate cancer cell invasiveness was associated with its ability to inhibit the activity of matrix metalloproteinases (MMPs), the key enzymes in the proteolysis of basement membrane during invasion. PC-3 and DU-145 cells that were treated with VES showed a significant reduction in the levels of MMP-9 in the culture medium. In contrast, LNCaP cells, which did not secrete MMP-9, were poorly invasive in Matrigel and were hardly affected by treatment with VES. This is the first report suggesting that VES inhibits human prostate cancer cell invasiveness and the reduction of secreted MMP-9 activity could be one of the contributory factors, which points to the potential use of VES in the prevention and therapy of prostate cancer invasion.	Univ Rochester, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Dept Pathol, Rochester, NY 14642 USA; Peking Univ, Inst Urol, Beijing 100871, Peoples R China	University of Rochester; University of Rochester; Peking University	Yeh, S (corresponding author), Univ Rochester, Dept Urol, Rochester, NY 14642 USA.	shuyuan_yeh@urmc.rochester.edu			NIDDK NIH HHS [DK60912] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060912] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBINI A, 1987, CANCER RES, V47, P3239; Barnett KT, 2002, J SURG RES, V106, P292, DOI 10.1006/jsre.2002.6466; CHEESEMAN KH, 1995, FREE RADICAL BIO MED, V19, P591, DOI 10.1016/0891-5849(95)00083-A; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Denmeade SR, 1997, BRIT J UROL, V79, P2, DOI 10.1111/j.1464-410X.1997.tb00794.x; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; HERRON GS, 1986, J BIOL CHEM, V261, P2814; Hu YC, 2002, J BIOL CHEM, V277, P33571, DOI 10.1074/jbc.M203531200; IWAMOTO Y, 1992, ADV EXP MED BIOL, V324, P141; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; JIANG WG, 1994, BRIT J SURG, V81, P1576, DOI 10.1002/bjs.1800811107; Kampa M, 2000, NUTR CANCER, V37, P223, DOI 10.1207/S15327914NC372_16; Li YW, 2002, CANCER LETT, V186, P157, DOI 10.1016/S0304-3835(02)00349-X; LOKESHWAR BL, 1993, CANCER RES, V53, P4493; Nagakawa O, 1998, CANCER LETT, V133, P27, DOI 10.1016/S0304-3835(98)00186-4; Ni J, 2003, BIOCHEM BIOPH RES CO, V300, P357, DOI 10.1016/S0006-291X(02)02851-6; Prasad KN, 2003, J AM COLL NUTR, V22, P108, DOI 10.1080/07315724.2003.10719283; Rasmussen HS, 1997, PHARMACOL THERAPEUT, V75, P69, DOI 10.1016/S0163-7258(97)00023-5; SOKOL RJ, 1993, GASTROENTEROLOGY, V104, P1727, DOI 10.1016/0016-5085(93)90652-S; Stearns ME, 1996, INVAS METAST, V16, P116; STEPHENSON RA, 1992, J NATL CANCER I, V84, P951, DOI 10.1093/jnci/84.12.951; TERRANOVA VP, 1986, JNCI-J NATL CANCER I, V77, P311; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Weber T, 2002, CLIN CANCER RES, V8, P863; Zhang Y, 2002, P NATL ACAD SCI USA, V99, P7408, DOI 10.1073/pnas.102014399; Zi XL, 2000, CANCER RES, V60, P5617	26	64	67	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3080	3088		10.1038/sj.onc.1207435	http://dx.doi.org/10.1038/sj.onc.1207435			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	15048090				2022-12-17	WOS:000220845200012
J	Huang, AM; Montagna, C; Sharan, S; Ni, YJ; Ried, T; Sterneck, E				Huang, AM; Montagna, C; Sharan, S; Ni, YJ; Ried, T; Sterneck, E			Loss of CCAAT/enhancer binding protein delta promotes chromosomal instability	ONCOGENE			English	Article						C/EBP; tumor suppressor; mouse embryo fibroblast; chromosomal rearrangements; genomic instability	GROWTH-FACTOR-BETA; I GENE-TRANSCRIPTION; ARREST-SPECIFIC GENE; ALPHA C/EBP-ALPHA; MICE LACKING; ADIPOCYTE DIFFERENTIATION; CENTROSOME AMPLIFICATION; CELL-PROLIFERATION; MESSENGER-RNA; EXPRESSION	The transcription factor CCAAT/enhancer binding protein delta (Cebpd, also known as C/EBPdelta, CRP3, CELF, NF-IL6beta) is implicated in diverse cellular functions such as the acute phase response, adipocyte differentiation, learning and memory, and mammary epithelial cell growth control. Here, we report that lack of Cebpd causes genomic instability and centrosome amplifications in primary embryonic fibroblasts derived from 129S1 mice. Upon spontaneous immortalization, Cebpd-deficient fibroblasts acquire transformed features such as impaired contact inhibition and reduced serum dependence. These data identify a novel role for Cebpd in the maintenance of chromosomal stability and suggest a potential tumor suppressor function in vivo.	Regulat Cell Growth Lab, Frederick, MD 21702 USA; NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sterneck, E (corresponding author), Regulat Cell Growth Lab, POB B, Frederick, MD 21702 USA.	sterneck@ncifcrf.gov		Huang, A-Mei/0000-0003-3723-0443; Sterneck, Esta/0000-0001-7716-8766	NATIONAL CANCER INSTITUTE [Z01BC010307, ZIABC010307] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Billiard J, 2001, J BIOL CHEM, V276, P31238, DOI 10.1074/jbc.M103634200; Breed DR, 1997, ENDOCRINOLOGY, V138, P5527, DOI 10.1210/en.138.12.5527; Cassel TN, 2000, AM J RESP CELL MOL, V22, P469, DOI 10.1165/ajrcmb.22.4.3916; Charles A, 2001, J CELL BIOCHEM, V83, P414, DOI 10.1002/jcb.1239; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; Choy L, 2003, J BIOL CHEM, V278, P9609, DOI 10.1074/jbc.M212259200; DAVISSON MT, 1994, GENE, V147, P157, DOI 10.1016/0378-1119(94)90060-4; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; Evdokiou A, 1998, INT J CANCER, V75, P568, DOI 10.1002/(SICI)1097-0215(19980209)75:4<568::AID-IJC13>3.0.CO;2-5; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Gigliotti AP, 2003, EXP BIOL MED, V228, P278, DOI 10.1177/153537020322800306; Gigliotti AP, 1998, J CELL PHYSIOL, V174, P232, DOI 10.1002/(SICI)1097-4652(199802)174:2<232::AID-JCP10>3.0.CO;2-E; Gigliotti AP, 1999, BREAST CANCER RES TR, V58, P57, DOI 10.1023/A:1006381906288; Glick A, 1999, P NATL ACAD SCI USA, V96, P14949, DOI 10.1073/pnas.96.26.14949; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Jackson RJ, 2002, ONCOGENE, V21, P8486, DOI 10.1038/sj.onc.1205946; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; Janssen RAJ, 1997, MOL BIOL CELL, V8, P897, DOI 10.1091/mbc.8.5.897; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Kreidberg JA, 2000, CANC DRUG DISC DEV, P3; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; Montagna C, 2002, ONCOGENE, V21, P890, DOI 10.1038/sj.onc.1205146; O'Rourke JP, 1999, J BIOL CHEM, V274, P16582, DOI 10.1074/jbc.274.23.16582; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Reitmair AH, 1997, CANCER RES, V57, P3765; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Sterneck E, 1998, P NATL ACAD SCI USA, V95, P10908, DOI 10.1073/pnas.95.18.10908; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Sugahara K, 1999, CELL TISSUE RES, V297, P261, DOI 10.1007/s004410051354; Takiguchi M, 1998, INT J EXP PATHOL, V79, P369, DOI 10.1046/j.1365-2613.1998.00082.x; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; Tessarollo L, 2000, METH MOL B, V158, P47; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P3621, DOI 10.1093/nar/27.17.3621; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Welm AL, 2002, J BIOL CHEM, V277, P33848, DOI 10.1074/jbc.M204096200; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zahnow CA, 2001, CANCER RES, V61, P261; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	62	64	64	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1549	1557		10.1038/sj.onc.1207285	http://dx.doi.org/10.1038/sj.onc.1207285			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14716301				2022-12-17	WOS:000189219500008
J	Logarajah, S; Hunter, P; Kraman, M; Steele, D; Lakhani, S; Bobrow, L; Venkitaraman, A; Wagner, S				Logarajah, S; Hunter, P; Kraman, M; Steele, D; Lakhani, S; Bobrow, L; Venkitaraman, A; Wagner, S			BCL-6 is expressed in breast cancer and prevents mammary epithelial differentiation	ONCOGENE			English	Article						mammary epithelium; differentiation; breast cancer; BCL-6; STAT	GERMINAL-CENTER FORMATION; TRANSCRIPTIONAL REPRESSOR; TERMINAL DIFFERENTIATION; ALPHA-6-BETA-4 INTEGRIN; GENE; PROTEIN; INFLAMMATION; PHOSPHORYLATION; MORPHOGENESIS; SUPPRESSION	Appropriately timed proliferation, differentiation and apoptosis are essential to the normal functions of the mammary epithelium. Here, we report that the transcription factor BCL-6 is expressed in mammary epithelium in nonpregnant animals as well as during early pregnancy. When overexpressed in the nontransformed EpH4 mammary epithelial cell line, BCL-6 prevents the STAT-driven expression of the milk protein beta-casein and duct formation, and prevents apoptosis. Consistent with an antiapoptotic function, we demonstrate that BCL-6 is expressed in 68% of histologically high-grade ductal breast carcinomas, which are clinically the most aggressive. BCL-6 has previously been characterized as a regulator of B lymphocyte growth and development, but our work identifies a novel role for it in mammary epithelial differentiation, which may also implicate it in carcinogenesis.	Univ Cambridge, Dept Med, Wellcome Trust Immunol Unit, Cambridge CB2 2SP, England; Inst Canc Res, Chester Beatty Labs, Breakthrough Toby Robbins Breast Canc Res Ctr, London SW3 6JB, England; Univ Cambridge, Dept Pathol, Cambridge CB2 2XZ, England; Univ Cambridge, Dept Oncol, Cambridge CB2 2XZ, England; Univ Cambridge, MRC, Canc Cell Unit, Cambridge CB2 2XZ, England; Univ Cambridge, Dept Haematol, Cambridge CB2 2XZ, England	University of Cambridge; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge	Wagner, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Haematol, Hammersmith Campus,Du Cane Rd, London W12 ONN, England.		Lakhani, Sunil R/I-1970-2018	Lakhani, Sunil R/0000-0003-4067-2760; Wagner, Simon/0000-0002-8914-0370; Kraman, Matthew/0000-0002-5040-0067; Hunter, Patricia/0000-0002-6224-0654				Allman D, 1996, BLOOD, V87, P5257, DOI 10.1182/blood.V87.12.5257.bloodjournal87125257; Bajalica-Lagercrantz S, 1998, BIOCHEM BIOPH RES CO, V247, P357, DOI 10.1006/bbrc.1998.8551; Baron BW, 2002, P NATL ACAD SCI USA, V99, P2860, DOI 10.1073/pnas.042702599; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Harris MB, 1999, MOL CELL BIOL, V19, P7264; Kanazawa N, 1997, PATHOL INT, V47, P600, DOI 10.1111/j.1440-1827.1997.tb04548.x; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Mori S, 2000, EMBO J, V19, P5772, DOI 10.1093/emboj/19.21.5772; Muschler J, 1999, MOL BIOL CELL, V10, P2817, DOI 10.1091/mbc.10.9.2817; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shvarts A, 2002, GENE DEV, V16, P681, DOI 10.1101/gad.929302; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Winklehner-Jennewein P, 1998, GENE, V217, P127, DOI 10.1016/S0378-1119(98)00380-1; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; YE BHH, 1993, CANCER RES, V53, P2732; Yoshida T, 1996, BIOCHEM BIOPH RES CO, V228, P216, DOI 10.1006/bbrc.1996.1642	27	64	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5572	5578		10.1038/sj.onc.1206689	http://dx.doi.org/10.1038/sj.onc.1206689			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944904				2022-12-17	WOS:000184865900005
J	Ohira, M; Morohashi, A; Inuzuka, H; Shishikura, T; Kawamoto, T; Kageyama, H; Nakamura, Y; Isogai, E; Takayasu, H; Sakiyama, S; Suzuki, Y; Sugano, S; Goto, T; Sato, S; Nakagawara, A				Ohira, M; Morohashi, A; Inuzuka, H; Shishikura, T; Kawamoto, T; Kageyama, H; Nakamura, Y; Isogai, E; Takayasu, H; Sakiyama, S; Suzuki, Y; Sugano, S; Goto, T; Sato, S; Nakagawara, A			Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets	ONCOGENE			English	Article						neuroblastoma; expression profile; oligo-capping cDNA library; differentiation; regression; MYCN	N-MYC AMPLIFICATION; NEUROTROPHIC FACTOR; MOLECULAR-CLONING; NEURO-BLASTOMA; RNA; ASSOCIATION; PROTEINS; LOCUS; GAIN; ONCOGENE	Neuroblastoma (NBL), one of the most common childhood solid tumors, has a distinct nature in different prognostic subgroups: NBL in patients under I year of age usually regresses spontaneously, whereas that in patients over 1 year of age often grows aggressively and eventually kills the patient. To understand the molecular mechanism of biology and tumorigenesis of NBL, we decided to perform a comprehensive approach to unveil the gene expression profiles among the NBL subsets. We constructed the subset-specific oligo-capping cDNA libraries from the primary NBL tissues with favorable (F: stage 1, high expression of TrkA and a single copy of MYCN) and unfavorable (UF: stage 3 or 4, decreased expression of TrkA and MYCN amplification) characteristics and randomly cloned 4654 cDNAs. Among 4243 cDNAs sequenced successfully, 1799 (42.4%) were the genes with unknown function. Excluding the housekeeping genes, an expression profile of each subset was extremely different. To determine the genes expressed differentially between F and UF subsets, we performed semiquantitative reverse transcriptase (RT)-PCR for each of the 1842 independent genes using RNA obtained from 16 F and 16 UF NBLs as template. This revealed that 278 genes were highly expressed in the F subset as compared to the UF one, while, surprisingly, only 27 genes were expressed at higher levels in the UF rather than the F subset. These differentially expressed genes included 194 genes with unknown function. Many of the genes expressed at high levels in the F subset were related to catecholamine biosynthesis, small GTPases, synapse formation, synaptic vesicle transport, and transcription factors regulating differentiation of the neural crest-derived cells. On the other hand, the genes expressed at high levels in the UF subset included transcription factors and/or receptors that might regulate neuronal growth and differentiation. The chromosomal mapping of those genes showed some clusters. Thus, our mass-identification and characterization of the differentially expressed genes between the subsets may become a powerful tool for finding the important genes of NBL as well as developing new diagnostic and therapeutic strategies against aggressive NBL.	Chiba Canc Ctr Res Inst, Div Biochem, Chiba 2608717, Japan; Univ Tokyo, Dept Canc Virol, Inst Med Sci, Tokyo 1088639, Japan; Hisamitsu Co Inc, Chiyoda Ku, Tokyo 100622, Japan	Chiba Cancer Center; University of Tokyo	Nakagawara, A (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, 666-2 Nitona, Chiba 2608717, Japan.							Abe A, 1999, J CLIN MICROBIOL, V37, P2899, DOI 10.1128/JCM.37.9.2899-2903.1999; Amler LC, 1996, GENE CHROMOSOME CANC, V15, P134, DOI 10.1002/(SICI)1098-2264(199602)15:2<134::AID-GCC9>3.0.CO;2-4; ANDERSON DJ, 1985, CELL, V42, P649, DOI 10.1016/0092-8674(85)90122-9; BARTRAM CR, 1987, EUR J PEDIATR, V146, P162, DOI 10.1007/BF02343225; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; Hamajima N, 1996, GENE, V180, P157, DOI 10.1016/S0378-1119(96)00445-3; Hirai M, 1999, GENE CHROMOSOME CANC, V25, P261, DOI 10.1002/(SICI)1098-2264(199907)25:3<261::AID-GCC8>3.0.CO;2-#; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; Hishiki T, 1998, CANCER RES, V58, P2158; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Inoue K, 1999, J HEPATOL, V30, P801, DOI 10.1016/S0168-8278(99)80132-9; Kawamoto T, 2003, INT J ONCOL, V22, P815; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; MARUYAMA K, 1994, GENE, V138, P171; MATSUMOTO K, 1995, CANCER RES, V55, P1798; MCCLELLAND M, 1995, TRENDS GENET, V11, P242, DOI 10.1016/S0168-9525(00)89058-7; MCCONNELL JE, 1995, DEV BIOL, V169, P218, DOI 10.1006/dbio.1995.1139; Mitsuya K, 1999, HUM MOL GENET, V8, P1209, DOI 10.1093/hmg/8.7.1209; NAKAGAWARA A, 1987, J PEDIATR SURG, V22, P895, DOI 10.1016/S0022-3468(87)80583-3; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1988, J PEDIATR SURG, V23, P346, DOI 10.1016/S0022-3468(88)80204-5; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; NAKAGAWARA A, 1990, SURGERY, V107, P43; Nakagawara A, 1998, Hum Cell, V11, P115; Noguchi T, 1996, GENE CHROMOSOME CANC, V15, P129, DOI 10.1002/(SICI)1098-2264(199602)15:2<129::AID-GCC8>3.3.CO;2-M; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; Okutsu T, 2000, J BIOCHEM-TOKYO, V127, P475, DOI 10.1093/oxfordjournals.jbchem.a022630; Ono R, 2001, GENOMICS, V73, P232, DOI 10.1006/geno.2001.6494; Plantaz D, 1997, AM J PATHOL, V150, P81; SAWADA T, 1984, LANCET, V2, P271; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SLAVC I, 1990, CANCER RES, V50, P1459; STUDLER JM, 1993, EUR J NEUROSCI, V5, P614, DOI 10.1111/j.1460-9568.1993.tb00527.x; Suzuki Y, 1997, GENE, V200, P149, DOI 10.1016/S0378-1119(97)00411-3; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Taguchi A, 1996, MOL BRAIN RES, V35, P31, DOI 10.1016/0169-328X(95)00178-U; Takita J, 1997, CANCER RES, V57, P907; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Velculescu VE, 2000, TRENDS GENET, V16, P423, DOI 10.1016/S0168-9525(00)02114-4	46	64	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2003	22	35					5525	5536		10.1038/sj.onc.1206853	http://dx.doi.org/10.1038/sj.onc.1206853			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934113				2022-12-17	WOS:000184735000018
J	Harvey, AJ; Crompton, MR				Harvey, AJ; Crompton, MR			Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation	ONCOGENE			English	Article						protein-tyrosine kinase; breast cancer; RNA interference; small interfering RNA; proliferation	NONRECEPTOR TYROSINE KINASE; MAMMARY EPITHELIAL-CELLS; EPIDERMAL-GROWTH-FACTOR; GASTROINTESTINAL-TRACT; EXPRESSION; 3-KINASE; PROTEIN; FAMILY; TUMORS; SIK	Brk (PTK6) is a nonreceptor protein tyrosine kinase, which is expressed in over 60% of breast carcinoma tissue samples and breast tumour cell lines, but not normal mammary tissue or benign lesions. Since experimental Brk expression in nontransformed mammary epithelial cells enhances their mitogenic response to epidermal growth factor, it was important to determine the role Brk plays in the proliferation of breast carcinoma cells and validate it as a therapeutic target. We have used RNA interference to efficiently and specifically downregulate Brk protein levels in breast carcinoma cells, and determined that this results in a significant suppression of their proliferation. Additionally, through the expression of a kinase-inactive mutant, we have determined that Brk can mediate promotion of proliferation via a kinase-independent mechanism, potentially functioning as an 'adapter'. These data identify Brk as a novel target for antiproliferative therapy in the majority of breast cancers, and illustrate the power of RNA interference for rapidly validating candidate therapeutic targets.	Univ London, Sch Biol Sci, Egham TW20 0EX, Surrey, England	University of London; Royal Holloway University London	Crompton, MR (corresponding author), Univ London, Sch Biol Sci, Egham TW20 0EX, Surrey, England.							Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fry MJ, 2001, BREAST CANCER RES, V3, P304, DOI 10.1186/bcr312; Gasco M, 2002, BREAST CANCER RES, V4, P70, DOI 10.1186/bcr426; Hayes DF, 2002, SEMIN ONCOL, V29, P231, DOI 10.1053/sonc.2002.32899; Hutvagner G, 2002, CURR OPIN GENET DEV, V12, P225, DOI 10.1016/S0959-437X(02)00290-3; Kamalati T, 2000, ONCOGENE, V19, P5471, DOI 10.1038/sj.onc.1203931; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; Lee HY, 1998, MOL CELLS, V8, P401; Llor X, 1999, CLIN CANCER RES, V5, P1767; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; QUI H, 2002, J BIOL CHEM, V277, P34634; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; Vasioukhin V, 1997, P NATL ACAD SCI USA, V94, P14477, DOI 10.1073/pnas.94.26.14477; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5	21	64	68	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 7	2003	22	32					5006	5010		10.1038/sj.onc.1206577	http://dx.doi.org/10.1038/sj.onc.1206577			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902983				2022-12-17	WOS:000184578900008
J	Lindstrom, MS; Wiman, KG				Lindstrom, MS; Wiman, KG			Myc and E2F1 induce p53 through p14ARF-independent mechanisms in human fibroblasts	ONCOGENE			English	Article						p14ARF; p53; Myc; E2F1; phosphorylation; apoptosis; caffeine; RNA interference	CELL-CYCLE ARREST; C-MYC; DNA-DAMAGE; TUMOR SUPPRESSION; P53-DEPENDENT APOPTOSIS; RADIOSENSITIZING AGENT; TRANSCRIPTION FACTOR; INDUCED SENESCENCE; ONCOGENIC STRESS; NUCLEAR EXPORT	p19ARF is induced in response to oncogene activation or during cellular senescence in mouse embryo fibroblasts, triggering p53-dependent and p53-independent cell cycle arrest and apoptosis. We have studied the involvement of human p14ARF as a regulator of p53 activity in normal human skin fibroblasts (NHFs) or WI38 lung embryonic fibroblasts expressing conditional Myc or E2F1 estrogen receptor fusion proteins. Both Myc and E2F1 activation rapidly induced p53 phosphorylation at Ser-15, p53 protein accumulation, and upregulation of the p53 target genes MDM2 and p21. Activation of E2F1 induced p14ARF mRNA and protein levels. In contrast, Myc activation did not induce any significant increase in p14ARF mRNA or protein levels in neither NHFs nor WI38 fibroblasts within 48 h. Myc and E2F1 induced p53 and cell cycle arrest even after silencing of p14ARF using short-interfering RNA. Treatment with the ATM/ATR kinase inhibitor caffeine prevented p53 accumulation upon activation of Myc or E2F1. Our results indicate that p53 phosphorylation, but not p14ARF, plays a major role for the induction of p53 in response to Myc and E2F1 activation in normal human fibroblasts.	Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, SE-17176 Stockholm, Sweden	Karolinska Institutet	Wiman, KG (corresponding author), Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, R8-04, SE-17176 Stockholm, Sweden.	Klas.Wiman@mtc.ki.se	Wiman, Klas/AAB-8399-2021; Lindström, Mikael S/AAA-1451-2019	Wiman, Klas/0000-0002-7113-524X; Lindström, Mikael S/0000-0003-1148-8497				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; ASKEW DS, 1991, ONCOGENE, V6, P1915; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Berkovich E, 2003, ONCOGENE, V22, P161, DOI 10.1038/sj.onc.1206144; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Deplanque G, 2000, BRIT J CANCER, V83, P346, DOI 10.1054/bjoc.2000.1259; Devasagayam TPA, 1996, BBA-BIOMEMBRANES, V1282, P63, DOI 10.1016/0005-2736(96)00040-5; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Drayton S, 2002, CURR OPIN GENET DEV, V12, P98, DOI 10.1016/S0959-437X(01)00271-4; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Ferbeyre G, 2000, GENE DEV, V14, P2015; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hashemi J, 2002, CANCER LETT, V180, P211, DOI 10.1016/S0304-3835(02)00027-7; Henriksson M, 2001, APOPTOSIS, V6, P133, DOI 10.1023/A:1009644716727; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hirst SK, 2000, ONCOGENE, V19, P5189, DOI 10.1038/sj.onc.1203904; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lee C, 2000, CLIN CHIM ACTA, V295, P141, DOI 10.1016/S0009-8981(00)00201-1; Li Q, 1999, MOL CELL BIOL, V19, P5339; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Wei WY, 1999, EXP CELL RES, V253, P519, DOI 10.1006/excr.1999.4665; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	91	64	65	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					4993	5005		10.1038/sj.onc.1206659	http://dx.doi.org/10.1038/sj.onc.1206659			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902982				2022-12-17	WOS:000184578900007
J	Steiling, H; Wustefeld, T; Bugnon, P; Brauchle, M; Fassler, R; Teupser, D; Thiery, J; Gordon, JI; Trautwein, C; Werner, S				Steiling, H; Wustefeld, T; Bugnon, P; Brauchle, M; Fassler, R; Teupser, D; Thiery, J; Gordon, JI; Trautwein, C; Werner, S			Fibroblast growth factor receptor signalling is crucial for liver homeostasis and regeneration	ONCOGENE			English	Article						cell cycle; hepatectomy; injury; keratinocyte growth factor; regeneration; steatosis	TARGETED EXPRESSION; TRANSGENIC MICE; DNA-SYNTHESIS; RAT; HEPATOCYTES; PROLIFERATION; MORPHOGENESIS; INITIATION; PROTEIN; FGF	Several growth factors have been suggested to play a crucial role in liver regeneration, but a functional proof is still missing. Since fibroblast growth factors are important for the initiation of mammalian liver development, we determined the roles of these mitogens in liver repair by targeted expression of a dominant-negative fibroblast growth factor receptor (FGFR) in hepatocytes of transgenic mice. The liver of young animals appeared histologically normal, and liver function was not obviously impaired. In aged transgenic mice, the frequency of fatty liver development was strongly increased compared to control animals. Following partial hepatectomy, transgenic mice showed markedly reduced hepatocyte proliferation because of an arrest in the late G(1) phase of the cell cycle. These data demonstrate a key role of FGFR signalling in repair after liver injury.	Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland; Hannover Med Sch, Dept Gastroenterol & Hepatol, D-30625 Hannover, Germany; Novatis Pharma AG, CH-4002 Basel, Switzerland; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Univ Klinikum Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, D-04103 Leipzig, Germany; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Hannover Medical School; Max Planck Society; Leipzig University; Washington University (WUSTL)	Werner, S (corresponding author), Swiss Fed Inst Technol, Inst Cell Biol, CH-8093 Zurich, Switzerland.	sabine.werner@cell.biol.ethz.ch		Werner, Sabine/0000-0001-7397-8710				Arora V, 2000, J PHARMACOL EXP THER, V292, P921; Behrens A, 2002, EMBO J, V21, P1782, DOI 10.1093/emboj/21.7.1782; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; De Moerlooze L, 2000, DEVELOPMENT, V127, P483; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; HOUSLEY RM, 1994, J CLIN INVEST, V94, P1764, DOI 10.1172/JCI117524; HU ZY, 1995, CELL GROWTH DIFFER, V6, P1019; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; Kan M, 1999, J BIOL CHEM, V274, P15947, DOI 10.1074/jbc.274.22.15947; KORHONEN J, 1992, INT J DEV BIOL, V36, P323; Loyer P, 1996, Prog Cell Cycle Res, V2, P37; Ludde T, 2001, ONCOGENE, V20, P5264, DOI 10.1038/sj.onc.1204690; MARSDEN ER, 1992, LAB INVEST, V67, P427; NONOGAKI K, 1995, ENDOCRINOLOGY, V136, P4278, DOI 10.1210/en.136.10.4278; Ornitz DM, 2001, GENOME BIOL, V2; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; Senaldi G, 1998, HEPATOLOGY, V27, P1584, DOI 10.1002/hep.510270618; STRAIN AJ, 1994, EXP CELL RES, V210, P253, DOI 10.1006/excr.1994.1037; SUZUKI M, 1993, FEBS LETT, V328, P17, DOI 10.1016/0014-5793(93)80956-U; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; Trautwein C, 1998, J CLIN INVEST, V101, P1960, DOI 10.1172/JCI504; UENO H, 1992, J BIOL CHEM, V267, P1470; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yu CD, 2000, J BIOL CHEM, V275, P15482, DOI 10.1074/jbc.275.20.15482	27	64	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4380	4388		10.1038/sj.onc.1206499	http://dx.doi.org/10.1038/sj.onc.1206499			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853974				2022-12-17	WOS:000183978900007
J	Oster, SK; Mao, DYL; Kennedy, J; Penn, LZ				Oster, SK; Mao, DYL; Kennedy, J; Penn, LZ			Functional analysis of the N-terminal domain of the Myc oncoprotein	ONCOGENE			English	Article						Myc; mutant; oncogene; transcription apoptosis; transformation	CELL-CYCLE PROGRESSION; HUMAN C-MYC; NEOPLASTIC TRANSFORMATION; TRANSCRIPTIONAL REPRESSION; NEGATIVE AUTOREGULATION; MYC/MAX/MAD NETWORK; GENE-EXPRESSION; BETA-RECEPTOR; BOX-II; GROWTH	Myc is a multifunctional nuclear phosphoprotein that can drive cell cycle progression, apoptosis and cellular transformation. Myc orchestrates these activities at the molecular level by functioning as a regulator of gene transcription to activate or repress specific target genes. Previous studies have shown that both the Myc N- terminal domain (NTD) and the C-terminal domain (CTD) are essential for Myc functions. The role of the CTD is relatively well understood as it encodes a basic helix-loop-helix leucine zipper motif important for DNA binding and protein-protein interactions. By contrast, the role of the NTD and the specific domains responsible for different Myc activities are not as well defined. To investigate the regions of the NTD necessary for Myc function and to determine whether these activities are overlapping or independent of one another, we have conducted a detailed structure-function analysis of the Myc NTD. We assessed the ability of a number of deletion and point mutants within the highly conserved regions of the Myc NTD to induce cell cycle progression, apoptosis and transformation as well as repress and activate expression of endogenous target genes. Our analyses highlight the complexity of the Myc NTD and extend previous studies. For example, we show most Myc mutants that were compromised as repressors of gene transcription retained the ability to activate gene transcription, reinforcing the concept that these activities can be uncoupled. Repression of two different target genes could be distinguished by specific mutants, further supporting the notion of at least two different Myc repression mechanisms. Mutants disabled at both inducing and repressing gene transcription could not maximally drive the biological activities of Myc, indicating these functions are tightly linked. Indeed, a close association of Myc repression and apoptosis was also observed.	Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Penn, LZ (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, Div Cellular & Mol Biol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Penn, Linda/0000-0001-8133-5459				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Dang CV, 1999, MOL CELL BIOL, V19, P1; DEPINHO RA, 1987, GENE DEV, V1, P1311, DOI 10.1101/gad.1.10.1311; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hirst SK, 2000, ONCOGENE, V19, P5189, DOI 10.1038/sj.onc.1203904; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; Izumi H, 2001, J CELL SCI, V114, P1533; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KI KW, 2002, J BIOL CHEM, V13, P13; Kuttler F, 2001, ONCOGENE, V20, P6084, DOI 10.1038/sj.onc.1204827; Landay M, 2000, CELL DEATH DIFFER, V7, P697, DOI 10.1038/sj.cdd.4400701; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Nesbit CE, 1998, CELL GROWTH DIFFER, V9, P731; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; Nolan GP, 1998, CURR OPIN BIOTECH, V9, P447, DOI 10.1016/S0958-1669(98)80027-X; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Oster SK, 2000, MOL CELL BIOL, V20, P6768, DOI 10.1128/MCB.20.18.6768-6778.2000; Park DS, 2001, BIOCHEMISTRY-US, V40, P3354, DOI 10.1021/bi002787b; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Wang XY, 1999, MOL ENDOCRINOL, V13, P254, DOI 10.1210/me.13.2.254; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245	53	64	66	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2003	22	13					1998	2010		10.1038/sj.onc.1206228	http://dx.doi.org/10.1038/sj.onc.1206228			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	662UR	12673205				2022-12-17	WOS:000181967700010
J	Lange, K; Uckert, W; Blankenstein, T; Nadrowitz, R; Bittner, C; Renauld, JC; van Snick, J; Feller, AC; Merz, H				Lange, K; Uckert, W; Blankenstein, T; Nadrowitz, R; Bittner, C; Renauld, JC; van Snick, J; Feller, AC; Merz, H			Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice	ONCOGENE			English	Article						t(2;5) translocation; anaplastic lymphoma kinase (ALK); IL-9 transgenic mice; retroviral-mediated gene transfer	NON-HODGKINS-LYMPHOMA; GENE-TRANSFER; TYROSINE KINASE; CELL LYMPHOMA; INTERLEUKIN-9; PROTEIN; FUSION; SUBTYPE; GROWTH; MODEL	Anaplastic large-cell lymphoma (ALCL) comprises approximately 25% of all non-Hodgkin lymphomas (NHL) in children and young adults, and up to 15% of high-grade NHL in older patients. Over 50% of these tumours carry the translocation t(2;5)(p23;q35). The result of this translocation is the fusion of the nucleophosmin (NPM) gene to the anaplastic lymphoma kinase (ALK) gene. The resulting hybrid protein contains the ALK catalytic domain that consequently confers transforming potential, which contributes to the pathogenesis of ALCL. To further analyse the transforming activity in an animal model, a cDNA encoding the protein product, NPM-ALK, was inserted into the retrovirus vector pLXSN and transduced into mouse bone marrow progenitors. These cells were subsequently used in a bone marrow transplant with the aim of reconstituting the haematopoietic compartments of lethally irradiated recipients. IL-9 transgenic mice were chosen as the animal model system, because dysregulated expression of the IL-9 gene in transgenic mice results in the sporadic development of spontaneous thymic lymphomas. Moreover, IL-9 is known to be expressed in cases of human ALCL. We used 15 IL-9 transgenic mice and eight corresponding wild-type mice (FVB/N) and transplanted them with NPM/ALK infected bone marrow cells. Eight IL-9 transgenic mice, serving as a control group, received pLXSN (vector only)-infected marrow. Reconstituted mice developed NPM-ALK-positive lymphomas, including lymphoblastic lymphomas of T-cell type (T-LB), mature and immature plasmacytoma (PC), and plasmoblastic/anaplastic diffuse large-B-cell lymphoma after about 19-20 weeks. The combined overexpression of NPM-ALK and IL-9 led to the transformation of murine lymphoid cells with accelerated and enhanced development of T-LB in 46% of the mice, which only very rarely occurs in IL-9 transgenic mice only. Of the 15 animals, five (33%) developed plasmacytic/plasmoblastic neoplasms, of which the most aggressive tumours share many features with anaplastic/plasmoblastic diffuse large-B-cell lymphoma on the basis of morphology, a characteristic growth pattern and ALK expression.	Med Univ Lubeck, Dept Pathol, D-23538 Lubeck, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Med Univ Lubeck, Inst Radiotherapy & Nucl Med, D-23538 Lubeck, Germany; Ludwig Inst Canc Res, B-1200 Brussels, Belgium	University of Lubeck; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Lubeck; Ludwig Institute for Cancer Research	Lange, K (corresponding author), Med Univ Lubeck, Dept Pathol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	lange@patho.mu-luebeck.de	Renauld, Jean-Christophe/B-7268-2012	Renauld, Jean-Christophe/0000-0003-1736-2131				Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Bittner C, 2000, LAB INVEST, V80, P1523, DOI 10.1038/labinvest.3780162; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Delsol G, 1997, BLOOD, V89, P1483, DOI 10.1182/blood.V89.5.1483.1483_1483_1490; Demoulin J B, 1998, Int Rev Immunol, V16, P345, DOI 10.3109/08830189809043001; DUGAS B, 1993, EUR J IMMUNOL, V23, P1687, DOI 10.1002/eji.1830230743; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Ladanyi M, 1997, CANCER SURV, V30, P59; Lawrence B, 2000, AM J PATHOL, V157, P377, DOI 10.1016/S0002-9440(10)64550-6; LEBEAU MM, 1989, LEUKEMIA, V3, P866; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Maes B, 2001, AM J PATHOL, V158, P2185, DOI 10.1016/S0002-9440(10)64690-1; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MERZ H, 1991, BLOOD, V78, P1311; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; PETITFRERE C, 1993, IMMUNOLOGY, V79, P146; Plowman GD, 1999, P NATL ACAD SCI USA, V96, P13603, DOI 10.1073/pnas.96.24.13603; Rabbitts TH, 2001, ONCOGENE, V20, P5763, DOI 10.1038/sj.onc.1204597; RENAULD JC, 1994, ONCOGENE, V9, P1327; RENAULD JC, 1995, BLOOD, V85, P1300, DOI 10.1182/blood.V85.5.1300.bloodjournal8551300; Robinson DR, 2000, ONCOGENE, V19, P5548, DOI 10.1038/sj.onc.1203957; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; Tort F, 2001, LAB INVEST, V81, P419, DOI 10.1038/labinvest.3780249; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Uckert W, 2000, METH MOLEC MED, V35, P275, DOI 10.1385/1-59259-086-1:275; UYTTENHOVE C, 1991, J EXP MED, V173, P519, DOI 10.1084/jem.173.2.519; VINK A, 1993, EUR J IMMUNOL, V23, P1134, DOI 10.1002/eji.1830230523; Wellmann A, 1997, FASEB J, V11, P965, DOI 10.1096/fasebj.11.12.9337149	33	64	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2003	22	4					517	527		10.1038/sj.onc.1206076	http://dx.doi.org/10.1038/sj.onc.1206076			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555065	Bronze			2022-12-17	WOS:000180538200005
J	Konduri, SD; Yanamandra, N; Siddique, K; Joseph, A; Dinh, DH; Olivero, WC; Gujrati, M; Kouraklis, G; Swaroop, A; Kyritsis, AP; Rao, JS				Konduri, SD; Yanamandra, N; Siddique, K; Joseph, A; Dinh, DH; Olivero, WC; Gujrati, M; Kouraklis, G; Swaroop, A; Kyritsis, AP; Rao, JS			Modulation of cystatin C expression impairs the invasive and tumorigenic potential of human glioblastoma cells	ONCOGENE			English	Article						glioma; invasion; cathepsin B; cystatin C	INHIBITORS STEFIN-A; CYSTEINE PROTEINASE-INHIBITORS; HUMAN COLORECTAL-CARCINOMA; HUMAN COLON-CARCINOMA; HUMAN BREAST-CANCER; CATHEPSIN-B; PROGNOSTIC-SIGNIFICANCE; ENDOGENOUS INHIBITORS; PROTEASE INHIBITORS; MOLECULAR-CLONING	Increases in the abundance of cathepsin B transcript and protein with increased tumor grade and changes in subcellular localization and activity of this enzyme. We observed progressive reductions in levels of the protease inhibitor cystatin C, an inhibitor of cathepsin B with corresponding increases in the malignancy of glioma cell lines, implying an inverse correlation between cystatin C and tumor grade. To investigate the role of cystatin C in the invasion of brain tumor cells, we stably transfected SNB19 glioblastoma cells with either a 0.4-kb cDNA construct of human cystatin C in the sense orientation or an empty vector. Clones expressing sense-cystatin C cDNA had higher cystatin C mRNA and protein levels than did control cells. Sense-transfected cells were also markedly less invasive than control cells in a Matrigel invasion assay and in a coculture assay of SNB19 spheroids and fetal rat brain aggregates. Finally, the sense-transfected cells did not form tumors in nude mice upon intracerebral injection. These results strongly implicate cystatin C in the invasiveness of human glioblastoma cells and suggest that sense transcripts of cystatin C may prove useful in cancer therapy.	Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; Univ Ioannina, Sch Med, Dept Neurol, GR-45110 Ioannina, Greece; Univ Michigan, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci & Human Genet, Ann Arbor, MI 48109 USA; Univ Athens, Sch Med, Dept Propedeut Surg, GR-11527 Athens, Greece; Univ Illinois, Dept Neuropathol, Peoria, IL USA; Univ Illinois, Dept Neurosurg, Peoria, IL USA	University of Illinois System; University of Illinois Peoria; University of Ioannina; University of Michigan System; University of Michigan; Athens Medical School; National & Kapodistrian University of Athens; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu		Swaroop, Anand/0000-0002-1975-1141	NCI NIH HHS [CA 76350] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076350] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSON M, 1987, FEBS LETT, V216, P229, DOI 10.1016/0014-5793(87)80695-6; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; BARRETT AJ, 1987, TRENDS BIOCHEM SCI, V12, P193, DOI 10.1016/0968-0004(87)90092-2; BOBEK LA, 1992, CRIT REV ORAL BIOL M, V3, P307, DOI 10.1177/10454411920030040101; Calkins CC, 1998, J HISTOCHEM CYTOCHEM, V46, P745, DOI 10.1177/002215549804600607; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CORTICCHIATO O, 1992, INT J CANCER, V52, P645; Coulibaly S, 1999, INT J CANCER, V83, P526, DOI 10.1002/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.3.CO;2-D; Cox JL, 1999, MELANOMA RES, V9, P369, DOI 10.1097/00008390-199908000-00005; Foekens JA, 1998, J CLIN ONCOL, V16, P1013, DOI 10.1200/JCO.1998.16.3.1013; Gaumann A, 2001, PATHOL RES PRACT, V197, P257, DOI 10.1078/0344-0338-00044; HAWLEYNELSON P, 1988, MOL CARCINOGEN, V1, P202, DOI 10.1002/mc.2940010309; HEIDTMANN HH, 1992, BRIT J CANCER, V65, P154, DOI 10.1038/bjc.1992.33; HEIDTMANN HH, 1989, CANCER RES, V49, P6960; Hirai K, 1999, HUM PATHOL, V30, P680, DOI 10.1016/S0046-8177(99)90094-1; Huh CG, 1999, J CLIN PATHOL-MOL PA, V52, P332, DOI 10.1136/mp.52.6.332; KEPPLER D, 1994, BBA-MOL BASIS DIS, V1226, P117, DOI 10.1016/0925-4439(94)90018-3; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; Kos J, 1997, CLIN CANCER RES, V3, P1815; Kos J, 2000, INT J BIOL MARKER, V15, P84, DOI 10.1177/172460080001500116; Kos J, 1998, CLIN CANCER RES, V4, P1511; Kos J, 2000, CLIN CANCER RES, V6, P505; Krepela E, 1998, NEOPLASMA, V45, P318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAH TT, 1992, CANCER LETT, V61, P243, DOI 10.1016/0304-3835(92)90295-7; Lah TT, 2000, CLIN CANCER RES, V6, P578; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0; Mangge H, 2000, CLIN CHIM ACTA, V300, P195, DOI 10.1016/S0009-8981(00)00322-3; Merz GS, 1997, J CELL PHYSIOL, V173, P423; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MORT JS, 1980, BIOCHIM BIOPHYS ACTA, V614, P134, DOI 10.1016/0005-2744(80)90174-6; MURNANE MJ, 1991, CANCER RES, V51, P1137; Pavlova A, 2000, FEBS LETT, V487, P156, DOI 10.1016/S0014-5793(00)02337-1; PEDERSEN PH, 1993, CANCER RES, V53, P5158; QIAN F, 1989, CANCER RES, V49, P4870; Randers E, 1999, CLIN CHEM LAB MED, V37, P389, DOI 10.1515/CCLM.1999.064; SCHMITT M, 1992, FIBRINOLYSIS, V6, P3; Sexton PS, 1997, MELANOMA RES, V7, P97, DOI 10.1097/00008390-199704000-00002; SHEAHAN K, 1989, CANCER RES, V49, P3809; Sloane B F, 1990, Semin Cancer Biol, V1, P137; SLOANE BF, 1990, CANCER METAST REV, V9, P333, DOI 10.1007/BF00049523; SLOANE BF, 1994, BIOCH MOL ASPECTS SE, V2, P411; Stabuc B, 2000, CLIN CHEM, V46, P193; Strojan P, 2000, CLIN CANCER RES, V6, P1052; Strojnik T, 1999, CLIN CANCER RES, V5, P559; SUKOH N, 1994, VIRCHOWS ARCH, V424, P33; TERADA T, 1995, HUM PATHOL, V26, P746, DOI 10.1016/0046-8177(95)90222-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATANABE M, 1989, BIOCHEM MED METAB B, V42, P21, DOI 10.1016/0885-4505(89)90037-6; Werle B, 1999, BRIT J CANCER, V81, P510, DOI 10.1038/sj.bjc.6690723; Yano M, 2001, SURG TODAY, V31, P385, DOI 10.1007/s005950170126; Yoshimura K, 2000, ONCOL REP, V7, P27	53	64	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2002	21	57					8705	8712		10.1038/sj.onc.1205949	http://dx.doi.org/10.1038/sj.onc.1205949			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZG	12483523				2022-12-17	WOS:000179734400004
J	Shivapurkar, N; Reddy, J; Matta, H; Sathyanarayana, UG; Huang, CX; Toyooka, S; Minna, JD; Chaudhary, PM; Gazdar, AF				Shivapurkar, N; Reddy, J; Matta, H; Sathyanarayana, UG; Huang, CX; Toyooka, S; Minna, JD; Chaudhary, PM; Gazdar, AF			Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification	ONCOGENE			English	Article						CASP8; DISC; MYC; TRAIL	NF-KAPPA-B; CASPASE 8; C-MYC; APOPTOSIS; ACTIVATION; ONCOGENE	We have previously reported that the key apoptosis related gene caspase 8 (CASP8) is frequently silenced in small cell lung cancer (SCLC) tumors and cell lines usually, but not always, by aberrant promoter methylation. Because CASP8 is a key component of the death-inducing signaling complex (DISC) when specific death receptors (including DR4, DR5, FAS) are activated by their specific ligands (TRAIL/FASL), we examined expression of the components of the DISC complex in lung cancer cell lines. MYC family members are frequently amplified (MYC+ve) in SCLC, and MYC is a potent inducer of apoptosis. We examined 34 SCLC tines (12 of which were MYC+ve) and 22 NSCLC lines. CASP8 gene expression was frequently lost (79%) at message and protein levels in SCLC but not in non-SCLC (NSCLC). MYC amplification was present in 45% of SCLC cell lines, which had lost CASP8 expression, but not in any of the CASP8 positive lines. The frequency of CASP8 loss was significantly higher in MYC+ve SCLC compared to MYC-ve SCLC or in NSCLC. Analyses of other DISC components showed significantly higher rates of loss of expression of CASP10, DR5, FAS and FASL in SCLC compared to NSCLC. The loss of expression of proapoptotic DISC components was significantly higher in MYC+ve SCLC cell lines and these lines were completely resistant to TRAIL. Expression of CASP10 (a caspase closely related to CASP8) was frequently absent at the protein level in both SCLC and NSCLC lines. Expression of c-FLIP (proteolytically inactive homolog of CASP8) was inversely related to expression of CASP8. Our major conclusions are: (a) The death receptor pathway is differently inactivated at multiple levels in lung cancer cell lines; and (b) MYC amplification in SCLC is associated with inactivation of most components of the DISC complex, with resistance to TRAIL and with expression of c-FLIP. These findings may have considerable clinical and therapeutic implications.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gazdar, AF (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, NB8 106,5323 Harry Hines Blvd, Dallas, TX 75390 USA.	adi.gazdar@UTSouthwestern.edu	Chaudhary, Preet/E-1970-2018		NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047230] Funding Source: NIH RePORTER; NCI NIH HHS [P50-CA70907] Funding Source: Medline; NIAID NIH HHS [AI/AR47230-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BROERS JLV, 1993, AM J RESP CELL MOL, V9, P33, DOI 10.1165/ajrcmb/9.1.33; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Griffith TS, 1998, J IMMUNOL, V161, P2833; Hopkins-Donaldson S, 2000, MED PEDIATR ONCOL, V35, P608; Johnson BE, 1996, J CELL BIOCHEM, P210; Joseph B, 1999, BIOCHEM BIOPH RES CO, V262, P381, DOI 10.1006/bbrc.1999.1191; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kumar A, 2001, ONCOGENE, V20, P1010, DOI 10.1038/sj.onc.1204154; MORSTYN G, 1984, JNCI-J NATL CANCER I, V73, P801; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; Ozkara HA, 1999, TUMORI J, V85, P508; Phelps RM, 1996, J CELL BIOCHEM, P32; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Schneider P, 2000, Pharm Acta Helv, V74, P281, DOI 10.1016/S0031-6865(99)00038-2; Shivapurkar N, 2002, CANCER BIOL THER, V1, P65, DOI 10.4161/cbt.1.1.45; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Wang XD, 2001, GENE DEV, V15, P2922; Zajac-Kaye M, 2001, LUNG CANCER-J IASLC, V34, pS43, DOI 10.1016/S0169-5002(01)00343-9; Zochbauer-Muller S, 2002, ANNU REV PHYSIOL, V64, P681, DOI 10.1146/annurev.physiol.64.081501.155828	23	64	67	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2002	21	55					8510	8514		10.1038/sj.onc.1205941	http://dx.doi.org/10.1038/sj.onc.1205941			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466971	Bronze			2022-12-17	WOS:000179480100014
J	Janda, E; Litos, G; Grunert, S; Downward, J; Beug, H				Janda, E; Litos, G; Grunert, S; Downward, J; Beug, H			Oncogenic Ras/Her-2 mediate hyperproliferation of polarized epithelial cells in 3D cultures and rapid tumor growth via the PI3K pathway	ONCOGENE			English	Article						proliferation; EMT; Ras mutants; PI3K; collagen gels; breast cancer	NIH 3T3 CELLS; HORMONE-INDEPENDENT PROLIFERATION; BREAST-CANCER CELLS; MAP KINASE KINASE; CYCLIN D1; E-CADHERIN; MAMMARY TUMORIGENESIS; SIGNALING PATHWAYS; INDUCED APOPTOSIS; CARCINOMA-CELLS	Carcinogenesis by oncogenic Ras and Her-2 involves enhanced proliferation of epithelial cells in vivo. However, hyperproliferation induced by these oncogenes, or their downstream pathways in vitro has mainly been studied in cultured, fibroblastic cell lines. Here, we demonstrate that oncogenic Ha-Ras or constitutively active Her-2 cause increased proliferation and cyclin D1 upregulation in fully polarized, mammary epithelial cells (EpH4), if cultivated as organotypic structures in three-dimensional collagen/ matrigel matrices. Under standard culture conditions, however, these oncogenes failed to induce hyperproliferation. Using both specific low molecular weight inhibitors and Ras-effector - specific mutants, we dissected signaling pathways downstream of oncogenic Ras (PI3K, Mek1/ MAPK) with respect to (i) hyperproliferation in collagen gels and tumorigenesis in mice and (ii) epithelial/ mesenchymal transition (EMT). We show that the Ras-activated PI3K pathway is required to induce rapid tumor growth and enhanced proliferation of EpH4 cells in collagen gels, but fails to cause EMT in vitro and in vivo. On the other hand, Ras-dependent activation of the Mek1/ MAPK pathway in EpH4 cells (previously shown to cause EMT and metastasis) did not induce hyperproliferation in collagen gels and caused only slow tumor growth. Our data thus indicate that Ras-dependent signaling through the PI3K- and MAPK pathways fulfil distinct, but complementary functions during carcinogenesis.	Inst Mol Pathol, A-1030 Vienna, Austria; Imperial Canc Res Fund, Signal Transduct Labs, London WC2A 3PX, England	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Cancer Research UK	Beug, H (corresponding author), Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Janda, Elzbieta/AFQ-7061-2022; Downward, Julian/A-3251-2012; Janda, Elzbieta/AAD-5126-2022; Gruenert, Stefan/T-7755-2019; Gruenert, Stefan/B-7598-2016	Janda, Elzbieta/0000-0002-6787-7291; Janda, Elzbieta/0000-0002-6787-7291; Gruenert, Stefan/0000-0003-0241-9297; Gruenert, Stefan/0000-0003-0241-9297; Downward, Julian/0000-0002-2331-4729				Cass LA, 2000, ONCOGENE, V19, P924, DOI 10.1038/sj.onc.1203393; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; De Vita G, 2000, CANCER RES, V60, P3916; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; FILMUS J, 1994, ONCOGENE, V9, P3627; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Klinowska TCM, 1999, DEV BIOL, V215, P13, DOI 10.1006/dbio.1999.9435; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Lenferink AEG, 2001, CANCER RES, V61, P6583; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; Montesano R, 1998, IN VITRO CELL DEV-AN, V34, P468; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Ojakian GK, 1997, J CELL SCI, V110, P2781; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Putz E, 1999, CANCER RES, V59, P241; Ram TG, 1996, CELL GROWTH DIFFER, V7, P551; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; SMITH MR, 1990, MOL CELL BIOL, V10, P3828, DOI 10.1128/MCB.10.7.3828; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Szuts D, 1998, GENE DEV, V12, P2022, DOI 10.1101/gad.12.13.2022; Treinies I, 1999, MOL CELL BIOL, V19, P321; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	46	64	66	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5148	5159		10.1038/sj.onc.1205661	http://dx.doi.org/10.1038/sj.onc.1205661			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140765				2022-12-17	WOS:000176975900013
J	Senoo, M; Matsumura, Y; Habu, S				Senoo, M; Matsumura, Y; Habu, S			TAp63 gamma (p51A) and dNp63 alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression	ONCOGENE			English	Article						p63; p51; p73L; p300; CBP; VEGF; HIF1 alpha	HYPOXIA-INDUCIBLE FACTOR-1; CELL LUNG-CANCER; WILD-TYPE P53; O-2 HOMEOSTASIS; FACTOR 1-ALPHA; TRANSCRIPTION; ACTIVATION; HOMOLOG; ANGIOGENESIS; PROTEIN	Tumor suppressor p53 has been shown to repress expression of vascular endothelial growth factor (VEGF), an endothelial cell-specific mitogen and a key mediator of tumor angiogenesis. The p63 gene, recently identified as a p53-relative, encodes multiple isoforms with structural and functional similarities and differences from p53. In this study, we show the evidence that the two major isoforms of the p63 gene, TAp63gamma (p51A) and dNp63alpha (p73L), represses and upregulates VEGF expression, respectively, on transcription and protein levels. Transient transfection assays show that a hypoxia-inducible factor (HIF) 1 binding site within the VEGF promoter region is responsible for both upregulation and repression by dNp63alpha and by TAp63gamma, respectively, of the VEGF promoter activity. We also show that TAp63gamma targets HIF1alpha for promoting proteasomal degradation but that dNp63alpha targets HIF1alpha for stabilization. Mammalian two-hybrid assays show that HIF1alpha-dependent transcription is repressed by TAp63gamma as well as by p53, whereas it is upregulated by dNp63alpha in collaboration with a transcription coactivator p300. Our data also show that dNp63alpha acts as a dominant-negative reagent toward both p53- and TAp63gamma-mediated degradation of HIF1alpha and repression of HIF1alpha-dependent transcription. These results suggest that p63 is involved in the regulation of the VEGF gene expression and that modulation of VEGF expression by TAp63gamma and dNp63alpha is closely correlated with their distinct roles on the regulation of HIF1alpha stability.	Tokai Univ, Sch Med, Dept Immunol, Isehara, Kanagawa 2591193, Japan	Tokai University	Habu, S (corresponding author), Tokai Univ, Sch Med, Dept Immunol, Isehara, Kanagawa 2591193, Japan.	sonoko@is.icc.u-tokai.ac.jp		Senoo, Makoto/0000-0002-0155-0683				Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Bouvet M, 1998, CANCER RES, V58, P2288; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; ENOO M, 2001, BIOCHEM BIOPH RES CO, V286, P628; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FOLKMAN J, 1997, CANC MED, P181; Fontanini G, 1998, EUR J CANCER, V34, P718, DOI 10.1016/S0959-8049(97)10145-9; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kanegae Y, 1996, GENE, V181, P207, DOI 10.1016/S0378-1119(96)00516-1; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MARTINYBARON G, 1995, CURR OPIN BIOTECH, V6, P675, DOI 10.1016/0958-1669(95)80111-1; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Nishi H, 2001, J BIOL CHEM, V276, P41717, DOI 10.1074/jbc.M101241200; Nishi H, 1999, INT J ONCOL, V15, P1149; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nylander K, 2000, INT J CANCER, V87, P368, DOI 10.1002/1097-0215(20000801)87:3<368::AID-IJC9>3.3.CO;2-A; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Park BJ, 2000, CANCER RES, V60, P3370; Ravi R, 2000, GENE DEV, V14, P34; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salimath B, 2000, ONCOGENE, V19, P3470, DOI 10.1038/sj.onc.1203672; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Senoo M, 2001, BRIT J CANCER, V84, P1235, DOI 10.1054/bjoc.2000.1735; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; Shimada A, 1999, CANCER RES, V59, P2781; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sunahara M, 1999, ONCOGENE, V18, P3761, DOI 10.1038/sj.onc.1202972; Suzuki K, 1996, CANCER RES, V56, P3004; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 1997, BIOL CHEM, V378, P609; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zhong H, 1999, CANCER RES, V59, P5830	52	64	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2455	2465		10.1038/sj.onc.1205330	http://dx.doi.org/10.1038/sj.onc.1205330			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971180				2022-12-17	WOS:000174918400002
J	Stewart, SA; Weinberg, RA				Stewart, SA; Weinberg, RA			Senescence: does it all happen at the ends?	ONCOGENE			English	Article						telomere; senescence; telomerase; capping; immortality	TELOMERASE ACTIVITY; HUMAN-CELLS; LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; GROWTH; FIBROBLASTS; EXTENSION; APOPTOSIS; CANCER; LENGTH	Over 60 years ago Barbara McClintock described the telomere and suggested that it protected the chromosome from illegitimate or end-to-end fusion, thus functioning to protect the genome. Since that time we have discovered that the telomere is a complex structure composed of both DNA and a growing list of associated proteins that together serve to regulate the length of the telomere and, as predicted by McClintock, protect genomic integrity. In addition to its protective role, the telomere has also been hypothesized to serve as a molecular clock that tallies the number of cell divisions and limits further divisions at a predetermined point. However, the precise role of telomeres in predicting and limiting cellular lifespan remains a matter of much debate. In this review, we highlight some of the salient points of basic telomere biology and relate them to the current controversies surrounding the role of telomeres and telomerase in cellular senescence.	MIT, Dept Biol, Cambridge, MA 02139 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute	Weinberg, RA (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	weinberg@wi.mit.edu	Stewart, Sheila A/C-5213-2012		NATIONAL CANCER INSTITUTE [R01CA078461] Funding Source: NIH RePORTER; NCI NIH HHS [5R01 CA78461] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brozmanova J, 2001, NEOPLASMA, V48, P85; Chen QM, 2001, EXP CELL RES, V265, P294, DOI 10.1006/excr.2001.5182; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Friedrich U, 2000, MECH AGEING DEV, V119, P89, DOI 10.1016/S0047-6374(00)00173-1; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Gajdusek C, 2001, J CELL PHYSIOL, V188, P8, DOI 10.1002/jcp.1091; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Greider CW, 1996, SCI AM, V274, P92, DOI 10.1038/scientificamerican0296-92; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Holt SE, 1999, MOL CARCINOGEN, V25, P241, DOI 10.1002/(SICI)1098-2744(199908)25:4<241::AID-MC2>3.0.CO;2-9; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Mondello C, 1999, EXP CELL RES, V248, P234, DOI 10.1006/excr.1999.4398; Munoz-Jordan JL, 2001, EMBO J, V20, P579, DOI 10.1093/emboj/20.3.579; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Rufer N, 2001, BLOOD, V98, P597, DOI 10.1182/blood.V98.3.597; Schulz VP, 1996, HUM GENET, V97, P750; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY M, 1991, ANN HEMATOL, V63, P116, DOI 10.1007/BF01707284; Shiloh Y, 1985, Kroc Found Ser, V19, P111; Suzuki K, 2001, RADIAT RES, V155, P248, DOI 10.1667/0033-7587(2001)155[0248:RISLGA]2.0.CO;2; Toussaint O, 2000, EXP GERONTOL, V35, P927, DOI 10.1016/S0531-5565(00)00180-7; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; von Zglinicki T, 2001, EXP GERONTOL, V36, P1049, DOI 10.1016/S0531-5565(01)00111-5; Walter CA, 1997, MECH AGEING DEV, V98, P203, DOI 10.1016/S0047-6374(97)00108-5; Watt PM, 1996, GENETICS, V144, P935; Wei S, 1999, CANCER RES, V59, P1539; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yudoh K, 2001, J BONE MINER RES, V16, P1453, DOI 10.1359/jbmr.2001.16.8.1453; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	47	64	65	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2002	21	4					627	630		10.1038/sj.onc.1205062	http://dx.doi.org/10.1038/sj.onc.1205062			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850788				2022-12-17	WOS:000173390500015
J	Lawlor, ER; Scheel, C; Irving, J; Sorensen, PHB				Lawlor, ER; Scheel, C; Irving, J; Sorensen, PHB			Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors	ONCOGENE			English	Article						Ewing tumor; spheroids; cyclin D1; PI3K-AKT; ERK	FACTOR-I RECEPTOR; PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; CYCLIN D1; PHOSPHATIDYLINOSITOL 3-KINASE; CHROMOSOME-TRANSLOCATION; CONSTITUTIVE ACTIVATION; NEUROECTODERMAL TUMOR; TRANSCRIPTION FACTOR; DNA-SYNTHESIS	Little is known about the growth-signaling pathways that govern the proliferation of Ewing tumor (ET) cells either in vitro or in vivo. We have studied signal transduction pathways in ET cell lines and compared kinase expression levels and proliferation rates with primary tumors. Cell lines were studied both as conventional adherent monolayers and as anchorage-independent multi-cellular spheroids. Importantly, we observed significant differences between these in vitro models and found that ET spheroids were more closely related to primary tumors with respect to cell morphology, cell-cell junctions, proliferative index and kinase activation. Monolayer ET cells demonstrated serum-dependent phosphorylation of ERK1/2 and AKT and constitutively high serum-independent cyclin D1 protein expression. However, when ET cells were placed in suspension culture, there was immediate serum-independent activation of ERK1/2 and AKT. In addition, cyclin DI protein expression was completely blocked until stable multicellular spheroids had formed, indicating that cell-cell adhesion is necessary for the proliferation of anchorage independent ET cells. This reduction in cyclin D1 expression was post-transcriptional and could be mimicked in monolayer cells by treatment with phosphatidyl inositol-3 kinase (PI3K) inhibitors. Moreover, PI3K inhibition significantly reduced ET cell proliferation and, in primary ET samples, cyclin DI expression correlated with expression of activated AKT. Thus, the PI3K-AKT pathway appears to be critical for the proliferation of ET cells both in vitro and in vivo and tumor cell growth in vivo may be better represented by the study of anchorage-independent multi-cellular spheroids.	Childrens & Womens Hlth Ctr British Columbia, Dept Pediat, Vancouver, BC V5Z 4H4, Canada; Childrens & Womens Hlth Ctr British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Vancouver, BC V5Z 4H4, Canada	BC Women's Hospital & Health Centre; BC Women's Hospital & Health Centre; University of British Columbia	Sorensen, PHB (corresponding author), BC Res Inst Childrens & Womens Hlth, Room 3082-950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	psor@interchange.ubc.ca			NCI NIH HHS [CA88199] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA088199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Baserga R, 1997, EXP CELL RES, V236, P1, DOI 10.1006/excr.1997.3732; Bates RC, 2000, CRIT REV ONCOL HEMAT, V36, P61, DOI 10.1016/S1040-8428(00)00077-9; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; de Alava E, 2000, AM J PATHOL, V156, P849, DOI 10.1016/S0002-9440(10)64953-X; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUNN T, 1994, CANCER GENET CYTOGEN, V76, P19, DOI 10.1016/0165-4608(94)90063-9; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Girnita L, 2000, ONCOGENE, V19, P4298, DOI 10.1038/sj.onc.1203755; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Kawamura K, 2000, ANAL QUANT CYTOL, V22, P107; Kopnin BP, 2000, BIOCHEMISTRY-MOSCOW+, V65, P2; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lawlor ER, 1998, CANCER RES, V58, P2469; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Mellin W, 1989, Curr Top Pathol, V80, P115; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; NIGGLI FK, 1994, BRIT J CANCER, V69, P1106, DOI 10.1038/bjc.1994.217; PONTEN J, 1971, SPONTANEOUS VIRUS IN; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V24, P1, DOI 10.1002/(SICI)1098-2744(199901)24:1<1::AID-MC1>3.0.CO;2-E; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Santini MT, 2000, CRIT REV ONCOL HEMAT, V36, P75, DOI 10.1016/S1040-8428(00)00078-0; Santini MT, 1999, PATHOBIOLOGY, V67, P148, DOI 10.1159/000028065; Scheid MP, 2000, CURR BIOL, V10, pR191, DOI 10.1016/S0960-9822(00)00349-3; SCOTLANDI K, 1995, CANCER, V75, P806, DOI 10.1002/1097-0142(19950201)75:3<806::AID-CNCR2820750310>3.0.CO;2-S; Scotlandi K, 1996, CANCER RES, V56, P4570; Shao JY, 2000, J BIOL CHEM, V275, P22916, DOI 10.1074/jbc.M002235200; Sherr CJ, 2000, CANCER RES, V60, P3689; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Silvany RE, 2000, ONCOGENE, V19, P4523, DOI 10.1038/sj.onc.1203811; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Toretsky JA, 1999, CANCER RES, V59, P5745; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; Treinies I, 1999, MOL CELL BIOL, V19, P321; TRICHE TJ, 1993, PRINCIPLES PRACTICE, V2, P115; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Vollmer E, 1989, Curr Top Pathol, V80, P91; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; Wong CW, 2001, CANCER RES, V61, P333; YEE D, 1990, J CLIN INVEST, V86, P1806, DOI 10.1172/JCI114910; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	53	64	67	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2002	21	2					307	318		10.1038/sj.onc.1205053	http://dx.doi.org/10.1038/sj.onc.1205053			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803474				2022-12-17	WOS:000173026200015
J	Rivera, R; Murre, C				Rivera, R; Murre, C			The regulation and function of the Id proteins in lymphocyte development	ONCOGENE			English	Review						E-proteins; bHLH; Id	LOOP-HELIX PROTEIN; B-CELL DEVELOPMENT; T-CELL; DNA-BINDING; MAP KINASE; THYMOCYTE MATURATION; SIGNALING PATHWAYS; NEGATIVE REGULATOR; MESSENGER-RNA; E2A ACTIVITY	Helix - loop - helix (HLH) proteins are essential factors for lymphocyte development and function. One class of HLH proteins, the E-proteins, regulate many aspects of lymphocyte maturation, survival, proliferation, and differentiation. E-proteins are negatively regulated by another class of HLH proteins known as the Id proteins. The Id proteins function as dominant negative inhibitors of E-proteins by inhibiting their ability to bind DNA. Here we discuss the function and regulation of the Id proteins in lymphocyte development.	Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Rivera, R (corresponding author), Univ Calif San Diego, Div Biol, 0366, La Jolla, CA 92093 USA.	r3@biomail.ucsd.edu						ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ARDAVIN C, 1993, NATURE, V362, P761, DOI 10.1038/362761a0; Bain G, 1999, J EXP MED, V190, P1605, DOI 10.1084/jem.190.11.1605; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; Bain G, 1997, IMMUNITY, V6, P145, DOI 10.1016/S1074-7613(00)80421-5; Bain G, 1999, J EXP MED, V189, P289, DOI 10.1084/jem.189.2.289; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; Barndt R, 1999, J IMMUNOL, V163, P3331; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Brunet A, 1997, ESSAYS BIOCHEM, V32, P1; Carlyle JR, 1997, J EXP MED, V186, P173, DOI 10.1084/jem.186.2.173; CHANTRY D, 1989, EUR J IMMUNOL, V19, P783, DOI 10.1002/eji.1830190433; Chen BB, 1997, NUCLEIC ACIDS RES, V25, P423, DOI 10.1093/nar/25.2.423; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; DEED RW, 1993, ONCOGENE, V8, P599; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; Engel I, 1999, P NATL ACAD SCI USA, V96, P996, DOI 10.1073/pnas.96.3.996; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; Gartner F, 1999, IMMUNITY, V10, P537, DOI 10.1016/S1074-7613(00)80053-9; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; Goldfarb AN, 1996, MOL IMMUNOL, V33, P947, DOI 10.1016/S0161-5890(96)00047-8; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Hagemann D, 1999, ONCOGENE, V18, P1391, DOI 10.1038/sj.onc.1202431; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heemskerk MHM, 1997, J EXP MED, V186, P1597, DOI 10.1084/jem.186.9.1597; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; Ikawa T, 1999, J EXP MED, V190, P1617, DOI 10.1084/jem.190.11.1617; Ikawa T, 2001, P NATL ACAD SCI USA, V98, P5164, DOI 10.1073/pnas.091537598; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; Kee BL, 2001, NAT IMMUNOL, V2, P242, DOI 10.1038/85303; KEE BL, 1995, INT REV CYTOL, V157, P129, DOI 10.1016/S0074-7696(08)62158-0; Kim D, 1999, MOL CELL BIOL, V19, P8240; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; Kleeff J, 1998, CANCER RES, V58, P3769; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Leclercq G, 1996, J EXP MED, V184, P325, DOI 10.1084/jem.184.2.325; LEE G, 1989, J IMMUNOL, V142, P3875; Lilja H, 1999, Mol Cell Biol Res Commun, V1, P188, DOI 10.1006/mcbr.1999.0131; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massy ZA, 1996, SEMIN NEPHROL, V16, P12; MATSUZAKI Y, 1993, J EXP MED, V178, P1283, DOI 10.1084/jem.178.4.1283; Mebius RE, 1997, IMMUNITY, V7, P493, DOI 10.1016/S1074-7613(00)80371-4; Miyazaki T, 1998, J EXP MED, V188, P715, DOI 10.1084/jem.188.4.715; Moldes M, 1997, MOL CELL BIOL, V17, P1796, DOI 10.1128/MCB.17.4.1796; Morrow MA, 1999, MOL IMMUNOL, V36, P491, DOI 10.1016/S0161-5890(99)00071-1; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakashima K, 2001, P NATL ACAD SCI USA, V98, P5868, DOI 10.1073/pnas.101109698; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Pan LH, 1999, MOL CELL BIOL, V19, P5969; Park ST, 1999, J EXP MED, V189, P501, DOI 10.1084/jem.189.3.501; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; Quong MW, 1999, EMBO J, V18, P6307, DOI 10.1093/emboj/18.22.6307; Res PCM, 1999, BLOOD, V94, P2647, DOI 10.1182/blood.V94.8.2647.420k06_2647_2657; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; RODEWALD HR, 1992, CELL, V69, P139, DOI 10.1016/0092-8674(92)90125-V; Romanow WJ, 2000, MOL CELL, V5, P343, DOI 10.1016/S1097-2765(00)80429-3; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ MJ, 1994, J EXP MED, V180, P569, DOI 10.1084/jem.180.2.569; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; SHOJI W, 1994, J BIOL CHEM, V269, P5078; Shortman K, 1996, ANNU REV IMMUNOL, V14, P29, DOI 10.1146/annurev.immunol.14.1.29; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Spits H, 2000, J EXP MED, V192, P1775, DOI 10.1084/jem.192.12.1775; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; Tournay O, 1996, MOL CELL BIOL, V16, P2418; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Yaswen L, 1996, BLOOD, V87, P1439, DOI 10.1182/blood.V87.4.1439.bloodjournal8741439; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZunigaPflucker JC, 1996, CURR OPIN IMMUNOL, V8, P215, DOI 10.1016/S0952-7915(96)80060-4	105	64	72	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	2001	20	58					8308	8316		10.1038/sj.onc.1205091	http://dx.doi.org/10.1038/sj.onc.1205091			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512HT	11840323				2022-12-17	WOS:000173319500004
J	Marienfeld, R; Berberich-Siebelt, F; Berberich, I; Denk, A; Serfling, E; Neumann, M				Marienfeld, R; Berberich-Siebelt, F; Berberich, I; Denk, A; Serfling, E; Neumann, M			Signal-specific and phosphorylation-dependent RelB degradation: a potential mechanism of NF-kappa B control	ONCOGENE			English	Article						phosphorylation; proteolysis; RelB; NF-kappa B; I kappa B	TRANSCRIPTION FACTORS; PROTEIN-KINASE; ALPHA; UBIQUITINATION; IDENTIFICATION; ACTIVATION; CANCER; FAMILY; CELLS; MICE	RelB is an unusual member of the ReI/NF-kappaB family of transcription factors which are involved in oncogenic processes. Due to a relaxed control by the I kappa Bs, the cytosolic NF-kappaB inhibitors, RelB is constitutively expressed in the nuclei of lymphoid cells. We show here that RelB is inducibly degraded upon activation of T cells in a fashion similar to the L kappa Bs. However, RelB degradation differs from that of I kappa Bs since it is not induced by TNF alpha but only by T cell receptor or TPA/ionomycin stimulation. Moreover, ReIB degradation occurs in three steps: (i) after stimulation RelB is rapidly phosphorylated at amino acids Thr84 and Ser552 followed by (U) an N-terminal cut and, finally, (iii) the complete degradation in the proteasomes. Since mutation of the two phosphoacceptor sites to non-acceptor sites abolished RelB phosphorylation in vivo and led to the stabilization of the mutated ReIBDM, site-specific phosphorylation appears to be a necessary prerequisite for RelB degradation. RelB is a crucial regulator of NF kappaB-dependent gene expression. Thus, the signal-induced degradation of RelB should be an important control mechanism of NF-kappaB activity.	Univ Wurzburg, Inst Pathol, Dept Mol Pathol, D-97080 Wurzburg, Germany; Univ Wurzburg, Inst Virol & Immunobiol, D-97074 Wurzburg, Germany; Univ Ulm, Inst Physiol Chem, D-89081 Ulm, Germany	University of Wurzburg; University of Wurzburg; Ulm University	Neumann, M (corresponding author), Univ Wurzburg, Inst Pathol, Dept Mol Pathol, Josef Schneider Str 2, D-97080 Wurzburg, Germany.		Serfling, Edgar/X-7212-2019					Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barton D, 2000, EUR J IMMUNOL, V30, P2323, DOI 10.1002/1521-4141(2000)30:8<2323::AID-IMMU2323>3.0.CO;2-H; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 1996, ONCOGENE, V13, P1367; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; Marienfeld R, 1997, EUR J IMMUNOL, V27, P1601, DOI 10.1002/eji.1830270703; Neumann M, 1997, INT J ONCOL, V11, P1335; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Suhasini M, 1997, ONCOGENE, V15, P1859, DOI 10.1038/sj.onc.1201530; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; WEIH F, 1994, ONCOGENE, V9, P3289; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Xia YY, 1999, MOL CELL BIOL, V19, P7688	23	64	71	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2001	20	56					8142	8147		10.1038/sj.onc.1204884	http://dx.doi.org/10.1038/sj.onc.1204884			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	496LJ	11781828				2022-12-17	WOS:000172396800012
J	Flynn, DC				Flynn, DC			Adaptor proteins	ONCOGENE			English	Article						adaptor; adapter protein and signal transduction			W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA	West Virginia University; West Virginia University	Flynn, DC (corresponding author), W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA.								0	64	68	1	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	2001	20	44					6270	6272		10.1038/sj.onc.1204769	http://dx.doi.org/10.1038/sj.onc.1204769			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607828				2022-12-17	WOS:000171640600001
J	Reichel, M; Gillert, E; Angermuller, S; Hensel, JP; Heidel, F; Lode, M; Leis, T; Biondi, A; Haas, OA; Strehl, S; Panzer-Grumayer, ER; Griesinger, F; Beck, JD; Greil, J; Fey, GH; Uckun, FM; Marschalek, R				Reichel, M; Gillert, E; Angermuller, S; Hensel, JP; Heidel, F; Lode, M; Leis, T; Biondi, A; Haas, OA; Strehl, S; Panzer-Grumayer, ER; Griesinger, F; Beck, JD; Greil, J; Fey, GH; Uckun, FM; Marschalek, R			Biased distribution of chromosomal breakpoints involving the MLL gene in infants versus children and adults with t(4;11) ALL	ONCOGENE			English	Article						chromosomal translocation t(4;11); ALL-1/MLL/HRX gene; AF4 gene	ACUTE-LEUKEMIA; CLUSTER REGION; TRANSLOCATION T(4-11); EXON/INTRON STRUCTURE; SEQUENCE-ANALYSIS; 11Q23; IDENTIFICATION; CLEAVAGE	Derivative chromosomes of 40 patients diagnosed with t(4;11) acute lymphoblastic leukemia (ALL),were analysed on the genomic DNA level. Chromosomal breakpoints were identified in most cases within the known breakpoint cluster regions of the involved MLL and AF4 genes, Due to our current knowledge of the primary DNA sequences of both breakpoint cluster regions, specific features were identified at the chromosomal fusion sites, including deletions, inversions and duplications of parental DNA sequences, After separation of all t(4;11) leukemia patients into two age classes (below and above 1 year of age), the analysis of chromosomal fusion sites revealed significant differences in the distribution of chromosomal breakpoints and led to the definition of two hotspot areas within the MLL breakpoint cluster region, This may point to the possibility of different age-linked mechanisms that sere leading to t(4;11) chromosomal translocations. Oncogene (2001) 20, 2900-2907.	Univ Frankfurt, Bioctr, Inst Pharmaceut Biol, D-60439 Frankfurt, Germany; Univ Erlangen Nurnberg, Chair Genet, D-91058 Erlangen, Germany; Univ Erlangen Nurnberg, Dept Pediat, D-91054 Erlangen, Germany; Osped S Gerardo, Ctr Ric M Tettamanti, I-20052 Monza, MI, Italy; St Anna Kinderspital, CCRI, A-1090 Vienna, Austria; Univ Hosp Gottingen, Div Haematol Oncol, D-37075 Gottingen, Germany; Parker Hughes Canc Ctr, St Paul, MN 55113 USA; Parker Hughes Inst, Childrens Canc Grp, ALL Biol Reference Lab, St Paul, MN 55113 USA	Goethe University Frankfurt; University of Erlangen Nuremberg; University of Erlangen Nuremberg; San Gerardo Hospital; Saint Anna Children's Hospital; University of Gottingen	Marschalek, R (corresponding author), Univ Frankfurt, Bioctr, Inst Pharmaceut Biol, N230,303 Marie-Curie Str 9, D-60439 Frankfurt, Germany.		Biondi, Andrea/AAX-1865-2020; Haas, Oskar/AAM-5794-2020; Biondi, Andrea/K-9997-2016; Marschalek, Rolf/D-3404-2011	Biondi, Andrea/0000-0002-6757-6173; Marschalek, Rolf/0000-0003-4870-3445; Heidel, Florian/0000-0003-2438-1955; Reichel, Martin/0000-0001-7886-2784; Strehl, Sabine/0000-0002-0179-0628; Uckun, Fatih M./0000-0001-9334-183X				BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; Cimino G, 1997, CANCER RES, V57, P2879; Cimino G, 1998, HAEMATOLOGICA, V83, P350; Felix CA, 1997, BLOOD, V90, P4679, DOI 10.1182/blood.V90.12.4679.4679_4679_4686; Gillert E, 1999, ONCOGENE, V18, P4663, DOI 10.1038/sj.onc.1202842; GU Y, 1994, CANCER RES, V54, P2327; Leis T, 1998, LEUKEMIA, V12, P758, DOI 10.1038/sj.leu.2401006; Marschalek R, 1997, LEUKEMIA LYMPHOMA, V27, P417, DOI 10.3109/10428199709058308; MARSCHALEK R, 1995, BRIT J HAEMATOL, V90, P308, DOI 10.1111/j.1365-2141.1995.tb05151.x; Nilson I, 1996, BRIT J HAEMATOL, V93, P966, DOI 10.1046/j.1365-2141.1996.d01-1748.x; Nilson I, 1997, BRIT J HAEMATOL, V98, P157, DOI 10.1046/j.1365-2141.1997.1522966.x; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Reichel M, 1999, CANCER RES, V59, P3357; Reichel M, 1998, ONCOGENE, V17, P3035, DOI 10.1038/sj.onc.1202229; Stanulla M, 1997, MOL CELL BIOL, V17, P4070, DOI 10.1128/MCB.17.7.4070; Strissel Gbroeker Pamela L., 1996, Blood, V87, P1912; Strissel PL, 1998, BLOOD, V92, P3793, DOI 10.1182/blood.V92.10.3793.422a24_3793_3803; Super HG, 1997, GENE CHROMOSOME CANC, V20, P185, DOI 10.1002/(SICI)1098-2264(199710)20:2<185::AID-GCC9>3.0.CO;2-#; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	19	64	68	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2001	20	23					2900	2907		10.1038/sj.onc.1204401	http://dx.doi.org/10.1038/sj.onc.1204401			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	435VA	11420702				2022-12-17	WOS:000168901800005
J	Acton, DS; Velthuyzen, D; Lips, CJM; Hoppener, JWM				Acton, DS; Velthuyzen, D; Lips, CJM; Hoppener, JWM			Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice	ONCOGENE			English	Article						medullary thyroid carcinoma; multiple endocrine neoplasia type 2B; human RET transgenic mice	TYROSINE KINASE; SOMATIC MUTATIONS; PROTOONCOGENE; 2A; ACTIVATION; GERMLINE; RECEPTOR; GENE	Multiple endocrine neoplasia type 2B (MEN 2B) is a familial cancer syndrome, in which the cardinal feature is medullary thyroid carcinoma (MTC), a malignant tumor arising from the calcitonin producing thyroid C-cells, MEN 2B is associated with a germline point mutation in the RET proto-oncogene, leading to a Met-->Thr substitution at codon 918 in the kinase domain, which alters the substrate specificity of the protein. we used the human calcitonin gene (CALC-1) promoter to generate transgenic mice expressing either the human RET oncogene with the MEN2B-specific 918 Met-->Thr mutation (CALC-MEN2B-RET) or the human nonmutated RET proto-oncogene (CALC-WT-AET) in the C-cells, At 20-22 months of age three out of eight CALC-MEN2B-RET transgenic founders presented with macroscopic bilateral MTC, In two founders nodular C-cell hyperplasia (CCH) was observed. Thyroid abnormalities were never observed in CALC-WT-RET transgenic mice or control non-transgenic mice analysed at this age. In some mice from established CALC-MEN2B-RET transgenic lines nodular CCH was observed from 8 months on whereas MTC was detected in 13% of mice from one CALC-MEN2B-RET line, from the age of 11 months on. These results show for the first time that the MEN2B mutation in the RET oncogene predisposes mice for MTC.	Univ Utrecht, Med Ctr, Dept Internal Med, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Pathol, NL-3508 GA Utrecht, Netherlands	Utrecht University; Utrecht University	Acton, DS (corresponding author), Univ Utrecht, Med Ctr, Dept Internal Med, POB 85500, NL-3508 GA Utrecht, Netherlands.							ASAI N, 1995, MOL CELL BIOL, V15, P1613; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CARNEY JA, 1976, ORAL SURG ORAL MED O, V41, P793; Coxon AB, 1998, ONCOGENE, V17, P1625, DOI 10.1038/sj.onc.1202381; DONISKELLER H, 1993, HUM MOL GENET, V2, P1579; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HORN RC, 1951, CANCER, V4, P697, DOI 10.1002/1097-0142(195107)4:4<697::AID-CNCR2820040407>3.0.CO;2-8; Landsvater RM, 1996, CANCER RES, V56, P4853; LIPS CJM, 1994, NEW ENGL J MED, V331, P828, DOI 10.1056/NEJM199409293311302; Marsh DJ, 1996, CANCER RES, V56, P1241; Michiels FM, 1997, P NATL ACAD SCI USA, V94, P3330, DOI 10.1073/pnas.94.7.3330; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MYERS SM, 1995, ONCOGENE, V11, P2039; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SIPPLE JH, 1961, AM J MED, V31, P163, DOI 10.1016/0002-9343(61)90234-0; Smith-Hicks CL, 2000, EMBO J, V19, P612, DOI 10.1093/emboj/19.4.612; STEINER AL, 1968, MEDICINE, V47, P371, DOI 10.1097/00005792-196809000-00001; Sweetser DA, 1999, ONCOGENE, V18, P877, DOI 10.1038/sj.onc.1202376; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, ONCOGENE, V3, P571; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0	23	64	65	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 22	2000	19	27					3121	3125		10.1038/sj.onc.1203648	http://dx.doi.org/10.1038/sj.onc.1203648			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329JM	10871866				2022-12-17	WOS:000087903900011
J	Voss, J; Posern, G; Hannemann, JR; Wiedemann, LM; Turhan, AG; Poirel, H; Bernard, OA; Adermann, K; Kardinal, C; Feller, SM				Voss, J; Posern, G; Hannemann, JR; Wiedemann, LM; Turhan, AG; Poirel, H; Bernard, OA; Adermann, K; Kardinal, C; Feller, SM			The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways	ONCOGENE			English	Article						kinase specificity; Crk; CRKL; Ras; MAPK/Erk; Akt/PKB	CHRONIC MYELOGENOUS LEUKEMIA; PROTEIN-TYROSINE KINASES; FAMILY ADAPTER PROTEINS; HEMATOPOIETIC-CELLS; C-ABL; BINDING ACTIVITY; CRK; DOMAIN; PHOSPHORYLATION; ONCOGENE	Inappropriate activation of Abl family kinases plays a crucial role in different human leukaemias, In addition to the well known oncoproteins p190Bcr-Abl and p210Bcr-Abl, Tel-Abl, a novel fusion protein resulting from a different chromosomal translocation, has recently been described. In this study, the kinase specificities of the Bcr-Abl and Tel-Abl proteins were compared to the physiological Abl family kinases c-Abl and Arg (nhl related gene). Using short peptides which correspond to the target epitopes in known substrate proteins of Abl family kinases, we found a higher catalytic promiscuity of Bcr-Abl and Tel-Abl. Similar to Bcr-Abl, Tel-Abl was found in complexes with the adapter protein CRKL. In addition, c-Crk II and CRKL are tyrosine phosphorylated and complexed with numerous other tyrosine phosphorylated proteins in Tel-Abl expressing Ba/F3 cells. GTPase analysis with a Ras GTP-specific precipitation assay showed constitutive elevation of GTP-loaded Ras in cells expressing the leukaemic Abl proteins. The mitogenic MAPK/Erk kinases as well as Akt/PKB, a kinase implicated to negatively regulate apoptosis, were also constitutively activated by both Bcr-Abl and Tel-Abl, The results indicate that the leukaemic Abl-fusion proteins have catalytic specificities different from the normal kinases c-Abl and Arg and that Tel-Abl is capable to activate at least some pathways which are also upregulated by Bcr-Abl.	Inst Med Strahlenkunde & Zellforsch, Oncol Mol Lab, D-97078 Wurzburg, Germany; CellTec GmbH, Strathmann AG, D-22459 Hamburg, Germany; Inst Canc Res, Chester Beatty Labs, Leukaemia Res Fund Ctr, London SW3 6JB, England; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; CEPH, INSERM, U434, F-75010 Paris, France; Niedersachs Inst Peptidforsch, D-30625 Hannover, Germany	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm)	Feller, SM (corresponding author), Inst Med Strahlenkunde & Zellforsch, Oncol Mol Lab, Versbacher Str 5, D-97078 Wurzburg, Germany.		Wiedemann, Leanne/E-3316-2010; Bernard, Olivier A./E-5721-2016	TURHAN, Ali/0000-0002-4861-0137; Wiedemann, Leanne/0000-0002-0964-4676; Bernard, Olivier/0000-0002-0463-9747				Ahmed M, 1998, ONCOGENE, V16, P489, DOI 10.1038/sj.onc.1201556; ANAFI M, 1992, J BIOL CHEM, V267, P4518; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Hannemann JR, 1998, BRIT J HAEMATOL, V102, P475, DOI 10.1046/j.1365-2141.1998.00803.x; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; Kolibaba KS, 1997, BBA-REV CANCER, V1333, pF217, DOI 10.1016/S0304-419X(97)00022-X; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; NICHOLS GL, 1994, BLOOD, V84, P2912; Nilsson T, 1998, LEUKEMIA, V12, P1167, DOI 10.1038/sj.leu.2401091; ODA T, 1994, J BIOL CHEM, V269, P22925; Oehrl W, 1998, ONCOGENE, V17, P1893, DOI 10.1038/sj.onc.1202108; Okuda K, 1996, ONCOGENE, V13, P1147; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Posern G, 1998, J BIOL CHEM, V273, P24297, DOI 10.1074/jbc.273.38.24297; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Raitano AB, 1997, BBA-REV CANCER, V1333, pF201, DOI 10.1016/S0304-419X(97)00023-1; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; Sattler M, 1996, ONCOGENE, V12, P839; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Tauchi T, 1998, INT J ONCOL, V12, P1269; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; TENHOEVE J, 1994, BLOOD, V84, P1731; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	64	67	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2000	19	13					1684	1690		10.1038/sj.onc.1203467	http://dx.doi.org/10.1038/sj.onc.1203467			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763825				2022-12-17	WOS:000086083800008
J	Humphreys, RC; Hennighausen, L				Humphreys, RC; Hennighausen, L			Transforming growth factor alpha and mouse models of human breast cancer	ONCOGENE			English	Article						TGF alpha; mammary gland; transformation; cancer; mouse models; transgenic	MAMMARY EPITHELIAL-CELLS; PROTEIN-KINASE-A; TRANSGENIC MICE; TGF-ALPHA; FACTOR RECEPTOR; C-MYC; NEU PROTOONCOGENE; CYCLIN D1; CONSTITUTIVE ACTIVATION; SYNERGISTIC INTERACTION	Transforming growth factor alpha (TGF alpha) is a principal molecule in the normal and neoplastic development of the mammary gland. Binding of TGF alpha to the epidermal growth factor receptor (EGFR), activates the EGFRs' endogenous tyrosine kinase activity and stimulates growth of the epithelium in the virgin and pregnant mouse mammary gland. TGF alpha expression can be detected in breast cancer cells in vivo and in vitro and overexpression can elicit partial transformation or immortalized human and rodent mammary epithelial cells. Despite evidence implicating TGF alpha in the development of mammary neoplasia, the actual mechanism of TGF alpha-induced transformation is unclear. Transgenic mouse models targeting heterologous TGF alpha to the mammary gland have established TGF alpha overexpression can induce hyperproliferation, hyperplasia and occasional carcinoma. These transgenic studies demonstrated a facilitating, proliferative role for TGF alpha in the development of neoplasia and implicated several oncogenes that can cooperate with TGF alpha to transform the mammary epithelium. From studies of EGFR signaling pathways, inhibitory and modulating agents such as anti-ECFR antibodies and specific kinases inhibitors have been used to block the action of this pathway and prevent the development of TGF alpha-induced neoplasia and tumor formation, Studies in Stat5a knockout mice have established that the JAK2/Stat5a pathway can facilitate the survival of the mammary epithelium and can impact the progression of TGF alpha-mandated mammary tumorigenesis, Together these experiments indicate that TGF alpha and the EGFR signaling pathway are potentially amenable to therapies for treatment of human breast disease.	NIDDKD, NIH, Lab Genet & Physiol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Humphreys, RC (corresponding author), NIDDKD, NIH, Lab Genet & Physiol, Bldg 8,Room 111, Bethesda, MD 20892 USA.			Hennighausen, Lothar/0000-0001-8319-9841	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK061000, ZIADK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Amundadottir LT, 1996, ONCOGENE, V13, P757; ARTEAGA CL, 1988, CANCER RES, V48, P5023; BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; Bianco C, 1997, CLIN CANCER RES, V3, P439; BONILLA M, 1988, J NATL CANCER I, V80, P665, DOI 10.1093/jnci/80.9.665; BORELLINI F, 1989, ENVIRON HEALTH PERSP, V80, P85, DOI 10.2307/3430734; Brenner T L, 1999, J Am Pharm Assoc (Wash), V39, P236; CALLAHAN R, 1989, JNCI-J NATL CANCER I, V81, P1780, DOI 10.1093/jnci/81.23.1780; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; Ciardiello F, 1999, CLIN CANCER RES, V5, P909; Ciardiello F, 1996, JNCI-J NATL CANCER I, V88, P1770, DOI 10.1093/jnci/88.23.1770; Ciardiello F, 1998, CLIN CANCER RES, V4, P821; CLARK AJL, 1989, J MOL ENDOCRINOL, V2, P3, DOI 10.1677/jme.0.0020003; COFFEY RJ, 1994, CANCER RES, V54, P1678; COLEMAN S, 1988, DEV BIOL, V127, P304, DOI 10.1016/0012-1606(88)90317-X; DANIEL CW, 1985, MAMMARY GLAND DEV RE, V1, P3; De Jong JS, 1998, J PATHOL, V184, P44; De Jong JS, 1998, J PATHOL, V184, P53, DOI 10.1002/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; EDERY M, 1985, ENDOCRINOLOGY, V117, P405, DOI 10.1210/endo-117-1-405; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; GILLETT C, 1994, CANCER RES, V54, P1812; Gillett CE, 1999, J PATHOL, V187, P200, DOI 10.1002/(SICI)1096-9896(199901)187:2<200::AID-PATH228>3.0.CO;2-M; Gullick WJ, 1998, BREAST CANCER RES TR, V52, P43, DOI 10.1023/A:1006107016969; GULLICK WJ, 1999, WOMEN CANC, V1, P29; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HALTER SA, 1992, AM J PATHOL, V140, P1131; Hanna W, 1999, MODERN PATHOL, V12, P827; Hayakawa F, 1998, BRIT J HAEMATOL, V101, P521, DOI 10.1046/j.1365-2141.1998.00720.x; Humphreys RC, 1999, CELL GROWTH DIFFER, V10, P685; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; KENNEY NJ, 1993, J CELL PHYSIOL, V156, P497, DOI 10.1002/jcp.1041560309; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LISCIA DS, 1990, DEV BIOL, V140, P123, DOI 10.1016/0012-1606(90)90059-R; LIU SC, 1987, MOL ENDOCRINOL, V1, P683, DOI 10.1210/mend-1-10-683; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; MARIANICOSTANTINI R, 1989, TUMORI J, V75, P311, DOI 10.1177/030089168907500404; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; Norgaard P, 1999, CLIN CANCER RES, V5, P35; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; PETERS GN, 1983, CANCER, V52, P680, DOI 10.1002/1097-0142(19830815)52:4<680::AID-CNCR2820520420>3.0.CO;2-E; Pilichowska M, 1997, MODERN PATHOL, V10, P969; Pircher TJ, 1999, MOL ENDOCRINOL, V13, P555, DOI 10.1210/mend.13.4.0263; Richer JK, 1998, J BIOL CHEM, V273, P31317, DOI 10.1074/jbc.273.47.31317; Robertson D, 1998, NAT BIOTECHNOL, V16, P615, DOI 10.1038/nbt0798-615; Robertson KW, 1996, CANCER RES, V56, P3823; Ross, 1998, Oncologist, V3, P237; SALOMON DS, 1984, CANCER RES, V44, P4069; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; Schroeder JA, 1997, J MAMMARY GLAND BIOL, V2, P119, DOI 10.1023/A:1026347629876; SHANKAR V, 1989, MOL CARCINOGEN, V2, P1, DOI 10.1002/mc.2940020102; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH GH, 1995, AM J PATHOL, V147, P1081; SMITH JA, 1989, J CELL PHYSIOL, V141, P362, DOI 10.1002/jcp.1041410218; SNEDEKER SM, 1991, P NATL ACAD SCI USA, V88, P276, DOI 10.1073/pnas.88.1.276; TELANG NT, 1990, CELL REGUL, V1, P863, DOI 10.1091/mbc.1.11.863; TODARO GJ, 1980, PROC R SOC SER B-BIO, V210, P367, DOI 10.1098/rspb.1980.0140; UMEKITA Y, 1992, VIRCHOWS ARCH A, V420, P345, DOI 10.1007/BF01600214; VALVERIUS EM, 1989, MOL ENDOCRINOL, V3, P203, DOI 10.1210/mend-3-1-203; VONDERHAAR BK, 1987, J CELL PHYSIOL, V132, P581, DOI 10.1002/jcp.1041320324; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wiesen JF, 1999, DEVELOPMENT, V126, P335; Xie W, 1997, MOL ENDOCRINOL, V11, P1766, DOI 10.1210/me.11.12.1766; Yu CL, 1997, J IMMUNOL, V159, P5206; ZAICHOWSKI DA, 1991, MOL ENDOCRINOL, V5, P1613; Zhang Q, 1996, P NATL ACAD SCI USA, V93, P9148, DOI 10.1073/pnas.93.17.9148	75	64	66	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1085	1091		10.1038/sj.onc.1203278	http://dx.doi.org/10.1038/sj.onc.1203278			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713694				2022-12-17	WOS:000085796400016
J	Sert, V; Cans, C; Tasca, C; Bret-Bennis, L; Oswald, E; Ducommun, B; De Rycke, J				Sert, V; Cans, C; Tasca, C; Bret-Bennis, L; Oswald, E; Ducommun, B; De Rycke, J			The bacterial cytolethal distending toxin (CDT) triggers a G2 cell cycle checkpoint in mammalian cells without preliminary induction of DNA strand breaks	ONCOGENE			English	Article						CDT; etoposide; G2 checkpoint; DNA damage; cyclin dependent kinase	PROTEIN-KINASE; NITROGEN-MUSTARD; CYTO-TOXICITY; HELA-CELLS; DAMAGE; ETOPOSIDE; REPLICATION; PHOSPHORYLATION; MITOSIS; REPAIR	The bacterial cytolethal distending toxin (CDT) was previously shown to arrest the tumor-derived HeLa cell line in the G2-phase of the cell cycle through inactivation of CDK1, a cyclin-dependent kinase whose state of activation determines entry into mitosis. We have analysed the effects induced in HeLa cells by CDT, in comparison to those induced by etoposide, a prototype anti-tumoral agent that triggers a G2 cell cycle checkpoint by inducing DNA damage. Both CDT and etoposide inhibit cell proliferation and induces the formation of enlarged mononucleated cells blocked in G2. In both cases, CDK1 from arrested cells could be reactivated both in vitro by dephosphorylation by recombinant Cdc25B phosphatase and in vivo by caffeine. However, the cell cycle arrest triggered by CDT, unlike etoposide, did not originate from DNA strand breaks as demonstrated in the single cell gel electrophoresis assay and by the absence of slowing down of S phase in synchronized cells, Together with additional observations on synchronized HeLa cells, our results suggest that CDT triggers a G2 cell cycle checkpoint that is initiated during DNA replication and that is independent of DNA damage.	INRA, Unite Associee Microbiol Mol, F-31076 Toulouse, France; Ecole Natl Vet, F-31076 Toulouse, France; INRA, Unite Associee Secur & Hyg Aliments, F-31076 Toulouse, France; Ecole Vet, F-31076 Toulouse, France; CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France	INRAE; Universite de Toulouse; Ecole Nationale Veterinaire de Toulouse; INRAE; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)	De Rycke, J (corresponding author), INRA, Unite Associee Microbiol Mol, 23 Chemin Capelles, F-31076 Toulouse, France.		DUCOMMUN, Bernard/B-3208-2008	Oswald, Eric/0000-0002-3017-0081; DUCOMMUN, Bernard/0000-0002-7126-8368				Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Barratt RA, 1998, CANCER RES, V58, P2639; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; Comayras C, 1997, INFECT IMMUN, V65, P5088, DOI 10.1128/IAI.65.12.5088-5095.1997; Cortes-Bratti X, 1999, J CLIN INVEST, V103, P107, DOI 10.1172/JCI3831; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; DOWNES CS, 1990, J CELL BIOL, V110, P1855, DOI 10.1083/jcb.110.6.1855; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FINGERT HJ, 1986, CANCER RES, V46, P2463; Friedrich TD, 1998, CYTOMETRY, V31, P260, DOI 10.1002/(SICI)1097-0320(19980401)31:4<260::AID-CYTO5>3.0.CO;2-N; GABRIELLI B, 1994, ADV PROT PHOSPHATASE, V8, P209; Gragerov A, 1998, VIROLOGY, V245, P323, DOI 10.1006/viro.1998.9138; ISHIDA R, 1994, J CELL BIOL, V126, P1341, DOI 10.1083/jcb.126.6.1341; Kaufmann WK, 1998, MUTAT RES-FUND MOL M, V400, P153, DOI 10.1016/S0027-5107(98)00041-4; KNEHR M, 1995, EXP CELL RES, V217, P546, DOI 10.1006/excr.1995.1121; Kumagai A, 1998, J CELL BIOL, V142, P1559, DOI 10.1083/jcb.142.6.1559; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LOCK RB, 1993, INT J ONCOL, V3, P33; LOCK RB, 1994, CANCER RES, V54, P4933; LOCK RB, 1992, CANCER RES, V52, P1817; LONG BH, 1984, BIOCHEMISTRY-US, V23, P1183, DOI 10.1021/bi00301a024; Maity A, 1996, ONCOGENE, V13, P1647; Munoz P, 1998, MOL CELL BIOL, V18, P5797, DOI 10.1128/MCB.18.10.5797; OLIVE PL, 1990, RADIAT RES, V122, P86, DOI 10.2307/3577587; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Peres SY, 1997, MOL MICROBIOL, V24, P1095, DOI 10.1046/j.1365-2958.1997.4181785.x; Poon B, 1997, J VIROL, V71, P3961, DOI 10.1128/JVI.71.5.3961-3971.1997; Poon RYC, 1997, CANCER RES, V57, P5168; SAELINGER CB, 1990, TRAFFICKING BACTERIA; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SCOTT DA, 1994, INFECT IMMUN, V62, P244, DOI 10.1128/IAI.62.1.244-251.1994; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Vock EH, 1998, MUTAT RES-GEN TOX EN, V413, P83, DOI 10.1016/S1383-5718(98)00019-9; Whitehouse CA, 1998, INFECT IMMUN, V66, P1934, DOI 10.1128/IAI.66.5.1934-1940.1998; WithersWard ES, 1997, J VIROL, V71, P9732, DOI 10.1128/JVI.71.12.9732-9742.1997; WOZNIAK AJ, 1983, CANCER RES, V43, P120; Ye XS, 1996, EMBO J, V15, P3599, DOI 10.1002/j.1460-2075.1996.tb00729.x	42	64	65	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6296	6304		10.1038/sj.onc.1203007	http://dx.doi.org/10.1038/sj.onc.1203007			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597228				2022-12-17	WOS:000083934100013
J	Allan, LA; Fried, M				Allan, LA; Fried, M			p53-dependent apoptosis or growth arrest induced by different forms of radiation in U2OS cells: p21(WAF1/CIP1) repression in UV induced apoptosis	ONCOGENE			English	Article						p53; p21(WAF1/CIP1); UV induced apoptosis; X-ray induced growth arrest; U2OS cells; radiation	WILD-TYPE P53; P53-MEDIATED G(1) ARREST; G1 CHECKPOINT CONTROL; TUMOR-SUPPRESSOR P53; DNA-DAMAGE; CYCLE ARREST; TRANSCRIPTIONAL ACTIVATION; P53-INDUCED APOPTOSIS; MEDIATED APOPTOSIS; GAMMA-RADIATION	Following exposure to DNA damaging agents the p53 tumour-suppressor gene induces either a growth arrest (primarily in G1) or apoptosis. The factors governing which response a cell undertakes, however, are unclear. We find that the osteosarcoma cell line, U20S, (wild-type for p53) is capable of undergoing either p53 dependent apoptosis or cell cycle arrest in response to distinct forms of radiation. Following exposure to UVC, the majority of U20S cells were apoptotic within 2 days and cells continued to cycle even as viability was being lost. In contrast, after X-ray treatment, U20S cells exhibited a cell cycle arrest. Western analysis showed that p53 protein was stabilized to a greater extent by UVC than X-ray. Treatment with X-rays induced P21(WAF1/CIP1) whereas p21(WAF1/CIP1) expression was specifically repressed at the post-transcriptional level after exposure to UVC, Ectopic expression of high levels of p21(WAF1/CIP1), which arrested U20S cells in G1 and G2, initially conferred considerable protection against UVC-induced apoptosis. Ultimately, however, cells underwent apoptosis indicating that a high level of p21(WAF1/CIP1) delays but does not block apoptosis. Taken together, these results show that cell cycle arrest and apoptosis can occur in the same cell type in response to different forms of radiation and that the repression of p21(WAF1/CIP1) after UVC may contribute to the efficient induction of apoptosis in response to this particular insult.	Imperial Canc Res Fund, Eukaryot Gene Org & Express Lab, London WC2A 3PX, England	Cancer Research UK	Fried, M (corresponding author), Imperial Canc Res Fund, Eukaryot Gene Org & Express Lab, Lincolns Inn Fields, London WC2A 3PX, England.							Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Canman CE, 1998, ONCOGENE, V16, P957, DOI 10.1038/sj.onc.1201612; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Guerra B, 1997, ONCOGENE, V14, P2683, DOI 10.1038/sj.onc.1201112; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; ISFORT RJ, 1995, MOL CARCINOGEN, V14, P170, DOI 10.1002/mc.2940140306; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Lu X, 1996, ONCOGENE, V13, P413; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; Mukhopadhyay T, 1997, ONCOGENE, V14, P379, DOI 10.1038/sj.onc.1200835; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Roemer K, 1996, ONCOGENE, V12, P2069; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Vater CA, 1996, ONCOGENE, V13, P739; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALDMAN T, 1995, CANCER RES, V55, P5187; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHAN QM, 1994, ONCOGENE, V9, P3743	63	64	64	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5403	5412		10.1038/sj.onc.1202931	http://dx.doi.org/10.1038/sj.onc.1202931			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498894				2022-12-17	WOS:000082718600005
J	Taylor, WR; Agarwal, ML; Agarwal, A; Stacey, DW; Stark, GR				Taylor, WR; Agarwal, ML; Agarwal, A; Stacey, DW; Stark, GR			p53 inhibits entry into mitosis when DNA synthesis is blocked	ONCOGENE			English	Article						cell cycle; checkpoint; hydroxyurea; PALA	CELL-CYCLE ARREST; WILD-TYPE P53; S-PHASE; GENE AMPLIFICATION; PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHORYLATION; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; BUDDING YEAST	Human and mouse fibroblasts with normal p53 fail to enter mitosis when DNA synthesis is blocked by aphidicolin or hydroxyurea, Isogenic p53-null fibroblasts do enter mitosis with incompletely replicated DNA, revealing that p53 contributes to a checkpoint that ensures that mitosis does not occur until DNA synthesis is complete, When treated with N-(phosphonacetyl)-L-aspartate (PALA), which inhibits pyrimidine nucleotide synthesis, leading to synthesis of damaged DNA from highly unbalanced dNTP pools, p53-null cells enter mitosis after they have completed DNA replication, but cells with wild-type p53 do not, revealing that p53 also mediates a checkpoint that monitors the quality of newly replicated DNA.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stark, GR (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biol Mol, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049345] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-49345] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; AGARWAL ML, 1998, IN PRESS P NATL ACAD; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Anderson GR, 1995, J SURG RES, V59, P666, DOI 10.1006/jsre.1995.1221; ATTARDI LD, 1996, EMBO J, V15, P3696; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; CHADEE DN, 1995, J BIOL CHEM, V270, P20098, DOI 10.1074/jbc.270.34.20098; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; Chen GQ, 1996, BLOOD, V88, P1052; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Di Leonardo A, 1997, CANCER RES, V57, P1013; DI LEONARDO A, 1993, COLD SPRING HARB SYM, V58, P655, DOI 10.1101/SQB.1993.058.01.073; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; HAIN J, 1993, CANCER RES, V53, P1507; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARVEY M, 1993, ONCOGENE, V8, P2457; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HERZINGER T, 1995, ONCOGENE, V11, P2151; Hughes TA, 1996, EXP CELL RES, V222, P275, DOI 10.1006/excr.1996.0035; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; JACOBBERGER J W, 1991, Methods (Orlando), V2, P207, DOI 10.1016/S1046-2023(05)80063-5; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KHANNA KK, 1993, ONCOGENE, V8, P3307; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU MJ, 1994, CHROMOSOMA, V103, P111; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MARTINEAU SN, 1995, J CELL BIOL, V131, P191, DOI 10.1083/jcb.131.1.191; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; MIYASHITA T, 1995, CELL, V80, P293; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Paulson TG, 1998, MOL CELL BIOL, V18, P3089, DOI 10.1128/MCB.18.5.3089; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POON RYC, 1996, J BIOL CHEM, V271, P13282; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; Shimizu N, 1998, J CELL BIOL, V140, P1307, DOI 10.1083/jcb.140.6.1307; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; STEWART N, 1995, ONCOGENE, V10, P109; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	82	64	66	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					283	295		10.1038/sj.onc.1202516	http://dx.doi.org/10.1038/sj.onc.1202516			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927185				2022-12-17	WOS:000078166500001
J	Somerville, RPT; Shoshan, Y; Eng, C; Barnett, G; Miller, D; Cowell, JK				Somerville, RPT; Shoshan, Y; Eng, C; Barnett, G; Miller, D; Cowell, JK			Molecular analysis of two putative tumour suppressor genes, PTEN and DMBT, which have been implicated in glioblastoma multiforme disease progression	ONCOGENE			English	Article						glioma; PTEN; DMBT; mutation; tumour suppressor; 10q24-26	GERMLINE MUTATIONS; HUMAN GLIOMAS; HEREDITARY RETINOBLASTOMA; BRAIN-TUMORS; CHROMOSOME-10; HETEROZYGOSITY; PHOSPHATASE; REGIONS; LOCI	The transition from low grade astrocytoma to glioblastoma multiforme is almost always accompanied by the loss of genetic markers from chromosome 10. Recently two genes, PTEN/MMAC1/TEP1 and DMBT, have been isolated from chromosome 10q. We have analysed these two genes for mutations in 21 primary glioblastomas, An exon by exon screen of the PTEN gene using SSCP failed to identify any mutations in this tumour series, In contrast, 38% of tumours showed intragenic homozygous deletions in the DMBT gene, The fact that the majority of gliomas do not carry mutations in either of these genes suggests that there may still be other genes on chromosome 10 which are important in the development of glioblastoma multiforme.	Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurosurg, Cleveland, OH 44195 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Somerville, RPT (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, 9500 Euclid Ave,NC30, Cleveland, OH 44195 USA.			Eng, Charis/0000-0002-3693-5145; Cowell, John/0000-0002-2079-5950				Albarosa R, 1996, AM J HUM GENET, V58, P1260; Baird Paul N., 1992, Human Molecular Genetics, V1, P301, DOI 10.1093/hmg/1.5.301; BIGNER SH, 1988, CANCER RES, V48, P405; BIGNER SH, 1990, CANCER GENET CYTOGEN, V47, P141, DOI 10.1016/0165-4608(90)90024-5; CHERNOVA O, 1998, IN PRESS CANC GENET; Cowell John K., 1994, European Journal of Human Genetics, V2, P281; DAVIS A, 1993, HUM MOL GENET, V2, P2093, DOI 10.1093/hmg/2.12.2093; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; HOGG A, 1992, ONCOGENE, V7, P1444; JAMES CD, 1988, CANCER RES, V48, P5546; KARLBOM AE, 1993, HUM GENET, V92, P169; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Li DM, 1997, CANCER RES, V57, P2124; LI J, 1997, SCIENCE, V275, P1945; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LIU ZX, 1995, GENE CHROMOSOME CANC, V14, P277, DOI 10.1002/gcc.2870140406; Louis David N., 1997, P2013; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P357, DOI 10.1002/gcc.2870050412; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; Rasheed BKA, 1997, CANCER RES, V57, P4187; RASHEED BKA, 1995, ONCOGENE, V10, P2243; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STECK PA, 1995, GENE CHROMOSOME CANC, V12, P255; WANG SI, 1997, CANCER RES, V57, P4138	28	64	64	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1755	1757		10.1038/sj.onc.1202066	http://dx.doi.org/10.1038/sj.onc.1202066			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796706				2022-12-17	WOS:000076200100015
J	El-Naggar, AK; Coombes, MM; Batsakis, JG; Hong, WK; Goepfert, H; Kagan, J				El-Naggar, AK; Coombes, MM; Batsakis, JG; Hong, WK; Goepfert, H; Kagan, J			Localization of chromosome 8p regions involved in early tumorigenesis of oral and laryngeal squamous carcinoma	ONCOGENE			English	Article						oral and laryngeal; chromosome 8p; squamous carcinoma; microsatellite; loss of heterozygosity	TUMOR-SUPPRESSOR GENES; PROSTATIC INTRAEPITHELIAL NEOPLASIA; CELL CARCINOMAS; ALLELIC LOSS; FREQUENT LOSS; SHORT ARM; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; BREAST-CANCER; NECK-CANCER	We analysed 30 primary invasive oral and laryngeal squamous carcinomas (SC), with concurrent dysplastic Lesions, for genetic alterations at 15 microsatellite loci on the short arm of chromosome 8. Overall, loss of heterozygosity (LOH) was observed, in at least one informative locus, in 27% of the dysplastic lesions and in 67% of the invasive carcinomas. The highest frequency of allele tosses in dysplasia (20% and 17%), and invasive carcinoma (40% and 48%) were detected in the same D8S298 and LPL-tet loci located on chromosomes 8p21 and 8p22 respectively. The minimal region with LOH was limited to 4.6 megaBases (mBs) at 8p22 and 7.1 mBs at 8p21. In addition, allelic losses in both dysplastic and corresponding invasive specimens were noted at the same loci in some tumors suggesting their emergence from a common preneoplastic clone. Allele losses correlated significantly with male gender, oral and laryngeal sites and high proliferative index. The data suggest that inactivation of tumor suppressor gene(s), within these loci, may constitute an early event in the evolution of oral and laryngeal SC.	Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Lab Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	El-Naggar, AK (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Pathol, Houston, TX 77030 USA.				NIH HHS [1P5ODE11906-01] Funding Source: Medline	NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ALSEE KW, 1994, CANCER RES, V54, P1617; Bockmuhl U, 1996, CANCER RES, V56, P5325; Bova GS, 1996, GENOMICS, V35, P46, DOI 10.1006/geno.1996.0321; BRZOSKA PM, 1995, CANCER RES, V55, P3055; Califano J, 1996, CANCER RES, V56, P2488; CHANG M, 1994, AM J PATHOL, V144, P1; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; COWAN JM, 1992, J NATL CANCER I, V84, P793, DOI 10.1093/jnci/84.10.793; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; ELNAGGAR AK, 1995, CANCER RES, V55, P2656; EMI M, 1992, CANCER RES, V52, P5368; EMMERTBUCK MR, 1995, CANCER RES, V55, P2959; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIELD JK, 1995, BRIT J CANCER, V72, P1180, DOI 10.1038/bjc.1995.483; FUJIWARA Y, 1995, ONCOGENE, V10, P891; Gustafson CE, 1996, CANCER RES, V56, P5238; ICHIKAWA T, 1994, CANCER RES, V54, P2299; JIN YS, 1995, CANCER RES, V55, P3204; KAGAN J, 1995, ONCOGENE, V11, P2121; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; KERANGUEVEN F, 1994, ONCOL REP, V1, P393; KIARIS H, 1994, INT J ONCOL, V5, P1243; Kishimoto Y, 1996, J CANCER RES CLIN, V122, P585, DOI 10.1007/BF01221189; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LEVINE AJ, 1992, CANC SURVEYS, V12; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; MacGrogan D, 1996, GENOMICS, V35, P55, DOI 10.1006/geno.1996.0322; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MERLO GR, 1992, AM J PATHOL, V140, P215; NAWROZ H, 1994, CANCER RES, V54, P1617; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; RADFORD DM, 1995, CANCER RES, V55, P5180; RAO PH, 1994, CANCER GENET CYTOGEN, V77, P60, DOI 10.1016/0165-4608(94)90150-3; SAKR WA, 1994, IN VIVO, V8, P439; Scholnick SB, 1996, J NATL CANCER I, V88, P1676, DOI 10.1093/jnci/88.22.1676; Scully C, 1997, INT J ONCOL, V10, P5; SPEICHER MR, 1995, CANCER RES, V55, P1010; SREEKANTAIAH C, 1994, GENE CHROMOSOME CANC, V11, P29, DOI 10.1002/gcc.2870110106; Sunwoo JB, 1996, GENE CHROMOSOME CANC, V16, P164, DOI 10.1002/(SICI)1098-2264(199607)16:3<164::AID-GCC2>3.0.CO;2-X; SUZUKI H, 1995, GENE CHROMOSOME CANC, V13, P168, DOI 10.1002/gcc.2870130306; TAMAKO K, 1996, ONCOGENE, V12, P405; TRAGANOS F, 1977, J HISTOCHEM CYTOCHEM, V25, P46, DOI 10.1177/25.1.64567; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WOOD S, 1994, GENOMICS, V24, P597, DOI 10.1006/geno.1994.1673; YAREMKO ML, 1995, GENE CHROMOSOME CANC, V13, P186, DOI 10.1002/gcc.2870130308; YAREMKO ML, 1994, GENE CHROMOSOME CANC, V10, P1, DOI 10.1002/gcc.2870100102	47	64	65	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 11	1998	16	23					2983	2987		10.1038/sj.onc.1201808	http://dx.doi.org/10.1038/sj.onc.1201808			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZT782	9662330				2022-12-17	WOS:000074125300004
J	Huang, HJ; Qian, JQ; Proffit, J; Wilber, K; Jenkins, R; Smith, DI				Huang, HJ; Qian, JQ; Proffit, J; Wilber, K; Jenkins, R; Smith, DI			FRA7G extends over a broad region: coincidence of human endogenous retroviral sequences (HERV-H) and small polydispersed circular DNAs (spcDNA) and fragile sites	ONCOGENE			English	Article						chromosome fragility; FRA7G; spcDNA; human endogenous retroviral sequence; fluorescence in situ hybridization	TUMOR-SUPPRESSOR GENE; HUMAN-CHROMOSOMES; FREQUENT LOSS; X-SYNDROME; PROSTATE-CANCER; BREAST-CANCER; FHIT GENE; INTEGRATION; 3P14.2; CELL	FRA7G is an aphidicolin-inducible common fragile site at human chromosomal band 7q31.2. This region is frequently altered in a number of different tumor types including prostate, breast, and ovarian cancer. It has also been hypothesized that this region contains an important tumor suppressor gene which is mutated during the development of these cancers or an oncogene which is amplified, We previously used a FISH-based approach to isolate YAC clones which spanned FRA7G. In this report, we describe the Isolation and restriction endonuclease mapping of three overlapping P1 clones which cover FRA7G and the region frequently altered in the different cancers. FISH-based analysis of these clones reveals that aphidicolin-induced breakage in the FRA7G region occurs over a region of at least 300 Kb in length, We have also localized a previously sequenced BAC clone to this region. The sequence obtained from this clone reveals the presence of an endogenous retroviral sequence (HERV-H) in the midst of the FRA7G region as well as sequences with homology to small polydispersed circular DNAs (spcDNAs). Thus for the first two cloned common fragile sites, FRA7G and FRA3B, there is an association with both spcDNAs and hot-spots for viral integration.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, Rochester, MN 55905 USA; Vysis Inc, Downers Grove, IL USA	Mayo Clinic	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL CANCER INSTITUTE [R01CA048031, P20CA058225] Funding Source: NIH RePORTER; NCI NIH HHS [CA58225, CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; BOLDOG FL, 1994, GENE CHROMOSOME CANC, V11, P216, DOI 10.1002/gcc.2870110403; CANNIZZARO LA, 1988, CANCER GENET CYTOGEN, V33, P93, DOI 10.1016/0165-4608(88)90054-4; CAPOROSSI D, 1991, CANCER GENET CYTOGEN, V54, P39, DOI 10.1016/0165-4608(91)90028-S; CHAMPEME MH, 1995, GENE CHROMOSOME CANC, V12, P304, DOI 10.1002/gcc.2870120411; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Cohen S, 1996, MOL CELL BIOL, V16, P2002; Devilee P, 1997, GENE CHROMOSOME CANC, V18, P193; DURNAM D, 1986, CANCER CELL, V4, P349; GLOVER TW, 1984, HUM GENET, V67, P882; GREEN ED, 1991, GENOMICS, V11, P548, DOI 10.1016/0888-7543(91)90062-J; GREEN ED, 1994, HUM MOL GENET, V3, P489, DOI 10.1093/hmg/3.3.489; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; HIRSCH B, 1991, HUM GENET, V87, P302; HUANG H, 1998, IN PRESS GENES CHROM; JONES C, 1994, HUM MOL GENET, V3, P2123, DOI 10.1093/hmg/3.12.2123; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; JONES NJ, 1990, MUTAGENESIS, V5, P15, DOI 10.1093/mutage/5.1.15; Kastury K, 1996, CANCER RES, V56, P978; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; KUWANO A, 1990, HUM GENET, V84, P527; LAIRD C, 1987, TRENDS GENET, V3, P274, DOI 10.1016/0168-9525(87)90268-X; LATIL A, 1995, B CANCER, V82, P589; LEBEAU MM, 1998, IN PRESS HUM MOL GEN; LEDBETTER SA, 1990, GENOMICS, V8, P614, DOI 10.1016/0888-7543(90)90247-R; Lin JC, 1996, ONCOGENE, V13, P2001; MacLaren DC, 1996, GENOMICS, V35, P299, DOI 10.1006/geno.1996.0360; NANCARROW JK, 1994, SCIENCE, V264, P1938, DOI 10.1126/science.8009225; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Pandis N, 1997, GENE CHROMOSOME CANC, V18, P241, DOI 10.1002/(SICI)1098-2264(199704)18:4<241::AID-GCC1>3.3.CO;2-7; Paradee W, 1996, GENOMICS, V35, P87, DOI 10.1006/geno.1996.0326; PENNY LA, 1995, AM J HUM GENET, V56, P676; RASSOOL FV, 1991, P NATL ACAD SCI USA, V88, P6657, DOI 10.1073/pnas.88.15.6657; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; RASSOOL FV, 1992, AM J HUM GENET, V50, P1243; RITCHIE RJ, 1994, HUM MOL GENET, V3, P2115, DOI 10.1093/hmg/3.12.2115; Sambrook J, 1989, MOL CLONING LAB MANU; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; SHIFMAN MI, 1995, J NEUROSCI METH, V59, P205, DOI 10.1016/0165-0270(94)00184-I; Shridhar R, 1996, CANCER RES, V56, P4347; Shridhar V, 1997, ONCOGENE, V14, P1269, DOI 10.1038/sj.onc.1201100; SMEETS DFCM, 1986, HUM GENET, V72, P215, DOI 10.1007/BF00291880; SMITH PP, 1992, GENE CHROMOSOME CANC, V5, P150, DOI 10.1002/gcc.2870050209; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; SUNNERHAGEN P, 1989, SOMAT CELL MOLEC GEN, V15, P61, DOI 10.1007/BF01534670; SUTHERLAND GR, 1995, OXFORD MONOGRAPHS ME, V13; TAKAHASHI S, 1995, CANCER RES, V55, P4114; VANDERDRIFT P, 1994, HUM MOL GENET, V3, P2131, DOI 10.1093/hmg/3.12.2131; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WAGATSUMA M, 1990, J VIROL, V64, P813, DOI 10.1128/JVI.64.2.813-821.1990; Wang L, 1997, GENOMICS, V41, P485, DOI 10.1006/geno.1997.4690; WANG L, 1998, IN PRESS ONCOGENE; WILKE CM, 1996, HUM MOL GENET, V5, P973; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; Yu S, 1997, CELL, V88, P367, DOI 10.1016/S0092-8674(00)81875-9; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zimonjic DB, 1997, CANCER RES, V57, P1166	65	64	67	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2311	2319		10.1038/sj.onc.1200202	http://dx.doi.org/10.1038/sj.onc.1200202			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620548				2022-12-17	WOS:000073428000003
J	Zhao, JQ; Hoare, SF; McFarlane, R; Muir, S; Parkinson, EK; Black, DM; Keith, WN				Zhao, JQ; Hoare, SF; McFarlane, R; Muir, S; Parkinson, EK; Black, DM; Keith, WN			Cloning and characterization of human and mouse telomerase RNA gene promoter sequences	ONCOGENE			English	Article						telomerase; gene expression; hTR; terc; gene promoter; gene transcription	IMMORTAL CELL-LINES; HUMAN-FIBROBLASTS; TRANSCRIPTION; ACTIVATION; MECHANISM; TISSUES; DRUGS; AP-1; RAS	Variation in telomerase activity is correlated with cellular senescence and tumour progression. However, although the enzymatic activity of telomerase has been well studied, very little is known about how expression of telomerase genes is regulated in mammalian cells. We have therefore cloned the promoter regions of the human (hTR), and mouse, (terc), telomerase RNA genes in order to identify the regulatory elements controlling telomerase RNA gene transcription, 1.76 kb encompassing the hTR gene promoter region was sequenced, as was 4 kb encompassing the terc promoter. No significant sequence similarity could be detected in comparisons between human and mouse 5'-regions, flanking the transcribed sequences. However, both the human and mouse telomerase RNA genes are within CpG islands and may therefore be under the regulation of DNA methylation. Transient expression of hTR-reporter gene constructs in HeLa and GM847 cells identified the elements responsible for promoter activity are contained in a 231 bp region upstream of the transcriptional start site, Transient expression of terc-reporter gene constructs in Swiss3T3 and A9 cells identified the elements responsible for promoter activity are contained in a 73 bp region upstream of the transcriptional start site. These studies have implications for novel transcription targeted cancer therapies.	Univ Glasgow, CRC, Beatson Labs, Dept Med Oncol, Glasgow G61 1BD, Lanark, Scotland; Beatson Inst Canc Res, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; University of Glasgow; Beatson Institute	Keith, WN (corresponding author), Univ Glasgow, CRC, Beatson Labs, Dept Med Oncol, Alexander Stone Bldg,Garscube Estate,Switchback R, Glasgow G61 1BD, Lanark, Scotland.		Keith, Nicol/D-3325-2009	Keith, Nicol/0000-0001-7862-3580; Zhao, Jiangqin/0000-0003-4672-0735				Avilion AA, 1996, CANCER RES, V56, P645; BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383; Bestilny LJ, 1996, CANCER RES, V56, P3796; Bird AP, 1996, CANCER SURV, V28, P87; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; Broccoli D, 1997, HUM MOL GENET, V6, P69, DOI 10.1093/hmg/6.1.69; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; Cai WZ, 1996, CURR OPIN BIOTECH, V7, P608, DOI 10.1016/S0958-1669(96)80071-1; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Cheng AJ, 1997, BIOCHEM BIOPH RES CO, V237, P438, DOI 10.1006/bbrc.1997.7157; Connors TA, 1995, GENE THER, V2, P702; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GALANG CK, 1994, ONCOGENE, V9, P2913; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Holt SE, 1997, EUR J CANCER, V33, P761, DOI 10.1016/S0959-8049(97)00066-X; IRVING J, 1992, EXP CELL RES, V202, P161, DOI 10.1016/0014-4827(92)90415-5; Kim NW, 1997, EUR J CANCER, V33, P781, DOI 10.1016/S0959-8049(97)00057-9; Kipling D, 1997, HUM MOL GENET, V6, P1999, DOI 10.1093/hmg/6.12.1999; Kipling D, 1997, EUR J CANCER, V33, P792, DOI 10.1016/S0959-8049(97)00060-9; Kuniyasu H, 1997, JPN J CANCER RES, V88, P103, DOI 10.1111/j.1349-7006.1997.tb00353.x; LAIRD PW, 1996, ANNU REV GENET, V30, P44; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Mandal M, 1997, J BIOL CHEM, V272, P14183, DOI 10.1074/jbc.272.22.14183; Miller N, 1997, HUM GENE THER, V8, P803, DOI 10.1089/hum.1997.8.7-803; Morin GB, 1997, EUR J CANCER, V33, P750, DOI 10.1016/S0959-8049(97)00061-0; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Norrback KF, 1997, EUR J CANCER, V33, P774, DOI 10.1016/S0959-8049(97)00059-2; Pan CG, 1997, EXP CELL RES, V231, P346, DOI 10.1006/excr.1997.3475; PETERSON MG, 1993, TRENDS BIOTECHNOL, V11, P11, DOI 10.1016/0167-7799(93)90069-L; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; Sharma S, 1997, ANN ONCOL, V8, P1063, DOI 10.1023/A:1008206420505; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Soder AI, 1997, GENOMICS, V41, P293, DOI 10.1006/geno.1997.4621; Soder AI, 1997, ONCOGENE, V14, P1013, DOI 10.1038/sj.onc.1201066; SODER AI, 1997, IN RPESS ONCOGENE; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; VERTINO PM, 1994, CELL GROWTH DIFFER, V5, P1395; WASYLYK C, 1994, ONCOGENE, V9, P3665; Wellinger RJ, 1997, EUR J CANCER, V33, P735, DOI 10.1016/S0959-8049(97)00067-1; WILSON V L, 1983, Science (Washington D C), V220, P1055, DOI 10.1126/science.6844925; Wright WE, 1996, DEV GENET, V18, P173; Zakian VA, 1997, CELL, V91, P1, DOI 10.1016/S0092-8674(01)80001-5	48	64	71	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1345	1350		10.1038/sj.onc.1201892	http://dx.doi.org/10.1038/sj.onc.1201892			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546436				2022-12-17	WOS:000072422000013
J	Nakamura, H; Yoshida, M; Tsuiki, H; Ito, K; Ueno, M; Nakao, M; Oka, K; Tada, M; Kochi, M; Kuratsu, J; Ushio, Y; Saya, H				Nakamura, H; Yoshida, M; Tsuiki, H; Ito, K; Ueno, M; Nakao, M; Oka, K; Tada, M; Kochi, M; Kuratsu, J; Ushio, Y; Saya, H			Identification of a human homolog of the Drosophila neuralized gene within the 10q25.1 malignant astrocytoma deletion region	ONCOGENE			English	Article						glioma; chromosome 10q25; tumor suppressor gene; neuralized; h-neu gene	GROWTH-FACTOR RECEPTOR; HUMAN GLIOMAS; NEUROGENIC GENES; ZINC-FINGER; HETEROZYGOSITY; AMPLIFICATION; ENCODES; CHROMOSOME-10; INHIBITORS; CANDIDATE	The loss of chromosome 10 is the most frequent genetic alteration found in malignant astrocytomas, In particular, the long arm of chromosome 10 was previously reported to have two or more common deletion regions where tumor suppressor genes may be located, In this study, we performed deletion mapping of 44 malignant astrocytomas using 12 microsatellite markers on chromosome 10q and demonstrated that the minimal common region of loss of heterozygosity (LOH) was present between D10S192 and D10S566 localized at 10q25.1. Subsequently, we have identified a novel gene, termed h-neu, within the region frequently deleted and found that h-neu encodes a protein with strong homology to the Drosophila neuralized (D-neu) protein, Northern blot and RT-PCR analyses revealed that h-neu mRNA was expressed at very low levels in human malignant astrocytoma tissues and the majority of glioma cell lines examined, while normal brains expressed h-neu transcript, Furthermore, DNA sequencing analysis of the h-neu transcript revealed one of the glioma cell lines, U251MG, had a single nucleotide substitution which resulted in an amino acid change from glycine (GGC) to serine (AGC) at codon 253, The D-neu gene is known to serve a critical function in neurogenesis in Drosophila, and loss-of-function mutations produce hyperplasia of primitive neuronal cells, These observations led us to hypothesize that h-neu gene plays a role in determination of cell fate in the human central nervous system and may act as a tumor suppressor whose inactivation could be associated with malignant progression of astrocytic tumors.	Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 860, Japan; Kumamoto Univ, Sch Med, Dept Neurosurg, Kumamoto 860, Japan; Nakamura Mem Hosp, Dept Neurosurg, Sapporo, Hokkaido 060, Japan; Hokkaido Univ, Sch Med, Dept Neurosurg, Sapporo, Hokkaido 060, Japan	Kumamoto University; Kumamoto University; Hokkaido University	Saya, H (corresponding author), Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, 2-2-1 Honjo, Kumamoto 860, Japan.		Saya, Hideyuki/J-4325-2013					Albarosa R, 1996, AM J HUM GENET, V58, P1260; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; BOULIANNE GL, 1991, EMBO J, V10, P2975, DOI 10.1002/j.1460-2075.1991.tb07848.x; COLLINS VP, 1993, FASEB J, V7, P926, DOI 10.1096/fasebj.7.10.8344489; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; FLEMING TP, 1992, CANCER RES, V52, P4550; Frank S, 1997, CANCER RES, V57, P2638; FULTS D, 1990, CANCER RES, V50, P5784; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; KANNO M, 1995, EMBO J, V14, P5672, DOI 10.1002/j.1460-2075.1995.tb00254.x; KARLBOM AE, 1993, HUM GENET, V92, P169; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; LI YJ, 1995, ONCOGENE, V11, P597; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; Makino K, 1997, ONCOGENE, V14, P2425, DOI 10.1038/sj.onc.1201087; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; PREISS A, 1988, EMBO J, V7, P3917, DOI 10.1002/j.1460-2075.1988.tb03278.x; PRICE BD, 1993, EMBO J, V12, P2411, DOI 10.1002/j.1460-2075.1993.tb05895.x; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RASHEED BKA, 1994, CANCER RES, V54, P1324; REED PW, 1994, NAT GENET, V7, P390, DOI 10.1038/ng0794-390; Reifenberger J, 1996, J NEUROPATH EXP NEUR, V55, P822, DOI 10.1097/00005072-199607000-00007; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; Sonoda Y, 1996, JPN J CANCER RES, V87, P363, DOI 10.1111/j.1349-7006.1996.tb00231.x; SONODA Y, 1995, ONCOGENE, V11, P2145; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; TAKAHASHI M, 1988, ONCOGENE, V3, P571; USHIO Y, 1991, Current Opinion in Oncology, V3, P467, DOI 10.1097/00001622-199106000-00005	33	64	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	1998	16	8					1009	1019		10.1038/sj.onc.1201618	http://dx.doi.org/10.1038/sj.onc.1201618			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519875	Bronze			2022-12-17	WOS:000072335900007
J	Paciucci, R; Tora, M; Diaz, VM; Real, FX				Paciucci, R; Tora, M; Diaz, VM; Real, FX			The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro	ONCOGENE			English	Article						tissue-type plasminogen activator; urokinase-type plasminogen activator; urokinase receptor; annexin II; invasion; pancreas cancer	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; ENDOTHELIAL-CELL RECEPTOR; UROKINASE-RECEPTOR; ANNEXIN-II; EXTRACELLULAR-MATRIX; GENE-TRANSCRIPTION; CARCINOMA-CELLS; GLYCOSYL-PHOSPHATIDYLINOSITOL; COLON ADENOCARCINOMAS	Plasminogen activators (PAs) play an important role in tumor cell invasion, We have analysed the expression of tissue-type PA (t-PA), urokinase-type PA (u-PA), and their respective receptors, annexin II and u-PAR, in normal and neoplastic cultures of pancreatic cells, as well as in pancreatic tissues, and have examined their role in tumor invasiveness in vitro. Using Northern blotting, Western blotting, and ELISA, t-PA is detected in cultured pancreas cancer cells displaying a well differentiated phenotype but it is undetectable in less differentiated cells and in normal pancreatic cultures, In contrast, u-PA transcripts, protein, and enzymatic activity are detected both in cancer cells and in normal cultures, Higher levels of u-PAR and annexin II are present in cancer cells than in normal cultures and, in SK-PC-1 cells, both receptors are localized in the basolateral membrane, In vitro invasion assays indicate that both t-PA and u-PA contribute to the invasiveness of SK-PC-1 cells through reconstituted extracellular matrix, To determine the relevance of these studies to pancreas cancer, immunohistochemical assays have been used to examine the expression of t-PA, u-PA, and their receptors in normal and neoplastic tissues, t-PA is absent from normal pancreas and from tumor associated pancreatitis, whereas it is detected in the majority of pancreas cancer tissues (16/17), Annexin II is also overexpressed in some tumors (5/13), u-PAR is overexpressed in most tumor samples examined (14/15), while u-PA is weakly detected in a low number of cases (3/14); both u-PAR and u-PA are overexpressed in areas of tumor associated pancreatitis, Indirect evidences indicate that K-ras and p53 mutated proteins can regulate the expression of PAs, In pancreatic cancer we have found an association between codon 12 K-ras mutations and t-PA expression (P=0.04). These results support the contention that, in the exocrine pancreas, activation of t-PA is more specifically associated to neoplastic transformation and to the invasive phenotype, whereas the induction of u-PA/u-PAR system might be more relevant to inflammatory or non-neoplastic events.	Inst Municipal Invest Med, Unit Biol Cellular & Mol, E-08003 Barcelona, Spain		Paciucci, R (corresponding author), Inst Municipal Invest Med, Unit Biol Cellular & Mol, E-08003 Barcelona, Spain.		Arribas, Francisco X Real/H-5275-2015; Díaz, Víctor Manuel/F-5013-2016; Paciucci, Rosanna/AGP-3844-2022	Arribas, Francisco X Real/0000-0001-9501-498X; Díaz, Víctor Manuel/0000-0001-8561-7576; Paciucci, Rosanna/0000-0001-5651-5933				AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BERROZPE G, 1994, INT J CANCER, V58, P185, DOI 10.1002/ijc.2910580207; Blasi Francesco, 1996, Seminars in Thrombosis and Hemostasis, V22, P513, DOI 10.1055/s-2007-999053; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CALDAS C, 1994, CANCER RES, V54, P3568; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARRATO C, 1994, GASTROENTEROLOGY, V107, P160, DOI 10.1016/0016-5085(94)90073-6; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Davis RG, 1995, J IMMUNOL METHODS, V188, P91, DOI 10.1016/0022-1759(95)00207-3; DEVRIES TJ, 1994, AM J PATHOL, V144, P70; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRIESS H, 1996, PANCREATIC CANC MOL, P51; GRESS TM, 1995, INT J CANCER, V62, P407, DOI 10.1002/ijc.2910620409; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; Hajjar KA, 1996, J BIOL CHEM, V271, P21652, DOI 10.1074/jbc.271.35.21652; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOORENS A, 1993, AM J PATHOL, V143, P685; HSU DW, 1995, AM J PATHOL, V147, P114; JANKUN J, 1991, CANCER RES, V51, P1221; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; KALTHOFF H, 1993, ONCOGENE, V8, P289; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; LENGYEL E, 1995, J BIOL CHEM, V270, P23007, DOI 10.1074/jbc.270.39.23007; LIMONGI P, 1995, FEBS LETT, V369, P207, DOI 10.1016/0014-5793(95)00742-R; LISANTI MP, 1990, J MEMBRANE BIOL, V113, P155, DOI 10.1007/BF01872889; LUND LR, 1991, EMBO J, V10, P3399, DOI 10.1002/j.1460-2075.1991.tb04904.x; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; Malats N, 1997, INT J CANCER, V70, P661, DOI 10.1002/(SICI)1097-0215(19970317)70:6<661::AID-IJC6>3.0.CO;2-T; MARS WM, 1993, AM J PATHOL, V143, P949; MEDCALF RL, 1991, MOL ENDOCRINOL, V5, P1773, DOI 10.1210/mend-5-12-1773; MEDCALF RL, 1990, J BIOL CHEM, V265, P14618; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MOSER TL, 1994, INT J CANCER, V56, P552, DOI 10.1002/ijc.2910560415; Moss SE, 1997, TRENDS CELL BIOL, V7, P87, DOI 10.1016/S0962-8924(96)10049-0; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; Nielsen BS, 1996, LAB INVEST, V74, P168; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1991, J CELL BIOL, V115, P1107, DOI 10.1083/jcb.115.4.1107; Paciucci R, 1996, FEBS LETT, V385, P72, DOI 10.1016/0014-5793(96)00352-3; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; PARKKINEN J, 1991, J BIOL CHEM, V266, P16730; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PITTMAN RN, 1995, J NEUROCHEM, V64, P566; PLOUG M, 1991, J BIOL CHEM, V266, P1926; POLLANEN J, 1987, J CELL BIOL, V104, P1085, DOI 10.1083/jcb.104.4.1085; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; PYKE C, 1995, CANCER RES, V55, P4132; PYKE C, 1991, AM J PATHOL, V138, P1059; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; STURZEBECHER J, 1988, FIBRINOLYSIS, V2, P49; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; VERSPAGET HW, 1995, EUR J CANCER, V31A, P1105, DOI 10.1016/0959-8049(95)00170-N; Vila Maya R., 1994, Zentralblatt fuer Pathologie, V140, P225; VILA MR, 1994, LAB INVEST, V71, P423; VILA MR, 1995, LAB INVEST, V72, P395; VILA MR, 1995, LAB INVEST, V73, P409; VISHWANATHA JK, 1993, CARCINOGENESIS, V14, P2575, DOI 10.1093/carcin/14.12.2575; WANG Y, 1994, FEBS LETT, V353, P138, DOI 10.1016/0014-5793(94)01032-3; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WILSON EL, 1983, BLOOD, V61, P568; WILSON EL, 1987, J EXP MED, V165, P1609, DOI 10.1084/jem.165.6.1609	78	64	65	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					625	633		10.1038/sj.onc.1201564	http://dx.doi.org/10.1038/sj.onc.1201564			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482108				2022-12-17	WOS:000071816600007
J	O'Hagan, RC; Hassell, JA				O'Hagan, RC; Hassell, JA			The PEA3 Ets transcription factor is a downstream target of the HER2/Neu receptor tyrosine kinase	ONCOGENE			English	Article						PEA3; Ets; breast cancer; c-ErbB-2/HER2/Neu; tumorigenesis; metastasis	HUMAN-BREAST-CANCER; ACTIVATED PROTEIN-KINASE; MAP KINASE; NEU ONCOGENE; POINT MUTATION; EWINGS-SARCOMA; DNA-BINDING; CHROMOSOME-TRANSLOCATION; SIGNALING PATHWAY; MOLECULAR-CLONING	The HER2/neu gene, which is overexpressed in 20-30% of human breast tumors, encodes a receptor tyrosine kinase that functions through multiple signaling pathways to regulate the activity of nuclear transcription factors. We have reported that PEAS, an Ets family transcription factor, is overexpressed in HER2/Neu-induced breast tumors and their metastases. To account for the increased levels of PEA3 in these turners we have suggested that HER2/Neu enhances PEAS transcriptional activity, which then acts to stimulate expression of the PEAS gene. This hypothesis is consistent with the occurrence of PEAS binding sites in the PEAS promoter and with the ability of PEA3 to transactivate this promoter. To learn whether HER2/Neu indeed regulates PEAS activity we measured the capacity of constitutively-activated HER2/Neu to affect PEAS-dependent reporter gene expression. Coexpression of PEA3 and HER2/Neu stimulated PEA3-dependent reporter gene expression to a much greater extent than did either protein alone suggesting that HER2/Neu upregulates the transcriptional activity of PEAS. To define the pathway whereby HER2/Neu functions we employed dominant-negative mutants of signaling proteins known to be downstream of HER2/Neu. Overexpression of Rap1a, a Pas-related protein capable of antagonizing Pas function, completely inhibited the ability of HER2/Neu to stimulate PEAS-dependent gene expression. Pas is known to stimulate at least two mitogen-activated protein kinase (MAPK) cascades, the extracellular-regulated kinase (ERK) cascade and the stress-activated kinase (SAPK) or Jun kinase (JNK) cascade. Similarly, HER2/Neu activated both ERKs and SAPKs/JNKs in a Pas-dependent fashion. Dominant-inhibitory mutants in either the ERK or SAPK/JNK cascades partially inhibited HER2/Neu activation of PEAS-dependent gene expression. These findings suggest that HER2/Neu regulates PEA3 activity through two different Ras-dependent MAPK pathways.	McMaster Univ, Inst Mol Biol & Biotechnol, Canc Res Grp, Hamilton, ON L8S 4K1, Canada	McMaster University	Hassell, JA (corresponding author), McMaster Univ, Inst Mol Biol & Biotechnol, Canc Res Grp, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.							BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENZ CC, 1997, IN PRESS ONCOGENE; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; IGLEHART JD, 1990, CANCER RES, V50, P6701; JANES PW, 1994, ONCOGENE, V9, P3601; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; Kaya M, 1996, ONCOGENE, V12, P221; KING CR, 1989, CANCER RES, V49, P4185; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU E, 1992, ONCOGENE, V7, P1027; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATRISIAN LM, 1994, ANN NY ACAD SCI, V91, P10129; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MONTE D, 1994, ONCOGENE, V9, P1397; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; OHagan RC, 1996, ONCOGENE, V13, P1323; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RICCI A, 1995, ONCOGENE, V11, P1519; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITE MRA, 1992, ONCOGENE, V7, P677; XIE YM, 1995, ONCOGENE, V10, P2409; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YAN MH, 1994, NATURE, V372, P798; ZHANG S, 1995, MOL CELL BIOL, V15, P4623	69	64	66	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					301	310		10.1038/sj.onc.1201547	http://dx.doi.org/10.1038/sj.onc.1201547			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467955				2022-12-17	WOS:000071582100002
J	Zauberman, A; Oren, M; Zipori, D				Zauberman, A; Oren, M; Zipori, D			Involvement of p21(WAF1/Cip1), CDK4 and Rb in activin A mediated signaling leading to hepatoma cell growth inhibition	ONCOGENE			English	Article						activin A; hepatoma; p21(WAF1/Cip1); CDK4; Rb; p53	ERYTHROID-DIFFERENTIATION FACTOR; RAT SEMINIFEROUS EPITHELIUM; CYCLIN-DEPENDENT KINASES; TGF-BETA; RETINOBLASTOMA PROTEIN; MESODERM INDUCTION; MESSENGER-RNA; DNA-SYNTHESIS; EXPRESSION; IDENTIFICATION	Cytokines are growth inhibitory in a target cell specific manner. The signaling pathways that characterize each cell type play a crucial role in determining the responsiveness to cytokine triggering. Activin A has been shown to suppress the growth of primary hepatocytes, Similarly, the human HepG2 hepatoma cell line was growth arrested by activin A as judged by lack of cell proliferation and suppression of DNA synthesis. In HepG2 cells activin A further induced accumulation of retinoblastoma protein in the hypophosphorylated form known to prevent entrance into S phase. This finding implies the involvement of cyclin dependent kinases and CDK inhibitors. Examination of HepG2 cells following addition of activin A revealed reduced expression of CDK4 and conversely, an increase in the CKI p21(WAF1/Cip1). This accumulation of p21(WAF1/Cip1) protein was partly due to increased transcriptional activity. Functional inactivation of p53, using a miniprotein that oligomerizes with p53 and abrogates DNA binding, abolished the ability of activin A to induce transcriptional activation from the p21(WAF1/Cip1) promoter. Thus, activin A, like transforming growth factor beta, seems to suppress cell growth through the downstream target Rb. However, each of these cytokines seem to operate through a distinct pathway.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ASASHIMA M, 1990, NATURWISSENSCHAFTEN, V77, P389, DOI 10.1007/BF01135742; Attisano L, 1996, MOL CELL BIOL, V16, P1066; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BHASIN S, 1989, ENDOCRINOLOGY, V124, P987, DOI 10.1210/endo-124-2-987; BROSH N, 1995, J BIOL CHEM, V270, P29594, DOI 10.1074/jbc.270.49.29594; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chun SY, 1996, ENDOCRINOLOGY, V137, P1447, DOI 10.1210/en.137.4.1447; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUJIMOTO K, 1991, BIOCHEM BIOPH RES CO, V174, P1163, DOI 10.1016/0006-291X(91)91543-L; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; HASHIMOTO M, 1993, ENDOCRINOLOGY, V133, P1934, DOI 10.1210/en.133.5.1934; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; KADOURI A, 1992, INT J CELL CLONING, V10, P299, DOI 10.1002/stem.5530100508; KAIPIA A, 1993, ENDOCRINOLOGY, V132, P477, DOI 10.1210/en.132.1.477; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KOSEKI T, 1995, FEBS LETT, V376, P247, DOI 10.1016/0014-5793(95)01290-7; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu QY, 1996, CANCER RES, V56, P1155; MASSAGUE J, 1995, CURR OPIN GENET DEV, V5, P91, DOI 10.1016/S0959-437X(95)90059-4; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; MINE T, 1989, ENDOCRINOLOGY, V125, P586, DOI 10.1210/endo-125-2-586; Miro F, 1996, ENDOCRINOLOGY, V137, P464, DOI 10.1210/en.137.2.464; MITAKA T, 1995, CELL STRUCT FUNCT, V20, P167, DOI 10.1247/csf.20.167; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULDER KM, 1992, J BIOL CHEM, V267, P5029; MURATA M, 1988, P NATL ACAD SCI USA, V85, P2434, DOI 10.1073/pnas.85.8.2434; MURTHY US, 1988, BIOCHEM BIOPH RES CO, V152, P1228, DOI 10.1016/S0006-291X(88)80416-9; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NISHIHARA T, 1993, BIOCHEM BIOPH RES CO, V197, P985, DOI 10.1006/bbrc.1993.2576; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Sambrook J, 1989, MOL CLONING LAB MANU; SEHY DW, 1992, J CELL BIOCHEM, V50, P255, DOI 10.1002/jcb.240500306; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; STERNBERG D, 1995, GROWTH FACTORS, V12, P227; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YASUDA H, 1993, J CLIN INVEST, V92, P1491, DOI 10.1172/JCI116727; ZIPORI D, 1986, P NATL ACAD SCI USA, V83, P4547, DOI 10.1073/pnas.83.12.4547	60	64	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1705	1711		10.1038/sj.onc.1201348	http://dx.doi.org/10.1038/sj.onc.1201348			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349504				2022-12-17	WOS:A1997XY63100010
J	Wei, MX; deTurenneTessier, M; Decaussin, G; Benet, G; Ooka, T				Wei, MX; deTurenneTessier, M; Decaussin, G; Benet, G; Ooka, T			Establishment of a monkey kidney epithelial cell line with the BARF1 open reading frame from Epstein-Barr virus	ONCOGENE			English	Article						EBV; BARF1; immortalization; epithelial cells	LYMPHOCYTE GROWTH TRANSFORMATION; NASOPHARYNGEAL CARCINOMA; GENE-EXPRESSION; DNA; TRANSCRIPTION; PROTEINS	We previously reported that the BARF1 (BamH1-A right frame 1) gene product from Epstein-Barr Virus (EBV) may have oncogenic properties since injection into new-born rats of transfected cell lines resulted in the development of BARF1 expressing tumors, which were agressive in the case of murine fibroblasts and transient in that of human B lymphocytes. As EBV has been associated with nasopharyngeal carcinoma (NPC) and evidence of BARF1 transcription in this cancer was emerging from our biopsy analyses, we examined the effects of BARF1 transfection into primate primary epithelial cells. The expression of the BARF1 open reading frame in primary monkey kidney epithelial cells led us to the establishment of continuously dividing lines. The BARF1 transfectants showed the major characteristics of immortalized cells: morphological change, short cell doubling time, ability to divide at low cell density and continuous growth over 50 passages. Injection of BARF1 transfectants into nude mice did not induce any tumor. Established subclones were shown to be epithelial cells expressing known keratins as well as the BARF1 coded mRNA and protein. This is the first report indicating that expression of the BARF1 gene product in primary epithelial cells may contribute to the establishment of cell lines.	FAC MED R LAENNEC,UMR 5537 CNRS,MOL VIROL LAB,IVMC,F-69372 LYON 08,FRANCE; RHONE MERIEUX,F-69007 LYON,FRANCE									BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BOUZID M, 1994, INT J CANCER, V56, P468, DOI 10.1002/ijc.2910560403; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; BUSSON P, 1992, J VIROL, V66, P3257, DOI 10.1128/JVI.66.5.3257-3262.1992; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DECAUSSIN G, 1995, J VIROL, V69, P7309, DOI 10.1128/JVI.69.11.7309-7314.1995; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; GILLIGAN K, 1990, J VIROL, V64, P4948, DOI 10.1128/JVI.64.10.4948-4956.1990; GRIFFIN BE, 1984, NATURE, V309, P78, DOI 10.1038/309078a0; HENLE G, 1966, J BACTERIOL, V91, P1248, DOI 10.1128/JB.91.3.1248-1256.1966; HITT MM, 1989, EMBO J, V8, P2639, DOI 10.1002/j.1460-2075.1989.tb08404.x; KARRAN L, 1990, INT J CANCER, V45, P763, DOI 10.1002/ijc.2910450432; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NIEDOBITEK G, 1992, VIRCHOWS ARCH B, V62, P55, DOI 10.1007/BF02899665; OOKA T, 1977, EXP CELL RES, V104, P319, DOI 10.1016/0014-4827(77)90097-0; SbihLammali F, 1996, J MED VIROL, V49, P7, DOI 10.1002/(SICI)1096-9071(199605)49:1&lt;7::AID-JMV2&gt;3.0.CO;2-A; SHEN YM, 1982, MOL CELL BIOL, V2, P1145, DOI 10.1128/MCB.2.9.1145; SUGDEN B, 1989, CELL, V57, P5, DOI 10.1016/0092-8674(89)90165-7; Tanner JE, 1997, J INFECT DIS, V175, P38, DOI 10.1093/infdis/175.1.38; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; TOOZE J, 1981, MOL BIOL TUMOUR VIRU; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WEI MX, 1989, EMBO J, V8, P2897, DOI 10.1002/j.1460-2075.1989.tb08438.x; WEI MX, 1994, CANCER RES, V54, P1843; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; ZHANG CX, 1988, J VIROL, V62, P1862, DOI 10.1128/JVI.62.6.1862-1869.1988	32	64	73	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3073	3081		10.1038/sj.onc.1201128	http://dx.doi.org/10.1038/sj.onc.1201128			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223671				2022-12-17	WOS:A1997XG10000010
J	Bartholomew, C; Kilbey, A; Clark, AM; Walker, M				Bartholomew, C; Kilbey, A; Clark, AM; Walker, M			The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation	ONCOGENE			English	Article						Evi-1; repression; leukaemogenesis; development	ZINC-FINGER PROTEIN; ACUTE MYELOGENOUS LEUKEMIAS; COLONY-STIMULATING FACTOR; MYELODYSPLASTIC SYNDROMES; RETROVIRAL INSERTIONS; CONSENSUS SEQUENCE; MAMMALIAN-CELLS; GENE-EXPRESSION; ACTIVATION; IDENTIFICATION	The myeloid transforming gene Evi-1 encodes a protein with two zinc finger domains, designated ZF1 and ZF2, with distinct DNA binding specificities. For the first time we demonstrate that Evi-1 has transcriptional repressor activity which is directly proportional to the amount of Evi-1 protein in cells. Repression has been observed with two distinct promoters: the minimal HSV-1 tk promoter and a VP16 inducible adenovirus E1b minimal promoter. Optimal repression is DNA binding dependent and is mediated by either ZF1 or a heterologous GAL4 DNA binding domain (GAL4DBD) but is significantly less efficient through the ZF2 binding site. Both GAL4DBD/Evi-1 fusion and non-fusion proteins have been used to map the repressor activity to a proline-rich region located within amino acids 514-724 between the ZF1 and ZF2 domains. Constitutive expression of mutant proteins lacking the repressor domain are defective for transformation of Rat1 fibroblasts demonstrating that this region is required for the oncogenic activity of the Evi-1 protein. These studies show that the Evi-1 gene encodes a transcriptional repressor and has important implications for the mechanism of action of the Evi-1 protein both in development and in the progression of some myeloid leukaemias.			Bartholomew, C (corresponding author), BEATSON INST CANC RES, CANC RES CAMPAIGN, BEATSON LABS, GARSCUBE ESTATE, SWITCHBACK RD, GLASGOW G61 1BD, LANARK, SCOTLAND.							BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BARTHOLOMEW C, 1991, MOL CELL BIOL, V11, P1820, DOI 10.1128/MCB.11.4.1820; BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORDEREAUX D, 1990, ONCOGENE, V5, P925; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BUNKER CA, 1994, MOL CELL BIOL, V14, P1721, DOI 10.1128/MCB.14.3.1721; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DREYFUS F, 1995, LEUKEMIA, V9, P203; FUNABIKI T, 1994, ONCOGENE, V9, P1575; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIRAMA T, 1995, BLOOD, V86, P841; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; KUROKAWA M, 1995, ONCOGENE, V11, P833; LEVY ER, 1994, BLOOD, V83, P1348; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MATSUGI T, 1995, ONCOGENE, V11, P191; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1995, ONCOGENE, V10, P1961; MORISHITA K, 1990, ONCOGENE RES, V5, P221; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPREY J, 1993, MOL CELL BIOL, V13, P6290, DOI 10.1128/MCB.13.10.6290; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERKINS AS, 1991, DEVELOPMENT, V111, P479; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RUSSELL M, 1994, BLOOD, V84, P1243, DOI 10.1182/blood.V84.4.1243.bloodjournal8441243; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SMARDOVA J, 1995, ONCOGENE, V10, P2017; SUZUKAWA K, 1994, BLOOD, V84, P2681; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	46	64	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	1997	14	5					569	577		10.1038/sj.onc.1200864	http://dx.doi.org/10.1038/sj.onc.1200864			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WF524	9053855				2022-12-17	WOS:A1997WF52400008
J	Zhang, WL; Lu, Q; Xie, ZJ; Mellgren, RL				Zhang, WL; Lu, Q; Xie, ZJ; Mellgren, RL			Inhibition of the growth of WI-38 fibroblasts by benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone: Evidence that cleavage of p53 by a calpain-like protease is necessary for G(1) to S-phase transition	ONCOGENE			English	Article						calpain; p53; cell proliferation; p21Waf1; peptide diazomethyl ketones	CYCLIN-DEPENDENT KINASES; CELL-CYCLE; UBIQUITIN PATHWAY; MU-CALPAIN; C-JUN; PROGRESSION; DEGRADATION; CALPASTATIN; CIP1; G1	The effect of a calpain-selective cell permeant inhibitor, benzyloxycarbonyl Leu-Leu-Tyr diazomethylketone (ZLLY-CHN2), on the serum-stimulated growth of WI-38 human fibroblasts has been investigated, Only cell permeant protease inhibitors with activity against calpains prevented progression into S-phase, Protein blotting experiments indicated that p53 immunoreactivity increased in late G(1) cells treated with ZLLY-CHN2. The content of p21(Waf1/Cip1) CDK inhibitor also increased, providing a mechanism for the observed failure to enter S-phase, Further studies indicated that p53 could be degraded by a ZLLY-CHN2-sensitive protease immediately prior to S-phase, but that proteolysis did not occur after this critical time point, Chelation of extracellular Ca2+ by addition of EGTA inhibited the p53 degradation, Consistent with proteolysis of p53 in late G(1) phase, mu-calpain immunoreactivity transiently accumulated in ceh nuclei at this time, ZLLY-CHN, did not appear to increase p53 mRNA in WI-38 cells, Purified mu-calpain required only 1 to 3 mu M Ca2+ to proteolyze p53 in WI-38 cell lysates. These results indicate that ZLLY-CHN, inhibits progression of WI-38 cells into S-phase by inactivating a calpain-like protease that is responsible for proteolysis of constitutively expressed p53 in late G(1).	MED COLL OHIO,DEPT THERAPEUT & PHARMACOL,TOLEDO,OH 43699						NHLBI NIH HHS [HL36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANAGLI J, 1993, BIOCHEM J, V289, P93, DOI 10.1042/bj2890093; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CARTER R, 1991, ONCOGENE, V6, P229; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; EARNSHAW WC, 1995, TRENDS CELL BIOL, V5, P217, DOI 10.1016/S0962-8924(00)89006-6; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRESHNEY RI, 1987, CULTURE ANIMAL CELLS, P236; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRANA X, 1995, ONCOGENE, V11, P211; HARPER JW, 1993, CELL, V75, P805; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; Hsu HL, 1996, J CELL SCI, V109, P277; Katsumoto T, 1995, BIOL CELL, V84, P167, DOI 10.1016/0248-4900(96)89426-3; KOUZARIDES T, 1995, TRENDS CELL BIOL, V5, P448, DOI 10.1016/S0962-8924(00)89109-6; LANE RD, 1992, EXP CELL RES, V203, P5, DOI 10.1016/0014-4827(92)90033-5; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; LU Q, 1996, IN PRESS ARCH BIOCH; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARCH KL, 1993, CIRC RES, V72, P413, DOI 10.1161/01.RES.72.2.413; Mellgren RL, 1996, J BIOL CHEM, V271, P15568, DOI 10.1074/jbc.271.26.15568; MELLGREN RL, 1994, EXP CELL RES, V215, P164, DOI 10.1006/excr.1994.1328; MELLGREN RL, 1991, J BIOL CHEM, V266, P13920; MINSHULL J, 1989, J CELL SCI S, V12, P77; MURACHI T, 1981, BIOCHEM INT, V2, P651; MURRAY AW, 1989, J CELL SCI S, V12, P65; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; Takahashi K, 1990, INTRACELLULAR CALCIU, P55; WAHL M, 1993, MOL BIOL CELL, V4, P293, DOI 10.1091/mbc.4.3.293; Zhang WL, 1996, J BIOL CHEM, V271, P18825, DOI 10.1074/jbc.271.31.18825	34	64	64	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					255	263		10.1038/sj.onc.1200841	http://dx.doi.org/10.1038/sj.onc.1200841			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018111				2022-12-17	WOS:A1997WD51600001
J	Miyazaki, Y; Sun, X; Uchida, H; Zhang, J; Nimer, S				Miyazaki, Y; Sun, X; Uchida, H; Zhang, J; Nimer, S			MEF, a novel transcription factor with an Elf-1 like DNA binding domain but distinct transcriptional activating properties	ONCOGENE			English	Article						transcriptional activator; ets protein; cytokine genes	STIMULATING FACTOR PROMOTER; ETS ONCOGENE FAMILY; EWINGS-SARCOMA TRANSLOCATION; T-CELLS; FACTOR PU.1; GM-CSF; RESTRICTED EXPRESSION; MOLECULAR-CLONING; NUCLEAR FACTORS; TEL GENE	To isolate novel ETS genes expressed in hematopoietic cells we used a nested, degenerate oligonucleotide PCR based technique to obtain a cDNA fragment that encodes an ETS domain from a human megakaryocytic cell line. This fragment was used to isolate a full length, 4.2 kb cDNA that encodes a 663 amino acid protein which we call MEF (myeloid elf-1-like factor). MEF contains a central ETS domain and is expressed in a variety of myeloid leukemia cell lines and in normal adult hematopoietic tissue such as spleen, thymus and peripheral blood, as well as non-hematopoietic tissue such as ovary, placenta and colon. Using an oligonucleotide binding selection assay, and bacterially expressed MEF, we demonstrated that MEF recognizes a consensus DNA binding sequence nearly identical to elf-1 (..WGGA..) and then showed that MEF specifically bound to known elf-1 binding sites in the human GMCSF and IL-3 promoters. To characterize the functional effect of MEF on transcription, we performed cotransfection experiments in myeloid cells, and T cells, and demonstrated transactivation of both promoters by MEF, but not by elf-1. MEF is a new member of the elf-1/E74 family of ETS proteins, that has DNA binding properties similar to elf-1 but distinct transcriptional activating effects in several hematopoietic cell lineages.	MEM SLOAN KETTERING CANC CTR, SLOAN KETTERING INST CANC RES, LAB MOL ASPECTS HEMATOPOIESIS, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT MED, DIV HEMATOL ONCOL, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NIDDK NIH HHS [R01 DK 43025] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043025] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORLES JC, 1995, NATURE, V377, P635; BUIJS A, 1995, ONCOGENE, V10, P1511; Chomczynski P, 1987, ANAL BIOCH, V162, P156; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FRASER JK, 1994, BLOOD, V84, P2523; FRASER JK, 1994, MOL CELL BIOL, V14, P2213, DOI 10.1128/MCB.14.3.2213; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; HROMAS R, 1994, INT J HEMATOL, V59, P257; HROMAS R, 1993, BLOOD, V82, P2998; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; INABA T, 1994, MOL CELL BIOL, V14, P3403, DOI 10.1128/MCB.14.5.3403; JEON IS, 1995, ONCOGENE, V10, P1229; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MIGNOTTE V, 1994, GENOMICS, V20, P5, DOI 10.1006/geno.1994.1120; MIYATAKE S, 1991, MOL CELL BIOL, V11, P5894, DOI 10.1128/MCB.11.12.5894; MONTE D, 1994, ONCOGENE, V9, P1397; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NIMER S, 1990, MOL CELL BIOL, V10, P6084, DOI 10.1128/MCB.10.11.6084; Nimer SD, 1996, BLOOD, V87, P3694, DOI 10.1182/blood.V87.9.3694.bloodjournal8793694; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OVAL J, 1990, BLOOD, V76, P1369; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; THOMAS RS, 1995, ONCOGENE, V11, P2135; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WOLIN M, 1993, ONCOGENE, V8, P1905; WURSTER AL, 1994, MOL CELL BIOL, V14, P6452, DOI 10.1128/MCB.14.10.6452; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	47	64	67	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1721	1729						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895518				2022-12-17	WOS:A1996VM88700017
J	Thomas, M; Matlashewski, G; Pim, D; Banks, L				Thomas, M; Matlashewski, G; Pim, D; Banks, L			Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation	ONCOGENE			English	Article						apoptosis; HPV; p53; transactivation; growth suppression	HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; CELL-CYCLE REGULATION; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; GROWTH ARREST; TRANSFORMING ACTIVITY; MUTATIONAL ANALYSIS; GENE-EXPRESSION; TUMOR-ANTIGEN	Inhibition of p53 function is a common feature of many DNA tumour viruses. Human papillomavirus (HPV) E6 proteins from the oncogenic HPVs inhibit p53 function either by blocking its ability to bind DNA or by labelling newly synthesised p53 as a target for ubiquitin mediated degradation. In this study we have investigated the role of the degradation function of E6 with respect to p53 function. Using a panel of previously characterised p53 mutant proteins we have been able to establish a series of assays which separates p53 growth suppression from transformation suppression and from induction of apoptosis. Only wild type p53 inhibits the growth of p53 null 10(1) cells, whereas wild type, dimeric and monomeric mutants of p53 suppress transformed cell growth of both Saos-2 cells and baby rat kidney cells. Cells expressing the different oligomeric forms of p53 all retain the ability to induce apoptosis upon u.v. treatment. Using HPV E6 and E7 we have been able to show that E7 will overcome p53 growth suppressor activity with an efficiency similar to that observed with E6. However, in contrast to E6, E7 has no effect on the ability of p53 to suppress transformed cell growth. Finally, we show that the ability of E6 to label p53 for ubiquitin mediated degradation is prerequisite for its ability to overcome p53 inhibition of transformed cell growth and induction of apoptosis. These observations argue that E6 inhibits p53 mediated apoptosis and suppression of transformation while E7 inhibits p53 suppression of cell proliferation.	INT CTR GENET ENGN & BIOTECHNOL,I-34012 TRIESTE,ITALY; MCGILL UNIV,INST PARASITOL,MONTREAL,PQ,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ,CANADA	International Center for Genetic Engineering & Biotechnology (ICGEB); McGill University; McGill University								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HARPER JW, 1993, CELL, V75, P805; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIM D, 1992, ONCOGENE, V7, P27; PIM D, 1994, ONCOGENE, V9, P1869; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STEWART N, 1995, ONCOGENE, V10, P109; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TARUNINA M, 1993, ONCOGENE, V8, P3165; THOMAS M, 1995, ONCOGENE, V10, P261; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	61	64	66	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					265	273						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710365				2022-12-17	WOS:A1996VA25200005
J	Chen, J; Nachabah, A; Scherer, C; Ganju, P; Reith, A; Bronson, R; Ruley, HE				Chen, J; Nachabah, A; Scherer, C; Ganju, P; Reith, A; Bronson, R; Ruley, HE			Germ-line inactivation of the murine Eck receptor tyrosine kinase by gene trap retroviral insertion	ONCOGENE			English	Article						Eck deficient mice; gene trap retrovirus; insertional mutagenesis; node	EMBRYONIC STEM-CELLS; RETINOIC ACID; SIGNAL TRANSDUCTION; PROTO-ONCOGENE; LACZ REPORTER; W-LOCUS; EXPRESSION; HINDBRAIN; DISRUPTION; MICE	The present study characterized a mutation in the Eck receptor tyrosine kinase gene induced by the U3 beta geo gene trap retrovirus. The mutation (eck(i)) was identified during an in vitro screen for proviruses that disrupt developmentally regulated genes in cultured ES cells. The germ-line eck(i) fusion gene was expressed in blastocyst and later restricted to the primitive streak, node and to regions of the hindbrain in 6.5-10.5 day embryos. This is identical to the pattern of Eck gene expression as determined by either in situ hybridization or immunostaining, suggesting that expression of the Eck promoter was not affected by provirus integration. The provirus inserted approximately 8 kb upstream of the 5' end of the published cDNA sequence, and 1.8 kb downstream of an alternatively spliced 5' exon. The eck(i) allele is essentially a null mutation since mutant mice are severely deficient for Eck protein as determined by Western blot analysis and irt vitro kinase assays. Nevertheless, mice homozygous for the mutation did not exhibit any discernable phenotype. These results suggest that other members of the Eph family of receptor tyrosine kinases can functionally compensate for loss of Eck.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; TUFTS UNIV, SCH MED, HUMAN NUTR RES CTR, BOSTON, MA 02111 USA	Massachusetts Institute of Technology (MIT); Ludwig Institute for Cancer Research; Tufts University	Chen, J (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, DEPT MICROBIOL & IMMUNOL, NASHVILLE, TN 37232 USA.			Chen, Jin/0000-0002-5557-2079	NIGMS NIH HHS [R01GM84688, 1 F32 GM17003-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017003] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; ANDRES AC, 1994, ONCOGENE, V9, P1461; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHEN J, 1994, METH MOL G, V4, P123; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; COLON FL, 1991, DEVELOPMENT, V111, P969; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DEGREGORI J, 1994, GENE DEV, V8, P265, DOI 10.1101/gad.8.3.265; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GANJU P, 1994, ONCOGENE, V9, P1613; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HAFEN E, 1991, DEVELOPMENT S, V112, P123; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HOGAN B, 1994, MANIPULATING MOUSE E; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; JOYNER AL, 1991, S POSTIMPLANTATION D, P277; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KURATANI SC, 1993, DEVELOPMENT, V117, P105; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LOEB DM, 1991, CELL, V66, P861; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MANSOUR SL, 1990, P NATL ACAD SCI USA, V87, P7688, DOI 10.1073/pnas.87.19.7688; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NODEN DM, 1988, DEVELOPMENT, V103, P121; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; REDDY S, 1992, P NATL ACAD SCI USA, V89, P6721, DOI 10.1073/pnas.89.15.6721; REITH AD, 1991, GENOME ANAL, V3, P105; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROGERS MB, 1991, DEVELOPMENT, V113, P815; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; RUIZ JC, 1994, MECH DEVELOP, V46, P87; Sambrook J, 1989, MOL CLONING LAB MANU; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; SKARNES WC, 1992, GENE DEV, V6, P903, DOI 10.1101/gad.6.6.903; STERNBERG PW, 1991, TRENDS GENET, V7, P336; VONMELCHNER H, 1992, GENE DEV, V6, P919, DOI 10.1101/gad.6.6.919; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	58	64	67	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					979	988						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649815				2022-12-17	WOS:A1996UA88400005
J	CERNI, C; BOUSSET, K; SEELOS, C; BURKHARDT, H; HENRIKSSON, M; LUSCHER, B				CERNI, C; BOUSSET, K; SEELOS, C; BURKHARDT, H; HENRIKSSON, M; LUSCHER, B			DIFFERENTIAL-EFFECTS BY MAD AND MAX ON TRANSFORMATION BY CELLULAR AND VIRAL ONCOPROTEINS	ONCOGENE			English	Article						RAS; C-MYC; ELA; P53; HPV16	C-MYC; DNA-BINDING; PHOSPHORYLATION SITES; RAS COTRANSFORMATION; EMBRYONIC LETHALITY; NEOPLASTIC-CELLS; PROTEIN; ONCOGENES; GROWTH; GENES	c-Myc is an essential component of the regulatory mechanisms controlling cell growth. Max is the obligatory partner of c-Myc for all its biological functions analysed to date. Recently two Max interacting proteins, Mad and Mxi1, have been identified. It has been suggested that these two proteins modulate c-Myc function, in the simplest model by competing with c-Myc for the interaction with Max. We have analysed different aspects of Mad function in comparison to Max, Native Mad/Max heterodimers bound specifically to a c-Myc/Max consensus DNA binding site. Furthermore Mad inhibited efficiently c-Myc, mutant p53, adenovirus Ela, or human papilloma virus type 16 transformation of rat embryo cells in cooperation with activated Ha-Ras, Myc transformed clones showed an increased cell cycle time and a reduced immortalization frequency after cotransfection with either mad or max. In contrast to Mad, Max did not inhibit E1a/Ha-Ras cotransformation but repressed c-Myc/Ha-Ras transformation efficiently. Mad Delta N, an N-terminal deletion mutant of Mad, was as efficient in repressing c-Myc/Ha-Ras cotransformation as full length Mad but showed little inhibitory activity when assayed on E1a/Ha-Ras. Unlike wt Mad, Mad Delta N had little effect on cell growth. Our data suggest that Mad affects cell growth at least in part by a c-Myc independent mechanism.	HANNOVER MED SCH, INST MOLEK BIOL, D-30623 HANNOVER, GERMANY; UNIV VIENNA, INST TUMORBIOL, A-1090 VIENNA, AUSTRIA	Hannover Medical School; University of Vienna			Henriksson, Marie Arsenian/F-5010-2015; Luscher, Bernhard/A-7330-2011	Arsenian Henriksson, Marie/0000-0001-6376-7792; Luscher, Bernhard/0000-0002-9622-8709				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOUSSET K, 1994, CELL MOL BIOL RES, V40, P501; BOUSSET K, 1993, ONCOGENE, V8, P3211; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CERNI C, 1989, P NATL ACAD SCI USA, V86, P3266, DOI 10.1073/pnas.86.9.3266; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COGLIATI T, 1993, ONCOGENE, V8, P1263; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; EDELHOFF S, 1994, ONCOGENE, V9, P665; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALAZONETIS TD, 1992, SCIENCE, V255, P464, DOI 10.1126/science.1734524; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LARSSON LG, 1994, ONCOGENE, V9, P1247; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; RALSTON R, 1991, NATURE, V353, P866, DOI 10.1038/353866a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SCHREIBERAGUS N, 1994, ONCOGENE, V9, P3167; SOLOMON DLC, 1993, NUCLEIC ACIDS RES, V21, P5372, DOI 10.1093/nar/21.23.5372; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	57	64	64	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	1995	11	3					587	596						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630643				2022-12-17	WOS:A1995RN53000020
J	HASEGAWA, H; UEDA, M; WATANABE, M; TERAMOTO, T; MUKAI, M; KITAJIMA, M				HASEGAWA, H; UEDA, M; WATANABE, M; TERAMOTO, T; MUKAI, M; KITAJIMA, M			K-RAS GENE-MUTATIONS IN EARLY COLORECTAL-CANCER ... FLAT ELEVATED VS POLYP-FORMING CANCER	ONCOGENE			English	Article						K-RAS; EARLY COLORECTAL CANCER; FLAT ELEVATED; POLYP-FORMING ADENOMA-CARCINOMA SEQUENCE	POLYMERASE CHAIN-REACTION; CONFORMATION POLYMORPHISM ANALYSIS; CHROMOSOME-5Q21; IDENTIFICATION; CARCINOMAS; COLON; ONCOGENES; ADENOMAS; DNA; FAP	K-ras gene mutations in early colorectal cancer were detected by two-step sensitive polymerase chain reaction (PCR) and enzyme digestion method. Early colorectal cancer was classified into fiat elevated cancer or polyp-forming cancer according to morphology and presence of adenomatous components. A total of 60 paraffin-embedded tissue specimens from patients with early colorectal cancer were analysed. K-ras codon 12 mutations were detected in 23.3% (7/30) of flat elevated cancer and 63.3% (19/30) of polyp-farming cancer. The incidence of K-ras codon 12 mutations in flat elevated cancer was significantly lower than in polyp-forming cancer (P < 0.01). These data suggested that K-ras gene mutations may be correlated with morphology or clinical features in flat elevated cancer, and that flat elevated cancer may originate from a pathway different from adenoma-carcinoma sequence.	KEIO UNIV, SCH MED, DEPT SURG, SHINJUKU KU, TOKYO 160, JAPAN; KEIO UNIV, SCH MED, DEPT PATHOL, SHINJUKU KU, TOKYO 160, JAPAN	Keio University; Keio University								ANDO M, 1991, JPN J CANCER RES, V82, P245, DOI 10.1111/j.1349-7006.1991.tb01836.x; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BURMER GC, 1989, CANCER RES, V49, P2141; CRAWFORD BE, 1983, CANCER, V51, P1760, DOI 10.1002/1097-0142(19830501)51:9<1760::AID-CNCR2820510933>3.0.CO;2-N; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KITAGAWA Y, 1991, CANCER RES, V51, P1504; LEVI S, 1991, CANCER RES, V51, P3497; MIYAKI M, 1990, CANCER RES, V50, P7166; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; SHIMODA T, 1989, CANCER, V64, P1138, DOI 10.1002/1097-0142(19890901)64:5<1138::AID-CNCR2820640529>3.0.CO;2-A; SUGANO K, 1993, LAB INVEST, V68, P361; SUZUKI Y, 1990, ONCOGENE, V5, P1037; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WOLBER RA, 1991, HUM PATHOL, V22, P70, DOI 10.1016/0046-8177(91)90064-V; YAMAGATA S, 1994, JPN J CANCER RES, V85, P147, DOI 10.1111/j.1349-7006.1994.tb02075.x; 1994, GENERAL RULES CLIN P	23	64	66	1	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1413	1416						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731692				2022-12-17	WOS:A1995QR65100019
J	BLANDINO, G; SCARDIGLI, R; RIZZO, MG; CRESCENZI, M; SODDU, S; SACCHI, A				BLANDINO, G; SCARDIGLI, R; RIZZO, MG; CRESCENZI, M; SODDU, S; SACCHI, A			WILD-TYPE P53 MODULATES APOPTOSIS OF NORMAL, IL-3 DEPRIVED, HEMATOPOIETIC-CELLS	ONCOGENE			English	Article						P53; APOPTOSIS; IL-3-DEPENDENCE	DIFFERENTIATION; GROWTH; LINE; CYCLE; GENE; SUPPRESSION; EXPRESSION; INDUCTION; MUTANT; TRANSFORMATION	Apoptotic cell death is an active process which regulates the maintenance of the hematopoietic homeostasis. It has been reported that wild-type p53 (wt-p53) protein induces apoptosis in leukemia cells. To assess whether p53 is involved in the apoptotic process of normal hematopoietic cells, we introduced the temperature-sensitive p53Val(135) mutant into the murine myeloid precursor cell line 32Dcl3. These are diploid, non-tumorigenic cells whose survival and proliferation are dependent upon growth factor supply (IL-3 and serum). Overexpression of wt-p53 protein does not affect morphology and proliferation of 32D cells as long as they are maintained in the presence of IL-3. However, after IL-3 withdrawal, wt-p53 overexpression significantly accelerates apoptosis. This phenomenon is IL-3 specific since no differences in death rates induced by serum starvation are found between parental cells and p53-transfectants. When the latter experiments are carried out at 37 degrees C with p53 protein in mutant conformation, an extended survival of 32D cells is observed after IL-3 deprivation, but not after serum withdrawal. Taken together, these results show that wt-p53 actively mediates the apoptosis due to the absence of specific growth factors, such as IL-3, suggesting that p53 might be involved in the response of myeloid precursors to environmental cytokines for the maintenance of the hematopoietic homeostasis.	CRS,REGINA ELENA CANC INST,MOLEC ONCOGENESIS LAB,I-00158 ROME,ITALY				Crescenzi, Marco/J-3603-2018; Soddu, Silvia/ABH-6774-2020; Blandino, Giovanni/B-1137-2013; Rizzo, Maria Giulia/B-2107-2018; Soddu, Silvia/K-2467-2018	Crescenzi, Marco/0000-0003-0156-1494; Soddu, Silvia/0000-0001-8526-0044; Blandino, Giovanni/0000-0002-6970-2241; Rizzo, Maria Giulia/0000-0002-5009-2412; Soddu, Silvia/0000-0001-8526-0044; Scardigli, Raffaella/0000-0003-1369-0496				ANDERSON SM, 1990, ONCOGENE, V5, P317; ASKEW DS, 1991, ONCOGENE, V6, P1915; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DUKE RC, 1983, J IMMUNOL, V137, P1442; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; GREENBERGER JS, 1983, FED PROC, V42, P2762; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; LEE JC, 1982, J IMMUNOL, V128, P2393; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; MAVILIO F, 1989, ONCOGENE, V4, P301; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; RIZZO MG, 1993, CLIN EXP METASTAS, V11, P368, DOI 10.1007/BF00132980; ROVERA G, 1987, ONCOGENE, V1, P29; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SODDU S, 1994, BLOOD, V83, P2230, DOI 10.1182/blood.V83.8.2230.bloodjournal8382230; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415	34	64	65	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 16	1995	10	4					731	737						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862450				2022-12-17	WOS:A1995QH61200013
J	PRASAD, MVVSV; SHORE, SK; DHANASEKARAN, N				PRASAD, MVVSV; SHORE, SK; DHANASEKARAN, N			ACTIVATED MUTANT OF G-ALPHA(13) INDUCES EGR-1, C-FOS, AND TRANSFORMATION IN NIH 3T3 CELLS	ONCOGENE			English	Article							ALPHA-SUBUNIT; NIH-3T3 CELLS; PROTEIN; GROWTH; DIFFERENTIATION; STIMULATION; FIBROBLAST; MECHANISM; MUTATIONS; ENCODES	Expression of the constitutively activated mutant alpha-subunit of the heterotrimeric G protein G alpha(13) (alpha(13)Q226L) leads to the transformation of NIH-3T3 cells. An analysis of the mitogenic pathway mediated by alpha(13)Q226L indicated that the expression of the primary response genes, early growth response gene-1 (Egr-1, a nuclear transcription factor with zinc-finger moth) and c-fos (a leucine zipper transcription factor as well as a protooncogene) are constitutively activated in alpha(13)Q226L-transformants. While ras-transformed cells did not express Egr-1, cells transformed by the GTPase deficient mutant a-subunit of G alpha(12) (alpha(12)Q229L) exhibited a ''weak'' expression, suggesting that the induction of Egr-1 and c-fos is intrinsic to G alpha(13) signaling pathway and not a consequence of the transformed phenotype. Taken together, these results provide the first evidence that the G alpha(13) signaling pathway involves the activation of specific transcription factors and defines the expression of these nuclear transcription factors as a possible molecular mechanism in alpha(13)Q226L-mediated cell proliferation and transformation.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NATIONAL CANCER INSTITUTE [P30CA012227] Funding Source: NIH RePORTER; NCI NIH HHS [5-P30-CA 12227] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HERMOUET S, 1991, P NATL ACAD SCI USA, V88, P10455, DOI 10.1073/pnas.88.23.10455; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MILLER AD, 1984, CELL, V36, P51; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; SHORE SK, 1989, ONCOGENE, V4, P1411; SIFFERT W, 1988, TRENDS BIOCHEM SCI, V13, P148, DOI 10.1016/0968-0004(88)90074-6; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	25	64	64	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2425	2429						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036026				2022-12-17	WOS:A1994NX62900038
J	SHIROUZU, M; KOIDE, H; FUJITAYOSHIGAKI, J; OSHIO, H; TOYAMA, Y; YAMASAKI, K; FUHRMAN, SA; VILLAFRANCA, E; YOKOYAMA, S; KAZIRO, Y				SHIROUZU, M; KOIDE, H; FUJITAYOSHIGAKI, J; OSHIO, H; TOYAMA, Y; YAMASAKI, K; FUHRMAN, SA; VILLAFRANCA, E; YOKOYAMA, S; KAZIRO, Y			MUTATIONS THAT ABOLISH THE ABILITY OF HA-RAS TO ASSOCIATE WITH RAF-1	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; AMINO-ACID-RESIDUES; PC12 CELLS; SIGNAL TRANSDUCTION; MOLECULAR SWITCH; EFFECTOR DOMAIN; IDENTIFICATION; P21; DIFFERENTIATION; RESOLUTION	Recent studies have revealed that Ras can associate physically with Raf. In the present study, we tested 34 mutants of Ha-Ras carrying substitution(s) in the region of residues 23- 71 for their ability to associate with Raf-1. Mouse Ba/F3 cell lysates were incubated w ith each mutant Ras protein, in either the guanosine 5'-[gamma-thio]triphosphate (GTP gamma S)- or the guanosine 5'-[beta-thio]diphosphate (GDP beta S)-bound form, and the anti-Ras antibody Y13-238. The immunoprecipitates were analysed for the presence of Raf-1 by Western blotting with an anti-Raf-1 antibody. Six mutants of Ras, E31K, P34G, T35S, D38N, D57A and A59T, failed to bind Raf-1. Mutations N26G, V29A, S39A, Y40W, R41A, V44A, V45E, L56A and T58A partially reduced the ability to bind Raf-1. All the other mutants could associate with Raf-1 with nearly the same efficiency as that of wild-type Ras. Thus, the Raf-1-binding ability of Ras appears to be affected by mutations in the N-terminal region, and in particular, by those in and neighboring the effector region (residues 32-40) and in the region (residues 56-59) banking the N-terminal of Switch II. The abilities to bind Raf-1 and to induce neurite outgrowth of pheochromocytoma (PC) 12 cells correlate to each other for 22 Ras mutants. However, mutation A59T, which does not reduce the neurite-inducing or transforming activities, abolishes the ability to bind Raf-1. In contrast, mutations Y32F, K42A and L53A, which impair the neurite-inducing activity of Ras, have no effect on the Ras.Raf-1 association. Partially reduced Raf-1-binding ability was observed for mutants V29A, S39A, Y40W, R31A, V44A, L56A and T58A, which exhibit full neurite-inducing activity, and also for mutant V45E, which has no activity of neurite induction.	UNIV TOKYO,GRAD SCH SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304; AGOURON PHARMACEUT INC,SAN DIEGO,CA 92121	University of Tokyo; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Pfizer			Yokoyama, Shigeyuki/N-6911-2015; Shirouzu, Mikako/A-6521-2016; Koide, Hiroshi/E-9000-2011; Yoshigaki, Junko/AAE-6702-2020; Yamasaki, Kazuhiko/L-7108-2018	Yokoyama, Shigeyuki/0000-0003-3133-7338; Yamasaki, Kazuhiko/0000-0003-0320-9697; Koide, Hiroshi/0000-0001-5916-3179				ANDREASON GL, 1989, ANAL BIOCHEM, V180, P269, DOI 10.1016/0003-2697(89)90429-6; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FUJITAYOSHIGAKI J, 1991, FEBS LETT, V294, P187, DOI 10.1016/0014-5793(91)80665-P; JOHN J, 1988, J BIOL CHEM, V263, P11792; KANAI T, 1987, JPN J CANCER RES, V78, P1314; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LACAL JC, 1986, CELL, V44, P609, DOI 10.1016/0092-8674(86)90270-9; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SHIROUZU M, 1992, ONCOGENE, V7, P475; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SRIVASTAVA SK, 1989, MOL CELL BIOL, V9, P1779, DOI 10.1128/MCB.9.4.1779; STONE JC, 1991, MOL CELL BIOL, V11, P6158, DOI 10.1128/MCB.11.12.6158; STONE JC, 1988, MOL CELL BIOL, V8, P3565, DOI 10.1128/MCB.8.8.3565; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P; YAMASAKI K, 1994, BIOCHEMISTRY-US, V33, P65, DOI 10.1021/bi00167a009; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	35	64	64	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2153	2157						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036000				2022-12-17	WOS:A1994NX62900005
J	GANDRILLON, O; FERRAND, N; MICHAILLE, JJ; ROZE, L; ZILE, MH; SAMARUT, J				GANDRILLON, O; FERRAND, N; MICHAILLE, JJ; ROZE, L; ZILE, MH; SAMARUT, J			C-ERBA-ALPHA/T3R AND RARS CONTROL COMMITMENT OF HEMATOPOIETIC SELF-RENEWING PROGENITOR CELLS TO APOPTOSIS OR DIFFERENTIATION AND ARE ANTAGONIZED BY THE V-ERBA ONCOGENE	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; THYROID-HORMONE RECEPTOR; RETINOIC ACID RECEPTOR; C-ERBA; ERYTHROID-DIFFERENTIATION; TERMINAL DIFFERENTIATION; B-CELLS; DEATH; BCL-2; INVITRO	In AEV-transformed erythroleukemic cells the v-erbA gene product is likely to antagonize the function of triiodothyronine (T3) and retinoic acid (RA) receptors and thereby to block cell differentiation. We have thus investigated the effects of T3 and RA on normal early erythrocytic progenitor cells. Here we show: (1) that either RA or T3 play an essential role during the early commitment to erythrocytic differentiation, (2) that both T3 and RA induce death by apoptosis and a strong inhibition of self-renewal in progenitor cells grown in the absence of differentiation-inducing agents and (3) that the v-erbA oncogene renders erythrocytic progenitor cells insensitive to apoptosis and to self-renewal inhibition induced by RA or T3. The behaviour of a nontransforming mutant of v-evbA suggests that this v-erbA-induced protection is related to its transforming potential.	UNIV JOSEPH FOURIER,CERMO,BIOL DIFFERNTIAT EPITHELIALE LAB 621,F-38041 GRENOBLE,FRANCE; MICHIGAN STATE UNIV,DEPT FOOD SCI & HUMAN NUTR,E LANSING,MI 48824	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Michigan State University	GANDRILLON, O (corresponding author), ECOLE NORMALE SUPER LYON,INRA,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 49,46 ALLEE ITALIE,F-69364 LYON 7,FRANCE.		Samarut, Jacques/AAD-2587-2019					BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BEUG H, 1982, CELL, V28, P907, DOI 10.1016/0092-8674(82)90070-8; BIGLER J, 1988, MOL CELL BIOL, V8, P4155, DOI 10.1128/MCB.8.10.4155; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CORREA PN, 1992, INT J CELL CLONING, V10, P286, DOI 10.1002/stem.5530100506; DAINIAK N, 1978, NATURE, V272, P260, DOI 10.1038/272260a0; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; EVANS CA, 1993, CANCER RES, V53, P1735; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FERRE F, 1989, NUCLEIC ACIDS RES, V17, P2141, DOI 10.1093/nar/17.5.2141; FUCHS E, 1981, CELL, V25, P617, DOI 10.1016/0092-8674(81)90169-0; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENTZEN D, 1987, MOL CELL BIOL, V7, P2416, DOI 10.1128/MCB.7.7.2416; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KERR JFR, 1991, APOPTOSIS MOL BASIS, P5; KOURY MJ, 1992, EXP HEMATOL, V20, P391; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NOJI S, 1991, NATURE, V350, P83, DOI 10.1038/350083a0; PAIN B, 1990, New Biologist, V2, P284; PAIN B, 1991, CELL, V65, P37, DOI 10.1016/0092-8674(91)90405-N; POPOVIC WJ, 1977, J CLIN INVEST, V60, P907, DOI 10.1172/JCI108845; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Robbins J., 1986, THYROID HORMONE META, P3; SAMARUT J, 1982, CELL, V28, P921, DOI 10.1016/0092-8674(82)90071-X; SANDE S, 1993, J VIROL, V67, P1067, DOI 10.1128/JVI.67.2.1067-1074.1993; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1993, EMBO J, V12, P951, DOI 10.1002/j.1460-2075.1993.tb05736.x; SCHROEDER C, 1992, ONCOGENE, V7, P217; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; STONE EM, 1985, P NATL ACAD SCI USA, V82, P1628, DOI 10.1073/pnas.82.6.1628; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VISANI G, 1992, BRIT J HAEMATOL, V81, P444, DOI 10.1111/j.1365-2141.1992.tb08254.x; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WELLINGER RJ, 1986, J VIROL, V60, P1; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; ZHOU HR, 1991, J IMMUNOL METHODS, V138, P211, DOI 10.1016/0022-1759(91)90169-G	48	64	65	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					749	758						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	7906409				2022-12-17	WOS:A1994MW55100009
J	REY, I; TAYLORHARRIS, P; VANERP, H; HALL, A				REY, I; TAYLORHARRIS, P; VANERP, H; HALL, A			R-RAS INTERACTS WITH RASGAP, NEUROFIBROMIN AND C-RAF BUT DOES NOT REGULATE CELL-GROWTH OR DIFFERENTIATION	ONCOGENE			English	Article							TYPE-1 GENE TRANSCRIPTS; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; PROTEIN GAP; P21; IDENTIFICATION; EXPRESSION; PRODUCT; DOMAIN; GTPASE	Within the superfamily of ras-related GTP-binding proteins, only ras itself has been shown to act as an oncogene. Seven other proteins, however, have greater than 50% amino acid identity to ras and one of them, rap1A, has been shown to interact with the ras GTPase activating protein, ras-GAP, and to inhibit ras function when overexpressed. In this paper, we have examined the biological and biochemical activities of another close relative of ras, R-ras. We show that in vitro, R-ras shares a number of activities with ras; it interacts with the catalytic domain of ras-GAP, with the GAP-related domain of neurofibromin and with the ser/thr kinase, c-raf. Furthermore, R-ras stimulates the expression of c-fos when microinjected into Swiss 3T3 cells. However, unlike ras, R-ras does not include DNA synthesis or membrane ruining in quiescent fibroblasts, nor does it induce maturation of Xenopus oocytes or differentiation of PC12 cells. In addition, we show that unlike rap1A, R-ras does not interfere with ras-stimulated gene transcription. We conclude from these experiments that although R-ras and ras share some biochemical activities, they control distinct biological processes.	INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BOLLAG G, 1992, CANCER BIOL, V3, P199; BOS JL, 1989, CANCER RES, V49, P4682; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HALL A, 1986, J BIOL CHEM, V261, P963; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LOWY DR, 1991, TRENDS GENET, V7, P346, DOI 10.1016/0168-9525(91)90253-M; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NISHI T, 1991, ONCOGENE, V6, P1555; PIZON V, 1988, ONCOGENE, V3, P201; REY I, 1989, MOL CELL BIOL, V9, P3904, DOI 10.1128/MCB.9.9.3904; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SAKODA T, 1992, ONCOGENE, V7, P1705; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SCHWEIGHOFFER F, 1993, ONCOGENE, V8, P1477; SELF AJ, 1993, ONCOGENE, V8, P655; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SKINNER RH, 1991, J BIOL CHEM, V266, P14163; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUZUKI Y, 1991, BIOCHEM BIOPH RES CO, V181, P955, DOI 10.1016/0006-291X(91)92029-J; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; UCHIDA T, 1992, BIOCHEM BIOPH RES CO, V187, P332, DOI 10.1016/S0006-291X(05)81497-4; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	52	64	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					685	692						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108110				2022-12-17	WOS:A1994MW55100002
J	JACOBSON, DR; MILLS, NE				JACOBSON, DR; MILLS, NE			A HIGHLY SENSITIVE ASSAY FOR MUTANT RAS GENES AND ITS APPLICATION TO THE STUDY OF PRESENTATION AND RELAPSE GENOTYPES IN ACUTE-LEUKEMIA	ONCOGENE			English	Article							ACUTE MYELOID-LEUKEMIA; POLYMERASE CHAIN-REACTION; ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; N-RAS; MYELODYSPLASTIC SYNDROMES; ONCOGENE MUTATIONS; POINT MUTATIONS; MYELOPROLIFERATIVE DISORDERS; CHROMOSOME-ABERRATIONS	Most studies of ras oncogene activation use assays for ras mutations based on the polymerase chain reaction (PCR) of DNA segments containing ras exons 1 and 2, followed by allele-specific oligonucleotide (ASO) hybridization or direct sequencing, which require that to be detectable, a mutation must be present in at least 3-25% of ras alleles. Thus, studies of tissues in which only a fraction of cells contains a ras mutation risk false negative results. To minimize this risk, we have developed a highly sensitive, non-radioactive assay for uas mutations. Ras genes were PCR-amplified using mismatched primers, to introduce restriction sites into products derived from normal alleles. Repeated restriction digestion and PCR enriched for mutant alleles, visualized by agarose gel electrophoresis. Serially diluted DNA samples containing I as mutations demonstrated detection of 1 mutant/10(6) normal alleles (four orders of magnitude more sensitive than PCR/ASO hybridization). This assay was applied to DNA from four patients with relapsed acute leukemia in whom ras mutations present at diagnosis were not detectable by PCR/ASO hybridization at relapse. In one case, the mutation present at diagnosis was demonstrated at relapse. In the others, loss of the mutation was confirmed, at a greatly increased sensitivity. This method is widely applicable to detection of mutant ras alleles admired with larger numbers of normal alleles.	NEW YORK VET AFFAIRS MED CTR,MED SERV,NEW YORK,NY; NYU,MED CTR,DEPT MED,NEW YORK,NY; NYU,MED CTR,KAPLAN COMPREHENS CANC CTR,NEW YORK,NY	New York University; New York University	JACOBSON, DR (corresponding author), NEW YORK VA MED CTR,RES SERV 151,423 E 23 ST,NEW YORK,NY 10010, USA.				NHLBI NIH HHS [T32HL07151] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007151] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHUJA HG, 1990, BLOOD, V75, P1684; BALL ED, 1990, PROG CLIN BIOL RES, V333, P499; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BARELI M, 1989, BLOOD, V73, P281; BARTRAM CR, 1992, HEMATOL ONCOL CLIN N, V6, P557, DOI 10.1016/S0889-8588(18)30328-9; BARTRAM CR, 1989, LEUKEMIA, V3, P247; BASHEY A, 1992, BLOOD, V79, P981; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BROWETT PJ, 1989, ONCOGENE, V4, P1029; CHEN J, 1991, ANAL BIOCHEM, V195, P51, DOI 10.1016/0003-2697(91)90293-3; CHIN IYM, 1992, ACTA HAEMATOL-BASEL, V87, P107; COGSWELL PC, 1989, BLOOD, V74, P2629; COLLINS SJ, 1991, ONCOGENE RES, V3, P117; FARR C, 1991, BRIT J HAEMATOL, V77, P323, DOI 10.1111/j.1365-2141.1991.tb08578.x; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FIALKOW PJ, 1987, NEW ENGL J MED, V317, P468, DOI 10.1056/NEJM198708203170802; GIRVITZ SC, 1980, ANAL BIOCHEM, V106, P492, DOI 10.1016/0003-2697(80)90553-9; HALIASSOS A, 1989, NUCLEIC ACIDS RES, V17, P8093, DOI 10.1093/nar/17.20.8093; HIRAI H, 1987, BIOCHEM BIOPH RES CO, V147, P108, DOI 10.1016/S0006-291X(87)80093-1; INOKUCHI K, 1991, ANN HEMATOL, V62, P211, DOI 10.1007/BF01729834; Jacobson D R, 1991, PCR Methods Appl, V1, P146; JACOBSON DR, 1992, HUM GENET, V89, P353; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; KAHN SM, 1991, ONCOGENE, V6, P1079; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LEVI S, 1991, CANCER RES, V51, P3497; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; LIU ET, 1990, CLIN LAB MED, V10, P797; LUBBERT M, 1992, ONCOGENE, V7, P263; LYONS J, 1988, BLOOD, V71, P1707; MANE SM, 1990, GENE CHROMOSOME CANC, V2, P71, DOI 10.1002/gcc.2870020113; MANO H, 1993, JPN J CANCER RES, V80, P102; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; MOSKOVITS T, 1992, AM J HEMATOL, V41, P302, DOI 10.1002/ajh.2830410422; NAKAGAWA T, 1992, ONCOLOGY, V49, P114; NAKAGAWA T, 1991, BRIT J HAEMATOL, V77, P250, DOI 10.1111/j.1365-2141.1991.tb07988.x; NEGRIN RS, 1991, BLOOD, V78, P255; PADUA RA, 1988, LEUKEMIA, V2, P503; PEDERSENBJERGAARD J, 1988, CANCER RES, V48, P1812; SAGLIO G, 1989, TUMORI, V75, P337, DOI 10.1177/030089168907500407; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SENN HP, 1988, INT J CANCER, V41, P59, DOI 10.1002/ijc.2910410112; SENN HP, 1988, BLOOD, V72, P931; SHEN WPV, 1987, ONCOGENE, V1, P157; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SMITH MT, 1992, J NATL CANCER I, V84, P1626; SYVANEN AC, 1992, INT J CANCER, V50, P713, DOI 10.1002/ijc.2910500508; TAYLOR JA, 1992, J NATL CANCER I, V84, P1626, DOI 10.1093/jnci/84.21.1626; TERADA N, 1990, BLOOD, V75, P453; TERADA N, 1991, LEUKEMIA RES, V15, P935, DOI 10.1016/0145-2126(91)90170-X; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; TODD AV, 1991, LEUKEMIA, V5, P160; TODD AV, 1991, AM J HEMATOL, V38, P207, DOI 10.1002/ajh.2830380310; TOKSOZ D, 1987, ONCOGENE, V1, P409; URBANOISPIZUA A, 1992, LEUKEMIA, V6, P342; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; YUNIS JJ, 1989, ONCOGENE, V4, P609	58	64	70	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					553	563						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290266				2022-12-17	WOS:A1994MW24800023
J	WATANABE, M; MURAMATSU, MA; HIRAI, H; SUZUKI, T; FUJISAWA, J; YOSHIDA, M; ARAI, KI; ARAI, N				WATANABE, M; MURAMATSU, MA; HIRAI, H; SUZUKI, T; FUJISAWA, J; YOSHIDA, M; ARAI, KI; ARAI, N			HTLV-I ENCODED TAX IN ASSOCIATION WITH NF-KAPPA-B PRECURSOR P105 ENHANCES NUCLEAR-LOCALIZATION OF NF-KAPPA-B P50 AND P65 IN TRANSFECTED CELLS	ONCOGENE			English	Article							VIRUS TYPE-I; LONG TERMINAL REPEAT; TRANSCRIPTIONAL ACTIVATOR; BINDING-PROTEINS; TRANS-ACTIVATION; CDNA CLONES; LEUKEMIA; EXPRESSION; GENES; INDUCTION	NF-kappaB is a heterodimeric protein composed of two subunits, p50 and p65, and is sequestered in the cytoplasm as an inactive form through the association with an inhibitory protein, IkappaB. In the present study, the effect of HTLV-1 encoded Tax on the exogenously expressed NF-kappaB p105, which encodes a precursor of p50, was investigated using a COS-7 expression system. When p105 was expressed in COS-7 cells, the precursor p105 and the processed p50 were retained in the cytosolic fraction by associating each other, and p50 was not detected in the nuclear fraction. In the cells co-expressing p105 and Tax, the p50/p105 ratio in the cytosolic fraction reduced with an induction of p50 in the nuclear fraction, which gave rise to a significant increase in NF-kappaB binding activity. Enhancement of NF-kappaB binding activity was not observed by adenovirus encoded EIA and bovine papilloma virus encoded E2, and correlated well with the ability of Tax to associate with p105. When p105DELTAX which lacks the repeats of the ankyrin motif was expressed in this system, p105DELTAX and processed p50 were detected in the nuclear fraction and p50/p105DELTAX ratio was not affected by co-expression with Tax. In the same expression system, exogenously expressed NF-kappaB p65 was retained in the cytoplasm by p105 and further expression of Tax allowed entry of p65 in the nucleus. These results suggest that, in this model system, p105 acts as an IkappaB to sequester p50 and p65 in the cytoplasm and that Tax by inhibiting IkappaB activity of p105, enhances nuclear localization of p50 and p65. These findings raise a possibility for a novel mechanism for the induction of NF-kappaB in the nucleus by Tax.	UNIV TOKYO,INST MED SCI,DEPT MOLEC & DEV BIOL,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; UNIV TOKYO,DEPT CELLULAR & MOLEC BIOL,TOKYO 108,JAPAN; DNAX INC,MOLEC & CELLULAR BIOL INST,DEPT MOLEC BIOL,PALO ALTO,CA 94304	University of Tokyo; University of Tokyo; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.								ARAI N, 1992, PHARMACOL THERAPEUT, V55, P303, DOI 10.1016/0163-7258(92)90054-4; ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; CRENON I, 1993, ONCOGENE, V8, P867; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; HEIKE T, 1989, EMBO J, V8, P1411, DOI 10.1002/j.1460-2075.1989.tb03522.x; HIRAI H, 1992, ONCOGENE, V7, P1737; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LINDHOLM P F, 1990, New Biologist, V2, P1034; LINDHOLM PF, 1992, J VIROL, V66, P1294, DOI 10.1128/JVI.66.3.1294-1302.1992; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OSAME M, 1986, LANCET, V1, P1031; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; Sambrook J., 1989, MOL CLONING LAB MANU; SAWADA M, 1990, J VIROL, V64, P4002, DOI 10.1128/JVI.64.8.4002-4006.1990; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHURMAN L, 1989, J IMMUNOL, V143, P3806; SODROSKI JG, 1984, SCIENCE, V226, P177; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TSUBOI A, 1991, INT IMMUNOL, V3, P807, DOI 10.1093/intimm/3.8.807; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; YOKOTA T, 1985, P NATL ACAD SCI USA, V82, P68, DOI 10.1073/pnas.82.1.68; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	38	64	64	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2949	2958						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414497				2022-12-17	WOS:A1993MC09300008
J	BUCHOU, T; KRANENBURG, O; VANDAM, H; ROELEN, D; ZANTEMA, A; HALL, FL; VANDEREB, A				BUCHOU, T; KRANENBURG, O; VANDAM, H; ROELEN, D; ZANTEMA, A; HALL, FL; VANDEREB, A			INCREASED CYCLIN-A AND DECREASED CYCLIN-D LEVELS IN ADENOVIRUS-5 E1A-TRANSFORMED RODENT CELL-LINES	ONCOGENE			English	Article							LARGE T-ANTIGEN; E1A PROTEINS; TRANSFORMED-CELLS; MONOCLONAL-ANTIBODIES; GROWTH-FACTOR; FACTOR-I; FUNCTIONAL DOMAINS; CONSERVED REGION-1; NUCLEAR ANTIGEN; MESSENGER-RNAS	Adenovirus-(Ad)- E1A proteins carry two conserved domains (CR1 and CR2) required for transformation of primary rodent cells and essential for association with cellular proteins, including p105RB, p58cyclin A and p33cdk 2. We show that in normal rat kidney 49F (NRK) cell lines expressing various mutant Ad5-E1A genes, CR2-, but not CR-1-, deletion mutants induce a typical transformed phenotype as characterized by morphology, absence of density arrest and loss of serum requirement. This indicates that induction of these transformed properties is a function of CR1. The fact that E1A proteins with deletions in CR2 show a greatly reduced association with RB, cyclin A and p33cdk 2 suggests that these associations are dispensable for E1A-mediated transformation of NRK cells. Induction of the transformed properties is accompanied by a CR1-dependent increase in Proliferating Cell Nuclear Antigen and cyclin A gene expression. Elevated mRNA and protein levels of cyclin A were also found in Ad12-E1-transformed NRK cells but not in ras-transformed NRK cells. On the other hand, cyclin D expression is decreased in a CR1-dependent manner. Although Ad5-E1A proteins are sufficient to transform NRK cells, further deregulation of growth is obtained when Ad5-E1B proteins are co-expressed. One of the Ad5-E1B effects is the sequestration of the p53 protein into a cytoplasmic body containing the p53/Ad5-E1B-55 kD complex. Interestingly, in NRK cell lines expressing Ad5-E1B-55 kD, cyclin A could be detected not only in the nucleus but also in the cytoplasmic bodies. These results indicate that the deregulation of cell cycle control by the Adenovirus-E1 region may be due to a CR1-dependent alteration of the expression of cyclins A and D.	LEIDEN UNIV, SYLVIUS LAB, MOLEC CARCINOGENESIS LAB, POB 9503, 2300 RA LEIDEN, NETHERLANDS; CTR RECH PARIS ST ANTOINE, INSERM, U55, F-75571 PARIS 12, FRANCE; CHILDRENS HOSP LOS ANGELES, DIV ORTHOPAED SURG, LOS ANGELES, CA 90054 USA	Leiden University; Leiden University - Excl LUMC; Institut National de la Sante et de la Recherche Medicale (Inserm); Children's Hospital Los Angeles			BUCHOU, THIERRY/N-2553-2013; Kranenburg, Onno/K-4115-2015; BUCHOU, Thierry/F-3136-2019	Kranenburg, Onno/0000-0002-2112-4390; BUCHOU, Thierry/0000-0002-9206-2377; van Dam, Hans/0000-0002-8307-4325				ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; BERNARDS R, 1986, VIROLOGY, V150, P126, DOI 10.1016/0042-6822(86)90272-2; BRANDS JHGM, 1986, EUR J BIOCHEM, V155, P167, DOI 10.1111/j.1432-1033.1986.tb09472.x; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FLINT SJ, 1990, MOL BIOL TUMOR VIRUS, V2, P547; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALL FL, 1991, J BIOL CHEM, V266, P17430; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KIMELMAN D, 1986, MOL CELL BIOL, V6, P1487, DOI 10.1128/MCB.6.5.1487; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; KLEINBERGER T, 1991, P NATL ACAD SCI USA, V88, P11143, DOI 10.1073/pnas.88.24.11143; LAMMIE GA, 1991, ONCOGENE, V6, P439; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NIELSCH U, 1991, ONCOGENE, V6, P1031; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; RILEY TEW, 1990, MOL CELL BIOL, V10, P6664, DOI 10.1128/MCB.10.12.6664; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; SVENSSON C, 1991, VIROLOGY, V182, P553, DOI 10.1016/0042-6822(91)90596-4; TIMMERS HTM, 1988, J BIOL CHEM, V263, P1329; TIMMERS HTM, 1988, ONCOGENE RES, V3, P67; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1989, ONCOGENE, V4, P1207; VANDENELSEN P, 1983, VIROLOGY, V128, P377; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	70	64	64	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1993	8	7					1765	1773						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510923				2022-12-17	WOS:A1993LG68200007
J	SCHONTHAL, A; FERAMISCO, JR				SCHONTHAL, A; FERAMISCO, JR			INHIBITION OF HISTONE H1 KINASE EXPRESSION, RETINOBLASTOMA PROTEIN-PHOSPHORYLATION, AND CELL-PROLIFERATION BY THE PHOSPHATASE INHIBITOR OKADAIC ACID	ONCOGENE			English	Article							SV40 LARGE-T; GENE-PRODUCT; TUMOR PROMOTER; CYCLIN-A; M-PHASE; SUSCEPTIBILITY GENE; MAMMALIAN-CELLS; FISSION YEAST; MESSENGER-RNA; CDC2 KINASE	Phosphorylation events are major regulatory mechanisms of signal transduction pathways that regulate gene expression and cell growth. To study the potential involvement of serine-threonine specific phosphatases in these processes we used okadaic acid (OA), an inhibitor of type 1 and type 2A protein phosphatases. Here we present evidence that OA arrests cells at defined points in the cell cycle. Concomitantly, expression and associated histone H1 kinase activity of cdc2 and cyclin A, two cell cycle regulatory proteins, are repressed by this agent. Furthermore, phosphorylation of the tumor suppressor protein retinoblastoma, an event thought to be necessary in order to permit cells to proliferate, is inhibited when OA is present. These effects are fully reversible since removal of OA restores cdc2 and cyclin A expression as well as histone H1 kinase activity, and the cells resume growth. Since cdc2 and cyclin A have previously been shown to be absolutely required for cell cycle progression it is likely that blockage of synthesis of these components contributes to the cytostatic effects of OA. Furthermore, our results suggest a positive role for OA sensitive protein phosphatases in the regulation of expression of these cell cycle regulatory proteins.	UNIV CALIF SAN DIEGO,CTR CANC,DEPT PHARMACOL,LA JOLLA,CA 92093	University of California System; University of California San Diego	SCHONTHAL, A (corresponding author), UNIV CALIF SAN DIEGO,CTR CANC,DEPT CHEM,LA JOLLA,CA 92093, USA.		Schonthal, Axel/ABH-3846-2020	Schonthal, Axel/0000-0003-0662-5653				ALBERTS AS, 1992, IN PRESS P NATL ACAD; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEAN NM, 1991, CARCINOGENESIS, V12, P665, DOI 10.1093/carcin/12.4.665; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HERSCHMAN HR, 1989, CARCINOGENESIS, V10, P1495, DOI 10.1093/carcin/10.8.1495; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; KIM SJ, 1990, CELL REGUL, V1, P269, DOI 10.1091/mbc.1.3.269; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAU LF, 1991, HORMONAL CONTROL REG, P165; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUSCHER B, 1991, EMBO J, V10, P865, DOI 10.1002/j.1460-2075.1991.tb08019.x; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORDAN LJ, 1990, CANCER COMMUN, V2, P237, DOI 10.3727/095535490820874290; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RIME H, 1990, CELL DIFFER DEV, V29, P47, DOI 10.1016/0922-3371(90)90023-P; RIVEDAL E, 1990, BIOCHEM BIOPH RES CO, V167, P1302, DOI 10.1016/0006-291X(90)90665-A; SAGER R, 1992, Current Opinion in Cell Biology, V4, P155, DOI 10.1016/0955-0674(92)90026-9; SAKAI R, 1989, P NATL ACAD SCI USA, V86, P9946, DOI 10.1073/pnas.86.24.9946; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SCHONTHAL A, 1991, NEW BIOL, V3, P977; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; SUGANUMA M, 1990, CANCER RES, V50, P3521; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDRE DD, 1992, J CELL SCI, V101, P79; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WILLIAMS RT, 1992, ONCOGENE, V7, P423; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	79	64	65	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					433	441						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8381221				2022-12-17	WOS:A1993KN00600023
J	DIRENZO, MF; BERTOLOTTO, A; OLIVERO, M; PUTZOLU, P; CREPALDI, T; SCHIFFER, D; PAGNI, CA; COMOGLIO, PM				DIRENZO, MF; BERTOLOTTO, A; OLIVERO, M; PUTZOLU, P; CREPALDI, T; SCHIFFER, D; PAGNI, CA; COMOGLIO, PM			SELECTIVE EXPRESSION OF THE MET/HGF RECEPTOR IN HUMAN CENTRAL-NERVOUS-SYSTEM MICROGLIA	ONCOGENE			English	Note							HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; MET PROTO-ONCOGENE; C-MET; SCATTER FACTOR; MOLECULAR-CLONING; TRK PROTOONCOGENE; EPITHELIAL-CELLS; HEPATOPOIETIN-A; GENE	The c-MET proto-oncogene encodes the tyrosine kinase receptor for hepatocyte growth factor (HGF), also known as scatter factor, a powerful mitogen and motility factor for epithelial cells. We now show that the two previously described forms of the Met/HGF receptor, the intact p190MET and the truncated p14OMET, are expressed in physiological conditions in the human central nervous system (CNS). The receptors were identified by Western blot analysis with monoclonal antibodies directed against different epitopes. By immunohistochemical staining the Met/HGF receptor was found to be expressed in a homogeneous cell population, equally distributed between the grey and the white matter, showing morphological features and immunochemical markers specific for the resident microglial cells. These data suggest a possible role for the c-MET proto-oncogene and HGF in microglial reactions to CNS injuries.	UNIV TURIN,SCH MED,NEUROL CLIN 2,I-10126 TURIN,ITALY; UNIV TURIN,SCH MED,NEUROSURG CLIN,I-10126 TURIN,ITALY	University of Turin; University of Turin	DIRENZO, MF (corresponding author), UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,I-10126 TURIN,ITALY.		DI RENZO, Maria Flavia/B-6091-2012; crepaldi, tiziana/AAY-7207-2020; Bertolotto, Antonio/K-8346-2015; olivero, martina/J-4811-2018	DI RENZO, Maria Flavia/0000-0002-5093-3373; crepaldi, tiziana/0000-0003-3410-947X; Bertolotto, Antonio/0000-0002-7052-1907; olivero, martina/0000-0002-6815-3498; Comoglio, Paolo/0000-0002-7056-5328				AKIYAMA H, 1990, J NEUROIMMUNOL, V30, P81, DOI 10.1016/0165-5728(90)90055-R; BARBACID M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P115, DOI 10.1016/0304-419X(91)90010-I; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO FD, 1992, IN PRESS J CELL BIOL; CHAN AML, 1988, ONCOGENE, V2, P593; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CUZNER ML, 1988, J NEUROIMMUNOL, V20, P203, DOI 10.1016/0165-5728(88)90161-0; Del Rio P., 1932, CYTOLOGY CELLULAR PA, P481; DICKSON DW, 1991, LAB INVEST, V64, P135; DIRENZO MF, 1991, ONCOGENE, V6, P1997; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAEBER MB, 1988, J NEUROCYTOL, V17, P573, DOI 10.1007/BF01189811; GRAEBER MB, 1988, J NEUROSCI RES, V21, P18, DOI 10.1002/jnr.490210104; GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q; HAASE VH, 1991, ONCOGENE, V6, P2319; HART IK, 1989, J CELL BIOL, V109, P3411, DOI 10.1083/jcb.109.6.3411; HART IK, 1989, DEVELOPMENT, V105, P595; HAYES GM, 1987, J NEUROL SCI, V80, P25, DOI 10.1016/0022-510X(87)90218-8; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1990, DEVELOPMENT, V109, P845; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PEUDENIER S, 1991, ANN NEUROL, V29, P152, DOI 10.1002/ana.410290207; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; PUTZOLU P, 1989, IMAGE ANAL NEUROHIST, P129; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SAWADA M, 1990, BRAIN RES, V509, P119, DOI 10.1016/0006-8993(90)90317-5; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; TAHIRA T, 1991, ONCOGENE, V6, P2333; TILLOTSON ML, 1989, GLIA, V2, P412; WEGIEL J, 1990, ACTA NEUROPATHOL, V81, P116, DOI 10.1007/BF00334499; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WEIDNER KM, 1990, J CELL BIOL, V111, P2907; ZARNEGAR R, 1989, BIOCHEM BIOPH RES CO, V163, P1370, DOI 10.1016/0006-291X(89)91130-3; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252	52	64	77	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					219	222						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8380919				2022-12-17	WOS:A1993KN00500028
J	MATHEW, S; MURTY, VVVS; DALLAFAVERA, R; CHAGANTI, RSK				MATHEW, S; MURTY, VVVS; DALLAFAVERA, R; CHAGANTI, RSK			CHROMOSOMAL LOCALIZATION OF GENES ENCODING THE TRANSCRIPTION FACTORS, C-REL, NF-KAPPA-BP50, NF-KAPPA-BP65, AND LYT-10 BY FLUORESCENCE INSITU HYBRIDIZATION	ONCOGENE			English	Note							NF-KAPPA-B; INT-2 GENES; CARCINOMAS; AMPLIFICATION; ONCOGENE; COAMPLIFICATION; LYMPHOMA; CLONING; SUBUNIT; CANCERS	We have used fluorescence in situ hybridization (FISH) to perform precise chromosomal mapping of the genes encoding the transcription factors c-rel, NF-kappaBp50, NF-kappaBp65, and lyt-10. The previously published assignments of c-rel and NF-kappaBp50 have been refined to specific bands. The map position of lyt-10, inferred from its isolation from a t(10;14)(q24;q32) translocation, has been confirmed. NF-kappaBp65 has now been mapped to 11q13, a site of frequent involvement in aberration in multiple tumor types.	MEM SLOAN KETTERING CANC CTR,CANC GENET LAB,1275 YORK AVE,NEW YORK,NY 10021; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	Memorial Sloan Kettering Cancer Center; Columbia University					NCI NIH HHS [CA-34775, CA-20194] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034775, P01CA020194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWNELL E, 1986, AM J HUM GENET, V39, P194; BROWNELL E, 1989, ONCOGENE, V4, P935; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LU D, 1991, ONCOGENE, V6, P1235; LUCIBELLO F C, 1991, Critical Reviews in Oncogenesis, V2, P259; MANIATIS T, 1982, MOL CLONING LABORATO, P109; MATHEW S, 1992, IN PRESS GENOMICS; NARAYANAN R, 1992, SCIENCE, V256, P357; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SOMERS KD, 1990, ONCOGENE, V5, P915; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; THEILLET C, 1989, ONCOGENE, V4, P915; TSUDA T, 1989, CANCER RES, V49, P5505; TSUTSUMI M, 1988, JPN J CANCER RES, V79, P428, DOI 10.1111/j.1349-7006.1988.tb01609.x; VANDENBERGHE H, 1979, CANCER, V44, P179; ZHOU DJ, 1988, ONCOGENE, V2, P279	23	64	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					191	193						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423996				2022-12-17	WOS:A1993KN00500023
J	ALEXANDRE, C; CHARNAY, P; VERRIER, B				ALEXANDRE, C; CHARNAY, P; VERRIER, B			TRANSACTIVATION OF KROX-20 AND KROX-24 PROMOTERS BY THE HTLV-1 TAX PROTEIN THROUGH COMMON REGULATORY ELEMENTS	ONCOGENE			English	Article							CELL LEUKEMIA-VIRUS; SERUM RESPONSE ELEMENT; ZINC-FINGER GENE; LONG TERMINAL REPEAT; RECEPTOR-ALPHA-GENE; NERVE GROWTH-FACTOR; C-FOS PROMOTER; TRANSCRIPTION FACTOR; CDNA CLONES; CYCLIC-AMP	The HTLV-1 Tax protein has been shown to induce the expression of host cellular genes, some of which play crucial roles in cell proliferation and differentiation. We have examined the effect of Tax on the expression of two immediate-early genes, Krox-20 and Krox-24, which encode transcription factors. Several HTLV-1-infected T-cell lines and a HeLa cell line that constitutively expresses the Tax protein have a high level of expression of the Krox-20 and Krox-24 genes. In addition, Tax transactivates the promoters of both Krox-20 and Krox-24 in a co-transfection assay. Tax-responsive elements in Krox-20 and Krox-24 include the serum response elements (SREs) and the putative cAMP-responsive element (CRE). A correlation exists between the ability of these elements to mediate Tax transactivation and their affinity for their cognate factors, the serum response factor (SRF) or the CRE-binding protein (CREB) respectively. Since Tax is also able to transactivate the human c-fos promoter through the SRE and the CRE-60, our findings support the idea that the HTLV-1 Tax protein uses common mechanisms for transactivation of these three immediate-early genes. Deregulation of their expression may contribute to malignant transformation associated with HTLV-1 infection.	ECOLE NORMALE SUPER LYON, CNRS, UNITE MIXTE 103, 46 ALLEE ITALIE, F-69364 Lyon 07, FRANCE; ECOLE NORM SUPER, GENET MOLEC LAB, CNRS D1302, F-75230 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)				Charnay, Patrick/0000-0002-3847-6042				ALEXANDRE C, 1991, ONCOGENE, V6, P543; BALLARD D W, 1989, New Biologist, V1, P83; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEIMLING P, 1990, ONCOGENE, V5, P361; BERKOWITZ LA, 1990, P NATL ACAD SCI USA, V87, P5258, DOI 10.1073/pnas.87.14.5258; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; GIAM CZ, 1989, J BIOL CHEM, V264, P15236; GILARDI P, 1991, BIOCHIMIE, V73, P85, DOI 10.1016/0300-9084(91)90079-G; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HIDAKA M, 1988, EMBO J, V7, P519, DOI 10.1002/j.1460-2075.1988.tb02840.x; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JANSSENTIMMEN U, 1989, GENE, V80, P325, DOI 10.1016/0378-1119(89)90296-5; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LILIENBAUM A, 1990, J VIROL, V64, P256, DOI 10.1128/JVI.64.1.256-263.1990; LIM RW, 1987, ONCOGENE, V1, P263; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MONTAGNE J, 1990, EMBO J, V9, P957, DOI 10.1002/j.1460-2075.1990.tb08194.x; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; POTEAT HT, 1989, J VIROL, V63, P1604, DOI 10.1128/JVI.63.4.1604-1611.1989; PRYWES R, 1987, MOL CELL BIOL, V7, P3482, DOI 10.1128/MCB.7.10.3482; RANGNEKAR VM, 1990, NUCLEIC ACIDS RES, V18, P2749, DOI 10.1093/nar/18.9.2749; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; RUBEN SM, 1989, NEW BIOL, V3, P275; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHROTER H, 1987, NUCLEIC ACIDS RES, V15, P10145, DOI 10.1093/nar/15.24.10145; SEIKI M, 1985, GANN, V76, P1127; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOSHIDA M, 1989, GENOME, V31, P662, DOI 10.1139/g89-121; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	61	64	64	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1991	6	10					1851	1857						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1833716				2022-12-17	WOS:A1991GX11800018
J	ADAM, D; MAUELER, W; SCHARTL, M				ADAM, D; MAUELER, W; SCHARTL, M			TRANSCRIPTIONAL ACTIVATION OF THE MELANOMA INDUCING XMRK ONCOGENE IN XIPHOPHORUS	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; EGF-RECEPTOR; AUTOPHOSPHORYLATION SITES; CELL-LINE; CANCER; GENE; SEQUENCES; LOCUS	The melanoma inducing locus of Xiphophorus encodes a tumorigenic version of a novel putative receptor tyrosine kinase (Xmrk). To elucidate the mechanism of oncogenic activation of Xmrk, we compared the structure and expression of two oncogenic loci with the corresponding proto-oncogene. Only minor structural alterations were found to be specific for the oncogenic Xmrk genes. Marked overexpression of the oncogene transcripts in melanoma, which are approximately 1 kb shorter than the proto-oncogene transcript, correlates with the malignancy of the tumors. The tumor transcripts are derived from an alternative transcription start site that is used only in the oncogenic loci. Thus, oncogenic activation of the melanoma inducing Xmrk gene appears primarily to be due to novel transcriptional control and overexpression.	MAX PLANCK INST BIOCHEM, GENZENTRUM, KLOPFERSPITZ 18A, W-8033 MARTINSRIED, GERMANY	Max Planck Society			Adam, Dieter/E-9763-2010	Adam, Dieter/0000-0002-5668-5032; Schartl, Manfred/0000-0001-9882-5948				ADAM D, 1988, NUCLEIC ACIDS RES, V16, P7212, DOI 10.1093/nar/16.14.7212; AHUJA MR, 1976, PROG EXP TUMOR RES, V20, P380; ANDERS A, 1978, BIOCHIM BIOPHYS ACTA, V516, P61, DOI 10.1016/0304-419X(78)90004-5; ANDERS F, 1984, ADV CANCER RES, V42, P191, DOI 10.1016/S0065-230X(08)60459-5; ATZ JAMES W., 1962, ZOOLOGICA [NEW YORK], V47, P153; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BOETTIGER D, 1989, CURR TOP MICROBIOL, V147, P31; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; CARPENTER CD, 1990, BIOTECHNIQUES, V8, P26; Chaconas G, 1980, Methods Enzymol, V65, P75; DALE RMK, 1985, PLASMID, V13, P31, DOI 10.1016/0147-619X(85)90053-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; GORDON M, 1958, ANN NY ACAD SCI, V71, P1213, DOI 10.1111/j.1749-6632.1958.tb54683.x; Gordon M, 1927, GENETICS, V12, P253; HAUSSLER G, 1928, KLINWOCHENSCHR, V33, P1561; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; JEFFREYS AJ, 1982, NATURE, V296, P9, DOI 10.1038/296009a0; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KOSSWIG C, 1965, Zoologischer Anzeiger, V175, P21; Kosswig C., 1928, Zeitschrift fuer Induktive Abstammungs- und Vererbungslehre, V47, P150; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MAUELER W, 1988, ONCOGENE, V2, P421; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; Nei M., 1987, MOL EVOLUTIONARY GEN; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; SCHARTL M, 1988, GENETICS, V119, P679; SCHARTL M, 1990, IN PRESS GENETICS; SCHWAB M, 1987, TRENDS GENET, V3, P38, DOI 10.1016/0168-9525(87)90164-8; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SINKOVICS JG, 1988, CRC CR REV IMMUNOL, V8, P217; TRONICK SR, 1988, ADV SEC MESS PHOSPH, V21, P201; Vielkind J. R., 1989, Journal of Aquatic Animal Health, V1, P69, DOI 10.1577/1548-8667(1989)001&lt;0069:GOMIXF&gt;2.3.CO;2; WAKAMATSU Y, 1981, CANCER RES, V41, P679; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WEINBERG RA, 1989, CANCER RES, V49, P3713; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZANDER C D, 1969, Mitteilungen aus dem Hamburgischen Zoologischen Museum und Institut, V66, P241; ZECHEL C, 1988, ONCOGENE, V3, P605	46	64	65	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1991	6	1					73	80						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1846957				2022-12-17	WOS:A1991EY03900010
J	CHOWDHURY, M; TAYLOR, JP; TADA, H; RAPPAPORT, J; WONGSTAAL, F; AMINI, S; KHALILI, K				CHOWDHURY, M; TAYLOR, JP; TADA, H; RAPPAPORT, J; WONGSTAAL, F; AMINI, S; KHALILI, K			REGULATION OF THE HUMAN NEUROTROPIC VIRUS PROMOTER BY JCV-T ANTIGEN AND HIV-1 TAT PROTEIN	ONCOGENE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE-DEFICIENCY SYNDROME; LONG TERMINAL REPEAT; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; CENTRAL NERVOUS-SYSTEM; TRANS-ACTIVATION; HTLV-III; CEREBROSPINAL-FLUID; SYNDROME AIDS; RNA ENHANCER	We compared the ability of HIV-1 tat protein and JCV T-antigen in inducing transcription from the JCV late promoter, JCV(L). A JCV(L) promoter-chloramphenicol acetyltransferase plasmid (pJC(L)-CAT) was transfected into human glial cells alone or together with plasmids producing T-antigen and tat protein. CAT enzyme activity obtained from the transfected cells indicated that both JCV T-antigen and HIV-1 tat proteins stimulated JCV late gene expressiom. However, the level of induction mediated by tat protein was significantly higher than that obtained with T-antigen. Moreover, in contrast to JCV T-antigen, tat stimulated JCV(L)-promoter activity over a narrow range of ptat expressor plasmid concentration. Co-transfection of both T-antigen and tat plasmids at optimal concentrations resulted in greater than additive CAT activity from the JCV(L) promoter. This synergism suggests that the two activator proteins utilize alternative mechanisms to exert their effects. Using deletion mutations from the 5' end of the JCV(L) promoter, we demonstrated that different regions within the JCV enhancer/promoter are important for T-antigen and tat induction, implying that these activators function through distinct targets to increase JCV(L) promoter activity.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	Jefferson University			Taylor, J. Paul/N-2482-2018	Taylor, J. Paul/0000-0002-5794-0349	NATIONAL CANCER INSTITUTE [R29CA047996] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47996] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; FAREED GC, 1978, MICROBIOLOGY 1978, P427; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FEIGENBAUM L, 1987, P NATL ACAD SCI USA, V84, P3695, DOI 10.1073/pnas.84.11.3695; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; GALLO R C, 1987, Scientific American, V256, P47; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; HAUBER J, 1986, P NATL ACAD SCI USA, V843, P6364; HO DD, 1985, NEW ENGL J MED, V313, P1493, DOI 10.1056/NEJM198512123132401; JAKABOVITS A, 1988, MOL CELL BIOL, V8, P2555; JEANG KT, 1988, P NATL ACAD SCI USA, V85, P8291, DOI 10.1073/pnas.85.21.8291; JOHNSON RT, 1983, POLYOMAVIRUSES HUMAN, P183; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KENNEY S, 1984, SCIENCE, V226, P1337, DOI 10.1126/science.6095453; KNIGHT DM, 1987, SCIENCE, V236, P837, DOI 10.1126/science.3033827; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; KRUPP LB, 1985, ANN NEUROL, V17, P344, DOI 10.1002/ana.410170407; LASHGARI MS, 1989, VIROLOGY, V170, P292, DOI 10.1016/0042-6822(89)90381-4; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LEVY JA, 1985, LANCET, V2, P586; NIELSEN SL, 1984, AM J CLIN PATHOL, V82, P678, DOI 10.1093/ajcp/82.6.678; PADGETT BL, 1977, INFECT IMMUN, V15, P656, DOI 10.1128/IAI.15.2.656-662.1977; PETITO CK, 1985, NEW ENGL J MED, V312, P874, DOI 10.1056/NEJM198504043121402; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; RADONOVICH M, 1989, J VIROL, V63, P2987, DOI 10.1128/JVI.63.7.2987-2994.1989; ROSEN CA, 1986, NATURE, V319, P555, DOI 10.1038/319555a0; SADAIE MR, 1988, SCIENCE, V239, P910, DOI 10.1126/science.3277284; SHARP PA, 1989, CELL, V59, P229, DOI 10.1016/0092-8674(89)90279-1; SHAW GM, 1985, SCIENCE, V227, P177, DOI 10.1126/science.2981429; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404; STONER GL, 1986, P NATL ACAD SCI USA, V83, P2271, DOI 10.1073/pnas.83.7.2271; TADA H, 1989, J VIROL, V63, P463, DOI 10.1128/JVI.63.1.463-466.1989; TADA H, 1989, IN PRESS P NATL ACAD; TAKEMOTO K, 1979, J VIROL, V80, P384; WALKER DL, 1978, HDB CLIN NEUROLOGY, P307; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; ZURHEIN GM, 1969, PROG MED VIROL, V11, P185	45	64	65	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1990	5	12					1737	1742						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET436	2178236				2022-12-17	WOS:A1990ET43600001
J	STEINMEYER, K; MAACKE, H; DEPPERT, W				STEINMEYER, K; MAACKE, H; DEPPERT, W			CELL-CYCLE CONTROL BY P53 IN NORMAL (3T3) AND CHEMICALLY TRANSFORMED (METH-A) MOUSE CELLS .1. REGULATION OF P53 EXPRESSION	ONCOGENE			English	Article									UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,MARTINISTR 52,W-2000 HAMBURG 13,GERMANY	Heinrich Pette Institute; University of Hamburg								AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BASERGA R, 1985, BIOL CELL REPRODUCTI; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P159; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; COOPER JL, 1985, J CELL PHYSIOL, V124, P433, DOI 10.1002/jcp.1041240311; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DENHARDT DT, 1986, BIOCHIM BIOPHYS ACTA, V865, P83, DOI 10.1016/0304-419X(86)90024-7; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; ELIYAHU D, 1988, ONCOGENE, V3, P313; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HOLLEY RW, 1975, NATURE, V258, P487, DOI 10.1038/258487a0; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JENKINS JR, 1988, ONCOGENE HDB, P403; KACZMAREK L, 1986, EXP CELL RES, V132, P105; KOHN A, 1975, EXP CELL RES, V94, P15, DOI 10.1016/0014-4827(75)90526-1; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; NIKAIDO T, 1989, EXP CELL RES, V182, P284, DOI 10.1016/0014-4827(89)90299-1; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PATSCHINSKY T, 1990, ONCOGENE, V5, P1071; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROSS F, 1989, ANN REV CELL BIOL, V5, P341; SHOHAT O, 1987, ONCOGENE, V1, P277; SKINNER MK, 1983, BIOCHEM J, V209, P281, DOI 10.1042/bj2090281; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STEINMEYER K, 1988, ONCOGENE, V3, P501; Tobey R A, 1973, Methods Cell Biol, V6, P67, DOI 10.1016/S0091-679X(08)60048-5; TOBEY RA, 1970, J CELL BIOL, V46, P151, DOI 10.1083/jcb.46.1.151; WYNFORDTHOMAS D, 1985, EXP CELL RES, V159, P191, DOI 10.1016/S0014-4827(85)80048-3; YEN A, 1978, EXP CELL RES, V114, P389, DOI 10.1016/0014-4827(78)90497-4	44	64	64	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1990	5	11					1691	1699						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EL401	2267135				2022-12-17	WOS:A1990EL40100012
J	MORISHITA, K; PARGANAS, E; PARHAM, DM; MATSUGI, T; IHLE, JN				MORISHITA, K; PARGANAS, E; PARHAM, DM; MATSUGI, T; IHLE, JN			THE EVI-1 ZINC FINGER MYELOID TRANSFORMING GENE IS NORMALLY EXPRESSED IN THE KIDNEY AND IN DEVELOPING OOCYTES	ONCOGENE			English	Note									ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, 332 N LAUDERDALE, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT PATHOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, CTR HLTH SCI, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, CTR HLTH SCI, DEPT PATHOL, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center			Parham, David M./AAN-1059-2020	Parham, David M./0000-0002-6912-9748	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765, CA51020] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P6687, DOI 10.1073/pnas.82.19.6687; HONDA BM, 1980, CELL, V22, P19203; IHLE JN, 1984, ADV VIRAL ONCOL, V4, P95; IHLE JN, 1989, INT J CELL CLONING, V1, P1; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1990, ONCOGENE RES, V5, P221; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, ONCOGENE RES, V2, P219; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; RAIMONDI SC, 1989, LEUKEMIA, V3, P42; RUIZ IAA, 1987, EMBO J, V6, P3065	15	64	68	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1419	1423						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	1699199				2022-12-17	WOS:A1990EC24100023
J	SATAKE, M; IBARAKI, T; ITO, Y				SATAKE, M; IBARAKI, T; ITO, Y			MODULATION OF POLYOMAVIRUS ENHANCER BINDING-PROTEINS BY HA-RAS ONCOGENE	ONCOGENE			English	Article									KYOTO UNIV,INST VIRUS RES,DEPT VIRAL ONCOL,SAKYO KU,KYOTO 606,JAPAN	Kyoto University								AMATI P, 1985, CELL, V43, P561, DOI 10.1016/0092-8674(85)90225-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENJAMIN CW, 1987, P NATL ACAD SCI USA, V84, P546, DOI 10.1073/pnas.84.2.546; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHNLEIN E, 1986, MOL CELL BIOL, V6, P1401; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; DEVILLIERS J, 1984, NATURE, V312, P242, DOI 10.1038/312242a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVA A, 1983, P NATL ACAD SCI-BIOL, V80, P4926, DOI 10.1073/pnas.80.16.4926; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FUJIMURA FK, 1986, NUCLEIC ACIDS RES, V14, P2845, DOI 10.1093/nar/14.7.2845; FUJIMURA FK, 1981, CELL, V23, P809, DOI 10.1016/0092-8674(81)90445-1; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEARING P, 1983, CELL, V33, P695, DOI 10.1016/0092-8674(83)90012-0; HEN R, 1986, NATURE, V321, P249, DOI 10.1038/321249a0; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; KATINKA M, 1980, CELL, V20, P393, DOI 10.1016/0092-8674(80)90625-X; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KOVESDI I, 1987, NATURE, V328, P87, DOI 10.1038/328087a0; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LAMINS L, 1982, P NATL ACAD SCI USA, V79, P6453; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Maxam A M, 1980, Methods Enzymol, V65, P499; MUELLER CR, 1984, MOL CELL BIOL, V4, P2594, DOI 10.1128/MCB.4.12.2594; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OSTAPCHUK P, 1986, P NATL ACAD SCI USA, V83, P8550, DOI 10.1073/pnas.83.22.8550; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; PENNINGTON SR, 1987, NATURE, V327, P188, DOI 10.1038/327188a0; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; PIETTE J, 1986, NUCLEIC ACIDS RES, V14, P9595, DOI 10.1093/nar/14.24.9595; PULCIANI S, 1982, J CELL BIOCHEM, V20, P51, DOI 10.1002/jcb.240200106; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; RODRIGUEZPENA MA, 1984, BIOCHEM BIOPH RES CO, V120, P1053; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SATAKE M, 1988, J VIROL, V62, P970, DOI 10.1128/JVI.62.3.970-977.1988; SEKIKAWA K, 1981, P NATL ACAD SCI-BIOL, V78, P1100, DOI 10.1073/pnas.78.2.1100; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P383, DOI 10.1073/pnas.80.2.383; TAHIRA T, 1986, MOL CELL BIOL, V6, P1349, DOI 10.1128/MCB.6.4.1349; TANAKA K, 1982, EMBO J, V1, P1521, DOI 10.1002/j.1460-2075.1982.tb01349.x; TOPOL J, 1985, CELL, V42, P527, DOI 10.1016/0092-8674(85)90110-2; TSUCHIDA N, 1982, SCIENCE, V217, P937, DOI 10.1126/science.6287573; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VELDMAN GM, 1985, MOL CELL BIOL, V5, P649, DOI 10.1128/MCB.5.4.649; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x	55	64	64	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1988	3	1					69	78						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	P0354					2022-12-17	WOS:A1988P035400010
J	Lloyd, RL; Wijnhoven, PWG; Ramos-Montoya, A; Wilson, Z; Illuzzi, G; Falenta, K; Jones, GN; James, N; Chabbert, CD; Stott, J; Dean, E; Lau, A; Young, LA				Lloyd, Rebecca L.; Wijnhoven, Paul W. G.; Ramos-Montoya, Antonio; Wilson, Zena; Illuzzi, Giuditta; Falenta, Katarzyna; Jones, Gemma N.; James, Neil; Chabbert, Christophe D.; Stott, Jonathan; Dean, Emma; Lau, Alan; Young, Lucy A.			Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; HOMOLOGOUS RECOMBINATION; SYNTHETIC LETHALITY; GASTRIC-CANCER; OLAPARIB; SENSITIVITY; MUTATIONS; THERAPY; PHOSPHORYLATION; REGULATOR	The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is FDA approved for the treatment of BRCA-mutated breast, ovarian and pancreatic cancers. Olaparib inhibits PARP1/2 enzymatic activity and traps PARP1 on DNA at single-strand breaks, leading to replication-induced DNA damage that requires BRCA1/2-dependent homologous recombination repair. Moreover, DNA damage response pathways mediated by the ataxia-telangiectasia mutated (ATM) and ataxia-telangiectasia mutated and Rad3-related (ATR) kinases are hypothesised to be important survival pathways in response to PARP-inhibitor treatment. Here, we show that olaparib combines synergistically with the ATR-inhibitor AZD6738 (ceralasertib), in vitro, leading to selective cell death in ATM-deficient cells. We observe that 24 h olaparib treatment causes cells to accumulate in G2-M of the cell cycle, however, co-administration with AZD6738 releases the olaparib-treated cells from G2 arrest. Selectively in ATM-knockout cells, we show that combined olaparib/AZD6738 treatment induces more chromosomal aberrations and achieves this at lower concentrations and earlier treatment time-points than either monotherapy. Furthermore, single-agent olaparib efficacy in vitro requires PARP inhibition throughout multiple rounds of replication. Here, we demonstrate in several ATM-deficient cell lines that the olaparib and AZD6738 combination induces cell death within 1-2 cell divisions, suggesting that combined treatment could circumvent the need for prolonged drug exposure. Finally, we demonstrate in vivo combination activity of olaparib and AZD6738 in xenograft and PDX mouse models with complete ATM loss. Collectively, these data provide a mechanistic understanding of combined PARP and ATR inhibition in ATM-deficient models, and support the clinical development of AZD6738 in combination with olaparib.	[Lloyd, Rebecca L.; Wijnhoven, Paul W. G.; Ramos-Montoya, Antonio; Illuzzi, Giuditta; Falenta, Katarzyna; Chabbert, Christophe D.; Lau, Alan; Young, Lucy A.] AstraZeneca, Oncol R&D, Biosci, Cambridge, England; [Lloyd, Rebecca L.] Univ Cambridge, Wellcome Trust, Cambridge, England; [Lloyd, Rebecca L.] Univ Cambridge, CRUK Gurdon Inst, Cambridge, England; [Lloyd, Rebecca L.] Univ Cambridge, Dept Biochem, Cambridge, England; [Wilson, Zena; James, Neil] AstraZeneca, Oncol R&D, Biosci, Alderley Pk, England; [Jones, Gemma N.] AstraZeneca, Oncol R&D, Translat Med, Cambridge, England; [Stott, Jonathan] AstraZeneca, Oncol R&D, Discovery Sci, Quantitat Biol, Cambridge, England; [Dean, Emma] AstraZeneca, Oncol R&D, Res & Early Dev, Cambridge, England	AstraZeneca; University of Cambridge; Wellcome Trust Sanger Institute; University of Cambridge; University of Cambridge; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca	Young, LA (corresponding author), AstraZeneca, Oncol R&D, Biosci, Cambridge, England.	Lucy.Young@astrazeneca.com	Kumar, Sushil/AAF-1312-2019	Kumar, Sushil/0000-0003-0547-745X; Lau, Alan/0000-0003-1055-9812; Young/Press, Lucy/0000-0001-9368-6213	AstraZeneca	AstraZeneca(AstraZeneca)	This study was funded by AstraZeneca. We are grateful to Sarah Ross for critical reading of the manuscript. We thank Anna Ramne and John W. Wiseman for providing the FaDu ATM-KO cell line and Jenni Nikkila for the A549 ATM-KO cell line. We thank the AstraZeneca Laboratory Animal Sciences and Oncology in vivo teams for their expert technical assistance. We thank Champions Oncology for their assistance with PDX studies.	[Anonymous], 2019, ANN ONCOL S5; Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8; Balmus G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07729-2; Bang YJ, 2017, LANCET ONCOL, V18, P1637, DOI 10.1016/S1470-2045(17)30682-4; Berges A, 2018, AM ASS CANC RES, V78; Blackford AN, 2017, MOL CELL, V66, P801, DOI 10.1016/j.molcel.2017.05.015; Boussios S, 2020, DRUGS R&D, V20, P55, DOI 10.1007/s40268-020-00301-8; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Buisson R, 2017, MOL CELL, V65, P336, DOI 10.1016/j.molcel.2016.12.007; Burgess BT, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10020121; Capoluongo E, 2017, SEMIN ONCOL, V44, P187, DOI 10.1053/j.seminoncol.2017.08.004; Choi M, 2016, MOL CANCER THER, V15, P1781, DOI 10.1158/1535-7163.MCT-15-0945; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Crafter C, 2015, INT J ONCOL, V47, P446, DOI 10.3892/ijo.2015.3062; DEBONO JS, 2019, J CLIN ONCOL, V37; Dillon M, 2019, ANN ONCOL, V30, P165; Durant ST, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aat1719; Fang Y, 2019, CANCER CELL, V35, P851, DOI 10.1016/j.ccell.2019.05.001; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fok JHL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12836-9; Foote KM, 2018, J MED CHEM, V61, P9889, DOI 10.1021/acs.jmedchem.8b01187; Forment JV, 2018, PHARMACOL THERAPEUT, V188, P155, DOI 10.1016/j.pharmthera.2018.03.005; Golan T, 2019, NEW ENGL J MED, V381, P317, DOI 10.1056/NEJMoa1903387; Illuzzi G, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-2077; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jette NR, 2019, BRIT J CANCER, V121, P600, DOI 10.1038/s41416-019-0565-8; Jones GN, 2018, BRIT J CANCER, V119, P1233, DOI 10.1038/s41416-018-0286-4; Kim H, 2017, CLIN CANCER RES, V23, P3097, DOI 10.1158/1078-0432.CCR-16-2273; Krebs MG, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-CT026; Kwok M, 2016, BLOOD, V127, P582, DOI 10.1182/blood-2015-05-644872; Laufer C, 2013, NAT METHODS, V10, P427, DOI [10.1038/NMETH.2436, 10.1038/nmeth.2436]; Loewe S, 1926, N-S ARCH EX PATH PH, V114, P313; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Lord CJ, 2015, ANNU REV MED, V66, P455, DOI 10.1146/annurev-med-050913-022545; Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859; Mateo J, 2020, LANCET ONCOL, V21, P162, DOI 10.1016/S1470-2045(19)30684-9; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Middleton FK, 2018, CANCERS, V10, DOI 10.3390/cancers10080275; Min A, 2017, MOL CANCER THER, V16, P566, DOI 10.1158/1535-7163.MCT-16-0378; Mu JJ, 2007, J BIOL CHEM, V282, P17330, DOI 10.1074/jbc.C700079200; Murai J, 2019, ANNU REV CANC BIOL, V3, P131, DOI 10.1146/annurev-cancerbio-030518-055914; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Nadeu F, 2016, BLOOD, V127, P2122, DOI 10.1182/blood-2015-07-659144; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; Ozeri-Galai E, 2008, ONCOGENE, V27, P2109, DOI 10.1038/sj.onc.1210849; Reaper PM, 2011, NAT CHEM BIOL, V7, P428, DOI [10.1038/NCHEMBIO.573, 10.1038/nchembio.573]; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Ruiz S, 2016, MOL CELL, V62, P307, DOI 10.1016/j.molcel.2016.03.006; Schmitt A, 2017, CANCER RES, V77, P3040, DOI 10.1158/0008-5472.CAN-16-3398; Stankovic T, 2014, LEUKEMIA LYMPHOMA, V55, P1227, DOI 10.3109/10428194.2013.829919; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; Stokes MP, 2007, P NATL ACAD SCI USA, V104, P19855, DOI 10.1073/pnas.0707579104; Trenz K, 2006, EMBO J, V25, P1764, DOI 10.1038/sj.emboj.7601045; Villaruz LC, 2016, ONCOTARGET, V7, P57714, DOI 10.18632/oncotarget.9757; Wang C, 2017, TRANSL ONCOL, V10, P190, DOI 10.1016/j.tranon.2017.01.007; Weber AM, 2016, ONCOTARGET, V7, P60807, DOI 10.18632/oncotarget.11845; Wengner AM, 2020, MOL CANCER THER, V19, P26, DOI 10.1158/1535-7163.MCT-19-0019; Weston VJ, 2010, BLOOD, V116, P4578, DOI 10.1182/blood-2010-01-265769; Yazinski SA, 2017, GENE DEV, V31, P318, DOI 10.1101/gad.290957.116; Young LA, 2019, CANCER RES, V79, P3762, DOI 10.1158/0008-5472.CAN-18-2480; Zhou DS, 2019, CLIN PHARMACOKINET, V58, P615, DOI 10.1007/s40262-018-0714-x	61	63	63	6	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 18	2020	39	25					4869	4883		10.1038/s41388-020-1328-y	http://dx.doi.org/10.1038/s41388-020-1328-y		MAY 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LZ3HT	32444694	Green Published, hybrid			2022-12-17	WOS:000534868800001
J	Wang, S; Zhang, X; Li, Z; Wang, WZ; Li, BW; Huang, XX; Sun, GL; Xu, JH; Li, Q; Xu, ZP; Xia, YW; Wang, L; Zhang, Q; Li, Q; Zhang, L; Chen, J; Wu, YJ; Cao, JC; Xu, PH; Zhang, DC; Xu, H; Xu, ZK				Wang, Sen; Zhang, Xing; Li, Zheng; Wang, Weizhi; Li, Bowen; Huang, Xiaoxu; Sun, Guangli; Xu, Jianghao; Li, Qing; Xu, Zhipeng; Xia, Yiwen; Wang, Lu; Zhang, Qiang; Li, Qiang; Zhang, Lu; Chen, Jie; Wu, Yangjun; Cao, Jiacheng; Xu, Penghui; Zhang, Diancai; Xu, Hao; Xu, Zekuan			Circular RNA profile identifies circOSBPL10 as an oncogenic factor and prognostic marker in gastric cancer	ONCOGENE			English	Article							HEPATOCELLULAR-CARCINOMA; CELL-GROWTH; CROSS-TALK; WNT2; CHINA; PROGRESSION; STATISTICS; EXPRESSION; CIRCHIPK3; MIGRATION	The prognosis after curative resection of gastric cancer (GC) remains unsatisfactory, and thus, the development of treatments involving alternative molecular and genetic targets is critical. Circular RNAs (circRNAs), which are newly discovered molecules with key roles in the non-coding RNA network, have been identified as critical regulators in various cancers. Here, we aimed to determine the circRNA expression profile and to investigate the functional and prognostic significance of circRNA in GC. Using next-generation sequencing profiling, we first characterized an abundant circRNA in GC, hsa_circ_0008549, derived from the OSBPL10 gene and named it circOSBPL10. The expression of circOSBPL10 was found to be upregulated in GC tissues by quantitative RT-PCR, and silencing of circOSBPL10 significantly inhibited GC cell growth, migration, and invasion in multiple experiments. We further confirmed that miR-136-5p is a downstream target of circOSBPL10 using RNA pull-down and luciferase reporter assays. Rescue experiments confirmed that circOSBPL10 regulates biological functions in GC cells via a circOSBPL10-miR-136-5p-WNT2 axis. In vivo experiments showed that circOSBPL10 promotes tumor growth and metastasis in mice. Furthermore, the level of circOSBPL10 was observed to be a prognostic marker of the overall survival and disease-free survival of patients with GC. Taken together, our findings reveal that circOSBPL10 may serve as a new proliferation factor and prognostic marker in GC.	[Wang, Sen; Zhang, Xing; Li, Zheng; Wang, Weizhi; Li, Bowen; Huang, Xiaoxu; Sun, Guangli; Xu, Jianghao; Li, Qing; Xu, Zhipeng; Xia, Yiwen; Wang, Lu; Zhang, Qiang; Li, Qiang; Zhang, Lu; Cao, Jiacheng; Xu, Penghui; Zhang, Diancai; Xu, Hao; Xu, Zekuan] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing 210029, Jiangsu, Peoples R China; [Chen, Jie; Wu, Yangjun] Fudan Univ, Shanghai Med Coll, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Xu, Zekuan] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Nanjing 210029, Jiangsu, Peoples R China	Nanjing Medical University; Fudan University; Nanjing Medical University	Xu, ZK (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing 210029, Jiangsu, Peoples R China.; Xu, ZK (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Nanjing 210029, Jiangsu, Peoples R China.	xuzekuan@njmu.edu.cn		xu, zekuan/0000-0001-5179-4128; Wang, Sen/0000-0001-7179-626X	National Natural Science Foundation of China [81572362]; National Natural Science Foundation Project of International Cooperation (NSFC-NIH) [81361120398]; Primary Research & Development Plan of Jiangsu Province [BE2016786]; Program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) [JX10231801]; 333 Project of Jiangsu Province [BRA2015474]; Jiangsu Key Medical Discipline (General Surgery) [ZDXKA2016005]; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation Project of International Cooperation (NSFC-NIH); Primary Research & Development Plan of Jiangsu Province; Program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); 333 Project of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Jiangsu Key Medical Discipline (General Surgery); Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University	This work was partially supported by the National Natural Science Foundation of China (81572362); the National Natural Science Foundation Project of International Cooperation (NSFC-NIH, 81361120398); the Primary Research & Development Plan of Jiangsu Province (BE2016786); the Program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU; the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD, JX10231801); 333 Project of Jiangsu Province (BRA2015474); Jiangsu Key Medical Discipline (General Surgery) (ZDXKA2016005); and Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University.	Abu N, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00355; Allemani C, 2015, LANCET, V385, P977, DOI 10.1016/S0140-6736(14)62038-9; Ashwal-Fluss R, 2014, MOL CELL, V56, P55, DOI 10.1016/j.molcel.2014.08.019; Burd CE, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001233; Chen J, 2017, CANCER LETT, V388, P208, DOI 10.1016/j.canlet.2016.12.006; Chen L, 2017, ONCOGENE, V36, P4551, DOI 10.1038/onc.2017.89; Chen PJ, 2018, ONCOL LETT, V15, P5995, DOI 10.3892/ol.2018.8081; Chen WQ, 2017, CANCER LETT, V401, P63, DOI 10.1016/j.canlet.2017.04.024; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Cheng XX, 2005, CLIN EXP METASTAS, V22, P85, DOI 10.1007/s10585-005-4578-8; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Cui JA, 2011, NUCLEIC ACIDS RES, V39, P1197, DOI 10.1093/nar/gkq960; Ding H, 2017, MOL MED REP, V16, P5393, DOI 10.3892/mmr.2017.7275; Dmitriev AA, 2015, DIS MARKERS, V2015, DOI 10.1155/2015/241301; Dong YP, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-016-0370-2; Du WW, 2017, EUR HEART J, V38, P1402, DOI 10.1093/eurheartj/ehw001; Ferreira Humberto J, 2018, Oncotarget, V9, P29208, DOI 10.18632/oncotarget.25673; Fu L, 2011, GUT, V60, P1635, DOI 10.1136/gut.2011.241638; Geng HH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151753; Han D, 2017, HEPATOLOGY, V66, P1151, DOI 10.1002/hep.29270; Hang D, 2018, CANCER MED-US, V7, P2783, DOI 10.1002/cam4.1514; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hentze MW, 2013, EMBO J, V32, P923, DOI 10.1038/emboj.2013.53; Huang L, 2006, HUM PATHOL, V37, P1557, DOI 10.1016/j.humpath.2006.05.015; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Jung YS, 2015, ONCOTARGET, V6, P37257, DOI 10.18632/oncotarget.6133; Karreth FA, 2013, CANCER DISCOV, V3, P1113, DOI 10.1158/2159-8290.CD-13-0202; Katoh M, 2003, INT J MOL MED, V12, P811; Kramer N, 2017, ONCOGENE, V36, P5460, DOI 10.1038/onc.2017.144; Kristensen H, 2016, ONCOTARGET, V7, P30760, DOI [10.16632/oncotarget.8953, 10.18632/oncotarget.8953]; Li DX, 2017, ONCOTARGET, V8, P88163, DOI 10.18632/oncotarget.21513; Li X, 2017, MOL CELL, V67, P214, DOI 10.1016/j.molcel.2017.05.023; Li YW, 2017, EMBO REP, V18, P1646, DOI 10.15252/embr.201643581; Liu J, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0630-y; Lu C, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0833-x; Meleshina AV, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0003-7; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Meng SJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0663-2; NIGRO JM, 1991, CELL, V64, P607, DOI 10.1016/0092-8674(91)90244-S; Oh SC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04179-8; Park JK, 2009, NEOPLASMA, V56, P119, DOI 10.4149/neo_2009_02_119; Pongor L, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0228-1; Qi JJ, 2016, GUT, V65, P1690, DOI 10.1136/gutjnl-2014-307900; Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733; Sarkar TR, 2015, ONCOGENE, V34, P2958, DOI 10.1038/onc.2014.245; Sierra B, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006220; Singh A, 2016, ONCOTARGET, V7, P17945, DOI 10.18632/oncotarget.7595; Sun GL, 2018, J GASTROENTEROL, V53, P725, DOI 10.1007/s00535-017-1408-0; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Vater I, 2015, LEUKEMIA, V29, P677, DOI 10.1038/leu.2014.264; Wang N, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0240-8; Weng WH, 2017, CLIN CANCER RES, V23, P3918, DOI 10.1158/1078-0432.CCR-16-2541; Yang YB, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx166; Yao ZC, 2017, MOL ONCOL, V11, P422, DOI 10.1002/1878-0261.12045; Yuan HJ, 2017, J CELL MOL MED, V21, P3254, DOI 10.1111/jcmm.13229; Zhang F, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201703326; Zhang J, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.006642; Zheng QP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11215; Zheng RS, 2016, CANCER LETT, V370, P33, DOI 10.1016/j.canlet.2015.10.003; Zhong ZY, 2017, CANCER LETT, V403, P305, DOI 10.1016/j.canlet.2017.06.027; Zhou Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160414	61	63	64	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2019	38	44					6985	7001		10.1038/s41388-019-0933-0	http://dx.doi.org/10.1038/s41388-019-0933-0			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ1AO	31409903				2022-12-17	WOS:000493892900003
J	Wang, C; Wang, G; Feng, X; Shepherd, P; Zhang, J; Tang, MF; Chen, Z; Srivastava, M; McLaughlin, ME; Navone, NM; Hart, GT; Chen, JJ				Wang, Chao; Wang, Gang; Feng, Xu; Shepherd, Peter; Zhang, Jie; Tang, Mengfan; Chen, Zhen; Srivastava, Mrinal; McLaughlin, Megan E.; Navone, Nora M.; Hart, Glen Traver; Chen, Junjie			Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition	ONCOGENE			English	Article							AICARDI-GOUTIERES-SYNDROME; CANCER-CELLS; REPLICATION STRESS; PROTEIN-KINASE; DNA-DAMAGE; H2; MUTATIONS; SENSITIVITY; PATHWAY; LEADS	Ataxia telangiectasia mutated and RAD3 related (ATR) protein kinase plays critical roles in ensuring DNA replication, DNA repair, and cell cycle control in response to replication stress, making ATR inhibition a promising therapeutic strategy for cancer treatment. To identify genes whose loss makes tumor cells hypersensitive to ATR inhibition, we performed CRISPR/ Cas9-based whole-genome screens in 3 independent cell lines treated with a highly selective ATR inhibitor, AZD6738. These screens uncovered a comprehensive genome-wide profile of ATR inhibitor sensitivity. From the candidate genes, we demonstrated that RNASEH2 deficiency is synthetic lethal with ATR inhibition both in vitro and in vivo. RNASEH2-deficient cells exhibited elevated levels of DNA damage and, when treated with AZD6738, underwent apoptosis (short-time treated) or senescence (long-time treated). Notably, RNASEH2 deficiency is frequently found in prostate adenocarcinoma; we found decreased RNASEH2B protein levels in prostate adenocarcinoma patient-derived xenograft (PDX) samples. Our findings suggest that ATR inhibition may be beneficial for cancer patients with reduced levels of RNASEH2 and that RNASEH2 merits further exploration as a potential biomarker for ATR inhibitor-based therapy.	[Wang, Chao; Feng, Xu; Zhang, Jie; Tang, Mengfan; Chen, Zhen; Srivastava, Mrinal; Chen, Junjie] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; [Wang, Gang; McLaughlin, Megan E.; Hart, Glen Traver] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA; [Shepherd, Peter; Navone, Nora M.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Chen, JJ (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA.	jchen8@mdanderson.org	Srivastava, Mrinal/AAM-5013-2020	Wang, Chao/0000-0001-6191-5261; Wang, Andy/0000-0001-6798-1032; Feng, Xu/0000-0003-1603-7070	CPRIT [RP160667]; NIH [CA157448, CA193124, CA210929, CA216911, CA216437]; MD Anderson's NIH Cancer Center Support Grant [CA016672]; NATIONAL CANCER INSTITUTE [P01CA193124, R01CA216437, R01CA216911, P01CA160032, R01CA210929, R01CA157448, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R35GM130119] Funding Source: NIH RePORTER	CPRIT; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MD Anderson's NIH Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the members of Dr. Junjie Chen's lab for their kind help and Dr. Lei Li for his suggestions regarding the experimental design. We also thank Amy Ninetto from the Department of Scientific Publications at MD Anderson for editing the manuscript. This work was supported in part by CPRIT (RP160667) and NIH grants (CA157448, CA193124, CA210929, CA216911, and CA216437) to JC and MD Anderson's NIH Cancer Center Support Grant (CA016672).	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Bartsch K, 2017, HUM MOL GENET, V26, P3960, DOI 10.1093/hmg/ddx283; Brown EJ, 2000, GENE DEV, V14, P397; Charrier JD, 2011, J MED CHEM, V54, P2320, DOI 10.1021/jm101488z; Checkley S, 2015, SCI REP-UK, V5, DOI 10.1038/srep13545; Chon H, 2013, NUCLEIC ACIDS RES, V41, P3130, DOI 10.1093/nar/gkt027; Crow YJ, 2006, NAT GENET, V38, P910, DOI 10.1038/ng1842; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Fokas E, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.181; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guichard SM, 2013, CANCER RES, V73, DOI 10.1158/1538-7445.AM2013-3343; Hall AB, 2014, ONCOTARGET, V5, P5674, DOI 10.18632/oncotarget.2158; Hart T, 2017, G3-GENES GENOM GENET, V7, P2719, DOI 10.1534/g3.117.041277; Hart T, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1015-8; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Hart T, 2014, MOL SYST BIOL, V10, DOI 10.15252/msb.20145216; He T, 2017, EPIGENOMICS-UK, V9, P849, DOI 10.2217/epi-2017-0019; Hiller B, 2012, J EXP MED, V209, P1419, DOI 10.1084/jem.20120876; Huang SD, 2012, CELL, V151, P937, DOI 10.1016/j.cell.2012.10.035; Keszthelyi A, 2016, GENES-BASEL, V7, DOI 10.3390/genes7120134; Kim H, 2017, CLIN CANCER RES, V23, P3097, DOI 10.1158/1078-0432.CCR-16-2273; Kim H, 2016, CLIN CANCER RES, V22, DOI 10.1158/1557-3265.OVCA15-A08; Kumar A, 2016, NAT MED, V22, P369, DOI 10.1038/nm.4053; Kwok M, 2016, BLOOD, V127, P582, DOI 10.1182/blood-2015-05-644872; Li T, 2018, J EXP MED, V215, P1287, DOI 10.1084/jem.20180139; Mackenzie KJ, 2016, EMBO J, V35, P831, DOI 10.15252/embj.201593339; McElhinny SAN, 2010, NAT CHEM BIOL, V6, P774, DOI [10.1038/nchembio.424, 10.1038/NCHEMBIO.424]; Mohni KN, 2014, CANCER RES, V74, P2835, DOI 10.1158/0008-5472.CAN-13-3229; Mu YH, 2016, EMBO REP, V17, P94, DOI 10.15252/embr.201540964; Pendergraft WF, 2015, J CLIN INVEST, V125, P102, DOI 10.1172/JCI78533; Perrino FW, 2009, J MOL MED-JMM, V87, P25, DOI 10.1007/s00109-008-0422-3; Pizzi S, 2015, HUM MOL GENET, V24, P649, DOI 10.1093/hmg/ddu485; Pokatayev V, 2016, J EXP MED, V213, P329, DOI 10.1084/jem.20151464; Prevo R, 2012, CANCER BIOL THER, V13, P1072, DOI 10.4161/cbt.21093; Reaper PM, 2011, NAT CHEM BIOL, V7, P428, DOI [10.1038/NCHEMBIO.573, 10.1038/nchembio.573]; Reijns MAM, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.011; Rice GI, 2013, HUM MUTAT, V34, P1066, DOI 10.1002/humu.22336; Robinson D, 2015, CELL, V162, P454, DOI 10.1016/j.cell.2015.06.053; Ruiz S, 2016, MOL CELL, V62, P307, DOI 10.1016/j.molcel.2016.03.006; Rundle S, 2017, CANCERS, V9, DOI 10.3390/cancers9050041; Saldivar JC, 2017, NAT REV MOL CELL BIO, V18, P622, DOI 10.1038/nrm.2017.67; Sidik SM, 2016, CELL, V166, P1423, DOI 10.1016/j.cell.2016.08.019; Steinhart Z, 2017, NAT MED, V23, P60, DOI 10.1038/nm.4219; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Techer H, 2017, NAT REV GENET, V18, P535, DOI 10.1038/nrg.2017.46; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Williams JS, 2017, DNA REPAIR, V53, P52, DOI 10.1016/j.dnarep.2017.02.016; Williamson CT, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13837; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Yang H, 2017, P NATL ACAD SCI USA, V114, pE4612, DOI 10.1073/pnas.1705499114; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhu SY, 2017, METHODS MOL BIOL, V1656, P175, DOI 10.1007/978-1-4939-7237-1_11; Zimmermann M, 2018, NATURE, V559, P285, DOI 10.1038/s41586-018-0291-z	54	63	63	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2451	2463		10.1038/s41388-018-0606-4	http://dx.doi.org/10.1038/s41388-018-0606-4			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30532030	Green Accepted			2022-12-17	WOS:000463335200002
J	Ramirez-Moya, J; Wert-Lamas, L; Santisteban, P				Ramirez-Moya, Julia; Wert-Lamas, Leon; Santisteban, Pilar			MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN	ONCOGENE			English	Article							NF-KAPPA-B; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; MOLECULAR PATHOGENESIS; GENETIC ALTERATIONS; EXPRESSION; MIR-146B; PROTEIN; MUTATIONS; STAT3	Recent studies have shown that miR-146b is the most upregulated microRNA in thyroid cancer and has a central role in cancer progression through mechanisms that remain largely unidentified. As phosphoinositide 3-kinase/protein kinase-B (PI3K/AKT) signaling is a fundamental oncogenic driver in many thyroid cancers, we explored a potential role for miR-146b and its target genes in PI3K/AKT activation. Among the predicted target genes of miR-146b, we found the tumor-suppressor phosphatase and tensin homolog (PTEN). Constitutive overexpression of miR-146b in thyroid epithelial cell lines significantly decreased PTEN mRNA and protein levels by direct binding to its 3'-UTR. This was accompanied by PI3K/AKT hyperactivation, leading to the exclusion of FOXO1 and p27 from the nucleus and a corresponding increase in cellular proliferation. Moreover, miR-146b overexpression led to protection from apoptosis and an increased migration and invasion potential, regulating genes involved in epithelial-mesenchymal transition. Notably, with the single exception of E-cadherin expression, all of these outcomes could be reversed by PTEN coexpression. Further analysis showed that miR-146b directly inhibits E-cadherin expression through binding to its 3'-UTR. Interestingly, miR-146b inhibition in human thyroid tumor xenografts, using a synthetic and clinically amenable molecule, blocked tumor growth when delivered intratumorally. Importantly, this inhibition increased PTEN protein levels. In conclusion, our data define a novel mechanism of PI3K/AKT hyperactivation and outline a regulatory role for miR-146b in suppressing PTEN expression, a frequent observation in thyroid cancer. Both events are related to a more aggressive tumoral phenotype. Targeting miR-146b therefore represents a promising therapeutic strategy for the treatment of this disease.	[Ramirez-Moya, Julia; Wert-Lamas, Leon; Santisteban, Pilar] Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Madrid, Spain; [Ramirez-Moya, Julia; Wert-Lamas, Leon; Santisteban, Pilar] Univ Autonoma Madrid, CSIC, Madrid, Spain; [Santisteban, Pilar] Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Instituto de Salud Carlos III	Santisteban, P (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Madrid, Spain.; Santisteban, P (corresponding author), Univ Autonoma Madrid, CSIC, Madrid, Spain.; Santisteban, P (corresponding author), Inst Salud Carlos III, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain.	psantisteban@iib.uam.es	Wert-Lamas, Leon/ABD-2880-2020; Ramírez-Moya, Julia/B-9104-2018; Santisteban, Pilar/E-7829-2016	Ramírez-Moya, Julia/0000-0002-2458-2186; Santisteban, Pilar/0000-0002-2758-796X	Ministerio de Economia y Competitividad (MINECO) of Spain [SAF2013-44709-R, SAF2016-75531-R]; Instituto de Salud Carlos III (ISCIII), Fondo Europeo de Desarrollo Regional (FEDER) [RD12/0036/0030]; Fundacion Espanola contra el Cancer [GCB14142311CRES]; Ministerio de Educacion Cultura y Deporte; MEC; ISCIII (Spain) [PI14/01980]	Ministerio de Economia y Competitividad (MINECO) of Spain(Spanish Government); Instituto de Salud Carlos III (ISCIII), Fondo Europeo de Desarrollo Regional (FEDER); Fundacion Espanola contra el Cancer; Ministerio de Educacion Cultura y Deporte(Spanish Government); MEC(European Commission); ISCIII (Spain)(Instituto de Salud Carlos III)	We are grateful to Andrea Martinez-Cano for her technical assistance, Javier Perez for the artwork and Dr Kenneth McCreath for helpful comments on the manuscript. We thank Dr Jeronimo Blanco (Catalonian Institute for Advance Chemistry-CSIC) and Dr Eugenia Mato (Institut de Reserca de l'Hospital de la Santa Creu i Sant Pau) Barcelona (Spain) for gifting the CMV-Firefly luc-IRES-EGFP and Cal62-Luc cells, respectively. We also thank the Histology Facility at CNB-CSIC for the histological preparation of biological samples. This work was supported by grants SAF2013-44709-R and SAF2016-75531-R from the Ministerio de Economia y Competitividad (MINECO) of Spain, RD12/0036/0030 from Instituto de Salud Carlos III (ISCIII), Fondo Europeo de Desarrollo Regional (FEDER), and GCB14142311CRES from Fundacion Espanola contra el Cancer. JR-M holds a FPU fellowship from Ministerio de Educacion Cultura y Deporte. LW-L was funded by an FPI fellowship from MEC and is currently an investigator of the project PI14/01980 from ISCIII (Spain).	Acibucu F, 2014, EXP CLIN ENDOCR DIAB, V122, P137, DOI 10.1055/s-0034-1367025; Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Bruni P, 2000, ONCOGENE, V19, P3146, DOI 10.1038/sj.onc.1203633; Burger ML, 2014, BLOOD, V123, P4089, DOI 10.1182/blood-2013-11-539411; Chou CK, 2016, J CLIN ENDOCR METAB, V101, P4357, DOI 10.1210/jc.2016-2276; Chou CK, 2013, J CLIN ENDOCR METAB, V98, pE196, DOI 10.1210/jc.2012-2666; Couto JP, 2012, P NATL ACAD SCI USA, V109, pE2361, DOI 10.1073/pnas.1201232109; Deng XZ, 2015, CELL PHYSIOL BIOCHEM, V35, P71, DOI 10.1159/000369676; Dettmer M, 2013, THYROID, V23, P1383, DOI 10.1089/thy.2012.0632; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fahiminiya S, 2016, NEW ENGL J MED, V375, P2306, DOI 10.1056/NEJMc1613118; Fassina A, 2014, CANCER CYTOPATHOL, V122, P274, DOI 10.1002/cncy.21383; Frisk T, 2002, GENE CHROMOSOME CANC, V35, P74, DOI 10.1002/gcc.10098; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Fuziwara CS, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/743450; Garcia-Rostan G, 2005, CANCER RES, V65, P10199, DOI 10.1158/0008-5472.CAN-04-4259; Geraldo MV, 2012, ONCOGENE, V31, P1910, DOI 10.1038/onc.2011.381; Greene SB, 2010, J CELL SCI, V123, P606, DOI 10.1242/jcs.056812; Guigon CJ, 2009, ONCOGENE, V28, P509, DOI 10.1038/onc.2008.407; Hein AL, 2014, INT J ONCOL, V45, P1813, DOI 10.3892/ijo.2014.2614; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Lancia I, 2016, J CLIN INVEST, V126, P1052, DOI 10.1172/JCI85271; Larrea MD, 2009, CELL CYCLE, V8, P3455, DOI 10.4161/cc.8.21.9789; Lee JC, 2013, CANCER-AM CANCER SOC, V119, P4358, DOI 10.1002/cncr.28254; LEMOINE NR, 1989, BRIT J CANCER, V60, P897, DOI 10.1038/bjc.1989.387; Li ZH, 2014, NAT REV DRUG DISCOV, V13, P622, DOI 10.1038/nrd4359; Lim H, 2017, JAMA-J AM MED ASSOC, V317, P1338, DOI 10.1001/jama.2017.2719; Lima CR, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2146-z; Liu CP, 2016, SCI REP-UK, V6, DOI 10.1038/srep36990; Liu FH, 2005, J CELL BIOCHEM, V96, P221, DOI 10.1002/jcb.20525; Liu RY, 2017, JAMA ONCOL, V3, P202, DOI 10.1001/jamaoncol.2016.3288; Liu Z, 2008, J CLIN ENDOCR METAB, V93, P3106, DOI 10.1210/jc.2008-0273; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Medina DL, 1999, ENDOCRINOLOGY, V140, P87, DOI 10.1210/en.140.1.87; Miller KA, 2009, CANCER RES, V69, P3689, DOI 10.1158/0008-5472.CAN-09-0024; Nikiforov YE, 2011, NAT REV ENDOCRINOL, V7, P569, DOI 10.1038/nrendo.2011.142; Pacifico F, 2010, MOL CELL ENDOCRINOL, V321, P29, DOI 10.1016/j.mce.2009.10.010; Paes JE, 2008, ENDOCRIN METAB CLIN, V37, P375, DOI 10.1016/j.ecl.2008.01.001; Pallante P, 2014, NAT REV ENDOCRINOL, V10, P88, DOI 10.1038/nrendo.2013.223; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pirnia F, 2002, CELL DEATH DIFFER, V9, P905, DOI 10.1038/sj.cdd.4401062; Ricarte-Filho JC, 2009, CANCER RES, V69, P4885, DOI 10.1158/0008-5472.CAN-09-0727; Riesco-Eizaguirre G, 2016, EUR J ENDOCRINOL, V175, pR203, DOI 10.1530/EJE-16-0202; Riesco-Eizaguirre G, 2015, CANCER RES, V75, P4119, DOI 10.1158/0008-5472.CAN-14-3547; Riesco-Eizaguirre G, 2009, CANCER RES, V69, P8317, DOI 10.1158/0008-5472.CAN-09-1248; Santarpia L, 2008, J CLIN ENDOCR METAB, V93, P278, DOI 10.1210/jc.2007-1076; SANTISTEBAN P, 1992, MOL ENDOCRINOL, V6, P1310, DOI 10.1210/me.6.8.1310; Sastre-Perona A, 2016, ONCOTARGET, V7, P49435, DOI 10.18632/oncotarget.10356; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Sosonkina N, 2014, CANCERS, V6, P526, DOI 10.3390/cancers6010526; Su XY, 2016, ONCOTARGETS THER, V9, P6965, DOI 10.2147/OTT.S116594; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang J, 2010, NUCLEIC ACIDS RES, V38, pD119, DOI 10.1093/nar/gkp803; Wojtas B, 2014, MOL CELL ENDOCRINOL, V388, P1, DOI 10.1016/j.mce.2014.02.011; Xiang M, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004497; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Xing MZ, 2010, THYROID, V20, P697, DOI 10.1089/thy.2010.1646; Xu B, 2017, THYROID, V27, P632, DOI 10.1089/thy.2016.0582; Yeager N, 2007, CANCER RES, V67, P959, DOI 10.1158/0008-5472.CAN-06-3524; Zaballos MA, 2013, MOL ENDOCRINOL, V27, P50, DOI 10.1210/me.2012-1032	62	63	64	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	25					3369	3383		10.1038/s41388-017-0088-9	http://dx.doi.org/10.1038/s41388-017-0088-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TC	29353884				2022-12-17	WOS:000436411300004
J	Cuyas, E; Fernandez-Arroyo, S; Verdura, S; Garcia, RAF; Stursa, J; Werner, L; Blanco-Gonzalez, E; Montes-Bayon, M; Joven, J; Viollet, B; Neuzil, J; Menendez, JA				Cuyas, E.; Fernandez-Arroyo, S.; Verdura, S.; Garcia, R. A-F; Stursa, J.; Werner, L.; Blanco-Gonzalez, E.; Montes-Bayon, M.; Joven, J.; Viollet, B.; Neuzil, J.; Menendez, J. A.			Metformin regulates global DNA methylation via mitochondrial one-carbon metabolism	ONCOGENE			English	Article							HUMAN CELL-LINE; MESENCHYMAL TRANSITION; CANCER-CELLS; GENOME-WIDE; BREAST-CANCER; BRCA1 LEADS; AMP-KINASE; BIGUANIDES; SERINE; REVEALS	The anti-diabetic biguanide metformin may exert health-promoting effects via metabolic regulation of the epigenome. Here we show that metformin promotes global DNA methylation in non-cancerous, cancer-prone and metastatic cancer cells by decreasing S-adenosylhomocysteine (SAH), a strong feedback inhibitor of S-adenosylmethionine (SAM)-dependent DNA methyltransferases, while promoting the accumulation of SAM, the universal methyl donor for cellular methylation. Using metformin and a mitochondria/complex I (mCI)-targeted analog of metformin (norMitoMet) in experimental pairs of wild-type and AMP-activated protein kinase (AMPK)-, serine hydroxymethyltransferase 2 (SHMT2)- and mCI-null cells, we provide evidence that metformin increases the SAM: SAH ratio-related methylation capacity by targeting the coupling between serine mitochondrial one-carbon flux and CI activity. By increasing the contribution of one-carbon units to the SAM from folate stores while decreasing SAH in response to AMPK-sensed energetic crisis, metformin can operate as a metabolo-epigenetic regulator capable of reprogramming one of the key conduits linking cellular metabolism to the DNA methylation machinery.	[Cuyas, E.; Verdura, S.; Menendez, J. A.] Catalan Inst Oncol, Metab & Canc Grp, ProCURE Program Canc Therapeut Resistance, Girona, Catalonia, Spain; [Cuyas, E.; Verdura, S.; Menendez, J. A.] Girona Biomed Res Inst IDIBGI, Girona, Catalonia, Spain; [Fernandez-Arroyo, S.; Joven, J.] Univ Rovira & Virgili, Inst Invest Sanitaria Pere Virgili, Hosp Univ St Joan, Unitat Recerca Biomed, Reus, Spain; [Fernandez-Arroyo, S.; Joven, J.] Campus Int Excellence Southern Catalonia, Tarragona, Spain; [Garcia, R. A-F; Blanco-Gonzalez, E.; Montes-Bayon, M.] Univ Oviedo, Fac Chem, Dept Phys & Analyt Chem, Oviedo, Spain; [Stursa, J.; Werner, L.; Neuzil, J.] Inst Chem Technol, Prague, Czech Republic; [Stursa, J.; Werner, L.] Czech Acad Sci, Inst Biotechnol, Prague West, Czech Republic; [Viollet, B.] Inst Cochin, INSERM, U1016, Paris, France; [Viollet, B.] CNRS, UMR 8104, Paris, France; [Viollet, B.] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Neuzil, J.] Griffith Univ, Sch Med Sci, Southport, Qld, Australia	Catalan Institute of Oncology; Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Institut d'Investigacio Biomedica de Girona (IDIBGI); Universitat Rovira i Virgili; Institut d'Investigacio Sanitaria Pere Virgili (IISPV); University of Oviedo; University of Chemistry & Technology, Prague; Czech Academy of Sciences; Institute of Biotechnology of the Czech Academy of Sciences; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Griffith University	Menendez, JA (corresponding author), Girona Biomed Res Inst IDIBGI, Edifici M2,Parc Hosp Marti & Julia, E-17190 Salt, Girona, Spain.	jmenendez@iconcologia.net	Viollet, Benoit/N-2397-2019; Fernández-Arroyo, Salvador/M-6955-2015; Viollet, Benoit/O-6927-2017; Stursa, Jan/J-4255-2014; Cuyas, Elisabet/G-8582-2018; WERNER, LUKÁŠ/AAL-7888-2021; verdura, Sara/AAC-3696-2022; MENENDEZ, JAVIER A/C-6148-2016	Viollet, Benoit/0000-0002-0121-0224; Fernández-Arroyo, Salvador/0000-0003-0147-1712; Viollet, Benoit/0000-0002-0121-0224; verdura, Sara/0000-0001-8980-0423; MENENDEZ, JAVIER A/0000-0001-8733-4561; Cuyas, Elisabet/0000-0001-5353-440X; Alvarez-Fernandez Garcia, Roberto/0000-0002-9537-2215; /0000-0002-2844-6739; Montes-Bayon, Maria/0000-0001-6114-9405	Ministerio de Ciencia e Innovacion [SAF2016-80639-P]; Plan Nacional de I+D+I, Spain; Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) [2014 SGR229]; Department d'Economia I Coneixement, Catalonia, Spain; Czech Science Foundation [16-12816S]; Czech Health Research Council [16-31704A]; Ministerio de Sanidad y Consumo, Fondo de Investigacion Sanitaria (FIS), Spain [CD15/00033]; Armangue family (Girona, Catalonia)	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Plan Nacional de I+D+I, Spain(Spanish Government); Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR)(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); Department d'Economia I Coneixement, Catalonia, Spain; Czech Science Foundation(Grant Agency of the Czech Republic); Czech Health Research Council; Ministerio de Sanidad y Consumo, Fondo de Investigacion Sanitaria (FIS), Spain(Instituto de Salud Carlos III); Armangue family (Girona, Catalonia)	This work was supported in part by grants from the Ministerio de Ciencia e Innovacion (Grant SAF2016-80639-P), Plan Nacional de I+D+I, Spain and the Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) (Grant 2014 SGR229), Department d'Economia I Coneixement, Catalonia, Spain, to Javier A Menendez and grants from the Czech Science Foundation (16-12816S) to Jan Stursa and Lukas Werner and the Czech Health Research Council (16-31704A) to Jiri Neuzil. Elisabet Cuyas is supported by a Sara Borrell post-doctoral contract CD15/00033 from the Ministerio de Sanidad y Consumo, Fondo de Investigacion Sanitaria (FIS), Spain, The Metabolism and Cancer laboratory is supported by an unrestricted grant from the Armangue family (Girona, Catalonia). This work is in memory of Joan Armangue who passed away after his brave fight against cancer in November 2016.	Banerjee P, 2016, J MOL MED, V94, P1397, DOI 10.1007/s00109-016-1455-7; Barzilai N, 2016, CELL METAB, V23, P1060, DOI 10.1016/j.cmet.2016.05.011; Boukalova S, 2016, MOL CANCER THER, V15, P2875, DOI 10.1158/1535-7163.MCT-15-1021; Bridges HR, 2016, BMC BIOL, V14, DOI 10.1186/s12915-016-0287-9; Cabreiro F, 2013, CELL, V153, P228, DOI 10.1016/j.cell.2013.02.035; Caudill MA, 2001, J NUTR, V131, P2811, DOI 10.1093/jn/131.11.2811; Cecco M, 2013, AGING CELL, V12, P247, DOI 10.1111/acel.12047; Cheng G, 2016, CANCER RES, V76, P3904, DOI 10.1158/0008-5472.CAN-15-2534; Corominas-Faja B, 2012, AGING-US, V4, P480, DOI 10.18632/aging.100472; Cuyas E, 2016, ONCOTARGET, V7, P52974, DOI 10.18632/oncotarget.9732; Cuyas E, 2014, ONCOTARGET, V5, P3970, DOI 10.18632/oncotarget.2147; Duncan CG, 2012, GENOME RES, V22, P2339, DOI 10.1101/gr.132738.111; Essletzbichler P, 2014, GENOME RES, V24, P2059, DOI 10.1101/gr.177220.114; Fernandez-Arroyo S., 2016, ONCOSCIENCE, V2, P958, DOI [10.18632/oncoscience.280, DOI 10.18632/ONCOSCIENCE.280]; Foretz M, 2014, CELL METAB, V20, P953, DOI 10.1016/j.cmet.2014.09.018; Gravel SP, 2014, CANCER RES, V74, P7521, DOI 10.1158/0008-5472.CAN-14-2643-T; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Houde VP, 2014, BIOCHEM J, V458, P41, DOI 10.1042/BJ20131324; Huang X, 2008, BIOCHEM J, V412, P211, DOI 10.1042/BJ20080557; Iglesias T, 2015, ANAL BIOANAL CHEM, V407, P2423, DOI 10.1007/s00216-014-8070-7; Kinnaird A, 2016, NAT REV CANCER, V16, P694, DOI 10.1038/nrc.2016.82; Kitkumthorn N, 2011, CLIN EPIGENETICS, V2, P315, DOI 10.1007/s13148-011-0032-8; Kodiha M, 2011, AM J PHYSIOL-CELL PH, V301, pC1307, DOI 10.1152/ajpcell.00309.2011; Konishi H, 2011, P NATL ACAD SCI USA, V108, P17773, DOI 10.1073/pnas.1110969108; Kotecki M, 1999, EXP CELL RES, V252, P273, DOI 10.1006/excr.1999.4656; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Liu XJ, 2016, CELL METAB, V24, P728, DOI 10.1016/j.cmet.2016.09.005; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Lopez-Otin C, 2016, CELL, V166, P802, DOI 10.1016/j.cell.2016.07.031; Maddocks ODK, 2017, NATURE, V544, P372, DOI 10.1038/nature22056; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mattaini KR, 2016, J CELL BIOL, V214, P248, DOI 10.1083/jcb.201604085; Meiser J, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1601273; Meiser J, 2016, FEBS J, V283, P3695, DOI 10.1111/febs.13731; Menendez JA, 2016, ONCOTARGET, V7, P11959, DOI 10.18632/oncotarget.7867; Menendez JA, 2016, STEM CELL REP, V6, P273, DOI 10.1016/j.stemcr.2015.12.012; Miller RA, 2013, NATURE, V494, P256, DOI 10.1038/nature11808; Miousse IR, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/131547; Newman AC, 2017, TRENDS CELL BIOL, V27, P645, DOI 10.1016/j.tcb.2017.05.001; Newman AC, 2017, BRIT J CANCER, V116, P1499, DOI 10.1038/bjc.2017.118; Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607; Pal S, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600584; Pollak M, 2013, J CLIN INVEST, V123, P3693, DOI 10.1172/JCI67232; Ross FA, 2016, BIOCHEM J, V473, P189, DOI 10.1042/BJ20150910; Sedic M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8505; Sharma U, 2017, CELL METAB, V25, P544, DOI 10.1016/j.cmet.2017.02.003; Talarico G, 2016, SCI REP-UK, V6, DOI 10.1038/srep18673; Tan AS, 2015, CELL METAB, V21, P81, DOI 10.1016/j.cmet.2014.12.003; Ulanovskaya OA, 2013, NAT CHEM BIOL, V9, P300, DOI [10.1038/NCHEMBIO.1204, 10.1038/nchembio.1204]; Vazquez-Martin A, 2010, CELL CYCLE, V9, P3807, DOI 10.4161/cc.9.18.13131; Viollet B, 2012, CLIN SCI, V122, P253, DOI 10.1042/CS20110386; Wheaton WW, 2014, ELIFE, V3, DOI 10.7554/eLife.02242; Yang M, 2013, J CLIN INVEST, V123, P3652, DOI 10.1172/JCI67228; Yang QY, 2016, CELL METAB, V24, P542, DOI 10.1016/j.cmet.2016.08.010; Zhong T, 2017, ONCOGENE, V36, P2345, DOI 10.1038/onc.2016.391; Zhou JC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10221	56	63	66	1	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					963	970		10.1038/onc.2017.367	http://dx.doi.org/10.1038/onc.2017.367			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059169				2022-12-17	WOS:000425281800013
J	Lucanus, AJ; Yip, GW				Lucanus, A. J.; Yip, G. W.			Kinesin superfamily: roles in breast cancer, patient prognosis and therapeutics	ONCOGENE			English	Review							SPINDLE PROTEIN INHIBITOR; FAST AXONAL-TRANSPORT; MOTOR PROTEIN; HEAVY-CHAIN; LAMELLIPODIA FORMATION; CELLS; MICROTUBULES; GENES; OVEREXPRESSION; APOPTOSIS	Breast cancer pathobiology is known to be influenced by the differential expression of a group of proteins called the kinesin superfamily (KIFs), which is instrumental in the intracellular transport of chromosomes along microtubules during mitosis. During cellular division, kinesins are strictly regulated through temporal synthesis so that they are present only when needed. However, their misregulation may contribute to uncontrolled cell growth owing to premature sister chromatid separation, highlighting their importance in cancer. This review covers the functions of kinesins in normal and breast cancer cells, the use of kinesins for breast cancer patient prognosis, and the targeting of these molecules for therapeutics. A better understanding of KIF proteins may be pivotal to improved disease outcomes for breast cancer patients.	[Lucanus, A. J.] Univ Western Australia, Sch Anat Human Biol & Physiol, Crawley, WA, Australia; [Lucanus, A. J.; Yip, G. W.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, 4 Med Dr,Block MD 10, Singapore 117594, Singapore	University of Western Australia; National University of Singapore	Yip, GW (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, 4 Med Dr,Block MD 10, Singapore 117594, Singapore.	georgeyip@nus.edu.sg		Lucanus, Anton/0000-0003-1801-5166	National Medical Research Council, Singapore [NMRC/CSA/0041/2012, NMRC/CIRG/1436/2015]; Australian Government's Department of Foreign Affairs and Trade	National Medical Research Council, Singapore(National Medical Research Council, Singapore); Australian Government's Department of Foreign Affairs and Trade(Australian Government)	The technical assistance of SL Bay in the preparation of Figure 1 is deeply appreciated. Work in the laboratory of GW Yip is supported by Grants NMRC/CSA/0041/2012 and NMRC/CIRG/1436/2015 from the National Medical Research Council, Singapore. AJ Lucanus thanks the Australian Government's Department of Foreign Affairs and Trade for the New Colombo Plan Scholarship. We apologise for the use of review articles and the failure to cite many relevant primary articles as a result of space constraints.	Ahmed SM, 2012, J CELL BIOL, V199, P951, DOI 10.1083/jcb.201206051; AIZAWA H, 1992, J CELL BIOL, V119, P1287, DOI 10.1083/jcb.119.5.1287; Banerjee M, 2010, FEBS J, V277, P3437, DOI 10.1111/j.1742-4658.2010.07750.x; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; Cardoso CMP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004424; Castillo A, 2007, CANCER RES, V67, P10138, DOI 10.1158/0008-5472.CAN-07-0326; Corson TW, 2006, INT J CANCER, V119, P1088, DOI 10.1002/ijc.21954; Corson TW, 2005, ONCOGENE, V24, P4741, DOI 10.1038/sj.onc.1208641; CYR JL, 1991, P NATL ACAD SCI USA, V88, P10114, DOI 10.1073/pnas.88.22.10114; Dagenbach EM, 2004, J CELL SCI, V117, P3, DOI 10.1242/jcs.00875; De Iuliis F, 2016, INVEST NEW DRUG, V34, P399, DOI 10.1007/s10637-016-0345-8; De S, 2009, CANCER RES, V69, P8035, DOI 10.1158/0008-5472.CAN-09-1224; Diefenbach RJ, 1998, BIOCHEMISTRY-US, V37, P16663, DOI 10.1021/bi981163r; Feng Yu-mei, 2006, Zhonghua Yi Xue Za Zhi, V86, P2749; Feng Yu-Mei, 2006, Ai Zheng, V25, P744; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Froidevaux-Klipfel L, 2011, PROTEOMICS, V11, P3877, DOI 10.1002/pmic.201000789; Ganguly A, 2011, MOL CANCER THER, V10, P929, DOI 10.1158/1535-7163.MCT-10-1109; Goldstein LSB, 1999, ANNU REV CELL DEV BI, V15, P141, DOI 10.1146/annurev.cellbio.15.1.141; Gomez HL, 2012, ANTI-CANCER DRUG, V23, P335, DOI 10.1097/CAD.0b013e32834e74d6; Groth-Pedersen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045381; Guerrero-Preston R, 2014, ONCOL REP, V32, P505, DOI 10.3892/or.2014.3262; Guido BC, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1274-1; Hallen MA, 2008, J CELL SCI, V121, P3834, DOI 10.1242/jcs.038497; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Holen KD, 2011, CANCER CHEMOTH PHARM, V67, P447, DOI 10.1007/s00280-010-1346-5; Hurd DD, 1996, GENETICS, V144, P1075; Itzel T, 2015, BIOINFORMATICS, V31, P216, DOI 10.1093/bioinformatics/btu586; Kapitein LC, 2005, NATURE, V435, P114, DOI 10.1038/nature03503; Kasahara M, 2016, ONCOL LETT, V12, P1909, DOI 10.3892/ol.2016.4823; Khongkow P, 2016, ONCOGENE, V35, P990, DOI 10.1038/onc.2015.152; Kim S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9087; Lawrence CJ, 2004, J CELL BIOL, V167, P19, DOI 10.1083/jcb.200408113; Li YH, 2015, CANCER BIOL THER, V16, P1316, DOI 10.1080/15384047.2015.1070980; Liu XR, 2012, J CELL MOL MED, V16, P1298, DOI 10.1111/j.1582-4934.2011.01396.x; Miki H, 2001, P NATL ACAD SCI USA, V98, P7004, DOI 10.1073/pnas.111145398; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Okada Y, 2000, P NATL ACAD SCI USA, V97, P640, DOI 10.1073/pnas.97.2.640; OKADA Y, 1995, CELL, V81, P769, DOI 10.1016/0092-8674(95)90538-3; Oki E, 2012, J GASTROENTEROL, V47, P351, DOI 10.1007/s00535-012-0565-4; Ostrow KL, 2009, CLIN CANCER RES, V15, P1184, DOI 10.1158/1078-0432.CCR-08-1304; Pannu V, 2015, ONCOTARGET, V6, P6076, DOI 10.18632/oncotarget.3475; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Rosenbaum JL, 2002, NAT REV MOL CELL BIO, V3, P813, DOI 10.1038/nrm952; Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008-5472.CAN-03-3839; Sanhaji M, 2011, ONCOTARGET, V2, P935; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; Scanlan M J, 2001, Cancer Immun, V1, P4; Shankaraiah N, 2014, BIOORG MED CHEM LETT, V24, P5413, DOI 10.1016/j.bmcl.2014.10.038; Shimo A, 2008, CANCER SCI, V99, P62, DOI 10.1111/j.1349-7006.2007.00635.x; Singel SM, 2014, NEOPLASIA, V16, DOI 10.1016/j.neo.2014.03.008; Singel SM, 2013, CLIN CANCER RES, V19, P2061, DOI 10.1158/1078-0432.CCR-13-0082; Skold HN, 2005, J CELL SCI, V118, P1745, DOI 10.1242/jcs.02304; Suzuki K, 2008, BIOCHEM BIOPH RES CO, V368, P199, DOI 10.1016/j.bbrc.2008.01.069; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; Takahashi K, 2008, EXP CELL RES, V314, P2313, DOI 10.1016/j.yexcr.2008.04.009; Tan MH, 2012, BREAST CANCER RES TR, V131, P849, DOI 10.1007/s10549-011-1500-8; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Wang CQ, 2015, CANCER LETT, V368, P105, DOI 10.1016/j.canlet.2015.07.037; Wang H, 2014, MOL CELLS, V37, P812, DOI 10.14348/molcells.2014.0210; Wang JL, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-461; Wang L, 2002, CURR BIOL, V12, P1496, DOI 10.1016/S0960-9822(02)01078-3; Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061640; Weil A, 2002, BIOTECHNIQUES, V33, P1244, DOI 10.2144/02336st01; Wordeman L, 2010, SEMIN CELL DEV BIOL, V21, P260, DOI 10.1016/j.semcdb.2010.01.018; Wu JQ, 2013, ACS CHEM BIOL, V8, P2201, DOI 10.1021/cb400186w; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; Yoon JR, 2011, BREAST CANCER RES TR, V129, P691, DOI 10.1007/s10549-010-1239-7; Zhang CP, 2010, CARCINOGENESIS, V31, P1676, DOI 10.1093/carcin/bgq134; Zhang W, 2016, BIOCHEM J, V473, P1027, DOI 10.1042/BJ20150992; Zhu L, 2016, ANTI-CANCER DRUG, V27, P863, DOI 10.1097/CAD.0000000000000402; Zou JX, 2014, MOL CANCER RES, V12, P539, DOI 10.1158/1541-7786.MCR-13-0459	75	63	67	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					833	838		10.1038/onc.2017.406	http://dx.doi.org/10.1038/onc.2017.406			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059174				2022-12-17	WOS:000425281800001
J	Heydt, Q; Larrue, C; Saland, E; Bertoli, S; Sarry, JE; Besson, A; Manenti, S; Joffre, C; Mas, VMD				Heydt, Q.; Larrue, C.; Saland, E.; Bertoli, S.; Sarry, J-E; Besson, A.; Manenti, S.; Joffre, C.; Mas, V. Mansat-De			Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia	ONCOGENE			English	Article							INTEGRATED STRESS-RESPONSE; CELL-DEATH; AML CELLS; INHIBITOR; DEGRADATION; CANCER; PROLIFERATION; SURVIVAL; THERAPY; PATHWAY	In acute myeloid leukemia (AML), internal tandem duplication mutations in the FLT3 tyrosine kinase receptor (FLT3-ITD) account for up to 25% of cases and are associated with a poor outcome. In order to better target this AML subtype, a comprehensive view of how FLT3-ITD impacts AML cell biology is required. Here, we found that FLT3-ITD expression increased basal autophagy in AML cells, and that both pharmacological and genetic inhibition of the receptor reduced autophagy in primary AML samples and cell lines. Conditional expression of shRNAs against key autophagy proteins demonstrated that autophagy is required for AML cell proliferation in vitro and for leukemic cells survival in a mouse model of xenograft. Importantly, autophagy inhibition also overcame FLT3 inhibitor resistance both in vitro and in vivo. The transcription factor ATF4 was identified as an essential actor of FLT3-ITD-induced autophagy. Cellular levels of ATF4 were highly dependent on FLT3-ITD activity, and downregulation of ATF4 inhibited autophagy-dependent AML cell proliferation and improved overall mouse survival similarly to autophagy inhibition. These results suggest that targeting autophagy or ATF4 in patients expressing FLT3 mutations may represent a novel promising and innovative therapeutic strategy for AML.	[Heydt, Q.; Larrue, C.; Saland, E.; Sarry, J-E; Besson, A.; Manenti, S.; Joffre, C.; Mas, V. Mansat-De] Univ Toulouse, CNRS, INSERM, U1037,ERL5294,CRCT, Toulouse, France; [Heydt, Q.; Manenti, S.; Joffre, C.; Mas, V. Mansat-De] La Ligue Canc, Equipe Labellisee, Toulouse, France; [Bertoli, S.] IUCT O, Serv Hematol, Toulouse, France; [Mas, V. Mansat-De] Inst Univ Canc Toulouse Oncopole, Lab Hematol, 1 Ave Irene Joliot Curie, F-31059 Toulouse 9, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Mas, VMD (corresponding author), Inst Univ Canc Toulouse Oncopole, Lab Hematol, 1 Ave Irene Joliot Curie, F-31059 Toulouse 9, France.; Joffre, C (corresponding author), CRCT, 2 Ave Hubert Curien, F-31037 Toulouse 1, France.	carine.joffre@inserm.fr; demas.veronique@iuct-oncopole.fr	JOFFRE, Carine/P-1551-2014; Besson, Arnaud/J-6254-2014; Sarry, Jean-Emmanuel/P-1633-2014; Sarry, Jean-Emmanuel/AAC-3664-2020; SALAND, Estelle/W-7996-2019; Bertoli, Sarah/GMZ-5043-2022; De Mas, Véronique/P-2414-2014; manenti, stephane/P-1518-2014	JOFFRE, Carine/0000-0002-7551-356X; Besson, Arnaud/0000-0002-9599-3943; Sarry, Jean-Emmanuel/0000-0002-6704-2032; Sarry, Jean-Emmanuel/0000-0002-6704-2032; Bertoli, Sarah/0000-0003-1084-2781; manenti, stephane/0000-0002-4793-3196; Larrue, Clement/0000-0001-5827-8433	ANR LABEX TOUCAN; Canceropole GSO; la Ligue regionale contre le Cancer; la Ligue nationale contre le Cancer; Ligue Nationale contre le Cancer	ANR LABEX TOUCAN(French National Research Agency (ANR)); Canceropole GSO; la Ligue regionale contre le Cancer; la Ligue nationale contre le Cancer(Ligue nationale contre le cancer); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer)	We are very grateful to Jerome Tamburini (Institut Cochin, Paris, France), Paulo De Sepulveda (CRCM, Marseille, France) and Pierre Brousset (CRCT, Toulouse, France) for providing us with specific leukemic cell lines (MOLM-14-TKD and MV4-11 shFLT3, TF-1-FLT3-ITD, and OCI-AML3 respectively). We thank Florence Capilla for performing and managing histochemistry experiments, and we acknowledge excellent technical assistance of Mathilde Gotanegre. We are grateful to Manon Farce and Laetitia Ligat for assistance with flow cytometry and microscopy, respectively. We thank HIMIP collection for patients' samples. This work was supported by the ANR LABEX TOUCAN, the Canceropole GSO, la Ligue regionale contre le Cancer and la Ligue nationale contre le Cancer. Quentin Heydt is a recipient of the Ligue Nationale contre le Cancer.	Alvarado Y, 2014, CANCER-AM CANCER SOC, V120, P2142, DOI 10.1002/cncr.28705; Ameri K, 2008, INT J BIOCHEM CELL B, V40, P14, DOI 10.1016/j.biocel.2007.01.020; B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563; Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660; Bosnjak M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094374; Choudhary C, 2009, MOL CELL, V36, P326, DOI 10.1016/j.molcel.2009.09.019; Colecchia D, 2015, AUTOPHAGY, V11, P1790, DOI 10.1080/15548627.2015.1084454; Corazzari M, 2015, CELL DEATH DIFFER, V22, P946, DOI 10.1038/cdd.2014.183; Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184; Domenech E, 2015, NAT CELL BIOL, V17, P1304, DOI 10.1038/ncb3231; Gallogly MM, 2016, J BLOOD MED, V7, P73, DOI 10.2147/JBM.S100283; Gammoh N, 2012, P NATL ACAD SCI USA, V109, P6561, DOI 10.1073/pnas.1204429109; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Isakson P, 2010, BLOOD, V116, P2324, DOI 10.1182/blood-2010-01-261040; Ishizawa J, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aac4380; Jia W, 2015, AUTOPHAGY, V11, P2335, DOI 10.1080/15548627.2015.1110666; Kayser S, 2009, BLOOD, V114, P2386, DOI 10.1182/blood-2009-03-209999; Kiyoi H, 2015, NAGOYA J MED SCI, V77, P7; Larrue C, 2016, BLOOD, V127, P882, DOI 10.1182/blood-2015-05-646497; Lee IH, 2012, SCIENCE, V336, P225, DOI 10.1126/science.1218395; Lefort S, 2014, AUTOPHAGY, V10, P2122, DOI 10.4161/15548627.2014.981788; Martinez-Lopez N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3799; Mitou G, 2015, ONCOTARGET, V6, P30149, DOI 10.18632/oncotarget.4999; Pakos-Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Pasquier B, 2015, J MED CHEM, V58, P376, DOI 10.1021/jm5013352; Piya S, 2016, BLOOD, V128, P1260, DOI 10.1182/blood-2016-01-692244; Rebecca VW, 2016, ONCOGENE, V35, P1, DOI 10.1038/onc.2015.99; Ronan B, 2014, NAT CHEM BIOL, V10, P1013, DOI 10.1038/nchembio.1681; Singleton DC, 2012, EXPERT OPIN THER TAR, V16, P1189, DOI 10.1517/14728222.2012.728207; Sujobert P, 2015, CELL REP, V11, P1446, DOI 10.1016/j.celrep.2015.04.063; Torgersen ML, 2013, BLOOD, V122, P2467, DOI 10.1182/blood-2013-05-500629; Visconte V, 2017, LEUKEMIA, V31, P505, DOI 10.1038/leu.2016.295; Watson AS, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.8; White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941; Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111; Zhou C, 2017, LEUKEMIA, V31, P1196, DOI 10.1038/leu.2016.329	37	63	66	3	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					787	797		10.1038/onc.2017.376	http://dx.doi.org/10.1038/onc.2017.376			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059168	Green Published, hybrid			2022-12-17	WOS:000424628100010
J	Chen, H; Cai, W; Chu, ESH; Tang, J; Wong, CC; Wong, SH; Sun, W; Liang, Q; Fang, J; Sun, Z; Yu, J				Chen, H.; Cai, W.; Chu, E. S. H.; Tang, J.; Wong, C-C; Wong, S. H.; Sun, W.; Liang, Q.; Fang, J.; Sun, Z.; Yu, J.			Hepatic cyclooxygenase-2 overexpression induced spontaneous hepatocellular carcinoma formation in mice	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; TUMOR-GROWTH; CANCER-CELLS; PROSTAGLANDIN E-2; INDUCED APOPTOSIS; DNA METHYLATION; MESSENGER-RNA; IN-VIVO; EXPRESSION; 5-HYDROXYMETHYLCYTOSINE	Cyclooxygenase (COX)-2 is upregulated in hepatocellular carcinoma (HCC). However, the direct causative effect of COX-2 in spontaneous HCC formation remains unknown. We thus investigate the role and molecular pathogenesis of COX-2 in HCC by using liver-specific COX-2 transgenic (TG) mice. We found spontaneous HCC formation with elevated inflammatory infiltrates and neovessels in male TG mice (3/21, 14.3%), but not in any of male WT mice (0/19). Reduced representation bisulfite sequencing (RRBS) and gene expression microarrays were performed in the HCC tumor and non-HCC liver tissues to investigate the molecular mechanisms of COX-2-driven HCC. By RRBS, DNA promoter hypermethylation was identified in HCC from TG mice. Induction of promoter hypermethylation was associated with reduced tet methylcytosine dioxygenase 1 (TET1) expression by COX-2. TET1 could catalyze the conversion of 5-methylcytosine into 5-hydroxymethylcytosine (5hmC) and prevents DNA hypermethylation. In keeping with this, loss of 5hmC was demonstrated in COX-2-induced HCC. Consistently, COX-2 overexpression in human HCC cell lines could reduce both TET1 expression and 5hmc levels. Integrative analyses of DNA methylation and gene expression profiles further identified significantly downregulated genes including LTBP1, ADCY5 and PRKCZ by promoter methylation in COX-2-induced HCC. Reduced expression of LTBP1, ADCY5 and PRKCZ by promoter hypermethylation was further validated in human HCCs. Bio-functional investigation revealed that LTBP1 inhibited cell proliferation in HCC cell lines, suggesting its potential role as a tumor suppressor in HCC. Gene expression microarrays revealed that signaling cascades (AKT (protein kinase B), STK33 (Serine/Threonine kinase 33) and MTOR (mechanistic target of rapamycin) pathways) were enriched in COX-2-induced HCC. In conclusion, this study demonstrated for the first time that enhanced COX-2 expression in hepatocytes is sufficient to induce HCC through inducing promoter hypermethylation by reducing TET1, silencing tumor-suppressive genes and activating key oncogenic pathways. Inhibition of COX-2 represents a mechanism-based target for HCC prevention.	[Chen, H.; Chu, E. S. H.; Tang, J.; Wong, C-C; Wong, S. H.; Sun, W.; Liang, Q.; Yu, J.] Chinese Univ Hong Kong, Inst Digest Dis, Room 707A,7-F,Li Ka Shing Med Sci Bldg 30-32, Shatin, Hong Kong, Peoples R China; [Chen, H.; Chu, E. S. H.; Tang, J.; Wong, C-C; Wong, S. H.; Sun, W.; Liang, Q.; Yu, J.] Chinese Univ Hong Kong, Prince Wales Hosp, CUHK Shenzhen Res Inst,Dept Med & Therapeut, Li Ka Shing Inst Hlth Sci,State Key Lab Digest Di, Room 707A,7-F,Li Ka Shing Med Sci Bldg 30-32, Shatin, Hong Kong, Peoples R China; [Cai, W.; Sun, Z.] Chinese Acad Sci, Beijing Inst Life Sci, Beijing, Peoples R China; [Tang, J.; Fang, J.] Shanghai Jiao Tong Univ, Sch Med,State Key Lab Oncogenes & Related Genes, Ren Ji Hosp,Key Lab Gastroenterol & Hepatol, Div Gastroenterol & Hepatol,Minist Hlth, Shanghai, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese Academy of Sciences; Shanghai Jiao Tong University	Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, Room 707A,7-F,Li Ka Shing Med Sci Bldg 30-32, Shatin, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, CUHK Shenzhen Res Inst,Dept Med & Therapeut, Li Ka Shing Inst Hlth Sci,State Key Lab Digest Di, Room 707A,7-F,Li Ka Shing Med Sci Bldg 30-32, Shatin, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Wong, Sunny H/N-3754-2015; Liang, Qiaoyi Jessie/G-9612-2019; chen, huarong/ABH-8561-2020; Chen, Huarong/ABZ-5810-2022; Wong, Chi Chun/C-4636-2016; Jun, Yu/D-8569-2015	Wong, Sunny H/0000-0002-3354-9310; Liang, Qiaoyi Jessie/0000-0001-8496-3442; chen, huarong/0000-0003-2192-1864; Jun, Yu/0000-0001-5008-2153	RGC-GRF from Hong Kong [766613, 14106145, 14111216]; National Basic Research Program of China (973 Program) [2013CB531401]; Shenzhen Virtual University Park Support Scheme; CUHK [4054100]	RGC-GRF from Hong Kong; National Basic Research Program of China (973 Program)(National Basic Research Program of China); Shenzhen Virtual University Park Support Scheme; CUHK(Chinese University of Hong Kong)	This project was supported by research funds from RGC-GRF (766613, 14106145 and 14111216) from Hong Kong; National Basic Research Program of China (973 Program, 2013CB531401); Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute; Direct grant for Research 2013/2014, CUHK (4054100).	Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Birkenkamp-Demtroder K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073593; Chan G, 1999, CANCER RES, V59, P991; Doug M, 2003, CARCINOGENESIS, V24, P307, DOI 10.1093/carcin/24.2.307; Drews F, 2008, BBA-MOL CELL RES, V1783, P34, DOI 10.1016/j.bbamcr.2007.08.004; Goc A, 2013, J BIOL CHEM, V288, P3025, DOI 10.1074/jbc.M112.424770; Gupta S, 2000, PROSTATE, V42, P73, DOI 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G; Hamidi T, 2015, EPIGENOMICS-UK, V7, P247, DOI [10.2217/epi.14.80, 10.2217/EPI.14.80]; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Jakubowski A, 2005, J CLIN INVEST, V115, P2330, DOI 10.1172/JCI23486; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kishimoto Y, 2002, J GASTROENTEROL, V37, P186, DOI 10.1007/s005350200019; Koga H, 1999, HEPATOLOGY, V29, P688, DOI 10.1002/hep.510290355; Kuehn HS, 2011, J BIOL CHEM, V286, P391, DOI 10.1074/jbc.M110.164772; Leng J, 2003, HEPATOLOGY, V38, P756, DOI 10.1053/jhep.2003.50380; Lim HY, 2000, CLIN CANCER RES, V6, P519; Liu C., 2013, ABSTR APPL ANAL, V2013, P1, DOI DOI 10.1371/J0URNAL.P0NE.0084849; Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165; Morinaga S, 2002, J GASTROEN HEPATOL, V17, P1110, DOI 10.1046/j.1440-1746.2002.02836.x; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; OBERHAMMER F, 1991, CANCER RES, V51, P2478; Ochiai M, 1999, JPN J CANCER RES, V90, P1338, DOI 10.1111/j.1349-7006.1999.tb00717.x; Oklu R, 2000, BIOCHEM J, V352, P601, DOI 10.1042/0264-6021:3520601; Ongusaha PP, 2004, CANCER RES, V64, P5283, DOI 10.1158/0008-5472.CAN-04-0925; Pei YF, 2016, ONCOTARGET, V7, P31322, DOI 10.18632/oncotarget.8900; Putiri EL, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-6-r81; Ramsay RG, 2003, INT J IMMUNOPATH PH, V16, P59; Robertson IB, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021907; Ryder SD, 2003, GUT, V52, pIII1, DOI 10.1136/gut.52.suppl_3.iii1; Santiago-Josefat B, 2004, J CELL SCI, V117, P849, DOI 10.1242/jcs.00932; Shen J, 2012, HEPATOLOGY, V55, P1799, DOI 10.1002/hep.25569; Sheng HM, 1998, CANCER RES, V58, P362; Singh B, 2005, INT J ONCOL, V26, P1393; Sobolewski Cyril, 2010, Int J Cell Biol, V2010, P215158, DOI 10.1155/2010/215158; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tang TC, 2005, WORLD J GASTROENTERO, V11, P1896; Thomson JP, 2016, CANCER RES, V76, P3097, DOI 10.1158/0008-5472.CAN-15-1910; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Wang Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132866; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Wu BK, 2014, CELL REP, V9, P1827, DOI 10.1016/j.celrep.2014.10.063; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; Yip-Schneider MT, 2000, CARCINOGENESIS, V21, P139, DOI 10.1093/carcin/21.2.139; Yoshida S, 2003, LAB INVEST, V83, P1385, DOI 10.1097/01.LAB.0000090159.53224.B9; Yu J, 2006, HEPATOLOGY, V43, P134, DOI 10.1002/hep.20994; Yu J, 2007, GUT, V56, P991, DOI 10.1136/gut.2006.097923; Zhang Y, 2016, COLD SPRING HARB PER	48	63	66	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4415	4426		10.1038/onc.2017.73	http://dx.doi.org/10.1038/onc.2017.73			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28346420	Green Published, hybrid			2022-12-17	WOS:000406806000004
J	Gueguinou, M; Crottes, D; Chantome, A; Rapetti-Mauss, R; Potier-Cartereau, M; Clarysse, L; Girault, A; Fourbon, Y; Jezequel, P; Guerin-Charbonnel, C; Fromont, G; Martin, P; Pellissier, B; Schiappa, R; Chamorey, E; Mignen, O; Uguen, A; Borgese, F; Vandier, C; Soriani, O				Gueguinou, M.; Crottes, D.; Chantome, A.; Rapetti-Mauss, R.; Potier-Cartereau, M.; Clarysse, L.; Girault, A.; Fourbon, Y.; Jezequel, P.; Guerin-Charbonnel, C.; Fromont, G.; Martin, P.; Pellissier, B.; Schiappa, R.; Chamorey, E.; Mignen, O.; Uguen, A.; Borgese, F.; Vandier, C.; Soriani, O.			The SigmaR1 chaperone drives breast and colorectal cancer cell migration by tuning SK3-dependent Ca2+ homeostasis	ONCOGENE			English	Article							ELECTRICAL-ACTIVITY; RECEPTOR; CHANNEL; PLASTICITY; ROLES; INHIBITION; MECHANISM; RESPONSES; MEMBRANE; COMPLEX	The remodeling of calcium homeostasis contributes to the cancer hallmarks and the molecular mechanisms involved in calcium channel regulation in tumors remain to be characterized. Here, we report that SigmaR1, a stress-activated chaperone, is required to increase calcium influx by triggering the coupling between SK3, a Ca2+-activated K+ channel (KCNN3) and the voltage- independent calcium channel Orai1. We show that SigmaR1 physically binds SK3 in BC cells. Inhibition of SigmaR1 activity, either by molecular silencing or by the use of sigma ligand (igmesine), decreased SK3 current and Ca2+ entry in breast cancer (BC) and colorectal cancer (CRC) cells. Interestingly, SigmaR1 inhibition diminished SK3 and/or Orai1 levels in lipid nanodomains isolated from BC cells. Analyses of tissue microarray from CRC patients showed higher SigmaR1 expression levels in cancer samples and a correlation with tumor grade. Moreover, the exploration of a cohort of 4937 BC patients indicated that high expression of SigmaR1 and Orai1 channels was significantly correlated to a lower overall survival. As the SK3/Orai1 tandem drives invasive process in CRC and bone metastasis progression in BC, our results may inaugurate innovative therapeutic approaches targeting SigmaR1 to control the remodeling of Ca2+ homeostasis in epithelial cancers.	[Gueguinou, M.; Chantome, A.; Potier-Cartereau, M.; Clarysse, L.; Girault, A.; Fourbon, Y.; Fromont, G.; Vandier, C.] Univ Tours, INSERM, U1069, Nutr Croissance & Canc, Tours, France; [Crottes, D.; Rapetti-Mauss, R.; Martin, P.; Pellissier, B.; Borgese, F.; Soriani, O.] Univ Cote Azur, INSERM, CNRS, iBV, Nice, France; [Jezequel, P.; Guerin-Charbonnel, C.] INSERM, UMR 892, Ctr Rech Cancerol, Unit Bioinfom,Inst Cancerol Ouest Rene Gauducheau, St Herblain, France; [Fromont, G.] CHRU Tours, Hop Bretonneau, Serv Anat Pathol, Tours, France; [Schiappa, R.; Chamorey, E.] Ctr Antoine Lacassagne, UEB, Nice, France; [Mignen, O.; Uguen, A.] Brest Univ Hosp, INSERM, U1078, Dept Pathol, Brest, France; [Gueguinou, M.; Chantome, A.; Potier-Cartereau, M.; Clarysse, L.; Girault, A.; Fourbon, Y.; Fromont, G.; Mignen, O.; Vandier, C.] Ion Channels & Canc Canceropole Grand Ouest IC CG, Brest, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut de Cancerologie de l'Ouest (ICO); CHU Tours; UNICANCER; Centre Antoine Lacassagne; CHU Brest; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bretagne Occidentale	Vandier, C; Soriani, O (corresponding author), Univ Nice Sophia Antipolis, Inst Biol Valrose, UFR Sci, iBV, Batiment Sci Nat,Parc Valrose,28 Ave Valrose, F-06108 Nice 2, France.	christophe.vandier@univ-tours.fr; soriani@unice.fr	MIGNEN, Olivier/M-3258-2019; fromont, gaelle/N-8708-2016; Girault, Alban/AAF-7808-2019; Rapetti-Mauss, Raphael/P-3437-2016; Chamorey, Emmanuel/AGO-9982-2022; Vandier, Christophe/AAC-1900-2022; Uguen, Arnaud/ABF-7583-2020; Girault, Alban/AAB-3323-2020; Crottès, David/AAC-2180-2022; SCHIAPPA, Renaud/K-8192-2019; Potier-Cartereau, marie/AAC-4510-2022	MIGNEN, Olivier/0000-0001-7913-6119; Vandier, Christophe/0000-0003-2559-0660; Girault, Alban/0000-0001-5478-9340; Crottès, David/0000-0002-4038-6345; Potier-Cartereau, marie/0000-0002-1361-3397; soriani, olivier/0000-0001-9485-3992; RAPETTI-MAUSS, Raphael/0000-0002-3518-4845; BORGESE, Franck/0000-0001-7718-2111; Gueguinou, Maxime/0000-0002-5793-2082	Universite Cote d'Azur; CNRS; La Ligue contre le Cancer; Region Centre; INSERM; Canceropole Grand Ouest; association 'CANCEN' and Tours' Hospital oncology association 'ACORT'; Association TiToine Normandie	Universite Cote d'Azur; CNRS(Centre National de la Recherche Scientifique (CNRS)); La Ligue contre le Cancer(Ligue nationale contre le cancer); Region Centre(Region Centre-Val de Loire); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Canceropole Grand Ouest; association 'CANCEN' and Tours' Hospital oncology association 'ACORT'; Association TiToine Normandie	The study was supported by Universite Cote d'Azur, CNRS, La Ligue contre le Cancer, Region Centre (LIPIDS project of ARD2020-Biomedicaments), INSERM, Canceropole Grand Ouest, the association 'CANCEN' and Tours' Hospital oncology association 'ACORT', Association TiToine Normandie. DC is a doctoral fellow with CNRS, Region PACA and Fondation ARC. RR-M is a post-doctoral fellow of La Ligue contre le Cancer and Fondation de France. The microscopy was carried out in the Prism facility, 'Plateforme Universite Cote d'Azur, CNRS, Inserm, iBV, France. MG and LC are respectively doctoral fellows of Region Centre and Region Centre/INSERM. Local tumor tissue biobank BB-0033-00037 ('CRB Sante/Tumorotheque de Brest').	Abou-lovergne A, 2011, CELL CALCIUM, V50, P62, DOI 10.1016/j.ceca.2011.05.008; Balasuriya D, 2014, J BIOL CHEM, V289, P32353, DOI 10.1074/jbc.M114.603506; Balasuriya D, 2012, J BIOL CHEM, V287, P37021, DOI 10.1074/jbc.M112.382077; Calaghan S, 2008, J MOL CELL CARDIOL, V45, P88, DOI 10.1016/j.yjmcc.2008.04.004; Chantome A, 2013, CANCER RES, V73, P4852, DOI 10.1158/0008-5472.CAN-12-4572; Chantome A, 2009, EXP CELL RES, V315, P3620, DOI 10.1016/j.yexcr.2009.07.021; Chu UB, 2016, MOL PHARMACOL, V89, P142, DOI 10.1124/mol.115.101170; Clarysse L, 2014, PFLUG ARCH EUR J PHY, V466, P1921, DOI 10.1007/s00424-013-1435-5; Crottes D, 2016, CANCER RES, V76, P607, DOI 10.1158/0008-5472.CAN-15-1465; Crottes D, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00175; Crottes D, 2011, J BIOL CHEM, V286, P27947, DOI 10.1074/jbc.M111.226738; Dubois C, 2014, CANCER CELL, V26, P19, DOI 10.1016/j.ccr.2014.04.025; Girault A, 2011, CURR CANCER DRUG TAR, V11, P1111, DOI 10.2174/156800911798073069; Gueguinou M, 2016, ONCOTARGET, V7, P36168, DOI 10.18632/oncotarget.8786; Gueguinou M, 2014, BBA-MOL CELL RES, V1843, P2322, DOI 10.1016/j.bbamcr.2014.02.019; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hayashi T, 2004, P NATL ACAD SCI USA, V101, P14949, DOI 10.1073/pnas.0402890101; Hayashi T, 2001, P NATL ACAD SCI USA, V98, P491, DOI 10.1073/pnas.021413698; Hayashi T, 2007, CELL, V131, P596, DOI 10.1016/j.cell.2007.08.036; Hayashi T, 2015, J PHARMACOL SCI, V127, P2, DOI 10.1016/j.jphs.2014.07.001; Hayashi T, 2010, SUBCELL BIOCHEM, V51, P381, DOI 10.1007/978-90-481-8622-8_13; Jezequel P, 2012, BREAST CANCER RES TR, V131, P765, DOI 10.1007/s10549-011-1457-7; Kondratska K, 2014, BBA-MOL CELL RES, V1843, P2263, DOI 10.1016/j.bbamcr.2014.02.012; Kourrich S, 2013, CELL, V152, P236, DOI 10.1016/j.cell.2012.12.004; Kourrich S, 2012, TRENDS NEUROSCI, V35, P762, DOI 10.1016/j.tins.2012.09.007; Martina M, 2007, J PHYSIOL-LONDON, V578, P143, DOI 10.1113/jphysiol.2006.116178; Maurice T, 2009, PHARMACOL THERAPEUT, V124, P195, DOI 10.1016/j.pharmthera.2009.07.001; Moenner M, 2007, CANCER RES, V67, P10631, DOI 10.1158/0008-5472.CAN-07-1705; Pal A, 2007, MOL PHARMACOL, V72, P921, DOI 10.1124/mol.107.038307; Prause J, 2013, HUM MOL GENET, V22, P1581, DOI 10.1093/hmg/ddt008; Prevarskaya N, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0097; Prevarskaya N, 2010, TRENDS MOL MED, V16, P107, DOI 10.1016/j.molmed.2010.01.005; Raphael M, 2014, P NATL ACAD SCI USA, V111, pE3870, DOI 10.1073/pnas.1413409111; Renaudo A, 2007, J BIOL CHEM, V282, P2259, DOI 10.1074/jbc.M607915200; ROMAN FJ, 1990, J PHARM PHARMACOL, V42, P439, DOI 10.1111/j.2042-7158.1990.tb06588.x; Ruscher K, 2011, BRAIN, V134, P732, DOI 10.1093/brain/awq367; Soriani O, 1998, J PHARMACOL EXP THER, V286, P163; Srivats S, 2016, J CELL BIOL, V213, P65, DOI 10.1083/jcb.201506022; Su TP, 2016, TRENDS PHARMACOL SCI, V37, P262, DOI 10.1016/j.tips.2016.01.003; Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248; van Waarde A., 2014, BIOCHIM BIOPHYS ACTA, V1848, P2703; Vollrath JT, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.243; Wu ZP, 2008, J BIOL CHEM, V283, P28198, DOI 10.1074/jbc.M802099200	43	63	63	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3640	3647		10.1038/onc.2016.501	http://dx.doi.org/10.1038/onc.2016.501			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28114279				2022-12-17	WOS:000403878600013
J	Zhu, G; Fan, Z; Ding, M; Zhang, H; Mu, L; Ding, Y; Zhang, Y; Jia, B; Chen, L; Chang, Z; Wu, W				Zhu, G.; Fan, Z.; Ding, M.; Zhang, H.; Mu, L.; Ding, Y.; Zhang, Y.; Jia, B.; Chen, L.; Chang, Z.; Wu, W.			An EGFR/PI3K/AKT axis promotes accumulation of the Rac1-GEF Tiam1 that is critical in EGFR-driven tumorigenesis	ONCOGENE			English	Article							EXCHANGE FACTOR TIAM1; RAC ACTIVATOR TIAM1; GROWTH-FACTOR; RHO-GTPASES; 14-3-3 PROTEINS; BREAST-CANCER; MOLECULAR-BASIS; INVASION; KINASES; GEF	Epidermal growth factor receptor (EGFR) signaling regulates cell growth and survival, and its overactivation drives cancer development. One important branch of EGFR signaling is through activation of GTPase Rac1, which further promotes cell proliferation, survival and cancer metastasis. Here, we show that EGFR activates Rac1 via inducing the accumulation of its specific guanine nucleotide exchange factor, T-cell lymphoma invasion and metastasis 1 (Tiam1) in non-small-cell lung cancer and colon cancer cells. Conversely, elevated Tiam1 is required for EGFR-induced tumorigenesis. In human lung adenocarcinoma and colon cancer specimens, Tiam1 expression strongly correlates with EGFR expression. We further reveal that AKT, a key downstream protein kinase of EGFR, phosphorylates Tiam1 at several consensus sites, facilitates the interaction of Tiam1 with scaffold proteins 14-3-3 and leads to an increase of Tiam1 stability. Subsequently, Tiam1 is dephosporylated and destabilized by PP2A. Together, our study identifies a bidirectional (phosphorylation and dephosphorylation) regulatory mechanism controlling Tiam1 stability and provides new insights on how EGFR signaling triggers Rac1 activation and cancer development.	[Zhu, G.; Fan, Z.; Mu, L.; Ding, Y.; Wu, W.] Tsinghua Univ, Sch Life Sci, MOE Key Lab Prot Sci, Beijing 100084, Peoples R China; [Zhu, G.] Tsinghua Peking Ctr Life Sci, Beijing, Peoples R China; [Ding, M.] Peking Univ, Sch Life Sci, Beijing 100871, Peoples R China; [Zhang, H.; Mu, L.; Chen, L.] Natl Inst Biol Sci, Beijing, Peoples R China; [Zhang, Y.; Chang, Z.] Tsinghua Univ, Sch Med, Dept Basic Med Sci, Beijing 100084, Peoples R China; [Jia, B.] Chinese Peoples Liberat Army Gen Hosp, Dept Gen Surg, Beijing 100853, Peoples R China; [Jia, B.] Chinese Peoples Liberat Army Gen Hosp, Dept Pathol, Beijing 100853, Peoples R China	Tsinghua University; Tsinghua University; Peking University; National Institute of Biological Sciences, Beijing; Tsinghua University; Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital	Wu, W (corresponding author), Tsinghua Univ, Sch Life Sci, Qinghuayuan 1, Beijing 100084, Peoples R China.	wwu@mail.tsinghua.edu.cn	Chang, Zhijie/AAH-8109-2019; Zhang, Yanquan/D-5615-2017	Zhang, Yanquan/0000-0003-3527-9972; Chen, Liang/0000-0001-7300-6604	National Natural Science Foundation of China [31221064, 81272235]; Tsinghua-Peking Center for Life Sciences	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tsinghua-Peking Center for Life Sciences	We thank Drs Ye-Guang Chen, John G. Collard, Chuanmao Zhang, Joseph R Testa and Yigong Shi for providing plasmids and reagents. We are grateful for Dr Haiteng Deng and Jieyuan Liu for mass spectrometry analysis. This work was supported by grants to WW from the National Natural Science Foundation of China (31221064 and 81272235). GZ is a postdoctoral fellow supported by Tsinghua-Peking Center for Life Sciences.	Adam L, 2001, J BIOL CHEM, V276, P28443, DOI 10.1074/jbc.M009769200; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Arai A, 2005, CELL SIGNAL, V17, P497, DOI 10.1016/j.cellsig.2004.09.007; Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Bid HK, 2013, MOL CANCER THER, V12, P1925, DOI 10.1158/1535-7163.MCT-13-0164; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Caporali S, 2008, MOL PHARMACOL, V74, P173, DOI 10.1124/mol.107.044743; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dise RS, 2008, AM J PHYSIOL-GASTR L, V294, pG276, DOI 10.1152/ajpgi.00340.2007; Ebi H, 2013, P NATL ACAD SCI USA, V110, P21124, DOI 10.1073/pnas.1314124110; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Ellenbroek SIJ, 2007, CLIN EXP METASTAS, V24, P657, DOI 10.1007/s10585-007-9119-1; Engers R, 2000, INT J CANCER, V88, P369, DOI 10.1002/1097-0215(20001101)88:3<369::AID-IJC8>3.0.CO;2-K; Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Habas R, 2006, METHOD ENZYMOL, V406, P500, DOI 10.1016/S0076-6879(06)06038-1; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Hofbauer SW, 2014, BLOOD, V123, P2181, DOI 10.1182/blood-2013-08-523563; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Itoh RE, 2008, J CELL SCI, V121, P2635, DOI 10.1242/jcs.028647; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Karpel-Massler G, 2013, MOL CANCER THER, V12, P1783, DOI 10.1158/1535-7163.MCT-13-0052; Kobayashi H, 2011, J BIOL CHEM, V286, P39259, DOI 10.1074/jbc.M111.255489; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Malliri A, 2006, J BIOL CHEM, V281, P543, DOI 10.1074/jbc.M507582200; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Minard ME, 2004, BREAST CANCER RES TR, V84, P21, DOI 10.1023/B:BREA.0000018421.31632.e6; Minard ME, 2006, CLIN EXP METASTAS, V23, P301, DOI 10.1007/s10585-006-9040-z; Morrison DK, 2009, TRENDS CELL BIOL, V19, P16, DOI 10.1016/j.tcb.2008.10.003; Mukohara T, 2005, JNCI-J NATL CANCER I, V97, P1185, DOI 10.1093/jnci/dji238; Mulloy R, 2007, CANCER RES, V67, P2325, DOI 10.1158/0008-5472.CAN-06-4293; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; O'Toole TE, 2011, J CELL PHYSIOL, V226, P2965, DOI 10.1002/jcp.22644; Palamidessi A, 2008, CELL, V134, P135, DOI 10.1016/j.cell.2008.05.034; Ramis G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038770; Santos GD, 2011, ANNU REV PATHOL-MECH, V6, P49, DOI 10.1146/annurev-pathol-011110-130206; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Shutes A, 2007, J BIOL CHEM, V282, P35666, DOI 10.1074/jbc.M703571200; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Sosa MS, 2010, MOL CELL, V40, P877, DOI 10.1016/j.molcel.2010.11.029; Steiner P, 2007, CLIN CANCER RES, V13, P1540, DOI 10.1158/1078-0432.CCR-06-1887; Strumane K, 2009, J CANCER RES CLIN, V135, P69, DOI 10.1007/s00432-008-0437-8; Su XN, 2014, GENE DEV, V28, P622, DOI 10.1101/gad.233239.113; Tokuzawa Y, 2003, MOL CELL BIOL, V23, P2699, DOI 10.1128/MCB.23.8.2699-2708.2003; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Viaud J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5080; Vlacich G, 2011, CANCER CELL, V20, P423, DOI 10.1016/j.ccr.2011.10.006; Wang L, 2013, J CELL SCI, V126, P1531, DOI 10.1242/jcs.124255; Wertheimer E, 2012, CELL SIGNAL, V24, P353, DOI 10.1016/j.cellsig.2011.08.011; Woodcock SA, 2009, J PROTEOME RES, V8, P5629, DOI 10.1021/pr900716e; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033; Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442; Zhu G, 2012, ONCOGENE, V31, P1001, DOI 10.1038/onc.2011.294; Zhu GX, 2014, J BIOL CHEM, V289, P15482, DOI 10.1074/jbc.M114.553388	61	63	64	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2015	34	49					5971	5982		10.1038/onc.2015.45	http://dx.doi.org/10.1038/onc.2015.45			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RO	25746002				2022-12-17	WOS:000366113500004
J	Kim, JY; Lim, SC; Kim, G; Yun, HJ; Ahn, SG; Choi, HS				Kim, J. Y.; Lim, S-C; Kim, G.; Yun, H. J.; Ahn, S-G; Choi, H. S.			Interleukin-33/ST2 axis promotes epithelial cell transformation and breast tumorigenesis via upregulation of COT activity	ONCOGENE			English	Article							NF-KAPPA-B; ACTIVATED SIGNAL TRANSDUCER; RECEPTOR ACCESSORY PROTEIN; IL-1 RECEPTOR; MAST-CELLS; NUCLEAR FACTOR; AP-1 ACTIVITY; CANCER CELLS; STAT3; GROWTH	Cytokines of the interleukin-1 (IL-1) family, such as IL-1 alpha/beta and IL-18, have pleiotropic activities in innate and adaptive immune responses in host defense and diseases. Insight into their biological functions helped develop novel therapeutic approaches to treat human inflammatory diseases. IL-33 is an important member of the IL-1 family of cytokines and is a ligand of the ST2 receptor, a member of the IL-1 receptor family. However, the role of the IL-33/ST2 axis in tumor growth and metastasis of breast cancer remains unclear. Here, we demonstrate that IL-33 is a critical tumor promoter during epithelial cell proliferation and tumorigenesis in the breast. IL-33 dose-and time-dependently increased Cancer Osaka Thyroid (COT) phosphorylation via ST2-COT interaction in normal epithelial and breast cancer cells. The IL-33/ST2/COT cascade induced the activation of the MEK-ERK (MEK-extracellular signal-regulated kinase), JNK-cJun (cJun N-terminal kinase-cJun) and STAT3 (signal transducer and activator of transcription 3) signaling pathways, followed by increased AP-1 and stat3 transcriptional activity. When small interfering RNAs of ST2 and COT were introduced into cells, IL-33-induced AP-1 and stat3 activity were significantly decreased, unlike that in the control cells. The inhibition of COT activity resulted in decreased IL-33-induced epithelial cell transformation, and knockdown of IL-33, ST2 and COT in breast cancer cells attenuated tumorigenicity of breast cancer cells. Consistent with these observations, ST2 levels were positively correlated with COT expression in human breast cancer. These findings provide a novel perspective on the role of the IL-33/ST2/COT signaling pathway in supporting cancer-associated inflammation in the tumor microenvironment. Therapeutic approaches that target this pathway may, therefore, effectively inhibit carcinogenesis in the breast.	[Kim, J. Y.; Kim, G.; Yun, H. J.; Choi, H. S.] Chosun Univ, Coll Pharm, Gwangju 501759, Jeollanamdo, South Korea; [Lim, S-C] Chosun Univ, Sch Med, Dept Pathol, Gwangju 501759, Jeollanamdo, South Korea; [Ahn, S-G] Chosun Univ, Sch Dent, Dept Pathol, Gwangju 501759, Jeollanamdo, South Korea	Chosun University; Chosun University; Chosun University	Choi, HS (corresponding author), Chosun Univ, Coll Pharm, Gwangju 501759, Jeollanamdo, South Korea.	chs@chosun.ac.kr			Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology (MEST) [NRF-2013R1A1A2004714]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology (MEST)	This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (MEST) (NRF-2013R1A1A2004714).	Ali S, 2007, P NATL ACAD SCI USA, V104, P18660, DOI 10.1073/pnas.0705939104; Allakhverdi Z, 2007, J IMMUNOL, V179, P2051, DOI 10.4049/jimmunol.179.4.2051; Alvarez JV, 2005, CANCER RES, V65, P5054, DOI 10.1158/0008-5472.CAN-04-4281; Baekkevold ES, 2003, AM J PATHOL, V163, P69, DOI 10.1016/S0002-9440(10)63631-0; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Berclaz G, 2001, INT J ONCOL, V19, P1155; BERGERS G, 1994, EMBO J, V13, P1176, DOI 10.1002/j.1460-2075.1994.tb06367.x; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Ceci JD, 1997, GENE DEV, V11, P688, DOI 10.1101/gad.11.6.688; Choi HS, 2008, FASEB J, V22, P113, DOI 10.1096/fj.07-9078com; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101; Diaz N, 2006, CLIN CANCER RES, V12, P20, DOI 10.1158/1078-0432.CCR-04-1749; Dolled-Filhart M, 2003, CLIN CANCER RES, V9, P594; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Funakoshi-Tago M, 2008, CELL SIGNAL, V20, P1679, DOI 10.1016/j.cellsig.2008.05.013; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; GELIN J, 1991, CANCER RES, V51, P415; Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Harmey JH, 2002, INT J CANCER, V101, P415, DOI 10.1002/ijc.10632; Hu WT, 2014, MOL HUM REPROD, V20, P358, DOI 10.1093/molehr/gat094; Itoh M, 2006, ONCOGENE, V25, P1195, DOI 10.1038/sj.onc.1209149; Jovanovic I, 2011, EUR J IMMUNOL, V41, P1902, DOI 10.1002/eji.201141417; Jovanovic IP, 2014, INT J CANCER, V134, P1669, DOI 10.1002/ijc.28481; Kakkar R, 2012, J BIOL CHEM, V287, P6941, DOI 10.1074/jbc.M111.298703; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Khanal P, 2011, MOL CARCINOGEN, V50, P961, DOI 10.1002/mc.20761; Kim G, 2013, CARCINOGENESIS, V34, P341, DOI 10.1093/carcin/bgs342; Kim K, 2014, CARCINOGENESIS, V35, P1352, DOI 10.1093/carcin/bgu044; Kolch W, 2005, NAT REV MOL CELL BIO, V6, P827, DOI 10.1038/nrm1743; Kontoyiannis D, 2002, J EXP MED, V196, P1563, DOI 10.1084/jem.20020281; Leslie K, 2006, CANCER RES, V66, P2544, DOI 10.1158/0008-5472.CAN-05-2203; Li L, 2002, J BIOL CHEM, V277, P17397, DOI 10.1074/jbc.M109962200; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Moulin D, 2007, CYTOKINE, V40, P216, DOI 10.1016/j.cyto.2007.09.013; Onda H, 1999, J CEREBR BLOOD F MET, V19, P1279, DOI 10.1097/00004647-199911000-00013; Palmer G, 2008, CYTOKINE, V42, P358, DOI 10.1016/j.cyto.2008.03.008; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pushparaj PN, 2009, P NATL ACAD SCI USA, V106, P9773, DOI 10.1073/pnas.0901206106; Radisky DC, 2004, SCIENCE, V303, P775, DOI 10.1126/science.1094412; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Sugimoto K, 2004, J CLIN INVEST, V114, P857, DOI 10.1172/JCI200420014; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; TOMINAGA S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P1, DOI 10.1016/0167-4781(91)90029-L; Tsatsanis C, 1998, P NATL ACAD SCI USA, V95, P3827, DOI 10.1073/pnas.95.7.3827	48	63	64	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2015	34	38					4928	4938		10.1038/onc.2014.418	http://dx.doi.org/10.1038/onc.2014.418			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9QZ	25531326				2022-12-17	WOS:000361693000003
J	Itkonen, HM; Engedal, N; Babaie, E; Luhr, M; Guldvik, IJ; Minner, S; Hohloch, J; Tsourlakis, MC; Schlomm, T; Mills, IG				Itkonen, H. M.; Engedal, N.; Babaie, E.; Luhr, M.; Guldvik, I. J.; Minner, S.; Hohloch, J.; Tsourlakis, M. C.; Schlomm, T.; Mills, I. G.			UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation	ONCOGENE			English	Article							ANDROGEN-DEPRIVATION THERAPY; HEXOSAMINE BIOSYNTHETIC-PATHWAY; GLUCOSE-METABOLISM; INSULIN-RESISTANCE; CELL-LINES; EXPRESSION; TRANSFERASE; TUNICAMYCIN; AUTOPHAGY; DIFFERENTIATION	Prostate cancer is the second most common cause of cancer-associated deaths in men, and signaling via a transcription factor called androgen receptor (AR) is an important driver of the disease. Consequently, AR target genes are prominent candidates to be specific for prostate cancer and also important for the survival of the cancer cells. Here we assess the levels of all hexosamine biosynthetic pathway (HBP) enzymes in 15 separate clinical gene expression data sets and identify the last enzyme in the pathway, UDP-N-acetylglucosamine pyrophosphorylase 1 (UAP1), to be highly overexpressed in prostate cancer. We analyzed 3261 prostate cancers on a tissue microarray and found that UAP1 staining correlates negatively with Gleason score (P = 0.0039) and positively with high AR expression (P<0.0001). Cells with high UAP1 expression have 10-fold increased levels of the HBP end-product, UDP-N-acetylglucosamine (UDP-GlcNAc). UDP-GlcNAc is essential for N-linked glycosylation occurring in the endoplasmic reticulum (ER) and high UAP1 expression associates with resistance against inhibitors of N-linked glycosylation (tunicamycin and 2-deoxyglucose) but not with a general ER stress-inducing agent, the calcium ionophore A23187. Knockdown of UAP1 expression re-sensitized cells towards inhibitors of N-linked glycosylation, as measured by proliferation and activation of ER stress markers. Taken together, we have identified an enzyme, UAP1, which is highly overexpressed in prostate cancer and protects cancer cells from ER stress conferring a growth advantage.	[Itkonen, H. M.; Engedal, N.; Luhr, M.; Guldvik, I. J.; Mills, I. G.] Univ Oslo, Ctr Mol Med Norway, Prostate Canc Res Grp, N-0318 Oslo, Norway; [Itkonen, H. M.; Engedal, N.; Luhr, M.; Guldvik, I. J.; Mills, I. G.] Oslo Univ Hosp, Oslo, Norway; [Babaie, E.] Univ Oslo, Biotechnol Ctr Oslo, N-0318 Oslo, Norway; [Minner, S.; Hohloch, J.; Tsourlakis, M. C.] Univ Med Ctr Hamburg Eppendorf, Inst Pathol, Hamburg, Germany; [Schlomm, T.] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Sect Translat Prostate Canc Res, Hamburg, Germany; [Schlomm, T.] Univ Med Ctr Hamburg Eppendorf, Prostate Canc Ctr, Martini Clin, Hamburg, Germany; [Mills, I. G.] Oslo Univ Hosp, Dept Canc Prevent, Oslo, Norway; [Mills, I. G.] Oslo Univ Hosp, Dept Urol, Oslo, Norway	University of Oslo; University of Oslo; University of Oslo; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Oslo; University of Oslo	Mills, IG (corresponding author), Univ Oslo, NCMM, Gaustadalleen 21,POB 1137, N-0318 Oslo, Norway.	harri.itkonen@ncmm.uio.no; ian.mills@ncmm.uio.no	Engedal, Nikolai/AAJ-8951-2020; Mills, Ian/AAK-9292-2020	Engedal, Nikolai/0000-0003-3718-3464; Mills, Ian/0000-0001-5347-5083; Schlomm, Thorsten/0000-0001-9557-4653; Itkonen, Harri/0000-0002-5194-7064	Early Stage Researcher fellowship as part of the EU FP7 Marie Curie Integrated Training Network; PRO-NEST (Prostate Research Organizations Network Early Stage Training) Norwegian Cancer Society; Finnish Cultural Foundation; Norwegian Research Council; Helse; University of Oslo through the Centre for Molecular Medicine (Norway), Nordic EMBL (European Molecular Biology Laboratory); Norwegian Cancer Society; EU	Early Stage Researcher fellowship as part of the EU FP7 Marie Curie Integrated Training Network; PRO-NEST (Prostate Research Organizations Network Early Stage Training) Norwegian Cancer Society; Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); Norwegian Research Council(Research Council of NorwayEuropean Commission); Helse; University of Oslo through the Centre for Molecular Medicine (Norway), Nordic EMBL (European Molecular Biology Laboratory); Norwegian Cancer Society(Norwegian Cancer Society); EU(European Commission)	HMI is funded by an Early Stage Researcher fellowship as part of the EU FP7 Marie Curie Integrated Training Network, PRO-NEST (Prostate Research Organizations Network Early Stage Training) Norwegian Cancer Society and Finnish Cultural Foundation. IGM is supported by funding from the Norwegian Research Council, Helse and the University of Oslo through the Centre for Molecular Medicine (Norway), which is a part of the Nordic EMBL (European Molecular Biology Laboratory) partnership. IGM is also supported by the Norwegian Cancer Society and by EU FP7 funding. IGM holds a visiting scientist position with Cancer Research UK through the Cambridge Research Institute and a Senior Visiting Research Fellowship with Cambridge University through the Department of Oncology. We thank Professor Olli Kallioniemi's group (Institute for Molecular Medicine Finland, Helsinki, Finland) for technical support.	Bassik MC, 2011, P NATL ACAD SCI USA, V108, P11731, DOI 10.1073/pnas.1109035108; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; BERTHON P, 1995, INT J ONCOL, V6, P333; Bosch RR, 2004, ENDOCRINE, V23, P17, DOI 10.1385/ENDO:23:1:17; Braga-Basaria M, 2006, J CLIN ONCOL, V24, P3979, DOI 10.1200/JCO.2006.05.9741; Buse MG, 2006, AM J PHYSIOL-ENDOC M, V290, pE1, DOI 10.1152/ajpendo.00329.2005; Butkinaree C, 2010, BBA-GEN SUBJECTS, V1800, P96, DOI 10.1016/j.bbagen.2009.07.018; Chen R, 2013, J CELL BIOCHEM, V114, P816, DOI 10.1002/jcb.24420; Dennis JW, 2009, TRAFFIC, V10, P1569, DOI 10.1111/j.1600-0854.2009.00981.x; Derweesh IH, 2007, BJU INT, V100, P1060, DOI 10.1111/j.1464-410X.2007.07184.x; Diekman AB, 1998, MOL REPROD DEV, V50, P284; Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200; Dricu A, 1997, CANCER RES, V57, P543; Grassian AR, 2011, COLD SH Q B, V76, P313, DOI 10.1101/sqb.2011.76.010967; Gross BJ, 2005, J AM CHEM SOC, V127, P14588, DOI 10.1021/ja0555217; Gunter Jennifer H, 2013, Int J Cell Biol, V2013, P834684, DOI 10.1155/2013/834684; Hagisawa S, 2005, GLYCOBIOLOGY, V15, P1016, DOI 10.1093/glycob/cwi086; Harris WP, 2009, NAT CLIN PRACT UROL, V6, P76, DOI 10.1038/ncpuro1296; Humphrey PA, 2007, J CLIN PATHOL, V60, P35, DOI 10.1136/jcp.2005.036442; Itkonen HM, 2013, CANCER RES, V73, P5277, DOI 10.1158/0008-5472.CAN-13-0549; Itkonen HM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065016; Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487; KELLER RK, 1979, BIOCHEMISTRY-US, V18, P3946, DOI 10.1021/bi00585a016; Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139; Kridel SJ, 2004, CANCER RES, V64, P2070, DOI 10.1158/0008-5472.CAN-03-3645; Krzeslak A, 2012, CLIN EXP MED, V12, P61, DOI 10.1007/s10238-011-0138-5; Kurtoglu M, 2007, MOL CANCER THER, V6, P3049, DOI 10.1158/1535-7163.MCT-07-0310; Lau KS, 2007, CELL, V129, P123, DOI 10.1016/j.cell.2007.01.049; Luo J, 2002, CANCER RES, V62, P2220; Lynch TP, 2012, J BIOL CHEM, V287, P11070, DOI 10.1074/jbc.M111.302547; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Mi WY, 2011, BBA-MOL BASIS DIS, V1812, P514, DOI 10.1016/j.bbadis.2011.01.009; Mio T, 1998, J BIOL CHEM, V273, P14392, DOI 10.1074/jbc.273.23.14392; Monauni T, 2000, DIABETES, V49, P926, DOI 10.2337/diabetes.49.6.926; Moon JS, 2011, BIOCHEM J, V433, P225, DOI 10.1042/BJ20101104; Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090; Nakajima K, 2010, GLYCOBIOLOGY, V20, P865, DOI 10.1093/glycob/cwq044; Patti ME, 1999, DIABETES, V48, P1562, DOI 10.2337/diabetes.48.8.1562; Peneff C, 2001, EMBO J, V20, P6191, DOI 10.1093/emboj/20.22.6191; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Sartor O, 2013, NAT REV CLIN ONCOL, V10, P6, DOI 10.1038/nrclinonc.2012.202; Schwarz F, 2011, CURR OPIN STRUC BIOL, V21, P576, DOI 10.1016/j.sbi.2011.08.005; Slawson C, 2010, TRENDS BIOCHEM SCI, V35, P547, DOI 10.1016/j.tibs.2010.04.005; Sreekumar A, 2009, NATURE, V457, P910, DOI 10.1038/nature07762; Wang ZV, 2014, CELL, V156, P1179, DOI 10.1016/j.cell.2014.01.014; Wellen KE, 2012, NAT REV MOL CELL BIO, V13, P270, DOI 10.1038/nrm3305; Wellen KE, 2010, GENE DEV, V24, P2784, DOI 10.1101/gad.1985910; Xi HB, 2011, CANCER CHEMOTH PHARM, V67, P899, DOI 10.1007/s00280-010-1391-0; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058	49	63	63	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3744	3750		10.1038/onc.2014.307	http://dx.doi.org/10.1038/onc.2014.307			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25241896				2022-12-17	WOS:000357679100012
J	King, ML; Lindberg, ME; Stodden, GR; Okuda, H; Ebers, SD; Johnson, A; Montag, A; Lengyel, E; MacLean, JA; Hayashi, K				King, M. L.; Lindberg, M. E.; Stodden, G. R.; Okuda, H.; Ebers, S. D.; Johnson, A.; Montag, A.; Lengyel, E.; MacLean, J. A., II; Hayashi, K.			WNT7A/beta-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer	ONCOGENE			English	Article							TUMOR-CELL GROWTH; E-CADHERIN; POTENTIAL REGULATION; ADVANCED-STAGE; WNT PATHWAY; EXPRESSION; INHIBITION; CATENIN; TARGET; GENE	We previously characterized the link between WNT7A and the progression of ovarian cancer. Other groups have identified FGF1 as a relevant risk factor in ovarian cancer. Here, we show a linkage between these two signaling pathways that may be exploited to improve treatment and prognosis of patients with ovarian cancer. High expression of WNT7A and FGF1 are correlated in ovarian carcinomas and poor overall patient survival. A chromatin immunoprecipitation assay demonstrated that WNT7A/beta-catenin signaling directly regulates FGF1 expression via TCF binding elements in the FGF1-1C promoter locus. In vitro gene manipulation studies revealed that FGF1 is sufficient to drive the tumor-promoting effects of WNT7A. In vivo xenograft studies confirmed that the stable overexpression of WNT7A or FGF1 induced a significant increase in tumor incidence, whereas FGF1 knockdown in WNT7A overexpressing cells caused a significant reduction in tumor size. Niclosamide most efficiently abrogated WNT7A/beta-catenin signaling in our model, inhibited beta-catenin transcriptional activity and cell viability, and increased cell death. Furthermore, niclosamide decreased cell migration following an increase in E-cadherin subsequent to decreased levels of SLUG. The effects of niclosamide on cell functions were more potent in WNT7A-overexpressing cells. Oral niclosamide inhibited tumor growth and progression in an intraperitoneal xenograft mouse model representative of human ovarian cancer. Collectively, these results indicate that FGF1 is a direct downstream target of WNT7A/beta-catenin signaling and this pathway has potential as a therapeutic target in ovarian cancer. Moreover, niclosamide is a promising inhibitor of this pathway and may have clinical relevance.	[King, M. L.; Lindberg, M. E.; Stodden, G. R.; Ebers, S. D.; MacLean, J. A., II; Hayashi, K.] So Illinois Univ, Sch Med, Dept Physiol, Carbondale, IL 62901 USA; [Okuda, H.] Kyoto Univ, Grad Sch Med, Lab Malignancy Control Res, Kyoto, Japan; [Johnson, A.; Lengyel, E.] Univ Chicago, Dept Obstet & Gynecol, Med Ctr, Gynecol Oncol Sect, Chicago, IL 60637 USA; [Montag, A.] Univ Chicago, Med Ctr, Dept Pathol, Chicago, IL 60637 USA	Southern Illinois University System; Southern Illinois University; Kyoto University; University of Chicago; University of Chicago Medical Center; University of Chicago; University of Chicago Medical Center	Hayashi, K (corresponding author), So Illinois Univ, Sch Med, Dept Physiol, 1135 Lincoln Dr, Carbondale, IL 62901 USA.	khayashi@siumed.edu	; Lengyel, Ernst/D-9220-2014	Hayashi, Kanako/0000-0002-5028-799X; Lengyel, Ernst/0000-0001-8624-1507; Okuda, Hiroshi/0000-0002-5747-8086	NIH/NCI [CA179214, ACS-IL 139038]; NIH/NICHD [HD065584]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R15HD065584] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R15CA179214] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Gail Isenberg for editing the manuscript. This work was supported by NIH/NCI CA179214 and ACS-IL 139038 (to KH), and NIH/NICHD HD065584 (to JAM).	Aletti GD, 2007, MAYO CLIN PROC, V82, P751; Arend RC, 2013, GYNECOL ONCOL, V131, P772, DOI 10.1016/j.ygyno.2013.09.034; Balgi AD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007124; Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154; Birrer MJ, 2007, J CLIN ONCOL, V25, P2281, DOI 10.1200/JCO.2006.09.0795; Bonome T, 2008, CANCER RES, V68, P5478, DOI 10.1158/0008-5472.CAN-07-6595; Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460; Chauhan SC, 2009, CANCER RES, V69, P765, DOI 10.1158/0008-5472.CAN-08-0587; Chen MY, 2009, BIOCHEMISTRY-US, V48, P10267, DOI 10.1021/bi9009677; Chen W, 2010, AM J PHYSIOL-GASTR L, V299, pG293, DOI 10.1152/ajpgi.00005.2010; Chotani MA, 1997, CELL GROWTH DIFFER, V8, P999; Cooke PS, 2013, MOL HUM REPROD, V19, P547, DOI 10.1093/molehr/gat031; Curtin JC, 2010, ONCOTARGET, V1, P563, DOI 10.18632/oncotarget.191; Denkert C, 2009, J PATHOL, V218, P273, DOI 10.1002/path.2547; Dodge ME, 2011, ANNU REV PHARMACOL, V51, P289, DOI 10.1146/annurev-pharmtox-010510-100558; Fonseca BD, 2012, J BIOL CHEM, V287, P17530, DOI 10.1074/jbc.M112.359638; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Goff BA, 2004, JAMA-J AM MED ASSOC, V291, P2705, DOI 10.1001/jama.291.22.2705; Hayashi K, 2007, ENDOCRINOLOGY, V148, P3496, DOI 10.1210/en.2007-0283; Hayashi K, 2009, BIOL REPROD, V80, P989, DOI 10.1095/biolreprod.108.075416; Hendrix ND, 2006, CANCER RES, V66, P1354, DOI 10.1158/0008-5472.CAN-05-3694; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Jin YL, 2010, CANCER RES, V70, P2516, DOI 10.1158/0008-5472.CAN-09-3950; Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108; Lau MT, 2011, ONCOGENE, V30, P2753, DOI 10.1038/onc.2011.6; Li R, 2013, MOL CANCER THER, V12, P2200, DOI 10.1158/1535-7163.MCT-13-0095; Lu WY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029290; MacLean JA, 2013, J BIOL CHEM, V288, P34809, DOI 10.1074/jbc.M113.486340; Madiai F, 1999, J BIOL CHEM, V274, P11937, DOI 10.1074/jbc.274.17.11937; Meijer L, 2004, TRENDS PHARMACOL SCI, V25, P471, DOI 10.1016/j.tips.2004.07.006; Meng QH, 2014, CLIN CHEM, V60, P222, DOI 10.1373/clinchem.2013.211490; Mook RA, 2013, BIOORG MED CHEM LETT, V23, P2187, DOI 10.1016/j.bmcl.2013.01.101; Osada T, 2011, CANCER RES, V71, P4172, DOI 10.1158/0008-5472.CAN-10-3978; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Sack U, 2011, JNCI-J NATL CANCER I, V103, P1018, DOI 10.1093/jnci/djr190; Sassoon D, 1999, MOL CELL ENDOCRINOL, V158, P1, DOI 10.1016/S0303-7207(99)00170-7; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Smith GS, 2012, NEUROPSYCHOPHARMACOL, V37, P1, DOI 10.1038/npp.2011.233; Steele IA, 2001, ONCOGENE, V20, P5878, DOI 10.1038/sj.onc.1204755; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Teo R, 2006, DEV BIOL, V289, P91, DOI 10.1016/j.ydbio.2005.10.009; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Wieland A, 2013, CLIN CANCER RES, V19, P4124, DOI 10.1158/1078-0432.CCR-12-2895; Yo YT, 2012, MOL CANCER THER, V11, P1703, DOI 10.1158/1535-7163.MCT-12-0002; Yoshioka S, 2012, MOL CANCER RES, V10, P469, DOI 10.1158/1541-7786.MCR-11-0177; You S, 2014, MOL CANCER THER, V13, P606, DOI 10.1158/1535-7163.MCT-13-0608; Zaid TM, 2013, CLIN CANCER RES, V19, P809, DOI 10.1158/1078-0432.CCR-12-2736	52	63	66	1	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3452	3462		10.1038/onc.2014.277	http://dx.doi.org/10.1038/onc.2014.277			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25174399	Green Accepted, hybrid			2022-12-17	WOS:000356871700010
J	Miyake, M; Goodison, S; Lawton, A; Gomes-Giacoia, E; Rosser, CJ				Miyake, M.; Goodison, S.; Lawton, A.; Gomes-Giacoia, E.; Rosser, C. J.			Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1/2 pathway	ONCOGENE			English	Article							BLADDER-CANCER; PROSTATE-CANCER; ENDOTHELIAL-CELLS; RIBONUCLEOLYTIC ACTIVITY; NUCLEAR TRANSLOCATION; UROTHELIAL CARCINOMA; BINDING-PROTEIN; ATHYMIC MICE; TISSUE; THERAPY	Tumor angiogenesis is essential for tumor growth and metastasis and is dependent on key angiogenic factors. Angiogenin (ANG), a 14.2-kDa polypeptide member of the RNase A superfamily, is an angiogenic protein that has been reported to be upregulated and associated with poor prognosis in some human cancers. The mechanisms through which aberrant ANG levels promote specific steps in tumor progression are unknown. Here, we show that ANG expression in human tissues is strongly correlated with an invasive cancer phenotype. We also show that ANG induces cellular survival, proliferation, endothelial tube formation and xenograft angiogenesis and growth. Novel mechanistic investigations revealed that ANG expression stimulated matrix metallopeptidase-2 (MMP2) expression through the phosphorylation of ERK1/2. Targeting ANG in vivo with N65828, a small-molecule inhibitor of the ribonucleolytic activity of human ANG, resulted in the diminution of xenograft tumoral growth through the inhibition of angiogenesis. Our findings support an unrecognized interplay between ANG, ERK1/2 and MMP2 that can impact tumor growth and progression. The targeting of ANG and associated factors could provide a novel strategy to inhibit tumor establishment and growth.	[Miyake, M.; Goodison, S.; Gomes-Giacoia, E.; Rosser, C. J.] MD Anderson Canc Ctr, Canc Res Inst, Orlando, FL USA; [Goodison, S.; Rosser, C. J.] Nonagen Biosci Corp, Orlando, FL USA; [Lawton, A.] Orlando Hlth, Dept Pathol, Orlando, FL USA	University of Texas System; UTMD Anderson Cancer Center	Rosser, CJ (corresponding author), Univ Hawaii, Ctr Canc, Sch Med, Clin & Translat Program, 701 Ilalo St, Honolulu, HI 96813 USA.	crosser@cc.hawaii.edu			Florida Biomedical Program James and Esther King Team Science Project [1KT-01]; NATIONAL CANCER INSTITUTE [R01CA116161] Funding Source: NIH RePORTER	Florida Biomedical Program James and Esther King Team Science Project; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by Florida Biomedical Program James and Esther King Team Science Project 1KT-01 (CJR). Dr Kwai Wa Cheng for reading this manuscript and offering editorial suggestions.	Anai S, 2007, MOL CANCER THER, V6, P101, DOI 10.1158/1535-7163.MCT-06-0367; Anai S, 2011, UROL ONCOL-SEMIN ORI, V29, P421, DOI 10.1016/j.urolonc.2009.04.009; BOCHNER BH, 1995, J NATL CANCER I, V87, P1603, DOI 10.1093/jnci/87.21.1603; Cantwell-Dorris ER, 2011, MOL CANCER THER, V10, P385, DOI 10.1158/1535-7163.MCT-10-0799; Chuang CK, 2010, ONCOL LETT, V1, P691, DOI 10.3892/ol_00000121; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gontero P, 2004, EUR UROL, V46, P296, DOI 10.1016/j.eururo.2004.04.001; Goodison S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047469; Grossfeld GD, 1997, J NATL CANCER I, V89, P219, DOI 10.1093/jnci/89.3.219; Hartmann A, 1999, CANCER RES, V59, P1578; Hirukawa S, 2005, CLIN CANCER RES, V11, P8745, DOI 10.1158/1078-0432.CCR-05-1495; Hisai H, 2003, CLIN CANCER RES, V9, P4852; HU GF, 1994, P NATL ACAD SCI USA, V91, P12096, DOI 10.1073/pnas.91.25.12096; HU GF, 1993, P NATL ACAD SCI USA, V90, P1217, DOI 10.1073/pnas.90.4.1217; HU GF, 1991, P NATL ACAD SCI USA, V88, P2227, DOI 10.1073/pnas.88.6.2227; Inoue K, 2000, CLIN CANCER RES, V6, P2104; Kao RYT, 2002, P NATL ACAD SCI USA, V99, P10066, DOI 10.1073/pnas.152342999; Katona TM, 2005, CLIN CANCER RES, V11, P8358, DOI 10.1158/1078-0432.CCR-05-0962; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; Knowles MA, 2006, CARCINOGENESIS, V27, P361, DOI 10.1093/carcin/bgi310; Kollermann J, 2001, AM J CLIN PATHOL, V116, P115; Kumar B, 2010, CANCER RES, V70, P832, DOI 10.1158/0008-5472.CAN-09-2918; LEE FS, 1989, BIOCHEM BIOPH RES CO, V161, P121, DOI 10.1016/0006-291X(89)91569-6; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1974, CANCER RES, V34, P997; Miyake H, 1999, CANCER, V86, P316, DOI 10.1002/(SICI)1097-0142(19990715)86:2<316::AID-CNCR16>3.0.CO;2-T; Miyake M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-322; Miyake M, 2012, BMC UROL, V12, DOI 10.1186/1471-2490-12-23; MOROIANU J, 1994, P NATL ACAD SCI USA, V91, P1677, DOI 10.1073/pnas.91.5.1677; Nilsson UW, 2010, CLIN CANCER RES, V16, P3659, DOI 10.1158/1078-0432.CCR-10-0501; OBrien T, 1997, CANCER RES, V57, P136; OBrien TS, 1996, CANCER RES, V56, P4799; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Piccoli R, 1998, P NATL ACAD SCI USA, V95, P4579, DOI 10.1073/pnas.95.8.4579; Sakai Y, 2009, WORLD J UROL, V27, P659, DOI 10.1007/s00345-009-0422-0; Shapiro R, 2000, J MOL BIOL, V302, P497, DOI 10.1006/jmbi.2000.4075; Tello-Montoliu A, 2006, J THROMB HAEMOST, V4, P1864, DOI 10.1111/j.1538-7836.2006.01995.x; Tsuji T, 2005, CANCER RES, V65, P1352, DOI 10.1158/0008-5472.CAN-04-2058; Uehara H, 2005, PROSTATE, V64, P40, DOI 10.1002/pros.20223; Urquidi V, 2012, CANCER EPIDEM BIOMAR, V21, P2149, DOI 10.1158/1055-9965.EPI-12-0428; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; Yoshioka N, 2006, P NATL ACAD SCI USA, V103, P14519, DOI 10.1073/pnas.0606708103; Zhao H, 2005, CANCER-AM CANCER SOC, V104, P30, DOI 10.1002/cncr.21136	46	63	67	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2015	34	7					890	901		10.1038/onc.2014.2	http://dx.doi.org/10.1038/onc.2014.2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB2QF	24561529	Green Accepted			2022-12-17	WOS:000349472000009
J	Sahasrabuddhe, AA; Chen, X; Chung, F; Velusamy, T; Lim, MS; Elenitoba-Johnson, KSJ				Sahasrabuddhe, A. A.; Chen, X.; Chung, F.; Velusamy, T.; Lim, M. S.; Elenitoba-Johnson, K. S. J.			Oncogenic Y641 mutations in EZH2 prevent Jak2/beta-TrCP-mediated degradation	ONCOGENE			English	Article						EZH2; SCF beta-TrCP ubiquitin ligase; protein degradation; lymphoma	POLYCOMB GROUP PROTEINS; BETA-TRCP; UBIQUITIN LIGASES; MOUSE DEVELOPMENT; STEM-CELLS; CANCER; LYMPHOMA; COMPLEX; BINDING; METHYLATION	EZH2 (enhancer of zeste homolog 2) is a critical enzymatic subunit of the polycomb repressive complex 2 (PRC2), which trimethylates histone H3 (H3K27) to mediate gene repression. Somatic mutations, overexpression and hyperactivation of EZH2 have been implicated in the pathogenesis of several forms of cancer. In particular, recurrent gain-of-function mutations targeting EZH2 Y641 occur most frequently in follicular lymphoma and aggressive diffuse large B-cell lymphoma and are associated with H3K27me3 hyperactivation, which contributes to lymphoma pathogenesis. However, the post-translational mechanisms of EZH2 regulation are not completely understood. Here we show that EZH2 is a novel interactor and substrate of the SCF E3 ubiquitin ligase beta-TrCP (FBXW1). beta-TrCP ubiquitinates EZH2 and Jak2-mediated phosphorylation on Y641 directs beta-TrCP-mediated EZH2 degradation. RNA interference-mediated silencing of beta-TrCP or inhibition of Jak2 results in EZH2 stabilization with attendant increase in H3K27 trimethylation activity. Importantly, the EZH2(Y641) mutants recurrently implicated in lymphoma pathogenesis are unable to bind beta-TrCP. Further, endogenous EZH2(Y641) mutants in lymphoma cells exhibit increased EZH2 stability and H3K27me3 hyperactivity. Our studies demonstrate that beta-TrCP has an important role in controlling H3K27 trimethylation activity and lymphoma pathogenesis by targeting EZH2 for degradation.	[Sahasrabuddhe, A. A.; Chen, X.; Chung, F.; Velusamy, T.; Lim, M. S.; Elenitoba-Johnson, K. S. J.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Elenitoba-Johnson, KSJ (corresponding author), Univ Michigan, Dept Pathol, 2037 BSRB,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	kojoelen@umich.edu		Elenitoba-Johnson, Kojo/0000-0002-1082-1545; Lim, Megan/0000-0002-0415-2867; Sahasrabuddhe, Anagh/0000-0002-3040-0019	NIH [R01 DE119249, R01 CA136905, R01 CA140806]; NATIONAL CANCER INSTITUTE [R01CA136905, R01CA140806] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by NIH Grants R01 DE119249, and R01 CA136905 to KSJ E-J, R01 CA140806 to MSL.	Argetsinger LS, 2004, MOL CELL BIOL, V24, P4955, DOI 10.1128/MCB.24.11.4955-4967.2004; Beguelin W, 2013, CANCER CELL, V23, P677, DOI 10.1016/j.ccr.2013.04.011; Bodor C, 2013, BLOOD, V122, P3165, DOI 10.1182/blood-2013-04-496893; Chen H, 2013, MOL CELL BIOL, V33, P1139, DOI 10.1128/MCB.01191-12; Ciferri C, 2012, ELIFE, V1, DOI 10.7554/eLife.00005; Dimri M, 2010, CARCINOGENESIS, V31, P489, DOI 10.1093/carcin/bgp305; Emanuele MJ, 2011, CELL, V147, P459, DOI 10.1016/j.cell.2011.09.019; Erhardt S, 2003, DEVELOPMENT, V130, P4235, DOI 10.1242/dev.00625; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Kaneko S, 2010, GENE DEV, V24, P2615, DOI 10.1101/gad.1983810; Knutson SK, 2013, P NATL ACAD SCI USA, V110, P7922, DOI 10.1073/pnas.1303800110; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407; Liu H, 2007, GENE DEV, V21, P2385, DOI 10.1101/gad.1574507; Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784; Martin-Perez D, 2010, BLOOD, V116, P5465, DOI 10.1182/blood-2010-05-267096; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Mills AA, 2010, NAT REV CANCER, V10, P669, DOI 10.1038/nrc2931; Morey L, 2010, TRENDS BIOCHEM SCI, V35, P323, DOI 10.1016/j.tibs.2010.02.009; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Piunti A, 2011, FUTURE ONCOL, V7, P57, DOI 10.2217/FON.10.157; Popovic R, 2013, THER ADV HEMATOL, V4, P81, DOI 10.1177/2040620712466864; Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84; Sahasrabuddhe AA, 2011, CELL CYCLE, V10, P1322, DOI 10.4161/cc.10.8.15372; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Simon JA, 2013, MOL CELL, V49, P808, DOI 10.1016/j.molcel.2013.02.013; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Surface LE, 2010, CELL STEM CELL, V7, P288, DOI 10.1016/j.stem.2010.08.004; Tan MKM, 2011, MOL CELL BIOL, V31, P3687, DOI 10.1128/MCB.05746-11; Velichutina I, 2010, BLOOD, V116, P5247, DOI 10.1182/blood-2010-04-280149; Velusamy T, 2013, P NATL ACAD SCI USA, V110, P3035, DOI 10.1073/pnas.1214326110; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Yadav AK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-158; Yu YL, 2013, EMBO MOL MED, V5, P531, DOI 10.1002/emmm.201201783; Zoabi M, 2011, BIOCHEM BIOPH RES CO, V408, P393, DOI 10.1016/j.bbrc.2011.04.025	39	63	64	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2015	34	4					445	454		10.1038/onc.2013.571	http://dx.doi.org/10.1038/onc.2013.571			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ8FU	24469040				2022-12-17	WOS:000348451300005
J	Dong, Y; Richards, JAE; Gupta, R; Aung, PP; Emley, A; Kluger, Y; Dogra, SK; Mahalingam, M; Wajapeyee, N				Dong, Y.; Richards, J-A E.; Gupta, R.; Aung, P. P.; Emley, A.; Kluger, Y.; Dogra, S. K.; Mahalingam, M.; Wajapeyee, N.			PTEN functions as a melanoma tumor suppressor by promoting host immune response	ONCOGENE			English	Article						tumor suppressor; melanoma; immune evasion	NF-KAPPA-B; BRAF MUTATIONS; EXPRESSION; CANCER; STAT3; CYTOKINES; PATHWAY; PHOSPHORYLATION; SENESCENCE; FAMILY	Cancer cells acquire several traits that allow for their survival and progression, including the ability to evade the host immune response. However, the mechanisms by which cancer cells evade host immune responses remain largely elusive. Here we study the phenomena of immune evasion in malignant melanoma cells. We find that the tumor suppressor phosphatase and tensin homolog (PTEN) is an important regulator of the host immune response against melanoma cells. Mechanistically, PTEN represses the expression of immunosuppressive cytokines by blocking the phosphatidylinositide 3-kinase (PI3K) pathway. In melanoma cells lacking PTEN, signal transducer and activator of transcription 3 activates the transcription of immunosuppressive cytokines in a PI3K-dependent manner. Furthermore, conditioned media from PTEN-deficient, patient-derived short-term melanoma cultures and established melanoma cell lines blocked the production of the interleukin-12 (IL-12) in human monocyte-derived dendritic cells. Inhibition of IL-12 production was rescued by restoring PTEN or using neutralizing antibodies against the immunosuppressive cytokines. Furthermore, we report that PTEN, as an alternative mechanism to promote the host immune response against cancer cells, represses the expression of programmed cell death 1 ligand, a known repressor of the host immune response. Finally, to establish the clinical significance of our results, we analyzed malignant melanoma patient samples with or without brisk host responses. These analyses confirmed that PTEN loss is associated with a higher percentage of malignant melanoma samples with non-brisk host responses compared with samples with brisk host responses. Collectively, these results establish that PTEN functions as a melanoma tumor suppressor in part by regulating the host immune response against melanoma cells and highlight the importance of assessing PTEN status before recruiting melanoma patients for immunotherapies.	[Dong, Y.; Gupta, R.; Kluger, Y.; Wajapeyee, N.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Dong, Y.] Hebei Med Univ, Coll Stomatol, Dept Oral & Maxillofacial Surg, Shijiazhuang, Peoples R China; [Richards, J-A E.; Aung, P. P.; Emley, A.; Mahalingam, M.] Boston Univ, Sch Med, Dept Dermatol, Dermatopathol Sect, Boston, MA 02118 USA; [Dogra, S. K.] ASTAR, Brenner Ctr Mol Med, Singapore Inst Clin Sci, Singapore, Singapore	Yale University; Hebei Medical University; Boston University; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Institute for Clinical Sciences (SICS)	Wajapeyee, N (corresponding author), Yale Univ, Sch Med, Dept Pathol, LH-214A,310 Cedar St, New Haven, CT 06510 USA.	mmahalin@bu.edu; Narendra.Wajapeyee@yale.edu	Dogra, Shaillay Kumar/K-7073-2015	Aung, Phyu/0000-0002-3398-0573	Melanoma Research Alliance; Melanoma Research Foundation; NATIONAL CANCER INSTITUTE [R33CA106709] Funding Source: NIH RePORTER	Melanoma Research Alliance; Melanoma Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	NW is a Sidney Kimmel Scholar for translational Cancer research and is supported by a team science award from Melanoma Research Alliance and a Career Development Award from Melanoma Research Foundation. NW and YK are members of the Yale Cancer Center.	Alcocer-Gonzalez JM, 2006, VIRAL IMMUNOL, V19, P481, DOI 10.1089/vim.2006.19.481; Blank C, 2007, CANCER IMMUNOL IMMUN, V56, P739, DOI 10.1007/s00262-006-0272-1; Brandl C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010800; Burikhanov R, 2009, CELL, V138, P377, DOI 10.1016/j.cell.2009.05.022; Caamano J, 2002, CLIN MICROBIOL REV, V15, P414, DOI 10.1128/CMR.15.3.414-429.2002; Cimica V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020188; Cozar Jose Manuel, 2008, J Med Case Rep, V2, P111, DOI 10.1186/1752-1947-2-111; Dadzie OE, 2009, BRIT J DERMATOL, V160, P368, DOI 10.1111/j.1365-2133.2008.08887.x; Dan HC, 2008, GENE DEV, V22, P1490, DOI 10.1101/gad.1662308; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Donia M, 2012, ONCOIMMUNOLOGY, V1, P1476, DOI 10.4161/onci.21940; Greene VR, 2009, J INVEST DERMATOL, V129, P1483, DOI 10.1038/jid.2008.374; Hart JR, 2011, P NATL ACAD SCI USA, V108, P13247, DOI 10.1073/pnas.1110486108; Khalaf H, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-26; Knight DA, 2013, J CLIN INVEST, V123, P1371, DOI 10.1172/JCI66236; Lengagne R, 2008, J IMMUNOL, V180, P130, DOI 10.4049/jimmunol.180.1.130; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li N, 2011, CANCER CELL, V19, P429, DOI 10.1016/j.ccr.2011.03.018; Liu L, 2005, P NATL ACAD SCI USA, V102, P8150, DOI 10.1073/pnas.0501643102; Loots GG, 2004, NUCLEIC ACIDS RES, V32, pW217, DOI 10.1093/nar/gkh383; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lund TC, 1999, CELL SIGNAL, V11, P789, DOI 10.1016/S0898-6568(99)00045-5; Mihm MC, 1996, LAB INVEST, V74, P43; Nguyen LT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013940; Nogueira C, 2010, ONCOGENE, V29, P6222, DOI 10.1038/onc.2010.349; O'Shea JJ, 2002, NAT REV IMMUNOL, V2, P37, DOI 10.1038/nri702; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Rosso Ritchie, 2009, J Invest Dermatol, V129, P1318, DOI 10.1038/jid.2009.107; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Santra MK, 2009, NATURE, V459, P722, DOI 10.1038/nature08011; Sumimoto H, 2006, J EXP MED, V203, P1651, DOI 10.1084/jem.20051848; Tsao H, 2003, J AM ACAD DERMATOL, V49, P865, DOI 10.1016/S0190-9622(03)02473-3; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Witten IH, 2011, MOR KAUF D, P1; Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936	40	63	65	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2014	33	38					4632	4642		10.1038/onc.2013.409	http://dx.doi.org/10.1038/onc.2013.409			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3VX	24141770				2022-12-17	WOS:000342007200002
J	Sun, M; Gomes, S; Chen, P; Frankenberger, CA; Sankarasharma, D; Chung, CH; Chada, KK; Rosner, MR				Sun, M.; Gomes, S.; Chen, P.; Frankenberger, C. A.; Sankarasharma, D.; Chung, C. H.; Chada, K. K.; Rosner, M. R.			RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2	ONCOGENE			English	Article						RKIP; HMGA2; LOX; SDC2; breast; metastasis	INHIBITOR PROTEIN EXPRESSION; CANCER METASTASIS; MESENCHYMAL TRANSITION; COLORECTAL-CANCER; SIGNALING PATHWAY; PROSTATE-CANCER; MIR-200 FAMILY; GENES; PROGRESSION; LET-7	Elucidating targets of physiological tumor metastasis suppressors can highlight key signaling pathways leading to invasion and metastasis. To identify downstream targets of the metastasis suppressor Raf-1 kinase inhibitory protein (RKIP/PEBP1), we utilized an integrated approach based upon statistical analysis of tumor gene expression data combined with experimental validation. Previous studies from our laboratory identified the architectural transcription factor and oncogene, high mobility group AT-hook 2 (HMGA2), as a target of inhibition by RKIP. Here we identify two signaling pathways that promote HMGA2-driven metastasis. Using both human breast tumor cells and an MMTV-Wnt mouse breast tumor model, we show that RKIP induces and HMGA2 inhibits expression of miR-200b; miR-200b directly inhibits expression of lysyl oxidase (LOX), leading to decreased invasion. RKIP also inhibits syndecan-2 (SDC2), which is aberrantly expressed in breast cancer, via downregulation of HMGA2; but this mechanism is independent of miR-200. Depletion of SDC2 induces apoptosis and suppresses breast tumor growth and metastasis in mouse xenografts. RKIP, LOX and SDC2 are coordinately regulated and collectively encompass a prognostic signature for metastasis-free survival in ER-negative breast cancer patients. Taken together, our findings reveal two novel signaling pathways targeted by the metastasis suppressor RKIP that regulate remodeling of the extracellular matrix and tumor survival.	[Sun, M.; Gomes, S.; Frankenberger, C. A.; Rosner, M. R.] Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA; [Sun, M.; Rosner, M. R.] Univ Chicago, Comm Genet Genom & Syst Biol, Chicago, IL 60637 USA; [Chen, P.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Sankarasharma, D.; Chada, K. K.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ USA; [Chung, C. H.] Vanderbilt Univ, Sch Med, Dept Med & Canc Biol, Div Hematol Oncol, Nashville, TN 37212 USA	University of Chicago; University of Chicago; University of Chicago; Rutgers State University New Brunswick; Rutgers State University Medical Center; Vanderbilt University	Rosner, MR (corresponding author), Univ Chicago, Ben May Dept Canc Res, GCIS W421C,929 E 57th St, Chicago, IL 60637 USA.	m-rosner@uchicago.edu			NIH [GM087630]; DOD Predoctoral Traineeship Award [W81XWH-10-1-0396]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM087630] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD Predoctoral Traineeship Award; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH grant GM087630 to MRR and DOD Predoctoral Traineeship Award W81XWH-10-1-0396 to MS. We also thank Eva Eves for technical support and helpful discussion.	Al-Mulla F, 2006, J CLIN ONCOL, V24, P5672, DOI 10.1200/JCO.2006.07.5499; Barbareschi M, 2003, CANCER-AM CANCER SOC, V98, P474, DOI 10.1002/cncr.11515; Berger JA, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-194; Corbit KC, 2003, J BIOL CHEM, V278, P13061, DOI 10.1074/jbc.M210015200; Csiszar K, 2001, PROG NUCLEIC ACID RE, V70, P1, DOI 10.1016/S0079-6603(01)70012-8; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; De Oliveira T, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-19; Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765; Efron B, 2007, ANN APPL STAT, V1, P107, DOI 10.1214/07-AOAS101; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Fu Z, 2003, J NATL CANCER I, V95, P878, DOI 10.1093/jnci/95.12.878; Fu Z, 2006, PROSTATE, V66, P248, DOI 10.1002/pros.20319; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952; Hagan S, 2005, CLIN CANCER RES, V11, P7392, DOI 10.1158/1078-0432.CCR-05-0283; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Jiang X, 2012, CANCER CELL, V22, P524, DOI 10.1016/j.ccr.2012.08.028; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lambaerts K, 2009, CURR OPIN CELL BIOL, V21, P662, DOI 10.1016/j.ceb.2009.05.002; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li YW, 2009, CANCER RES, V69, P6704, DOI 10.1158/0008-5472.CAN-09-1298; Li ZJ, 2008, P NATL ACAD SCI USA, V105, P15535, DOI 10.1073/pnas.0808266105; Loussouarn D, 2008, BRIT J CANCER, V98, P1993, DOI 10.1038/sj.bjc.6604400; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Marion A, 2012, INT J CANCER, V130, P2514, DOI 10.1002/ijc.26246; Massague J, 2007, NEW ENGL J MED, V356, P294, DOI 10.1056/NEJMe068292; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; Minn AJ, 2012, CELL CYCLE, V11, P2452, DOI 10.4161/cc.20624; Minoo P, 2007, AM J CLIN PATHOL, V127, P820, DOI 10.1309/5D7MM22DAVGDT1R8; Morishita A, 2013, CANCER RES, V73, P4289, DOI 10.1158/0008-5472.CAN-12-3848; Nikolova V, 2009, CARCINOGENESIS, V30, P397, DOI 10.1093/carcin/bgp001; Park H, 2002, J BIOL CHEM, V277, P29730, DOI 10.1074/jbc.M202435200; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Peter ME, 2009, CELL CYCLE, V8, P843, DOI 10.4161/cc.8.6.7907; Popovic A, 2010, PROSTATE CANCER P D, V13, P78, DOI 10.1038/pcan.2009.43; Ritchie ME, 2007, BIOINFORMATICS, V23, P2700, DOI 10.1093/bioinformatics/btm412; Schuetz CS, 2006, CANCER RES, V66, P5278, DOI 10.1158/0008-5472.CAN-05-4610; Smith SC, 2009, NAT REV CANCER, V9, P253, DOI 10.1038/nrc2594; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Sun M, 2013, P NATL ACAD SCI USA, V110, P9920, DOI 10.1073/pnas.1305172110; Team RDC. R, 2009, R LANG ENV STAT COMP; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Xu YF, 2010, J HEPATOL, V53, P872, DOI 10.1016/j.jhep.2010.05.019; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Yun JU, 2011, EMBO J, V30, P4500, DOI 10.1038/emboj.2011.312	55	63	67	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2014	33	27					3528	3537		10.1038/onc.2013.328	http://dx.doi.org/10.1038/onc.2013.328			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2FK	23975428	Green Accepted			2022-12-17	WOS:000338941100005
J	Nottingham, LK; Yan, CH; Yang, X; Si, H; Coupar, J; Bian, Y; Cheng, TF; Allen, C; Arun, P; Gius, D; Dang, L; Van Waes, C; Chen, Z				Nottingham, L. K.; Yan, C. H.; Yang, X.; Si, H.; Coupar, J.; Bian, Y.; Cheng, T-F; Allen, C.; Arun, P.; Gius, D.; Dang, L.; Van Waes, C.; Chen, Z.			Aberrant IKK alpha and IKK beta cooperatively activate NF-kappa B and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer	ONCOGENE			English	Article						IKK alpha; IKK beta; NF-kappa B; AP1; head and neck cancers	SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; INDUCED GENE-EXPRESSION; PROSTATE-CANCER; KINASE-ALPHA; TGF-BETA; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTORS; TUMOR-GROWTH; IN-VIVO	The inhibitor-kappa B kinase-nuclear factor-kappa B (IKK-NF-kappa B) and epidermal growth factor receptor-activator protein-1 (EGFR-AP1) pathways are often co-activated and promote malignant behavior, but the underlying basis for this relationship is unclear. Resistance to inhibitors of IKK beta or EGFR is observed in head and neck squamous cell carcinomas (HNSCC). Here, we reveal that both IKK alpha and beta contribute to nuclear activation of canonical and alternate NF-kappa B/REL family transcription factors, and overexpression of signal components that enhance co-activation of the EGFR-AP1 pathway. We observed that IKK alpha and IKK beta exhibit increased protein expression, nuclear localization, and phosphorylation in HNSCC tissues and cell lines. Individually, IKK activity varied among different cell lines, but overexpression of both IKKs induced the strongest NF-kappa B activation. Conversely, siRNA knock down of both IKKs significantly decreased nuclear localization and phosphorylation of canonical RELA and I kappa B alpha and alternative p52 and RELB subunits. Knock down of both IKKs more effectively inhibited NF-kappa B activation, broadly modulated gene expression and suppressed cell proliferation and migration. Global expression profiling revealed that NF-kappa B, cytokine, inflammatory response and growth factor signaling are among the top pathways and networks regulated by IKKs. Importantly, IKK alpha and IKK beta together promoted the expression and activity of transforming growth factor a, EGFR and AP1 transcription factors cJun, JunB and Fra1. Knock down of AP1 subunits individually decreased 8/15 (53%) of IKK-targeted genes sampled and similarly inhibited cell proliferation and migration. Mutations of NF-kappa B and AP1-binding sites abolished or decreased IKK-induced interleukin-8 (IL-8) promoter activity. Compounds such as wedelactone with dual IKK inhibitory activity and geldanomycins that block IKK alpha/beta and EGFR pathways were more active than IKK beta-specific inhibitors in suppressing NF-kappa B activation and proliferation and inducing cell death. We conclude that IKK alpha and IKK beta cooperatively activate NF-kappa B and EGFR/AP1 networks of signaling pathways and contribute to the malignant phenotype and the intrinsic or acquired therapeutic resistance of HNSCC.	[Nottingham, L. K.; Yan, C. H.; Yang, X.; Si, H.; Coupar, J.; Bian, Y.; Cheng, T-F; Allen, C.; Arun, P.; Van Waes, C.; Chen, Z.] NIDCD, Tumor Biol Sect, Head & Neck Surg Branch, NIH, Bethesda, MD 20892 USA; [Yan, C. H.] NIH, Howard Hughes Med Inst, Res Scholars Program, Bethesda, MD 20892 USA; [Allen, C.] Clin Res Training Program, Bethesda, MD USA; [Allen, C.] Pfizer Inc, Bethesda, MD USA; [Gius, D.] Vanderbilt Univ, Med Ctr, Dept Radiat Oncol, Nashville, TN USA; [Dang, L.] Millennium Pharmaceut Inc, Cambridge, MA USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; Pfizer; Pfizer; Vanderbilt University; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Chen, Z (corresponding author), NIDCD, Tumor Biol Sect, Head & Neck Surg Branch, NIH, 10-5D55,MSC-1419, Bethesda, MD 20892 USA.	vanwaesc@nidcd.nih.gov; chenz@nidcd.nih.gov	Allen, Clint/AAD-7016-2021	Allen, Clint/0000-0001-6586-5804; Yan, Carol/0000-0003-1934-4922; Dang, Lenny/0000-0002-2073-6109	NIDCD [Z01-DC-00016, Z01-DC-00073, Z01-DC-00074]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000016, K08DC000073] Funding Source: NIH RePORTER	NIDCD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This project is supported by NIDCD Intramural projects Z01-DC-00016, Z01-DC-00073 and Z01-DC-00074. We thank Dr Michael Karin (UC San Diego) and Dr Ulrich Siebenlist (NIH/NIAID) for kindly providing the IKK plasmids; Dr Neil Perkins (Newcastle University, UK) for kindly providing anti-p-p52 antibody; Dr Jialing Zhang for technical assistance; and Dr Michael Karin, Dr Christophe Cataisson (NCI/NIH) and Dr Claire Sauvageot (Millennium Pharmaceuticals, Inc) for critique of the manuscript.	Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Allen C, 2008, CLIN CANCER RES, V14, P4175, DOI 10.1158/1078-0432.CCR-07-4470; Ammirante M, 2010, NATURE, V464, P302, DOI 10.1038/nature08782; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Anest V, 2004, J BIOL CHEM, V279, P31183, DOI 10.1074/jbc.M404380200; Argiris A, 2011, CLIN CANCER RES, V17, P5755, DOI 10.1158/1078-0432.CCR-11-0861; Barre B, 2010, CELL CYCLE, V9, P4774, DOI 10.4161/cc.9.24.14246; Barre B, 2010, MOL CELL, V38, P524, DOI 10.1016/j.molcel.2010.03.018; Basak S, 2008, CYTOKINE GROWTH F R, V19, P187, DOI 10.1016/j.cytogfr.2008.04.005; Basak S, 2008, MOL CELL BIOL, V28, P3139, DOI 10.1128/MCB.01469-07; Bednarski BK, 2008, MOL CANCER THER, V7, P1827, DOI 10.1158/1535-7163.MCT-08-0321; Bian Y, 2012, ONCOGENE, V31, P3322, DOI 10.1038/onc.2011.494; Bivona TG, 2011, NATURE, V471, P523, DOI 10.1038/nature09870; Carayol N, 2006, J BIOL CHEM, V281, P31142, DOI 10.1074/jbc.M603417200; Chen Z, 2008, MOL CANCER THER, V7, P1949, DOI 10.1158/1535-7163.MCT-07-2046; Cohen J, 2009, CANCER RES, V69, P3415, DOI 10.1158/0008-5472.CAN-08-3704; Debinski W, 2011, CANCER BIOL THER, V11, P254, DOI 10.4161/cbt.11.2.13953; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Duffey DC, 1999, CANCER RES, V59, P3468; Egorin MJ, 2002, CANCER CHEMOTH PHARM, V49, P7, DOI 10.1007/s00280-001-0380-8; Freudlsperger C, 2013, ONCOGENE, V32, P1549, DOI 10.1038/onc.2012.171; Fusco AJ, 2008, J BIOL CHEM, V283, P12324, DOI 10.1074/jbc.M707898200; Gomard T, 2010, PLOS ONE, V5, pA178, DOI 10.1371/journal.pone.0009585; GRANDIS JR, 1993, CANCER RES, V53, P3579; Hacker H., 2006, SCI STKE, V2006, P13, DOI [10.1126/stke.3572006re13, DOI 10.1126/STKE.3572006RE13]; Hertlein E, 2010, BLOOD, V116, P45, DOI 10.1182/blood-2010-01-263756; Hinz M, 2012, IMMUNOL REV, V246, P59, DOI 10.1111/j.1600-065X.2012.01102.x; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kobori M, 2004, CELL DEATH DIFFER, V11, P123, DOI 10.1038/sj.cdd.4401325; Krappmann D, 2004, MOL CELL BIOL, V24, P6488, DOI 10.1128/MCB.24.14.6488-6500.2004; Lam LT, 2008, P NATL ACAD SCI USA, V105, P20798, DOI 10.1073/pnas.0806491106; Lam LT, 2005, CLIN CANCER RES, V11, P28; Lee TL, 2006, MOL CANCER THER, V5, P8, DOI 10.1158/1535-7163.MCT-05-0069; Liu BG, 2008, CANCER CELL, V14, P212, DOI 10.1016/j.ccr.2008.07.017; Madge LA, 2008, J IMMUNOL, V180, P3467, DOI 10.4049/jimmunol.180.5.3467; Madge LA, 2010, J BIOL CHEM, V285, P38069, DOI 10.1074/jbc.M110.147207; Marinari B, 2008, P NATL ACAD SCI USA, V105, P17091, DOI 10.1073/pnas.0809288105; Mishra A, 2010, INT J CANCER, V126, P819, DOI 10.1002/ijc.24807; Nagashima K, 2006, BLOOD, V107, P4266, DOI 10.1182/blood-2005-09-3852; Ndlovu MN, 2009, MOL CELL BIOL, V29, P5488, DOI 10.1128/MCB.01657-08; Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N; Park EM, 2011, FUTURE ONCOL, V7, P123, DOI [10.2217/fon.10.166, 10.2217/FON.10.166]; Pernas FG, 2009, CLIN CANCER RES, V15, P2361, DOI 10.1158/1078-0432.CCR-08-1011; Savinova OV, 2009, MOL CELL, V34, P591, DOI 10.1016/j.molcel.2009.04.033; Scheidereit C, 2012, KEYST S NF KAPPAB SI; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Sharafinski ME, 2010, HEAD NECK-J SCI SPEC, V32, P1412, DOI 10.1002/hed.21365; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sunwoo JB, 2001, CLIN CANCER RES, V7, P1419; Van Waes C, 2007, CLIN CANCER RES, V13, P1076, DOI 10.1158/1078-0432.CCR-06-2221; Wolf MJ, 2010, ONCOGENE, V29, P5006, DOI 10.1038/onc.2010.260; Yamamoto Y, 2000, MOL CELL BIOL, V20, P3655, DOI 10.1128/MCB.20.10.3655-3666.2000; Yang XP, 2011, CANCER RES, V71, P3688, DOI 10.1158/0008-5472.CAN-10-3445; Yemelyanov A, 2006, ONCOGENE, V25, P387, DOI 10.1038/sj.onc.1209066; Younes F, 1996, Oral Dis, V2, P25; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zerbini LF, 2003, CANCER RES, V63, P2206	58	63	67	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1135	1147		10.1038/onc.2013.49	http://dx.doi.org/10.1038/onc.2013.49			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23455325	Green Accepted			2022-12-17	WOS:000331933800007
J	Ammoun, S; Provenzano, L; Zhou, L; Barczyk, M; Evans, K; Hilton, DA; Hafizi, S; Hanemann, CO				Ammoun, S.; Provenzano, L.; Zhou, L.; Barczyk, M.; Evans, K.; Hilton, D. A.; Hafizi, S.; Hanemann, C. O.			Axl/Gas6/NF kappa B signalling in schwannoma pathological proliferation, adhesion and survival	ONCOGENE			English	Article						Gas6/Axl; NF kappa B; merlin; proliferation/adhesion/survival; schwannoma	RECEPTOR TYROSINE KINASE; NF-KAPPA-B; UBIQUITIN LIGASE CRL4(DCAF1); GROWTH-FACTOR; UP-REGULATION; SOLUBLE FORM; ACTIVATION; EXPRESSION; CELLS; MERLIN	TAM family receptor tyrosine kinases comprising Tyro3 (Sky), Axl, and Mer are overexpressed in some cancers, correlate with multidrug resistance and contribute to tumourigenesis by regulating invasion, angiogenesis, cell survival and tumour growth. Mutations in the gene coding for a tumour suppressor merlin cause development of multiple tumours of the nervous system such as schwannomas, meningiomas and ependymomas occurring spontaneously or as part of a hereditary disease neurofibromatosis type 2. The benign character of merlin-deficient tumours makes them less responsive to chemotherapy. We previously showed that, amongst other growth factor receptors, TAM family receptors (Tyro3, Axl and Mer) are significantly overexpressed in schwannoma tissues. As Axl is negatively regulated by merlin and positively regulated by E3 ubiquitin ligase CRL4DCAF1, previously shown to be a key regulator in schwannoma growth we hypothesized that Axl is a good target to study in merlin-deficient tumours. Moreover, Axl positively regulates the oncogene Yes-associated protein, which is known to be under merlin regulation in schwannoma and is involved in increased proliferation of merlin-deficient meningioma and mesothelioma. Here, we demonstrated strong overexpression and activation of Axl receptor as well as its ligand Gas6 in human schwannoma primary cells compared to normal Schwann cells. We show that Gas6 is mitogenic and increases schwannoma cell-matrix adhesion and survival acting via Axl in schwannoma cells. Stimulation of the Gas6/Axl signalling pathway recruits Src, focal adhesion kinase (FAK) and NFkB. We showed that NFkB mediates Gas6/Axl-mediated overexpression of survivin, cyclin D1 and FAK, leading to enhanced survival, cell-matrix adhesion and proliferation of schwannoma. We conclude that Axl/FAK/Src/NF kappa B pathway is relevant in merlin-deficient tumours and is a potential therapeutic target for schwannoma and other merlin-deficient tumours.	[Ammoun, S.; Provenzano, L.; Zhou, L.; Barczyk, M.; Evans, K.; Hanemann, C. O.] Univ Plymouth, Inst Translat & Stratified Med, Peninsula Sch Med, Plymouth PL68BU, Devon, England; [Ammoun, S.; Provenzano, L.; Zhou, L.; Barczyk, M.; Evans, K.; Hanemann, C. O.] Univ Plymouth, Inst Translat & Stratified Med, Peninsula Sch Dent, Plymouth PL68BU, Devon, England; [Hilton, D. A.] Derriford Hosp, Dept Histopathol, Plymouth PL6 8DH, Devon, England; [Hafizi, S.] Univ Portsmouth, IBBS, Div Pharmacol, Portsmouth, Hants, England	University of Plymouth; University of Plymouth; Derriford Hospital; University of Portsmouth	Ammoun, S (corresponding author), Univ Plymouth, Inst Translat & Stratified Med, Peninsula Sch Med, John Bull Bldg,Tamar Sci Pk,Res Way, Plymouth PL68BU, Devon, England.	sylwia.ammoun@pms.ac.uk	Hanemann, C Oliver/AAV-6257-2020; Hafizi, Sassan/W-4424-2019	Hanemann, C Oliver/0000-0002-1951-1025; Hafizi, Sassan/0000-0002-4539-0888	Children tumour foundation	Children tumour foundation	Work was supported by the Children tumour foundation and Dr Hadwen Trust support. We thank Dr Federiko Roncoroli for providing human tissues and Leanne Turner for technical assistance.	Ammoun S, 2012, ONCOGENE, V31, P1710, DOI 10.1038/onc.2011.357; Ammoun S, 2008, CANCER RES, V68, P5236, DOI 10.1158/0008-5472.CAN-07-5849; Ammoun S, 2012, GLIA, V60, P1721, DOI 10.1002/glia.22391; Ammoun S, 2011, NAT REV NEUROL, V7, P392, DOI 10.1038/nrneurol.2011.82; Ammoun S, 2011, NEURO-ONCOLOGY, V13, P759, DOI 10.1093/neuonc/nor056; Ammoun S, 2010, NEURO-ONCOLOGY, V12, P834, DOI 10.1093/neuonc/noq012; Ammoun S, 2010, NEUROBIOL DIS, V37, P141, DOI 10.1016/j.nbd.2009.09.017; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Boyle K, 2005, NEUROBIOL DIS, V20, P412, DOI 10.1016/j.nbd.2005.03.022; Burchert A, 1998, ONCOGENE, V16, P3177, DOI 10.1038/sj.onc.1201865; Cooper J, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002314; Costa M, 1996, J CELL PHYSIOL, V168, P737, DOI 10.1002/(SICI)1097-4652(199609)168:3<737::AID-JCP27>3.0.CO;2-U; Demarchi F, 2001, J BIOL CHEM, V276, P31738, DOI 10.1074/jbc.M104457200; Du J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015940; Flaiz C, 2009, EXP NEUROL, V218, P137, DOI 10.1016/j.expneurol.2009.04.019; Georgakis GV, 2006, EXP HEMATOL, V34, P1670, DOI 10.1016/j.exphem.2006.07.002; Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004; Hanemann CO, 2006, NEUROPATH APPL NEURO, V32, P605, DOI 10.1111/j.1365-2990.2006.00769.x; Hanemann CO, 1997, ACTA NEUROPATHOL, V94, P310, DOI 10.1007/s004010050712; Hilton DA, 2009, HISTOPATHOLOGY, V55, P744, DOI 10.1111/j.1365-2559.2009.03440.x; Kaempchen K, 2003, HUM MOL GENET, V12, P1211, DOI 10.1093/hmg/ddg146; Kim H, 2002, MOL CELLS, V14, P108; Kim JY, 2002, BIOCHEM BIOPH RES CO, V296, P1295, DOI 10.1016/S0006-291X(02)02077-6; Kim RJ, 2010, CANCER LETT, V287, P172, DOI 10.1016/j.canlet.2009.06.010; Klein EA, 2007, CELL CYCLE, V6, P1115, DOI 10.4161/cc.6.9.4147; Lee H, 2007, MOL CELL BIOL, V27, P2103, DOI 10.1128/MCB.00572-06; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Li RH, 1996, J NEUROSCI, V16, P2012; Li W, 2010, CELL, V140, P477, DOI 10.1016/j.cell.2010.01.029; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Liu WG, 2008, CARCINOGENESIS, V29, P1096, DOI 10.1093/carcin/bgn026; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Ou WB, 2011, ONCOGENE, V30, P1643, DOI 10.1038/onc.2010.555; Rexhepaj R, 2010, CELL PHYSIOL BIOCHEM, V25, P715, DOI 10.1159/000315091; Rosenbaum C, 1998, NEUROBIOL DIS, V5, P55, DOI 10.1006/nbdi.1998.0179; Rosenbaum C, 2000, NEUROBIOL DIS, V7, P483, DOI 10.1006/nbdi.2000.0307; Sakai H, 2010, PEPTIDES, V31, P2216, DOI 10.1016/j.peptides.2010.09.012; Sather S, 2007, BLOOD, V109, P1026, DOI 10.1182/blood-2006-05-021634; Sayan AE, 2012, ONCOGENE, V31, P1493, DOI 10.1038/onc.2011.336; Shiozawa Y, 2010, NEOPLASIA, V12, P116, DOI 10.1593/neo.91384; Stenhoff J, 2004, BIOCHEM BIOPH RES CO, V319, P871, DOI 10.1016/j.bbrc.2004.05.070; Taylor ICA, 1995, ONCOGENE, V11, P2619; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Utermark T, 2005, BRAIN PATHOL, V15, P17; Utermark T, 2003, BRAIN PATHOL, V13, P352; Valverde P, 2005, BIOCHEM BIOPH RES CO, V333, P180, DOI 10.1016/j.bbrc.2005.05.086; Wickremesekera A, 2007, J CLIN NEUROSCI, V14, P1199, DOI 10.1016/j.jocn.2007.05.009; Wu CW, 2002, ANTICANCER RES, V22, P1071; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Yi CL, 2010, GENE DEV, V24, P1673, DOI 10.1101/gad.1964810; Zhao YF, 2012, CANCER INVEST, V30, P287, DOI 10.3109/07357907.2012.657816; Zhou L, 2011, NEOPLASIA, V13, P1101, DOI 10.1593/neo.111060	54	63	65	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					336	346		10.1038/onc.2012.587	http://dx.doi.org/10.1038/onc.2012.587			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318455	Green Published			2022-12-17	WOS:000330214000008
J	Monteiro, LJ; Khongkow, P; Kongsema, M; Morris, JR; Man, C; Weekes, D; Koo, CY; Gomes, AR; Pinto, PH; Varghese, V; Kenny, LM; Coombes, RC; Freire, R; Medema, RH; Lam, EWF				Monteiro, L. J.; Khongkow, P.; Kongsema, M.; Morris, J. R.; Man, C.; Weekes, D.; Koo, C-Y; Gomes, A. R.; Pinto, P. H.; Varghese, V.; Kenny, L. M.; Coombes, R. Charles; Freire, R.; Medema, R. H.; Lam, E. W-F			The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment	ONCOGENE			English	Article						FOXM1; BRIP1; DNA damage; epirubicin; resistance; breast cancer	BREAST-CANCER CELLS; TRANSCRIPTION FACTOR FOXM1; DOUBLE-STRAND BREAKS; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; BINDING DOMAIN; RESISTANCE; BACH1; PROGRESSION; GENE	FOXM1 is implicated in genotoxic drug resistance but its role and mechanism of action remain unclear. Here, we establish that gamma H2AX foci, indicative of DNA double-strand breaks (DSBs), accumulate in a time-dependent manner in the drug-sensitive MCF-7 cells but not in the resistant counterparts in response to epirubicin. We find that FOXM1 expression is associated with epirubicin sensitivity and DSB repair. Ectopic expression of FOXM1 can increase cell viability and abrogate DSBs sustained by MCF-7 cells following epirubicin, owing to an enhancement in repair efficiency. Conversely, alkaline comet and gamma H2AX foci formation assays show that Foxm1-null cells are hypersensitive to DNA damage, epirubicin and gamma-irradiation. Furthermore, we find that FOXM1 is required for DNA repair by homologous recombination (HR) but not non-homologous end joining (NHEJ), using HeLa cell lines harbouring an integrated direct repeat green fluorescent protein reporter for DSB repair. We also identify BRIP1 as a direct transcription target of FOXM1 by promoter analysis and chromatin-immunoprecipitation assay. In agreement, depletion of FOXM1 expression by small interfering RNA downregulates BRIP1 expression at the protein and mRNA levels in MCF-7 and the epirubicin-resistant MCF-7 Epi(R) cells. Remarkably, the requirement for FOXM1 for DSB repair can be circumvented by reintroduction of BRIP1, suggesting that BRIP1 is an important target of FOXM1 in DSB repair. Indeed, like FOXM1, BRIP1 is needed for HR. These data suggest that FOXM1 regulates BRIP1 expression to modulate epirubicin-induced DNA damage repair and drug resistance.	[Monteiro, L. J.; Khongkow, P.; Kongsema, M.; Koo, C-Y; Gomes, A. R.; Pinto, P. H.; Varghese, V.; Kenny, L. M.; Coombes, R. Charles; Lam, E. W-F] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, London W12 0NN, England; [Morris, J. R.] Univ Birmingham, Coll Med & Dent Sci, Sch Canc Sci, Birmingham, W Midlands, England; [Man, C.] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China; [Weekes, D.] Kings Coll London, Guys Hosp, Dept Med & Mol Genet, London SE1 9RT, England; [Freire, R.] Hosp Univ Canarias, Unidad Invest, Inst Tecnol Biomed, Tenerife, Spain; [Medema, R. H.] Netherlands Canc Inst, Div Cell Biol, Amsterdam, CX, Netherlands	Imperial College London; University of Birmingham; Hong Kong Polytechnic University; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Universidad de la Laguna; Netherlands Cancer Institute	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Room 134,1st Floor,Hammersmith Hosp Campus,Du Can, London W12 0NN, England.	eric.lam@imperial.ac.uk	Monteiro, Lara J/AAU-8518-2020; Kongsema, Mesayamas/H-3063-2017; Lam, Eric W-F/AAW-8566-2020; Medema, Rene H/E-2981-2013; Morris, Joanna/AAK-3388-2021; Freire, Raimundo/Q-7660-2019	Lam, Eric W-F/0000-0003-1274-3576; Freire, Raimundo/0000-0003-4473-8894; Koo, Chuay Yeng/0000-0002-9495-0554; Kongsema, Mesayamas/0000-0001-7146-9349; Medema, Rene/0000-0002-6754-0381; Morris, Joanna/0000-0001-9762-8133; Weekes, Daniel/0000-0001-8083-7617; Khongkow, Pasarat/0000-0003-3068-2412; Coombes, Raoul Charles/0000-0002-4811-1100	Cancer Research UK; Breast Cancer Campaign; Fundacao para a Ciencia e a Tecnologia; Royal Thai Government Scholarships; Imperial College NHS Trust; Cancer Research UK [12011] Funding Source: researchfish; National Institute for Health Research [NIHR/CS/009/009] Funding Source: researchfish; Breast Cancer Campaign [2012NovPhD016, 2012MayPR070] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Breast Cancer Campaign; Fundacao para a Ciencia e a Tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission); Royal Thai Government Scholarships; Imperial College NHS Trust; Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR)); Breast Cancer Campaign	EW-FL, ARG and RCC were supported by grants from Cancer Research UK, EW-FL and C-YK by grants from Breast Cancer Campaign and Imperial College NHS Trust, LJM grants from Fundacao para a Ciencia e a Tecnologia, and PK and MK from the Royal Thai Government Scholarships. We also thank Dr Keng Heng for help with the microscopy and flow cytometry work.	Ahmad A, 2010, BREAST CANCER RES TR, V122, P337, DOI 10.1007/s10549-009-0572-1; Alvarez RH, 2010, J CLIN ONCOL, V28, P3366, DOI 10.1200/JCO.2009.25.4011; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Cantor S, 2004, P NATL ACAD SCI USA, V101, P2357, DOI 10.1073/pnas.0308717101; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Carr JR, 2010, CANCER RES, V70, P5054, DOI 10.1158/0008-5472.CAN-10-0545; Dai B, 2007, ONCOGENE, V26, P6212, DOI 10.1038/sj.onc.1210443; de Olano N, 2012, MOL CANCER RES, V10, P1189, DOI 10.1158/1541-7786.MCR-11-0559; Delacote F, 2002, NUCLEIC ACIDS RES, V30, P3454, DOI 10.1093/nar/gkf452; Dohrn L, 2012, BIOCHEM J, V441, P919, DOI 10.1042/BJ20110314; Fu Z, 2008, NAT CELL BIOL, V10, P1076, DOI 10.1038/ncb1767; Garinis GA, 2005, EMBO J, V24, P3952, DOI 10.1038/sj.emboj.7600849; Gong ZH, 2010, MOL CELL, V37, P438, DOI 10.1016/j.molcel.2010.01.002; Hegde NS, 2011, NAT CHEM, V3, P725, DOI [10.1038/nchem.1114, 10.1038/NCHEM.1114]; Karadedou CT, 2012, ONCOGENE, V31, P1845, DOI 10.1038/onc.2011.368; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Korver W, 1997, GENOMICS, V46, P435, DOI 10.1006/geno.1997.5065; Kruse V, 2011, ACTA CLIN BELG, V66, P2, DOI 10.1179/ACB.66.1.2062507; Kwok JMM, 2010, MOL CANCER RES, V8, P24, DOI 10.1158/1541-7786.MCR-09-0432; Kwok JMM, 2008, MOL CANCER THER, V7, P2022, DOI 10.1158/1535-7163.MCT-08-0188; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Li Q, 2009, CANCER RES, V69, P3501, DOI 10.1158/0008-5472.CAN-08-3045; Lin SX, 2010, NAT REV ENDOCRINOL, V6, P485, DOI 10.1038/nrendo.2010.92; Litman R, 2005, CANCER CELL, V8, P255, DOI 10.1016/j.ccr.2005.08.004; Madureira PA, 2006, J BIOL CHEM, V281, P25167, DOI 10.1074/jbc.M603906200; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Millour J, 2010, ONCOGENE, V29, P2983, DOI 10.1038/onc.2010.47; Millour J, 2011, MOL CANCER THER, V10, P1046, DOI 10.1158/1535-7163.MCT-11-0024; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Myatt SS, 2008, NAT REV CANCER, V8, P244, DOI 10.1038/nrc2223-c2; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nowak DE, 2005, BIOTECHNIQUES, V39, P715, DOI 10.2144/000112014; Palmieri C, 2010, NAT REV CLIN ONCOL, V7, P561, DOI 10.1038/nrclinonc.2010.122; Park HJ, 2008, MOL CELL BIOL, V28, P5162, DOI 10.1128/MCB.00387-08; Park YY, 2012, CARCINOGENESIS, V33, P1843, DOI 10.1093/carcin/bgs167; Peck B, 2010, MOL CANCER THER, V9, P844, DOI 10.1158/1535-7163.MCT-09-0971; Raguz S, 2008, BRIT J CANCER, V99, P387, DOI 10.1038/sj.bjc.6604510; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Stearns V, 2004, PHARMACOGENOMICS J, V4, P143, DOI 10.1038/sj.tpj.6500242; Tan YJ, 2007, MOL CELL BIOL, V27, P1007, DOI 10.1128/MCB.01068-06; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; Turnbull C, 2008, ANNU REV GENOM HUM G, V9, P321, DOI 10.1146/annurev.genom.9.081307.164339; Weinstock David M, 2007, Nat Cell Biol, V9, P978; Weinstock DM, 2006, METHOD ENZYMOL, V409, P524, DOI 10.1016/S0076-6879(05)09031-2; Xie J, 2010, ONCOGENE, V29, P2499, DOI 10.1038/onc.2010.18; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zelnak A, 2010, BREAST J, V16, P309, DOI 10.1111/j.1524-4741.2010.00911.x; Zhang HJ, 2006, MOL ENDOCRINOL, V20, P1853, DOI 10.1210/me.2006-0056	50	63	67	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2013	32	39					4634	4645		10.1038/onc.2012.491	http://dx.doi.org/10.1038/onc.2012.491			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23108394	Green Accepted			2022-12-17	WOS:000325072200005
J	Zhang, X; Wang, W; Wang, H; Wang, MH; Xu, W; Zhang, R				Zhang, X.; Wang, W.; Wang, H.; Wang, M-H; Xu, W.; Zhang, R.			Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loop	ONCOGENE			English	Article						RPS25; p53; MDM2; ribosomal stress	EMBRYONIC LETHALITY; P53 UBIQUITINATION; ONCOPROTEIN MDM2; STABILIZES P53; C-MYC; ACTIVATION; TRANSLATION; DEGRADATION; L11; INHIBITION	There is an increasing interest in determining the role of ribosomal proteins (RPs) in the regulation of MDM2-p53 pathway in coordinating cellular response to stress. Herein, we report a novel regulatory role of ribosomal protein S25 (RPS25) in MDM2-mediated p53 degradation and a feedback regulation of S25 by p53. We demonstrated that S25 interacted with MDM2 and inhibited its E3 ligase activity, resulting in the reduction of MDM2-mediated p53 ubiquitination and the stabilization and activation of p53. S25, MDM2 and p53 formed a ternary complex following ribosomal stress. The nucleolar localization and MDM2-binding domains of S25 were critical for its role in MDM2-mediated p53 regulation. Knockdown of S25 by siRNA attenuated the induction and activation of p53 following ribosomal stress. S25 stabilized and cooperated with MDMX to regulate MDM2 E3 ligase activity. Furthermore, S25 was identified to be a transcriptional target of p53; p53 directly bound to S25 promoter and suppressed S25 expression. Our results suggest that there is a S25-MDM2-p53 regulatory feedback loop, which may have an important role in cancer development and progression.	[Zhang, X.; Wang, W.; Zhang, R.] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Amarillo, TX 79106 USA; [Zhang, X.; Xu, W.] Jiangsu Univ, Affiliated Hosp, Ctr Clin Lab, Sch Med Sci & Lab Med, Zhenjiang, Peoples R China; [Wang, W.; Wang, M-H; Zhang, R.] Texas Tech Univ, Hlth Sci Ctr, Canc Biol Ctr, Sch Pharm, Amarillo, TX 79106 USA; [Wang, H.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Shanghai, Peoples R China; [Wang, M-H] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dept Biomed Sci, Amarillo, TX 79106 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo; Jiangsu University; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University Health Sciences Center Amarillo	Zhang, R (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Pharmaceut Sci, 1300 Coulter Dr, Amarillo, TX 79106 USA.	ruiwen.zhang@ttuhsc.edu			NIH/NCI [R01 CA112029, R01 CA121211]; Susan G Komen Foundation [BCTR0707731]; NIH grant [R01 CA91980]; One Hundred Talents Program, Chinese Academy of Sciences; National Nature Science Foundation [30870513, 31070680, 91029715, 81025017]; Ministry of Science and Technology of China [2007CB947100]; Science and Technology Commission of Shanghai Municipality [08391910800, 10391902100]; National Science and Technology Major Project 'Key New Drug Creation and Manufacturing Program' [2009ZX09102-114, 2009ZX09301-011]; NATIONAL CANCER INSTITUTE [R01CA112029, R01CA121211, R01CA091980] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); One Hundred Talents Program, Chinese Academy of Sciences; National Nature Science Foundation(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); National Science and Technology Major Project 'Key New Drug Creation and Manufacturing Program'; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr J Chen for the kind gift of the MDMX plasmid; Dr G Lozano for the mdmx<SUP>-/-</SUP>p53<SUP>-/-</SUP> and mdm2<SUP>-/-</SUP>p53<SUP>-/-</SUP> MEF cell lines; and Drs G Jin, D Chen, Z Zhang, L Ao, X Yang, J Qin and S Voruganti for helpful discussions and excellent technical support. This work was supported in part by NIH/NCI grants R01 CA112029, R01 CA121211 and a Susan G Komen Foundation grant BCTR0707731 (to RZ). MW was supported by NIH grant R01 CA91980. HW was supported by the One Hundred Talents Program, Chinese Academy of Sciences, grants from National Nature Science Foundation (30870513, 31070680, 91029715 and 81025017) and Ministry of Science and Technology of China (2007CB947100), the Science and Technology Commission of Shanghai Municipality (08391910800, 10391902100), National Science and Technology Major Project 'Key New Drug Creation and Manufacturing Program' (2009ZX09102-114, 2009ZX09301-011).	Adilakshmi T, 2002, J BIOL CHEM, V277, P4147, DOI 10.1074/jbc.M109785200; Argentini M, 2001, ONCOGENE, V20, P1267, DOI 10.1038/sj.onc.1204241; Artero-Castro A, 2011, HUM PATHOL, V42, P194, DOI 10.1016/j.humpath.2010.04.020; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Budde A, 1999, ONCOGENE, V18, P1119, DOI 10.1038/sj.onc.1202402; Castro ME, 2008, CARCINOGENESIS, V29, P1343, DOI 10.1093/carcin/bgm302; Chen D, 2007, ONCOGENE, V26, P5029, DOI 10.1038/sj.onc.1210327; Chen D, 2009, EMBO REP, V10, P166, DOI 10.1038/embor.2008.231; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2006, J BIOL CHEM, V281, P24304, DOI 10.1074/jbc.M602596200; Gilkes DM, 2006, EMBO J, V25, P5614, DOI 10.1038/sj.emboj.7601424; Golomb L, 2012, MOL CELL, V45, P222, DOI 10.1016/j.molcel.2011.11.022; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Horn HF, 2008, ONCOGENE, V27, P5774, DOI 10.1038/onc.2008.189; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAINE RO, 1994, J BIOL CHEM, V269, P9693; Landry DM, 2009, GENE DEV, V23, P2753, DOI 10.1101/gad.1832209; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; LI ML, 1992, FEBS LETT, V298, P142, DOI 10.1016/0014-5793(92)80041-E; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; Lindstrom MS, 2007, MOL CELL BIOL, V27, P1056, DOI 10.1128/MCB.01307-06; Loging WT, 1999, CANCER EPIDEM BIOMAR, V8, P1011; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Mancini F, 2010, INT J BIOCHEM CELL B, V42, P1080, DOI 10.1016/j.biocel.2010.04.010; Mancini F, 2009, EMBO J, V28, P1926, DOI 10.1038/emboj.2009.154; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Marine JCW, 2007, J CELL SCI, V120, P371, DOI 10.1242/jcs.03362; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Narla A, 2010, BLOOD, V115, P3196, DOI 10.1182/blood-2009-10-178129; Nishiyama T, 2007, NUCLEIC ACIDS RES, V35, P1514, DOI 10.1093/nar/gkl1121; Ofir-Rosenfeld Y, 2008, MOL CELL, V32, P180, DOI 10.1016/j.molcel.2008.08.031; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Sun XX, 2008, J BIOL CHEM, V283, P12387, DOI 10.1074/jbc.M801387200; Sun XX, 2007, J BIOL CHEM, V282, P8052, DOI 10.1074/jbc.M610621200; Sun XX, 2011, J BIOL CHEM, V286, P22730, DOI 10.1074/jbc.M111.223651; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Warner JR, 2009, MOL CELL, V34, P3, DOI 10.1016/j.molcel.2009.03.006; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xiong X, 2011, ONCOGENE, V30, P1798, DOI 10.1038/onc.2010.569; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhang Z, 2008, EMBO J, V27, P852, DOI 10.1038/emboj.2008.25; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014	55	63	63	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2013	32	22					2782	2791		10.1038/onc.2012.289	http://dx.doi.org/10.1038/onc.2012.289			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FU	22777350	Green Accepted			2022-12-17	WOS:000319808000009
J	Yuan, G; Regel, I; Lian, F; Friedrich, T; Hitkova, I; Hofheinz, RD; Strobel, P; Langer, R; Keller, G; Rocken, C; Zimmermann, W; Schmid, RM; Ebert, MPA; Burgermeister, E				Yuan, G.; Regel, I.; Lian, F.; Friedrich, T.; Hitkova, I.; Hofheinz, R. D.; Stroebel, P.; Langer, R.; Keller, G.; Roecken, C.; Zimmermann, W.; Schmid, R. M.; Ebert, M. P. A.; Burgermeister, E.			WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells	ONCOGENE			English	Article						WNT; caveolin; stomach; gastric cancer; epirubicin	ACTIVATED-RECEPTOR-GAMMA; BETA-CATENIN; SIGNALING PATHWAY; UP-REGULATION; P53 ACTIVATION; POOR-PROGNOSIS; NEOADJUVANT CHEMOTHERAPY; DIFFERENTIAL EXPRESSION; DRUG-RESISTANCE; CARCINOMA-CELLS	Resistance to chemotherapy is a major obstacle for curative treatment of human gastric cancer (GC). However, the underlying molecular mechanisms are largely unknown. Wingless-type MMTV integration site family members (WNTs) are secreted glycoproteins involved in embryogenesis and, on inappropriate expression in the adult, in cancer. Here, we show expression of WNT6 in GC patient specimens, human GC cell lines and in a mouse model of GC. In human GC cells, WNT6 expression was enhanced by caveolin-1 (Cav1), a scaffold protein of plasma membrane caveolae. WNT6 knock-down and overexpression experiments demonstrated that WNT6 increased the resistance to apoptotic cell death induced by the anthracycline chemotherapeutics epirubicin (Epi) and doxorubicin (Dox). Epi increased the activity of the human WNT6 promoter through Cav1-dependent binding of beta-catenin to the proximal WNT6 promoter. Epi increased both WNT6/Wnt6 and Cav1 expression in human GC cells and within the tumor area of a murine model of GC (CEA424-SV40 TAg). In GC patients, WNT6 expression was positively associated with the tumor stage and the nodal status, and inversely correlated with the response to ECF (Epi, cisplatin, 5-fluorouracil) chemotherapy. These results showed that WNT6 and Cav1 are upregulated by chemotherapeutics and enhance the resistance of GC cells to anthracycline drugs. Understanding the molecular mechanisms driving WNT6/Cav1-induced drug resistance will provide benefits in developing new therapies for GC. Oncogene (2013) 32, 375-387; doi:10.1038/onc.2012.40; published online 27 February 2012	[Yuan, G.; Regel, I.; Friedrich, T.; Schmid, R. M.] Tech Univ Munich, Klinikum Rechts Isar, Dept Med 2, D-80290 Munich, Germany; [Yuan, G.; Lian, F.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol, Guangzhou 510275, Guangdong, Peoples R China; [Hitkova, I.; Ebert, M. P. A.; Burgermeister, E.] Heidelberg Univ, Univ Klinikum Mannheim, Dept Med 2, D-68167 Mannheim, Baden Wurttembe, Germany; [Hofheinz, R. D.] Heidelberg Univ, Univ Klinikum Mannheim, Dept Med 3, D-68167 Mannheim, Baden Wurttembe, Germany; [Stroebel, P.] Heidelberg Univ, Univ Klinikum Mannheim, Inst Pathol, D-68167 Mannheim, Baden Wurttembe, Germany; [Langer, R.; Keller, G.] Tech Univ Munich, Klinikum Rechts Isar, Inst Pathol, D-80290 Munich, Germany; [Roecken, C.] Univ Kiel, Inst Pathol, Kiel, Germany; [Zimmermann, W.] Univ Munich, Tumor Immunol Lab, LIFE Ctr, Munich, Germany	Technical University of Munich; Sun Yat Sen University; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Technical University of Munich; University of Kiel; University of Munich	Burgermeister, E (corresponding author), Heidelberg Univ, Univ Klinikum Mannheim, Dept Med 2, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Baden Wurttembe, Germany.	elke.burgermeister@medma.uni-heidelberg.de	Regel, Ivonne/AFS-1831-2022; Röcken, Christoph/A-9239-2010; Langer, Rupert/AAU-1174-2021	Röcken, Christoph/0000-0002-6989-8002; Langer, Rupert/0000-0001-9491-3609	Deutsche Krebshilfe [107885, 108096, 108287]; DFG [SFB 824, TP B1, BU-2285]; Else Kroner Stiftung [P14/07//A104/06]; BMBF (Mobimed) [01EZ0802]; BMBF (KMU-innovativ Initiative of the BMBF) [0315116B]	Deutsche Krebshilfe(Deutsche Krebshilfe); DFG(German Research Foundation (DFG)); Else Kroner Stiftung; BMBF (Mobimed)(Federal Ministry of Education & Research (BMBF)); BMBF (KMU-innovativ Initiative of the BMBF)(Federal Ministry of Education & Research (BMBF))	We are grateful to Minhu Chen, Xiao Chen, Jie Chen for support on collaborations. M Ebert is supported by grants from the Deutsche Krebshilfe (107885, 108096), the DFG (SFB 824, TP B1), the Else Kroner Stiftung (Nr P14/07//A104/06), the BMBF (Mobimed 01EZ0802 and KMU-innovativ Initiative of the BMBF No 0315116B). E Burgermeister receives funds from the Deutsche Krebshilfe (108287) and DFG (BU-2285).	Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Asciutti S, 2011, ONCOGENE, V30, P956, DOI 10.1038/onc.2010.475; Barresi V, 2006, ACTA NEUROPATHOL, V112, P617, DOI 10.1007/s00401-006-0097-1; Becker K, 2003, CANCER-AM CANCER SOC, V98, P1521, DOI 10.1002/cncr.11660; Becker K, 2011, ANN SURG, V253, P934, DOI 10.1097/SLA.0b013e318216f449; Belanger MM, 2004, CANCER BIOL THER, V3, P954, DOI 10.4161/cbt.3.10.1112; Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Bist A, 2000, BIOCHEMISTRY-US, V39, P1966, DOI 10.1021/bi991721h; Bourquin C, 2010, J IMMUNOL, V185, P2580, DOI 10.4049/jimmunol.0903231; Burgermeister E, 2006, MOL ENDOCRINOL, V20, P809, DOI 10.1210/me.2005-0171; Burgermeister E, 2007, CANCER RES, V67, P8519, DOI 10.1158/0008-5472.CAN-07-1125; Burgermeister E, 2011, MOL CELL BIOL, V31, P3497, DOI 10.1128/MCB.01421-10; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Chen J, 2005, GUT, V54, P920, DOI 10.1136/gut.2004.047340; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Cunningham D, 2008, NEW ENGL J MED, V358, P36, DOI 10.1056/NEJMoa073149; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; Du ZM, 2009, INT J CANCER, V125, P1832, DOI 10.1002/ijc.24531; Dvory-Sobol H, 2007, CANCER-AM CANCER SOC, V109, P188, DOI 10.1002/cncr.22416; Ebert MPA, 2002, CARCINOGENESIS, V23, P87, DOI 10.1093/carcin/23.1.87; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Flahaut M, 2009, ONCOGENE, V28, P2245, DOI 10.1038/onc.2009.80; Galbiati F, 2000, J BIOL CHEM, V275, P23368, DOI 10.1074/jbc.M002020200; Goetz JG, 2008, CANCER METAST REV, V27, P715, DOI 10.1007/s10555-008-9160-9; Hadjihannas MV, 2006, P NATL ACAD SCI USA, V103, P10747, DOI 10.1073/pnas.0604206103; Hausmann G, 2007, NAT REV MOL CELL BIO, V8, P331, DOI 10.1038/nrm2141; Ho CC, 2008, LUNG CANCER, V59, P105, DOI 10.1016/j.lungcan.2007.07.024; Huang J, 2011, CANCER RES, V71, P6310, DOI 10.1158/0008-5472.CAN-10-3397; Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437; Joo HJ, 2004, BJU INT, V93, P291, DOI 10.1111/j.1464-410X.2004.04604.x; Kang HC, 2004, CLIN CANCER RES, V10, P272, DOI 10.1158/1078-0432.CCR-1025-3; Karam JA, 2007, PROSTATE, V67, P614, DOI 10.1002/pros.20557; Kelley JR, 2003, J CLIN EPIDEMIOL, V56, P1, DOI 10.1016/S0895-4356(02)00534-6; Kikuchi A, 2009, TRENDS CELL BIOL, V19, P119, DOI 10.1016/j.tcb.2009.01.003; Kirikoshi H, 2001, BIOCHEM BIOPH RES CO, V283, P798, DOI 10.1006/bbrc.2001.4855; Kobune M, 2007, MOL CANCER THER, V6, P1774, DOI 10.1158/1535-7163.MCT-06-0684; Krawetz R, 2008, CELL SIGNAL, V20, P506, DOI 10.1016/j.cellsig.2007.11.001; Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008-5472.CAN-06-2359; Lavie Y, 1998, J BIOL CHEM, V273, P32380, DOI 10.1074/jbc.273.49.32380; Lee KH, 2010, P NATL ACAD SCI USA, V107, P69, DOI 10.1073/pnas.0909734107; Li QX, 2009, NAT CELL BIOL, V11, P1128, DOI 10.1038/ncb1927; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Millour J, 2011, MOL CANCER THER, V10, P1046, DOI 10.1158/1535-7163.MCT-11-0024; Noda T, 2009, BRIT J CANCER, V100, P1647, DOI 10.1038/sj.bjc.6605064; Nyeng P, 2007, DEV BIOL, V303, P295, DOI 10.1016/j.ydbio.2006.11.017; Ordway JM, 2006, CARCINOGENESIS, V27, P2409, DOI 10.1093/carcin/bgl161; Parton RG, 2007, NAT REV MOL CELL BIO, V8, P185, DOI 10.1038/nrm2122; Ravid D, 2005, ONCOGENE, V24, P1338, DOI 10.1038/sj.onc.1208337; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Shatz M, 2004, LEUKEMIA RES, V28, P907, DOI 10.1016/j.leukres.2004.03.013; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Thompson J, 2000, INT J CANCER, V86, P863, DOI 10.1002/(SICI)1097-0215(20000615)86:6<863::AID-IJC16>3.0.CO;2-4; Wei Y, 2000, ONCOGENE, V19, P498, DOI 10.1038/sj.onc.1203356; Williams TM, 2005, AM J PHYSIOL-CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004; Yamamoto H, 2006, DEV CELL, V11, P213, DOI 10.1016/j.devcel.2006.07.003; Yamamoto H, 2009, GASTROENTEROLOGY, V137, P242, DOI 10.1053/j.gastro.2009.02.003; Yang CPH, 1998, FEBS LETT, V439, P368, DOI 10.1016/S0014-5793(98)01354-4	58	63	68	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2013	32	3					375	387		10.1038/onc.2012.40	http://dx.doi.org/10.1038/onc.2012.40			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087BP	22370641	Bronze			2022-12-17	WOS:000314736600011
J	Leucci, E; Zriwil, A; Gregersen, LH; Jensen, KT; Obad, S; Bellan, C; Leoncini, L; Kauppinen, S; Lund, AH				Leucci, E.; Zriwil, A.; Gregersen, L. H.; Jensen, K. T.; Obad, S.; Bellan, C.; Leoncini, L.; Kauppinen, S.; Lund, A. H.			Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo	ONCOGENE			English	Article						miR-9; cytokines; Hodgkin lymphoma; HuR; DICER1	MICRORNA EXPRESSION; BINDING PROTEINS; POSTTRANSCRIPTIONAL CONTROL; STERNBERG CELLS; CANCER; INFLAMMATION; INVOLVEMENT; TRANSCRIPTION; METASTASIS; CYTOKINES	MicroRNAs are important regulators of gene expression in normal development and disease. miR-9 is overexpressed in several cancer forms, including brain tumours, hepatocellular carcinomas, breast cancer and Hodgkin lymphoma (HL). Here we demonstrated a relevance for miR-9 in HL pathogenesis and identified two new targets Dicer1 and HuR. HL is characterized by a massive infiltration of immune cells and fibroblasts in the tumour, whereas malignant cells represent only 1% of the tumour mass. These infiltrates provide important survival and growth signals to the tumour cells, and several lines of evidence indicate that they are essential for the persistence of HL. We show that inhibition of miR-9 leads to derepression of DICER and HuR, which in turn results in a decrease in cytokine production by HL cells followed by an impaired ability to attract normal inflammatory cells. Finally, inhibition of miR-9 by a systemically delivered antimiR-9 in a xenograft model of HL increases the protein levels of HuR and DICER1 and results in decreased tumour outgrowth, confirming that miR-9 actively participates in HL pathogenesis and points to miR-9 as a potential therapeutic target. Oncogene (2012) 31, 5081-5089; doi:10.1038/onc.2012.15; published online 6 February 2012	[Leucci, E.; Zriwil, A.; Gregersen, L. H.; Jensen, K. T.; Lund, A. H.] Univ Copenhagen, Copenhagen Bioctr, Biotech Res & Innovat Ctr, DK-2200 Copenhagen N, Denmark; [Obad, S.; Kauppinen, S.] Santaris Pharma, Horsholm, Denmark; [Bellan, C.; Leoncini, L.] Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy; [Kauppinen, S.] Aalborg Univ, Copenhagen Inst Technol, Ballerup, Denmark	University of Copenhagen; University of Siena; Aalborg University	Lund, AH (corresponding author), Univ Copenhagen, Copenhagen Bioctr, Biotech Res & Innovat Ctr, DK-2200 Copenhagen N, Denmark.	anders.lund@bric.ku.dk	LEONCINI, Lorenzo/U-4413-2019; Lund, Anders H./F-4786-2014; BELLAN, CRISTIANA/ABG-4750-2021; Gregersen, Lea H/AAI-2386-2021; BELLAN, CRISTIANA/L-3903-2013; leoncini, lorenzo/P-8361-2018; Leucci, Eleonora/G-4938-2011	LEONCINI, Lorenzo/0000-0002-7457-300X; Lund, Anders H./0000-0002-7407-3398; BELLAN, CRISTIANA/0000-0001-6119-9007; Gregersen, Lea H/0000-0002-1205-604X; BELLAN, CRISTIANA/0000-0001-6119-9007; leoncini, lorenzo/0000-0002-7457-300X; Leucci, Eleonora/0000-0002-2898-748X; Zriwil, Alya/0000-0001-6262-7253	Danish National Advanced Technology Foundation; EC FP7 ONCOMIRS consortium [201102]; Novo Nordisk Foundation; Lundbeck Foundation; Danish Cancer Society; Danish National Research Foundation; Monte dei Paschi di Siena Foundation; Danish Medical Research Council	Danish National Advanced Technology Foundation; EC FP7 ONCOMIRS consortium; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Lundbeck Foundation(Lundbeckfonden); Danish Cancer Society(Danish Cancer Society); Danish National Research Foundation(Danmarks Grundforskningsfond); Monte dei Paschi di Siena Foundation; Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by The Danish National Advanced Technology Foundation, The EC FP7 ONCOMIRS consortium (Grant agreement number 201102: this publication reflects only authors' views; the commission is not liable for any use that may be made of the information herein), The Novo Nordisk Foundation, The Lundbeck Foundation, The Danish Cancer Society and the Danish National Research Foundation. Dr Bellan's and Professor Leoncini's work is supported by the Monte dei Paschi di Siena Foundation. Dr Leucci is supported by a grant from the Danish Medical Research Council.	Aldinucci D, 2008, INT J CANCER, V122, P769, DOI 10.1002/ijc.23119; Anderson P, 2008, NAT IMMUNOL, V9, P353, DOI 10.1038/ni1584; Bazzoni F, 2009, P NATL ACAD SCI USA, V106, P5282, DOI 10.1073/pnas.0810909106; Christoffersen NR, 2010, CELL DEATH DIFFER, V17, P236, DOI 10.1038/cdd.2009.109; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Dewan MZ WM, 2005, CANCER SCI, V96, P7; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Gentleman R, 2005, BIOINFORMATICS COMPU, P473; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Katsanou V, 2005, MOL CELL, V19, P777, DOI 10.1016/j.molcel.2005.08.007; Kawai T, 2006, MOL CELL BIOL, V26, P3295, DOI 10.1128/MCB.26.8.3295-3307.2006; Khabar KSA, 2010, CELL MOL LIFE SCI, V67, P2937, DOI 10.1007/s00018-010-0383-x; Khan G, 2006, EXP HEMATOL, V34, P399, DOI 10.1016/j.exphem.2005.11.008; Kota SK, 2010, DRUG DISCOV TODAY, V15, P733, DOI 10.1016/j.drudis.2010.07.003; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Kuppers R, 2009, NAT REV CANCER, V9, P15, DOI 10.1038/nrc2542; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Lambertz I, 2010, CELL DEATH DIFFER, V17, P633, DOI 10.1038/cdd.2009.202; Lawrie CH, 2008, LEUKEMIA, V22, P1440, DOI 10.1038/sj.leu.2405083; Lebedeva S, 2011, MOL CELL, V43, P340, DOI 10.1016/j.molcel.2011.06.008; Limma G.S., 2005, BIOINFORMATICS COMPU, P23; Linker K, 2005, NUCLEIC ACIDS RES, V33, P4813, DOI 10.1093/nar/gki797; Lopez-Rodriguez C, 2001, IMMUNITY, V15, P47, DOI 10.1016/S1074-7613(01)00165-0; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu JY, 2004, J BIOL CHEM, V279, P12974, DOI 10.1074/jbc.M310433200; Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Marstrand TT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001623; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Medzhitov R, 2009, NAT REV IMMUNOL, V9, P692, DOI 10.1038/nri2634; Mukherjee N, 2011, MOL CELL, V43, P327, DOI 10.1016/j.molcel.2011.06.007; Navarro A, 2008, BLOOD, V111, P2825, DOI 10.1182/blood-2007-06-096784; Nie K, 2008, AM J PATHOL, V173, P242, DOI 10.2353/ajpath.2008.080009; Obad S, 2011, NAT GENET, V43, P371, DOI 10.1038/ng.786; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Schetter AJ, 2009, CLIN CANCER RES, V15, P5878, DOI 10.1158/1078-0432.CCR-09-0627; Skinnider BF, 2002, BLOOD, V99, P4283, DOI 10.1182/blood-2002-01-0099; Stein CA, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp841; Van Vlierberghe P, 2009, BRIT J HAEMATOL, V147, P686, DOI 10.1111/j.1365-2141.2009.07909.x; Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005; Wynendaele J, 2010, CANCER RES, V70, P9641, DOI 10.1158/0008-5472.CAN-10-0527	44	63	67	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2012	31	49					5081	5089		10.1038/onc.2012.15	http://dx.doi.org/10.1038/onc.2012.15			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	049RK	22310293				2022-12-17	WOS:000312000900004
J	Petrelli, A; Perra, A; Schernhuber, K; Cargnelutti, M; Salvi, A; Migliore, C; Ghiso, E; Benetti, A; Barlati, S; Ledda-Columbano, GM; Portolani, N; De Petro, G; Columbano, A; Giordano, S				Petrelli, A.; Perra, A.; Schernhuber, K.; Cargnelutti, M.; Salvi, A.; Migliore, C.; Ghiso, E.; Benetti, A.; Barlati, S.; Ledda-Columbano, G. M.; Portolani, N.; De Petro, G.; Columbano, A.; Giordano, S.			Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression	ONCOGENE			English	Article						miRNA; HCC; animal model; PLK1; hepatocarcinogenesis	HUMAN HEPATOCELLULAR-CARCINOMA; MICRORNA EXPRESSION PROFILES; AGGRESSIVE LIVER-CANCER; POLO-LIKE KINASES; GENE-EXPRESSION; CELLS; IDENTIFICATION; MODEL; CARCINOGENESIS; MICROARRAY	MicroRNAs (miRNAs) have an important role in a wide range of physiological and pathological processes, and their dysregulation has been reported to affect the development and progression of cancers, including hepatocellular carcinoma (HCC). However, in the plethora of dysregulated miRNAs, it is largely unknown which of them have a causative role in the hepatocarcinogenic process. In the present study, we first aimed to determine changes in the expression profile of miRNAs in human HCCs and to compare them with liver tumors generated in a rat model of chemically induced HCC. We found that members of the miR-100 family (miR-100, miR-99a) were downregulated in human HCCs; a similar downregulation was also observed in rat HCCs. Their reduction was paralleled by an increased expression of polo like kinase 1 (PLK1), a target of these miRNAs. The introduction of miR-100 in HCC cells impaired their growth ability and their capability to form colonies in soft agar. Next, we aimed at investigating, in the same animal model, if dysregulation of miR-100 and PLK1 is an early or late event along the multistep process of hepatocarcinogenesis. The obtained results showed that miR-100 downregulation (i) is already evident in very early preneoplastic lesions generated 9 weeks after carcinogenic treatment; (ii) is also observed in adenomas and early HCCs; and (iii) is not simply a marker of proliferating hepatocytes. To our knowledge, this is the first work unveiling the role of a miRNA family along HCC progression. Oncogene (2012) 31, 4517-4526; doi:10.1038/onc.2011.631; published online 16 January 2012	[Petrelli, A.; Schernhuber, K.; Cargnelutti, M.; Migliore, C.; Ghiso, E.; Giordano, S.] Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, Turin, Italy; [Perra, A.; Ledda-Columbano, G. M.; Columbano, A.] Univ Cagliari, Dept Toxicol, Unit Oncol & Mol Pathol, Cagliari, Italy; [Salvi, A.; Barlati, S.; De Petro, G.] Univ Brescia, Sch Med, Div Biol & Genet, Dept Biomed Sci & Biotechnol, Brescia, Italy; [Benetti, A.] Univ Brescia, Sch Med, Dept Pathol, Brescia, Italy; [Portolani, N.] Univ Brescia, Sch Med, Surg Clin, Dept Med & Surg Sci, Brescia, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Cagliari; University of Brescia; University of Brescia; University of Brescia	Petrelli, A (corresponding author), Inst Canc Res & Treatment, Div Mol Oncol, SP 142km 3-9, I-10060 Candiolo, TO, Italy.	annalisa.petrelli@ircc.it; columbano@unica.it; silvia.giordano@unito.it	Columbano, Amedeo/C-7463-2011; Salvi, Alessandro/AAB-7896-2019; De Petro, Giuseppina/C-2719-2011; Giordano, Silvia/J-9858-2018	Columbano, Amedeo/0000-0002-6956-9030; Salvi, Alessandro/0000-0001-6993-1565; De Petro, Giuseppina/0000-0001-9306-0851; Giordano, Silvia/0000-0003-1854-1086; Migliore, Cristina/0000-0003-3722-2814	Associazione Italiana per la Ricerca sul Cancro (AIRC); Regione Piemonte; MIUR	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Regione Piemonte(Regione Piemonte); MIUR(Ministry of Education, Universities and Research (MIUR))	We thank L Tamagnone, S Corso, MM Angioni and our colleagues for helpful discussions; C Manca for the preparation of rat samples and C Isella for statistical analysis; L Palmas for technical assistance. Work was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC grants to SG, AC), Regione Piemonte (grant to SG) and MIUR (grants to SG, AC, GMLC, GDP).	Andersen JB, 2010, HEPATOLOGY, V51, P1401, DOI 10.1002/hep.23488; Cairo S, 2010, P NATL ACAD SCI USA, V107, P20471, DOI 10.1073/pnas.1009009107; Christodoulou F, 2010, NATURE, V463, P1084, DOI 10.1038/nature08744; De Petro G, 1998, CANCER RES, V58, P2234; Eckerdt F, 2005, ONCOGENE, V24, P267, DOI 10.1038/sj.onc.1208273; ENOMOTO K, 1982, CANCER RES, V42, P2330; Fu LM, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-3; Henson BJ, 2009, GENE CHROMOSOME CANC, V48, P569, DOI 10.1002/gcc.20666; Hou J, 2011, CANCER CELL, V19, P232, DOI 10.1016/j.ccr.2011.01.001; Imbeaud S, 2010, SEMIN LIVER DIS, V30, P75, DOI 10.1055/s-0030-1247134; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Ledda-Columbano GM, 1998, ONCOGENE, V17, P1039, DOI 10.1038/sj.onc.1202018; Lee EJ, 2007, INT J CANCER, V120, P1046, DOI 10.1002/ijc.22394; Lee JS, 2004, GASTROENTEROLOGY, V127, pS51, DOI 10.1053/j.gastro.2004.09.015; Leite KR, 2009, UROL ONCOL, V29, P265; Liu W, 2009, CHINESE MED J-PEKING, V122, P2405, DOI 10.3760/cma.j.issn.0366-6999.2009.20.002; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; Oneyama C, 2011, ONCOGENE, V30, P3489, DOI 10.1038/onc.2011.63; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; Pellegrino R, 2010, HEPATOLOGY, V51, P857, DOI 10.1002/hep.23467; SATOH K, 1985, P NATL ACAD SCI USA, V82, P3964, DOI 10.1073/pnas.82.12.3964; Shi W, 2010, INT J CANCER, V126, P2036, DOI 10.1002/ijc.24880; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; SOLT DB, 1977, AM J PATHOL, V88, P595; Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886; Tarantino C, 2010, FASEB J, V24, P3255, DOI 10.1096/fj.09-152207; Thorgeirsson SS, 2011, J HEPATOL, V55, P486, DOI 10.1016/j.jhep.2011.01.042; Ueda T, 2010, LANCET ONCOL, V11, P136, DOI 10.1016/S1470-2045(09)70343-2; Varnholt H, 2008, HEPATOLOGY, V47, P1223, DOI 10.1002/hep.22158; Wang FZ, 2008, J VIROL, V82, P9065, DOI 10.1128/JVI.00961-08; Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519; Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666	33	63	66	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2012	31	42					4517	4526		10.1038/onc.2011.631	http://dx.doi.org/10.1038/onc.2011.631			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	022SH	22249248	Green Submitted			2022-12-17	WOS:000309982100003
J	Tomas, G; Tarabichi, M; Gacquer, D; Hebrant, A; Dom, G; Dumont, JE; Keutgen, X; Fahey, TJ; Maenhaut, C; Detours, V				Tomas, G.; Tarabichi, M.; Gacquer, D.; Hebrant, A.; Dom, G.; Dumont, J. E.; Keutgen, X.; Fahey, T. J., III; Maenhaut, C.; Detours, V.			A general method to derive robust organ-specific gene expression-based differentiation indices: application to thyroid cancer diagnostic	ONCOGENE			English	Article						gene expression; differentiation; proliferation; cancer; thyroid	FOLLICULAR VARIANT; PAPILLARY; CARCINOMA; PROFILES; TRANSFORMATION; PHENOTYPE; LEUKEMIA	Differentiation is central to development, while dedifferentiation is central to cancer progression. Hence, a quantitative assessment of differentiation would be most useful. We propose an unbiased method to derive organ-specific differentiation indices from gene expression data and demonstrate its usefulness in thyroid cancer diagnosis. We derived a list of thyroid-specific genes by selecting automatically those genes that are expressed at higher level in the thyroid than in any other organ in a normal tissue's genome-wide gene expression compendium. The thyroid index of a tissue was defined as the median expression of these thyroid-specific genes in that tissue. As expected, the thyroid index was inversely correlated with meta-PCNA, a proliferation metagene, across a wide range of thyroid tumors. By contrast, the two indices were positively correlated in a time course of thyroid-stimulating hormone (TSH) activation of primary thyrocytes. Thus, the thyroid index captures biological information not integrated by proliferation rates. The differential diagnostic of follicular thyroid adenomas and follicular thyroid carcinoma is a notorious challenge for pathologists. The thyroid index discriminated them as accurately as did machine-learning classifiers trained on the genome-wide cancer data. Hence, although it was established exclusively from normal tissue data, the thyroid index integrates the relevant diagnostic information contained in tumoral transcriptomes. Similar results were obtained for the classification of the follicular vs classical variants of papillary thyroid cancers, that is, tumors dedifferentiating along a different route. The automated procedures demonstrated in the thyroid are applicable to other organs. Oncogene (2012) 31, 4490-4498; doi: 10.1038/onc.2011.626; published online 23 January 2012	[Tomas, G.; Tarabichi, M.; Gacquer, D.; Hebrant, A.; Dom, G.; Dumont, J. E.; Maenhaut, C.; Detours, V.] Univ Libre Bruxelles, IRIBHM, B-1070 Brussels, Belgium; [Keutgen, X.; Fahey, T. J., III] Weill Cornell Med Coll, Div Endocrine Surg, Dept Surg, New York, NY USA	Universite Libre de Bruxelles; Cornell University	Detours, V (corresponding author), Univ Libre Bruxelles, Inst Interdisciplinary Res IRIBHM, 808 Route Lennik, B-1070 Brussels, Belgium.	vdetours@ulb.ac.be	Tarabichi, Maxime/ABA-9246-2020; Keutgen, Xavier/H-9323-2018	Tarabichi, Maxime/0000-0002-1635-2348; Keutgen, Xavier/0000-0002-4627-3560	Wallonie-Bruxelles International grant [7450/AMG/VDL/IN, WBI/doh/2009/21649]; FRIA fellowship from FNRS; Brussels-Capital IRSIB project ICT-impulse	Wallonie-Bruxelles International grant; FRIA fellowship from FNRS(Fonds de la Recherche Scientifique - FNRS); Brussels-Capital IRSIB project ICT-impulse	This research was partially funded by the Brussels-Capital IRSIB project ICT-impulse 2006, In Silico Wet Lab. GT is supported by the Wallonie-Bruxelles International grant (7450/AMG/VDL/IN, WBI/doh/2009/21649). MT is supported by a FRIA fellowship from FNRS.	Aldred MA, 2004, J CLIN ONCOL, V22, P3531, DOI 10.1200/JCO.2004.08.127; Baloch ZW, 2001, DIAGN CYTOPATHOL, V25, P231, DOI 10.1002/dc.2044; Clary KM, 2005, ACTA CYTOL, V49, P378, DOI 10.1159/000326169; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Delys L, 2007, ONCOGENE, V26, P7894, DOI 10.1038/sj.onc.1210588; Detours V, 2007, BRIT J CANCER, V97, P818, DOI 10.1038/sj.bjc.6603938; Finley DJ, 2004, ANN SURG, V240, P425, DOI 10.1097/01.sla.0000137128.64978.bc; Ge XJ, 2005, GENOMICS, V86, P127, DOI 10.1016/j.ygeno.2005.04.008; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hegedus L, 2004, NEW ENGL J MED, V351, P1764, DOI 10.1056/NEJMcp031436; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jongeneel CV, 2005, GENOME RES, V15, P1007, DOI 10.1101/gr.4041005; Kebebew E, 2005, CANCER-AM CANCER SOC, V103, P1330, DOI 10.1002/cncr.20936; Kim D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r72; Kohlmann A, 2008, BRIT J HAEMATOL, V142, P802, DOI 10.1111/j.1365-2141.2008.07261.x; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Lang BHH, 2006, WORLD J SURG, V30, P752, DOI 10.1007/s00268-005-0356-7; Lin HW, 2010, LARYNGOSCOPE, V120, pS163, DOI 10.1002/lary.21627; Lubitz CC, 2005, SURGERY, V138, P1042, DOI 10.1016/j.surg.2005.09.009; Mills KI, 2009, BLOOD, V114, P1063, DOI 10.1182/blood-2008-10-187203; Moreno JC, 2008, NEW ENGL J MED, V358, P1811, DOI 10.1056/NEJMoa0706819; Mullighan CG, 2008, NATURE, V453, P110, DOI 10.1038/nature06866; Novershtern N, 2011, CELL, V144, P296, DOI 10.1016/j.cell.2011.01.004; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Roberts A, 2011, BIOINFORMATICS, V27, P2325, DOI 10.1093/bioinformatics/btr355; Roth RB, 2006, NEUROGENETICS, V7, P67, DOI 10.1007/s10048-006-0032-6; Ruschhaupt M, 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1078; Singh B, 2005, SURGERY, V138, P1048; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Taminau J, 2011, BIOINFORMATICS; The R Development Core Team, R LANG ENV STAT COMP; van Staveren WCG, 2006, P NATL ACAD SCI USA, V103, P413, DOI 10.1073/pnas.0507354102; Venet D, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002240; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wu ZJ, 2004, J AM STAT ASSOC, V99, P909, DOI 10.1198/016214504000000683; ZURZOLO C, 1991, J CELL SCI, V98, P65	37	63	64	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	41					4490	4498		10.1038/onc.2011.626	http://dx.doi.org/10.1038/onc.2011.626			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	018YR	22266856				2022-12-17	WOS:000309704500007
J	Santoro, R; Marani, M; Blandino, G; Muti, P; Strano, S				Santoro, R.; Marani, M.; Blandino, G.; Muti, P.; Strano, S.			Melatonin triggers p53(Ser) phosphorylation and prevents DNA damage accumulation	ONCOGENE			English	Article						melatonin; p53; cancer; prevention; DNA; repair	BREAST-CANCER; P53 STABILITY; PML; RISK; APOPTOSIS; PROSTATE; PROTEIN; LIGHT; PREMENOPAUSAL; GAMMA-H2AX	Several epidemiological studies have shown that high levels of melatonin, an indolic hormone secreted mainly by the pineal gland, reduce the risks of developing cancer, thus suggesting that melatonin triggers the activation of tumor-suppressor pathways that lead to the prevention of malignant transformation. This paper illustrates that melatonin induces phosphorylation of p53 at Ser-15 inhibiting cell proliferation and preventing DNA damage accumulation of both normal and transformed cells. This activity requires p53 and promyelocytic leukemia (PML) expression and efficient phosphorylation of p53 at Ser-15 residue. Melatonin-induced p53 phosphorylation at Ser-15 residue does not require ataxia telangiectasia-mutated activity, whereas it is severely impaired upon chemical inhibition of p38 mitogen-activated protein kinase activity. By and large, these findings imply that the activation of the p53 tumor-suppressor pathway is a critical mediator of melatonin and its anticancer effects. Therefore, it provides molecular insights into increasing observational evidence for the role that melatonin has in cancer prevention.	[Santoro, R.; Marani, M.; Strano, S.] Italian Natl Canc Inst Regina Elena, Mol Chemoprevent Grp, Dept Mol Med, I-00144 Rome, Italy; [Blandino, G.] Italian Natl Canc Inst Regina Elena, Dept Mol Med, Translat Oncogenom Unit ROC, I-00144 Rome, Italy; [Muti, P.] Italian Natl Canc Inst Regina Elena, Sci Director Off, I-00144 Rome, Italy		Strano, S (corresponding author), Italian Natl Canc Inst Regina Elena, Mol Chemoprevent Grp, Dept Mol Med, Via Elio Chianesi 53, I-00144 Rome, Italy.	strano@ifo.it	Strano, Sabrina/K-9654-2016; Muti, Paola/AAD-9108-2020; Santoro, Raffaela/B-1152-2013; Blandino, Giovanni/B-1137-2013; strano, sabrina/B-6743-2013	Santoro, Raffaela/0000-0003-3218-2358; Blandino, Giovanni/0000-0002-6970-2241; strano, sabrina/0000-0002-6341-4230; Marani, Marina/0000-0003-1585-3586	Associazione Italiana Ricerca sul Cancro (AIRC); Ministero della Salute; Fondazione Veronesi; FIRB; New Idea Award; Fondazione Italiana Ricerca sul Cancro (FIRC) fellowship	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Ministero della Salute(Ministry of Health, Italy); Fondazione Veronesi(Fondazione Umberto Veronesi); FIRB(Ministry of Education, Universities and Research (MIUR)Fund for Investment in Basic Research (FIRB)); New Idea Award; Fondazione Italiana Ricerca sul Cancro (FIRC) fellowship(Fondazione AIRC per la ricerca sul cancro)	We thank Dr E O'Neill and Dr Y Shiloh for gift of reagents and cell lines. Moreover, we also thank T Merlino for kindly revising the English text. This study was supported by Associazione Italiana Ricerca sul Cancro (AIRC, to SS and GB), Ministero della Salute (GB and PM), Fondazione Veronesi (GB), FIRB (GB), New Idea Award (SS) and Fondazione Italiana Ricerca sul Cancro (FIRC, fellowship to RS).	Alpert M, 2009, MED HYPOTHESES, V73, P324, DOI 10.1016/j.mehy.2009.02.027; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Chiu SJ, 2008, TOXICOL LETT, V179, P63, DOI 10.1016/j.toxlet.2008.04.004; FARAGHER RGA, 1993, P NATL ACAD SCI USA, V90, P12030, DOI 10.1073/pnas.90.24.12030; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Flynn-Evans EE, 2009, CANCER CAUSE CONTROL, V20, P1753, DOI 10.1007/s10552-009-9405-0; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Helton ES, 2007, J CELL BIOCHEM, V100, P883, DOI 10.1002/jcb.21091; Ji CX, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-50; KANE MA, 1994, MELANOMA RES, V4, P59, DOI 10.1097/00008390-199402000-00009; Kim CH, 2010, KOREAN J PHYSIOL PHA, V14, P365, DOI 10.4196/kjpp.2010.14.6.365; Kinner A, 2008, NUCLEIC ACIDS RES, V36, P5678, DOI 10.1093/nar/gkn550; Kliukiene J, 2001, BRIT J CANCER, V84, P397, DOI 10.1054/bjoc.2000.1617; Kloog I, 2009, CHRONOBIOL INT, V26, P108, DOI 10.1080/07420520802694020; Kloog I, 2008, CHRONOBIOL INT, V25, P65, DOI 10.1080/07420520801921572; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lapi E, 2008, MOL CELL, V32, P803, DOI 10.1016/j.molcel.2008.11.019; Lipton J, 2009, NEUROLOGY, V73, P323, DOI 10.1212/WNL.0b013e3181af78a5; Lukas J, 2009, NATURE, V458, P581, DOI 10.1038/458581a; Markantonis SL, 2008, J CLIN PHARMACOL, V48, P240, DOI 10.1177/0091270007311112; Mediavilla MD, 1999, LIFE SCI, V65, P415, DOI 10.1016/S0024-3205(99)00262-3; Nur-E-Kamal A, 2003, J BIOL CHEM, V278, P12475, DOI 10.1074/jbc.M212915200; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; Roy D, 2001, ENDOCRINOLOGY, V142, P4711, DOI 10.1210/en.142.11.4711; Sainz RM, 2005, PROSTATE, V63, P29, DOI 10.1002/pros.20155; Schernhammer ES, 2008, JNCI-J NATL CANCER I, V100, P898, DOI 10.1093/jnci/djn171; Schernhammer ES, 2010, CANCER EPIDEM BIOMAR, V19, P729, DOI 10.1158/1055-9965.EPI-09-1229; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; Sliwinski T, 2007, MUTAT RES-GEN TOX EN, V634, P220, DOI 10.1016/j.mrgentox.2007.07.013; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; VAKKURI O, 1985, LIFE SCI, V37, P489, DOI 10.1016/0024-3205(85)90412-6; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Xi SC, 2000, J PINEAL RES, V29, P172, DOI 10.1034/j.1600-079X.2000.d01-64.x; Xian ZH, 2005, WORLD J GASTROENTERO, V11, P4102, DOI 10.3748/wjg.v11.i26.4102	43	63	65	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	24					2931	2942		10.1038/onc.2011.469	http://dx.doi.org/10.1038/onc.2011.469			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960LD	22002314	Green Published			2022-12-17	WOS:000305388400003
J	Wang, Y; Sheng, Q; Spillman, MA; Behbakht, K; Gu, H				Wang, Y.; Sheng, Q.; Spillman, M. A.; Behbakht, K.; Gu, H.			Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells	ONCOGENE			English	Article						Gab2; PI3K; Zeb1; E-cadherin; EMT; ovarian cancer	EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; SIGNAL-TRANSDUCTION; DOCKING PROTEIN; HIGH-FREQUENCY; PIK3CA GENE; METASTASIS; PROLIFERATION; TUMORIGENESIS; AMPLIFICATION	Ovarian cancer, the most deadly gynecologic malignancy, is often diagnosed late and at the advanced stage when the cancer cells have already migrated and invaded into other tissues and organs. Better understanding of the mechanism of metastasis in ovarian cancer cells is essential to the design of effective therapy. In this study, we investigated the function of scaffolding adaptor protein Gab2 in ovarian cancer cells. Gab2 is found to be overexpressed in a subset of ovarian tumors and cancer cell lines. Gab2 expression mainly regulates the migratory behaviors of ovarian cancer cells. Overexpression of Gab2 promotes the migration and invasion, and downregulates E-cadherin expression in ovarian cancer cells with low-Gab2 expression. Conversely, knockdown of Gab2 expression inhibits the migration and invasion, and promotes E-cadherin expression in ovarian cancer cells with high-Gab2 expression. By expressing Gab2 wild-type and Gab2 mutants that are defective in activation of the PI3K and Shp2-Erk pathways, we find that Gab2 inhibits E-cadherin expression and enhances the expression of Zeb1, a transcription factor involved in epithelial-to-mesenchymal transition (EMT), and cell migration and invasion through the activation of the PI3K pathway. Knockdown of Zeb1 expression blocks Gab2-induced suppression of E-cadherin expression and increase in cell invasion. LY294002 and GDC-0941, inhibitors of PI3K, or Rapamycin, an inhibitor of PI3K downstream target mTOR, can reverse the effects of Gab2 on migration and invasion. Overall, our studies reveal that Gab2 overexpression, via activation of the PI3K-Zeb1 pathway, promotes characteristics of EMT in ovarian cancer cells. Oncogene (2012) 31, 2512-2520; doi:10.1038/onc.2011.435; published online 26 September 2011	[Wang, Y.; Gu, H.] Univ Colorado Denver, Dept Pathol, Aurora, CO 80045 USA; [Sheng, Q.] Univ Colorado Denver, Div Bas Reprod Sci & Gynecol Oncol, Dept Obstet & Gynecol, Aurora, CO 80045 USA; [Spillman, M. A.; Behbakht, K.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Spillman, M. A.; Behbakht, K.] Harvard Univ, Sch Med, Boston, MA USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Gu, H (corresponding author), Univ Colorado Denver, Dept Pathol, Anschutz Med Campus,Mail Stop 8104,POB 6511, Aurora, CO 80045 USA.	haihua.gu@ucdenver.edu	ravegnini, gloria/K-1330-2016	ravegnini, gloria/0000-0002-7774-402X; Behbakht, Kian/0000-0003-4793-9958	Department of Pathology, University of Colorado, Anschutz Medical Campus; National Institutes of Health [R01-AI51612]; NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051612] Funding Source: NIH RePORTER	Department of Pathology, University of Colorado, Anschutz Medical Campus; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Dr Sam Mok for the HOSE lines. This work is supported by the Department of Pathology, University of Colorado, Anschutz Medical Campus and in part by the National Institutes of Health grant R01-AI51612 (to HG).	Abreu MTH, 2011, MOL BIOL CELL, V22, P105, DOI 10.1091/mbc.E10-03-0185; Agarwal R, 2010, CURR OPIN INVEST DR, V11, P615; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Battini JL, 1999, P NATL ACAD SCI USA, V96, P1385, DOI 10.1073/pnas.96.4.1385; Bennett HL, 2008, ONCOGENE, V27, P2693, DOI 10.1038/sj.onc.1210928; Bentires-Alj M, 2006, NAT MED, V12, P114, DOI 10.1038/nm1341; Bocanegra M, 2010, ONCOGENE, V29, P774, DOI 10.1038/onc.2009.364; Brown LA, 2008, GENE CHROMOSOME CANC, V47, P481, DOI 10.1002/gcc.20549; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummer T, 2006, J BIOL CHEM, V281, P626, DOI 10.1074/jbc.M509567200; Cheng JC, 2011, ONCOGENE, V30, P1020, DOI 10.1038/onc.2010.486; Daly RJ, 2002, ONCOGENE, V21, P5175, DOI 10.1038/sj.onc.1205522; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Feeley KM, 2001, HISTOPATHOLOGY, V38, P87, DOI 10.1046/j.1365-2559.2001.01042.x; Fleuren EDG, 2010, INT J CANCER, V127, P1486, DOI 10.1002/ijc.25172; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Horst B, 2009, AM J PATHOL, V174, P1524, DOI 10.2353/ajpath.2009.080543; Jemal A, 2004, CA-CANCER J CLIN, V54, P8, DOI 10.3322/canjclin.54.1.8; Karst AM, 2011, P NATL ACAD SCI USA, V108, P7547, DOI 10.1073/pnas.1017300108; Ke Y, 2007, ONCOGENE, V26, P4951, DOI 10.1038/sj.onc.1210315; Kolasa IK, 2009, CANCER BIOL THER, V8, P21, DOI 10.4161/cbt.8.1.7209; Kong DX, 2010, EUR J CANCER, V46, P1111, DOI 10.1016/j.ejca.2010.01.005; Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Levanon K, 2008, J CLIN ONCOL, V26, P5284, DOI 10.1200/JCO.2008.18.1107; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Ries LAG, 2007, SEER SURVIVAL MONOGR, P133; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sheng Q, 2010, CANCER CELL, V17, P298, DOI 10.1016/j.ccr.2009.12.047; Shih IM, 2004, AM J PATHOL, V164, P1511, DOI 10.1016/S0002-9440(10)63708-X; Shih LM, 2005, P NATL ACAD SCI USA, V102, P14004, DOI 10.1073/pnas.0504195102; Spandidos A, 2010, NUCLEIC ACIDS RES, V38, pD792, DOI 10.1093/nar/gkp1005; Tan DSP, 2008, ADV EXP MED BIOL, V622, P153, DOI 10.1007/978-0-387-68969-2_13; Tan DSP, 2006, LANCET ONCOL, V7, P925, DOI 10.1016/S1470-2045(06)70939-1; Wells A, 2008, CLIN EXP METASTAS, V25, P621, DOI 10.1007/s10585-008-9167-1; Wohrle FU, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-22; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009	40	63	73	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	20					2512	2520		10.1038/onc.2011.435	http://dx.doi.org/10.1038/onc.2011.435			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	944ID	21996746	Green Accepted			2022-12-17	WOS:000304191800002
J	Wu, J; Liu, S; Liu, G; Dombkowski, A; Abrams, J; Martin-Trevino, R; Wicha, MS; Ethier, SP; Yang, ZQ				Wu, J.; Liu, S.; Liu, G.; Dombkowski, A.; Abrams, J.; Martin-Trevino, R.; Wicha, M. S.; Ethier, S. P.; Yang, Z-Q			Identification and functional analysis of 9p24 amplified genes in human breast cancer	ONCOGENE			English	Article						chromosome 9p24; GASC1; UHRF2; gene amplification	HISTONE LYSINE METHYLATION; TUMOR-SUPPRESSOR GENE; CELL-LINES; JMJD2 FAMILY; DNA METHYLATION; AMPLICON; PROTEIN; AMPLIFICATION; PTPRD; DEMETHYLATION	Previously, our group identified a novel amplicon at chromosome 9p24 in human esophageal and breast cancers, and cloned the novel gene, GASC1 (gene amplified in squamous cell carcinoma 1, also known as JMJD2C/KDM4C), from this amplicon. GASC1 is a histone demethylase involved in the deregulation of histone methylation in cancer cells. In the current study, we aimed to comprehensively characterize the genes in the 9p24 amplicon in human breast cancer. We performed extensive genomic analyses on a panel of cancer cell lines and narrowed the shortest region of overlap to approximately 2 Mb. Based on statistical analysis of copy number increase and overexpression, the 9p24 amplicon contains six candidate oncogenes. Among these, four genes (GASC1 UHRF2, KIAA1432 and C9orf123) are overexpressed only in the context of gene amplification while two genes (ERMP1 and IL33) are overexpressed independent of the copy number increase. We then focused our studies on the UHRF2 gene, which has a potential involvement in both DNA methylation and histone modification. Knocking down UHRF2 expression inhibited the growth of breast cancer cells specifically with 9p24 amplification. Conversely, ectopic overexpression of UHRF2 in non-tumorigenic MCF10A cells promoted cell proliferation. Furthermore, we demonstrated that UHRF2 has the ability to suppress the expression of key cell-cycle inhibitors, such as p16(INK4a), p21(Waf1/Cip1) and p27(Kip1). Taken together, our studies support the notion that the 9p24 amplicon contains multiple oncogenes that may integrate genetic and epigenetic codes and have important roles in human tumorigenesis. Oncogene (2012) 31, 333-341; doi:10.1038/onc.2011.227; published online 13 June 2011	[Wu, J.; Liu, G.; Ethier, S. P.; Yang, Z-Q] Wayne State Univ, Breast Canc Program, Detroit, MI 48201 USA; [Liu, S.; Martin-Trevino, R.; Wicha, M. S.] Univ Michigan, Dept Internal Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Dombkowski, A.] Wayne State Univ, Dept Pediat, Detroit, MI 48201 USA; [Abrams, J.; Yang, Z-Q] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI 48201 USA	Wayne State University; University of Michigan System; University of Michigan; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Yang, ZQ (corresponding author), Wayne State Univ, Karmanos Canc Inst, Dept Oncol, 4100 John R St,HWCRC 815, Detroit, MI 48201 USA.	yangz@karmanos.org	Liu, Sheng/K-2815-2013; LIU, GANG/AAR-4584-2021; Liu, Suling/N-2796-2013; Wicha, Max/AAE-7268-2019	LIU, GANG/0000-0001-6620-176X; Liu, Suling/0000-0002-0475-0242; Dombkowski, Alan/0000-0002-0312-8750	Department of Defense [BC086177, BC083945]; National Institutes of Health [RO1 CA100724, P30-CA022453-29]; Taubman Institute; NATIONAL CANCER INSTITUTE [P30CA022453, R01CA100724] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Taubman Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Grants from the Department of Defense Breast Cancer Program (BC086177 and BC083945) to Zeng-Quan Yang, a grant from the National Institutes of Health grant RO1 CA100724 to Stephen P. Ethier, and the Taubman Scholar Award from Taubman Institute to Max S. Wicha. The Biostatistics Core of the Karmanos Cancer Institute is supported by the National Institutes of Health Grant P30-CA022453-29. We thank Michele L. Dziubinski for technical assistance on the cell culture. We thank Dr Steve Guest, Dr Aliccia Bollig-Fischer and Kimberly Lyons for discussions and careful reading of a draft manuscript.	Akiyama M, 2005, BIOCHEM BIOPH RES CO, V335, P1264, DOI 10.1016/j.bbrc.2005.08.019; Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bronner C, 2007, PHARMACOL THERAPEUT, V115, P419, DOI 10.1016/j.pharmthera.2007.06.003; Chan DW, 2009, PROTEOMICS, V9, P2343, DOI 10.1002/pmic.200800600; Chan TA, 2008, PLOS MED, V5, P823, DOI 10.1371/journal.pmed.0050114; Chen ZZ, 2006, CELL, V125, P691, DOI 10.1016/j.cell.2006.04.024; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741; Garcia-Rudaz C, 2007, DEVELOPMENT, V134, P945, DOI 10.1242/dev.02795; Gelsi-Boyer W, 2005, MOL CANCER RES, V3, P655, DOI 10.1158/1541-7786.MCR-05-0128; Giefing M, 2011, GENE CHROMOSOME CANC, V50, P154, DOI 10.1002/gcc.20840; Han W, 2008, GENE CHROMOSOME CANC, V47, P490, DOI 10.1002/gcc.20550; He XY, 2009, FEBS LETT, V583, P3501, DOI 10.1016/j.febslet.2009.10.007; Hopfner R, 2000, CANCER RES, V60, P121; Ishimura A, 2009, BIOCHEM BIOPH RES CO, V389, P366, DOI 10.1016/j.bbrc.2009.08.155; Italiano A, 2006, CANCER GENET CYTOGEN, V167, P122, DOI 10.1016/j.cancergencyto.2006.01.004; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Katoh M, 2004, INT J ONCOL, V24, P1623; Kim JK, 2009, NUCLEIC ACIDS RES, V37, P493, DOI 10.1093/nar/gkn961; Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143; Kohno T, 2010, GENE CHROMOSOME CANC, V49, P342, DOI 10.1002/gcc.20746; Kurowska-Stolarska M, 2011, J INTERN MED, V269, P29, DOI 10.1111/j.1365-2796.2010.02316.x; Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297; Loh YH, 2007, GENE DEV, V21, P2545, DOI 10.1101/gad.1588207; Mori T, 2002, BIOCHEM BIOPH RES CO, V296, P530, DOI 10.1016/S0006-291X(02)00890-2; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Natrajan R, 2009, CLIN CANCER RES, V15, P2711, DOI 10.1158/1078-0432.CCR-08-1878; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; Pole JCM, 2006, ONCOGENE, V25, P5693, DOI 10.1038/sj.onc.1209570; Qian CM, 2008, J BIOL CHEM, V283, P34490, DOI 10.1074/jbc.C800169200; Rottach A, 2010, NUCLEIC ACIDS RES, V38, P1796, DOI 10.1093/nar/gkp1152; Rui LX, 2010, CANCER CELL, V18, P590, DOI 10.1016/j.ccr.2010.11.013; Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771; Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Solomon DA, 2008, CANCER RES, V68, P10300, DOI 10.1158/0008-5472.CAN-08-3272; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Unoki M, 2009, BIOCHEM PHARMACOL, V78, P1279, DOI 10.1016/j.bcp.2009.05.035; Veeriah S, 2009, P NATL ACAD SCI USA, V106, P9435, DOI 10.1073/pnas.0900571106; Vinatzer U, 2008, CLIN CANCER RES, V14, P6426, DOI 10.1158/1078-0432.CCR-08-0702; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang JL, 2010, BIOL REPROD, V82, P105, DOI 10.1095/biolreprod.109.078055; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Yang ZQ, 2006, CANCER RES, V66, P11632, DOI 10.1158/0008-5472.CAN-06-2946; Yang ZQ, 2010, CANCER RES, V70, P8487, DOI 10.1158/0008-5472.CAN-10-1013; Yang ZQ, 2004, CANCER GENET CYTOGEN, V155, P57, DOI 10.1016/j.cancergencyto.2004.03.013; Yang ZQ, 2000, CANCER RES, V60, P4735	56	63	65	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	3					333	341		10.1038/onc.2011.227	http://dx.doi.org/10.1038/onc.2011.227			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	882DQ	21666724	Green Accepted			2022-12-17	WOS:000299542100006
J	Taniuchi, K; Cerny, RL; Tanouchi, A; Kohno, K; Kotani, N; Honke, K; Saibara, T; Hollingsworth, MA				Taniuchi, K.; Cerny, R. L.; Tanouchi, A.; Kohno, K.; Kotani, N.; Honke, K.; Saibara, T.; Hollingsworth, M. A.			Overexpression of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell growth	ONCOGENE			English	Article						polypeptide N-acetylgalactosaminyl-transferase; GalNAc-T3; pancreatic cancer; O-glycosylation; cell growth; apoptosis	ALPHA-D-GALACTOSAMINE; POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; CDNA CLONING; EXPRESSION; METASTASIS; MUCIN; IDENTIFICATION; GLYCANS; TARGETS; ANTIGEN	O-linked glycans of secreted and membrane-bound proteins have an important role in the pathogenesis of pancreatic cancer by modulating immune responses, inflammation and tumorigenesis. A critical aspect of O-glycosylation, the position at which proteins are glycosylated with N-acetyl-galactosamine on serine and threonine residues, is regulated by the substrate specificity of UDP-GalNAc: polypeptide N-acetylgalactosaminyl-transferases (GalNAc-Ts). Thus, GalNAc-Ts regulate the first committed step in O-glycosylated protein biosynthesis, determine sites of O-glycosylation on proteins and are important for understanding normal and carcinoma-associated O-glycosylation. We have found that one of these enzymes, GalNAc-T3, is overexpressed in human pancreatic cancer tissues and suppression of GalNAc-T3 significantly attenuates the growth of pancreatic cancer cells in vitro and in vivo. In addition, suppression of GalNAc-T3 induces apoptosis of pancreatic cancer cells. Our results indicate that GalNAc-T3 is likely involved in pancreatic carcinogenesis. Modification of cellular glycosylation occurs in nearly all types of cancer as a result of alterations in the expression levels of glycosyltransferases. We report guanine the nucleotide-binding protein, a-transducing activity polypeptide-1 (GNAT1) as a possible substrate protein of GalNAc-T3. GalNAc-T3 is associated with O-glycosylation of GNAT1 and affects the subcellular distribution of GNAT1. Knocking down endogenous GNAT1 significantly suppresses the growth/survival of PDAC cells. Our results imply that GalNAc-T3 contributes to the function of O-glycosylated proteins and thereby affects the growth and survival of pancreatic cancer cells. Thus, substrate proteins of GalNAc-T3 should serve as important therapeutic targets for pancreatic cancers. Oncogene (2011) 30, 4843-4854; doi:10.1038/onc.2011.194; published online 30 May 2011	[Taniuchi, K.] Kochi Univ, Sch Med, Dept Gastroenterol & Hepatol, Nanko Ku, Kochi 7838505, Japan; [Taniuchi, K.; Hollingsworth, M. A.] Univ Nebraska Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE USA; [Taniuchi, K.; Hollingsworth, M. A.] Univ Nebraska Med Ctr, Dept Pathol & Microbiol, Omaha, NE USA; [Cerny, R. L.] Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA; [Kohno, K.] Univ Occupat & Environm Hlth, Sch Med, Dept Biol Mol, Fukuoka, Japan; [Kotani, N.; Honke, K.] Kochi Univ, Sch Med, Dept Biochem, Kochi 7838505, Japan	Kochi University; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Lincoln; University of Occupational & Environmental Health - Japan; Kochi University	Taniuchi, K (corresponding author), Kochi Univ, Sch Med, Dept Gastroenterol & Hepatol, Nanko Ku, Kochi 7838505, Japan.	jm-ktaniuchi@kochi-u.ac.jp		Kotani, Norihiro/0000-0003-3739-6478	Tamotsu Takeuchi; NIH [U01CA111294, R01CA057362]; NATIONAL CANCER INSTITUTE [U01CA128437, P50CA127297, R01CA057362, U01CA111294, P30CA036727] Funding Source: NIH RePORTER	Tamotsu Takeuchi; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Michel Ouellette for providing the HPNE cells and Tamotsu Takeuchi for supporting pathological experiments and helpful discussion. We also thank Janice Taylor and James Talaska for excellent technical assistance. This work was funded by the NIH with grants to MAH (U01CA111294; R01CA057362).	Alenzi FQB, 2004, BRIT J BIOMED SCI, V61, P1; Andersen MH, 2005, NAT REV DRUG DISCOV, V4, P399, DOI 10.1038/nrd1717; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; BRAGA VMM, 1992, DEVELOPMENT, V115, P427; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; CATTORETTI G, 1992, J PATHOL, V168, P357, DOI 10.1002/path.1711680404; Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649; GRAY JW, 1980, ANNU REV BIOPHYS BIO, V9, P509, DOI 10.1146/annurev.bb.09.060180.002453; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; IWAMURA T, 1987, JPN J CANCER RES, V78, P54; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jensen ON, 2006, NAT REV MOL CELL BIO, V7, P391, DOI 10.1038/nrm1939; Joshi S. S., 2001, Current Pharmaceutical Biotechnology, V2, P187, DOI 10.2174/1389201013378725; Kannagi R, 2004, CANCER SCI, V95, P377, DOI 10.1111/j.1349-7006.2004.tb03219.x; Kondo A, 2006, BBA-PROTEINS PROTEOM, V1764, P1881, DOI 10.1016/j.bbapap.2006.10.011; Lee KM, 2005, LAB INVEST, V85, P1003, DOI 10.1038/labinvest.3700298; Li M, 2010, J BIOSCIENCES, V35, P665, DOI 10.1007/s12038-010-0073-8; Mayoral MA, 2008, CANCER INVEST, V26, P615, DOI 10.1080/07357900701837051; MELLORS A, 1995, METHOD ENZYMOL, V248, P728; Merighi Stefania, 2006, Purinergic Signal, V2, P627, DOI 10.1007/s11302-006-9020-4; Moniaux N, 2004, BRIT J CANCER, V91, P1633, DOI 10.1038/sj.bjc.6602163; Nomoto M, 1999, CANCER RES, V59, P6214; Reis CA, 1999, CANCER RES, V59, P1003; Rosenzweig DH, 2007, J NEUROSCI, V27, P5484, DOI 10.1523/JNEUROSCI.1421-07.2007; RUIZAVILA L, 1995, NATURE, V376, P80, DOI 10.1038/376080a0; Spiro RG, 2002, GLYCOBIOLOGY, V12, p43R, DOI 10.1093/glycob/12.4.43R; Sutherlin ME, 1997, CANCER RES, V57, P4744; Takenaka Y, 2002, GLYCOCONJUGATE J, V19, P543, DOI 10.1023/B:GLYC.0000014084.01324.15; TELFORD WG, 1991, CELL PROLIFERAT, V24, P447, DOI 10.1111/j.1365-2184.1991.tb01173.x; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; Wray CJ, 2005, GASTROENTEROLOGY, V128, P1626, DOI 10.1053/j.gastro.2005.03.035	32	63	66	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	49					4843	4854		10.1038/onc.2011.194	http://dx.doi.org/10.1038/onc.2011.194			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YI	21625220	Green Accepted, Green Published			2022-12-17	WOS:000298346400001
J	Al-Bahlani, S; Fraser, M; Wong, AYC; Sayan, BS; Bergeron, R; Melino, G; Tsang, BK				Al-Bahlani, S.; Fraser, M.; Wong, A. Y. C.; Sayan, B. S.; Bergeron, R.; Melino, G.; Tsang, B. K.			P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism	ONCOGENE			English	Article						CDDP; p73 alpha; calpain; calcium; ovarian cancer	X-LINKED INHIBITOR; P53 FAMILY; NEUROBLASTOMA-CELLS; CARCINOMA CELLS; FEEDBACK LOOP; IN-VIVO; CALPAIN; PROTEIN; BAX; CHEMOSENSITIVITY	P73 is important in drug-induced apoptosis in some cancer cells, yet its role in the regulation of chemosensitivity in ovarian cancer (OVCA) is poorly understood. Furthermore, if and how the deregulation of p73-mediated apoptosis confers resistance to cisplatin (CDDP) treatment is unclear. Here we demonstrate that TAp73 alpha over-expression enhanced CDDP-induced PARP cleavage and apoptosis in both chemosensitive (OV2008 and A2780s) and their resistant counterparts (C13* and A2780cp) and another chemoresistant OVCA cells (Hey); in contrast, the effect of Delta Np73 alpha over-expression was variable. P73 alpha downregulation attenuated CDDP-induced PUMA and NOXA upregulation and apoptosis in OV2008 cells. CDDP decreased p73 alpha steady-state protein levels in OV2008, but not in C13*, although the mRNA expression was identical. CDDP-induced p73 alpha downregulation was mediated by a calpain-dependent pathway. CDDP induced calpain activation and enhanced its cytoplasmic interaction and co-localization with p73 alpha in OV2008, but not C13* cells. CDDP increased the intracellular calcium concentration ([Ca(2+)](i)) in OV2008 but not C13* whereas cyclopiazonic acid (CPA), a Ca(2+)-ATPase inhibitor, caused this response and calpain activation, p73 alpha processing and apoptosis in both cell types. CDDP-induced [Ca(2+)](i) increase in OV2008 cells was not effected by the elimination of extracellular Ca(2+), but this was attenuated by the depletion of internal Ca(2+) store, indicating that mobilization of intracellular Ca(2+1) stores was potentially involved. These findings demonstrate that p73 alpha and its regulation by the Ca(2+)-mediated calpain pathway are involved in CDDP-induced apoptosis in OVCA cells and that dysregulation of Ca(2+)/calpain/p73 signaling may in part be the pathophysiology of CDDP resistance. Understanding the cellular and molecular mechanisms of chemoresistance will direct the development of effective strategies for the treatment of chemoresistant OVCA. Oncogene (2011) 30, 4219-4230; doi: 10.1038/onc.2011.134; published online 25 April 2011	[Al-Bahlani, S.; Fraser, M.; Tsang, B. K.] Univ Ottawa, Ottawa Hosp, Res Inst, Dept Obstet & Gynaecol, Ottawa, ON K1Y 4E9, Canada; [Al-Bahlani, S.; Fraser, M.; Wong, A. Y. C.; Bergeron, R.; Tsang, B. K.] Univ Ottawa, Ottawa Hosp, Res Inst, Dept Cellular & Mol Med, Ottawa, ON K1Y 4E9, Canada; [Al-Bahlani, S.; Fraser, M.] Ottawa Hosp, Res Inst, Chron Dis Program, Ottawa, ON, Canada; [Al-Bahlani, S.] Sultan Qaboos Univ, Dept Pathol, Muscat, Oman; [Wong, A. Y. C.; Bergeron, R.] Ottawa Hosp, Res Inst, Neurosci Program, Ottawa, ON, Canada; [Sayan, B. S.; Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England; [Bergeron, R.; Tsang, B. K.] Univ Ottawa, Dept Psychiat, Ottawa, ON K1N 6N5, Canada; [Melino, G.] Univ Rome, Dept Expt Med, IDI IRCCS Biochem Lab, Rome, Italy; [Fraser, M.] Princess Margaret Hosp, Ontario Canc Inst, Radiat Med Program, Toronto, ON M4X 1K9, Canada; [Fraser, M.] Princess Margaret Hosp, Ontario Canc Inst, STTARR Innovat Facil, Toronto, ON M4X 1K9, Canada; [Tsang, B. K.] Seoul Natl Univ, World Class Univ WCU Biomodulat Major, Dept Agr Biotechnol, Coll Agr & Life Sci, Seoul, South Korea	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; Sultan Qaboos University; University of Ottawa; Ottawa Hospital Research Institute; University of Leicester; University of Ottawa; Sapienza University Rome; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Seoul National University (SNU)	Tsang, BK (corresponding author), Univ Ottawa, Ottawa Hosp, Res Inst, Dept Obstet & Gynaecol, 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.	btsang@ohri.ca	Bahlani, Shadia/AAZ-3711-2020	Tsang, Benjamin K./0000-0003-1213-3946; Bergeron, Richard/0000-0002-5632-750X; Wong, Adrian/0000-0001-5652-3482	Canadian Institute of Health Research [MOP-15691]; WCU (World Class University) through National Research Foundation of Korea [R31-10056]; Ministry of Education, Science and Technology; UK Medical Research Council; Sultan Qaboos University, Sultanate of Oman; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); WCU (World Class University) through National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Sultan Qaboos University, Sultanate of Oman; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by grants from the Canadian Institute of Health Research (MOP-15691), the WCU (World Class University) program (R31-10056) through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology and the UK Medical Research Council. SA is a scholarship recipient of Sultan Qaboos University, Sultanate of Oman.	Abedini MR, 2010, ONCOGENE, V29, P11, DOI 10.1038/onc.2009.300; Abedini MR, 2008, CANCER RES, V68, P4511, DOI 10.1158/0008-5472.CAN-08-0673; Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Chen CL, 2000, CLIN CANCER RES, V6, P3910; Di Sano F, 2006, J BIOL CHEM, V281, P2693, DOI 10.1074/jbc.M509110200; Eltabbakh G H, 2001, Expert Opin Pharmacother, V2, P109, DOI 10.1517/14656566.2.1.109; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Fraser M, 2003, CANCER RES, V63, P7081; Fraser M, 2008, INT J CANCER, V122, P534, DOI 10.1002/ijc.23086; Fraser Michael, 2003, Reprod Biol Endocrinol, V1, P66, DOI 10.1186/1477-7827-1-66; Gao G, 2000, J CELL BIOCHEM, V80, P53; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Gunes DA, 2009, NEUROTOXICOLOGY, V30, P194, DOI 10.1016/j.neuro.2008.12.001; Holcakova J, 2008, CELL MOL BIOL LETT, V13, P404, DOI 10.2478/s11658-008-0011-z; Irwin MS, 2004, CELL CYCLE, V3, P319; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Kobayashi S, 2002, J BIOL CHEM, V277, P33968, DOI 10.1074/jbc.M203350200; Liu G, 2004, MOL CELL BIOL, V24, P487, DOI 10.1128/MCB.24.2.487-501.2004; Marabese M, 2005, CELL DEATH DIFFER, V12, P805, DOI 10.1038/sj.cdd.4401622; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Million K, 2006, INT J ONCOL, V29, P147; Moncoq K, 2007, J BIOL CHEM, V282, P9748, DOI 10.1074/jbc.M611653200; Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171; Muller M, 2006, DRUG RESIST UPDATE, V9, P288, DOI 10.1016/j.drup.2007.01.001; Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774; Munarriz E, 2005, BIOCHEM BIOPH RES CO, V333, P954, DOI 10.1016/j.bbrc.2005.05.188; Muscolini M, 2008, MOL CANCER THER, V7, P1410, DOI 10.1158/1535-7163.MCT-08-0299; Nyman U, 2005, J BIOL CHEM, V280, P34159, DOI 10.1074/jbc.M500394200; Ozaki T, 2005, CANCER SCI, V96, P729, DOI 10.1111/j.1349-7006.2005.00116.x; Perrin BJ, 2002, INT J BIOCHEM CELL B, V34, P722, DOI 10.1016/S1357-2725(02)00009-2; Pietsch EC, 2008, ONCOGENE, V27, P6507, DOI 10.1038/onc.2008.315; Ramadan S, 2005, BIOCHEM BIOPH RES CO, V331, P713, DOI 10.1016/j.bbrc.2005.03.156; Righetti SC, 2008, CANCER LETT, V263, P140, DOI 10.1016/j.canlet.2007.12.024; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Sabatino MA, 2007, INT J CANCER, V120, P506, DOI 10.1002/ijc.22362; Sang MX, 2009, GENES CELLS, V14, P775, DOI 10.1111/j.1365-2443.2009.01309.x; Sayan AE, 2005, BIOCHEM BIOPH RES CO, V330, P186, DOI 10.1016/j.bbrc.2005.02.145; Shaw TJ, 2004, MOL THER, V10, P1032, DOI 10.1016/j.ymthe.2004.08.013; Splettstoesser F, 2007, BRIT J PHARMACOL, V151, P1176, DOI 10.1038/sj.bjp.0707335; Sullivan A, 2007, BRIT J CANCER, V96, P196, DOI 10.1038/sj.bjc.6603525; Toyota H, 2003, CANCER LETT, V189, P221, DOI 10.1016/S0304-3835(02)00552-9; Vayssade M, 2005, INT J CANCER, V116, P860, DOI 10.1002/ijc.21033; Vikhanskaya F, 2001, CANCER RES, V61, P935; Yoshida K, 2008, ONCOGENE, V27, P1183, DOI 10.1038/sj.onc.1210722	50	63	63	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	41					4219	4230		10.1038/onc.2011.134	http://dx.doi.org/10.1038/onc.2011.134			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HO	21516125	Green Published, hybrid			2022-12-17	WOS:000296356300001
J	Babu, E; Ramachandran, S; CoothanKandaswamy, V; Elangovan, S; Prasad, PD; Ganapathy, V; Thangaraju, M				Babu, E.; Ramachandran, S.; CoothanKandaswamy, V.; Elangovan, S.; Prasad, P. D.; Ganapathy, V.; Thangaraju, M.			Role of SLC5A8, a plasma membrane transporter and a tumor suppressor, in the antitumor activity of dichloroacetate	ONCOGENE			English	Article						SLC5A8; dichloroacetate; anticancer drug; Warburg effect; pyruvate dehydrogenase kinase; mitochondrial oxidation in cancer	NA+-COUPLED TRANSPORTER; CANCER-CELLS; COLON-CANCER; GENE SLC5A8; ELECTROGENIC TRANSPORT; PYRUVATE-DEHYDROGENASE; PERIPHERAL NEUROPATHY; IN-VITRO; APOPTOSIS; WARBURG	There has been growing interest among the public and scientists in dichloroacetate (DCA) as a potential anticancer drug. Credible evidence exists for the antitumor activity of this compound, but high concentrations are needed for significant therapeutic effect. Unfortunately, these high concentrations produce detrimental side effects involving the nervous system, thereby precluding its use for cancer treatment. The mechanistic basis of the compound's antitumor activity is its ability to activate the pyruvate dehydrogenase complex through inhibition of pyruvate dehydrogenase kinase. As the compound inhibits the kinase at micromolar concentrations, it is not known why therapeutically prohibitive high doses are needed for suppression of tumor growth. We hypothesized that lack of effective mechanisms for the entry of DCA into tumor cells may underlie this phenomenon. Here we show that SLC5A8 transports DCA very effectively with high affinity. This transporter is expressed in normal cells, but expression is silenced in tumor cells by epigenetic mechanisms. The lack of the transporter makes tumor cells resistant to the antitumor activity of DCA. However, if the transporter is expressed in tumor cells ectopically, the cells become sensitive to the drug at low concentrations. This is evident in breast cancer cells, colon cancer cells and prostate cancer cells. Normal cells, which constitutively express the transporter, are however not affected by the compound, indicating tumor cell-selective therapeutic activity. The mechanism of the compound's antitumor activity still remains its ability to inhibit pyruvate dehydrogenase kinase and force mitochondrial oxidation of pyruvate. As silencing of SLC5A8 in tumors involves DNA methylation and its expression can be induced by treatment with DNA methylation inhibitors, our findings suggest that combining DCA with a DNA methylation inhibitor would offer a means to reduce the doses of DCA to avoid detrimental effects associated with high doses but without compromising antitumor activity. Oncogene (2011) 30, 4026-4037; doi:10.1038/onc. 2011.113; published online 18 April 2011	[Babu, E.; Ramachandran, S.; CoothanKandaswamy, V.; Elangovan, S.; Prasad, P. D.; Ganapathy, V.; Thangaraju, M.] Georgia Hlth Sci Univ, Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Thangaraju, M (corresponding author), Georgia Hlth Sci Univ, Med Coll Georgia, Dept Biochem & Mol Biol, 1459 Laney Walker Blvd,CB 2515, Augusta, GA 30912 USA.	mthangaraju@georgiahealth.edu	Elangovan, Selvakumar/ABB-9558-2021	Elangovan, Selvakumar/0000-0001-9906-5477	National Institutes of Health [CA131402]; NATIONAL CANCER INSTITUTE [R01CA131402] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The work described here is supported in part by the National Institutes of Health Grant CA131402.	Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; Brahimi-Horn MC, 2007, CURR OPIN CELL BIOL, V19, P223, DOI 10.1016/j.ceb.2007.02.003; Brandsma D, 2010, J NEUROL, V257, P2099, DOI 10.1007/s00415-010-5654-9; Calcutt NA, 2009, J NEUROPATH EXP NEUR, V68, P985, DOI 10.1097/NEN.0b013e3181b40217; Cao WG, 2008, PROSTATE, V68, P1223, DOI 10.1002/pros.20788; Chen Z, 2007, J BIOENERG BIOMEMBR, V39, P267, DOI 10.1007/s10863-007-9086-x; Coady MJ, 2004, J PHYSIOL-LONDON, V557, P719, DOI 10.1113/jphysiol.2004.063859; COOPER RH, 1974, BIOCHEM J, V143, P625, DOI 10.1042/bj1430625; Ganapathy V, 2005, BIOCHEM SOC T, V33, P237, DOI 10.1042/BST0330237; Ganapathy V, 2009, PHARMACOL THERAPEUT, V121, P29, DOI 10.1016/j.pharmthera.2008.09.005; Ganapathy V, 2008, AAPS J, V10, P193, DOI 10.1208/s12248-008-9022-y; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gopal E, 2005, BIOCHEM J, V388, P309, DOI 10.1042/BJ20041916; Gopal E, 2004, J BIOL CHEM, V279, P44522, DOI 10.1074/jbc.M405365200; Gupta N, 2006, LIFE SCI, V78, P2419, DOI 10.1016/j.lfs.2005.10.028; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Heshe D, 2011, CANCER CHEMOTH PHARM, V67, P647, DOI 10.1007/s00280-010-1361-6; Hong CB, 2005, CANCER RES, V65, P3617, DOI 10.1158/0008-5472.CAN-05-0048; Jackson VN, 1996, J BIOL CHEM, V271, P861, DOI 10.1074/jbc.271.2.861; Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501; Li H, 2003, P NATL ACAD SCI USA, V100, P8412, DOI 10.1073/pnas.1430846100; Madhok BM, 2010, BRIT J CANCER, V102, P1746, DOI 10.1038/sj.bjc.6605701; Martin PM, 2006, J NEUROCHEM, V98, P279, DOI 10.1111/j.1471-4159.2006.03878.x; Mathupala SP, 2010, BBA-BIOENERGETICS, V1797, P1225, DOI 10.1016/j.bbabio.2010.03.025; Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Miyauchi S, 2004, J BIOL CHEM, V279, P13293, DOI 10.1074/jbc.C400059200; Miyauchi S, 2010, BBA-BIOMEMBRANES, V1798, P1164, DOI 10.1016/j.bbamem.2010.03.002; Park JY, 2008, PANCREAS, V36, pE32, DOI 10.1097/MPA.0b013e3181630ffe; Park JY, 2007, CANCER DETECT PREV, V31, P359, DOI 10.1016/j.cdp.2007.09.002; Pearson H, 2007, NATURE, V446, P474, DOI 10.1038/446474a; Porra V, 2005, J CLIN ENDOCR METAB, V90, P3028, DOI 10.1210/jc.2004-1394; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Stacpoole PW, 1998, DRUG METAB REV, V30, P499, DOI 10.3109/03602539808996323; Stacpoole PW, 2003, J CLIN PHARMACOL, V43, P683, DOI 10.1177/0091270003254637; Stapoole PW, 2008, ADV DRUG DELIVER REV, V60, P1478, DOI 10.1016/j.addr.2008.02.014; Stockwin LH, 2010, INT J CANCER, V127, P2510, DOI 10.1002/ijc.25499; Sun RC, 2010, BREAST CANCER RES TR, V120, P253, DOI 10.1007/s10549-009-0435-9; Thangaraju M, 2008, J GASTROINTEST SURG, V12, P1773, DOI 10.1007/s11605-008-0573-0; Thangaraju M, 2006, CANCER RES, V66, P11560, DOI 10.1158/0008-5472.CAN-06-1950; Thangaraju M, 2009, CANCER, V115, P4655, DOI 10.1002/cncr.24532; Thangaraju M, 2009, BIOCHEM J, V417, P379, DOI 10.1042/BJ20081132; Ueno M, 2004, TUMOR BIOL, V25, P134, DOI 10.1159/000079145; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Weimer LH, 2009, CURR NEUROL NEUROSCI, V9, P69, DOI 10.1007/s11910-009-0011-z; WHITEHOUSE S, 1974, BIOCHEM J, V141, P761, DOI 10.1042/bj1410761; Wong JYY, 2008, GYNECOL ONCOL, V109, P394, DOI 10.1016/j.ygyno.2008.01.038; Xiao LL, 2010, MOL CELL BIOCHEM, V340, P31, DOI 10.1007/s11010-010-0397-6	49	63	67	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	38					4026	4037		10.1038/onc.2011.113	http://dx.doi.org/10.1038/onc.2011.113			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823KR	21499304	Green Accepted			2022-12-17	WOS:000295121600004
J	Moncho-Amor, V; Ibanez de Caceres, I; Bandres, E; Martinez-Poveda, B; Orgaz, JL; Sanchez-Perez, I; Zazo, S; Rovira, A; Albanell, J; Jimenez, B; Rojo, F; Belda-Iniesta, C; Garcia-Foncillas, J; Perona, R				Moncho-Amor, V.; Ibanez de Caceres, I.; Bandres, E.; Martinez-Poveda, B.; Orgaz, J. L.; Sanchez-Perez, I.; Zazo, S.; Rovira, A.; Albanell, J.; Jimenez, B.; Rojo, F.; Belda-Iniesta, C.; Garcia-Foncillas, J.; Perona, R.			DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer	ONCOGENE			English	Article						non-small-cell lung cancer; DUSP1/MKP1; VEGFC; angiogenesis; metastasis; DUSP6/MKP3	PROTEIN-KINASE PHOSPHATASE-1; LYMPH-NODE METASTASIS; BREAST-CANCER; TUMOR-GROWTH; MAP KINASE; ACTIVATION; PROGNOSIS; CARCINOMAS; EXPRESSION; PATHWAYS	DUSP1/MKP1 is a dual-specific phosphatase that regulates MAPKs activity, with an increasingly recognized role in tumor biology. To understand more about the involvement of DUSP1 in lung cancer, we performed gene expression analyses of parental and DUSP1-interfered H460 non-small-cell lung cancer (NSCLC) cells. Downregulation of DUSP1 induced changes in the expression levels of genes involved in specific biological pathways, including angiogenesis, MAP kinase phosphatase activity, cell-cell signaling, growth factor and tyrosine-kinase receptor activity. Changes in the expression of some of these genes were due to modulation of c-Jun-N-terminal kinase and/or p38 activity by DUSP1. Complementary functional assays were performed to focus on the implication of DUSP1 in angiogenesis and metastasis. In H460 cells, interference of DUSP1 resulted in a diminished capacity to invade through Matrigel, to grow tumors in nude mice and also to induce metastasis through tail-vein injection. Furthermore, the angiogenic potential of H460 cells was also impaired, correlating with a decrease in VEGFC production and indicating that DUSP1 could be required to induce angiogenesis. Finally, we studied whether a similar relationship occurred in patients. In human NSCLC specimens, DUSP1 was mainly expressed in those tumor cells close to CD31 vascular structures and a statistically significant correlation was found between VEGFC and DUSP1 expression. Overall, these results provide evidence for a role of DUSP1 in angiogenesis, invasion and metastasis in NSCLC. Oncogene (2011) 30, 668-678; doi:10.1038/onc.2010.449; published online 4 October 2010	[Moncho-Amor, V.; Sanchez-Perez, I.; Perona, R.] CSIC UAM, Inst Invest Biomed, CIBER Enfermedades Raras CIBERER, IdiPAZ, Madrid 28029, Spain; [Ibanez de Caceres, I.] FIB La Paz Univ Hosp, IdiPAZ, Oncol Res Lab, Res Unit, Madrid, Spain; [Bandres, E.; Garcia-Foncillas, J.] Univ Navarra, Ctr Appl Med Res CIMA, Div Oncol, Lab Pharmacogenom, Navarra, Spain; [Martinez-Poveda, B.; Orgaz, J. L.; Jimenez, B.] CSIC UAM, Inst Invest Biomed, Dept Mol & Cellular Biol Canc, Madrid 28029, Spain; [Zazo, S.; Rojo, F.] Capio Fdn Jimenez Diaz, Dept Pathol, Madrid, Spain; [Rovira, A.; Albanell, J.; Rojo, F.] Autonomous Univ Barcelona, Hosp Mar IMAS, Dept Med Oncol, Barcelona, Spain; [Rovira, A.; Albanell, J.; Rojo, F.] Autonomous Univ Barcelona, Canc Res Program, IMIM Hosp Mar, Barcelona, Spain; [Belda-Iniesta, C.] La Paz Univ Hosp, Dept Med Oncol, IdiPAZ, Madrid, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Navarra; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Autonomous University of Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Hospital Universitario La Paz	Perona, R (corresponding author), CSIC UAM, Inst Invest Biomed, CIBER Enfermedades Raras CIBERER, IdiPAZ, C Arturo Duperier 4, Madrid 28029, Spain.	RPerona@iib.uam.es	Rovira, Ana/ABH-5661-2020; Moncho, Veronica/AAB-5931-2019; Albanell, Joan/R-9470-2019; Orgaz, Jose L./ABH-1835-2020; Martinez-Poveda, Beatriz/T-6973-2017; Cuenca, Benilde Jimenez/K-9959-2014; Sánchez-Pérez, Isabel/R-4107-2016; Rojo, Federico/S-6551-2016	Rovira, Ana/0000-0003-1301-2599; Moncho, Veronica/0000-0001-7914-6683; Orgaz, Jose L./0000-0002-9776-7544; Martinez-Poveda, Beatriz/0000-0003-3927-3877; Sánchez-Pérez, Isabel/0000-0002-4829-201X; BANDRES, EVA/0000-0002-9497-5356; Jimenez Cuenca, Benilde/0000-0002-1806-6636; J, Garcia-Foncillas/0000-0002-7591-8006; Rojo, Federico/0000-0001-9989-0290; Belda Iniesta, Cristobal/0000-0003-3254-7492	Fondo de Investigacion Sanitaria (ISCIII) [CP 08/000689]; Spanish Ministerio de Educacion y Ciencia; Spanish Health Ministry grant 'Fondo de Investigacion Sanitaria' [PI05/2019, PI05/1305, PI06/1513, PI081485, PI09/1296, PS09/01285, PS09/00472]; Ministerio de Educacion y Ciencia [SAF2007-62292]; Comunidad Autonoma de Madrid [SAL-0311-2006];  [RTICC 06/0020/19]	Fondo de Investigacion Sanitaria (ISCIII)(Instituto de Salud Carlos III); Spanish Ministerio de Educacion y Ciencia(Spanish Government); Spanish Health Ministry grant 'Fondo de Investigacion Sanitaria'; Ministerio de Educacion y Ciencia(Spanish Government); Comunidad Autonoma de Madrid(Comunidad de Madrid); 	Ibanez de Caceres was partially supported by the Fondo de Investigacion Sanitaria (ISCIII) through the 'Miguel Servet' program (CP 08/000689); VM-A is a recipient of FIS fellowship. IS-P is in receipt of career development awards from the Ramon y Cajal program funded by the Spanish Ministerio de Educacion y Ciencia. We acknowledge Leandro Sastre for helping with cTAP constructs and helpful discussions. We thank Silvia Menendez (Hospital del Mar-IMAS) and Nuria Perez-Gonzalez (Fundacion Jimenez Diaz) for the technical support. We also thank Javier Perez and Fernando Nunez (IIB) for the artwork and animal facility, respectively. This work was supported by PI05/2019, PI05/1305, PI06/1513, PI081485, PI09/1296, PS09/01285 and PS09/00472 (Spanish Health Ministry grant 'Fondo de Investigacion Sanitaria'), SAF2007-62292 (Ministerio de Educacion y Ciencia grant), SAL-0311-2006 (Comunidad Autonoma de Madrid) and RTICC 06/0020/19 grant. We especially thank Fundacio Privada Cellex (Barcelona) and Fundacion Medical Mutua Madrilena for a generous grant to the Medical Oncology Service, Hospital del Mar-IMAS and to Instituto de Investigaciones Biomedicas (IIB), respectively.	Chattopadhyay S, 2006, ONCOGENE, V25, P3335, DOI 10.1038/sj.onc.1209364; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Denkert C, 2002, INT J CANCER, V102, P507, DOI 10.1002/ijc.10746; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Downward J, 2008, NAT MED, V14, P1315, DOI 10.1038/nm1208-1315; Ekerot M, 2008, BIOCHEM J, V412, P287, DOI 10.1042/BJ20071512; Espina C, 2008, AM J PATHOL, V172, P156, DOI 10.2353/ajpath.2008.070561; He YL, 2005, CANCER RES, V65, P4739, DOI 10.1158/0008-5472.CAN-04-4576; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Keyse SM, 2008, CANCER METAST REV, V27, P253, DOI 10.1007/s10555-008-9123-1; Langenfeld EM, 2003, CARCINOGENESIS, V24, P1445, DOI 10.1093/carcin/bgg100; LING L, 1995, MOL CELL BIOL, V15, P6582; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Loda M, 1996, AM J PATHOL, V149, P1553; Lu X, 2010, CANCER RES, V70, P3905, DOI 10.1158/0008-5472.CAN-09-3739; Marinov M, 2009, CLIN CANCER RES, V15, P1277, DOI 10.1158/1078-0432.CCR-08-2166; Morrison DJ, 2008, MOL CANCER RES, V6, P1225, DOI 10.1158/1541-7786.MCR-08-0078; Nutt JE, 2007, BRIT J CANCER, V96, P762, DOI 10.1038/sj.bjc.6603620; Offersen BV, 2007, LUNG CANCER, V56, P43, DOI 10.1016/j.lungcan.2006.11.018; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Renyi-Vamos F, 2005, CLIN CANCER RES, V11, P7344, DOI 10.1158/1078-0432.CCR-05-1077; Rojo F, 2009, CLIN CANCER RES, V15, P3530, DOI 10.1158/1078-0432.CCR-08-2070; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Sato M, 2006, CANCER RES, V66, P2116, DOI 10.1158/0008-5472.CAN-05-2521; Sos ML, 2009, CANCER RES, V69, P3256, DOI 10.1158/0008-5472.CAN-08-4055; Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Yamabuki T, 2007, CANCER RES, V67, P2517, DOI 10.1158/0008-5472.CAN-06-3369; Yu B, 2009, J HEPATOL, V50, P948, DOI 10.1016/j.jhep.2008.11.020; Zhang SC, 2006, CLIN CANCER RES, V12, P1735, DOI 10.1158/1078-0432.CCR-05-1982	34	63	66	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	6					668	678		10.1038/onc.2010.449	http://dx.doi.org/10.1038/onc.2010.449			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	719GY	20890299				2022-12-17	WOS:000287192000004
J	Lavergne, E; Hendaoui, I; Coulouarn, C; Ribault, C; Leseur, J; Eliat, PA; Mebarki, S; Corlu, A; Clement, B; Musso, O				Lavergne, E.; Hendaoui, I.; Coulouarn, C.; Ribault, C.; Leseur, J.; Eliat, P-A; Mebarki, S.; Corlu, A.; Clement, B.; Musso, O.			Blocking Wnt signaling by SFRP-like molecules inhibits in vivo cell proliferation and tumor growth in cells carrying active beta-catenin	ONCOGENE			English	Article						frizzled; collagen XVIII; Wnt; beta-catenin; colorectal cancer; secreted frizzled-related proteins	HUMAN COLORECTAL-CANCER; BASEMENT-MEMBRANE ZONES; COLON-CANCER; XVIII COLLAGEN; EXPRESSION; GENE; PATHWAY; CARCINOMA; MOUSE; ACTIVATION	Constitutive activation of Wnt/beta-catenin signaling in cancer results from mutations in pathway components, which frequently coexist with autocrine Wnt signaling or epigenetic silencing of extracellular Wnt antagonists. Among the extracellular Wnt inhibitors, the secreted frizzled-related proteins (SFRPs) are decoy receptors that contain soluble Wnt-binding frizzled domains. In addition to SFRPs, other endogenous molecules harboring frizzled motifs bind to and inhibit Wnt signaling. One of such molecules is V3Nter, a soluble SFRP-like frizzled polypeptide that binds to Wnt3a and inhibits Wnt signaling and expression of the beta-catenin target genes cyclin D1 and c-myc. V3Nter is derived from the cell surface extracellular matrix component collagen XVIII. Here, we used HCT116 human colon cancer cells carrying the Delta S45 activating mutation in one of the alleles of beta-catenin to show that V3Nter and SFRP-1 decrease baseline and Wnt3a-induced beta-catenin stabilization. Consequently, V3Nter reduces the growth of human colorectal cancer xenografts by specifically controlling cell proliferation and cell cycle progression, without affecting angiogenesis or apoptosis, as shown by decreased [H-3]-thymidine (in vitro) or BrdU (in vivo) incorporation, clonogenesis assays, cell cycle analysis and magnetic resonance imaging in living mice. Additionally, V3Nter switches off the beta-catenin target gene expression signature in vivo. Moreover, experiments with b-catenin allele-targeted cells showed that the DS45 beta-catenin allele hampers, but does not abrogate, inhibition of Wnt signaling by SFRP-1 or by the SFRP-like frizzled domain. Finally, neither SFRP-1 nor V3Nter affect beta-catenin signaling in SW480 cells carrying nonfunctional Adenomatous polyposis coli. Thus, SFRP-1 and the SFRP-like molecule V3Nter can inhibit tumor growth of beta-catenin-activated tumor cells in vivo. Oncogene (2011) 30, 423-433; doi: 10.1038/onc.2010.432; published online 20 September 2010	[Musso, O.] Univ Rennes, INSERM, UMR991, Hop Pontchaillou, F-35033 Rennes, France; [Lavergne, E.; Hendaoui, I.; Coulouarn, C.; Ribault, C.; Leseur, J.; Eliat, P-A; Mebarki, S.; Corlu, A.; Clement, B.; Musso, O.] Univ Rennes 1, Rennes, France; [Leseur, J.] Ctr Reg Lutte Canc, Rennes, France; [Eliat, P-A] PRISM, IFR 140, Rennes, France	CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes 1; Universite de Rennes 1	Musso, O (corresponding author), Univ Rennes, INSERM, UMR991, Hop Pontchaillou, Rue Henri le Guilloux, F-35033 Rennes, France.	orlando.musso@inserm.fr	Eliat, Pierre-Antoine/AAL-2600-2020; Clement, Bruno/E-5546-2016; Coulouarn, Cedric/E-5472-2011; Musso, Orlando/N-5756-2017; Corlu, Anne/U-8030-2018	Eliat, Pierre-Antoine/0000-0002-8082-4477; Clement, Bruno/0000-0001-8827-146X; Coulouarn, Cedric/0000-0002-5692-9586; Corlu, Anne/0000-0002-7370-0564; Musso, Orlando/0000-0001-8881-6925	Institut National de la Sante et de la Recherche Medicale; Institut National du Cancer; Agence Nationale de la Recherche; Universite de Rennes 1; Region Bretagne	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Institut National du Cancer(Institut National du Cancer (INCA) France); Agence Nationale de la Recherche(French National Research Agency (ANR)); Universite de Rennes 1; Region Bretagne(Region Bretagne)	We thank technical assistance from C Rocher at the Small Animal Imaging Platform, A Fautrel and P Bellaud at the Core HistoPathology Platform, R Le Guevel at the ImpactCell Platform, D Le Quilleuc and B Turlin at the Center for Biological Ressources and the animal husbandry group. We are indebted to B Vogelstein, S Bayling and H Suzuki, R Moon, R Nusse, T Pihlajaniemi and J Pouyssegur for generously providing cells, cDNAs or antibodies and to Christine Perret (Institut Cochin, Department Endocrinology, Metabolism and Cancer, Paris, France) for critical reading of the paper. This study was supported by Institut National de la Sante et de la Recherche Medicale, Institut National du Cancer, Agence Nationale de la Recherche (Emergence-BIO Program 2008), Universite de Rennes 1, Region Bretagne.	Ahmed N, 2003, PROTEOMICS, V3, P288, DOI 10.1002/pmic.200390042; Albihn A, 2010, ADV CANCER RES, V107, P163, DOI 10.1016/S0065-230X(10)07006-5; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Barker N, 2006, NAT REV DRUG DISCOV, V5, P997, DOI 10.1038/nrd2154; Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999; Chitalia VC, 2008, NAT CELL BIOL, V10, P1208, DOI 10.1038/ncb1781; Coulouarn C, 2009, ONCOGENE, V28, P3526, DOI 10.1038/onc.2009.211; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DeAlmeida VI, 2007, CANCER RES, V67, P5371, DOI 10.1158/0008-5472.CAN-07-0266; Dimitriadis A, 2001, CANCER LETT, V166, P185, DOI 10.1016/S0304-3835(01)00428-1; Dimitrova YN, 2010, J BIOL CHEM, V285, P13507, DOI 10.1074/jbc.M109.049411; Elamaa H, 2003, MATRIX BIOL, V22, P427, DOI 10.1016/S0945-053X(03)00073-8; Elamaa H, 2002, MECH DEVELOP, V114, P109, DOI 10.1016/S0925-4773(02)00014-X; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; He BA, 2005, ONCOGENE, V24, P3054, DOI 10.1038/sj.onc.1208511; Holcombe RF, 2002, J CLIN PATHOL-MOL PA, V55, P220, DOI 10.1136/mp.55.4.220; Hu J, 2009, CANCER RES, V69, P6951, DOI 10.1158/0008-5472.CAN-09-0541; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kenny PA, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-3; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Kyle AH, 2003, CANCER RES, V63, P5707; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Mikels AJ, 2006, ONCOGENE, V25, P7461, DOI 10.1038/sj.onc.1210053; Mita AC, 2008, CLIN CANCER RES, V14, P5000, DOI 10.1158/1078-0432.CCR-08-0746; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Munz M, 2009, CANCER RES, V69, P5627, DOI 10.1158/0008-5472.CAN-09-0654; MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763; Musso O, 2001, HEPATOLOGY, V33, P868, DOI 10.1053/jhep.2001.23189; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Quelard D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001878; Ramanujan S, 2000, CANCER RES, V60, P1442; Rehn M, 1996, GENOMICS, V32, P436, DOI 10.1006/geno.1996.0139; Saarela J, 1998, AM J PATHOL, V153, P611, DOI 10.1016/S0002-9440(10)65603-9; Salahshor S, 2005, J CLIN PATHOL, V58, P225, DOI 10.1136/jcp.2003.009506; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sekine S, 2002, ONCOGENE, V21, P5906, DOI 10.1038/sj.onc.1205756; Smith K, 1999, BRIT J CANCER, V81, P496, DOI 10.1038/sj.bjc.6690721; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; Takeuchi T, 2004, CLIN CANCER RES, V10, P5572, DOI 10.1158/1078-0432.CCR-03-0656; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tolwinski NS, 2004, TRENDS GENET, V20, P177, DOI 10.1016/j.tig.2004.02.003; Topol L, 2003, J CELL BIOL, V162, P899, DOI 10.1083/jcb.200303158; Treanor D, 2007, CLIN ONCOL-UK, V19, P769, DOI 10.1016/j.clon.2007.08.012; Ueno K, 2008, NEOPLASIA, V10, P697, DOI 10.1593/neo.08320; Vider BZ, 1996, ONCOGENE, V12, P153; Wang ZH, 2003, CANCER RES, V63, P5234; Yang J, 2006, J BIOL CHEM, V281, P17751, DOI 10.1074/jbc.M600831200	53	63	67	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	4					423	433		10.1038/onc.2010.432	http://dx.doi.org/10.1038/onc.2010.432			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711WH	20856206	Green Submitted, Green Accepted			2022-12-17	WOS:000286621600005
J	Sutter, R; Shakhova, O; Bhagat, H; Behesti, H; Sutter, C; Penkar, S; Santuccione, A; Bernays, R; Heppner, FL; Schuller, U; Grotzer, M; Moch, H; Schraml, P; Marino, S				Sutter, R.; Shakhova, O.; Bhagat, H.; Behesti, H.; Sutter, C.; Penkar, S.; Santuccione, A.; Bernays, R.; Heppner, F. L.; Schueller, U.; Grotzer, M.; Moch, H.; Schraml, P.; Marino, S.			Cerebellar stem cells act as medulloblastoma-initiating cells in a mouse model and a neural stem cell signature characterizes a subset of human medulloblastomas	ONCOGENE			English	Article						medulloblastoma; mouse model; CD133; Sox2; neural stem cells; tumor stem cells	SONIC HEDGEHOG; STEM/PROGENITOR CELLS; SOMATIC INACTIVATION; NERVOUS-SYSTEM; P53(-/-) MICE; HUMAN HOMOLOG; ADULT; EXPRESSION; PATHWAY; BRAIN	Cells with stem cell properties have been isolated from various areas of the postnatal mammalian brain, most recently from the postnatal mouse cerebellum. We show here that inactivation of the tumor suppressor genes Rb and p53 in these endogenous neural stem cells induced deregulated proliferation and resistance to apoptosis in vitro. Moreover, injection of these cells into mice formed medulloblastomas. Medulloblastomas are the most common malignant brain tumors of childhood, and despite recent advances in treatment they are associated with high morbidity and mortality. They are highly heterogeneous tumors characterized by a diverse genetic make-up and expression profile as well as variable prognosis. Here, we describe a novel ontogenetic pathway of medulloblastoma that significantly contributes to understanding their heterogeneity. Experimental medulloblastomas originating from neural stem cells preferentially expressed stem cell markers Nestin, Sox2 and Sox9, which were not expressed in medulloblastomas originating from granule-cell-restricted progenitors. Furthermore, the expression of these markers identified a subset of human medulloblastomas associated with a poorer clinical outcome. Oncogene (2010) 29, 1845-1856; doi:10.1038/onc.2009.472; published online 11 January 2010	[Sutter, R.; Shakhova, O.; Bhagat, H.; Behesti, H.; Penkar, S.; Marino, S.] Univ London, Barts & London Sch Med & Dent, Blizard Inst Cell & Mol Sci, Ctr Neurosci, London E1 2AT, England; [Sutter, C.; Santuccione, A.; Moch, H.; Schraml, P.] Univ Zurich Hosp, Dept Pathol, Inst Surg Pathol, CH-8091 Zurich, Switzerland; [Bernays, R.] Univ Zurich Hosp, Dept Neurosurg, CH-8091 Zurich, Switzerland; [Heppner, F. L.] Univ Zurich Hosp, Dept Pathol, Inst Neuropathol, CH-8091 Zurich, Switzerland; [Schueller, U.] Univ Munich, Ctr Neuropathol, Munich, Germany; [Grotzer, M.] Univ Childrens Hosp Zurich, Dept Oncol, Zurich, Switzerland	University of London; Queen Mary University London; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital; University of Munich; University Children's Hospital Zurich	Marino, S (corresponding author), Univ London, Barts & London Sch Med & Dent, Blizard Inst Cell & Mol Sci, Ctr Neurosci, 4 Newark St, London E1 2AT, England.	s.marino@qmul.ac.uk	Heppner, Frank/ABH-8393-2020; santuccione chadha, antonella/HDL-9230-2022; Sutter, Reto/D-6783-2013	Heppner, Frank/0000-0001-9816-8917; Sutter, Reto/0000-0001-6355-9838; Behesti, Hourinaz/0000-0001-9383-9929; Grotzer, Michael/0000-0002-1154-2732; Marino, Silvia/0000-0002-9612-2883; Santuccione Chadha, Antonella/0000-0002-4021-3129; Schuller, Ulrich/0000-0002-8731-1121	St Bartholomew's Charitable Foundation; Cancer Research UK; Ali's Dream and Charlie's Challenge Charities; Janggen-Pohn Foundation; Swiss National Science Foundation	St Bartholomew's Charitable Foundation; Cancer Research UK(Cancer Research UK); Ali's Dream and Charlie's Challenge Charities; Janggen-Pohn Foundation; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	We thank Rob Wechsler-Reya and James Briscoe for the gift of ptc+/- medulloblastoma pellets and Sox9 antibody respectively. We thank Gary Warnes for expert assistance with the flow cytometry analysis. This work was supported by grants of St Bartholomew's Charitable Foundation, Cancer Research UK, Ali's Dream and Charlie's Challenge Charities to SM and by personal fellowships of Janggen-Pohn Foundation and Swiss National Science Foundation to RS.	Akagi K, 1997, NUCLEIC ACIDS RES, V25, P1766, DOI 10.1093/nar/25.9.1766; Bar EE, 2007, STEM CELLS, V25, P2524, DOI 10.1634/stemcells.2007-0166; Behesti H, 2009, INT J BIOCHEM CELL B, V41, P435, DOI 10.1016/j.biocel.2008.06.017; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Cheung M, 2003, DEVELOPMENT, V130, P5681, DOI 10.1242/dev.00808; Corti S, 2007, EXP NEUROL, V205, P547, DOI 10.1016/j.expneurol.2007.03.021; Crawford JR, 2007, LANCET NEUROL, V6, P1073, DOI 10.1016/S1474-4422(07)70289-2; de Bont JM, 2008, NEURO-ONCOLOGY, V10, P648, DOI 10.1215/15228517-2008-032; DRESCHER DG, 1993, J NEUROCHEM, V61, P1167, DOI 10.1111/j.1471-4159.1993.tb03638.x; Eberhart CG, 2003, AM J PATHOL, V162, P7, DOI 10.1016/S0002-9440(10)63792-3; Ellis P, 2004, DEV NEUROSCI-BASEL, V26, P148, DOI 10.1159/000082134; Ellison DW, 2005, J CLIN ONCOL, V23, P7951, DOI 10.1200/JCO.2005.01.5479; Ferri ALM, 2004, DEVELOPMENT, V131, P3805, DOI 10.1242/dev.01204; Foroni C, 2007, CANCER RES, V67, P3725, DOI 10.1158/0008-5472.CAN-06-4577; Galli Rosselia, 2008, V438, P67, DOI 10.1007/978-1-59745-133-8_7; Gilbertson RJ, 2008, ANNU REV PATHOL-MECH, V3, P341, DOI 10.1146/annurev.pathmechdis.3.121806.151518; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Huang HT, 2000, AM J PATHOL, V156, P433, DOI 10.1016/S0002-9440(10)64747-5; Jackson EL, 2006, NEURON, V51, P187, DOI 10.1016/j.neuron.2006.06.012; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kimura H, 2005, ONCOGENE, V24, P4026, DOI 10.1038/sj.onc.1208567; Lee A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473; Lee J, 1997, DEVELOPMENT, V124, P2537; Lee Y, 2003, CANCER RES, V63, P5428; Llaguno SA, 2009, CANCER CELL, V15, P45, DOI 10.1016/j.ccr.2008.12.006; Lumpkin EA, 2003, GENE EXPR PATTERNS, V3, P389, DOI 10.1016/S1567-133X(03)00089-9; Marino S, 2000, GENE DEV, V14, P994; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Palma V, 2005, DEVELOPMENT, V132, P335, DOI 10.1242/dev.01567; Palma V, 2004, DEVELOPMENT, V131, P337, DOI 10.1242/dev.00930; Pfenninger CV, 2007, CANCER RES, V67, P5727, DOI 10.1158/0008-5472.CAN-07-0183; Phi JH, 2008, AM J SURG PATHOL, V32, P103, DOI 10.1097/PAS.0b013e31812f6ba6; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Rajewsky K, 1996, J CLIN INVEST, V98, P600, DOI 10.1172/JCI118828; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Shakhova O, 2006, CANCER RES, V66, P5190, DOI 10.1158/0008-5472.CAN-05-3545; Shu Q, 2008, STEM CELLS, V26, P1414, DOI 10.1634/stemcells.2007-1009; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Sottile V, 2006, BRAIN RES, V1099, P8, DOI 10.1016/j.brainres.2006.04.127; Suh H, 2007, CELL STEM CELL, V1, P515, DOI 10.1016/j.stem.2007.09.002; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Tong WM, 2003, AM J PATHOL, V162, P343, DOI 10.1016/S0002-9440(10)63825-4; Weiss William A., 2002, Oncogene, V21, P7453, DOI 10.1038/sj.onc.1205936; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Zhao H, 2008, GENE DEV, V22, P722, DOI 10.1101/gad.1636408; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V	49	63	64	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2010	29	12					1845	1856		10.1038/onc.2009.472	http://dx.doi.org/10.1038/onc.2009.472			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20062081	Green Accepted			2022-12-17	WOS:000276022800013
J	Ahn, BY; Trinh, DLN; Zajchowski, LD; Lee, B; Elwi, AN; Kim, SW				Ahn, B. Y.; Trinh, D. L. N.; Zajchowski, L. D.; Lee, B.; Elwi, A. N.; Kim, S-W			Tid1 is a new regulator of p53 mitochondrial translocation and apoptosis in cancer	ONCOGENE			English	Article						p53; Tid1; tumor suppressor; mitochondria; apoptosis	MUTANT P53; MEMBRANE PERMEABILIZATION; MEDIATED APOPTOSIS; DNA-DAMAGE; CELLS; ACTIVATION; BAX; PROTEIN; DEGRADATION; CHAPERONES	The p53 tumor suppressor protein induces apoptosis in response to genotoxic and environmental stresses. Recent studies have revealed the existence of a transcription-independent mitochondrial p53 apoptotic pathway; however, the mechanism that regulates its translocation to the mitochondria has been unknown. In this study, we show that the tumor suppressor Tid1 forms a complex with p53 under hypoxic conditions that directs p53 translocation to the mitochondria and the subsequent initiation of the mitochondrial apoptosis pathway. Loss of Tid1 expression abrogated p53 translocation to the mitochondria and inhibited apoptosis, whereas the over-expression of Tid1 promoted p53 mitochondrial localization and apoptosis. Tid1's mitochondrial signal sequence and DnaJ domain were both required for the movement of the p53-Tid1 complex from the cytosol to the mitochondria. When Tid is over-expressed in cancer cell lines expressing mutant p53 isoforms defective in transcriptional activity, mitochondrial localization and pro-apoptotic activities of the mutant p53 proteins was restored. Our results establish Tid1 as a novel regulator of p53-mediated apoptosis, and suggest that therapies designed to enhance Tid1's function in promoting mitochondrial localization of p53 and apoptosis could be an effective therapy in many cancers. Oncogene (2010) 29, 1155-1166; doi: 10.1038/onc.2009.413; published online 23 November 2009	[Ahn, B. Y.; Trinh, D. L. N.; Lee, B.; Elwi, A. N.; Kim, S-W] Univ Calgary, Dept Biochem, Calgary, AB T2N 4N1, Canada; [Ahn, B. Y.; Trinh, D. L. N.; Lee, B.; Elwi, A. N.; Kim, S-W] Univ Calgary, Dept Mol Biol, Calgary, AB T2N 4N1, Canada; [Kim, S-W] Univ Calgary, So Alberta Canc Res Inst, Calgary, AB T2N 4N1, Canada; [Zajchowski, L. D.; Kim, S-W] Univ Calgary, Clark H Smith Brain Tumour Ctr, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary	Kim, SW (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, 3330 Hosp Dr,HRIC 2A08, Calgary, AB T2N 4N1, Canada.	swkim@ucalgary.ca			Alberta Cancer Research Institute [23123]; Canada Research Chairs Program [950203751]; Canada Institute of Health Research [MOP97962]; Alberta Cancer Board	Alberta Cancer Research Institute; Canada Research Chairs Program(Canada Research Chairs); Canada Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Alberta Cancer Board	We thank Drs F Jirik, S Robbins, P Forsyth, K Riabowol, S Grewal and X Feng for their invaluable suggestions, critical review of the paper and encouragement. This work was supported in part by grants from the Alberta Cancer Research Institute (23123), the Canada Research Chairs Program (950203751) and the Canada Institute of Health Research (MOP97962) to SWK. BYA and DT were supported by a postdoctoral fellowship and graduate scholarship, respectively, from the Alberta Cancer Board.	Anderson ARA, 2006, CELL, V127, P905, DOI 10.1016/j.cell.2006.09.042; Bissonnette N, 1997, BIOCHEM CELL BIOL, V75, P351, DOI 10.1139/bcb-75-4-351; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007; Chopin V, 2002, BRIT J PHARMACOL, V135, P79, DOI 10.1038/sj.bjp.0704456; Cui Q, 2007, ACTA PHARMACOL SIN, V28, P1057, DOI 10.1111/j.1745-7254.2007.00588.x; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Edwards KM, 2004, ONCOGENE, V23, P8419, DOI 10.1038/sj.onc.1207732; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gomez JA, 2007, BIOCHEM SOC T, V35, P797, DOI 10.1042/BST0350797; Hammond EM, 2005, BIOCHEM BIOPH RES CO, V331, P718, DOI 10.1016/j.bbrc.2005.03.154; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Kim BM, 2007, TOXICOLOGY, V229, P226, DOI 10.1016/j.tox.2006.10.022; Kim SW, 2005, CANCER RES, V65, P8784, DOI 10.1158/0008-5472.CAN-04-4422; Kim SW, 2004, CANCER RES, V64, P7732, DOI 10.1158/0008-5472.CAN-04-1323; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Lu B, 2006, J BIOL CHEM, V281, P13150, DOI 10.1074/jbc.M509179200; Lukashchuk N, 2007, MOL CELL BIOL, V27, P8284, DOI 10.1128/MCB.00050-07; Marchenko ND, 2007, EMBO J, V26, P923, DOI 10.1038/sj.emboj.7601560; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mooney LM, 2002, BRIT J CANCER, V87, P909, DOI 10.1038/sj.bjc.6600541; Murphy ME, 2004, CELL CYCLE, V3, P836; Nemajerova A, 2005, CELL DEATH DIFFER, V12, P197, DOI 10.1038/sj.cdd.4401526; Perfettini JL, 2004, NAT CELL BIOL, V6, P386, DOI 10.1038/ncb0504-386; Pietsch EC, 2008, J BIOL CHEM, V283, P21294, DOI 10.1074/jbc.M710539200; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang LH, 1998, ANTICANCER RES, V18, P321; Wang P, 2007, P NATL ACAD SCI USA, V104, P4054, DOI 10.1073/pnas.0700020104; Wolff S, 2008, CELL RES, V18, P733, DOI 10.1038/cr.2008.62	37	63	66	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1155	1166		10.1038/onc.2009.413	http://dx.doi.org/10.1038/onc.2009.413			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19935715				2022-12-17	WOS:000274912100007
J	Robinson, JP; VanBrocklin, MW; Guilbeault, AR; Signorelli, DL; Brandner, S; Holmen, SL				Robinson, J. P.; VanBrocklin, M. W.; Guilbeault, A. R.; Signorelli, D. L.; Brandner, S.; Holmen, S. L.			Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation	ONCOGENE			English	Article						glioma; BRAF; KRas; Akt; Ink4a; Arf	SPINDLE-CELL GLIOBLASTOMA; LEUKOSIS-SARCOMA VIRUSES; CENTRAL-NERVOUS-SYSTEM; B-RAF GENE; PROTEIN-KINASE; NEGATIVE REGULATION; PATHWAY ACTIVATION; NEURAL PROGENITORS; TUMOR SUPPRESSION; CYCLE ARREST	Mutations in receptor tyrosine kinase (RTK) growth factor receptors (epidermal growth factor receptor, platelet-derived growth factor receptor, MET and ERBB2), which result in downstream activation of the RAS/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) pathway and PI(3)K/Akt pathway, are found in almost all high-grade gliomas and MAPK signaling is necessary for continued glioma maintenance. In addition, BRAF is mutated in the majority of low-grade gliomas and its expression and activity is significantly increased in the majority of high-grade gliomas. Although the importance of RTKs and RAS signaling in glioma development has been shown, the role of BRAF has yet to be characterized. We evaluated the effect of activated BRAF in glioma formation using the retroviral replication-competent avian leukosis virus long terminal repeat, splice acceptor (RCAS)/TVA system to transfer genes encoding activated forms of BRAF, KRas, Akt and Cre to nestin-expressing neural progenitor cells in Ink4a/Arf(lox/lox) mice in vivo. Although expression of activated BRAF alone is not sufficient for tumorigenesis, the combination of activated BRAF and Akt or BRAF with Ink4a/Arf loss is transforming. Interestingly, activated BRAF generates gliomas with characteristics similar to activated KRas in the context of Akt but not Ink4a/Arf loss. Our studies show a role for BRAF activation and signaling in glioma development and as potential target for glioma therapy. Oncogene (2010) 29, 335-344; doi:10.1038/onc.2009.333; published online 26 October 2009	[Robinson, J. P.; VanBrocklin, M. W.; Guilbeault, A. R.; Signorelli, D. L.; Holmen, S. L.] Nevada Canc Inst, Drug Dev Dept, Las Vegas, NV 89135 USA; [Brandner, S.] UCL, Inst Neurol, Dept Neurogenerat Dis, Div Neuropathol, London, England	University of California System; University of California San Diego; University of London; University College London	Holmen, SL (corresponding author), Nevada Canc Inst, Drug Dev Dept, 1 Breakthrough Way,Lab 3, Las Vegas, NV 89135 USA.	sholmen@nvcancer.org	Brandner, Sebastian/J-4562-2014	Brandner, Sebastian/0000-0002-9821-0342; Robinson, James/0000-0002-6585-0116	Nevada Cancer Institute; National Brain Tumor Foundation; American Cancer Society [RSG-06-198-01-TBE]; NATIONAL CANCER INSTITUTE [R01CA121118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS073870, R01NS075155] Funding Source: NIH RePORTER	Nevada Cancer Institute(University of California System); National Brain Tumor Foundation; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the Nevada Cancer Institute, the National Brain Tumor Foundation, and RSG-06-198-01-TBE from the American Cancer Society. We thank Nick Henderson and Robert Kirsh for animal husbandry. We also thank Eric Holland, Martin McMahon, and Ronald DePinho for the reagents. SLH designed the research; JPR, MWV and SLH performed the research; SB performed the pathological analysis; DLS and ARG provided technical support; JPR and SLH prepared the images and wrote the paper.	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; Balmanno K, 2009, CELL DEATH DIFFER, V16, P368, DOI 10.1038/cdd.2008.148; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; Basto D, 2005, ACTA NEUROPATHOL, V109, P207, DOI 10.1007/s00401-004-0936-x; Bromberg-White JL, 2004, J VIROL, V78, P4914, DOI 10.1128/JVI.78.9.4914-4916.2004; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; DAHLSTRAND J, 1992, CANCER RES, V52, P5334; Dai C, 2003, CANCER J, V9, P72, DOI 10.1097/00130404-200303000-00002; Dai CK, 2005, NEOPLASIA, V7, P397, DOI 10.1593/neo.04691; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Guan KL, 2000, J BIOL CHEM, V275, P27354; HAMEL W, 1993, J NEURO-ONCOL, V16, P159, DOI 10.1007/BF01324703; Hill JR, 1999, ARCH NEUROL-CHICAGO, V56, P439, DOI 10.1001/archneur.56.4.439; Hmitou I, 2007, MOL CELL BIOL, V27, P31, DOI 10.1128/MCB.01265-06; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 1998, GENE DEV, V12, P3644, DOI 10.1101/gad.12.23.3644; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Holmen SL, 1999, J VIROL, V73, P10051, DOI 10.1128/JVI.73.12.10051-10060.1999; Holmen SL, 2005, CANCER RES, V65, P8250, DOI 10.1158/0008-5472.CAN-05-1173; Hu XY, 2005, NEOPLASIA, V7, P356, DOI 10.1593/neo.04595; Jeuken J, 2007, ACTA NEUROPATHOL, V114, P121, DOI 10.1007/s00401-007-0239-0; Jones DTW, 2009, ONCOGENE, V28, P2119, DOI 10.1038/onc.2009.73; Jones DTW, 2008, CANCER RES, V68, P8673, DOI 10.1158/0008-5472.CAN-08-2097; JONES H, 1991, NEUROPATH APPL NEURO, V17, P177, DOI 10.1111/j.1365-2990.1991.tb00713.x; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lyustikman Y, 2008, NEOPLASIA, V10, P501, DOI 10.1593/neo.08206; Marino S, 2000, GENE DEV, V14, P994; Mizoguchi M, 2004, BRAIN PATHOL, V14, P372, DOI 10.1111/j.1750-3639.2004.tb00080.x; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; PAULUS W, 1992, NEUROPATH APPL NEURO, V18, P207; Pfister S, 2008, J CLIN INVEST, V118, P1739, DOI 10.1172/JCI33656; Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960-9822(02)00548-1; QUELLE DE, 1995, CELL, V83, P993; Reis RM, 2000, AM J PATHOL, V156, P425, DOI 10.1016/S0002-9440(10)64746-3; Riemenschneider MJ, 2006, CANCER RES, V66, P5618, DOI 10.1158/0008-5472.CAN-06-0364; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Schaefer-Klein J, 1998, VIROLOGY, V248, P305, DOI 10.1006/viro.1998.9291; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; SMITH EJ, 1979, AVIAN DIS, V23, P698, DOI 10.2307/1589746; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; Uhrbom L, 2005, CANCER RES, V65, P2065, DOI 10.1158/0008-5472.CAN-04-3588; Uhrbom L, 2002, CANCER RES, V62, P5551; VanBrocklin MW, 2009, CANCER RES, V69, P1985, DOI 10.1158/0008-5472.CAN-08-3934; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Wojnowski L, 1998, MECH DEVELOP, V76, P141, DOI 10.1016/S0925-4773(98)00111-7	51	63	68	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					335	344		10.1038/onc.2009.333	http://dx.doi.org/10.1038/onc.2009.333			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19855433	Green Accepted			2022-12-17	WOS:000273793200003
J	Bui, LC; Tomkiewicz, C; Chevallier, A; Pierre, S; Bats, AS; Mota, S; Raingeaud, J; Pierre, J; Diry, M; Transy, C; Garlatti, M; Barouki, R; Coumoul, X				Bui, L-C; Tomkiewicz, C.; Chevallier, A.; Pierre, S.; Bats, A-S; Mota, S.; Raingeaud, J.; Pierre, J.; Diry, M.; Transy, C.; Garlatti, M.; Barouki, R.; Coumoul, X.			Nedd9/Hef1/Cas-L mediates the effects of environmental pollutants on cell migration and plasticity	ONCOGENE			English	Article						PAHs; cellular plasticity; toxicology; xenobiotics; metastasis marker	DOCKING PROTEIN HEF1; HYDROCARBON RECEPTOR; GENE-EXPRESSION; AH RECEPTOR; CANCER; ACTIVATION; DIOXIN; IDENTIFICATION; METASTASIS; NETWORKS	Aryl hydrocarbon receptor (AhR), or dioxin receptor, is a transcription factor that induces adaptive metabolic pathways in response to environmental pollutants. Recently, other pathways were found to be altered by AhR and its ligands. Indeed, developmental defects elicited by AhR ligands suggest that additional cellular functions may be targeted by this receptor, including cell migration and plasticity. Here, we show that dioxin-mediated activation of Ahr induces Nedd9/Hef1/Cas-L, a member of the Cas protein family recently identified as a metastasis marker. The Hef1 gene induction is mediated by two xenobiotic responsive elements present in this gene promoter. Moreover, using RNA interference, we show that Nedd9/Hef1/Cas-L mediates the dioxin-elicited changes related to cell plasticity, including alterations of cellular adhesion and shape, cytoskeleton reorganization, and increased cell migration. Furthermore, we show that both E-cadherin repression and Jun N-terminal kinases activation by dioxin and AhR also depend on the expression of Nedd9/Hef1/Cas-L. Our study unveils, for the first time, a link between pollutants exposure and the induced expression of a metastasis marker and shows that cellular migration and plasticity markers are regulated by AhR and its toxic ligands. Oncogene (2009) 28, 3642-3651; doi:10.1038/onc.2009.224; published online 3 August 2009	[Bui, L-C; Tomkiewicz, C.; Chevallier, A.; Pierre, S.; Bats, A-S; Mota, S.; Garlatti, M.; Barouki, R.; Coumoul, X.] INSERM, UMR S 747, Paris, France; [Bui, L-C; Tomkiewicz, C.; Chevallier, A.; Pierre, S.; Bats, A-S; Mota, S.; Diry, M.; Transy, C.; Garlatti, M.; Barouki, R.; Coumoul, X.] Univ Paris 05, Ctr Univ Saints Peres, Paris, France; [Raingeaud, J.; Pierre, J.] Univ Paris 11, Fac Pharm, INSERM, U461, F-92290 Chatenay Malabry, France; [Diry, M.; Transy, C.] INSERM, U490, Paris, France; [Barouki, R.] Hop Necker Enfants Malad, APHP, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	Barouki, R (corresponding author), Univ Paris 05, INSERM, Fac Med Saints Peres, UMR Toxicol Pharmacol & Signalisat Cellulaire S 7, 45 Rue Saints Peres, F-75006 Paris, Ile De France, France.	robert.barouki@univ-paris5.fr; xavier.coumoul@parisdescartes.fr	COUMOUL, Xavier/AAR-3649-2020; Chevallier, Aline/O-5939-2014; Mota, Sandra/AAB-6073-2019	COUMOUL, Xavier/0000-0003-2928-9648; Mota, Sandra/0000-0001-9623-5012; BATS, Anne-Sophie/0000-0001-5333-3296	AFSSET (Agence Francaise de Securite Sanitaire de l'Environnement et du Travail); ANR (Agence Nationale de la Recherche) [06SEST26]; ARC (Association pour la Recherche sur le Cancer) [3927]; Fondation pour la Recherche Medicale (Bourse postdoctorale, Linh-Chi Bui); INSERM (Institut National de la Sante et de la Recherche Medicale); Ligue contre le Cancer; Ministere de l'enseignement superieur et de la recherche; Region Ile de France; Universite Paris Descartes	AFSSET (Agence Francaise de Securite Sanitaire de l'Environnement et du Travail); ANR (Agence Nationale de la Recherche)(French National Research Agency (ANR)); ARC (Association pour la Recherche sur le Cancer)(Fondation ARC pour la Recherche sur le Cancer); Fondation pour la Recherche Medicale (Bourse postdoctorale, Linh-Chi Bui)(Fondation pour la Recherche Medicale); INSERM (Institut National de la Sante et de la Recherche Medicale)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Ligue contre le Cancer(Ligue nationale contre le cancer); Ministere de l'enseignement superieur et de la recherche; Region Ile de France(Region Ile-de-France); Universite Paris Descartes	This work was supported by AFSSET (Agence Francaise de Securite Sanitaire de l'Environnement et du Travail; all authors); ANR (Agence Nationale de la Recherche, 06SEST26, Oncopop; all authors); ARC (Association pour la Recherche sur le Cancer, 3927; all authors); Fondation pour la Recherche Medicale (Bourse postdoctorale, Linh-Chi Bui); INSERM (Institut National de la Sante et de la Recherche Medicale; all authors); Ligue contre le Cancer (Bourse postdoctorale, Linh-Chi Bui); Ministere de l'enseignement superieur et de la recherche (Bourse doctorale, Aline Chevallier); Region Ile de France (bourse doctorale, Stephane Pierre); Universite Paris Descartes.	Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Crews ST, 2006, GENE DEV, V20, P2773, DOI 10.1101/gad.1487706; Diry M, 2006, ONCOGENE, V25, P5570, DOI 10.1038/sj.onc.1209553; Downie D, 2005, CLIN CANCER RES, V11, P7369, DOI 10.1158/1078-0432.CCR-05-0466; Frueh FW, 2001, TOXICOL LETT, V122, P189, DOI 10.1016/S0378-4274(01)00364-2; Haas S, 2006, INT J CANCER, V119, P1785, DOI 10.1002/ijc.21915; Huang C, 2004, CELL CYCLE, V3, P4, DOI 10.4161/cc.3.1.601; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Kohle C, 2007, BIOCHEM PHARMACOL, V73, P1853, DOI 10.1016/j.bcp.2007.01.009; Kumarakulasingham M, 2005, CLIN CANCER RES, V11, P3758, DOI 10.1158/1078-0432.CCR-04-1848; Law SF, 1996, MOL CELL BIOL, V16, P3327; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Ma Q, 1996, MOL CELL BIOL, V16, P2144; Marchand A, 2005, MOL PHARMACOL, V67, P444, DOI 10.1124/mol.104.004010; McMillan BJ, 2007, P NATL ACAD SCI USA, V104, P1412, DOI 10.1073/pnas.0607296104; Mulero-Navarro S, 2005, J BIOL CHEM, V280, P28731, DOI 10.1074/jbc.M504538200; Natarajan M, 2006, ONCOGENE, V25, P1721, DOI 10.1038/sj.onc.1209199; O'Neill GM, 2001, MOL CELL BIOL, V21, P5094, DOI 10.1128/MCB.21.15.5094-5108.2001; Puga A, 2005, BIOCHEM PHARMACOL, V69, P199, DOI 10.1016/j.bcp.2004.06.043; Pugacheva EN, 2007, CELL, V129, P1351, DOI 10.1016/j.cell.2007.04.035; Pugacheva EN, 2006, CELL CYCLE, V5, P384, DOI 10.4161/cc.5.4.2439; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Qin HT, 2006, DEV BIOL, V298, P606, DOI 10.1016/j.ydbio.2006.07.017; Regelmann AG, 2006, IMMUNITY, V25, P907, DOI 10.1016/j.immuni.2006.09.014; Seo S, 2006, CRIT REV IMMUNOL, V26, P391, DOI 10.1615/CritRevImmunol.v26.i5.20; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Wernet MF, 2006, NATURE, V440, P174, DOI 10.1038/nature04615; Ziegler WH, 2006, TRENDS CELL BIOL, V16, P453, DOI 10.1016/j.tcb.2006.07.004	29	63	68	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2009	28	41					3642	3651		10.1038/onc.2009.224	http://dx.doi.org/10.1038/onc.2009.224			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KJ	19648964				2022-12-17	WOS:000270851800005
J	Eisenmann, KM; Dykema, KJ; Matheson, SF; Kent, NF; DeWard, AD; West, RA; Tibes, R; Furge, KA; Alberts, AS				Eisenmann, K. M.; Dykema, K. J.; Matheson, S. F.; Kent, N. F.; DeWard, A. D.; West, R. A.; Tibes, R.; Furge, K. A.; Alberts, A. S.			5q-myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics	ONCOGENE			English	Review						Rho GTPase; actin assembly; formin; myeloproliferative neoplasms; tumor-suppressor	SERUM RESPONSE FACTOR; DIAPHANOUS-RELATED FORMINS; TRANSCRIPTION FACTOR EGR1; COMMONLY DELETED REGION; FARNESYLTRANSFERASE INHIBITORS; MYELODYSPLASTIC SYNDROMES; ALPHA-CATENIN; HEMATOPOIETIC STEM; CD34(+) CELLS; RHO GTPASE	Complete loss or interstitial deletions of chromosome 5 are the most common karyotypic abnormality in myelodysplastic syndromes (MDSs). Isolated del(5q)/5q- MDS patients have a more favorable prognosis than those with additional karyotypic defects, who tend to develop myeloproliferative neoplasms (MPNs) and acute myeloid leukemia. The frequency of unbalanced chromosome 5 deletions has led to the idea that 5q harbors one or more tumor-suppressor genes that have fundamental roles in the growth control of hematopoietic stem/progenitor cells (HSCs/HPCs). Cytogenetic mapping of commonly deleted regions (CDRs) centered on 5q31 and 5q32 identified candidate tumor-suppressor genes, including the ribosomal subunit RPS14, the transcription factor Egr1/Krox20 and the cytoskeletal remodeling protein, alpha-catenin. Although each acts as a tumor suppressor, alone or in combination, no molecular mechanism accounts for how defects in individual 5q candidates may act as a lesion driving MDS or contributing to malignant progression in MPN. One candidate gene that resides between the conventional del(5q)/5q- MDS-associated CDRs is DIAPH1 (5q31.3). DIAPH1 encodes the mammalian Diaphanous-related formin, mDia1. mDia1 has critical roles in actin remodeling in cell division and in response to adhesive and migratory stimuli. This review examines evidence, with a focus on mouse gene-targeting experiments, that mDia1 acts as a node in a tumor-suppressor network that involves multiple 5q gene products. The network has the potential to sense dynamic changes in actin assembly. At the root of the network is a transcriptional response mechanism mediated by the MADS-box transcription factor, serum response factor (SRF), its actin-binding myocardin family coactivator, MAL, and the SRF-target 5q gene, EGR1, which regulate the expression of PTEN and p53-family tumor-suppressor proteins. We hypothesize that the network provides a homeostatic mechanism balancing HPC/HSC growth control and differentiation decisions in response to microenvironment and other external stimuli. Oncogene (2009) 28, 3429-3441; doi: 10.1038/onc.2009.207; published online 13 July 2009	[Eisenmann, K. M.; Matheson, S. F.; Kent, N. F.; DeWard, A. D.; West, R. A.; Alberts, A. S.] Van Andel Res Inst, Lab Cell Struct & Signal Integrat, Grand Rapids, MI 49503 USA; [Dykema, K. J.; Furge, K. A.] Van Andel Res Inst, Lab Computat Biol, Grand Rapids, MI 49503 USA; [Matheson, S. F.] Calvin Coll, Dept Biol, Grand Rapids, MI 49506 USA; [Tibes, R.] Translat Genom Clin Res Serv, Scottsdale, AZ USA	Van Andel Institute; Van Andel Institute; Calvin University	Alberts, AS (corresponding author), Van Andel Res Inst, Lab Cell Struct & Signal Integrat, 333 Bostwick Ave,NE, Grand Rapids, MI 49503 USA.	art.alberts@vai.org	Tibes, Raoul/AAV-1683-2020	Eisenmann, Kathryn/0000-0002-5337-5928; Matheson, Stephen/0000-0003-0561-8152; Tibes, Raoul/0000-0002-1372-8733; West, Richard/0000-0003-1459-0825	Van Andel Foundation; JP McCarthy Foundation; American Cancer Society [RSG-05-033-01-CSM]	Van Andel Foundation; JP McCarthy Foundation; American Cancer Society(American Cancer Society)	ASA and RAW were supported by the Van Andel Foundation, the JP McCarthy Foundation and the American Cancer Society (RSG-05-033-01-CSM). We are grateful to David Nadziejka for vigilant editing as well as Nick Duesbery, Cindy Miranti and Jeff Mackeigan for their thoughtful discussion.	Adamson E, 2003, CANCER BIOL THER, V2, P617; Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711; Adini I, 2003, GENE DEV, V17, P2721, DOI 10.1101/gad.1134603; Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Basso AD, 2006, J LIPID RES, V47, P15, DOI 10.1194/jlr.R500012-JLR200; Benjamin JM, 2008, SEMIN CANCER BIOL, V18, P53, DOI 10.1016/j.semcancer.2007.08.003; Bilanges B, 2007, ONCOGENE, V26, P5973, DOI 10.1038/sj.onc.1210431; BOULTWOOD J, 1995, LEUKEMIA LYMPHOMA, V17, P71, DOI 10.3109/10428199509051705; Boultwood J, 2002, BLOOD, V99, P4638, DOI 10.1182/blood.V99.12.4638; Boultwood J, 2007, BRIT J HAEMATOL, V139, P578, DOI 10.1111/j.1365-2141.2007.06833.x; Chhabra ES, 2007, NAT CELL BIOL, V9, P1110, DOI 10.1038/ncb1007-1110; Cmejla R, 2007, HUM MUTAT, V28, P1178, DOI 10.1002/humu.20608; Colucci-Guyon E, 2005, CURR BIOL, V15, P2007, DOI 10.1016/j.cub.2005.09.051; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; Cortes JE, 2002, SEMIN HEMATOL, V39, P26, DOI 10.1053/shem.2002.35984; Crescenzi B, 2004, HAEMATOLOGICA, V89, P281; Dai MS, 2008, J CELL BIOCHEM, V105, P670, DOI 10.1002/jcb.21895; Dent EW, 2007, NAT CELL BIOL, V9, P1347, DOI 10.1038/ncb1654; Desmond JC, 2007, LEUKEMIA, V21, P1026, DOI 10.1038/sj.leu.2404611; Du W, 1999, MOL CELL BIOL, V19, P1831; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Eisenmann KM, 2007, CURR BIOL, V17, P579, DOI 10.1016/j.cub.2007.03.024; Evers C, 2007, GENE CHROMOSOME CANC, V46, P1119, DOI 10.1002/gcc.20498; Farrar JE, 2008, BLOOD, V112, P1582, DOI 10.1182/blood-2008-02-140012; Fernandez-Borja M, 2005, J CELL SCI, V118, P2661, DOI 10.1242/jcs.02384; Gates J, 2005, CELL, V123, P769, DOI 10.1016/j.cell.2005.11.009; Gazda HT, 2006, AM J HUM GENET, V79, P1110, DOI 10.1086/510020; Giagounidis A A N, 2004, Hematology, V9, P271, DOI 10.1080/10245330410001723824; Giagounidis AAN, 2006, CLIN CANCER RES, V12, P5, DOI 10.1158/1078-0432.CCR-05-1437; Goode BL, 2007, ANNU REV BIOCHEM, V76, P593, DOI 10.1146/annurev.biochem.75.103004.142647; Greer JM, 2000, NATURE, V403, P661, DOI 10.1038/35001077; Guettler S, 2008, MOL CELL BIOL, V28, P732, DOI 10.1128/MCB.01623-07; Gupton SL, 2007, J CELL SCI, V120, P3475, DOI 10.1242/jcs.006049; Herry A, 2007, EUR J HAEMATOL, V78, P457, DOI 10.1111/j.1600-0609.2007.00847.x; Higgs HN, 2005, TRENDS BIOCHEM SCI, V30, P342, DOI 10.1016/j.tibs.2005.04.014; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Horrigan SK, 2000, BLOOD, V95, P2372, DOI 10.1182/blood.V95.7.2372.007k20_2372_2377; Huang XK, 2003, LEUKEMIA LYMPHOMA, V44, P157, DOI 10.1080/1042819021000040387; Joslin JM, 2007, BLOOD, V110, P719, DOI 10.1182/blood-2007-01-068809; Kamasani U, 2007, CANCER BIOL THER, V6, P1422; KIM JH, 1994, J BIOL CHEM, V269, P13740; Kotsianidis I, 2008, ACTA HAEMATOL-BASEL, V120, P51, DOI 10.1159/000158577; Kovar DR, 2006, CURR OPIN CELL BIOL, V18, P11, DOI 10.1016/J.CEB.2005.12.011; Krones-Herzig A, 2003, P NATL ACAD SCI USA, V100, P3233, DOI 10.1073/pnas.2628034100; Kurzrock R, 2002, SEMIN HEMATOL, V39, P18, DOI 10.1053/shem.2002.35981; Kurzrock R, 2002, SEMIN HEMATOL, V39, P20, DOI 10.1053/shem.2002.36925; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; Lehmann S, 2007, LEUKEMIA, V21, P1931, DOI 10.1038/sj.leu.2404852; Li F, 2005, J BIOL CHEM, V280, P6986, DOI 10.1074/jbc.M411605200; Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lien WH, 2006, SCIENCE, V311, P1609, DOI 10.1126/science.1121449; List A, 2005, NEW ENGL J MED, V352, P549, DOI 10.1056/NEJMoa041668; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu TX, 2007, NAT MED, V13, P78, DOI 10.1038/nm1512; Malcovati Luca, 2008, Cancer Control, V15 Suppl, P4; Merdek KD, 2008, BIOCHEM BIOPH RES CO, V366, P717, DOI 10.1016/j.bbrc.2007.12.012; Min IM, 2008, CELL STEM CELL, V2, P380, DOI 10.1016/j.stem.2008.01.015; Mora-Garcia P, 2000, J BIOL CHEM, V275, P22418, DOI 10.1074/jbc.M001731200; Moseley JB, 2007, J BIOL CHEM, V282, P12661, DOI 10.1074/jbc.M610615200; Neuwirtova R, 1996, LEUKEMIA RES, V20, P717, DOI 10.1016/0145-2126(96)00028-8; Nimer SD, 2008, BLOOD, V111, P4841, DOI 10.1182/blood-2007-08-078139; Nimer Stephen D, 2008, Hematology Am Soc Hematol Educ Program, P43, DOI 10.1182/asheducation-2008.1.43; Nolte F, 2008, ANN HEMATOL, V87, P777, DOI 10.1007/s00277-008-0502-z; Olney HJ, 2007, LEUKEMIA RES, V31, P427, DOI 10.1016/j.leukres.2006.10.023; Otomo T, 2005, NATURE, V433, P488, DOI 10.1038/nature03251; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Pellagatti A, 2004, BRIT J HAEMATOL, V125, P576, DOI 10.1111/j.1365-2141.2004.04958.x; Pellagatti A, 2008, BRIT J HAEMATOL, V142, P57, DOI 10.1111/j.1365-2141.2008.07178.x; Pellagatti A, 2006, BLOOD, V108, P337, DOI 10.1182/blood-2005-12-4769; Peng J, 2003, CURR BIOL, V13, P534, DOI 10.1016/S0960-9822(03)00170-2; Peng J, 2007, CANCER RES, V67, P7565, DOI 10.1158/0008-5472.CAN-07-1467; Posern G, 2004, EMBO J, V23, P3973, DOI 10.1038/sj.emboj.7600404; Posern G, 2006, TRENDS CELL BIOL, V16, P588, DOI 10.1016/j.tcb.2006.09.008; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Prendergast GC, 2001, HISTOL HISTOPATHOL, V16, P269, DOI 10.14670/HH-16.269; Qian ZJ, 2008, J EXP MED, V205, P2163, DOI 10.1084/jem.20080578; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Santana-Davila R, 2008, LEUKEMIA RES, V32, P1927, DOI 10.1016/j.leukres.2008.04.022; Shannon KM, 2008, NATURE, V451, P252, DOI 10.1038/451252a; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Sportoletti P, 2008, BLOOD, V111, P3859, DOI 10.1182/blood-2007-06-098251; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamguney T, 2007, J CELL SCI, V120, P4071, DOI 10.1242/jcs.015230; Tefferi A, 2007, CELL CYCLE, V6, P550, DOI 10.4161/cc.6.5.3919; Tibes R, 2008, BRIT J HAEMATOL, V140, P344, DOI 10.1111/j.1365-2141.2007.06920.x; Tominaga T, 2002, J BIOL CHEM, V277, P47686, DOI 10.1074/jbc.M207539200; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; Valencia A, 2008, BLOOD, V112, P918, DOI 10.1182/blood-2008-05-159707; VANDENBERGHE H, 1985, CANCER GENET CYTOGEN, V17, P189, DOI 10.1016/0165-4608(85)90016-0; VARDIMAN JW, 2009, BLOOD; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; Virolle T, 2003, J BIOL CHEM, V278, P11802, DOI 10.1074/jbc.M210279200; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wallar BJ, 2006, J BIOL CHEM, V281, P4300, DOI 10.1074/jbc.M510277200; Wallar BJ, 2003, TRENDS CELL BIOL, V13, P435, DOI 10.1016/S0962-8924(03)00153-3; Wallar BJ, 2007, EXP CELL RES, V313, P560, DOI 10.1016/j.yexcr.2006.10.033; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Xu YW, 2004, CELL, V116, P711, DOI 10.1016/S0092-8674(04)00210-7; Yang C, 2007, PLOS BIOL, V5, P2624, DOI 10.1371/journal.pbio.0050317; Yu J, 2007, CELL DEATH DIFFER, V14, P436, DOI 10.1038/sj.cdd.4402029	110	63	100	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	39					3429	3441		10.1038/onc.2009.207	http://dx.doi.org/10.1038/onc.2009.207			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	502RR	19597464				2022-12-17	WOS:000270478300001
J	Simioni, MB; De Thonel, A; Hammann, A; Joly, AL; Bossis, G; Fourmaux, E; Bouchot, A; Landry, J; Piechaczyk, M; Garrido, C				Simioni, M. Brunet; De Thonel, A.; Hammann, A.; Joly, A. L.; Bossis, G.; Fourmaux, E.; Bouchot, A.; Landry, J.; Piechaczyk, M.; Garrido, C.			Heat shock protein 27 is involved in SUMO-2/3 modification of heat shock factor 1 and thereby modulates the transcription factor activity	ONCOGENE			English	Article						HSP27; SUMOylation; HSF1; transcriptional activity; stress; cancer	NECROSIS-FACTOR-ALPHA; HSP27 OLIGOMERIZATION; MODIFIER SUMO; CELL-DEATH; IN-VIVO; PHOSPHORYLATION; STRESS; SUMOYLATION; HEAT-SHOCK-PROTEIN-27; TUMORIGENICITY	Heat shock protein 27 (HSP27) accumulates in stressed cells and helps them to survive adverse conditions. We have already shown that HSP27 has a function in the ubiquitination process that is modulated by its oligomerization/phosphorylation status. Here, we show that HSP27 is also involved in protein sumoylation, a ubiquitinatio-nrelated process. HSP27 increases the number of cell proteins modified by small ubiquitin-like modi. er (SUMO)-2/3 but this effect shows some selectivity as it neither affects all proteins nor concerns SUMO-1. Moreover, no such alteration in SUMO-2/3 conjugation is achievable by another HSP, such as HSP70. Heat shock factor 1 (HSF1), a transcription factor responsible for HSP expression, is one of the targets of HSP27. In stressed cells, HSP27 enters the nucleus and, in the form of large oligomers, binds to HSF1 and induces its modification by SUMO-2/3 on lysine 298. HSP27-induced HSF1 modification by SUMO-2/3 takes place downstream of the transcription factor phosphorylation on S303 and S307 and does not affect its DNA-binding ability. In contrast, this modi. cation blocks HSF1 transactivation capacity. These data show that HSP27 exerts a feedback inhibition of HSF1 transactivation and enlighten the strictly regulated interplay between HSPs and HSF1. As we also show that HSP27 binds to the SUMO-E2-conjugating enzyme, Ubc9, our study raises the possibility that HSP27 may act as a SUMO-E3 ligase specific for SUMO-2/3. Oncogene (2009) 28, 3332-3344; doi:10.1038/onc.2009.188; published online 13 July 2009	[Garrido, C.] Fac Med, INSERM, U866, F-21000 Dijon, France; [Simioni, M. Brunet; De Thonel, A.; Hammann, A.; Joly, A. L.; Garrido, C.] Univ Burgundy, Fac Med & Pharm, Dijon, France; [Bossis, G.; Piechaczyk, M.] CNRS, Inst Genet Mol, UMR 5535, Montpellier 5, France; [Bossis, G.; Piechaczyk, M.] Univ Montpellier 2, F-34095 Montpellier 5, France; [Bossis, G.; Piechaczyk, M.] Univ Montpellier 1, Montpellier 2, France; [Landry, J.] Univ Laval, Ctr Rech Cancerol, Quebec City, PQ, Canada; [Landry, J.] Univ Laval, Dept Med, Quebec City, PQ G1K 7P4, Canada; [Garrido, C.] CHU Dijon, Dijon, France	Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Bourgogne; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier; Universite de Montpellier; Laval University; Laval University; CHU Dijon Bourgogne	Garrido, C (corresponding author), Fac Med, INSERM, U866, 7 Blvd Jeanne Arc, F-21000 Dijon, France.	cgarrido@u-bourgogne.fr	Garrido, Carolina/GWM-5557-2022; PIECHACZYK, Marc/E-7896-2013; Bossis, Guillaume/C-7172-2012; Garrido, carmen/G-1633-2018	PIECHACZYK, Marc/0000-0003-1367-2597; Garrido, carmen/0000-0003-1368-1493; bossis, guillaume/0000-0002-3349-8250; de Thonel, Aurelie/0000-0003-0405-0745	'Ligue Nationale Contre le Cancer'; 'Nievre'; 'Saone et Loire'; 'L' Association pour la Recherche contre le Cancer'; INCa	'Ligue Nationale Contre le Cancer'(Ligue nationale contre le cancer); 'Nievre'; 'Saone et Loire'; 'L' Association pour la Recherche contre le Cancer'; INCa(Institut National du Cancer (INCA) France)	We thank L Sistonen and J Anckar (Turku Centre for Biotechnology, Finland) for HSF1 and SUMO-2/3 tools, their helpful advices and discussions. We thank M Gaestel and A Vertii for sharing with us HSP27 phosphorylation mutants' constructions. This work was supported by grants from the 'Ligue Nationale Contre le Cancer' and its committees in the 'Nievre' and 'Saone et Loire'. MB and ALJ are recipients of a doctoral fellowship from the 'Ligue Nationale contre le Cancer', ADT has a postdoctoral fellowship from 'L' Association pour la Recherche contre le Cancer', and EF has an INCa financing. CG and MP lead teams 'Labellisees' from the 'Ligue Nationale contre le Cancer'.	Anckar J, 2007, BIOCHEM SOC T, V35, P1409, DOI 10.1042/BST0351409; Anckar J, 2006, MOL CELL BIOL, V26, P955, DOI 10.1128/MCB.26.3.955-964.2006; Anckar J, 2007, ADV EXP MED BIOL, V594, P78; Ayaydin F, 2004, MOL BIOL CELL, V15, P5208, DOI 10.1091/mbc.E04-07-0589; Blomster HA, 2009, MOL CELL PROTEOMICS, V8, P1382, DOI 10.1074/mcp.M800551-MCP200; Bossis G, 2005, MOL CELL BIOL, V25, P6964, DOI 10.1128/MCB.25.16.6964-6979.2005; Bossis G, 2006, MOL CELL, V21, P349, DOI 10.1016/j.molcel.2005.12.019; Bruey JM, 2000, ONCOGENE, V19, P4855, DOI 10.1038/sj.onc.1203850; CAIGNARD A, 1990, INT J CANCER, V46, P633, DOI 10.1002/ijc.2910460414; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Didelot C, 2006, HANDB EXP PHARM, V172, P171; Didelot C, 2007, CURR MED CHEM, V14, P2839, DOI 10.2174/092986707782360079; During RL, 2007, EMBO J, V26, P2240, DOI 10.1038/sj.emboj.7601687; Garrido C, 1998, CANCER RES, V58, P5495; Garrido C, 2006, CELL CYCLE, V5, P2592, DOI 10.4161/cc.5.22.3448; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Gill G, 2003, CURR OPIN GENET DEV, V13, P108, DOI 10.1016/S0959-437X(03)00021-2; Guo DH, 2005, BIOCHEM BIOPH RES CO, V337, P1308, DOI 10.1016/j.bbrc.2005.09.191; Gurbuxani S, 2001, ONCOGENE, V20, P7478, DOI 10.1038/sj.onc.1204948; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hietakangas V, 2003, MOL CELL BIOL, V23, P2953, DOI 10.1128/MCB.23.8.2953-2968.2003; Hietakangas V, 2006, P NATL ACAD SCI USA, V103, P45, DOI 10.1073/pnas.0503698102; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Holmberg CI, 2001, EMBO J, V20, P3800, DOI 10.1093/emboj/20.14.3800; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; JAATTELA M, 1995, INT J CANCER, V60, P689, DOI 10.1002/ijc.2910600520; Joanisse DR, 1998, BIOCHEM BIOPH RES CO, V244, P102, DOI 10.1006/bbrc.1998.8214; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; Lee YJ, 2008, CANCER RES, V68, P7550, DOI 10.1158/0008-5472.CAN-08-0129; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; Parcellier A, 2006, FASEB J, V20, P1179, DOI 10.1096/fj.05-4184fje; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Schmitt E, 2007, J LEUKOCYTE BIOL, V81, P15, DOI 10.1189/jlb.0306167; Shi YH, 1998, GENE DEV, V12, P654, DOI 10.1101/gad.12.5.654; Voellmy R, 2007, ADV EXP MED BIOL, V594, P89; Westerheide SD, 2006, J BIOL CHEM, V281, P9616, DOI 10.1074/jbc.M512044200; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Zhu JM, 2008, J BIOL CHEM, V283, P29405, DOI 10.1074/jbc.M803632200	43	63	64	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2009	28	37					3332	3344		10.1038/onc.2009.188	http://dx.doi.org/10.1038/onc.2009.188			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495LS	19597476				2022-12-17	WOS:000269893700007
J	Olsson, M; Vakifahmetoglu, H; Abruzzo, PM; Hogstrand, K; Grandien, A; Zhivotovsky, B				Olsson, M.; Vakifahmetoglu, H.; Abruzzo, P. M.; Hogstrand, K.; Grandien, A.; Zhivotovsky, B.			DISC-mediated activation of caspase-2 in DNA damage-induced apoptosis	ONCOGENE			English	Article						apoptosis; caspase-2; caspase-8; DISC; DNA damage	CYTOCHROME-C RELEASE; CELL-DEATH; P53-INDUCED PROTEIN; GENOTOXIC STRESS; HCT116 CELLS; PIDD; P53; MITOCHONDRIAL; CLEAVAGE; PATHWAY	The tumor suppressor p53 protein supports growth arrest and is able to induce apoptosis, a signaling cascade regulated by sequential activation of caspases. Mechanisms that lead from p53 to activation of individual initiator caspases are still unclear. The present model for caspase-2 activation includes PIDDosome complex formation. However, in certain experimental models, elimination of complex constituents PIDD or RAIDD did not significantly influence caspase-2 activation, suggesting the existence of an alternative activation platform for caspase-2. Here we have investigated the link between p53 and caspase-2 in further detail and report that the latter is able to utilize the CD95 DISC as an activation platform. The recruitment of caspase-8 to this complex is required for activation of caspase-2. In the experimental system used, the DISC is formed through a distinct, p53-dependent upregulation of CD95. Moreover, we show that caspase-2 and -8 cleave Bid, and that both act simultaneously upstream of mitochondrial cytochrome c release. Finally, a direct interaction between the two caspases and the ability of caspase-8 to cleave caspase-2 are demonstrated. Thus, the observed functional link between caspase-8 and -2 within the DISC represents an alternative mechanism to the PIDDosome for caspase-2 activation in response to DNA damage. Oncogene (2009) 28, 1949-1959; doi:10.1038/onc.2009.36; published online 6 April 2009	[Olsson, M.; Vakifahmetoglu, H.; Abruzzo, P. M.; Zhivotovsky, B.] Karolinska Inst, Inst Environm Med, Div Toxicol, SE-17177 Stockholm, Sweden; [Hogstrand, K.; Grandien, A.] Karolinska Univ Hosp Huddinge, Karolinska Inst, Ctr Infect Med, Dept Med, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Zhivotovsky, B (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol, SE-17177 Stockholm, Sweden.	Boris.Zhivotovsky@ki.se	Abruzzo, Provvidenza Maria/G-7009-2015; Zhivotovsky, Boris/A-4346-2014; Olsson, Magnus/E-3140-2012	Abruzzo, Provvidenza Maria/0000-0001-5242-9448; Zhivotovsky, Boris/0000-0002-2238-3482; Olsson, Magnus/0000-0002-6370-8423	Swedish Science Foundation; Swedish and Stockholm Cancer Societies; Swedish Childhood Cancer Foundation; Swedish Society of Medical Research; EC-FP-6; EC-FP-7	Swedish Science Foundation; Swedish and Stockholm Cancer Societies; Swedish Childhood Cancer Foundation(European Commission); Swedish Society of Medical Research; EC-FP-6(European CommissionEuropean Commission Joint Research Centre); EC-FP-7(European Commission)	We thank Professor PH Krammer and Dr IN Lavrik (German Cancer Research Center, Heidelberg, Germany) for Abs and Dr GP Nolan (Stanford University, Stanford, CA, USA) for the Phoenix-Ampho packaging cell line. We also thank Professor Sten Orrenius for critical review of the paper and permanent support. This study was supported by grants from the Swedish Science Foundation, the Swedish and Stockholm Cancer Societies, the Swedish Childhood Cancer Foundation and the EC-FP-6 (Oncodeath and Chemores) and EC-FP-7 (APO-SYS). MO is a fellow of the Swedish Society of Medical Research.	Baliga BC, 2004, CELL DEATH DIFFER, V11, P1234, DOI 10.1038/sj.cdd.4401492; Baptiste-Okoh N, 2008, P NATL ACAD SCI USA, V105, P1937, DOI 10.1073/pnas.0711800105; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Berube C, 2005, P NATL ACAD SCI USA, V102, P14314, DOI 10.1073/pnas.0506475102; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Borralho PM, 2007, BBA-MOL BASIS DIS, V1772, P40, DOI 10.1016/j.bbadis.2006.09.005; Cuenin S, 2008, ONCOGENE, V27, P387, DOI 10.1038/sj.onc.1210635; Dirsch VM, 2003, CANCER RES, V63, P8869; Djerbi M, 2001, SCAND J IMMUNOL, V54, P180, DOI 10.1046/j.1365-3083.2001.00941.x; Droin N, 2001, BLOOD, V97, P1835, DOI 10.1182/blood.V97.6.1835; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Festjens N, 2007, CELL DEATH DIFFER, V14, P400, DOI 10.1038/sj.cdd.4402085; Galligan L, 2005, MOL CANCER THER, V4, P2026, DOI 10.1158/1535-7163.MCT-05-0262; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Guerrero AD, 2008, APOPTOSIS, V13, P177, DOI 10.1007/s10495-007-0139-8; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Lamkanfi M, 2005, J BIOL CHEM, V280, P6923, DOI 10.1074/jbc.M411180200; Lavrik IN, 2005, J CLIN INVEST, V115, P2665, DOI 10.1172/JCI26252; Lavrik IN, 2006, BLOOD, V108, P559, DOI 10.1182/blood-2005-07-007096; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Park HH, 2007, ANNU REV IMMUNOL, V25, P561, DOI 10.1146/annurev.immunol.25.022106.141656; Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Pop C, 2006, MOL CELL, V22, P269, DOI 10.1016/j.molcel.2006.03.009; Pop C, 2007, BIOCHEMISTRY-US, V46, P4398, DOI 10.1021/bi602623b; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Samraj AK, 2007, MOL BIOL CELL, V18, P84, DOI 10.1091/mbc.E06-04-0263; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tinel A, 2007, EMBO J, V26, P197, DOI 10.1038/sj.emboj.7601473; Troy CM, 2003, CELL DEATH DIFFER, V10, P101, DOI 10.1038/sj.cdd.4401175; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Vakifahmetoglu H, 2006, ONCOGENE, V25, P5683, DOI 10.1038/sj.onc.1209569; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Wagner KW, 2004, J BIOL CHEM, V279, P35047, DOI 10.1074/jbc.M400708200; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Yamaguchi H, 2003, CANCER RES, V63, P1483; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Zhivotovsky B, 2005, BIOCHEM BIOPH RES CO, V331, P859, DOI 10.1016/j.bbrc.2005.03.191	43	63	66	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 7	2009	28	18					1949	1959		10.1038/onc.2009.36	http://dx.doi.org/10.1038/onc.2009.36			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	442DT	19347032				2022-12-17	WOS:000265820900002
J	Yue, S; Chen, Y; Cheng, SY				Yue, S.; Chen, Y.; Cheng, S. Y.			Hedgehog signaling promotes the degradation of tumor suppressor Sufu through the ubiquitin-proteasome pathway	ONCOGENE			English	Article						hedgehog; Sufu; ubiquitin; lung cancer	CUBITUS INTERRUPTUS; NUCLEAR IMPORT; GLI; DROSOPHILA; COMPLEX; MEDULLOBLASTOMA; TRANSCRIPTION; TRANSDUCTION; DIVERGENCE; PARADIGMS	Sustained Sonic hedgehog (Shh) pathway activity is associated with tumorigenesis in a wide variety of tissues. Mutational inactivation of Shh receptor Patched (Ptch) and a downstream gene Suppressor of fused (Sufu), both of which are negative regulators of the pathway, increases susceptibility to cerebellum cancer in humans and mice. Sufu is a binding partner of Shh pathway transcription factor Gli. Recent data indicate that inactivation of Sufu, through either gene targeting in mice or RNAi-mediated silencing in cultured. broblasts, is sufficient to turn on Shh target gene expression. Here, we report that Sufu is degraded rapidly in certain cancer cells and we show that Shh signaling promotes ubiquitination of Sufu, which leads to its destruction in the proteasomes. We identified an ubiquitin attachment site on K257 of Sufu, and showed that Sufu-K257R mutant is more potent as a transcription repressor and cell growth inhibitor because of increased stability. These results indicate that Shh signaling regulates Sufu activity by inducing its turnover via the ubiquitin-proteasome system.	[Cheng, S. Y.] Nanjing Med Univ, Dept Dev Genet, Lab Reprod Med, Nanjing, Jiangsu, Peoples R China; [Yue, S.; Cheng, S. Y.] Nanjing Med Univ, Ctr Canc, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Nanjing Medical University	Cheng, SY (corresponding author), Nanjing Med Univ, Dept Dev Genet, Lab Reprod Med, 140 Hanzhong Rd,Xianzhi Lou 1908, Nanjing, Jiangsu, Peoples R China.	sycheng@njmu.edu.cn			Chinese National Science Foundation [30771079]; 973 State Key Research Project [2009CB918403]	Chinese National Science Foundation(National Natural Science Foundation of China (NSFC)); 973 State Key Research Project(National Basic Research Program of China)	We thank Drs YE Zhang, A Ruiz i Altaba, R Toftgard, DJ Robbins and CM Fan for valuable reagents and suggestions. This work is supported by a Chinese National Science Foundation Grant (30771079 to SYC) and a 973 State Key Research Project Grant (2009CB918403 to SYC).	Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Cheng SY, 2002, P NATL ACAD SCI USA, V99, P5442, DOI 10.1073/pnas.082096999; Cooper AF, 2005, DEVELOPMENT, V132, P4407, DOI 10.1242/dev.02021; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Ho KS, 2005, DEVELOPMENT, V132, P1401, DOI 10.1242/dev.01689; Huangfu D, 2006, DEVELOPMENT, V133, P3, DOI 10.1242/dev.02169; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; JACOB L, 2007, SCI STKE, pCM6, DOI DOI 10.1126/STKE.4072007CM6; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Kovacs JJ, 2008, SCIENCE, V320, P1777, DOI 10.1126/science.1157983; Lee Y, 2007, ONCOGENE, V26, P6442, DOI 10.1038/sj.onc.1210467; Lum L, 2003, MOL CELL, V12, P1261, DOI 10.1016/S1097-2765(03)00426-X; Merchant M, 2004, MOL CELL BIOL, V24, P8627, DOI 10.1128/MCB.24.19.8627-8641.2004; Monnier V, 1998, CURR BIOL, V8, P583, DOI 10.1016/S0960-9822(98)70227-1; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; Paces-Fessy M, 2004, BIOCHEM J, V378, P353, DOI 10.1042/BJ20030786; PREAT T, 1993, GENETICS, V135, P1047; Ruiz i Altaba A, 2007, TRENDS CELL BIOL, V17, P438, DOI 10.1016/j.tcb.2007.06.007; Sisson BE, 2006, DEV BIOL, V294, P258, DOI 10.1016/j.ydbio.2006.02.050; Stegman MA, 2000, J BIOL CHEM, V275, P21809, DOI 10.1074/jbc.C000043200; Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Varjosalo M, 2006, DEV CELL, V10, P177, DOI 10.1016/j.devcel.2005.12.014; Wang Y, 2007, CURR OPIN CELL BIOL, V19, P159, DOI 10.1016/j.ceb.2007.02.005; Yuan Z, 2007, ONCOGENE, V26, P1046, DOI 10.1038/sj.onc.1209860	28	63	72	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2009	28	4					492	499		10.1038/onc.2008.403	http://dx.doi.org/10.1038/onc.2008.403			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	400KM	18997815				2022-12-17	WOS:000262866500003
J	Fukuyama, R; Niculaita, R; Ng, KP; Obusez, E; Sanchez, J; Kalady, M; Aung, PP; Casey, G; Sizemore, N				Fukuyama, R.; Niculaita, R.; Ng, K. P.; Obusez, E.; Sanchez, J.; Kalady, M.; Aung, P. P.; Casey, G.; Sizemore, N.			Mutated in colorectal cancer, a putative tumor suppressor for serrated colorectal cancer, selectively represses beta-catenin-dependent transcription	ONCOGENE			English	Article						colorectal cancer; MCC; Wnt; beta-catenin; serrated	NF-KAPPA-B; NUCLEAR EXPORT; E-CADHERIN; TNF-ALPHA; GENE; MCC; IDENTIFICATION; LOCALIZATION; EXPRESSION; PROTEIN	Mutated in colorectal cancer (MCC) was originally identified as a candidate gene for familial adenomatous polyposis (FAP) but further study identified adenomatous polyposis coli (APC) as responsible for FAP and the physiologic/pathologic roles of MCC remained poorly understood. Recently, MCC promoter methylation was discovered as a frequent early event in a distinct subset of precursor lesions and colorectal cancer (CRC) associated with the serrated CRC pathway. Here we provide the first evidence of the biological significance of MCC loss in CRC and the molecular pathways involved. We show MCC expression is dramatically decreased in many CRC cell lines and the distinct subset of sporadic CRC characterized by the CpG island methylator phenotype and BRAFV600E mutation due to promoter methylation as reported previously. Importantly, we find MCC interacts with beta-catenin and that reexpression of MCC in CRC cells specifically inhibits Wnt signaling, beta-catenin/T-cell factor/lymphoid-enhancer factor-dependent transcription and cellular proliferation even in the presence of oncogenic mutant APC. We also show that MCC is localized in the nucleus and identify two functional nuclear localization signals. Taken together, MCC is a nuclear, beta-cateninin-interacting protein that can act as a potential tumor suppressor in the serrated CRC	[Fukuyama, R.; Niculaita, R.; Ng, K. P.; Aung, P. P.; Casey, G.; Sizemore, N.] Cleveland Clin, Dept Canc Biol, Cleveland, OH 44195 USA; [Niculaita, R.; Sizemore, N.] Kent State Univ, Sch Biomed Sci, Kent, OH 44242 USA; [Obusez, E.; Casey, G.; Sizemore, N.] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Cleveland, OH 44106 USA; [Sanchez, J.; Kalady, M.; Casey, G.; Sizemore, N.] Cleveland Clin, Dept Colorectal Surg, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; University System of Ohio; Kent State University; Kent State University Kent; Kent State University Salem; Case Western Reserve University; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Sizemore, N (corresponding author), Cleveland Clin, Dept Canc Biol ND50, 9500 Euclid Ave, Cleveland, OH 44195 USA.	sizemon@ccf.org		Aung, Phyu/0000-0002-3398-0573	National Cancer Institute [CA 100748]; NATIONAL CANCER INSTITUTE [R01CA100748] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Kenneth W Kinzler, Dr Kazuo Maruyama, Dr Inder Verma, Dr Bert Vogelstein and Dr Bryan Williams for the various reagents used for this work as well as Lisa Krumroy and Alona Merkulova for technical assistance. This work was supported by grants to NS from the Cleveland Clinic Taussig Cancer Center/Scott Hamilton CARES Initiative and the National Cancer Institute Grant CA 100748.	Agarwal A, 2005, ONCOGENE, V24, P1021, DOI 10.1038/sj.onc.1208296; ASHTONRICKARDT PG, 1991, ONCOGENE, V6, P1881; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Eleftheriou A, 2001, J BIOL CHEM, V276, P25883, DOI 10.1074/jbc.M102656200; Fukuyama R, 2007, MOL CARCINOGEN, V46, P402, DOI 10.1002/mc.20288; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Heyer J, 1999, ONCOGENE, V18, P5325, DOI 10.1038/sj.onc.1203036; Ishikawa S, 2001, GENE, V267, P101, DOI 10.1016/S0378-1119(01)00378-X; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x; Jass JR, 2003, J CLIN PATHOL, V56, P69, DOI 10.1136/jcp.56.1.69; Jass JR, 2005, NAT CLIN PRACT ONCOL, V2, P398, DOI 10.1038/ncponc0248; Jass JR, 2002, GASTROENTEROLOGY, V123, P862, DOI 10.1053/gast.2002.35392; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kohonen-Corish MRJ, 2007, ONCOGENE, V26, P4435, DOI 10.1038/sj.onc.1210210; Lindor Noralane M., 2006, Cancer Biomarkers, V2, P5; Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012; Matsumine A, 1996, J BIOL CHEM, V271, P10341, DOI 10.1074/jbc.271.17.10341; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; NOURRY C, 2003, SCI STKE; Ogino S, 2006, J MOL DIAGN, V8, P582, DOI 10.2353/jmoldx.2006.060082; Prall F, 2007, HUM PATHOL, V38, P1696, DOI 10.1016/j.humpath.2007.04.002; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Senda T, 1999, J HISTOCHEM CYTOCHEM, V47, P1149, DOI 10.1177/002215549904700907; Shinto E, 2005, LAB INVEST, V85, P257, DOI 10.1038/labinvest.3700199; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zlobec I, 2007, J PATHOL, V212, P260, DOI 10.1002/path.2164	36	63	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2008	27	46					6044	6055		10.1038/onc.2008.204	http://dx.doi.org/10.1038/onc.2008.204			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	358BO	18591935	Green Accepted			2022-12-17	WOS:000259891600007
J	Aghi, M; Visted, T; DePinho, RA; Chiocca, EA				Aghi, M.; Visted, T.; DePinho, R. A.; Chiocca, E. A.			Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16	ONCOGENE			English	Article						oncolytic virus; gene therapy; glioma; brain tumor; mechanism of replication; tumor-suppressor gene	RIBONUCLEOTIDE REDUCTASE; GLIOBLASTOMA-MULTIFORME; HUMAN GLIOMAS; THERAPY; CANCER; PATHWAY; DELETION; KINASE; MUTANT; PERMISSIVENESS	Oncolytic herpes simplex viruses (HSVs), in clinical trials for the treatment of malignant gliomas, are assumed to be selective for tumor cells because their replication is strongly attenuated in quiescent cells, but not in cycling cells. Oncolytic selectivity is thought to occur because mutations in viral ICP6 (encoding a viral ribonucleotide reductase function) and/or gamma 34.5 function are respectively complemented by mammalian ribonucleotide reductase and GADD34, whose genes are expressed in cycling cells. However, it is estimated that only 5-15% of malignant glioma cells are in mitosis at any one time. Therefore, effective replication of HSV oncolytic viruses might be limited to a subpopulation of tumor cells, since at any one time the majority of tumor cells would not be cycling. However, we report that an HSV with defective ICP6 function replicates in quiescent cultured murine embryonic fibroblasts obtained from mice with homozygous p16 deletions. Furthermore, intracranial inoculation of this virus into the brains of p16-/- mice provides evidence of viral replication that does not occur when the virus is injected into the brains of wild-type mice. These approaches provide in vitro and in vivo evidence that ICP6-negative HSVs are 'molecularly targeted,' because they replicate in quiescent tumor cells carrying specific oncogene deletions, independent of cell cycle status.	[Chiocca, E. A.] Ohio State Univ, Dept Neurosurg, Med Ctr, Dardinger Lab Neurooncol & Neurosci, Columbus, OH 43210 USA; [Chiocca, E. A.] Ohio State Univ, James Comprehens Canc Ctr, Med Ctr, Columbus, OH 43210 USA; [Aghi, M.; Visted, T.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA; [DePinho, R. A.] Harvard Univ, Sch Med,Belfer Inst Innovat Canc Sci, Dana Farber Canc Inst,Ctr Appl Canc sci, Dept Med Oncol & Med Genet, Boston, MA 02115 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Chiocca, EA (corresponding author), Ohio State Univ, Dept Neurosurg, Med Ctr, Dardinger Lab Neurooncol & Neurosci, Wiseman Hall,400 W 10th Ave, Columbus, OH 43210 USA.	EA.Chiocca@osumc.edu		DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [P01 CA095616, U01 CA084628, P01 CA069246, R01 CA85139, R01 CA084628, R01 CA085139, P01 CA69246] Funding Source: Medline; NINDS NIH HHS [R01 NS41571, R01 NS041571] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069246, P01CA095616, R01CA084628, R01CA085139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041571] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aghi M, 2005, ONCOGENE, V24, P7802, DOI 10.1038/sj.onc.1209037; Burns KL, 1998, J NEUROPATH EXP NEUR, V57, P122, DOI 10.1097/00005072-199802000-00003; Costello JF, 1996, CANCER RES, V56, P2405; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; Farassati F, 2001, NAT CELL BIOL, V3, P745, DOI 10.1038/35087061; Finney D.J., 1971, PROBIT ANAL; Fu XP, 2006, MOL THER, V13, P882, DOI 10.1016/j.ymthe.2006.02.007; GOLDSTEIN DJ, 1988, VIROLOGY, V166, P41, DOI 10.1016/0042-6822(88)90144-4; GrayBablin J, 1997, CANCER RES, V57, P604; HOSHINO T, 1989, J NEUROSURG, V71, P335, DOI 10.3171/jns.1989.71.3.0335; Ikeda K, 1999, NAT MED, V5, P881, DOI 10.1038/11320; Jiang H, 2005, NEOPLASIA, V7, P48, DOI 10.1593/neo.04391; Kamiryo T, 2002, J NEUROSURG, V96, P815, DOI 10.3171/jns.2002.96.5.0815; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Komata T, 2000, GENE THER, V7, P2071, DOI 10.1038/sj.gt.3301327; McCart JA, 2001, CANCER RES, V61, P8751; Nakamura M, 1998, Brain Tumor Pathol, V15, P83, DOI 10.1007/BF02478888; Nakamura T, 2005, NAT BIOTECHNOL, V23, P209, DOI 10.1038/nbt1060; Norman KL, 2004, P NATL ACAD SCI USA, V101, P11099, DOI 10.1073/pnas.0404310101; O'Shea CC, 2005, CANCER CELL, V8, P61, DOI 10.1016/j.ccr.2005.06.009; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Ono Y, 1996, J NEUROPATH EXP NEUR, V55, P1026, DOI 10.1097/00005072-199655100-00002; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Smith KD, 2006, J VIROL, V80, P1110, DOI 10.1128/JVI.80.3.1110-1120.2006; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Ueki K, 1996, CANCER RES, V56, P150; Wang CC, 2006, CANCER RES, V66, P6756, DOI 10.1158/0008-5472.CAN-06-0185; Watanabe T, 2001, ACTA NEUROPATHOL, V101, P185; Wein LM, 2003, CANCER RES, V63, P1317; Wurdinger T, 2005, GENE THER, V12, P1394, DOI 10.1038/sj.gt.3302535; Yoon SS, 1999, J GASTROINTEST SURG, V3, P34, DOI 10.1016/S1091-255X(99)80005-5	31	63	70	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2008	27	30					4249	4254		10.1038/onc.2008.53	http://dx.doi.org/10.1038/onc.2008.53			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18345032	Green Published, Bronze, Green Submitted			2022-12-17	WOS:000257496800012
J	Melchor, L; Honrado, E; Garcia, MJ; Alvarez, S; Palacios, J; Osorio, A; Nathanson, KL; Benitez, J				Melchor, L.; Honrado, E.; Garcia, M. J.; Alvarez, S.; Palacios, J.; Osorio, A.; Nathanson, K. L.; Benitez, J.			Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes	ONCOGENE			English	Article						hereditary breast cancer; BRCA1; BRCA2; BRCAX; array-CGH; breast cancer subtypes	MOLECULAR PORTRAITS; TISSUE MICROARRAY; COPY NUMBER; BRCA2 GENES; EXPRESSION; TUMORS; CARCINOMAS; MUTATIONS; PROFILES; CLASSIFICATION	Five breast cancer subtypes have been described in sporadic breast cancer (SBC) using expression arrays: basal-like, ERBB2, normal breast-like, luminal A and B. These molecular subtypes show different genomic aberration patterns (GAPs). Recently, our group described these breast cancer subtypes in 50 non-BRCA1/2 familial tumors using immunohistochemistry assays. We extended this study to the other classes of familial breast cancer (FBC), including 62 tumors (18 BRCA1, 16 BRCA2 and 28 non-BRCA1/2), with the same panel of 25 immunohistochemical (IHC) markers and histological grade obtaining a similar classification. We combined these data with results generated by a 1Mb BAC array-based CGH study to evaluate the genomic aberrations of each group. We found that BRCA1-related tumors are preferentially basal-like, whereas non-BRCA1/2 familial tumors are mainly luminal A subtype. We described distinct GAPs related to each IHC subtype. Basal tumors had a greater number of gains/losses, while luminal B tumors had more high-level DNA amplifications. Our data are similar to those obtained in SBC studies, highlighting the existence of distinct genetic pathways of tumor evolution, common to both SBC and FBC.	[Melchor, L.; Honrado, E.; Garcia, M. J.; Osorio, A.; Benitez, J.] Ctr Biomed Res Rare Dis CIBERER, Spanish Natl Canc Ctr CNIO, Human Canc Genet Program, Human Genet Grp, Madrid 28029, Spain; [Alvarez, S.] Spanish Natl Canc Ctr CNIO, Human Canc Genet Program, Mol Cytogenet Grp, Madrid, Spain; [Palacios, J.] Spanish Natl Canc Ctr CNIO, Mol Pathol Program, Breast & Gynecol Grp, Madrid, Spain; [Nathanson, K. L.] Univ Penn, Dept Med, Div Med Genet, Philadelphia, PA 19104 USA	Centro Nacional de Investigaciones Oncologicas (CNIO); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); University of Pennsylvania	Benitez, J (corresponding author), Ctr Biomed Res Rare Dis CIBERER, Spanish Natl Canc Ctr CNIO, Human Canc Genet Program, Human Genet Grp, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	jbenitez@cnio.es	Osorio, Ana/I-4324-2014; García, María J/G-1361-2016; Palacios, Jose/AAV-3765-2020; Melchor, Lorenzo/H-7221-2015	Osorio, Ana/0000-0001-8124-3984; García, María J/0000-0002-2236-9912; Melchor, Lorenzo/0000-0002-5322-2817; Nathanson, Katherine/0000-0002-6740-0901; Honrado Franco, Emiliano/0000-0001-5668-4083				Adem C, 2004, GENE CHROMOSOME CANC, V41, P1, DOI 10.1002/gcc.20057; Al-Kuraya K, 2004, CANCER RES, V64, P8534, DOI 10.1158/0008-5472.CAN-04-1945; Alvarez S, 2005, CLIN CANCER RES, V11, P1146; Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Diez O, 2003, HUM MUTAT, V22, P301, DOI 10.1002/humu.10260; ELSHEIKH S, 2007, BREAST CANC RES TREA; Greshock J, 2004, GENOME RES, V14, P179; Grushko TA, 2002, CANCER RES, V62, P1481; Herrero J, 2001, BIOINFORMATICS, V17, P126, DOI 10.1093/bioinformatics/17.2.126; Herrero J, 2003, NUCLEIC ACIDS RES, V31, P3461, DOI 10.1093/nar/gkg591; Honrado E, 2005, J CLIN ONCOL, V23, P7503, DOI 10.1200/JCO.2005.01.3698; Honrado E, 2005, MODERN PATHOL, V18, P1305, DOI 10.1038/modpathol.3800453; Honrado E, 2007, MODERN PATHOL, V20, P1298, DOI 10.1038/modpathol.3800969; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Jonsson G, 2005, CANCER RES, V65, P7612, DOI 10.1158/0008-5472.CAN-05-0570; Lacroix M, 2005, BREAST CANCER RES TR, V89, P297, DOI 10.1007/s10549-004-2172-4; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138; MELCHOR L, IN PRESS CLIN CANC R; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Oldenburg RA, 2006, CLIN CANCER RES, V12, P1693, DOI 10.1158/1078-0432.CCR-05-2230; Osorio A, 2000, BRIT J CANCER, V82, P1266, DOI 10.1054/bjoc.1999.1089; Palacios J, 2003, CLIN CANCER RES, V9, P3606; Palacios J, 2005, BREAST CANCER RES TR, V90, P5, DOI 10.1007/s10549-004-1536-0; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Reis JS, 2006, MODERN PATHOL, V19, P999, DOI 10.1038/modpathol.3800621; Rodriguez-Pinilla SM, 2007, J CLIN PATHOL, V60, P1017, DOI 10.1136/jcp.2006.043869; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Staff S, 2003, CANCER RES, V63, P4978; Tirkkonen M, 1997, CANCER RES, V57, P1222; Tischkowitz MD, 2006, CELL CYCLE, V5, P963, DOI 10.4161/cc.5.9.2713; Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014; Turner NC, 2006, ONCOGENE, V25, P5846, DOI 10.1038/sj.onc.1209876; van Beers EH, 2005, CANCER RES, V65, P822; Vaquerizas JM, 2005, NUCLEIC ACIDS RES, V33, pW616, DOI 10.1093/nar/gki500; Vaquerizas JM, 2004, BIOINFORMATICS, V20, P3656, DOI 10.1093/bioinformatics/bth401; Vincent-Salomon A, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1666; Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yehiely F, 2006, TRENDS MOL MED, V12, P537, DOI 10.1016/j.molmed.2006.09.004	44	63	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	22					3165	3175		10.1038/sj.onc.1210975	http://dx.doi.org/10.1038/sj.onc.1210975			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18071313				2022-12-17	WOS:000255897600009
J	Mahanivong, C; Chen, HM; Yee, SW; Pan, ZK; Dong, Z; Huang, S				Mahanivong, C.; Chen, H. M.; Yee, S. W.; Pan, Z. K.; Dong, Z.; Huang, S.			Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells	ONCOGENE			English	Article						ovarian cancer; LPA; uPA; NF-kappa B	GROWTH-FACTOR EXPRESSION; EPITHELIAL-CELLS; RECEPTOR; TUMOR; BCL10; LYSOPHOSPHOLIPIDS; PHOSPHORYLATION; PROGRESSION; INDUCTION; SECRETION	We reported previously that a signaling pathway consisting of G(i)-Ras-NF-kappa B mediates lysophosphatidic acid (LPA)-induced urokinase plasminogen activator (uPA) upregulation in ovarian cancer cells. However, it is not clear what signaling components link Ras to nuclear factor (NF)-kappa B for this LPA-induced event. In the present study, we found that treatment of protein kinase C (PKC) inhibitors including conventional PKC (cPKC) inhibitor Go6976 abolished LPA-induced uPA upregulation in ovarian cancer cell lines tested, indicating the importance of cPKC activity in this LPA-induced event. Indeed, LPA stimulation led to the activation of PKC alpha and Ras-PKC alpha interaction. Although constitutively active mutants of PKC alpha (a cPKC), PKC theta (a novel PKC (nPKC)) and PKC zeta (an atypical PKC (aPKC)) were all able to activate NF-kappa B and upregulate uPA expression, only dominant-negative PKCa mutant attenuated LPA-induced NF-kappa B activation and uPA upregulation. These results suggest that PKCa, rather than PKC isoforms in other PKC classes, participates in LPA-induced NF-kappa B activation and uPA upregulation in ovarian cancer cells. To determine the signaling components downstream of PKC alpha mediating LPA-induced uPA upregulation, we showed that forced expression of dominant-negative CARMA3 or silencing CARMA3, Bcl10 and MALT1 with specific siRNAs diminished these LPA-induced events. Furthermore, we demonstrated that PKC alpha/CARMA3 signaling axis is important in LPA-induced ovarian cancer cell in vitro invasion.	[Mahanivong, C.; Chen, H. M.; Yee, S. W.; Huang, S.] Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; [Pan, Z. K.] Med Univ Ohio, Dept Med Microbiol & Immunol, Toledo, OH USA; [Dong, Z.] Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Huang, S (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, 1459 Laney Walker Blvd, Augusta, GA 30912 USA.	shuang@mcg.edu		Yee, Sook Wah/0000-0001-8121-8746	NCI NIH HHS [R01 CA93926, R01 CA093926] Funding Source: Medline; NIAID NIH HHS [R01 AI043524-11, R01 AI043524] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043524] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Birgbauer E, 2006, CELL MOL LIFE SCI, V63, P2695, DOI 10.1007/s00018-006-6155-y; Corbalan-Garcia S, 2006, BBA-MOL CELL BIOL L, V1761, P633, DOI 10.1016/j.bbalip.2006.04.015; Cummings R, 2004, J BIOL CHEM, V279, P41085, DOI 10.1074/jbc.M404045200; DLUGOSZ AA, 1994, CANCER RES, V54, P6413; Do TV, 2007, MOL CANCER RES, V5, P121, DOI 10.1158/1541-7786.MCR-06-0319; Eder AM, 2000, CLIN CANCER RES, V6, P2482; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fischer K, 1998, FEBS LETT, V438, P101, DOI 10.1016/S0014-5793(98)01279-4; Fishman DA, 2001, CANCER RES, V61, P3194; Grabiner BC, 2007, GENE DEV, V21, P984, DOI 10.1101/gad.1502507; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; Kjoller L, 2001, J CELL BIOL, V152, P1145, DOI 10.1083/jcb.152.6.1145; Klemm S, 2007, P NATL ACAD SCI USA, V104, P134, DOI 10.1073/pnas.0608388103; Konecny G, 2001, CLIN CANCER RES, V7, P1743; LaVallie ER, 2006, J BIOL CHEM, V281, P24124, DOI 10.1074/jbc.M601905200; Li HB, 2005, J BIOL CHEM, V280, P10564, DOI 10.1074/jbc.M412152200; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Matsumoto R, 2005, IMMUNITY, V23, P575, DOI 10.1016/j.immuni.2005.10.007; McAllister-Lucas LM, 2001, J BIOL CHEM, V276, P30589, DOI 10.1074/jbc.M103824200; Murthi P, 2004, GYNECOL ONCOL, V92, P80, DOI 10.1016/j.ygyno.2003.09.016; Pal S, 2001, J BIOL CHEM, V276, P2395, DOI 10.1074/jbc.M007818200; Perletti GP, 1996, ONCOGENE, V12, P847; Pustilnik TB, 1999, CLIN CANCER RES, V5, P3704; SCHMALFELDT B, 1995, CANCER RES, V55, P3958; Schwartz BM, 2001, GYNECOL ONCOL, V81, P291, DOI 10.1006/gyno.2001.6124; Sommer K, 2005, IMMUNITY, V23, P561, DOI 10.1016/j.immuni.2005.09.014; Suzuki M, 2004, J BIOL CHEM, V279, P14899, DOI 10.1074/jbc.M313130200; Tanyi JL, 2003, CANCER RES, V63, P1073; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Wang DH, 2007, P NATL ACAD SCI USA, V104, P145, DOI 10.1073/pnas.0601894104; Wang P, 2007, GYNECOL ONCOL, V104, P714, DOI 10.1016/j.ygyno.2006.10.016; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719	33	63	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2008	27	9					1273	1280		10.1038/sj.onc.1210746	http://dx.doi.org/10.1038/sj.onc.1210746			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17724468	Green Accepted			2022-12-17	WOS:000253407000009
J	McConnell, JL; Gomez, RJ; McCorvey, LRA; Law, BK; Wadzinski, BE				McConnell, J. L.; Gomez, R. J.; McCorvey, L. R. A.; Law, B. K.; Wadzinski, B. E.			Identification of a PP2A-interacting protein that functions as a negative regulator of phosphatase activity in the ATM/ATR signaling pathway	ONCOGENE			English	Article						PP2A; TIP; alpha4; ATM/ATR; Tip41; Tap42	CATALYTIC SUBUNIT; TOR PROTEINS; CELL-GROWTH; 2A PP2A; BINDING; FAMILY; PURIFICATION; TAP42; ATM; PHOSPHORYLATION	Protein serine/ threonine phosphatase 2A ( PP2A) activity must be tightly controlled to maintain cell homeostasis. Here, we report the identification of a previously uncharacterized mammalian protein, type 2A- interacting protein ( TIP), as a novel regulatory protein of PP2A and the PP2A- like enzymes PP4 and PP6. TIP is a ubiquitously express ed protein and parallels the distribution of the PP2A catalytic subunit. Unlike its role in yeast, TIP does not interact with the mammalian homolog of type 2A-associated protein of 42 kDa ( Tap42), alpha 4, but instead associates with PP2A, PP4 and PP6 catalytic subunits independently of mammalian target of rapamycin kinase activity. Interestingly, the 20 kDa TIP splice variant TIP_i2, which lacks amino acids 173-272 of TIP's C- terminus, does not interact with PP2A; this finding indicates that residues 173 - 272 are important for the assembly of the TIP. phosphatase complex. In contrast to purified PP2A holoenzymes, TIP. PP2A complexes are devoid of phosphatase activity. Furthermore, alterations in the cellular levels of TIP influence the phosphorylation state of a specific protein substrate of ataxia- telangiectasia mutated ( ATM)/ ATM- and Rad3-related ( ATR) kinases. Elevated levels of TIP result in an increase in the phosphorylation state of this protein substrate, whereas TIP- depleted cells exhibit a significant decrease in this protein's phosphorylation state, which is reversed by treatment with the PP2A inhibitor okadaic acid. These results indicate TIP is a novel inhibitory regulator of PP2A and implicate a role for TIP. PP2A complexes within the ATM/ ATR signaling pathway controlling DNA replication and repair.	Vanderbilt Univ, Ctr Med, Dept Pharmacol, Nashville, TN 37232 USA; Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL USA	Vanderbilt University; State University System of Florida; University of Florida	Wadzinski, BE (corresponding author), Vanderbilt Univ, Ctr Med, Dept Pharmacol, 424 RRB, Nashville, TN 37232 USA.	brian.wadzinski@vanderbilt.edu	Law, Brian/L-6043-2019		NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070787, P60DK020593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM051366, R01GM051366] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [DK070787, DK20593] Funding Source: Medline; NIGMS NIH HHS [GM51366] Funding Source: Medline; NIMH NIH HHS [MH19732] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adams DG, 2005, J BIOL CHEM, V280, P42644, DOI 10.1074/jbc.M502464200; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Dozier C, 2004, BIOL CELL, V96, P509, DOI 10.1016/j.biolcel.2004.04.010; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gingras AC, 2005, MOL CELL PROTEOMICS, V4, P1725, DOI 10.1074/mcp.M500231-MCP200; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Inui S, 1998, BLOOD, V92, P539, DOI 10.1182/blood.V92.2.539.414k23_539_546; Jacinto E, 2001, MOL CELL, V8, P1017, DOI 10.1016/S1097-2765(01)00386-0; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Kloeker S, 2003, PROTEIN EXPRES PURIF, V31, P19, DOI 10.1016/S1046-5928(03)00141-4; Kloeker S, 1999, J BIOL CHEM, V274, P5339, DOI 10.1074/jbc.274.9.5339; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Luke MM, 1996, MOL CELL BIOL, V16, P2744; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nanahoshi M, 1998, BIOCHEM BIOPH RES CO, V251, P520, DOI 10.1006/bbrc.1998.9493; Petersen P, 2006, MOL CELL BIOL, V26, P1997, DOI 10.1128/MCB.26.5.1997-2011.2006; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; Sontag E, 1996, NEURON, V17, P1201, DOI 10.1016/S0896-6273(00)80250-0; Strasser G, 1998, PHYSICA E, V2, P515, DOI 10.1016/S1386-9477(98)00106-4; Trockenbacher A, 2001, NAT GENET, V29, P287, DOI 10.1038/ng762; Van Hoof C, 2005, BIOCHEM J, V386, P93, DOI 10.1042/BJ20040887; Wada T, 2001, J AM SOC NEPHROL, V12, P2601, DOI 10.1681/ASN.V12122601; Walsh AH, 1997, FEBS LETT, V416, P230, DOI 10.1016/S0014-5793(97)01210-6	33	63	65	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2007	26	41					6021	6030		10.1038/sj.onc.1210406	http://dx.doi.org/10.1038/sj.onc.1210406			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	207US	17384681				2022-12-17	WOS:000249277200005
J	Grifoni, D; Garoia, F; Bellosta, P; Parisi, F; De Biase, D; Collina, G; Strand, D; Cavicchi, S; Pession, A				Grifoni, D.; Garoia, F.; Bellosta, P.; Parisi, F.; De Biase, D.; Collina, G.; Strand, D.; Cavicchi, S.; Pession, A.			aPKC zeta cortical loading is associated with Lgl cytoplasmic release and tumor growth in Drosophila and human epithelia	ONCOGENE			English	Article						lethal giant larvae; Hugl-1; aPKC zeta; cell polarity; ovarian epithelial cancers; Drosophila	OVARIAN SURFACE EPITHELIUM; PROTEIN-KINASE-C; CELL POLARITY; SUPPRESSOR GENE; GIANT LARVAE; CANCER; EXPRESSION; COMPLEX; PROLIFERATION; HUGL-1	Atypical protein kinase C ( aPKC) and Lethal giant larvae ( Lgl) regulate apical-basal polarity in Drosophila and mammalian epithelia. At the apical domain, aPKC phosphorylates and displaces Lgl that, in turn, maintains aPKC inactive at the basolateral region. The mutual exclusion of these two proteins seems to be crucial for the correct epithelial structure and function. Here we show that a cortical aPKC loading induces Lgl cytoplasmic release and massive overgrowth in Drosophila imaginal epithelia, whereas a cytoplasmic expression does not alter proliferation and epithelial overall structure. As two aPKC isoforms ( iota and zeta) exist in humans and we previously showed that Drosophila Lgl is the functional homologue of the Human giant larvae-1 ( Hugl-1) protein, we argued if the same mechanism of mutual exclusion could be impaired in human epithelial disorders and investigated aPKC iota, aPKC zeta and Hugl-1 localization in cancers deriving from ovarian surface epithelium. Both in mucinous and serous histotypes, aPKC zeta showed an apical-to-cortical redistribution and Hugl-1 showed a membrane-to-cytoplasm release, perfectly recapitulating the Drosophila model. Although several recent works support a causative role for aPKCi overexpression in human carcinomas, our results suggest a key role for aPKC zeta in apical-basal polarity loosening, a mechanism that seems to be driven by changes in protein localization rather than in protein abundance.	Alma Mater Studiorum, Dipartimento Biol Evoluzionist Sperimentale, I-40126 Bologna, Italy; Alma Mater Studiorum, Dipartimento Patol Sperimentale, I-40126 Bologna, Italy; CUNY City Coll, Dept Biol, New York, NY 10031 USA; Univ Bologna, Osped Bellaria, Sez Anat Patol, Alma Mater Studiorum, I-40139 Bologna, Italy; Johannes Gutenberg Univ Mainz, Dept Internal Med 1, D-6500 Mainz, Germany	City University of New York (CUNY) System; City College of New York (CUNY); University of Bologna; Johannes Gutenberg University of Mainz	Grifoni, D (corresponding author), Alma Mater Studiorum, Dipartimento Biol Evoluzionist Sperimentale, Via Selmi 3, I-40126 Bologna, Italy.	daniela.grifoni@unibo.it	Garoia, Flavio/AAL-4528-2020; de Biase, Dario/B-9274-2012; Messier, Claude/A-2322-2008; Garoia, Flavio/AAW-1313-2020; Grifoni, Daniela/A-3954-2012; Bellosta, Paola/AAA-3413-2020; Pession, Annalisa/B-9014-2012	de Biase, Dario/0000-0002-0609-8817; Messier, Claude/0000-0002-4791-1763; Bellosta, Paola/0000-0003-1913-5661; GRIFONI, DANIELA/0000-0001-7429-4062; Garoia, Flavio/0000-0001-7849-0036; Pession, Annalisa/0000-0001-9035-9698				Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Bell DA, 2005, MODERN PATHOL, V18, pS19, DOI 10.1038/modpathol.3800306; Betschinger J, 2005, CURR BIOL, V15, P276, DOI 10.1016/j.cub.2005.01.012; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRYANT PJ, 1990, J CELL SCI, P169; Chalmers AD, 2005, DEVELOPMENT, V132, P977, DOI 10.1242/dev.01645; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Filip S, 2006, NEOPLASMA, V53, P87; Gibson MC, 2006, NATURE, V442, P1038, DOI 10.1038/nature05014; Grifoni D, 2004, ONCOGENE, V23, P8688, DOI 10.1038/sj.onc.1208023; Harris TJC, 2004, J CELL BIOL, V167, P135, DOI 10.1083/jcb.200406024; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Hutterer A, 2004, DEV CELL, V6, P845, DOI 10.1016/j.devcel.2004.05.003; Katabuchi Hidetaka, 2003, Medical Electron Microscopy, V36, P74; Kovac J, 2007, GENE EXPR PATTERNS, V7, P187, DOI 10.1016/j.modgep.2006.07.002; Kuphal S, 2006, ONCOGENE, V25, P103, DOI 10.1038/sj.onc.1209008; Lee CY, 2006, NATURE, V439, P594, DOI 10.1038/nature04299; Manfruelli P, 1996, DEVELOPMENT, V122, P2283; Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Okamura H, 2006, MICROSC RES TECHNIQ, V69, P469, DOI 10.1002/jemt.20306; Ong A, 2000, INT J CANCER, V85, P430, DOI 10.1002/(SICI)1097-0215(20000201)85:3<430::AID-IJC21>3.0.CO;2-Q; Pilot F, 2005, DEV DYNAM, V232, P685, DOI 10.1002/dvdy.20334; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Polyak K, 2006, NAT MED, V12, P296, DOI 10.1038/nm1379; Queenan AM, 1997, DEVELOPMENT, V124, P3871; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Rolls MM, 2003, J CELL BIOL, V163, P1089, DOI 10.1083/jcb.200306079; Sarrio D, 2006, HUM PATHOL, V37, P1042, DOI 10.1016/j.humpath.2006.03.003; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; Scott M, 2006, HISTOL HISTOPATHOL, V21, P81, DOI 10.14670/HH-21.81; Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219; SIEMENS CH, 1988, J CELL PHYSIOL, V134, P347, DOI 10.1002/jcp.1041340305; Sundfeldt K, 2003, MOL CELL ENDOCRINOL, V202, P89, DOI 10.1016/S0303-7207(03)00068-6; Suzuki A, 2006, J CELL SCI, V119, P979, DOI 10.1242/jcs.02898; Suzuki A, 2001, J CELL BIOL, V152, P1183, DOI 10.1083/jcb.152.6.1183; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vanderhyden Barbara C, 2003, Reprod Biol Endocrinol, V1, P67, DOI 10.1186/1477-7827-1-67; Weinkove D, 2000, CURR OPIN GENET DEV, V10, P75, DOI 10.1016/S0959-437X(99)00042-8; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yamanaka T, 2006, J CELL SCI, V119, P2107, DOI 10.1242/jcs.02938	44	63	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5960	5965		10.1038/sj.onc.1210389	http://dx.doi.org/10.1038/sj.onc.1210389			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369850	Green Published			2022-12-17	WOS:000249123100013
J	Sumi, T; Tsuneyoshi, N; Nakatsuji, N; Suemori, H				Sumi, T.; Tsuneyoshi, N.; Nakatsuji, N.; Suemori, H.			Apoptosis and differentiation of human embryonic stem cells induced by sustained activation of c-Myc	ONCOGENE			English	Article						c-Myc; human ES cells; self-renewal; differentiation	SELF-RENEWAL; ERYTHROID-DIFFERENTIATION; P53-DEPENDENT APOPTOSIS; CASPASE-3 ACTIVITY; MOUSE EMBRYOS; CANCER CELLS; ES CELLS; IN-VIVO; PLURIPOTENCY; MAINTENANCE	Embryonic stem (ES) cells are self-renewing, pluripotent cell lines, characterized by their potential to differentiate into all cell types. The proto-oncogene product c-Myc has a crucial role in the self-renewal of mouse ES (mES) cells, but its role in human ES (hES) cells is unknown. To investigate c-Myc functions in hES cells, we expressed an inducible c-Myc fused to the hormone-binding domain of the estrogen receptor (c-MycER) protein that is activated by 4-hydroxy-tamoxifen. In contrast to its role in mES cells, activation of c-MycER in hES cells induced apoptosis and differentiation into extraembryonic endoderm and trophectoderm lineages concomitant with reduced expression of the pluripotent markers Oct4 and Nanog. Neither inhibition of caspase activity nor knockdown of p53 by RNA interference impaired the induction of differentiation markers induced by c-Myc activation. In addition, differentiation induced by c-Myc activation was associated with downregulation of alpha 6 integrin expression, suggesting an important role for the integrin/extracellular matrix interaction in the regulation of ES cell behavior. None of these effects occurred with deletion of the c-Myc transactivation domain, indicating that c-Myc promotes both apoptosis and differentiation in a transcriptional activity-dependent manner. Together, our results provide new insights into the c-Myc functions regulating hES cell fate.	Kyoto Univ, Inst Frontier Med Sci, Stem Cell Res Ctr, Lab Embryon Stem Cell Res,Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Inst Frontier Med Sci, Dept Dev & Differentiat, Kyoto, Japan	Kyoto University; Kyoto University	Suemori, H (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Stem Cell Res Ctr, Lab Embryon Stem Cell Res,Sakyo Ku, 53 Kawahara Cho,Shogoin, Kyoto 6068507, Japan.	hsuemori@frontier.kyoto-u.ac.jp						Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Babaie Y, 2007, STEM CELLS, V25, P500, DOI 10.1634/stemcells.2006-0426; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Canelles M, 1997, ONCOGENE, V14, P1315, DOI 10.1038/sj.onc.1200948; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chen S.-C., 2000, KLUW INT S ADV DATA, V21; Czyz J, 2001, DIFFERENTIATION, V68, P167, DOI 10.1046/j.1432-0436.2001.680404.x; Duval D, 2006, CELL DEATH DIFFER, V13, P564, DOI 10.1038/sj.cdd.4401789; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Fernando P, 2005, FASEB J, V19, P1671, DOI 10.1096/fj.04-2981fje; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Frye M, 2003, DEVELOPMENT, V130, P2793, DOI 10.1242/dev.00462; Fujioka T, 2004, INT J DEV BIOL, V48, P1149, DOI 10.1387/ijdb.041852tf; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gebhardt A, 2006, J CELL BIOL, V172, P139, DOI 10.1083/jcb.200506057; Hatton KS, 1996, MOL CELL BIOL, V16, P1794; Hay DC, 2004, STEM CELLS, V22, P225, DOI 10.1634/stemcells.22-2-225; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Hoffman LM, 2005, NAT BIOTECHNOL, V23, P699, DOI 10.1038/nbt1102; Humphrey RK, 2004, STEM CELLS, V22, P522, DOI 10.1634/stemcells.22-4-522; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Hyslop L, 2005, STEM CELLS, V23, P1035, DOI 10.1634/stemcells.2005-0080; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kippin TE, 2005, GENE DEV, V19, P756, DOI 10.1101/gad.1272305; Leung LK, 1999, BRIT J CANCER, V81, P387, DOI 10.1038/sj.bjc.6690706; Lin TX, 2005, NAT CELL BIOL, V7, P165, DOI 10.1038/ncb1211; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Meletis K, 2006, DEVELOPMENT, V133, P363, DOI 10.1242/dev.02208; Miner JH, 2004, ANNU REV CELL DEV BI, V20, P255, DOI 10.1146/annurev.cellbio.20.010403.094555; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; MORGENBESSER SD, 1995, EMBO J, V14, P743, DOI 10.1002/j.1460-2075.1995.tb07053.x; Nguyen L, 2006, GENE DEV, V20, P1511, DOI 10.1101/gad.377106; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Okuyama R, 2004, DEV CELL, V6, P551, DOI 10.1016/S1534-5807(04)00098-X; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Selvakumaran M, 1996, BLOOD, V88, P1248, DOI 10.1182/blood.V88.4.1248.bloodjournal8841248; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Suemori H, 2006, BIOCHEM BIOPH RES CO, V345, P926, DOI 10.1016/j.bbrc.2006.04.135; Sumi T, 2004, STEM CELLS, V22, P861, DOI 10.1634/stemcells.22-5-861; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Wilson A, 2004, GENE DEV, V18, P2747, DOI 10.1101/gad.313104; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Xu RH, 2002, NAT BIOTECHNOL, V20, P1261, DOI 10.1038/nbt761; Xu RH, 2005, NAT METHODS, V2, P185, DOI 10.1038/NMETH744; Yamane T, 2005, P NATL ACAD SCI USA, V102, P3312, DOI 10.1073/pnas.0500167102; Yao S, 2006, P NATL ACAD SCI USA, V103, P6907, DOI 10.1073/pnas.0602280103; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yuan YZ, 2004, NAT CELL BIOL, V6, P436, DOI 10.1038/ncb1126; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	67	63	75	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5564	5576		10.1038/sj.onc.1210353	http://dx.doi.org/10.1038/sj.onc.1210353			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17369859				2022-12-17	WOS:000248801900002
J	Tong, Y; Tan, Y; Zhou, C; Melmed, S				Tong, Y.; Tan, Y.; Zhou, C.; Melmed, S.			Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition	ONCOGENE			English	Article						PTTG1; pituitary; cell cycle	TRANSCRIPTIONAL ACTIVATION FUNCTION; BREAST-CANCER CELLS; CYCLE PROGRESSION; POTENTIAL ROLE; GROWTH-FACTOR; C-MYC; EXPRESSION; PTTG; MICE; IDENTIFICATION	Pituitary tumor transforming gene (PTTG1) was isolated from rat pituitary tumor cells, and subsequently identified as a securin protein as well as a transcription factor. We show here a global transcriptional effect of PTTG1 in human choriocarcinoma JEG-3 cells by simultaneously assessing 20 000 gene promoters using chromatin immunoprecipitation (ChIP)-on-Chip experiments. Seven hundred and forty-six gene promoters (P < 0.001) were found enriched, with functions relating to cell cycle, metabolic control and signal transduction. Significant interaction between PTTG1 and Sp1 (P < 0.000001) was found by transcriptional pattern analysis of ChIP data and further confirmed by immunoprecipitation and pull-down assays. PTTG1 acts coordinately with Sp1 to induce cyclin D3 expression similar to threefold, and promotes G1/S-phase transition independently of p21. PTTG1 deletion was also protective for anchorage-independent cell colony formation. The results show that PTTG1 exhibits properties of a global transcription factor, and specifically modulates the G1/S-phase transition by interacting with Sp1. This novel signaling pathway may be required for PTTG1 transforming activity.	Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Cedars Sinai Res Inst, Los Angeles, CA 90024 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Melmed, S (corresponding author), Acad Affairs, Room 2015,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	melmed@csmc.edu	Zhou, Cuiqi/B-1568-2010		NATIONAL CANCER INSTITUTE [R01CA075979, K99CA138914] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA075979, K99 CA138914, R01 CA075979-09, CA 75979] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdelrahim M, 2002, J BIOL CHEM, V277, P28815, DOI 10.1074/jbc.M203828200; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Boelaert K, 2003, FASEB J, V17, P1631, DOI 10.1096/fj.02-0948com; Chesnokova V, 2005, MOL ENDOCRINOL, V19, P2371, DOI 10.1210/me.2005-0137; Chien WW, 2000, J BIOL CHEM, V275, P19422, DOI 10.1074/jbc.M910105199; Clem AL, 2003, GENE, V322, P113, DOI 10.1016/j.gene.2003.08.012; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Grinstein E, 2002, ONCOGENE, V21, P1485, DOI 10.1038/sj.onc.1205211; Heaney AP, 1999, NAT MED, V5, P1317, DOI 10.1038/15275; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Honda S, 2003, ANTICANCER RES, V23, P3775; Khan S, 2003, ENDOCRINOLOGY, V144, P2325, DOI 10.1210/en.2002-0149; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; McCabe CJ, 2003, CLIN ENDOCRINOL, V58, P141, DOI 10.1046/j.1365-2265.2003.01598.x; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pei L, 2001, J BIOL CHEM, V276, P8484, DOI 10.1074/jbc.M009654200; Pei L, 2000, J BIOL CHEM, V275, P31191, DOI 10.1074/jbc.M002451200; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Saez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914; Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006; Solbach C, 2004, BREAST, V13, P80, DOI 10.1016/j.breast.2003.09.008; Tarabykin V, 2000, MECH DEVELOP, V92, P301, DOI 10.1016/S0925-4773(00)00243-4; Wang ZY, 1999, BLOOD, V93, P4208, DOI 10.1182/blood.V93.12.4208.412k17_4208_4221; Wang ZY, 2000, J BIOL CHEM, V275, P7459, DOI 10.1074/jbc.275.11.7459; Wang ZY, 2003, P NATL ACAD SCI USA, V100, P3428, DOI 10.1073/pnas.0638052100; Wang ZY, 2001, MOL ENDOCRINOL, V15, P1870, DOI 10.1210/me.15.11.1870; Yu R, 2000, MOL ENDOCRINOL, V14, P1137, DOI 10.1210/me.14.8.1137; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	29	63	69	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5596	5605		10.1038/sj.onc.1210339	http://dx.doi.org/10.1038/sj.onc.1210339			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17353909	Green Accepted			2022-12-17	WOS:000248801900005
J	Sharif, A; Legendre, P; Prevot, V; Allet, C; Romao, L; Studler, JM; Chneiweiss, H; Junier, MP				Sharif, A.; Legendre, P.; Prevot, V.; Allet, C.; Romao, L.; Studler, J.-M.; Chneiweiss, H.; Junier, M.-P.			Transforming growth factor a promotes sequential conversion of mature astrocytes into neural progenitors and stem cells	ONCOGENE			English	Article						erbB1; differentiation; radial glia; gliogenesis; oncogenesis; EGFR	RADIAL GLIAL-CELLS; FACTOR-ALPHA; TGF-ALPHA; MOUSE; DIFFERENTIATION; EXPRESSION; PROTEIN; RECEPTOR; NEURONS; NESTIN	An instability of the mature cell phenotype is thought to participate to the formation of gliomas, primary brain tumors deriving from astrocytes and/or neural stem cells. Transforming growth factor alpha (TGF alpha) is an erbB1 ligand overexpressed in the earliest stages of gliomas, and exerts trophic effects on gliomal cells and astrocytes. Here, we questioned whether prolonged TGF alpha exposure affects the stability of the normal mature astrocyte phenotype. We first developed astrocyte cultures devoid of residual neural stem cells or progenitors. We demonstrate that days of TGF alpha treatment result in the functional conversion of a population of mature astrocytes into radial glial cells, a population of neural progenitors. TGF alpha-generated radial glial cells support embryonic neurons migration, and give birth to cells of the neuronal lineage, expressing neuronal markers and the electrophysiological properties of neuroblasts. Lengthening TGF alpha treatment to months results in the delayed appearance of cells with neural stem cells properties: they form floating cellular spheres that are self-renewing, can be clonally derived from a single cell and differentiated into cells of the neuronal lineage. This study uncovers a novel population of mature astrocytes capable, in response to a single epigenetic factor, to regress progressively into a neural stem-like cell stage via an intermediate progenitor stage.	INSERM, U752, Coll France, F-75005 Paris, France; INSERM, U114, F-75005 Paris, France; Univ Paris 05, Paris, France; Univ Paris 06, CNRS, UMR 7102, Paris, France; INSERM, U816, F-59045 Lille, France; Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Anat, Ctr Ciencias Saude, Rio De Janeiro, Brazil	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universidade Federal do Rio de Janeiro	Junier, MP (corresponding author), INSERM, U752, Coll France, 11 Pl Marcelin Berthelot, F-75005 Paris, France.	marie-pierre.junier@college-de-france.fr	Prevot, Vincent/E-5720-2016; Romao, Luciana/I-4291-2015; Sharif, Ariane/AGW-8363-2022; herve, chneiweiss/Q-6818-2019	Prevot, Vincent/0000-0001-7185-3615; herve, chneiweiss/0000-0001-7675-5061; ALLET, Cecile/0000-0003-1294-9064; Sharif, Ariane/0000-0003-0810-400X				Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bahrey HLP, 2003, CEREB CORTEX, V13, P239, DOI 10.1093/cercor/13.3.239; BIGNAMI A, 1974, NATURE, V252, P55, DOI 10.1038/252055a0; Burrows RC, 1997, NEURON, V19, P251, DOI 10.1016/S0896-6273(00)80937-X; Chanas-Sacre G, 2000, DEV DYNAM, V219, P514, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1078>3.0.CO;2-0; Dai C, 2003, CANCER J, V9, P72, DOI 10.1097/00130404-200303000-00002; Dihne M, 2001, BRAIN RES, V902, P178, DOI 10.1016/S0006-8993(01)02378-2; Doetsch F, 2003, NAT NEUROSCI, V6, P1127, DOI 10.1038/nn1144; Feldman DH, 1996, EXP NEUROL, V140, P206, DOI 10.1006/exnr.1996.0130; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; Figiel M, 2003, EXP NEUROL, V183, P124, DOI 10.1016/S0014-4886(03)00134-1; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; Fukuda S, 2003, J NEUROSCI, V23, P9357; Fukuda S, 2004, CELL DEATH DIFFER, V11, P196, DOI 10.1038/sj.cdd.4401332; Gregg C, 2003, J NEUROSCI, V23, P11587; Hack MA, 2004, MOL CELL NEUROSCI, V25, P664, DOI 10.1016/j.mcn.2003.12.012; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harris H, 2004, NATURE, V427, P201, DOI 10.1038/427201a; Imura T, 2006, GLIA, V53, P277, DOI 10.1002/glia.20281; Imura T, 2003, J NEUROSCI, V23, P2824; Jung M, 1998, EUR J NEUROSCI, V10, P3246, DOI 10.1046/j.1460-9568.1998.00344.x; Junier MP, 2000, PROG NEUROBIOL, V62, P443, DOI 10.1016/S0301-0082(00)00017-4; KRESSIN K, 1995, GLIA, V15, P173, DOI 10.1002/glia.440150210; Kriegstein AR, 2003, GLIA, V43, P37, DOI 10.1002/glia.10250; Laywell ED, 2000, P NATL ACAD SCI USA, V97, P13883, DOI 10.1073/pnas.250471697; Leavitt BR, 1999, EXP NEUROL, V157, P43, DOI 10.1006/exnr.1999.6982; LEE DC, 1995, PHARMACOL REV, V47, P51; LILLIEN L, 1995, NATURE, V377, P158, DOI 10.1038/377158a0; LIN RCS, 1995, NEUROBIOL DIS, V2, P79, DOI 10.1006/nbdi.1995.0008; Liu B, 2004, DEV BIOL, V273, P297, DOI 10.1016/j.ydbio.2004.06.006; Marshall CAG, 2005, J NEUROSCI, V25, P7289, DOI 10.1523/JNEUROSCI.1924-05.2005; Miller S, 1996, J NEUROCHEM, V67, P1435; Muroyama Y, 2005, NATURE, V438, P360, DOI 10.1038/nature04139; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Pekny M, 1998, EXP CELL RES, V239, P332, DOI 10.1006/excr.1997.3922; Prevot V, 2005, ENDOCRINOLOGY, V146, P1465, DOI 10.1210/en.2004-1146; Raff M, 2003, ANNU REV CELL DEV BI, V19, P1, DOI 10.1146/annurev.cellbio.19.111301.143037; Rakic P, 2003, GLIA, V43, P19, DOI 10.1002/glia.10244; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Scherer SS, 1997, CURR OPIN NEUROL, V10, P386, DOI 10.1097/00019052-199710000-00006; Seaberg RM, 2005, DEV BIOL, V278, P71, DOI 10.1016/j.ydbio.2004.10.017; Sharif A, 2006, ONCOGENE, V25, P4076, DOI 10.1038/sj.onc.1209443; Sharif A, 2004, NEUROSCIENCE, V126, P263, DOI 10.1016/j.neuroscience.2004.02.039; SHARIF A, 2006, M SOC NEUR ATL US OC; Singh SK, 2004, ONCOGENE, V23, P7267, DOI 10.1038/sj.onc.1207946; Sun Y, 2005, NEURON, V45, P873, DOI 10.1016/j.neuron.2005.01.045; Sutherland ML, 1996, J NEUROSCI, V16, P2191; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Verkhratsky A, 2000, BRAIN RES REV, V32, P380, DOI 10.1016/S0165-0173(99)00093-4; Wagner B, 2006, EMBO J, V25, P752, DOI 10.1038/sj.emboj.7600988; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Zhou RX, 2001, BRAIN RES BULL, V56, P37, DOI 10.1016/S0361-9230(01)00591-3	54	63	70	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2695	2706		10.1038/sj.onc.1210071	http://dx.doi.org/10.1038/sj.onc.1210071			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17057735				2022-12-17	WOS:000246210600004
J	Berlingieri, MT; Pallante, P; Guida, M; Nappi, C; Masciullo, V; Scambia, G; Ferraro, A; Leone, V; Sboner, A; Barbareschi, M; Ferro, A; Troncone, G; Fusco, A				Berlingieri, M. T.; Pallante, P.; Guida, M.; Nappi, C.; Masciullo, V.; Scambia, G.; Ferraro, A.; Leone, V.; Sboner, A.; Barbareschi, M.; Ferro, A.; Troncone, G.; Fusco, A.			UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas	ONCOGENE			English	Article						UbcH10; ovarian; carcinomas; immunohistochemistry	CANCER; OVEREXPRESSION; BREAST	The UbcH10 gene codes for a protein that belongs to the ubiquitin-conjugating enzyme family. Previous studies of our group suggest UbcH10 expression as a valid indicator of the proliferative and aggressive status of thyroid carcinomas. Therefore, to better understand the process of ovarian carcinogenesis, and to look for possible tools to be used as prognostic markers in these neoplasias, we decided to extend the analysis of the UbcH10 expression to the ovarian neoplastic disease. We found that the UbcH10 gene was upregulated in some ovarian carcinoma cell lines analysed. Then, immunohistochemical studies demonstrate that UbcH10 expression significantly correlates with the tumor grade and the undifferentiated histotype of the ovarian carcinomas. Furthermore, a significant relationship between UbcH10 expression and overall survival was observed. Finally, the block of UbcH10 protein synthesis by RNA interference inhibited the growth of ovarian carcinoma cell lines, suggesting a role of UbcH10 overexpression in ovarian carcinogenesis. Therefore, all these data taken together suggest the possibility to use UbcH10 detection as a marker for the diagnosis and prognosis of these neoplastic diseases and open the perspective of a therapy of some ovarian carcinomas based on the suppression of the UbcH10 synthesis and/or function.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Mol, Ist Endocrinol & Oncol Sperimenatle,CNR, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med, Dipartimento Ginecol & Ostetr, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med, Dipartimento Fisiopatol Riproduz Umana, I-80131 Naples, Italy; Univ Naples Federico II, Chirurg Napoli, I-80131 Naples, Italy; Univ Cattolica S Cuore, Ist Clin Ostet & Ginecol, Rome, Italy; European Sch Mol Med, SEMM, Naples, Italy; Naples Oncogenom Ctr, CEINGE, NOGEC, Naples, Italy; Ctr Sci & Technol Res, SRA Div ITC Irst, Trento, Italy; UO Anatomia Patol Osped S Chiara Largo Medaglie O, Trento, Italy; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Anat Patol & Citopatol, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Naples Federico II; University of Naples Federico II; University of Naples Federico II; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; CEINGE Biotecnologie Avanzate; University of Naples Federico II	Fusco, A (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare, Ist Endocrinol & Oncol Sperimenatle,CNR, I-80131 Naples, Italy.	afusco@napoli.com	Ferro, Antonella/AAA-8241-2020; Pallante, Pierlorenzo/AAX-8758-2020; Ferraro, Angelo/A-4172-2014; Sboner, Andrea/C-6487-2008; Barbareschi, Mattia/AAF-2043-2020; Ferraro, Angelo/H-3193-2019	Ferro, Antonella/0000-0003-4109-6769; Ferraro, Angelo/0000-0002-2044-7569; Sboner, Andrea/0000-0001-6915-3070; Ferraro, Angelo/0000-0002-2044-7569; Fusco, Alfredo/0000-0003-3332-5197				ALDOVINI D, 2006, INT J CANCER, P27; [Anonymous], 2003, WHO CLASSIFICATION T; Benedet JL, 2000, INT J GYNECOL OBSTET, V70, P209; Feki A, 2004, CRIT REV ONCOL HEMAT, V52, P103, DOI 10.1016/j.critrevonc.2004.07.002; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Liu Xueli, 2004, J Biopharm Stat, V14, P671, DOI 10.1081/BIP-200025657; Masciullo V, 2003, CARCINOGENESIS, V24, P1191, DOI 10.1093/carcin/bgg075; Ozols RF, 2004, CANCER CELL, V5, P19, DOI 10.1016/S1535-6108(04)00002-9; Pallante P, 2005, BRIT J CANCER, V93, P464, DOI 10.1038/sj.bjc.6602721; PIERANTONI GM, 2005, CELL DEATH DIFFER, P1; *R DEV COR TEAM, 2004, LANG ENV STAT COMP; Troncone G, 2003, J CLIN PATHOL, V56, P587, DOI 10.1136/jcp.56.8.587; VACHERLAVENU MC, 1993, B CANCER, V80, P135; Wagner KW, 2004, ONCOGENE, V23, P6621, DOI 10.1038/sj.onc.1207861; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705	17	63	72	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2136	2140		10.1038/sj.onc.1210010	http://dx.doi.org/10.1038/sj.onc.1210010			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17016443				2022-12-17	WOS:000245313400016
J	Bai, Y; Liu, YJ; Wang, H; Xu, Y; Stamenkovic, I; Yu, Q				Bai, Y.; Liu, Y-j; Wang, H.; Xu, Y.; Stamenkovic, I.; Yu, Q.			Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin	ONCOGENE			English	Article						CD44; hyaluronan; merlin; tumor suppressor; schwannoma growth	TYPE-2 GENE-PRODUCT; MEDIATES CONTACT INHIBITION; GERM-LINE MUTATIONS; MUTANT NF2 PROTEIN; NEUROFIBROMATOSIS TYPE-2; INCREASED EXPRESSION; SIGNALING PATHWAY; GLYCOPROTEIN CD44; HOMING RECEPTOR; CARCINOMA-CELLS	Mutation or loss of expression of merlin is responsible for neurofibromatosis type 2 (NF2), which is characterized by the development of schwannomas and other tumors of the nervous system. Like the ERM(ezrin-radixin-moesin) proteins, merlin interacts with CD44, a cell-surface receptor for hyaluronan (HA) that promotes tumorigenesis. However, the relationship between merlin and CD44 and the mechanism by which merlin exerts its tumor-suppressor function have not been elucidated. In the present study, we show that increased expression of wildtype merlin in Tr6BC1 schwannoma cells inhibits HA binding to CD44. Furthermore, we demonstrate that the residues required for this inhibitory effect and the interaction between CD44 and merlin lie within the first 50 amino acids of merlin. Overexpression of merlin inhibited subcutaneous growth of Tr6BC1 cells in immunocompromised Rag1 mice. In contrast, knocking down expression of endogenous merlin promoted tumor cell growth, as did overexpression of a merlin deletion mutant (merlinDel-1) that lacks the first 50 amino acids but not of other NH2-terminal deletion mutants. Together, our results demonstrate that inhibition of the CD44-HA interaction contributes to the tumor-suppressor function of merlin, and they suggest that merlin inhibits tumor growth, at least in part, by negatively regulating CD44 function.	Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA; Univ Lausanne, Inst Pathol, Div Expt Pathol, CH-1015 Lausanne, Switzerland	University of Pennsylvania; University of Lausanne	Yu, Q (corresponding author), Univ Penn, Sch Vet Med, Dept Pathobiol, 372E Old Vet,3800 Spruce St, Philadelphia, PA 19104 USA.	qyu@vet.upenne.edu			NCI NIH HHS [R01 CA116510, R01 CA135158] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; Chan HM, 2005, GENE DEV, V19, P196, DOI 10.1101/gad.1280205; Deguen B, 1998, HUM MOL GENET, V7, P217, DOI 10.1093/hmg/7.2.217; Evans DGR, 1998, J MED GENET, V35, P450, DOI 10.1136/jmg.35.6.450; EVANS DGR, 1992, Q J MED, V84, P603; Giovannini M, 2000, GENE DEV, V14, P1617; Giovannini M, 1999, GENE DEV, V13, P978, DOI 10.1101/gad.13.8.978; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUTMANN DH, 1994, CURR OPIN NEUROL, V7, P166, DOI 10.1097/00019052-199404000-00014; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; Gutmann DH, 1999, J NEUROSCI RES, V58, P706, DOI 10.1002/(SICI)1097-4547(19991201)58:5<706::AID-JNR12>3.3.CO;2-Q; Hannon Gregory J, 2004, Methods Mol Biol, V257, P255, DOI 10.1385/1-59259-750-5:255; HARA T, 1994, CANCER RES, V54, P330; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Huynh DP, 1996, ONCOGENE, V13, P73; Kang BS, 2002, ACTA CRYSTALLOGR D, V58, P381, DOI 10.1107/S0907444901021175; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Khanna C, 2001, CANCER RES, V61, P3750; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Koga H, 1998, ONCOGENE, V17, P801, DOI 10.1038/sj.onc.1202010; LaJeunesse DR, 1998, J CELL BIOL, V141, P1589, DOI 10.1083/jcb.141.7.1589; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LUTCHMAN M, 1995, CANCER RES, V55, P2270; Martin TA, 2003, CRIT REV ONCOL HEMAT, V46, P165, DOI 10.1016/S1040-8428(02)00172-5; McClatchey AI, 2005, GENE DEV, V19, P2265, DOI 10.1101/gad.1335605; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; MEREL P, 1995, GENE CHROMOSOME CANC, V12, P117, DOI 10.1002/gcc.2870120206; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Obremski VJ, 1998, J NEUROBIOL, V37, P487, DOI 10.1002/(SICI)1097-4695(199812)37:4<487::AID-NEU1>3.3.CO;2-2; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Paddison Patrick J, 2004, Methods Mol Biol, V265, P85; Parry DM, 1996, AM J HUM GENET, V59, P529; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; RONG R, 2004, ONCOGENE, V4, P1; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Ruttledge MH, 1996, AM J HUM GENET, V59, P331; Sainio M, 1997, J CELL SCI, V110, P2249; Scoles DR, 1998, NAT GENET, V18, P354, DOI 10.1038/ng0498-354; SCREATON GR, 1993, J BIOL CHEM, V268, P12235; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Shimizu T, 2002, J BIOL CHEM, V277, P10332, DOI 10.1074/jbc.M109979200; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Stickney JT, 2004, CANCER RES, V64, P2717, DOI 10.1158/0008-5472.CAN-03-3798; TROFATTER JA, 1993, CELL, V72, P1; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Xu Y, 2003, J BIOL CHEM, V278, P8661, DOI 10.1074/jbc.M208181200; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yu Q, 2001, AM J PATHOL, V158, P563, DOI 10.1016/S0002-9440(10)63998-3; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Zoltan-Jones A, 2003, J BIOL CHEM, V278, P45801, DOI 10.1074/jbc.M308168200	68	63	66	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					836	850		10.1038/sj.onc.1209849	http://dx.doi.org/10.1038/sj.onc.1209849			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16953231				2022-12-17	WOS:000244063800005
J	Singh, P; Wu, H; Clark, C; Owlia, A				Singh, P.; Wu, H.; Clark, C.; Owlia, A.			Annexin II binds progastrin and gastrin-like peptides, and mediates growth factor effects of autocrine and exogenous gastrins on colon cancer and intestinal epithelial cells	ONCOGENE			English	Article						Mr of gastrin-binding proteins; SELDI-TOFMS; antisense and sense Annexin II RNA	GLYCINE-EXTENDED GASTRIN; C-OXIDASE VB; TRANSGENIC MICE; CALPACTIN-I; TENASCIN-C; ENHANCED EXPRESSION; SIGNALING PATHWAYS; PANCREATIC CANCERS; INSULIN-RECEPTOR; GENE-EXPRESSION	We and others have reported the presence of novel progastrin (PG)/gastrin receptors on normal and cancerous intestinal cells. We had earlier reported the presence of 33 - 36 kDa gastrin-binding proteins on cellular membranes of colon cancer cells. The goal of the current study was to identify the protein(s) in the 33 - 36 kDa band, and analyse its functional significance. A carbodiimide crosslinker was used for crosslinking radio-labeled gastrins to membrane proteins from gastrin/PG responsive cell lines. Native membrane proteins, crosslinked to the ligand, were solubulized and enriched by > 1000-fold, and analysed by surface-enhanced laser desorption/ionization-time of light-mass spectrometry. The peptide masses were researched against the NCBInr database using the ProFound search engine. Annexin II (ANX II) was identified, and confirmed by matrix-assisted laser desorption/ionization-time of flight-mass spectrometry. As HCT-116 cells express autocrine PG, the in situ association of PG with ANX II was demonstrated in pulldown assays. Direct binding of PG with ANX II was confirmed in an in vitro binding assay. In order to confirm a functional importance of these observations, sense and anti-sense (AS) ANX II RNA-expressing clones of intestinal epithelial (IEC-18) and human colon cancer (HCT-116) cell lines were generated. AS clones demonstrated a significant loss in the growth response to exogenous (IEC-18) and autocrine (HCT-116) PG. We have thus discovered that membrane-associated ANX II binds PG/gastrins, and partially mediates growth factor effects of the peptides.	Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; Ciphergen Biosyst Inc, Fremont, CA USA	University of Texas System; University of Texas Medical Branch Galveston	Singh, P (corresponding author), Univ Texas, Med Branch, Dept Neurosci & Cell Biol, 10-104 Med Res Bldg,Route 1043, Galveston, TX 77555 USA.	posingh@utmb.edu			NATIONAL CANCER INSTITUTE [R01CA097959, R01CA072992] Funding Source: NIH RePORTER; NCI NIH HHS [CA72992, CA097959, R01 CA097959] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aly A, 2001, INT J CANCER, V94, P307, DOI 10.1002/ijc.1483; Baldwin GS, 2001, J BIOL CHEM, V276, P7791, DOI 10.1074/jbc.M009985200; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; BRAMBILLA R, 1991, BIOCHEM J, V278, P447, DOI 10.1042/bj2780447; Brown D, 2003, ENDOCRINOLOGY, V144, P201, DOI 10.1210/en.2002-220501; Chakladar A, 2005, BIOCHEM BIOPH RES CO, V336, P190, DOI 10.1016/j.bbrc.2005.08.061; Chiang YP, 1999, MOL CELL BIOCHEM, V199, P139, DOI 10.1023/A:1006942128672; CHIANG YP, 1993, CANCER RES, V53, P6017; CHICONE L, 1989, BIOCHEM BIOPH RES CO, V164, P512, DOI 10.1016/0006-291X(89)91749-X; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; Cobb S, 2004, CANCER-AM CANCER SOC, V100, P1311, DOI 10.1002/cncr.20094; Das S, 2005, J PROTEOME RES, V4, P920, DOI 10.1021/pr050023i; Dockray GJ, 1996, PHYSIOL REV, V76, P767, DOI 10.1152/physrev.1996.76.3.767; Emoto K, 2001, CANCER, V92, P1419, DOI 10.1002/1097-0142(20010915)92:6<1419::AID-CNCR1465>3.0.CO;2-J; Ferrand A, 2005, CANCER RES, V65, P2770, DOI 10.1158/0008-5472.CAN-04-0978; FROHLICH M, 1990, MOL CELL BIOL, V10, P3216, DOI 10.1128/MCB.10.6.3216; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GINSBERG BH, 1978, BIOCHIM BIOPHYS ACTA, V542, P88, DOI 10.1016/0304-4165(78)90235-0; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; GOULD RJ, 1981, BIOCHEMISTRY-US, V20, P6776, DOI 10.1021/bi00527a006; Hajjar KA, 2000, ANN NY ACAD SCI, V902, P265; Hollande F, 1997, GASTROENTEROLOGY, V113, P1576, DOI 10.1053/gast.1997.v113.pm9352860; Hollande F, 2001, J BIOL CHEM, V276, P40402, DOI 10.1074/jbc.M105090200; KEUTZER JC, 1990, EXP CELL RES, V188, P153, DOI 10.1016/0014-4827(90)90291-H; Koh TJ, 1999, J CLIN INVEST, V103, P1119, DOI 10.1172/JCI4910; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; Kucharczak J, 2001, ONCOGENE, V20, P7021, DOI 10.1038/sj.onc.1204882; Lambert O, 2004, J BIOL CHEM, V279, P10872, DOI 10.1074/jbc.M313657200; Laumonnier Y, 2006, BLOOD, V107, P3342, DOI 10.1182/blood-2005-07-2840; Lei S, 2004, J BIOL CHEM, V279, P42492, DOI 10.1074/jbc.M404025200; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; NALDINI L, 1990, BIOCHEMISTRY-US, V29, P5153, DOI 10.1021/bi00473a022; NARAYAN S, 1992, MOL CELL BIOCHEM, V112, P163; Ottewell PD, 2005, AM J PHYSIOL-GASTR L, V288, pG541, DOI 10.1152/ajpgi.00268.2004; OYAMA F, 1991, CANCER RES, V51, P4876; OZAKI T, 1993, ONCOGENE, V8, P1707; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Rengifo-Cam W, 2005, GASTROENTEROLOGY, V128, pA485; Rengifo-Cam W, 2004, CURR PHARM DESIGN, V10, P2345, DOI 10.2174/1381612043383999; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; Siddheshwar RK, 2001, GUT, V48, P47, DOI 10.1136/gut.48.1.47; SINGH P, 1994, AM J PHYSIOL, V267, pG235, DOI 10.1152/ajpgi.1994.267.2.G235; SINGH P, 1987, CANCER RES, V47, P5000; Singh P, 2000, GASTROENTEROLOGY, V119, P162, DOI 10.1053/gast.2000.8527; Singh P, 1996, CANCER RES, V56, P4111; SINGH P, 1995, J BIOL CHEM, V270, P8429, DOI 10.1074/jbc.270.15.8429; Singh P, 2000, AM J PHYSIOL-GASTR L, V278, pG390, DOI 10.1152/ajpgi.2000.278.3.G390; Singh P, 2003, AM J PHYSIOL-GASTR L, V284, pG328, DOI 10.1152/ajpgi.00351.2002; SINGH P, 1994, CANCER RES, V54, P6563; SINGH P, 1994, AM J PHYSIOL, V267, P608; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; Tanaka T, 2004, ONCOGENE, V23, P3980, DOI 10.1038/sj.onc.1207555; VISHWANATHA JK, 1993, CARCINOGENESIS, V14, P2575, DOI 10.1093/carcin/14.12.2575; VISHWANATHA JK, 1993, J CELL SCI, V105, P533; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691; Wu H, 2000, J BIOL CHEM, V275, P32491, DOI 10.1074/jbc.M002458200; Wu H, 2003, AM J PHYSIOL-GASTR L, V285, pG1097, DOI 10.1152/ajpgi.00216.2003; ZHANG QX, 1994, BBA-GENE STRUCT EXPR, V1219, P567, DOI 10.1016/0167-4781(94)90091-4	61	63	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					425	440		10.1038/sj.onc.1209798	http://dx.doi.org/10.1038/sj.onc.1209798			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832341				2022-12-17	WOS:000243544000011
J	Huang, MC; Chen, HY; Huang, HC; Huang, J; Liang, JT; Shen, TL; Lin, NY; Ho, CC; Cho, IM; Hsu, SM				Huang, MC; Chen, HY; Huang, HC; Huang, J; Liang, JT; Shen, TL; Lin, NY; Ho, CC; Cho, IM; Hsu, SM			C2GnT-M is downregulated in colorectal cancer and its re-expression causes growth inhibition of colon cancer cells	ONCOGENE			English	Article						C2GnT-M; colon cancer; apoptosis; migration; invasion	O-GLYCAN BIOSYNTHESIS; CORE 2 BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE; EXTRACELLULAR-MATRIX; MOLECULAR-CLONING; TUMOR PROGRESSION; BRANCH FORMATION; PROSTATE-CANCER; GENE-TRANSFER; TN-EPITOPES; EXPRESSION	Changes in carbohydrates on the cell surface are associated with tumor malignancy. The mucin-type core 2 beta-1,6- N-acetylglucosaminyltransferase (C2GnT-M) is highly expressed in the gastrointestinal tract and catalyses the formation of core 2, core 4, and blood group I branches on O-glycans. In the present study, we evaluated the role of C2GnT-M in colorectal cancer. C2GnT-M downexpression was observed in 73.6% of the primary tumors from colorectal cancer patients (39 of 53) analysed by cancer pro. ling array. Consistently, the majority of colon cancer cell lines and primary colon tumors expressed lower levels of C2GnT-M than did normal colon tissues by RT-PCR. HCT116 cells stably transfected with C2GnT-M inhibited expression of the core 1 structure, Gal beta 1,3GalNAc alpha 1-Ser/Thr, on the cell surface. Moreover, C2GnT-M expression suppressed cell adhesion, motility, and invasion as well as colony formation ability. The growth of C2GnT-M-transfected HCT116 and SW480 cells was dramatically suppressed, and the cell death induced by C2GnT-M was demonstrated by an increase in the annexin V-positive cells. Interestingly, C2GnT-M inhibited cell adhesion to collagen IV and fibronectin, and decreased tyrosine phosphorylation of paxillin, indicating that the changes in cancer behavior may be partly mediated by integrin-signaling pathways. Tumor growth in vivo was also significantly suppressed by C2GnT-M in the xenografts of nude mice. These results demonstrate that C2GnT-M is frequently downregulated in colorectal cancer and suppresses colon cancer cell growth.	Natl Taiwan Univ, Coll Med, Inst Anat & Cell Biol, Taipei, Taiwan; Anim Technol Inst Taiwan, Miaoli, Taiwan; Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Pathol, Taipei 100, Taiwan; Natl Taiwan Univ, Dept Plant Pathol & Microbiol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University	Huang, MC (corresponding author), Natl Taiwan Univ, Coll Med, Inst Anat & Cell Biol, 1 Sec 1 Ren Ai Rd, Taipei, Taiwan.	mchuang@ha.mc.ntu.edu.tw	Shen, Tang-Long/C-7460-2011	Liang, Jin-Tung/0000-0002-0264-7735; HO, CHAO-CHI/0000-0002-8156-2413; HUANG, MIN-CHUAN/0000-0002-0704-3447; LIN, NENG-YU/0000-0003-0746-0483; Shen, Tang-Long/0000-0001-6264-3608				Baldus SE, 2000, CANCER-AM CANCER SOC, V88, P1536, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1536::AID-CNCR6>3.3.CO;2-N; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; Brockhausen I, 1998, GLYCOCONJUGATE J, V15, P595, DOI 10.1023/A:1006967910803; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CAO Y, 1995, CANCER-AM CANCER SOC, V76, P1700, DOI 10.1002/1097-0142(19951115)76:10<1700::AID-CNCR2820761005>3.0.CO;2-Z; Clement M, 2004, J CELL SCI, V117, P5059, DOI 10.1242/jcs.01350; Duncan G, 2001, J CLIN INVEST, V108, P511, DOI 10.1172/JCI13737; Fukuda M, 1996, CANCER RES, V56, P2237; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; Hanisch FG, 1997, HISTOL HISTOPATHOL, V12, P263; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Huang MC, 2002, J BIOL CHEM, V277, P47786, DOI 10.1074/jbc.M208283200; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Inaba Y, 2003, INT J CANCER, V107, P949, DOI 10.1002/ijc.11513; Iwai T, 2005, P NATL ACAD SCI USA, V102, P4572, DOI 10.1073/pnas.0407983102; Khaldoyanidi SK, 2003, J BIOL CHEM, V278, P4127, DOI 10.1074/jbc.M209590200; Lamorte L, 2003, MOL BIOL CELL, V14, P2818, DOI 10.1091/mbc.E02-08-0497; LIOTTA LA, 1991, CANCER RES, V51, pS5054; OVADIA H, 1975, EUR J CANCER, V11, P413, DOI 10.1016/0014-2964(75)90072-9; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Quattrocchi CC, 2002, J BIOL CHEM, V277, P303, DOI 10.1074/jbc.M106996200; Schneider F, 2001, CANCER RES, V61, P4605; Schwientek T, 2000, J BIOL CHEM, V275, P11106, DOI 10.1074/jbc.275.15.11106; Schwientek T, 1999, J BIOL CHEM, V274, P4504, DOI 10.1074/jbc.274.8.4504; Shimodaira K, 1997, CANCER RES, V57, P5201; Springer GF, 1997, J MOL MED, V75, P594, DOI 10.1007/s001090050144; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; Steiner MS, 2000, CANCER RES, V60, P4419; Tsubouchi A, 2002, J CELL BIOL, V159, P673, DOI 10.1083/jcb.200202117; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VAVASSEUR F, 1995, GLYCOBIOLOGY, V5, P351, DOI 10.1093/glycob/5.3.351; VAVASSEUR F, 1994, EUR J BIOCHEM, V222, P415, DOI 10.1111/j.1432-1033.1994.tb18880.x; Xia LJ, 2004, J CELL BIOL, V164, P451, DOI 10.1083/jcb.200311112; YANG JM, 1994, GLYCOBIOLOGY, V4, P873, DOI 10.1093/glycob/4.6.873; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215	38	63	66	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 1	2006	25	23					3267	3276		10.1038/sj.onc.1209350	http://dx.doi.org/10.1038/sj.onc.1209350			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16418723				2022-12-17	WOS:000237951200005
J	Zhang, DW; Jeang, KT; Lee, CGL				Zhang, DW; Jeang, KT; Lee, CGL			p53 negatively regulates the expression of FAT10, a gene upregulated in various cancers	ONCOGENE			English	Article						FAT10; diubiquitin; promoter; 5 ' UTR; p53	UBIQUITIN-LIKE PROTEIN; WILD-TYPE P53; MHC CLASS-I; CELL-CYCLE; TRANSCRIPTIONAL REPRESSION; HEPATOCELLULAR-CARCINOMA; INTERFERON-GAMMA; TUMOR-SUPPRESSOR; MAMMALIAN-CELLS; CHECKPOINT	FAT10 is a member of the ubiquitin-like modi. er family of proteins and has been implicated to play important roles in antigen presentation, cytokine response, apoptosis and mitosis. We have recently demonstrated the upregulation of FAT10 gene expression in 90% of hepatocellular carcinoma patients. Here, we identified and characterized the promoter of the FAT10 gene to elucidate the mechanism of FAT10 gene expression. Notably, we found that the 50 untranslated region (5'UTR), from the transcription start site to 15 bases before the translational start site, displays significant promoter activity. Regions upstream of the 5'UTR (from +26 to -1997) do not confer any promoter activity. Curiously, FAT10 promoter activity and expression is significantly repressed in KB3-1 and HepG2 cells, which have wild-type p53, than in p53-negative Hep3B cells. The role of p53 in regulating FAT10 expression was evident by the significant down-regulation (P < 0.05) of FAT10 mRNA expression and promoter activity when wild-type p53 was transfected into p53-null Hep3B cells. Conversely, inhibiting p53 expression through siRNA against p53 significantly enhanced FAT10 expression and promoter activity. p53 was found to bind in vivo to the 50 half consensus sequence of p53binding site located at the FAT10 promoter. Hence, we propose that FAT10 is a downstream target of p53 and dysregulation of FAT10 expression in p53-defective cells could contribute to carcinogenesis.	Natl Canc Ctr, Div Med Sci, Singapore 169610, Singapore; Natl Univ Singapore, Dept Biochem, Yong Loo Lin Sch Med, Singapore 117548, Singapore; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	National Cancer Centre Singapore (NCCS); National University of Singapore; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lee, CGL (corresponding author), Natl Canc Ctr, Div Med Sci, Level 6,Lab 5,11 Hosp Dr, Singapore 169610, Singapore.	bchleec@nus.edu.sg	Lee, Caroline G/M-8918-2019; Jeang, Kuan-Teh/A-2424-2008	Lee, Caroline G/0000-0002-4323-3635; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000547, Z01AI001023, Z01AI000547, ZIAAI001023] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aguiar J, 1999, BIOCHEM BIOPH RES CO, V254, P315, DOI 10.1006/bbrc.1998.9929; Bates EFM, 1997, EUR J IMMUNOL, V27, P2471, DOI 10.1002/eji.1830271002; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chun ACS, 2003, J BIOL CHEM, V278, P37439, DOI 10.1074/jbc.M307185200; Clark IM, 1997, BIOCHEM J, V324, P611, DOI 10.1042/bj3240611; Dokmanovic M, 2002, CANCER BIOL THER, V1, P24, DOI 10.4161/cbt.1.1.35; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fan WF, 1996, IMMUNOGENETICS, V44, P97, DOI 10.1007/s002510050095; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Haupt Ygal, 2002, Oncogene, V21, P8223, DOI 10.1038/sj.onc.1206137; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Kumanovics A, 2003, ANNU REV IMMUNOL, V21, P629, DOI 10.1146/annurev.immunol.21.090501.080116; LANE DP, 1992, NATURE, V358, P16; Lee CGL, 2000, FASEB J, V14, P516, DOI 10.1096/fasebj.14.3.516; Lee CGL, 2003, ONCOGENE, V22, P2592, DOI 10.1038/sj.onc.1206337; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li GQ, 2003, WORLD J GASTROENTERO, V9, P1972, DOI 10.3748/wjg.v9.i9.1972; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; Maeda Y, 2002, MOL ENDOCRINOL, V16, P402, DOI 10.1210/me.16.2.402; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Pagano M, 1997, FASEB J, V11, P1067, DOI 10.1096/fasebj.11.13.9367342; PINES J, 1994, NATURE, V371, P742, DOI 10.1038/371742a0; Raasi S, 1999, EUR J IMMUNOL, V29, P4030, DOI 10.1002/(SICI)1521-4141(199912)29:12<4030::AID-IMMU4030>3.0.CO;2-Y; Stahler F, 1998, ONCOGENE, V17, P3507, DOI 10.1038/sj.onc.1202245; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; van den Elsen PJ, 1998, IMMUNOGENETICS, V48, P208, DOI 10.1007/s002510050425; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang XH, 2002, CANCER RES, V62, P1662; Zhao RB, 2000, GENE DEV, V14, P981	41	63	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2006	25	16					2318	2327		10.1038/sj.onc.1209220	http://dx.doi.org/10.1038/sj.onc.1209220			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16501612				2022-12-17	WOS:000236764300004
J	Seiden-Long, IM; Brown, KR; Shih, W; Wigle, DA; Radulovich, N; Jurisica, I; Tsao, MS				Seiden-Long, IM; Brown, KR; Shih, W; Wigle, DA; Radulovich, N; Jurisica, I; Tsao, MS			Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer	ONCOGENE			English	Article						hepatocyte growth factor; protein-protein interaction; microarray; real-time RT-PCR; tumor markers; tissue array	FACTOR SCATTER FACTOR; FACTOR-RECEPTOR; C-MYC; MEDIATED APOPTOSIS; BETA-CATENIN; MET; CELLS; GENE; EXPRESSION; PATHWAY	Both Ki-ras mutation and hepatocyte growth factor (HGF) receptor Met overexpression occur at high frequency in colon cancer. This study investigates the transcriptional changes induced by Ki-ras oncogene and HGF/Met signaling activation in colon cancer cell lines in vitro and in vivo. The model system used in these studies included the DLD-1 colon cancer cell line with a mutated Ki-ras allele, and the DKO-4 cell line generated from DLD-1, with its mutant Ki-ras allele inactivated by targeted disruption. These cell lines were transduced with cDNAs of full-length Met receptor. Microarray transcriptional pro. ling was conducted on cell lines stimulated with HGF, as well as on tumor xenograft tissues. Overlapping genes between in vitro and in vivo microarray data sets were selected as a subset of HGF/Met and Ki-ras oncogene-regulated targets. Using the Online Predicted Human Interaction Database, novel HGF/Met and Ki-ras regulated proteins with putative functional linkage were identifi. ed. Novel proteins identified included histone acetyltransferase 1, phosphoribosyl pyrophosphate synthetase 2, chaperonin containing TCP1, subunit 8, CSE1 chromosome segregation 1-like (yeast)/cellular apoptosis susceptibility (mammals), CCR4-NOT transcription complex, subunit 8, and cyclin H. Transcript levels for these Met-signaling targets were correlated with Met expression levels, and were significantly elevated in both primary and metastatic human colorectal cancer samples compared to normal colorectal mucosa. These genes represent novel Met and/ or Ki-ras transcriptionally coregulated genes with a high degree of validation in human colorectal cancers.	Univ Toronto, Ontario Canc Inst, Dept Pathol, Princess Margaret Hosp,Univ Hlth Network, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Comp Sci, Toronto, ON, Canada; Univ Toronto, Dept Lab Med & Pathol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Tsao, MS (corresponding author), Univ Toronto, Ontario Canc Inst, Dept Pathol, Princess Margaret Hosp,Univ Hlth Network, Room 4-302,610 Univ Ave,9-610, Toronto, ON M5G 2M9, Canada.	ming.tsao@uhn.on.ca	Tsao, Ming Sound/AFQ-7332-2022; Tsao, Ming-Sound/M-3503-2017	Tsao, Ming Sound/0000-0002-9160-5405; Brown, Kevin/0000-0002-5514-2538				Balkovetz DF, 2004, AM J PHYSIOL-RENAL, V286, pF702, DOI 10.1152/ajprenal.00270.2003; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; Behrens P, 2003, APOPTOSIS, V8, P39, DOI 10.1023/A:1021644918117; Bertotti A, 2003, TRENDS BIOCHEM SCI, V28, P527, DOI 10.1016/j.tibs.2003.09.001; Bhattacharjee RN, 2001, MOL CELL BIOL, V21, P5417, DOI 10.1128/MCB.21.16.5417-5425.2001; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Brinkmann U, 1996, BIOCHEMISTRY-US, V35, P6891, DOI 10.1021/bi952829+; Brown KR, 2005, BIOINFORMATICS, V21, P2076, DOI 10.1093/bioinformatics/bti273; Conner EA, 1999, CARCINOGENESIS, V20, P583, DOI 10.1093/carcin/20.4.583; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Dugan KA, 2002, ONCOGENE, V21, P5835, DOI 10.1038/sj.onc.1205763; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fazekas K, 2001, CLIN EXP METASTAS, V18, P639, DOI 10.1023/A:1013136303880; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; Gerritsen ME, 2003, BRIT J PHARMACOL, V140, P595, DOI 10.1038/sj.bjp.0705494; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HALABAN R, 1992, ONCOGENE, V7, P2195; Jiang MC, 2004, J EXP CLIN CANC RES, V23, P325; Jiang MC, 2002, BIOCHEM BIOPH RES CO, V294, P900, DOI 10.1016/S0006-291X(02)00551-X; Jiang W, 1999, CRIT REV ONCOL HEMAT, V29, P209, DOI 10.1016/S1040-8428(98)00019-5; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; LIU C, 1992, ONCOGENE, V7, P181; Liu J, 2004, ONCOGENE, V23, P6316, DOI 10.1038/sj.onc.1207795; Martinez-Garza SG, 1999, DIGEST DIS, V17, P225, DOI 10.1159/000016940; Monga SPS, 2002, CANCER RES, V62, P2064; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; SEIDENLONG I, 2003, MOL CANCER RES, V1, P393; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Sultan M, 2002, Bioinformatics, V18 Suppl 1, pS111; Tortola S, 1999, J CLIN ONCOL, V17, P1375, DOI 10.1200/JCO.1999.17.5.1375; Tsao MS, 1998, LUNG CANCER, V20, P1, DOI 10.1016/S0169-5002(98)00007-5; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Yarwood SJ, 2001, P NATL ACAD SCI USA, V98, P4472, DOI 10.1073/pnas.081069098	42	63	66	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					91	102		10.1038/sj.onc.1209005	http://dx.doi.org/10.1038/sj.onc.1209005			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16158056				2022-12-17	WOS:000234406400010
J	Beiter, K; Hiendlmeyer, E; Brabletz, T; Hlubek, F; Haynl, A; Knoll, C; Kirchner, T; Jung, A				Beiter, K; Hiendlmeyer, E; Brabletz, T; Hlubek, F; Haynl, A; Knoll, C; Kirchner, T; Jung, A			beta-Catenin regulates the expression of tenascin-C in human colorectal tumors	ONCOGENE			English	Article						beta-catenin; tenascin-C; Wnt signalling; colorectal cancer	INVASION FRONT; CANCER; CELLS; TRANSCRIPTION; GASTRULATION; TARGET	Tenascin-C (TN-C) is a component of the extracellular matrix (ECM). It is expressed during development and re-expressed in many types of cancers, where it is involved in the modulation of adhesion and proliferation. TN-C expression is especially high at sites of epithelial mesenchymal transition (EMT), which are found frequently at the invasion front of well-differentiated human colorectal adenocarcinomas. Tumor cells in this compartment are characterized by a strong nuclear expression of the oncogenic transcription factor beta-catenin. Here, we demonstrate that TN-C is a beta-catenin target gene in human colorectal tumors. Thus, by far the most common mutations in colorectal tumors, found in the Wnt-signaling pathway and leading to the stabilizing of beta-catenin, might influence invasion by altering adhesive properties and EMT of tumor cells.	Univ Erlangen Nurnberg, Inst Pathol Anat, D-91054 Erlangen, Germany	University of Erlangen Nuremberg	Jung, A (corresponding author), Univ Erlangen Nurnberg, Inst Pathol Anat, Krankenhausstr 8-10, D-91054 Erlangen, Germany.	andreas.jung@patho.imed.uni-erlangen.de						Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Brabletz T, 1998, PATHOL RES PRACT, V194, P701, DOI 10.1016/S0344-0338(98)80129-5; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brabletz T, 2002, VIRCHOWS ARCH, V441, P1, DOI 10.1007/s00428-002-0642-9; Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604; Chiquet-Ehrismann R, 2003, J PATHOL, V200, P488, DOI 10.1002/path.1415; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Hanamura N, 1997, INT J CANCER, V73, P10, DOI 10.1002/(SICI)1097-0215(19970926)73:1<10::AID-IJC2>3.0.CO;2-4; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hiendlmeyer E, 2004, CANCER RES, V64, P1209, DOI 10.1158/0008-5472.CAN-3627-2; Jones PL, 2000, MATRIX BIOL, V19, P581, DOI 10.1016/S0945-053X(00)00106-2; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Kirchner T, 2000, AM J PATHOL, V157, P1113, DOI 10.1016/S0002-9440(10)64626-3; Kodjabachian L, 1999, DEV BIOL, V213, P231, DOI 10.1006/dbio.1999.9392; Rosin-Arbesfeld R, 2003, EMBO J, V22, P1101, DOI 10.1093/emboj/cdg105; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Verma UN, 2003, CLIN CANCER RES, V9, P1291	22	63	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8200	8204		10.1038/sj.onc.1208960	http://dx.doi.org/10.1038/sj.onc.1208960			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16091738				2022-12-17	WOS:000233809400011
J	Yang, XH; Liu, DH; Murray, TJ; Mitchell, GC; Hesterman, EV; Karchner, SI; Merson, RR; Hahn, ME; Sherr, DH				Yang, XH; Liu, DH; Murray, TJ; Mitchell, GC; Hesterman, EV; Karchner, SI; Merson, RR; Hahn, ME; Sherr, DH			The aryl hydrocarbon receptor constitutively represses c-myc transcription in human mammary tumor cell	ONCOGENE			English	Review						aryl hydrocarbon receptor; c-Myc; mammary tumorigenesis	NF-KAPPA-B; BREAST-CANCER CELLS; AH RECEPTOR; AROMATIC-HYDROCARBON; ESTROGEN-RECEPTOR; GENE-EXPRESSION; RECEPTOR/TRANSCRIPTION FACTOR; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; RETINOBLASTOMA PROTEIN; TRANSIENT EXPRESSION	The aryl hydrocarbon receptor (AhR) is an environmental carcinogen-activated transcription factor associated with tumorigenesis. High levels of apparently active AhR characterize a variety of tumors, even in the absence of environmental ligands. Despite this association between transformation and AhR upregulation, little is known of the transcriptional consequences of constitutive AhR activation. Here, the effects of constitutively active and environmental ligand-induced AhR on c-myc, an oncogene whose promoter contains six AhR-binding sites (AhREs (aryl hydrocarbon response elements)), were investigated. A reporter containing the human c-myc promoter, with its six AhREs and two NF-kappa B-binding sites, was constructed. This vector, and variants with deletions in the NF-kappa B and/or AhR-binding sites, was transfected into a human breast cancer cell line, Hs578T, which expresses high levels of apparently active, nuclear AhR. Results indicate that: (1) the AhR constitutively binds the c-myc promoter; (2) there is a low but significant baseline level of c-myc promoter activity, which is not regulated by NF-kappa B and is not affected by an environmental AhR ligand; (3) deletion of any one of the AhREs has no effect on constitutive reporter activity, while deletion of all six increases reporter activity approximately fivefold; (4) a similar increase in reporter activity occurs when constitutively active AhR is suppressed by transfection with an AhR repressor plasmid (AhRR); (5) AhRR transfection significantly increases background levels of endogenous c-myc mRNA and c-Myc protein. These results suggest that the AhR influences the expression of c-Myc, a protein critical to malignant transformation.	Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA; Furman Univ, Dept Biol, Greenville, SC 29613 USA; Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA	Boston University; Woods Hole Oceanographic Institution	Sherr, DH (corresponding author), Boston Univ, Sch Publ Hlth, Dept Environm Hlth, 715 Albany St,R-408, Boston, MA 02118 USA.	dsherr@bu.edu	Hahn, Mark/AAV-7516-2020	Hahn, Mark/0000-0003-4358-2082; Sherr, David/0000-0003-3353-0553	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES007381, R01ES006086, P01ES011624] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01-ES06086, P42-ES07381, P01-ES11624] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abdelrahim M, 2003, MOL PHARMACOL, V63, P1373, DOI 10.1124/mol.63.6.1373; Allan LL, 2005, MOL PHARMACOL, V67, P1740, DOI 10.1124/mol.104.009100; Baba T, 2001, J BIOL CHEM, V276, P33101, DOI 10.1074/jbc.M011497200; Beischlag TV, 2005, J BIOL CHEM, V280, P21607, DOI 10.1074/jbc.C500090200; Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Bellas RE, 1999, CELL GROWTH DIFFER, V10, P287; Blaustein JD, 2004, ENDOCRINOLOGY, V145, P1075, DOI 10.1210/en.2003-1485; BORG A, 1992, INT J CANCER, V51, P687, DOI 10.1002/ijc.2910510504; Buters JTM, 1999, P NATL ACAD SCI USA, V96, P1977, DOI 10.1073/pnas.96.5.1977; CALAF G, 1993, CARCINOGENESIS, V14, P483, DOI 10.1093/carcin/14.3.483; Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; Caruso JA, 2004, MOL PHARMACOL, V65, P1016, DOI 10.1124/mol.65.4.1016; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; Chan WK, 1999, J BIOL CHEM, V274, P12115, DOI 10.1074/jbc.274.17.12115; Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525; Channavajhala P, 2002, ONCOGENE, V21, P5280, DOI 10.1038/sj.onc.1205640; CHEN HS, 1994, J BIOL CHEM, V269, P27554; Chen ZP, 1998, CANCER LETT, V129, P173, DOI 10.1016/S0304-3835(98)00108-6; Chesire DR, 2004, CANCER RES, V64, P2523, DOI 10.1158/0008-5472.CAN-03-3309; CHRISTOU M, 1987, CARCINOGENESIS, V8, P73, DOI 10.1093/carcin/8.1.73; Corton JC, 1996, TOXICOL LETT, V85, P67, DOI 10.1016/0378-4274(96)03636-3; DANIEL FB, 1984, CARCINOGENESIS, V5, P1021, DOI 10.1093/carcin/5.8.1021; DAS SK, 1989, CANCER RES, V49, P920; Davarinos NA, 1999, J BIOL CHEM, V274, P28708, DOI 10.1074/jbc.274.40.28708; DEAN M, 1988, CURR TOP MICROBIOL, V141, P216; Dertinger SD, 2001, CARCINOGENESIS, V22, P171, DOI 10.1093/carcin/22.1.171; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; Fallone F, 2004, BIOCHEM BIOPH RES CO, V322, P551, DOI 10.1016/j.bbrc.2004.07.153; Fowler AM, 2004, FASEB J, V18, P81, DOI 10.1096/fj.03-0038com; Garrison PM, 1996, FUND APPL TOXICOL, V30, P194, DOI 10.1006/faat.1996.0056; Ge NL, 1998, J BIOL CHEM, V273, P22708, DOI 10.1074/jbc.273.35.22708; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; HACKETT AJ, 1977, J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795; Han D, 2004, BIOFACTORS, V20, P11, DOI 10.1002/biof.5520200102; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pa.35.040195.001515; Hayashibara T, 2003, BIOCHEM BIOPH RES CO, V300, P128, DOI 10.1016/S0006-291X(02)02793-6; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Hestermann EV, 2003, MOL CELL BIOL, V23, P7920, DOI 10.1128/MCB.23.21.7920-7925.2003; Ishibe N, 1998, CANCER RES, V58, P667; JERRY DJ, 1994, MOL CARCINOGEN, V9, P175, DOI 10.1002/mc.2940090309; Karchner SI, 2002, J BIOL CHEM, V277, P6949, DOI 10.1074/jbc.M110779200; KESSLER DJ, 1992, ONCOGENE, V7, P2447; Kikuchi Y, 2003, J BIOCHEM, V134, P83, DOI 10.1093/jb/mvg115; Kim DW, 2000, ONCOGENE, V19, P5498, DOI 10.1038/sj.onc.1203945; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Koliopanos A, 2002, ONCOGENE, V21, P6059, DOI 10.1038/sj.onc.1205633; Korkalainen M, 2004, BIOCHEM BIOPH RES CO, V315, P123, DOI 10.1016/j.bbrc.2004.01.028; Kumar MB, 1999, GENE EXPRESSION, V8, P273; Kumar MB, 1999, J BIOL CHEM, V274, P22155, DOI 10.1074/jbc.274.32.22155; Lai ZW, 1996, CHEM-BIOL INTERACT, V100, P97, DOI 10.1016/0009-2797(96)03691-5; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; LARSEN M, 1997, FUND APPL TOXICOL, V36, P24; Latil A, 2000, INT J CANCER, V89, P172; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Levine-Fridman A, 2004, MOL PHARMACOL, V65, P461, DOI 10.1124/mol.65.2.461; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Liao DJ, 2003, LAB INVEST, V83, P1437, DOI 10.1097/01.LAB.0000090153.13977.AE; Liu CQ, 2003, J BIOL CHEM, V278, P44857, DOI 10.1074/jbc.M304489200; Ma Q, 1996, MOL CELL BIOL, V16, P2144; Maecker B, 2003, BLOOD, V102, P3287, DOI 10.1182/blood-2003-05-1374; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Marcus RS, 1998, J PHARMACOL EXP THER, V287, P1113; Matikainen T, 2001, NAT GENET, V28, P355, DOI 10.1038/ng575; Matikainen TM, 2002, ENDOCRINOLOGY, V143, P615, DOI 10.1210/en.143.2.615; McDougal A, 1997, CANCER LETT, V120, P53, DOI 10.1016/S0304-3835(97)00299-1; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Nazarenko I, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e37; NEBERT DW, 1991, PHARMACOGENETICS, V1, P68, DOI 10.1097/00008571-199111000-00003; Negri E, 2003, EUR J CANCER PREV, V12, P509, DOI 10.1097/00008469-200312000-00010; Nguyen TA, 1999, ARCH BIOCHEM BIOPHYS, V367, P250, DOI 10.1006/abbi.1999.1282; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; OKEY AB, 1994, TOXICOL LETT, V70, P1, DOI 10.1016/0378-4274(94)90139-2; Pelengaris S, 2003, ARCH BIOCHEM BIOPHYS, V416, P129, DOI 10.1016/S0003-9861(03)00294-7; POLAND A, 1991, MOL PHARMACOL, V39, P20; POLAND AP, 1974, J BIOL CHEM, V249, P5599; Porter W, 2001, J MOL ENDOCRINOL, V26, P31, DOI 10.1677/jme.0.0260031; Puga A, 2002, CHEM-BIOL INTERACT, V141, P117, DOI 10.1016/S0009-2797(02)00069-8; Puga A, 2000, J BIOL CHEM, V275, P2943, DOI 10.1074/jbc.275.4.2943; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Rushing SR, 2002, ARCH BIOCHEM BIOPHYS, V403, P189, DOI 10.1016/S0003-9861(02)00233-3; RUSSO J, 1987, LAB INVEST, V57, P112; Ryu HY, 2003, J IMMUNOL, V170, P4897, DOI 10.4049/jimmunol.170.10.4897; SADEK CM, 1994, J BIOL CHEM, V269, P31505; Saez AI, 2003, LAB INVEST, V83, P143, DOI 10.1097/01.LAB.0000057000.41585.FD; Safe S, 1998, TOXICOL LETT, V103, P343; Safe S, 2001, TOXICOL LETT, V120, P1, DOI 10.1016/S0378-4274(01)00301-0; Singh SS, 1996, ARCH BIOCHEM BIOPHYS, V329, P47, DOI 10.1006/abbi.1996.0190; Sulentic CEW, 2000, J PHARMACOL EXP THER, V295, P705; Sulentic CEW, 1998, MOL PHARMACOL, V53, P623, DOI 10.1124/mol.53.4.623; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; THOMSEN JS, 1994, CARCINOGENESIS, V15, P933, DOI 10.1093/carcin/15.5.933; Thomsen JS, 2004, MOL PHARMACOL, V65, P165, DOI 10.1124/mol.65.1.165; Tian Y, 1999, J BIOL CHEM, V274, P510, DOI 10.1074/jbc.274.1.510; Tohkin M, 2000, MOL PHARMACOL, V58, P845, DOI 10.1124/mol.58.4.845; Trombino AF, 2000, BREAST CANCER RES TR, V63, P117, DOI 10.1023/A:1006443104670; Vaziri C, 1996, J BIOL CHEM, V271, P25921, DOI 10.1074/jbc.271.42.25921; Wang F, 1999, BIOCHEMISTRY-US, V38, P11490, DOI 10.1021/bi982578f; Wang F, 2001, MOL CELL ENDOCRINOL, V172, P91, DOI 10.1016/S0303-7207(00)00379-8; Wang S, 2004, J BIOL CHEM, V279, P13593, DOI 10.1074/jbc.M312274200; Wang WL, 1996, BRIT J CANCER, V73, P316, DOI 10.1038/bjc.1996.55; WANG XH, 1995, EUR J PHARM-ENVIRON, V293, P191, DOI 10.1016/S0922-4106(05)80044-6; Wang Y, 2004, CANCER CELL, V5, P501, DOI 10.1016/S1535-6108(04)00113-8; Watanabe T, 2001, J HUM GENET, V46, P342, DOI 10.1007/s100380170070; WEIGEL NL, 1995, J STEROID BIOCHEM, V53, P509, DOI 10.1016/0960-0760(95)00098-K; Weiss C, 1996, EXP CELL RES, V226, P154, DOI 10.1006/excr.1996.0214; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; Wormke M, 2003, MOL CELL BIOL, V23, P1843, DOI 10.1128/MCB.23.6.1843-1855.2003; Wu M, 1996, MOL CELL BIOL, V16, P5015; Yamaguchi K, 1997, J IMMUNOL, V158, P2165; Zhang S, 2003, ENVIRON HEALTH PERSP, V111, P1877, DOI 10.1289/ehp.6322; Ziccardi MH, 2000, TOXICOL SCI, V54, P183, DOI 10.1093/toxsci/54.1.183; [No title captured]	119	63	72	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7869	7881		10.1038/sj.onc.1208938	http://dx.doi.org/10.1038/sj.onc.1208938			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16091746				2022-12-17	WOS:000233463000006
J	Feki, A; Jefford, CE; Berardi, P; Wu, JY; Cartier, L; Krause, KH; Irminger-Finger, I				Feki, A; Jefford, CE; Berardi, P; Wu, JY; Cartier, L; Krause, KH; Irminger-Finger, I			BARD1 induces apoptosis by catalysing phosphorylation of p53 by DNA-damage response kinase	ONCOGENE			English	Article						apoptosis; BARD1; DNA-PK; Ku-70; p53; phosphorylation	DEPENDENT PROTEIN-KINASE; BREAST-CANCER; IN-VIVO; TUMOR-SUPPRESSOR; P53-DEPENDENT APOPTOSIS; LATENT POPULATION; BRCA1; GENE; MUTATION; DOMAIN	The BRCA1-associated RING domain protein BARD1 acts with BRCA1 in double-strand break repair and ubiquitination. BARD1 plays a role as mediator of apoptosis by binding to and stabilizing p53, and BARD1-repressed cells are resistant to apoptosis. We therefore investigated the mechanism by which BARD1 induces p53 stability and apoptosis. The apoptotic activity of p53 is regulated by phosphorylation. We demonstrate that BARD1 binds to unphosphorylated and serine-15 phosphorylated forms of p53 in several cell types and that the region required for binding comprises the region sufficient for apoptosis induction. In addition, BARD1 binds to Ku-70, the regulatory subunit of DNA-PK, suggesting that the mechanism of p53-induced apoptosis requires BARD1 for the phosphorylation of p53. Upregulation of BARD1 alone is sufficient for stabilization of p53 and phosphorylation on serine-15, as shown in nonmalignant epithelial cells and ovarian cancer cells, NuTu-19, which are defective in apoptosis induction and express aberrant splice variants of BARD1. Stabilization and phosphorylation of p53 in NuTu-19 cells, as well as apoptosis, can be induced by the exogenous expression of wild-type BARD1, suggesting that BARD1, by binding to the kinase and its substrate, catalyses p53 phosphorylation.	Univ Geneva, Dept Geriatr, Biol Aging Lab, CH-1225 Geneva, Switzerland; Univ Hosp Geneva, Dept Obstet & Gynecol, Geneva, Switzerland; Univ Calgary, Calgary, AB, Canada	University of Geneva; University of Geneva; University of Calgary	Irminger-Finger, I (corresponding author), Univ Geneva, Dept Geriatr, Biol Aging Lab, Chemin Petit Bel Air 2, CH-1225 Geneva, Switzerland.	irmgard.irminger@medecine.unige.ch	Krause, Karl-Heinz/E-8030-2011	Krause, Karl-Heinz/0000-0002-9033-6768; Feki, Anis/0000-0002-9817-9445; Berardi, Philip/0000-0002-2302-6145				Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brown KD, 2000, J BIOL CHEM, V275, P6651, DOI 10.1074/jbc.275.9.6651; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Fabbro M, 2004, J BIOL CHEM, V279, P31251, DOI 10.1074/jbc.M405372200; Fathalla M F, 1972, Obstet Gynecol Surv, V27, P751, DOI 10.1097/00006254-197211000-00001; Feki A, 2004, BIOL REPROD, V71, P1614, DOI 10.1095/biolreprod.104.029678; Gautier F, 2000, CANCER RES, V60, P6895; Ghimenti C, 2002, GENE CHROMOSOME CANC, V33, P235, DOI 10.1002/gcc.1223; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda T, 2002, CANCER BIOL THER, V1, P163, DOI 10.4161/cbt.63; Irminger-Finger I, 2001, MOL CELL, V8, P1255, DOI 10.1016/S1097-2765(01)00406-3; Irminger-Finger I, 2002, INT J BIOCHEM CELL B, V34, P582, DOI 10.1016/S1357-2725(01)00161-3; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Ishitobi M, 2003, CANCER LETT, V200, P1, DOI 10.1016/S0304-3835(03)00387-2; Iyengar P, 2003, ONCOGENE, V22, P6408, DOI 10.1038/sj.onc.1206737; Jack MT, 2004, J BIOL CHEM, V279, P15269, DOI 10.1074/jbc.M309917200; Jefford CE, 2004, ONCOGENE, V23, P3509, DOI 10.1038/sj.onc.1207427; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Karppinen SM, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.020669; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lohrum M, 1996, ONCOGENE, V13, P2527; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; Milczarek GJ, 1996, LIFE SCI, V60, P1, DOI 10.1016/S0024-3205(96)00479-1; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Rodriguez M, 2003, J BIOL CHEM, V278, P52914, DOI 10.1074/jbc.C300407200; Rose GS, 1996, AM J OBSTET GYNECOL, V175, P593; Schafer R, 2003, ADV ENZYME REGUL, V43, P379, DOI 10.1016/S0065-2571(02)00040-7; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shangary S, 2000, J BIOL CHEM, V275, P30163, DOI 10.1074/jbc.M004302200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Stark JM, 2004, MOL CELL BIOL, V24, P9305, DOI 10.1128/MCB.24.21.9305-9316.2004; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zuco V, 2003, BIOCHEM PHARMACOL, V65, P1281, DOI 10.1016/S0006-2952(03)00079-0; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	57	63	69	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3726	3736		10.1038/sj.onc.1208491	http://dx.doi.org/10.1038/sj.onc.1208491			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782130				2022-12-17	WOS:000229346300004
J	Dessauge, G; Hilaly, S; Baumgartner, M; Blumen, B; Werling, D; Langsley, G				Dessauge, G; Hilaly, S; Baumgartner, M; Blumen, B; Werling, D; Langsley, G			C-Myc activation by Theileria parasites promotes survival of infected B-lymphocytes	ONCOGENE			English	Article						apoptosis; c-Myc; STAT3; Theileria; transformation	INDUCED APOPTOSIS; CELLS; PARVA; EXPRESSION; KINASE; ANNULATA; STAT3; TRANSFORMATION; PROLIFERATION; LEUKOCYTES	Theileria parasites infect and transform bovine lymphocytes, but host cell immortalization is reversible, as upon parasite death the lymphocytes rapidly die of apoptosis. Infection leads to a marked augmentation in the levels of lymphocyte c-Myc, and the parasite achieves this by inducing increased c-myc transcription and by prolonging the half-life of the transcription factor. Reduction in c-Myc turnover can be ascribed to CK2-mediated phosphorylation of the transcription factor. A parasite-dependent GM-CSF autocrine loop activates a JAK2/ STAT3 signalling pathway that contributes to heightened c-myc transcription, and inhibition of the pathway leads to caspase 9 activation and apoptosis that can be directly ascribed to a reduction in c-Myc. An antiapoptotic role for c-Myc was clearly demonstrated by specific inhibition of c-myc expression with antisense oligonucleotides, and this correlates with loss of the antiapoptotic protein Mcl-1, and, consistently, ectopic expression of c-Myc abrogates B-cell death induced upon JAK2 inhibition. Thus, Theileria parasites ensure the survival of their host lymphocytes via specific activation of c-Myc.	Inst Pasteur, Dept Parasitol, CNRS URA CNRS 2581, Lab Signalisat Immunoparasitaire, F-75724 Paris 15, France; Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; Royal Vet Coll, N Mymms AL9 7TA, Herts, England	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of California System; University of California San Francisco; University of London; University of London Royal Veterinary College	Langsley, G (corresponding author), Inst Pasteur, Dept Parasitol, CNRS URA CNRS 2581, Lab Signalisat Immunoparasitaire, Batiment Elie Metchnikoff,25-28 Rue Dr Roux, F-75724 Paris 15, France.	langsley@pasteur.fr	Werling, Dirk/F-5555-2013	Werling, Dirk/0000-0001-5411-4044; Baumgartner, Martin/0000-0001-9539-7204				Albert T, 2001, J BIOL CHEM, V276, P20482, DOI 10.1074/jbc.M100265200; Baumgartner M, 2000, CELL MICROBIOL, V2, P329, DOI 10.1046/j.1462-5822.2000.00062.x; Baumgartner M, 2003, BLOOD, V101, P1874, DOI 10.1182/blood-2002-02-0456; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cavin LG, 2003, HEPATOLOGY, V38, P1540, DOI 10.1016/j.hep.2003.09.019; Channavajhala P, 2002, ONCOGENE, V21, P5280, DOI 10.1038/sj.onc.1205640; Chaussepied M, 1996, RES IMMUNOL, V147, P127, DOI 10.1016/0923-2494(96)83165-8; Chaussepied M, 1998, MOL BIOCHEM PARASIT, V94, P215, DOI 10.1016/S0166-6851(98)00070-X; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Dobbelaere D, 1999, ANNU REV MICROBIOL, V53, P1, DOI 10.1146/annurev.micro.53.1.1; DOBBELAERE DAE, 1990, INFECT IMMUN, V58, P3847, DOI 10.1128/IAI.58.12.3847-3855.1990; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Grumont RJ, 2002, MOL CELL, V10, P1283, DOI 10.1016/S1097-2765(02)00779-7; Guergnon J, 2003, BIOCHIMIE, V85, P771, DOI 10.1016/j.biochi.2003.09.013; Guergnon J, 2003, CELL MICROBIOL, V5, P709, DOI 10.1046/j.1462-5822.2003.00314.x; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Heussler VT, 2002, SCIENCE, V298, P1033, DOI 10.1126/science.1075462; HUDSON AT, 1985, PARASITOLOGY, V90, P45, DOI 10.1017/S0031182000049003; Iavarone C, 2003, J BIOL CHEM, V278, P50024, DOI 10.1074/jbc.M308617200; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Kuenzi P, 2003, J IMMUNOL, V171, P1224, DOI 10.4049/jimmunol.171.3.1224; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; McGuire K, 2004, VET IMMUNOL IMMUNOP, V99, P87, DOI 10.1016/j.vetimm.2004.01.003; McKeever DJ, 1997, PARASITE IMMUNOL, V19, P319, DOI 10.1046/j.1365-3024.1997.d01-214.x; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Moreau MF, 1999, INFECT IMMUN, V67, P6678; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; OLEMOIYOI OK, 1992, BIOCHEMISTRY-US, V31, P6193, DOI 10.1021/bi00142a004; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Yuste VJ, 2002, J NEUROCHEM, V80, P126, DOI 10.1046/j.0022-3042.2001.00695.x	35	63	66	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1075	1083		10.1038/sj.onc.1208314	http://dx.doi.org/10.1038/sj.onc.1208314			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15580287				2022-12-17	WOS:000226749200013
J	Staalesen, V; Falck, J; Geisler, S; Bartkova, J; Borresen-Dale, AL; Lukas, J; Lillehaug, JR; Bartek, J; Lonning, PE				Staalesen, V; Falck, J; Geisler, S; Bartkova, J; Borresen-Dale, AL; Lukas, J; Lillehaug, JR; Bartek, J; Lonning, PE			Alternative splicing and mutation status of CHEK2 in stage III breast cancer	ONCOGENE			English	Article						breast cancer; CHEK2; mutation; splicing; p53	DNA-DAMAGE CHECKPOINT; MDM2 TRANSCRIPTS; TUMOR-SUPPRESSOR; HEREDITARY BREAST; KINASE CHK2; P53; PHOSPHORYLATION; EXPRESSION; PROTEIN; GENE	The DNA damage checkpoint kinase, CHK2, promotes growth arrest or apoptosis through phosphorylating targets such as Cdc25A, Cdc25C, BRCA1, and p53. Both germline and somatic loss-of-function CHEK2 mutations occur in human tumours, the former linked to the Li Fraumeni syndrome, and the latter found in diverse types of sporadic malignancies. Here we examined the status of CHK2 by genetic and immunohistochemical analyses in 53 breast carcinomas previously characterized for TP53 status. We identified two CHEK2 mutants, 470T>C (Ile157Thr), and a novel mutation, 1368insA leading to a premature stop codon in exon 13. The truncated protein encoded by CHEK2 carrying the 1368insA was stable yet mislocalized to the cytoplasm in tumour sections and when ectopically expressed in cultured cells. Unexpectedly, we found CHEK2 to be subject to extensive alternative splicing, with some 90 splice variants detected in our tumour series. While all cancers expressed normal-length CHEK2 mRNA together with the spliced transcripts, we demonstrate and/or predict some of these splice variants to lack CHK2 function and/or localize aberrantly. We conclude that cytoplasmic sequestration may represent a novel mechanism to disable CHK2, and propose to further explore the significance of the complex splicing patterns of this tumour suppressor gene in oncogenesis.	Univ Bergen, Dept Mol Biol, Bergen, Norway; Danish Canc Soc, Inst Canc Biol, Copenhagen, Denmark; Haukeland Hosp, Inst Med, Sect Oncol, N-5021 Bergen, Norway; Norwegian Radium Hosp, Dept Genet, Oslo, Norway	University of Bergen; Danish Cancer Society; University of Bergen; Haukeland University Hospital; University of Oslo	Lonning, PE (corresponding author), Univ Bergen, Dept Mol Biol, Bergen, Norway.	per.lonning@helse-bergen.no	Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X; Lonning, Per Eystein/0000-0002-8890-6303				Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Allinen M, 2001, BRIT J CANCER, V85, P209, DOI 10.1054/bjoc.2001.1858; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartel F, 2004, INT J ONCOL, V24, P143; Bartkova J, 2001, ONCOGENE, V20, P5897, DOI 10.1038/sj.onc.1204746; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Chehab NH, 2000, GENE DEV, V14, P278; Craig A, 2003, EMBO REP, V4, P787, DOI 10.1038/sj.embor.embor901; Dong XY, 2003, AM J HUM GENET, V72, P270, DOI 10.1086/346094; Evdokiou A, 2001, INT J ONCOL, V19, P625; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Frebourg T, 2001, B CANCER, V88, P581; Geisler S, 2003, CLIN CANCER RES, V9, P5582; Geisler S, 2001, CANCER RES, V61, P2505; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Hofmann WK, 2001, LEUKEMIA RES, V25, P333, DOI 10.1016/S0145-2126(00)00130-2; Hori M, 2000, PATHOL INT, V50, P786, DOI 10.1046/j.1440-1827.2000.01119.x; Ishimoto O, 2002, CANCER RES, V62, P636; Kraus A, 1999, INT J CANCER, V80, P930, DOI 10.1002/(SICI)1097-0215(19990315)80:6<930::AID-IJC20>3.3.CO;2-D; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lee SB, 2001, CANCER RES, V61, P8062; Lonning PE, 2004, TRENDS MOL MED, V10, P113, DOI 10.1016/j.molmed.2004.01.005; Lonning PE, 2003, LANCET ONCOL, V4, P177; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Lukas C, 2001, CANCER RES, V61, P4990; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Matsuoka S, 2001, CANCER RES, V61, P5362; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Meijers-Heijboer H, 2003, AM J HUM GENET, V72, P1308, DOI 10.1086/375121; O'Nions J, 2001, BRIT J CANCER, V85, P1551, DOI 10.1054/bjoc.2001.2138; Reddy A, 2002, BRIT J CANCER, V86, P756, DOI 10.1038/sj.bjc.6600131; Seppala EH, 2003, BRIT J CANCER, V89, P1966, DOI 10.1038/sj.bjc.6601425; Shieh SY, 2000, GENE DEV, V14, P289; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Sodha N, 2002, HUM MUTAT, V19, P173, DOI 10.1002/humu.10031; Sodha N, 2000, Science, V289, P359; Sodha N, 2002, BRIT J CANCER, V87, P1445, DOI 10.1038/sj.bjc.6600637; Sullivan A, 2002, ONCOGENE, V21, P1316, DOI 10.1038/sj.onc.1205207; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Theard D, 2001, BIOCHEM BIOPH RES CO, V289, P1199, DOI 10.1006/bbrc.2001.6095; Tominaga K, 1999, J BIOL CHEM, V274, P31463, DOI 10.1074/jbc.274.44.31463; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Zheng YX, 2001, CARCINOGENESIS, V22, P2005, DOI 10.1093/carcin/22.12.2005; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296	52	63	64	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8535	8544		10.1038/sj.onc.1207928	http://dx.doi.org/10.1038/sj.onc.1207928			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15361853				2022-12-17	WOS:000224870700014
J	Gomyo, Y; Sasaki, J; Branch, C; Roth, JA; Mukhopadhyay, T				Gomyo, Y; Sasaki, J; Branch, C; Roth, JA; Mukhopadhyay, T			5-aza-2 '-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells	ONCOGENE			English	Article						5-aza-2-deoxycytidine; caspase-9; p53; lung tumor; apoptosis	DNA METHYLATION; P53-DEPENDENT APOPTOSIS; CPG METHYLATION; DOWN-REGULATION; IN-VITRO; GENE; ACTIVATION; GROWTH; INHIBITION; APAF-1	Treating lung cancer cell lines using low-dose 5-aza-2'-deoxycytidine (DAC) caused an accumulation of procaspase-9 through mRNA upregulation, but the cells did not undergo apoptosis. However, when cells were treated with DAC and infected with a low dose of a recombinant wildtype p53 adenovirus vector (Ad-p53), a synergistic growth inhibitory effect was observed. Combination treatment induced Apaf-1 and procaspase-9 expression in which cytochrome c releases by Ad-p53 triggered the mitochondrial pathway of apoptosis. Selective blockage of caspase-9 activities by Z-LEHD-FMK completely attenuated DAC-induced enhancement of apoptosis mediated by Ad-p53 infection, and ectopic overexpression of procaspase-9 sensitized cells to Ad-p53-induced apoptosis in p53-null cells. In addition, DAC sensitized lung cancer cells to cisplatin and paclitaxel. Induction of the mitochondrial pathway of apoptosis using a slightly toxic dose of DAC may therefore be a strategy for treating lung cancer, and DAC treatment may have clinical implications when combined with chemotherapy or apoptosis-inducing gene therapy.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Unit 023, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Sasaki, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Unit 023, 1515 Holcombe Blvd, Houston, TX 77030 USA.	saji@gpo.kumamoto-u.ac.jp			NCI NIH HHS [P01 CA78778-01A1, P50-CA709007, 2P50-CA70970-04, CA 16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA078778] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ammanamanchi S, 1998, J BIOL CHEM, V273, P16527, DOI 10.1074/jbc.273.26.16527; Ammanamanchi S, 2001, J BIOL CHEM, V276, P32854, DOI 10.1074/jbc.M103951200; Bender CM, 1998, CANCER RES, V58, P95; CHARACHE S, 1983, P NATL ACAD SCI-BIOL, V80, P4842, DOI 10.1073/pnas.80.15.4842; Debatin KM, 2000, TOXICOL LETT, V112, P41, DOI 10.1016/S0378-4274(99)00252-0; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; HERMAN JG, 1995, CANCER RES, V55, P4525; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jones PA, 1996, CANCER RES, V56, P2463; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jordan P, 2000, CELL MOL LIFE SCI, V57, P1229, DOI 10.1007/PL00000762; Kano Y, 1998, CANCER CHEMOTH PHARM, V42, P91, DOI 10.1007/s002800050790; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; LENZI R, 1995, INT J ONCOL, V6, P447; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; MYEROFF LL, 1995, CANCER RES, V55, P5545; Nishiyama J, 2001, BIOCHEM J, V360, P49, DOI 10.1042/0264-6021:3600049; Nishizaki M, 2001, CLIN CANCER RES, V7, P2887; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; PINTO A, 1984, BLOOD, V64, P922; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; STEEL GG, 1979, INT J RADIAT ONCOL, V5, P85; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Wu GS, 2002, ONCOGENE, V21, P1, DOI 10.1038/sj.onc.1205020; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	35	63	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6779	6787		10.1038/sj.onc.1207381	http://dx.doi.org/10.1038/sj.onc.1207381			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273730				2022-12-17	WOS:000223653600009
J	Kinlen, L				Kinlen, L			Infections and immune factors in cancer: the role of epidemiology	ONCOGENE			English	Article						infections; immune impairment; cancer	EPSTEIN-BARR-VIRUS; CHILDHOOD LEUKEMIA; HUMAN-PAPILLOMAVIRUS; BREAST-CANCER; HEPATITIS-B; RISK; CARCINOMA; AFLATOXIN; EXPOSURE; TRANSPLANTATION	An infective, mostly viral, basis has been found in an increasing number of different human cancers. In all cases, the neoplasm is a rare response to the relevant infection, which is usually present in persistent form, and requiring specific cofactors for malignancy to develop. In some cases, epidemiological evidence of infectivity preceded and promoted identification of the specific infection involved and even the discovery of the microbe itself, as in Burkitt's lymphoma and cervix cancer. In other cases, the discovery of the agent came first as in stomach and nasopharynx cancers, and epidemiology has been concerned mainly with confirming the relationship, measuring the size of the risk and identifying cofactors. Infection-linked cancers include some of the commonest malignancies in certain large world regions, amounting to over 20% of all cancer in the developing countries. In addition to these cancers are others such as childhood leukaemia that show features indicative of an infective basis though no underlying agent has been identified. Advances in this field invite speculation about possible future discoveries and how these might be promoted. However, in that majority of cancers that are unrelated to sexual behaviour, there will be nothing even at the population level to suggest an infective basis because what is transmitted from one individual to another is not the neoplasm itself, but the underlying, often silent, infection to which the malignancy is an uncommon response. The increasing prevalence of immune impairment in human populations, as a result of the use of immunosuppressive drugs with organ transplants and the spread of HIV infection, has produced marked effects on cancer incidence in the affected groups including increases, of skin cancers, non-Hodgkin's lymphoma and Kaposi's sarcoma and to a lesser extent of many other cancers, in some cases at least due to the release from immunological control of incipient infection-based malignancies.	Radcliffe Infirm, Canc Epidemiol Unit, Oxford OX2 6HE, England	Radcliffe Infirmary; University of Oxford	Kinlen, L (corresponding author), Radcliffe Infirm, Canc Epidemiol Unit, Gibson Bldg, Oxford OX2 6HE, England.	leo.kinlen@dphpc.ox.ac.uk						Adami J, 2003, BRIT J CANCER, V89, P1221, DOI 10.1038/sj.bjc.6601219; Alexander FE, 1997, BRIT J CANCER, V75, P457, DOI 10.1038/bjc.1997.77; Alexander FE, 1999, EUR J CANCER, V35, P439, DOI 10.1016/S0959-8049(98)00385-2; BEASLEY RP, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P532; BEASLEY RP, 1981, LANCET, V2, P1129; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BIRKELAND SA, 1995, INT J CANCER, V60, P183, DOI 10.1002/ijc.2910600209; Boshoff C, 2002, NAT REV CANCER, V2, P373, DOI 10.1038/nrc797; Boutou O, 2002, BRIT J CANCER, V87, P740, DOI 10.1038/sj.bjc.6600529; BURKITT D, 1962, NATURE, V194, P232, DOI 10.1038/194232a0; BURNET FM, 1970, PROG EXP TUMOR RES, V13, P1; Castellsague Xavier, 2003, J Natl Cancer Inst Monogr, P20; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CRAWFORD DH, 1981, INT J CANCER, V28, P705, DOI 10.1002/ijc.2910280608; DANESH J, 1999, INFECT HUMAN CANC CA, V33; DEMETER LM, 1993, J INFECT DIS, V168, P38, DOI 10.1093/infdis/168.1.38; Dickinson HO, 1999, BRIT J CANCER, V81, P144, DOI 10.1038/sj.bjc.6690664; Dockerty JD, 2001, INT J EPIDEMIOL, V30, P1428, DOI 10.1093/ije/30.6.1428; Doll R, 1999, BRIT J CANCER, V81, P3, DOI 10.1038/sj.bjc.6690642; Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;347::AID-IJC4&gt;3.0.CO;2-2; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; Franceschi S, 2000, LANCET, V356, P871, DOI 10.1016/S0140-6736(00)02673-8; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; GREAVES MF, 1988, LEUKEMIA, V7, P349; HANTO DW, 1981, CANCER RES, V41, P4253; Herrero R, 2003, JNCI-J NATL CANCER I, V95, P1772, DOI [10.1093/jnci/djg/107, 10.1093/jnci/djg107]; HERRINGTON MM, 1996, CANC EPIDEMIOLOGY PR; HOOVER R, 1973, LANCET, V2, P55; *IARC, 1994, MON EV CARC RISKS HU, V61; IARC, 1994, MON EV CARC RISKS HU; *IARC, 1995, IARC MON EV CARC RIS, V64; Infante-Rivard C, 2000, BRIT J CANCER, V83, P1559, DOI 10.1054/bjoc.2000.1495; Jourdan-Da Silva N, 2004, BRIT J CANCER, V90, P139, DOI 10.1038/sj.bjc.6601384; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1979, BRIT MED J, V2, P1461, DOI 10.1136/bmj.2.6203.1461; KINLEN LJ, 1971, LANCET, V2, P398; KINLEN LJ, 1993, BRIT MED J, V306, P743, DOI 10.1136/bmj.306.6880.743; KINLEN LJ, 1995, BMJ-BRIT MED J, V310, P763, DOI 10.1136/bmj.310.6982.763; KINLEN LJ, 1995, CANCER CAUSE CONTROL, V6, P445, DOI 10.1007/BF00052185; KINLEN LJ, 1990, LANCET, V336, P577, DOI 10.1016/0140-6736(90)93389-7; KINLEN LJ, 1991, BRIT MED J, V303, P1357, DOI 10.1136/bmj.303.6814.1357; KINLEN LJ, 1995, BRIT J CANCER, V71, P1, DOI 10.1038/bjc.1995.1; KINLEN LJ, 1994, BRIT MED J, V309, P1197, DOI 10.1136/bmj.309.6963.1197; Kinlen LJ, 2001, LANCET, V357, P858, DOI 10.1016/S0140-6736(00)04208-2; KINLEN LJ, 2000, RADIOL PROT B, V226, P9; KINLEN LJ, UNPUB; Koushik A, 2001, CANCER CAUSE CONTROL, V12, P483, DOI 10.1023/A:1011266413087; LABRECQUE LG, 1995, CANCER RES, V55, P39; Lin CT, 1997, AM J PATHOL, V150, P1745; LITTLE J, 1999, IARC SCI PUBLICATION, V149; Ma X, 2002, BRIT J CANCER, V86, P1419, DOI 10.1038/sj.bjc.6600274; MACMAHON B, 1966, CANCER RES, V26, P1189; Magrath I, 1999, JNCI-J NATL CANCER I, V91, P1349, DOI 10.1093/jnci/91.16.1349; Newton R, 1999, CANCER SURV, V33, P291; Newton R, 1996, BRIT J CANCER, V74, P1511, DOI 10.1038/bjc.1996.581; Newton R, 1999, CANCER SURV, V33, P237; OLD LJ, 1966, P NATL ACAD SCI USA, V56, P1699, DOI 10.1073/pnas.56.6.1699; ORTH G, 1978, P NATL ACAD SCI USA, V75, P1537, DOI 10.1073/pnas.75.3.1537; PARKIN DM, 1999, INFECT HUM CANC CANC, V33; Petridou E, 1996, BRIT J CANCER, V73, P1278, DOI 10.1038/bjc.1996.245; PETRIDOU E, 1993, BRIT MED J, V307, P774, DOI 10.1136/bmj.307.6907.774; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; QIAN GS, 1994, CANCER EPIDEM BIOMAR, V3, P3; Rigoni-Stern D, 1842, G SERVIRE PROGR PA 2, V2, P507; Rosenbaum PF, 2000, AM J EPIDEMIOL, V152, P1136, DOI 10.1093/aje/152.12.1136; ROSS RK, 1992, LANCET, V339, P943, DOI 10.1016/0140-6736(92)91528-G; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Smith EM, 1998, LARYNGOSCOPE, V108, P1098, DOI 10.1097/00005537-199807000-00027; STEENBERGEN RDM, 1995, CANCER RES, V55, P5465; Thomas L, 1959, CELLULAR HUMORAL ASP, P529; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; VIZCAINO P, 1994, CANCER CAUSE CONTROL, V5, P517, DOI 10.1007/BF01831379; VONKA V, 1984, INT J CANCER, V33, P61, DOI 10.1002/ijc.2910330111; WARREN JR, 1983, LANCET, V1, P1273; WILD CP, 1991, LANCET, V337, P1602, DOI 10.1016/0140-6736(91)93295-K; Xue SA, 2003, BRIT J CANCER, V89, P113, DOI 10.1038/sj.bjc.6601027; Yasui Y, 2001, CANCER EPIDEM BIOMAR, V10, P9; YU MW, 1993, CANCER RES, V53, P790	80	63	63	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2004	23	38					6341	6348		10.1038/sj.onc.1207898	http://dx.doi.org/10.1038/sj.onc.1207898			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	848LJ	15322509				2022-12-17	WOS:000223468800003
J	Luwor, RB; Zhu, HJ; Walker, F; Vitali, AA; Perera, RM; Burgess, AW; Scott, AM; Johns, TG				Luwor, RB; Zhu, HJ; Walker, F; Vitali, AA; Perera, RM; Burgess, AW; Scott, AM; Johns, TG			The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR	ONCOGENE			English	Article						epidermal growth factor receptor; phosphatidylinositol-3 kinase; cell survial; dimerization	CONFERS ENHANCED TUMORIGENICITY; HUMAN GLIOBLASTOMA CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; SIGNAL-TRANSDUCTION; KINASE ACTIVATION; CELLULAR-RESPONSE; LUNG CARCINOMAS; CANCER-THERAPY	Mutations of the epidermal growth factor receptor (EGFR) gene are found at a relatively high frequency in glioma, with the most common being the de2-7 EGFR (or EGFRvIII). This mutation arises from an in-frame deletion of exons 2-7, which removes 267 amino acids from the extracellular domain of the receptor. Despite being unable to bind ligand, the de2-7 EGFR is constitutively active and imparts a significant in vivo growth advantage to glioma cells. In order to examine the signalling pathways activated by the de2-7 EGFR and its biological effects in an in vitro system, the de2-7 EGFR gene was transfected into the murine IL-3-dependent pro-B-cell line BaF/3. Expression of the de2-7 EGFR enhanced the survival of BaF/3 cells in the absence of IL-3 by reducing apoptosis in a phosphatidylinositol 3-kinase (PI3-K)-dependent manner. Interestingly, while de2-7 EGFR also enhanced proliferation of BaF/3 cells in low levels of IL-3, this effect was independent of PI3-K. Survival and proliferation were further enhanced when BaF/3 cells were cotransfected with the de2-7 and wt EGFR. This was due to heterodimerization between the de2-7 and wt EGFR leading to trans-phosphorylation of the wt EGFR. This observation is directly relevant to glioma where de2-7 and wt EGFR appear to be coexpressed. Thus, expression of de2-7 EGFR in BaF/3 cells provides an in vitro model for evaluating the signalling pathways activated by this receptor.	Austin Hosp, Ludwig Inst Canc Res, Oncogen Signalling Lab, Tumour Targeting Program,Melbourne Branch, Heidelberg, Vic 3084, Australia; Royal Melbourne Hosp, Epithelial Biochem Lab, Parkville, Vic 3050, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Johns, TG (corresponding author), Austin Hosp, Ludwig Inst Canc Res, Oncogen Signalling Lab, Tumour Targeting Program,Melbourne Branch, Heidelberg, Vic 3084, Australia.	Terry.Johns@ludwig.edu.au	Johns, Terrance/C-2441-2008	Johns, Terrance/0000-0002-8874-4543; Luwor, Rodney/0000-0002-3020-4245; Zhu, Hong-Jian/0000-0002-1478-995X; Scott, Andrew/0000-0002-6656-295X				BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; Burri SH, 1999, INT J RADIAT ONCOL, V43, P423, DOI 10.1016/S0360-3016(98)00385-X; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Klingler-Hoffmann M, 2003, INT J CANCER, V105, P331, DOI 10.1002/ijc.11085; Korshunov A, 1999, J CLIN PATHOL, V52, P574, DOI 10.1136/jcp.52.8.574; Kuan CT, 2001, ENDOCR-RELAT CANCER, V8, P83, DOI 10.1677/erc.0.0080083; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; Lorimer IAJ, 2001, BBA-MOL CELL RES, V1538, P1, DOI 10.1016/S0167-4889(00)00129-4; Luwor RB, 2001, CANCER RES, V61, P5355; MASUI H, 1984, CANCER RES, V44, P1002; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; Narita Y, 2002, CANCER RES, V62, P6764; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; O'Rourke DM, 1998, ONCOGENE, V16, P1197, DOI 10.1038/sj.onc.1201635; Olapade-Olaopa EO, 2000, BRIT J CANCER, V82, P186; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Tang CK, 2000, CANCER RES, V60, P3081; Walker F, 1998, GROWTH FACTORS, V16, P53, DOI 10.3109/08977199809017491; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; Weinmann P, 1999, BLOOD, V93, P3106; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; Wikstrand CJ, 1998, J NEUROVIROL, V4, P148, DOI 10.3109/13550289809114515; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Wu CJ, 1999, DNA CELL BIOL, V18, P731, DOI 10.1089/104454999314872; Zhu HJ, 2003, GROWTH FACTORS, V21, P15, DOI 10.1080/0897719031000096424	45	63	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6095	6104		10.1038/sj.onc.1207870	http://dx.doi.org/10.1038/sj.onc.1207870			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15221011				2022-12-17	WOS:000223261000009
J	Hou, YF; Yuan, ST; Li, HC; Wu, J; Lu, JS; Liu, G; Lu, LJ; Shen, ZZ; Ding, J; Shao, ZM				Hou, YF; Yuan, ST; Li, HC; Wu, J; Lu, JS; Liu, G; Lu, LJ; Shen, ZZ; Ding, J; Shao, ZM			ER beta exerts multiple stimulative effects on human breast carcinoma cells	ONCOGENE			English	Article						breast carcinoma; estrogen receptor; matrix metalloproteinases (MMPs)	ESTROGEN-RECEPTOR-BETA; MESSENGER-RNA EXPRESSION; MATRIX METALLOPROTEINASE-2; METASTATIC PHENOTYPE; ALPHA; GENE; PROLIFERATION; TRANSFECTION; PROTEINASE; INVASION	Recent studies of ERs in breast cancer have demonstrated the existence of ERbeta in addition to ERalpha. Some clinical data indicated that ERbeta had prognostic value for patient's survival, which suggested that ERbeta plays a key role in breast cancer development and,metastasis. To test this hypothesis, we generated an ERbeta high-expression cell line by reintroduced human ERbeta cDNA into MDA-MB-435 cells. We demonstrated that ERbeta exerted multiple tumor-stimulative effects on human breast carcinoma cells both in vivo and in vitro. In in vitro studies, ERbeta was able to increase the proliferation and invasion of MDA-MB-435 cells significantly, while these effects were totally estradiol independent. Also, this stimulation was characterized by downregulation of p2l and upregulation of MMP-9, as well as transcriptional factor Est-1. In in vivo studies, we also demonstrated that ERbeta-transfected MDA-MB-435 cells grew much faster and had more pulmonary metastasis than mock or wild-type cells in nude mice. In ERbeta-transfected MDA-MB-435 xenografts, ERbeta caused significant reduction in p2l protein levels. Similar effects of ERbeta on MMP-9 and Ets-1 expression noted in vitro studies were also observed in the in vivo studies. These in vitro and in vivo studies indicated that ERbeta exerted multiple stimulative effects on breast cancer development and metastasis.	Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, Shanghai 201203, Peoples R China; Fudan Univ, Dept Surg, Canc Hosp, Inst Canc, Shanghai 200032, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; Fudan University	Ding, J (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, Div Antitumor Pharmacol, State Key Lab Drug Res, 555 Zu Chong Zhi Rd, Shanghai 201203, Peoples R China.	jding@mail.shcnc.ac.cn; zhimingshao@yahoo.com	LIU, GANG/AAR-4584-2021	LIU, GANG/0000-0001-6620-176X				Albini A, 1998, Pathol Oncol Res, V4, P230; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Bhat RA, 1998, J STEROID BIOCHEM, V67, P233, DOI 10.1016/S0960-0760(98)00115-0; DelSal G, 1996, CRIT REV ONCOGENESIS, V7, P127, DOI 10.1615/CritRevOncog.v7.i1-2.80; Dotzlaw H, 1999, CANCER RES, V59, P529; Dotzlaw H, 1997, J CLIN ENDOCR METAB, V82, P2371, DOI 10.1210/jc.82.7.2371; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; FOLKMAN J, 1990, CANCER METAST REV, V9, P171, DOI 10.1007/BF00046358; HAGGITT RC, 1994, HUM PATHOL, V25, P982, DOI 10.1016/0046-8177(94)90057-4; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Hu YF, 1998, INT J ONCOL, V12, P1225; Irwin JC, 1996, J CLIN INVEST, V97, P438, DOI 10.1172/JCI118433; Jarvinen TAH, 2000, AM J PATHOL, V156, P29, DOI 10.1016/S0002-9440(10)64702-5; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Leygue E, 1998, CANCER RES, V58, P3197; Lurlaro M, 1999, EUR J CLIN INVEST, V29, P793; Mizumoto H, 2002, INT J CANCER, V100, P401, DOI 10.1002/ijc.10504; Moore JT, 1998, BIOCHEM BIOPH RES CO, V247, P75, DOI 10.1006/bbrc.1998.8738; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Nakayama T, 2001, MODERN PATHOL, V14, P415, DOI 10.1038/modpathol.3880328; Ogawa S, 1998, BIOCHEM BIOPH RES CO, V243, P122, DOI 10.1006/bbrc.1997.7893; Palmieri C, 2002, ENDOCR-RELAT CANCER, V9, P1, DOI 10.1677/erc.0.0090001; Saeki H, 2000, CANCER, V89, P1670, DOI 10.1002/1097-0142(20001015)89:8<1670::AID-CNCR4>3.0.CO;2-J; Shao ZM, 1998, EXP CELL RES, V241, P394, DOI 10.1006/excr.1998.4066; Shao ZM, 2002, INT J CANCER, V98, P234, DOI 10.1002/ijc.10183; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sillem M, 1999, EUR J GYNAECOL ONCOL, V20, P367; Tonetti DA, 2003, J STEROID BIOCHEM, V87, P47, DOI 10.1016/j.jsbmb.2003.07.003; Urquidi V, 2002, CLIN CANCER RES, V8, P61; vanGolen KL, 1996, CLIN EXP METASTAS, V14, P95, DOI 10.1007/BF00121206; Wen XF, 2002, ONCOL REP, V9, P937	32	63	71	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5799	5806		10.1038/sj.onc.1207765	http://dx.doi.org/10.1038/sj.onc.1207765			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15208676				2022-12-17	WOS:000222629800009
J	Ala-aho, R; Ahonen, M; George, SJ; Heikkila, J; Grenman, R; Kallajoki, M; Kahari, VM				Ala-aho, R; Ahonen, M; George, SJ; Heikkila, J; Grenman, R; Kallajoki, M; Kahari, VM			Targeted inhibition of human collagenase-3 (MMP-13) expression inhibits squamous cell carcinoma growth in vivo	ONCOGENE			English	Article						collagenase; squamous cell carcinoma; invasion; ribozyme	ACTIVATED PROTEIN-KINASE; MATRIX METALLOPROTEINASE-13; TISSUE INHIBITOR; HUMAN KERATINOCYTES; FACTOR-BETA; RIBOZYMES; INVASION; CANCER; INFLAMMATION; CHONDROCYTES	Squamous cell carcinomas (SCCs) of the head and neck are characterized by a high tendency for local invasion and metastasis to lymph nodes. Collagenase-3 (MMP-13) is specifically expressed by tumor cells in SCCs of the head and neck and its expression correlates with their invasion capacity. To specifically examine the role of MMP-13 in the growth and invasion of SCC, we constructed a hammerhead ribozyme targeted against human MMP-13 mRNA. The anti-MMP-13 ribozyme effectively cleaved MMP-13 transcripts in vitro. Adenoviral delivery of the anti-MMP-13 ribozyme to cutaneous metastatic SCC cells in culture resulted in potent and specific inhibition of the production of proMMP-13 and markedly suppressed invasion of SCC cells through Matrigel. In addition, adenoviral delivery of anti-MMP-13 ribozyme promoted apoptosis in SCC cells within 72 h. Intratumoral injection of anti-MMP-13 ribozyme coding adenovirus into human SCC xenografts established in SCID mice potently suppressed tumor growth, inhibited MMP-13 expression and gelatinolytic activity and reduced the number of proliferating cells within the tumors. These results provide evidence for an important role for MMP-13 in SCC growth and invasion and identify MMP-13 as a promising target for ribozyme-based therapy of SCC in vivo.	Univ Turku, Dept Med Biochem & Mol Biol, FIN-20520 Turku, Finland; Univ Turku, Dept Dermatol, FIN-20520 Turku, Finland; Univ Turku, Ctr Biotechnol, SF-20500 Turku, Finland; Bristol Royal Infirm & Gen Hosp, Bristol Heart Inst, Bristol BS2 8HW, Avon, England; Abo Akad Univ, Dept Biochem & Pharm, FIN-20520 Turku, Finland; Univ Turku, Cent Hosp, Dept Otorhinolaryngol Head & Neck Surg, FIN-20520 Turku, Finland; Univ Turku, Cent Hosp, Dept Pathol, FIN-20520 Turku, Finland	University of Turku; University of Turku; University of Turku; Bristol Royal Infirmary; University of Bristol; Abo Akademi University; University of Turku; University of Turku	Kahari, VM (corresponding author), Univ Turku, Dept Med Biochem & Mol Biol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.	veli-matti.kahari@utu.fi	Kahari, Veli-Matti/T-4925-2019; Kähäri, Veli-Matti/E-5144-2011	Kahari, Veli-Matti/0000-0003-2421-9368; Kähäri, Veli-Matti/0000-0003-2421-9368				Ahonen M, 2003, ONCOGENE, V22, P2121, DOI 10.1038/sj.onc.1206292; Ahonen M, 2002, MOL THER, V5, P705, DOI 10.1006/mthe.2002.0606; Airola K, 1999, BRIT J CANCER, V80, P733, DOI 10.1038/sj.bjc.6690417; Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; Ala-aho R, 2000, ONCOGENE, V19, P248, DOI 10.1038/sj.onc.1203306; Ala-Aho R, 2002, INT J CANCER, V97, P283, DOI 10.1002/ijc.1619; Ala-Aho R, 2002, ONCOGENE, V21, P1187, DOI 10.1038/sj.onc.1205198; Ashworth JL, 1999, BIOCHEM J, V340, P171, DOI 10.1042/0264-6021:3400171; Bostrom PJ, 2000, INT J CANCER, V88, P417, DOI 10.1002/1097-0215(20001101)88:3<417::AID-IJC14>3.3.CO;2-7; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Cazorla M, 1998, J PATHOL, V186, P144, DOI 10.1002/(SICI)1096-9896(1998100)186:2<144::AID-PATH147>3.0.CO;2-#; Etoh T, 2000, GUT, V47, P50, DOI 10.1136/gut.47.1.50; Fernando FS, 2001, J MOL MED-JMM, V79, P695, DOI 10.1007/s001090100272; Fosang AJ, 1996, FEBS LETT, V380, P17, DOI 10.1016/0014-5793(95)01539-6; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; George SJ, 2000, CIRCULATION, V101, P296, DOI 10.1161/01.CIR.101.3.296; Hernandez YJ, 1999, J VIROL, V73, P8549, DOI 10.1128/JVI.73.10.8549-8558.1999; Hua J, 1996, CANCER RES, V56, P5279; Jarvis TC, 2000, J IMMUNOL, V165, P493, DOI 10.4049/jimmunol.165.1.493; Johansson N, 1999, AM J PATHOL, V154, P469, DOI 10.1016/S0002-9440(10)65293-5; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; Johansson N, 1997, CELL GROWTH DIFFER, V8, P243; Johansson N, 1997, AM J PATHOL, V151, P499; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knauper V, 1997, EUR J BIOCHEM, V248, P369, DOI 10.1111/j.1432-1033.1997.00369.x; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; Lewin AS, 2001, TRENDS MOL MED, V7, P221, DOI 10.1016/S1471-4914(01)01965-7; Lindy O, 1997, ARTHRITIS RHEUM-US, V40, P1391, DOI 10.1002/art.1780400806; Lu Y, 1998, DNA CELL BIOL, V17, P643, DOI 10.1089/dna.1998.17.643; Mao DL, 1999, BIOCHEM BIOPH RES CO, V261, P904, DOI 10.1006/bbrc.1999.1142; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nielsen BS, 2001, CANCER RES, V61, P7091; Nikkola J, 2001, MELANOMA RES, V11, P157, DOI 10.1097/00008390-200104000-00011; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Pavco PA, 2000, CLIN CANCER RES, V6, P2094; Ravanti L, 2001, FASEB J, V15, P1098, DOI 10.1096/fj.00-0588fje; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Reboul P, 1996, J CLIN INVEST, V97, P2011, DOI 10.1172/JCI118636; Sukhova GK, 1999, CIRCULATION, V99, P2503, DOI 10.1161/01.CIR.99.19.2503; Uitto VJ, 1998, AM J PATHOL, V152, P1489; Uria JA, 1998, AM J PATHOL, V153, P91, DOI 10.1016/S0002-9440(10)65549-6; Usman N, 2000, J CLIN INVEST, V106, P1197, DOI 10.1172/JCI11631; Vaalamo M, 1998, AM J PATHOL, V152, P1005; Vaalamo M, 1997, J INVEST DERMATOL, V109, P96, DOI 10.1111/1523-1747.ep12276722; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233	51	63	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	2004	23	30					5111	5123		10.1038/sj.onc.1207678	http://dx.doi.org/10.1038/sj.onc.1207678			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	834AE	15094779				2022-12-17	WOS:000222382500001
J	Feshchenko, EA; Smirnova, EV; Swaminathan, G; Teckchandani, AM; Agrawal, R; Band, H; Zhang, XL; Annan, RS; Carr, SA; Tsygankov, AY				Feshchenko, EA; Smirnova, EV; Swaminathan, G; Teckchandani, AM; Agrawal, R; Band, H; Zhang, XL; Annan, RS; Carr, SA; Tsygankov, AY			TULA: an SH3- and UBA-containing protein that binds to c-Cbl and ubiquitin	ONCOGENE			English	Article						TULA; c-Cbl; UBA; SH3; ubiquitin; protein tyrosine kinase	GROWTH-FACTOR RECEPTOR; T-CELL-RECEPTOR; DAMAGE-INDUCIBLE PROTEINS; TYROSINE KINASE; RING FINGER; EGF-RECEPTOR; NEGATIVE REGULATION; PHOSPHORYLATION SITES; HERPESVIRUS-SAIMIRI; MASS-SPECTROMETRY	Downregulation of protein tyrosine kinases is a major function of the multidomain protein c-Cbl. This effect of c-Cbl is critical for both negative regulation of normal physiological stimuli and suppression of cellular transformation. In spite of the apparent importance of these effects of c-Cbl, their own regulation is poorly understood. To search for possible novel regulators of c-Cbl, we purified a number of c-Cbl-associated proteins by affinity chromatography and identified them by mass spectrometry. Among them, we identified the UBA- and SH3-containing protein T-cell Ubiquitin LigAnd (TULA), which can also bind to ubiquitin. Functional studies in a model system based on co-expression of TULA, c-Cbl, and EGF receptor in 293T cells demonstrate that TULA is capable of inhibiting c-Cbl-mediated downregulation of EGF receptor. Furthermore, modulation of TULA concentration in Jurkat T-lymphoblastoid cells demonstrates that TULA upregulates the activity of both Zap kinase and NF-AT transcription factor. Therefore, our study indicates that TULA counters the inhibitory effect of c-Cbl on protein tyrosine kinases and, thus, may be involved in the regulation of biological effects of c-Cbl. Finally, our results suggest that TULA-mediated inhibition of the effects of c-Cbl on protein tyrosine kinases is caused by TULA-induced ubiquitylation and degradation of c-Cbl.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; GlaxoSmithKline, King Of Prussia, PA USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; GlaxoSmithKline; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Tsygankov, AY (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.	alexander.tsygankov@temple.edu	Carr, Steven A./AAH-8366-2019; Tsygankov, Alexander Y/K-6205-2017		NATIONAL CANCER INSTITUTE [R01CA078499] Funding Source: NIH RePORTER; NCI NIH HHS [CA78499] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Bertolaet BL, 2001, J MOL BIOL, V313, P955, DOI 10.1006/jmbi.2001.5105; Broome MA, 1999, ONCOGENE, V18, P2908, DOI 10.1038/sj.onc.1202873; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; de Melker AA, 2001, J CELL SCI, V114, P2167; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Ettenberg SA, 1999, ONCOGENE, V18, P1855, DOI 10.1038/sj.onc.1202499; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Gatlin CL, 1998, ANAL BIOCHEM, V263, P93, DOI 10.1006/abio.1998.2809; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hartley D, 1996, J BIOL CHEM, V271, P21939, DOI 10.1074/jbc.271.36.21939; Hasham MG, 2004, VIROLOGY, V320, P313, DOI 10.1016/j.virol.2003.11.032; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Klapper LN, 2000, CANCER RES, V60, P3384; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Magnifico A, 2003, J BIOL CHEM, V278, P43169, DOI 10.1074/jbc.M308009200; Mancini A, 2002, J BIOL CHEM, V277, P14635, DOI 10.1074/jbc.M109214200; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Merlo JJ, 2001, VIROLOGY, V279, P325, DOI 10.1006/viro.2000.0714; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; Oksvold MP, 2001, EUR J CELL BIOL, V80, P285, DOI 10.1078/0171-9335-00160; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Rao N, 2000, J IMMUNOL, V164, P4616, DOI 10.4049/jimmunol.164.9.4616; Rao NV, 2002, P NATL ACAD SCI USA, V99, P3794, DOI 10.1073/pnas.062055999; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; SANJAY A, 2001, SCI STKE, pE40; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Teckchandani AM, 2001, ONCOGENE, V20, P1739, DOI 10.1038/sj.onc.1204246; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; TSYGANKOV AY, 1994, J LEUKOCYTE BIOL, V55, P289, DOI 10.1002/jlb.55.3.289; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; Wang HY, 2001, J BIOL CHEM, V276, P26004, DOI 10.1074/jbc.M010738200; Wang J, 2001, BIOTECHNIQUES, V31, P722, DOI 10.2144/01314bm01; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Wattenhofer M, 2001, HUM GENET, V108, P140, DOI 10.1007/s004390000453; Wilhelmsen K, 2002, ONCOGENE, V21, P1079, DOI 10.1038/sj.onc.1205166; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	72	63	64	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4690	4706		10.1038/sj.onc.1207627	http://dx.doi.org/10.1038/sj.onc.1207627			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15107835				2022-12-17	WOS:000221799200005
J	Mitani, K				Mitani, K			Molecular mechanisms of leukemogenesis by AML1/EVI-1	ONCOGENE			English	Article						AML1/EVI-1; apoptosis; dominant-negative effects; JNK; TGF beta; transcription factor	CHRONIC MYELOCYTIC-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; T(3/21) FUSION PRODUCT; ACUTE MYELOID-LEUKEMIA; FACTOR-BETA; GROWTH-INHIBITION; BLASTIC CRISIS; EVI-1; GENE; AML1	The AML1/EVI-1 chimeric gene is generated by the t(3; 21)(q26; q22) translocation and plays a pivotal role in progression of hematopoietic stem cell malignancies such as chronic myelocytic leukemia and myelodysplastic syndrome. In AML1/EVI-1, an N-terminal half of AML1 including a runt homology domain is fused to the entire zinc-finger EVI-1 protein. AML1 is essential for hematopoietic cell development in fetal liver and its lineage-specific differentiation in adult. In contrast, EVI-1 is barely expressed in normal hematopoietic cells, but it is overexpressed in chronic myelocytic leukemia in blastic crisis and myelodysplastic syndrome-derived leukemia. There are at least four mechanisms identified in AML1/EVI-1 fusion protein that possibly lead into malignant transformation of hematopoietic stem cells. Firstly, AML1/EVI-1 exerts dominant-negative effects over AML1-induced transcriptional activation. Although target genes repressed by AML1/EVI-1 are still not known, binding competition to a specific DNA sequence and histone deacetylase recruitment through a co-repressor CtBP in EVI-1 part are conceivable underlying mechanisms for the dominant-negative effects. Secondly, AML1/EVI-1 interferes with TGFbeta signaling and antagonizes the growth-inhibitory effects of TGFbeta. The first zinc-finger domain of EVI-1 associates with Smad3, a TGFb signal transducer, and represses its transcriptional activity by recruiting histone deacetylase through CtBP that interacts with EVI-1. Thirdly, AML1/EVI-1 blocks JNK activity and prevents stress-induced apoptosis. AML1/EVI-1 associates with JNK through the first zinc-finger domain of EVI-1 and disturbs the association between JNK and its substrates. Lastly, AML1/EVI-1 enhances AP-1 activity by activating the c-Fos promoter depending on the second zinc-finger domain of EVI-1, and promotes cell proliferation. All these functions cooperatively contribute to the malignant transformation of the hematopoietic stem cells by AML1/EVI-1.	Dokkyo Univ, Sch Med, Dept Hematol, Mibu, Tochigi 3210293, Japan	Dokkyo Medical University	Mitani, K (corresponding author), Dokkyo Univ, Sch Med, Dept Hematol, 880 Kitakobayashi, Mibu, Tochigi 3210293, Japan.	kinukom-tky@umin.ac.jp						BAE SC, 1993, ONCOGENE, V8, P809; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Izutsu K, 2002, ONCOGENE, V21, P2695, DOI 10.1038/sj.onc.1205356; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 2000, EMBO J, V19, P2958, DOI 10.1093/emboj/19.12.2958; Kurokawa M, 1998, BLOOD, V92, P4003, DOI 10.1182/blood.V92.11.4003.423a56_4003_4012; KUROKAWA M, 1995, ONCOGENE, V11, P833; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MITANI K, 1995, BRIT J HAEMATOL, V90, P711, DOI 10.1111/j.1365-2141.1995.tb05606.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Ogawa S, 1996, LEUKEMIA, V10, P788; Ogawa S, 1996, ONCOGENE, V13, P183; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Tanaka K, 1998, BLOOD, V91, P1688, DOI 10.1182/blood.V91.5.1688.1688_1688_1699; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444	28	63	70	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4263	4269		10.1038/sj.onc.1207777	http://dx.doi.org/10.1038/sj.onc.1207777			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156182				2022-12-17	WOS:000221586000011
J	Lu, T; Sathe, SS; Swiatkowski, SM; Hampole, CV; Stark, GR				Lu, T; Sathe, SS; Swiatkowski, SM; Hampole, CV; Stark, GR			Secretion of cytokines and growth factors as a general cause of constitutive NF kappa B activation in cancer	ONCOGENE			English	Article						TGF beta 2; FGF5; microarrays; mutant 293 cells; ELISA	FACTOR-C EXPRESSION; TUMOR-NECROSIS-FACTOR; LYMPH-NODE METASTASIS; RECEPTOR ACTIVATOR; FACTOR-BETA; AUTOCRINE PRODUCTION; PANCREATIC-CANCER; LIGAND RANKL; II-RECEPTOR; KINASE	The constitutive activation of nuclear factor kappaB ( NFkappaB) helps a variety of tumors to resist apoptosis and desensitizes them to chemotherapy, but the causes are still largely unknown. W e have analysed this phenomenon in eight mutant cell lines derived from human 293 cells, selected for NFkappaB- dependent expression of a marker gene, and also in seven tumor- derived cell lines. Conditioned media from all of these cells stimulated the activation of NFkappaB ( up to 30- fold) in indicator cells carrying an NFkappaB- responsive reporter. Therefore, secretion of extracellular factors as the cause of constitutive activation seems to be general. The mRNAs encoding several different cytokines and growth factors were greatly overexpressed in the tumor and mutant cells. The pattern of overexpression was distinct in each cell line, indicating that the phenomenon is complex. Two secreted factors whose roles in the constitutive activation of NFkappaB are not well defined were investigated further as pure proteins: transforming growth factor beta2 ( TGFbeta2) and fibroblast growth factor 5 ( FGF5) were both highly expressed in some mutant clones and tumor cell lines, each activated NFkappaB alone, and the combination was synergistic. Our data indicate that a group of different factors, expressed at abnormally high levels, can contribute singly and synergistically to the constitutive activation of NFkappaB in all of the mutant and tumor cell lines we studied. Since several NFkappaB target genes encode secreted proteins that induce NFkappaB, autocrine loops are likely to be ubiquitously important in the constitutive activation of NFkappaB in cancer. We provide the first evidence of the general, complex, and synergistic activation of NFkappaB in tumor and mutant cell lines through the action of secreted factors and suggest that the same explanation is likely for the constitutive activation of NFkappaB in cancers.	Cleveland Clin Fdn, Lerner Res Inst NB21, Dept Mol Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stark, GR (corresponding author), Cleveland Clin Fdn, Lerner Res Inst NB21, Dept Mol Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	starkg@ccf.org		Swiatkowski, Shannon/0000-0003-4110-268X				Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; Arlt A, 2002, CANCER RES, V62, P910; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; BRACH MA, 1991, PATHOBIOLOGY, V59, P284, DOI 10.1159/000163664; Brown JM, 2001, UROLOGY, V57, P611, DOI 10.1016/S0090-4295(00)01122-5; Byrd VM, 1999, J IMMUNOL, V162, P5853; Chen TP, 1999, INT J CANCER, V82, P43; Chen TP, 1998, CANCER RES, V58, P4805; Clauss M, 2000, SEMIN THROMB HEMOST, V26, P561, DOI 10.1055/s-2000-13213; Coussens LM, 2001, J EXP MED, V193, pF23, DOI 10.1084/jem.193.6.F23; Coward WR, 2002, J IMMUNOL, V169, P5287, DOI 10.4049/jimmunol.169.9.5287; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; Furudoi A, 2002, ONCOLOGY-BASEL, V62, P157, DOI 10.1159/000048262; Furuta K, 1999, INT J CANCER, V81, P851, DOI 10.1002/(SICI)1097-0215(19990611)81:6<851::AID-IJC2>3.0.CO;2-D; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Held-Feindt J, 2002, INT J CANCER, V98, P352, DOI 10.1002/ijc.10207; Hermouet S, 2000, LEUKEMIA LYMPHOMA, V38, P39, DOI 10.3109/10428190009060317; Hishima T, 2000, AM J SURG PATHOL, V24, P742, DOI 10.1097/00000478-200005000-00014; Iacopetta BJ, 1999, J PATHOL, V187, P428, DOI 10.1002/(SICI)1096-9896(199903)187:4<428::AID-PATH264>3.0.CO;2-A; KACINSKI BM, 1995, ANN MED, V27, P79, DOI 10.3109/07853899509031941; Karkkainen MJ, 2000, ONCOGENE, V19, P5598, DOI 10.1038/sj.onc.1203855; Karkkainen MJ, 2002, NAT CELL BIOL, V4, pE2, DOI 10.1038/ncb0102-e2; Kascinski Barry, 2002, Cancer Treat Res, V107, P285; Klomp HJ, 2002, CLIN CANCER RES, V8, P823; Kornmann M, 1997, ONCOGENE, V15, P1417, DOI 10.1038/sj.onc.1201307; Koubek K, 1999, EUR J HAEMATOL, V63, P1; Li JM, 1998, MOL CELL BIOL, V18, P110, DOI 10.1128/MCB.18.1.110; LU TB, UNPUB; Mattila MMT, 2002, INT J CANCER, V98, P946, DOI 10.1002/ijc.10283; McDermott RS, 2002, EUR CYTOKINE NETW, V13, P121; Mentlein R, 2002, J NEUROCHEM, V83, P747, DOI 10.1046/j.1471-4159.2002.01179.x; Michigami T, 2001, CANCER RES, V61, P1637; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992-1000.2002; O'Neill LAJ, 2002, MOL CELL, V10, P969, DOI 10.1016/S1097-2765(02)00754-2; OCONNELL MA, 1995, J BIOL CHEM, V270, P7399, DOI 10.1074/jbc.270.13.7399; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Romieu-Mourez R, 2002, CANCER RES, V62, P6770; Roux S, 2002, AM J CLIN PATHOL, V117, P210; Sapi E, 1999, P SOC EXP BIOL MED, V220, P1, DOI 10.1046/j.1525-1373.1999.d01-1.x; SATHE SS, UNPUB; Schiemann WP, 1999, BLOOD, V94, P2854, DOI 10.1182/blood.V94.8.2854.420k07_2854_2861; Sezer O, 2002, BLOOD, V99, P4646, DOI 10.1182/blood-2002-01-0148; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Takahashi A, 2002, ONCOLOGY-BASEL, V62, P121, DOI 10.1159/000048257; Ueda M, 2002, INT J CANCER, V98, P335, DOI 10.1002/ijc.10193; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wolf JS, 2001, CLIN CANCER RES, V7, P1812; Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200; Yamamoto H, 1998, J IMMUNOL, V161, P4753; Yonemura Y, 1999, CLIN CANCER RES, V5, P1823; Zhang N, 1999, J BIOL CHEM, V274, P12959, DOI 10.1074/jbc.274.19.12959	56	63	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2138	2145		10.1038/sj.onc.1207332	http://dx.doi.org/10.1038/sj.onc.1207332			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14676835				2022-12-17	WOS:000220280900003
J	Nielsen, FC; Jager, AC; Lutzen, A; Bundgaard, JR; Juel, L; Rasmussen, LJ				Nielsen, FC; Jager, AC; Lutzen, A; Bundgaard, JR; Juel, L; Rasmussen, LJ			Characterization of human exonuclease 1 in complex with mismatch repair proteins, subcellular localization and association with PCNA	ONCOGENE			English	Article						hEXO1; hMSH2; hMLH1; PCNA; DNA mismatch repair; HNPCC	CELL NUCLEAR ANTIGEN; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE EXO1; NUCLEOTIDE EXCISION-REPAIR; MEIOTIC CROSSING-OVER; DNA POLYMERASE-DELTA; COLORECTAL-CANCER; WERNER-SYNDROME; S-PHASE; REPLICATION FACTORIES	Human exonuclease 1 ( hEXO1) has been implicated in DNA mismatch repair (MMR), replication, and recombination, but the nature of its interaction with these cellular processes is still ambiguous. We show that hEXO1 colocalizes with proliferating cell nuclear antigen ( PCNA) at DNA replication sites and that the C-terminal region of hEXO1 is sufficient for this localization. We also show that both hMLH1-hPMS2 (MutLalpha) and hMLH1 hEXO1 complexes are formed in a reaction mixture containing all three proteins. Moreover, hEXO1 50 double-stranded exonuclease activity on a homoduplex substrate but not on a substrate containing a G/T mismatch was inhibited by complex formation with hMSH2-hMSH6 (MutSalpha) or MutLalpha. Taken together, the results support a model in which hEXO1 plays a role in events at the replication sites as well as a functional role in the MMR and/or recombination processes.	Roskilde Univ Ctr, Dept Chem & Life Sci, DK-4000 Roskilde, Denmark; Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark	Roskilde University; Rigshospitalet; University of Copenhagen	Rasmussen, LJ (corresponding author), Roskilde Univ Ctr, Dept Chem & Life Sci, DK-4000 Roskilde, Denmark.	ljr@ruc.dk	Nielsen, Finn Cilius/AAA-4926-2020	Rasmussen, Lene Juel/0000-0001-6864-963X				Amin NS, 2001, MOL CELL BIOL, V21, P5142, DOI 10.1128/MCB.21.15.5142-5155.2001; Aquilina G, 2001, J CELL PHYSIOL, V187, P145, DOI 10.1002/jcp.1067; Argueso JL, 2002, GENETICS, V160, P909; Baker SM, 1998, CANCER RES, V58, P1087; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BRENOTBOSC F, 1995, CHROMOSOMA, V103, P517, DOI 10.1007/BF00355316; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; Datta A, 2000, MOL CELL, V6, P593, DOI 10.1016/S1097-2765(00)00058-7; de Wind N, 2001, CURR BIOL, V11, pR545, DOI 10.1016/S0960-9822(01)00338-4; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Digilio FA, 1996, DEV BIOL, V178, P90, DOI 10.1006/dbio.1996.0200; Drotschmann K, 1999, P NATL ACAD SCI USA, V96, P2970, DOI 10.1073/pnas.96.6.2970; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 2000, CANCER RES, V60, P803; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Fiorentini P, 1997, MOL CELL BIOL, V17, P2764, DOI 10.1128/MCB.17.5.2764; Fuss J, 2002, J BIOL CHEM, V277, P8658, DOI 10.1074/jbc.M110615200; Genschel J, 2002, J BIOL CHEM, V277, P13302, DOI 10.1074/jbc.M111854200; Heyer J, 1999, ONCOGENE, V18, P5325, DOI 10.1038/sj.onc.1203036; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; Jager AC, 2001, ONCOGENE, V20, P3590, DOI 10.1038/sj.onc.1204467; Kamath-Loeb AS, 2001, J BIOL CHEM, V276, P16439, DOI 10.1074/jbc.M100253200; Karran P, 2001, CARCINOGENESIS, V22, P1931, DOI 10.1093/carcin/22.12.1931; Kawamura K, 2000, ANAL QUANT CYTOL, V22, P107; Khazanehdari KA, 2000, CHROMOSOMA, V109, P94, DOI 10.1007/s004120050416; Kirkpatrick DT, 2000, GENETICS, V156, P1549; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; Kondo E, 2001, NUCLEIC ACIDS RES, V29, P1695, DOI 10.1093/nar/29.8.1695; Leach FS, 1996, CANCER RES, V56, P235; Lebel M, 2001, CELL MOL LIFE SCI, V58, P857, DOI 10.1007/s00018-001-8398-y; Lee BI, 1999, J BIOL CHEM, V274, P37763, DOI 10.1074/jbc.274.53.37763; Lee BI, 1999, NUCLEIC ACIDS RES, V27, P4114, DOI 10.1093/nar/27.20.4114; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Lin YL, 1998, J BIOL CHEM, V273, P1453, DOI 10.1074/jbc.273.3.1453; Marra G, 1996, ONCOGENE, V13, P2189; Marra G, 1999, BIOCHEM J, V338, P1, DOI 10.1042/0264-6021:3380001; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; Nielsen FC, 2002, J CELL SCI, V115, P2087; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Rasmussen LJ, 2000, MUTAT RES-DNA REPAIR, V460, P41, DOI 10.1016/S0921-8777(00)00012-4; Rasmussen LJ, 2000, EXP CELL RES, V257, P127, DOI 10.1006/excr.2000.4865; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Rothstein R, 2000, GENE DEV, V14, P1; Schmutte C, 1998, CANCER RES, V58, P4537; Schmutte C, 2001, J BIOL CHEM, V276, P33011, DOI 10.1074/jbc.M102670200; Sharma S, 2003, J BIOL CHEM, V278, P23487, DOI 10.1074/jbc.M212798200; Shcherbakova PV, 2001, MOL CELL BIOL, V21, P940, DOI 10.1128/MCB.21.3.940-951.2001; Smith BT, 2001, MOL CELL, V8, P1197, DOI 10.1016/S1097-2765(01)00402-6; Sokolsky T, 2000, GENETICS, V155, P589; Somanathan S, 2001, J CELL BIOCHEM, V81, P56, DOI 10.1002/1097-4644(20010401)81:1<56::AID-JCB1023>3.0.CO;2-#; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; Sun XM, 2002, CANCER RES, V62, P6026; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; Thomas David C., 1995, Methods (Orlando), V7, P187, DOI 10.1006/meth.1995.1024; Tishkoff DX, 1998, CANCER RES, V58, P5027; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tran HT, 1999, MOL CELL BIOL, V19, P2000; Tran PT, 2002, DNA REPAIR, V1, P895, DOI 10.1016/S1568-7864(02)00114-3; Tsubouchi H, 2000, MOL BIOL CELL, V11, P2221, DOI 10.1091/mbc.11.7.2221; Wang Y, 2000, GENE DEV, V14, P927; Wilson DM, 1998, NUCLEIC ACIDS RES, V26, P3762, DOI 10.1093/nar/26.16.3762; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; Wu Y, 2001, GASTROENTEROLOGY, V120, P1580, DOI 10.1053/gast.2001.25117	74	63	69	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1457	1468		10.1038/sj.onc.1207265	http://dx.doi.org/10.1038/sj.onc.1207265			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14676842				2022-12-17	WOS:000189035800013
J	Syed, V; Ho, SM				Syed, V; Ho, SM			Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL	ONCOGENE			English	Article						caspases; Fas; Fas ligand; caspase-8; hormonal carcinogenesis; ovarian neoplasm	TUMOR-NECROSIS-FACTOR; LIGAND EXPRESSION; UP-REGULATION; MONOCLONAL-ANTIBODY; ENDOMETRIAL CANCER; IMMUNE PRIVILEGE; RECEPTOR; RISK; ACTIVATION; CARCINOMA	Progesterone (P4) has been implicated as a protective factor for epithelial ovarian cancers, yet little is known about its mechanism of action. We previously reported that pregnancy-equivalent doses of P4 inhibited the growth of normal and malignant human ovarian surface epithelial (HOSE) cells. Here, we investigated how P4-induced cell death in two immortalized normal (HOSE 642, HOSE 12-12) and two malignant (OVCA 429, OVCA 432) HOSE cell lines. The exposure of HOSE or OVCA cell cultures to 10(-6) m P4 induced time-dependent increases in early and late apoptotic cells and activation of caspase-8 and -3, but not that of caspase-9. A general caspase inhibitor Z-VAD effectively blocked the P4-induced cell death in a dose-dependent manner. Comparable levels of Fas mRNA and protein were expressed in HOSE and OVCA cell lines, and these levels were unaffected by P4. In contrast, levels of FasL mRNA and protein were higher in OVCA cells than in HOSE cells. Interestingly, the hormone enhanced levels of FasL mRNA and protein in HOSE cells, but lowered their levels in OVCA cells. The exposure of HOSE or OVCA cells to an activating anti-Fas antibody induced cell loss, whereas treatment of cells with a blocking anti-FasL antibody reduced the P4-induced cell loss. Cotreatment of cells with the activating anti-Fas antibody and P4 produced additive effects on cell loss. These results reveal for the first time that P4 induces apoptosis in HOSE and OVCA cells via activation of a caspase-8-initiated Fas/FasL signaling pathway. They also demonstrate differential P4-regulation of FasL expression between HOSE and OVCA cells.	Univ Massachusetts, Sch Med, Dept Surg, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Cell Biol & Physiol, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Ho, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Surg, Rm 504,Lazare Res Bldg,364 Plantat St,5th Floor, Worcester, MA 01605 USA.				NATIONAL CANCER INSTITUTE [R01CA094221, R03CA091250] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NCI NIH HHS [CA94221, CA091250] Funding Source: Medline; NIDDK NIH HHS [P30 DK32520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMI HO, 1994, LANCET, V344, P1250, DOI 10.1016/S0140-6736(94)90749-8; ADAMI HO, 1995, LANCET, V345, P789, DOI 10.1016/S0140-6736(95)90666-5; Akhmedkhanov A, 2001, ANN NY ACAD SCI, V943, P296, DOI 10.1111/j.1749-6632.2001.tb03811.x; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Bennett MW, 2001, J CLIN PATHOL, V54, P598, DOI 10.1136/jcp.54.8.598; Bennett MW, 1998, J IMMUNOL, V160, P5669; Bu SZ, 1997, CANCER, V79, P1944, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1944::AID-CNCR15>3.0.CO;2-V; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P711; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P717; Das H, 2000, BRIT J CANCER, V82, P1682; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Ghahremani M, 1998, GYNECOL ONCOL, V70, P275, DOI 10.1006/gyno.1998.5091; Gratas C, 1998, CANCER RES, V58, P2057; Griffith TS, 1997, IMMUNOL TODAY, V18, P240, DOI 10.1016/S0167-5699(97)81663-5; Hayakawa A, 2002, APOPTOSIS, V7, P107, DOI 10.1023/A:1014302212321; Hu Z, 2000, Zhonghua Fu Chan Ke Za Zhi, V35, P423; Keane MM, 1996, CANCER RES, V56, P4791; Lambe M, 1999, LANCET, V353, P1941, DOI 10.1016/S0140-6736(99)02000-0; Lepple-Wienhues A, 1999, P NATL ACAD SCI USA, V96, P13795, DOI 10.1073/pnas.96.24.13795; Milner AE, 2002, CELL DEATH DIFFER, V9, P287, DOI 10.1038/sj/cdd/4400945; MOLLER P, 1994, INT J CANCER, V57, P371, DOI 10.1002/ijc.2910570314; Munakata S, 2000, BRIT J CANCER, V82, P1446, DOI 10.1054/bjoc.1999.1073; Murdoch WJ, 2002, REPRODUCTION, V123, P743, DOI 10.1530/rep.0.1230743; NAGATA S, 1994, PHILOS T ROY SOC B, V345, P281, DOI 10.1098/rstb.1994.0107; O'Connell J, 2001, NAT MED, V7, P271, DOI 10.1038/85395; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; Pinkoski MJ, 2000, CURR OPIN GENET DEV, V10, P114, DOI 10.1016/S0959-437X(99)00048-9; Reimer T, 2000, CANCER RES, V60, P822; Riman T, 1998, CLIN ENDOCRINOL, V49, P695, DOI 10.1046/j.1365-2265.1998.00577.x; Rodriguez GC, 2002, JNCI-J NATL CANCER I, V94, P50; Sampalo A, 2000, BLOOD, V96, P3168; Sapi E, 2002, J SOC GYNECOL INVEST, V9, P243, DOI 10.1016/S1071-5576(02)00162-4; Selam B, 2001, BIOL REPROD, V65, P979, DOI 10.1095/biolreprod65.4.979; Song J, 2002, MOL HUM REPROD, V8, P447, DOI 10.1093/molehr/8.5.447; Song KM, 2000, J EXP MED, V191, P1095, DOI 10.1084/jem.191.7.1095; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Syed V, 2001, CANCER RES, V61, P6768; Syed V, 2002, JNCI-J NATL CANCER I, V94, P617; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; Ungefroren H, 1998, CANCER RES, V58, P1741; Van Haaften-Day C, 2003, HUM PATHOL, V34, P74, DOI 10.1053/hupa.2003.7; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Wang S, 2003, GYNECOL ONCOL, V88, P108, DOI 10.1016/S0090-8258(02)00008-2; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Yu S, 2001, J CELL BIOCHEM, V82, P445, DOI 10.1002/jcb.1171; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	50	63	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2003	22	44					6883	6890		10.1038/sj.onc.1206828	http://dx.doi.org/10.1038/sj.onc.1206828			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	730RH	14534535				2022-12-17	WOS:000185843400009
J	Biroccio, A; Leonetti, C; Zupi, G				Biroccio, A; Leonetti, C; Zupi, G			The future of antisense therapy: combination with anticancer treatments	ONCOGENE			English	Review						antisense; molecular targets; proliferation; apoptosis; combination therapy	PROTEIN-KINASE-A; RI-ALPHA-SUBUNIT; BREAST-CANCER CELLS; C-MYC EXPRESSION; HUMAN-MELANOMA CELLS; BCL-XL EXPRESSION; FIBROBLAST-GROWTH-FACTOR; INHIBITS TUMOR-GROWTH; IN-VIVO ACTIVITIES; PROSTATE-CANCER	The current direction in cancer research is rational drug design, which is based on the evidence that transformed cells are characterized by alterations of genes devoted to the regulation of both cell proliferation and apoptosis. A variety of approaches have been carried out to develop new agents selective for cancer cells. Among these, antisense oligonucleotides (ASOs) are one of such class of new agents able to inhibit specifically the synthesis of a particular cancer-associated protein by binding to protein-encoding RNA, thereby preventing RNA function. In the past decade, several ASOs have been developed and tested in preclinical and clinical studies. Many have shown convincing in vitro reduction in target gene expression and promising activity against a wide variety of tumors. However, because of the multigenic alterations of tumors, the use of ASOs as single agents does not seem to be effective in the treatment of malignancies. Antisense therapy that interferes with signaling pathways involved in cell proliferation and apoptosis are particularly promising in combination with conventional anticancer treatment. An overview of the progress of ASOs used in combination therapy is provided.	Regina Elena Inst Canc Res, Expt Chemotherapy Lab, I-00158 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Zupi, G (corresponding author), Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Via Messi Oro 156, I-00158 Rome, Italy.	zupi@ifo.it	Biroccio, Annamaria/B-2861-2018; Leonetti, Carlo/B-2860-2018	Biroccio, Annamaria/0000-0003-3198-3532; Leonetti, Carlo/0000-0002-3526-7827				Agrawal S, 2002, INT J ONCOL, V21, P65; Agrawal S, 1998, ANTISENSE NUCLEIC A, V8, P135, DOI 10.1089/oli.1.1998.8.135; Akie K, 2000, ANTISENSE NUCLEIC A, V10, P243, DOI 10.1089/108729000421420; ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; Baker BF, 1999, BBA-GENE STRUCT EXPR, V1489, P3, DOI 10.1016/S0167-4781(99)00146-3; Balaji KC, 1997, UROLOGY, V50, P1007, DOI 10.1016/S0090-4295(97)00390-7; Biroccio A, 2000, FASEB J, V14, P652, DOI 10.1096/fasebj.14.5.652; Biroccio A, 2002, ONCOGENE, V21, P3011, DOI 10.1038/sj.onc.1205415; Biroccio A, 2001, MOL PHARMACOL, V60, P174, DOI 10.1124/mol.60.1.174; Biroccio A, 2003, MOL PHARMACOL, V63, P632, DOI 10.1124/mol.63.3.632; Biroccio A, 2002, J BIOL CHEM, V277, P43763, DOI 10.1074/jbc.M207684200; Biroccio A, 2001, AM J PATHOL, V158, P1289, DOI 10.1016/S0002-9440(10)64080-1; Boggs RT, 1997, ANTISENSE NUCLEIC A, V7, P461, DOI 10.1089/oli.1.1997.7.461; CALABRETTA B, 1991, P NATL ACAD SCI USA, V88, P2351, DOI 10.1073/pnas.88.6.2351; Carroll JS, 2002, CANCER RES, V62, P3126; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chi KN, 2000, BREAST CANCER RES TR, V63, P199, DOI 10.1023/A:1017371013487; Cho YS, 2003, CLIN CANCER RES, V9, P1171; ChoChung YS, 1997, P ASSOC AM PHYSICIAN, V109, P23; Citro G, 1998, CANCER RES, V58, P283; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Cotter FE, 1997, HEMATOL ONCOL, V15, P3, DOI 10.1002/(SICI)1099-1069(199702)15:1<3::AID-HON583>3.0.CO;2-S; Crooke ST, 1999, BBA-GENE STRUCT EXPR, V1489, P31, DOI 10.1016/S0167-4781(99)00148-7; Dang CV, 1999, MOL CELL BIOL, V19, P1; DelBufalo D, 1996, BRIT J CANCER, V74, P387, DOI 10.1038/bjc.1996.370; Ebinuma H, 2001, J CELL PHYSIOL, V188, P56, DOI 10.1002/jcp.1195; Elez R, 2003, ONCOGENE, V22, P69, DOI 10.1038/sj.onc.1206038; FENNEWALD SM, 1995, J BIOL CHEM, V270, P21718, DOI 10.1074/jbc.270.37.21718; Fernandez A, 2001, J NATL CANCER I, V93, P208, DOI 10.1093/jnci/93.3.208; Funato T, 2001, ONCOL REP, V8, P807; Gautschi O, 2001, J NATL CANCER I, V93, P463, DOI 10.1093/jnci/93.6.463; GELMON K, 2001, P AACR NCI EORT TARG; Gleave ME, 1999, UROLOGY, V54, P36, DOI 10.1016/S0090-4295(99)00453-7; GRIFFIN CA, 1985, CANCER RES, V45, P272; Grover R, 1996, EUR J SURG ONCOL, V22, P347, DOI 10.1016/S0748-7983(96)90176-6; GUVAKOVA MA, 1995, J BIOL CHEM, V270, P2620, DOI 10.1074/jbc.270.6.2620; Heere-Ress E, 2002, INT J CANCER, V99, P29, DOI 10.1002/ijc.10248; HIJIYA N, 1994, P NATL ACAD SCI USA, V91, P4499, DOI 10.1073/pnas.91.10.4499; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HUANG Y, 1995, MOL MED, V1, P647, DOI 10.1007/BF03401605; Iervolino A, 2002, FASEB J, V16, P1453, DOI 10.1096/fj.02-0122fje; Itano Y, 1996, J NEUROCHEM, V67, P131; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; JANSSEN JWG, 1986, CYTOGENET CELL GENET, V41, P129, DOI 10.1159/000132217; Jiang ZH, 2003, J NEUROCHEM, V84, P273, DOI 10.1046/j.1471-4159.2003.01522.x; Kang Y, 1996, J NATL CANCER I, V88, P279, DOI 10.1093/jnci/88.5.279; Klasa RJ, 2000, CLIN CANCER RES, V6, P2492; Knapp DC, 2003, ANTI-CANCER DRUG, V14, P39, DOI 10.1097/00001813-200301000-00006; Koller E, 2000, TRENDS PHARMACOL SCI, V21, P142, DOI 10.1016/S0165-6147(00)01448-6; Konopleva M, 2000, BLOOD, V95, P3929; Lebedeva I, 2000, CANCER RES, V60, P6052; Leech SH, 2000, INT J CANCER, V86, P570, DOI 10.1002/(SICI)1097-0215(20000515)86:4<570::AID-IJC20>3.0.CO;2-T; Leonetti C, 1999, CLIN CANCER RES, V5, P2588; Leonetti C, 2001, CANCER GENE THER, V8, P459, DOI 10.1038/sj.cgt.7700326; Leonetti C, 1996, JNCI-J NATL CANCER I, V88, P419, DOI 10.1093/jnci/88.7.419; Luger SM, 2002, BLOOD, V99, P1150, DOI 10.1182/blood.V99.4.1150; Mercatante DR, 2002, J BIOL CHEM, V277, P49374, DOI 10.1074/jbc.M209236200; Miayake H, 2000, J NATL CANCER I, V92, P34, DOI 10.1093/jnci/92.1.34; Milella M, 2002, BLOOD, V99, P3461, DOI 10.1182/blood.V99.9.3461; Miller P. S., 1992, Antisense RNA and DNA., P241; MILLER PS, 1987, ANTI-CANCER DRUG DES, V2, P117; Miyake H, 2000, CLIN CANCER RES, V6, P1655; Miyake H, 2000, CANCER RES, V60, P2547; Miyake H, 2001, CLIN CANCER RES, V7, P4245; Miyake H, 2000, INT J CANCER, V86, P855, DOI 10.1002/(SICI)1097-0215(20000615)86:6<855::AID-IJC15>3.3.CO;2-#; Olie RA, 2002, J INVEST DERMATOL, V118, P505, DOI 10.1046/j.0022-202x.2001.01677.x; Pakunlu RI, 2003, PHARMACEUT RES, V20, P351, DOI 10.1023/A:1022687617318; PEREZ JR, 1994, P NATL ACAD SCI USA, V91, P5957, DOI 10.1073/pnas.91.13.5957; Ramsay RG, 2003, EXPERT OPIN THER TAR, V7, P235; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P11823, DOI 10.1073/pnas.89.24.11823; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Simoes-Wust AP, 2002, BREAST CANCER RES TR, V76, P157, DOI 10.1023/A:1020543004400; Simoes-Wust AP, 2000, INT J CANCER, V87, P582, DOI 10.1002/1097-0215(20000815)87:4<582::AID-IJC19>3.0.CO;2-P; SKORSKI T, 1995, J EXP MED, V182, P1645, DOI 10.1084/jem.182.6.1645; Skorski T, 1996, BLOOD, V88, P1005, DOI 10.1182/blood.V88.3.1005.1005; Smith JB, 1998, J NATL CANCER I, V90, P1146, DOI 10.1093/jnci/90.15.1146; Smith JB, 1998, ADV EXP MED BIOL, V451, P17; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; Srivastava RK, 1999, MOL CELL BIOCHEM, V195, P25, DOI 10.1023/A:1006990231186; STEC WJ, 1984, J AM CHEM SOC, V106, P6077, DOI 10.1021/ja00332a054; Steiner MS, 1998, HUM GENE THER, V9, P747, DOI 10.1089/hum.1998.9.5-747; Stewart DA, 2002, NUCLEIC ACIDS RES, V30, P2565, DOI 10.1093/nar/30.11.2565; Stewart DA, 2001, NUCLEIC ACIDS RES, V29, P4052, DOI 10.1093/nar/29.19.4052; Supino R, 2001, EUR J CANCER, V37, P2247, DOI 10.1016/S0959-8049(01)00268-4; Tanabe K, 2003, INT J ONCOL, V22, P875; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; THIELE CJ, 1987, J CLIN INVEST, V80, P804, DOI 10.1172/JCI113137; Thompson MA, 1998, CANCER RES, V58, P5168; Tortora G, 2000, INT J CANCER, V88, P804, DOI 10.1002/1097-0215(20001201)88:5<804::AID-IJC19>3.0.CO;2-Z; Tortora G, 2003, CLIN CANCER RES, V9, P1566; Tortora G, 1997, ONCOGENE, V14, P923, DOI 10.1038/sj.onc.1200906; Tortora G, 2001, CLIN CANCER RES, V7, P2537; Tortora G, 2000, CLIN CANCER RES, V6, P2506; Tortora G, 2000, ANN ONCOL, V11, P777, DOI 10.1023/A:1008390206250; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Vilenchik M, 2002, CANCER RES, V62, P2175; VLASSOV VV, 1994, BBA-REV BIOMEMBRANES, V1197, P95, DOI 10.1016/0304-4157(94)90001-9; WACHECK V, 2002, NUCL ACID DRUG DEV, V12, P359; Wang H, 1999, P NATL ACAD SCI USA, V96, P13989, DOI 10.1073/pnas.96.24.13989; Wang H, 2003, PROSTATE, V54, P194, DOI 10.1002/pros.10187; Wang H, 2002, MOL MED, V8, P185, DOI 10.1007/BF03402011; Wang H, 2002, INT J ONCOL, V21, P73; Wang H, 2001, CLIN CANCER RES, V7, P3613; WATSON PH, 1991, CANCER RES, V51, P3996; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; Wooldridge JE, 1997, BLOOD, V89, P2994, DOI 10.1182/blood.V89.8.2994; YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454; Yang WL, 1998, BIOCHEMISTRY-US, V37, P14175, DOI 10.1021/bi981402a; YOKOZAKI H, 1993, CANCER RES, V53, P868; Zangemeister-Wittke U, 2000, CLIN CANCER RES, V6, P2547; Zangemeister-Wittke U, 1998, BRIT J CANCER, V78, P1035, DOI 10.1038/bjc.1998.624; Zellweger T, 2002, CLIN CANCER RES, V8, P3276; Zellweger T, 2001, NEOPLASIA, V3, P360, DOI 10.1038/sj.neo.7900174; Zellweger T, 2001, J PHARMACOL EXP THER, V298, P934	117	63	74	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6579	6588		10.1038/sj.onc.1206812	http://dx.doi.org/10.1038/sj.onc.1206812			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528283				2022-12-17	WOS:000185700700015
J	Oikawa, S; Murakami, K; Kawanishi, S				Oikawa, S; Murakami, K; Kawanishi, S			Oxidative damage to cellular and isolated DNA by homocysteine: implications for carcinogenesis	ONCOGENE			English	Article						DNA damage; homocysteine; 8-oxo-7, 8-dihydro-2 '-deoxyguanosine; hydrogen peroxide; singlet oxygen	TOTAL PLASMA HOMOCYSTEINE; NESTED CASE-CONTROL; SINGLET OXYGEN; HORDALAND HOMOCYSTEINE; HYDROGEN-PEROXIDE; COLORECTAL-CANCER; STRANDED-DNA; RISK-FACTORS; MALE SMOKERS; FOLATE	Homocysteine is considered to be an important risk factor for cancer as well as cardiovascular diseases. To clarify whether homocysteine has potential carcinogenicity, we investigated formation of 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG), which is known to be correlated with the incidence of cancer, induced by homocysteine in human cultured cell lines. Homocysteine increased the amount of 8-oxodG in human leukemia cell line HL-60, whereas the amount of 8-oxodG in its hydrogen peroxide (H2O2)-resistant clone HP100 was not increased. We investigated the mechanism for oxidative DNA damage by homocysteine using P-32-labeled DNA fragments obtained from human tumor suppressor genes and a protooncogene. There were two mechanisms by which homocysteine caused DNA damage in the presence of Cu(II). A low concentration of homocysteine (20 muM) frequently induced piperidine-labile sites at thymine residues, whereas a high concentration of homocysteine (100 muM) resulted in damage principally to guanine residues. Catalase inhibited DNA damage by 20 muM homocysteine, indicating the participation of H2O2, but was ineffective in preventing DNA damage by 100 muM homocysteine. Experiments using a singlet oxygen probe showed that 100 muM homocysteine enhanced chemiluminescence intensity in deuterium oxide more than that in H2O. These results indicated that the metal-dependent DNA damage through H2O2 is likely to be a more relevant mechanism for homocysteine carcinogenicity.	Mie Univ, Sch Med, Dept Environm & Mol Med, Tsu, Mie 5148507, Japan	Mie University	Kawanishi, S (corresponding author), Mie Univ, Sch Med, Dept Environm & Mol Med, Tsu, Mie 5148507, Japan.							Ames BN, 1999, ANN NY ACAD SCI, V889, P87, DOI 10.1111/j.1749-6632.1999.tb08727.x; BANNAI S, 1984, BIOCHIM BIOPHYS ACTA, V779, P289, DOI 10.1016/0304-4157(84)90014-5; Blom HJ, 1998, AM J CLIN NUTR, V67, P188, DOI 10.1093/ajcn/67.2.188; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CHIU SM, 1995, BIOCHEMISTRY-US, V34, P2653, DOI 10.1021/bi00008a032; CHUMAKOV P, 1990, X54156 EMBL DAT LIB; Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; DIZDAROGLU M, 1991, ARCH BIOCHEM BIOPHYS, V285, P317, DOI 10.1016/0003-9861(91)90366-Q; DIZDAROGLU M, 1990, BIOCHEMISTRY-US, V29, P8447, DOI 10.1021/bi00488a035; El-Khairy L, 1999, AM J CLIN NUTR, V70, P1016; EPE B, 1991, CHEM-BIOL INTERACT, V80, P239, DOI 10.1016/0009-2797(91)90086-M; Fenech M, 1998, CARCINOGENESIS, V19, P1163, DOI 10.1093/carcin/19.7.1163; Fenech MF, 1997, CARCINOGENESIS, V18, P1329, DOI 10.1093/carcin/18.7.1329; Glynn SA, 1996, CANCER EPIDEM BIOMAR, V5, P487; Gray RG, 2000, LANCET, V355, P1588; Griffith OW, 1999, FREE RADICAL BIO MED, V27, P922, DOI 10.1016/S0891-5849(99)00176-8; Guttormsen AB, 1996, J CLIN INVEST, V98, P2174, DOI 10.1172/JCI119024; Hall DB, 1998, BIOCHEMISTRY-US, V37, P15933, DOI 10.1021/bi981750c; HALL RD, 1989, J BIOL CHEM, V264, P7900; Heijmans BT, 1999, EUR J HUM GENET, V7, P197, DOI 10.1038/sj.ejhg.5200283; Huschtscha LI, 1998, CANCER RES, V58, P3508; ITO K, 1993, J BIOL CHEM, V268, P13221; Kark JD, 1999, ANN INTERN MED, V131, P321, DOI 10.7326/0003-4819-131-5-199909070-00002; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; KASUGAI I, 1992, LEUKEMIA RES, V16, P173, DOI 10.1016/0145-2126(92)90129-U; Kato I, 1999, BRIT J CANCER, V79, P1917, DOI 10.1038/sj.bjc.6690305; KAWANISHI S, 1991, BIOCHEMISTRY-US, V30, P3069, DOI 10.1021/bi00226a013; KAWANISHI S, 1986, J BIOL CHEM, V261, P6090; Langman LJ, 1999, CRIT REV CL LAB SCI, V36, P365, DOI 10.1080/10408369991239231; Linder MC, 2001, MUTAT RES-FUND MOL M, V475, P141, DOI 10.1016/S0027-5107(01)00076-8; LINDIG BA, 1980, J AM CHEM SOC, V102, P5590, DOI 10.1021/ja00537a030; Loft S, 1996, J MOL MED, V74, P297, DOI 10.1007/s001090050031; Martinez ME, 1999, CANCER RES, V59, P5181; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCULLY KS, 1993, ANN CLIN LAB SCI, V23, P477; Miller H, 2000, BIOCHEMISTRY-US, V39, P1029, DOI 10.1021/bi991789x; Murata M, 2000, J BIOL CHEM, V275, P2003, DOI 10.1074/jbc.275.3.2003; NYGARD O, 1995, JAMA-J AM MED ASSOC, V274, P1526, DOI 10.1001/jama.274.19.1526; Oikawa S, 1998, BBA-GENE STRUCT EXPR, V1399, P19, DOI 10.1016/S0167-4781(98)00092-X; PIETTE J, 1991, J PHOTOCH PHOTOBIO B, V11, P241, DOI 10.1016/1011-1344(91)80030-L; PRYOR WA, 1978, BIOCHEM BIOPH RES CO, V81, P498, DOI 10.1016/0006-291X(78)91562-0; Ravanat JL, 2000, J BIOL CHEM, V275, P40601, DOI 10.1074/jbc.M006681200; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Schneede J, 2000, SEMIN THROMB HEMOST, V26, P263, DOI 10.1055/s-2000-8471; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEVILLA MD, 1987, BIOCHEM BIOPH RES CO, V144, P1037, DOI 10.1016/S0006-291X(87)80068-2; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Stevenson C, 1999, CHEM RES TOXICOL, V12, P38, DOI 10.1021/tx980158l; Stolzenberg-Solomon RZ, 1999, JNCI-J NATL CANCER I, V91, P535, DOI 10.1093/jnci/91.6.535; Tada-Oikawa S, 2000, METHOD ENZYMOL, V319, P331; Tanaka T, 1999, ONCOGENE, V18, P3793, DOI 10.1038/sj.onc.1202707; Theophanides T, 2002, CRIT REV ONCOL HEMAT, V42, P57, DOI 10.1016/S1040-8428(02)00007-0; Thomson SW, 2000, NUTRITION, V16, P411, DOI 10.1016/S0899-9007(00)00284-7; TUITE EM, 1993, J PHOTOCH PHOTOBIO B, V21, P103, DOI 10.1016/1011-1344(93)80173-7; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298	58	63	65	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3530	3538		10.1038/sj.onc.1206440	http://dx.doi.org/10.1038/sj.onc.1206440			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789261				2022-12-17	WOS:000183399200003
J	Srinivasan, RS; de Erkenez, AC; Hemenway, CS				Srinivasan, RS; de Erkenez, AC; Hemenway, CS			The mixed lineage leukemia fusion partner AF9 binds specific isoforms of the BCL-6 corepressor	ONCOGENE			English	Article						oncogenic fusion proteins; alternative RNA splicing; gene repression; leukemia cell lines	ACUTE MYELOID-LEUKEMIA; DROSOPHILA-TRITHORAX; NUCLEAR-PROTEIN; HUMAN HOMOLOG; MLL; GENE; POLYCOMB; 11Q23; ENL; TRANSLOCATIONS	The mixed lineage leukemia (MLL) gene at chromosome band 11q23 is commonly involved in reciprocal translocations that are detected in acute leukemias. Evidence suggests that the resulting MLL fusion genes contribute to leukemogenesis. AF9 is a common MLL fusion partner in acute myeloid leukemia. The AF9 protein functions as a transcriptional activator in artificial reporter gene assays and a structurally related protein in yeast, ANC1/TFG3, is a component of the SWI/SNF complex. Apart from these observations, little is known about the biologic function of AF9 in mammals. We have found that a recently described transcriptional repressor, BCL-6 corepressor (BCoR), interacts with the carboxy-terminus of AF9. The interaction of AF9 with BCoR has been confirmed by independent in vitro and in vivo protein-binding studies. The BCoR gene is expressed as several alternatively spliced transcripts. AF9 only binds BCoR isoforms that contain a unique 34 aa sequence located in the mid-portion of the protein. In artificial reporter gene assays, a BCoR isoform that binds AF9 efficiently suppresses AF9 transcriptional activity, while a nonbinding isoform does not. These results indicate that different isoforms of BCoR have unique biologic properties and that cell function may be partly determined by the different isoforms that are present within the cell.	Tulane Univ, Sch Med, Tulane Canc Ctr, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Mol & Cellular Biol Program, Dept Pediat, New Orleans, LA 70112 USA	Tulane University; Tulane University	Hemenway, CS (corresponding author), Tulane Univ, Sch Med, Tulane Canc Ctr, 1430 Tulane Ave,SL-37, New Orleans, LA 70112 USA.	chemenw@tulane.edu			NATIONAL CANCER INSTITUTE [K01CA078318] Funding Source: NIH RePORTER; NCI NIH HHS [CA78318] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler HT, 1999, MOL CELL BIOL, V19, P7050; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Cairns BR, 1996, MOL CELL BIOL, V16, P3308; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Collins EC, 2002, MOL CELL BIOL, V22, P7313, DOI 10.1128/MCB.22.20.7313-7324.2002; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DOWNING JR, 1996, MOL GENETICS THERAPY; Erfurth F, 2000, BLOOD, V96, p700A; Garcia-Cuellar MP, 2001, ONCOGENE, V20, P411, DOI 10.1038/sj.onc.1204108; Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Gu YH, 1996, NAT GENET, V13, P109, DOI 10.1038/ng0596-109; Hemenway CS, 2001, ONCOGENE, V20, P3798, DOI 10.1038/sj.onc.1204478; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; HENRY NL, 1992, J BIOL CHEM, V267, P23388; Hess JL, 1997, BLOOD, V90, P1799, DOI 10.1182/blood.V90.5.1799; Huynh KD, 2000, GENE DEV, V14, P1810; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Joh T, 1996, ONCOGENE, V13, P1945; Kuwada N, 2001, CANCER RES, V61, P2665; Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; Odero MD, 2000, GENE CHROMOSOME CANC, V29, P333, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1040>3.3.CO;2-Q; Ono R, 2002, CANCER RES, V62, P333; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; ROWLEY JD, 1993, SEMIN CANCER BIOL, V4, P377; RUBNITZ JE, 1994, BLOOD, V84, P1747; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; SMITH MA, 1994, MED PEDIATR ONCOL, V23, P86, DOI 10.1002/mpo.2950230205; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; WELCH MD, 1994, MOL BIOL CELL, V5, P617, DOI 10.1091/mbc.5.6.617; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	38	63	66	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3395	3406		10.1038/sj.onc.1206361	http://dx.doi.org/10.1038/sj.onc.1206361			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776190				2022-12-17	WOS:000183128500005
J	Agirre, X; Vizmanos, JL; Calasanz, MJ; Garcia-Delgado, M; Larrayoz, MJ; Novo, FJ				Agirre, X; Vizmanos, JL; Calasanz, MJ; Garcia-Delgado, M; Larrayoz, MJ; Novo, FJ			Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients	ONCOGENE			English	Article						TP53; methylation analysis; promoter analysis; gene expression; ALL	TUMOR-SUPPRESSOR GENE; P53 GENE; DNA METHYLATION; IN-VIVO; CARCINOGENESIS; REGION; CELLS	It has been shown that methylation of CpG dinucleotides located in the promoter region of TP53 is associated with low expression levels of this gene. We have analysed the methylation status of one CpG dinucleotide and of three CCWGG motifs, also located in the promoter region of the gene, in bone marrow samples obtained from patients with acute lymphoblastic leukemia (ALL). Eight out of 25 samples analysed showed methylation of either the CpG dinucleotide, the CCWGG motifs or both. Relative to nonmethylated leukemia samples, TP53 expression levels were decreased in all methylated samples in which TP53 expression could be measured. Methylation of CpG and CCWGG motifs in the promoter of TP53 could represent a novel mechanism leading to functional impairment of this tumor suppressor gene in ALL.	Univ Navarra, Sch Sci, Dept Genet, E-31080 Pamplona, Navarra, Spain	University of Navarra	Vizmanos, JL (corresponding author), Univ Navarra, Sch Sci, Dept Genet, C Irunlarrea S-N, E-31080 Pamplona, Navarra, Spain.		Vizmanos, José L./G-2833-2012; Agirre, Xabier/ABE-4110-2020; Novo, Francisco/M-7596-2015; Calasanz, MJ/R-5813-2016	Vizmanos, José L./0000-0001-7416-3679; Novo, Francisco/0000-0003-4961-3097; Calasanz, MJ/0000-0002-0374-3008				Agirre X, 2002, BIOTECHNIQUES, V32, P1064, DOI 10.2144/02325rr01; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; Davis CD, 2000, J NUTR, V130, P2903, DOI 10.1093/jn/130.12.2903; Herman JG, 1996, CANCER RES, V56, P722; Kang JH, 2001, LAB INVEST, V81, P573, DOI 10.1038/labinvest.3780266; Malone CS, 2001, P NATL ACAD SCI USA, V98, P10404, DOI 10.1073/pnas.181206898; Mass MJ, 1997, MUTAT RES-REV MUTAT, V386, P263, DOI 10.1016/S1383-5742(97)00008-2; Pogribny IP, 2000, CANCER RES, V60, P588; Pogribny IP, 2002, CANCER LETT, V176, P169, DOI 10.1016/S0304-3835(01)00748-0; Preudhomme C, 1997, BRIT J HAEMATOL, V98, P502, DOI 10.1046/j.1365-2141.1997.2403057.x; Roman-Gomez J, 2002, BLOOD, V99, P2291, DOI 10.1182/blood.V99.7.2291; Schroeder M, 1997, BIOCHEM BIOPH RES CO, V235, P403, DOI 10.1006/bbrc.1997.6796; Schutte M, 1997, CANCER RES, V57, P3126; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657	15	63	64	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					1070	1072		10.1038/sj.onc.1206236	http://dx.doi.org/10.1038/sj.onc.1206236			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592393				2022-12-17	WOS:000180926100012
J	Wong, JMS; Ionescu, D; Ingles, CJ				Wong, JMS; Ionescu, D; Ingles, CJ			Interaction between BRCA2 and replication protein A is compromised by a cancer-predisposing mutation in BRCA2	ONCOGENE			English	Article						replication protein A; BRCA2; DSB repair; protein-protein interaction	NUCLEOTIDE EXCISION-REPAIR; RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION DOMAINS; DNA-REPLICATION; RAD51; RPA; P53; BIND; GENE; SUSCEPTIBILITY	Mutations in the BRCA1 and BRCA2 genes predispose women to familial, early-onset breast cancer. Both the BRCA1 and BRCA2 proteins appear to function in the homologous recombination pathway of DNA double-strand break repair. Both BRCA1 and BRCA2 have also been implicated in transcription by RNA polymerase II, for both proteins have domains which, when tethered adjacent to a promoter, can activate transcription. In experiments reported here, we have used protein affinity chromatography and coimmunoprecipitation techniques to show that the putative N-terminal acidic transcriptional activation domain of BRCA2 interacts with replication protein A (RPA), a protein essential for DNA repair, replication and recombination. This interaction was not mediated by DNA and was specific for human RPA but not yeast RPA. Since the cancer-predisposing mutation Y42C in BRCA2 significantly compromised the interaction between RPA and BRCA2, this interaction may be biologically important. That BRCA2 protein in HeLa cell extract also coimmunoprecipitated with RPA suggested that this interaction occurs in vivo. Therefore, the transcriptional activation domains within BRCA2, and perhaps BRCA1, may provide links to RPA and DNA repair processes rather than transcription.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1L6, Canada	University of Toronto; University of Toronto	Ingles, CJ (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.							BARDWELL AJ, 1994, MOL CELL BIOL, V14, P3569, DOI 10.1128/MCB.14.6.3569; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Choudhary SK, 2002, J CELL BIOCHEM, V84, P666, DOI 10.1002/jcb.10081; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; Greenblatt J, 1996, METHOD ENZYMOL, V274, P120; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; He ZG, 1996, J BIOL CHEM, V271, P28243, DOI 10.1074/jbc.271.45.28243; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Kerr P, 2001, CURR BIOL, V11, pR668, DOI 10.1016/S0960-9822(01)00389-X; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; Lim DS, 1996, MOL CELL BIOL, V16, P7133; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; McIlwraith MJ, 2000, J MOL BIOL, V304, P151, DOI 10.1006/jmbi.2000.4180; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Nordling M, 1998, CANCER RES, V58, P1372; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; SOPTA M, 1985, J BIOL CHEM, V260, P353; van Golen K, 1999, J LAB CLIN MED, V134, P11, DOI 10.1016/S0022-2143(99)90049-5; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Warren M, 2002, HUM MOL GENET, V11, P841, DOI 10.1093/hmg/11.7.841; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049	39	63	64	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					28	33		10.1038/sj.onc.1206071	http://dx.doi.org/10.1038/sj.onc.1206071			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527904				2022-12-17	WOS:000180166900003
J	Sanceau, J; Poupon, MF; Delattre, O; Sastre-Garau, X; Wietzerbin, J				Sanceau, J; Poupon, MF; Delattre, O; Sastre-Garau, X; Wietzerbin, J			Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide	ONCOGENE			English	Article						Ewing's sarcoma; IFN-alpha; IFN-beta; ifosfamide; xenograft	SIGNAL-TRANSDUCTION; P53 MUTATIONS; THERAPY; SARCOMA; CANCER; GENE; ANGIOGENESIS; SUPPRESSION; CISPLATIN; ETOPOSIDE	Ewing sarcoma is the second most common bone tumor in childhood. Despite aggressive chemotherapy and radiotherapy strategies, the prognosis of patients with metastatic disease remains poor. We have recently reported that Ewing tumor cell proliferation was strongly inhibited by IFN-beta and to a lesser degree by IFN-alpha. Moreover, under IFN-beta treatment, some cell lines undergo apoptosis. Since the possibility of using IFNs for Ewing tumor treatments may be of interest, we have evaluated the efficacy of Hu-IFNs in a nude mice model of Ewing tumor xenografts. The results reported here show that human type I IFNs, Hu-IFN-alpha and Hu-IFN-beta impaired tumor xenograft take and displayed an anti-growth effect toward established xenografts. Furthermore, we have also shown that combined therapy with Hu-IFNs and ifosfamide (IFO), an alkylating agent widely used in high-dose chemotherapy of Ewing tumors, results in a strong antitumor effect. Pathological analysis showed that Hu-IFN-alpha/IFO and Hu-IFN-beta/IFO were characterized by a dramatic decrease in the mitotic index and marked necrosis, as well as extensive fibrosis associated with numerous calcifications. To our knowledge, this is the first demonstration of a potential antitumor effect of human type I IFNs and IFO on Ewing tumors, providing a rational foundation for a promising therapeutic approach to Ewing sarcoma.	Inst Curie, INSERM, U365, Sect Rech, F-75248 Paris 05, France; Inst Curie, Sect Rech, CNRS, UMR 147, F-75248 Paris 05, France; Inst Curie, Sect Rech, INSERM, U509, F-75248 Paris 05, France; Inst Curie, Med Sect, Dept Pathol, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Wietzerbin, J (corresponding author), Inst Curie, INSERM, U365, Sect Rech, 26 Rue Ulm, F-75248 Paris 05, France.	Jeanne.Wietzerbin@curie.fr		Sastre-Garau, Xavier/0000-0001-5992-2083; delattre, olivier/0000-0002-8730-2276				AURIAS A, 1983, NEW ENGL J MED, V309, P496; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Biron CA, 2001, IMMUNITY, V14, P661, DOI 10.1016/S1074-7613(01)00154-6; Borden, 1998, Oncologist, V3, P198; Borden EC, 2000, SEMIN CANCER BIOL, V10, P125, DOI 10.1006/scbi.2000.0315; Brockmeyer NH, 1998, CHEMOTHERAPY, V44, P174, DOI 10.1159/000007112; BROSJO O, 1985, CANCER RES, V45, P5598; Chapman BA, 2001, NEW ZEAL MED J, V114, P103; Comi G, 2001, LANCET, V357, P1576, DOI 10.1016/S0140-6736(00)04725-5; Daponte A, 2000, CANCER, V89, P2630, DOI 10.1002/1097-0142(20001215)89:12<2630::AID-CNCR16>3.0.CO;2-Z; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Dong ZY, 1999, CANCER RES, V59, P872; Eck SL, 2001, HUM GENE THER, V12, P97; Faderl S, 1999, ONCOLOGY-NY, V13, P169; Fizazi K, 1998, J CLIN ONCOL, V16, P3736, DOI 10.1200/JCO.1998.16.12.3736; Freneaux P, 2000, BRIT J CANCER, V83, P1318, DOI 10.1054/bjoc.2000.1438; Garmendia G, 2001, J INTERF CYTOK RES, V21, P31, DOI 10.1089/107999001459132; Grander D, 2000, ACTA ONCOL, V39, P801, DOI 10.1080/028418600750063532; Grander D, 1997, EUR J HAEMATOL, V59, P129; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; Hall GL, 1997, TRENDS NEUROSCI, V20, P63, DOI 10.1016/S0166-2236(96)10071-0; HAMELIN R, 1994, INT J CANCER, V57, P336, DOI 10.1002/ijc.2910570308; Horowitz Marc E., 1997, P831; Horton HM, 1999, CANCER RES, V59, P4064; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; KOVAR H, 1993, ONCOGENE, V8, P2683; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; KURZROCK R, 1991, BRIT J HAEMATOL, V79, P17, DOI 10.1111/j.1365-2141.1991.tb08112.x; Kushner BH, 2001, J CLIN ONCOL, V19, P870, DOI 10.1200/JCO.2001.19.3.870; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Mizuno M, 1998, CANCER IMMUNOL IMMUN, V47, P227, DOI 10.1007/s002620050525; Monshouwer M, 1996, TOXICOL APPL PHARM, V137, P237, DOI 10.1006/taap.1996.0077; Nemati F, 2000, CLIN CANCER RES, V6, P2075; OUCHIDA M, 1995, ONCOGENE, V11, P1049; Ozawa S, 2001, NEOPLASIA, V3, P154, DOI 10.1038/sj.neo.7900128; Paulussen M, 2001, J CLIN ONCOL, V19, P1818, DOI 10.1200/JCO.2001.19.6.1818; Pfeffer LM, 1998, CANCER RES, V58, P2489; Pinkerton CR, 2001, EUR J CANCER, V37, P1338, DOI 10.1016/S0959-8049(01)00131-9; Qin XQ, 1998, P NATL ACAD SCI USA, V95, P14411, DOI 10.1073/pnas.95.24.14411; Rosito P, 1999, CANCER-AM CANCER SOC, V86, P421, DOI 10.1002/(SICI)1097-0142(19990801)86:3<421::AID-CNCR10>3.0.CO;2-O; Rosolen A, 1997, MODERN PATHOL, V10, P55; Ross C, 2000, ANN NEUROL, V48, P706, DOI 10.1002/1531-8249(200011)48:5<706::AID-ANA3>3.3.CO;2-M; Rumi MG, 1997, BLOOD, V89, P3529; Runkel L, 1998, J BIOL CHEM, V273, P8003, DOI 10.1074/jbc.273.14.8003; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Sandler AB, 1998, SEMIN ONCOL, V25, P38; Slaton JW, 1999, CLIN CANCER RES, V5, P2726; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Strander H, 1996, BIOTHERAPY, V8, P213, DOI 10.1007/BF01877207; Surin B, 2002, INT J MOL MED, V10, P25; Tada H, 2001, J CLIN INVEST, V108, P83, DOI 10.1172/JCI200109841; Talpaz M, 2001, SEMIN HEMATOL, V38, P22, DOI 10.1053/shem.2001.27080; Tanneberger S, 1996, J INTERF CYTOK RES, V16, P339, DOI 10.1089/jir.1996.16.339; Todesco A, 2000, CANCER-AM CANCER SOC, V89, P2661, DOI 10.1002/1097-0142(20001215)89:12<2661::AID-CNCR20>3.0.CO;2-9; Wadler, 1997, Oncologist, V2, P254; WADLER S, 1990, CANCER RES, V50, P3473; Wexler LH, 1996, CANCER, V78, P901; Wollina U, 2001, J AM ACAD DERMATOL, V44, P253, DOI 10.1067/mjd.2001.110645; Worle H, 1999, EUR J PEDIATR, V158, P344, DOI 10.1007/s004310051089	60	63	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2002	21	50					7700	7709		10.1038/sj.onc.1205881	http://dx.doi.org/10.1038/sj.onc.1205881			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400012				2022-12-17	WOS:000178756200009
J	Lei, XF; Bandyopadhyay, A; Le, T; Sun, LZ				Lei, XF; Bandyopadhyay, A; Le, T; Sun, LZ			Autocrine TGF beta supports growth and survival of human breast cancer MDA-MB-231 cells	ONCOGENE			English	Article						autocrine TGF beta; carcinoma cell; growth; apoptosis	RECEPTOR SUPPRESSES TUMORIGENICITY; COLON-CARCINOMA-CELLS; II GENE MUTATION; TUMOR-SUPPRESSOR; MICROSATELLITE INSTABILITY; C-MYC; EXPRESSION CLONING; EPITHELIAL-CELLS; MCF-7 CELLS; APOPTOSIS	Using a cell model system established by ectopic expression of a soluble TGFbeta type III receptor (sRIII) containing the whole extracellular domain of the type III receptor in human breast cancer MDA-MB-231 cells, we observed that the expression of sRIII antagonized TGFbeta activity and inhibited both anchorage-dependent and anchorage-independent cell growth. Further studies revealed that sRIII expression induced apoptosis both in vitro and in vivo. Treatment with TGFbeta neutralizing antibodies or a recombinant human sRIII also induced apoptosis in the MDA-MB-231 parental cells, suggesting that the increased apoptosis after sRIII expression was specifically due to antagonization of autocrine TGFbeta signaling. Western blotting showed that sRIII clones had a higher PTEN expression level than the control cells did. Treatment with TGFbeta(1) decreased PTEN and inhibited apoptosis in sRIII cells to a level similar to that in the control cells. sRIII clones also showed a lower level of phosphorylated-Akt than the control cells, consistent with the inhibitory activity of PTEN on Akt activation. Treatment with LY294002, a specific inhibitor of Akt activator, phosphatidylinositol 3-kinase, also induced apoptosis in a dose dependent manner in the control cells. Our results suggest that autocrine TGFbeta signaling is necessary for the growth and survival of MDA-MB-231 cells.	Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Sun, LZ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, 7703 Floyd Curl Dr,Mail Code 7762, San Antonio, TX 78229 USA.		, LuZhe/AAW-4095-2021		NCI NIH HHS [CA75253, CA79683] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075253, R01CA079683] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe T, 1996, EUR J SURG ONCOL, V22, P474, DOI 10.1016/S0748-7983(96)92824-3; ARTEAGA CL, 1990, CELL GROWTH DIFFER, V1, P367; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bandyopadhyay A, 1999, CANCER RES, V59, P5041; BARRETTLEE P, 1990, BRIT J CANCER, V61, P612, DOI 10.1038/bjc.1990.136; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BASSING CH, 1994, J BIOL CHEM, V269, P14861; Chen CG, 1997, J BIOL CHEM, V272, P12862, DOI 10.1074/jbc.272.19.12862; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; COOMBES RC, 1990, J STEROID BIOCHEM, V37, P833, DOI 10.1016/0960-0760(90)90428-N; DALY RJ, 1990, J CELL BIOCHEM, V43, P199, DOI 10.1002/jcb.240430302; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GORSCH SM, 1992, CANCER RES, V52, P6949; Grady WM, 1998, CANCER RES, V58, P3101; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; HSU S, 1994, CELL GROWTH DIFFER, V5, P267; Landstrom M, 2000, CURR BIOL, V10, P535, DOI 10.1016/S0960-9822(00)00470-X; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1998, CANCER RES, V58, P5667; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1994, J CELL BIOL, V124, P557, DOI 10.1083/jcb.124.4.557; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsuzaki K, 2000, CANCER RES, V60, P1394; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; MULDER KM, 1989, MOL ENDOCRINOL, V3, P1215, DOI 10.1210/mend-3-8-1215; MURPHY CS, 1991, COLD SPRING HARB SYM, V56, P129; MYEROFF LL, 1995, CANCER RES, V55, P5545; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; Riggins GJ, 1997, CANCER RES, V57, P2578; ROBERTS AB, 1991, TRANSFORMING GROWTH, P419; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Schutte M, 1996, CANCER RES, V56, P2527; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Sun LZ, 1997, J BIOL CHEM, V272, P25367, DOI 10.1074/jbc.272.40.25367; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tomita S, 1999, BREAST CANCER RES TR, V53, P33, DOI 10.1023/A:1006167210269; Vilchis-Landeros MM, 2001, BIOCHEM J, V355, P215, DOI 10.1042/0264-6021:3550215; WALKER RA, 1995, J PATHOL, V177, P123, DOI 10.1002/path.1711770204; Wang D, 2000, CANCER RES, V60, P4507; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; Wilentz RE, 2000, CANCER RES, V60, P2002; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yan ZF, 2001, J BIOL CHEM, V276, P1555, DOI 10.1074/jbc.M004553200; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; ZAR JH, 1984, BIOSTAT ANAL, P122; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	66	63	70	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 24	2002	21	49					7514	7523		10.1038/sj.onc.1205966	http://dx.doi.org/10.1038/sj.onc.1205966			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	604JX	12386814				2022-12-17	WOS:000178618200007
J	el-Ghissassi, F; Valsesia-Wittmann, S; Falette, N; Duriez, C; Walden, PD; Puisieux, A				el-Ghissassi, F; Valsesia-Wittmann, S; Falette, N; Duriez, C; Walden, PD; Puisieux, A			BTG2(TIS21/PC3) induces neuronal differentiation and prevents apoptosis of terminally differentiated PC12 cells	ONCOGENE			English	Article						BTG2(TIS21/PC3); PC12 cells; cell differentiation; apoptosis	NERVE GROWTH-FACTOR; PHEOCHROMOCYTOMA CELLS; PC3/BTG/TOB FAMILY; CELLULAR-RESPONSE; TOB/BTG1 FAMILY; MESSENGER-RNA; GENE; PC3; EXPRESSION; MEMBER	The p53-transcriptional target, BTG2(TIS21/PC3), was previously identified as an antiproliferative gene. However, the precise biological functions of the protein product remain to be elucidated. BTG(2TIS21/PC3) expression is induced in vivo during neurogenesis, and the gene is transiently expressed in vitro in rat pheochromocytoma PC12 cells after induction of neuronal differentiation by addition of nerve growth factor (NGF). These observations suggest that BTG2(TIS21/PC3) is functionally significant during the neuronal differentiation process. To test this hypothesis, a vector that expressed BTG2(TIS21/PC3) under the control of an inducible promoter was introduced into PC12 cells. Growth arrest and differentiation in response to NGF were greatly enhanced by BTG2(TIS21/PC3) overexpression. Furthermore, an antisense oligonucleotide complementary to BTG2(TIS21/PC3) mRNA, which was able to inhibit endogenous BTG2(TIS21/PC3) expression, triggered programmed cell death in differentiated PC12 cells. These observations confirm that BTG2(TIS21/PC3) expression promotes neuronal differentiation and that it is required for survival of terminally differentiated cells.	INSERM, Ctr Leon Berard, Unite 453, Dept Oncol Fondamentale & Appl, F-69008 Lyon, France; NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; NYU, Sch Med, Dept Urol, New York, NY 10016 USA; Fac Pharm Lyon, Dept Genet Mol & Biochim Clin, F-69008 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; New York University; New York University; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Puisieux, A (corresponding author), INSERM, Ctr Leon Berard, Unite 453, Dept Oncol Fondamentale & Appl, 28 Rue Laennec, F-69008 Lyon, France.	puisieux@lyon.fnclcc.fr		PUISIEUX, Alain/0000-0002-9938-3798				ALTIN JG, 1991, J BIOL CHEM, V266, P5401; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; Buanne P, 2000, GENOMICS, V68, P253, DOI 10.1006/geno.2000.6288; Cimato TR, 1997, J CELL BIOL, V138, P1089, DOI 10.1083/jcb.138.5.1089; Corrente G, 2002, NEUROREPORT, V13, P417, DOI 10.1097/00001756-200203250-00011; Cortes U, 2000, MOL CARCINOGEN, V27, P57, DOI 10.1002/(SICI)1098-2744(200002)27:2<57::AID-MC1>3.3.CO;2-9; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; GUPTA M, 1987, BRAIN RES BULL, V18, P555, DOI 10.1016/0361-9230(87)90119-5; Iacopetti P, 1999, P NATL ACAD SCI USA, V96, P4639, DOI 10.1073/pnas.96.8.4639; IACOPETTI P, 1994, MECH DEVELOP, V47, P127, DOI 10.1016/0925-4773(94)90085-X; Ikematsu N, 1999, ONCOGENE, V18, P7432, DOI 10.1038/sj.onc.1203193; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Malatesta P, 2000, MECH DEVELOP, V90, P17, DOI 10.1016/S0925-4773(99)00224-5; Marz P, 1997, EUR J NEUROSCI, V9, P2765, DOI 10.1111/j.1460-9568.1997.tb01705.x; Matsuda S, 1996, ONCOGENE, V12, P705; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; Tirone F, 2001, J CELL PHYSIOL, V187, P155, DOI 10.1002/jcp.1062; vanGrunsven LA, 1996, ONCOGENE, V12, P855; VINORES SA, 1981, J NEUROCHEM, V37, P597; Walden PD, 1998, EXP CELL RES, V245, P19, DOI 10.1006/excr.1998.4237; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yoshida Y, 1998, ONCOGENE, V16, P2687, DOI 10.1038/sj.onc.1201805; Zhu JH, 1998, CANCER RES, V58, P5061	32	63	65	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6772	6778		10.1038/sj.onc.1205888	http://dx.doi.org/10.1038/sj.onc.1205888			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360398				2022-12-17	WOS:000178315800007
J	Zhang, YX; Fondell, JD; Wang, QB; Xia, XM; Cheng, AW; Lu, ML; Hamburger, AW				Zhang, YX; Fondell, JD; Wang, QB; Xia, XM; Cheng, AW; Lu, ML; Hamburger, AW			Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1	ONCOGENE			English	Article						prostate cancer; androgen receptor; ErbB receptors; Ebp1	DIFFERENTIATION FACTOR HEREGULIN; LIGAND-INDEPENDENT ACTIVATION; PROSTATE-CANCER CELLS; GROWTH-FACTORS; CYCLIN D1; EXPRESSION; MECHANISM; C-ERBB-2; COMPLEX; BENIGN	Members of the ErbB family of receptors have been implicated in regulation of androgen receptor (AR) activity. Ebp1, an ErbB-3 binding protein recently cloned in our laboratory, possesses an LXXLL motif important in mediating interactions with nuclear hormone receptors. Therefore, we sought to determine if Ebp1 could bind AR and influence AR transcriptional activation potential. We demonstrate in this study that Ebp1 bound to AR in vitro and in vivo, and that this binding was increased by androgen treatment. The C terminal 79 amino acids of Ebp1 were sufficient to bind AR. The N terminal domain of AR was responsible for binding Ebp1. Ligand-mediated transcriptional activation of both artificial and natural AR regulated promoters was inhibited by ectopic expression of ebp1 in transient transfection systems. Ebp1 deletion mutants that either lacked the C terminal AR binding region or had a mutated LXXLL motif failed to inhibit AR activated transcription. PSA expression from its endogenous promoter was also decreased in LNCaP prostate cancer cells overexpressing Ebp1. The growth of AR positive LNCaP cells was inhibited by ectopic expression of ebp1, but mutants that failed to repress transcription did not inhibit cell growth. These studies suggest that Ebp1 may play a role in the function of the AR and provide a link between ErbB receptors and the AR.	Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Dept Pathol, Baltimore, MD 21201 USA; Univ Maryland, Dept Physiol, Baltimore, MD 21201 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Harvard University; Harvard Medical School	Hamburger, AW (corresponding author), Univ Maryland, Greenebaum Canc Ctr, 655 W Baltimore St, Baltimore, MD 21201 USA.	ahamburg@umaryland.edu	Wang, Qianben/E-4267-2011		NATIONAL CANCER INSTITUTE [R01CA076047] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA76047] Funding Source: Medline; PHS HHS [R21 088882-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aarnisalo P, 1999, ENDOCRINOLOGY, V140, P3097, DOI 10.1210/en.140.7.3097; Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Alen P, 1999, MOL CELL BIOL, V19, P6085; BACUS SS, 1993, CANCER RES, V53, P5251; Bacus SS, 1996, ONCOGENE, V12, P2535; Barton J, 2001, UROLOGY, V58, P114, DOI 10.1016/S0090-4295(01)01253-5; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Hayes SA, 2001, CANCER RES, V61, P2112; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Jenster G, 2000, J PATHOL, V191, P227; Kallioniemi OP, 1996, ADV CANCER RES, V68, P225, DOI 10.1016/S0065-230X(08)60355-3; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Knudsen KE, 1999, CANCER RES, V59, P2297; Lessor TJ, 2001, MOL CELL ENDOCRINOL, V175, P185, DOI 10.1016/S0303-7207(01)00387-2; Lessor TJ, 2000, J CELL PHYSIOL, V183, P321, DOI 10.1002/(SICI)1097-4652(200006)183:3<321::AID-JCP4>3.0.CO;2-O; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Lyne JC, 1997, CANCER J SCI AM, V3, P21; MELLON K, 1992, J UROLOGY, V147, P496, DOI 10.1016/S0022-5347(17)37287-7; Morote J, 1999, INT J CANCER, V84, P421, DOI 10.1002/(SICI)1097-0215(19990820)84:4<421::AID-IJC16>3.0.CO;2-9; MYERS RB, 1994, J NATL CANCER I, V86, P1140, DOI 10.1093/jnci/86.15.1140; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; PRIGENT SA, 1992, ONCOGENE, V7, P1273; RADOMSKI N, 1995, EXP CELL RES, V220, P434, DOI 10.1006/excr.1995.1335; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; Sharma D, 2000, MOL ENDOCRINOL, V14, P2001, DOI 10.1210/me.14.12.2001; Signoretti S, 2000, JNCI-J NATL CANCER I, V92, P1918, DOI 10.1093/jnci/92.23.1918; Slagsvold T, 2001, J BIOL CHEM, V276, P31030, DOI 10.1074/jbc.M104310200; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; WARE JL, 1991, HUM PATHOL, V22, P254, DOI 10.1016/0046-8177(91)90159-M; Wen Y, 2000, CANCER RES, V60, P6841; Whitfield GK, 1999, J CELL BIOCHEM, P110; WILSON EM, 1991, ANN NY ACAD SCI, V637, P56, DOI 10.1111/j.1749-6632.1991.tb27300.x; XIA X, 2001, J CELL PHYSL, V187, P809; Xia XM, 1999, BIOCHEM J, V341, P831, DOI 10.1042/0264-6021:3410831; Xia XM, 2001, BIOCHEM BIOPH RES CO, V289, P240, DOI 10.1006/bbrc.2001.5942; YEH S, 1999, NAT MED, V5, P280; Yoo JY, 2000, BRIT J CANCER, V82, P683; Zhou YC, 1999, J BIOL CHEM, V274, P29874, DOI 10.1074/jbc.274.42.29874	46	63	74	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2002	21	36					5609	5618		10.1038/sj.onc.1205638	http://dx.doi.org/10.1038/sj.onc.1205638			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	583ZM	12165860				2022-12-17	WOS:000177442000011
J	Zhang, CJ; Vilk, G; Canton, DA; Litchfield, DW				Zhang, CJ; Vilk, G; Canton, DA; Litchfield, DW			Phosphorylation regulates the stability of the regulatory CK2 beta subunit	ONCOGENE			English	Article						protein kinase CK2; ubiquitin; phosphorylation; proteasome	CASEIN KINASE-II; TUMOR-SUPPRESSOR PROTEIN; BETA-SUBUNIT; CYCLIN-E; DNA-DAMAGE; CELL-CYCLE; INDUCIBLE EXPRESSION; CK2 SUBUNITS; C-JUN; P53	Protein kinase CK2 is a protein serine/threonine kinase that exhibits elevated expression in a number of cancers and displays oncogenic activity in mice. The regulatory CK2beta subunit has a central role in assembly of functional tetrameric CK2 complexes where it participates in modulation of catalytic activity and substrate specificity. Since overexpression of CK2beta results in elevated levels of CK2 activity, we investigated the molecular mechanisms that control its degradation since perturbations in these pathways could contribute to elevated CK2 in cancer. In this study, we demonstrate that CK2beta is degraded by a proteasome-dependent pathway and that it is ubiquitinated. We have also investigated the role of phosphorylation and a putative destruction box in regulating its stability in cells. Importantly, replacement of three serine residues within the autophosphorylation site of CK2beta with glutamic acid residues resulted in a significant decrease in its degradation indicating that autophosphorylation is involved in regulating its stability. Notably, although the autophosphorylation site of CUP is remarkably conserved between species, this is the first functional role ascribed to this site. Furthermore, based on these results, we speculate that alterations in the phosphorylation or dephosphorylation of the regulatory CK2beta subunit could underlie the elevated expression of CK2 that is observed in cancer cells.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Litchfield, DW (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	litchfi@uwo.ca	Canton, David/N-7463-2015; Litchfield, David/E-4636-2015	Litchfield, David/0000-0002-2425-6620				ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; BODENBACH L, 1994, EUR J BIOCHEM, V220, P263, DOI 10.1111/j.1432-1033.1994.tb18622.x; Boldyreff B, 1997, FEBS LETT, V403, P197, DOI 10.1016/S0014-5793(97)00010-0; Bosc DG, 1999, MOL CELL BIOCHEM, V191, P213, DOI 10.1023/A:1006840329973; Bosc DG, 2000, J BIOL CHEM, V275, P14295, DOI 10.1074/jbc.275.19.14295; Canton DA, 2001, BIOCHEM J, V358, P87, DOI 10.1042/0264-6021:3580087; Castro A, 2001, MOL BIOL CELL, V12, P2660, DOI 10.1091/mbc.12.9.2660; Chen MZ, 1997, P NATL ACAD SCI USA, V94, P9136, DOI 10.1073/pnas.94.17.9136; Chen MZ, 1997, MOL CELL BIOL, V17, P1904, DOI 10.1128/MCB.17.4.1904; DAYAMAKIN M, 1994, CANCER RES, V54, P2262; de Hoog CL, 2001, MOL CELL BIOL, V21, P2107, DOI 10.1128/MCB.21.6.2107-2117.2001; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Dick LR, 1997, J BIOL CHEM, V272, P182; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Faust M, 2000, CELL TISSUE RES, V301, P329, DOI 10.1007/s004410000256; Faust RA, 1996, CANCER LETT, V101, P31, DOI 10.1016/0304-3835(96)04110-9; FILHOL O, 1992, J BIOL CHEM, V267, P20577; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Gerber DA, 2000, J BIOL CHEM, V275, P23919, DOI 10.1074/jbc.M002697200; Ghavidel A, 2001, CELL, V106, P575, DOI 10.1016/S0092-8674(01)00473-1; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Glover CVC, 1998, PROG NUCLEIC ACID RE, V59, P95; Graham KC, 2000, J BIOL CHEM, V275, P5003, DOI 10.1074/jbc.275.7.5003; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HANNA DE, 1995, J BIOL CHEM, V270, P25905, DOI 10.1074/jbc.270.43.25905; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; KREK W, 1992, J CELL BIOL, V116, P43, DOI 10.1083/jcb.116.1.43; Krippner-Heidenreich A, 2001, BIOCHEM J, V358, P705, DOI 10.1042/0264-6021:3580705; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Li DX, 1999, J BIOL CHEM, V274, P32988, DOI 10.1074/jbc.274.46.32988; LIN WJ, 1994, BIOCHEMISTRY-US, V33, P6998, DOI 10.1021/bi00188a032; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LITCHFIELD DW, 1991, J BIOL CHEM, V266, P20380; LORENZ P, 1993, J BIOL CHEM, V268, P2733; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Niefind K, 2001, EMBO J, V20, P5320, DOI 10.1093/emboj/20.19.5320; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; Penner CG, 1997, J CELL BIOCHEM, V64, P525; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; Pham CD, 1999, ONCOGENE, V18, P4287, DOI 10.1038/sj.onc.1202804; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Prowald A, 1997, FEBS LETT, V408, P99, DOI 10.1016/S0014-5793(97)00399-2; Rethinaswamy A, 1998, J BIOL CHEM, V273, P5869, DOI 10.1074/jbc.273.10.5869; Rifkin IR, 1998, J IMMUNOL, V161, P5164; Sayed M, 2000, J BIOL CHEM, V275, P16569, DOI 10.1074/jbc.M000312200; Sayed M, 2001, ONCOGENE, V20, P6994, DOI 10.1038/sj.onc.1204894; Schwab M, 2001, NATURE, V413, P268, DOI 10.1038/35095157; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Shi XY, 2001, J BIOL CHEM, V276, P2075, DOI 10.1074/jbc.M008583200; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; TEITZ T, 1990, MUTAT RES, V236, P85, DOI 10.1016/0921-8777(90)90036-5; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Vilk G, 1999, J BIOL CHEM, V274, P14406, DOI 10.1074/jbc.274.20.14406; Vilk G, 2002, J CELL BIOCHEM, V84, P84, DOI 10.1002/jcb.1268; Winston JT, 1999, GENE DEV, V13, P2751, DOI 10.1101/gad.13.21.2751; YENICE S, 1994, PROSTATE, V24, P11, DOI 10.1002/pros.2990240105; Yew PR, 2001, J CELL PHYSIOL, V187, P1, DOI 10.1002/1097-4652(2001)9999:9999<1::AID-JCP1049>3.0.CO;2-O; YOI OKO, 1993, EMBO J, V12, P1621; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217	76	63	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3754	3764		10.1038/sj.onc.1205467	http://dx.doi.org/10.1038/sj.onc.1205467			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032843				2022-12-17	WOS:000175676000010
J	Shiratori, M; Suzuki, T; Itoh, C; Goto, M; Furuichi, Y; Matsumoto, T				Shiratori, M; Suzuki, T; Itoh, C; Goto, M; Furuichi, Y; Matsumoto, T			WRN helicase accelerates the transcription of ribosomal RNA as a component of an RNA polymerase I-associated complex	ONCOGENE			English	Article						nucleolar localization; RNA polymerase 1; rRNA transcription; senescence; Werner syndrome; WRN	WERNER-SYNDROME PROTEIN; SYNDROME GENE; DNA HELICASE; NUCLEAR-LOCALIZATION; GENOMIC STRUCTURE; YEAST SGS1; TOPOISOMERASE; REPLICATION; INTERACTS; HOMOLOG	Werner syndrome (WS) is a rare autosmomal recessive genetic disorder causing premature aging. The gene (WRN) responsible for WS encodes a protein homologous to the RecQ-type helicase. WRN has a nucleolar localization signal and shows intranuclear trafficking between the nucleolus and the nucleoplasm. WRN is recruited into the nucleolus when rRNA transcription is reactivated in quiescent cells. Inhibition of mRNA transcription with alpha-amanitin has no effect on nucleolar localization of WRN whereas inhibition of rRNA transcription with actinomycin D releases WRN from nucleoli, suggesting that nucleolar WRN is closely related to rRNA transcription by RNA polymerase I (RPI). A possible function of WRN on rRNA transcription through interaction with RPI is supported by the results described here showing that WRN is co-immunoprecipitated with an RPI subunit, RPA40. Here we show that WS fibroblasts are characterized by a decreased level of rRNA transcription compared with wild-type cells, and that the decreased level of rRNA transcription in WS fibroblasts recovers when wild-type WRN is exogenously expressed. By contrast, exogenously expressed mutant-type WRN lacking an ability to migrate into the nucleolus fails to stimulate rRNA transcription. These results suggest that WRN promotes rRNA transcription as a component of an RPI-associated complex in the nucleolus.	AGENE Res Inst, Kanagawa 2470063, Japan; Tokyo Metropolitan Otsuka Hosp, Dept Rheumatol, Toshima Ku, Tokyo 1700005, Japan		Matsumoto, T (corresponding author), Japanese Fdn Canc Res, Genome Ctr, Toshima Ku, 1-37-1 Kami Ikebukuro, Tokyo 1708455, Japan.	takehisa.matsumoto@jfcr.or.jp						Balajee AS, 1999, MOL BIOL CELL, V10, P2655, DOI 10.1091/mbc.10.8.2655; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cooper MP, 2000, GENE DEV, V14, P907; Dammann R, 1998, BBA-GENE STRUCT EXPR, V1396, P153, DOI 10.1016/S0167-4781(97)00206-6; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FARAGHER RGA, 1993, P NATL ACAD SCI USA, V90, P12030, DOI 10.1073/pnas.90.24.12030; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; Gray MD, 1998, EXP CELL RES, V242, P487, DOI 10.1006/excr.1998.4124; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Kadener S, 2001, EMBO J, V20, P5759, DOI 10.1093/emboj/20.20.5759; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kitao S, 1999, GENOMICS, V61, P268, DOI 10.1006/geno.1999.5959; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Lee SK, 1999, SCIENCE, V286, P2339, DOI 10.1126/science.286.5448.2339; Lombard DB, 2000, MOL CELL BIOL, V20, P3286, DOI 10.1128/MCB.20.9.3286-3291.2000; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Matsumoto T, 1997, HUM GENET, V100, P123, DOI 10.1007/s004390050477; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Mushegian AR, 1997, P NATL ACAD SCI USA, V94, P5831, DOI 10.1073/pnas.94.11.5831; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; RONG L, 1991, GENETICS, V127, P75; RONG L, 1993, J BIOL CHEM, V268, P1252; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; SALK D, 1985, ADV EXP MED BIOL, V190, P305; Shen JC, 2000, TRENDS GENET, V16, P213, DOI 10.1016/S0168-9525(99)01970-8; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; Shiratori M, 1999, J CELL BIOL, V144, P1, DOI 10.1083/jcb.144.1.1; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; STEIN GH, 1994, METHOD ENZYMOL, V58, P279; Suzuki N, 1999, NUCLEIC ACIDS RES, V27, P2361, DOI 10.1093/nar/27.11.2361; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Suzuki T, 2001, ONCOGENE, V20, P2551, DOI 10.1038/sj.onc.1204344; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	44	63	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2447	2454		10.1038/sj.onc.1205334	http://dx.doi.org/10.1038/sj.onc.1205334			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971179				2022-12-17	WOS:000174918400001
J	Karsunky, H; Mende, I; Schmidt, T; Moroy, T				Karsunky, H; Mende, I; Schmidt, T; Moroy, T			High levels of the onco-protein Gfi-1 accelerate T-cell proliferation and inhibit activation induced T-cell death in Jurkat T-cells	ONCOGENE			English	Article						Gfi-1; T-cell activation; p21(WAF1); Rb; G1 checkpoint	ZINC-FINGER PROTEIN; TRANSCRIPTIONAL REPRESSOR; TRANSGENIC MICE; MYC; LYMPHOMAGENESIS; LYMPHOCYTES; APOPTOSIS; CYCLE; ELIMINATION; SELECTION	Gfi-1 is a nuclear zinc finger protein with the activity of a transcriptional repressor and the ability to predispose for the development of T-cell lymphoma when expressed constitutively at high levels. Whereas thymic T-cell precursors express endogenous Gfi-1, mature peripheral T-cells lack Gfi-1 but upregulate its expression transiently after antigenic stimulation and activation of Erk1/2 demonstrating a role of Gfi-1 in T-cell activation. Here we show that constitutive expression of Gfi-1 accelerates S phase entry of primary, resting T-cells upon antigenic stimulation. In addition, high level Gfi-1 expression inhibits phorbol ester induced G1 arrest and activation induced cell death in Jurkat T-cells. We demonstrate that these effects of Gfi-1 concur with lower absolute levels and hyperphosphorylation of the pocket protein pRb. Moreover, phorbol ester induced expression of the negative cell cycle regulator p21(WAF1) is blocked in the presence of Gfi-1. These findings suggest that Gfi-1 contributes to T-cell lymphomagenesis by overriding a late G1 cell cycle checkpoint which controls activation induced death and S phase entry of T-cells.	Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany	University of Duisburg Essen	Moroy, T (corresponding author), Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, Virchowstr 173, D-45122 Essen, Germany.		Moroy, Tarik/D-9923-2011					Brehm A, 1999, BRIT J CANCER, V80, P38; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; JONES LA, 1990, SCIENCE, V250, P1726, DOI 10.1126/science.2125368; KABELITZ D, 1993, IMMUNOL TODAY, V14, P338, DOI 10.1016/0167-5699(93)90231-9; Karas M, 1999, MOL BIOL CELL, V10, P4441, DOI 10.1091/mbc.10.12.4441; Karsunky H, 1999, ONCOGENE, V18, P7816, DOI 10.1038/sj.onc.1203205; Lenardo M J, 1995, Int Rev Immunol, V13, P115, DOI 10.3109/08830189509061742; Li QS, 2000, EUR J IMMUNOL, V30, P3329, DOI 10.1002/1521-4141(200011)30:11<3329::AID-IMMU3329>3.0.CO;2-#; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; Liu S, 2000, ANN HUM GENET, V64, P83, DOI 10.1017/S0003480000007971; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; Schmidt T, 1996, NUCLEIC ACIDS RES, V24, P2528, DOI 10.1093/nar/24.13.2528; Schmidt T, 1998, ONCOGENE, V17, P2661, DOI 10.1038/sj.onc.1202191; Stankunas K, 1999, COLD SPRING HARB SYM, V64, P505, DOI 10.1101/sqb.1999.64.505; Wells AD, 1997, J CLIN INVEST, V100, P3173, DOI 10.1172/JCI119873; ZIEGLER SF, 1994, STEM CELLS, V12, P456, DOI 10.1002/stem.5530120502; Zornig M, 1996, ONCOGENE, V12, P1789; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	27	63	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 28	2002	21	10					1571	1579		10.1038/sj/onc/1205216	http://dx.doi.org/10.1038/sj/onc/1205216			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896586				2022-12-17	WOS:000173956800013
J	Fan, SJ; Yuan, RQ; Ma, YX; Meng, QH; Goldberg, ID; Rosen, EM				Fan, SJ; Yuan, RQ; Ma, YX; Meng, QH; Goldberg, ID; Rosen, EM			Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1	ONCOGENE			English	Article						BRCA1; prostate cancer; breast cancer; DNA repair; apoptosis; estrogen receptor (ER)	BREAST-CANCER CELLS; INTERACT IN-VIVO; TUMOR-SUPPRESSOR; OVARIAN-CANCER; GERMLINE MUTATIONS; EXPRESSION; PROTEIN; INHIBITION; PROGRESSION; GROWTH	Unregulated expression of wild-type BRCA1 (wtBRCA1) confers an altered phenotype in cultured human prostate cancer cells, characterized by chemosensitivity, susceptibility to apoptosis, decreased DNA repair activity, and alterations of key cell regulatory proteins. We now report that the expression of truncated or mutant full-length BRCA1 genes can abrogate certain phenotypic characteristics and/or confer the opposite phenotype to the wild-type BRCA1 gene. In particular, several carboxyl-terminal truncated BRCA1 proteins conferred chemoresistance, decreased susceptibility to apoptosis, and decreased ability to suppress in vivo tumor growth. These truncated BRCA1 proteins also blocked the ability of ectopically expressed wtBRCA1 to induce chemosensitivity and to inhibit estrogen receptor transcriptional activity. Studies using epitope-tagged truncated proteins confirmed their expression, nuclear localization, and functionality. On the other hand, in cells with no endogenous wild-type BRCA1 (HCC1937 human breast cancer cells), the wtBRCA1 gene enhanced cellular DNA repair activity and rendered the cells resistant to DNA damage; while truncated BRCA1 proteins blocked the wtBRCA1-induced chemoresistance. Our findings suggest that truncated BRCA1 proteins can inhibit the function of wild-type BRCA1. They raise the possibility that some inherited BRCA1 mutations may actively promote oncogenesis by blocking the function of the remaining wild-type BRCA1 allele, although this hypothesis remains to be proved.	Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Pk, NY 11040 USA	Northwell Health; Yeshiva University	Rosen, EM (corresponding author), Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, Long Isl Campus,270-05 76th Ave, New Hyde Pk, NY 11040 USA.	erosen@lij.edu	Meng, Q./GSI-6185-2022		NCI NIH HHS [R01-CA-80000, R01-CA82599] Funding Source: Medline; NIEHS NIH HHS [R01-ES09169] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080000, R01CA082599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; ALLEY MC, 1988, CANCER RES, V48, P589; Andres JL, 1998, ONCOGENE, V16, P2229, DOI 10.1038/sj.onc.1201752; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; BERTRAND R, 1995, CELL GROWTH APOPTOSI, P97; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen YM, 1996, CANCER RES, V56, P3168; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Freundlieb S, 1997, METHOD ENZYMOL, V283, P159; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Gao B, 2001, FEBS LETT, V488, P179, DOI 10.1016/S0014-5793(00)02430-3; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; LUKAS J, 1994, ONCOGENE, V9, P2159; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rao VN, 1996, ONCOGENE, V12, P523; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shao NS, 1996, ONCOGENE, V13, P1; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Taylor J, 1998, INT J CANCER, V79, P334, DOI 10.1002/(SICI)1097-0215(19980821)79:4<334::AID-IJC5>3.0.CO;2-W; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tirkkonen M, 1997, CANCER RES, V57, P1222; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yuan RQ, 1999, PROSTATE, V40, P37; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	53	63	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2001	20	57					8215	8235		10.1038/sj.onc.1205033	http://dx.doi.org/10.1038/sj.onc.1205033			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781837				2022-12-17	WOS:000172507800006
J	Nair, PN; De Armond, DT; Adamo, ML; Strodel, WE; Freeman, JW				Nair, PN; De Armond, DT; Adamo, ML; Strodel, WE; Freeman, JW			Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-IR) are mediated by an induction of IGF-IR promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2	ONCOGENE			English	Article						IGF-IR; pancreatic cancer; growth regulation; signal transduction; apoptosis	INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; SIGNAL-TRANSDUCTION; FACTOR-ALPHA; PHOSPHATIDYLINOSITOL 3-KINASE; CONSTITUTIVE ACTIVATION; GENE-EXPRESSION; DOWN-REGULATION; PROTEIN-KINASE; APOPTOSIS; PATHWAYS	In the present study we investigated the mechanisms responsible for and the biological consequences of the constitutive activation of the insulin-like growth factor-1 receptor (IGF-IR) in the MIA PaCa-2 cells. An aberrant increase in the expression and activation of the IGF-IR was observed during the transition of growth states from exponential to quiescent. The increase in IGF-1R expression is preceded by an increase in IGF-1R mRNA transcript and is associated with an increase in the IGF-IR promoter activity. Inhibition of de novo transcription by actinomycin D increased the stability of IGF-IR mRNA in exponentially growing cells, thereby increasing the expression of IGF-IR to a level similar to that seen in quiescent cells. Increased IGF-IR signaling mediated the growth factor independence of quiescent MIA PaCa-2 cells through the constitutive activation of mitogen-activated protein kinase (MAPK). Exogenous IGF-I increased cell proliferation and activated MAPK and AKT signaling pathways. The resistance of cells to apoptosis by IGF-IR signaling was mediated through MAPK and phosphatidylinositol 3-kinase (PI3K) pathways and a yet unidentified pathway(s). Thus, aberrant regulation of IGF-1R signaling is required for resistance to apoptosis and growth factor independence of MIA PaCa-2 cells. This likely protects cells from unfavorable conditions and allows cells to rapidly re-enter the cell cycle when conditions are favorable.	Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Freeman, JW (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.							Baron V, 2000, J BIOL CHEM, V275, P39318, DOI 10.1074/jbc.M003618200; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; BERGMANN U, 1995, CANCER RES, V55, P2007; Bergmann U, 1996, BIOCHEM BIOPH RES CO, V220, P886, DOI 10.1006/bbrc.1996.0500; Butler AA, 1998, COMP BIOCHEM PHYS B, V121, P19, DOI 10.1016/S0305-0491(98)10106-2; Chen Jie, 1994, Zentralblatt fuer Pathologie, V140, P265; Chi MMY, 2000, ENDOCRINOLOGY, V141, P4784, DOI 10.1210/en.141.12.4784; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Coppola D, 2000, Cancer Control, V7, P421; Devi GR, 2000, ENDOCRINOLOGY, V141, P4171, DOI 10.1210/en.141.11.4171; DiGiovanni J, 2000, CANCER RES, V60, P1561; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Flossmann-Kast BBM, 1998, CANCER RES, V58, P3551; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; GIANNELLANETO D, 1992, CIRC RES, V71, P646, DOI 10.1161/01.RES.71.3.646; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Grothey A, 1999, J CANCER RES CLIN, V125, P166, DOI 10.1007/s004320050259; HERNANDEZ ER, 1992, J CLIN ENDOCR METAB, V74, P419, DOI 10.1210/jc.74.2.419; Howell GM, 1998, MOL CELL BIOL, V18, P303, DOI 10.1128/MCB.18.1.303; Ignatoski KMW, 1999, ENDOCRINOLOGY, V140, P3615, DOI 10.1210/en.140.8.3615; Ishiwata T, 1997, PANCREAS, V15, P367, DOI 10.1097/00006676-199711000-00006; Jackson JG, 1999, GROWTH HORM IGF RES, V9, P280, DOI 10.1054/ghir.1999.0113; Jiang DH, 1998, J BIOL CHEM, V273, P31471, DOI 10.1074/jbc.273.47.31471; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; Kornmann M, 1998, CANCER RES, V58, P4250; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lee CT, 1996, CANCER RES, V56, P3038; Lin JQ, 1999, CANCER RES, V59, P2891; Liu RY, 1999, BLOOD, V93, P2369, DOI 10.1182/blood.V93.7.2369.407k18_2369_2379; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Parrizas M, 1997, J BIOL CHEM, V272, P154; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Prisco M, 1999, HORM METAB RES, V31, P80, DOI 10.1055/s-2007-978703; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; Reiss K, 1999, J CELL PHYSIOL, V181, P124, DOI 10.1002/(SICI)1097-4652(199910)181:1<124::AID-JCP13>3.0.CO;2-0; Ricort JM, 2001, ENDOCRINOLOGY, V142, P108, DOI 10.1210/en.142.1.108; Supino-Rosin L, 2000, J BIOL CHEM, V275, P21850, DOI 10.1074/jbc.M001834200; Swantek JL, 1999, ENDOCRINOLOGY, V140, P3163, DOI 10.1210/en.140.7.3163; Tominaga S, 1998, SEMIN SURG ONCOL, V15, P3, DOI 10.1002/(SICI)1098-2388(199807/08)15:1<3::AID-SSU2>3.0.CO;2-9; Wang L, 2000, ENDOCRINOLOGY, V141, P2481, DOI 10.1210/en.141.7.2481; WERNER H, 1992, MOL ENDOCRINOL, V6, P1545, DOI 10.1210/me.6.10.1545; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Zahradka P, 1998, BBA-BIOMEMBRANES, V1375, P131, DOI 10.1016/S0005-2736(98)00144-8; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	50	63	66	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 13	2001	20	57					8203	8214		10.1038/sj.onc.1205044	http://dx.doi.org/10.1038/sj.onc.1205044			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781836				2022-12-17	WOS:000172507800005
J	Ohmine, K; Ota, J; Ueda, M; Ueno, S; Yoshida, K; Yamashita, Y; Kirito, K; Imagawa, S; Nakamura, Y; Saito, K; Akutsu, M; Mitani, K; Kano, Y; Komatsu, N; Ozawa, K; Mano, H				Ohmine, K; Ota, J; Ueda, M; Ueno, S; Yoshida, K; Yamashita, Y; Kirito, K; Imagawa, S; Nakamura, Y; Saito, K; Akutsu, M; Mitani, K; Kano, Y; Komatsu, N; Ozawa, K; Mano, H			Characterization of stage progression in chronic myeloid leukemia by DNA microarray with purified hematopoietic stem cells	ONCOGENE			English	Article						chronic myeloid leukemia; DNA microarray; AC133; PIASy	EXPRESSION; GENE; KINASE; TUMOR; CDNA	Chronic myeloid leukemia (CML) is characterized by the clonal expansion of hematopoietic stem cells (HSCs). Without effective treatment, individuals in the indolent, chronic phase (CP) of CML undergo blast crisis (BC), the prognosis for which is poor. It is therefore important to clarify the mechanism underlying stage progression in CML. DNA microarray is a versatile tool for such a purpose. However, simple comparison of bone marrow mononuclear cells from individuals at different disease stages is likely to result in the identification of pseudo-positive genes whose change in expression only reflects the different proportions of leukemic blasts in bone marrow. We have therefore compared with DNA microarray the expression profiles of 3456 genes in the purified HSC-like fractions that had been isolated from 13 CML patients and healthy volunteers. Interestingly, expression of the gene for PIASy, a potential inhibitor of STAT (signal transducer and activator of transcription) proteins, was down-regulated in association with stage progression in CML. Furthermore, forced expression of PIASy has induced apoptosis in a CML cell line. These data suggest that microarray analysis with background-matched samples is an efficient approach to identify molecular events underlying the stage progression in CML.	Jichi Med Sch, Div Funct Genom, Tochigi 3290498, Japan; Jichi Med Sch, Div Hematol, Tochigi 3290498, Japan; Jichi Med Sch, Div Cardiol, Tochigi 3290498, Japan; Univ Tsukuba, Sch Med, Dept Hematol, Tsukuba, Ibaraki 3058575, Japan; Dokkyo Univ, Sch Med, Dept Hematol, Mibu, Tochigi 3210293, Japan; Tochigi Canc Ctr, Utsunomiya, Tochigi 3200834, Japan	Jichi Medical University; Jichi Medical University; Jichi Medical University; University of Tsukuba; Dokkyo Medical University; Tochigi Prefectural Cancer Center	Mano, H (corresponding author), Jichi Med Sch, Div Funct Genom, 3311-1 Yakushiji, Tochigi 3290498, Japan.	hmano@jichi.ac.jp	Kirito, Keita/AEO-6802-2022					Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; BOEL P, 1995, IMMUNITY, V2, P167, DOI 10.1016/S1074-7613(95)80053-0; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; Gouilleux-Gruart V, 1997, LEUKEMIA LYMPHOMA, V28, P83, DOI 10.3109/10428199709058334; HIN AH, 1997, BLOOD, V90, P5002; Iida A, 1996, J VIROL, V70, P6054, DOI 10.1128/JVI.70.9.6054-6059.1996; IZUMI M, 1991, EXP CELL RES, V197, P229, DOI 10.1016/0014-4827(91)90427-V; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KANTARJIAN HM, 1993, BLOOD, V82, P691; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Lethe B, 1998, INT J CANCER, V76, P903, DOI 10.1002/(SICI)1097-0215(19980610)76:6<903::AID-IJC22>3.0.CO;2-1; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Loeffen JLCM, 1998, BIOCHEM BIOPH RES CO, V253, P415, DOI 10.1006/bbrc.1998.9786; Miyazato A, 2001, BLOOD, V98, P422, DOI 10.1182/blood.V98.2.422; Onishi M, 1996, EXP HEMATOL, V24, P324; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Silver RT, 1999, BLOOD, V94, P1517; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; WATHELET MG, 1988, SOMAT CELL MOLEC GEN, V14, P415, DOI 10.1007/BF01534709; Yamashita Y, 2001, J BIOL CHEM, V276, P39012, DOI 10.1074/jbc.M106249200	23	63	68	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2001	20	57					8249	8257		10.1038/sj.onc.1205029	http://dx.doi.org/10.1038/sj.onc.1205029			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	498KC	11781839				2022-12-17	WOS:000172507800008
J	Constantino, S; Santos, R; Lacronique, V; Bouchaert, I; Monni, R; Bernard, O; Gisselbrecht, S; Gouilleux, F				Constantino, S; Santos, R; Lacronique, V; Bouchaert, I; Monni, R; Bernard, O; Gisselbrecht, S; Gouilleux, F			Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a PI 3-kinase/Akt dependent pathway	ONCOGENE			English	Article						STAT5; PI 3-kinase; TEL-JAK2; survival	PERIPHERAL-BLOOD CELLS; BCR-ABL ONCOGENE; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; INDEPENDENT PATHWAYS; CYCLE PROGRESSION; FUSION PROTEIN; ACTIVATION; RECEPTOR; KINASE	Signal Transducer and Activator of Transcription (STATs) are important mediators of cytokine and growth factor-induced signal transduction, STAT5A and STAT5B have been shown to play a role in survival and proliferation of hematopoietic cells both in vitro and in viro and to contribute to the growth and viability of cells transformed by the TEL-JAK2 oncoprotein, In this study, we investigated the molecular mechanisms by which constitutively active STAT5 proteins induce cell proliferation and survival of Ba/F3 cell lines expressing either dominant positive STAT5A or STAT5B variants or TEL-JAK2 or TEL-ABL fusion proteins. Our results showed that active STAT5 constitutively interacted with p85, the regulatory subunit of the PT 3-kinase, A constitutive activity of the PI 3-kinase/Akt pathway was observed in these cells and required for their cell cycle progression. In contrast, while activity of the PI 3-kinase/Akt pathway was required for survival of Ba/F3 cells expressing the constitutively active forms of STAT5A or STAT5B, it was dispensable for cells transformed by TEL-JAK2 or TEL-ABL fusion proteins, suggesting that additional survival pathways take place in these transformed cells.	Hop Cochin, INSERM, U363, Inst Cochin Genet Mol, F-75014 Paris, France; INSERM, U434, CEPH, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Gouilleux, F (corresponding author), Hop Cochin, INSERM, U363, Inst Cochin Genet Mol, 27 Rue Fbg St Jacques, F-75014 Paris, France.		Bernard, Olivier A./E-5721-2016; Penard-Lacronique, Virginie/R-1938-2019; Santos, Susana/AAM-8902-2021; Penard-Lacronique, Virginie/E-5729-2016	Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; Gouilleux, Fabrice/0000-0001-6047-1718; Constantino Rosa Santos, Susana/0000-0002-5711-1292; Bernard, Olivier/0000-0002-0463-9747				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chai SK, 1997, J IMMUNOL, V159, P4720; Craddock BL, 1997, J BIOL CHEM, V272, P29281, DOI 10.1074/jbc.272.46.29281; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DEL PL, 1997, SCIENCE, V278, P687; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Kieslinger M, 2000, GENE DEV, V14, P232; Kuribara R, 1999, MOL CELL BIOL, V19, P2754; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; Shuai K, 1996, ONCOGENE, V13, P247; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; TOKER A, 1994, J BIOL CHEM, V269, P32358; Verdier F, 1997, J BIOL CHEM, V272, P26173, DOI 10.1074/jbc.272.42.26173; Voss J, 2000, ONCOGENE, V19, P1684, DOI 10.1038/sj.onc.1203467; Yamauchi T, 1998, J BIOL CHEM, V273, P15719, DOI 10.1074/jbc.273.25.15719; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	39	63	62	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2001	20	17					2080	2090		10.1038/sj.onc.1204308	http://dx.doi.org/10.1038/sj.onc.1204308			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	422KH	11360192	Green Published			2022-12-17	WOS:000168116700003
J	Offermanns, S				Offermanns, S			In vivo functions of heterotrimeric G-proteins: studies in G alpha-deficient mice	ONCOGENE			English	Article						G-protein; knock-out; transgenic mouse; signal transduction	CEREBELLAR PURKINJE-CELLS; CLIMBING FIBER INNERVATION; PERTUSSIS-TOXIN; SIGNAL-TRANSDUCTION; NEURAL CREST; G-ALPHA-I2-DEFICIENT MICE; PHOSPHOLIPASE C-BETA-4; BIOCHEMICAL-PROPERTIES; MOLECULAR MECHANISMS; PLATELET ACTIVATION	Heterotrimeric guanine nucleotide binding proteins (G-proteins) mediate the effects of numerous hormones, neurotransmitters or sensory stimuli by coupling their transmembranous receptors to various effecters like enzymes and ion channels. Changes in the activity of these effector molecules eventually lead to the regulation of multiple cellular functions ranging from short term regulatory processes like the control of secretion rates, muscle tonus or metabolic processes to long term effects like regulation of growth and differentiation. Heterotrimeric G-proteins play a pivotal role in this transmembrane signaling process as they take part in processing and sorting of incoming signals as well as in adjusting the sensitivity of the system, This review describes some of the new insights into the biological role of G-protein mediated signaling processes provided by the analysis of mice genetically engineered to lack distinct G-protein alpha -subunits.	Heidelberg Univ, Inst Pharmakol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Offermanns, S (corresponding author), Heidelberg Univ, Inst Pharmakol, Neuenheimer Feld 366, D-69120 Heidelberg, Germany.		Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805				AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; Belluscio L, 1998, NEURON, V20, P69, DOI 10.1016/S0896-6273(00)80435-3; Broaddus R, 1998, FASEB J, V12, pA736; BRONNERFRASER M, 1995, EXP CELL RES, V218, P405, DOI 10.1006/excr.1995.1173; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Calvert PD, 2000, P NATL ACAD SCI USA, V97, P13913, DOI 10.1073/pnas.250478897; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; CHAFFIN KE, 1991, EUR J IMMUNOL, V21, P2565, DOI 10.1002/eji.1830211038; Choi DS, 1997, DEVELOPMENT, V124, P1745; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Clouthier DE, 1998, DEVELOPMENT, V125, P813; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Davignon I, 2000, MOL CELL BIOL, V20, P797, DOI 10.1128/MCB.20.3.797-804.2000; Fields TA, 1997, BIOCHEM J, V321, P561, DOI 10.1042/bj3210561; Gachet C, 1997, THROMB HAEMOSTASIS, V78, P271; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; GOLDMAN DW, 1985, J EXP MED, V162, P145, DOI 10.1084/jem.162.1.145; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hendry IA, 2000, BRAIN RES, V870, P10, DOI 10.1016/S0006-8993(00)02387-8; HERVE D, 1993, J NEUROSCI, V13, P2237, DOI 10.1523/jneurosci.13-05-02237.1993; HERVE D, 1995, MOL BRAIN RES, V32, P125, DOI 10.1016/0169-328X(95)00070-9; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Ho MKC, 1998, BIOL SIGNAL RECEPT, V7, P80; Hornquist CE, 1997, J IMMUNOL, V158, P1068; Jantzen HM, 1999, BLOOD, V94, p618A; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3269, DOI 10.1073/pnas.95.6.3269; Johnson GJ, 1996, BIOCHEM J, V318, P1023, DOI 10.1042/bj3181023; Kano M, 1997, NEURON, V18, P71, DOI 10.1016/S0896-6273(01)80047-7; Kano M, 1998, P NATL ACAD SCI USA, V95, P15724, DOI 10.1073/pnas.95.26.15724; Kim JJ, 1997, TRENDS NEUROSCI, V20, P177, DOI 10.1016/S0166-2236(96)10081-3; Kinnamon SC, 1996, CURR OPIN NEUROBIOL, V6, P506, DOI 10.1016/S0959-4388(96)80057-2; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Knall C, 1998, J CELL BIOCHEM, P137; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; KURIHARA Y, 1995, J CLIN INVEST, V96, P293, DOI 10.1172/JCI118033; Lem J., 1998, IOVS, V39, pS644; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Lindemann B, 1996, CURR BIOL, V6, P1234, DOI 10.1016/S0960-9822(96)00704-X; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; Mende U, 1998, P NATL ACAD SCI USA, V95, P13893, DOI 10.1073/pnas.95.23.13893; Meng JW, 1999, J BIOL CHEM, V274, P36663, DOI 10.1074/jbc.274.51.36663; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Moser B, 1998, Int Rev Immunol, V16, P323, DOI 10.3109/08830189809043000; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Offermanns S, 1997, P NATL ACAD SCI USA, V94, P14089, DOI 10.1073/pnas.94.25.14089; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; Ohman L, 2000, SCAND J IMMUNOL, V52, P80; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; ROUSTAN P, 1995, NEUROREPORT, V6, P1837, DOI 10.1097/00001756-199510020-00004; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Sasaki T, 2000, NATURE, V406, P897, DOI 10.1038/35022585; Schild D, 1998, PHYSIOL REV, V78, P429, DOI 10.1152/physrev.1998.78.2.429; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPANGRUDE GJ, 1985, J IMMUNOL, V135, P4135; SPANGRUDE GJ, 1984, J IMMUNOL, V132, P354; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; Tanaka J, 2000, EUR J NEUROSCI, V12, P781, DOI 10.1046/j.1460-9568.2000.00959.x; Valenzuela D, 1997, P NATL ACAD SCI USA, V94, P1727, DOI 10.1073/pnas.94.5.1727; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Warnock RA, 1998, J EXP MED, V187, P205, DOI 10.1084/jem.187.2.205; Watanabe M, 1998, EUR J NEUROSCI, V10, P2016, DOI 10.1046/j.1460-9568.1998.00213.x; Weinstein LS, 1999, TRENDS ENDOCRIN MET, V10, P81, DOI 10.1016/S1043-2760(98)00124-6; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; Wong GT, 1996, NATURE, V381, P796, DOI 10.1038/381796a0; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; Yanagisawa H, 1998, DEVELOPMENT, V125, P825; Yang J, 2000, P NATL ACAD SCI USA, V97, P9984, DOI 10.1073/pnas.180194597; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; Ye CP, 1999, J MOL CELL CARDIOL, V31, P1771, DOI 10.1006/jmcc.1999.1015; Yu SH, 2000, J CLIN INVEST, V105, P615, DOI 10.1172/JCI8437; Yu SH, 1998, P NATL ACAD SCI USA, V95, P8715, DOI 10.1073/pnas.95.15.8715; Zamponi GW, 1998, CURR OPIN NEUROBIOL, V8, P351, DOI 10.1016/S0959-4388(98)80060-3; Zhuang XX, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-16-j0001.2000	89	63	63	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2001	20	13					1635	1642		10.1038/sj.onc.1204189	http://dx.doi.org/10.1038/sj.onc.1204189			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421XX	11313911				2022-12-17	WOS:000168089800014
J	Offer, H; Milyavsky, M; Erez, N; Matas, D; Zurer, I; Harris, CC; Rotter, V				Offer, H; Milyavsky, M; Erez, N; Matas, D; Zurer, I; Harris, CC; Rotter, V			Structural and functional involvement of p53 in BER in vitro and in vivo	ONCOGENE			English	Article						p53; BER; transactivation; DNA repair	NUCLEOTIDE-EXCISION-REPAIR; INHIBITS DNA-REPLICATION; TATA-BINDING PROTEIN; CELL NUCLEAR ANTIGEN; TRANSCRIPTIONAL ACTIVATION; TERMINAL DOMAIN; 3'-TO-5' EXONUCLEASE; WILD-TYPE; IN-VIVO; APOPTOSIS	p53 is involved in several DNA repair pathways. Some of these require the specific transactivation of p53-dependent genes and others involve direct interactions between the p53 protein and DNA repair associated proteins. Previously, we have shown that p53 acts directly in Base Excision Repair (BER) when assayed under in vitro conditions. Our present data indicate that this involvement is independent of the transcriptional activity of the p53 molecule. We found that under both in vitro and in vivo conditions, a p53 transactivation-deficient molecule, p53-22-23,was more efficient in BER activity than was wild type p53. However, mutations in the core domain or C-terminal alterations strongly reduced p53-mediated BER activity, These results are consistent with the hypothesis that the involvement of p53 in BER activity, a housekeeping DNA repair pathway, is a prompt and immediate one that does not involve the activation of D53 transactivation-dependent mechanisms, but rather concerns with the p53 protein itself. In an endogenous DNA damage status p53 is active in BER pathways as a protein and not as a transcription factor.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20896 USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Milyavsky, Michael/E-8306-2011	Erez, Neta/0000-0001-6506-9074				Abramova NA, 1997, P NATL ACAD SCI USA, V94, P7186, DOI 10.1073/pnas.94.14.7186; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHANG J, 1995, J BIOL CHEM, V270, P25014, DOI 10.1074/jbc.270.42.25014; CHEN IT, 1995, ONCOGENE, V11, P1931; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; Farmer G, 1996, MOL CELL BIOL, V16, P4295; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Grombacher T, 1998, ONCOGENE, V17, P845, DOI 10.1038/sj.onc.1202000; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HENDERSON EE, 1989, MUTAT RES, V220, P151, DOI 10.1016/0165-1110(89)90021-3; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNGER HD, 1994, ANAL BIOCHEM, V217, P98, DOI 10.1006/abio.1994.1088; Hussain SP, 1998, CANCER RES, V58, P4023; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Janus F, 1999, MOL CELL BIOL, V19, P2155; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; KANEKO Y, 1995, CANCER LETT, V91, P11, DOI 10.1016/0304-3835(95)03709-6; KASTAN MB, 1991, CANCER RES, V51, P4279; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lloyd DR, 2000, CANCER RES, V60, P517; McKay BC, 1999, CARCINOGENESIS, V20, P1389, DOI 10.1093/carcin/20.8.1389; Miller DL, 1997, WETLANDS, V17, P31, DOI 10.1007/BF03160716; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; Myung K, 1998, P NATL ACAD SCI USA, V95, P7664, DOI 10.1073/pnas.95.13.7664; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Oliver FJ, 1999, AM J HUM GENET, V64, P1282, DOI 10.1086/302389; Peled A, 1996, CANCER RES, V56, P2148; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tang W, 1999, CANCER RES, V59, P2562; Therrien JP, 1999, P NATL ACAD SCI USA, V96, P15038, DOI 10.1073/pnas.96.26.15038; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; Wani MA, 1999, CARCINOGENESIS, V20, P765, DOI 10.1093/carcin/20.5.765; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Yang TT, 1997, ONCOGENE, V14, P1511, DOI 10.1038/sj.onc.1200979; YEE JK, 1994, METHOD CELL BIOL, V43, P99; Yokote H, 1998, MUTAT RES-DNA REPAIR, V409, P147, DOI 10.1016/S0921-8777(98)00052-4; Zhou XL, 1999, CANCER RES, V59, P843	48	63	64	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 1	2001	20	5					581	589		10.1038/sj.onc.1204120	http://dx.doi.org/10.1038/sj.onc.1204120			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	398KE	11313990	Bronze			2022-12-17	WOS:000166755000005
J	Yeh, CT; Shen, CH; Tai, DI; Chu, CM; Liaw, YF				Yeh, CT; Shen, CH; Tai, DI; Chu, CM; Liaw, YF			Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma	ONCOGENE			English	Article						hepatitis B virus; hepatocellular carcinoma; mutant; X protein	TRANSGENIC MICE; HBX PROTEIN; DELETION MUTANTS; GENE PRODUCT; ANTIGEN; DNA; KINASE; PATHOGENESIS; INFECTIONS; APOPTOSIS	The aim of this study was to investigate whether there was a particular hepatitis B virus (HBV) X protein (HBx) mutant associated with Taiwanese patients with hepatocellular carcinoma (HCC). Initially, the entire coding region of HBx gene from the serum samples of 14 Taiwanese patients were sequenced. A novel mutant, HBx-A31, was preferentially found in patients with HCC. Sera from 67 patients with HCC and 100 patients with chronic hepatitis B were thus subjected for codon 31 analysis using a dual amplification created restriction site method. HBx-A31 was detected more frequently in patients with HCC (52% versus 12%; P<0.001) and in patients with liver cirrhosis (44% versus 6%; P<0.001). Site directed mutagenesis experiment revealed that HBx-A31 was less effective in transactivating HBV enhancer I-X promoter complex, less efficient in supporting HBV replication, and less potent in enhancing TNF-alpha induced increment of CPP32/caspase 3 activities in HepG2 cells. In conclusion, a prevalent HBx mutant was identified in Taiwanese patients with hepatocellular carcinoma. Development of this mutant might represent a strategy of the virus to escape immune surveillance and thus contribute to the process of multiple-step hepatocarcinogenesis.	Chang Gung Mem Hosp, Liver Res Unit, Taipei 105, Taiwan; Chang Gung Univ, Sch Med, Taipei 105, Taiwan	Chang Gung Memorial Hospital; Chang Gung University	Yeh, CT (corresponding author), Chang Gung Mem Hosp, Liver Res Unit, 199 Tung Hwa N Rd, Taipei 105, Taiwan.		Liaw, Yun-Fan/B-4305-2009					BEASLEY RP, 1981, LANCET, V2, P1129; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; Chu CM, 1996, J CLIN MICROBIOL, V34, P1815, DOI 10.1128/JCM.34.7.1815-1818.1996; Dopheide TAA, 1996, J GEN VIROL, V77, P173, DOI 10.1099/0022-1317-77-2-173; DUNSFORD HA, 1990, CANCER RES, V50, P3400; FEITELSON M, 1992, CLIN MICROBIOL REV, V5, P275, DOI 10.1128/CMR.5.3.275-301.1992; FEITELSON MA, 1995, GASTROENTEROLOGY, V108, P1810, DOI 10.1016/0016-5085(95)90144-2; FEITELSON MA, 1993, ONCOGENE, V8, P1109; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; Gottlob K, 1998, CANCER RES, V58, P3566; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Greenblatt MS, 1997, CANCER RES, V57, P426; Hsia CC, 1997, BIOCHEM BIOPH RES CO, V241, P726, DOI 10.1006/bbrc.1997.7882; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; LIAW YF, 1988, HEPATOLOGY, V8, P493, DOI 10.1002/hep.1840080310; LIAW YF, 1994, VIRAL HEPATITIS LIVE, P419; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; OHAKI Y, 1983, CANCER, V51, P822, DOI 10.1002/1097-0142(19830301)51:5<822::AID-CNCR2820510513>3.0.CO;2-C; Qadri I, 1996, J BIOL CHEM, V271, P15443, DOI 10.1074/jbc.271.26.15443; ROBINSON WS, 1994, ANNU REV MED, V45, P297; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; Schuster R, 2000, ONCOGENE, V19, P1173, DOI 10.1038/sj.onc.1203417; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Szmuness W, 1978, Prog Med Virol, V24, P40; Tai DI, 2000, HEPATOLOGY, V31, P656, DOI 10.1002/hep.510310316; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; WANG XW, 1995, CANCER RES, V55, P6012; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; Yeh CT, 1998, J MED VIROL, V55, P42, DOI 10.1002/(SICI)1096-9071(199805)55:1<42::AID-JMV8>3.0.CO;2-O; Yeh CT, 2000, HEPATOLOGY, V31, P1318, DOI 10.1053/jhep.2000.7296; Yeh CT, 1997, J VIROL METHODS, V65, P219, DOI 10.1016/S0166-0934(97)02187-3; Yeh CT, 2000, J HEPATOL, V32, P829, DOI 10.1016/S0168-8278(00)80253-6; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20	39	63	67	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2000	19	46					5213	5220		10.1038/sj.onc.1203903	http://dx.doi.org/10.1038/sj.onc.1203903			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077437				2022-12-17	WOS:000165059700001
J	Sueoka, N; Lee, HY; Wiehle, S; Cristiano, RJ; Fang, BL; Ji, L; Roth, JA; Hong, WK; Cohen, P; Kurie, JM				Sueoka, N; Lee, HY; Wiehle, S; Cristiano, RJ; Fang, BL; Ji, L; Roth, JA; Hong, WK; Cohen, P; Kurie, JM			Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells	ONCOGENE			English	Article						apoptosis; tumor; growth inhibition	FACTOR-I RECEPTOR; BREAST-CANCER; EXPRESSION; APOPTOSIS; DIFFERENTIATION; IDENTIFICATION; INHIBITION; INDUCTION; LINES; RISK	Insulin-like growth factor binding proteins (IGFBPs) are secreted into the extra-cellular matrix and inhibit cell growth through IGF-dependent and -independent mechanisms. In this study, we investigated the role of IGFBP-6, a relatively unexplored member of the IGFBP family, in the proliferation of non-small cell lung cancer (NSCLC) cells. Infection of NSCLC cell lints in vitro with an adenovirus expressing human IGFBP-6 under the control of a CMV promoter (Ad5CMV-BP6) reduced NSCLC cell number through activation of programmed cell death, as shown by cell staining with Hoechst 33342 or DIVA end-labeling with bromodeoxyuridine triphosphate, The growth regulatory effect of IGFBP-6 was investigated in vivo by intratumoral injection of Ad5CMV-BP6 in NSCLC xenografts established in nu/nu mice. A single injection of Ad5CMV-BP6 reduced the size of NSCLC xenografts by 45%. These findings indicate that IGFBP-6 is a potent inducer of programmed cell death in cancer cells and support investigations into IGFBP-6 as a potential target in cancer therapeutics.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90095 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Los Angeles	Kurie, JM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 80,1515 Holcombe Blvd, Houston, TX 77030 USA.			Lee, Ho-Young/0000-0001-7556-9312	NATIONAL CANCER INSTITUTE [R29CA067353, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA70907, R29 CA67353] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLOC F, 1994, CYTOMETRY, V17, P59, DOI 10.1002/cyto.990170108; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CARMICHAEL J, 1987, CANCER RES, V47, P936; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; CollettSolberg PF, 1996, ENDOCRIN METAB CLIN, V25, P591, DOI 10.1016/S0889-8529(05)70342-X; Dunn SE, 1998, CANCER RES, V58, P3353; Fang BL, 1997, ANAL BIOCHEM, V254, P139, DOI 10.1006/abio.1997.2417; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Grellier P, 1998, CANCER RES, V58, P1670; Gucev ZS, 1996, CANCER RES, V56, P1545; HAVEMANN K, 1990, J STEROID BIOCHEM, V37, P877, DOI 10.1016/0960-0760(90)90436-O; Hongo A, 1998, CANCER RES, V58, P2477; Huynh H, 1996, CELL GROWTH DIFFER, V7, P1501; HWANG CC, 1995, CANCER LETT, V94, P157, DOI 10.1016/0304-3835(95)03845-N; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Lee CT, 1996, CANCER RES, V56, P3038; Liu YM, 1998, CANCER RES, V58, P570; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; Milasincic DJ, 1996, MOL CELL BIOL, V16, P5964; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Porras A, 1998, MOL ENDOCRINOL, V12, P825, DOI 10.1210/me.12.6.825; Quinn KA, 1996, J BIOL CHEM, V271, P11477, DOI 10.1074/jbc.271.19.11477; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Scotlandi K, 1998, CANCER RES, V58, P4127; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; SIEGFRIED JM, 1992, P NATL ACAD SCI USA, V89, P8107, DOI 10.1073/pnas.89.17.8107; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; VAVERDE AM, 1998, MOL ENDOCRINOL, V12, P688; Yu H, 1999, JNCI-J NATL CANCER I, V91, P151, DOI 10.1093/jnci/91.2.151	31	63	70	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4432	4436		10.1038/sj.onc.1203813	http://dx.doi.org/10.1038/sj.onc.1203813			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980619				2022-12-17	WOS:000089271900014
J	Iglesias, M; Frontelo, P; Gamallo, C; Quintanilla, M				Iglesias, M; Frontelo, P; Gamallo, C; Quintanilla, M			Blockade of Smad4 in transformed keratinocytes containing a Ras oncogene leads to hyperactivation of the Ras-dependent Erk signalling pathway associated with progression to undifferentiated carcinomas	ONCOGENE			English	Article						TGF-beta(1); Smad4; Ras; Erk; urokinase; carcinoma	GROWTH-FACTOR-BETA; PROTEIN-KINASE KINASE; CELL-CYCLE ARREST; TGF-BETA; EPITHELIAL-CELLS; UROKINASE EXPRESSION; P21(WAF1) EXPRESSION; COLORECTAL CANCERS; INVASIVE PHENOTYPE; SIGNALING PATHWAY	Smad4 functions as a transcription factor in TGF-beta signalling. We have investigated the role of Smad4 in the TGF-beta(1) cell responses of transformed PDV keratinocytes, which contain a Ras oncogene, and of non-tumorigenic MCA3D keratinocytes, by transfecting both cell lines with a dominant-negative Smad4 construct. Smad4 mediates TGF-beta(1)-induced up-regulation of p21(Cip1) and growth arrest in MCA3D cells, However, in PDV keratinocytes, Smad4 is only partially involved in TGF-beta(1)-induced growth inhibition, and does not mediate enhancement of p21(Cip1) levels by the growth factor. TGF-beta(1) activates Ras/Erk signalling activity in both cell lines, PD098059, a specific inhibitor of MEK, disminishes TGF-beta(1)-induced p21(Cip1) levels in PDV but not in MCA3D cells, suggesting an involvement of Erk in upregulation of p21(Cip1) by TGF-beta(1) in PDV cells, PDV dominant-negative Smad4 cell transfectants, but not MCA3D transfectants, showed constitutive hyperactivation of the Ras/Erk signalling pathway, increased secretion of urokinase, higher motility properties, and a change to a fibroblastoid cell morphology associated in vivo with the transition from a well differentiated to a poorly differentiated tumour phenotype. infection of MCA3D control and dominant negative Smad4 cell transfectants with retroviruses carrying a Ras oncogene led to enhanced p21(Cip1) and urokinase secreted levels, independently of TGF-beta(1) stimulation, that were reduced by PD098059, These results suggest that Smad4 acts inhibiting Ras-dependent Erk signalling activity in Ras-transformed keratinocytes. Loss of Smad4 function in these cells results in hyperactivation of Erk signalling and progression to undifferentiated carcinomas.	UAM, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; UAM, Fac Med, Dept Anat Patol, Hosp Princesa, Madrid 28029, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Hospital de La Princesa	Quintanilla, M (corresponding author), UAM, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.		Quintanilla, Miguel/K-9293-2017	Quintanilla, Miguel/0000-0002-2124-7657				Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BURMER GC, 1990, GASTROENTEROLOGY, V99, P416, DOI 10.1016/0016-5085(90)91024-Z; BURNS PA, 1991, ONCOGENE, V6, P2363; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; deWinter JP, 1997, ONCOGENE, V14, P1891, DOI 10.1038/sj.onc.1201017; Farina AR, 1998, INT J CANCER, V75, P721; Frontelo P, 1998, EXP CELL RES, V244, P420, DOI 10.1006/excr.1998.4219; Grau AM, 1997, CANCER RES, V57, P3929; HADDOW S, 1991, ONCOGENE, V6, P1465; Hahn SA, 1998, DIGESTION, V59, P493, DOI 10.1159/000007526; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Hunt KK, 1998, CANCER RES, V58, P5656; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LAIHO M, 1992, Critical Reviews in Oncogenesis, V3, P1; Lloyd AC, 1998, CURR OPIN GENET DEV, V8, P43, DOI 10.1016/S0959-437X(98)80060-9; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; Malliri A, 1996, CELL GROWTH DIFFER, V7, P1291; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Min HY, 1996, CANCER RES, V56, P2428; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; Montesano R, 1999, CELL GROWTH DIFFER, V10, P317; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; QUINTANILLA M, 1991, CARCINOGENESIS, V12, P1875, DOI 10.1093/carcin/12.10.1875; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rozenblum E, 1997, CANCER RES, V57, P1731; Santibanez JF, 1999, J CELL BIOCHEM, V74, P61, DOI 10.1002/(SICI)1097-4644(19990701)74:1<61::AID-JCB7>3.3.CO;2-2; Santibanez JF, 2000, BIOCHEM BIOPH RES CO, V273, P521, DOI 10.1006/bbrc.2000.2946; Schwarte-Waldhoff I, 1999, ONCOGENE, V18, P3152, DOI 10.1038/sj.onc.1202641; Simon C, 1996, CANCER RES, V56, P5369; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Yue JB, 1998, ONCOGENE, V17, P47, DOI 10.1038/sj.onc.1201903; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2	53	63	68	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4134	4145		10.1038/sj.onc.1203764	http://dx.doi.org/10.1038/sj.onc.1203764			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962574	Green Submitted			2022-12-17	WOS:000088955100007
J	Salimath, B; Marme, D; Finkenzeller, G				Salimath, B; Marme, D; Finkenzeller, G			Expression of the vascular endothelial growth factor gene is inhibited by p73	ONCOGENE			English	Article						vascular endothelial growth factor; p73; p53; promoter; Sp1; leukemia	TUMOR-SUPPRESSOR GENE; INDUCED TRANSCRIPTION; HEMATOPOIETIC-CELLS; HUMAN CANCERS; KINASE-C; P53; ANGIOGENESIS; PROTEIN; DNA; ACTIVATION	Recently, p73, a new member of the p53 family, has been cloned and mapped to chromosome 1p36, a region that is frequently deleted in a variety of human cancers. p73 can activate p53-responsive promoters and induce apoptosis when overexpressed in certain p53-deficient tumor cells, In contrast to p53, analysis of the p73 gene in several human solid tumors did not reveal loss of p73 expression or mutations in the p73 gene, However, transcriptional silencing of the p73 gene by hypermethylation of a CpG island was observed in several leukemias and lymphomas, These lymphoid neoplasms also show increased expression of vascular endothelial growth factor (VEGF), an endothelial cell-specific mitogen and a key mediator of angiogenesis, To evaluate a possible relationship between p73 status and VEGF expression, we have studied the effect of ectopically expressed p73 on the regulation of the VEGF gene, Our results demonstrate that p73 can down-regulate endogenous VEGF gene expression on mRNA and protein level. This effect is mediated by transcriptional repression of the VEGF promoter and involves the promoter region -85 to -50 bp, containing a cluster of Sp 1 binding sites. Our results suggest a regulatory role for p73 in tumor angiogenesis.	Tumor Biol Ctr, Inst Mol Med, D-79106 Freiburg, Germany; Univ Mysore, Dept Biochem, Mysore 570006, Karnataka, India	University of Mysore	Finkenzeller, G (corresponding author), Tumor Biol Ctr, Inst Mol Med, Breisacher Str 117, D-79106 Freiburg, Germany.							Agami R, 1999, NATURE, V399, P809; Aguayo A, 1999, BLOOD, V94, P3717, DOI 10.1182/blood.V94.11.3717.423k09_3717_3721; Bellamy WT, 1999, CANCER RES, V59, P728; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Corn PG, 1999, CANCER RES, V59, P3352; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FINKENZELLER G, 1992, CANCER RES, V52, P4821; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hussong JW, 2000, BLOOD, V95, P309; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KATOH O, 1995, CANCER RES, V55, P5687; Katoh O, 1998, CANCER RES, V58, P5565; Kawano S, 1999, BLOOD, V94, P1113; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KOLCH W, 1995, BREAST CANCER RES TR, V36, P139, DOI 10.1007/BF00666036; Kroiss MM, 1998, MELANOMA RES, V8, P504, DOI 10.1097/00008390-199812000-00005; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MARTINYBARON G, 1995, CURR OPIN BIOTECH, V6, P675, DOI 10.1016/0958-1669(95)80111-1; MEKLE C, 1998, GENE THER, V5, P1631; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Sunahara M, 1998, INT J ONCOL, V13, P319; Suzuki K, 1996, CANCER RES, V56, P3004; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	37	63	69	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2000	19	31					3470	3476		10.1038/sj.onc.1203672	http://dx.doi.org/10.1038/sj.onc.1203672			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918605				2022-12-17	WOS:000088346500003
J	Brenner, KA; Corbett, SA; Schwarzbauer, JE				Brenner, KA; Corbett, SA; Schwarzbauer, JE			Regulation of fibronectin matrix assembly by activated Ras in transformed cells	ONCOGENE			English	Article						Ras; fibronectin; matrix assembly	CHICK-EMBRYO FIBROBLASTS; FOCAL ADHESION KINASE; FIBRO-SARCOMA CELLS; PROTEIN-KINASE; EXTRACELLULAR-MATRIX; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; INTEGRIN ACTIVATION; CYCLE PROGRESSION; GROWTH-FACTOR	Fibronectin extracellular matrix plays a critical role in the microenvironment of cells. Loss of this matrix frequently accompanies oncogenic transformation, allowing changes in cell growth, morphology, and tissue organization. The HT1080 human fibrosarcoma cell lint is deficient in formation of fibronectin match fibrils but assembly can be induced by the glucocorticoid dex-amethasone, Here we show that fibronectin assembly can also be restored by stimulation of alpha(5)beta(1) integrin with activating antibody or with Mn2+ suggesting that integrin activity is reduced in these cells. While dexamethasone promoted actin stress fiber formation, actin filaments remained cortical following Mn2+ treatment shelving that the dexamethasone effect is not due solely to cytoskeletal changes. HT1080 cells have one activated allele of N-ras and PD98059 inhibition of signaling from Ras through ERK increased fibronectin matrix accumulation. Conversely, the p38 MAP kinase inhibitor SB203580 blocked induction of matrix and increased ERK phosphorylation, Thus, two MAP kinase pathways contribute to the control of integrin-mediated fibronectin assembly, ERK activity and fibronectin assembly were linked in three different ras-transformed cell Lines but not in SV40- or RSV-transformed cells indicating that oncogenic Ras uses a distinct mechanism to down-regulate cell-fibronectin interactions.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Surg, New Brunswick, NJ 08903 USA	Princeton University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Schwarzbauer, JE (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.			Schwarzbauer, Jean/0000-0003-1012-7593				AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; DAMSKY CH, 1992, J CLIN INVEST, V89, P210, DOI 10.1172/JCI115565; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; FURCHT LT, 1979, CANCER RES, V39, P2077; GAILIT J, 1988, J BIOL CHEM, V263, P12927; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GRENZ H, 1993, J CELL SCI, V105, P739; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HEMLER ME, 1984, J IMMUNOL, V132, P3011; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Hulley PA, 1998, ENDOCRINOLOGY, V139, P2423, DOI 10.1210/en.139.5.2423; HYNES RO, 1975, VIROLOGY, V64, P492, DOI 10.1016/0042-6822(75)90126-9; HYNES RO, 1977, J SUPRAMOL STR CELL, V7, P397, DOI 10.1002/jss.400070311; Hynes RO, 1990, FIBRONECTINS; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; Keely P, 1998, TRENDS CELL BIOL, V8, P101, DOI 10.1016/S0962-8924(97)01219-1; KOHNO M, 1985, J BIOL CHEM, V260, P1771; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; MARCANTONIO EE, 1988, J CELL BIOL, V106, P1765, DOI 10.1083/jcb.106.5.1765; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1987, J CELL BIOL, V104, P601, DOI 10.1083/jcb.104.3.601; MEYER M, 1991, J BIOL CHEM, V266, P8230; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; MOSHER DF, 1993, CURR OPIN STRUC BIOL, V3, P214, DOI 10.1016/S0959-440X(05)80155-1; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Moustakas A, 1999, J CELL SCI, V112, P1169; OLDEN K, 1977, CELL, V11, P957, DOI 10.1016/0092-8674(77)90307-5; OLIVER N, 1983, CELL, V33, P287, DOI 10.1016/0092-8674(83)90357-4; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHWARZBAUER JE, 1989, J CELL BIOL, V109, P3445, DOI 10.1083/jcb.109.6.3445; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; Sechler JL, 1998, J BIOL CHEM, V273, P25533, DOI 10.1074/jbc.273.40.25533; Sechler JL, 1997, MOL BIOL CELL, V8, P2563, DOI 10.1091/mbc.8.12.2563; Sechler JL, 1996, CELL ADHES COMMUN, V4, P413, DOI 10.3109/15419069709004458; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; Sottile J, 1998, J CELL SCI, V111, P2933; Stice Ligaya L., 1999, Frontiers in Bioscience, V4, pD72, DOI 10.2741/Stice; STONE KR, 1974, VIROLOGY, V58, P86, DOI 10.1016/0042-6822(74)90143-3; Uht RM, 1997, ENDOCRINOLOGY, V138, P2900, DOI 10.1210/en.138.7.2900; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; WAHRMAN MZ, 1985, TUMOUR BIOL, V6, P41; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; Wu C, 1997, HISTOL HISTOPATHOL, V12, P233; YAMADA KM, 1976, P NATL ACAD SCI USA, V73, P1217, DOI 10.1073/pnas.73.4.1217; YAMADA KM, 1990, CANCER RES, V50, P4485; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415; ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447; Zhong CL, 1998, J CELL BIOL, V141, P539, DOI 10.1083/jcb.141.2.539; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	63	63	65	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3156	3163		10.1038/sj.onc.1203626	http://dx.doi.org/10.1038/sj.onc.1203626			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918570				2022-12-17	WOS:000088019200004
J	Schuster, R; Gerlich, WH; Schaefer, S				Schuster, R; Gerlich, WH; Schaefer, S			Induction of apoptosis by the transactivating domains of the hepatitis B virus X gene leads to suppression of oncogenic transformation of primary rat embryo fibroblasts	ONCOGENE			English	Article						apoptosis; Bcl-2; E1B; HBV; HBx; HCC	PROGRAMMED CELL-DEATH; HBX PROTEIN; C-JUN; MALIGNANT TRANSFORMATION; IN-VITRO; ACTIVATION; EXPRESSION; P53; MURINE; DNA	Epidemiology shows a clear correlation between chronic infection with the hepatitis B virus (HBV) and development of hepatocellular carcinoma (HCC). The potential role of the transactivating hepatitis B virus X protein (HBx) in transformation by HBV is controversial, Here we report that HBx suppresses transformation of primary rat embryo fibroblasts (REFs), Cooperating oncogenes like c-Ha-ras and c-myc transform REF very efficiently but cotransfection with HBx suppressed transformation of REFs down to 5%, Similarly, transfection of HBx together with the cooperating oncogenes Ha-ras and SV40 LTAg or c-Ha-ras and mutant p53 reduced the number of foci to 13%. Comparable results were obtained with HBx in the context of the whole HBV, Suppression of focus formation in REF could be partly relieved by cotransfection of apoptosis inhibitors Bcl-2 or E1B, However, cotransfection of apoptosis inhibitors crmA and p35 did not influence the proapoptotic functions of HBx, Thus, HBx may specifically activate the Bcl-2 sensitive pathway leading to apoptosis. Experiments with 13 HBx linker scanning mutants revealed that the domains necessary for HBx dependent transactivation overlap with the domains needed for the apoptotic/growth arrest functions of HBx.	Univ Giessen, Inst Med Virol, D-35392 Giessen, Germany	Justus Liebig University Giessen	Schaefer, S (corresponding author), Univ Giessen, Inst Med Virol, Frankfurter Str 107, D-35392 Giessen, Germany.							AUSUBEL FM, 1998, CURRENT PROTOCOLS MO, P914; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; BLUM HE, 1992, J VIROL, V66, P1223, DOI 10.1128/JVI.66.2.1223-1227.1992; Brechot C, 1998, J HEPATOL, V29, P173, DOI 10.1016/S0168-8278(98)80001-9; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Cory S, 1998, BBA-REV CANCER, V1377, pR25, DOI 10.1016/S0304-419X(98)00003-1; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Gottlob K, 1998, CANCER RES, V58, P3566; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; Kairat A, 1999, INTERVIROLOGY, V42, P228, DOI 10.1159/000024982; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; LAND H, 1995, METHOD ENZYMOL, V254, P37; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; NATOLI G, 1994, ONCOGENE, V9, P2837; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Parker GA, 1996, ONCOGENE, V13, P2541; PEACOCK JW, 1990, ONCOGENE, P1769; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; PONCHEL F, 1994, CANCER RES, V54, P2064; Poussin K, 1999, INT J CANCER, V80, P497, DOI 10.1002/(SICI)1097-0215(19990209)80:4<497::AID-IJC3>3.0.CO;2-8; Qi XM, 1997, ONCOGENE, V15, P1207, DOI 10.1038/sj.onc.1201290; RAKOTOMAHANINA CK, 1994, ONCOGENE, V9, P2613; RUNKEL L, 1993, VIROLOGY, V197, P529, DOI 10.1006/viro.1993.1626; Schaefer S, 1998, J GEN VIROL, V79, P767, DOI 10.1099/0022-1317-79-4-767; Schaefer S, 1995, INTERVIROLOGY, V38, P143, DOI 10.1159/000150425; SCHAEFER S, 1999, ADV ONCOLOGY, V3; SCHLUTER V, 1994, ONCOGENE, V9, P3335; SEEGER C, 1989, J VIROL, V63, P4665, DOI 10.1128/JVI.63.11.4665-4669.1989; SEIFER M, 1990, VIROLOGY, V179, P300, DOI 10.1016/0042-6822(90)90298-6; SEIFER M, 1991, J HEPATOL, V13, pS61, DOI 10.1016/0168-8278(91)90026-8; SEIFER M, 1990, VIROLOGY, V179, P287, DOI 10.1016/0042-6822(90)90297-5; SEIFER M, 1991, VIRAL HEPATITIS 1990, P58; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Tarn C, 1999, J BIOL CHEM, V274, P2327, DOI 10.1074/jbc.274.4.2327; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TWU JS, 1993, VIROLOGY, V192, P346, DOI 10.1006/viro.1993.1041; WANG XW, 1995, CANCER RES, V55, P6012; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	62	63	68	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1173	1180		10.1038/sj.onc.1203417	http://dx.doi.org/10.1038/sj.onc.1203417			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713705				2022-12-17	WOS:000085567800007
J	Seol, DW; Chen, QY; Zarnegar, R				Seol, DW; Chen, QY; Zarnegar, R			Transcriptional activation of the Hepatocyte Growth Factor receptor (c-met) gene by its ligand (Hepatocyte Growth Factor) is mediated through AP-1	ONCOGENE			English	Article						c-Met; AP-1; SP-1; hepatocyte growth factor	FUNCTIONAL-CHARACTERIZATION; EARLY RESPONSE; SCATTER FACTOR; EXPRESSION; PROTEIN-1; BINDING; HGF; JUN; MORPHOGENESIS; INDUCTION	Hepatocyte Growth Factor (HGF) exerts its biological effects via binding and activating a transmembrane protein tyrosine kinase receptor known as c-Met. Previous studies from our laboratory demonstrated that c-met gene expression is inducible by its own ligand (HGF), However, the molecular mechanism(s) involved in this process are unknown. The present study,vas carried out to address this question. Transfection of various c-met-CAT promoter constructs into the mouse hepatocellular carcinoma cell line Hepa 1-6 in combination with electrophoretic mobility shift assays (EMSA) identified the responsive element as an activated protein-1 (AP-1) binding site (TGAGTCA) within the c-mct core promoter region at position -158 to -152. The c-met AP-I element binds specifically to AP-I protein as, verified by supershift assays. EMSA studies and mutational analyses of the promoter region also revealed that the members of the Sp family of transcription factors (Sp-1 and Sp-3) bind to the c-met Sp-1 element (located at position -124) which is adjacent to the AP-1 site. We show that Sp binding dampens binding of AP-1 to its cognate site in the c-met promoter region. Stimulation of Hepa 1-6 cells with HGF resulted in a rapid and dramatic enhancement of the AP-1 binding activity as well as an overall increase in the le,el of AP-I protein. Cotransfection of AP-1 expression vectors (c-Fos plus c-Jun) with c-met promoter constructs resulted in stimulation of c-met promoter activity. We found that transactivation of the c-met promoter by AP-1 can be blocked by Curcumin, an inhibitor of AP-I, Moreover, we found that the induction of the endogenous c-met gene by HGF is inhibited by the addition of Curcumin, The results demonstrate that the HGF-induced transcription of the c-met gene by HGF is, at least in part, due to activation of the AP-1 pathway.	Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Zarnegar, R (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Div Cellular & Mol Pathol, Room S-411A,BST S, Pittsburgh, PA 15261 USA.							Ahmad M, 1998, J BIOL CHEM, V273, P4616, DOI 10.1074/jbc.273.8.4616; Bell A, 1999, ONCOGENE, V18, P887, DOI 10.1038/sj.onc.1202379; BLADT F, 1995, NATURE, V373, P702; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Chen QY, 1997, HEPATOLOGY, V26, P59; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; Gambarotta G, 1996, ONCOGENE, V13, P1911; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; JANSON L, 1991, GENE, V109, P297, DOI 10.1016/0378-1119(91)90625-L; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1996, CELL GROWTH DIFFER, V7, P1805; Jiang JG, 1997, ONCOGENE, V14, P3039, DOI 10.1038/sj.onc.1201152; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kida M, 1999, J BIOL CHEM, V274, P6138, DOI 10.1074/jbc.274.10.6138; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEIDEN JM, 1989, J AUTOIMMUN, V2, P67, DOI 10.1016/0896-8411(89)90118-2; LIU YH, 1994, J BIOL CHEM, V269, P4152; Maffe A, 1998, EUR J MORPHOL, V36, P74; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Seol DW, 1999, J BIOL CHEM, V274, P3565, DOI 10.1074/jbc.274.6.3565; Seol DW, 1998, BBA-GENE STRUCT EXPR, V1395, P252, DOI 10.1016/S0167-4781(97)00202-9; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; Tamagnone Luca, 1997, Cytokine and Growth Factor Reviews, V8, P129, DOI 10.1016/S1359-6101(97)00007-5; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEIR E, 1994, HEPATOLOGY, V20, P955, DOI 10.1002/hep.1840200426; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	33	63	66	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 24	2000	19	9					1132	1137		10.1038/sj.onc.1203404	http://dx.doi.org/10.1038/sj.onc.1203404			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MX	10713700				2022-12-17	WOS:000085567800002
J	Scharnhorst, V; Menke, AL; Attema, J; Haneveld, JK; Riteco, N; van Steenbrugge, GJ; van der Eb, AJ; Jochemsen, AG				Scharnhorst, V; Menke, AL; Attema, J; Haneveld, JK; Riteco, N; van Steenbrugge, GJ; van der Eb, AJ; Jochemsen, AG			EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity	ONCOGENE			English	Article						Wilms' tumor 1 gene products; early growth response 1 gene product; tumorigenesis; tumor suppression; Wilms' tumor	DNA-BINDING SPECIFICITY; ZINC FINGER PROTEIN; RAT-KIDNEY-CELLS; WT1 GENE; TRANSFORMING GROWTH-FACTOR-BETA-1; SUPPRESSOR GENE; PROTOONCOGENE TRANSCRIPTION; 3T3 CELLS; EXPRESSION; P53	The Wilms' tumor 1 gene (WT1) encodes a transcription factor of the zinc-finger family and is homozygously mutated or deleted in a subset of Wilms' tumors. Through alternative mRNA splicing, the gene is expressed as four main polypeptides that differ by a stretch of 17 amino acids just N-terminal of the four zinc-fingers and three amino acids between zinc fingers 3 and 4, We have previously shown that expression of the WT1(-/-) isoform, lacking both inserts, increases the tumor growth rate of the adenovirus-transformed baby rat kidney (AdBRK) cell line 7C3H2, whereas expression of the WT1(-/+) isoform, lacking the 17aa insert, strongly suppresses the tumorigenic phenotype. In the present study we show that expression of these splice variants does not affect the tumorigenic potential of the similar AdBRK cell line, 7C1T1, In contrast to the 7C3H2 cell line, this AdBRK cell line expresses high endogenous levels of EGR-1 (early growth response-1) protein, a transcription factor structurally related to WT1, Ectopic expression of EGR-1 in the 7C3H2 AdBRK cells significantly increases their in vivo growth rate and nullifies the tumor suppressor activity of the WT1(-/+) protein. Furthermore, we find that EGR-1 levels are elevated in some Wilms' tumors. These data are the first to show that EGR-1 overexpression causes enhanced tumor growth and that WT1 and EGR-1 exert antagonizing effects on growth regulation in baby rat kidney cells, which might reflect the situation in some Wilms' tumors.	Leiden Univ, Med Ctr, Mol Carcinogenesis Lab, Dept Mol Cell Biol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Ctr Biomed Genet, NL-2300 RA Leiden, Netherlands; Erasmus Univ, Dept Expt Urol, NL-3000 DR Rotterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam	Jochemsen, AG (corresponding author), Leiden Univ, Med Ctr, Mol Carcinogenesis Lab, Dept Mol Cell Biol, POb 9503, NL-2300 RA Leiden, Netherlands.		Menke, Aswin/AAC-6809-2021	Menke, Aswin/0000-0002-0724-0897; Scharnhorst, Volkher/0000-0002-1243-9251				BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BONETTA L, 1990, SCIENCE, V250, P940; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Cipriano SC, 1998, ONCOGENE, V17, P1549, DOI 10.1038/sj.onc.1202069; DEGROOT RP, 1995, CELL GROWTH DIFFER, V6, P531; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; Duarte A, 1998, BRIT J CANCER, V77, P253, DOI 10.1038/bjc.1998.41; Eid MA, 1998, CANCER RES, V58, P2461; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HUANG RP, 1995, CANCER RES, V55, P5054; KINANE TB, 1994, J BIOL CHEM, V269, P27503; Kinane TB, 1995, J BIOL CHEM, V270, P30760, DOI 10.1074/jbc.270.51.30760; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Lee YI, 1996, DNA CELL BIOL, V15, P99, DOI 10.1089/dna.1996.15.99; LEVIN WJ, 1995, ONCOGENE, V11, P1261; LIM RW, 1987, ONCOGENE, V1, P263; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; LUO XN, 1995, ONCOGENE, V11, P743; MACHIN GA, 1984, HISTOPATHOLOGY, V8, P35, DOI 10.1111/j.1365-2559.1984.tb02320.x; Maheswaran S, 1998, ONCOGENE, V16, P2041, DOI 10.1038/sj.onc.1201741; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MCMASTER ML, 1995, CELL GROWTH DIFFER, V6, P1609; Menke AL, 1996, ONCOGENE, V12, P537; Menke AL, 1998, INT REV CYTOL, V181, P151, DOI 10.1016/S0074-7696(08)60418-0; MENKE AL, 1995, INT J CANCER, V63, P76, DOI 10.1002/ijc.2910630115; MILLBRANDT J, 1987, SCIENCE, V238, P797; MORRIS JF, 1991, ONCOGENE, V6, P2339; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; RACKLEY RR, 1995, J UROLOGY, V154, P700, DOI 10.1016/S0022-5347(01)67136-2; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; REDDY JC, 1995, J BIOL CHEM, V270, P29976; Royuela M, 1998, GROWTH FACTORS, V16, P101, DOI 10.3109/08977199809002121; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; Scharnhorst V, 1997, CELL GROWTH DIFFER, V8, P133; SLATER RM, 1992, CANCER GENET CYTOGEN, V61, P111, DOI 10.1016/0165-4608(92)90071-F; STEEGENGA WT, 1995, VIROLOGY, V212, P543, DOI 10.1006/viro.1995.1512; Thigpen AE, 1996, J UROLOGY, V155, P975, DOI 10.1016/S0022-5347(01)66361-4; VANDENHEUVEL SJ, 1993, J VIROL, V67, P5526; WANG ZY, 1995, ONCOGENE, V10, P415; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	48	63	64	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					791	800		10.1038/sj.onc.1203390	http://dx.doi.org/10.1038/sj.onc.1203390			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698497				2022-12-17	WOS:000085192100009
J	Nikolopoulos, SN; Spengler, BA; Kisselbach, K; Evans, AE; Biedler, JL; Ross, RA				Nikolopoulos, SN; Spengler, BA; Kisselbach, K; Evans, AE; Biedler, JL; Ross, RA			The human non-muscle alpha-actinin protein encoded by the ACTN4 gene suppresses tumorigenicity of human neuroblastoma cells	ONCOGENE			English	Article						alpha-actinin; chromosome #4; tumor suppression; human neuroblastoma	NEURO-BLASTOMA CELLS; RAS-TRANSFORMED FIBROBLASTS; SIGNALING PATHWAYS; CYTOPLASMIC DOMAIN; BETA-CATENIN; EXPRESSION; ADHESION; CDNA; CYTOSKELETAL; GROWTH	alpha-Actinins are actin-binding proteins important in organization of the cytoskeleton and in cell adhesion. We have cloned and characterized a cDNA from human neuroblastoma cell variants which encodes the second non-muscle alpha-actinin isoform designated ACTN4 (actinin-4), mRNA encoded by the ACTN4 gene, mapped to chromosome 4, is abundant in non-tumorigenic, substrate-adherent human neuroblastoma cell variants but absent or only weakly expressed in malignant, poorly substrate-adherent neuroblasts, It is also present in many adherent tumor cell lines of diverse tissue origins. Cell lines typically co-express ACTN4 and ACTN1, a second non-muscle alpha-actinin gene. Expression is correlated with substrate adhesivity, Analysis of deduced amino acid sequences suggests that the two isoforms may differ in function and in regulation by calcium. Moreover, ACTN4 exhibits tumor suppressor activity. Stable clones containing increased levels of alpha-actinin, isolated from highly malignant neuroblastoma stem cells [BE(2)-C] after transfection with a full-length ACTN4 cDNA, show decreased anchorage-independent growth ability, loss of tumorigenicity in nude mice, and decreased expression of the N-myc proto-oncogene.	Fordham Univ, Dept Biol Sci, Neurobiol Lab, Bronx, NY 10458 USA; Childrens Hosp Philadelphia, Div Oncol, Abramson Pediat Res Ctr, Philadelphia, PA 19104 USA	Fordham University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Ross, RA (corresponding author), Fordham Univ, Dept Biol Sci, Neurobiol Lab, 441 E Fordham Road, Bronx, NY 10458 USA.							Akamatsu H, 1996, CANCER RES, V56, P4541; BARON MD, 1987, J BIOL CHEM, V262, P2558; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEDLER JL, 1988, ADV NEUROBLASTOMA RE, V2, P265; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; Bullions LC, 1997, MOL CELL BIOL, V17, P4501, DOI 10.1128/MCB.17.8.4501; BURN P, 1985, NATURE, V314, P469, DOI 10.1038/314469a0; BURRIDGE K, 1981, NATURE, V294, P565, DOI 10.1038/294565a0; Chan YM, 1998, BIOCHEM BIOPH RES CO, V248, P134, DOI 10.1006/bbrc.1998.8920; CICCARONE V, 1989, CANCER RES, V49, P219; Dosaka-Akita H, 1998, CANCER RES, V58, P322; EBASHI S, 1964, NATURE, V203, P645, DOI 10.1038/203645a0; ENDO T, 1982, J BIOCHEM, V92, P1457, DOI 10.1093/oxfordjournals.jbchem.a134070; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; GEIGER B, 1992, COLD SPRING HARB SYM, V57, P631, DOI 10.1101/SQB.1992.057.01.069; Gimona M, 1996, P NATL ACAD SCI USA, V93, P9618, DOI 10.1073/pnas.93.18.9618; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; Han X, 1997, BIOCHEMISTRY-US, V36, P10364, DOI 10.1021/bi962929v; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; IMAMURA M, 1994, EUR J BIOCHEM, V223, P395, DOI 10.1111/j.1432-1033.1994.tb19006.x; IMAMURA M, 1992, J BIOL CHEM, V267, P25927; JANMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111, DOI 10.1016/0955-0674(95)80052-2; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kretsinger R H, 1980, Ann N Y Acad Sci, V356, P14, DOI 10.1111/j.1749-6632.1980.tb29594.x; LANDON F, 1985, EUR J BIOCHEM, V153, P231, DOI 10.1111/j.1432-1033.1985.tb09291.x; Lazarova DL, 1999, ONCOGENE, V18, P2703, DOI 10.1038/sj.onc.1202621; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; MILLAKE DB, 1989, NUCLEIC ACIDS RES, V17, P6725, DOI 10.1093/nar/17.16.6725; Nikolopoulos S. N., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P510; NOEGEL A, 1987, FEBS LETT, V221, P391, DOI 10.1016/0014-5793(87)80962-6; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; PAVALKO FM, 1991, J CELL BIOL, V114, P481, DOI 10.1083/jcb.114.3.481; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; ROSS RA, 1983, J NATL CANCER I, V71, P741; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SCHULTHEISS T, 1992, P NATL ACAD SCI USA, V89, P9282, DOI 10.1073/pnas.89.19.9282; Spengler BA, 1997, ONCOL RES, V9, P467; SPENGLER BA, 1994, P AM ASSOC CANC RES, V35, P302; STOKER M, 1968, INT J CANCER, V3, P683, DOI 10.1002/ijc.2910030517; TANAKA M, 1995, CANCER RES, V55, P3228; Travers H, 1996, CELL GROWTH DIFFER, V7, P1353; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; YOUSSOUFIAN H, 1990, AM J HUM GENET, V47, P62; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	59	63	68	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2000	19	3					380	386		10.1038/sj.onc.1203310	http://dx.doi.org/10.1038/sj.onc.1203310			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656685				2022-12-17	WOS:000084873700008
J	Jaishankar, S; Zhang, J; Roussel, MF; Baker, SJ				Jaishankar, S; Zhang, J; Roussel, MF; Baker, SJ			Transforming activity of EWS/FLI is not strictly dependent upon DNA-binding activity	ONCOGENE			English	Article						EWS/FLI; transformation; DNA-binding; Ewing sarcoma; ETS	EWINGS-SARCOMA TRANSLOCATION; TRANSCRIPTION FACTOR; RNA-BINDING; ETS-FAMILY; CHROMOSOME-TRANSLOCATION; MYXOID LIPOSARCOMA; GENE FUSION; EWS GENE; PROTEIN; DOMAIN	In approximately 85% of Ewing sarcomas, chromosomal translocations give rise to the chimeric gene EWS/FLI, encoding the N-terminus of the RNA binding protein EWS fused to the DNA-binding domain of the ETS protein FLI-1, EWS/FLI is a stronger transcriptional activator than wild-type FLI-1, although both proteins bind to the same DNA sequences in vitro. In addition, EWS/FLI, but not FLI-1, is a transforming oncogene in NIH3T3 fibroblasts. EWS/FLI is thought to transform through its ability to deregulate the expression of target genes. We introduced several paint mutations into the ETS domain of EWS/FLI that abolished DNA-binding activity. Although two of these mutations disrupted the transforming activity of EWS/FLI, one mutated protein containing a substitution of isoleucine 347 with glutamic acid (I347E) retained diminished transforming activity. In addition, EWS/FLI I347E did not activate expression of the endogenous EWS/FLI target gene manic fringe (MFNG). These studies demonstrate that a portion of the oncogenic activity of EWS/FLI is independent of nr DNA-binding activity.	Univ Tennessee, Dept Pathol, Memphis, TN 38163 USA; St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA	University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Baker, SJ (corresponding author), Univ Tennessee, Dept Pathol, Memphis, TN 38163 USA.		Roussel, Martine F/F-1469-2016	Roussel, Martine F/0000-0002-1740-8139; Natarajan, Thanemozhi/0000-0002-0598-9693	NATIONAL CANCER INSTITUTE [P30CA021765, P01CA071907] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765, P01-CA-71907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Barr FG, 1998, NAT GENET, V19, P121, DOI 10.1038/475; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Dubnau J, 1996, NATURE, V379, P694, DOI 10.1038/379694a0; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; ICHIKAWA H, 1994, CANCER RES, V54, P2865; Inukai T, 1998, MOL CELL BIOL, V18, P6035, DOI 10.1128/MCB.18.10.6035; JEON IS, 1995, ONCOGENE, V10, P1229; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; LADANYI M, 1994, CANCER RES, V54, P2837; Ladomery M, 1997, BIOESSAYS, V19, P903, DOI 10.1002/bies.950191010; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MAO XH, 1994, J BIOL CHEM, V269, P18216; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OHNO T, 1993, CANCER RES, V53, P5859; Panagopoulos I, 1996, ONCOGENE, V12, P489; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Pio F, 1996, J BIOL CHEM, V271, P23329, DOI 10.1074/jbc.271.38.23329; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RiveraPomar R, 1996, NATURE, V379, P746, DOI 10.1038/379746a0; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; SOUDANT N, 1994, NUCLEIC ACIDS RES, V22, P3871, DOI 10.1093/nar/22.19.3871; THAYER MJ, 1993, P NATL ACAD SCI USA, V90, P6483, DOI 10.1073/pnas.90.14.6483; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341	43	63	66	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	1999	18	40					5592	5597		10.1038/sj.onc.1202940	http://dx.doi.org/10.1038/sj.onc.1202940			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523836				2022-12-17	WOS:000082894700012
J	Huang, SM; Qiu, Y; Stein, RW; Brandt, SJ				Huang, SM; Qiu, Y; Stein, RW; Brandt, SJ			P300 functions as a transcriptional coactivator for the TAL1/SCL oncoprotein	ONCOGENE			English	Article						TAL1/SCL; p300; transcriptional coactivator	T-CELL LEUKEMIA; LOOP-HELIX PROTEIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; SCL GENE-PRODUCT; PEDIATRIC-ONCOLOGY-GROUP; CBP-INDUCED STIMULATION; RNA-POLYMERASE-II; ADENOVIRUS E1A; IN-VIVO; ERYTHROID-DIFFERENTIATION	Activation of the TALI (or SCL) gene, originally identified through its involvement by a recurrent chromosomal translocation, is the most frequent gain-of-function mutation recognized in T-cell acute lymphoblastic leukemia (T-ALL). The TAL1 proteins contain a basic helix-loop-helix (bHLH) motif characteristic of a large family of transcription factors that control transcription from an E box target element as heterodimers with the E2A- and HEB-encoded gene products. Gene knockout studies in mice indicate that this transcription factor is required for embryonic and adult hematopoiesis, and considerable evidence suggests it has specific functions in terminal erythroid differentiation. We investigated whether the broadly expressed nuclear protein p300, known to function as a coactivator for other bHLH proteins involved in cellular differentiation, also interacts with TAL1, p300 was found to coimmunoprecipitate with Tal1 in extracts from murine erythroleukemia (MEL) cells induced to differentiate with dimethylsulfoxide (DMSO), and p300 and Tal1 were observed in a common E box DNA-binding complex in extracts from differentiating MEL cells. p300 also interacted with Tal1 in protein pulldown assays, suggesting this was a direct interaction. Finally, p300 augmented transcription by Tal1 from an E box-containing promoter and by a GAL4-Tal1 fusion from a promoter containing the GAL4 DNA-binding element. Deletion analysis identified the bHLH domain of Tall and amino-terminal sequences of p300 as necessary for p300-stimulated transactivation and Tal1-p300 interaction in vitro. These results indicate that recruitment of the transcriptional coactivator p300 can positively regulate TAL1-directed gene expression. The dependence of their interaction in MEL cells on addition of a differentiation inducer suggests, further, that this TAL1-p300 complete may have an important role in terminal erythroid differentiation.	Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Brandt, SJ (corresponding author), Vanderbilt Univ, Med Ctr, Div Hematol Oncol, Room 547,MRB 2, Nashville, TN 37232 USA.			, Yi/0000-0002-3282-6072	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055091] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL49118] Funding Source: Medline; NIDDK NIH HHS [R01 DK55091] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; Aplan PD, 1997, EMBO J, V16, P2408, DOI 10.1093/emboj/16.9.2408; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Bain G, 1998, SEMIN IMMUNOL, V10, P143, DOI 10.1006/smim.1998.0116; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bannister AJ, 1995, ONCOGENE, V11, P2509; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; BASH RO, 1993, BLOOD, V81, P2110; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARUSO M, 1993, ONCOGENE, V8, P267; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, ONCOGENE, V8, P677; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CONDORELLI G, 1995, BLOOD, V86, P164, DOI 10.1182/blood.V86.1.164.bloodjournal861164; Condorelli GL, 1996, CANCER RES, V56, P5113; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Dambly-Chaudiere C, 1998, INT J DEV BIOL, V42, P269; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Eckner R, 1996, BIOL CHEM, V377, P685; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Elwood NJ, 1998, BLOOD, V91, P3756; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hoang T, 1996, BLOOD, V87, P102; Hofmann TJ, 1996, ONCOGENE, V13, P617; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HWANG LY, 1993, ONCOGENE, V8, P3043; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; KALLIANPUR AR, 1994, BLOOD, V83, P1200; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Kitabayashi I, 1998, EMBO J, V17, P2994, DOI 10.1093/emboj/17.11.2994; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Lee JS, 1996, MOL CELL BIOL, V16, P4312; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MILLER BA, 1994, BLOOD, V84, P2971; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; MOUTHON MA, 1993, BLOOD, V81, P647; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; Ono Y, 1997, J BIOL CHEM, V272, P4576, DOI 10.1074/jbc.272.7.4576; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; Park ST, 1998, J BIOL CHEM, V273, P7030, DOI 10.1074/jbc.273.12.7030; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; PRASAD KSS, 1995, J BIOL CHEM, V270, P11603, DOI 10.1074/jbc.270.19.11603; PULFORD K, 1995, BLOOD, V85, P675, DOI 10.1182/blood.V85.3.675.bloodjournal853675; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7339; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SANDER M, 1997, J MOL MED, V75, P321; Sandmoller A, 1996, MOL CELL BIOL, V16, P5846; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VISVADER J, 1991, ONCOGENE, V6, P187; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WADMAN IA, 1994, ONCOGENE, V9, P3713; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	92	63	64	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 2	1999	18	35					4958	4967		10.1038/sj.onc.1202889	http://dx.doi.org/10.1038/sj.onc.1202889			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490830				2022-12-17	WOS:000082321700008
J	Maeda, M; Matsui, T; Imamura, M; Tsukita, S; Tsukita, S				Maeda, M; Matsui, T; Imamura, M; Tsukita, S; Tsukita, S			Expression level, subcellular distribution and Rho-GDI binding affinity of merlin in comparison with ezrin/radixin/moesin proteins	ONCOGENE			English	Article						ERM; ezrin; radixin; moesin; merlin; neurofibromatosis	NEUROFIBROMATOSIS-2 TUMOR-SUPPRESSOR; TRANSMEMBRANE CONDUCTANCE REGULATOR; CELL EXTENSION ACTIVITY; ERM FAMILY MEMBERS; ACTIN-BINDING; PLASMA-MEMBRANE; TERMINAL DOMAIN; GENE-PRODUCT; F-ACTIN; BETA(2)-ADRENERGIC RECEPTOR	Merlin, a neurofibromatosis type-2 tumor suppressor, shows significant sequence similarity to ERM (Ezrin/ Radixin/Moesin) proteins, general actin filament/plasma membrane cross-linkers, which are regulated in a Rho-dependent manner. To understand its physiological functions, we compared merlin with ERM proteins in vivo and in vitro. Quantitative immunoblotting revealed that the molar ratio of merlin/ERM in cultured epithelial or non-epithelial cells was similar to 0.14 or similar to 0.05, respectively. After centrifugation of cell homogenate, merlin was mostly recovered in the insoluble fraction, whereas almost half of ERM proteins were found in the soluble fraction. Merlin and ERM proteins mere concentrated at microvilli when introduced into fibroblasts, In contrast, in epithelial cells, introduced merlin was co-distributed with E-cadherin in lateral membranes, whereas ERM proteins were concentrated in epical microvilli, Finally, we examined the binding affinity of merlin to Rho GDP dissociation inhibitor (Rho-GDI), to which N-terminal halves of ERM proteins but not the full-length molecules specifically bind, In vitro binding assays revealed that the N-terminal halves of merlin isoform-I and -II as well as full-length merlin isoform-II bound to Rho-GDI with similar binding affinity to ERM proteins. Immunoprecipitation confirmed these findings in vivo. These findings do not favor the notion that merlin functions simply in a redundant or competitive manner to ERM proteins.	Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Kyoto 606, Japan; Kyoto Univ, Fac Med, Dept Surg & Surg Basic Sci, Sakyo Ku, Kyoto 606, Japan; Kyoto Univ, Coll Med Technol, Dept Surg & Surg Basic Sci, Sakyo Ku, Kyoto 606, Japan	Kyoto University; Kyoto University; Kyoto University	Tsukita, S (corresponding author), Kyoto Univ, Fac Med, Dept Cell Biol, Sakyo Ku, Konoe Yoshida, Kyoto 606, Japan.							ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BERRYMAN M, 1995, J CELL BIOL, V131, P1231, DOI 10.1083/jcb.131.5.1231; Bretscher A, 1997, J CELL SCI, V110, P3011; CHEN J, 1995, P NATL ACAD SCI USA, V92, P7495, DOI 10.1073/pnas.92.16.7495; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Deguen B, 1998, HUM MOL GENET, V7, P217, DOI 10.1093/hmg/7.2.217; DENBAKKER MA, 1995, ONCOGENE, V10, P757; Doi Y, 1999, J BIOL CHEM, V274, P2315, DOI 10.1074/jbc.274.4.2315; EGERTON M, 1992, J IMMUNOL, V149, P1847; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; HARA T, 1994, CANCER RES, V54, P330; Helander TS, 1996, NATURE, V382, P265, DOI 10.1038/382265a0; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Huang LQ, 1998, BIOCHEM BIOPH RES CO, V248, P548, DOI 10.1006/bbrc.1998.9009; Huynh DP, 1996, ONCOGENE, V13, P73; Kondo T, 1997, J CELL BIOL, V139, P749, DOI 10.1083/jcb.139.3.749; LaJeunesse DR, 1998, J CELL BIOL, V141, P1589, DOI 10.1083/jcb.141.7.1589; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; MAGENDANTZ M, 1995, J BIOL CHEM, V270, P25324, DOI 10.1074/jbc.270.43.25324; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; Martin M, 1997, MOL BIOL CELL, V8, P1543, DOI 10.1091/mbc.8.8.1543; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; McCartney BM, 1996, J CELL BIOL, V133, P843, DOI 10.1083/jcb.133.4.843; McClatchey AI, 1997, GENE DEV, V11, P1253, DOI 10.1101/gad.11.10.1253; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; NIGGLI V, 1995, FEBS LETT, V376, P172, DOI 10.1016/0014-5793(95)01270-1; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Roy C, 1997, J BIOL CHEM, V272, P20088, DOI 10.1074/jbc.272.32.20088; Sainio M, 1997, J CELL SCI, V110, P2249; SATO N, 1991, J CELL BIOL, V113, P321, DOI 10.1083/jcb.113.2.321; SATO N, 1992, J CELL SCI, V103, P131; Scherer SS, 1996, J NEUROSCI RES, V46, P595, DOI 10.1002/(SICI)1097-4547(19961201)46:5<595::AID-JNR8>3.0.CO;2-E; Serrador JM, 1997, J CELL BIOL, V138, P1409, DOI 10.1083/jcb.138.6.1409; Serrador JM, 1998, BLOOD, V91, P4632, DOI 10.1182/blood.V91.12.4632.412k17_4632_4644; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 1998, CELL GROWTH DIFFER, V9, P287; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; THUILLIER L, 1994, CELL IMMUNOL, V156, P322, DOI 10.1006/cimm.1994.1178; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; Vaheri A, 1997, CURR OPIN CELL BIOL, V9, P659, DOI 10.1016/S0955-0674(97)80119-6; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7; Xu L, 1998, EXP CELL RES, V238, P231, DOI 10.1006/excr.1997.3843; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yun CHC, 1998, J BIOL CHEM, V273, P25856, DOI 10.1074/jbc.273.40.25856	64	63	64	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4788	4797		10.1038/sj.onc.1202871	http://dx.doi.org/10.1038/sj.onc.1202871			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490812	Green Submitted			2022-12-17	WOS:000082184800003
J	Majello, B; Napolitano, G; Giordano, A; Lania, L				Majello, B; Napolitano, G; Giordano, A; Lania, L			Transcriptional regulation by targeted recruitment of cyclin-dependent CDK9 kinase in vivo	ONCOGENE			English	Article						CDK9 kinase; cyclin T; transcription elongation; recruitment	RNA-POLYMERASE-II; TATA-BINDING PROTEIN; FACTOR P-TEFB; HIV-1 TAT; IN-VITRO; CDC2-RELATED KINASE; CATALYTIC SUBUNIT; TERMINAL DOMAIN; CELL-CYCLE; ELONGATION	The CDK9 kinase in association with Cyclin T is a component of the transcription positive-acting complex pTEFb which facilitates the transition from abortive to productive transcription elongation by phosphorylating the carboxyl-terminal domain of RNA polymerase II. The Cyclin T1/CDK9 complex is implicated in Tat transactivation, and it has been suggested that Tat functions by recruiting this complex to RNAPII through cooperative binding to RNA. Here, we demonstrate that targeted recruitment of Cyclin T1/CDK9 kinase complex to specific promoters, through fusion to a DNA-binding domain of either Cyclin T1 or CDK9 kinase, stimulates transcription in vivo. Transcriptional enhancement was dependent on active CDK9, as a catalytically inactive form had no transcriptional effect. We determined that, unlike conventional activators, DNA-bound CDK9 does not activate enhancerless TATA-promoters unless TBP is overexpressed, suggesting that CDK9 acts in vivo at a step subsequent to TFIID recruitment DNA-bound, Finally, we determined that CDK9-mediated transcriptional activation is mediated by preferentially stimulating productive transcription elongation.	Univ Naples Federico II, Dept Genet Mol & Gen Biol, Naples, Italy; CNR, Int Inst Genet & Biophys, I-80125 Naples, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19107 USA	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Jefferson University	Lania, L (corresponding author), Univ Naples Federico II, Dept Genet Mol & Gen Biol, Naples, Italy.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Napolitano, Giuliana/0000-0002-1637-6016; Majello, Barbara/0000-0003-2789-3585				Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; De Falco G, 1998, J CELL PHYSIOL, V177, P501, DOI 10.1002/(SICI)1097-4652(199812)177:4<501::AID-JCP1>3.0.CO;2-4; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Garriga J, 1996, BIOCHEM J, V319, P293, DOI 10.1042/bj3190293; Gold MO, 1998, J VIROL, V72, P4448, DOI 10.1128/JVI.72.5.4448-4453.1998; Gold MO, 1996, NUCLEIC ACIDS RES, V24, P3771, DOI 10.1093/nar/24.19.3771; Gold MO, 1998, NUCLEIC ACIDS RES, V26, P3784, DOI 10.1093/nar/26.16.3784; GonzalezCouto E, 1997, P NATL ACAD SCI USA, V94, P8036, DOI 10.1073/pnas.94.15.8036; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; He S, 1998, MOL CELL BIOL, V18, P2876, DOI 10.1128/MCB.18.5.2876; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.biochem.63.1.717; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; Majello B, 1998, AIDS, V12, P1957, DOI 10.1097/00002030-199815000-00006; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Majello B, 1998, J BIOL CHEM, V273, P16509, DOI 10.1074/jbc.273.26.16509; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Peng JM, 1998, J BIOL CHEM, V273, P13855, DOI 10.1074/jbc.273.22.13855; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Rickert P, 1996, ONCOGENE, V12, P2631; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Xiao H, 1997, MOL CELL BIOL, V17, P6898, DOI 10.1128/MCB.17.12.6898; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhou QA, 1996, SCIENCE, V274, P605, DOI 10.1126/science.274.5287.605; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	33	63	65	1	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 12	1999	18	32					4598	4605		10.1038/sj.onc.1202822	http://dx.doi.org/10.1038/sj.onc.1202822			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467404				2022-12-17	WOS:000082018600009
J	Ronnstrand, L; Arvidsson, AK; Kallin, A; Rorsman, C; Hellman, U; Engstrom, U; Wernstedt, C; Heldin, CH				Ronnstrand, L; Arvidsson, AK; Kallin, A; Rorsman, C; Hellman, U; Engstrom, U; Wernstedt, C; Heldin, CH			SHP-2 binds to Tyr763 and Tyr1009 in the PDGF beta-receptor and mediates PDGF-induced activation of the Ras MAP kinase pathway and chemotaxis	ONCOGENE			English	Article						PDGF beta-receptor; SHP-2; chemotaxis; Ras MAP kinase pathway	PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-FACTOR RECEPTOR; MITOGENIC SIGNAL-TRANSDUCTION; PHOSPHOLIPASE C-GAMMA; TANDEM SH2 DOMAINS; PHOSPHOTYROSINE PHOSPHATASE; REGULATED KINASE; CELL-ADHESION; 3T3 CELLS; SH-PTP2	Activation of the beta-receptor for platelet-derived growth factor (PDGF) by its ligand leads to autophosphorylation on a number of tyrosine residues. Here me show that Tyr763 in the kinase insert region is a novel autophosphorylation site, which after phosphorylation binds the protein tyrosine phosphatase SHP-2. SHP-2 has also previously been shown to bind to phosphorylated Tyr1009 in the PDGF beta-receptor. Porcine aortic endothelial (PAE) cells transfected with a PDGF beta-receptor in which Tyr763 and Tyr1009 were mutated to phenylalanine residues failed to associate with SHP-2 after ligand stimulation. Moreover, PDGF-BB-induced Ras GTP-loading and Erk2 activation were severely compromised in the receptor mutant. Whereas the mitogenic response to PDGF-BB remained at the same level as in cells expressing wild-type PDGF beta-receptor, chemotaxis induced by PDGF-BB was significantly decreased in the case of the Y763F/Y1009F mutant cells, suggesting an important role for SHP-2 in chemotactic signaling.	Ludwig Inst Canc Res, Ctr Biomed, S-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research	Ronnstrand, L (corresponding author), Ludwig Inst Canc Res, Ctr Biomed, Box 595, S-75124 Uppsala, Sweden.		Ronnstrand, Lars/A-2429-2011	Ronnstrand, Lars/0000-0003-1275-5809				Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; ANDREWS DM, 1991, INT J PEPT PROT RES, V38, P469; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BLUMEJENSEN P, 1995, J BIOL CHEM, V270, P14192, DOI 10.1074/jbc.270.23.14192; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CASE RD, 1994, J BIOL CHEM, V269, P10467; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; ERIKSSON A, 1995, J BIOL CHEM, V270, P7773, DOI 10.1074/jbc.270.13.7773; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HooshmandRad R, 1997, EXP CELL RES, V234, P434, DOI 10.1006/excr.1997.3636; Jackson DE, 1997, J BIOL CHEM, V272, P24868, DOI 10.1074/jbc.272.40.24868; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; Lu XL, 1998, ONCOGENE, V17, P441, DOI 10.1038/sj.onc.1201988; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MORI S, 1991, J BIOL CHEM, V266, P21158; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; REUTER CWM, 1995, METHOD ENZYMOL, V255, P245; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; WENNSTROM S, 1994, ONCOGENE, V9, P651; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	53	63	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	1999	18	25					3696	3702		10.1038/sj.onc.1202705	http://dx.doi.org/10.1038/sj.onc.1202705			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391677				2022-12-17	WOS:000081140200003
J	Huang, CS; Ma, WY; Dong, ZG				Huang, CS; Ma, WY; Dong, ZG			The extracellular-signal-regulated protein kinases (Erks) are required for UV-induced AP-1 activation in JB6 cells	ONCOGENE			English	Article						UV; Erks; JNKs; AP-1	GROWTH-FACTOR RECEPTORS; C-JUN; COUPLED RECEPTORS; TYROSINE KINASES; MAP KINASES; TRANSFORMATION; PHOSPHORYLATION; TRANSDUCTION; PATHWAYS; SPHINGOMYELINASE	Mitogen activated protein (MAP) kinase belongs to a large family of serine/threonine protein kinases, including extracellular-signal-regulated protein kinases (Erks), P38 kinase and c-Jun N-terminal kinases (JNKs), Although previous work has shown that both Erks and JNKs are activated in cells in response to ultraviolet (UV) irradiation, most studies have focused only on the role of JNKs in UV-induced AP-1 activation. Hence, the role of Erks in UV-induced AP-1 activity is not well defined. We here have investigated this issue by using MAP kinase kinase (MEK,) inhibitor PD098059 and a dominant negative Erk2, as a ell as wild-type Erk2, in a JB6 cell model. PD098059 inhibited UVB- or UVC-induced AP-1 activity and phosphorylation of MEK1, and Erks, but not JNKs, in JB6 Cl 41 cells. Overexpression of mild-type Erk2 in Cl 30.7b cells that contain small amounts of Erks caused a 46.6- or 138.1-fold increase of AP-1 activity by UVB and UVC, respectively; introduction of a dominant negative Erk2 into Cl 41 cells significantly blocked the UV-induced Erks activation as well as the AP-1 activation. In contrast, overexpression of wild-type Erk2 in Cl 30.7b cells and dominant negative Erk2 in Cl 41 cells did not show a marked influence on the phosphorylation of JNKs, These results demonstrate that activation of Erks, in addition to the previously reported JNKs, is required for UV-induced AP-1 activation.	Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	University of Minnesota System	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.			Huang, Chuanshu/0000-0003-4133-5096				ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Adler V, 1996, J BIOL CHEM, V271, P23304, DOI 10.1074/jbc.271.38.23304; BENARI ET, 1992, MOL CARCINOGEN, V5, P62, DOI 10.1002/mc.2940050111; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BUSCHER M, 1988, ONCOGENE, V3, P301; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COBB MH, 1994, SEMIN CANCER BIOL, V5, P261; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1995, INT J ONCOL, V7, P359; FITZPATRICK TB, 1976, RES PHOTOBIOLOGY, P485; FORBES PD, 1976, RES PHOTOBIOLOGY, P469; HUANG C, 1996, J BIOL CHEM, V49, P31262; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Huang CS, 1996, INT J ONCOL, V8, P389; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LALLEMAIN G, 1992, MOL CELL BIOL, V12, P2222, DOI 10.1128/MCB.12.5.2222; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RAINES MA, 1993, J BIOL CHEM, V268, P14572; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Rosenberger SF, 1996, ONCOGENE, V12, P2301; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEIVA E, 1993, J BIOL CHEM, V268, P2250; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; STRICKLAND PT, 1986, J INVEST DERMATOL, V87, P272, DOI 10.1111/1523-1747.ep12696669; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WATTS RG, 1998, IN PRESS ONCOGENE, V17; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	55	63	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	1999	18	18					2828	2835		10.1038/sj.onc.1202639	http://dx.doi.org/10.1038/sj.onc.1202639			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362253				2022-12-17	WOS:000080125100005
J	Arriola, EL; Rodriguez-Lopez, AM; Hickman, JA; Chresta, CM				Arriola, EL; Rodriguez-Lopez, AM; Hickman, JA; Chresta, CM			Bcl-2 overexpression results in reciprocal downregulation of Bcl-X-L and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis	ONCOGENE			English	Article						testicular tumours; apoptosis; Bcl-2; Bcl-X-L	CISPLATIN-INDUCED APOPTOSIS; ETOPOSIDE-INDUCED APOPTOSIS; CYTOCHROME-C; IN-VIVO; IMMUNOHISTOCHEMICAL ANALYSIS; CLONOGENIC SURVIVAL; UP-REGULATION; DEATH; EXPRESSION; PROTEIN	Testicular germ cell tumours are hypersentive to chemotherapy and cell lines derived from these tumours are chemosensitive in vitro. We have previously shown that these cell lines express undetectable levels of the suppressor of apoptosis Bcl-2 and relatively high levels of the apoptosis inducer Bar (Chresta et al., 1996). To determine whether the absence of Bcl-2 in these cell lines makes them highly susceptible to drug-induced apoptosis, Bcl-2 was expressed ectopically in the 833K testicular germ cell tumour cell line. Stable overexpressing clones were isolated and three clones were studied further. Surprisingly, Eel-2 overexpressing cells were sensitized to chemotherapy-induced apoptosis compared to the parental and vector control cells. Analysis of potential mechanisms of sensitization revealed there was reciprocal downregulation of the endogenously expressed Bcl-X-L in the Eel-2 overexpressing clones. Downregulation of Bcl-X-L to the same extent using antisense oligonucleotides enhanced etoposide-induced apoptosis by twofold. Our results indicate that Eel-2 and Bcl-X-L have different abilities to protect against chemotherapy-induced apoptosis in testicular germ cell tumours. In contrast to findings in some tumour cell types, Eel-2 did not act as a gatekeeper to prevent entry of p53 to the nucleus.	Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Res Grp, Manchester M13 9PT, Lancs, England	University of Manchester	Chresta, CM (corresponding author), Univ Manchester, Sch Biol Sci, CRC, Mol & Cellular Pharmacol Res Grp, G38 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.							Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; BERTRAND R, 1991, CANCER RES, V51, P6280; Boersma AWM, 1997, CYTOMETRY, V27, P275, DOI 10.1002/(SICI)1097-0320(19970301)27:3<275::AID-CYTO10>3.0.CO;2-Q; Burger H, 1997, INT J CANCER, V73, P592, DOI 10.1002/(SICI)1097-0215(19971114)73:4<592::AID-IJC22>3.0.CO;2-A; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chresta CM, 1996, CANCER RES, V56, P1834; Cosulich SC, 1996, CURR BIOL, V6, P997, DOI 10.1016/S0960-9822(02)00644-9; Dibbert B, 1998, BLOOD, V92, P778, DOI 10.1182/blood.V92.3.778.415k38_778_783; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; EINHORN LH, 1990, J CLIN ONCOL, V8, P1777, DOI 10.1200/JCO.1990.8.11.1777; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; FISHER TC, 1993, CANCER RES, V53, P3321; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Han ZY, 1996, CANCER RES, V56, P1621; HASHIMOTO H, 1995, CANCER RES, V55, P4029; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; KAMESAKI S, 1993, CANCER RES, V53, P4251; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lock RB, 1996, CANCER RES, V56, P4006; LU QL, 1993, J PATHOL, V169, P431, DOI 10.1002/path.1711690408; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; PIETENPOL JA, 1994, CANCER RES, V54, P3714; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SCHWARZE MMK, 1995, CANCER RES, V55, P2262; Simonian PL, 1997, BLOOD, V90, P1208, DOI 10.1182/blood.V90.3.1208.1208_1208_1216; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; Uhlmann EJ, 1998, J BIOL CHEM, V273, P17926, DOI 10.1074/jbc.273.28.17926; Walker A, 1997, CANCER RES, V57, P1939; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN DX, 1995, CANCER RES, V55, P4922; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	50	63	65	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	1999	18	7					1457	1464		10.1038/sj.onc.1202420	http://dx.doi.org/10.1038/sj.onc.1202420			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050882				2022-12-17	WOS:000078651600007
J	Zamanian-Daryoush, M; Der, SD; Williams, BRG				Zamanian-Daryoush, M; Der, SD; Williams, BRG			Cell cycle regulation of the double stranded RNA activated protein kinase, PKR	ONCOGENE			English	Article						interferon; PKR; cell cycle	NF-KAPPA-B; SENSITIVE HEMATOPOIETIC-CELLS; C-MYC SUPPRESSION; RETINOBLASTOMA PROTEIN; ALPHA-INTERFERON; MALIGNANT TRANSFORMATION; INTERLEUKIN-6 SUPPRESS; GROWTH SUPPRESSION; INDUCED APOPTOSIS; BINDING PROTEIN	The interferon (IFN)-induced, double stranded RNA (dsRNA)-activated serine/threonine kinase, PKR, is a potent negative regulator of cell growth when overexpressed in yeast or mammalian cells. To determine whether endogenous PKR plays a role in cell growth control, we have investigated the regulation of PKR levels and activity during the cell cycle in human glioblastoma T98G cells. The steady-state level of PKR mRNA in T98G cells was highest in growth arrested cells, dropped sharply within 3h of serum stimulation then gradually increased as cells progressed through G1, reaching a plateau in early S phase. PKR protein level increased following serum stimulation reaching a peak at the G2 + M boundary and declining thereafter, In contrast, PKR kinase activity exhibited two peaks, in early G1 and at the G1/S boundary, declining sharply in early S phase. Thus, the activity profile did not follow the protein profile indicating a tight regulation of PKR at the level of activity. In T98G cells expressing the catalytically inactive PKRK296R the dsRNA-induced activation of NF-kappa B and IRF-1 was suppressed and the mutant cells exhibited resistance to stress induced apoptosis, Cell cycle distribution analysis shared that the mutant expressing cells exhibited longer G1 phase and fewer cells engaged in S phase, Furthermore, early passage mouse embryo fibroblasts derived from PKR knockout mice grew more slowly compared with the control cells. Taken together these results suggest that PKR may play a role in cell cycle progression.	Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Williams, BRG (corresponding author), Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI034039, R01AI034039] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34039] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BARBER GN, 1994, P NATL ACAD SCI USA, V91, P4278, DOI 10.1073/pnas.91.10.4278; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; BURKE LC, 1992, ONCOGENE, V7, P783; BYBEE A, 1992, BIOCHIM BIOPHYS ACTA, V1137, P73, DOI 10.1016/0167-4889(92)90102-H; Carpick BW, 1997, J BIOL CHEM, V272, P9510, DOI 10.1074/jbc.272.14.9510; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Chu WM, 1998, MOL CELL BIOL, V18, P58, DOI 10.1128/MCB.18.1.58; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; FIECK A, 1992, NUCLEIC ACIDS RES, V20, P1785, DOI 10.1093/nar/20.7.1785; GALABRU J, 1985, CELL, V43, P685, DOI 10.1016/0092-8674(85)90241-7; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNIGAN G, 1986, EMBO J, V5, P1607, DOI 10.1002/j.1460-2075.1986.tb04403.x; HOVANESSIAN AG, 1993, SEMIN VIROL, V4, P237, DOI 10.1006/smvy.1993.1020; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; Iwase S, 1997, J BIOL CHEM, V272, P12406, DOI 10.1074/jbc.272.19.12406; IWASE S, 1997, J BIOL CHEM, V272, P12414; JUDWARE R, 1991, MOL CELL BIOL, V11, P3259, DOI 10.1128/MCB.11.6.3259; JUDWARE R, 1992, J BIOL CHEM, V267, P21685; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KERR IM, 1977, NATURE, V268, P540, DOI 10.1038/268540a0; KIMCHI A, 1988, MOL CELL BIOL, V8, P2828, DOI 10.1128/MCB.8.7.2828; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; Krek W, 1995, CELL, V83, P1149, DOI 10.1016/0092-8674(95)90141-8; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MAYOL X, 1995, ONCOGENE, V11, P801; MCMILLAN NAG, 1996, CELL GROWTH REGULATI; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; Melville MW, 1997, P NATL ACAD SCI USA, V94, P97, DOI 10.1073/pnas.94.1.97; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUNDSCHAU LJ, 1992, J BIOL CHEM, V267, P23092; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; PATEL RC, 1994, J BIOL CHEM, V269, P18593; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; Polyak SJ, 1996, J BIOL CHEM, V271, P1702, DOI 10.1074/jbc.271.3.1702; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; SAITO S, 1991, MICROBIOL IMMUNOL, V35, P1105, DOI 10.1111/j.1348-0421.1991.tb01632.x; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; Subramaniam PS, 1997, J INTERF CYTOK RES, V17, P11, DOI 10.1089/jir.1997.17.11; THOMAS NSB, 1991, ONCOGENE, V6, P317; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; ZHOU AM, 1993, CELL, V72, P753, DOI 10.1016/0092-8674(93)90403-D	65	63	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					315	326		10.1038/sj.onc.1202293	http://dx.doi.org/10.1038/sj.onc.1202293			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927188				2022-12-17	WOS:000078166500004
J	Vanacker, JM; Bonnelye, E; Delmarre, C; Laudet, V				Vanacker, JM; Bonnelye, E; Delmarre, C; Laudet, V			Activation of the thyroid hormone receptor alpha gene promoter by the orphan nuclear receptor ERR alpha	ONCOGENE			English	Article						nuclear receptors; ERR alpha; thyroid hormone; transcription factor cross-talk	ESTROGEN-RELATED RECEPTOR; STEROIDOGENIC FACTOR-I; EXPRESSION; DIFFERENTIATION; IDENTIFICATION; TRANSCRIPTION; PROTEIN; CELLS; TRANSACTIVATION; REGULATOR	The superfamily of nuclear receptors comprises transcription factors that depend on a ligand for their activity, In addition, the superfamily includes a number of orphan receptors, for which no ligand is known. We report here that the orphan receptor estrogen receptor related alpha receptor (ERR alpha) stimulates the expression of the thyroid hormone receptor alpha (TR alpha) gene promoter. We characterized a responsive site that is both necessary and sufficient for ERR alpha-induced transactivation. In addition, we show that both TR alpha and ERR alpha are coexpressed in embryonic intestine, brown fat and heart as well as in the adult gonads, In the testis, expression of both receptors can be found in the seminiferous tubes where it is totally restricted to spermatocytes I. Altogether this suggests that TRa is an in vivo target of ERR alpha.	Inst Pasteur, Inst Biol, UMR 319, CNRS, F-59019 Lille, France; Ecole Normale Super Lyon, CNRS, UMR 49, F-69364 Lyon 07, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Vanacker, JM (corresponding author), Univ Toronto, Dept Anat & Cell Biol, Toronto, ON M5S 1A8, Canada.		Bonnelye, Edith/AAT-9134-2021					Baas D, 1997, GLIA, V19, P324, DOI 10.1002/(SICI)1098-1136(199704)19:4<324::AID-GLIA5>3.0.CO;2-X; Bonnelye E, 1997, MOL ENDOCRINOL, V11, P905, DOI 10.1210/me.11.7.905; Bonnelye E, 1997, MECH DEVELOP, V65, P71, DOI 10.1016/S0925-4773(97)00059-2; BOSHART M, 1992, GENE, V110, P123; BRITTO JM, 1994, ENDOCRINOLOGY, V134, P169, DOI 10.1210/en.134.1.169; CARNAC G, 1993, ONCOGENE, V8, P3103; Chassande O, 1997, MOL ENDOCRINOL, V11, P1278, DOI 10.1210/me.11.9.1278; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; Fraichard A, 1997, EMBO J, V16, P4412, DOI 10.1093/emboj/16.14.4412; FRANCAVILLA S, 1992, J ENDOCRINOL INVEST, V15, P240; GANDRILLON O, 1994, ONCOGENE, V9, P749; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; IKEDA Y, 1994, MOL ENDOCRINOL, V8, P654, DOI 10.1210/me.8.5.654; JANNINI EA, 1994, MOL ENDOCRINOL, V8, P89, DOI 10.1210/me.8.1.89; Johnston SD, 1997, MOL ENDOCRINOL, V11, P342, DOI 10.1210/me.11.3.342; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAUDET V, 1993, ONCOGENE, V8, P975; LAZAR J, 1994, J BIOL CHEM, V269, P20352; LAZAR MA, 1990, J BIOL CHEM, V265, P12859; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; Parker KL, 1996, TRENDS ENDOCRIN MET, V7, P203, DOI 10.1016/1043-2760(96)00105-1; QUEVA C, 1992, DEVELOPMENT, V114, P125; SAKURAI A, 1992, BIOCHEM BIOPH RES CO, V185, P78, DOI 10.1016/S0006-291X(05)80957-X; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SATO K, 1987, ENDOCRINOLOGY, V120, P1873, DOI 10.1210/endo-120-5-1873; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SHIIO Y, 1993, ONCOGENE, V8, P2059; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; STRAIT KA, 1991, P NATL ACAD SCI USA, V88, P3887, DOI 10.1073/pnas.88.9.3887; Vanacker JM, 1996, J VIROL, V70, P2369, DOI 10.1128/JVI.70.4.2369-2377.1996; VANACKER JM, 1993, J VIROL, V67, P7668, DOI 10.1128/JVI.67.12.7668-7672.1993; VARGA F, 1994, FEBS LETT, V345, P67, DOI 10.1016/0014-5793(94)00442-0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILEY SR, 1993, GENE DEV, V7, P2206, DOI 10.1101/gad.7.11.2206; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; Yang NY, 1996, J BIOL CHEM, V271, P5795, DOI 10.1074/jbc.271.10.5795	39	63	65	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2429	2435		10.1038/sj.onc.1202167	http://dx.doi.org/10.1038/sj.onc.1202167			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824153				2022-12-17	WOS:000076927300002
J	Paramio, JM; Lain, S; Segrelles, C; Lane, EB; Jorcano, JL				Paramio, JM; Lain, S; Segrelles, C; Lane, EB; Jorcano, JL			Differential expression and functionally co-operative roles for the retinoblastoma family of proteins in epidermal differentiation	ONCOGENE			English	Article						cell cycle; epidermal differentiation; retinoblastoma family	HUMAN PAPILLOMAVIRUS TYPE-16; TUMOR-SUPPRESSOR PROTEIN; CELL-CYCLE CONTROL; HUMAN KERATINOCYTES; TRANSGENIC MICE; GROWTH SUPPRESSION; MUSCLE-CELLS; P107; E2F; RB	Terminal differentiation requires cell cycle withdrawal, suggesting the involvement of negative cell cycle controllers in the process, We have analysed the involvement of the retinoblastoma family of proteins (pRb, p107 and p130) in epidermal proliferation and differentiation. These proteins play key roles as inhibitors of cell cycle progression and are involved in muscle and neuron differentiation, We found that during in vitro differentiation of human HaCaT keratinocytes, pRb, p107 and p130 are sequentially expressed, in contrast to the co-expression observed during cell cycle progression in the same cells. Immunofluorescence studies on skin sections revealed the presence of pRb and p107 in basal and suprabasal cell layers, whilst p130 is restricted to cells already committed to differentiation in the suprabasal compartments, To explore the functional significance of the differential expression of these proteins, transfection experiments mere performed in HaCaT keratinocytes. We observed that the forced over-expression of pRb, p107 or p130 individually did not induce differentiation of the transfected cells, However, the co-transfection of pRb and p107 induced the expression of early differentiation markers (keratin k10) and triple transfectants pRb + p107 + p130 expressed markers representative of later stages of epidermal differentiation (involucrin). Finally, we observed that these three proteins repress keratinocyte proliferation, although to a different extent (p107 > pRb greater than or equal to p130). These results indicate that the members of the pRb family play specific, yet coordinated roles during epidermal differentiation, and that the ordered progression along the different stages of this process results from the effects of different combinations of these proteins.	CIEMAT, Cell & Mol Biol Program, E-28040 Madrid, Spain; Univ Dundee, Inst Med Sci, Dept Anat & Physiol, CRC,Cell Struct Grp, Dundee DD1 4HN, Scotland	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; University of Dundee	Paramio, JM (corresponding author), CIEMAT, Cell & Mol Biol Program, E-28040 Madrid, Spain.		Lain, Sonia/B-6980-2014; Paramio, Jesus M/M-8482-2014; Segrelles, Carmen/E-3655-2016	Lain, Sonia/0000-0001-9693-5246; Paramio, Jesus M/0000-0001-7520-3177; Segrelles, Carmen/0000-0001-9340-2102; Lane, Birgit/0000-0003-1457-2934				ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; AUEWARAKUL P, 1994, MOL CELL BIOL, V14, P8250, DOI 10.1128/MCB.14.12.8250; BANKSSCHLEGEL S, 1981, J CELL BIOL, V90, P732, DOI 10.1083/jcb.90.3.732; BANKSSCHLEGEL SP, 1983, J CELL BIOL, V96, P330, DOI 10.1083/jcb.96.2.330; BARRANDON Y, 1989, P NATL ACAD SCI USA, V86, P4102, DOI 10.1073/pnas.86.11.4102; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; CORBEIL HB, 1995, ONCOGENE, V11, P909; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEE WH, 1994, COLD SPRING HARB SYM, V59, P97, DOI 10.1101/SQB.1994.059.01.013; Leigh I., 1994, KERATINOCYTE HDB; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MISSERO C, 1993, J CELL BIOL, V121, P1109, DOI 10.1083/jcb.121.5.1109; NEAD MA, 1995, J INVEST DERMATOL, V105, P668, DOI 10.1111/1523-1747.ep12324367; NEVINS JR, 1992, SCIENCE, V258, P424; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; PARAMIO JM, 1994, EXP CELL RES, V215, P319, DOI 10.1006/excr.1994.1348; Paramio JM, 1997, BRIT J DERMATOL, V137, P44, DOI 10.1111/j.1365-2133.1997.tb03699.x; PICKSLEY SM, 1994, CURR OPIN CELL BIOL, V6, P853, DOI 10.1016/0955-0674(94)90056-6; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Richon VM, 1996, CELL GROWTH DIFFER, V7, P31; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SZEKELY L, 1992, CELL GROWTH DIFFER, V3, P149; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; THORBURN AM, 1993, MOL BIOL CELL, V4, P705, DOI 10.1091/mbc.4.7.705; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	48	63	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	1998	17	8					949	957		10.1038/sj.onc.1202031	http://dx.doi.org/10.1038/sj.onc.1202031			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747874				2022-12-17	WOS:000075560900003
J	Qu, CK; Feng, GS				Qu, CK; Feng, GS			Shp-2 has a positive regulatory role in ES cell differentiation and proliferation	ONCOGENE			English	Article						tyrosine phosphatase; ES cell differentiation; cell proliferation; signal transduction	PROTEIN-TYROSINE-PHOSPHATASE; SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; EMBRYONIC STEM-CELLS; FACTOR RECEPTOR-BETA; SIGNAL-TRANSDUCTION; MOTH-EATEN; ANTIGEN RECEPTOR; SH2 DOMAINS; IN-VITRO; SYP	Shp-2 is a ubiquitously expressed tyrosine phosphatase with two SH2 domains. Homozygous mutant mice with a targeted deletion of 65 amino acid residues in the N-terminal SH2 domain of Shp-2 die in utero at midgestation, with multiple defects in mesodermal patterning To surpass the embryonic lethality in dissecting the Shp-2 function in cell growth and differentiation, we established homozygous Shp-2 mutant embryonic stem (ES) cell lines. Our previous data showed a severe suppression of hematopoietic cell differentiation from Shp-2 mutant ES cells. Here rye demonstrate that development of cardiac muscle cells was dramatically delayed and impaired in embryoid bodies (EBs) of Shp-2 mutant origin. Shp-2 mutant ES cells failed to differentiate into epithelial and fibroblast cells in vitro. However, higher efficiency of secondary EB formation was observed from the mutant than the wild-type ES cells. Further, mutant ES cells were more sensitive than wild-type cells to the differentiation suppressing effect of leukemia inhibitory factor (LIF). In addition, mutant ES cells showed a reduced growth rate compared to wildtype cells. These results suggest that the Shp-2 tyrosine phosphatase is a positive regulator for both cell differentiation and proliferation, in contrast to the Src-family kinases which promote cell growth but block differentiation.	Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Feng, GS (corresponding author), Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053660] Funding Source: NIH RePORTER; NIGMS NIH HHS [R29GM53660] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arrandale JM, 1996, J BIOL CHEM, V271, P21353, DOI 10.1074/jbc.271.35.21353; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOULTER CA, 1988, ONCOGENE, V2, P207; BOULTER CA, 1991, DEVELOPMENT, V111, P357; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; ERNST M, 1994, EMBO J, V13, P1574, DOI 10.1002/j.1460-2075.1994.tb06420.x; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FUHRER DK, 1995, J BIOL CHEM, V270, P24826, DOI 10.1074/jbc.270.42.24826; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MALTSEV VA, 1993, MECH DEVELOP, V44, P41, DOI 10.1016/0925-4773(93)90015-P; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MILLERHANCE WC, 1993, J BIOL CHEM, V268, P25244; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; THOMAS ML, 1995, J EXP MED, V181, P1953, DOI 10.1084/jem.181.6.1953; TSUI FWL, 1994, IMMUNOL REV, V138, P185, DOI 10.1111/j.1600-065X.1994.tb00852.x; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WOBUS AM, 1991, DIFFERENTIATION, V48, P173, DOI 10.1111/j.1432-0436.1991.tb00255.x; Wurst W., 1993, Gene targeting: a practical approach., P33; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577	43	63	66	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					433	439		10.1038/sj.onc.1201920	http://dx.doi.org/10.1038/sj.onc.1201920			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696036				2022-12-17	WOS:000075043000005
J	Greco, A; Fusetti, L; Miranda, C; Villa, R; Zanotti, S; Pagliardini, S; Pierotti, MA				Greco, A; Fusetti, L; Miranda, C; Villa, R; Zanotti, S; Pagliardini, S; Pierotti, MA			Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene	ONCOGENE			English	Article						TRK oncogenes; coiled-coil domain; oncogenic transformation	RECEPTOR TYROSINE KINASE; PROTEIN; OLIGOMERIZATION; DIMERIZATION; LEUKEMIA; CELLS; TEL	The thyroid TRK-T3 oncogene results from the fusion of the tyrosine kinase (TK) domain of NTRK1 (one of the receptors for the Nerve Growth Factor) on chromosome 1 to sequences of a novel gene, TFG, on chromosome 3., The 68 kDa TRK-T3 fusion oncoprotein displays a constitutive tyrosine kinase activity resulting in its capability to transform mouse NIH3T3 cells, The TFG portion of TRK-T3 contains a coiled-coil domain most likely responsible for the constitutive, ligand-independent activation of the receptor tyrosine kinase activity. We have previously shown that TRK-T3 oncoprotein forms, in vivo, complexes of three or four molecules. By mean of different experimental approaches, we show here that TRK-T3 activity depends on oligomers formation, In addition, the analysis of different TRK-T3 mutants indicates that the TFG coiled-coil domain and its N-terminal region are both required for the activation and the fully transforming activity of the TRK-T3 oncoprotein, although, most likely, they play a role in different steps of the transforming process, The deletion of the coiled-coil domain abrogates the oligomers formation leading to a constitutive activation; the deletion of the N-terminal region, although not affecting phosphorylation and complexes formation, abrogates transformation, thus suggesting a role in cellular localization and/or interaction with substrata.	Ist Nazl Tumori, Div Expt Oncol A, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan	Greco, A (corresponding author), Ist Nazl Tumori, Div Expt Oncol A, Via Venezian 1, I-20133 Milan, Italy.		Pierotti, Marco Alessandro/AAC-4728-2022; Greco, Angela/C-1953-2017	Pierotti, Marco Alessandro/0000-0002-7431-8332; Greco, Angela/0000-0003-2994-0349; Zanotti, Simona/0000-0003-4520-4966; Villa, Riccardo/0000-0001-8385-800X				BONGARZONE I, 1989, ONCOGENE, V4, P1457; BORRELLO MG, 1994, ONCOGENE, V9, P1661; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GRECO A, 1995, MOL CELL BIOL, V15, P6118; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MENCINGER M, 1997, ONCOGENE, V41, P327; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Tong Q, 1997, J BIOL CHEM, V272, P9043	21	63	65	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					809	816		10.1038/sj.onc.1201596	http://dx.doi.org/10.1038/sj.onc.1201596			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488046				2022-12-17	WOS:000071931800014
J	Kolesnikova, TV; Lau, LF				Kolesnikova, TV; Lau, LF			Human CYR61-mediated enhancement of bFGF-induced DNA synthesis in human umbilical vein endothelial cells	ONCOGENE			English	Article						extracellular matrix; heparin-binding protein; connective tissue growth factor; Nov	FIBROBLAST-GROWTH-FACTOR; IMMEDIATE-EARLY GENE; SUBENDOTHELIAL EXTRACELLULAR-MATRIX; NOV PROTOONCOGENE; INDUCIBLE GENE; EXPRESSION; CYR61; IDENTIFICATION; PRODUCT; FAMILY	CYR61 is a member of an emerging family of growth regulators that includes the human connective tissue growth factor and the chicken protooncoprotein Nov, Encoded by a growth factor-inducible immediate-early gene, CYR61 is a secreted, cysteine-rich heparin-binding protein that associates with the extracellular matrix and cell surface. In this report, we describe the cloning of the human hCYR61 cDNA and expression and purification of the hCYR61 protein. The hCYR61 mRNA is abundant in the heart, lung, pancreas and placenta, is present at a low level in skeletal muscle and brain and is not detectable in liver and kidney, Purified recombinant hCYR61 protein does not induce thymidine incorporation in human umbilical vein endothelial cells by itself, but enhances bFGF-induced DNA synthesis. We show that hCYR61 acts in this cell system in part by displacement of bFGF bound to the extracellular matrix. thus increasing the effective concentration of bFGF, Possible biological implications of these observations are discussed.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lau, LF (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.			Lau, Lester/0000-0002-4364-2914	NCI NIH HHS [CA46565] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046565] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENEZRA M, 1993, BLOOD, V81, P3324; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BROWN KJ, 1994, BIOCHEMISTRY-US, V33, P13918, DOI 10.1021/bi00250a047; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Garfinkel S, 1996, J CELL BIOL, V134, P783, DOI 10.1083/jcb.134.3.783; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; ISHIGAKI M, 1997, RINSHO BYORI, V44, P439; Jay P, 1997, ONCOGENE, V14, P1753, DOI 10.1038/sj.onc.1200986; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; LATINKIC BV, 1994, THESIS U ILLINOIS CH; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; MARTINERIE C, 1994, ONCOGENE, V9, P2729; MARTINERIE C, 1992, ONCOGENE, V7, P2529; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P893, DOI 10.1101/SQB.1988.053.01.102; Niu DM, 1996, HUM GENET, V98, P65, DOI 10.1007/s004390050161; OBRIEN TP, 1992, CELL GROWTH DIFFER, V3, P645; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; RYSECK RP, 1991, CELL GROWTH DIFFER, V2, P225; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WATSON JB, 1994, J CLIN INVEST, V94, P261, DOI 10.1172/JCI117316; WILLIAMS GT, 1992, MOL CELLULAR APPROAC, P115; WONG M, 1998, IN PRESS DEV BIOL; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351	36	63	71	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	1998	16	6					747	754		10.1038/sj.onc.1201572	http://dx.doi.org/10.1038/sj.onc.1201572			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488038				2022-12-17	WOS:000071931800006
J	Valgeirsdottir, S; Paukku, K; Silvennoinen, O; Heldin, CH; Claesson-Welsh, L				Valgeirsdottir, S; Paukku, K; Silvennoinen, O; Heldin, CH; Claesson-Welsh, L			Activation of Stat5 by platelet-derived growth factor (PDGF) is dependent on phosphorylation sites in PDGF beta-receptor juxtamembrane and kinase insert domains	ONCOGENE			English	Article						PDGF; receptor; Stat; JAK; phosphorylation, binding sites	SIGNAL-TRANSDUCTION PATHWAYS; COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASES; DNA-BINDING ACTIVITY; PHOSPHOLIPASE-C-GAMMA; AUTOPHOSPHORYLATION SITES; TARGETED DISRUPTION; MOUSE-LIVER; IDENTIFICATION; GENE	Signal transducers and activators of transcription (Stats) are known to transduce signals from the cell surface to the nucleus in cytokine receptor signaling. We examined the capacity of platelet-derived gron th factor (PDGF) receptor to interact with and activate Stat molecules. Activation of the PDGF beta-receptor led to tyrosine phosphorylation of Stat1, Stat3 and Stat5, which was accompanied by specific DNA-binding activities, These events were only weakly stimulated by the activated PDGF alpha-receptor. In cells expressing PDGF beta-receptors mutated at Tyr579, Tyr581 or Tyr775, tyrosine phosphorylation as well as DNA-binding activity of Stat5 was reduced. Immobilized peptides containing phosphorylated Tyr579, Tyr581 or Tyr775 bound Stat5, suggesting direct binding of Stat5 to these tyrosine residues of the PDGF beta-receptor. Members of the Janus kinase family were also shown to interact with the PDGF beta-receptor, and to a lesser extent with the alpha-receptor, but their importance for PDGF-induced Stat activation remains to be determined.	Biomed Ctr, Dept Med & Physiol Chem, S-75123 Uppsala, Sweden; Biomed Ctr, Ludwig Inst Canc Res, Uppsala, Sweden; Univ Helsinki, Dept Virol, Haartman Inst, Helsinki, Finland; Tampere Univ, Inst Med Technol, FIN-33101 Tampere, Finland	Ludwig Institute for Cancer Research; University of Helsinki; Tampere University	Claesson-Welsh, L (corresponding author), Biomed Ctr, Dept Med & Physiol Chem, Box 575, S-75123 Uppsala, Sweden.							ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CLAESSONWELSH L, 1989, J BIOL CHEM, V264, P1742; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Heldin CH., 1996, MOL CELLULAR BIOL WO, P249; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LEBRUN JJ, 1995, P NATL ACAD SCI USA, V92, P4031, DOI 10.1073/pnas.92.9.4031; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; Novak U, 1996, J BIOL CHEM, V271, P18350, DOI 10.1074/jbc.271.31.18350; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Patel BKR, 1996, J BIOL CHEM, V271, P22175, DOI 10.1074/jbc.271.36.22175; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; Raines E.W., 1990, PEPTIDE GROWTH FACTO, DOI [10.1007/978-3-642-49295-2_5, DOI 10.1007/978-3-642-49295-2_5]; RAZ R, 1994, J BIOL CHEM, V269, P24391; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; VALGEIRSDOTTIR S, 1995, J BIOL CHEM, V270, P10161, DOI 10.1074/jbc.270.17.10161; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WEIMA SM, 1990, EXP CELL RES, V186, P324, DOI 10.1016/0014-4827(90)90312-X; WENNSTROM S, 1994, ONCOGENE, V9, P651; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	54	63	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	1998	16	4					505	515		10.1038/sj.onc.1201555	http://dx.doi.org/10.1038/sj.onc.1201555			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YU644	9484840				2022-12-17	WOS:000071739400009
J	Allouche, M; Bettaieb, A; Vindis, C; Rousse, A; Grignon, C; Laurent, G				Allouche, M; Bettaieb, A; Vindis, C; Rousse, A; Grignon, C; Laurent, G			Influence of Bcl-2 overexpression on the ceramide pathway in daunorubicin-induced apoptosis of leukemic cells	ONCOGENE			English	Article						Bcl-2; apoptosis; anticancer agents; anthracyclins; ceramide; leukemic cells	DNA FRAGMENTATION; B-CELLS; INTERNUCLEOSOMAL FRAGMENTATION; CHEMOTHERAPEUTIC DRUGS; ANTICANCER DRUGS; DEATH; EXPRESSION; RESISTANCE; PROTEIN; PREVENTION	We have previously demonstrated that daunorubicin (DNR) induces apoptosis in some leukemic myeloid cell lines. We investigated a potential protective role for Bcl-2 in apoptosis induced by DNR in two leukemic cell lines, one myeloid and one lymphoid, overexpressing the anti-apoptotic gene Bcl-2. Parental cells treated with DNR exhibited classical features of apoptosis 6 h after drug exposure, all the cells being dead after 30-48 h. In contrast, overexpression of Bcl-2 significantly delayed, but did not prevent the occurrence of DNR-induced apoptosis, with no surviving cells 96 h after drug exposure. To elucidate the mechanism of the protection mediated by Bcl-2, we explored the signaling pathway which initiates DNR-induced apoptosis. In this report, we show that, in both the myeloid and lymphoid parental cell lines, DNR triggered a sphingomyelin (SM) hydrolysis after 10-15 min with a concomitant ceramide generation. Moreover, exogenous ceramide induced DNA fragmentation in these cells, with levels similar to those observed with DNR treatment. In contrast, Bcl-2 overexpression protected the cells against apoptosis induced by ceramide treatment, without preventing the early SM hydrolysis nor the ceramide generation in these cells. Our results strongly suggest that Bcl-2-mediated protection of DNR-induced apoptosis is effected downstream of the SM-ceramide signaling pathway.			Allouche, M (corresponding author), CJF INSERM 9503,CTR CLAUDIUS REGAUD,20-24 RUE PONT ST PIERRE,F-31052 TOULOUSE,FRANCE.		Vindis, Cécile/AAH-2708-2019	Vindis, Cécile/0000-0003-2421-1155; Bettaieb, Ali/0000-0002-6018-9592				BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BROWN DG, 1993, J BIOL CHEM, V268, P3037; CAMPOS L, 1993, BLOOD, V81, P3091; CATCHPOOLE DR, 1993, CANCER RES, V53, P4287; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; FALCIERI E, 1993, BIOCHEM BIOPH RES CO, V193, P19, DOI 10.1006/bbrc.1993.1584; FANG W, 1995, J IMMUNOL, V155, P66; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FISHER TC, 1993, CANCER RES, V53, P3321; FOLCH J, 1957, J BIOL CHEM, V226, P497; GROMOVA II, 1995, P NATL ACAD SCI USA, V92, P102, DOI 10.1073/pnas.92.1.102; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Huang P, 1995, CLIN CANCER RES, V1, P1005; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levade T, 1996, M S-MED SCI, V12, P1219, DOI 10.4267/10608/654; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; MARTIN SJ, 1995, CELL DEATH DIFFER, V2, P253; MILNER AE, 1992, INT J CANCER, V52, P636, DOI 10.1002/ijc.2910520424; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1992, CANCER RES, V52, P5407; NAUMOVSKI L, 1994, BLOOD, V83, P2261; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; QuilletMary A, 1996, LEUKEMIA, V10, P417; REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7; REYNOLDS JE, 1994, CANCER RES, V54, P6348; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SINHA BK, 1990, FREE RADICAL BIO MED, V8, P567, DOI 10.1016/0891-5849(90)90155-C; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WALKER PR, 1991, CANCER RES, V51, P1078; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YIN DX, 1995, CANCER RES, V55, P4922; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	51	63	67	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 17	1997	14	15					1837	1845		10.1038/sj.onc.1201023	http://dx.doi.org/10.1038/sj.onc.1201023			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW166	9150390				2022-12-17	WOS:A1997WW16600010
J	Bunone, G; Mariotti, A; Compagni, A; Morandi, E; DellaValle, G				Bunone, G; Mariotti, A; Compagni, A; Morandi, E; DellaValle, G			Induction of apoptosis by p75 neurotrophin receptor in human neuroblastoma cells	ONCOGENE			English	Article						NGF receptors; apoptosis; neuroblastoma; tumor progression	NERVE GROWTH-FACTOR; AFFINITY NGF RECEPTOR; TRK PROTOONCOGENE; N-MYC; NEURONAL DIFFERENTIATION; INVERSE RELATIONSHIP; SIGNAL-TRANSDUCTION; RET PROTOONCOGENE; EXPRESSION; SYSTEM	The low-affinity nerve growth factor receptor p75(NTR) belongs to a membrane receptor superfamily whose members, in certain cell types, are able to transduce an apoptotic signal. To investigate the effect of p75(NTR) expression in neuroblastoma cells, we transfected the p75(NTR) CDNA into SK-N-BE cells, a neuroblastoma cell line that lacks expression of both p75(NTR) and TrkA. Cell clones expressing elevated levels of p75(NTR) showed a high degree of cell death by apoptosis, even in serum-supplemented medium. Moreover, the level of apoptosis correlated directly with the expression lever of the receptor, indicating that p75(NTR) could activate the cell death program by itself. Clones expressing p75(NTR) showed a dramatic increase of cell death when switched into serum-free medium; these cultures rapidly extinguished. This apoptotic effect was greatly inhibited by NGF treatment. Our results support the hypothesis that p75(NTR), when it is not bound by NGF, may play a role in neuronal selection during embryonic development and suggest that neuroblastomas may arise from immature neuroblasts that escape programmed cell death. Therefore, the loss of p75(NTR) expression in developing neural crest cells might be a primary event in the genesis of neuroblastoma.	UNIV PAVIA,DEPT GENET & MICROBIOL,I-27100 PAVIA,ITALY; UNIV BOLOGNA,DEPT BIOL,I-40126 BOLOGNA,ITALY	University of Pavia; University of Bologna				Mariotti, Agnese/0000-0002-3704-7908; compagni, amelia/0000-0003-1744-3134				AZAR CG, 1990, CELL GROWTH DIFFER, V1, P421; BARBACID M, 1993, ONCOGENE, V8, P2033; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; BIEDLER JL, 1973, CANCER RES, V33, P2643; BONGARZONE I, 1994, CANCER RES, V54, P2979; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BUNONE G, 1995, EXP CELL RES, V217, P92, DOI 10.1006/excr.1995.1067; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRISTIANSEN H, 1990, ONCOGENE, V5, P437; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Frade JM, 1996, NATURE, V383, P166; GUIN GH, 1969, AM J CLIN PATHOL, V51, P126; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; Kinnier-Wilson LM, 1974, BRIT MED J, V3, P301; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOGNER P, 1993, CANCER RES, V53, P2044; LAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEE KF, 1994, DEVELOPMENT, V120, P1027; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; Peverali FA, 1996, ONCOGENE, V12, P457; PFLUG BR, 1992, CANCER RES, V52, P5403; PRITCHARD J, 1994, LANCET, V344, P869, DOI 10.1016/S0140-6736(94)92834-7; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; REPRESA J, 1991, P NATL ACAD SCI USA, V88, P8016, DOI 10.1073/pnas.88.18.8016; Reynolds C P, 1988, Prog Clin Biol Res, V271, P291; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1	46	63	66	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1463	1470		10.1038/sj.onc.1200972	http://dx.doi.org/10.1038/sj.onc.1200972			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136990				2022-12-17	WOS:A1997WT58400009
J	Simons, A; MelamedBessudo, C; Wolkowicz, R; Sperling, J; Sperling, R; Eisenbach, L; Rotter, V				Simons, A; MelamedBessudo, C; Wolkowicz, R; Sperling, J; Sperling, R; Eisenbach, L; Rotter, V			PACT: Cloning and characterization of a cellular p53 binding protein that interacts with Rb	ONCOGENE			English	Article						p53; Rb; SR proteins; splicing	RETINOBLASTOMA GENE-PRODUCT; WILD-TYPE P53; LARGE-T-ANTIGEN; LARGE TUMOR-ANTIGEN; RNA SPLICING FACTORS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; SUSCEPTIBILITY GENE; SV40-TRANSFORMED CELLS; EMBRYONIC LETHALITY	Cellular functions of tumor suppressor proteins can be mediated by protein-protein interactions. Using p53 as a probe to screen an expression library, a cDNA encoding a 250 kDa protein was isolated. Recombinant forms of this protein, designated PACT, bind to wild type p53 while two different mutations abolish this interaction. PACT protein can also interfere with p53 specific DNA binding. PACT contains a serine/arginine (SR) rich region and a C' terminal lysine rich domain. The 250 kDa PACT protein can be precipitated from cell lysates by a method specific for SR proteins. snRNPs can be co-immunoprecipitated from cells with anti-PACT antibodies. These antibodies stain cell nuclei in a speckled pattern reminiscent of the distribution of known splicing factors. Recently, RBQ1, a truncated human homologue of PACT was identified by virtue of Rb binding. We show that RBQ1 is truncated as a result of a possible mutational event. PACT can interact with both cellular Rb and p53.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT ORGAN CHEM,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT IMMUNOL,IL-76100 REHOVOT,ISRAEL; HEBREW UNIV JERUSALEM,DEPT GENET,IL-91904 JERUSALEM,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Hebrew University of Jerusalem				Eisenbach, Lea R/0000-0002-4816-1968				ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BLENCOWE BJ, 1995, RNA, V1, P852; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFROMENTEL CC, 1986, EXP CELL RES, V164, P35, DOI 10.1016/0014-4827(86)90452-0; DEPPERT W, 1990, ONCOGENE, V5, P1701; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELKIND NB, 1995, ONCOGENE, V11, P841; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FU XD, 1995, RNA, V1, P663; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; Harlow E., ANTIBODIES LAB MANUA; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUNA RMD, 1995, NATURE, V378, P203; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MANIATIS T, MOL CLONING; MARSTON NJ, 1994, ONCOGENE, V9, P2523; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOLE SE, 1987, PHILOS T ROY SOC B, V317, P455, DOI 10.1098/rstb.1987.0072; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOORE MJ, SPLICING PRECURSORS, P303; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; SAKAI Y, 1995, GENOMICS, V30, P98, DOI 10.1006/geno.1995.0017; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHOHATFOORD O, 1991, NUCLEIC ACIDS RES, V19, P5191; Spector DL, 1993, CURR OPIN CELL BIOL, V5, P442, DOI 10.1016/0955-0674(93)90009-F; STEITZ JA, FUNCTIONS ABUNDANT U, P115; STEWART N, 1995, ONCOGENE, V10, P109; STURZBECHER HW, 1988, ONCOGENE, V3, P405; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; WOLKOWICZ R, 1995, ONCOGENE, V10, P1167; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929; ZHANG W, 1994, ONCOGENE, V9, P2513	74	63	67	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					145	155		10.1038/sj.onc.1200825	http://dx.doi.org/10.1038/sj.onc.1200825			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010216				2022-12-17	WOS:A1997WC81800002
J	Liu, PK; Kraus, E; Wu, TA; Strong, LC; Tainsky, MA				Liu, PK; Kraus, E; Wu, TA; Strong, LC; Tainsky, MA			Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations	ONCOGENE			English	Review						tumor suppressor gene; germline mutations; chromosome instability; shuttle vector mutagenesis; DNA replication	DNA-POLYMERASE-ALPHA; SIMIAN VIRUS-40 DNA; LARGE-T-ANTIGEN; SHUTTLE VECTOR PLASMID; CELLULAR TUMOR-ANTIGEN; INDUCED POINT MUTATIONS; WILD-TYPE P53; HUMAN-CELLS; ATAXIA-TELANGIECTASIA; REPLICATION INVITRO	Germline p53 mutations are frequently observed in the normal DNA of cancer-prone patients with Li-Fraumeni syndrome (LFS), Fibroblasts from LFS patients develop chromosomal aberrations, loss of cell cycle control, and spontaneous immortalization, We transfected four different mutant p53 genes into human skin fibroblasts from normal donors with two copies of wild-type p53 (p53(wt/wt)), Each mutant p53 expression-plasmid induced genomic instability equivalent to that seen in LFS cells, To test the role of wild-type and mutant p53 alleles in DNA replication and fidelity in LFS cells, we analysed the replication of the SV40-based shuttle vector pZ189 in four types of cells, We used p53(wt/mut) and p53(mut/-) LFS fibroblasts, and p53(-/-) non-LFS cells, Replication of pZ189 in vivo was significantly reduced by the presence of a p53(wt) allele, To show that this was not just due to inhibition of the function of T-antigen in SV40-based replication, we constructed a shuttle vector, pZ402, that contains a mutation in SV40 T-antigen which blocks its ability to interact with p53, Replication of pZ402 in LFS cells was also reduced by the presence of p53(wt), indicating that p53 can inhibit replication by interacting with proteins within the cellular replication machinery, Replicative errors in this shuttle vector are detected as mutations in a marker gene, supF: In addition to supF: mutations, we observed deletion of a portion of the SV40 T-antigen gene in 100% of replicated plasmid pZ189 mutants (supF(-)) from the p53(wt/mut) fibroblasts and in 88% of the supF(-) mutants from the p53(mut/-) (amino acid 175 arg to his) LFS cells, In one cell strain of immortal LFS cells, p53(mut/-), containing a p53 frameshift mutation at amino acid 184, pZ189 replication yielded very few of these deleted shuttle vector plasmids (15%), These large deletions were not detected in plasmids replicated in p53(-/-) non-LFS cells, Saos-2 cells, Replicated plasmids with a normal supF gene were never found to have this large deletion regardless of the cell from which they were derived, Because the supF; gene is not in the same region of the shuttle vector as the T-antigen gene it appears that second, independent gene deletions are frequent when replicative errors in supF occur in cells with a mutant p53, We conclude, therefore, that p53(wt/mut) LFS cells contain an activity that promotes mutations, Such an activity, which is likely to be due to the p53(mut), could result in the high rate of chromosomal instability and allelic loss of the wild-type p53 observed as these cells spontaneously immortalize.	UNIV TEXAS,MD ANDERSON CANC CTR,DIV LAB MED,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPTL PEDIAT,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPTL PEDIAT,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center				Tainsky, Michael/0000-0002-0261-831X	NATIONAL CANCER INSTITUTE [P01CA034936, P30CA016672, T32CA009299] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16672, P01 CA034936, CA-09299, P01 CA034936-14A1, P30 CA016672, T32 CA009299, CA-P01 34936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AIZAWA S, 1987, MOL GEN GENET, V208, P342, DOI 10.1007/BF00330463; ARIGA H, 1983, J VIROL, V48, P481, DOI 10.1128/JVI.48.2.481-491.1983; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BEETT WP, 1994, CANC PERTURBATIONS C; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; BISHOP M, 1986, SCIENCE, V235, P305; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BREDBERG A, 1987, CARCINOGENESIS, V8, P1923, DOI 10.1093/carcin/8.12.1923; BUBLEY GJ, 1991, MOL CARCINOGEN, V4, P397, DOI 10.1002/mc.2940040512; CARTY MP, 1993, MOL CELL BIOL, V13, P533, DOI 10.1128/MCB.13.1.533; CARTY MP, 1990, MUTAT RES, V232, P141, DOI 10.1016/0027-5107(90)90119-O; CHAN JYH, 1979, P NATL ACAD SCI USA, V76, P814, DOI 10.1073/pnas.76.2.814; CHANG CC, 1981, SOMAT CELL GENET, V7, P235; CLARKE P, 1991, VIROLOGY, V182, P597, DOI 10.1016/0042-6822(91)90600-G; CLEAVER JE, 1989, MUTAT RES, V220, P161, DOI 10.1016/0165-1110(89)90022-5; COMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324, DOI 10.1073/pnas.70.12.3324; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DRESLER SL, 1982, BIOCHEMISTRY-US, V21, P2557, DOI 10.1021/bi00539a040; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GREEN AP, 1993, BIOCHEM BIOPH RES CO, V190, P111, DOI 10.1006/bbrc.1993.1018; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HARVEY M, 1993, ONCOGENE, V8, P2457; HAY RT, 1989, BIOCHEM J, V258, P3, DOI 10.1042/bj2580003; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JABERABOANSARI A, 1991, RADIAT RES, V127, P202, DOI 10.2307/3577966; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENNINGS PA, 1987, EMBO J, V6, P3043, DOI 10.1002/j.1460-2075.1987.tb02610.x; KARASUYAMA H, 1989, J EXP MED, V169, P13, DOI 10.1084/jem.169.1.13; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIENZLE H, 1989, EUR J BIOCHEM, V184, P181, DOI 10.1111/j.1432-1033.1989.tb15005.x; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kolodner Richard D., 1994, Current Opinion in Biotechnology, V5, P585, DOI 10.1016/0958-1669(94)90079-5; KRESS M, 1979, J VIROL, V31, P472, DOI 10.1128/JVI.31.2.472-483.1979; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIN J, 1991, J VIROL, V64, P2066; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU PK, 1993, MUTAT RES, V288, P229, DOI 10.1016/0027-5107(93)90089-X; LIU PK, 1983, P NATL ACAD SCI-BIOL, V80, P797, DOI 10.1073/pnas.80.3.797; LIU PK, 1984, SCIENCE, V254, P833; LOEB LA, 1991, CANCER RES, V51, P3075; LOEB LA, 1974, CANCER RES, V34, P2311; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAH MCM, 1989, CARCINOGENESIS, V10, P2321, DOI 10.1093/carcin/10.12.2321; MAHER VM, 1989, MUTAT RES, V220, P83, DOI 10.1016/0165-1110(89)90013-4; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCCORMICK F, 1980, J VIROL, V34, P213, DOI 10.1128/JVI.34.1.213-224.1980; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; MURAKAMI Y, 1985, P NATL ACAD SCI USA, V82, P1761, DOI 10.1073/pnas.82.6.1761; MURIEL WJ, 1991, MUTAT RES, V254, P119, DOI 10.1016/0921-8777(91)90002-7; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; PARRIS CN, 1992, EXP CELL RES, V201, P462, DOI 10.1016/0014-4827(92)90295-J; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; RUNGER TM, 1992, MUTAT RES, V293, P47, DOI 10.1016/0921-8777(92)90007-P; RUSCETTI SK, 1983, J VIROL, V46, P1022, DOI 10.1128/JVI.46.3.1022-1026.1983; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEETHARAM S, 1991, NUCLEIC ACIDS RES, V19, P1601, DOI 10.1093/nar/19.7.1601; SEIDMAN MM, 1985, GENE, V38, P233, DOI 10.1016/0378-1119(85)90222-7; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SIKPI MO, 1992, RADIAT RES, V130, P331, DOI 10.2307/3578378; SPEYER JF, 1965, BIOCHEM BIOPH RES CO, V21, P6, DOI 10.1016/0006-291X(65)90417-1; SPRINGGATE CF, 1973, P NATL ACAD SCI USA, V70, P245, DOI 10.1073/pnas.70.1.245; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; STRONG LC, 1992, AM J EPIDEMIOL, V135, P190, DOI 10.1093/oxfordjournals.aje.a116271; STURZBECHER HW, 1988, ONCOGENE, V3, P405; TACK LC, 1989, J VIROL, V63, P1310, DOI 10.1128/JVI.63.3.1310-1317.1989; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG P, 1990, CANCER RES, V50, P7527; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YAGI T, 1992, MUTAT RES, V273, P213, DOI 10.1016/0921-8777(92)90082-E; YAMAGUCHI M, 1986, P NATL ACAD SCI USA, V83, P1646, DOI 10.1073/pnas.83.6.1646; YANG JL, 1988, MOL CELL BIOL, V8, P3364, DOI 10.1128/MCB.8.8.3364; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	119	63	63	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2267	2278						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649766				2022-12-17	WOS:A1996UQ22000003
J	Augenlicht, LH; Richards, C; Corner, G; Pretlow, TP				Augenlicht, LH; Richards, C; Corner, G; Pretlow, TP			Evidence for genomic instability in human colonic aberrant crypt foci	ONCOGENE			English	Article						colon cancer precursors; premalignant lesions; genomic instability; aberrant crypt foci	QUANTIFICATION; MUTATIONS; CANCER	Aberrant crypt foci (ACF) are morphologically abnormal structures that can be identified in whole mounts of colonic tissue from rodents treated with colon carcinogens and from patients at risk for development of colon tumors, ACF are heterogeneous and exhibit properties, such as altered patterns of cell proliferation, the presence of dysplasia, and mutations in protooncogenes and tumor suppressor genes, consistent with the hypothesis that a subset of these structures are precursors to tumor formation, In this study, we have investigated the presence of genomic instability in DNA isolated from human ACF from patients with colon cancer, Altered allele length detected by electrophoretic separation of PCR amplified oligo A or microsatellite loci was used to identify candidate samples which were then more rigorously investigated by sequence analysis for instability, Of 20 patients examined, two exhibited alterations at two loci, and this instability could be confirmed by sequence analysis, An additional seven of the 20 patients had evidence for instability at a single locus, Quantitative sequence analysis of the DNA from an ACF of one of these seven patients was consistent with alteration of allele length in this patient, but the alteration was not sufficiently different from normal to reach statistical significance, Thus, genomic instability, manifest as altered length of microsatellite and oligo A sequences, is present in some ACF, and therefore can be a very early event in the development of some human colon cancers.	CASE WESTERN RESERVE UNIV,SCH MED,INST PATHOL,CLEVELAND,OH 44106	Case Western Reserve University	Augenlicht, LH (corresponding author), MONTEFIORE MED CTR,ALBERT EINSTEIN CANC CTR,DEPT ONCOL,111 E 210TH ST,BRONX,NY 10467, USA.				NATIONAL CANCER INSTITUTE [R21CA066642, R01CA048032, R01CA057694] Funding Source: NIH RePORTER; NCI NIH HHS [CA57694, CA66642, CA48032] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AUGENLICHT L, 1994, GASTROENTEROLOGY, V107, P1894, DOI 10.1016/0016-5085(94)90840-0; BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1; CHEN JS, 1995, CANCER RES, V55, P174; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JEN J, 1994, CANCER RES, V54, P5523; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOEB LA, 1994, CANCER RES, V54, P5059; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PRETLOW TP, 1991, CANCER RES, V51, P1564; PRETLOW TP, 1994, GASTROENTEROLOGY, V107, P1719, DOI 10.1016/0016-5085(94)90812-5; PRETLOW TP, 1993, J NATL CANCER I, V85, P2004, DOI 10.1093/jnci/85.24.2004; PRETLOW TP, 1994, INT J CANCER, V56, P599, DOI 10.1002/ijc.2910560422; RONCUCCI L, 1991, HUM PATHOL, V22, P287, DOI 10.1016/0046-8177(91)90163-J; RONCUCCI L, 1993, CANCER RES, V53, P3726; SMITH AJ, 1994, CANCER RES, V54, P5527; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367	23	63	64	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1767	1772						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622897				2022-12-17	WOS:A1996UG45800019
J	Venanzoni, MC; Robinson, LR; Hodge, DR; Kola, I; Seth, A				Venanzoni, MC; Robinson, LR; Hodge, DR; Kola, I; Seth, A			ETS1 and ETS2 in p53 regulation: Spatial separation of ETS binding sites (EBS) modulate protein: DNA interaction	ONCOGENE			English	Article						ETS1; ETS2; p53 promoter; transactivation; gene regulation	TRANSCRIPTION FACTORS; ONCOGENIC ACTIVITY; GENE; PROTOONCOGENE; FAMILY; CELLS; EMBRYOGENESIS; EXPRESSION; PROMOTER	p53 is an extensively studied tumor suppressor gene implicated in the genesis of a large number of varied tumours. However, the pathways of regulation for the wild-type p53 gene and its product are as yet unknown. In situ hybridization analyses of ETS1 and ETS2 expression during mouse embryogenesis, have shown a pattern similar to that of p53 gene expression. Significantly, we have identified several ETS-binding sites (EBS) in the promoter regions of the human and mouse p53 genes. In the human promoter two of these EBS are present in the form of a palindrome, with the two EBS cores being separated by four nucleotides. This report shows that the EBS palindrome of the human p53 promoter has a high affinity for ETS1 and ETS2, and that such binding interaction intracellularly is able to activate the transcription of a CAT reporter gene by 5-10-fold using COS cells. To investigate whether the spacing between the two EBS cores influences the DNA binding activity, we synthesized oligonucleotides with increasing distances (4,12,16 and 20 bases respectively) between the two EBS cores of the palindrome. We observed an inverse correlation between an increasing distance in the two EBS cores of the palindrome and the ETS1 and ETS2 DNA binding activity respectively. Interestingly, optimal DNA binding activity was observed when the distance between the two EBS cores was four bases, identical to that which occurs in the natural promoter. Furthermore we show that the p53 mRNA is expressed at higher levels in NIH3T3 cells over-expressing ETS2 gene product, suggesting that the ETS2 transcription factor is a likely candidate for regulating the expression of p53 in vivo.	UNIV TORONTO, FAC MED, DEPT PATHOL, TORONTO, ON M5S 1B2, CANADA; NCI, FREDERICK CANC RES & DEV CTR, MOLEC ONCOL LAB, FREDERICK, MD 21702 USA; FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA; MONASH UNIV, MOL GENET & DEV GRP, MELBOURNE, VIC 3168, AUSTRALIA; UNIV TORONTO, FAC DENT, TORONTO, ON M5S 1B2, CANADA; WOMENS COLL HOSP, TORONTO, ON M5S 1B2, CANADA	University of Toronto; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Monash University; University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital			Kola, Ismail/C-5254-2013					ASCIONE R, 1992, INT J ONCOL, V1, P631; ASCIONE R, 1993, GENOME RES MOL MED V, V13, P199; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; HALL PA, 1993, ONCOGENE, V8, P203; Hodge DR, 1996, ONCOGENE, V12, P11; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; SCHMID P, 1991, DEVELOPMENT, V113, P857; SETH A, 1990, ADV AP BIOT, V6, P285; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1994, ONCOGENE, V9, P469; SETH A, 1990, ONCOGENE, V5, P1761; SETH A, 1993, CANCER PRINCIPLES PR, P23; SHOHAT O, 1987, ONCOGENE, V1, P277; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; VENANZONI M, 1994, MIAMI SHORT REP, V6, P78; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WERNERT N, 1992, AM J PATHOL, V140, P119	35	63	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1199	1204						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649821				2022-12-17	WOS:A1996UC06700004
J	EISEN, T; EASTY, DJ; BENNETT, DC; GODING, CR				EISEN, T; EASTY, DJ; BENNETT, DC; GODING, CR			THE POU DOMAIN TRANSCRIPTION FACTOR BRN-2 - ELEVATED EXPRESSION IN MALIGNANT-MELANOMA AND REGULATION OF MELANOCYTE-SPECIFIC GENE-EXPRESSION	ONCOGENE			English	Article						MELANOCYTES; MELANOMA; TRANSCRIPTION; POU DOMAIN; BRN-2; N-OCT3	OCTAMER-BINDING-PROTEIN; DNA-BINDING; CELLS; PIGMENTATION; DISTINCT; PROMOTER; BRAIN; OCT-1	Previous work has shown that melanoma cell lines express a distinct octamer binding protein. Given the role of octamer-binding proteins in cell differentiation and development, the role this factor is a key issue in understanding melanocyte differentiation and transformation. Using a proteolytic clipping assay, we show that the melanoma-specific octamer factor is Brn-2/N-Oct3, a POU domain protein previously known to be expressed in adult brain and in the developing nervous system. N-Oct3 mRNA was detected in a range of human melanoma cell lines and was around 10-fold elevated compared to normal human melanocytes while mRNA for Brn-2 was also detected in a mouse melanoblast cell line. Expression of Brn-2/N-Oct3, in melanoma cells in cotransfection assays activated the expression of the MHC class II DR alpha promoter but repressed the activity of the melanocyte-specific tyrosinase promoter. Repression correlated with Brn-2/N-Oct3 binding in a mutually exclusive fashion with basic-helix-loop-helix-leucine-zipper (bHLH-LZ) transcription factor USF in vitro and with Brn-2 expression preventing activation of the tyrosinase promoter by the bHLH-LZ factor Microphthalmia in vivo. The potential role of Brn-2/N-Oct3 in melanocyte differentiation and gene expression is discussed.	MARIE CURIE RES INST, EUKARYOT TRANSCRIPT LAB, OXTED RH8 0TL, SURREY, ENGLAND; UNIV LONDON ST GEORGES HOSP, SCH MED, LONDON SW17 0RE, ENGLAND	St Georges University London			Bennett, Dorothy C/C-2418-2008	Bennett, Dorothy C/0000-0002-3639-7527; Goding, Colin/0000-0002-1614-3909				ANGUS J, 1995, ONCOGENE, V11, P691; BENNETT DC, 1985, J CELL SCI, V77, P167; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COX PM, 1988, NUCLEIC ACIDS RES, V16, P11047, DOI 10.1093/nar/16.23.11047; COX PM, 1994, TRANSCRIPTIONAL REGU; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; EASTY DJ, 1993, J INVEST DERMATOL, V101, P679, DOI 10.1111/1523-1747.ep12371675; EDMONDSON DG, 1993, J BIOL CHEM, V268, P755; FITZPATRICK TB, 1979, BIOL MELANIN PIGMENT; FUJII H, 1993, NEURON, V11, P1197, DOI 10.1016/0896-6273(93)90231-F; GODING CR, 1987, NUCLEIC ACIDS RES, V15, P7761, DOI 10.1093/nar/15.19.7761; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SCHREIBER E, 1990, NUCLEIC ACIDS RES, V18, P5495, DOI 10.1093/nar/18.18.5495; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SCHREIBER E, 1992, CANCER RES, V52, P6121; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; STURM RA, 1991, CELL GROWTH DIFFER, V2, P519; STURM RA, 1994, PIGM CELL RES, V7, P235, DOI 10.1111/j.1600-0749.1994.tb00055.x; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; THOMSON JAF, 1993, PIGM CELL RES, V6, P13, DOI 10.1111/j.1600-0749.1993.tb00576.x; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YAVUZER U, 1994, MOL CELL BIOL, V14, P3494, DOI 10.1128/MCB.14.5.3494; YAVUZER U, 1995, ONCOGENE, V10, P123	29	63	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	1995	11	10					2157	2164						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478537				2022-12-17	WOS:A1995TF29700028
J	FUTAMURA, M; MONDEN, Y; OKABE, T; FUJITAYOSHIGAKI, J; YOKOYAMA, S; NISHIMURA, S				FUTAMURA, M; MONDEN, Y; OKABE, T; FUJITAYOSHIGAKI, J; YOKOYAMA, S; NISHIMURA, S			TRICHOSTATIN-A INHIBITS BOTH RAS-INDUCED NEURITE OUTGROWTH OF PC12 CELLS AND MORPHOLOGICAL TRANSFORMATION OF NIH3T3 CELLS	ONCOGENE			English	Article						ONCOGENES; RAS; PC12; TRICHOSTATIN A HEURITE DIFFERENTIATION	NERVE GROWTH-FACTOR; C-FOS INDUCTION; NEURONAL DIFFERENTIATION; HISTONE ACETYLATION; BINDING AFFINITIES; DNA-BINDING; JUN; SEQUENCES; LINE; MICROINJECTION	During screening for inhibitors of ras-mediated differentiation of PC12 cells, trichostatin A (TSA) was isolated from the metabolites of Streptomyces as a potent inhibitor, TSA blocked both oncogenic ras- and NGF-induced neurite outgrowth from PC12 cells, However, addition of TSA 1 h after NGF-stimulation did not inhibit neuronal differentiation, suggesting that TSA affects an early step in the NGF- signaling pathway mediated by ras, Northern blotting analysis showed that TSA prolonged the maximum expression period of c-fos mRNA triggered by NGF and delayed its return to the basal level, TSA reduced c-jun mRNA induction by NGF but greatly enhanced c-myc mRNA induced by NGF, Yoshida et al, (J. Biol. Chem., 265, 17174-17179, 1990) showed that TSA inhibits histone deacetylation, which might influence the gene expression involved in cellular differentiation, In this study, we also found that TSA prevents histone deacetylation in PC12 cells as well as other cell lines, suggesting that inhibition of histone deacetylation by TSA might affect the expression of early-response genes, We also demonstrated that TSA induced reversion of oncogenic ras-transformed NIH3T3 cells to a normal morphology, suggesting that inhibitors of ras-mediated differentiation of PC12 cells may be effective as anticancer agents,	BANYU TSUKUBA RES INST MERCK, ONCOGENE RES LAB, TSUKUBA, IBARAKI 30033, JAPAN; UNIV TOKYO, FAC SCI, DEPT BIOPHYS & BIOCHEM, TOKYO 113, JAPAN	Merck & Company; University of Tokyo			Yokoyama, Shigeyuki/N-6911-2015; Yoshigaki, Junko/AAE-6702-2020	Yokoyama, Shigeyuki/0000-0003-3133-7338; 				ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; CHO KO, 1989, MOL CELL BIOL, V9, P135, DOI 10.1128/MCB.9.1.135; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; FUJITAYOSHIGAKI J, 1992, ONCOGENE, V7, P2019; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HEBBES TR, 1992, NUCLEIC ACIDS RES, V20, P1017, DOI 10.1093/nar/20.5.1017; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; IZAWA M, 1992, CANCER RES, V52, P1628; KANAI T, 1987, JPN J CANCER RES, V78, P1314; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; NARANJO JR, 1990, NUCLEIC ACIDS RES, V18, P3605, DOI 10.1093/nar/18.12.3605; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; SHINDOOKADA N, 1990, BASIC LIFE SCI, V52, P309; SPANDIDOS DA, 1989, INT J DEV NEUROSCI, V7, P1, DOI 10.1016/0736-5748(89)90039-7; STERNER R, 1987, NUCLEIC ACIDS RES, V15, P4375, DOI 10.1093/nar/15.11.4375; SUGITA K, 1992, CANCER RES, V52, P168; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; WU BY, 1989, J BIOL CHEM, V264, P9000; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YOSHIDA M, 1988, CELL TECHNOL S, V4, P91	34	63	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 16	1995	10	6					1119	1123						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700637				2022-12-17	WOS:A1995QN35300012
J	HUANG, RP; ADAMSON, ED				HUANG, RP; ADAMSON, ED			A BIOLOGICAL ROLE FOR EGR-1 IN CELL-SURVIVAL FOLLOWING ULTRA-VIOLET IRRADIATION	ONCOGENE			English	Article						ANTISENSE EGR-1; NIH3T3; IMMUNOBLOTTING; OXIDATIVE STRESS; DNA DAMAGE	IONIZING-RADIATION; CANCER MORTALITY; P53 GENE; C-FOS; PROTEIN; UV; ACTIVATION; INDUCTION; ELEMENTS; PROMOTER	The response to ultra-violet (u.v.) irradiation varies among cells, but commonly involves the rapid increase in expression of one or more transcription factors. The specific roles of this increased expression are largely unknown. We show here that in mouse NIH3T3 cells, Egr-1 expression is increased two-fold 10 min after u.v. irradiation, rises to a maximum (eightfold induction) after about 2 h and then declines. The expression of p53 protein is also strongly induced but is maximal between 2 to 4 h before declining. In contrast, the expression of c-Fos, and c-Jun proteins are only slightly affected by u.v. The Egr-1 response is independent of the growth state of the cells but depends on tyrosine kinase and protein kinase C activities. c-Ha-Ras is also involved in the induction of Egr-1 in u.v. irradiated cells. Evidence presented suggests that the mechanism for the response involves oxidative stress rather than DNA damage. We show that Egr-1 functions in the protection of cells against u.v. damage since NIH3T3 cells that constitutively; express antisense Egr-1 and consequently cannot produce an Egr-1 response to u.v., grow at a rate 26% less than similarly irradiated parental cells and 36% less than nonirradiated parental cells. This is the second protective role described for Egr-1.			HUANG, RP (corresponding author), LA JOLLA CANC RES FDN,10901 N TORREY PINES RD,LA JOLLA,CA 92037, USA.				NCI NIH HHS [P30-CA30199] Funding Source: Medline; NICHD NIH HHS [HD 21957] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021957] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA030199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BLACK HS, 1987, PHOTOCHEM PHOTOBIOL, V46, P213, DOI 10.1111/j.1751-1097.1987.tb04759.x; BLAUSTEIN AR, 1994, P NATL ACAD SCI USA, V91, P1791, DOI 10.1073/pnas.91.5.1791; BRYANT PE, 1992, MUTAT RES, V268, P27, DOI 10.1016/0027-5107(92)90079-H; BUSCHER M, 1988, ONCOGENE, V3, P301; DATTA R, 1992, P NATL ACAD SCI USA, V89, P10149, DOI 10.1073/pnas.89.21.10149; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DING RC, 1992, J BIOL CHEM, V267, P12804; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FORNACE AJ, 1992, ANN REV GENET, V26, P506; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V86, P901; GARLAND FC, 1990, PREV MED, V19, P614, DOI 10.1016/0091-7435(90)90058-R; GHOSH R, 1993, MOL CELL BIOL, V13, P6992, DOI 10.1128/MCB.13.11.6992; GINSBERG D, 1990, ONCOGENE, V5, P1285; GORHAM ED, 1989, CAN J PUBLIC HEALTH, V80, P96; GORHAM ED, 1990, INT J EPIDEMIOL, V19, P820, DOI 10.1093/ije/19.4.820; GROVERBARDWICK A, 1994, CARCINOGENESIS, V15, P1667, DOI 10.1093/carcin/15.8.1667; HALLAHAN DE, 1992, RADIAT RES, V129, P345, DOI 10.2307/3578035; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HUANG RP, 1994, ONCOGENE, V9, P1367; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; HUANG RP, 1993, DNA CELL BIOL, V12, P265, DOI 10.1089/dna.1993.12.265; HUANG RP, 1994, J CELL BIOCHEM, V57, P1; KANNER SB, 1992, P NATL ACAD SCI USA, V89, P300, DOI 10.1073/pnas.89.1.300; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; MERCOLA D, 1992, ONCOGENE, V7, P1793; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; OCHI T, 1987, P NATL ACAD SCI USA, V84, P990, DOI 10.1073/pnas.84.4.990; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; RACHAL MJ, 1989, NUCLEIC ACIDS RES, V17, P5135, DOI 10.1093/nar/17.13.5135; RONAI ZA, 1988, ONCOGENE, V2, P201; SACHSENMAIER C, 1994, BIOCHEM PHARMACOL, V47, P129, DOI 10.1016/0006-2952(94)90446-4; SATOH MS, 1992, NATURE, V365, P356; SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; WAZER DE, 1994, MOL CELL BIOL, V14, P2468, DOI 10.1128/MCB.14.4.2468; WILSON RE, 1993, ONCOGENE, V8, P3229; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XANTHOUDAKIS S, 1992, EMBO J, V11, P3233; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	47	63	68	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					467	475						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845671				2022-12-17	WOS:A1995QF64800007
J	BRUSSELBACH, S; MOHLESTEINLEIN, U; WANG, ZQ; SCHREIBER, M; LUCIBELLO, FC; MULLER, R; WAGNER, EF				BRUSSELBACH, S; MOHLESTEINLEIN, U; WANG, ZQ; SCHREIBER, M; LUCIBELLO, FC; MULLER, R; WAGNER, EF			CELL PROLIFERATION AND CELL-CYCLE PROGRESSION ARE NOT IMPAIRED IN FIBROBLASTS AND ES CELLS LACKING C-FOS	ONCOGENE			English	Article						C-FOS; CELL PROLIFERATION; CELL CYCLE; ES CELLS; FIBROBLASTS	EMBRYONIC STEM-CELLS; TRANSGENIC MICE; G0-TO-G1 TRANSITION; MOUSE FIBROBLASTS; NERVOUS-SYSTEM; ANTISENSE RNA; NULL MUTATION; AP-1 ACTIVITY; DNA-SYNTHESIS; JUN	The transcription factor AP-1 is thought to play an important role in the control of cell proliferation, but the function of individual Fos and Jun family members is a largely unresolved issue. To directly analyse the function of c-Fos in the control of cell proliferation we have used embryonic stem (ES) cells and fibroblasts lacking c-Fos due to a disruption of the c-fos gene by homologous recombination, Our results demonstrate that proliferation of normally cycling cells and reentry of quiescent cells into the cell cycle following serum stimulation are not c-Fos-dependent and occur with similar efficiency in c-fos-/- and control cells. We also show that there is no compensatory overexpression or activation of other known Pos or Jun family members. On the contrary, the c-fos-/- cells showed a reduced induction of fra-1 after serum stimulation which is in agreement with the previous identification of fra-1 as a c-Fos target gene. Comparison of the AP-1 binding and transactivation activities in c-fos-/- and +/+ fibroblasts by electrophoretic mobility antibody supershift and CAT assays suggests that c-Fos is not a major component of AP-1 complexes in these cells. It is therefore conceivable that the lack of any detectable effect on cell proliferation in c-fos-/- cells might be due to a functional redundancy among the different AP-1 family members.	RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Müller, Rolf/L-4997-2016; Martin, Schreiber/F-2175-2013	Müller, Rolf/0000-0003-3339-4248; Martin, Schreiber/0000-0003-1102-7789; Wagner, Erwin F/0000-0001-7872-0196				ADAMKIEWICZ J, 1990, ONCOGENE, V5, P525; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BRASELMANN S, 1992, J CELL SCI S, V16, P97; BURKERT U, 1991, NEW BIOL, V3, P698; CHEN JZ, 1994, IMMUNITY, V1, P65, DOI 10.1016/1074-7613(94)90010-8; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; FIELD SJ, 1992, P NATL ACAD SCI USA, V89, P9306, DOI 10.1073/pnas.89.19.9306; GORMAN CM, 1982, P NATL ACAD SCI USA, V79, P433; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Grigoriadis Agamemnon E., 1993, P497; HILBERG F, 1992, ONCOGENE, V7, P2371; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; JAIN JN, 1994, MOL CELL BIOL, V14, P1566, DOI 10.1128/MCB.14.3.1566; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; MILLER AD, 1984, CELL, V36, P259; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; MULLER R, 1994, FOS JUN FAMILIES TRA, P189; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; OKADA S, 1994, MOL CELL BIOL, V14, P382, DOI 10.1128/MCB.14.1.382; OKUNO H, 1991, ONCOGENE, V6, P1491; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RIABOWOL K, 1992, P NATL ACAD SCI USA, V89, P157, DOI 10.1073/pnas.89.1.157; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHUERMANN M, 1993, ONCOGENE, V8, P2781; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WICK M, 1992, ONCOGENE, V7, P859	46	63	63	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					79	86						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824281				2022-12-17	WOS:A1995QA98000010
J	LECOINTE, N; BERNARD, O; NAERT, K; JOULIN, V; LARSEN, CJ; ROMEO, PH; MATHIEUMAHUL, D				LECOINTE, N; BERNARD, O; NAERT, K; JOULIN, V; LARSEN, CJ; ROMEO, PH; MATHIEUMAHUL, D			GATA-BINDING AND SP1-BINDING SITES ARE REQUIRED FOR THE FULL ACTIVITY OF THE TISSUE-SPECIFIC PROMOTER OF THE TAL-1 GENE	ONCOGENE			English	Article							T-CELL LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSCRIPTION FACTOR GATA-1; DNA-BINDING PROTEIN; LOOP-HELIX GENE; SCL GENE; CHROMOSOMAL LOCALIZATION; HEMATOPOIETIC-CELLS; MAMMALIAN-CELLS; CONTROL REGION	The tal-1 gene, which is frequently activated in human T cell acute leukemias (T-ALLs), codes for a protein of the basic helix-loop-helix family (b-HLH) and potentially a transcription factor. In human and murine hematopoiesis tal-1 is expressed during the differentiation of the erythroid, megakaryocytic and mastocytic cell lineages. The expression of tal-1 appears to be comodulated with that of the transcription factor GATA-1 gene, suggesting that the GATA-1 protein may regulate the tal-1 gene activity in these hematopoietic lineages. To get further insights into the molecular mechanisms that control tal-1 expression, we have isolated 5' sequences of the murine gene and compared them to their human counterparts. The 5' flanking sequences from the two genes show several regions of high homology. The alignment of both sequences enabled us to predict that similarly, to the human, the mouse gene contains two alternative first exons (Ia and Ib). Remarkably, in both species, the proximal region of the tissue-specific exon Ia (i.e. gene segment -122 to +1) contains two GATA-motifs (at -65 and -33) and one SP-1 consensus binding site (-59). Mobility shift assays demonstrate that GATA proteins are able to interact with both GATA-motifs in a sequence specific fashion, but with different efficiencies. Moreover transfection studies show that the GATA-1 protein directly mediates tal-1 transcription by interacting with the -122/+1 fragment, defined as a minimal promoter in erythroid cells. Mutagenesis of the promoter establishes that the -33 GATA-binding site present in this fragment is critical for tal-1 expression in erythroid cells, but by itself does not lead to full promoter activity. Indeed, further mutations show that the second -65 GATA-binding site and the binding motif for SP1 (-59) significantly contribute to the overall activity of the proximal tal-1 promoter. Altogether, our data provide evidence that GATA-1 cooperates with the transcription factor SP1 to mediate the erythroid-specific expression of the tal-1 gene.	INST GENET MOLEC MONTPELLIER,CNRS,UMR 9942,F-34033 MONTPELLIER 1,FRANCE; INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE; HOP HENRI MONDOR,INSERM,U91,F-94010 CRETEIL,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Mathieu, Daniele/G-6092-2012; Bernard, Olivier A./E-5721-2016; Romeo, Paul-Henri/L-5989-2017	Romeo, Paul-Henri/0000-0002-8294-0367; JOULIN, Virginie/0000-0003-1091-7819; Bernard, Olivier/0000-0002-0463-9747				APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1992, BLOOD, V79, P1327; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1992, J EXP MED, V176, P919, DOI 10.1084/jem.176.4.919; BERNARD O, 1991, ONCOGENE, V6, P1477; BORIES JC, 1990, J EXP MED, V171, P75, DOI 10.1084/jem.171.1.75; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARROLL AJ, 1990, BLOOD, V76, P1220; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; FISCHER KD, 1993, J BIOL CHEM, V268, P23915; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; HWANG LY, 1993, ONCOGENE, V8, P3043; JOULIN V, 1991, EMBO J, V10, P1809, DOI 10.1002/j.1460-2075.1991.tb07706.x; KNEZETIC JA, 1993, MOL CELL BIOL, V13, P4632, DOI 10.1128/MCB.13.8.4632; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; KOLJ, 1993, MOL CELL BIOL, V13, P4011; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MARTIN DIK, 1990, NATURE, V344, P1777; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOUHTON MA, 1993, BLOOD, V81, P647; MURRE C, 1989, CELL, V58, P777; ORKIN SH, 1992, BLOOD, V80, P575; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; RAHUEL C, 1992, EMBO J, V11, P4095, DOI 10.1002/j.1460-2075.1992.tb05502.x; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; REDONDO JM, 1990, SCIENCE, V247, P1225, DOI 10.1126/science.2156339; ROMEO PH, 1990, NATURE, V344, P447, DOI 10.1038/344447a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VISVADER J, 1991, ONCOGENE, V6, P187; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444; XIA Y, 1992, GENE CHROMOSOME CANC, V4, P211, DOI 10.1002/gcc.2870040304; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	52	63	64	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2623	2632						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058326				2022-12-17	WOS:A1994PC05400022
J	ZHEN, Z; GIORDANO, S; LONGATI, P; MEDICO, E; CAMPIGLIO, M; COMOGLIO, PM				ZHEN, Z; GIORDANO, S; LONGATI, P; MEDICO, E; CAMPIGLIO, M; COMOGLIO, PM			STRUCTURAL AND FUNCTIONAL DOMAINS CRITICAL FOR CONSTITUTIVE ACTIVATION OF THE HGF-RECEPTOR (MET)	ONCOGENE			English	Article							HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR-RECEPTOR; C-MET; TYROSINE KINASE; EPITHELIAL-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; ONCOGENIC REARRANGEMENT; THYROID CARCINOMAS; TPR; PROTOONCOGENE	The MET gene, encoding the tyrosine kinase receptor for Hepatocyte Growth Factor, is a potentially harmful oncogene overexpressed ina significant fraction of human cancers. To study the molecular mechanisms responsible for oncogenic activation, the biochemical and biological properties of a number of MET constructs were analysed. The native heterodimeric receptor (alpha beta), the beta chain alone, as well as a kinase defective mutant did not transform rodent fibroblasts upon transfection. The cytoplasmic domain, truncated immediately below the transmembrane region, acquired constitutive tyrosine kinase activity in vivo, produced foci of transformation, and was tumorigenic in nude mice. Removal of the first 39 amino acids of the juxtamembrane domain resulted in loss of constitutive activation in vivo and transforming potential, without impairment of the in vitro kinase activity. Replacement of the juxtamembrane domain with 5' TPR sequences restored constitutive kinase activation and transforming properties. Site-directed mutagenesis of either of the two tyrosine residues involved in the positive regulation of the catalytic activity upon phosphorylation (Y-1234 or Y-1235 in the kinase domain of the HGF receptor), strongly impaired TPR-MET transforming potential. These data show that: (1) the truncated cytoplasmic HGF receptor has constitutive kinase activity and is oncogenic; (2) the first 39 amino acids of the juxtamembrane domain and (3) the regulatory tyrosines in the catalytic domain are required to unleash its transforming potential.	UNIV TURIN,SCH MED,DEPT BIOMED SCI & ONCOL,TURIN,ITALY; NATL CANC INST,DEPT EXPTL ONCOL E,MILAN,ITALY	University of Turin; Fondazione IRCCS Istituto Nazionale Tumori Milan			Giordano, Silvia/J-9858-2018; Medico, Enzo/AAC-3185-2021	Giordano, Silvia/0000-0003-1854-1086; Medico, Enzo/0000-0002-3917-2438; Comoglio, Paolo/0000-0002-7056-5328				BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CAPETANAKI Y, 1990, ONCOGENE, V5, P645; COCHET C, 1988, J BIOL CHEM, V263, P3290; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DEAN M, 1987, MOL CELL BIOL, V7, P921, DOI 10.1128/MCB.7.2.921; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; GANDINO L, 1991, J BIOL CHEM, V266, P16098; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GANDINO L, 1990, ONCOGENE, V5, P721; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; GRECO A, 1992, ONCOGENE, V7, P237; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KING HWS, 1988, ONCOGENE, V2, P617; LIU C, 1992, ONCOGENE, V7, P181; LONGATI P, 1994, ONCOGENE, V9, P49; MICHELIN S, 1993, ONCOGENE, V8, P1983; MITCHELL PJ, 1992, ONCOGENE, V7, P383; MITCHELL PJ, 1992, ONCOGENE, V7, P2329; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MORUZZI EV, 1993, J BIOL CHEM, V268, P18176; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, IN PRESS CELL; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; QUI F, 1988, EMBO J, V7, P1003; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; SOMAN NR, 1990, P NATL ACAD SCI USA, V87, P738, DOI 10.1073/pnas.87.2.738; TEMPEST PR, 1986, CARCINOGENESIS, V7, P2051, DOI 10.1093/carcin/7.12.2051; UEHARA Y, 1992, J CELL BIOL, V117, P889, DOI 10.1083/jcb.117.4.889; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	61	63	76	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1691	1697						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183564				2022-12-17	WOS:A1994NL81500021
J	CROOK, T; FISHER, C; MASTERSON, PJ; VOUSDEN, KH				CROOK, T; FISHER, C; MASTERSON, PJ; VOUSDEN, KH			MODULATION OF TRANSCRIPTIONAL REGULATORY PROPERTIES OF P53 BY HPV-E6	ONCOGENE			English	Note							HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; CARCINOMA CELL-LINES; CERVICAL-CARCINOMA; E6 ONCOPROTEIN; RETINOBLASTOMA GENES; BINDING PROTEIN; DEGRADATION; PROMOTERS; TRANSACTIVATION	The E6 protein encoded by human papillomavirus type 16 (HPV16), a genital virus with oncogenic potential, can target cellular p53 for rapid degradation following the formation of a complex including the two proteins. Some studies suggest that the E6 proteins encoded by HPV6 and 11, viral types which are normally limited to benign lesions, may also interact with p53, although the association is weaker than that seen with HPV16 E6. The present study demonstrates that E6 proteins from HPV16 and HPV6 can modulate the transcriptional regulatory functions of p53 in several cell types. A series of E6 mutants was used to show that association between E6 and p53 is necessary for this activity and that E6 proteins which retain the ability to associate with p53 but show no detectable degradation activity in vitro can, to some extent, abrogate p53 mediated transcriptional trans-regulation. This activity is augmented, however, by the ability of the E6 protein to target bound p53 for rapid degradation. These results suggest that some degree of modulation of p53 function is necessary in the normal viral life cycle but also demonstrate a correlation between the efficiency of this activity and oncogenic potential of the virus.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,NORFOLK PL,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research								BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARK Y, 1993, EMBO J, V12, P461; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHOO KB, 1993, VIROLOGY, V193, P1042; CROOK T, 1992, LANCET, V339, P1070, DOI 10.1016/0140-6736(92)90662-M; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1991, ONCOGENE, V6, P873; CROOK T, 1991, ONCOGENE, V6, P1251; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DESAINTES C, 1992, J VIROL, V66, P325, DOI 10.1128/JVI.66.1.325-333.1992; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FUJITA M, 1992, CANCER RES, V52, P5323; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JACKSON P, 1993, ONCOGENE, V8, P589; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SEGAWA K, 1993, ONCOGENE, V8, P543; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TRUANT R, 1993, J BIOL CHEM, V268, P2284; TUCK SP, 1989, ONCOGENE RES, V4, P81; VOUSDEN KH, 1991, SEMIN VIROL, V2, P307; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	51	63	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1225	1230						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134125				2022-12-17	WOS:A1994NC04800026
J	ROSS, IL; DUNN, TL; YUE, X; ROY, S; BARNETT, CJK; HUME, DA				ROSS, IL; DUNN, TL; YUE, X; ROY, S; BARNETT, CJK; HUME, DA			COMPARISON OF THE EXPRESSION AND FUNCTION OF THE TRANSCRIPTION FACTOR PU.1 (SPI-1 PROTOONCOGENE) BETWEEN MURINE MACROPHAGES AND B-LYMPHOCYTES	ONCOGENE			English	Article							HEAVY-CHAIN GENE; CELL-LINE; NUCLEAR FACTOR; ENHANCER; ACTIVATION; IDENTIFICATION; INVOLVEMENT; TUMOR	The expression of mRNA encoding the DNA-binding protein PU.1(Spi-1) is restricted to B lymphocytes and macrophages. The role of PU.1 in tissue-specific transcriptional regulation in the two cell types was examined by co-transfection of a PU.1 expression plasmid with vectors containing B cell (IgH enhancer) or macrophage-specific (c-fms) transcription control elements. Cotransfection of the PU.1 expression plasmid in MOPC31C B cells trans-repressed the IgH enhancer but trans-activated the c-fms promoter. The latter was insufficient to overcome a block to transcription elongation that determines macrophage-specific c-fms gene expression. In the macrophage line RAW264, PU.1 had no effect on the c-fms promoter, but trans-repressed the activity of a c-fms reporter plasmid containing the transcription attenuator. The effects of PU.1 in both cell types were distinct from those of c-ets-2, a related factor, which trans-activated the c-fms promoter in both B cells and macrophages but also repressed the IgH enhancer. PU.1 was shown to be one of several nuclear proteins that bound a critical cis-acting element of the IgH enhancer, mu B, but analysis of nuclear extracts of a wide range of B cell and macrophage lines demonstrated a strong correlation between macrophage phenotype and nuclear PU.1 expression. The data suggest that differences in nuclear PU.1 expression and function between macrophages and B cells may play a role in lineage divergence.	UNIV QUEENSLAND,CTR MOLEC BIOL & BIOTECHNOL,ST LUCIA,QLD 4072,AUSTRALIA	University of Queensland			Ross, Ian/A-8622-2011; Hume, David A/C-7695-2013	Ross, Ian/0000-0002-2389-4292; Hume, David/0000-0002-2615-1478				ARAKI K, 1988, CELL, V53, P723, DOI 10.1016/0092-8674(88)90090-6; BAUER SR, 1986, J IMMUNOL, V136, P4695; BORZILLO GV, 1990, MOL CELL BIOL, V10, P2703, DOI 10.1128/MCB.10.6.2703; BOYD AW, 1982, NATURE, V297, P691, DOI 10.1038/297691a0; CASSADY AI, 1991, NUCLEIC ACIDS RES, V19, P6839, DOI 10.1093/nar/19.24.6839; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; DAVIDSON WF, 1988, J EXP MED, V168, P1293; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FISHER CL, 1991, J IMMUNOL, V146, P1743; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GRANT PA, 1992, NUCLEIC ACIDS RES, V20, P4401, DOI 10.1093/nar/20.17.4401; HUME DA, 1989, IMMUNOL CELL BIOL, V67, P243, DOI 10.1038/icb.1989.37; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P3155, DOI 10.1128/MCB.10.6.3155; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; NELSEN B, 1990, MOL CELL BIOL, V10, P3145, DOI 10.1128/MCB.10.6.3145; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PAUL HL, 1993, J BIOL CHEM, V268, P5014; PETERSSON M, 1987, GENE DEV, V1, P962; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RALPH P, 1975, NATURE, V257, P393, DOI 10.1038/257393a0; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; Sambrook J., 1989, MOL CLONING; SCHEUTZE S, 1992, MOL CELL BIOL, V12, P2967; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; YUE X, 1993, MOL CELL BIOL, V13, P3191, DOI 10.1128/MCB.13.6.3191; YUE X, 1993, BRIT J HAEMATOL, V84, P392	31	63	63	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					121	132						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302571				2022-12-17	WOS:A1994MW24700015
J	CHOWDHURY, M; KUNDU, M; KHALILI, K				CHOWDHURY, M; KUNDU, M; KHALILI, K			GA GC-RICH SEQUENCE CONFERS TAT RESPONSIVENESS TO HUMAN NEUROTROPIC VIRUS PROMOTER, JCVL, IN CELLS DERIVED FROM CENTRAL-NERVOUS-SYSTEM	ONCOGENE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; HUMAN-BRAIN CELLS; TRANS-ACTIVATION; HIV-1 TAT; GENE-EXPRESSION; LOOP SEQUENCE; PROTEIN; RNA; TYPE-1	The human immunodeficiency virus type I (HIV-1) nuclear protein, Tat, is a potent transactivating factor that stimulates the rate of transcription of responsive promoters. Evidently, to exert its activity, Tat requires to be localized in close proximity of the transcription initiation site. Previous studies in our laboratory have demonstrated that Tat has the capacity to increase transcriptional activity of the late gene of a human neurotropic virus JC (JCV) in glial cells. In the present study, using deletion mutation analysis, we have identified a region upstream of the JCV late RNA start sites, termed upstream target (upTAR), that positively responds to Tat activation in glial cells. Using synthetic oligonucleotides spanning the upTAR sequence linked to a heterologous promoter, we have identified a GA/GC-rich region (GGAGGCGGAGGC) that confers TAT responsiveness preferentially on glial cell lines. Using gel mobility-shift and UV cross-linking assays, we have demonstrated that four major complexes (a-d) from glial and HeLa (non-glial) cells interact with the upTAR sequence. Whereas the molecular weights of the participant proteins in these complexes are similar in both glial and non-glial extracts, glial cells are enriched in proteins that form a major c complex. Interestingly, the participant proteins in complex c are developmentally regulated during brain development. The possible role of these proteins in increasing local concentrations of Tat in the vicinity of the JCV late RNA start sites is discussed.	THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	Jefferson University			Kundu, Mondira/N-8139-2018	Kundu, Mondira/0000-0001-9946-2472	NCI NIH HHS [CA 47996] Funding Source: Medline; NIAID NIH HHS [AI 28272] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028272] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKSAMIT AJ, 1988, ANN NEUROL, V24, P471; BERGER JR, 1987, ANN INTERN MED, V107, P78, DOI 10.7326/0003-4819-107-1-78; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CHOWDHURY M, 1992, J VIROL, V66, P7355, DOI 10.1128/JVI.66.12.7355-7361.1992; CHOWDHURY M, 1990, ONCOGENE, V5, P1737; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KAMINE J, 1992, J VIROL, V66, P3932, DOI 10.1128/JVI.66.6.3932-3936.1992; KENNEY S, 1984, SCIENCE, V226, P1337, DOI 10.1126/science.6095453; KENNEY S, 1986, J VIROL, V58, P210; KHALILI K, 1988, EMBO J, V7, P1205, DOI 10.1002/j.1460-2075.1988.tb02932.x; KRUPP LB, 1985, ANN NEUROL, V17, P344, DOI 10.1002/ana.410170407; LEVY RM, 1985, J NEUROSURG, V62, P475, DOI 10.3171/jns.1985.62.4.0475; LIU JS, 1992, J VIROL, V66, P3883, DOI 10.1128/JVI.66.6.3883-3887.1992; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MULLER WEG, 1990, J BIOL CHEM, V265, P3803; PADGETT BL, 1973, J INFECT DIS, V127, P467, DOI 10.1093/infdis/127.4.467; ROSEN CA, 1991, GENE EXPRESSION, V1, P85; ROY S, 1990, J VIROL, V64, P1402, DOI 10.1128/JVI.64.3.1402-1406.1990; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; STONER GL, 1991, J NEUROPATH EXP NEUR, V50, P342; TADA H, 1989, J VIROL, V63, P463, DOI 10.1128/JVI.63.1.463-466.1989; TADA H, 1990, P NATL ACAD SCI USA, V87, P3479, DOI 10.1073/pnas.87.9.3479; TADA H, 1991, VIROLOGY, V52, P456; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; WALKER DL, 1978, HDB CLIN NEUROLOGY, V34, P307; WALKER DL, 1985, HDB CLIN NEUROLOGY, V47, P503; WROBLEWSKA Z, 1980, ARCH VIROL, V65, P141, DOI 10.1007/BF01317325; ZURHEIN GM, 1969, PROG MED VIROL, V11, P185	40	63	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					887	892						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8384357				2022-12-17	WOS:A1993KT22000009
J	PASLEAU, F; GROOTECLAES, M; GOLWINKLER, R				PASLEAU, F; GROOTECLAES, M; GOLWINKLER, R			EXPRESSION OF THE C-ERBB2 GENE IN THE BT474 HUMAN MAMMARY-TUMOR CELL-LINE - MEASUREMENT OF C-ERBB2 MESSENGER-RNA HALF-LIFE	ONCOGENE			English	Article							HUMAN BREAST-CANCER; PROTO-ONCOGENE; GROWTH-FACTOR; EGF-RECEPTOR; C-MYC; HER-2/NEU PROTOONCOGENE; OVARIAN-CANCER; OVEREXPRESSION; LIGAND; ACTIVATION	BT474 and SK-BR-3 mammary adenocarcinoma cells contain eight copies of the c-erbB2 gene but overexpress the mRNA 80 times over the levels measured in normal breast or in the HBL-100 cell line. Using Northern blot analysis and molecular titration based on RNAase protection assay, the decrease in the c-erbB2 mRNA level was monitored in BT474 cells treated with actinomycin D from 1 up to 24 h. The c-erbB2 degradation rate during the first 12 h corresponds to a calculated c-erbB2 mRNA half-life of approximately 7 h. Forty percent of the mRNA present in the cells before treatment remains undegraded after transcription has been blocked for 24 h. Pretreatment with cycloheximide results in complete mRNA degradation in 24 h, suggesting that labile proteins stabilize part of the c-erbB2 mRNA population. Comparison with the c-erbB2 mRNA turnover in HBL100 'normal' cells indicated that the accumulation of the c-erbB2 gene product in the tumor cells is not the result of stabilization of the messenger. Rather, it is correlated with an increased rate of c-erbB2 mRNA transcription as indicated by run-on transcription assays. Both BT474 and SK-BR-3 tumor cell lines were found to synthesize 20-40 times more c-erbB2 mRNA than HBL-100 cells.			PASLEAU, F (corresponding author), UNIV LIEGE,DEPT RADIOIMMUNOL,MOLEC ONCOL LAB,TOUR PATHOL B23,B-4000 SART,BELGIUM.							AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BERCHUCK A, 1990, CANCER RES, V50, P4087; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DATI C, 1990, ONCOGENE, V5, P1001; DELVENNE CG, 1992, EUR J CANCER, V28A, P700; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; JINNO Y, 1988, NUCLEIC ACIDS RES, V16, P4957, DOI 10.1093/nar/16.11.4957; KERN JA, 1990, CANCER RES, V50, P5184; KESAVAN P, 1990, ONCOGENE, V5, P483; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LACY J, 1989, EMBO J, V8, P1973, DOI 10.1002/j.1460-2075.1989.tb03603.x; LEE JJ, 1987, METHOD ENZYMOL, V152, P633; LEMOINE NR, 1990, ONCOGENE, V5, P237; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MARCU KB, 1983, P NATL ACAD SCI-BIOL, V80, P519, DOI 10.1073/pnas.80.2.519; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; PASLEAU F, 1990, ARCH INT PHYSL BIOCH, V98, P40; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PERREN TJ, 1991, BRIT J CANCER, V63, P328, DOI 10.1038/bjc.1991.78; PRESS MF, 1990, ONCOGENE, V5, P953; RAYMOND V, 1989, ONCOGENE RES, V5, P1; READ LD, 1990, CANCER RES, V50, P3947; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TARAKHOVSKY A, 1991, ONCOGENE, V6, P2179; THOMPSON KL, 1989, J BIOL CHEM, V264, P3230; WATHELET MG, 1989, EUR J BIOCHEM, V184, P503, DOI 10.1111/j.1432-1033.1989.tb15043.x; WEBER B, 1989, MOL CELL BIOL, V9, P769, DOI 10.1128/MCB.9.2.769; WEINER DB, 1990, CANCER RES, V50, P421; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179	35	63	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					849	854						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8096075				2022-12-17	WOS:A1993KT22000005
J	ROSENBERG, CL; MOTOKURA, T; KRONENBERG, HM; ARNOLD, A				ROSENBERG, CL; MOTOKURA, T; KRONENBERG, HM; ARNOLD, A			CODING SEQUENCE OF THE OVEREXPRESSED TRANSCRIPT OF THE PUTATIVE ONCOGENE PRAD1/CYCLIN D1 IN 2 PRIMARY HUMAN TUMORS	ONCOGENE			English	Note							CANDIDATE ONCOGENE; CHROMOSOME 11Q13; SQUAMOUS-CELL; AMPLIFICATION; BCL-1; GENE; CARCINOMAS; EXPRESSION; CYCLINS; LOCUS	PRAD1 (cyclin Dl) is a recently identified member of the family of cyclin genes, believed to play roles in regulating transitions through the cell cycle. The PRAD1 gene, located at 11q13, has been implicated in the pathogenesis of a variety of tumors, including parathyroid adenomas, t(11;14) bearing B-lymphoid tumors (particularly centrocytic lymphomas) where it is highly likely to be the BCL1 oncogene, and possibly in breast carcinomas and squamous cell cancers of the head and neck as well. PRAD1's tumorigenic influence appears to be effected through overexpression of its normal-sized transcript, but it has not been established whether the transcript's coding sequence is normal or contains oncogenic mutations. We have sequenced the coding region of the overexpressed PRAD1 transcript from two primary tumors with clonal PRAD1 region rearrangements: a benign parathyroid adenoma and a malignant centrocytic lymphoma. Each sequence is identical to the normal PRAD1 cDNA sequence, and presumably encodes normal PRAD1 protein. Thus, PRAD1 likely functions as a direct-acting oncogene whose rearrangement in tumors leads to overexpression or deregulated expression of its normal protein product.	MASSACHUSETTS GEN HOSP, ENDOCRINE UNIT, WELLMAN 503, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, CTR CANC, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Motokura, Toru/X-3682-2019		NCI NIH HHS [CA55909] Funding Source: Medline; NIDDK NIH HHS [DK11794] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055909] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; BERENSON JR, 1990, ONCOGENE, V5, P1343; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LISCIA DS, 1989, ONCOGENE, V4, P1219; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; PROCTOR AJ, 1991, ONCOGENE, V6, P789; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; Sambrook J., 1989, MOL CLONING LAB MANU; SCHUURING E, 1992, ONCOGENE, V7, P355; SETO M, 1992, ONCOGENE, V7, P1401; THEILLET C, 1989, ONCOGENE, V4, P915; WILLIAMS ME, 1992, IN PRESS LEUKEMIA; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YANDELL DW, 1989, AM J HUM GENET, V45, P547; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	20	63	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					519	521						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426754				2022-12-17	WOS:A1993KN00600034
J	SAKODA, T; KAIBUCHI, K; KISHI, K; KISHIDA, S; DOI, K; HOSHINO, M; HATTORI, S; TAKAI, Y				SAKODA, T; KAIBUCHI, K; KISHI, K; KISHIDA, S; DOI, K; HOSHINO, M; HATTORI, S; TAKAI, Y			SMG/RAP-1/KREV-1 P21S INHIBIT THE SIGNAL PATHWAY TO THE C-FOS PROMOTER ENHANCER FROM C-KI-RAS P21 BUT NOT FROM C-RAF-1 KINASE IN NIH3T3-CELLS	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; NUCLEOTIDE EXCHANGE-REACTION; PUTATIVE EFFECTOR DOMAIN; SERUM-RESPONSE ELEMENT; BOVINE BRAIN; MAMMALIAN-CELLS; GROWTH-FACTOR; SMG P21; CATALYZED PHOSPHORYLATION; TYROSINE PHOSPHORYLATION	smg/rap1A/Krev-1 p21 cDNA is known to inhibit v-Kiras p21-induced cell transformation in NIH3T3 cells, but the inhibitory mechanism is not clear at present. In the present study, we examined the effect of smg p21s on the c-fos promoter/enhancer linked to the luciferase reporter gene (c-fos-luciferase). After transfection of c-fos-luciferase into NIH3T3 cells constitutively expressing c-Ki-ras(val-12) p21 or activated c-raf-1 kinase, expression of c-fos-luciferase was much higher than after transfection into control NIH3T3 cells. Addition of platelet-derived growth factor (PDGF), 12-O-tetradecanoyl phorbol 13-acetate (TPA) or dibutyryl cyclic AMP (Bt2cAMP) to the control NIH3T3 cells stimulated c-fos-luciferase expression. Transfection of the smg p21 cDNAs inhibited the activated ras p21-, PDGF- or TPA-stimulated c-fos-luciferase expression, but did not inhibit the activated c-raf-1 kinase- or Bt2cAMP-stimulated reaction. These results indicate that smg p21s inhibit the signal pathways from the PDGF receptor, protein kinase C, and ras p21s to the c-fos promoter/enhancer, but not those from c-raf-1 kinase and cyclic AMP-dependent protein kinase to the c-fos promoter/enhancer.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; UNIV TOKYO,COLL ARTS & SCI,DEPT PURE & APPL SCI,TOKYO 153,JAPAN	Kobe University; University of Tokyo				kishida, shosei/0000-0003-0405-851X				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.biochem.56.1.159; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOSCH HVD, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CAMPA MJ, 1991, BIOCHEM BIOPH RES CO, V174, P1, DOI 10.1016/0006-291X(91)90475-M; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FUJIOKA H, 1992, J BIOL CHEM, V267, P926; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HATA Y, 1991, J BIOL CHEM, V266, P6571; HATA Y, 1990, J BIOL CHEM, V265, P7104; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; HUANG YK, 1990, P NATL ACAD SCI USA, V87, P8008, DOI 10.1073/pnas.87.20.8008; ITOH T, 1991, BIOCHEM BIOPH RES CO, V177, P1319, DOI 10.1016/0006-291X(91)90685-Z; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KIM S, 1990, MOL CELL BIOL, V10, P2645, DOI 10.1128/MCB.10.6.2645; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; MITSUNOBU F, 1989, ONCOGENE, V4, P437; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OKU N, 1990, FEBS LETT, V269, P148, DOI 10.1016/0014-5793(90)81141-A; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; RAPP UR, 1991, ONCOGENE, V6, P495; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Sambrook J., 1989, MOL CLONING LAB MANU; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WEST M, 1990, FEBS LETT, V259, P245, DOI 10.1016/0014-5793(90)80019-F; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; ZIPSER D, 1981, P NATL ACAD SCI-BIOL, V78, P6276, DOI 10.1073/pnas.78.10.6276	67	63	63	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1705	1711						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1323817				2022-12-17	WOS:A1992JJ37600005
J	SCHLEGEL, U; MOOTS, PL; ROSENBLUM, MK; THALER, HT; FURNEAUX, HM				SCHLEGEL, U; MOOTS, PL; ROSENBLUM, MK; THALER, HT; FURNEAUX, HM			EXPRESSION OF TRANSFORMING GROWTH-FACTOR ALPHA IN HUMAN GLIOMAS	ONCOGENE			English	Note							MALIGNANT GLIOMAS; FACTOR RECEPTOR; MESSENGER-RNAS; EGF-RECEPTOR; CELL-LINES; TGF-ALPHA; INDUCTION; KERATINOCYTES; AMPLIFICATION; MACROPHAGES	Expression of transforming growth factor alpha (TGF alpha) is frequently associated with the development of human and animal tumors. Using a sensitive immunohistochemical assay, which can be applied on formalin-fixed, paraffin-embedded tissue, we have examined the expression of TGF alpha in 71 human gliomas (63 untreated and 8 recurrent tumors). Tumors were graded by a 3-grade-system: grade I = low grade gliomas, grade II = anaplastic gliomas and grade III = glioblastomas. A strong positive correlation between tumor grade and extent of TGF alpha expression was found (P < 0.0001). Polymerase chain reaction (PCR) was used to amplify the fourth exon of the TGF alpha gene of 8 glioma DNA specimens and increasing amounts of normal human DNA, which served as a standard. No amplification of the TGF alpha gene copy number in tumors could be detected.	CORNELL UNIV,MED CTR,COLL MED,MEM SLOAN KETTERING CTR CANC RES,DEPT EPIDEMIOL & BIOSTAT,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,COTZIAS LABS NEUROONCOL,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,DEPT PATHOL,NEW YORK,NY 10021; CORNELL UNIV,MED CTR,COLL MED,GRAD PROGRAM NEUROSCI,NEW YORK,NY 10021	Cornell University; Cornell University; Cornell University; Cornell University				furneaux, henry/0000-0003-2212-1017; Moots, Paul/0000-0002-2277-802X				BURGER PC, 1982, SURGICAL PATHOLOGY N, P226; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1987, CANCER RES, V47, P707; DIMARCO E, 1989, ONCOGENE, V4, P831; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MADTES DK, 1988, CELL, V53, P285, DOI 10.1016/0092-8674(88)90390-X; MARQUARDT H, 1982, J BIOL CHEM, V257, P5220; NISTER M, 1988, CANCER RES, V48, P3910; OZANNE B, 1980, J CELL PHYSIOL, V105, P163, DOI 10.1002/jcp.1041050118; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; Sambrooke J., 1989, MOL CLONING LAB MANU, pE3; SAMUELS V, 1989, AM J PATHOL, V134, P895; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SORVILLO JM, 1990, ONCOGENE, V5, P377; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; WONG DTW, 1988, CANCER RES, V48, P3130; YUNG W K A, 1989, Neurology, V39, P261	20	63	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1990	5	12					1839	1842						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET436	2284103				2022-12-17	WOS:A1990ET43600015
J	RAY, D; CULINE, S; TAVITIAN, A; MOREAUGACHELIN, F				RAY, D; CULINE, S; TAVITIAN, A; MOREAUGACHELIN, F			THE HUMAN HOMOLOG OF THE PUTATIVE PROTOONCOGENE SPI-1 - CHARACTERIZATION AND EXPRESSION IN TUMORS	ONCOGENE			English	Article											RAY, D (corresponding author), FAC MED LARIBOISIERE,INSERM,U248,10 AVE VERDUN,F-75010 PARIS,FRANCE.		Ray-Gallet, Dominique/A-9224-2019					BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; COLLINS SJ, 1987, BLOOD, V70, P1233; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DOMEN J, 1987, ONCOGENE RES, V1, P103; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LISCIA DS, 1989, ONCOGENE, V4, P1219; MATHIS DJ, 1981, NATURE, V290, P310, DOI 10.1038/290310a0; MEEKER TC, 1987, ONCOGENE RES, V1, P87; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOREAUGACHELIN F, 1989, IN PRESS LEUKEMIA; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NGUYEN VC, 1990, IN PRESS HUMAN GENET; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OLOFSSON B, 1988, ONCOGENE, V3, P231; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; REYNOLDS GA, 1984, CELL, V38, P275, DOI 10.1016/0092-8674(84)90549-X; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; SILVERSTEIN RL, 1987, J CLIN INVEST, V79, P867, DOI 10.1172/JCI112896; TELERMAN A, 1988, MOL CELL BIOL, V8, P1498, DOI 10.1128/MCB.8.4.1498; THEILLET C, 1989, ONCOGENE, V4, P915; VANTVEER LJ, 1984, MOL CELL BIOL, V4, P2532, DOI 10.1128/MCB.4.11.2532; ZHOU DJ, 1988, ONCOGENE, V2, P279	36	63	65	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1990	5	5					663	668						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	1693183				2022-12-17	WOS:A1990DG37400005
J	BROWETT, PJ; NORTON, JD				BROWETT, PJ; NORTON, JD			ANALYSIS OF RAS GENE-MUTATIONS AND METHYLATION STATE IN HUMAN LEUKEMIAS	ONCOGENE			English	Article									ROYAL FREE HOSP,SCH MED,DEPT HEMATOL,POND ST,LONDON NW3 2QG,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1986, TRENDS GENET, V2, P188, DOI 10.1016/0168-9525(86)90222-2; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLOOMFIELD CD, 1984, LEUKEMIAS, P163; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BROWETT PJ, 1988, LEUKEMIA RES, V12, P25, DOI 10.1016/S0145-2126(98)80005-2; BROWETT PJ, 1988, LEUKAEMIA, V3, P86; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CATOVSKY D, 1984, LEUKAEMIAS, P266; CHANDLER LA, 1986, CANCER RES, V46, P2944; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; EVA A, 1983, P NATL ACAD SCI-BIOL, V80, P4926, DOI 10.1073/pnas.80.16.4926; EVANS JPM, 1988, BRIT J HAEMATOL, V69, P41, DOI 10.1111/j.1365-2141.1988.tb07600.x; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIORUCCI G, 1988, BIOCHIM BIOPHYS ACTA, V950, P81, DOI 10.1016/0167-4781(88)90076-0; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; GALILI U, 1974, J IMMUNOL, V112, P1628; GREAVES MF, 1986, SCIENCE, V234, P697, DOI 10.1126/science.3535067; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; HIRAI H, 1987, NATURE, V327, P430, DOI 10.1038/327430a0; JANOSSY G, 1986, METHODS HAEMATOLOGY, V13, P97; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; LIU E, 1988, P NATL ACAD SCI USA, V85, P1952, DOI 10.1073/pnas.85.6.1952; LIU E, 1987, NATURE, V327, P430; LUZZATTO L, 1986, PROG HEMATOL, V14, P303; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NEEDLEMAN SW, 1986, BLOOD, V67, P753; NERI A, 1988, P NATL ACAD SCI USA, V85, P9268, DOI 10.1073/pnas.85.23.9268; NORTON JD, 1988, BLOOD, V71, P178; PADUA RA, 1988, LEUKEMIA, V2, P503; RAMSDEN M, 1985, EMBO J, V4, P1449, DOI 10.1002/j.1460-2075.1985.tb03801.x; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; RIGGS AD, 1983, ADV CANCER RES, V40, P1, DOI 10.1016/S0065-230X(08)60678-8; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; RODENHUIS S, 1986, BLOOD, V67, P1698; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SHEN WPV, 1987, ONCOGENE, V1, P157; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; SMITH HO, 1976, NUCLEIC ACIDS RES, V3, P2387, DOI 10.1093/nar/3.9.2387; TOKSOZ D, 1989, BRIT J HAEMATOL, V71, P1, DOI 10.1111/j.1365-2141.1989.tb06265.x; VEDEL M, 1983, NUCLEIC ACIDS RES, V11, P4335, DOI 10.1093/nar/11.13.4335; VERLAANDEVRIES M, 1986, GENE, V50, P313, DOI 10.1016/0378-1119(86)90335-5; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WODNARFILIPOWICZ A, 1987, ONCOGENE, V1, P457; WOOD WI, 1985, P NATL ACAD SCI USA, V82, P1585, DOI 10.1073/pnas.82.6.1585; YOSHIKAI Y, 1984, NATURE, V312, P521, DOI 10.1038/312521a0	59	63	64	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					1029	1036						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2668844				2022-12-17	WOS:A1989AJ29700013
J	MCMAHON, J; HOWE, KM; WATSON, RJ				MCMAHON, J; HOWE, KM; WATSON, RJ			THE INDUCTION OF FRIEND-ERYTHROLEUKEMIA DIFFERENTIATION IS MARKEDLY AFFECTED BY EXPRESSION OF A TRANSFECTED C-MYB CDNA	ONCOGENE			English	Article									ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND,DOMINION HOUSE,BARTHOLOMEW CLOSE,LONDON EC1A 7BE,ENGLAND	Cancer Research UK; University of London; Queen Mary University London								ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; BISHOP JM, 1985, MOL BIOL TUMOR VIR 4, P351; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; BRELVI ZS, 1987, J CELL PHYSIOL, V131, P43, DOI 10.1002/jcp.1041310108; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CASTLE S, 1985, BIOCHEM BIOPH RES CO, V132, P688, DOI 10.1016/0006-291X(85)91187-8; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CRAIG RW, 1984, CANCER RES, V44, P442; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUPREY SP, 1985, P NATL ACAD SCI USA, V78, P3600; FIBACH E, 1977, CANCER RES, V37, P440; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; HAYMAN MJ, 1986, VIROLOGY, V150, P270, DOI 10.1016/0042-6822(86)90287-4; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KERBEL RS, 1987, P NATL ACAD SCI USA, V84, P1236; KIRSCH IR, 1986, J CELL BIOCHEM, V32, P11, DOI 10.1002/jcb.240320103; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; MUSHINSKI JF, 1983, SCIENCE, V220, P795, DOI 10.1126/science.6687762; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; REUBEN RC, 1976, P NATL ACAD SCI USA, V73, P862, DOI 10.1073/pnas.73.3.862; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SPANDIDOS DA, 1982, EMBO J, V1, P15, DOI 10.1002/j.1460-2075.1982.tb01117.x; TSIFTSOGLOU AS, 1985, ANTICANCER RES, V5, P81; WATSON RJ, 1987, EMBO J, V6, P1643, DOI 10.1002/j.1460-2075.1987.tb02413.x; WATSON RJ, 1988, ONCOGENE, V2, P267; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WEIS JH, 1983, NATURE, V302, P72, DOI 10.1038/302072a0; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WILKINSON D, 1988, J EXP MED, V167, P1442, DOI 10.1084/jem.167.4.1442	41	63	64	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1988	3	6					717	720						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R6460	2577875				2022-12-17	WOS:A1988R646000015
J	Sun, Z; Xue, SL; Zhang, MY; Xu, H; Hu, XM; Chen, SH; Liu, YY; Guo, MZ; Cui, HM				Sun, Zhen; Xue, Songlei; Zhang, Meiying; Xu, Hui; Hu, Xuming; Chen, Shihao; Liu, Yangyang; Guo, Mingzhou; Cui, Hengmi			Aberrant NSUN2-mediated m(5)C modification of H19 lncRNA is associated with poor differentiation of hepatocellular carcinoma	ONCOGENE			English	Article							METHYLTRANSFERASE MISU NSUN2; NONCODING RNA; CELL-PROLIFERATION; CANCER METASTASIS; EXPRESSION; METHYLATION; PROTEIN; 5-METHYLCYTOSINE; OVEREXPRESSION; BINDING	RNA methylation is an important epigenetic modification. Recent studies on RNA methylation mainly focus on the m(6)A modification of mRNA, but very little is known about the m(5)C modification. NSUN2 is an RNA methyltransferase responsible for the m(5)C modification of multiple RNAs. In this study, we knocked down the NSUN2 gene in HepG2 cells by CRISPR/Cas9 technology and performed high-throughput RNA-BisSeq. An important tumor-related lncRNA H19 was identified to be targeted by NSUN2. Studies have shown that the expression ofH19lncRNA is abnormally elevated and has a carcinogenic effect in many types of tumors. Our results demonstrated that m(5)C modification ofH19lncRNA can increase its stability. Interestingly, m(5)C-modifiedH19lncRNA can be specifically bound by G3BP1, a well-known oncoprotein which further leads to MYC accumulation. This may be a novel mechanism by which lncRNA H19 exerts its oncogenic effect. Besides, both the m(5)C methylation level and the expression level ofH19lncRNA in hepatocellular carcinoma tissues were significantly higher than those in adjacent non-cancer tissues, which were closely associated with poor differentiation of hepatocellular carcinoma (HCC). In conclusion, we found thatH19RNA is a specific target for the NSUN2 modifier. The m(5)C-modifiedH19lncRNA may promote the occurrence and development of tumors by recruiting the G3BP1 oncoprotein. Our findings may provide a potential target and biomarker for the diagnosis and treatment of HCC.	[Sun, Zhen; Xue, Songlei; Xu, Hui; Hu, Xuming; Chen, Shihao; Liu, Yangyang; Cui, Hengmi] Yangzhou Univ, Inst Epigenet & Epigen, 48 East Wenhui Rd, Yangzhou 225009, Jiangsu, Peoples R China; [Sun, Zhen; Xue, Songlei; Xu, Hui; Hu, Xuming; Chen, Shihao; Liu, Yangyang; Cui, Hengmi] Yangzhou Univ, Coll Anim Sci & Technol, 48 East Wenhui Rd, Yangzhou 225009, Jiangsu, Peoples R China; [Zhang, Meiying; Guo, Mingzhou] Gen Hosp Peoples Liberat Army PLAGH, Beijing, Peoples R China; [Cui, Hengmi] Yangzhou Univ, Minist Educ China, Joint Int Res Lab Agr & Agriprod Safety, Yangzhou 225009, Jiangsu, Peoples R China; [Cui, Hengmi] Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou 225009, Jiangsu, Peoples R China; [Cui, Hengmi] Yangzhou Univ, Inst Comparat Med, Yangzhou 225009, Jiangsu, Peoples R China; [Cui, Hengmi] Yangzhou Univ, Minist Educ, Key Lab Avian Prevent Med, Yangzhou 225009, Jiangsu, Peoples R China	Yangzhou University; Yangzhou University; Ministry of Education, China; Yangzhou University; Yangzhou University; Yangzhou University	Cui, HM (corresponding author), Yangzhou Univ, Inst Epigenet & Epigen, 48 East Wenhui Rd, Yangzhou 225009, Jiangsu, Peoples R China.; Cui, HM (corresponding author), Yangzhou Univ, Coll Anim Sci & Technol, 48 East Wenhui Rd, Yangzhou 225009, Jiangsu, Peoples R China.; Guo, MZ (corresponding author), Gen Hosp Peoples Liberat Army PLAGH, Beijing, Peoples R China.; Cui, HM (corresponding author), Yangzhou Univ, Minist Educ China, Joint Int Res Lab Agr & Agriprod Safety, Yangzhou 225009, Jiangsu, Peoples R China.; Cui, HM (corresponding author), Jiangsu Coinnovat Ctr Prevent & Control Important, Yangzhou 225009, Jiangsu, Peoples R China.; Cui, HM (corresponding author), Yangzhou Univ, Inst Comparat Med, Yangzhou 225009, Jiangsu, Peoples R China.; Cui, HM (corresponding author), Yangzhou Univ, Minist Educ, Key Lab Avian Prevent Med, Yangzhou 225009, Jiangsu, Peoples R China.	mzguo@hotmail.com; hmcui@yzu.edu.cn		Sun, Zhen/0000-0003-0144-3594	National Key Research and Development Program in China [2016YFC1303604, 2018YFA0208902]; National Natural Science Foundation of China [81773013, 91540117, U1604281]; Priority Academic Program Development of Jiangsu Higher Education Institutions (Animal Science and Veterinary Medicine)	National Key Research and Development Program in China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (Animal Science and Veterinary Medicine)	This research was supported by the the National Key Research and Development Program in China (grant nos. 2016YFC1303604 and 2018YFA0208902), the National Natural Science Foundation of China (grant nos. 81773013, 91540117, and U1604281) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (Animal Science and Veterinary Medicine).	Amort T, 2013, RNA BIOL, V10, P1003, DOI 10.4161/rna.24454; Barnes CJ, 2002, CANCER RES, V62, P1251; Barsyte-Lovejoy D, 2006, CANCER RES, V66, P5330, DOI 10.1158/0008-5472.CAN-06-0037; Bian ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep23892; Chen X, 2019, NAT CELL BIOL, V21, P978, DOI 10.1038/s41556-019-0361-y; Choe J, 2018, NATURE, V561, P556, DOI 10.1038/s41586-018-0538-8; Chu C, 2012, JOVE-J VIS EXP, DOI 10.3791/3912; Ding K, 2018, BIOCHEM BIOPH RES CO, V502, P194, DOI 10.1016/j.bbrc.2018.05.143; Dou N, 2016, AM J CANCER RES, V6, P2641; Edupuganti RR, 2017, NAT STRUCT MOL BIOL, V24, P870, DOI 10.1038/nsmb.3462; Frye M, 2006, CURR BIOL, V16, P971, DOI 10.1016/j.cub.2006.04.027; Han D, 2016, ONCOTARGET, V7, P22159, DOI 10.18632/oncotarget.8063; Huang T, 2019, NAT STRUCT MOL BIOL, V26, P380, DOI 10.1038/s41594-019-0218-x; Hussain S, 2013, CELL REP, V4, P255, DOI 10.1016/j.celrep.2013.06.029; Hussain S, 2009, J CELL BIOL, V186, P27, DOI 10.1083/jcb.200810180; Li Q, 2017, J CELL BIOCHEM, V118, P2587, DOI 10.1002/jcb.25957; Li SP, 2016, ONCOTARGET, V7, P42431, DOI 10.18632/oncotarget.9883; Li Y, 2018, CANCER LETT, V430, P57, DOI 10.1016/j.canlet.2018.05.013; Lin SB, 2016, MOL CELL, V62, P335, DOI 10.1016/j.molcel.2016.03.021; Liu YY, 2017, J BIOL CHEM, V292, P5624, DOI 10.1074/jbc.M116.769034; Lottin S, 2002, CARCINOGENESIS, V23, P1885, DOI 10.1093/carcin/23.11.1885; Luo M, 2013, CANCER LETT, V333, P213, DOI 10.1016/j.canlet.2013.01.033; Ma CC, 2014, TUMOR BIOL, V35, P9163, DOI 10.1007/s13277-014-2185-5; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Okamoto M, 2012, DNA CELL BIOL, V31, P660, DOI 10.1089/dna.2011.1446; Parker F, 1996, MOL CELL BIOL, V16, P2561; Shi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086295; Shinoda S, 2019, NUCLEIC ACIDS RES, V47, P8734, DOI 10.1093/nar/gkz575; Squires JE, 2012, NUCLEIC ACIDS RES, V40, P5023, DOI 10.1093/nar/gks144; Sun Z, 2019, EPIGENOMICS-UK, V11, P439, DOI 10.2217/epi-2018-0169; Taketo K, 2018, INT J ONCOL, V52, P621, DOI 10.3892/ijo.2017.4219; Tenenbaum SA, 2002, METHODS, V26, P191, DOI 10.1016/S1046-2023(02)00022-1; Tourriere H, 2001, MOL CELL BIOL, V21, P7747, DOI 10.1128/MCB.21.22.7747-7760.2001; Tsang WP, 2010, CARCINOGENESIS, V31, P350, DOI 10.1093/carcin/bgp181; Tuorto F, 2012, NAT STRUCT MOL BIOL, V19, P900, DOI 10.1038/nsmb.2357; Wang XL, 2017, ONCOTARGET, V8, P98918, DOI 10.18632/oncotarget.22041; Wang Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0504-2; Winslow S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-156; Xing JY, 2015, MOL CELL BIOL, V35, P4043, DOI 10.1128/MCB.00742-15; Yang X, 2017, CELL RES, V27, P606, DOI 10.1038/cr.2017.55; Yang YW, 2014, ELIFE, V3, DOI 10.7554/eLife.02046; Yi J, 2017, ONCOTARGET, V8, P20751, DOI 10.18632/oncotarget.10612; Zhang EB, 2016, TUMOR BIOL, V37, P5653, DOI 10.1007/s13277-015-4347-5; Zhang LN, 2019, J CELL PHYSIOL, V234, P20469, DOI 10.1002/jcp.28648; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhang XT, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1692; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40; Zhao XG, 2018, CANCER BIOMARK, V21, P859, DOI 10.3233/CBM-170791; Zhu L, 2013, BIOCHEM BIOPH RES CO, V432, P612, DOI 10.1016/j.bbrc.2013.02.036; Zhuang M, 2014, BIOCHEM BIOPH RES CO, V448, P315, DOI 10.1016/j.bbrc.2013.12.126	50	62	66	3	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2020	39	45					6906	6919		10.1038/s41388-020-01475-w	http://dx.doi.org/10.1038/s41388-020-01475-w		SEP 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ON7IM	32978516	Green Published, hybrid			2022-12-17	WOS:000572714000008
J	Filippou, PS; Karagiannis, GS; Constantinidou, A				Filippou, Panagiota S.; Karagiannis, George S.; Constantinidou, Anastasia			Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; EMBRYONAL CARCINOMA-CELLS; ANGIOGENIC FACTOR MIDKINE; ACID-RESPONSIVE GENE; WILMS-TUMOR; HEPATOCELLULAR-CARCINOMA; CLINICAL-SIGNIFICANCE; BIOLOGICAL-ACTIVITIES; MIDGESTATION PERIOD; ALTERED EXPRESSION	Midkine is a heparin-binding growth factor, originally reported as the product of a retinoic acid-responsive gene during embryogenesis, but currently viewed as a multifaceted factor contributing to both normal tissue homeostasis and disease development. Midkine is abnormally expressed at high levels in various human malignancies and acts as a mediator for the acquisition of critical hallmarks of cancer, including cell growth, survival, metastasis, migration, and angiogenesis. Several studies have investigated the role of midkine as a cancer biomarker for the detection, prognosis, and management of cancer, as well as for monitoring the response to cancer treatment. Moreover, several efforts are also being made to elucidate its underlying mechanisms in therapeutic resistance and immunomodulation within the tumor microenvironment. We hereby summarize the current knowledge on midkine expression and function in cancer development and progression, and highlight its promising potential as a cancer biomarker and as a future therapeutic target in personalized cancer medicine.	[Filippou, Panagiota S.] Teesside Univ, Sch Hlth & Life Sci, Middlesbrough TS1 3BX, Cleveland, England; [Filippou, Panagiota S.] Teesside Univ, Natl Horizons Ctr, 38 John Dixon Ln, Darlington DL1 1HG, Durham, England; [Karagiannis, George S.] Albert Einstein Coll Med, Dept Anat & Struct Biol, Bronx, NY 10467 USA; [Karagiannis, George S.] Albert Einstein Coll Med, Integrated Imaging Program, Bronx, NY 10467 USA; [Karagiannis, George S.] Albert Einstein Coll Med, Gruss Lipper Biophoton Ctr, Bronx, NY 10467 USA; [Constantinidou, Anastasia] Univ Cyprus, Med Sch, Nicosia, Cyprus; [Constantinidou, Anastasia] Bank Cyprus Oncol Ctr, Nicosia, Cyprus; [Constantinidou, Anastasia] Cyprus Canc Res Inst, Nicosia, Cyprus	University of Teesside; University of Teesside; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Cyprus	Filippou, PS (corresponding author), Teesside Univ, Sch Hlth & Life Sci, Middlesbrough TS1 3BX, Cleveland, England.; Filippou, PS (corresponding author), Teesside Univ, Natl Horizons Ctr, 38 John Dixon Ln, Darlington DL1 1HG, Durham, England.	P.Philippou@tees.ac.uk	Filippou, Panagiota S./ABF-1969-2021	CONSTANTINIDOU, ANASTASIA/0000-0001-5316-7574; Filippou, Panagiota/0000-0003-3974-988X				Adachi Y, 1996, ONCOGENE, V13, P2197; [Anonymous], 2013, ISRN ONCOL; ARIDOME K, 1995, JPN J CANCER RES, V86, P655, DOI 10.1111/j.1349-7006.1995.tb02449.x; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Cheng Yen-Po, 2014, Surg Neurol Int, V5, P78, DOI 10.4103/2152-7806.133205; Choudhuri R, 1997, CANCER RES, V57, P1814; Cohen S, 2014, BRIT J PHARMACOL, V171, P888, DOI 10.1111/bph.12419; Cohen S, 2012, J IMMUNOL, V188, P259, DOI 10.4049/jimmunol.1101468; Couch G, 2016, CANCER PREV RES, V9, P558, DOI 10.1158/1940-6207.CAPR-15-0379; Dai LC, 2007, WORLD J GASTROENTERO, V13, P1208, DOI 10.3748/wjg.v13.i8.1208; Van DV, 2016, ONCOL LETT, V12, P3143, DOI 10.3892/ol.2016.5040; Erdogan S, 2017, AM J MED SCI, V354, P299, DOI 10.1016/j.amjms.2017.04.019; Erguven M, 2011, CANCER CELL INT, V11, DOI 10.1186/1475-2867-11-18; FABRI L, 1993, J CHROMATOGR, V646, P213, DOI 10.1016/S0021-9673(99)87023-X; Fernandez-Calle R, 2018, NEUROSCI LETT, V662, P213, DOI 10.1016/j.neulet.2017.10.038; Filippou PS, 2017, BIOCHEM J, V474, P2417, DOI 10.1042/BCJ20170174; Filippou PS, 2016, CRIT REV CL LAB SCI, V53, P277, DOI 10.3109/10408363.2016.1154643; Fischer V, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072070; GARVER RI, 1994, CANCER, V74, P1584, DOI 10.1002/1097-0142(19940901)74:5<1584::AID-CNCR2820740514>3.0.CO;2-V; GARVER RI, 1993, AM J RESP CELL MOL, V9, P463, DOI 10.1165/ajrcmb/9.5.463; Gela A, 2014, BRIT J PHARMACOL, V171, P859, DOI 10.1111/bph.12402; Geng XC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186847; Grupp K, 2018, EXP MOL PATHOL, V104, P109, DOI 10.1016/j.yexmp.2018.01.005; Gungor C, 2014, BRIT J PHARMACOL, V171, P849, DOI 10.1111/bph.12401; Gungor C, 2011, CANCER RES, V71, P5009, DOI 10.1158/0008-5472.CAN-11-0036; Gustavsson H, 2008, PROSTATE, V68, P161, DOI 10.1002/pros.20672; Haddada M, 2018, BIOL CHEM, V399, P1099, DOI 10.1515/hsz-2017-0339; Haffner-Luntzer M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116282; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao HF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071093; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Hovanessian AG, 2006, CELL RES, V16, P174, DOI 10.1038/sj.cr.7310024; Hu RH, 2010, INT J HEMATOL, V92, P105, DOI 10.1007/s12185-010-0613-x; Huang Y, 2008, CELL CYCLE, V7, P1613, DOI 10.4161/cc.7.11.5952; Ibusuki M, 2009, CANCER SCI, V100, P1735, DOI 10.1111/j.1349-7006.2009.01233.x; Ikematsu S, 2000, BRIT J CANCER, V83, P701, DOI 10.1054/bjoc.2000.1339; Ikematsu S, 2003, BIOCHEM BIOPH RES CO, V306, P329, DOI 10.1016/S0006-291X(03)00984-7; Ikematsu S, 2008, CANCER SCI, V99, P2070, DOI 10.1111/j.1349-7006.2008.00957.x; Inazumi T, 1997, ARCH DERMATOL RES, V289, P471, DOI 10.1007/s004030050223; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jia HL, 2007, CLIN CANCER RES, V13, P1133, DOI 10.1158/1078-0432.CCR-06-1025; Jin Z, 2008, CLIN CANCER RES, V14, P5033, DOI 10.1158/1078-0432.CCR-08-0092; Jing X, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180511; Jones DR, 2014, BRIT J PHARMACOL, V171, P2925, DOI 10.1111/bph.12601; Jono Hirofumi, 2010, Cancers (Basel), V2, P624, DOI 10.3390/cancers2020624; KADOMATSU K, 1990, J CELL BIOL, V110, P607, DOI 10.1083/jcb.110.3.607; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; Kadomatsu K, 2013, J BIOCHEM, V153, P511, DOI 10.1093/jb/mvt035; Kadomatsu KJ, 2004, CANCER LETT, V204, P127, DOI 10.1016/S0304-3835(03)00450-6; Kaifi JT, 2007, J CANCER RES CLIN, V133, P431, DOI 10.1007/s00432-006-0180-y; KANAME T, 1993, GENOMICS, V17, P514, DOI 10.1006/geno.1993.1359; Kang HC, 2004, CLIN CANCER RES, V10, P272, DOI 10.1158/1078-0432.CCR-1025-3; Kaplan F, 2003, AM J RESP CELL MOL, V28, P33, DOI 10.1165/rcmb.2002-0047OC; Karaman S, 2017, DEV CELL, V42, P205, DOI 10.1016/j.devcel.2017.07.015; Kato M, 2000, ARCH PATHOL LAB MED, V124, P848; Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371; Kawai H, 2004, AM J PATHOL, V165, P1603, DOI 10.1016/S0002-9440(10)63417-7; Kerzerho J, 2013, J BIOL CHEM, V288, P13370, DOI 10.1074/jbc.M112.427302; Kerzerho J, 2010, J IMMUNOL, V185, P418, DOI 10.4049/jimmunol.0901014; Kishida S, 2014, BRIT J PHARMACOL, V171, P896, DOI 10.1111/bph.12442; Kohno S, 2004, ONCOL REP, V12, P73; Konishi N, 1999, ONCOLOGY-BASEL, V57, P253, DOI 10.1159/000012039; Kurosawa N, 2001, GLYCOCONJUGATE J, V18, P499, DOI 10.1023/A:1016042303253; Lautz T, 2018, EBIOMEDICINE, V27, P237, DOI 10.1016/j.ebiom.2017.11.020; Lee SH, 2012, J CELL PHYSIOL, V227, P1731, DOI 10.1002/jcp.22897; Liedert A, 2011, BONE, V48, P945, DOI 10.1016/j.bone.2010.12.019; Lorente M, 2011, CELL DEATH DIFFER, V18, P959, DOI 10.1038/cdd.2010.170; Lorente M, 2011, AUTOPHAGY, V7, P1071, DOI 10.4161/auto.7.9.15866; Lu YL, 2018, INT J MOL MED, V41, P2003, DOI 10.3892/ijmm.2018.3399; Ma JY, 2014, J CLIN NEUROSCI, V21, P1885, DOI 10.1016/j.jocn.2014.02.020; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; Maeda S, 2007, BRIT J CANCER, V97, P405, DOI 10.1038/sj.bjc.6603879; Mashour GA, 2001, ONCOGENE, V20, P97, DOI 10.1038/sj.onc.1204026; MATSUBARA S, 1990, J BIOL CHEM, V265, P9441; Matsuda Y, 1996, BIOCHEM BIOPH RES CO, V228, P176, DOI 10.1006/bbrc.1996.1635; Maza S, 2018, BIOORGAN MED CHEM, V26, P1076, DOI 10.1016/j.bmc.2018.01.022; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Mirkin BL, 2005, ONCOGENE, V24, P4965, DOI 10.1038/sj.onc.1208671; Mishima K, 1997, NEUROSCI LETT, V233, P29, DOI 10.1016/S0304-3940(97)00619-8; Mitchell MS, 2007, CANCER IMMUNOL IMMUN, V56, P287, DOI 10.1007/s00262-006-0191-1; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; Miyashiro I, 1997, BREAST CANCER RES TR, V43, P1, DOI 10.1023/A:1005748728351; Miyauchi M, 1999, JPN J CANCER RES, V90, P469, DOI 10.1111/j.1349-7006.1999.tb00771.x; Muramaki M, 2003, CLIN CANCER RES, V9, P5152; MURAMATSU H, 1991, BIOCHEM BIOPH RES CO, V177, P652, DOI 10.1016/0006-291X(91)91838-4; Muramatsu H, 2004, J CELL SCI, V117, P5405, DOI 10.1242/jcs.01423; MURAMATSU H, 1993, DEV BIOL, V159, P392, DOI 10.1006/dbio.1993.1250; Muramatsu H, 2000, BIOCHEM BIOPH RES CO, V270, P936, DOI 10.1006/bbrc.2000.2549; Muramatsu H, 1996, J BIOCHEM-TOKYO, V119, P1171; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; Muramatsu T, 2014, BRIT J PHARMACOL, V171, P814, DOI 10.1111/bph.12353; Muramatsu T, 2014, BRIT J PHARMACOL, V171, P811, DOI 10.1111/bph.12571; Muramatsu T, 2011, CURR PHARM DESIGN, V17, P410, DOI 10.2174/138161211795164167; Muramatsu T, 2010, P JPN ACAD B-PHYS, V86, P410, DOI 10.2183/pjab.86.410; Murasugi A, 2003, PROTEIN EXPRES PURIF, V27, P244, DOI 10.1016/S1046-5928(02)00587-9; Music M, 2018, CRIT REV CL LAB SCI, V55, P466, DOI 10.1080/10408363.2018.1499706; Nakamura E, 1998, GENES CELLS, V3, P811, DOI 10.1046/j.1365-2443.1998.00231.x; Nordin SL, 2013, AM J RESP CELL MOL, V49, P935, DOI 10.1165/rcmb.2013-0106OC; NOVOTNY WF, 1993, ARTERIOSCLER THROMB, V13, P1798, DOI 10.1161/01.ATV.13.12.1798; OBrien T, 1996, CANCER RES, V56, P2515; Ohgake S, 2009, PROG NEURO-PSYCHOPH, V33, P541, DOI 10.1016/j.pnpbp.2009.02.005; Ohhashi S, 2009, DIGEST DIS SCI, V54, P811, DOI 10.1007/s10620-008-0434-4; Ohuchida T, 2004, CANCER-AM CANCER SOC, V100, P2430, DOI 10.1002/cncr.20266; Olive KP, 2015, CLIN CANCER RES, V21, P3366, DOI 10.1158/1078-0432.CCR-15-0416; Olmeda D, 2017, NATURE, V546, P676, DOI 10.1038/nature22977; Ota T, 2012, ONCOL REP, V27, P1674, DOI 10.3892/or.2012.1684; Owada K, 1999, J Med Dent Sci, V46, P45; Paley PJ, 2001, CURR OPIN ONCOL, V13, P399, DOI 10.1097/00001622-200109000-00015; Papageorgis P, 2015, J ONCOL, V2015, DOI 10.1155/2015/587193; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Paul S, 2001, CANCER LETT, V163, P245, DOI 10.1016/S0304-3835(00)00696-0; PEDRAZA C, 1995, J BIOCHEM-TOKYO, V117, P845; Poon RTP, 2002, ANN SURG, V235, P373, DOI 10.1097/00000658-200203000-00009; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; Qi MS, 2000, J BIOCHEM, V127, P269, DOI 10.1093/oxfordjournals.jbchem.a022604; Raave R, 2018, J CONTROL RELEASE, V274, P1, DOI 10.1016/j.jconrel.2018.01.029; Rakha EA, 2010, BREAST CANCER RES TR, V120, P293, DOI 10.1007/s10549-010-0746-x; Rawnaq T, 2014, MOL CANCER RES, V12, P670, DOI 10.1158/1541-7786.MCR-13-0467; Rebbaa A, 2001, MOL MED, V7, P393, DOI 10.1007/BF03402185; Ren YJ, 2006, WORLD J GASTROENTERO, V12, P2006, DOI 10.3748/wjg.v12.i13.2006; Reynolds PR, 2004, J BIOL CHEM, V279, P37124, DOI 10.1074/jbc.M405254200; Rice GE, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-62; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Sandra F, 2004, ORAL ONCOL, V40, P274, DOI 10.1016/j.oraloncology.2003.08.011; Shimada H, 2003, CANCER SCI, V94, P628, DOI 10.1111/j.1349-7006.2003.tb01494.x; Shimwell NJ, 2013, BRIT J CANCER, V108, P1854, DOI 10.1038/bjc.2013.157; Soukup V, 2015, UROL INT, V95, P56, DOI 10.1159/000368166; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Sueyoshi T, 2012, CANCER LETT, V316, P23, DOI 10.1016/j.canlet.2011.10.013; Takei Y, 2002, J BIOL CHEM, V277, P23800, DOI 10.1074/jbc.M112100200; Tang SL, 2015, INT J CLIN EXP MED, V8, P12644; Tao P, 2007, CANCER LETT, V253, P60, DOI 10.1016/j.canlet.2007.01.019; Tazzyman S, 2009, INT J EXP PATHOL, V90, P222, DOI 10.1111/j.1365-2613.2009.00641.x; Tian WY, 2017, ONCOL REP, V38, P745, DOI 10.3892/or.2017.5743; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Torres A, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5556-x; Toyoda E, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-30; TSUTSUI J, 1993, CANCER RES, V53, P1281; Vongsuvanh R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155800; Wang QL, 2007, J BIOMED SCI, V14, P783, DOI 10.1007/s11373-007-9192-0; Weckbach LT, 2014, BLOOD, V123, P1887, DOI 10.1182/blood-2013-06-510875; Weckbach LT, 2012, AM J PHYSIOL-HEART C, V303, pH429, DOI 10.1152/ajpheart.00934.2011; Weckbach LT, 2011, THESCIENTIFICWORLDJO, V11, P2491, DOI 10.1100/2011/517152; Wu XQ, 2015, AM J CANCER RES, V5, P629; Xia X, 2016, ONCOTARGET, V7, P87462, DOI 10.18632/oncotarget.13865; Xu YY, 2012, TUMOR BIOL, V33, P1543, DOI 10.1007/s13277-012-0406-3; Ye C, 1999, BRIT J CANCER, V79, P179, DOI 10.1038/sj.bjc.6690030; Yin Zhengfeng, 2002, Zhonghua Zhongliu Zazhi, V24, P27; Yu L, 2004, EUR J CANCER, V40, P1787, DOI 10.1016/j.ejca.2004.04.014; Yu YJ, 2015, J BIOL CHEM, V290, P17762, DOI 10.1074/jbc.M115.643551; Yuan KH, 2015, ARCH MED RES, V46, P635, DOI 10.1016/j.arcmed.2015.11.006; Zhang DY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13431-y; Zhang Luo, 2018, Oncotarget, V9, P24821, DOI 10.18632/oncotarget.23892; Zhao GF, 2012, MOL ENDOCRINOL, V26, P1304, DOI 10.1210/me.2012-1028; Zhao JJ, 2017, CELL PHYSIOL BIOCHEM, V43, P589, DOI 10.1159/000480531; Zheng W, 2014, J CLIN INVEST, V124, P878, DOI 10.1172/JCI71603; Zou P, 2006, LAB INVEST, V86, P645, DOI 10.1038/labinvest.3700428	157	62	63	4	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	10					2040	2054		10.1038/s41388-019-1124-8	http://dx.doi.org/10.1038/s41388-019-1124-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KS8UR	31801970	Green Submitted, Bronze			2022-12-17	WOS:000518584000002
J	Rossi, F; Legnini, I; Megiorni, F; Colantoni, A; Santini, T; Morlando, M; Di Timoteo, G; Dattilo, D; Dominici, C; Bozzoni, I				Rossi, Francesca; Legnini, Ivano; Megiorni, Francesca; Colantoni, Alessio; Santini, Tiziana; Morlando, Mariangela; Di Timoteo, Gaia; Dattilo, Dario; Dominici, Carlo; Bozzoni, Irene			Circ-ZNF609 regulates G1-S progression in rhabdomyosarcoma	ONCOGENE			English	Article							E2F TARGET GENES; CIRCULAR RNAS; CELL-PROLIFERATION; PROMOTES; PATHWAY; IDENTIFICATION; TRANSLATION; MECHANISMS; EXPRESSION; CIRCRNAS	Circular RNAs (circRNAs) represent a class of covalently closed RNAs, derived from non-canonical splicing events, which are expressed in all eukaryotes and often conserved among different species. We previously showed that the circRNA originating from the ZNF609 locus (circ-ZNF609) acts as a crucial regulator of human primary myoblast growth: indeed, the downregulation of the circRNA, and not of its linear counterpart, strongly reduced the proliferation rate of in vitro cultured myoblasts. To deepen our knowledge about circ-ZNF609 role in cell cycle regulation, we studied its expression and function in rhabdomyosarcoma (RMS), a pediatric skeletal muscle malignancy. We found that circ-ZNF609 is upregulated in biopsies from the two major RMS subtypes, embryonal (ERMS) and alveolar (ARMS). Moreover, we discovered that in an ERMS-derived cell line circ-ZNF609 knock-down induced a specific block at the G1-S transition, a strong decrease of p-Akt protein level and an alteration of the pRb/Rb ratio. Regarding p-Akt, we were able to show that circ-ZNF609 acts by counteracting p-Akt proteasome-dependent degradation, thus working as a new regulator of cell proliferation-related pathways. As opposed to ERMS-derived cells, the circRNA depletion had no cell cycle effects in ARMS-derived cells. Since in these cells the p53 gene resulted downregulated, with a concomitant upregulation of its cell cycle-related target genes, we suggest that this could account for the lack of circ-ZNF609 effect in ARMS.	[Rossi, Francesca; Legnini, Ivano; Colantoni, Alessio; Morlando, Mariangela; Di Timoteo, Gaia; Dattilo, Dario; Bozzoni, Irene] Sapienza Univ Rome, Dept Biol & Biotechnol Charles Darwin, Rome, Italy; [Megiorni, Francesca; Dominici, Carlo] Sapienza Univ Rome, Dept Pediat, Rome, Italy; [Santini, Tiziana; Bozzoni, Irene] Ist Italiano Tecnol, Ctr Life Nano Sci Sapienza, Rome, Italy	Sapienza University Rome; Sapienza University Rome; Istituto Italiano di Tecnologia - IIT	Bozzoni, I (corresponding author), Sapienza Univ Rome, Dept Biol & Biotechnol Charles Darwin, Rome, Italy.; Bozzoni, I (corresponding author), Ist Italiano Tecnol, Ctr Life Nano Sci Sapienza, Rome, Italy.	irene.bozzoni@uniroma1.it	Megiorni, Francesca/AAC-1597-2019; di timoteo, gaia/AAD-1952-2021	Megiorni, Francesca/0000-0003-3705-3248; Legnini, Ivano/0000-0002-8984-5215; COLANTONI, ALESSIO/0000-0001-7402-0176; Di TIMOTEO, Gaia/0000-0003-4516-9945; Dattilo, Dario/0000-0003-2774-3835; Morlando, Mariangela/0000-0002-8327-4423; bozzoni, irene/0000-0002-3485-8537; Rossi, Francesca/0000-0001-7327-6364	ERC-2013 [AdG 340172-MUNCODD]; Telethon [GGP16213]; Human Frontiers Science Program Award [RGP0009/2014]; Parent Project Italia; AFM-Telethon [17835]; Epigen-Epigenomics Flagship Project; EU-H2020 Marie Sklodowska-Curie Action (circRTrain) [721890]	ERC-2013; Telethon(Fondazione Telethon); Human Frontiers Science Program Award; Parent Project Italia; AFM-Telethon(Association Francaise contre les Myopathies); Epigen-Epigenomics Flagship Project; EU-H2020 Marie Sklodowska-Curie Action (circRTrain)	The authors acknowledge O. Sthandier and M. Marchioni for technical help, S. Camero and M. Guarnacci for experimental support, M. Caruso for anti-Rb and anti-phospho-Rb antibodies, B. Pizer and R. Shukla for biological samples. The Telethon Network Genetic Biobanks (GTB12001F) and EuroBioBank are acknowledged for biological samples. This work was partially supported by grants from: ERC-2013 (AdG 340172-MUNCODD), Telethon (GGP16213), Human Frontiers Science Program Award RGP0009/2014, Parent Project Italia, AFM-Telethon (17835), Epigen-Epigenomics Flagship Project and EU-H2020 Marie Sklodowska-Curie Action (721890, circRTrain).	Abdelmohsen K, 2017, RNA BIOL, V14, P361, DOI 10.1080/15476286.2017.1279788; Ahmed I, 2016, ONCOTARGET, V7, P36366, DOI 10.18632/oncotarget.8917; Alvarez MJ, 2016, NAT GENET, V48, P838, DOI 10.1038/ng.3593; Besson A, 2006, GENE DEV, V20, P47, DOI 10.1101/gad.1384406; Bonizzato A, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.81; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Chen TD, 2012, J BIOL CHEM, V287, P37540, DOI 10.1074/jbc.M111.260679; CLEMENS MJ, 1985, BIOCHEM J, V226, P345, DOI 10.1042/bj2260345; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027; Egas-Bejar D, 2014, ADOLESC HEALTH MED T, V5, P115, DOI 10.2147/AHMT.S44582; Endo H, 2012, J BIOCHEM, V151, P139, DOI 10.1093/jb/mvr128; Fabregat A, 2018, NUCLEIC ACIDS RES, V46, pD649, DOI [10.1093/nar/gkx1132, 10.1093/nar/gkz1031]; FELIX CA, 1992, CANCER RES, V52, P2243; Feng GG, 2017, FEBS LETT, V591, P760, DOI 10.1002/1873-3468.12587; Galea GL, 2017, GENE, V599, P36, DOI 10.1016/j.gene.2016.11.006; Geistlinger L, 2011, BIOINFORMATICS, V27, pI366, DOI 10.1093/bioinformatics/btr228; Guarnerio J, 2016, CELL, V165, P289, DOI 10.1016/j.cell.2016.03.020; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; HERTZOG PJ, 1994, MOL REPROD DEV, V39, P226; Hinson ARP, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00183; Iwanaga R, 2006, ONCOGENE, V25, P1786, DOI 10.1038/sj.onc.1209210; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Krautkramer KA, 2013, AM J PHYSIOL-ENDOC M, V305, pE600, DOI 10.1152/ajpendo.00147.2013; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Legnini I, 2017, MOL CELL, V66, P22, DOI 10.1016/j.molcel.2017.02.017; Liu PJ, 2009, CELL CYCLE, V8, P125, DOI 10.4161/cc.8.1.7528; Megiorni F, 2016, ONCOTARGET, V7, P79328, DOI 10.18632/oncotarget.12688; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Mio C, 2016, ENDOCR-RELAT CANCER, V23, P335, DOI 10.1530/ERC-15-0322; Miyachi M, 2009, CLIN CANCER RES, V15, P4077, DOI 10.1158/1078-0432.CCR-08-2955; Mori K, 2016, CANCER SCI, V107, P963, DOI 10.1111/cas.12953; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Pamudurti NR, 2017, MOL CELL, V66, P9, DOI 10.1016/j.molcel.2017.02.021; Patop IL, 2018, CURR OPIN GENET DEV, V48, P121, DOI 10.1016/j.gde.2017.11.007; Peng L, 2017, ONCOTARGET, V8, P808, DOI 10.18632/oncotarget.13656; Piwecka M, 2017, SCIENCE, V357, DOI 10.1126/science.aam8526; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Qu K, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.352; Remoli ME, 2002, J IMMUNOL, V169, P366, DOI 10.4049/jimmunol.169.1.366; Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733; Sangfelt O, 2000, FRONT BIOSCI-LANDMRK, V5, pD479, DOI 10.2741/Sangfelt; Schaaf GJ, 2005, FASEB J, V19, P404, DOI 10.1096/fj.04-2104fje; Sun Xin, 2015, Sarcoma, V2015, P232010, DOI 10.1155/2015/232010; Tang CM, 2017, SCI REP-UK, V7, DOI 10.1038/srep40342; Taylor AC, 2000, MED PEDIATR ONCOL, V35, P96, DOI 10.1002/1096-911X(200008)35:2<96::AID-MPO2>3.0.CO;2-Z; Wang S, 2017, ONCOL REP, V38, P735, DOI 10.3892/or.2017.5769; Xia WJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep35576; Ying HN, 2018, ONCOTARGETS THER, V11, P689, DOI 10.2147/OTT.S152138; Zhang ML, 2018, ONCOGENE, V37, P1805, DOI 10.1038/s41388-017-0019-9; Zheng QP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11215	52	62	65	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2019	38	20					3843	3854		10.1038/s41388-019-0699-4	http://dx.doi.org/10.1038/s41388-019-0699-4			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HY3OI	30670781	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000468035600006
J	Pai, VC; Hsu, CC; Chan, TS; Liao, WY; Chuu, CP; Chen, WY; Li, CR; Lin, CY; Huang, SP; Chen, LT; Tsai, KK				Pai, Vincent C.; Hsu, Chung-Chi; Chan, Tze-Sian; Liao, Wen-Ying; Chuu, Chih-Pin; Chen, Wei-Yu; Li, Chi-Rong; Lin, Ching-Yu; Huang, Shu-Pin; Chen, Li-Tzong; Tsai, Kelvin K.			ASPM promotes prostate cancer stemness and progression by augmenting Wnt-Dvl-3-beta-catenin signaling	ONCOGENE			English	Article							PLANAR CELL POLARITY; TUMOR; MARKER; METASTASIS; EXPRESSION; PATHWAY; SOX9; IDENTIFICATION; ELEVATION; RECEPTOR	Recurrent and hormone-refractory prostate cancer (PCA) exhibits aggressive behaviors while current therapeutic approaches show little effect of prolonging the survival of patients with PCA. Thus, a deeper understanding of the patho-molecular mechanisms underlying the disease progression in PCA is crucial to identify novel diagnostic and/or therapeutic targets to improve the outcome of patients. Recent evidence suggests that activation of Wnt signaling in cancer stem cells (CSCs) contributes to cancer progression in malignant tumors. Here, we report that a novel Wnt co-activator ASPM (abnormal spindle-like microcephaly associated) maintains the prostate CSC subpopulation by augmenting the Wnt-beta-catenin signaling in PCA. ASPM expression is incrementally upregulated in primary and metastatic PCA, implicating its potential role in PCA progression. Consistently, downregulation of ASPM expression pronouncedly attenuated the proliferation, colony formation, and the invasive behavior of PCA cells, and dramatically reduced the number of ALDH(+) CSCs and inhibited cancer stemness and tumorigenicity. Mechanistically, ASPM interacts with disheveled-3 (Dvl-3), a cardinal upstream regulator of canonical Wnt signaling, and inhibits its proteasome-dependent degradation, thereby increasing its protein stability and enabling the Wnt-induced beta-catenin transcriptional activity in PCA cells. In keeping with the role of ASPM as a CSC-regulator, ASPM co-localizes with ALDH in PCA tissues and its expression exhibits high intra-tumoral heterogeneity. The proportion of high-ASPM-expressing cells in the tumor inversely correlates with the relapse-free survival of PCA patients. Collectively, our data points to ASPM as a novel oncoprotein and an essential regulator of Wnt signaling and cancer stemness in PCA, which has important clinical and therapeutic significance.	[Pai, Vincent C.; Hsu, Chung-Chi; Chan, Tze-Sian; Tsai, Kelvin K.] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei 11031, Taiwan; [Hsu, Chung-Chi; Chan, Tze-Sian; Tsai, Kelvin K.] Taipei Med Univ, Wan Fang Hosp, Dept Internal Med, Lab Adv Mol Therapeut,Div Gastroenterol, Taipei 11696, Taiwan; [Pai, Vincent C.; Liao, Wen-Ying; Chen, Li-Tzong; Tsai, Kelvin K.] Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan 35053, Miaoli County, Taiwan; [Chuu, Chih-Pin; Lin, Ching-Yu] Natl Hlth Res Inst, Inst Cellular & Syst Med, Zhunan 35053, Miaoli County, Taiwan; [Chen, Wei-Yu] Taipei Med Univ, Wan Fang Hosp, Dept Pathol, Taipei 11696, Taiwan; [Li, Chi-Rong] Minist Hlth & Welf, Dept Teaching & Res, Taichung Hosp, Taichung 40343, Taiwan; [Huang, Shu-Pin] Kaohsiung Med Univ, Dept Urol, Chung Ho Mem Hosp, Kaohsiung 80756, Taiwan	Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; Taipei Medical University; Taipei Municipal WanFang Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital	Tsai, KK (corresponding author), Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei 11031, Taiwan.; Tsai, KK (corresponding author), Taipei Med Univ, Wan Fang Hosp, Dept Internal Med, Lab Adv Mol Therapeut,Div Gastroenterol, Taipei 11696, Taiwan.; Tsai, KK (corresponding author), Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan 35053, Miaoli County, Taiwan.	tsaik@tmu.edu.tw	Lin, Ching Yu/AAN-9581-2020	Lin, Ching Yu/0000-0001-9041-5653; Tsai, Kelvin/0000-0002-1612-2868; Li, Chi-Rong/0000-0002-0314-8284	Ministry of Science and Technology [MOST 104-2314-B-400-022, MOST 105-2314-B-400-018, MOST 105-2314-B-400-003]; Taipei Medical University [DP2-107-21121-C-04]; Ministry of Health and Welfare grant [MOHW107-TDU-B-212-114020]; National Health Research Institutes intramural grant [CA-106-PP-09]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Taipei Medical University; Ministry of Health and Welfare grant; National Health Research Institutes intramural grant	Supported in part by Ministry of Science and Technology grants MOST 104-2314-B-400-022, MOST 105-2314-B-400-018 (KKT), MOST 105-2314-B-400-003 (L-TC), Taipei Medical University grant DP2-107-21121-C-04 (KKT), Ministry of Health and Welfare grant MOHW107-TDU-B-212-114020 (KKT) and National Health Research Institutes intramural grant CA-106-PP-09 (KKT).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Angers S, 2006, NAT CELL BIOL, V8, P348, DOI 10.1038/ncb1381; Arensman MD, 2014, ONCOGENE, V33, P899, DOI 10.1038/onc.2013.23; Bikeye SNN, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-1; Bill-Axelson A, 2005, NEW ENGL J MED, V352, P1977, DOI 10.1056/NEJMoa043739; Bisson I, 2009, CELL RES, V19, P683, DOI 10.1038/cr.2009.43; Bruning-Richardson A, 2011, BRIT J CANCER, V104, P1602, DOI 10.1038/bjc.2011.117; Buchman JJ, 2011, GENE DEV, V25, P1909, DOI 10.1101/gad.16830211; BUDWITNOVOTNY DA, 1986, CANCER RES, V46, P5419; Capecchi MR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9763; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Fish JL, 2006, P NATL ACAD SCI USA, V103, P10438, DOI 10.1073/pnas.0604066103; Gao C, 2010, CELL SIGNAL, V22, P717, DOI 10.1016/j.cellsig.2009.11.021; Gilligan T, 2002, UROLOGY, V60, P94, DOI 10.1016/S0090-4295(02)01583-2; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gray RS, 2011, DEV CELL, V21, P120, DOI 10.1016/j.devcel.2011.06.011; Hellerstedt BA, 2002, CA-CANCER J CLIN, V52, P154, DOI 10.3322/canjclin.52.3.154; Jiang K, 2017, NAT CELL BIOL, V19, P480, DOI 10.1038/ncb3511; Keller ET, 2001, CANCER METAST REV, V20, P333, DOI 10.1023/A:1015599831232; Kouprina N, 2005, HUM MOL GENET, V14, P2155, DOI 10.1093/hmg/ddi220; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li T, 2010, LAB INVEST, V90, P234, DOI 10.1038/labinvest.2009.127; Lin SY, 2008, CLIN CANCER RES, V14, P4814, DOI 10.1158/1078-0432.CCR-07-5262; Liu C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14270; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Ma F, 2016, J CLIN INVEST, V126, P1745, DOI 10.1172/JCI78815; Major MB, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.2000037; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Nandana S, 2017, CANCER RES, V77, P1331, DOI 10.1158/0008-5472.CAN-16-0497; Narimatsu M, 2009, CELL, V137, P295, DOI 10.1016/j.cell.2009.02.025; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Pound CR, 1999, JAMA-J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Richardson GD, 2004, J CELL SCI, V117, P3539, DOI 10.1242/jcs.01222; Schneider JA, 2018, MOL CELL ENDOCRINOL, V462, P3, DOI 10.1016/j.mce.2017.02.008; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Thomsen MK, 2010, CANCER RES, V70, P979, DOI 10.1158/0008-5472.CAN-09-2370; van den Hoogen C, 2010, CANCER RES, V70, P5163, DOI 10.1158/0008-5472.CAN-09-3806; van der Voet M, 2009, NAT CELL BIOL, V11, P269, DOI 10.1038/ncb1834; Vange P, 2015, J PATHOL, V237, P447, DOI 10.1002/path.4591; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wang HY, 2007, CANCER RES, V67, P528, DOI 10.1158/0008-5472.CAN-06-1672; Wang WY, 2013, GASTROENTEROLOGY, V145, P1110, DOI 10.1053/j.gastro.2013.07.040; Xie JJ, 2017, INT UROL NEPHROL, V49, P817, DOI 10.1007/s11255-017-1545-7; Yokoyama NN, 2014, AM J CLIN EXP UROL, V2, P27; YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	49	62	65	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2019	38	8					1340	1353		10.1038/s41388-018-0497-4	http://dx.doi.org/10.1038/s41388-018-0497-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HM1XR	30266990				2022-12-17	WOS:000459249800014
J	Liu, YY; Chen, MB; Cheng, L; Zhang, ZQ; Yu, ZQ; Jiang, Q; Chen, G; Cao, C				Liu, Yuan-yuan; Chen, Min-Bin; Cheng, Long; Zhang, Zhi-qing; Yu, Zheng-quan; Jiang, Qin; Chen, Gang; Cao, Cong			microRNA-200a downregulation in human glioma leads to G alpha i1 over-expression, Akt activation, and cell proliferation	ONCOGENE			English	Article							CANCER STATISTICS; TUMOR-SUPPRESSOR; COMPLEX; GENE; RESISTANCE; SURVIVAL; THERAPY; KINASE	We previously identified a pivotal role for G protein alpha inhibitory subunit 1 (G alpha i1) in mediating PI3K-Akt signaling by receptor tyrosine kinases (RTKs). Here, we examined the expression and biological function of G alpha i1 in human glioma. G alpha i1 mRNA and protein expression were significantly upregulated in human glioma tissues, which correlated with downregulation of an anti-G alpha i1 miRNA: microRNA-200a ("miR-200a"). Forced-expression of miR-200a in established (A172/U251MG lines) and primary (patient-derived) human glioma cells resulted in G alpha i1 downregulation, Akt inactivation and proliferation inhibition. Reduction of G alpha i1 expression by shRNA, dominant negative mutant interference, or complete G alpha i1 depletion inhibited Akt activation and cell proliferation. Notably, miR-200a was unable to inhibit glioma cell proliferation when G alpha i1 was silenced or mutated. Co-immunoprecipitation studies, in human glioma cells and tissues, show that G alpha i1 forms a complex with multiple RTKs (EGFR, PDGFR alpha, and FGFR) and the adapter protein Gab1. In vivo, the growth of subcutaneous and orthotopic glioma xenografts in nude mice was largely inhibited by expression of G alpha i1 shRNA or miRNA-200a. Collectively, miR-200a downregulation in human glioma leads to G alpha i1 over-expression, Akt activation and glioma cell proliferation.	[Liu, Yuan-yuan] Jiangsu Univ, Kunshan Peoples Hosp 1, Clin Res & Lab Ctr, Kunshan, Peoples R China; [Liu, Yuan-yuan; Cheng, Long; Zhang, Zhi-qing; Cao, Cong] Soochow Univ, Jiangsu Key Lab Neuropsychiat Dis, Suzhou, Peoples R China; [Liu, Yuan-yuan; Cheng, Long; Zhang, Zhi-qing; Cao, Cong] Soochow Univ, Inst Neurosci, Suzhou, Peoples R China; [Chen, Min-Bin] Jiangsu Univ, Kunshan Peoples Hosp 1, Dept Radiotherapy & Oncol, Kunshan, Peoples R China; [Cheng, Long] Soochow Univ, Affiliated Hosp 2, Dept Intervent Radiol, Suzhou, Peoples R China; [Yu, Zheng-quan; Chen, Gang] Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, Suzhou, Peoples R China; [Jiang, Qin; Cao, Cong] Nanjing Med Univ, Affiliated Eye Hosp, Nanjing, Jiangsu, Peoples R China; [Cao, Cong] Municipal Hosp Suzhou, Suzhou, Peoples R China	Jiangsu University; Soochow University - China; Soochow University - China; Jiangsu University; Soochow University - China; Soochow University - China; Nanjing Medical University	Cao, C (corresponding author), Soochow Univ, Jiangsu Key Lab Neuropsychiat Dis, Suzhou, Peoples R China.; Cao, C (corresponding author), Soochow Univ, Inst Neurosci, Suzhou, Peoples R China.; Chen, G (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, Suzhou, Peoples R China.; Jiang, Q; Cao, C (corresponding author), Nanjing Med Univ, Affiliated Eye Hosp, Nanjing, Jiangsu, Peoples R China.; Cao, C (corresponding author), Municipal Hosp Suzhou, Suzhou, Peoples R China.	Jqin710@vip.sina.com; nju_neurosurgery@163.com; caocong@suda.edu.cn	liu, yuanyuan/GWZ-5838-2022		National Natural Science Foundation of China [81771457, 81371055, 81570859, 81302195, 31371139, 81502162, 81571282, 81472786, 81773192]; Natural Science Foundation of Jiangsu Province [BK20130301, BK20170060, BK20171248]; Clinical Special Project of Suzhou [LCZX201601]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Clinical Special Project of Suzhou	This study was supported in part by grants from the National Natural Science Foundation of China (81502162, 81771457, 81371055, and 81570859, 81302195, 31371139 and 81502162, 81571282, 81472786, and 81773192); Grants from Natural Science Foundation of Jiangsu Province (BK20130301, BK20170060, and BK20171248), and by Clinical Special Project of Suzhou (LCZX201601). We thank Dr. John Marshall for English edits and proof-reading of the manuscript.	Agnihotri S, 2012, J CLIN INVEST, V122, P253, DOI 10.1172/JCI59334; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Andradas C, 2011, ONCOGENE, V30, P245, DOI 10.1038/onc.2010.402; Bostrom J, 1998, CANCER RES, V58, P29; Cai S, 2017, ONCOTARGET, V8, P35061, DOI 10.18632/oncotarget.17043; Cao C, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001478; Cao C, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000118; Du H, 2008, NAT MED, V14, P1097, DOI 10.1038/nm.1868; Faivre S, 2001, MOL PHARMACOL, V60, P363, DOI 10.1124/mol.60.2.363; Fan JB, 2016, ONCOTARGET, V7, P70613, DOI 10.18632/oncotarget.12138; FURMAN MA, 1977, J NEUROSURG, V46, P477, DOI 10.3171/jns.1977.46.4.0477; Gong YQ, 2016, ONCOTARGET, V7, P60123, DOI 10.18632/oncotarget.11164; He XL, 2014, NAT MED, V20, P1035, DOI 10.1038/nm.3666; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; Huang TT, 2009, NEUROTHERAPEUTICS, V6, P500, DOI 10.1016/j.nurt.2009.04.008; Khasraw M, 2009, NAT REV NEUROL, V5, P646, DOI 10.1038/nrneurol.2009.194; Lefranc F, 2009, ADV TECH STAND NEURO, V34, P3, DOI 10.1007/978-3-211-78741-0_1; Li KR, 2016, SCI REP-UK, V6, DOI 10.1038/srep25525; Li XJ, 2015, P NATL ACAD SCI USA, V112, P4731, DOI 10.1073/pnas.1503779112; Li XM, 2016, ONCOTARGET, V7, P33440, DOI [10.18632/oncotarget.7961, 10.18632/oncotarget.6497]; Li Z, 2016, ONCOTARGET; Liu M, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150092; Lo Hui-Wen, 2010, Curr Mol Pharmacol, V3, P37; Mabuchi S, 2007, CLIN CANCER RES, V13, P4261, DOI 10.1158/1078-0432.CCR-06-2770; Pollack IF, 2010, NAT REV NEUROL, V6, P533, DOI 10.1038/nrneurol.2010.144; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Shashidhar S, 2005, ONCOGENE, V24, P1673, DOI 10.1038/sj.onc.1208395; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Snuderl M, 2011, CANCER CELL, V20, P810, DOI 10.1016/j.ccr.2011.11.005; Stommel JM, 2007, SCIENCE, V318, P287, DOI 10.1126/science.1142946; Wang YZ, 2013, CANCER LETT, V331, P139, DOI 10.1016/j.canlet.2012.12.024; Wang ZW, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478-811X-12-10; Westphal M, 2011, NAT REV NEUROSCI, V12, P495, DOI 10.1038/nrn3060; Zhang D, 2016, TUMOR BIOL, V37, P1327, DOI 10.1007/s13277-015-3922-0; Zhang H, 2014, FREE RADICAL BIO MED, V69, P219, DOI 10.1016/j.freeradbiomed.2014.01.025; Zhang YM, 2015, J INVEST DERMATOL, V135, P181, DOI 10.1038/jid.2014.326	39	62	63	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	21					2890	2902		10.1038/s41388-018-0184-5	http://dx.doi.org/10.1038/s41388-018-0184-5			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG8EE	29520106				2022-12-17	WOS:000432929800010
J	Zhai, Z; Liu, W; Kaur, M; Luo, Y; Domenico, J; Samson, JM; Shellman, YG; Norris, DA; Dinarello, CA; Spritz, RA; Fujita, M				Zhai, Z.; Liu, W.; Kaur, M.; Luo, Y.; Domenico, J.; Samson, J. M.; Shellman, Y. G.; Norris, D. A.; Dinarello, C. A.; Spritz, R. A.; Fujita, M.			NLRP1 promotes tumor growth by enhancing inflammasome activation and suppressing apoptosis in metastatic melanoma	ONCOGENE			English	Article							CASPASE-1 ACTIVATION; EXPRESSION PROFILES; CELL-DEATH; CANCER; PROGRESSION; IMMUNITY; NALP1	Inflammasomes are mediators of inflammation, and constitutively activated NLRP3 inflammasomes have been linked to interleukin-1 beta (IL-1 beta)-mediated tumorigenesis in human melanoma. Whereas NLRP3 regulation of caspase-1 activation requires the adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD (caspase recruitment domain)), caspase-1 activation by another danger-signaling sensor NLRP1 does not require ASC because NLRP1 contains a C-terminal CARD domain that facilitates direct caspase-1 activation via CARD-CARD interaction. We hypothesized that NLRP1 has additional biological activities besides IL-1 beta maturation and investigated its role in melanoma tumorigenesis. NLRP1 expression in melanoma was confirmed by analysis of 216 melanoma tumors and 13 human melanoma cell lines. Unlike monocytic THP-1 cells with prominent nuclear localization of NLRP1, melanoma cells expressed NLRP1 mainly in the cytoplasm. Knocking down NLRP1 revealed a tumor-promoting property of NLRP1 both in vitro and in vivo. Mechanistic studies showed that caspase-1 activity, IL-1 beta production, IL-1 beta secretion and nuclear factor-kB activity were reduced by knocking down of NLRP1 in human metastatic melanoma cell lines 1205Lu and HS294T, indicating that NLRP1 inflammasomes are active in metastatic melanoma. However, unlike previous reports showing that NLRP1 enhances pyroptosis in macrophages, NLRP1 in melanoma behaved differently in the context of cell death. Knocking down NLRP1 increased caspase-2, -9 and 3/7 activities and promoted apoptosis in human melanoma cells. Immunoprecipitation revealed interaction of NLRP1 with CARD-containing caspase-2 and -9, whereas NLRP3 lacking a CARD motif did not interact with the caspases. Consistent with these findings, NLRP1 activation but not NLRP3 activation reduced caspase-2, -9 and 3/7 activities and provided protection against apoptosis in human melanoma cells, suggesting a suppressive role of NLRP1 in caspase-3/7 activation and apoptosis via interaction with caspase-2 and -9. In summary, we showed that NLRP1 promotes melanoma growth by enhancing inflammasome activation and suppressing apoptotic pathways. Our study demonstrates a tumor-promoting role of NLRP1 in cancer cells.	[Zhai, Z.; Liu, W.; Kaur, M.; Luo, Y.; Domenico, J.; Samson, J. M.; Shellman, Y. G.; Norris, D. A.; Fujita, M.] Univ Colorado Denver SOM, Dept Dermatol, 12801 E 17th Ave,RC-1 South,Room 4124, Aurora, CO 80045 USA; [Norris, D. A.; Fujita, M.] Denver Vet Affairs Med Ctr, Denver, CO USA; [Dinarello, C. A.] Univ Colorado Denver SOM, Dept Med, Aurora, CO 80045 USA; [Spritz, R. A.] Univ Colorado Denver SOM, Human Med Genet & Genom Program, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Fujita, M (corresponding author), Univ Colorado Denver SOM, Dept Dermatol, 12801 E 17th Ave,RC-1 South,Room 4124, Aurora, CO 80045 USA.	mayumi.fujita@ucdenver.edu	Dinarello, Charles/C-8524-2013	Shellman, Yiqun/0000-0003-0598-5753; Zhai, Zili/0000-0001-5164-3696	University of Colorado Cancer Center (UCCC) [P30CA046934]; Skin Diseases Research Cores Grant [P30AR057212]; NIH/NCATS Colorado CTSI [UL1 TR001082]; Veterans Affairs Merit Review [5I01BX001228]; NIH/NCI [R01CA197919]; Cancer League of Colorado; NIH/NIAMS [2R01AR045584];  [5T32AR007411-32]; NATIONAL CANCER INSTITUTE [R01CA197919, P30CA046934] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007411, P30AR057212, R01AR045584] Funding Source: NIH RePORTER; Veterans Affairs [I01BX001228] Funding Source: NIH RePORTER	University of Colorado Cancer Center (UCCC); Skin Diseases Research Cores Grant; NIH/NCATS Colorado CTSI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Veterans Affairs Merit Review(US Department of Veterans Affairs); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer League of Colorado; NIH/NIAMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Veterans Affairs(US Department of Veterans Affairs)	We thank the University of Colorado Cancer Center (UCCC) Support Grant (P30CA046934), the Skin Diseases Research Cores Grant (P30AR057212), the Flow Cytometry Core (Christine Childs and Karen Helm) for helping with FACS, and Dr Archana Gopalan (University of Colorado Anschutz Medical Campus) for helping with animal experiments. Imaging experiments were performed in the University of Colorado Anschutz Medical Campus Advance Light Microscopy Core (Radu Moldovan) supported in part by NIH/NCATS Colorado CTSI Grant Number UL1 TR001082. ZZ and JMS are recipients of a training grant, 5T32AR007411-32. This work was supported, in whole or in part, by Veterans Affairs Merit Review Award 5I01BX001228 (to MF), NIH/NCI R01CA197919 (to MF), Cancer League of Colorado (to MF) and NIH/NIAMS 2R01AR045584 (to RAS and MF).	Ahmad I, 2013, TOXICOL APPL PHARM, V270, P70, DOI 10.1016/j.taap.2013.03.027; Bani MR, 1996, CANCER RES, V56, P3075; Baptiste-Okoh N, 2008, P NATL ACAD SCI USA, V105, P1937, DOI 10.1073/pnas.0711800105; Bouchier-Hayes L, 2002, EMBO REP, V3, P616, DOI 10.1093/embo-reports/kvf139; Brennan MA, 2000, MOL MICROBIOL, V38, P31, DOI 10.1046/j.1365-2958.2000.02103.x; Bruey JM, 2007, CELL, V129, P45, DOI 10.1016/j.cell.2007.01.045; Caporali S, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-252; Cervantes J, 2008, CELL MICROBIOL, V10, P41, DOI 10.1111/j.1462-5822.2007.01012.x; Chanput W, 2014, INT IMMUNOPHARMACOL, V23, P37, DOI 10.1016/j.intimp.2014.08.002; Chavarria-Smith J, 2015, IMMUNOL REV, V265, P22, DOI 10.1111/imr.12283; Chow MT, 2012, CANCER RES, V72, P5721, DOI 10.1158/0008-5472.CAN-12-0509; Chu ZL, 2001, J BIOL CHEM, V276, P9239, DOI 10.1074/jbc.M006309200; Datta-Mitra A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121626; Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405; Diakos CI, 2014, LANCET ONCOL, V15, pE493, DOI 10.1016/S1470-2045(14)70263-3; Dunn JH, 2012, CANCER LETT, V314, P24, DOI 10.1016/j.canlet.2011.10.001; Faustin B, 2007, MOL CELL, V25, P713, DOI 10.1016/j.molcel.2007.01.032; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Kabbarah O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010770; Kent A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00185; Kodiha M, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-25; Kolb R, 2014, PROTEIN CELL, V5, P12, DOI 10.1007/s13238-013-0001-4; Kumar S, 2009, NAT REV CANCER, V9, P897, DOI 10.1038/nrc2745; Kummer JA, 2007, J HISTOCHEM CYTOCHEM, V55, P443, DOI 10.1369/jhc.6A7101.2006; Labbe K, 2011, PROG INFLAMM RES SER, P17, DOI 10.1007/978-3-0348-0148-5_2; Levinsohn JL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002638; Liu WM, 2013, J INVEST DERMATOL, V133, P518, DOI 10.1038/jid.2012.317; Lo CF, 2008, BIOCHEM BIOPH RES CO, V366, P664, DOI 10.1016/j.bbrc.2007.11.174; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Meng XF, 2014, MOL NEUROBIOL, V49, P673, DOI 10.1007/s12035-013-8551-2; Modlin IM, 2006, ANN SURG, V244, P52, DOI 10.1097/01.sla.0000217617.06782.d5; Multhoff G, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00098; Newman ZL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000906; Okamoto M, 2010, J BIOL CHEM, V285, P6477, DOI 10.1074/jbc.M109.064907; Pommier Y, 2010, CHEM BIOL, V17, P421, DOI 10.1016/j.chembiol.2010.04.012; Raskin L, 2013, J INVEST DERMATOL, V133, P2585, DOI 10.1038/jid.2013.197; Rayamajhi Manira, 2013, Methods Mol Biol, V1040, P85, DOI 10.1007/978-1-62703-523-1_7; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Solinas G, 2010, CANCER METAST REV, V29, P243, DOI 10.1007/s10555-010-9227-2; Song XP, 2005, J IMMUNOL, V175, P8200, DOI 10.4049/jimmunol.175.12.8200; Tarassishin L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103432; TRASK DK, 1988, P NATL ACAD SCI USA, V85, P1417, DOI 10.1073/pnas.85.5.1417; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Watari K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099568; Zhong FL, 2016, CELL, V167, P187, DOI 10.1016/j.cell.2016.09.001	45	62	67	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3820	3830		10.1038/onc.2017.26	http://dx.doi.org/10.1038/onc.2017.26			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28263976	Green Accepted, Green Submitted			2022-12-17	WOS:000404848200003
J	Strickaert, A; Saiselet, M; Dom, G; De Deken, X; Dumont, JE; Feron, O; Sonveaux, P; Maenhaut, C				Strickaert, A.; Saiselet, M.; Dom, G.; De Deken, X.; Dumont, J. E.; Feron, O.; Sonveaux, P.; Maenhaut, C.			Cancer heterogeneity is not compatible with one unique cancer cell metabolic map	ONCOGENE			English	Review							CYCLIC HYPOXIA; TUMOR HYPOXIA; LACTATE; GLUTAMINE; GLUCOSE; GROWTH; ANGIOGENESIS; OXYGENATION; COMPARTMENTS; METASTASIS	The Warburg effect and its accompanying metabolic features (anaplerosis, cataplerosis) are presented in textbooks and reviews as a hallmark (general characteristic): the metabolic map of cancer. On the other hand, research articles on specific tumors since a few years emphasize various biological features of different cancers, different cells in a cancer and the dynamic heterogeneity of these cells. We have analysed the research literature of the subject and show the generality of a dynamic, evolving biological and metabolic, spatial and temporal heterogeneity of individual cancers. We conclude that there is no one metabolic map of cancer but several and describe the two extremes of a panel from the hypoxic to the normoxic state. The implications for the significance of general 'omic' studies, and on therapeutic conclusions drawn from them and for the diagnostic use of fractional biopsies is discussed.	[Strickaert, A.; Saiselet, M.; Dom, G.; De Deken, X.; Dumont, J. E.; Maenhaut, C.] ULB, IRIBHM, Campus Erasme,808 Route Lenn, B-1070 Brussels, Belgium; [Feron, O.; Sonveaux, P.] UCL, IREC, Pole Pharmacol & Therapeut, Brussels, Belgium	Universite Libre de Bruxelles; Universite Catholique Louvain	Dumont, JE (corresponding author), ULB, IRIBHM, Campus Erasme,808 Route Lenn, B-1070 Brussels, Belgium.	jedumont@ulb.ac.be	FERON, Olivier/AAM-6395-2020	FERON, Olivier/0000-0001-5360-0286	EU Horizon Marie Sklodowska-Curie Innovative Training Networks (ITN) [642623 RADIATE]; Interuniversity Attraction Pole (IAP) grant from the Belgian Science Policy Office (Belspo) [UP7-03]; Belgian Fonds National de la Recherche Scientifique (F.R.S.-FNRS); Televie; Belgian Fondation contre le Cancer [2012-186]; Belgian Fonds National de la Recherche Scientifique, Plan Cancer (action 29); Welbio; Action de Recherche Concertee from the Communaute Francaise de Belgique [ARC 14/19-058]	EU Horizon Marie Sklodowska-Curie Innovative Training Networks (ITN); Interuniversity Attraction Pole (IAP) grant from the Belgian Science Policy Office (Belspo); Belgian Fonds National de la Recherche Scientifique (F.R.S.-FNRS)(Fonds de la Recherche Scientifique - FNRS); Televie; Belgian Fondation contre le Cancer; Belgian Fonds National de la Recherche Scientifique, Plan Cancer (action 29); Welbio(WELBIO); Action de Recherche Concertee from the Communaute Francaise de Belgique	The work of PS and OF is supported by EU Horizon2020 Marie Sklodowska-Curie Innovative Training Networks (ITN No. 642623 RADIATE), Interuniversity Attraction Pole (IAP) grant #UP7-03 from the Belgian Science Policy Office (Belspo), an Action de Recherche Concertee from the Communaute Francaise de Belgique (ARC 14/19-058), the Belgian Fonds National de la Recherche Scientifique (F.R.S.-FNRS), the Televie, and the Belgian Fondation contre le Cancer (2012-186). Pierre Sonveaux is a Research Associate of the F.R.S.-FNRS. Other authors of the University of Brussels are supported by the Belgian Fonds National de la Recherche Scientifique, Plan Cancer (action 29) and Welbio.	Afonso J, 2016, CELL CYCLE, V15, P368, DOI 10.1080/15384101.2015.1121329; Andor N, 2016, NAT MED, V22, P105, DOI 10.1038/nm.3984; Avery SV, 2006, NAT REV MICROBIOL, V4, P577, DOI 10.1038/nrmicro1460; Bhatia S, 2012, NAT BIOTECHNOL, V30, P604, DOI 10.1038/nbt.2294; Boidot R, 2014, ONCOTARGET, V5, P6947, DOI 10.18632/oncotarget.2285; Boidot R, 2012, CANCER RES, V72, P939, DOI 10.1158/0008-5472.CAN-11-2474; Bonuccelli G, 2010, CELL CYCLE, V9, P3506, DOI 10.4161/cc.9.17.12731; Boroughs LK, 2015, NAT CELL BIOL, V17, P351, DOI 10.1038/ncb3124; Caillou B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022567; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Calbo J, 2011, CANCER CELL, V19, P244, DOI 10.1016/j.ccr.2010.12.021; Cardenas-Navia LI, 2008, CANCER RES, V68, P5812, DOI 10.1158/0008-5472.CAN-07-6387; Cleary AS, 2015, SCIENCE, V350, P1174, DOI 10.1126/science.aad7103; Corbet C, 2015, CURR OPIN CLIN NUTR, V18, P346, DOI 10.1097/MCO.0000000000000178; Corbet C, 2014, CANCER RES, V74, P5507, DOI 10.1158/0008-5472.CAN-14-0705; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; Dalerba P, 2011, NAT BIOTECHNOL, V29, P1120, DOI 10.1038/nbt.2038; Daneau G, 2010, CLIN CANCER RES, V16, P410, DOI 10.1158/1078-0432.CCR-09-0583; Daye D, 2012, SEMIN CELL DEV BIOL, V23, P362, DOI 10.1016/j.semcdb.2012.02.002; Dewhirst MW, 2009, RADIAT RES, V172, P653, DOI 10.1667/RR1926.1; Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741; Draoui N, 2011, DIS MODEL MECH, V4, P727, DOI 10.1242/dmm.007724; Fernandez LC, 2016, NAT REV CANCER, V16, P43, DOI 10.1038/nrc.2015.1; Feron O, 2009, RADIOTHER ONCOL, V92, P329, DOI 10.1016/j.radonc.2009.06.025; Ferreira LMR, 2012, ONCOGENE, V31, P3999, DOI 10.1038/onc.2011.576; Fiaschi T, 2013, CELL CYCLE, V12, P1791, DOI 10.4161/cc.24902; Floor SL, 2012, TRENDS MOL MED, V18, P509, DOI 10.1016/j.molmed.2012.06.005; Friedl P, 2004, CURR OPIN IMMUNOL, V16, P389, DOI 10.1016/j.coi.2004.05.022; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Galie M, 2007, NEOPLASIA, V9, P900, DOI 10.1593/neo.07541; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hensley CT, 2016, CELL, V164, P681, DOI 10.1016/j.cell.2015.12.034; Hirschhaeuser F, 2011, CANCER RES, V71, P6921, DOI 10.1158/0008-5472.CAN-11-1457; Hyodo F, 2012, INT J ONCOL, V41, P2103, DOI 10.3892/ijo.2012.1638; Jolly LA, 2016, CANCER RES, V76, P1804, DOI 10.1158/0008-5472.CAN-15-2351; Kamarajugadda S, 2012, MOL CELL BIOL, V32, P1893, DOI 10.1128/MCB.06248-11; Krall AS, 2015, NAT CELL BIOL, V17, P1515, DOI 10.1038/ncb3278; Lee GH, 2011, ONCOL LETT, V2, P831, DOI 10.3892/ol.2011.353; Ling SP, 2016, P NATL ACAD SCI USA, V113, pE663, DOI 10.1073/pnas.1600151113; Macaulay IC, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004126; MALAISE EP, 1973, EUR J CANCER, V9, P305, DOI 10.1016/0014-2964(73)90099-6; Marchiq I, 2016, J MOL MED, V94, P155, DOI 10.1007/s00109-015-1307-x; Martinez-outschoorn UE, 2012, NIH PUBLIC ACCESS, V43, P1045; Martinive P, 2009, FEBS J, V276, P509, DOI 10.1111/j.1742-4658.2008.06798.x; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Nakajima EC, 2013, MOL CARCINOGEN, V52, P329, DOI 10.1002/mc.21863; Natrajan R, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001961; Neveu MA, 2015, RADIOTHER ONCOL, V116, P400, DOI 10.1016/j.radonc.2015.04.023; Ostergaard L, 2013, CANCER RES, V73, P5618, DOI 10.1158/0008-5472.CAN-13-0964; Payen VL, 2015, CANCER J, V21, P75, DOI 10.1097/PPO.0000000000000098; Perez-Escuredo J, 2016, BBA-MOL CELL RES, V1863, P2481, DOI 10.1016/j.bbamcr.2016.03.013; Perez-Escuredo J, 2016, CELL CYCLE, V15, P72, DOI 10.1080/15384101.2015.1120930; Polet F, 2013, J INTERN MED, V273, P156, DOI 10.1111/joim.12016; Porporato PE, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00049; Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405; Rivera LB, 2013, CANCER CELL, V24, P687, DOI 10.1016/j.ccr.2013.11.014; Sanchez-Alvarez R, 2013, CELL CYCLE, V12, P172, DOI 10.4161/cc.23058; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Snijder B, 2011, NAT REV MOL CELL BIO, V12, P119, DOI 10.1038/nrm3044; Swanton C, 2012, CANCER RES, V72, P4875, DOI 10.1158/0008-5472.CAN-12-2217; Tabassum DP, 2015, NAT REV CANCER, V15, P473, DOI 10.1038/nrc3971; Tarabichi M, 2013, CANCER METAST REV, V32, P403, DOI 10.1007/s10555-013-9431-y; Tarabichi M, 2016, J PATHOL UNPUB; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Turtoi A, 2014, HEPATOLOGY, V59, P924, DOI 10.1002/hep.26608; van Staveren WCG, 2009, BBA-REV CANCER, V1795, P92, DOI 10.1016/j.bbcan.2008.12.004; Vaupel P, 2004, METHOD ENZYMOL, V381, P335; Walenta S, 2004, SEMIN RADIAT ONCOL, V14, P267, DOI 10.1016/j.semradonc.2004.04.004; Walenta S, 2000, CANCER RES, V60, P916; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Whitaker-Menezes D, 2011, CELL CYCLE, V10, P1772, DOI 10.4161/cc.10.11.15659; Yeung TL, 2015, AM J PHYSIOL-CELL PH, V309, pC444, DOI 10.1152/ajpcell.00188.2015; Zhang XY, 2016, CANCER RES, V76, P1305, DOI 10.1158/0008-5472.CAN-15-1907	78	62	62	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 11	2017	36	19					2637	2642		10.1038/onc.2016.411	http://dx.doi.org/10.1038/onc.2016.411			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EU6CF	27797377	hybrid, Green Published			2022-12-17	WOS:000401120900002
J	Fang, D; Chen, H; Zhu, JY; Wang, W; Teng, Y; Ding, HF; Jing, Q; Su, SB; Huang, S				Fang, D.; Chen, H.; Zhu, J. Y.; Wang, W.; Teng, Y.; Ding, H-F; Jing, Q.; Su, S-B; Huang, S.			Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1/2 and Src signaling pathways	ONCOGENE			English	Article							NF-KAPPA-B; E-CADHERIN; DOWN-REGULATION; BETA-CATENIN; EMT; METASTASIS; EXPRESSION; CARCINOMA; INFLAMMATION; MIGRATION	Epithelial-mesenchymal transition (EMT) is regarded as a crucial contributing factor to cancer progression. Diverse factors have been identified as potent EMT inducers in ovarian cancer. However, molecular mechanism sustaining EMT of ovarian cancer cells remains elusive. Here we show that the presence of SOS1/EPS8/ABI1 complex is critical for sustained EMT traits of ovarian cancer cells. Consistent with the role of SOS1/EPS8/ABI1 complex as a Rac1-specific guanine nucleotide exchange factor, depleting Rac1 results in the loss of most of mesenchymal traits in mesenchymal-like ovarian cancer cells, whereas expressing constitutively active Rac1 leads to EMT in epithelial-like ovarian cancer cells. With the aid of clinically tested inhibitors targeting various EMT-associated signaling pathways, we show that only combined treatment of mitogen-activated extracellular signal-regulated kinase 1/2 (MEK1/2) and Src inhibitors can abolish constitutively active Rac1-led EMT and mesenchymal traits displayed by mesenchymal-like ovarian cancer cells. Further experiments also reveal that EMT can be induced in epithelial-like ovarian cancer cells by co-expressing constitutively active MEK1 and Src rather than either alone. As the activities of Erk and Src are higher in ovarian cancer cells with constitutively active Rac1, we conclude that Rac1 sustains ovarian cancer cell EMT through simultaneous activation of MEK1/2 and Src signaling pathways. Importantly, we demonstrate that combined use of MEK1/2 and Src inhibitors effectively suppresses development of intraperitoneal xenografts and prolongs the survival of ovarian cancer-bearing mice. This study suggests that cocktail of MEK1/2 and Src inhibitors represents an effective therapeutic strategy against ovarian cancer progression.	[Fang, D.; Wang, W.; Su, S-B; Huang, S.] Shanghai Univ Tradit Chinese Med, Res Ctr Tradit Chinese Med Complex Syst, Shanghai, Peoples R China; [Fang, D.; Su, S-B; Huang, S.] Shanghai Univ Tradit Chinese Med, E Inst Shanghai Municipal Educ Comm, Shanghai, Peoples R China; [Chen, H.] Wuhan Univ, Zhongnan Hosp, Dept Obstet & Gynecol, Wuhan, Peoples R China; [Zhu, J. Y.; Huang, S.] Univ Florida, Coll Med, Dept Anat & Cell Biol, 2033 Mowry Rd,POB 103633, Gainesville, FL 32610 USA; [Teng, Y.] Augusta Univ, Dent Coll Georgia, Dept Oral Biol, Augusta, GA USA; [Teng, Y.; Ding, H-F] Augusta Univ, Georgia Canc Ctr, Augusta, GA USA; [Jing, Q.] Changhai Hosp, Dept Cardiol, Shanghai, Peoples R China	Shanghai University of Traditional Chinese Medicine; Shanghai Municipal Education Commission (SHMEC); Shanghai University of Traditional Chinese Medicine; Wuhan University; State University System of Florida; University of Florida; University System of Georgia; Augusta University; University System of Georgia; Augusta University; Naval Medical University	Su, SB (corresponding author), Shanghai Univ Tradit Chinese Med, Res Ctr Tradit Chinese Med Complex Syst, Shanghai, Peoples R China.; Huang, S (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, 2033 Mowry Rd,POB 103633, Gainesville, FL 32610 USA.	shibingsu07@163.com; shuanghuang@ufl.edu	Teng, Yong/AAK-4160-2020; Jing, Qing/F-6752-2016	Teng, Yong/0000-0002-1856-7289; Jing, Qing/0000-0001-9834-1214; Ding, Han-Fei/0000-0001-5702-3439	E-Institutes of Shanghai Municipal Education Commission [E03008]; Shanghai University of TCM [085ZY1206]; National Science Foundation of China [31229002]; NIH [CA 187152]; DoD [OC120313, W81XWH-13-1-0122]; NATIONAL CANCER INSTITUTE [R01CA187152] Funding Source: NIH RePORTER	E-Institutes of Shanghai Municipal Education Commission; Shanghai University of TCM; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by E-Institutes of Shanghai Municipal Education Commission (Project E03008), '085' First-Class Discipline Construction Innovation Science and Technology Support Project of Shanghai University of TCM (085ZY1206), National Science Foundation of China (31229002), NIH CA 187152 and DoD OC120313 (W81XWH-13-1-0122).	Ahmed N, 2010, CURR CANCER DRUG TAR, V10, P268, DOI 10.2174/156800910791190175; Bid HK, 2013, MOL CANCER THER, V12, P1925, DOI 10.1158/1535-7163.MCT-13-0164; Brabletz S, 2011, EMBO J, V30, P770, DOI 10.1038/emboj.2010.349; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Chen DY, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-50; Chen HM, 2009, CANCER RES, V69, P9228, DOI 10.1158/0008-5472.CAN-09-1950; Chen HJ, 2010, CANCER RES, V70, P9979, DOI 10.1158/0008-5472.CAN-10-2394; Cheng SM, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0494-1; Cichon MA, 2014, ONCOTARGET, V5, P2827, DOI 10.18632/oncotarget.1940; Condello S, 2013, FASEB J, V27, P3100, DOI 10.1096/fj.12-222620; Davidson B, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00033; Davidson B, 2015, HUM PATHOL, V46, P1, DOI 10.1016/j.humpath.2014.10.004; Gou WF, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-477; Hong S, 2014, NEOPLASIA, V16, P279, DOI 10.1016/j.neo.2014.03.010; Hu Q, 2013, ONCOGENE, V32, P3933, DOI 10.1038/onc.2012.414; Huang RYJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.442; Huang RYJ, 2012, CURR DRUG TARGETS, V13, P1649; Javle MM, 2007, ANN SURG ONCOL, V14, P3527, DOI 10.1245/s10434-007-9540-3; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Leng RB, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0329-5; Lester RD, 2007, J CELL BIOL, V178, P425, DOI 10.1083/jcb.200701092; Li Y., 2012, GENES CANC, V2, P880; Li Y, 2014, ONCOTARGET, V5, P2596, DOI 10.18632/oncotarget.1841; Li Y, 2010, CANCER RES, V70, P7894, DOI 10.1158/0008-5472.CAN-10-1675; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Mandal M, 2008, CANCER-AM CANCER SOC, V112, P2088, DOI 10.1002/cncr.23410; McGrail DJ, 2014, J CELL SCI, V127, P2621, DOI 10.1242/jcs.144378; Lopez-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043; Moustakas A, 2012, SEMIN CANCER BIOL, V22, P446, DOI 10.1016/j.semcancer.2012.04.002; Parvani JG, 2011, J MAMMARY GLAND BIOL, V16, P127, DOI 10.1007/s10911-011-9207-3; Ponnusamy MP, 2010, ONCOGENE, V29, P5741, DOI 10.1038/onc.2010.309; Prasanphanich AE, 2014, FREE RADICAL BIO MED, V76, P1, DOI 10.1016/j.freeradbiomed.2014.07.032; Radisky DC, 2007, NAT CELL BIOL, V9, P361, DOI 10.1038/ncb0407-361; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Seward SM, 2015, CANCER METAST REV, V34, P5, DOI 10.1007/s10555-014-9536-y; Takai M, 2014, J OVARIAN RES, V7, DOI [10.1186/1757-2215-7-38, 10.1186/1757-2215-7-76]; Tan TZ, 2014, EMBO MOL MED, V6, P1279, DOI 10.15252/emmm.201404208; Theriault BL, 2007, CARCINOGENESIS, V28, P1153, DOI 10.1093/carcin/bgm015; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tian LL, 2015, SCI REP-UK, V5, DOI 10.1038/srep12357; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Wu YY, 2012, MOL CANCER RES, V10, P1597, DOI 10.1158/1541-7786.MCR-12-0155-T; Yamada SD, 2002, CANCER RES, V62, P6717; Yang L, 2015, ONCOTARGET, V6, P20801, DOI 10.18632/oncotarget.4600; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yang WH, 2012, NAT CELL BIOL, V14, P366, DOI 10.1038/ncb2455; Yoshida S, 2009, INT J GYNECOL CANCER, V19, P992, DOI 10.1111/IGC.0b013e3181aaa93a; Zhang Z, 2014, ONCOGENE, V33, P3374, DOI 10.1038/onc.2013.337	50	62	64	0	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1546	1558		10.1038/onc.2016.323	http://dx.doi.org/10.1038/onc.2016.323			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27617576	Green Accepted			2022-12-17	WOS:000397458100009
J	Matsumura, K; Kawasaki, Y; Miyamoto, M; Kamoshida, Y; Nakamura, J; Negishi, L; Suda, S; Akiyama, T				Matsumura, K.; Kawasaki, Y.; Miyamoto, M.; Kamoshida, Y.; Nakamura, J.; Negishi, L.; Suda, S.; Akiyama, T.			f0 The novel G-quadruplex-containing long non-coding RNA GSEC antagonizes DHX36 and modulates colon cancer cell migration	ONCOGENE			English	Article							HUMAN COLORECTAL-CANCER; TETRAMOLECULAR QUADRUPLEX; RESOLVING ACTIVITY; PROSTATE-CANCER; MAJOR SOURCE; PROMOTES; EXPRESSION; METASTASIS; GROWTH; GENE	Long non-coding RNAs (lncRNAs) are frequently dysregulated in a variety of human cancers. However, their biological roles in these cancers remain incompletely understood. In this study, we analyze the gene expression profiles of colon cancer tissues and identify a previously unannotated lncRNA, FLJ39051, that we term GSEC (G-quadruplex-forming sequence containing lncRNA), as a lncRNA that is upregulated in colorectal cancer. We further demonstrate that knockdown of GSEC results in the reduction of colon cancer cell motility. We also show that GSEC binds to the DEAH box polypeptide 36 (DHX36) RNA helicase via its G-quadruplex-forming sequence and inhibits DHX36 G-quadruplex unwinding activity. Moreover, knockdown of DHX36 restores the reduced migratory activity of colon cancer cells caused by GSEC knockdown. These results suggest that GSEC plays an important role in colon cancer cell migration by inhibiting the function of DHX36 via its G-quadruplex structure.	[Matsumura, K.; Kawasaki, Y.; Miyamoto, M.; Kamoshida, Y.; Nakamura, J.; Negishi, L.; Suda, S.; Akiyama, T.] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Tokyo, Japan	University of Tokyo	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	akiyama@iam.u-tokyo.ac.jp			Research Program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct); Ministry of Education, Culture, Sports, Science and Technology of Japan; Japan Society for the Promotion of Science [13J08104]	Research Program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by Grants-in-Aid for Scientific Research on Innovative Areas (Integrative Research on Cancer Microenvironment Network) and Research Program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of Education, Culture, Sports, Science and Technology of Japan and Japan Society for the Promotion of Science Grant-in-Aid for JSPS Fellows (Grant Number 13J08104).	Arab K, 2014, MOL CELL, V55, P604, DOI 10.1016/j.molcel.2014.06.031; Bicker S, 2013, GENE DEV, V27, P991, DOI 10.1101/gad.211243.112; Bierhoff H, 2014, MOL CELL, V54, P675, DOI 10.1016/j.molcel.2014.03.032; Booy EP, 2012, NUCLEIC ACIDS RES, V40, P4110, DOI 10.1093/nar/gkr1306; Booy EP, 2014, NUCLEIC ACIDS RES, V42, P3346, DOI 10.1093/nar/gkt1340; Burge S, 2006, NUCLEIC ACIDS RES, V34, P5402, DOI 10.1093/nar/gkl655; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Creacy SD, 2008, J BIOL CHEM, V283, P34626, DOI 10.1074/jbc.M806277200; Dimitrova N, 2014, MOL CELL, V54, P777, DOI 10.1016/j.molcel.2014.04.025; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701; Graham Lloyd D, 2011, Genes Cancer, V2, P829, DOI 10.1177/1947601911431081; Gumireddy K, 2013, EMBO J, V32, P2672, DOI 10.1038/emboj.2013.188; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; Hock J, 2007, EMBO REP, V8, P1052, DOI 10.1038/sj.embor.7401088; Hu XW, 2014, CANCER CELL, V26, P344, DOI 10.1016/j.ccr.2014.07.009; Huang J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.541; Huang WW, 2012, NUCLEIC ACIDS RES, V40, P1033, DOI 10.1093/nar/gkr849; Jayaraj GG, 2012, RNA BIOL, V9, P81, DOI 10.4161/rna.9.1.18047; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kim HN, 2011, J BONE MINER RES, V26, P2161, DOI 10.1002/jbmr.426; Kino T, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000568; Kretz M, 2013, NATURE, V493, P231, DOI 10.1038/nature11661; Lam MTY, 2014, TRENDS BIOCHEM SCI, V39, P170, DOI 10.1016/j.tibs.2014.02.007; Lin NW, 2014, MOL CELL, V53, P1005, DOI 10.1016/j.molcel.2014.01.021; Liu XF, 2012, EMBO J, V31, P4415, DOI 10.1038/emboj.2012.292; Millevoi S, 2012, WIRES RNA, V3, P495, DOI 10.1002/wrna.1113; O'Leary VB, 2015, CELL REP, V11, P474, DOI 10.1016/j.celrep.2015.03.043; Prensner JR, 2013, NAT GENET, V45, P1392, DOI 10.1038/ng.2771; Richards EJ, 2015, J BIOL CHEM, V290, P6857, DOI 10.1074/jbc.M114.610915; Sun M, 2015, MOL CELL, V59, P698, DOI 10.1016/j.molcel.2015.06.023; Takayama K, 2013, EMBO J, V32, P1665, DOI 10.1038/emboj.2013.99; Tsang WP, 2010, CARCINOGENESIS, V31, P350, DOI 10.1093/carcin/bgp181; Tseng YY, 2014, NATURE, V512, P82, DOI 10.1038/nature13311; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Vaughn JP, 2005, J BIOL CHEM, V280, P38117, DOI 10.1074/jbc.C500348200; Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456; Xiang JF, 2014, CELL RES, V24, P513, DOI 10.1038/cr.2014.35; Xing Z, 2014, CELL, V159, P1110, DOI 10.1016/j.cell.2014.10.013; Yanagida S, 2013, SCI REP-UK, V3, DOI 10.1038/srep01305; Yang F, 2013, MOL CELL, V49, P1083, DOI 10.1016/j.molcel.2013.01.010; Yang LQ, 2013, NATURE, V500, P598, DOI 10.1038/nature12451; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010	44	62	65	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1191	1199		10.1038/onc.2016.282	http://dx.doi.org/10.1038/onc.2016.282			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27797375				2022-12-17	WOS:000395861300003
J	Saha, SK; Choi, HY; Kim, BW; Dayem, AA; Yang, GM; Kim, KS; Yin, YF; Cho, SG				Saha, S. K.; Choi, H. Y.; Kim, B. W.; Dayem, A. A.; Yang, G-M; Kim, K. S.; Yin, Y. F.; Cho, S-G			KRT19 directly interacts with beta-catenin/RAC1 complex to regulate NUMB-dependent NOTCH signaling pathway and breast cancer properties	ONCOGENE			English	Article							KERATIN 19 EXPRESSION; BETA-CATENIN; ESTROGEN-RECEPTOR; PERIPHERAL-BLOOD; GENE SIGNATURE; INTERMEDIATE-FILAMENTS; CELL-PROLIFERATION; DOWN-REGULATION; POOR-PROGNOSIS; TUMOR-CELLS	Studies have reported that interactions between keratins (KRTs) and other proteins initiate signaling cascades that regulate cell migration, invasion, and metastasis. In the current study, we found that expression of KRT19 was specifically high in breast cancers and significantly correlated with their invasiveness. Moreover, knockdown of KRT19 led to increased proliferation, migration, invasion, drug resistance, and sphere formation in breast cancer cells via an upregulated NOTCH signaling pathway. This was owing to reduced expression of NUMB, an inhibitory protein of the NOTCH signaling pathway. In addition, we found that KRT19 interacts with beta-catenin/RAC1 complex and enhances the nuclear translocation of beta-catenin. Concordantly, knockdown of KRT19 suppressed the nuclear translocation of beta-catenin as well as beta-catenin-mediated NUMB expression. Furthermore, modulation of KRT19mediated regulation of NUMB and NOTCH1 expression led to the repression of the cancer stem cell properties of breast cancer patient-derived CD133(high)/CXCR4(high)/ALDH1(high) cancer stem-like cells (CSLCs), which showed very low KRT19 and high NOTCH1 expression. Taken together, our study suggests a novel function for KRT19 in the regulation of nuclear import of the beta-catenin/RAC1 complex, thus modulating the NUMB-dependent NOTCH signaling pathway in breast cancers and CSLCs, which might bear potential clinical implications for cancer or CSLC treatment.	[Cho, S-G] Konkuk Univ, Dept Anim Biotechnol Stem Cell & Regenerat Biotec, 120 Neungdong Ro, Seoul 05029, South Korea; [Cho, S-G] Konkuk Univ, Incurable Dis Anim Model & Stem Cell Inst IDASI, 120 Neungdong Ro, Seoul, South Korea	Konkuk University; Konkuk University	Cho, SG (corresponding author), Konkuk Univ, Dept Anim Biotechnol Stem Cell & Regenerat Biotec, 120 Neungdong Ro, Seoul 05029, South Korea.; Cho, SG (corresponding author), Konkuk Univ, Incurable Dis Anim Model & Stem Cell Inst IDASI, 120 Neungdong Ro, Seoul, South Korea.	ssangoo@konkuk.ac.kr	Saha, Subbroto Kumar/L-2627-2018; CHOI, HYEYEON/O-1234-2019; Dayem, Ahmed M Abdal/D-4773-2011	Saha, Subbroto Kumar/0000-0003-1325-3499; Dayem, Ahmed M Abdal/0000-0003-3873-9903; Cho, Ssang-Goo/0000-0002-0968-7932	National Research Foundation (NRF) - Korean government [2013M3A9D3045880, 2015R1A5A1009701]	National Research Foundation (NRF) - Korean government(Korean Government)	This work was supported by grants from the National Research Foundation (NRF) funded by the Korean government (2013M3A9D3045880 and 2015R1A5A1009701).	Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Ayyanan A, 2006, P NATL ACAD SCI USA, V103, P3799, DOI 10.1073/pnas.0600065103; Bambang IF, 2009, EXP CELL RES, V315, P1964, DOI 10.1016/j.yexcr.2009.02.017; Bernemann C, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-174; Bolos V, 2007, ENDOCR REV, V28, P339, DOI 10.1210/er.2006-0046; Borggrefe T, 2009, CELL MOL LIFE SCI, V66, P1631, DOI 10.1007/s00018-009-8668-7; Boulter L, 2012, NAT MED, V18, P572, DOI 10.1038/nm.2667; Bozionellou V, 2004, CLIN CANCER RES, V10, P8185, DOI 10.1158/1078-0432.CCR-03-0094; Buongiorno P, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-73; Buyse M, 2006, JNCI-J NATL CANCER I, V98, P1183, DOI 10.1093/jnci/djj329; Camps J, 2013, CANCER RES, V73, P2003, DOI 10.1158/0008-5472.CAN-12-3159; Carter S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-5-221; Caulin C, 2000, J CELL BIOL, V149, P17, DOI 10.1083/jcb.149.1.17; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Chen JQ, 2009, BBA-REV CANCER, V1796, P162, DOI 10.1016/j.bbcan.2009.06.003; Chen TF, 2007, LUNG CANCER, V56, P105, DOI 10.1016/j.lungcan.2006.11.006; Cheng X, 2008, DEVELOPMENT, V135, P3447, DOI 10.1242/dev.025916; Coulombe PA, 2004, NAT CELL BIOL, V6, P699, DOI 10.1038/ncb0804-699; Dayem AA, 2014, BIOTECHNOL J, V9, P934, DOI 10.1002/biot.201300555; de Silanes IL, 2007, CELL ONCOL, V29, P1; Esufali S, 2004, ONCOGENE, V23, P8260, DOI 10.1038/sj.onc.1208007; Esufali S, 2007, FEBS LETT, V581, P4850, DOI 10.1016/j.febslet.2007.09.013; Feldman JP, 2009, J APPL QUANT METHODS, V4, P455, DOI DOI 10.1111/J.2042-3306.2010.TB05629.X; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Fradette J, 1998, J BIOL CHEM, V273, P35176, DOI 10.1074/jbc.273.52.35176; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; Govaere O, 2014, GUT, V63, P674, DOI 10.1136/gutjnl-2012-304351; Gulino A, 2010, EXP CELL RES, V316, P900, DOI 10.1016/j.yexcr.2009.11.017; Hendrix MJC, 1996, CANCER METAST REV, V15, P507, DOI 10.1007/BF00054016; Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889; Hua GJ, 2014, ONCOL REP, V31, P2727, DOI 10.3892/or.2014.3156; Ignatiadis M, 2007, J CLIN ONCOL, V25, P5194, DOI 10.1200/JCO.2007.11.7762; Jamieson C, 2015, J CELL SCI, V128, P3933, DOI 10.1242/jcs.167742; Jang GB, 2015, SCI REP-UK, V5, DOI 10.1038/srep12465; Ju JH, 2015, CELL DEATH DIFFER, V22, P665, DOI 10.1038/cdd.2014.155; Ju JH, 2013, CLIN CANCER RES, V19, P4335, DOI 10.1158/1078-0432.CCR-12-3295; Ribeiro MSJ, 2007, BIOCHEM J, V404, P289, DOI 10.1042/BJ20061900; Kabir NN, 2014, MOL BIOL REP, V41, P7729, DOI 10.1007/s11033-014-3684-6; Karaczyn A, 2010, NEURAL DEV, V5, DOI 10.1186/1749-8104-5-31; Katoh M, 2006, INT J MOL MED, V18, P517; Kawai T, 2015, CLIN CANCER RES, V21, P3081, DOI 10.1158/1078-0432.CCR-14-1936; Kim H, 2011, HEPATOLOGY, V54, P1707, DOI 10.1002/hep.24559; Kim HA, 2012, J CLIN INVEST, V122, P3248, DOI 10.1172/JCI61216; Kim S, 2006, NATURE, V441, P362, DOI 10.1038/nature04659; Kujawski M, 2008, J CLIN INVEST, V118, P3367, DOI 10.1172/JCI35213; Kwon C, 2011, NAT CELL BIOL, V13, P1244, DOI 10.1038/ncb2313; Lamb R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067811; Lee CW, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2200; Lee JM, 2010, MOL CELL, V37, P183, DOI 10.1016/j.molcel.2009.12.022; Leung WH, 2013, J EXP MED, V210, P2675, DOI 10.1084/jem.20122292; Lien HC, 2007, ONCOGENE, V26, P7859, DOI 10.1038/sj.onc.1210593; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; Liu XH, 2013, J BIOL CHEM, V288, P17990, DOI 10.1074/jbc.M113.478487; Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; Moggs JG, 2004, ENVIRON HEALTH PERSP, V112, P1589, DOI 10.1289/ehp.7345; Moggs JG, 2004, ENVIRON HEALTH PERSP, V112, P1137, DOI 10.1289/ehp.7028; Moon SH, 2013, INT J ONCOL, V42, P921, DOI 10.3892/ijo.2013.1765; Myant KB, 2013, CELL STEM CELL, V12, P761, DOI 10.1016/j.stem.2013.04.006; Nishikawa S, 2015, ONCOL LETT, V9, P2361, DOI 10.3892/ol.2015.3063; Nishimura T, 2007, DEV CELL, V13, P15, DOI 10.1016/j.devcel.2007.05.003; Omary MB, 2006, TRENDS BIOCHEM SCI, V31, P383, DOI 10.1016/j.tibs.2006.05.008; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; Patsialou A, 2015, ONCOGENE, V34, P2721, DOI 10.1038/onc.2014.226; Peignon G, 2011, GUT, V60, P166, DOI 10.1136/gut.2009.204719; Pethe VV, 2011, INT J ONCOL, V39, P805, DOI 10.3892/ijo.2011.1066; Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037; Pui CH, 2009, CANCER CELL, V15, P85, DOI 10.1016/j.ccr.2009.01.007; Radvanyi L, 2005, P NATL ACAD SCI USA, V102, P11005, DOI 10.1073/pnas.0500904102; Rizzo P, 2008, CANCER RES, V68, P5226, DOI 10.1158/0008-5472.CAN-07-5744; Rodilla V, 2009, P NATL ACAD SCI USA, V106, P6315, DOI 10.1073/pnas.0813221106; Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Salmon Patrick, 2007, Curr Protoc Hum Genet, VChapter 12, DOI 10.1002/0471142905.hg1210s54; Shao S, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0295-3; Shaw FL, 2012, J MAMMARY GLAND BIOL, V17, P111, DOI 10.1007/s10911-012-9255-3; Skrzypczak M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013091; Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052; Stathopoulos EN, 2005, ANN ONCOL, V16, P240, DOI 10.1093/annonc/mdi043; StoneO MR, 2007, J CELL SCI, V120, P3999, DOI 10.1242/jcs.009241; Strazzabosco M, 2013, J HEPATOL, V58, P181, DOI 10.1016/j.jhep.2012.08.006; Tee MK, 2004, MOL BIOL CELL, V15, P1262, DOI 10.1091/mbc.E03-06-0360; Valkenburg Kenneth C, 2011, Cancers (Basel), V3, P2050, DOI 10.3390/cancers3022050; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wang ZW, 2010, J CELL BIOCHEM, V109, P726, DOI 10.1002/jcb.22451; Wang ZW, 2006, CANCER RES, V66, P2778, DOI 10.1158/0008-5472.CAN-05-4281; Westhoff B, 2009, P NATL ACAD SCI USA, V106, P22293, DOI 10.1073/pnas.0907781106; Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052; WU YJ, 1981, CELL, V25, P627, DOI 10.1016/0092-8674(81)90170-7; Xiao YF, 2016, INT J ONCOL, V48, P437, DOI 10.3892/ijo.2015.3280; Yang XR, 2008, CLIN CANCER RES, V14, P3850, DOI 10.1158/1078-0432.CCR-07-4338; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zardawi SJ, 2010, HISTOPATHOLOGY, V56, P286, DOI 10.1111/j.1365-2559.2009.03475.x; Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786	95	62	66	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	2017	36	3					332	349		10.1038/onc.2016.221	http://dx.doi.org/10.1038/onc.2016.221			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IB	27345400	Green Published, hybrid			2022-12-17	WOS:000394166000004
J	Ramadoss, S; Guo, G; Wang, CY				Ramadoss, S.; Guo, G.; Wang, C-Y			Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53	ONCOGENE			English	Article							STEM-CELLS; MESENCHYMAL TRANSITION; TUMOR; METHYLATION; ACETYLATION; TRANSCRIPTION; METASTASIS; ACTIVATION; MECHANISMS; BIOLOGY	Invasive growth and apoptosis resistance of breast cancer cells are associated with metastasis and disease relapse. Here we identified that the lysine-specific demethylase KDM3A played a dual role in breast cancer cell invasion and apoptosis by demethylating histone and the non-histone protein p53, respectively. While inducing pro-invasive genes by erasing repressive histone H3 lysine 9 methylation, KDM3A promotes chemoresistance by demethylating p53. KDM3A suppressed pro-apoptotic functions of p53 by erasing p53-K372me1, as this methylation is crucial for the stability of chromatin-bound p53. Unexpectedly, depletion of KDM3A was capable of reactivating mutated p53 to induce the expression of pro-apoptotic genes in breast cancer with mutant p53. Moreover, KDM3A knockdown also potently inhibited tumorigenic potentials of breast cancer stem-like cells and rendered them sensitive to apoptosis induced by chemotherapeutic drugs. Taken together, our results suggest that KDM3A might be a potential therapeutic target for human breast cancer treatment and prevention.	[Ramadoss, S.; Guo, G.; Wang, C-Y] Univ Calif Los Angeles, Sch Dent, Div Oral Biol & Med, Lab Mol Signaling, 10833 Le Conte Ave, Los Angeles, CA 90095 USA; [Ramadoss, S.; Guo, G.; Wang, C-Y] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, 10833 Le Conte Ave, Los Angeles, CA 90095 USA; [Wang, C-Y] Univ Calif Los Angeles, Dept Bioengn, Henry Samueli Sch Engn & Appl Sci, Los Angeles, CA USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Wang, CY (corresponding author), Univ Calif Los Angeles, Sch Dent, Div Oral Biol & Med, Lab Mol Signaling, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.; Wang, CY (corresponding author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	cunywang@ucla.edu			NIH [R3713848, DE15964]; Shapiro Family Charitable Foundation; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE023874, R01DE015964, R37DE013848] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Shapiro Family Charitable Foundation; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by the NIH grants R3713848 and DE15964 and the Shapiro Family Charitable Foundation. We thank Dr Yi Zhang for the generous gift of KDM3A plasmid.	Alexander S, 2012, TRENDS MOL MED, V18, P13, DOI 10.1016/j.molmed.2011.11.003; Baccelli I, 2013, NAT BIOTECHNOL, V31, P539, DOI 10.1038/nbt.2576; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Boye K, 2010, AM J PATHOL, V176, P528, DOI 10.2353/ajpath.2010.090526; Campaner S, 2011, MOL CELL, V43, P681, DOI 10.1016/j.molcel.2011.08.007; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Cheng L, 2010, TOXICOL PATHOL, V38, P62, DOI 10.1177/0192623309354109; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Ding XM, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003884; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Ginestier C, 2012, CELL CYCLE, V11, P2583, DOI 10.4161/cc.21092; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588; Ivanov GS, 2007, MOL CELL BIOL, V27, P6756, DOI 10.1128/MCB.00460-07; Jiao XM, 2010, J BIOL CHEM, V285, P8218, DOI 10.1074/jbc.M110.100792; Joerger AC, 2007, ADV CANCER RES, V97, P1, DOI 10.1016/S0065-230X(06)97001-8; Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327; Krieg AJ, 2010, MOL CELL BIOL, V30, P344, DOI 10.1128/MCB.00444-09; Kurash JK, 2008, MOL CELL, V29, P392, DOI 10.1016/j.molcel.2007.12.025; Kuroki S, 2013, SCIENCE, V341, P1106, DOI 10.1126/science.1239864; Kwon M, 2014, CANCER GENE THER, V21, P179, DOI 10.1038/cgt.2014.17; Lane D, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000893; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lehnertz B, 2011, MOL CELL, V43, P673, DOI 10.1016/j.molcel.2011.08.006; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Mizuno H, 2010, P NATL ACAD SCI USA, V107, P22745, DOI 10.1073/pnas.1017001108; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Okada Y, 2007, NATURE, V450, P119, DOI 10.1038/nature06236; Perez RE, 2010, J CELL PHYSIOL, V225, P394, DOI 10.1002/jcp.22285; Ramadoss S, 2012, J BIOL CHEM, V287, P44508, DOI 10.1074/jbc.M112.424903; Ramadoss S, 2011, MOL CELL BIOL, V31, P924, DOI 10.1128/MCB.00576-10; Scully OJ, 2012, CANCER GENOM PROTEOM, V9, P311; Shetzer Y, 2014, CARCINOGENESIS, V35, P1196, DOI 10.1093/carcin/bgu073; Shi XB, 2007, MOL CELL, V27, P636, DOI 10.1016/j.molcel.2007.07.012; Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Tateishi K, 2009, NATURE, V458, P757, DOI 10.1038/nature07777; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; Wade MA, 2015, NUCLEIC ACIDS RES, V43, P196, DOI 10.1093/nar/gku1298; Zeng QH, 2005, CANCER CELL, V8, P13, DOI 10.1016/j.ccr.2005.06.004	46	62	68	0	34	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2017	36	1					47	59		10.1038/onc.2016.174	http://dx.doi.org/10.1038/onc.2016.174			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK6XJ	27270439	Green Accepted			2022-12-17	WOS:000394069100005
J	Rupaimoole, R; Ivan, C; Yang, D; Gharpure, KM; Wu, SY; Pecot, CV; Previs, RA; Nagaraja, AS; Armaiz-Pena, GN; McGuire, M; Pradeep, S; Mangala, LS; Rodriguez-Aguayo, C; Huang, L; Bar-Eli, M; Zhang, W; Lopez-Berestein, G; Calin, GA; Sood, AK				Rupaimoole, R.; Ivan, C.; Yang, D.; Gharpure, K. M.; Wu, S. Y.; Pecot, C. V.; Previs, R. A.; Nagaraja, A. S.; Armaiz-Pena, G. N.; McGuire, M.; Pradeep, S.; Mangala, L. S.; Rodriguez-Aguayo, C.; Huang, L.; Bar-Eli, M.; Zhang, W.; Lopez-Berestein, G.; Calin, G. A.; Sood, A. K.			Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression	ONCOGENE			English	Article							DOWN-REGULATION; POOR-PROGNOSIS; LUNG-CANCER; EXPRESSION; DROSHA; METASTASIS; BIOGENESIS; MIR-210	MicroRNAs (miRNAs) are small RNA molecules that affect cellular processes by controlling gene expression. Recent studies have shown that hypoxia downregulates Drosha and Dicer, key enzymes in miRNA biogenesis, causing a decreased pool of miRNAs in cancer and resulting in increased tumor growth and metastasis. Here we demonstrate a previously unrecognized mechanism by which hypoxia downregulates Dicer. We found that miR-630, which is upregulated under hypoxic conditions, targets and downregulates Dicer expression. In an orthotopic mouse model of ovarian cancer, delivery of miR-630 using 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) nanoliposomes resulted in increased tumor growth and metastasis, and decreased Dicer expression. Treatment with the combination of anti-miR-630 and anti-vascular endothelial growth factor antibody in mice resulted in rescue of Dicer expression and significantly decreased tumor growth and metastasis. These results indicate that targeting miR-630 is a promising approach to overcome Dicer deregulation in cancer. As demonstrated in the study, use of DOPC nanoliposomes for anti-miR delivery serves as a better alternative approach to cell line-based overexpression of sense or antisense miRNAs, while avoiding potential in vitro selection effects. Findings from this study provide a new understanding of miRNA biogenesis downregulation observed under hypoxia and suggest therapeutic avenues to target this dysregulation in cancer.	[Rupaimoole, R.; Ivan, C.; Gharpure, K. M.; Wu, S. Y.; Previs, R. A.; Nagaraja, A. S.; Armaiz-Pena, G. N.; McGuire, M.; Pradeep, S.; Mangala, L. S.; Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA; [Rupaimoole, R.; Gharpure, K. M.; Nagaraja, A. S.] Univ Texas MD Anderson Canc Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA; [Ivan, C.; Mangala, L. S.; Rodriguez-Aguayo, C.; Lopez-Berestein, G.; Calin, G. A.; Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Houston, TX 77030 USA; [Yang, D.] Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA USA; [Pecot, C. V.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Med, Chapel Hill, NC 27599 USA; [Rodriguez-Aguayo, C.; Lopez-Berestein, G.; Calin, G. A.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Huang, L.; Bar-Eli, M.; Sood, A. K.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Dept Canc Biol, Houston, TX 77030 USA; [Zhang, W.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Sood, AK (corresponding author), Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Dept Gynecol Oncol & Reprod Med & Canc Biol, 1155 Hemann P Pressler,Unit 1362, Houston, TX 77030 USA.	asood@mdanderson.org	Calin, George/E-9390-2011; Sood, Anoop Kumar/A-7344-2013; Nagaraja, Archana/AAE-8529-2021; Nagaraja, Archana Sidalaghatta/AAE-2205-2021; Rupaimoole, Rajesha/K-3272-2016	Sood, Anoop Kumar/0000-0001-5702-4108; Calin, George/0000-0002-7427-0578; Rupaimoole, Rajesha/0000-0002-4795-7921; Nagaraja, Archana/0000-0002-2851-9272; Previs, Rebecca/0000-0001-8087-9120; Ivan, Cristina/0000-0002-4848-0168; Yang, Da/0000-0002-8336-9457; Gharpure, Kshipra/0000-0003-4954-5696; Calin, George/0000-0001-6704-5615; RODRIGUEZ-AGUAYO, CRISTIAN/0000-0002-7880-7723; Armaiz-Pena, Guillermo N/0000-0002-9081-5339; McGuire, Michael/0000-0003-2699-8430	National Institutes of Health [P30 CA016672, CA109298, UH2TR000943-01, P50 CA083639, P50 CA098258, CA128797, U54 CA151668, U24CA143835]; Cancer Prevention and Research Institute of Texas [RP110595]; Ovarian Cancer Research Fund, Inc. (Program Project Development Grant); Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer; RGK Foundation; Gilder Foundation; Blanton-Davis Ovarian Cancer Research Program; Betty Anne Asche Murray Distinguished Professorship; Russell and Diana Hawkins Family Foundation Discovery Fellowship; Ovarian Cancer Research Fund, Inc.; Foundation for Women's Cancer; Cancer Prevention and Research Institute of Texas training grants [RP101502, RP101489]; NCI-DHHS-NIH T32 training grant [T32 CA101642]; NCI (T32 training grant) [CA009666]; Conquer Cancer Foundation ASCO Young Investigator Award; DoCM Advanced Scholar Program; Research Training Award from Cancer Prevention and Research Institute of Texas (CPRIT) [RP140106]; Altman Goldstein Discovery fellowship; NATIONAL CANCER INSTITUTE [R01CA128797, R01CA182905, P50CA083639, T32CA009666, R01CA109298, U54CA151668, T32CA101642, P30CA016672, U24CA143835, P50CA098258] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UH3TR000943, UH2TR000943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [RC2GM092599] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas; Ovarian Cancer Research Fund, Inc. (Program Project Development Grant); Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer; RGK Foundation; Gilder Foundation; Blanton-Davis Ovarian Cancer Research Program; Betty Anne Asche Murray Distinguished Professorship; Russell and Diana Hawkins Family Foundation Discovery Fellowship; Ovarian Cancer Research Fund, Inc.; Foundation for Women's Cancer; Cancer Prevention and Research Institute of Texas training grants; NCI-DHHS-NIH T32 training grant; NCI (T32 training grant); Conquer Cancer Foundation ASCO Young Investigator Award; DoCM Advanced Scholar Program; Research Training Award from Cancer Prevention and Research Institute of Texas (CPRIT); Altman Goldstein Discovery fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Portions of this work were supported by the National Institutes of Health (P30 CA016672, CA109298, UH2TR000943-01, P50 CA083639, P50 CA098258, CA128797, U54 CA151668 and U24CA143835); the Cancer Prevention and Research Institute of Texas (RP110595); the Ovarian Cancer Research Fund, Inc. (Program Project Development Grant); the Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer; the RGK Foundation; the Gilder Foundation; the Blanton-Davis Ovarian Cancer Research Program; and the Betty Anne Asche Murray Distinguished Professorship (AKS). RR is supported in part by the Russell and Diana Hawkins Family Foundation Discovery Fellowship. S.Y.W. is supported by the Ovarian Cancer Research Fund, Inc., Foundation for Women's Cancer and Cancer Prevention and Research Institute of Texas training grants (RP101502 and RP101489). RAP is supported by the NCI-DHHS-NIH T32 training grant (T32 CA101642). CVP is supported by a grant from the NCI (T32 training grant CA009666), the 2011 Conquer Cancer Foundation ASCO Young Investigator Award and the DoCM Advanced Scholar Program. ASN is supported by a Research Training Award from the Cancer Prevention and Research Institute of Texas (CPRIT RP140106). KMG is supported by Altman Goldstein Discovery fellowship. We thank Dr Xinna Zhang for assistance with the in situ hybridization analysis.	Allegra D, 2014, LEUKEMIA, V28, P98, DOI 10.1038/leu.2013.246; Armaiz-Pena GN, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2413; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Dedes KJ, 2011, EUR J CANCER, V47, P138, DOI 10.1016/j.ejca.2010.08.007; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Galluzzi L, 2010, CANCER RES, V70, P1793, DOI 10.1158/0008-5472.CAN-09-3112; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Huang X, 2009, MOL CELL, V35, P856, DOI 10.1016/j.molcel.2009.09.006; Karube Y, 2005, CANCER SCI, V96, P111, DOI 10.1111/j.1349-7006.2005.00015.x; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Kuo TC, 2013, J CLIN INVEST, V123, P1082, DOI 10.1172/JCI64044; Landen CN, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530; Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222; Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Mutharasan RK, 2011, AM J PHYSIOL-HEART C, V301, pH1519, DOI 10.1152/ajpheart.01080.2010; Nishimura M, 2013, CANCER DISCOV, V3, P1302, DOI 10.1158/2159-8290.CD-13-0159; Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427; Pecot CV, 2011, NAT REV CANCER, V11, P59, DOI 10.1038/nrc2966; Puissegur MP, 2011, CELL DEATH DIFFER, V18, P465, DOI 10.1038/cdd.2010.119; Rupaimoole R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6202; Shannon AM, 2003, CANCER TREAT REV, V29, P297, DOI 10.1016/S0305-7372(03)00003-3; Shen J, 2013, NATURE, V497, P383, DOI 10.1038/nature12080; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Tokumaru S, 2008, CARCINOGENESIS, V29, P2073, DOI 10.1093/carcin/bgn187; van den Beucken T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6203; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Wang XW, 2013, SCI REP-UK, V3, DOI 10.1038/srep01942; Wu SY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4459; Yamagishi N, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-229	31	62	66	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4312	4320		10.1038/onc.2015.492	http://dx.doi.org/10.1038/onc.2015.492			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26725326	Green Accepted, Green Submitted			2022-12-17	WOS:000382152100003
J	Wang, H; Liang, L; Fang, JY; Xu, J				Wang, H.; Liang, L.; Fang, J-Y; Xu, J.			Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers	ONCOGENE			English	Review							LONG NONCODING RNA; LYMPH-NODE METASTASIS; CELL LUNG-CANCER; POOR-PROGNOSIS; MITOCHONDRIAL-DNA; COLON-CANCER; MUTUAL EXCLUSIVITY; CHROMOSOME 20Q; PROTEIN EXPRESSION; MULTIPLE PATHWAYS	Colorectal cancer (CRC) results from the accumulation of genetic alterations, and somatic copy number alterations (CNAs) are crucial for the development of CRC. Genome-wide survey of CNAs provides opportunities for identifying cancer driver genes in an unbiased manner. The detection of aberrant CNAs may provide novel markers for the early diagnosis and personalized treatment of CRC. A major challenge in array-based profiling of CNAs is to distinguish the alterations that play causative roles from the random alterations that accumulate during colorectal carcinogenesis. In this view, we systematically discuss the frequent CNAs in CRC, focusing on functional genes that have potential diagnostic, prognostic and therapeutic significance.	[Xu, J.] Minist Hlth, Key Lab Gastroenterol & Hepatol, State Key Lab Oncogenes & Related Genes, Mid Shandong Rd 145, Shanghai 200001, Peoples R China; [Xu, J.] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Div Gastroenterol & Hepatol, Mid Shandong Rd 145, Shanghai 200001, Peoples R China; [Xu, J.] Shanghai Inst Digest Dis, Shanghai Canc Inst, Mid Shandong Rd 145, Shanghai 200001, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Xu, J (corresponding author), Minist Hlth, Key Lab Gastroenterol & Hepatol, State Key Lab Oncogenes & Related Genes, Mid Shandong Rd 145, Shanghai 200001, Peoples R China.; Xu, J (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Div Gastroenterol & Hepatol, Mid Shandong Rd 145, Shanghai 200001, Peoples R China.; Xu, J (corresponding author), Shanghai Inst Digest Dis, Shanghai Canc Inst, Mid Shandong Rd 145, Shanghai 200001, Peoples R China.	xujieletter@gmail.com	Xu, Jie/K-3712-2019; Xu, Jie/C-4283-2016	Xu, Jie/0000-0001-9163-3898; Xu, Jie/0000-0001-9163-3898	National Natural Science Foundation of China [30971330, 31371420, 81320108024, 81000861, 81322036, 81272383]; Foundation for Innovative Research Groups of the National Natural Science Foundation of China [81421001]; Program for Innovative Research Team of Shanghai Municipal Education Commission; Shanghai 'Oriental Scholars' project [2013XJ]; Shanghai Science and Technology Commission 'Pujiang Project' [13PJ1405900]; Shanghai Natural Science Foundation [12ZR1417900]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Foundation for Innovative Research Groups of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Innovative Research Team of Shanghai Municipal Education Commission; Shanghai 'Oriental Scholars' project; Shanghai Science and Technology Commission 'Pujiang Project'; Shanghai Natural Science Foundation(Natural Science Foundation of Shanghai)	This project was supported by grants from the National Natural Science Foundation of China (30971330, 31371420, 81320108024, 81000861, 81322036 and 81272383); Foundation for Innovative Research Groups of the National Natural Science Foundation of China (Grant No. 81421001), the Program for Innovative Research Team of Shanghai Municipal Education Commission; Shanghai 'Oriental Scholars' project (2013XJ); Shanghai Science and Technology Commission 'Pujiang Project' (13PJ1405900); and Shanghai Natural Science Foundation (12ZR1417900). The sponsors of this study had no role in the analysis and interpretation of the literatures, the decision to submit the manuscript for publication or the writing of the manuscript.	Ali RH, 2014, INT J MOL SCI, V15, P17344, DOI 10.3390/ijms151017344; ALIHASSAN NZ, 2014, PLOS ONE, V0009; Amgalan B, 2015, BIOINFORMATICS, V31, P2452, DOI 10.1093/bioinformatics/btv175; Andersen CL, 2011, INT J CANCER, V129, P1848, DOI 10.1002/ijc.25841; Aytekin T, 2010, CANCER GENET CYTOGEN, V201, P32, DOI 10.1016/j.cancergencyto.2010.05.005; Bacolod MD, 2010, J MOL DIAGN, V12, P552, DOI 10.2353/jmoldx.2010.100098; Bavi P, 2013, BRIT J CANCER, V109, P2735, DOI 10.1038/bjc.2013.641; Benedettini E, 2010, AM J PATHOL, V177, P415, DOI 10.2353/ajpath.2010.090863; Berg M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-100; Berteaux N, 2008, MOL CELL BIOL, V28, P6731, DOI 10.1128/MCB.02103-07; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bouteille N, 2009, ONCOGENE, V28, P2569, DOI 10.1038/onc.2009.120; Brosens RPM, 2010, ANAL CELL PATHOL, V33, P95, DOI [10.1155/2010/161608, 10.3233/ACP-CLO-2010-0531]; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carvalho B, 2009, GUT, V58, P79, DOI 10.1136/gut.2007.143065; Chen HY, 2014, MOL ONCOL, V8, P1393, DOI 10.1016/j.molonc.2014.05.010; Chen T, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-8; Chen WX, 2013, GENOMICS, V102, P27, DOI 10.1016/j.ygeno.2013.02.003; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Choi J, 2012, ANTICANCER RES, V32, P559; Ciriello G, 2012, GENOME RES, V22, P398, DOI 10.1101/gr.125567.111; Cowling VH, 2010, BIOCHEM J, V425, P295, DOI 10.1042/BJ20091352; Cui HH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-110; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Darsigny M, 2010, CANCER RES, V70, P9423, DOI 10.1158/0008-5472.CAN-10-1697; Deng QW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103022; Diep CB, 2006, GENE CHROMOSOME CANC, V45, P31, DOI 10.1002/gcc.20261; Eldai H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076251; Fang ZY, 2010, ONCOL LETT, V1, P925, DOI 10.3892/ol_00000163; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; Feng S, 2011, ONCOL LETT, V2, P899, DOI 10.3892/ol.2011.322; Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149; Fernandez-Sanchez ME, 2009, MOL CELL BIOL, V29, P6182, DOI 10.1128/MCB.00973-09; Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200; Fleming NI, 2013, CANCER RES, V73, P725, DOI 10.1158/0008-5472.CAN-12-2706; Flora M, 2012, CANCER GENET-NY, V205, P630, DOI 10.1016/j.cancergen.2012.10.005; Fu JY, 2007, MOL CANCER RES, V5, P1, DOI 10.1158/1541-7786.MCR-06-0208; Gonzalez-Gonzalez M, 2014, CANCER-AM CANCER SOC, V120, P1948, DOI 10.1002/cncr.28681; Gonzalez-Perez A, 2013, NAT METHODS, V10, P723, DOI 10.1038/nmeth.2562; Gonzalez-Perez A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks743; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; Gruber SB, 2002, SCIENCE, V297, P2013, DOI 10.1126/science.1074399; Guilmeau S, 2008, GASTROENTEROLOGY, V135, P849, DOI 10.1053/j.gastro.2008.05.050; Han CB, 2012, CANCER LETT, V314, P63, DOI 10.1016/j.canlet.2011.09.012; Han D, 2015, CANCER LETT, V361, P13, DOI 10.1016/j.canlet.2015.03.002; Han SW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064271; Hastings PJ, 2009, NAT REV GENET, V10, P551, DOI 10.1038/nrg2593; Henningham A, 2014, J BIOL CHEM, V289, P32303, DOI 10.1074/jbc.M114.602847; Hermsen M, 2002, GASTROENTEROLOGY, V123, P1109, DOI 10.1053/gast.2002.36051; Hoang Don, 2013, BMJ Case Rep, V2013, DOI 10.1136/bcr-2013-008684; Honma K, 2008, NAT MED, V14, P939, DOI 10.1038/nm.1858; Hornstein Max, 2008, Cancer Genomics & Proteomics, V5, P123; Horvath HC, 2010, J HISTOCHEM CYTOCHEM, V58, P277, DOI 10.1369/jhc.2009.954339; Hossini AM, 2008, BIOCHEM PHARMACOL, V76, P1612, DOI 10.1016/j.bcp.2008.08.013; Hou JP, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0056-8; Hu Y, 2014, CANCER RES, V74, P6890, DOI 10.1158/0008-5472.CAN-14-0686; Hu Y, 2014, ONCOTARGET, V5, P2230, DOI 10.18632/oncotarget.1895; Iguchi T, 2015, ANTICANCER RES, V35, P1385; Issa JP, 2008, CLIN CANCER RES, V14, P5939, DOI 10.1158/1078-0432.CCR-08-1596; Iwatsuki M, 2010, INT J CANCER, V126, P1828, DOI 10.1002/ijc.24879; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jones NP, 2005, J CELL SCI, V118, P2695, DOI 10.1242/jcs.02374; Kazuo M, 2008, ANN SURG ONCOL, V15, P1530, DOI 10.1245/s10434-007-9746-4; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; King AN, 2010, ANTI-CANCER AGENT ME, V10, P213; Knosel T, 2004, NEOPLASIA, V6, P23, DOI 10.1016/s1476-5586(04)80050-2; Kruszewski W, 2004, FOLIA HISTOCHEM CYTO, V42, P173; Kumarakulasingham M, 2005, CLIN CANCER RES, V11, P3758, DOI 10.1158/1078-0432.CCR-04-1848; Kurashina K, 2008, CANCER SCI, V99, P1835, DOI 10.1111/j.1349-7006.2008.00881.x; Lam AKY, 2011, MOL ONCOL, V5, P475, DOI 10.1016/j.molonc.2011.06.003; Larsson A, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-282; Liang L, 2016, ONCOGENE, V35, P1475, DOI 10.1038/onc.2015.209; Liang LX, 2015, SCI REP-UK, V5, DOI 10.1038/srep11763; Liang WC, 2015, ONCOTARGET; Lin CH, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-36; Little SE, 2012, CANCER RES, V72, P1614, DOI 10.1158/0008-5472.CAN-11-4069; Liu J, 2009, ONCOGENE, V28, P994, DOI 10.1038/onc.2008.450; Liu J, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-261; Liu XP, 2007, ONCOL REP, V17, P261; Liu ZH, 2005, MOL CANCER RES, V3, P21; Loo LWM, 2013, GENE CHROMOSOME CANC, V52, P450, DOI 10.1002/gcc.22043; Lu YM, 2012, CANCER BIOMARK, V11, P219, DOI 10.3233/CBM-2012-00282; Ma YL, 2014, CHINESE J CANCER RES, V26, P525, DOI 10.3978/j.issn.1000-9604.2014.09.02; Maffei M, 2014, CYTOGENET GENOME RES, V144, P9, DOI 10.1159/000367909; Mekenkamp LJM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-292; Meng XB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018715; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Mitra AK, 2011, ONCOGENE, V30, P1566, DOI 10.1038/onc.2010.532; Miyabe I, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002407; Molina JR, 2012, ONCOGENE, V31, P1264, DOI 10.1038/onc.2011.324; Moniz S, 2010, CELL MOL LIFE SCI, V67, P1265, DOI 10.1007/s00018-010-0261-6; MUSCATELLI F, 1995, P NATL ACAD SCI USA, V92, P4987, DOI 10.1073/pnas.92.11.4987; Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698; Nehls O, 2007, BRIT J CANCER, V96, P1409, DOI 10.1038/sj.bjc.6603728; Ogunbiyi OA, 1997, GASTROENTEROLOGY, V113, P761, DOI 10.1016/S0016-5085(97)70169-0; Orsetti B, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-121; Park DY, 2007, AM J PATHOL, V171, P1509, DOI 10.2353/ajpath.2007.070331; Park SY, 2009, MITOCHONDRION, V9, P318, DOI 10.1016/j.mito.2009.04.006; Pillaire MJ, 2010, ONCOGENE, V29, P876, DOI 10.1038/onc.2009.378; Postma C, 2007, CELL ONCOL, V29, P73; Postma C, 2009, ANN ONCOL, V20, P1048, DOI 10.1093/annonc/mdn738; Poulogiannis G, 2010, J PATHOL, V220, P338, DOI 10.1002/path.2640; Price TJ, 2013, CANCER MED-US, V2, P277, DOI 10.1002/cam4.75; Quinlan KGR, 2007, BBA-REV CANCER, V1775, P333, DOI 10.1016/j.bbcan.2007.05.001; Ramirez-Ramirez R, 2015, GENET MOL RES, V14, P362, DOI 10.4238/2015.January.23.9; Rand V, 2008, BRIT J CANCER, V99, P1136, DOI 10.1038/sj.bjc.6604651; Rebhun JF, 2000, J BIOL CHEM, V275, P34901, DOI 10.1074/jbc.M005327200; Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329; Reimand J, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2012.68; Sabbah M, 2011, MOL CELL BIOL, V31, P1459, DOI 10.1128/MCB.01316-10; Sapkota Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053850; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schunke D, 2007, CANCER RES, V67, P10694, DOI 10.1158/0008-5472.CAN-07-1621; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Sheffer M, 2009, P NATL ACAD SCI USA, V106, P7131, DOI 10.1073/pnas.0902232106; Shi DB, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0031-7; Sillars-Hardebol AH, 2012, GUT, V61, P1568, DOI 10.1136/gutjnl-2011-301153; Sillars-Hardebol AH, 2012, J PATHOL, V226, P442, DOI 10.1002/path.2983; Silva FP, 2005, NEOPLASIA, V7, P348, DOI 10.1593/neo.04544; Singhal SS, 2007, CANCER RES, V67, P4382, DOI 10.1158/0008-5472.CAN-06-4124; Sokolenko AP, 2012, INT J CANCER, V130, P2867, DOI 10.1002/ijc.26342; Stahl M, 2008, J BIOL CHEM, V283, P13638, DOI 10.1074/jbc.M802027200; Stawski R, 2013, BRAIN TUMOR PATHOL, V30, P160, DOI 10.1007/s10014-012-0117-x; Stemmer V, 2008, ONCOGENE, V27, P5075, DOI 10.1038/onc.2008.140; Storojeva I, 2005, ONCOLOGY-BASEL, V68, P246, DOI 10.1159/000086781; Takagi Y, 1998, BRIT J CANCER, V78, P1152, DOI 10.1038/bjc.1998.645; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Tamborero D, 2013, SCI REP-UK, V3, DOI 10.1038/srep02650; Tamborero D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055489; The Cancer Genome Atlas Network, 2012, NATURE, V487, P330, DOI [DOI 10.1038/NATURE11252, 10.1038/nature11252]; Thean LF, 2010, GENE CHROMOSOME CANC, V49, P99, DOI 10.1002/gcc.20724; Thomas SM, 2003, CANCER RES, V63, P5629; Ungerback J, 2012, CARCINOGENESIS, V33, P2126, DOI 10.1093/carcin/bgs256; Veronese A, 2010, CANCER RES, V70, P3140, DOI 10.1158/0008-5472.CAN-09-4456; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Wells A, 2003, CLIN EXP METASTAS, V20, P285, DOI 10.1023/A:1024088922957; Westermarck J, 2008, TRENDS MOL MED, V14, P152, DOI 10.1016/j.molmed.2008.02.001; Wierzbicki PM, 2009, J PHYSIOL PHARMACOL, V60, P63; Wu CL, 2001, CANCER RES, V61, P7325; Xiang JF, 2014, CELL RES, V24, P513, DOI 10.1038/cr.2014.35; Xie T, 2014, GENOMICS, V104, P234, DOI 10.1016/j.ygeno.2014.07.012; Xie T, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0042001, 10.1371/journal.pone.0047577]; Xue Y, 2015, MUTAGENESIS, V30, P303, DOI 10.1093/mutage/geu076; Yamada S, 2006, EJSO-EUR J SURG ONC, V32, P303, DOI 10.1016/j.ejso.2006.01.002; Yang RX, 2014, CARCINOGENESIS, V35, P315, DOI 10.1093/carcin/bgt344; Yao D, 2011, BLOOD, V117, P5652, DOI 10.1182/blood-2010-12-326074; Yoshida T, 2010, CANCER INFORM, V9, P147; Yue SQ, 2003, WORLD J GASTROENTERO, V9, P2863; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zhang CW, 2011, MOL GENET METAB, V103, P104, DOI 10.1016/j.ymgme.2011.02.005; Zhang Zi-Chao, 2015, Asian Pac J Cancer Prev, V16, P2459; Zhao D, 2011, HUM PATHOL, V42, P1514, DOI 10.1016/j.humpath.2010.03.012; Zhu J, 2015, BIOINFORMATICS, V31, P1436, DOI 10.1093/bioinformatics/btu834; Zuern C, 2010, ONCOL REP, V23, P183, DOI 10.3892/or_00000621	154	62	63	1	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2011	2019		10.1038/onc.2015.304	http://dx.doi.org/10.1038/onc.2015.304			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26257062				2022-12-17	WOS:000374505600001
J	Mir, R; Pradhan, SJ; Patil, P; Mulherkar, R; Galande, S				Mir, R.; Pradhan, S. J.; Patil, P.; Mulherkar, R.; Galande, S.			Wnt/beta-catenin signaling regulated SATB1 promotes colorectal cancer tumorigenesis and progression	ONCOGENE			English	Article							CHROMATIN ORGANIZER SATB1; TUMOR PROGRESSION; GENE-EXPRESSION; GASTRIC-CANCER; UP-REGULATION; IN-VITRO; METASTASIS; GROWTH; CARCINOMA; GENOME	The chromatin organizer SATB1 has been implicated in the development and progression of multiple cancers including breast and colorectal cancers. However, the regulation and role of SATB1 in colorectal cancers is poorly understood. Here, we demonstrate that expression of SATB1 is induced upon hyperactivation of Wnt/beta-catenin signaling and repressed upon depletion of TCF7L2 (TCF4) and beta-catenin. Using several colorectal cancer cell line models and the APC min mutant zebrafish in vivo model, we established that SATB1 is a novel target of Wnt/beta-catenin signaling. We show that direct binding of TCF7L2/beta-catenin complex on Satb1 promoter is required for the regulation of SATB1. Moreover, SATB1 is sufficient to regulate the expression of beta-catenin, members of TCF family, multiple downstream effectors and mediators of Wnt pathway. SATB1 potentiates the cellular changes and expression of key cancer-associated genes in non-aggressive colorectal cells, promotes their aggressive phenotype and tumorigenesis in vivo. Conversely, depletion of SATB1 from aggressive cells reprograms the expression of cancer-associated genes, reverses their cancer phenotype and reduces the potential of these cells to develop tumors in vivo. We also show that SATB1 and beta-catenin bind to the promoters of TCF7L2 and the downstream targets of Wnt signaling and regulate their expression. Our findings suggest that SATB1 shares a feedback regulatory network with TCF7L2/beta-catenin signaling and is required for Wnt signaling-dependent regulation of beta-catenin. Collectively, these results provide unequivocal evidence to establish that SATB1 reprograms the expression of tumor growth-and metastasis-associated genes to promote tumorigenesis and functionally overlaps with Wnt signaling critical for colorectal cancer tumorigenesis.	[Mir, R.; Pradhan, S. J.; Galande, S.] Indian Inst Sci Educ & Res, Pune, Maharashtra, India; [Patil, P.] Tata Mem Hosp, Mumbai 400012, Maharashtra, India; [Mulherkar, R.] Adv Ctr Treatment Res & Educ Canc, Kharghar, Navi Mumbai, India; [Galande, S.] Natl Ctr Cell Sci, Pune, Maharashtra, India	Indian Institute of Science Education & Research (IISER) Pune; Tata Memorial Centre (TMC); Tata Memorial Hospital; Tata Memorial Centre (TMC); Advance Centre for Treatment, Research & Education in Cancer (ACTREC); Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Galande, S (corresponding author), Indian Inst Sci Educ & Res, Ctr Excellence Epigenet, Dr Homi Bhabha Rd, Pune 411008, Maharashtra, India.	sanjeev@iiserpune.ac.in		Patil, Prachi/0000-0002-5809-6282	Centre of Excellence in Epigenetics program of the Department of Biotechnology; Department of Science and Technology, Government of India; University Grants Commission, India	Centre of Excellence in Epigenetics program of the Department of Biotechnology; Department of Science and Technology, Government of India(Department of Science & Technology (India)); University Grants Commission, India(University Grants Commission, India)	We thank the staff of the experimental animal facility and in vivo imaging facility of NCCS. Work was supported by grants from the Centre of Excellence in Epigenetics program of the Department of Biotechnology and the Swarnajayanti Fellowship from the Department of Science and Technology, Government of India to SG. RM is supported by fellowship from the University Grants Commission, India. We thank Mahendra Sonawane for providing RNA and whole cell lysates from APC min mutant Zebrafish.	Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Azzolin L, 2012, CELL, V151, P1443, DOI 10.1016/j.cell.2012.11.027; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Cai ST, 2006, NAT GENET, V38, P1278, DOI 10.1038/ng1913; Cheng C, 2010, APMIS, V118, P855, DOI 10.1111/j.1600-0463.2010.02673.x; Chu SH, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-149; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Frietze S, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r52; Fromberg A, 2014, INT J CANCER, V135, P2537, DOI 10.1002/ijc.28895; Galande S, 2007, CURR OPIN GENET DEV, V17, P408, DOI 10.1016/j.gde.2007.08.003; Galande S, 2002, CURR CANCER DRUG TAR, V2, P157, DOI 10.2174/1568009023333917; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781; Karmodiya K, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-424; Kohwi-Shigematsu T, 2013, SEMIN CANCER BIOL, V23, P72, DOI 10.1016/j.semcancer.2012.06.009; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Lu XM, 2010, ONCOL REP, V24, P981, DOI 10.3892/or_00000945; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; McInnes N, 2012, ONCOGENE, V31, P1045, DOI 10.1038/onc.2011.293; Meng WJ, 2012, INT J COLORECTAL DIS, V27, P143, DOI 10.1007/s00384-011-1302-9; Meng WJ, 2011, MED HYPOTHESES, V76, P277, DOI 10.1016/j.mehy.2010.10.022; Mir R, 2012, CURR DRUG TARGETS, V13, P1603, DOI 10.2174/138945012803530008; Najdi Rani, 2011, J Carcinog, V10, P5, DOI 10.4103/1477-3163.78111; Nodin B, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-115; Notani D, 2011, J BIOSCIENCES, V36, P461, DOI 10.1007/s12038-011-9091-4; Notani D, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000296; Ordinario E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051786; Thorne CA, 2010, NAT CHEM BIOL, V6, P829, DOI 10.1038/NCHEMBIO.453; Tu W, 2012, LIVER INT, V32, P1064, DOI 10.1111/j.1478-3231.2012.02815.x; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wagner RT, 2010, STEM CELLS, V28, P1794, DOI 10.1002/stem.502; Wang S, 2009, J PATHOL, V219, P114, DOI 10.1002/path.2575; Xiang JD, 2012, ONCOL LETT, V3, P865, DOI 10.3892/ol.2012.571; Zhang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0047902; Zhang LZ, 2004, MOL CELL BIOL, V24, P2169, DOI 10.1128/MCB.24.5.2169-2180.2004; Zhang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100413; Zhao F, 2005, NUCLEIC ACIDS RES, V33, pD103, DOI 10.1093/nar/gki004	40	62	66	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2016	35	13					1679	1691		10.1038/onc.2015.232	http://dx.doi.org/10.1038/onc.2015.232			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RP	26165840				2022-12-17	WOS:000373064200007
J	Koppens, M; van Lohuizen, M				Koppens, M.; van Lohuizen, M.			Context-dependent actions of Polycomb repressors in cancer	ONCOGENE			English	Review							H3 LYSINE 27; HISTONE METHYLTRANSFERASE EZH2; EPITHELIAL-MESENCHYMAL TRANSITION; REGULATES CELL-PROLIFERATION; EMBRYONIC STEM-CELLS; BMI-1 MESSENGER-RNA; GENE-EXPRESSION; BREAST-CANCER; TUMOR-SUPPRESSOR; H2A UBIQUITYLATION	Polycomb Group (PcG) proteins form Polycomb Repressive Complexes (PRCs) that function as epigenetic repressors of gene expression. The large variety of PcG proteins, in addition to the high number of paralogs, allows for the formation of diverse PRCs with different properties, providing fine-tuned control over cell specification. Initially identified as being oncogenes, a small number of PcG genes are involved in tumor development in part through the repression of the CDKN2A locus. Therefore, enhanced PcG-mediated repression has long been assumed to be cancer promoting. However, recent data have revealed that for some cancers, PcG proteins act as tumor suppressors, indicating that this traditional view is oversimplified. In this review, we present an overview of the roles of PcG genes in oncogenesis and how the nature of their role is context dependent.	[Koppens, M.; van Lohuizen, M.] Netherlands Canc Inst, Div Mol Genet, H4012,Plesmanlaan 121,Postbus 90203, NL-1066 Amsterdam, Netherlands; [van Lohuizen, M.] Canc Genom Ctr Netherlands, Utrecht, Netherlands	Netherlands Cancer Institute	van Lohuizen, M (corresponding author), Netherlands Canc Inst, Div Mol Genet, H4012,Plesmanlaan 121,Postbus 90203, NL-1066 Amsterdam, Netherlands.	M.V.Lohuizen@NKI.NL						Abdouh M, 2009, J NEUROSCI, V29, P8884, DOI 10.1523/JNEUROSCI.0968-09.2009; Aguilo F, 2011, CANCER RES, V71, P5365, DOI 10.1158/0008-5472.CAN-10-4379; Akasaka T, 1996, DEVELOPMENT, V122, P1513; Akasaka T, 2001, DEVELOPMENT, V128, P1587; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Beguelin W, 2013, CANCER CELL, V23, P677, DOI 10.1016/j.ccr.2013.04.011; Behrens C, 2013, CLIN CANCER RES, V19, P6556, DOI 10.1158/1078-0432.CCR-12-3946; Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343; Benard A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108265; Bender S, 2013, CANCER CELL, V24, P660, DOI 10.1016/j.ccr.2013.10.006; Bengani H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067217; Berezovska OP, 2006, CELL CYCLE, V5, P1886; Berg T, 2014, BLOOD, V123, P3914, DOI 10.1182/blood-2012-12-473439; Bernard D, 2005, ONCOGENE, V24, P5543, DOI 10.1038/sj.onc.1208735; Blackledge NP, 2014, CELL, V157, P1445, DOI 10.1016/j.cell.2014.05.004; Borodovsky A, 2013, ONCOTARGET, V4, P1737, DOI 10.18632/oncotarget.1408; Brockdorff N, 2013, RNA, V19, P429, DOI 10.1261/rna.037598.112; Bruggeman SWM, 2007, CANCER CELL, V12, P328, DOI 10.1016/j.ccr.2007.08.032; Caganova M, 2013, J CLIN INVEST, V123, P5009, DOI 10.1172/JCI70626; Cai MY, 2011, GUT, V60, P967, DOI 10.1136/gut.2010.231993; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Chan KM, 2013, GENE DEV, V27, P985, DOI 10.1101/gad.217778.113; Chen S, 2014, ONCOTARGET, V5, P10421, DOI 10.18632/oncotarget.2126; Chowdhury M, 2007, LEUKEMIA, V21, P1116, DOI 10.1038/sj.leu.2404623; Clermont PL, 2014, BRIT J CANCER, V111, P1663, DOI 10.1038/bjc.2014.474; Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533; Cooper S, 2014, CELL REP, V7, P1456, DOI 10.1016/j.celrep.2014.04.012; Core N, 2004, ONCOGENE, V23, P7660, DOI 10.1038/sj.onc.1207998; Core N, 1997, DEVELOPMENT, V124, P721; Crea F, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-265; Cuddapah S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036365; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561; de Vries NA, 2015, CELL REP, V10, P383, DOI 10.1016/j.celrep.2014.12.028; Khuong-Quang DA, 2012, ACTA NEUROPATHOL, V124, P439, DOI 10.1007/s00401-012-0998-0; Eisele G, 2006, BRAIN, V129, P2416, DOI 10.1093/brain/awl205; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Facchino S, 2010, J NEUROSCI, V30, P10096, DOI 10.1523/JNEUROSCI.1634-10.2010; Federico A, 2009, CANCER RES, V69, P7079, DOI 10.1158/0008-5472.CAN-09-1542; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Forzati F, 2012, J CLIN INVEST, V122, P612, DOI 10.1172/JCI58620; Funato K, 2014, SCIENCE, V346, P1529, DOI 10.1126/science.1253799; Gao ZH, 2012, MOL CELL, V45, P344, DOI 10.1016/j.molcel.2012.01.002; Gargiulo G, 2013, CANCER CELL, V23, P660, DOI 10.1016/j.ccr.2013.03.030; Gil J, 2004, NAT CELL BIOL, V6, P67, DOI 10.1038/ncb1077; Gilbertson RJ, 2011, CELL, V145, P25, DOI 10.1016/j.cell.2011.03.019; Ginjala V, 2011, MOL CELL BIOL, V31, P1972, DOI 10.1128/MCB.00981-10; Grossmann V, 2011, LEUKEMIA, V25, P877, DOI 10.1038/leu.2011.10; Guglielmelli P, 2014, LEUKEMIA, V28, P1804, DOI 10.1038/leu.2014.76; Guglielmelli P, 2011, BLOOD, V118, P5227, DOI 10.1182/blood-2011-06-363424; Guo BH, 2010, ANN ONCOL, V21, P2361, DOI 10.1093/annonc/mdq241; Guo BH, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-10; Guo WJ, 2007, CANCER RES, V67, P5083, DOI 10.1158/0008-5472.CAN-06-4368; Guo WJ, 2007, MOL BIOL CELL, V18, P536, DOI 10.1091/mbc.E06-05-0447; Hashizume R, 2014, NAT MED, V20, P1394, DOI 10.1038/nm.3716; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; Hinz S, 2008, TUMOR BIOL, V29, P323, DOI 10.1159/000170879; Hosogane M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003698; Huang J, 2012, MED ONCOL, V29, P1606, DOI 10.1007/s12032-011-9998-5; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jaffe JD, 2013, NAT GENET, V45, P1386, DOI 10.1038/ng.2777; Jankowska AM, 2011, BLOOD, V118, P3932, DOI 10.1182/blood-2010-10-311019; Jermann P, 2014, P NATL ACAD SCI USA, V111, pE3415, DOI 10.1073/pnas.1400672111; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kajiume T, 2009, EXP HEMATOL, V37, P857, DOI 10.1016/j.exphem.2009.04.011; Kalb R, 2014, NAT STRUCT MOL BIOL, V21, P569, DOI 10.1038/nsmb.2833; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; KANNO M, 1995, EMBO J, V14, P5672, DOI 10.1002/j.1460-2075.1995.tb00254.x; Karamitopoulou E, 2010, EUR J CANCER, V46, P1438, DOI 10.1016/j.ejca.2010.01.033; Karapetyan Armen R, 2013, Cancers (Basel), V5, P462, DOI 10.3390/cancers5020462; Katoh-Fukui Y, 1998, NATURE, V393, P688, DOI 10.1038/31482; Katoh-Fukui Y, 2005, BLOOD, V106, P1612, DOI 10.1182/blood-2004-08-3367; Katoh-Fukui Y, 2012, ENDOCRINOLOGY, V153, P913, DOI 10.1210/en.2011-1055; Kaustov L, 2011, J BIOL CHEM, V286, P521, DOI 10.1074/jbc.M110.191411; Khan SN, 2013, LEUKEMIA, V27, P1301, DOI 10.1038/leu.2013.80; Kim W, 2013, NAT CHEM BIOL, V9, P643, DOI [10.1038/NCHEMBIO.1331, 10.1038/nchembio.1331]; Klauke K, 2013, NAT CELL BIOL, V15, P353, DOI 10.1038/ncb2701; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kranc KR, 2003, MOL CELL BIOL, V23, P7658, DOI 10.1128/MCB.23.21.7658-7666.2003; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242; Lee JY, 2014, ONCOGENE, V33, P1325, DOI 10.1038/onc.2013.53; Lee JY, 2008, CANCER RES, V68, P4201, DOI 10.1158/0008-5472.CAN-07-2570; Lee SH, 2013, CANCER LETT, V335, P397, DOI 10.1016/j.canlet.2013.02.051; Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095; Lessard J, 1998, BLOOD, V91, P1216, DOI 10.1182/blood.V91.4.1216; Lewis PW, 2013, SCIENCE, V340, P857, DOI 10.1126/science.1232245; Li DW, 2010, J CANCER RES CLIN, V136, P997, DOI 10.1007/s00432-009-0745-7; Li G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080970; Li J, 2014, CANCER CELL, V25, P118, DOI 10.1016/j.ccr.2013.12.008; Ligon KL, 2007, NEURON, V53, P503, DOI 10.1016/j.neuron.2007.01.009; Liu JH, 2008, J SURG ONCOL, V97, P267, DOI 10.1002/jso.20934; Liu L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081484; Liu PW, 2014, J DIGEST DIS, V15, P166, DOI 10.1111/1751-2980.12129; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Lu YW, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-143; Lynch MD, 2012, EMBO J, V31, P317, DOI 10.1038/emboj.2011.399; Maertens GN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006380; Maethner E, 2013, CELL REP, V3, P1553, DOI 10.1016/j.celrep.2013.03.038; Makishima H, 2010, LEUKEMIA, V24, P1799, DOI 10.1038/leu.2010.167; Mansueto Gelsomina, 2010, Genes Cancer, V1, P210, DOI 10.1177/1947601910366860; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; McCabe MT, 2012, P NATL ACAD SCI USA, V109, P2989, DOI 10.1073/pnas.1116418109; Mendenhall EM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001244; Mihara K, 2006, BLOOD, V107, P305, DOI 10.1182/blood-2005-06-2393; Miki J, 2007, GENES CELLS, V12, P1371, DOI 10.1111/j.1365-2443.2007.01135.x; Min JR, 2003, GENE DEV, V17, P1823, DOI 10.1101/gad.269603; Mohty M, 2007, BLOOD, V110, P380, DOI 10.1182/blood-2006-12-065599; Morey L, 2012, CELL STEM CELL, V10, P47, DOI 10.1016/j.stem.2011.12.006; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Muto T, 2013, J EXP MED, V210, P2627, DOI 10.1084/jem.20131144; Nacerddine K, 2012, J CLIN INVEST, V122, P1920, DOI 10.1172/JCI57477; Neff T, 2012, P NATL ACAD SCI USA, V109, P5028, DOI 10.1073/pnas.1202258109; Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Ntziachristos P, 2012, NAT MED, V18, P298, DOI 10.1038/nm.2651; O'Loghlen A, 2012, CELL STEM CELL, V10, P33, DOI 10.1016/j.stem.2011.12.004; Oguro H, 2010, CELL STEM CELL, V6, P279, DOI 10.1016/j.stem.2010.01.005; Oh EJ, 2014, HUM PATHOL, V45, P2043, DOI 10.1016/j.humpath.2014.07.002; Ougolkov AV, 2008, CLIN CANCER RES, V14, P6790, DOI 10.1158/1078-0432.CCR-08-1013; Pallante P, 2008, CANCER RES, V68, P6770, DOI 10.1158/0008-5472.CAN-08-0695; Pallante P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098295; Pallante P, 2010, EUR J CANCER, V46, P2304, DOI 10.1016/j.ejca.2010.05.011; Park JH, 2011, ONCOGENE, V30, P4578, DOI 10.1038/onc.2011.174; Parris TZ, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-324; Parris TZ, 2014, INT J CANCER, V134, P1617, DOI 10.1002/ijc.28497; Pemberton H, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r23; Peschansky VJ, 2014, EPIGENETICS-US, V9, P3, DOI 10.4161/epi.27473; Proctor E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055820; Qian T, 2010, ONCOGENE, V29, P5818, DOI 10.1038/onc.2010.317; Riis Margit L H, 2012, ISRN Oncol, V2012, P450267, DOI 10.5402/2012/450267; Riising EM, 2014, MOL CELL, V55, P347, DOI 10.1016/j.molcel.2014.06.005; Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062; Sahasrabuddhe AA, 2015, ONCOGENE, V34, P445, DOI 10.1038/onc.2013.571; Sashida G, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5177; Scelfo A, 2015, FEBS J, V282, P1703, DOI 10.1111/febs.13112; Schwartz YB, 2014, CELL REP, V8, P321, DOI 10.1016/j.celrep.2014.07.001; Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1038/nature10833, 10.1007/s13311-012-0137-6]; Score J, 2012, BLOOD, V119, P1208, DOI 10.1182/blood-2011-07-367243; Scott CL, 2007, P NATL ACAD SCI USA, V104, P5389, DOI 10.1073/pnas.0608721104; Shinjo K, 2014, INT J CANCER, V135, P308, DOI 10.1002/ijc.28692; Silva J, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1760; Simon C, 2012, GENE DEV, V26, P651, DOI 10.1101/gad.186411.111; Sing A, 2009, CELL, V138, P885, DOI 10.1016/j.cell.2009.08.020; Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Song WJ, 2010, CANCER SCI, V101, P1754, DOI 10.1111/j.1349-7006.2010.01577.x; Stock K, 2012, NAT MED, V18, P1232, DOI 10.1038/nm.2827; Stojic L, 2011, EPIGENET CHROMATIN, V4, DOI 10.1186/1756-8935-4-16; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Suarez-Merino B, 2005, NEURO-ONCOLOGY, V7, P20; Takawa M, 2011, CANCER SCI, V102, P1298, DOI 10.1111/j.1349-7006.2011.01958.x; Tanaka S, 2012, BLOOD, V120, P1107, DOI 10.1182/blood-2011-11-394932; Tanay A, 2007, P NATL ACAD SCI USA, V104, P5521, DOI 10.1073/pnas.0609746104; Tao J, 2014, TUMOR BIOL, V35, P9619, DOI 10.1007/s13277-014-2220-6; Tateishi K, 2006, CLIN CANCER RES, V12, P6960, DOI 10.1158/1078-0432.CCR-06-0449; Tavares L, 2012, CELL, V148, P664, DOI 10.1016/j.cell.2011.12.029; Tetsu O, 1998, IMMUNITY, V9, P439, DOI 10.1016/S1074-7613(00)80627-5; Turcan S, 2013, ONCOTARGET, V4, P1729, DOI 10.18632/oncotarget.1412; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; van Galen JC, 2007, J CLIN PATHOL, V60, P167, DOI 10.1136/jcp.2006.038752; van Leenders GJLH, 2007, EUR UROL, V52, P455, DOI 10.1016/j.eururo.2006.11.020; Vandamme J, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002642; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; Vannucchi AM, 2013, LEUKEMIA, V27, P1861, DOI 10.1038/leu.2013.119; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Velichutina I, 2010, BLOOD, V116, P5247, DOI 10.1182/blood-2010-04-280149; Venneti S, 2013, BRAIN PATHOL, V23, P558, DOI 10.1111/bpa.12042; Wagener N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-524; Wan LY, 2013, CLIN TRANSL ONCOL, V15, P132, DOI 10.1007/s12094-012-0897-9; Wang BQ, 2013, ANN SURG ONCOL, V20, pS684, DOI 10.1245/s10434-013-3171-7; Wang CG, 2010, WORLD J GASTROENTERO, V16, P2421, DOI 10.3748/wjg.v16.i19.2421; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang W, 2014, ONCOTARGET, V5, P11604, DOI 10.18632/oncotarget.2598; Wang W, 2011, UROL ONCOL-SEMIN ORI, V29, P244, DOI 10.1016/j.urolonc.2009.02.004; Wang W, 2009, INT J CANCER, V125, P2836, DOI 10.1002/ijc.24721; Won HY, 2012, FASEB J, V26, P5002, DOI 10.1096/fj.12-209247; Woo CJ, 2010, CELL, V140, P99, DOI 10.1016/j.cell.2009.12.022; Wu G, 2012, NAT GENET, V44, P251, DOI 10.1038/ng.1102; Xu F, 2011, ANN HEMATOL, V90, P643, DOI 10.1007/s00277-010-1128-5; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yang GF, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-133; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208; Yap KL, 2010, MOL CELL, V38, P662, DOI 10.1016/j.molcel.2010.03.021; Yuan W, 2012, SCIENCE, V337, P971, DOI 10.1126/science.1225237; Zhang F., 2008, Experimental Oncology, V30, P70; Zhang XW, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-40; Zingg D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7051	194	62	62	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 17	2016	35	11					1341	1352		10.1038/onc.2015.195	http://dx.doi.org/10.1038/onc.2015.195			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG6LQ	26050622				2022-12-17	WOS:000372196400001
J	Huang, W; Dong, Z; Chen, Y; Wang, F; Wang, CJ; Peng, H; He, Y; Hangoc, G; Pollok, K; Sandusky, G; Fu, XY; Broxmeyer, HE; Zhang, ZY; Liu, JY; Zhang, JT				Huang, W.; Dong, Z.; Chen, Y.; Wang, F.; Wang, C. J.; Peng, H.; He, Y.; Hangoc, G.; Pollok, K.; Sandusky, G.; Fu, X-Y; Broxmeyer, H. E.; Zhang, Z-Y; Liu, J-Y; Zhang, J-T			Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo	ONCOGENE			English	Article							SIGNAL TRANSDUCER; CANCER; TRANSCRIPTION; ACTIVATOR; PHOSPHORYLATION; IL-6	Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in malignant tumors and has important roles in multiple aspects of cancer aggressiveness. Thus targeting STAT3 promises to be an attractive strategy for treatment of advanced metastatic tumors. Although many STAT3 inhibitors targeting the SH2 domain have been reported, few have moved into clinical trials. Targeting the DNA-binding domain (DBD) of STAT3, however, has been avoided due to its 'undruggable' nature and potentially limited selectivity. In a previous study, we reported an improved in silico approach targeting the DBD of STAT3 that resulted in a small-molecule STAT3 inhibitor (inS3-54). Further studies, however, showed that inS3-54 has off-target effect although it is selective to STAT3 over STAT1. In this study, we describe an extensive structure and activity-guided hit optimization and mechanistic characterization effort, which led to identification of an improved lead compound (inS3-54A18) with increased specificity and pharmacological properties. InS3-54A18 not only binds directly to the DBD and inhibits the DNA-binding activity of STAT3 both in vitro and in situ but also effectively inhibits the constitutive and interleukin-6-stimulated expression of STAT3 downstream target genes. InS3-54A18 is completely soluble in an oral formulation and effectively inhibits lung xenograft tumor growth and metastasis with little adverse effect on animals. Thus inS3-54A18 may serve as a potential candidate for further development as anticancer therapeutics targeting the DBD of human STAT3 and DBD of transcription factors may not be 'undruggable' as previously thought.	[Huang, W.; Dong, Z.; Chen, Y.; Wang, F.; Wang, C. J.; Peng, H.; Pollok, K.; Liu, J-Y; Zhang, J-T] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; [He, Y.; Zhang, Z-Y] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Hangoc, G.; Fu, X-Y; Broxmeyer, H. E.] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; [Pollok, K.] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; [Pollok, K.; Sandusky, G.; Fu, X-Y; Broxmeyer, H. E.; Zhang, Z-Y; Zhang, J-T] Indiana Univ Sch Med, IU Simon Canc Ctr, 980W Walnut St, Indianapolis, IN 46202 USA; [Sandusky, G.] Indiana Univ Sch Med, Dept Pathol & Mol Med, Indianapolis, IN 46202 USA; [Liu, J-Y] Indiana Univ Purdue Univ, Dept Comp & Informat Sci, Indianapolis, IN 46202 USA; [Huang, W.] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100871, Peoples R China	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University-Purdue University Indianapolis; Peking University	Zhang, JT (corresponding author), Indiana Univ Sch Med, IU Simon Canc Ctr, 980W Walnut St, Indianapolis, IN 46202 USA.; Liu, JY (corresponding author), IUPUI, Dept Comp & Informat Sci, 635 Barnhill Dr,MS550, Indianapolis, IN 46202 USA.	jliu2@iu.edu; jianzhan@iu.edu	Zhang, Jian-Ting/L-8334-2015	Wang, Chao/0000-0001-8951-5657; Zhang, Jian-Ting/0000-0002-2803-9914	Lung Cancer Working Group at IUSCC	Lung Cancer Working Group at IUSCC	We thank Anthony Sinn in the In Vivo Therapeutics Core and Sheng Zhang in the Chemical Genomics Core for their technical assistance for in vivo studies and chemical synthesis, respectively. Jiayuh Lin at Ohio State University provided MDA-MB-231-STAT3 cells with the STAT3-dependent luciferase reporter while George R Stark at Cleveland Clinic provided STAT1 cDNA. This work was supported in part by the Lung Cancer Working Group at IUSCC.	Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Caboni L, 2013, MED RES REV, V33, P1081, DOI 10.1002/med.21275; Chen Z, 2008, MED RES REV, V28, P185, DOI 10.1002/med.20101; Cheng L, 2004, CLIN CANCER RES, V10, P3064, DOI 10.1158/1078-0432.CCR-03-0652; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Choi CH, 2010, J OBSTET GYNAECOL RE, V36, P304, DOI 10.1111/j.1447-0756.2009.01131.x; Debnath B, 2012, J MED CHEM, V55, P6645, DOI 10.1021/jm300207s; Deng JX, 2007, CURR CANCER DRUG TAR, V7, P91, DOI 10.2174/156800907780006922; Devarajan E, 2009, CURR MOL MED, V9, P626, DOI 10.2174/156652409788488720; Diaz N, 2006, CLIN CANCER RES, V12, P20, DOI 10.1158/1078-0432.CCR-04-1749; Dolled-Filhart M, 2003, CLIN CANCER RES, V9, P594; Fletcher S, 2009, CHEMBIOCHEM, V10, P1959, DOI 10.1002/cbic.200900172; Hao WS, 2008, BIOORG MED CHEM LETT, V18, P4988, DOI 10.1016/j.bmcl.2008.08.032; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Huang W, 2014, ACS CHEM BIOL, V9, P1188, DOI 10.1021/cb500071v; Lee H, 2011, CURR TOP MICROBIOL, V344, P41, DOI 10.1007/82_2010_51; Leung CH, 2013, MED RES REV, V33, P823, DOI 10.1002/med.21266; Lin L, 2010, CANCER RES, V70, P2445, DOI 10.1158/0008-5472.CAN-09-2468; Lin L, 2010, NEOPLASIA, V12, P39, DOI 10.1593/neo.91196; Mantel C, 2012, BLOOD, V120, P2589, DOI 10.1182/blood-2012-01-404004; Nkansah E, 2013, FEBS LETT, V587, P833, DOI 10.1016/j.febslet.2013.01.065; Ren ZY, 2003, BIOORG MED CHEM LETT, V13, P633, DOI 10.1016/S0960-894X(02)01050-8; Schust J, 2004, ANAL BIOCHEM, V330, P114, DOI 10.1016/j.ab.2004.03.024; Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Siddiquee KAZ, 2007, ACS CHEM BIOL, V2, P787, DOI 10.1021/cb7001973; Song H, 2005, P NATL ACAD SCI USA, V102, P4700, DOI 10.1073/pnas.0409894102; Timofeeva OA, 2012, J BIOL CHEM, V287, P14192, DOI 10.1074/jbc.M111.323899; Turkson J, 2004, MOL CANCER THER, V3, P261; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Welte T, 2003, P NATL ACAD SCI USA, V100, P1879, DOI 10.1073/PNAS.0237137100; Yang JB, 2007, GENE DEV, V21, P1396, DOI 10.1101/gad.1553707; Yang Youyun, 2011, Int J Biochem Mol Biol, V2, P89; Yue P, 2009, EXPERT OPIN INV DRUG, V18, P45, DOI [10.1517/13543780802565791, 10.1517/13543780802565791 ]	35	62	67	2	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2016	35	6					783	792		10.1038/onc.2015.215	http://dx.doi.org/10.1038/onc.2015.215			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RF	26073084				2022-12-17	WOS:000370331300011
J	Nakagawa, H; Wardell, CP; Furuta, M; Taniguchi, H; Fujimoto, A				Nakagawa, H.; Wardell, C. P.; Furuta, M.; Taniguchi, H.; Fujimoto, A.			Cancer whole-genome sequencing: present and future	ONCOGENE			English	Review							TERT PROMOTER MUTATIONS; SOMATIC MUTATIONS; GENE; IDENTIFICATION; LANDSCAPE; DNA; RETROTRANSPOSITION; REARRANGEMENTS; INTEGRATION; FREQUENCY	Recent explosive advances in next-generation sequencing technology and computational approaches to massive data enable us to analyze a number of cancer genome profiles by whole-genome sequencing (WGS). To explore cancer genomic alterations and their diversity comprehensively, global and local cancer genome-sequencing projects, including ICGC and TCGA, have been analyzing many types of cancer genomes mainly by exome sequencing. However, there is limited information on somatic mutations in non-coding regions including untranslated regions, introns, regulatory elements and non-coding RNAs, and rearrangements, sometimes producing fusion genes, and pathogen detection in cancer genomes remain widely unexplored. WGS approaches can detect these unexplored mutations, as well as coding mutations and somatic copy number alterations, and help us to better understand the whole landscape of cancer genomes and elucidate functions of these unexplored genomic regions. Analysis of cancer genomes using the present WGS platforms is still primitive and there are substantial improvements to be made in sequencing technologies, informatics and computer resources. Taking account of the extreme diversity of cancer genomes and phenotype, it is also required to analyze much more WGS data and integrate these with multi-omics data, functional data and clinical-pathological data in a large number of sample sets to interpret them more fully and efficiently.	[Nakagawa, H.; Wardell, C. P.; Furuta, M.; Taniguchi, H.; Fujimoto, A.] RIKEN Ctr Integrat Med Sci, Lab Genome Sequencing Anal, Tokyo, Japan	RIKEN	Nakagawa, H (corresponding author), RIKEN Ctr Integrat Med Sci, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	hidewaki@ims.u-tokyo.ac.jp	Taniguchi, Hiroaki/H-6329-2016; Wardell, Christopher/B-5053-2018	Wardell, Christopher/0000-0002-9416-7818; Taniguchi, Hiroaki/0000-0001-7270-390X	RIKEN President's Fund; Princess Takamatsu Cancer Research Fund; Takeda Science Foundation	RIKEN President's Fund; Princess Takamatsu Cancer Research Fund; Takeda Science Foundation(Takeda Science Foundation (TSF))	We thank researchers and technical staffs in RIKEN-IMS and Professor Miyano and his fellows in Human Genome Center, Institute of Medical Science, The University of Tokyo for their great efforts to cancer genome sequencing in ICGC project. The supercomputing resource 'SHIROKANE' was provided by Human Genome Center, The University of Tokyo (http://sc.hgc.jp/shirokane.html). This work was supported partially by RIKEN President's Fund 2011, the Princess Takamatsu Cancer Research Fund, and Takeda Science Foundation.	Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Andersson R, 2014, NATURE, V507, P455, DOI 10.1038/nature12787; Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Boutros PC, 2014, NAT GENET, V46, P318, DOI 10.1038/ng.2932; Campbell PJ, 2008, NAT GENET, V40, P722, DOI 10.1038/ng.128; Cao SB, 2015, J VIROL, V89, P713, DOI 10.1128/JVI.02570-14; Chen J, 2015, ONCOGENE, V34, P1, DOI 10.1038/onc.2013.570; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Clark MJ, 2011, NAT BIOTECHNOL, V29, P908, DOI 10.1038/nbt.1975; Cook LB, 2014, BLOOD, V123, P3925, DOI 10.1182/blood-2014-02-553602; Dekker J, 2013, NAT REV GENET, V14, P390, DOI 10.1038/nrg3454; Dove ES, 2015, EUR J HUM GENET, V23, P1271, DOI 10.1038/ejhg.2014.196; DULBECCO R, 1986, SCIENCE, V231, P1055, DOI 10.1126/science.3945817; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Fredriksson NJ, 2014, NAT GENET, V46, P1258, DOI 10.1038/ng.3141; Freedman ML, 2011, NAT GENET, V43, P513, DOI 10.1038/ng.840; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Gnirke A, 2009, NAT BIOTECHNOL, V27, P182, DOI 10.1038/nbt.1523; Gonzalez-Perez A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks743; Gottlieb B, 2004, HUM MUTAT, V23, P527, DOI 10.1002/humu.20044; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Kim TM, 2013, CELL, V155, P858, DOI 10.1016/j.cell.2013.10.015; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kohno T, 2012, NAT MED, V18, P375, DOI 10.1038/nm.2644; Korbel JO, 2013, CELL, V152, P1226, DOI 10.1016/j.cell.2013.02.023; Koren S, 2012, NAT BIOTECHNOL, V30, P692, DOI 10.1038/nbt.2280; Kostic AD, 2012, GENOME RES, V22, P292, DOI 10.1101/gr.126573.111; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee E, 2012, SCIENCE, V337, P967, DOI 10.1126/science.1222077; Leiserson MDM, 2015, NAT GENET, V47, P106, DOI 10.1038/ng.3168; Ley TJ, 2008, NATURE, V456, P66, DOI 10.1038/nature07485; Liang H, 2012, GENOME RES, V22, P2120, DOI 10.1101/gr.137596.112; Mansour MR, 2014, SCIENCE, V346, P1373, DOI 10.1126/science.1259037; Mardis ER, 2009, HUM MOL GENET, V18, pR163, DOI 10.1093/hmg/ddp396; Mermel CH, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-r41; Meyerson M, 2010, NAT REV GENET, V11, P685, DOI 10.1038/nrg2841; Nagarajan N, 2013, NAT REV GENET, V14, P157, DOI 10.1038/nrg3367; Nakao M, 1996, LEUKEMIA, V10, P1911; Northcott PA, 2014, NATURE, V511, P428, DOI 10.1038/nature13379; Oda Y, 2009, CANCER SCI, V100, P200, DOI 10.1111/j.1349-7006.2008.01024.x; Oikonomou P, 2014, CELL REP, V7, P281, DOI 10.1016/j.celrep.2014.03.001; Ojesina AI, 2014, NATURE, V506, P371, DOI 10.1038/nature12881; Pajares MJ, 2007, LANCET ONCOL, V8, P349, DOI 10.1016/S1470-2045(07)70104-3; Parfenov M, 2014, P NATL ACAD SCI USA, V111, P15544, DOI 10.1073/pnas.1416074111; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Rausch T, 2012, CELL, V148, P59, DOI 10.1016/j.cell.2011.12.013; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shen R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035236; Shiraishi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114263; Shukla R, 2013, CELL, V153, P101, DOI 10.1016/j.cell.2013.02.032; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Sung WK, 2012, NAT GENET, V44, P765, DOI 10.1038/ng.2295; Supek F, 2014, CELL, V156, P1324, DOI 10.1016/j.cell.2014.01.051; Takeuchi K, 2012, NAT MED, V18, P378, DOI 10.1038/nm.2658; Tamborero D, 2013, SCI REP-UK, V3, DOI 10.1038/srep02650; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Treangen TJ, 2012, NAT REV GENET, V13, P36, DOI 10.1038/nrg3117; Vinagre J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3185; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wang QG, 2013, GENOME MED, V5, DOI 10.1186/gm495; Weinhold N, 2014, NAT GENET, V46, P1160, DOI 10.1038/ng.3101; Xiong HY, 2015, SCIENCE, V347, DOI 10.1126/science.1254806; Yang LX, 2013, CELL, V153, P919, DOI 10.1016/j.cell.2013.04.010; Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438; Zhao WX, 2014, NAT BIOTECHNOL, V32, P387, DOI 10.1038/nbt.2851	81	62	64	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2015	34	49					5943	5950		10.1038/onc.2015.90	http://dx.doi.org/10.1038/onc.2015.90			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CY0RO	25823020				2022-12-17	WOS:000366113500001
J	Hsu, YL; Hung, JY; Chou, SH; Huang, MS; Tsai, MJ; Lin, YS; Chiang, SY; Ho, YW; Wu, CY; Kuo, PL				Hsu, Y-L; Hung, J-Y; Chou, S-H; Huang, M-S; Tsai, M-J; Lin, Y-S; Chiang, S-Y; Ho, Y-W; Wu, C-Y; Kuo, P-L			Angiomotin decreases lung cancer progression by sequestering oncogenic YAP/TAZ and decreasing Cyr61 expression	ONCOGENE			English	Article							YES-ASSOCIATED PROTEIN; CELL-MIGRATION; HIPPO PATHWAY; BREAST-CANCER; IN-VIVO; YAP; GROWTH; PROLIFERATION; OVEREXPRESSION; TRANSCRIPTION	Lung cancer is the leading cause of cancer death worldwide, with metastasis underlying majority of related deaths. Angiomotin (AMOT), a scaffold protein, has been shown to interact with oncogenic Yes-associated protein/transcriptional co-activator with a PDZ-binding motif (YAP/TAZ) proteins, suggesting a potential role in tumor progression. However, the functional role of AMOT in lung cancer remains unknown. This study aimed to identify the patho-physiological characteristics of AMOT in lung cancer progression. Results revealed that AMOT expression was significantly decreased in clinical lung cancer specimens. Knockdown of AMOT in a low metastatic CL1-0 lung cancer cell line initiated cancer proliferation, migration, invasion and epithelial-mesenchymal transition. The trigger of cancer progression caused by AMOT loss was transduced by decreased cytoplasmic sequestration and increased nuclear translocation of oncogenic co-activators YAP/TAZ, leading to increased expression of the growth factor, Cyr61. Tumor promotion by AMOT knockdown was reversed when YAP/TAZ or Cyr61 was absent. Further, AMOT knockdown increased the growth and spread of Lewis lung carcinoma in vivo. These findings suggest that AMOT is a crucial suppressor of lung cancer metastasis and highlight its critical role as a tumor suppressor and its potential as a prognostic biomarker and therapeutic target for lung cancer.	[Hsu, Y-L; Tsai, M-J] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung 807, Taiwan; [Hung, J-Y; Huang, M-S; Tsai, M-J; Lin, Y-S; Wu, C-Y] Kaohsiung Med Univ Hosp, Div Pulm & Crit Care Med, Dept Internal Med, Kaohsiung, Taiwan; [Hung, J-Y; Huang, M-S] Kaohsiung Med Univ, Coll Med, Sch Med, Kaohsiung, Taiwan; [Chou, S-H] Kaohsiung Med Univ Hosp, Dept Surg, Div Chest Surg, Kaohsiung, Taiwan; [Chiang, S-Y; Ho, Y-W; Kuo, P-L] Kaohsiung Med Univ, Coll Med, Inst Clin Med, Kaohsiung, Taiwan; [Kuo, P-L] Kaohsiung Med Univ, Res Ctr Environm Med, Kaohsiung 807, Taiwan; [Kuo, P-L] Natl Sun Yat Sen Univ, Inst Med Sci & Technol, Kaohsiung 80424, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; National Sun Yat Sen University	Kuo, PL (corresponding author), Kaohsiung Med Univ, Coll Med, Inst Clin Med, 100 Shih Chuan First Rd, Kaohsiung 807, Taiwan.	kuopolin@seed.net.tw	Tsai, Ming-Ju/D-5566-2011		National Science Council of Taiwan [NSC 101-2628-B-037-001-MY3, NSC 101-2320-B-037-043-MY3]; Ministry of Science and Technology [MOST 103-2320-B-037-006-MY3, MOST 103-2314-B-037-052]; Kaohsiung Medical University [KMU-DT103008]; Research Center for Environmental Medicine, Kaohsiung Medical University [KMU-TP103A19, KMU-TP103A20]; Kaohsiung Medical University Hospital Research Foundation [KMUH102-2T06]; Center for Resources, Research, and Development of Kaohsiung Medical University	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Kaohsiung Medical University; Research Center for Environmental Medicine, Kaohsiung Medical University; Kaohsiung Medical University Hospital Research Foundation; Center for Resources, Research, and Development of Kaohsiung Medical University	This study was supported by grants from the National Science Council of Taiwan (NSC 101-2628-B-037-001-MY3; NSC 101-2320-B-037-043-MY3), the Ministry of Science and Technology (MOST 103-2320-B-037-006-MY3; MOST 103-2314-B-037-052), the Kaohsiung Medical University "Aim for the top 500 universities grant, Grant No. KMU-DT103008", the Research Center for Environmental Medicine, Kaohsiung Medical University (KMU-TP103A19; KMU-TP103A20) and the Kaohsiung Medical University Hospital Research Foundation (KMUH102-2T06). We also thank the Center for Resources, Research, and Development of Kaohsiung Medical University for their support with the instrumentation.	Adler JJ, 2013, P NATL ACAD SCI USA, V110, P17368, DOI 10.1073/pnas.1308236110; Arigoni M, 2012, ANGIOGENESIS, V15, P305, DOI 10.1007/s10456-012-9263-3; Avruch J, 2012, CELL CYCLE, V11, P1090, DOI 10.4161/cc.11.6.19453; Bratt A, 2005, J BIOL CHEM, V280, P34859, DOI 10.1074/jbc.M503915200; Cai H, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-31; Chan SW, 2011, J BIOL CHEM, V286, P7018, DOI 10.1074/jbc.C110.212621; Chen PP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000534; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Dai XM, 2013, J BIOL CHEM, V288, P34041, DOI 10.1074/jbc.M113.518019; Ernkvist M, 2008, BBA-MOL CELL RES, V1783, P429, DOI 10.1016/j.bbamcr.2007.11.018; Fanning AS, 2012, MOL BIOL CELL, V23, P577, DOI 10.1091/mbc.E11-09-0791; Harris LG, 2012, ONCOGENE, V31, P3370, DOI 10.1038/onc.2011.496; Holmgren L, 2006, P NATL ACAD SCI USA, V103, P9208, DOI 10.1073/pnas.0603110103; Hsu YL, 2013, CARCINOGENESIS, V34, P1370, DOI 10.1093/carcin/bgt040; Hung JJ, 2013, ANN SURG, V258, P1079, DOI 10.1097/SLA.0b013e31828920c0; Jandova J, 2012, CELL BIOCHEM FUNCT, V30, P687, DOI 10.1002/cbf.2853; Jones AC, 2012, PROSTATE, V72, P1159, DOI 10.1002/pros.22465; Kanai F, 2000, EMBO J, V19, P6778, DOI 10.1093/emboj/19.24.6778; Kao YR, 2003, CLIN CANCER RES, V9, P2807; Kozu Y, 2013, EUR J CARDIO-THORAC, V44, pE53, DOI 10.1093/ejcts/ezt192; Lin JPA, 2012, CANCER IMMUNOL IMMUN, V61, P677, DOI 10.1007/s00262-011-1135-y; Mizuno T, 2012, ONCOGENE, V31, P5117, DOI 10.1038/onc.2012.5; Moleirinho S, 2014, FEBS LETT, V588, P2693, DOI 10.1016/j.febslet.2014.02.006; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Muramatsu T, 2011, CARCINOGENESIS, V32, P389, DOI 10.1093/carcin/bgq254; Navab R, 2011, P NATL ACAD SCI USA, V108, P7160, DOI 10.1073/pnas.1014506108; Oka T, 2012, ONCOGENE, V31, P128, DOI 10.1038/onc.2011.216; Paramasivam M, 2011, MOL BIOL CELL, V22, P3725, DOI 10.1091/mbc.E11-04-0300; Park HW, 2013, TRENDS PHARMACOL SCI, V34, P581, DOI 10.1016/j.tips.2013.08.006; Pobbati AV, 2013, CANCER BIOL THER, V14, P390, DOI 10.4161/cbt.23788; Ranahan WP, 2011, CANCER RES, V71, P2203, DOI 10.1158/0008-5472.CAN-10-1995; Reck M, 2013, LANCET, V382, P709, DOI 10.1016/S0140-6736(13)61502-0; Schutte U, 2014, TRANSL ONCOL, V7, P309, DOI 10.1016/j.tranon.2014.02.005; Shih JY, 2011, CARCINOGENESIS, V32, P1299, DOI 10.1093/carcin/bgr110; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Su LL, 2012, CHINESE MED J-PEKING, V125, P4003, DOI 10.3760/cma.j.issn.0366-6999.2012.22.017; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Sun XJ, 2014, CARCINOGENESIS, V35, P184, DOI 10.1093/carcin/bgt276; Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247; Wang LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065539; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Wells CD, 2006, CELL, V125, P535, DOI 10.1016/j.cell.2006.02.045; Wu DD, 2014, J BIOL CHEM, V289, P5774, DOI 10.1074/jbc.M113.533042; Xu CM, 2013, CANCER GENE THER, V20, P453, DOI 10.1038/cgt.2013.40; Yi CL, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004060; Yi CL, 2011, CANCER CELL, V19, P527, DOI 10.1016/j.ccr.2011.02.017; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zhang HY, 2011, P NATL ACAD SCI USA, V108, P2270, DOI 10.1073/pnas.1019603108; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111; Zhi X, 2012, AM J PATHOL, V180, P2452, DOI 10.1016/j.ajpath.2012.02.025; Zhou Z, 2011, ONCOGENE, V30, P2181, DOI 10.1038/onc.2010.606	52	62	69	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4056	4068		10.1038/onc.2014.333	http://dx.doi.org/10.1038/onc.2014.333			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25381822				2022-12-17	WOS:000358780500004
J	Jin, R; Yamashita, H; Yu, X; Wang, J; Franco, OE; Wang, Y; Hayward, SW; Matusik, RJ				Jin, R.; Yamashita, H.; Yu, X.; Wang, J.; Franco, O. E.; Wang, Y.; Hayward, S. W.; Matusik, R. J.			Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression	ONCOGENE			English	Article							TRAIL-INDUCED APOPTOSIS; LYMPH-NODE METASTASES; SPLICE VARIANTS; NUCLEAR-LOCALIZATION; ANTITUMOR-ACTIVITY; CHROMOGRANIN-A; SOLID TUMORS; PROGRESSION; ACTIVATION; MECHANISMS	Androgen receptor splicing variants (ARVs) that lack the ligand-binding domain (LBD) are associated with the development of castration-resistant prostate cancer (CRPC), including resistance to the new generation of high-affinity anti-androgens. However, the mechanism by which ARV expression is regulated is not fully understood. In this study, we show that the activation of classical nuclear factor-kappa B (NF-kappa B) signaling increases the expression of ARVs in prostate cancer (PCa) cells and converts androgen-sensitive PCa cells to become androgen-insensitive, whereas downregulation of NF-kappa B signaling inhibits ARV expression and restores responsiveness of CRPC to anti-androgen therapy. In addition, we demonstrated that combination of anti-androgen with NF-kappa B-targeted therapy inhibits efficiently tumor growth of human CRPC xenografts. These results indicate that induction of ARVs by activated NF-kappa B signaling in PCa cells is a critical mechanism by which the PCa progresses to CRPC. This has important implications as it can prolong the survival of CRPC patients by restoring the tumors to once again respond to conventional androgen-deprivation therapy (ADT).	[Jin, R.; Yamashita, H.; Yu, X.; Wang, J.; Franco, O. E.; Wang, Y.; Hayward, S. W.; Matusik, R. J.] Vanderbilt Univ, Med Ctr, Vanderbilt Prostate Canc Ctr, Dept Urol Surg, Nashville, TN 37232 USA	Vanderbilt University	Jin, R (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Prostate Canc Ctr, Dept Urol Surg, A1329,MCN,1161 21st Ave South, Nashville, TN 37232 USA.	renjie.jin@vanderbilt.edu		Hayward, Simon/0000-0002-6059-6550; Yamashita, Hironobu/0000-0003-2587-7100; Yu, Xiuping/0000-0003-2844-7026; Matusik, Robert/0000-0003-2057-9892	Department of Defense (DOD) Prostate Cancer Research Program (PCRP) [W81XWH-10-1-0236]; National Cancer Institute [4R01 CA076142-14]; Frances Preston Laboratories of the TJ Martell Foundation; NATIONAL CANCER INSTITUTE [R01CA076142] Funding Source: NIH RePORTER	Department of Defense (DOD) Prostate Cancer Research Program (PCRP); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Frances Preston Laboratories of the TJ Martell Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Martin Leverkus (University of Magdeburg, Germany) for providing us with IKK2-EE and IKK2-KD retroviral vectors, and Tom C Case and Manik Paul for technical assistance. This work was supported to RJ by the Department of Defense (DOD) Prostate Cancer Research Program (PCRP; W81XWH-10-1-0236); to RJM by the National Cancer Institute (4R01 CA076142-14) and the Frances Preston Laboratories of the TJ Martell Foundation.	Adams J, 2004, CANCER INVEST, V22, P304, DOI 10.1081/CNV-120030218; Akfirat C, 2013, J PATHOL, V230, P291, DOI 10.1002/path.4180; Berruti A, 2005, ENDOCR-RELAT CANCER, V12, P109, DOI 10.1677/erc.1.00876; Claessens Frank, 2008, Nucl Recept Signal, V6, pe008, DOI 10.1621/nrs.06008; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; di Sant'Agnese PA, 1998, PROSTATE, P74; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Diessenbacher P, 2008, J INVEST DERMATOL, V128, P1134, DOI 10.1038/sj.jid.5701141; Domingo-Domenech J, 2005, BRIT J CANCER, V93, P1285, DOI 10.1038/sj.bjc.6602851; Domingo-Domenech J, 2006, CLIN CANCER RES, V12, P5578, DOI 10.1158/1078-0432.CCR-05-2767; Everhart MB, 2006, J IMMUNOL, V176, P4995, DOI 10.4049/jimmunol.176.8.4995; Gannon PO, 2013, EUR J CANCER, V49, P2441, DOI 10.1016/j.ejca.2013.02.026; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2011, PROSTATE, V71, P1656, DOI 10.1002/pros.21382; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Inoue J, 2007, CANCER SCI, V98, P268, DOI 10.1111/j.1349-7006.2007.00389.x; Ismail H, 2004, PROSTATE, V58, P308, DOI 10.1002/pros.10335; Jin RJ, 2008, CANCER RES, V68, P6762, DOI 10.1158/0008-5472.CAN-08-0107; Jin RJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060983; Jin RJ, 2004, CANCER RES, V64, P5489, DOI 10.1158/0008-5472.CAN-03-3117; Karin M, 2006, MOL CARCINOGEN, V45, P355, DOI 10.1002/mc.20217; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Knudsen KE, 2009, CLIN CANCER RES, V15, P4792, DOI 10.1158/1078-0432.CCR-08-2660; Kraft AS, 2011, CANCER BIOL THER, V12, P119, DOI 10.4161/cbt.12.2.15723; Lessard L, 2005, BRIT J CANCER, V93, P1019, DOI 10.1038/sj.bjc.6602796; Lessard L, 2006, CLIN CANCER RES, V12, P5741, DOI 10.1158/1078-0432.CCR-06-0330; Leverkus M, 2003, J INVEST DERMATOL, V121, P149, DOI 10.1046/j.1523-1747.2003.12332.x; Li Y, 2012, ONCOGENE, V31, P4759, DOI 10.1038/onc.2011.637; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Li YM, 2011, CANCER RES, V71, P2108, DOI 10.1158/0008-5472.CAN-10-1998; Lin DL, 2001, PROSTATE, V47, P212, DOI 10.1002/pros.1065; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; McCall P, 2012, BRIT J CANCER, V107, P1554, DOI 10.1038/bjc.2012.372; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Morris MJ, 2007, J UROLOGY, V178, P2378, DOI 10.1016/j.juro.2007.08.015; Mostaghel EA, 2011, CLIN CANCER RES, V17, P5913, DOI 10.1158/1078-0432.CCR-11-0728; Nadiminty N, 2013, MOL CANCER THER, V12, P1629, DOI 10.1158/1535-7163.MCT-13-0027; Pacifico F, 2006, BIOCHEM PHARMACOL, V72, P1142, DOI 10.1016/j.bcp.2006.07.032; Papandreou CN, 2004, J CLIN ONCOL, V22, P2108, DOI 10.1200/JCO.2004.02.106; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Ross JS, 2004, CLIN CANCER RES, V10, P2466, DOI 10.1158/1078-0432.CCR-0543-3; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Scher HI, 2010, LANCET, V375, P1437, DOI 10.1016/S0140-6736(10)60172-9; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Setlur SR, 2007, CANCER RES, V67, P10296, DOI 10.1158/0008-5472.CAN-07-2173; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Taplin ME, 2005, UROLOGY, V66, P386, DOI 10.1016/j.urology.2005.03.040; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Tuominen VJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2615; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Yu X, 2011, ONCOGENE, V30, P1868, DOI 10.1038/onc.2010.560; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Yuan X, 2009, UROL ONCOL-SEMIN ORI, V27, P36, DOI 10.1016/j.urolonc.2008.03.021; Zhang LY, 2009, AM J PATHOL, V175, P489, DOI 10.2353/ajpath.2009.080727	61	62	64	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3700	3710		10.1038/onc.2014.302	http://dx.doi.org/10.1038/onc.2014.302			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25220414	Green Accepted			2022-12-17	WOS:000357679100008
J	Lei, ZJ; Wang, J; Xiao, HL; Guo, Y; Wang, T; Li, Q; Liu, L; Luo, X; Fan, LL; Lin, L; Mao, CY; Wang, SN; Wei, YL; Lan, CH; Jiang, J; Yang, XJ; Liu, PD; Chen, DF; Wang, B				Lei, Z-J; Wang, J.; Xiao, H-L; Guo, Y.; Wang, T.; Li, Q.; Liu, L.; Luo, X.; Fan, L-L; Lin, L.; Mao, C-Y; Wang, S-N; Wei, Y-L; Lan, C-H; Jiang, J.; Yang, X-J; Liu, P-D; Chen, D-F; Wang, B.			Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5(+) liver cancer initiating cells by suppressing negative regulators of beta-catenin signaling	ONCOGENE			English	Article							COUPLED RECEPTOR 5; DRIVE SELF-RENEWAL; THERAPEUTIC TARGET; LSD1; METASTASIS; COLON; DIFFERENTIATION; IDENTIFICATION; CONTRIBUTES; INHIBITION	Cancer initiating cells (CICs) are responsible for the unrestrained cell growth and chemoresistance of malignant tumors. Histone demethylation has been shown to be crucial for self-renewal/differentiation of stem cells, but it remains elusive whether lysine-specific demethylase 1 (LSD1) regulates the stemness properties of CICs. Here we report that the abundant expression of leucinerich repeat-containing G-protein-coupled receptor 5 (Lgr5) is associated with the progression of hepatocellular carcinoma (HCC). Lgr5(+) HCC cells behave similarly to CICs and are highly tumorigenic and resistant to chemotherapeutic agents. Importantly, Lgr5(+) cells express higher levels of LSD1, which in turn regulates Lgr5 expression and promotes the self-renewal and drug resistance of Lgr5(+) CICs. Mechanistically, LSD1 promotes beta-catenin activation by inhibiting the expression of several suppressors of beta-catenin signaling, especially Prickle1 and APC in Lgr5(+) CICs, by directly regulating the levels of mono- and di-methylation of histone H3 lysine-4 at the promoters of these genes. Furthermore, LSD1-associated activation of the beta-catenin signaling is essential for maintaining the activity of Lgr5(+) CICs. Together, our findings unravel the LSD1/Prickle1/APC/beta-catenin signaling axis as a novel molecular circuit regulating the stemness and chemoresistance of hepatic Lgr5(+) CICs and provide potential targets to improve chemotherapeutic efficacies against HCC.	[Lei, Z-J; Wang, J.; Guo, Y.; Wang, T.; Li, Q.; Liu, L.; Luo, X.; Fan, L-L; Wei, Y-L; Lan, C-H; Chen, D-F; Wang, B.] Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Gastroenterol, Chongqing 400042, Peoples R China; [Xiao, H-L; Lin, L.; Mao, C-Y] Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Pathol, Chongqing 400042, Peoples R China; [Wang, S-N] Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Radiol, Chongqing 400042, Peoples R China; [Jiang, J.] Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Urol, Chongqing 400042, Peoples R China; [Yang, X-J] Shantou Univ, Coll Med, Ctr Neurosci, Shantou, Peoples R China; [Liu, P-D] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA	Army Medical University; Army Medical University; Army Medical University; Army Medical University; Shantou University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Chen, DF (corresponding author), Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Gastroenterol, Chongqing 400042, Peoples R China.	chendongfeng1981@126.com; wb_tmmu@126.com	黄, 梦茜/AAE-9495-2020; Wang, Bin/W-9917-2019	Wang, Bin/0000-0001-5574-1760	National Natural Science Foundation of China (NSFC) [81472294, 81201949, 81372558]; Natural Science Foundation Project of CQ CSTC [CSTC2012JJA10124]; Science Foundation of Third Military Medical University [2012XJQ22]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Natural Science Foundation Project of CQ CSTC(Natural Science Foundation Project of CQ CSTC); Science Foundation of Third Military Medical University	We are indebted to Prof Xiang Xu (Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China) for his technical assistance. We are grateful to Miss Chunhua Quan, Ya Li and Qing Li (Department of Gastroenterology, Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, China) for their help in collecting clinical data. This work was supported by the grants from the National Natural Science Foundation of China (NSFC Nos. 81472294, 81201949, and 81372558), the Natural Science Foundation Project of CQ CSTC (No. CSTC2012JJA10124), and the Science Foundation of Third Military Medical University (No. 2012XJQ22).	Adamo A, 2011, NAT CELL BIOL, V13, P652, DOI 10.1038/ncb2246; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Blaschke K, 2013, NATURE, V500, P222, DOI 10.1038/nature12362; Chan DW, 2006, GASTROENTEROLOGY, V131, P1218, DOI 10.1053/j.gastro.2006.07.020; Ding J, 2013, BRIT J CANCER, V109, P994, DOI 10.1038/bjc.2013.364; Flesken-Nikitin A, 2013, NATURE, V495, P241, DOI 10.1038/nature11979; Fukuma M, 2013, EXP CELL RES, V319, P113, DOI 10.1016/j.yexcr.2012.10.011; Furuyama K, 2011, NAT GENET, V43, P34, DOI 10.1038/ng.722; Gil-Sanchis C, 2013, MOL HUM REPROD, V19, P407, DOI 10.1093/molehr/gat014; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Haraguchi N, 2010, J CLIN INVEST, V120, P3326, DOI 10.1172/JCI42550; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; Hayami S, 2011, INT J CANCER, V128, P574, DOI 10.1002/ijc.25349; Hirsch D, 2014, CARCINOGENESIS, V35, P849, DOI 10.1093/carcin/bgt377; Hu M, 2007, GASTROENTEROLOGY, V133, P1579, DOI 10.1053/j.gastro.2007.08.036; Huang ZB, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0070077, 10.1371/journal.pone.0075007]; Huch M, 2013, NATURE, V494, P247, DOI 10.1038/nature11826; Kemper K, 2012, STEM CELLS, V30, P2378, DOI 10.1002/stem.1233; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; Lee TKW, 2011, CELL STEM CELL, V9, P50, DOI 10.1016/j.stem.2011.06.005; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Ma S, 2007, GASTROENTEROLOGY, V132, P2542, DOI 10.1053/j.gastro.2007.04.025; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; O'Brien CA, 2012, CANCER CELL, V21, P777, DOI 10.1016/j.ccr.2012.04.036; Plaks V, 2013, CELL REP, V3, P70, DOI 10.1016/j.celrep.2012.12.017; Qin Y, 2014, CANCER LETT, V347, P225, DOI 10.1016/j.canlet.2014.02.013; Qiu W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.125; Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661; Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676; Shan JJ, 2012, HEPATOLOGY, V56, P1004, DOI 10.1002/hep.25745; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Wang B, 2014, CANCER RES, V74, P5746, DOI 10.1158/0008-5472.CAN-13-2563; Wang B, 2013, J GASTROENTEROL, V48, P798, DOI 10.1007/s00535-012-0711-z; Wang B, 2011, STEM CELL REV REP, V7, P458, DOI 10.1007/s12015-010-9175-9; Wang J, 2011, CANCER RES, V71, P7238, DOI 10.1158/0008-5472.CAN-11-0896; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Wang Z, 2015, ONCOGENE, V34, P1407, DOI 10.1038/onc.2014.75; Wu YD, 2013, CELL REP, V5, P224, DOI 10.1016/j.celrep.2013.08.030; Xi HQ, 2014, BRIT J CANCER, V110, P2011, DOI 10.1038/bjc.2014.112; Yamashita T, 2013, J CLIN INVEST, V123, P1911, DOI 10.1172/JCI66024; Yamashita T, 2013, HEPATOLOGY, V57, P1484, DOI 10.1002/hep.26168; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; Yang W, 2008, CANCER RES, V68, P4287, DOI 10.1158/0008-5472.CAN-07-6691; Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013; Yu YY, 2013, BIOCHEM BIOPH RES CO, V437, P192, DOI 10.1016/j.bbrc.2013.05.123; Zhang XM, 2013, CELL REP, V5, P445, DOI 10.1016/j.celrep.2013.09.018; Zhao ZK, 2013, TUMOR BIOL, V34, P173, DOI 10.1007/s13277-012-0525-x	50	62	65	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3188	3198		10.1038/onc.2015.129	http://dx.doi.org/10.1038/onc.2015.129			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25893304				2022-12-17	WOS:000356101100010
J	Bessede, E; Dubus, P; Megraud, F; Varon, C				Bessede, E.; Dubus, P.; Megraud, F.; Varon, C.			Helicobacter pylori infection and stem cells at the origin of gastric cancer	ONCOGENE			English	Review							EPITHELIAL-MESENCHYMAL TRANSITION; MARROW-DERIVED CELLS; MOUSE MODEL; INTESTINAL METAPLASIA; PROGENITOR-CELL; CHIEF CELLS; CAGA; PROGRESSION; ERADICATION; EXPRESSION	Helicobacter pylori infection is now recognized as the main and specific infectious cause of cancer in the world. It is responsible for gastric adenocarcinomas of both intestinal and diffuse types, which are the long-term consequences of the chronic infection of the gastric mucosa. Case-control studies have shown an association between the two, recognized as early as 1994 and further substantiated by interventional studies in which H. pylori eradication has led to the prevention of at least part of the gastric cancers. Experimental studies have highlighted the role of bone marrow-derived cells (BMDCs) and particularly mesenchymal stem cells, in the neoplastic process in about a quarter of the cases and possibly an epithelial-mesenchymal transition (EMT) in the other cases. Different studies have confirmed that chronic infection with H. pylori induces a chronic inflammation and subsequent damage of the gastric epithelial mucosa, leading to BMDC recruitment. Once recruited, these cells home and differentiate by cell-cell fusion with local gastric epithelial cells, bearing local stem cell failure and participating in tissue regeneration. The context of chronic infection and inflammation leads to an EMT and altered tissue regeneration and differentiation from both local epithelial stem cells and BMDC. EMT induces the emergence of CD44+ cells possessing mesenchymal and stem cell properties, resulting in metaplastic and dysplastic lesions to give rise, after additional epigenetic and mutational events, to the emergence of cancer stem cells (CSCs) and adenocarcinoma.	[Bessede, E.; Megraud, F.; Varon, C.] Univ Bordeaux, Lab Bacteriol, F-33076 Bordeaux, France; [Bessede, E.; Megraud, F.; Varon, C.] INSERM, U853, Bordeaux, France; [Dubus, P.] Univ Bordeaux, Lab Histol, F-33076 Bordeaux, France; [Dubus, P.] Univ Bordeaux, Histol & Pathol Mol Tumeurs, EA2406, F-33076 Bordeaux, France	UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux	Megraud, F (corresponding author), Univ Bordeaux, INSERM, U853, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	francis.megraud@chu-bordeaux.fr		Dubus, Pierre/0000-0003-1803-4711; Varon, Christine/0000-0003-4026-2016	SIRIC BRIO (Site de Recherche Integree sur le Cancer - Bordeaux Recherche Integree Oncologie) [INCa-DGOS-Inserm 6046]	SIRIC BRIO (Site de Recherche Integree sur le Cancer - Bordeaux Recherche Integree Oncologie)	This project was supported by SIRIC BRIO (Site de Recherche Integree sur le Cancer - Bordeaux Recherche Integree Oncologie) [Grant: INCa-DGOS-Inserm 6046]. We thank Genevieve Belleannee (Service Anatomopathologie, Centre Hospitalier Universitaire de Bordeaux, 33076 Bordeaux France) for her help in histopathological analysis of human gastric adenocarcinoma cases.	Almeida R, 2005, J PATHOL, V207, P396, DOI 10.1002/path.1861; Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; Atherton JC, 1997, GASTROENTEROLOGY, V112, P92, DOI 10.1016/S0016-5085(97)70223-3; Backert S, 2008, CELL MICROBIOL, V10, P1573, DOI 10.1111/j.1462-5822.2008.01156.x; Backert S, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-28; Backert S, 2010, HELICOBACTER, V15, P163, DOI 10.1111/j.1523-5378.2010.00759.x; Bagnoli F, 2005, P NATL ACAD SCI USA, V102, P16339, DOI 10.1073/pnas.0502598102; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Barros R, 2011, GUT, V60, P290, DOI 10.1136/gut.2010.222323; Baud J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060315; Bessede E, 2013, ONCOGENE; BLASER MJ, 1995, CANCER RES, V55, P2111; Cahill RJ, 1996, GUT, V38, P177, DOI 10.1136/gut.38.2.177; Cai X, 2005, GASTROENTEROLOGY, V128, P1937, DOI 10.1053/j.gastro.2005.02.066; CORREA P, 1992, CANCER RES, V52, P6735; Cover TL, 2003, CANCER RES, V63, P951; de Sablet T, 2011, GUT, V60, P1189, DOI 10.1136/gut.2010.234468; Ekstrom AM, 2001, GASTROENTEROLOGY, V121, P784, DOI 10.1053/gast.2001.27999; Ferrand J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029007; Ferrand J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019569; Ferreira RM, 2012, J CLIN MICROBIOL, V50, P3983, DOI 10.1128/JCM.02087-12; Fox JG, 2007, AM J PATHOL, V171, P1520, DOI 10.2353/ajpath.2007.070249; Fox JG, 2003, GASTROENTEROLOGY, V124, P1879, DOI 10.1016/S0016-5085(03)00406-2; Fukase K, 2008, LANCET, V372, P392, DOI 10.1016/S0140-6736(08)61159-9; Galmiche A, 2000, EMBO J, V19, P6361, DOI 10.1093/emboj/19.23.6361; Gebert B, 2003, SCIENCE, V301, P1099, DOI 10.1126/science.1086871; GHIRA P, 1995, INFECT IMMUN, V63, P4154, DOI 10.1128/IAI.63.10.4154-4160.1995; Gonzalez CA, 2012, ANN ONCOL, V23, P1320, DOI 10.1093/annonc/mdr384; Hahm KB, 2002, ALIMENT PHARM THERAP, V16, P115, DOI 10.1046/j.1365-2036.16.s2.3.x; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513; Hutchinson L, 2011, STEM CELLS DEV, V20, P11, DOI 10.1089/scd.2010.0139; Janin A, 2009, BLOOD, V113, P1834, DOI 10.1182/blood-2008-07-171702; Judd LM, 2006, GASTROENTEROLOGY, V131, P1073, DOI 10.1053/j.gastro.2006.07.018; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0; Khurana SS, 2013, J BIOL CHEM, V288, P16085, DOI 10.1074/jbc.M112.445551; KUIPERS EJ, 1995, J NATL CANCER I, V87, P1777, DOI 10.1093/jnci/87.23.1777; Kuzushita N, 2005, GASTROENTEROLOGY, V129, P1544, DOI 10.1053/j.gastro.2005.07.056; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; LEBLOND CP, 1948, SCIENCE, V108, P531, DOI 10.1126/science.108.2811.531; Lee A, 1997, GASTROENTEROLOGY, V112, P1386, DOI 10.1016/S0016-5085(97)70155-0; Lee YC, 2013, GUT, V62, P676, DOI 10.1136/gutjnl-2012-302240; Lu HS, 2009, J BIOL CHEM, V284, P23024, DOI 10.1074/jbc.M109.001008; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; Moss SF, 1996, GUT, V38, P498, DOI 10.1136/gut.38.4.498; Nam KT, 2010, GASTROENTEROLOGY, V139, P2028, DOI 10.1053/j.gastro.2010.09.005; Nam KT, 2009, GASTROENTEROLOGY, V136, P1288, DOI 10.1053/j.gastro.2008.12.037; Occhialini A, 2001, INFECT IMMUN, V69, P1902, DOI 10.1128/IAI.69.3.1902-1908.2001; Ohnishi N, 2008, P NATL ACAD SCI USA, V105, P1003, DOI 10.1073/pnas.0711183105; Ohtani M, 2007, CARCINOGENESIS, V28, P2597, DOI 10.1093/carcin/bgm150; Okumura T, 2010, CANCER RES, V70, P8435, DOI 10.1158/0008-5472.CAN-10-1506; Palena C, 2012, FUTURE ONCOL, V8, P713, DOI [10.2217/FON.12.59, 10.2217/fon.12.59]; Parsonnet J, 1997, GUT, V40, P297, DOI 10.1136/gut.40.3.297; Peterson AJ, 2010, GASTROENTEROLOGY, V139, P2005, DOI 10.1053/j.gastro.2010.08.043; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Qiao XT, 2007, GASTROENTEROLOGY, V133, P1989, DOI 10.1053/j.gastro.2007.09.031; Quante M, 2010, GASTROENTEROLOGY, V139, P2018, DOI 10.1053/j.gastro.2010.08.003; Rogers AB, 2005, CANCER RES, V65, P10709, DOI 10.1158/0008-5472.CAN-05-1846; Sarosi G, 2008, DIS ESOPHAGUS, V21, P43, DOI 10.1111/j.1442-2050.2007.00744.x; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Solis MA, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/346972; Stange DE, 2013, CELL, V155, P357, DOI 10.1016/j.cell.2013.09.008; Su YJ, 2011, EMBO J, V30, P3186, DOI 10.1038/emboj.2011.211; Suzuki R, 2012, INFECT GENET EVOL, V12, P203, DOI 10.1016/j.meegid.2011.12.002; Takaishi S, 2005, GASTROENTEROLOGY, V128, P1965, DOI 10.1053/j.gastro.2005.03.027; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thompson LJ, 2004, INFECT IMMUN, V72, P4668, DOI 10.1128/IAI.72.8.4668-4679.2004; Touati E, 2003, GASTROENTEROLOGY, V124, P1408, DOI 10.1016/S0016-5085(03)00266-X; Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011; Varon C, 2012, GASTROENTEROLOGY, V142, P281, DOI 10.1053/j.gastro.2011.10.036; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Watanabe T, 1998, GASTROENTEROLOGY, V115, P642, DOI 10.1016/S0016-5085(98)70143-X; Watanabe T, 2014, INT J CANCER, V134, P2373, DOI 10.1002/ijc.28582; Webb PM, 2001, GUT, V49, P347, DOI 10.1136/gut.49.3.347; Weis VG, 2009, GASTRIC CANCER, V12, P189, DOI 10.1007/s10120-009-0527-6; Wong BCY, 2004, JAMA-J AM MED ASSOC, V291, P187, DOI 10.1001/jama.291.2.187; Worthley DL, 2009, STEM CELLS, V27, P1463, DOI 10.1002/stem.63; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; Wu C, 2013, GENE, V525, P18, DOI 10.1016/j.gene.2013.04.067; Wu CY, 2009, GASTROENTEROLOGY, V137, P1641, DOI 10.1053/j.gastro.2009.07.060; Yin YF, 2010, GUT, V59, P1037, DOI 10.1136/gut.2009.199794; Zhu YL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035147	85	62	65	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2547	2555		10.1038/onc.2014.187	http://dx.doi.org/10.1038/onc.2014.187			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25043305				2022-12-17	WOS:000354541300001
J	Wu, DW; Hsu, NY; Wang, YC; Lee, MC; Cheng, YW; Chen, CY; Lee, H				Wu, D-W; Hsu, N-Y; Wang, Y-C; Lee, M-C; Cheng, Y-W; Chen, C-Y; Lee, H.			c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT	ONCOGENE			English	Article							NF-KAPPA-B; DNA METHYLTRANSFERASES; ABERRANT METHYLATION; PROTEIN EXPRESSION; ALLELIC DELETION; CHRONIC SMOKERS; DOWN-REGULATION; GENE; CARCINOMA; APOPTOSIS	The dual role of the microRNA-29 (miR-29) family in tumor progression and metastasis in solid tumors has been reported. Evidence for the role of miR-29 in tumor malignancy and its prognostic value in overall survival (OS) and relapse-free survival (RFS) in non-small cell lung cancer (NSCLC) remains conflicting. Mechanistic studies presented herein demonstrated that c-Myc suppressed the expression of miR-29b, promoting soft agar growth and invasion capability in lung cancer cells. Interestingly, the decrease in the expression of miR-29b by c-Myc is responsible for soft agar growth and invasiveness mediated by FHIT loss due to promoter methylation. Among patients, low expression of miR-29b and FHIT was more common in tumors with high c-Myc expression than in tumors with low c-Myc expression. Kaplan-Meier and Cox regression analysis showed that tumors with high c-Myc, low miR-29b and low FHIT expression had shorter OS and RFS periods than their counterparts. In conclusion, the decrease in the expression of miR-29b by c-Myc may be responsible for FHIT loss-mediated tumor aggressiveness and for poor outcome in NSCLC. Therefore, we suggest that restoration of the miR-29b expression using the c-Myc inhibitor might be helpful in suppressing tumor aggressiveness mediated by FHIT loss and consequently improving outcomes in NSCLC patients with tumors with low expression of FHIT.	[Wu, D-W; Hsu, N-Y; Cheng, Y-W; Lee, H.] Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, Taipei 115, Taiwan; [Wang, Y-C] Chung Shan Med Univ, Sch Med, Taichung, Taiwan; [Wang, Y-C] Chung Shan Med Univ Hosp, Dept Chest Med, Taichung 40201, Taiwan; [Lee, M-C] Taichung Vet Gen Hosp, Dept Thorac Surg, Taichung, Taiwan; [Chen, C-Y] China Med Univ Hosp, Dept Surg, Taichung, Taiwan	Taipei Medical University; Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; Taichung Veterans General Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan	Lee, H (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, Room 5,12th Floor,3,Pk St, Taipei 115, Taiwan.	hl@tmu.edu.tw			National Health Research Institute [NHRI96-TD-G-111-006, NHRI97-TD-G-111-006]; National Science Council of Taiwan, ROC [100-2314-B-038-043-MY3]	National Health Research Institute(National Health Research Institutes - Taiwan); National Science Council of Taiwan, ROC(Ministry of Science and Technology, Taiwan)	This work was jointly supported by grants from the National Health Research Institute (NHRI96-TD-G-111-006; NHRI97-TD-G-111-006) and the National Science Council(100-2314-B-038-043-MY3) of Taiwan, ROC.	Braconi C, 2011, ONCOGENE, V30, P4750, DOI 10.1038/onc.2011.193; Burke L, 1998, CANCER RES, V58, P2533; Butler D, 2000, J PATHOL, V192, P502, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH718&gt;3.0.CO;2-H; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Cheng YW, 2007, CANCER RES, V67, P10686, DOI 10.1158/0008-5472.CAN-07-1461; Connolly DC, 2000, CLIN CANCER RES, V6, P3505; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Gebeshuber CA, 2009, EMBO REP, V10, P400, DOI 10.1038/embor.2009.9; Gong JN, 2014, CELL DEATH DIFFER, V21, P100, DOI 10.1038/cdd.2013.133; Jamerson MH, 2000, ONCOGENE, V19, P1065, DOI 10.1038/sj.onc.1203268; James MA, 2006, J VIROL, V80, P5301, DOI 10.1128/JVI.01942-05; Jin BL, 2013, ADV EXP MED BIOL, V754, P3, DOI 10.1007/978-1-4419-9967-2_1; Kim JS, 2004, CARCINOGENESIS, V25, P2165, DOI 10.1093/carcin/bgh217; Kim JS, 2006, CANCER RES, V66, P4049, DOI 10.1158/0008-5472.CAN-05-3813; Kong GY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019518; Kristensen LS, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn113; Lee YC, 2004, BRIT J CANCER, V90, P2378, DOI 10.1038/sj.bjc.6601778; Li Y, 2011, J PATHOL, V224, P484, DOI 10.1002/path.2873; Maruyama R, 2004, CANCER-AM CANCER SOC, V100, P1472, DOI 10.1002/cncr.20144; McMurray HR, 2003, J VIROL, V77, P9852, DOI 10.1128/JVI.77.18.9852-9861.2003; Mott JL, 2010, J CELL BIOCHEM, V110, P1155, DOI 10.1002/jcb.22630; Napoli C, 2002, NEOPLASIA, V4, P185, DOI 10.1038/sj.neo.7900232; Okuyama H, 2010, CANCER RES, V70, P10213, DOI 10.1158/0008-5472.CAN-10-2720; Pavelic K, 2001, MOL MED, V7, P442, DOI 10.1007/BF03401849; Plaisier CL, 2012, GENOME RES, V22, P2302, DOI 10.1101/gr.133991.111; Pylkkanen L, 2002, INT J ONCOL, V20, P285; Robson S, 2006, RECENT PAT ANTI-CANC, V1, P305, DOI 10.2174/157489206778776934; Rothschild SI, 2012, ONCOGENE, V31, P4221, DOI 10.1038/onc.2011.578; Tomizawa Y, 1998, CANCER RES, V58, P5478; Treppendahl MB, 2012, BLOOD, V119, P206, DOI 10.1182/blood-2011-06-362541; Tseng JE, 1999, CANCER RES, V59, P4798; Wang J, 2006, CANCER LETT, V235, P18, DOI 10.1016/j.canlet.2005.03.058; Wolfer A, 2011, CANCER RES, V71, P2034, DOI 10.1158/0008-5472.CAN-10-3776; Wu DW, 2012, AM J PATHOL, V181, P1796, DOI 10.1016/j.ajpath.2012.07.032; Wu DW, 2010, CANCER RES, V70, P10392, DOI 10.1158/0008-5472.CAN-10-2341; Wu MF, 2005, INT J CANCER, V113, P440, DOI 10.1002/ijc.20597; Xiong YJ, 2010, HEPATOLOGY, V51, P836, DOI 10.1002/hep.23380; Xu M, 2010, J VIROL, V84, P11461, DOI 10.1128/JVI.00538-10; Yoon SO, 2007, HUM PATHOL, V38, P326, DOI 10.1016/j.humpath.2006.08.012; Yu PN, 2014, INT J CANCER, V134, P542, DOI 10.1002/ijc.28399; Zhang XW, 2012, CANCER CELL, V22, P506, DOI 10.1016/j.ccr.2012.09.003	41	62	68	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2072	2082		10.1038/onc.2014.152	http://dx.doi.org/10.1038/onc.2014.152			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909176				2022-12-17	WOS:000353173400007
J	Gao, W; Gu, Y; Li, Z; Cai, H; Peng, Q; Tu, M; Kondo, Y; Shinjo, K; Zhu, Y; Zhang, J; Sekido, Y; Han, B; Qian, Z; Miao, Y				Gao, W.; Gu, Y.; Li, Z.; Cai, H.; Peng, Q.; Tu, M.; Kondo, Y.; Shinjo, K.; Zhu, Y.; Zhang, J.; Sekido, Y.; Han, B.; Qian, Z.; Miao, Y.			miR-615-5p is epigenetically inactivated and functions as a tumor suppressor in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							HUMAN CANCER-CELLS; DNA METHYLATION; MICRORNA EXPRESSION; MICROSATELLITE INSTABILITY; GENE POLYMORPHISMS; DISEASE; RISK; PROGNOSIS; IGF2	Pancreatic ductal adenocarcinoma (PDAC) is a highly invasive cancer with a poor prognosis. Although microRNA (miRNA) transcripts have a crucial role in carcinogenesis and development, little information is known regarding the aberrant DNA methylation of miRNAs in PDAC. Using methylated DNA immunoprecipitation-chip analysis, we found that miR-615-5p was hypermethylated in its putative promoter region, which silenced its expression in PDAC cell lines. In addition, the overexpression of miR-615-5p in pancreatic cancer cells suppressed cell proliferation, migration and invasion. Insulin-like growth factor 2 (IGF2) is an imprinted gene, and its abnormal expression contributes to tumor growth. Here, we identified IGF2 as a target of miR-615-5p using a luciferase reporter assay. IGF2 upregulation in PDAC tissues was not correlated with a loss of imprinting but was inversely correlated with miR-615-5p downregulation. In addition, miR-615-5p suppressed pancreatic cancer cell proliferation, migration and invasion by directly targeting IGF2, and this effect could be reversed by co-transfection with IGF2. Furthermore, the stable overexpression of miR-615-5p inhibited tumor growth in vivo and was correlated with IGF2 expression. Using RNA sequencing, we further identified miR-615-5p as potentially targeting other genes, such as the proto-oncogene JUNB, and interfering with the insulin signaling pathway. Taken together, our results demonstrate that miR-615-5p was abnormally downregulated in PDAC cells due to promoter hypermethylation, which limited its inhibition of IGF2 and other target genes, thereby contributing to tumor growth, invasion and migration. These data demonstrate a novel and important role of miR-615-5p as a tumor suppressor in PDAC.	[Gao, W.; Gu, Y.; Li, Z.; Tu, M.; Zhu, Y.; Zhang, J.; Qian, Z.; Miao, Y.] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing 210029, Jiangsu, Peoples R China; [Cai, H.] First Peoples Hosp Changzhou, Dept Hepatobiliary Surg, Changzhou, Peoples R China; [Peng, Q.] PLA 105 Hosp, Dept Gen Surg, Hefei, Peoples R China; [Kondo, Y.; Shinjo, K.] Aichi Canc Ctr, Res Inst, Div Epigenom, Nagoya, Aichi 464, Japan; [Sekido, Y.] Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi 464, Japan; [Han, B.] Nanjing Med Univ, Nanjing Childrens Hosp, Dept Endocrinol, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University; Aichi Cancer Center; Aichi Cancer Center; Nanjing Medical University	Gao, W (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, 300 GuangZhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	gao11@hotmail.com; qianzhusilver@163.com; miaoyi@njmu.edu.cn	Sekido, Yoshitaka/P-9756-2015	Sekido, Yoshitaka/0000-0002-2428-3848	National Nature Science Foundation of China [81172267, 30901627]; National Project For Translational Research Of Early Diagnosis And Comprehensive Treatment In Pancreatic Cancer [201202007]; Priority Academic Program Development of Jiangsu Higher Education Institutions [JX10231801]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Project For Translational Research Of Early Diagnosis And Comprehensive Treatment In Pancreatic Cancer; Priority Academic Program Development of Jiangsu Higher Education Institutions	This work was supported by grants from the National Nature Science Foundation of China (Nos 81172267 and 30901627), the National Project For Translational Research Of Early Diagnosis And Comprehensive Treatment In Pancreatic Cancer (201202007) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (JX10231801).	Boeri M, 2011, P NATL ACAD SCI USA, V108, P3713, DOI 10.1073/pnas.1100048108; Chao W, 2008, CYTOKINE GROWTH F R, V19, P111, DOI 10.1016/j.cytogfr.2008.01.005; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045; Dong XQ, 2012, CANCER EPIDEMIOL, V36, P206, DOI 10.1016/j.canep.2011.05.013; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; El TH, 2012, FEBS LETT, V586, P3309; Fiorucci G, 2012, CURR MED CHEM, V19, P461, DOI 10.2174/092986712798918798; Gao W, 2008, CARCINOGENESIS, V29, P1901, DOI 10.1093/carcin/bgn170; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Han L, 2007, CANCER BIOL THER, V6, P1284; Ingram WJ, 2002, ONCOGENE, V21, P8196, DOI 10.1038/sj.onc.1205975; Jacinto FV, 2008, BIOTECHNIQUES, V44, P35, DOI 10.2144/000112708; Kim M, 2011, LANCET ONCOL, V12, P319, DOI 10.1016/S1470-2045(11)70067-5; Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797; Kunej T, 2011, MUTAT RES-FUND MOL M, V717, P77, DOI 10.1016/j.mrfmmm.2011.03.008; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Mardin W, 2009, ANN SURG ONCOL, V16, P3183, DOI 10.1245/s10434-009-0623-1; Mou HQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077217; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Rachagani S, 2010, CANCER LETT, V292, P8, DOI 10.1016/j.canlet.2009.11.010; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Sato F, 2011, FEBS J, V278, P1598, DOI 10.1111/j.1742-4658.2011.08089.x; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Soares MR, 2010, GROWTH HORM IGF RES, V20, P295, DOI 10.1016/j.ghir.2010.03.006; Suzuki H, 2008, CANCER EPIDEM BIOMAR, V17, P3467, DOI 10.1158/1055-9965.EPI-08-0514; Teschendorff AE, 2012, BIOINFORMATICS, V28, P1487, DOI 10.1093/bioinformatics/bts170; Tricoli James V, 2007, Cancer Res, V67, P4553, DOI 10.1158/0008-5472.CAN-07-0563; van Kouwenhove M, 2011, NAT REV CANCER, V11, P644, DOI 10.1038/nrc3107; Wang J, 2011, J BIOSCIENCES, V36, P481, DOI 10.1007/s12038-011-9083-4; Weber B, 2007, CELL CYCLE, V6, P1001, DOI 10.4161/cc.6.9.4209; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Yang Y, 2012, BIOCHEM GENET, V50, P122, DOI 10.1007/s10528-011-9478-9; Zhou X, 2007, PLOS COMPUT BIOL, V3	36	62	65	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1629	1640		10.1038/onc.2014.101	http://dx.doi.org/10.1038/onc.2014.101			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24769899				2022-12-17	WOS:000351848400003
J	Chitnis, MM; Lodhia, KA; Aleksic, T; Gao, S; Protheroe, AS; Macaulay, VM				Chitnis, M. M.; Lodhia, K. A.; Aleksic, T.; Gao, S.; Protheroe, A. S.; Macaulay, V. M.			IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination	ONCOGENE			English	Article						IGF-1R; radiosensitization; DNA repair; double-strand break; non-homologous end joining; homologous recombination	GROWTH-FACTOR RECEPTOR; PROSTATE-CANCER CELLS; DNA-DAMAGE RESPONSE; DEPENDENT PROTEIN-KINASE; PTEN WILD-TYPE; MITOTIC CATASTROPHE; IONIZING-RADIATION; DOWN-REGULATION; TUMOR-CELLS; CYCLIN D1	Inhibition of type 1 insulin-like growth factor receptor (IGF-1R) enhances tumor cell sensitivity to ionizing radiation. It is not clear how this effect is mediated, nor whether this approach can be applied effectively in the clinic. We previously showed that IGF-1R depletion delays repair of radiation-induced DNA double-strand breaks (DSBs), unlikely to be explained entirely by reduction in homologous recombination (HR) repair. The current study tested the hypothesis that IGF-1R inhibition induces a repair defect that involves non-homologous end joining (NHEJ). IGF-1R inhibitor AZ12253801 blocked cell survival and radiosensitized IGF-1R-overexpressing murine fibroblasts but not isogenic IGF-1R-null cells, supporting specificity for IGF-1R. IGF-1R inhibition enhanced radiosensitivity in DU145, PC3 and 22Rv1 prostate cancer cells, comparable to effects of Ataxia Telangiectasia Mutated inhibition. AZ12253801-treated DU145 cells showed delayed resolution of gamma H2AX foci, apparent within 1 h of irradiation and persisting for 24 h. In contrast, IGF-1R inhibition did not influence radiosensitivity or gamma H2AX focus resolution in LNCaP-LN3 cells, suggesting that radiosensitization tracks with the ability of IGF-1R to influence DSB repair. To differentiate effects on repair from growth and cell-survival responses, we tested AZ12253801 in DU145 cells at sub-SF50 concentrations that had no early (<= 48 h) effects on cell cycle distribution or apoptosis induction. Irradiated cultures contained abnormal mitoses, and after 5 days IGF-1R-inhibited cells showed enhanced radiation-induced polyploidy and nuclear fragmentation, consistent with the consequences of entry into mitosis with incompletely repaired DNA. AZ12253801 radiosensitized DNA-dependent protein kinase (DNA-PK)-proficient but not DNA-PK-deficient glioblastoma cells, and did not radiosensitize DNA-PK-inhibited DU145 cells, suggesting that in the context of DSB repair, IGF-1R functions in the same pathway as DNA-PK. Finally, IGF-1R inhibition attenuated repair by both NHEJ and HR in HEK293 reporter assays. These data indicate that IGF-1R influences DSB repair by both major DSB repair pathways, findings that may inform clinical application of this approach.	[Chitnis, M. M.; Lodhia, K. A.; Aleksic, T.; Gao, S.; Macaulay, V. M.] Univ Oxford, Weatherall Inst Mol Med, John Radcliffe Hosp, Dept Oncol Labs, Oxford OX3 9DS, England; [Chitnis, M. M.; Protheroe, A. S.; Macaulay, V. M.] Churchill Hosp, Canc & Haematol Ctr, Dept Oncol, Oxford OX3 7LJ, England	University of Oxford; University of Oxford	Macaulay, VM (corresponding author), Univ Oxford, Weatherall Inst Mol Med, John Radcliffe Hosp, Dept Oncol Labs, Oxford OX3 9DS, England.	valentine.macaulay@oncology.ox.ac.uk			NIHR Oxford Biomedical Research Centre; Molecular and Cellular Medicine Board of the MRC; Cancer Research UK Clinical Research Fellowship; Prostate Cancer UK; NIHR Research Capability Funding; Breast Cancer Campaign; Medical Research Council [G0601061] Funding Source: researchfish; Prostate Cancer UK [G2012-25] Funding Source: researchfish; Breast Cancer Campaign [2012NovPR046] Funding Source: researchfish; MRC [G0601061] Funding Source: UKRI	NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); Molecular and Cellular Medicine Board of the MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK Clinical Research Fellowship; Prostate Cancer UK; NIHR Research Capability Funding; Breast Cancer Campaign; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Prostate Cancer UK; Breast Cancer Campaign; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the NIHR Oxford Biomedical Research Centre, Molecular and Cellular Medicine Board of the MRC, Cancer Research UK Clinical Research Fellowship to MMC, Prostate Cancer UK support to KL and TA, NIHR Research Capability Funding to KL, Breast Cancer Campaign for support to SG and HEFCE Clinical Senior Lectureship to VMM. We are grateful to Elaine Kilgour and Elizabeth Anderson at AstraZeneca for providing AZ12253801; Walter Bodmer for LNCaP-LN3 cells; Renato Baserga for R+ and R- cells; Dr Anne Kiltie for M059J and M059K cells; Jeremy Stark and Wojciech Niedzwiedz for HEK293 EJ5-GFP/TST and HEK293 DR-GFP/TST cells; Olga Perestenko for primary renal cancer cells; and Peter McHugh and Tim Humphrey for comments on the manuscript.	Aleksic T, 2010, CANCER RES, V70, P6412, DOI 10.1158/0008-5472.CAN-10-0052; ALLALUNISTURNER MJ, 1995, RADIAT RES, V144, P288, DOI 10.2307/3578948; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Bielen A, 2012, P NATL ACAD SCI USA, V109, pE1267, DOI 10.1073/pnas.1105034109; Bolderson E, 2009, CLIN CANCER RES, V15, P6314, DOI 10.1158/1078-0432.CCR-09-0096; Bowen C, 2002, J BIOL CHEM, V277, P44969, DOI 10.1074/jbc.M202000200; Carboni JM, 2009, MOL CANCER THER, V8, P3341, DOI 10.1158/1535-7163.MCT-09-0499; Cosaceanu D, 2007, ONCOGENE, V26, P2423, DOI 10.1038/sj.onc.1210037; Dittmann K, 2005, J BIOL CHEM, V280, P31182, DOI 10.1074/jbc.M506591200; Dupont J, 2003, CELL CYCLE, V2, P270, DOI 10.4161/cc.2.4.408; Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364; Fabbri F, 2008, J CELL PHYSIOL, V217, P494, DOI 10.1002/jcp.21522; Ferte C, 2013, MOL CANCER THER, V12, P1213, DOI 10.1158/1535-7163.MCT-12-1067; Flanigan SA, 2010, CLIN CANCER RES, V16, P5436, DOI 10.1158/1078-0432.CCR-10-2054; Fraser M, 2012, CLIN CANCER RES, V18, P1015, DOI 10.1158/1078-0432.CCR-11-2189; Gonzalez-Vasconcellos I, 2013, CANCER RES, V73, P4247, DOI 10.1158/0008-5472.CAN-12-3117; Goodarzi AA, 2008, MOL CELL, V31, P167, DOI 10.1016/j.molcel.2008.05.017; Grzmil M, 2004, J PATHOL, V202, P50, DOI 10.1002/path.1492; Harrington KJ, 2011, BRIT J CANCER, V105, P628, DOI 10.1038/bjc.2011.240; Hellawell GO, 2002, CANCER RES, V62, P2942; Hinz JM, 2005, DNA REPAIR, V4, P782, DOI 10.1016/j.dnarep.2005.03.005; Isebaert SF, 2011, INT J RADIAT ONCOL, V81, P239, DOI 10.1016/j.ijrobp.2011.03.030; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Javle M.M., 2011, J CLIN ONCOL S, V29; Jeon JH, 2008, CANCER LETT, V272, P232, DOI 10.1016/j.canlet.2008.07.011; Jirawatnotai S, 2011, NATURE, V474, P230, DOI 10.1038/nature10155; Johnson N, 2011, NAT MED, V17, P875, DOI 10.1038/nm.2377; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; Krueckl SL, 2004, CANCER RES, V64, P8620, DOI 10.1158/0008-5472.CAN-04-2446; Kuemmerle JF, 2004, AM J PHYSIOL-GASTR L, V286, pG412, DOI 10.1152/ajpgi.00403.2003; Kurmasheva RT, 2006, BBA-REV CANCER, V1766, P1, DOI 10.1016/j.bbcan.2006.05.003; Lehmann BD, 2007, CELL CYCLE, V6, P595, DOI 10.4161/cc.6.5.3901; Liao YD, 2005, HUM PATHOL, V36, P1186, DOI 10.1016/j.humpath.2005.07.023; Litzenburger BC, 2011, CLIN CANCER RES, V17, P2314, DOI 10.1158/1078-0432.CCR-10-1903; Lloret M, 2009, INT J RADIAT ONCOL, V73, P976, DOI 10.1016/j.ijrobp.2008.11.013; Lobrich M, 2010, CELL CYCLE, V9, P662, DOI 10.4161/cc.9.4.10764; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; McConkey DJ, 1996, CANCER RES, V56, P5594; Molife LR, 2010, BRIT J CANCER, V103, P332, DOI 10.1038/sj.bjc.6605767; Mujoo K, 2005, PROSTATE, V62, P91, DOI 10.1002/pros.20114; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Riesterer O, 2011, INT J RADIAT ONCOL, V79, P1179, DOI 10.1016/j.ijrobp.2010.10.003; Roberts DJ, 2012, ENVIRON MOL MUTAGEN, V53, P297, DOI 10.1002/em.21684; Rochester MA, 2005, CANCER GENE THER, V12, P90, DOI 10.1038/sj.cgt.7700775; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Sarfstein R, 2012, J BIOL CHEM, V287, P2766, DOI 10.1074/jbc.M111.281782; Scott SL, 2003, CANCER RES, V63, P7190; Scurr LL, 2010, CELL, V141, P717, DOI 10.1016/j.cell.2010.04.021; Sehat B, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000628; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; Shaw PHS, 2011, BRIT J CANCER, V105, P649, DOI 10.1038/bjc.2011.291; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; Solier S, 2011, CANCER RES, V71, P906, DOI 10.1158/0008-5472.CAN-10-3297; Solier S, 2009, CELL CYCLE, V8, P1853, DOI 10.4161/cc.8.12.8865; Sprenger CC, 2002, ONCOGENE, V21, P140, DOI 10.1038/sj.onc.1205021; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; Sroka IC, 2008, PROSTATE, V68, P463, DOI 10.1002/pros.20718; Steiner MS, 2000, CANCER GENE THER, V7, P360, DOI 10.1038/sj.cgt.7700151; Tezuka M, 2001, CLIN CANCER RES, V7, P3206; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; Turney BW, 2012, RADIOTHER ONCOL, V103, P402, DOI 10.1016/j.radonc.2012.03.009; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; Valenciano A, 2012, TRANSL ONCOL, V5, P1, DOI 10.1593/tlo.11265; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Wouters B., 2009, CELL DEATH IRRADIATI; Wu JD, 2005, CLIN CANCER RES, V11, P3065, DOI 10.1158/1078-0432.CCR-04-1586; Xu NH, 2012, J ONCOL, V2012, DOI 10.1155/2012/951724; Yata K, 2009, DNA REPAIR, V8, P6, DOI 10.1016/j.dnarep.2008.09.002; Yee D, 2012, JNCI-J NATL CANCER I, V104, P975, DOI 10.1093/jnci/djs258; Zhang RG, 2007, CELL CYCLE, V6, P784, DOI 10.4161/cc.6.7.4079; Zhao Y, 2006, CANCER RES, V66, P5354, DOI 10.1158/0008-5472.CAN-05-4275	73	62	62	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2014	33	45					5262	5273		10.1038/onc.2013.460	http://dx.doi.org/10.1038/onc.2013.460			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MD	24186206	Green Accepted			2022-12-17	WOS:000345120400004
J	Bosch-Presegue, L; Vaquero, A				Bosch-Presegue, L.; Vaquero, A.			Sirtuins in stress response: guardians of the genome	ONCOGENE			English	Review						Sirtuins; genome stability; stress response; SIRT1-7; epigenetics	METHYL-TRANSFERASE SUV39H1; FOXO TRANSCRIPTION FACTORS; HISTONE DEACETYLASE SIRT6; FATTY-ACID OXIDATION; DNA-DAMAGE RESPONSE; TUMOR-SUPPRESSOR; GENE-EXPRESSION; CALORIE RESTRICTION; TELOMERE LENGTH; HOMOLOGOUS RECOMBINATION	Sirtuins, a family of NAD(+)-dependent deacetylases, help organisms to respond to metabolic and genotoxic stress through diverse pathways, including metabolic homeostasis, cell survival pathways and cell-cycle control. Evidence accumulated over the past decade, including recent descriptions of mouse knockout models for each of the seven mammalian Sirtuins, suggests that protection of genome stability is among the most important roles of Sirtuins during stress response. Our current knowledge suggests that Sirtuins promote genome integrity through a variety of mechanisms, the majority of which involve a direct role in chromatin-related functions. Here, we review these mechanisms and discuss their implications for cell physiology and tumorigenesis.	[Bosch-Presegue, L.; Vaquero, A.] Inst Invest Biomed Bellvitge IDIBEL, Canc Epigenet & Biol Program PEBC, Chromatin Biol Lab, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL)	Vaquero, A (corresponding author), Hosp Llobregat, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Av Gran Via Hosp 199-203, Barcelona 08908, Spain.	avaquero@idibell.cat	Vaquero, Alejandro/I-9845-2014; Vaquero, Alejandro/ABG-8634-2020	Vaquero, Alejandro/0000-0002-8735-4156; Bosch-Presegue, Laia/0000-0001-8025-2416	Spanish Ministry of Science and Innovation (MICINN) [SAF2011-25860]; Catalonian Government Agency AGAUR [2009SGR914]; Association Francaise Ataxie de Friedreich (AFAF)	Spanish Ministry of Science and Innovation (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Catalonian Government Agency AGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); Association Francaise Ataxie de Friedreich (AFAF)	We wish to apologize to many colleagues whose work could not be cited in this review due to space limitations. We thank members of the Vaquero group for fruitful discussions. The Chromatin Biology group is supported by the Spanish Ministry of Science and Innovation (MICINN) grant SAF2011-25860, the Catalonian Government Agency AGAUR grant 2009SGR914 and a grant from the Association Francaise Ataxie de Friedreich (AFAF).	Ahn BH, 2008, P NATL ACAD SCI USA, V105, P14447, DOI 10.1073/pnas.0803790105; Allison SJ, 2007, CELL CYCLE, V6, P2669, DOI 10.4161/cc.6.21.4866; Aster JC, 2008, ANNU REV PATHOL-MECH, V3, P587, DOI 10.1146/annurev.pathmechdis.3.121806.154300; Aykin-Burns N, 2009, BIOCHEM J, V418, P29, DOI 10.1042/BJ20081258; Bae NS, 2004, J BIOCHEM, V135, P695, DOI 10.1093/jb/mvh084; Barber MF, 2012, NATURE, V487, P114, DOI 10.1038/nature11043; Binda O, 2008, ONCOGENE, V27, P3384, DOI 10.1038/sj.onc.1211014; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Boily G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001759; Bordone L, 2006, PLOS BIOL, V4, P210, DOI 10.1371/journal.pbio.0040031; Borra MT, 2002, J BIOL CHEM, V277, P12632, DOI 10.1074/jbc.M111830200; Bosch-Presegue Laia, 2011, Genes Cancer, V2, P648, DOI 10.1177/1947601911417862; Bosch-Presegue L, 2011, MOL CELL, V42, P210, DOI 10.1016/j.molcel.2011.02.034; Burkle A, 2000, BIOGERONTOLOGY, V1, P41, DOI 10.1023/A:1010089924898; Celic I, 2006, CURR BIOL, V16, P1280, DOI 10.1016/j.cub.2006.06.023; Chang CJ, 2012, BRIT J CANCER, V106, P243, DOI 10.1038/bjc.2011.551; Chen J, 2012, CANCER RES, V71, P4138; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Chua KF, 2005, CELL METAB, V2, P67, DOI 10.1016/j.cmet.2005.06.007; Cimini D, 2003, MOL BIOL CELL, V14, P3821, DOI 10.1091/mbc.E03-01-0860; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Craig JM, 2005, BIOESSAYS, V27, P17, DOI 10.1002/bies.20145; Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861; di Fagagna FD, 1999, NAT GENET, V23, P76; Dotto GP, 2008, ONCOGENE, V27, P5115, DOI 10.1038/onc.2008.225; Dryden SC, 2003, MOL CELL BIOL, V23, P3173, DOI 10.1128/MCB.23.9.3173-3185.2003; Du JT, 2011, SCIENCE, V334, P806, DOI 10.1126/science.1207861; El Ramy R, 2009, CELL MOL LIFE SCI, V66, P3219, DOI 10.1007/s00018-009-0105-4; Fan W, 2010, MOL CELL, V39, P247, DOI 10.1016/j.molcel.2010.07.006; Fatoba ST, 2011, CELL CYCLE, V10, P2317, DOI 10.4161/cc.10.14.15913; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Ford E, 2006, GENE DEV, V20, P1075, DOI 10.1101/gad.1399706; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Fulco M, 2003, MOL CELL, V12, P51, DOI 10.1016/S1097-2765(03)00226-0; Furukawa-Hibi Y, 2005, ANTIOXID REDOX SIGN, V7, P752, DOI 10.1089/ars.2005.7.752; Garcia-Cao M, 2004, NAT GENET, V36, P94, DOI 10.1038/ng1278; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Grob A, 2009, J CELL SCI, V122, P489, DOI 10.1242/jcs.042382; Grummt I, 2003, NAT REV MOL CELL BIO, V4, P641, DOI 10.1038/nrm1171; Gupta A, 2008, MOL CELL BIOL, V28, P397, DOI 10.1128/MCB.01045-07; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Hallows WC, 2011, MOL CELL, V41, P139, DOI 10.1016/j.molcel.2011.01.002; Han MK, 2008, CELL STEM CELL, V2, P241, DOI 10.1016/j.stem.2008.01.002; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Hassa PO, 2006, MICROBIOL MOL BIOL R, V70, P789, DOI 10.1128/MMBR.00040-05; Herranz D, 2011, CELL CYCLE, V10, P2215, DOI 10.4161/cc.10.13.16185; Hirschey MD, 2011, MOL CELL, V44, P177, DOI 10.1016/j.molcel.2011.07.019; Hirschey MD, 2010, NATURE, V464, P121, DOI 10.1038/nature08778; Hochegger H, 2006, EMBO J, V25, P1305, DOI 10.1038/sj.emboj.7601015; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Inoue T, 2007, ONCOGENE, V26, P945, DOI 10.1038/sj.onc.1209857; Inoue T, 2007, CELL CYCLE, V6, P1011, DOI 10.4161/cc.6.9.4219; Iwahara T, 2012, MOL CELL BIOL, V32, P5022, DOI 10.1128/MCB.00822-12; Jeggo PA, 1998, CURR BIOL, V8, pR49, DOI 10.1016/S0960-9822(98)70032-6; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jeong J, 2007, EXP MOL MED, V39, P8, DOI 10.1038/emm.2007.2; Jeong SM, 2013, CANCER CELL, V23, P450, DOI 10.1016/j.ccr.2013.02.024; Jia GX, 2012, MOL CELL BIOCHEM, V364, P345, DOI 10.1007/s11010-012-1236-8; Jiang H, 2013, NATURE, V496, P110, DOI 10.1038/nature12038; Jing EX, 2011, P NATL ACAD SCI USA, V108, P14608, DOI 10.1073/pnas.1111308108; Kahyo T, 2008, FEBS LETT, V582, P2479, DOI 10.1016/j.febslet.2008.06.031; Kaidi A, 2010, SCIENCE, V329, P1348, DOI 10.1126/science.1192049; Karachentsev D, 2005, GENE DEV, V19, P431, DOI 10.1101/gad.1263005; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kawahara TLA, 2009, CELL, V136, P62, DOI 10.1016/j.cell.2008.10.052; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Law IKM, 2009, PROTEOMICS, V9, P2444, DOI 10.1002/pmic.200800738; Lee CW, 2012, CANCER RES, V72, P4394, DOI 10.1158/0008-5472.CAN-12-0429; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Li K, 2008, J BIOL CHEM, V283, P7590, DOI 10.1074/jbc.M709707200; Li YZ, 2011, GENES CELLS, V16, P34, DOI 10.1111/j.1365-2443.2010.01460.x; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lombard DB, 2008, J INTERN MED, V263, P128, DOI 10.1111/j.1365-2796.2007.01902.x; Lombard DB, 2007, MOL CELL BIOL, V27, P8807, DOI 10.1128/MCB.01636-07; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Magnaghi-Jaulin L, 2006, CHROMOSOME RES, V14, P319, DOI 10.1007/s10577-006-1049-2; Mao ZY, 2012, P NATL ACAD SCI USA, V109, P11800, DOI 10.1073/pnas.1200583109; Mao ZY, 2011, SCIENCE, V332, P1443, DOI 10.1126/science.1202723; Martinez-Redondo P, 2013, GENES CANC, DOI 10.11771947601913483767; Matsushita N, 2005, GENES CELLS, V10, P321, DOI 10.1111/j.1365-2443.2005.00836.x; McAinsh AD, 1999, CURR BIOL, V9, P963, DOI 10.1016/S0960-9822(99)80424-2; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; McCord RA, 2009, AGING-US, V1, P109, DOI 10.18632/aging.100011; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Michishita E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736; Michishita E, 2009, CELL CYCLE, V8, P2664, DOI 10.4161/cc.8.16.9367; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; Min LH, 2012, NAT CELL BIOL, V14, P1203, DOI 10.1038/ncb2590; Ming M, 2010, P NATL ACAD SCI USA, V107, P22623, DOI 10.1073/pnas.1010377108; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Moss T, 2007, CELL MOL LIFE SCI, V64, P29, DOI 10.1007/s00018-006-6278-1; Mostoslavsky R, 2006, CELL, V124, P315, DOI [10.1016/j.cell.2005.11.044, 10.1016/J.CEL.2005.11.044]; Mulligan P, 2011, MOL CELL, V42, P689, DOI 10.1016/j.molcel.2011.04.020; Murayama A, 2008, CELL, V133, P627, DOI 10.1016/j.cell.2008.03.030; Muth V, 2001, EMBO J, V20, P1353, DOI 10.1093/emboj/20.6.1353; Nakagawa T, 2009, CELL, V137, P560, DOI 10.1016/j.cell.2009.02.026; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Narala SR, 2008, MOL BIOL CELL, V19, P1210, DOI 10.1091/mbc.E07-09-0965; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; North BJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000784; North BJ, 2007, J BIOL CHEM, V282, P19546, DOI 10.1074/jbc.M702990200; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Oda H, 2009, MOL CELL BIOL, V29, P2278, DOI 10.1128/MCB.01768-08; Onyango P, 2002, P NATL ACAD SCI USA, V99, P13653, DOI 10.1073/pnas.222538099; Ou XA, 2011, BLOOD, V117, P440, DOI 10.1182/blood-2010-03-273011; Paddock MN, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000428; Palacios JA, 2010, J CELL BIOL, V191, P1299, DOI 10.1083/jcb.201005160; Palacios OM, 2009, AGING-US, V1, P771, DOI 10.18632/aging.100075; Peng C, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.012658; Peng LR, 2012, MOL CELL BIOL, V32, P2823, DOI 10.1128/MCB.00496-12; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Planavila A, 2012, J MOL CELL CARDIOL, V53, P521, DOI 10.1016/j.yjmcc.2012.07.019; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Qiu XL, 2010, CELL METAB, V12, P662, DOI 10.1016/j.cmet.2010.11.015; Raptis S, 2006, EXP SUPPL, V96, P303; Rea S, 2007, ONCOGENE, V26, P5385, DOI 10.1038/sj.onc.1210607; RINE J, 1979, GENETICS, V93, P877; Rusin M, 2009, MECH AGEING DEV, V130, P528, DOI 10.1016/j.mad.2009.06.005; Sanders SL, 2004, CELL, V119, P603, DOI 10.1016/j.cell.2004.11.009; Sasaki T, 2006, AGING CELL, V5, P413, DOI 10.1111/j.1474-9726.2006.00235.x; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Scher MB, 2007, GENE DEV, V21, P920, DOI 10.1101/gad.1527307; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Schotta G, 2008, GENE DEV, V22, P2048, DOI 10.1101/gad.476008; Schwer B, 2002, J CELL BIOL, V158, P647, DOI 10.1083/jcb.200205057; Sebastian C, 2012, J BIOL CHEM, V287, P42444, DOI 10.1074/jbc.R112.402768; Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; Serrano L, 2013, GENE DEV, V27, P639, DOI 10.1101/gad.211342.112; Shen ZY, 2011, J MOL CELL BIOL, V3, P1, DOI 10.1093/jmcb/mjq057; Shimazu T, 2010, CELL METAB, V12, P654, DOI 10.1016/j.cmet.2010.11.003; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Singh KK, 2006, ANN NY ACAD SCI, V1067, P182, DOI 10.1196/annals.1354.022; Someya S, 2010, CELL, V143, P802, DOI 10.1016/j.cell.2010.10.002; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; Sun YL, 2009, NAT CELL BIOL, V11, P1376, DOI 10.1038/ncb1982; Sundaresan NR, 2008, MOL CELL BIOL, V28, P6384, DOI 10.1128/MCB.00426-08; Sundaresan NR, 2009, J CLIN INVEST, V119, P2758, DOI 10.1172/JCI39162; Takata T, 2003, BIOCHEM BIOPH RES CO, V301, P250, DOI 10.1016/S0006-291X(02)03020-6; Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013; Tennen RI, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1443; Uhl M, 2010, DNA REPAIR, V9, P383, DOI 10.1016/j.dnarep.2009.12.020; Vaitiekunaite R, 2007, MECH AGEING DEV, V128, P650, DOI 10.1016/j.mad.2007.09.004; Vakhrusheva O, 2008, CIRC RES, V102, P703, DOI 10.1161/CIRCRESAHA.107.164558; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vaquero A, 2007, ONCOGENE, V26, P5505, DOI 10.1038/sj.onc.1210617; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaquero A, 2007, NATURE, V450, P440, DOI 10.1038/nature06268; Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706; Vaquero A, 2009, INT J DEV BIOL, V53, P303, DOI 10.1387/ijdb.082675av; Vaute O, 2002, NUCLEIC ACIDS RES, V30, P475, DOI 10.1093/nar/30.2.475; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Wilson JM, 2006, EMBO REP, V7, P1247, DOI 10.1038/sj.embor.7400829; Wong S, 2007, BIOCHEM J, V407, P451, DOI 10.1042/BJ20070151; Wu SM, 2010, GENE DEV, V24, P2531, DOI 10.1101/gad.1984210; Yang B, 2009, CELL CYCLE, V8, P2662, DOI 10.4161/cc.8.16.9329; Yang XJ, 2008, MOL CELL, V31, P449, DOI 10.1016/j.molcel.2008.07.002; Yang YJ, 2010, J BIOL CHEM, V285, P7417, DOI 10.1074/jbc.M109.053421; Yuan J, 2009, CELL CYCLE, V8, P1747, DOI 10.4161/cc.8.11.8620; Yuan Z, 2007, CELL CYCLE, V6, P2869, DOI 10.4161/cc.6.23.5026; Yuan Z, 2007, MOL CELL, V27, P149, DOI 10.1016/j.molcel.2007.05.029; Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041	179	62	65	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2014	33	29					3764	3775		10.1038/onc.2013.344	http://dx.doi.org/10.1038/onc.2013.344			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL8MU	23995787				2022-12-17	WOS:000339394100002
J	Adam, J; Yang, M; Soga, T; Pollard, PJ				Adam, J.; Yang, M.; Soga, T.; Pollard, P. J.			Rare insights into cancer biology	ONCOGENE			English	Review						fumarate hydratase; HLRCC; dysregulated metabolism; succinate dehydrogenase; isocitrate dehydrogenase; clinical biomarkers	FUMARATE-HYDRATASE DEFICIENCY; RENAL-CELL CANCER; ISOCITRATE DEHYDROGENASE MUTATIONS; ACUTE MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR; SUCCINATE-DEHYDROGENASE; GENE-MUTATIONS; IDH2 MUTATIONS; COMPLEX-II; HEREDITARY LEIOMYOMATOSIS	Cancer-associated mutations have been identified in the metabolic genes succinate dehydrogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH), advancing and challenging our understanding of cellular function and disease mechanisms and providing direct links between dysregulated metabolism and cancer. Some striking parallels exist in the cellular consequences of the genetic mutations within this triad of cancer syndromes, including accumulation of oncometabolites and competitive inhibition of 2-oxoglutarate-dependent dioxygenases, particularly, hypoxia-inducible factor (HIF) prolyl hydroxylases, JmjC domain-containing histone demethylases (part of the JMJD family) and the ten-eleven translocation (TET) family of 5methyl cytosine (5mC) DNA hydroxylases. These lead to activation of HIF-dependent oncogenic pathways and inhibition of histone and DNA demethylation. Mutations in FH, resulting in loss of enzyme activity, predispose affected individuals to a rare cancer, hereditary leiomyomatosis and renal cell cancer (HLRCC), characterised by benign smooth muscle cutaneous and uterine tumours (leiomyomata) and an aggressive form of collecting duct and type 2 papillary renal cancer. Interestingly, loss of FH activity results in the accumulation of high levels of fumarate that can lead to the non-enzymatic modification of cysteine residues in multiple proteins (succination) and in some cases to their disrupted function. Here we consider that the study of rare diseases such as HLRCC, combining analyses of human tumours and cell lines with in vitro and in vivo murine models has provided novel insights into cancer biology associated with dysregulated metabolism and represents a useful paradigm for cancer research.	[Adam, J.; Yang, M.; Pollard, P. J.] Univ Oxford, Nuffield Dept Med, Canc Biol & Metab Grp, Oxford OX3 7BN, England; [Soga, T.] Keio Univ, Inst Adv Biosci, Yamagata, Japan; [Soga, T.] Keio Univ, Oxford Keio Metabol Consortium, Yamagata, Japan; [Pollard, P. J.] Oxford Keio Metabol Consortium, Oxford, England	University of Oxford; Keio University; Keio University	Pollard, PJ (corresponding author), Univ Oxford, Nuffield Dept Med, Canc Biol & Metab Grp, Henry Wellcome Bldg Mol Physiol,Roosevelt Dr, Oxford OX3 7BN, England.	patrick.pollard@well.ox.ac.uk	Soga, Tomoyoshi/B-8105-2014	Soga, Tomoyoshi/0000-0001-9502-2509; Adam, Julie/0000-0002-7980-7151	European Research Council under the European Community's Seventh Framework Programme/ERC [310837]; Cancer Research UK; Yamagata Prefectural Government and City of Tsuruoka;  [22134007]	European Research Council under the European Community's Seventh Framework Programme/ERC; Cancer Research UK(Cancer Research UK); Yamagata Prefectural Government and City of Tsuruoka; 	The Cancer Biology and Metabolism Group, led by Dr Pollard, is funded by the European Research Council under the European Community's Seventh Framework Programme (FP7/2007-2013)/ERC grant agreement no. 310837 and Cancer Research UK. Professor Soga is funded from a Grant-in-Aid for scientific research on Innovative Areas, Japan No. 22134007 and the Yamagata Prefectural Government and City of Tsuruoka.	Adam J, 2013, CELL REP, VS2211-1247, P00173; Adam J, 2011, ONCOTARGET, V2, P820; Adam J, 2011, CANCER CELL, V20, P524, DOI 10.1016/j.ccr.2011.09.006; Alderson NL, 2006, ARCH BIOCHEM BIOPHYS, V450, P1, DOI 10.1016/j.abb.2006.03.005; Amar L, 2007, J CLIN ENDOCR METAB, V92, P3822, DOI 10.1210/jc.2007-0709; Amary MF, 2011, NAT GENET, V43, P1262, DOI 10.1038/ng.994; Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913; Ashcroft FM, 2012, CELL, V148, P1160, DOI 10.1016/j.cell.2012.02.010; Ashrafian H, 2010, CANCER RES, V70, P9153, DOI 10.1158/0008-5472.CAN-10-1949; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Bardella C, 2011, BBA-BIOENERGETICS, V1807, P1432, DOI 10.1016/j.bbabio.2011.07.003; Bardella C, 2011, J PATHOL, V225, P4, DOI 10.1002/path.2932; Bayley JP, 2010, CURR OPIN GENET DEV, V20, P324, DOI 10.1016/j.gde.2010.02.008; Bayley JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007987; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Biatnik M, 2008, ANN NY ACAD SCI, V1126, P272, DOI 10.1196/annals.1433.047; Blatnik M, 2008, DIABETES, V57, P41, DOI 10.2337/db07-0838; Borger DR, 2012, ONCOLOGIST, V17, P72, DOI 10.1634/theoncologist.2011-0386; Briere JJ, 2005, HUM MOL GENET, V14, P3263, DOI 10.1093/hmg/ddi359; Brosnan ME, 2004, J NUTR, V134, p2791S, DOI 10.1093/jn/134.10.2791S; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Burnichon N, 2010, HUM MOL GENET, V19, P3011, DOI 10.1093/hmg/ddq206; Cairns RA, 2012, BLOOD, V119, P1901, DOI 10.1182/blood-2011-11-391748; Choi C, 2012, NAT MED, V18, P624, DOI 10.1038/nm.2682; Choi C, 2011, MAGN RESON MED, V66, P609, DOI 10.1002/mrm.22857; Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43; Copeland NG, 2010, NAT REV CANCER, V10, P696, DOI 10.1038/nrc2916; Dahia PLM, 2006, ANN NY ACAD SCI, V1073, P208, DOI 10.1196/annals.1353.023; Dahia PLM, 2005, PLOS GENET, V1, P72, DOI 10.1371/journal.pgen.0010008; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Dang L, 2010, NATURE, V465, P966, DOI 10.1038/nature09132; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; DeBerardinis RJ, 2012, CELL, V148, P1132, DOI 10.1016/j.cell.2012.02.032; Dupuy AJ, 2005, NATURE, V436, P221, DOI 10.1038/nature03691; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Frezza C, 2011, NATURE, V477, P225, DOI 10.1038/nature10363; Frezza C, 2011, J MOL MED, V89, P213, DOI 10.1007/s00109-011-0728-4; Frizzell N, 2011, FREE RADICAL RES, V45, P101, DOI 10.3109/10715762.2010.524643; Frizzell N, 2009, J BIOL CHEM, V284, P25772, DOI 10.1074/jbc.M109.019257; Gaal J, 2010, J CLIN ENDOCR METAB, V95, P1274, DOI 10.1210/jc.2009-2170; Gimenez-Roqueplo AP, 2003, CANCER RES, V63, P5615; Gimenez-Roqueplo AP, 2001, AM J HUM GENET, V69, P1186, DOI 10.1086/324413; Glunde K, 2011, NAT REV CANCER, V11, P835, DOI 10.1038/nrc3162; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; Guzy RD, 2008, MOL CELL BIOL, V28, P718, DOI 10.1128/MCB.01338-07; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanan EJ, 2012, J MED CHEM, V55, P10090, DOI 10.1021/jm3012239; Hao HX, 2009, SCIENCE, V325, P1139, DOI 10.1126/science.1175689; Hayes JD, 2010, ANTIOXID REDOX SIGN, V13, P1713, DOI 10.1089/ars.2010.3221; Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hemerly JP, 2010, EUR J ENDOCRINOL, V163, P747, DOI 10.1530/EJE-10-0473; Hewitson KS, 2007, J BIOL CHEM, V282, P3293, DOI 10.1074/jbc.M608337200; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Ishii T, 2005, CANCER RES, V65, P203; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Itoh Ken, 2009, Seikagaku, V81, P447; Janeway KA, 2011, P NATL ACAD SCI USA, V108, P314, DOI 10.1073/pnas.1009199108; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kaelin WG, 2009, GENOME MED, V1, DOI 10.1186/gm99; Kaelin WG, 2009, CANCER CELL, V16, P180, DOI 10.1016/j.ccr.2009.08.013; Kang MR, 2009, INT J CANCER, V125, P353, DOI 10.1002/ijc.24379; Kiuru M, 2001, AM J PATHOL, V159, P825, DOI 10.1016/S0002-9440(10)61757-9; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Ko M, 2010, NATURE, V468, P839, DOI 10.1038/nature09586; Koglin N, 2011, CLIN CANCER RES, V17, P6000, DOI 10.1158/1078-0432.CCR-11-0687; Koivunen P, 2007, J BIOL CHEM, V282, P4524, DOI 10.1074/jbc.M610415200; Koivunen P, 2012, NATURE, V483, P485, DOI 10.1038/nature10898; Korpershoek E, 2011, J CLIN ENDOCR METAB, V96, pE1472, DOI 10.1210/jc.2011-1043; Launonen V, 2001, P NATL ACAD SCI USA, V98, P3387, DOI 10.1073/pnas.051633798; Lehtonen HJ, 2006, J MED GENET, V43, P523, DOI 10.1136/jmg.2005.036400; Lenders JWM, 2005, LANCET, V366, P665, DOI 10.1016/S0140-6736(05)67139-5; Leonardi R, 2012, J BIOL CHEM, V287, P14615, DOI 10.1074/jbc.C112.353946; Linehan WM, 2007, CLIN CANCER RES, V13, p671S, DOI 10.1158/1078-0432.CCR-06-1870; Lorsbach RB, 2003, LEUKEMIA, V17, P637, DOI 10.1038/sj.leu.2402834; Losman JA, 2013, SCIENCE, V339, P1621, DOI 10.1126/science.1231677; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; MacKenzie ED, 2007, MOL CELL BIOL, V27, P3282, DOI 10.1128/MCB.01927-06; Maher EA, 2012, NMR BIOMED, V25, P1234, DOI 10.1002/nbm.2794; Marcucci G, 2010, J CLIN ONCOL, V28, P2348, DOI 10.1200/JCO.2009.27.3730; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Maxwell PH, 2011, J PATHOL, V225, P1, DOI 10.1002/path.2950; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Murugan AK, 2010, BIOCHEM BIOPH RES CO, V393, P555, DOI 10.1016/j.bbrc.2010.02.095; Nagai R, 2007, J BIOL CHEM, V282, P34219, DOI 10.1074/jbc.M703551200; Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; O'Flaherty L, 2010, HUM MOL GENET, V19, P3844, DOI 10.1093/hmg/ddq305; Ooi A, 2013, CANCER RES, V73, P2044, DOI 10.1158/0008-5472.CAN-12-3227; Ooi A, 2011, CANCER CELL, V20, P511, DOI 10.1016/j.ccr.2011.08.024; Pansuriya TC, 2011, NAT GENET, V43, P1256, DOI 10.1038/ng.1004; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pasini B, 2009, J INTERN MED, V266, P19, DOI 10.1111/j.1365-2796.2009.02111.x; Piruat JI, 2004, MOL CELL BIOL, V24, P10933, DOI 10.1128/MCB.24.24.10933-10940.2004; Pollard P, 2005, J PATHOL, V205, P41, DOI 10.1002/path.1686; Pollard PJ, 2007, CANCER CELL, V11, P311, DOI 10.1016/j.ccr.2007.02.005; Pollard PJ, 2009, SCIENCE, V324, P192, DOI 10.1126/science.1173362; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Qu WC, 2011, J AM CHEM SOC, V133, P1122, DOI 10.1021/ja109203d; Rankin EB, 2006, CANCER RES, V66, P2576, DOI 10.1158/0008-5472.CAN-05-3241; Ratcliffe PJ, 2007, CANCER CELL, V11, P303, DOI 10.1016/j.ccr.2007.03.015; Rawson JB, 2012, NUTR CANCER, V64, P919, DOI 10.1080/01635581.2012.711418; Ricketts C, 2008, J NATL CANCER I, V100, P1260, DOI 10.1093/jnci/djn254; Salway J.G., 2017, METABOLISM GLANCE; Sasaki M, 2012, GENE DEV, V26, P2038, DOI 10.1101/gad.198200.112; Sasaki M, 2012, NATURE, V488, P656, DOI 10.1038/nature11323; Scatena R, 2007, AM J PHYSIOL-CELL PH, V293, pC12, DOI 10.1152/ajpcell.00314.2006; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Semenza GL, 2011, NEW ENGL J MED, V365, P537, DOI [10.1056/NEJMra1011165, 10.1056/NEJMc1110602]; SHAMBAUGH GE, 1977, AM J CLIN NUTR, V30, P2083, DOI 10.1093/ajcn/30.12.2083; Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218; Shibata T, 2011, AM J PATHOL, V178, P1395, DOI 10.1016/j.ajpath.2010.12.011; Soga T, 2003, J PROTEOME RES, V2, P488, DOI 10.1021/pr034020m; Soga T, 2006, J BIOL CHEM, V281, P16768, DOI 10.1074/jbc.M601876200; Soga T, 2009, ANAL CHEM, V81, P6165, DOI 10.1021/ac900675k; STEPINSKI J, 1989, AM J KIDNEY DIS, V14, P307, DOI 10.1016/S0272-6386(89)80209-4; Stratton MR, 2013, EMBO MOL MED, V5, P169, DOI 10.1002/emmm.201202388; Sudarshan S, 2009, MOL CELL BIOL, V29, P4080, DOI 10.1128/MCB.00483-09; Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tan AY, 2009, J MOL CELL BIOL, V1, P82, DOI 10.1093/jmcb/mjp025; Ternette N, 2013, CELL REP, V3, P689, DOI 10.1016/j.celrep.2013.02.013; Thomas SA, 2012, OBESITY, V20, P263, DOI 10.1038/oby.2011.340; Thompson CB, 2009, NEW ENGL J MED, V360, P813, DOI 10.1056/NEJMe0810213; Tomita M, 2012, SCIENCE, V336, P990, DOI 10.1126/science.1223066; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Toro JR, 2003, AM J HUM GENET, V73, P95, DOI 10.1086/376435; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Traykova-Brauch M, 2008, NAT MED, V14, P979, DOI 10.1038/nm.1865; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; van Nederveen FH, 2009, LANCET ONCOL, V10, P764, DOI 10.1016/S1470-2045(09)70164-0; Vanharanta S, 2004, AM J HUM GENET, V74, P153, DOI 10.1086/381054; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Varier RA, 2011, BBA-REV CANCER, V1815, P75, DOI 10.1016/j.bbcan.2010.10.002; WARBURG O, 1956, SCIENCE, V124, P269; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2012, ONCOGENE, V31, P2491, DOI 10.1038/onc.2011.416; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108; Xiao MT, 2012, GENE DEV, V26, P1326, DOI 10.1101/gad.191056.112; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yang M, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00085; Yang YF, 2012, CANCER GENET-NY, V205, P377, DOI 10.1016/j.cancergen.2012.05.001; Yang Y, 2010, CANCER GENET CYTOGEN, V196, P45, DOI 10.1016/j.cancergencyto.2009.08.018; Yogev O, 2011, FEBS J, V278, P4230, DOI 10.1111/j.1742-4658.2011.08359.x; Yogev O, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000328; Young RM, 2012, NAT MED, V18, P1024, DOI 10.1038/nm.2865; Zhang DD, 2006, DRUG METAB REV, V38, P769, DOI 10.1080/03602530600971974	158	62	65	0	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2547	2556		10.1038/onc.2013.222	http://dx.doi.org/10.1038/onc.2013.222			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23812428				2022-12-17	WOS:000336502700001
J	Loreni, F; Mancino, M; Biffo, S				Loreni, F.; Mancino, M.; Biffo, S.			Translation factors and ribosomal proteins control tumor onset and progression: how?	ONCOGENE			English	Review						eIF6; ribosome; translation; PKC; ribosomal proteins; ribosomopathy; cancer	DIAMOND-BLACKFAN ANEMIA; IRES-MEDIATED TRANSLATION; MESSENGER-RNA TRANSLATION; BREAST-CANCER CELLS; INITIATION-FACTOR; MULTIPLE-MYELOMA; DYSKERATOSIS-CONGENITA; GENE-EXPRESSION; AMINO-ACIDS; DNA-DAMAGE	Gene expression is shaped by translational control. The modalities and the extent by which translation factors modify gene expression have revealed therapeutic scenarios. For instance, eukaryotic initiation factor ( eIF) 4E activity is controlled by the signaling cascade of growth factors, and drives tumorigenesis by favoring the translation of specific mRNAs. Highly specific drugs target the activity of eIF4E. Indeed, the antitumor action of mTOR complex 1 ( mTORc1) blockers like rapamycin relies on their capability to inhibit eIF4E assembly into functional eIF4F complexes. eIF4E biology, from its inception to recent pharmacological targeting, is proof-of-principle that translational control is druggable. The case for eIF4E is not isolated. The translational machinery is involved in the biology of cancer through many other mechanisms. First, untranslated sequences on mRNAs as well as noncoding RNAs regulate the translational efficiency of mRNAs that are central for tumor progression. Second, other initiation factors like eIF6 show a tumorigenic potential by acting downstream of oncogenic pathways. Third, genetic alterations in components of the translational apparatus underlie an entire class of inherited syndromes known as ` ribosomopathies' that are associated with increased cancer risk. Taken together, data suggest that in spite of their evolutionary conservation and ubiquitous nature, variations in the activity and levels of ribosomal proteins and translation factors generate highly specific effects. Beside, as the structures and biochemical activities of several noncoding RNAs and initiation factors are known, these factors may be amenable to rational pharmacological targeting. The future is to design highly specific drugs targeting the translational apparatus.	[Loreni, F.] Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; [Mancino, M.; Biffo, S.] Osped San Raffaele, San Raffaele Sci Inst, I-20132 Milan, Italy; [Mancino, M.; Biffo, S.] DISIT, Alessandria, Italy	University of Rome Tor Vergata	Loreni, F (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	loreni@uniroma2.it; biffo.stefano@hsr.it	Mancino, Marilena/AAA-5481-2019	Mancino, Marilena/0000-0002-3461-0427; biffo, stefano/0000-0002-3780-1050	Fondazione Buzzi [AIRC IG 10653, PRIN 20104AE23N];  [5 x mille];  [13-0045];  [10653];  [20104AE23N]; Worldwide Cancer Research [09-0061, 13-0045] Funding Source: researchfish; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Fondazione Buzzi; ; ; ; ; Worldwide Cancer Research; Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	We apologize to those whose work we were unable to cite. This work is supported by grants AIRC IG 2011, AIRC 5 x mille, AICR 13-0045 and Fondazione Buzzi to SB, AIRC IG 10653 to FL, PRIN 20104AE23N to SB and FL.	Alain T, 2012, CANCER RES, V72, P6468, DOI 10.1158/0008-5472.CAN-12-2395; Alter BP, 2009, BLOOD, V113, P6549, DOI 10.1182/blood-2008-12-192880; Amsterdam A, 2004, PLOS BIOL, V2, P690, DOI 10.1371/journal.pbio.0020139; Anderson SJ, 2007, IMMUNITY, V26, P759, DOI 10.1016/j.immuni.2007.04.012; Angelini M, 2007, HUM MOL GENET, V16, P1720, DOI 10.1093/hmg/ddm120; Badura M, 2012, P NATL ACAD SCI USA, V109, P18767, DOI 10.1073/pnas.1203853109; Baird TD, 2012, ADV NUTR, V3, P307, DOI 10.3945/an.112.002113; Balvay L, 2009, BBA-GENE REGUL MECH, V1789, P542, DOI 10.1016/j.bbagrm.2009.07.005; Barlow JL, 2010, NAT MED, V16, P59, DOI 10.1038/nm.2063; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Basu A, 2011, MOL CELL BIOL, V31, P4482, DOI 10.1128/MCB.05804-11; Belin S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007147; Bellodi C, 2010, CANCER RES, V70, P6026, DOI 10.1158/0008-5472.CAN-09-4730; Bellodi C, 2010, EMBO J, V29, P1865, DOI 10.1038/emboj.2010.83; Ben-Shem A, 2011, SCIENCE, V334, P1524, DOI 10.1126/science.1212642; Blagden SP, 2011, NAT REV CLIN ONCOL, V8, P280, DOI 10.1038/nrclinonc.2011.16; Blau L, 2012, P NATL ACAD SCI USA, V109, pE2875, DOI 10.1073/pnas.1203659109; Boocock GRB, 2003, NAT GENET, V33, P97, DOI 10.1038/ng1062; Boria I, 2008, HUM MUTAT, V29, pE263, DOI 10.1002/humu.20864; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Brina D, 2011, CELL CYCLE, V10, P3441, DOI 10.4161/cc.10.20.17796; Browne GJ, 2004, MOL CELL BIOL, V24, P2986, DOI 10.1128/MCB.24.7.2986-2997.2004; Burroughs L, 2009, HEMATOL ONCOL CLIN N, V23, P233, DOI 10.1016/j.hoc.2009.01.007; Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508; Ceci M, 2003, NATURE, V426, P579, DOI 10.1038/nature02160; Ceci M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035034; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Choesmel V, 2007, BLOOD, V109, P1275, DOI 10.1182/blood-2006-07-038372; Cobbold LC, 2010, ONCOGENE, V29, P2884, DOI 10.1038/onc.2010.31; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; CROCKER J, 1987, J CLIN PATHOL, V40, P885, DOI 10.1136/jcp.40.8.885; Da Costa L, 2010, TRANSFUS CLIN BIOL, V17, P112, DOI 10.1016/j.tracli.2010.06.001; Dabo S, 2012, VIRUSES-BASEL, V4, P2598, DOI 10.3390/v4112598; Dalton LE, 2012, PROG MOL BIOL TRANSL, V106, P189, DOI 10.1016/B978-0-12-396456-4.00003-1; Danilova N, 2008, BLOOD, V112, P5228, DOI 10.1182/blood-2008-01-132290; Daxinger L, 2012, G3-GENES GENOM GENET, V2, P1393, DOI 10.1534/g3.112.004036; De Keersmaecker K, 2013, NAT GENET, V45, P186, DOI 10.1038/ng.2508; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Devlin JR, 2013, FEBS J, V280, P5307, DOI 10.1111/febs.12135; Di Nicolantonio F, 2010, J CLIN INVEST, V120, P2858, DOI 10.1172/JCI37539; Diggle TA, 1996, BIOCHEM J, V316, P447, DOI 10.1042/bj3160447; Dobrikov M, 2011, MOL CELL BIOL, V31, P2947, DOI 10.1128/MCB.05589-11; Doerfel LK, 2013, SCIENCE, V339, P85, DOI 10.1126/science.1229017; Donati G, 2012, CANCER RES, V72, P1602, DOI 10.1158/0008-5472.CAN-11-3992; Dong HJ, 2009, LEUKEMIA LYMPHOMA, V50, P974, DOI 10.1080/10428190902895780; Dowling RJ, 2012, SCIENCE, V328, P1172; Drexler HCA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004161; Dumstorf CA, 2010, MOL CANCER THER, V9, P3158, DOI 10.1158/1535-7163.MCT-10-0413; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Ellis SR, 2008, CURR TOP DEV BIOL, V82, P217, DOI 10.1016/S0070-2153(07)00008-7; Fabian MR, 2012, NAT STRUCT MOL BIOL, V19, P586, DOI 10.1038/nsmb.2296; Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103; Fasolo A, 2012, CURR PHARM DESIGN, V18, P2766, DOI 10.2174/138161212800626210; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Flygare J, 2007, BLOOD, V109, P980, DOI 10.1182/blood-2006-07-038232; Fumagalli S, 2012, GENE DEV, V26, P1028, DOI 10.1101/gad.189951.112; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Gallagher JW, 2008, CANCER RES, V68, P8752, DOI 10.1158/0008-5472.CAN-08-1042; Gallinetti J, 2013, BIOCHEM J, V449, P1, DOI 10.1042/BJ20121098; Ganapathi KA, 2008, BRIT J HAEMATOL, V141, P376, DOI 10.1111/j.1365-2141.2008.07095.x; Gandin V, 2008, NATURE, V455, P684, DOI 10.1038/nature07267; Gazda HT, 2008, AM J HUM GENET, V83, P769, DOI 10.1016/j.ajhg.2008.11.004; Gibson TJ, 2012, FEBS LETT, V586, P2787, DOI 10.1016/j.febslet.2012.04.048; Gorrini C, 2005, P NATL ACAD SCI USA, V102, P9200, DOI 10.1073/pnas.0409513102; Graber TE, 2007, MOL BIOSYST, V3, P825, DOI 10.1039/b708867a; Grosso S, 2008, BIOCHEM J, V415, P77, DOI 10.1042/BJ20080463; Grosso S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029136; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Horos R, 2012, BLOOD, V119, P262, DOI 10.1182/blood-2011-06-358200; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021; Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936; Iadevaia V, 2010, ONCOGENE, V29, P5490, DOI 10.1038/onc.2010.279; Iborra FJ, 2001, SCIENCE, V293, P1139, DOI 10.1126/science.1061216; Idol RA, 2007, BLOOD CELL MOL DIS, V39, P35, DOI 10.1016/j.bcmd.2007.02.001; Ingolia NT, 2011, CELL, V147, P789, DOI 10.1016/j.cell.2011.10.002; Ingolia NT, 2009, SCIENCE, V324, P218, DOI 10.1126/science.1168978; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838; Jadersten M, 2011, J CLIN ONCOL, V29, P1971, DOI 10.1200/JCO.2010.31.8576; Jannot G, 2011, EMBO REP, V12, P581, DOI 10.1038/embor.2011.66; Jopling CL, 2004, RNA, V10, P287, DOI 10.1261/rna.5138804; Kervestin S, 2012, NAT REV MOL CELL BIO, V13, P700, DOI 10.1038/nrm3454; Kirn-Safran CB, 2007, DEV DYNAM, V236, P447, DOI 10.1002/dvdy.21046; Komar AA, 2012, GENE, V502, P75, DOI 10.1016/j.gene.2012.04.039; Komar AA, 2011, CELL CYCLE, V10, P229, DOI 10.4161/cc.10.2.14472; Kondrashov N, 2011, CELL, V145, P383, DOI 10.1016/j.cell.2011.03.028; Kressler D, 2010, BBA-MOL CELL RES, V1803, P673, DOI 10.1016/j.bbamcr.2009.10.009; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Lam YW, 2007, CURR BIOL, V17, P749, DOI 10.1016/j.cub.2007.03.064; Landry DM, 2009, GENE DEV, V23, P2753, DOI 10.1101/gad.1832209; Lewis SM, 2005, CELL DEATH DIFFER, V12, P547, DOI 10.1038/sj.cdd.4401602; Lindstrom MS, 2010, PLOS ONE, V5, pA116, DOI 10.1371/journal.pone.0009578; Liu JM, 2011, ANN NY ACAD SCI, V1242, P26, DOI 10.1111/j.1749-6632.2011.06348.x; LODISH HF, 1971, J BIOL CHEM, V246, P7131; Luft F, 2010, J MOL MED-JMM, V88, P1, DOI 10.1007/s00109-009-0570-0; MacInnes AW, 2008, P NATL ACAD SCI USA, V105, P10408, DOI 10.1073/pnas.0805036105; Magnuson B, 2012, BIOCHEM J, V441, P1, DOI 10.1042/BJ20110892; Mayer C, 2006, ONCOGENE, V25, P6384, DOI 10.1038/sj.onc.1209883; McGowan KA, 2008, NAT GENET, V40, P963, DOI 10.1038/ng.188; Miluzio A, 2011, CANCER CELL, V19, P765, DOI 10.1016/j.ccr.2011.04.018; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Montanaro L, 2012, BBA-REV CANCER, V1825, P101, DOI 10.1016/j.bbcan.2011.10.006; Montanaro L, 2010, CANCER RES, V70, P4767, DOI 10.1158/0008-5472.CAN-09-4024; Mujtaba T, 2011, DISCOV MED, V12, P471; Nana-Sinkam SP, 2013, CLIN PHARMACOL THER, V93, P98, DOI 10.1038/clpt.2012.192; Narla A, 2010, BLOOD, V115, P3196, DOI 10.1182/blood-2009-10-178129; Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531; Oh WJ, 2010, EMBO J, V29, P3939, DOI 10.1038/emboj.2010.271; Otsuka M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024359; Panic L, 2007, CELL CYCLE, V6, P20, DOI 10.4161/cc.6.1.3666; Parsyan A, 2011, NAT REV MOL CELL BIO, V12, P235, DOI 10.1038/nrm3083; Payne EM, 2012, BLOOD, V120, P2214, DOI 10.1182/blood-2011-10-382986; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Petroulakis E, 2006, BRIT J CANCER, V94, P195, DOI 10.1038/sj.bjc.6602902; Petrov A, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011551; Pichon X, 2012, CURR PROTEIN PEPT SC, V13, P294, DOI 10.2174/138920312801619475; Podar K, 2011, CURR CANCER DRUG TAR, V11, P1005, DOI 10.2174/156800911798073113; Pradet-Balade B, 2001, TRENDS BIOCHEM SCI, V26, P225, DOI 10.1016/S0968-0004(00)01776-X; Proud CG, 2005, SEMIN CELL DEV BIOL, V16, P3, DOI 10.1016/j.semcdb.2004.11.004; Proud CG, 2006, BIOCHEM SOC T, V34, P213, DOI 10.1042/BST0340213; Proud CG, 2007, BIOCHEM J, V403, P217, DOI 10.1042/BJ20070024; Ramirez-Fort MK, 2014, AM J CLIN ONCOL-CANC, V37, P266, DOI 10.1097/COC.0b013e318277d62f; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Ridanpaa M, 2001, CELL, V104, P195, DOI 10.1016/S0092-8674(01)00205-7; Robledo S, 2008, RNA, V14, P1918, DOI 10.1261/rna.1132008; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; Ruan YY, 2012, J CLIN INVEST, V122, P2554, DOI 10.1172/JCI58488; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Ruggero D., 2012, COLD SPRING HARB PER, V5; Ruggero D, 2009, CANCER RES, V69, P8839, DOI 10.1158/0008-5472.CAN-09-1970; Saini P, 2009, NATURE, V459, P118, DOI 10.1038/nature08034; Sanvito F, 1999, J CELL BIOL, V144, P823, DOI 10.1083/jcb.144.5.823; Sanvito F, 2000, CANCER RES, V60, P510; Schewe DM, 2009, CANCER RES, V69, P1545, DOI 10.1158/0008-5472.CAN-08-3858; Schoenberg DR, 2012, NAT REV GENET, V13, P246, DOI 10.1038/nrg3160; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Scuoppo C, 2012, NATURE, V487, P244, DOI 10.1038/nature11126; Sharma G, 2013, J STRUCT BIOL, V181, P190, DOI 10.1016/j.jsb.2012.11.006; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Si K, 1999, MOL CELL BIOL, V19, P1416; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Silvera D, 2009, CELL CYCLE, V8, P3091, DOI 10.4161/cc.8.19.9637; Silvera D, 2009, NAT CELL BIOL, V11, P903, DOI 10.1038/ncb1900; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Spizzo R, 2012, ONCOGENE, V31, P4577, DOI 10.1038/onc.2011.621; Spriggs KA, 2008, BIOL CELL, V100, P27, DOI 10.1042/BC20070098; Stumpf CR, 2011, CURR OPIN GENET DEV, V21, P474, DOI 10.1016/j.gde.2011.03.007; Suh DH, 2012, ANN NY ACAD SCI, V1271, P20, DOI 10.1111/j.1749-6632.2012.06739.x; Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184; Taskinen M, 2008, AM J MED GENET A, V146A, P2370, DOI 10.1002/ajmg.a.32478; Torihara H, 2011, BRIT J HAEMATOL, V152, P648, DOI 10.1111/j.1365-2141.2010.08535.x; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Valdez BC, 2004, P NATL ACAD SCI USA, V101, P10709, DOI 10.1073/pnas.0402492101; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Vlachos A, 2012, BLOOD, V119, P3815, DOI 10.1182/blood-2011-08-375972; Volta V, 2013, CELL MOL LIFE SCI, V70, P1439, DOI 10.1007/s00018-012-1215-y; WALDEN WE, 1986, BIOCHEMISTRY-US, V25, P2033, DOI 10.1021/bi00356a030; WALDEN WE, 1981, J BIOL CHEM, V256, P1739; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang D, 2011, MOL CELL BIOL, V31, P3670, DOI 10.1128/MCB.05704-11; Wang XM, 2005, MOL CELL BIOL, V25, P2558, DOI 10.1128/MCB.25.7.2558-2572.2005; Wang XM, 2008, MOL CELL BIOL, V28, P1429, DOI 10.1128/MCB.01512-07; Wen F, 2011, PLOS ONE, V7; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Willimott S, 2010, BIOCHEM SOC T, V38, P1571, DOI 10.1042/BST0381571; Wong CC, 2011, BLOOD, V118, P4305, DOI 10.1182/blood-2011-06-353938; Wu XY, 2013, NUCLEIC ACIDS RES, V41, P2644, DOI 10.1093/nar/gks1453; Xu M, 2012, CELL MOL LIFE SCI, V69, P3601, DOI 10.1007/s00018-012-1129-8; Yoon A, 2006, SCIENCE, V312, P902, DOI 10.1126/science.1123835; Zhang LL, 2008, J BIOL CHEM, V283, P24047, DOI 10.1074/jbc.M800956200; Zinzalla V, 2011, CELL, V144, P757, DOI 10.1016/j.cell.2011.02.014; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	179	62	63	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2145	2156		10.1038/onc.2013.153	http://dx.doi.org/10.1038/onc.2013.153			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23644661	Green Published			2022-12-17	WOS:000334996000001
J	Walters, ZS; Villarejo-Balcells, B; Olmos, D; Buist, TWS; Missiaglia, E; Allen, R; Al-Lazikani, B; Garrett, MD; Blagg, J; Shipley, J				Walters, Z. S.; Villarejo-Balcells, B.; Olmos, D.; Buist, T. W. S.; Missiaglia, E.; Allen, R.; Al-Lazikani, B.; Garrett, M. D.; Blagg, J.; Shipley, J.			JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells	ONCOGENE			English	Article						rhabdomyosarcoma; PAX3-FOXO1; histone methylation; polycomb repressive complex 2; JARID2; myogenic differentiation	CHILDRENS ONCOLOGY GROUP; HIGH-RISK NEUROBLASTOMA; REPRESSIVE COMPLEX 2; MUSCLE STEM-CELLS; ALVEOLAR RHABDOMYOSARCOMA; GENE-EXPRESSION; HISTONE DEMETHYLASES; 13-CIS-RETINOIC ACID; TRANSCRIPTION FACTOR; CARDIAC DEVELOPMENT	Rhabdomyosarcomas (RMS) are the most frequent soft-tissue sarcoma in children and characteristically show features of developing skeletal muscle. The alveolar subtype is frequently associated with a PAX3-FOXO1 fusion protein that is known to contribute to the undifferentiated myogenic phenotype of RMS cells. Histone methylation of lysine residues controls developmental processes in both normal and malignant cell contexts. Here we show that JARID2, which encodes a protein known to recruit various complexes with histone-methylating activity to their target genes, is significantly overexpressed in RMS with PAX3-FOXO1 compared with the fusion gene-negative RMS (t-test; P<0.0001). Multivariate analyses showed that higher JARID2 levels are also associated with metastases at diagnosis, independent of fusion gene status and RMS subtype (n = 120; P = 0.039). JARID2 levels were altered by silencing or overexpressing PAX3-FOXO1 in RMS cell lines with and without the fusion gene, respectively. Consistent with this, we demonstrated that JARID2 is a direct transcriptional target of the PAX3-FOXO1 fusion protein. Silencing JARID2 resulted in reduced cell proliferation coupled with myogenic differentiation, including increased expression of Myogenin (MYOG) and Myosin Light Chain (MYL1) in RMS cell lines representative of both the alveolar and embryonal subtypes. Induced myogenic differentiation was associated with a decrease in JARID2 levels and this phenotype could be rescued by overexpressing JARID2. Furthermore, we that showed JARID2 binds to and alters the methylation status of histone H3 lysine 27 in the promoter regions of MYOG and MYL1 and that the interaction of JARID2 at these promoters is dependent on EED, a core component of the polycomb repressive complex 2 (PRC2). Therefore, JARID2 is a downstream effector of PAX3-FOXO1 that maintains an undifferentiated myogenic phenotype that is characteristic of RMS. JARID2 and other components of PRC2 may represent novel therapeutic targets for treating RMS patients.	[Walters, Z. S.; Villarejo-Balcells, B.; Olmos, D.; Buist, T. W. S.; Missiaglia, E.; Allen, R.; Shipley, J.] Inst Canc Res, Div Mol Pathol, Sarcoma Mol Pathol Team, London SM2 5NG, England; [Walters, Z. S.; Villarejo-Balcells, B.; Olmos, D.; Buist, T. W. S.; Missiaglia, E.; Allen, R.; Shipley, J.] Inst Canc Res, Div Canc Therapeut, Sarcoma Mol Pathol Team, London SM2 5NG, England; [Olmos, D.] Royal Marsden Hosp NHS Trust, Sarcoma Unit, London, England; [Buist, T. W. S.; Al-Lazikani, B.; Blagg, J.] Inst Canc Res, Div Canc Therapeut, Canc Res UK Canc Therapeut Unit, London SM2 5NG, England; [Missiaglia, E.] Univ Lausanne, Swiss Inst Bioinformat, Bioinformat Core Facil, Lausanne, Switzerland; [Garrett, M. D.] Inst Canc Res, Div Canc Therapeut, Canc Res UK Canc Therapeut Unit, Cell Cycle Control Team, London SM2 5NG, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Swiss Institute of Bioinformatics; University of Lausanne; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Shipley, J (corresponding author), Inst Canc Res, Div Mol Pathol, Sarcoma Mol Pathol Team, London SM2 5NG, England.	janet.shipley@icr.ac.uk	Al-Lazikani, Bissan/AFK-6457-2022; Al-Lazikani, Bissan/AAG-4723-2022; Olmos, David/L-5664-2015	Al-Lazikani, Bissan/0000-0003-3367-2519; missiaglia, edoardo/0000-0001-9221-0117; Shipley, Janet/0000-0001-6748-8678; Olmos Hidalgo, David/0000-0002-7003-4826; Walters, Zoe/0000-0002-1835-5868	Cancer Research UK [C5066/A10399]; Sarcoma UK; Chris Lucas Trust; Rob's ARTTT Charity; Medical Research Council; Spanish Society of Medical Oncology (SEOM) Translational Research Fellowship; NHS; Cancer Research UK [11566] Funding Source: researchfish; Sarcoma UK [SUK01.2009] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Sarcoma UK; Chris Lucas Trust; Rob's ARTTT Charity; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Spanish Society of Medical Oncology (SEOM) Translational Research Fellowship; NHS; Cancer Research UK(Cancer Research UK); Sarcoma UK	We are very grateful for help and support with tumor collection and annotation from the Children's Cancer and Leukemia Group. We also thank David Landeira for help with the JARID2 antibody. This work was supported by grants from Cancer Research UK (C5066/A10399); Sarcoma UK; the Chris Lucas Trust; Rob's ARTTT Charity; the Medical Research Council for a studentship (TWSB); the Spanish Society of Medical Oncology (SEOM) Translational Research Fellowship (DO). We acknowledge NHS funding to the NIHR Biomedical Research Center.	AGUANNO S, 1990, CANCER RES, V50, P3377; Asp P, 2011, P NATL ACAD SCI USA, V108, pE149, DOI 10.1073/pnas.1102223108; Barlow JW, 2006, PEDIATR BLOOD CANCER, V47, P773, DOI 10.1002/pbc.20650; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; Calhabeu F, 2013, ONCOGENE, V32, P651, DOI 10.1038/onc.2012.73; Cao LA, 2010, CANCER RES, V70, P6497, DOI 10.1158/0008-5472.CAN-10-0582; Chang CJ, 2012, BRIT J CANCER, V106, P243, DOI 10.1038/bjc.2011.551; Charytonowicz E, 2009, CANCER LETT, V279, P126, DOI 10.1016/j.canlet.2008.09.039; Ciarapica R, 2009, CELL CYCLE, V8, P172, DOI 10.4161/cc.8.1.7292; Cloos PAC, 2008, GENE DEV, V22, P1115, DOI 10.1101/gad.1652908; Davicioni E, 2006, CANCER RES, V66, P6936, DOI 10.1158/0008-5472.CAN-05-4578; Davicioni E, 2009, AM J PATHOL, V174, P550, DOI 10.2353/ajpath.2009.080631; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; Grimwade D, 2010, CANCER TREAT RES, V145, P219, DOI 10.1007/978-0-387-69259-3_13; Juan AH, 2011, GENE DEV, V25, P789, DOI 10.1101/gad.2027911; Jung J, 2005, J BIOL CHEM, V280, P30916, DOI 10.1074/jbc.M414482200; Kikuchi K, 2008, BIOCHEM BIOPH RES CO, V365, P568, DOI 10.1016/j.bbrc.2007.11.017; Kim T, 2004, MOL CELL BIOL, V24, P10151, DOI 10.1128/MCB.24.23.10151-10160.2004; Kim TG, 2003, J BIOL CHEM, V278, P42247, DOI 10.1074/jbc.M307386200; Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945; Landeira D, 2010, NAT CELL BIOL, V12, P618, DOI 10.1038/ncb2065; Lee MH, 2011, CANCER RES, V71, P3921, DOI 10.1158/0008-5472.CAN-10-3358; Li G, 2010, GENE DEV, V24, P368, DOI 10.1101/gad.1886410; Linardic CM, 2008, CANCER LETT, V270, P10, DOI 10.1016/j.canlet.2008.03.035; LOLLINI PL, 1991, INVAS METAST, V11, P116; Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633; Luo XL, 2011, J AM CHEM SOC, V133, P9451, DOI 10.1021/ja201597b; Matthay KK, 2009, J CLIN ONCOL, V27, P1007, DOI 10.1200/JCO.2007.13.8925; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Missiaglia E, 2012, J CLIN ONCOL, V30, P1670, DOI 10.1200/JCO.2011.38.5591; Palacios D, 2010, MOL CELL BIOL, V30, P3805, DOI 10.1128/MCB.00050-10; Pasini D, 2010, NATURE, V464, P306, DOI 10.1038/nature08788; Peng JC, 2009, CELL, V139, P1290, DOI 10.1016/j.cell.2009.12.002; Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106; Schildhaus HU, 2011, HUM PATHOL, V42, P1667, DOI 10.1016/j.humpath.2010.12.025; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Shen XH, 2009, CELL, V139, P1303, DOI 10.1016/j.cell.2009.12.003; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Stojic L, 2011, EPIGENET CHROMATIN, V4, DOI 10.1186/1756-8935-4-16; Takeuchi T, 1999, MECH DEVELOP, V86, P29, DOI 10.1016/S0925-4773(99)00100-8; Tonelli R, 2012, CLIN CANCER RES, V18, P796, DOI 10.1158/1078-0432.CCR-11-1981; Upadhyay AK, 2012, J MOL BIOL, V416, P319, DOI 10.1016/j.jmb.2011.12.036; Veal GJ, 2007, BRIT J CANCER, V96, P424, DOI 10.1038/sj.bjc.6603554; Verrier L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001390; Williamson D, 2010, J CLIN ONCOL, V28, P2151, DOI 10.1200/JCO.2009.26.3814; Xia SJ, 2009, AM J PATHOL, V175, P2600, DOI 10.2353/ajpath.2009.090192; Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104; Zhang L, 2007, ONCOGENE, V26, P1595, DOI 10.1038/sj.onc.1209958	50	62	65	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1148	1157		10.1038/onc.2013.46	http://dx.doi.org/10.1038/onc.2013.46			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23435416	Green Accepted, Green Submitted			2022-12-17	WOS:000331933800008
J	Streppel, MM; Lata, S; DelaBastide, M; Montgomery, EA; Wang, JS; Canto, MI; Macgregor-Das, AM; Pai, S; Morsink, FHM; Offerhaus, GJ; Antoniou, E; Maitra, A; McCombie, WR				Streppel, M. M.; Lata, S.; DelaBastide, M.; Montgomery, E. A.; Wang, J. S.; Canto, M. I.; Macgregor-Das, A. M.; Pai, S.; Morsink, F. H. M.; Offerhaus, G. J.; Antoniou, E.; Maitra, A.; McCombie, W. R.			Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus	ONCOGENE			English	Article						next-generation sequencing; endoscopic mucosal biopsies; Barrett's esophagus; esophageal adenocarcinoma; ARID1A	CALCIUM-BINDING PROTEIN; CARCINOEMBRYONIC ANTIGEN; FREQUENT MUTATIONS; SOMATIC MUTATIONS; CANCER; ADENOCARCINOMA; PROGRESSION; BREAST; TARGET; EXPRESSION	The incidence of Barrett's esophagus (BE)-associated esophageal adenocarcinoma (EAC) is increasing. Next-generation sequencing (NGS) provides an unprecedented opportunity to uncover genomic alterations during BE pathogenesis and progression to EAC, but treatment-naive surgical specimens are scarce. The objective of this study was to establish the feasibility of using widely available endoscopic mucosal biopsies for successful NGS, using samples obtained from a BE 'progressor'. Paired-end whole-genome NGS was performed on the Illumina platform using libraries generated from mucosal biopsies of normal squamous epithelium (NSE), BE and EAC obtained from a patient who progressed to adenocarcinoma during endoscopic surveillance. Selective validation studies, including Sanger sequencing, immunohistochemistry and functional assays, were performed to confirm the NGS findings. NGS identified somatic nonsense mutations of AT-rich interactive domain 1A (SWI like) (ARID1A) and PPIE and an additional 37 missense mutations in BE and/or EAC, which were confirmed by Sanger sequencing. ARID1A mutations were detected in 15% (3/20) high-grade dysplasia (HGD)/EAC patients. Immunohistochemistry performed on an independent archival cohort demonstrated ARID1A protein loss in 0% (0/76), 4.9% (2/40), 14.3% (4/28), 16.0% (8/50) and 12.2% (12/98) of NSE, BE, low-grade dysplasia, HGD and EAC tissues, respectively, and was inversely associated with nuclear p53 accumulation (P - 0.028). Enhanced cell growth, proliferation and invasion were observed on ARID1A knockdown in EAC cells. In addition, genes downstream of ARID1A that potentially contribute to the ARID1A knockdown phenotype were identified. Our studies establish the feasibility of using mucosal biopsies for NGS, which should enable the comparative analysis of larger 'progressor' versus 'non-progressor' cohorts. Further, we identify ARID1A as a novel tumor-suppressor gene in BE pathogenesis, reiterating the importance of aberrant chromatin in the metaplasiadysplasia sequence.	[Streppel, M. M.; Montgomery, E. A.; Macgregor-Das, A. M.; Pai, S.; Maitra, A.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD USA; [Streppel, M. M.] Univ Med Ctr Utrecht, Dept Gastroenterol & Hepatol, Utrecht, Netherlands; [Streppel, M. M.; Morsink, F. H. M.; Offerhaus, G. J.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [Lata, S.; DelaBastide, M.; Antoniou, E.; McCombie, W. R.] Cold Spring Harbor Lab, Stanley Inst Cognit Genom, Woodbury, NY USA; [Wang, J. S.] Washington Univ, Sch Med, Dept Med, Div Gastroenterol, St Louis, MO 63110 USA; [Canto, M. I.] Johns Hopkins Med Inst, Dept Med, Div Gastroenterol & Hepatol, Baltimore, MD USA; [Macgregor-Das, A. M.] Johns Hopkins Med Inst, Pathobiol Program, Baltimore, MD USA; [Maitra, A.] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD USA; [Maitra, A.] Johns Hopkins Med Inst, Dept Med Genet, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Cold Spring Harbor Laboratory; Washington University (WUSTL); Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Maitra, A (corresponding author), Johns Hopkins Med Inst, Dept Pathol, CRBII Bldg,Room 341,1550 Orleans St, Baltimore, MD 21231 USA.	amaitra1@jhmi.edu; mccombie@cshl.edu		McCombie, W. Richard/0000-0003-1899-0682	Jerry D'Amato foundation; NIH [1K23DK068149, S10 RR023702-01]; NCI [CA045508]; Fulbright/the Netherland America Foundation; Rene Vogels Foundation; NATIONAL CANCER INSTITUTE [P30CA045508, R01CA113669] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR023702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK068149] Funding Source: NIH RePORTER	Jerry D'Amato foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Fulbright/the Netherland America Foundation; Rene Vogels Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The work at Johns Hopkins Medical Institutions was funded by the Jerry D'Amato foundation and the NIH (1K23DK068149) and the work at WRM's laboratory was supported by a Cancer Center Support Grant (CA045508) from the NCI and NIH Shared Instrument grant S10 RR023702-01. MMS has been sponsored by Fulbright/the Netherland America Foundation and the Rene Vogels Foundation.	Agrawal N, 2012, CANCER DISCOV, V2, P899, DOI 10.1158/2159-8290.CD-12-0189; Alvarez H, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001356; Alvarez H, 2010, CANCER BIOL THER, V10, P1009, DOI 10.4161/cbt.10.10.13248; Alvarez H, 2008, CANCER BIOL THER, V7, P1753; Ashworth A, 2011, CELL, V145, P30, DOI 10.1016/j.cell.2011.03.020; Berinstein NL, 2002, J CLIN ONCOL, V20, P2197, DOI 10.1200/JCO.2002.08.017; Birnbaum DJ, 2011, GENE CHROMOSOME CANC, V50, P456, DOI 10.1002/gcc.20870; Camacho-Leal P, 2008, ONCOGENE, V27, P1545, DOI 10.1038/sj.onc.1210789; Clark MJ, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000832; Cornen S, 2012, ONCOGENE, V31, P4255, DOI 10.1038/onc.2011.598; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; di Pietro M, 2012, P NATL ACAD SCI USA, V109, P9077, DOI 10.1073/pnas.1116933109; Fair K, 2001, MOL CELL BIOL, V21, P3589, DOI 10.1128/MCB.21.10.3589-3597.2001; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Galipeau PC, 2007, PLOS MED, V4, P342, DOI 10.1371/jourmal.pmed.0040067; Gilbert EW, 2011, J GASTROINTEST SURG, V15, P708, DOI 10.1007/s11605-011-1485-y; Goh XY, 2011, GUT, V60, P1317, DOI 10.1136/gut.2010.234179; GRIFFIN M, 1987, HISTOPATHOLOGY, V11, P53; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Gupta S, 2012, CLIN CANCER RES, V18, P280, DOI 10.1158/1078-0432.CCR-11-2165; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang JM, 2007, GENE CHROMOSOME CANC, V46, P745, DOI 10.1002/gcc.20459; Hvid-Jensen F, 2011, NEW ENGL J MED, V365, P1375, DOI 10.1056/NEJMoa1103042; Jin Z, 2009, CANCER RES, V69, P4112, DOI 10.1158/0008-5472.CAN-09-0028; Jones S, 2012, HUM MUTAT, V33, P100, DOI 10.1002/humu.21633; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Kaz AM, CANC LETT; Kumar A, 2011, P NATL ACAD SCI USA, V108, P17087, DOI 10.1073/pnas.1108745108; Lee OJ, 2006, GASTROENTEROLOGY, V130, pA273; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903; Li XH, 2008, CANCER PREV RES, V1, P413, DOI 10.1158/1940-6207.CAPR-08-0121; Link DC, 2011, JAMA-J AM MED ASSOC, V305, P1568, DOI 10.1001/jama.2011.473; Luby TM, 2008, EXPERT REV VACCINES, V7, P995, DOI 10.1586/14760584.7.7.995; Mamo A, 2012, ONCOGENE, V31, P2090, DOI 10.1038/onc.2011.386; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Martinez VG, 2008, BRIT J CANCER, V98, P564, DOI 10.1038/sj.bjc.6604195; McFadyen MCE, 2004, MOL CANCER THER, V3, P363; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mishra SK, 2012, CANCER METAST REV, V31, P163, DOI 10.1007/s10555-011-9338-4; Nik-Zainal S, 2012, CELL, V149, P5; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Ordonez C, 2000, CANCER RES, V60, P3419; Park S, 2010, BIOCHEMISTRY-US, V49, P6576, DOI 10.1021/bi1009387; Paulson TG, 2009, CLIN CANCER RES, V15, P3305, DOI 10.1158/1078-0432.CCR-08-2494; Paulson TG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003809; Reid BJ, 2001, AM J GASTROENTEROL, V96, P1321; Reid BJ, 2010, NAT REV CANCER, V10, P87, DOI 10.1038/nrc2773; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rozen S, 2000, Methods Mol Biol, V132, P365; Sato F, 2006, CANCER-AM CANCER SOC, V106, P483, DOI 10.1002/cncr.21657; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Sherbet GV, 1998, ANTICANCER RES, V18, P2415; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Streppel MM, 2012, HUM PATHOL, V43, P1755, DOI 10.1016/j.humpath.2012.01.005; van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; Wang Kenneth K, 2005, Gastroenterology, V128, P1468, DOI 10.1053/j.gastro.2005.03.076; Wang S, 2006, ONCOGENE, V25, P3346, DOI 10.1038/sj.onc.1209357; Wang ZX, 2010, CELL, V141, P1183, DOI 10.1016/j.cell.2010.05.016; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Wu J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002543; Yates LR, 2012, NAT REV GENET, V13, P795, DOI 10.1038/nrg3317; Yousef F, 2008, AM J EPIDEMIOL, V168, P237, DOI 10.1093/aje/kwn121; Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246	67	62	69	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					347	357		10.1038/onc.2012.586	http://dx.doi.org/10.1038/onc.2012.586			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318448	Green Accepted			2022-12-17	WOS:000330214000009
J	Teng, Y; Mei, Y; Hawthorn, L; Cowell, JK				Teng, Y.; Mei, Y.; Hawthorn, L.; Cowell, J. K.			WASF3 regulates miR-200 inactivation by ZEB1 through suppression of KISS1 leading to increased invasiveness in breast cancer cells	ONCOGENE			English	Article						breast cancer; metastasis; invasion; KISS1; WASF3; ZEB1	EPITHELIAL-MESENCHYMAL TRANSITION; WAVE FAMILY PROTEINS; E-CADHERIN; LAMELLIPODIA FORMATION; FEEDBACK LOOP; METASTASIS; EXPRESSION; INVASION; GENE; MIGRATION	The WASF3 gene promotes invasion and metastasis in breast cancer cells, which have undergone epithelial-to-mesenchyme transition (EMT). Overexpression of WASF3 in cells that do not show EMT increases their invasion potential as a result of increased ZEB1/2 levels, which specifically suppress the anti-invasion chromosome 1 miR-200a/200b/429 cluster. ZEB1/2 upregulation by WASF3 results from downregulation of KISS1, leading to the release of inhibition of nuclear factor (NF) kB by IkBa. We further show that ZEB1 expression is regulated by the NFkB transcription factor. Knockdown of WASF3 in breast cancer cells leads to reduced ZEB1 levels and increased miR-200 and E-cadherin levels, resulting in loss of invasion potential. The central regulation of this interactive pathway by WASF3 accounts for the increased invasion associated with increased WASF3 expression seen in aggressive breast cancer cells. WASF3, therefore, is a potential target to suppress invasion and metastasis in breast cancer cells.	[Teng, Y.; Mei, Y.; Hawthorn, L.; Cowell, J. K.] Georgia Hlth Sci Univ, Ctr Canc, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Teng, Y (corresponding author), Georgia Hlth Sci Univ, Ctr Canc, CN 2133,1120 15th St, Augusta, GA 30912 USA.	yteng@georgiahealth.edu; jcowell@georgiahealth.edu	Teng, Yong/AAK-4160-2020	Teng, Yong/0000-0002-1856-7289; Hawthorn, Lesleyann/0000-0001-8179-0937	Georgia Cancer Coalition; NIH; National Institutes of Health [CA120510]; NATIONAL CANCER INSTITUTE [R01CA120510] Funding Source: NIH RePORTER	Georgia Cancer Coalition; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Dr Leslie Ann Lesoon for the technical assistance and helpful comments during the writing of this manuscript. We also thank the staff of Cancer Center Shared Resources at GHSU for assistance during microarray data collection. Dr Cowell is supported by the Georgia Cancer Coalition as a distinguished cancer scholar and funded by the NIH. This study was supported, in part, by the National Institutes of Health Grant CA120510.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Ahmad A, 2011, CANCER RES, V71, P3400, DOI 10.1158/0008-5472.CAN-10-0965; Almeida MI, 2010, CELL RES, V20, P603, DOI 10.1038/cr.2010.70; Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Brabletz S, 2011, EMBO J, V30, P770, DOI 10.1038/emboj.2010.349; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cabanillas AM, 1996, DNA CELL BIOL, V15, P643, DOI 10.1089/dna.1996.15.643; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Chuang TC, 2011, CANCER LETT, V311, P11, DOI 10.1016/j.canlet.2011.06.007; Edwards LA, 2011, JNCI-J NATL CANCER I, V103, P1162, DOI 10.1093/jnci/djr224; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Ghoshal P, 2012, INT J CANCER, V131, pE905, DOI 10.1002/ijc.27631; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hurst DR, 2009, CANCER RES, V69, P7495, DOI 10.1158/0008-5472.CAN-09-2111; Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Johnson E, 2010, J BIOL CHEM, V285, P29491, DOI 10.1074/jbc.M110.136770; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kurisu S, 2010, CANCER SCI, V101, P2093, DOI 10.1111/j.1349-7006.2010.01654.x; Levy C, 2010, MOL CELL, V40, P841, DOI 10.1016/j.molcel.2010.11.020; Ma L, 2008, CELL CYCLE, V7, P570, DOI 10.4161/cc.7.5.5547; Mazda M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028688; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Pollock CB, 2005, CANCER RES, V65, P1244, DOI 10.1158/0008-5472.CAN-04-1911; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Schliekelman MJ, 2011, CANCER RES, V71, P7670, DOI 10.1158/0008-5472.CAN-11-0964; Sossey-Alaoui K, 2005, EXP CELL RES, V308, P135, DOI 10.1016/j.yexcr.2005.04.011; Sossey-Alaoui K, 2005, J BIOL CHEM, V280, P21748, DOI 10.1074/jbc.M500503200; Sossey-Alaoui K, 2002, ONCOGENE, V21, P5967, DOI 10.1038/sj.onc.1205734; Sossey-Alaoui K, 2007, J BIOL CHEM, V282, P26257, DOI 10.1074/jbc.M701484200; Sossey-Alaoui K, 2007, AM J PATHOL, V170, P2112, DOI 10.2353/ajpath.2007.060975; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Steeg Patricia S, 2003, Clin Breast Cancer, V4, P51, DOI 10.3816/CBC.2003.n.012; Takenawa T, 2001, J CELL SCI, V114, P1801; Takenawa T, 2007, NAT REV MOL CELL BIO, V8, P37, DOI 10.1038/nrm2069; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Teng Y, 2010, BRIT J CANCER, V103, P1066, DOI 10.1038/sj.bjc.6605850; Teng Y, 2012, J BIOL CHEM, V287, P10051, DOI 10.1074/jbc.M111.335000; Teng Y, 2011, INT J CANCER, V129, P2825, DOI 10.1002/ijc.25964; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007	45	62	63	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					203	211		10.1038/onc.2012.565	http://dx.doi.org/10.1038/onc.2012.565			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23318438	Green Accepted			2022-12-17	WOS:000329440700008
J	Wu, J; Patmore, DM; Jousma, E; Eaves, DW; Breving, K; Patel, AV; Schwartz, EB; Fuchs, JR; Cripe, TP; Stemmer-Rachamimov, AO; Ratner, N				Wu, J.; Patmore, D. M.; Jousma, E.; Eaves, D. W.; Breving, K.; Patel, A. V.; Schwartz, E. B.; Fuchs, J. R.; Cripe, T. P.; Stemmer-Rachamimov, A. O.; Ratner, N.			EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors	ONCOGENE			English	Article						EGFR; STAT3; sarcoma; MPNST; NF1	GROWTH-FACTOR RECEPTOR; NEUROFIBROMATOSIS TYPE-1; SELF-RENEWAL; MOUSE MODELS; CANCER-CELLS; NF1; TRANSCRIPTION-3; TRANSDUCER; ACTIVATOR; PATHWAY	Malignant peripheral nerve sheath tumors (MPNSTs) develop sporadically or in the context of neurofibromatosis type 1. Epidermal growth factor receptor (EGFR) overexpression has been implicated in MPNST formation, but its precise role and relevant signaling pathways remain unknown. We found that EGFR overexpression promotes mouse neurofibroma transformation to aggressive MPNST (GEM-PNST). Immunohistochemistry demonstrated phosphorylated STAT3 (Tyr705) in both human MPNST and mouse GEM-PNST. A specific JAK2/STAT3 inhibitor FLLL32 delayed MPNST formation in an MPNST xenograft nude mouse model. STAT3 knockdown by shRNA prevented MPNST formation in vivo. Finally, reducing EGFR activity strongly reduced pSTAT3 in vivo. Thus, an EGFR-STAT3 pathway is necessary for MPNST transformation and establishment of MPNST xenografts growth but not for tumor maintenance. Efficacy of the FLLL32 pharmacological inhibitor in delaying MPNST growth suggests that combination therapies targeting JAK/STAT3 might be useful therapeutics.	[Wu, J.; Patmore, D. M.; Jousma, E.; Eaves, D. W.; Breving, K.; Patel, A. V.; Cripe, T. P.; Ratner, N.] Cincinnati Childrens Hosp Med Ctr, Cincinnati Childrens Hosp Res Fdn, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA; [Schwartz, E. B.; Fuchs, J. R.] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA; [Stemmer-Rachamimov, A. O.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Stemmer-Rachamimov, A. O.] Harvard Univ, Sch Med, Boston, MA USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; Ohio State University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Ratner, N (corresponding author), Cincinnati Childrens Hosp, Dept Pediat, Div Exp Hematol & Canc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	nancy.ratner@cchmc.org		Fuchs, James/0000-0002-8743-6389; RATNER, NANCY/0000-0001-5030-9354	National Institutes of Health [R01 NS28840, P50 NS057531]; Department of Defense New Investigator Award [NF100053]; Ohio State University Comprehensive Cancer Center Pelotonia Idea Grant; American Cancer Society [IRG-67-003-44]; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS057531, R01NS028840] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense New Investigator Award(United States Department of Defense); Ohio State University Comprehensive Cancer Center Pelotonia Idea Grant; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr Andre Bernards (Massachusetts General Hospital) and Drs Jiayuh Lin, Pui-Kai Li and Gregory B Lesinski (Ohio State University) for helpful discussions. This work was supported by the National Institutes of Health (R01 NS28840 and P50 NS057531 to NR), and Department of Defense New Investigator Award (NF100053) and an Ohio State University Comprehensive Cancer Center Pelotonia Idea Grant (to JW). The American Cancer Society (IRG-67-003-44) supported JRF.	Banerjee S, 2010, CANCER RES, V70, P1356, DOI 10.1158/0008-5472.CAN-09-2178; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Beert E, 2011, GENE CHROMOSOME CANC, V50, P1021, DOI 10.1002/gcc.20921; Carroll SL, 2008, GLIA, V56, P1590, DOI 10.1002/glia.20776; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; DeClue JE, 2000, J CLIN INVEST, V105, P1233, DOI 10.1172/JCI7610; Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311; Ferner RE, 2002, CANCER RES, V62, P1573; Ferner RE, 2007, EUR J HUM GENET, V15, P131, DOI 10.1038/sj.ejhg.5201676; Frahm S, 2004, NEUROBIOL DIS, V16, P85, DOI 10.1016/j.nbd.2004.01.006; Frohnert PW, 2003, GLIA, V43, P104, DOI 10.1002/glia.10232; Fukuda A, 2011, CANCER CELL, V19, P441, DOI 10.1016/j.ccr.2011.03.002; Guryanova OA, 2011, CANCER CELL, V19, P498, DOI 10.1016/j.ccr.2011.03.004; Joseph NM, 2008, CANCER CELL, V13, P129, DOI 10.1016/j.ccr.2008.01.003; Katz D, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001227; Keizman D, 2009, J NEURO-ONCOL, V94, P383, DOI 10.1007/s11060-009-9862-z; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Li HZ, 2002, CANCER RES, V62, P4507; Lin L, 2010, CANCER RES, V70, P2445, DOI 10.1158/0008-5472.CAN-09-2468; Ling BC, 2005, CANCER CELL, V7, P65, DOI 10.1016/j.ccr.2004.10.016; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Miller SJ, 2009, EMBO MOL MED, V1, P236, DOI 10.1002/emmm.200900027; Miller SJ, 2006, CANCER RES, V66, P2584, DOI 10.1158/0008-5472.CAN-05-3330; Perry A, 2002, J NEUROPATH EXP NEUR, V61, P702, DOI 10.1093/jnen/61.8.702; Reilly KM, 2006, CANCER RES, V66, P62, DOI 10.1158/0008-5472.CAN-05-1480; Reilly KM, 2004, P NATL ACAD SCI USA, V101, P13008, DOI 10.1073/pnas.0401236101; Rosenbaum T, 2000, J NEUROSCI RES, V61, P524, DOI 10.1002/1097-4547(20000901)61:5<524::AID-JNR7>3.3.CO;2-Q; Shao H, 2003, CANCER RES, V63, P3923; Sherry MM, 2009, STEM CELLS, V27, P2383, DOI 10.1002/stem.185; Stemmer-Rachamimov AO, 2004, CANCER RES, V64, P3718, DOI 10.1158/0008-5472.CAN-03-4079; Sun Daochun, 2012, Transl Oncogenomics, V5, P1, DOI 10.4137/TOG.S8830; Torres KE, 2011, CLIN CANCER RES, V17, P3943, DOI 10.1158/1078-0432.CCR-11-0193; Tucker T, 2005, NEUROLOGY, V65, P205, DOI 10.1212/01.wnl.0000168830.79997.13; Vigneron A, 2008, CANCER RES, V68, P815, DOI 10.1158/0008-5472.CAN-07-5115; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Walrath JC, 2009, MAMM GENOME, V20, P214, DOI 10.1007/s00335-009-9179-4; Widemann BC, 2009, CURR ONCOL REP, V11, P322, DOI 10.1007/s11912-009-0045-z; Wu JQ, 2008, CANCER CELL, V13, P105, DOI 10.1016/j.ccr.2007.12.027; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734	42	62	67	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					173	180		10.1038/onc.2012.579	http://dx.doi.org/10.1038/onc.2012.579			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23318430	Green Accepted			2022-12-17	WOS:000329440700005
J	Lee-Sherick, AB; Eisenman, KM; Sather, S; McGranahan, A; Armistead, PM; McGary, CS; Hunsucker, SA; Schlegel, J; Martinson, H; Cannon, C; Keating, AK; Earp, HS; Liang, X; DeRyckere, D; Graham, DK				Lee-Sherick, A. B.; Eisenman, K. M.; Sather, S.; McGranahan, A.; Armistead, P. M.; McGary, C. S.; Hunsucker, S. A.; Schlegel, J.; Martinson, H.; Cannon, C.; Keating, A. K.; Earp, H. S.; Liang, X.; DeRyckere, D.; Graham, D. K.			Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia	ONCOGENE			English	Article						tyrosine kinase; targeted therapy; acute leukemia; pediatric	ACUTE LYMPHOBLASTIC-LEUKEMIA; PEDIATRIC AML; FLT3 MUTATIONS; SURVIVAL; CELLS; AXL; PROTOONCOGENE; APOPTOSIS; CREB; OVEREXPRESSION	Acute myeloid leukemia (AML) continues to be extremely difficult to treat successfully, and the unacceptably low overall survival rates mandate that we assess new potential therapies to ameliorate poor clinical response to conventional therapy. Abnormal tyrosine kinase activation in AML has been associated with poor prognosis and provides strategic targets for novel therapy development. We found that Mer receptor tyrosine kinase was over-expressed in a majority of pediatric (29/36, 80%) and adult (10/10, 100%) primary AML patient blasts at the time of diagnosis, and 100% of patient samples at the time of relapse. Mer was also found to be expressed in 12 of 14 AML cell lines (86%). In contrast, normal bone marrow myeloid precursors expressed little to no Mer. Following AML cell line stimulation with Gas6, a Mer ligand, we observed activation of prosurvival and proliferative signaling pathways, including phosphorylation of ERK1/2, p38, MSK1, CREB, ATF1, AKT and STAT6. To assess the phenotypic role of Mer in AML, two independent short-hairpin RNA (shRNA) constructs were used to decrease Mer expression in the AML cell lines Nomo-1 and Kasumi-1. Reduction of Mer protein levels significantly increased rates of myeloblast apoptosis two to threefold in response to serum starvation. Furthermore, myeloblasts with knocked-down Mer demonstrated decreased colony formation by 67-87%, relative to control cell lines (P<0.01). NOD-SCID-gamma mice transplanted with Nomo-1 myeloblasts with reduced levels of Mer had a significant prolongation in survival compared with mice transplanted with the parental or control cell lines (median survival 17 days in parental and control cell lines, versus 32-36 days in Mer knockdown cell lines, P<0.0001). These data suggest a role for Mer in acute myeloid leukemogenesis and indicate that targeted inhibition of Mer may be an effective therapeutic strategy in pediatric and adult AML.	[Lee-Sherick, A. B.; Eisenman, K. M.; Sather, S.; Schlegel, J.; Cannon, C.; Keating, A. K.; DeRyckere, D.; Graham, D. K.] Dept Pediat, Div Hematol Oncol & Bone Marrow Transplantat, Aurora, CO USA; [McGranahan, A.; Liang, X.] Univ Colorado, Dept Pathol, Aurora, CO 80045 USA; [Armistead, P. M.; McGary, C. S.; Hunsucker, S. A.; Earp, H. S.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Chapel Hill, NC 27599 USA; [Martinson, H.] Univ Colorado, Dept Med Oncol, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus	Graham, DK (corresponding author), Univ Colorado, Dept Pediat, Anschutz Med Campus,12800 E 19th Ave,P18-4408,MS, Aurora, CO 80045 USA.	doug.graham@ucdenver.edu		Lee Sherick, Alisa/0000-0002-1177-7208; Hunsucker, Sally/0000-0002-7034-7355; Armistead, Paul/0000-0003-3983-5534; Martinson, Holly/0000-0003-2745-2755	American Academy of Pediatrics; American Pediatric Society; Eunice Kennedy Shriver National Institute of Child Health and Human Development [K12-HD000850]; National Institutes of Health [R01CA137078]; For Julie Foundation; Damon Runyon Cancer Research Foundation [CI-39-07]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD000850] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA082086, P30CA046934, R01CA137078] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL113594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK057516] Funding Source: NIH RePORTER	American Academy of Pediatrics; American Pediatric Society; Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); For Julie Foundation; Damon Runyon Cancer Research Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We would like to thank the Children's Oncology Group, AML Biology Reference Laboratory for providing us with the frozen pediatric patient samples, and for the help of Christine Childs and Karen Helm of the University of Colorado Cancer Center Flow Cytometry Shared Resource, and the DERC Molecular Biology Core (NIH P30-DK57516) for expert technical assistance. ABLS is a Fellow of the Pediatric Scientist Development Program, supported by grants from the American Academy of Pediatrics, the American Pediatric Society, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12-HD000850). This research was also supported by grants from the National Institutes of Health (R01CA137078, DKG), and the For Julie Foundation (KE). DKG is a Damon Runyon-Novartis Clinical Investigator supported (in part) by the Damon Runyon Cancer Research Foundation (CI-39-07).	Advani AS, 2008, LEUKEMIA RES, V32, P913, DOI 10.1016/j.leukres.2007.08.019; Advani AS, 2010, LEUKEMIA RES, V34, P1622, DOI 10.1016/j.leukres.2010.03.021; Avanzi GC, 1997, EXP HEMATOL, V25, P1219; Brown P, 2004, BLOOD, V104, P1841, DOI 10.1182/blood-2004-03-1034; Bunting KD, 2004, J LEUKOCYTE BIOL, V76, P484, DOI 10.1189/jlb.0903440; Caberoy NB, 2012, J CELL PHYSIOL, V227, P401, DOI 10.1002/jcp.22955; Caberoy NB, 2010, EMBO J, V29, P3898, DOI 10.1038/emboj.2010.265; Graham DK, 2006, CLIN CANCER RES, V12, P2662, DOI 10.1158/1078-0432.CCR-05-2208; Guttridge KL, 2002, J BIOL CHEM, V277, P24057, DOI 10.1074/jbc.M112086200; Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004; Hong CC, 2008, CANCER LETT, V268, P314, DOI 10.1016/j.canlet.2008.04.017; Keating AK, 2006, ONCOGENE, V25, P6092, DOI 10.1038/sj.onc.1209633; Keating AK, 2010, MOL CANCER THER, V9, P1298, DOI 10.1158/1535-7163.MCT-09-0707; Kinjo K, 2005, CELL CYCLE, V4, P1134, DOI 10.4161/cc.4.9.1991; LING L, 1995, MOL CELL BIOL, V15, P6582; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Liu J, 2012, ACS MED CHEM LETT, V3, P129, DOI 10.1021/ml200239k; Lunghi P, 2003, LEUKEMIA, V17, P1783, DOI 10.1038/sj.leu.2403032; Meshinchi S, 2006, BLOOD, V108, P3654, DOI 10.1182/blood-2006-03-009233; Migdall-Wilson J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031635; Muller-Tidow C, 2010, BLOOD, V116, P3564, DOI 10.1182/blood-2009-09-240978; Odgerel T, 2010, LEUKEMIA, V24, P1087, DOI 10.1038/leu.2010.48; Pfirrmann M, 2012, LANCET ONCOL, V13, P207, DOI 10.1016/S1470-2045(11)70326-6; Pigazzi M, 2007, HAEMATOLOGICA, V92, P1435, DOI 10.3324/haematol.11122; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Pui CH, 2011, J CLIN ONCOL, V29, P551, DOI 10.1200/JCO.2010.30.7405; Pulte D, 2010, ANN ONCOL, V21, P335, DOI 10.1093/annonc/mdp309; Rogers AEJ, 2012, ONCOGENE, V31, P4171, DOI 10.1038/onc.2011.588; Sander A, 2010, LEUKEMIA, V24, P1422, DOI 10.1038/leu.2010.127; Sather S, 2007, BLOOD, V109, P1026, DOI 10.1182/blood-2006-05-021634; Shankar DB, 2005, CANCER CELL, V7, P351, DOI 10.1016/j.ccr.2005.02.018; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Trifilio SM, 2012, LEUKEMIA RES, V36, P394, DOI 10.1016/j.leukres.2011.10.027; Wang HK, 2007, HAEMATOL-HEMATOL J, V92, P643, DOI 10.3324/haematol.10939; Xu Q, 2003, BLOOD, V102, P972, DOI 10.1182/blood-2002-11-3429	35	62	73	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2013	32	46					5359	5368		10.1038/onc.2013.40	http://dx.doi.org/10.1038/onc.2013.40			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IU	23474756	Green Published, hybrid			2022-12-17	WOS:000326922400006
J	Tsai, HY; Yang, YF; Wu, AT; Yang, CJ; Liu, YP; Jan, YH; Lee, CH; Hsiao, YW; Yeh, CT; Shen, CN; Lu, PJ; Huang, MS; Hsiao, M				Tsai, H-Y; Yang, Y-F; Wu, A. T.; Yang, C-J; Liu, Y-P; Jan, Y-H; Lee, C-H; Hsiao, Y-W; Yeh, C-T; Shen, C-N; Lu, P-J; Huang, M-S; Hsiao, M.			Endoplasmic reticulum ribosome-binding protein 1 (RRBP1) overexpression is frequently found in lung cancer patients and alleviates intracellular stress-induced apoptosis through the enhancement of GRP78	ONCOGENE			English	Article						RRBP1; GRP78; UPR; apoptosis; lung cancer	GLUCOSE-REGULATED PROTEINS; CHAPERONE GRP78/BIP; DRUG-RESISTANCE; ER; INDUCTION; RECEPTOR; IDENTIFICATION; PROLIFERATION; EXPRESSION; CHEMOTHERAPY	Lung cancer is the leading cause of cancer deaths and is the most occurring malignancy worldwide. Unraveling the molecular mechanisms involved in lung tumorigenesis will greatly improve therapy. During early tumorigenesis, rapid proliferating tumor cells require increased activity of endoplasmic reticulum (ER) for protein synthesis, folding and secretion, thereby are subjected to ER stress. Ribosome-binding protein 1 (RRBP1) was originally identified as a ribosome-binding protein located on the rough ER and associated with unfolding protein response (UPR). In this report, we investigated the role of RRBP1 in lung cancer. RRBP1 was highly expressed in lung cancer tissue, as compared with adjacent normal tissues as assessed by immunohistochemistry (IHC) using lung cancer tissue array (n=87). Knockdown of RRBP1 by short-hairpin RNAs caused ER stress and significantly reduced cell viability and tumorigenicity. This effect was associated with a significant reduction in the expression of glucose-regulated protein 78 (GRP78). UPR regulator GRP78, an anti-apoptotic protein that is widely upregulated in cancer, has a critical role in chemotherapy resistance in some cancers. According to our results, cells with a higher level of RRBP1 were more resistant to ER stress. Ectopic expression of RRBP1 alleviated apoptosis that was induced by the ER-stress agent tunicamycin, 2-deoxy-D-glucose (2DG) or doxorubicin via enhancing GRP78 protein expression. A strong correlation was observed between the expression of RRBP1 and GRP78 in tumor biopsies using the database GSE10072. Our results also indicated that RRBP1 may involve in the regulation of mRNA stability of UPR components including ATF6 and GRP78. Taken together, RRBP1 could alleviate ER stress and help cancer cell survive. RRBP1 is critical for tumor cell survival, which may make it a useful target in lung cancer treatment and a candidate for the development of new targeted therapeutics.	[Tsai, H-Y; Yang, Y-F] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan; [Tsai, H-Y; Yang, Y-F; Jan, Y-H; Hsiao, Y-W; Shen, C-N; Hsiao, M.] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Wu, A. T.] Taipei Med Univ, Coll Sci & Technol, PhD Program Translat Med, Taipei, Taiwan; [Yang, C-J; Huang, M-S] Kaohsiung Med Univ, Sch Med, Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Liu, Y-P; Lu, P-J] Natl Cheng Kung Univ, Inst Clin Med, Tainan 70101, Taiwan; [Wu, A. T.] Taipei Med Univ Hosp, Ctr Canc, Translat Res Lab, Taipei, Taiwan; [Lee, C-H] Taipei Tzu Chi Gen Hosp, Dept Pharm, Taipei, Taiwan; [Yeh, C-T; Shen, C-N] Taipei Med Univ, Grad Inst Clin Med, Taipei, Taiwan; [Yeh, C-T] Taipei Med Univ, Shuang Ho Hosp, Ctr Canc, Taipei, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Taipei Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; National Cheng Kung University; Taipei Medical University; Taipei Medical University Hospital; Buddhist Tzu Chi General Hospital; Taipei Medical University; Taipei Medical University; Shuang Ho Hospital	Hsiao, M (corresponding author), Acad Sinica, Genom Res Ctr, 128 Acad Rd,Sect 2, Taipei 115, Taiwan.	mhsiao@gate.sinica.edu.tw	Hsiao, Michael/U-6238-2019; SHEN, CHIA-NING/C-6878-2011	Hsiao, Michael/0000-0001-8529-9213; SHEN, CHIA-NING/0000-0002-0747-217X; Jan, Yi-Hua/0000-0001-7344-7602	National Science Council; Academia Sinica	National Science Council(Ministry of Science and Technology, Taiwan); Academia Sinica(Academia Sinica - Taiwan)	We thank Miss Tracy Tsai for assisting in the pathological staining analysis. RRBP1 plasmids were kindly provided by Dr Kiyoko, Japan Institute of Leather Research. The study was supported by grants from the National Science Council and Academia Sinica.	Arcamone F, 1997, PHARMACOL THERAPEUT, V76, P117, DOI 10.1016/S0163-7258(97)00096-X; Bai JZ, 2008, CELL BIOL INT, V32, P473, DOI 10.1016/j.cellbi.2007.10.002; Becker F, 1999, J CELL BIOL, V146, P273, DOI 10.1083/jcb.146.2.273; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Chang J, 2008, J PROTEOMICS, V71, P530, DOI 10.1016/j.jprot.2008.08.003; Cox JS, 1997, MOL BIOL CELL, V8, P1805, DOI 10.1091/mbc.8.9.1805; Cui XA, 2012, PLOS BIOL, V10, P1; Dong DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950; FIDLER IJ, 1990, CANCER RES, V50, P6130; Fu Y, 2006, CANCER BIOL THER, V5, P741, DOI 10.4161/cbt.5.7.2970; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hoffman RM, 1999, INVEST NEW DRUG, V17, P343, DOI 10.1023/A:1006326203858; Hoffman RM, 2005, NAT REV CANCER, V5, P796, DOI 10.1038/nrc1717; Hoffman RM, 2006, NAT PROTOC, V1, P928, DOI 10.1038/nprot.2006.119; Hyde M, 2002, J CELL BIOL, V156, P993, DOI 10.1083/jcb.200112008; Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690; Kim YJ, 2000, GENE, V261, P337, DOI 10.1016/S0378-1119(00)00496-0; Kong Q, 1998, MED HYPOTHESES, V51, P405, DOI 10.1016/S0306-9877(98)90036-6; Krasnov GS, 2009, MOL BIOL+, V43, P321, DOI 10.1134/S0026893309020149; Kurtoglu M, 2007, MOL CANCER THER, V6, P3049, DOI 10.1158/1535-7163.MCT-07-0310; Langley R, 1998, DNA CELL BIOL, V17, P449, DOI 10.1089/dna.1998.17.449; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523; Maschek G, 2004, CANCER RES, V64, P31, DOI 10.1158/0008-5472.CAN-03-3294; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Ogawa-Goto K, 2002, J VIROL, V76, P2350, DOI 10.1128/JVI.76.5.2350-2362.2002; Onn A, 2003, CLIN CANCER RES, V9, P5532; Pyrko P, 2007, CANCER RES, V67, P9809, DOI 10.1158/0008-5472.CAN-07-0625; Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Sasaya H, 2008, J BIOCHEM, V144, P251, DOI 10.1093/jb/mvn063; SAVITZ AJ, 1990, NATURE, V346, P540, DOI 10.1038/346540a0; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shepherd FA, 2000, J CLIN ONCOL, V18, p35S; Sobin LH, 1997, CANCER, V80, P1803, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9; Spear E, 2001, TRAFFIC, V2, P515, DOI 10.1034/j.1600-0854.2001.20801.x; Strauss GM, 2005, HEMATOL ONCOL CLIN N, V19, P263, DOI 10.1016/j.hoc.2005.02.008; Travis WD, 2002, CLIN CHEST MED, V23, P65, DOI 10.1016/S0272-5231(03)00061-3; Uramoto H, 2005, LUNG CANCER, V49, P55, DOI 10.1016/j.lungcan.2004.12.011; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Virrey JJ, 2008, MOL CANCER RES, V6, P1268, DOI 10.1158/1541-7786.MCR-08-0060; Wang Q, 2005, CANCER DETECT PREV, V29, P544, DOI 10.1016/j.cdp.2005.09.010; WANKER EE, 1995, J CELL BIOL, V130, P29, DOI 10.1083/jcb.130.1.29; Yang M, 1998, CANCER RES, V58, P4217; Yeung BHY, 2008, ONCOGENE, V27, P6782, DOI 10.1038/onc.2008.290	50	62	62	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4921	4931		10.1038/onc.2012.514	http://dx.doi.org/10.1038/onc.2012.514			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23318453				2022-12-17	WOS:000325717800008
J	Shortt, J; Hsu, AK; Johnstone, RW				Shortt, J.; Hsu, A. K.; Johnstone, R. W.			Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy	ONCOGENE			English	Review						immune modulation; therapeutics; hematological malignancies	MULTIPLE-MYELOMA CELLS; NATURAL-KILLER-CELL; NF-KAPPA-B; LENALIDOMIDE-INDUCED IMMUNOMODULATION; HUMAN-IMMUNODEFICIENCY-VIRUS; DIAMOND-BLACKFAN ANEMIA; COMMONLY DELETED REGION; NECROSIS-FACTOR-ALPHA; T REGULATORY CELLS; IN-VITRO	Thalidomide and its analogues (lenalidomide and pomalidomide) are small molecule glutamic acid derivatives of the immunomodulatory drug (IMiD) class. In addition to the immuno-adjuvant and anti-inflammatory properties that define an IMiD, the thalidomide analogues demonstrate an overlapping and diverse range of biological activities, including anti-angiogenic, teratogenic and epigenetic effects. Importantly, the IMiDs possess anti-cancer activity with selectivity for molecularly defined subgroups of hematological malignancies, specifically mature B-cell neoplasms and myelodysplasia with deletion of chromosome 5q. Emerging insight into the pathophysiological drivers of these IMiD-responsive disease states can now be synthesized using previously disclosed IMiD activities and recently discovered thalidomide targets to build unifying models of IMiD mechanism of action. Attention to mechanisms of IMiD-induced clinical toxicities, in particular the recently identified association of lenalidomide with second primary malignancies, provides an additional tool for determination of drug mechanism. This review seeks to define the molecular IMiD targets and biological outputs that underpin their anti-neoplastic activity. It is anticipated that elucidation of important IMiD targets will allow the rational development of new-generation therapeutics with the potential to separate thalidomide-analogue efficacy from clinical toxicity.	[Shortt, J.; Johnstone, R. W.] Peter MacCallum Canc Ctr, Canc Therapeut Program, Gene Regulat Lab, Melbourne, Vic, Australia; [Shortt, J.] Monash Med Ctr, Dept Clin Haematol, Clayton, Vic 3168, Australia; [Shortt, J.] Monash Univ, Southern Clin Sch, Dept Med, Clayton, Vic, Australia; [Hsu, A. K.] Peter MacCallum Canc Ctr, Canc Immunol Program, Haematol Immunol Translat Res Lab, Melbourne, Vic, Australia; [Johnstone, R. W.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3052, Australia	Peter Maccallum Cancer Center; Monash University; Monash University; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne	Johnstone, RW (corresponding author), Peter MacCallum Canc Inst, Canc Therapeut Program, St Andrews Pl, Melbourne, Vic 3002, Australia.	ricky.johnstone@petermac.org	Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237; Shortt, Jake/0000-0003-3185-6488				Arastu-Kapur S, 2011, CLIN CANCER RES, V17, P2734, DOI 10.1158/1078-0432.CCR-10-1950; Ashby J, 1997, MUTAT RES-FUND MOL M, V396, P45, DOI 10.1016/S0027-5107(97)00174-7; Attal M, 2012, NEW ENGL J MED, V366, P1782, DOI 10.1056/NEJMoa1114138; Barlow JL, 2010, NAT MED, V16, P59, DOI 10.1038/nm.2063; BARNES PF, 1992, INFECT IMMUN, V60, P1441, DOI 10.1128/IAI.60.4.1441-1446.1992; Bartlett JB, 2004, NAT REV CANCER, V4, P314, DOI 10.1038/nrc1323; Bauer KS, 1998, BIOCHEM PHARMACOL, V55, P1827, DOI 10.1016/S0006-2952(98)00046-X; Benson DM, 2011, BLOOD, V118, P6387, DOI 10.1182/blood-2011-06-360255; Benson DM, 2010, BLOOD, V116, P2286, DOI 10.1182/blood-2010-02-271874; Bernal M, 2009, HUM IMMUNOL, V70, P854, DOI 10.1016/j.humimm.2009.07.004; Boultwood J, 2002, BLOOD, V99, P4638, DOI 10.1182/blood.V99.12.4638; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Chaudhry V, 2008, J PERIPHER NERV SYST, V13, P275, DOI 10.1111/j.1529-8027.2008.00193.x; Cheng JP, 2011, INT J NANOMED, V6, P2007, DOI 10.2147/IJN.S20145; Cheung WC, 2001, LEUKEMIA, V15, P264, DOI 10.1038/sj.leu.2402022; Cook G, 1999, J LEUKOCYTE BIOL, V66, P981, DOI 10.1002/jlb.66.6.981; Corral LG, 1999, J IMMUNOL, V163, P380; Cortes-Hernandez J, 2012, BRIT J DERMATOL, V166, P616, DOI 10.1111/j.1365-2133.2011.10693.x; Croker BA, 2008, SEMIN CELL DEV BIOL, V19, P414, DOI 10.1016/j.semcdb.2008.07.010; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Dauguet N, 2010, CELL IMMUNOL, V264, P163, DOI 10.1016/j.cellimm.2010.06.003; Davies FE, 2001, BLOOD, V98, P210, DOI 10.1182/blood.V98.1.210; Depil S, 2003, LEUKEMIA, V17, P1678, DOI 10.1038/sj.leu.2403012; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; Dredge K, 2005, MICROVASC RES, V69, P56, DOI 10.1016/j.mvr.2005.01.002; Dredge K, 2002, BRIT J CANCER, V87, P1166, DOI 10.1038/sj.bjc.6600607; Dredge K, 2002, J IMMUNOL, V168, P4914, DOI 10.4049/jimmunol.168.10.4914; Dutt S, 2011, BLOOD, V117, P2567, DOI 10.1182/blood-2010-07-295238; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Ehrenpreis ED, 1999, GASTROENTEROLOGY, V117, P1271, DOI 10.1016/S0016-5085(99)70276-3; El-Sherbiny YM, 2007, CANCER RES, V67, P8444, DOI 10.1158/0008-5472.CAN-06-4230; ERIKSSON T, 1995, CHIRALITY, V7, P44, DOI 10.1002/chir.530070109; Escoubet-Lozach L, 2009, CANCER RES, V69, P7347, DOI 10.1158/0008-5472.CAN-08-4898; Ferguson GD, 2007, J CLIN IMMUNOL, V27, P210, DOI 10.1007/s10875-007-9070-6; Figg WD, 1999, J PHARM SCI, V88, P121, DOI 10.1021/js980172i; Frassanito MA, 2001, CLIN EXP IMMUNOL, V125, P190, DOI 10.1046/j.1365-2249.2001.01582.x; Galustian C, 2009, CANCER IMMUNOL IMMUN, V58, P1033, DOI 10.1007/s00262-008-0620-4; Gandhi AK, 2010, CURR CANCER DRUG TAR, V10, P155; Gandhi AK, 2006, LEUKEMIA RES, V30, P849, DOI 10.1016/j.leukres.2006.01.010; Gazda HT, 2006, AM J HUM GENET, V79, P1110, DOI 10.1086/510020; Giamarellos-Bourboulis EJ, 2003, ANTIMICROB AGENTS CH, V47, P2445, DOI 10.1128/AAC.47.8.2445-2449.2003; Giannopoulos K, 2012, BRIT J CANCER, V106, P546, DOI 10.1038/bjc.2011.575; Gorgun G, 2010, BLOOD, V116, P3227, DOI 10.1182/blood-2010-04-279893; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Groen HJM, 2011, J CLIN ONCOL, V29, P4320, DOI 10.1200/JCO.2011.35.5214; Gupta D, 2001, LEUKEMIA, V15, P1950, DOI 10.1038/sj.leu.2402295; Hamuryudan V, 1998, ANN INTERN MED, V128, P443, DOI 10.7326/0003-4819-128-6-199803150-00004; Hansen JM, 2002, DEV DYNAM, V225, P186, DOI 10.1002/dvdy.10150; Haslett PAJ, 2003, J INFECT DIS, V187, P946, DOI 10.1086/368126; Haslett PAJ, 1998, J EXP MED, V187, P1885, DOI 10.1084/jem.187.11.1885; Hayashi T, 2005, BRIT J HAEMATOL, V128, P192, DOI 10.1111/j.1365-2141.2004.05286.x; Hernandez-Ilizaliturri FJ, 2005, CLIN CANCER RES, V11, P5984, DOI 10.1158/1078-0432.CCR-05-0577; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Higgins JJ, 2004, NEUROLOGY, V63, P1927, DOI 10.1212/01.WNL.0000146196.01316.A2; HIRATA RK, 1993, HEMATOL PATHOL, V7, P225; Hoang B, 2006, BLOOD, V107, P4484, DOI 10.1182/blood-2005-09-3926; Hohberger B, 2009, FEBS LETT, V583, P633, DOI 10.1016/j.febslet.2009.01.018; Hsu AK, 2011, BLOOD, V117, P1605, DOI 10.1182/blood-2010-04-278432; Huang PHT, 1997, TERATOGEN CARCIN MUT, V17, P1, DOI 10.1002/(SICI)1520-6866(1997)17:1<1::AID-TCM2>3.0.CO;2-L; Ito T, 2011, CELL MOL LIFE SCI, V68, P1569, DOI 10.1007/s00018-010-0619-9; Ito T, 2010, SCIENCE, V327, P1345, DOI 10.1126/science.1177319; IYER CGS, 1971, B WORLD HEALTH ORGAN, V45, P719; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jacobson JM, 1997, NEW ENGL J MED, V336, P1487, DOI 10.1056/NEJM199705223362103; Jadersten M, 2009, HAEMATOL-HEMATOL J, V94, P1762, DOI 10.3324/haematol.2009.011528; Jakubikova J, 2011, BLOOD, V117, P4409, DOI 10.1182/blood-2010-02-267344; Jinushi M, 2008, P NATL ACAD SCI USA, V105, P1285, DOI 10.1073/pnas.0711293105; Jo S, 2005, J NEUROCHEM, V94, P1212, DOI 10.1111/j.1471-4159.2005.03344.x; Johnson DC, 2008, BLOOD, V112, P4924, DOI 10.1182/blood-2008-02-140434; JONSSON NA, 1972, ACTA PHARM SUEC, V9, P543; Kenyon BM, 1997, EXP EYE RES, V64, P971, DOI 10.1006/exer.1997.0292; Knobloch J, 2008, MOL CELL BIOL, V28, P529, DOI 10.1128/MCB.00533-07; Knobloch J, 2007, FASEB J, V21, P1410, DOI 10.1096/fj.06-7603com; Kumar MS, 2011, BLOOD, V118, P4666, DOI 10.1182/blood-2010-12-324715; Kumar S, 2007, LEUKEMIA, V21, P2035, DOI 10.1038/sj.leu.2404801; Kyle RA, 2008, BLOOD, V111, P2962, DOI 10.1182/blood-2007-10-078022; Lacy MQ, 2009, J CLIN ONCOL, V27, P5008, DOI 10.1200/JCO.2009.23.6802; Landowski TH, 2005, CANCER RES, V65, P3828, DOI 10.1158/0008-5472.CAN-04-3684; Lanier LL, 2008, NAT IMMUNOL, V9, P495, DOI 10.1038/ni1581; LeBlanc R, 2004, BLOOD, V103, P1787, DOI 10.1182/blood-2003-02-0361; Lee KM, 2011, BBA-MOL CELL RES, V1813, P448, DOI 10.1016/j.bbamcr.2011.01.005; LENZ W, 1962, LANCET, V1, P45; Leppert ER, 2006, CURR DRUG METAB, V7, P677, DOI 10.2174/138920006778017777; Li SR, 2011, BLOOD, V117, P5157, DOI 10.1182/blood-2010-10-314278; List A, 2006, NEW ENGL J MED, V355, P1456, DOI 10.1056/NEJMoa061292; Lopez-Girona A, 2012, LEUKEMIA, V26, P2326, DOI 10.1038/leu.2012.119; Lu L, 2009, MICROVASC RES, V77, P78, DOI 10.1016/j.mvr.2008.08.003; Luptakova K, CANC IMMUNOL IMMUNOT; Madan S, 2011, BLOOD, V118, P1763, DOI 10.1182/blood-2011-04-350009; Masferrer JL, 2000, CANCER RES, V60, P1306; Matsui W, 2008, CANCER RES, V68, P190, DOI 10.1158/0008-5472.CAN-07-3096; MCBRIDE WG, 1961, LANCET, V2, P1358; McCarthy PL, 2012, NEW ENGL J MED, V366, P1770, DOI 10.1056/NEJMoa1114083; McMillin DW, 2010, NAT MED, V16, P483, DOI 10.1038/nm.2112; MELLIN G W, 1962, N Engl J Med, V267, P1184, DOI 10.1056/NEJM196212062672305; Mileshkin L, 2006, J CLIN ONCOL, V24, P4507, DOI 10.1200/JCO.2006.05.6689; Mitsiades CS, 2007, J CELL BIOCHEM, V101, P950, DOI 10.1002/jcb.21213; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Mitsiades N, 2002, BLOOD, V99, P4525, DOI 10.1182/blood.V99.12.4525; MOREIRA AL, 1993, J EXP MED, V177, P1675, DOI 10.1084/jem.177.6.1675; Muller GW, 1999, BIOORG MED CHEM LETT, V9, P1625, DOI 10.1016/S0960-894X(99)00250-4; Muller GW, 1996, J MED CHEM, V39, P3238, DOI 10.1021/jm9603328; Narayan VA, 1997, J BIOL CHEM, V272, P7801, DOI 10.1074/jbc.272.12.7801; Nefedova Y, 2003, LEUKEMIA, V17, P1175, DOI 10.1038/sj.leu.2402924; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Noonan K, 2012, CLIN CANCER RES, V18, P1426, DOI 10.1158/1078-0432.CCR-11-1221; Noonan K, 2010, BLOOD, V116, P3554, DOI 10.1182/blood-2010-05-283895; Pal R, 2010, BLOOD, V115, P605, DOI 10.1182/blood-2009-05-221077; Palumbo A, 2012, NEW ENGL J MED, V366, P1759, DOI 10.1056/NEJMoa1112704; Palumbo A, 2012, EXPERT OPIN DRUG SAF, V11, P107, DOI 10.1517/14740338.2011.619975; Parman T, 1999, NAT MED, V5, P582, DOI 10.1038/8466; Payvandi F, 2005, J INTERF CYTOK RES, V25, P604, DOI 10.1089/jir.2005.25.604; Peacock CD, 2007, P NATL ACAD SCI USA, V104, P4048, DOI 10.1073/pnas.0611682104; Pellagatti A, 2007, P NATL ACAD SCI USA, V104, P11406, DOI 10.1073/pnas.0610477104; Pilarski LM, 2002, CLIN CANCER RES, V8, P3198; Prince HM, 2005, CLIN CANCER RES, V11, P5504, DOI 10.1158/1078-0432.CCR-05-0213; Racanelli V, 2010, BLOOD, V115, P1185, DOI 10.1182/blood-2009-06-228676; Raitakari M, 2000, BRIT J HAEMATOL, V110, P203, DOI 10.1046/j.1365-2141.2000.02131.x; SAMPAIO EP, 1991, J EXP MED, V173, P699, DOI 10.1084/jem.173.3.699; Schafer PH, 2003, J PHARMACOL EXP THER, V305, P1222, DOI 10.1124/jpet.102.048496; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; SHESKIN J, 1965, CLIN PHARMACOL THER, V6, P303; Shi YJ, 2011, J BIOL CHEM, V286, P67, DOI 10.1074/jbc.M110.153221; Solomon DH, 2004, CIRCULATION, V109, P2068, DOI 10.1161/01.CIR.0000127578.21885.3E; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stephens TD, 2000, BIOCHEM PHARMACOL, V59, P1489, DOI 10.1016/S0006-2952(99)00388-3; Sze DMY, 2001, BLOOD, V98, P2817, DOI 10.1182/blood.V98.9.2817; Tai YT, 2005, CANCER RES, V65, P11712, DOI 10.1158/0008-5472.CAN-05-1657; Tai YT, 2012, BLOOD, V119, P2074, DOI 10.1182/blood-2011-06-364521; Cibeira MT, 2011, LEUKEMIA RES, V35, P1178, DOI 10.1016/j.leukres.2011.02.009; Therapontos C, 2009, P NATL ACAD SCI USA, V106, P8573, DOI 10.1073/pnas.0901505106; Tsenova L, 2002, ANTIMICROB AGENTS CH, V46, P1887, DOI 10.1128/AAC.46.6.1887-1895.2002; Tsimberidou AM, 2003, LEUKEMIA RES, V27, P375, DOI 10.1016/S0145-2126(02)00082-6; VANDENBERGHE H, 1974, NATURE, V251, P437, DOI 10.1038/251437a0; Verhelle D, 2007, CANCER RES, V67, P746, DOI 10.1158/0008-5472.CAN-06-2317; Wei S, 2013, ONCOGENE, V32, P1110, DOI 10.1038/onc.2012.139; Wei S, 2009, P NATL ACAD SCI USA, V106, P12974, DOI 10.1073/pnas.0811267106; Welm AL, 2000, J BIOL CHEM, V275, P27406; Wittschieben BO, 2005, J BIOL CHEM, V280, P39982, DOI 10.1074/jbc.M507854200; Wohl DA, 2002, J INFECT DIS, V185, P1359, DOI 10.1086/340133; Xin W, 2008, MOL BIOL REP, V35, P251, DOI 10.1007/s11033-007-9077-3; Yabu T, 2005, BLOOD, V106, P125, DOI 10.1182/blood-2004-09-3679; Yaccoby S, 2002, BLOOD, V100, P4162, DOI 10.1182/blood-2002-03-0939; Yang YB, 2012, CANCER CELL, V21, P723, DOI 10.1016/j.ccr.2012.05.024; Zhu YX, 2011, BLOOD, V118, P4771, DOI 10.1182/blood-2011-05-356063	146	62	62	1	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2013	32	36					4191	4202		10.1038/onc.2012.599	http://dx.doi.org/10.1038/onc.2012.599			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23318436				2022-12-17	WOS:000324168000001
J	Perez-Gomez, E; Andradas, C; Flores, JM; Quintanilla, M; Paramio, JM; Guzman, M; Sanchez, C				Perez-Gomez, E.; Andradas, C.; Flores, J. M.; Quintanilla, M.; Paramio, J. M.; Guzman, M.; Sanchez, C.			The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas	ONCOGENE			English	Article						GPR55; G protein-coupled receptors; skin carcinogenesis; squamous cell carcinoma; cannabinoids	LYSOPHOSPHATIDIC ACID RECEPTOR-2; L-ALPHA-LYSOPHOSPHATIDYLINOSITOL; PROTEIN-COUPLED RECEPTORS; CANNABINOID RECEPTOR; OVARIAN-CANCER; LPA RECEPTORS; COLORECTAL-CANCER; OVER-EXPRESSION; GROWTH-FACTOR; IDENTIFICATION	G protein-coupled receptors (GPCRs) control crucial physiological processes and their dysfunction contributes to various human diseases, including cancer. The orphan GPCR GPR55 was identified and cloned more than a decade ago, but very little is known about its physio-pathological relevance. It has been recently shown that GPR55 controls the behavior of human cancer cell lines in culture and xenografts. However, the assessment of the actual role of this receptor in malignant transformation in vivo is hampered by the lack of studies on its functional impact in clinically-relevant models of cancer. Here we demonstrate that GPR55 drives mouse skin tumor development. Thus, GPR55-deficient mice were more resistant to DMBA/TPA-induced papilloma and carcinoma formation than their wild-type littermates. GPR55 exerted this pro-tumor effect primarily by conferring a proliferative advantage on cancer cells. In addition, GPR55 enhanced skin cancer cell anchorage-independent growth, invasiveness and tumorigenicity in vivo, suggesting that it promotes not only tumor development but also tumor aggressiveness. Finally, we observed that GPR55 is upregulated in human skin tumors and other human squamous cell carcinomas compared with the corresponding healthy tissues. Altogether, these findings reveal the pivotal importance of GPR55 in skin tumor development, and suggest that this receptor may be used as a new biomarker and therapeutic target in squamous cell carcinomas.	[Perez-Gomez, E.; Andradas, C.; Guzman, M.; Sanchez, C.] Univ Complutense Madrid, Sch Biol, Dept Biochem & Mol Biol 1, E-28040 Madrid, Spain; [Flores, J. M.] Univ Complutense Madrid, Sch Vet, Dept Anim Surg & Med, E-28040 Madrid, Spain; [Quintanilla, M.] Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain; [Paramio, J. M.] CIEMAT, Div Biomed, Mol Oncol Unit, E-28040 Madrid, Spain; [Guzman, M.] Ctr Invest Biomed Red Enfermedade Neurodegenerat, Madrid, Spain; [Guzman, M.] Inst Ramon y Cajal Invest Sanitaria, Madrid, Spain	Complutense University of Madrid; Complutense University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; CIBERNED	Sanchez, C (corresponding author), Univ Complutense Madrid, Sch Biol, Dept Biochem & Mol Biol 1, C Jose Antonio Novais 2, E-28040 Madrid, Spain.	cristina.sanchez@quim.ucm.es	Perez-gomez, Eduardo/F-5906-2015; Sanchez, Cristina/H-4980-2017; Quintanilla, Miguel/K-9293-2017; Paramio, Jesus M/M-8482-2014; Pérez-Gómez, Eduardo/GYA-5856-2022; Sanchez, Cristina/AFQ-4745-2022	Perez-gomez, Eduardo/0000-0003-0160-5565; Sanchez, Cristina/0000-0002-1428-3078; Paramio, Jesus M/0000-0001-7520-3177; Pérez-Gómez, Eduardo/0000-0003-0160-5565; Guzman, Manuel/0000-0001-7475-118X	Fondo de Investigaciones Sanitarias [PI080253]; Fundacion Mutua Madrilena; GW Pharmaceuticals/Otsuka Pharmaceuticals; Comunidad de Madrid [S2010/BMD-2038]; Spanish Ministry of Science and Innovation [SAF2010-19152, SAF2008-00121, SAF2011-26122-C02-01]; Fundacion Cientifica Asociacion Espanola Contra el Cancer (AECC); Spanish Ministry of Science and Innovation	Fondo de Investigaciones Sanitarias(Instituto de Salud Carlos III); Fundacion Mutua Madrilena(Instituto de Salud Carlos III); GW Pharmaceuticals/Otsuka Pharmaceuticals(Otsuka Pharmaceutical); Comunidad de Madrid(Comunidad de Madrid); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Fundacion Cientifica Asociacion Espanola Contra el Cancer (AECC); Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	We are indebted to the members of our laboratories and to Dr MM Caffarel for critical discussion on this work. We thank Dr Manuel M Morente, Head of the CNIO Tumor Bank Core Unit, for kindly provided us with human tumor samples. This work was supported by grants from Fondo de Investigaciones Sanitarias (PI080253 to CS), Fundacion Mutua Madrilena (to CS), GW Pharmaceuticals/Otsuka Pharmaceuticals (to CS), Comunidad de Madrid (S2010/BMD-2038 to MG) and Spanish Ministry of Science and Innovation (SAF2010-19152 to MQ and SAF2008-00121 and SAF2011-26122-C02-01 to JMP). EPG and CA were the recipients of a Postdoctoral Research Contract from Fundacion Cientifica Asociacion Espanola Contra el Cancer (AECC) and a PFIS PhD studentship from the Spanish Ministry of Science and Innovation, respectively.	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Andradas C, 2011, ONCOGENE, V30, P245, DOI 10.1038/onc.2010.402; Cantarella G, 2011, BIOCHEM PHARMACOL, V82, P380, DOI 10.1016/j.bcp.2011.05.004; Choi JW, 2010, ANNU REV PHARMACOL, V50, P157, DOI 10.1146/annurev.pharmtox.010909.105753; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Falasca M, 1998, ONCOGENE, V16, P2357, DOI 10.1038/sj.onc.1201758; FALASCA M, 1994, EUR J BIOCHEM, V221, P383, DOI 10.1111/j.1432-1033.1994.tb18750.x; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Ford LA, 2010, BRIT J PHARMACOL, V160, P762, DOI 10.1111/j.1476-5381.2010.00743.x; Henstridge CM, 2011, MOL ENDOCRINOL, V25, P1835, DOI 10.1210/me.2011-1197; Henstridge CM, 2009, FASEB J, V23, P183, DOI 10.1096/fj.08-108670; Houben AJS, 2011, CANCER METAST REV, V30, P557, DOI 10.1007/s10555-011-9319-7; Huang L, 2011, LAB INVEST, V91, P1007, DOI 10.1038/labinvest.2011.62; Kapur A, 2009, J BIOL CHEM, V284, P29817, DOI 10.1074/jbc.M109.050187; Kitayama J, 2004, BREAST CANCER RES, V6, pR640, DOI 10.1186/bcr935; Lappano R, 2011, NAT REV DRUG DISCOV, V10, P47, DOI 10.1038/nrd3320; Lauckner JE, 2008, P NATL ACAD SCI USA, V105, P2699, DOI 10.1073/pnas.0711278105; Ligresti A, 2003, GASTROENTEROLOGY, V125, P677, DOI 10.1016/S0016-5085(03)00881-3; Lin ME, 2010, PROSTAG OTH LIPID M, V91, P130, DOI 10.1016/j.prostaglandins.2009.02.002; Oka S, 2007, BIOCHEM BIOPH RES CO, V362, P928, DOI 10.1016/j.bbrc.2007.08.078; Oka S, 2010, J BIOCHEM, V147, P671, DOI 10.1093/jb/mvp208; Oka S, 2009, J BIOCHEM, V145, P13, DOI 10.1093/jb/mvn136; Pagotto U, 2001, J CLIN ENDOCR METAB, V86, P2687, DOI 10.1210/jc.86.6.2687; Patterson AD, 2011, CANCER RES, V71, P6590, DOI 10.1158/0008-5472.CAN-11-0885; Perez-Gomez E, 2007, CANCER RES, V67, P10268, DOI 10.1158/0008-5472.CAN-07-1348; Petersen G, 2005, J NEUROCHEM, V93, P299, DOI 10.1111/j.1471-4159.2005.03013.x; Pineiro R, 2011, ONCOGENE, V30, P142, DOI 10.1038/onc.2010.417; Ross RA, 2009, TRENDS PHARMACOL SCI, V30, P156, DOI 10.1016/j.tips.2008.12.004; Sawzdargo M, 1999, MOL BRAIN RES, V64, P193, DOI 10.1016/S0169-328X(98)00277-0; Schicho R, 2011, INFLAMM BOWEL DIS, V17, P1651, DOI 10.1002/ibd.21538; Schmid PC, 2002, LIPIDS, V37, P907, DOI 10.1007/s11745-002-0978-z; Schulte KM, 2001, INT J CANCER, V92, P249, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1166>3.0.CO;2-D; Shida D, 2004, LAB INVEST, V84, P1352, DOI 10.1038/labinvest.3700146; Staton PC, 2008, PAIN, V139, P225, DOI 10.1016/j.pain.2008.04.006; Sticht C, 2008, NEOPLASIA, V10, P462, DOI 10.1593/neo.08164; Sutphen R, 2004, CANCER EPIDEM BIOMAR, V13, P1185; Whyte LS, 2009, P NATL ACAD SCI USA, V106, P16511, DOI 10.1073/pnas.0902743106; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Yamashita H, 2006, J SURG ONCOL, V93, P30, DOI 10.1002/jso.20397; Yin H, 2009, J BIOL CHEM, V284, P12328, DOI 10.1074/jbc.M806516200; Yun CC, 2005, AM J PHYSIOL-CELL PH, V289, pC2, DOI 10.1152/ajpcell.00610.2004; Zeng Y, 2009, PROSTATE, V69, P283, DOI 10.1002/pros.20879	44	62	65	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 16	2013	32	20					2534	2542		10.1038/onc.2012.278	http://dx.doi.org/10.1038/onc.2012.278			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22751111				2022-12-17	WOS:000319274300005
J	DeGregori, J				DeGregori, J.			Challenging the axiom: does the occurrence of oncogenic mutations truly limit cancer development with age?	ONCOGENE			English	Review						mutation; evolution; aging	HEMATOPOIETIC STEM-CELLS; DETECTABLE CLONAL MOSAICISM; SELF-RENEWAL; DNA-DAMAGE; C-CBL; MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR; MICE; DIFFERENTIATION; QUIESCENCE	A widely accepted paradigm in cancer research holds that the development of cancers is rate limited by the occurrence of oncogenic mutations. In particular, the exponential rise in the incidence of most cancers with age is thought to reflect the time required for cells to accumulate the multiple oncogenic mutations needed to confer the cancer phenotype. Here I will argue against the axiom that the occurrence of oncogenic mutations limits cancer incidence with age, based on several observations, including that the rate of mutation accumulation is maximal during ontogeny, oncogenic mutations are frequently detected in normal tissues, the evolution of complex multicellularity was not accompanied by reductions in mutation rates, and that many oncogenic mutations have been shown to impair stem cell activity. Moreover, although evidence that has been used to support the current paradigm includes increased cancer incidence in individuals with inherited DNA repair deficiencies or exposed to mutagens, the pleotropic effects of these contexts could enhance tumorigenesis at multiple levels. I will further argue that age-dependent alteration of selection for oncogenic mutations provides a more plausible explanation for increased cancer incidence in the elderly. Although oncogenic mutations are clearly required for cancer evolution, together these observations counter the common view that age dependence of cancers is largely explained by the time required to accumulate sufficient oncogenic mutations. Oncogene (2013) 32, 1869-1875; doi:10.1038/onc.2012.281; published online 2 July 2012	Univ Colorado, Dept Biochem & Mol Genet, Dept Immunol, Dept Pediat,Sch Med,Program Mol Biol, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus	DeGregori, J (corresponding author), Univ Colorado, Dept Biochem & Mol Genet, Dept Immunol, Dept Pediat,Sch Med,Program Mol Biol, Mail Stop 8101,POB 6511, Aurora, CO 80045 USA.	james.degregori@ucdenver.edu		DeGregori, James/0000-0002-1287-1976	National Institutes of Health [R01-CA157850]; Leukemia Lymphoma Society; NATIONAL CANCER INSTITUTE [R01CA157850] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Leukemia Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	These studies were supported by grants from the National Institutes of Health (R01-CA157850) and the Leukemia Lymphoma Society. I thank Robert Sclafani, Michael Weil, Andriy Marusyk, Ruth Hershberg, Andrew Thorburn and members of my laboratory for their critical comments and suggestions.	ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1; ARMITAGE P, 1957, BRIT J CANCER, V11, P161, DOI 10.1038/bjc.1957.22; Bagby Grover C, 2011, Front Biosci (Schol Ed), V3, P487, DOI 10.2741/s167; Bagley J, 2004, BLOOD, V104, P572, DOI 10.1182/blood-2003-12-4226; Bensimon A, 2011, FEBS LETT, V585, P1625, DOI 10.1016/j.febslet.2011.05.013; BIERNAUX C, 1995, BLOOD, V86, P3118; Bilousova G, 2005, PLOS BIOL, V3, P2135, DOI 10.1371/journal.pbio.0030401; Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328; Blagosklonny MV, 2005, CELL DEATH DIFFER, V12, P592, DOI 10.1038/sj.cdd.4401610; Bondar T, 2010, CELL STEM CELL, V6, P309, DOI 10.1016/j.stem.2010.03.002; Bose S, 1998, BLOOD, V92, P3362, DOI 10.1182/blood.V92.9.3362; Campbell TB, 2009, BLOOD, V114, P3392, DOI 10.1182/blood-2008-12-195214; Chen C, 2008, J EXP MED, V205, P2397, DOI 10.1084/jem.20081297; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cortopassi GA, 1996, MECH AGEING DEV, V91, P211, DOI 10.1016/S0047-6374(96)01788-5; Crawford YG, 2004, CANCER CELL, V5, P263, DOI 10.1016/S1535-6108(04)00023-6; Daria D, 2008, BLOOD, V111, P1894, DOI 10.1182/blood-2007-02-071746; DeGregori J, 2011, CANCER RES, V71, P3739, DOI 10.1158/0008-5472.CAN-11-0342; Dolle MET, 1997, NAT GENET, V17, P431, DOI 10.1038/ng1297-431; Fleenor CJ, 2010, CELL CYCLE, V9, P3005, DOI 10.4161/cc.9.15.12311; Forsberg LA, 2012, AM J HUM GENET, V90, P217, DOI 10.1016/j.ajhg.2011.12.009; Frank SA, 2010, P NATL ACAD SCI USA, V107, P1725, DOI 10.1073/pnas.0909343106; Freitas AA, 2011, MUTAT RES-REV MUTAT, V728, P12, DOI 10.1016/j.mrrev.2011.05.001; FRITH CH, 1993, TOXICOL PATHOL, V21, P206, DOI 10.1177/019262339302100213; Gan BY, 2010, NATURE, V468, P701, DOI 10.1038/nature09595; Gan B, 2008, P NATL ACAD SCI USA, V105, P19384, DOI 10.1073/pnas.0810584105; Gatenby RA, 2008, NAT REV CANCER, V8, P56, DOI 10.1038/nrc2255; Giese H, 2002, MUTAT RES-GEN TOX EN, V514, P153, DOI 10.1016/S1383-5718(01)00329-1; Gomes NMV, 2011, AGING CELL, V10, P761, DOI 10.1111/j.1474-9726.2011.00718.x; Gorbunova V, 2009, MECH AGEING DEV, V130, P3, DOI 10.1016/j.mad.2008.02.008; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Greaves MF, 2003, NAT REV CANCER, V3, P1, DOI DOI 10.1038/NRC1164; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Henry CJ, 2011, AGING-US, V3, P643, DOI 10.18632/aging.100351; Henry CJ, 2010, P NATL ACAD SCI USA, V107, P21713, DOI 10.1073/pnas.1005486107; Hoeijmakers JHJ, 2009, NEW ENGL J MED, V361, P1475, DOI 10.1056/NEJMra0804615; Holyoake TL, 2002, LEUKEMIA, V16, P549, DOI 10.1038/sj.leu.2402444; Huang J, 2009, J CLIN INVEST, V119, P3519, DOI 10.1172/JCI40572; Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989; Jacobs KB, 2012, NAT GENET, V44, P651, DOI 10.1038/ng.2270; Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159; Kennedy SR, 2012, MECH AGEING DEV, V133, P118, DOI 10.1016/j.mad.2011.10.009; Kirstetter P, 2006, NAT IMMUNOL, V7, P1048, DOI 10.1038/ni1381; Laconi E, 2008, SEMIN CANCER BIOL, V18, P322, DOI 10.1016/j.semcancer.2008.03.019; Laurie CC, 2012, NAT GENET, V44, P642, DOI 10.1038/ng.2271; Li WG, 2012, GERONTOLOGY, V58, P129, DOI 10.1159/000334368; Lynch M, 2010, TRENDS GENET, V26, P345, DOI 10.1016/j.tig.2010.05.003; Maillard I, 2009, BLOOD, V113, P1661, DOI [10.1182/blood-2008-01-135012, 10.1182/blood-2009-01-135012]; Marusyk A, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000324; Marusyk A, 2008, BBA-REV CANCER, V1785, P1, DOI 10.1016/j.bbcan.2007.09.001; Matioli GT, 2002, MED HYPOTHESES, V59, P588, DOI 10.1016/S0306-9877(02)00220-7; Matsuoka S, 2008, GENE DEV, V22, P986, DOI 10.1101/gad.1621808; Min IM, 2008, CELL STEM CELL, V2, P380, DOI 10.1016/j.stem.2008.01.015; Mullighan CG, 2008, NATURE; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Mutter GL, 2001, CANCER RES, V61, P4311; Naumov GN, 2006, CELL CYCLE, V5, P1779, DOI 10.4161/cc.5.16.3018; Nichogiannopoulou A, 1999, J EXP MED, V190, P1201, DOI 10.1084/jem.190.9.1201; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ogawa S, 2010, CLIN CANCER RES, V16, P3825, DOI 10.1158/1078-0432.CCR-09-2341; Papathanasiou P, 2003, IMMUNITY, V19, P131, DOI 10.1016/S1074-7613(03)00168-7; Papathanasiou P, 2009, STEM CELLS, V27, P3082, DOI 10.1002/stem.232; Perry JM, 2011, GENE DEV, V25, P1928, DOI 10.1101/gad.17421911; PETO R, 1975, BRIT J CANCER, V32, P411, DOI 10.1038/bjc.1975.242; Preston BD, 2010, SEMIN CANCER BIOL, V20, P281, DOI 10.1016/j.semcancer.2010.10.009; PROMISLOW DEL, 1994, J THEOR BIOL, V170, P291, DOI 10.1006/jtbi.1994.1190; Qian ZJ, 2008, J EXP MED, V205, P2163, DOI 10.1084/jem.20080578; Rando TA, 2006, NATURE, V441, P1080, DOI 10.1038/nature04958; Rathinam C, 2008, GENE DEV, V22, P992, DOI 10.1101/gad.1651408; Rathinam C, 2010, CANCER CELL, V18, P341, DOI 10.1016/j.ccr.2010.09.008; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reynaud D, 2011, CANCER CELL, V20, P661, DOI 10.1016/j.ccr.2011.10.012; Rodriguez-Santiago B, 2010, AM J HUM GENET, V87, P129, DOI 10.1016/j.ajhg.2010.06.002; Sabnis AJ, 2009, PLOS BIOL, V7, P537, DOI 10.1371/journal.pbio.1000059; Scheller M, 2006, NAT IMMUNOL, V7, P1037, DOI 10.1038/ni1387; Schemionek M, 2010, BLOOD, V115, P3185, DOI 10.1182/blood-2009-04-215376; Serrano M, 2007, NAT REV MOL CELL BIO, V8, P715, DOI 10.1038/nrm2242; Sieber OM, 2005, NAT REV CANCER, V5, P649, DOI 10.1038/nrc1674; Spike BT, 2004, EMBO J, V23, P4319, DOI 10.1038/sj.emboj.7600432; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; Thompson BJ, 2008, J EXP MED, V205, P1395, DOI 10.1084/jem.20080277; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Venkatesan RN, 2007, MOL CELL BIOL, V27, P7669, DOI 10.1128/MCB.00002-07; Vickers M, 1996, BRIT J HAEMATOL, V94, P1; Vijg J, 2005, ANN NY ACAD SCI, V1055, P35, DOI 10.1196/annals.1323.007; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Walkley CR, 2007, CELL, V129, P1081, DOI 10.1016/j.cell.2007.03.055; Weinberg RA, 2007, BIOL CANC; Weng NP, 1998, IMMUNITY, V9, P151, DOI 10.1016/S1074-7613(00)80597-X; Westbrook AM, 2010, CANCER RES, V70, P1875, DOI 10.1158/0008-5472.CAN-09-2584; Wilson A, 2004, GENE DEV, V18, P2747, DOI 10.1101/gad.313104; Wilson A, 2009, CURR OPIN GENET DEV, V19, P461, DOI 10.1016/j.gde.2009.08.005; Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747	95	62	63	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2013	32	15					1869	1875		10.1038/onc.2012.281	http://dx.doi.org/10.1038/onc.2012.281			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126GB	22751134	Green Accepted			2022-12-17	WOS:000317599900001
J	Natsume, A; Kato, T; Kinjo, S; Enomoto, A; Toda, H; Shimato, S; Ohka, F; Motomura, K; Kondo, Y; Miyata, T; Takahashi, M; Wakabayashi, T				Natsume, A.; Kato, T.; Kinjo, S.; Enomoto, A.; Toda, H.; Shimato, S.; Ohka, F.; Motomura, K.; Kondo, Y.; Miyata, T.; Takahashi, M.; Wakabayashi, T.			Girdin maintains the stemness of glioblastoma stem cells	ONCOGENE			English	Article						Girdin; glioblastoma; cancer stem cells; migration; stemness	INITIATING CELLS; PROTEIN GIRDIN; HUMAN CANCER; AKT; PATHWAY; GLIOMA; BRAIN; ACTIVATION; ANGIOGENESIS; SURVIVAL	Glioblastomas (GBMs) are the most common and aggressive type of brain tumor. GBMs usually show hyperactivation of the PI3K-Akt pathway, a pro-tumorigenic signaling cascade that contributes to pathogenesis. Girdin, an actin-binding protein identified as a novel substrate of Akt, regulates the sprouting of axons and the migration of neural progenitor cells during early postnatal-stage neurogenesis in the hippocampus. Here, we show that Girdin is highly expressed in human glioblastoma (GBM). Stable Girdin knockdown in isolated GBM stem cells resulted in decreased expression of stem cell markers, including CD133, induced multilineage neural differentiation, and inhibited in vitro cell motility, ex vivo invasion, sphere-forming capacity and in vivo tumor formation. Furthermore, exogenous expression of the Akt-binding domain of Girdin, which competitively inhibits its Akt-mediated phosphorylation, diminished the expression of stem cell markers, SOX2 and nestin, and migration on the brain slice and induced the expression of neural differentiation markers glial fibrillary acidic protein/beta III Tubulin. Our results reveal that Girdin is required for GBM-initiating stem cells to sustain the stemness and invasive properties. Oncogene (2012) 31, 2715-2724; doi: 10.1038/onc.2011.466; published online 24 October 2011	[Natsume, A.; Kato, T.; Kinjo, S.; Toda, H.; Shimato, S.; Ohka, F.; Motomura, K.; Wakabayashi, T.] Nagoya Univ, Dept Neurosurg, Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan; [Enomoto, A.; Takahashi, M.] Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; [Kondo, Y.] Aichi Canc Ctr Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi, Japan; [Miyata, T.] Nagoya Univ, Dept Anat & Cell Biol, Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan	Nagoya University; Nagoya University; Aichi Cancer Center; Nagoya University	Natsume, A (corresponding author), Nagoya Univ, Dept Neurosurg, Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	anatsume@med.nagoya-u.ac.jp	TAKAHASHI, Masahide/I-7244-2014; Ohka, Fumiharu/A-3420-2016; MIYATA, TAKAKI/I-7066-2014; Motomura, Kazuya/AAF-8776-2021; Enomoto, Atsushi/I-7272-2014; Natsume, Atsushi/I-7364-2014; Wakabayashi, Toshihiko/I-3526-2012; Takahashi, Masahide/AAN-4770-2020	Motomura, Kazuya/0000-0002-4376-1104; Enomoto, Atsushi/0000-0002-9206-6116; Natsume, Atsushi/0000-0002-9113-0470; Wakabayashi, Toshihiko/0000-0001-5254-2088; Takahashi, Masahide/0000-0002-2803-2683; Ohka, Fumiharu/0000-0002-5569-5626	Grants-in-Aid for Scientific Research [22117005] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Anai M, 2005, J BIOL CHEM, V280, P18525, DOI 10.1074/jbc.M500586200; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Castellino RC, 2007, NAT CLIN PRACT NEURO, V3, P682, DOI 10.1038/ncpneuro0661; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Enomoto A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001; Enomoto A, 2009, NEURON, V63, P774, DOI 10.1016/j.neuron.2009.08.015; Eyler CE, 2008, STEM CELLS, V26, P3027, DOI 10.1634/stemcells.2007-1073; Gunther HS, 2008, ONCOGENE, V27, P2897, DOI 10.1038/sj.onc.1210949; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Jiang P, 2008, CANCER RES, V68, P1310, DOI 10.1158/0008-5472.CAN-07-5111; Kato H, 2008, LAB INVEST, V88, P731, DOI 10.1038/labinvest.2008.42; Kim JY, 2009, NEURON, V63, P761, DOI 10.1016/j.neuron.2009.08.008; Kitamura T, 2008, NAT CELL BIOL, V10, P329, DOI 10.1038/ncb1695; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Matsumoto K, 2009, CANCER RES, V69, P7160, DOI 10.1158/0008-5472.CAN-09-1289; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252; Sonoda Y, 2001, CANCER RES, V61, P6674; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wakimoto H, 2009, CANCER RES, V69, P3472, DOI 10.1158/0008-5472.CAN-08-3886; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Yuki K, 2009, CANCER LETT, V284, P71, DOI 10.1016/j.canlet.2009.04.020; Zhang BB, 2009, INT J CANCER, V125, P585, DOI 10.1002/ijc.24314	28	62	66	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	22					2715	2724		10.1038/onc.2011.466	http://dx.doi.org/10.1038/onc.2011.466			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	952DB	22020337				2022-12-17	WOS:000304769000002
J	Noetzel, E; Rose, M; Bornemann, J; Gajewski, M; Knuchel, R; Dahl, E				Noetzel, E.; Rose, M.; Bornemann, J.; Gajewski, M.; Knuechel, R.; Dahl, E.			Nuclear transport receptor karyopherin-alpha 2 promotes malignant breast cancer phenotypes in vitro	ONCOGENE			English	Article						KPNA2; colony spreading; migration; adhesion; human breast cancer	GENE-EXPRESSION DATA; NF-KAPPA-B; CELL-MIGRATION; IMPORTIN-ALPHA; PROGNOSTIC MARKER; OVARIAN-CANCER; TUMOR; CARCINOMA; P53; OVEREXPRESSION	Tumorigenesis and tumor progression are associated with dysfunction of the nuclear transport machinery at the level of import and export receptors (karyopherins). Recent studies have shown that the nuclear import factor karyopherin-alpha 2 (KPNA2) is a novel prognostic marker for poor prognosis in human breast cancer. Based on the well-defined hallmarks of cancer progression, we performed a detailed in vitro characterization of the phenotypic effects caused by KPNA2 overexpression and KPNA2 silencing in benign and malignant human breast cells. KPNA2 overexpression clearly increased proliferation of MCF7 tumor cells and further led to a reduction of cell-matrix adhesion in benign MCF10A cells, whereas cell migration was significantly increased (P<0.0001) in both tumor models. Remarkably, these individual effects of KPNA2 overexpression on proliferation, cell-matrix adhesion and migration resulted in an increased colony spreading of benign MCF10A breast cells and malignant MCF7 tumor cells (P<0.001), which is a hallmark of cancer progression. Conversely, RNA interference-mediated KPNA2 silencing caused a complete inhibition of MCF7 tumor cell proliferation and migration (P<0.0001). In addition, in these experiments apoptosis was increased (P<0.05) and formation of tumor cell colonies was reduced (P<0.01). Thus, KPNA2 overexpression provoked increased aggressiveness of malignant MCF7 breast tumor cells and induced a shift in benign MCF10A breast cells toward a malignant breast cancer phenotype. In conclusion, we demonstrate for the first time in experimental tumor models that forced KPNA2 expression drives malignant features relevant for breast cancer progression, while its silencing is required for the remission of those progressive phenotypes. This study gives clear evidence that KPNA2 acts as a novel oncogenic factor in human breast cancer, in vitro. Oncogene (2012) 31, 2101-2114; doi: 10.1038/onc.2011.403; published online 12 September 2011	[Noetzel, E.; Rose, M.; Gajewski, M.; Knuechel, R.; Dahl, E.] Rhein Westfal TH Aachen, Fac Med, Inst Pathol, Mol Oncol Grp, Aachen, Germany; [Bornemann, J.] Rhein Westfal TH Aachen, Fac Med, Electron Microscop Facil, Aachen, Germany	RWTH Aachen University; RWTH Aachen University	Dahl, E (corresponding author), Rhein Westfal TH Aachen, Univ Hosp, Inst Pathol, Mol Oncol Grp, Pauwelsstr 30, D-52074 Aachen, Germany.	edahl@ukaachen.de	Noetzel-Reiss, Erik/GYV-0999-2022	Noetzel-Reiss, Erik/0000-0003-3163-6848	Mediacal Faculty of the RWTH Aachen (START)	Mediacal Faculty of the RWTH Aachen (START)	The excellent technical assistance of Sonja von Serenyi is thankfully acknowledged. This work was supported by a grant from the Mediacal Faculty of the RWTH Aachen (START program 'Tumor marker and their function' Project 1: Inflammation and Cancer).	Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Brunet Anne, 1995, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V189, P43; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Cunningham MD, 2003, BIOCHEM BIOPH RES CO, V300, P403, DOI 10.1016/S0006-291X(02)02863-2; Dahl E, 2005, J PATHOL, V205, P21, DOI 10.1002/path.1687; Dahl E, 2006, CLIN CANCER RES, V12, P3950, DOI 10.1158/1078-0432.CCR-05-2090; Dankof A, 2007, VIRCHOWS ARCH, V451, P877, DOI 10.1007/s00428-007-0513-5; Ezeh UI, 2005, CANCER-AM CANCER SOC, V104, P2255, DOI 10.1002/cncr.21432; Flamini G, 1996, EUR J CANCER, V32A, P802, DOI 10.1016/0959-8049(95)00625-7; Gluz O, 2008, INT J CANCER, V123, P1433, DOI 10.1002/ijc.23628; Goldfarb DS, 2004, TRENDS CELL BIOL, V14, P505, DOI 10.1016/j.tcb.2004.07.016; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; HALL PA, 1990, J PATHOL, V162, P285, DOI 10.1002/path.1711620403; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harreman MT, 2003, J BIOL CHEM, V278, P21361, DOI 10.1074/jbc.M301114200; Hu TS, 2008, CANCER RES, V68, P6533, DOI 10.1158/0008-5472.CAN-07-6642; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274; Klein A, 2007, INT J CANCER, V121, P683, DOI 10.1002/ijc.22630; Lange A, 2007, J BIOL CHEM, V282, P5101, DOI 10.1074/jbc.R600026200; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lu WG, 2000, ONCOGENE, V19, P232, DOI 10.1038/sj.onc.1203262; Mayhew TM, 2009, ANN ANAT, V191, P153, DOI 10.1016/j.aanat.2008.11.001; Mortezavi A, 2011, CLIN CANCER RES, V17, P1111, DOI 10.1158/1078-0432.CCR-10-0081; Mosammaparast N, 2004, TRENDS CELL BIOL, V14, P547, DOI 10.1016/j.tcb.2004.09.004; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Noetzel E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-154; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Pankov R, 2005, J CELL BIOL, V170, P793, DOI 10.1083/jcb.200503152; Paris S, 2002, INT J CANCER, V97, P615, DOI 10.1002/ijc.10120; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Runnebaum IB, 1996, GYNECOL ONCOL, V61, P266, DOI 10.1006/gyno.1996.0137; Sakai M, 2010, ANTICANCER RES, V30, P851; Sandrock K, 2010, TRAFFIC, V11, P198, DOI 10.1111/j.1600-0854.2009.01015.x; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Stuart-Harris R, 2008, BREAST, V17, P323, DOI 10.1016/j.breast.2008.02.002; Veeck J, 2008, ONCOGENE, V27, P865, DOI 10.1038/sj.onc.1210669; Wang CI, 2011, INT J CANCER, V128, P2364, DOI 10.1002/ijc.25568	44	62	65	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2012	31	16					2101	2114		10.1038/onc.2011.403	http://dx.doi.org/10.1038/onc.2011.403			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21909132				2022-12-17	WOS:000303008600010
J	Mullany, LK; Fan, HY; Liu, Z; White, LD; Marshall, A; Gunaratne, P; Anderson, ML; Creighton, CJ; Xin, L; Deavers, M; Wong, KK; Richards, JS				Mullany, L. K.; Fan, H-Y; Liu, Z.; White, L. D.; Marshall, A.; Gunaratne, P.; Anderson, M. L.; Creighton, C. J.; Xin, L.; Deavers, M.; Wong, K-K; Richards, J. S.			Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo	ONCOGENE			English	Article						Kras; Pten; Trp53; ovarian cancer; serous	GENE-EXPRESSION PROFILES; SEROUS CARCINOMA; GRANULOSA-CELLS; PATHWAY ACTIVATION; WNT/BETA-CATENIN; K-RAS; CANCER; P53; ORIGIN; PROLIFERATION	Ovarian cancer is a complex and deadly disease that remains difficult to detect at an early curable stage. Furthermore, although some oncogenic (Kras, Pten/PI3K and Trp53) pathways that are frequently mutated, deleted or amplified in ovarian cancer are known, how these pathways initiate and drive specific morphological phenotypes and tumor outcomes remain unclear. We recently generated Pten(fl/fl); Kras(G12D); Amhr2-Cre mice to disrupt the Pten gene and express a stable mutant form of Kras(G12D) in ovarian surface epithelial (OSE) cells. On the basis of histopathologic criteria, the mutant mice developed low-grade ovarian serous papillary adenocarcinomas at an early age and with 100% penetrance. This highly reproducible phenotype provides the first mouse model in which to study this ovarian cancer subtype. OSE cells isolated from ovaries of mutant mice at 5 and 10 weeks of age exhibit temporal changes in the expression of specific Mullerian epithelial marker genes, grow in soft agar and develop ectopic invasive tumors in recipient mice, indicating that the cells are transformed. Gene profiling identified specific mRNAs and microRNAs differentially expressed in purified OSE cells derived from tumors of the mutant mice compared with wild-type OSE cells. Mapping of transcripts or genes between the mouse OSE mutant data sets, the Kras signature from human cancer cell lines and the human ovarian tumor array data sets, documented significant overlap, indicating that KRAS is a key driver of OSE transformation in this context. Two key hallmarks of the mutant OSE cells in these mice are the elevated expression of the tumor-suppressor Trp53 (p53) and its microRNA target, miR-34a-c. We propose that elevated TRP53 and miR-34a-c may exert negatively regulatory effects that reduce the proliferative potential of OSE cells leading to the low-grade serous adenocarcinoma phenotype. Oncogene (2011) 30, 3522-3536; doi:10.1038/onc.2011.70; published online 21 March 2011	[Mullany, L. K.; Fan, H-Y; Liu, Z.; Marshall, A.; Xin, L.; Richards, J. S.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [White, L. D.; Creighton, C. J.] Baylor Coll Med, Dept Mol & Human Genet & Mol & Cellular Biol, Houston, TX 77030 USA; [White, L. D.; Creighton, C. J.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Gunaratne, P.] Univ Houston, Dept Biol & Biochem, Houston, TX USA; [Anderson, M. L.] Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; [Deavers, M.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Wong, K-K] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Houston System; University of Houston; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Richards, JS (corresponding author), Baylor Coll Med BCM130, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	joanner@bcm.tmc.edu	Parry, Lee/A-9623-2011; Wong, K.-k./AAA-6589-2020; Anderson, Matthew/C-4755-2019	Parry, Lee/0000-0002-4467-9196; Wong, K.-k./0000-0002-0375-6669; Anderson, Matthew/0000-0002-2081-4672; Marshall, Alexandra/0000-0003-4888-643X	NRSA; Ovarian Cancer Research Fund; The University of Texas MD Anderson Cancer Center [P50 CA08369];  [NIH-HD-16229]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD016229, U54HD007495] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016229, R56HD016229] Funding Source: NIH RePORTER	NRSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ovarian Cancer Research Fund; The University of Texas MD Anderson Cancer Center; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We Alan J Herron DVM, Professor and Head of the Comparative Pathology Laboratory for his advice and insights into the mouse ovarian tumor phenotype, Yuet Lo and Azam Zariff for technical assistance and the Microscopy Core at Baylor College of Medicine for their expertise. We also thank the Immunohistochemistry Laboratory at The University of Texas MD Anderson Cancer Center for performing the calretinin and ESR1 immunostaining. Supported in part by NIH-HD-16229 (JSR), NRSA (LM), a Program Project Development Grant from the Ovarian Cancer Research Fund (CJC, PG, MA) and The University of Texas MD Anderson Cancer Center Specialized Program of Research Excellence in Ovarian Cancer (P50 CA08369) (KKW).	Abdullah M, 2009, PATHOL RES PRACT, V205, P639, DOI 10.1016/j.prp.2009.04.007; Astanehe A, 2008, J CELL SCI, V121, P664, DOI 10.1242/jcs.013029; Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255; Auersperg N, 2008, GYNECOL ONCOL, V110, P452, DOI 10.1016/j.ygyno.2008.05.031; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Bohlig L, 2008, CELL CYCLE, V7, P1254, DOI 10.4161/cc.7.9.5812; Bowen NJ, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-71; Cheng WJ, 2005, NAT MED, V11, P531, DOI 10.1038/nm1230; Cho KR, 2009, ARCH PATHOL LAB MED, V133, P1775, DOI 10.1043/1543-2165-133.11.1775; Cho KR, 2009, ANNU REV PATHOL-MECH, V4, P287, DOI 10.1146/annurev.pathol.4.110807.092246; Clark-Knowles KV, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008534; Connolly DC, 2003, CANCER RES, V63, P1389; Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585; Corney DC, 2010, CLIN CANCER RES, V16, P1119, DOI 10.1158/1078-0432.CCR-09-2642; Costa BM, 2010, CANCER RES, V70, P453, DOI 10.1158/0008-5472.CAN-09-2189; Creighton CJ, 2010, CANCER RES, V70, P1906, DOI 10.1158/0008-5472.CAN-09-3875; Crum CP, 2007, CLIN MED RES, V5, P35, DOI 10.3121/cmr.2007.702; DAHLYA N, 2008, PLOS ONE, V3, P1; Despierre E, 2010, GYNECOL ONCOL, V117, P358, DOI 10.1016/j.ygyno.2010.02.012; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Dubeau L, 2008, LANCET ONCOL, V9, P1191, DOI 10.1016/S1470-2045(08)70308-5; Fan HY, 2008, DEVELOPMENT, V135, P2127, DOI 10.1242/dev.020560; Fan HY, 2009, CANCER RES, V69, P6463, DOI 10.1158/0008-5472.CAN-08-3363; Fan HY, 2009, SCIENCE, V324, P938, DOI 10.1126/science.1171396; Flesken-Nikitin A, 2003, CANCER RES, V63, P3459; Gaval N, 2008, J MOL ENDOCRINOL, V40, P281, DOI 10.1677/JME-07-0149; Gorringe KL, 2009, MOL ONCOL, V3, P157, DOI 10.1016/j.molonc.2008.12.005; *GSK, 2008, CANC CELL LIN GEN PR; Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Jamin SP, 2002, NAT GENET, V32, P408, DOI 10.1038/ng1003; Ji Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006816; KAPLINAS K, 2009, J CELL BIOCHEM, V108, P216; Karst AM, 2010, J ONCOL, V2010, DOI 10.1155/2010/932371; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; Ko SY, 2010, MOL CELL ENDOCRINOL, V317, P112, DOI 10.1016/j.mce.2009.12.025; Kobel M, 2008, PLOS MED, V5, P1749, DOI 10.1371/journal.pmed.0050232; Konstantinopoulos PA, 2008, NAT CLIN PRACT ONCOL, V5, P577, DOI 10.1038/ncponc1178; Krichevsky AM, 2009, J CELL MOL MED, V13, px, DOI 10.1111/j.1582-4934.2008.00556.x; Kurman RJ, 2010, AM J SURG PATHOL, V34, P433, DOI 10.1097/PAS.0b013e3181cf3d79; Lague MN, 2008, CARCINOGENESIS, V29, P2062, DOI 10.1093/carcin/bgn186; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lee Y, 2007, J PATHOL, V211, P26, DOI 10.1002/path.2091; Liang S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004295; Malpica A, 2004, AM J SURG PATHOL, V28, P496, DOI 10.1097/00000478-200404000-00009; Miller KA, 2009, CANCER RES, V69, P3689, DOI 10.1158/0008-5472.CAN-09-0024; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; PAGE CL, 2006, BRIT J CANCER, V94, P436; Park SY, 2009, NAT STRUCT MOL BIOL, V16, P23, DOI 10.1038/nsmb.1533; Raimondi AR, 2009, CANCER RES, V69, P4159, DOI 10.1158/0008-5472.CAN-08-4645; Roh MH, 2010, MODERN PATHOL, V23, P1316, DOI 10.1038/modpathol.2010.119; Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007; Rybak A, 2008, NAT CELL BIOL, V10, P987, DOI 10.1038/ncb1759; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Santin AD, 2004, INT J CANCER, V112, P14, DOI 10.1002/ijc.20408; Schwartz DR, 2002, CANCER RES, V62, P4722; Stefani G, 2008, NAT REV MOL CELL BIO, V9, P219, DOI 10.1038/nrm2347; Wang DZ, 2010, NAT REV CANCER, V10, P181, DOI 10.1038/nrc2809; Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; Wong KK, 2007, INT J GYNECOL PATHOL, V26, P404, DOI 10.1097/pgp.0b013e31803025cd; Wu R, 2007, CANCER CELL, V11, P321, DOI 10.1016/j.ccr.2007.02.016; Wyman SK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005311; Xing D, 2009, CANCER RES, V69, P8231, DOI 10.1158/0008-5472.CAN-09-2543; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Zhang CC, 2006, NAT MED, V12, P240, DOI 10.1038/nm1342; Zhao Z, 2010, GENE DEV, V24, P1389, DOI 10.1101/gad.1940710	68	62	64	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	32					3522	3536		10.1038/onc.2011.70	http://dx.doi.org/10.1038/onc.2011.70			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806CR	21423204	Green Accepted			2022-12-17	WOS:000293782300005
J	Wani, AA; Jafarnejad, SM; Zhou, J; Li, G				Wani, A. A.; Jafarnejad, S. M.; Zhou, J.; Li, G.			Integrin-linked kinase regulates melanoma angiogenesis by activating NF-kappa B/interleukin-6 signaling pathway	ONCOGENE			English	Article						ILK; angiogenesis; melanoma; NF-kappa B; IL-6; VEGF	ENDOTHELIAL GROWTH-FACTOR; NF-KAPPA-B; GLYCOGEN-SYNTHASE KINASE; PROSTATE-CANCER CELLS; PROTEIN-KINASE; DEPENDENT ANGIOGENESIS; EXPRESSION INCREASES; EXTRACELLULAR-MATRIX; TRANSCRIPTION FACTOR; TUMOR ANGIOGENESIS	Integrin-linked kinase (ILK) is a highly conserved serine-threonine protein kinase involved in cell-extracellular matrix interactions, cytoskeletal organization and cell signaling. Overexpression of ILK in epithelial cells leads to anchorage-independent growth with increased cell cycle progression. Previously, we have shown that ILK upregulation strongly correlates with melanoma progression, invasion and inversely correlates with 5-year survival of melanoma patients. However, the molecular mechanism by which ILK enhances melanoma progression is currently unknown. In the present study, we found that proangiogenic molecule interleukin-6 (IL-6) is the downstream target of ILK in melanoma cells. ILK overexpression increased IL-6, whereas silencing of ILK suppressed IL-6 expression at both messenger RNA and protein levels. ILK also altered the activity and subcellular localization of nuclear factor-kappaB (NF-kappa B) subunit p65. We further found that ILK enhanced the IL-6 gene transcription by promoting the binding of NF-kB p65 to IL-6 promoter. Moreover, ILK overexpression in melanoma cells enhanced the tube-forming ability of endothelial cells in vitro and microvessel formation in vivo. ILK-induced tube and blood vessel formation of endothelial cells was significantly reduced upon IL-6 inhibition in ILK-overexpressing melanoma cells. To delineate the mechanism by which ILK-induced IL-6 production can enhance angiogenesis, further analysis of the downstream targets of IL-6 signaling showed an increased activity of the signal transducer and activator of transcription 3 (STAT3) in ILK-overexpressing cells. As STAT3 binds to vascular endothelial growth factor (VEGF) promoter, we found that VEGF levels were elevated in ILK-overexpressing cells and declined upon transfection of IL-6 small interfering RNA, suggesting that ILK may regulate VEGF expression through IL-6 pathway by activating STAT3. Oncogene (2011) 30, 2778-2788; doi: 10.1038/onc.2010.644; published online 31 January 2011	[Wani, A. A.; Jafarnejad, S. M.; Li, G.] Univ British Columbia, Vancouver Coastal Hlth Res Inst, Jack Bell Res Ctr, Dept Dermatol & Skin Sci, Vancouver, BC V6H 3Z6, Canada; [Zhou, J.] Nanjing Med Univ, Sch Publ Hlth, Ctr Canc, Dept Mol Cell Biol & Toxicol, Nanjing, Peoples R China	University of British Columbia; Vancouver Coastal Health Research Institute; Nanjing Medical University	Li, G (corresponding author), Univ British Columbia, Vancouver Coastal Hlth Res Inst, Jack Bell Res Ctr, Dept Dermatol & Skin Sci, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.	gangli@interchange.ubc.ca	Li, Gang/A-8257-2011	Jafarnejad, Seyed Mehdi/0000-0002-5129-7081	Canadian Institutes of Health Research [MOP-84559, MOP-93810]; Cancer Research Society; Canadian Dermatology Foundation; Michael Smith Foundation for Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Cancer Research Society; Canadian Dermatology Foundation; Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research)	We thank Drs R Byers and AP Albinos for providing melanoma cell lines, Dr M Garate and Mr K Assi for valuable suggestions, and Dr S Hendy for technical assistance. This study was supported by the Canadian Institutes of Health Research (MOP-84559 and MOP-93810), the Cancer Research Society and the Canadian Dermatology Foundation to GL. AAW is supported by the Postdoctoral Fellowship from Michael Smith Foundation for Health Research.	Adachi Y, 2006, INT J CANCER, V119, P1303, DOI 10.1002/ijc.22006; Ahmed N, 2003, J PATHOL, V201, P229, DOI 10.1002/path.1441; Bravou V, 2003, BRIT J CANCER, V89, P2340, DOI 10.1038/sj.bjc.6601482; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dai DL, 2003, CLIN CANCER RES, V9, P4409; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Delrieu I, 1999, BIOCHEM J, V340, P201, DOI 10.1042/0264-6021:3400201; Dutcher J P, 2001, Curr Oncol Rep, V3, P353, DOI 10.1007/s11912-001-0089-1; Gao K, 2006, CANCER RES, V66, P8382, DOI 10.1158/0008-5472.CAN-05-4402; Graff JR, 2001, CLIN CANCER RES, V7, P1987; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hershko DD, 2002, AM J PHYSIOL-REG I, V283, pR1140, DOI 10.1152/ajpregu.00161.2002; Hoek K, 2004, CANCER RES, V64, P5270, DOI 10.1158/0008-5472.CAN-04-0731; Houghton AN, 2002, CANCER CELL, V2, P275, DOI 10.1016/S1535-6108(02)00161-7; Huang SP, 2004, J BIOMED SCI, V11, P517, DOI 10.1159/000077902; Ito R, 2003, VIRCHOWS ARCH, V442, P118, DOI 10.1007/s00428-002-0718-6; Jee SH, 2004, J INVEST DERMATOL, V123, P1169, DOI 10.1111/j.0022-202X.2004.23497.x; Jerant AF, 2000, AM FAM PHYSICIAN, V62, P357; Karst AM, 2009, INT J CANCER, V124, P494, DOI 10.1002/ijc.23973; Koul D, 2005, MOL CANCER THER, V4, P1681, DOI 10.1158/1535-7163.MCT-05-0258; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Loeffler S, 2005, INT J CANCER, V115, P202, DOI 10.1002/ijc.20871; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Mahnke JL, 2000, FERTIL STERIL, V73, P166, DOI 10.1016/S0015-0282(99)00466-5; Matsui H, 1999, CARDIOVASC RES, V42, P104, DOI 10.1016/S0008-6363(98)00285-5; Mouawad R, 2002, CYTOKINES CELL MOL T, V7, P151, DOI 10.1080/13684730210002328; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Ries LAG, 2000, CANCER-AM CANCER SOC, V88, P2398, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2398::AID-CNCR26>3.0.CO;2-I; Saidi A, 2009, INT J CANCER, V125, P1054, DOI 10.1002/ijc.24380; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Tan C, 2002, J BIOL CHEM, V277, P3109, DOI 10.1074/jbc.M108673200; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Watanabe M, 2005, BIOL PROCED ONLINE, V7, P41, DOI 10.1251/bpo104; Wei LH, 2003, ONCOGENE, V22, P1517, DOI 10.1038/sj.onc.1206226; Wong RPC, 2007, MOL CANCER THER, V6, P1692, DOI 10.1158/1535-7163.MCT-07-0134; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Xiao WH, 2004, PROSTATE, V61, P354, DOI 10.1002/pros.20113	48	62	69	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	24					2778	2788		10.1038/onc.2010.644	http://dx.doi.org/10.1038/onc.2010.644			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778DB	21278793				2022-12-17	WOS:000291678500008
J	Ehata, S; Johansson, E; Katayama, R; Koike, S; Watanabe, A; Hoshino, Y; Katsuno, Y; Komuro, A; Koinuma, D; Kano, MR; Yashiro, M; Hirakawa, K; Aburatani, H; Fujita, N; Miyazono, K				Ehata, S.; Johansson, E.; Katayama, R.; Koike, S.; Watanabe, A.; Hoshino, Y.; Katsuno, Y.; Komuro, A.; Koinuma, D.; Kano, M. R.; Yashiro, M.; Hirakawa, K.; Aburatani, H.; Fujita, N.; Miyazono, K.			Transforming growth factor-beta decreases the cancer-initiating cell population within diffuse-type gastric carcinoma cells	ONCOGENE			English	Article						ABCG2; cancer-initiating cell; diffuse type gastric carcinoma; SP cell; TGF-beta	STEM-CELLS; TGF-BETA; SIDE-POPULATION; SCIRRHOUS CARCINOMA; METASTATIC MODEL; TUMOR-GROWTH; PROTEIN; GROWTH-FACTOR-BETA-1; DIFFERENTIATION; OVEREXPRESSION	Stem cells in normal tissues and cancer-initiating cells (CICs) are known to be enriched in side population (SP) cells. However, the factors responsible for the regulation of expression of ABCG2, involved in efflux of dyes, in SP cells have not been fully investigated. Here, we characterized the SP cells within diffuse-type gastric carcinoma, and examined the effects of transforming growth factor-beta (TGF-beta) on SP cells. Diffuse-type gastric carcinoma cells established from four independent patients universally contained SP cells between 1 and 4% of total cells, which displayed greater tumorigenicity than non-SP cells did. TGF-beta repressed the transcription of ABCG2 through direct binding of Smad2/3 to its promoter/enhancer, and the number of SP cells and the tumor-forming ability of cancer cells were decreased by TGF-beta, although ABCG2 is not directly involved in the tumor-forming ability of SP cells. Cancer cells from metastatic site expressed much higher levels of ABCG2 and included a greater percentage of SP cells than parental cancer cells did. SP cells are thus responsible for the progression of diffuse-type gastric carcinoma, and TGF-beta negatively contributes to maintain the CICs within the cancer. Oncogene (2011) 30, 1693-1705; doi:10.1038/onc.2010.546; published online 6 December 2010	[Ehata, S.; Johansson, E.; Hoshino, Y.; Katsuno, Y.; Komuro, A.; Koinuma, D.; Kano, M. R.; Miyazono, K.] Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo 1130033, Japan; [Ehata, S.; Katayama, R.; Koike, S.; Fujita, N.] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Koto Ku, Tokyo 170, Japan; [Watanabe, A.; Aburatani, H.] Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Meguro Ku, Tokyo, Japan; [Yashiro, M.; Hirakawa, K.] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Abeno Ku, Osaka 558, Japan	University of Tokyo; Japanese Foundation for Cancer Research; University of Tokyo; Osaka Metropolitan University	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono@m.u-tokyo.ac.jp	Koinuma, Daizo/Y-8716-2018; Katayama, Ryohei/K-8537-2014; Fujita, Naoya/A-7349-2010	Koinuma, Daizo/0000-0001-5611-2122; Katayama, Ryohei/0000-0001-7394-895X; Fujita, Naoya/0000-0002-9631-9264; Ehata, Shogo/0000-0002-6740-9391; Kano, Mitsunobu/0000-0003-1593-1855	Ministry of Education, Culture, Sports, Science and Technology of Japan; Japan Society for the Promotion of Science	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We thank Dr H Miyoshi (RIKEN) for the lentivirus vector system and Dr K Yanagihara (Yasuda Women's University) for HSC-43 cells. This study was supported by Grants-in-Aid for Scientific Research on Priority Areas from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and Grants-in-Aid for Young Scientists (Start-up) from the Japan Society for the Promotion of Science.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Crew KD, 2006, WORLD J GASTROENTERO, V12, P354, DOI 10.3748/wjg.v12.i3.354; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Ehata S, 2007, CANCER RES, V67, P9694, DOI 10.1158/0008-5472.CAN-07-1522; Ehata S, 2007, CANCER SCI, V98, P127, DOI 10.1111/j.1349-7006.2006.00357.x; Fujihara T, 1998, CLIN EXP METASTAS, V16, P389; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Gradhand U, 2008, DRUG METAB REV, V40, P317, DOI [10.1080/03602530801952617, 10.1080/03602530801952617 ]; Grady William M., 2008, P889; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hohenberger P, 2003, LANCET, V362, P305, DOI 10.1016/S0140-6736(03)13975-X; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Inoue T, 1997, JPN J CANCER RES, V88, P152, DOI 10.1111/j.1349-7006.1997.tb00360.x; Iwasaki H, 2009, CANCER SCI, V100, P1166, DOI 10.1111/j.1349-7006.2009.01177.x; Katayama R, 2009, CANCER SCI, V100, P2060, DOI 10.1111/j.1349-7006.2009.01288.x; Kinugasa S, 1998, ONCOLOGY-BASEL, V55, P582, DOI 10.1159/000011916; Kiyono K, 2009, CANCER SCI, V100, P1809, DOI 10.1111/j.1349-7006.2009.01248.x; Koinuma D, 2009, MOL CELL BIOL, V29, P172, DOI 10.1128/MCB.01038-08; Komuro A, 2009, JNCI-J NATL CANCER I, V101, P592, DOI 10.1093/jnci/djp058; LABOISSE CL, 1981, CANCER RES, V41, P310; Lee J, 2008, CANCER CELL, V13, P69, DOI 10.1016/j.ccr.2007.12.005; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mishra L, 2005, ONCOGENE, V24, P5775, DOI 10.1038/sj.onc.1208924; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; MIZOI T, 1993, CANCER RES, V53, P183; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Nishii T, 2009, CANCER SCI, V100, P1397, DOI 10.1111/j.1349-7006.2009.01211.x; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Penuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Rabindran SK, 2000, CANCER RES, V60, P47; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; Sneddon JB, 2006, P NATL ACAD SCI USA, V103, P14842, DOI 10.1073/pnas.0606857103; Stingl J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2212; Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30; Takemura S, 2004, CANCER SCI, V95, P893, DOI 10.1111/j.1349-7006.2004.tb02199.x; Vagenas K, 2007, J SURG RES, V139, P182, DOI 10.1016/j.jss.2006.10.005; Velamakanni S, 2007, J BIOENERG BIOMEMBR, V39, P465, DOI 10.1007/s10863-007-9122-x; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu C, 2008, CANCER LETT, V268, P1, DOI 10.1016/j.canlet.2008.03.048; YANAGIHARA K, 1993, INT J CANCER, V54, P200, DOI 10.1002/ijc.2910540207; YASHIRO M, 1994, JPN J CANCER RES, V85, P883, DOI 10.1111/j.1349-7006.1994.tb02963.x; Yashiro M, 1996, CLIN EXP METASTAS, V14, P43, DOI 10.1007/BF00157685; Yashiro M, 2009, INT J ONCOL, V35, P997, DOI 10.3892/ijo_00000414; Yin LQ, 2008, CANCER RES, V68, P800, DOI 10.1158/0008-5472.CAN-07-2545; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	55	62	64	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	14					1693	1705		10.1038/onc.2010.546	http://dx.doi.org/10.1038/onc.2010.546			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	746IS	21132002				2022-12-17	WOS:000289239400007
J	Prazeres, H; Torres, J; Rodrigues, F; Pinto, M; Pastoriza, MC; Gomes, D; Cameselle-Teijeiro, J; Vidal, A; Martins, TC; Sobrinho-Simoes, M; Soares, P				Prazeres, H.; Torres, J.; Rodrigues, F.; Pinto, M.; Pastoriza, M. C.; Gomes, D.; Cameselle-Teijeiro, J.; Vidal, A.; Martins, T. C.; Sobrinho-Simoes, M.; Soares, P.			Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells	ONCOGENE			English	Article						tumor suppressor gene; low-density lipoprotein receptor family; EP300 histone-acetyltransferase; microRNA; matrix metalloproteinase 2; endocytosis and tumor microenvironment	RECEPTOR-RELATED PROTEIN; TUMOR-SUPPRESSOR GENE; LINKAGE ANALYSIS; SUSCEPTIBILITY LOCUS; DNA METHYLATION; LUNG-CANCER; UROKINASE; CARCINOMA; FAMILY; EXPRESSION	The low-density lipoprotein receptor-related protein (LRP1B), encoding an endocytic LDL-family receptor, is among the 10 most significantly deleted genes across 3312 human cancer specimens. However, currently the apparently crucial role of this lipoprotein receptor in carcinogenesis is not clear. Here we show that LRP1B inactivation (by chromosomal, epigenetic and microRNA (miR)-mediated mechanisms) results in changes to the tumor environment that confer cancer cells an increased growth and invasive capacity. LRP1B displays frequent DNA copy number loss and CpG island methylation, resulting in mRNA underexpression. By using CpG island reporters methylated in vitro, we found that DNA methylation disrupts a functional binding site for the histone-acetyltransferase p300 located at intron 1. We identified and validated an miR targeting LRP1B (miR-548a-5p), which is overexpressed in cancer cell lines as a result of 8q22 DNA gains. Restoration of LRP1B impaired in vitro and in vivo tumor growth, inhibited cell invasion and led to a reduction of matrix metalloproteinase 2 in the extracellular medium. We emphasized the role of an endocytic receptor acting as a tumor suppressor by modulating the extracellular environment composition in a way that constrains the invasive behavior of the cancer cells. Oncogene (2011) 30, 1302-1317; doi:10.1038/onc.2010.512; published online 8 November 2010	[Prazeres, H.; Torres, J.; Pinto, M.; Sobrinho-Simoes, M.; Soares, P.] Univ Porto IPATIMUP, Dept Canc Biol, Inst Mol Pathol & Immunol, P-4200465 Oporto, Portugal; [Prazeres, H.; Sobrinho-Simoes, M.; Soares, P.] Univ Porto, Fac Med, P-4100 Oporto, Portugal; [Prazeres, H.; Martins, T. C.] EPE, Dept Mol Pathol, Serv Portuguese Inst Oncol Coimbra, Coimbra, Portugal; [Rodrigues, F.] EPE, Dept Endocrinol, Serv Portuguese Inst Oncol Coimbra, Coimbra, Portugal; [Pastoriza, M. C.; Vidal, A.] Univ Santiago de Compostela, Inst Sanitary Res IDIS, Dept Physiol, Sch Med, Santiago De Compostela, Spain; [Gomes, D.] EPE, Anat Pathol Serv, Portuguese Inst Oncol Coimbra, Coimbra, Portugal; [Cameselle-Teijeiro, J.] Univ Santiago de Compostela, Dept Anat Pathol, Clin Univ Hosp CHUS, SERGAS, Santiago De Compostela, Spain	Universidade do Porto; Universidade do Porto; Universidade de Coimbra; Universidade de Coimbra; Universidade de Santiago de Compostela; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Universidade de Santiago de Compostela	Soares, P (corresponding author), Univ Porto IPATIMUP, Dept Canc Biol, Inst Mol Pathol & Immunol, Rua Dr Roberto Frias S-N, P-4200465 Oporto, Portugal.	psoares@ipatimup.pt	Sobrinho-Simões, Manuel/J-8290-2013; Soares, Paula/B-6054-2008; Pinto, Marta T/J-2519-2013; Vidal, Anxo/B-5010-2015	Soares, Paula/0000-0001-9607-6998; Pinto, Marta T/0000-0002-8521-2904; Vidal, Anxo/0000-0002-0866-4202; Martins, Teresa/0000-0003-4271-2869; Rodrigues, Fernando/0000-0002-4913-3889; Torres, Joana/0000-0002-5651-4575; Sobrinho-Simoes, Manuel/0000-0003-1613-1235; Prazeres, Hugo/0000-0002-5504-6642	Portuguese Foundation for Science and Technology [SFRH/BD30041/2006, PTDC/SAU-OBD/101242/2008]; Portuguese Society of Endocrinology and Metabolism; Portuguese Ministry of Health [13/2007]; Ministry of Science and Innovation (Instituto de Salud Carlos III), Spain [PS09/02050-FEDER]; Portuguese Foundation for Science and Technology	Portuguese Foundation for Science and Technology(Portuguese Foundation for Science and Technology); Portuguese Society of Endocrinology and Metabolism; Portuguese Ministry of Health; Ministry of Science and Innovation (Instituto de Salud Carlos III), Spain(Instituto de Salud Carlos IIIMinistry of Science and Innovation, Spain (MICINN)Spanish Government); Portuguese Foundation for Science and Technology(Portuguese Foundation for Science and Technology)	We would like to acknowledge funding from grants from the Portuguese Foundation for Science and Technology (SFRH/BD30041/2006 and PTDC/SAU-OBD/101242/2008), the Portuguese Society of Endocrinology and Metabolism (Edward Limber Prize) and the Portuguese Ministry of Health (project 13/2007). Jose Cameselle-Teijeiro was supported by Grant PS09/02050-FEDER, from the Ministry of Science and Innovation (Instituto de Salud Carlos III), Spain. IPATIMUP is an associated laboratory of the Portuguese Ministry of Science, Technology and Higher Education and is partially supported by the Portuguese Foundation for Science and Technology.	ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Asami Y, 2009, J ANTIBIOT, V62, P105, DOI 10.1038/ja.2008.17; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bignell GR, 1997, AM J HUM GENET, V61, P1123, DOI 10.1086/301610; Canzian F, 1998, AM J HUM GENET, V63, P1743, DOI 10.1086/302164; Cavaco BM, 2008, J CLIN ENDOCR METAB, V93, P4426, DOI 10.1210/jc.2008-0449; Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; Dedieu S, 2008, MOL CELL BIOL, V28, P2980, DOI 10.1128/MCB.02238-07; Desrosiers RR, 2006, PEDIATR BLOOD CANCER, V46, P40, DOI 10.1002/pbc.20566; Emonard H, 2005, BIOCHIMIE, V87, P369, DOI 10.1016/j.biochi.2004.11.013; Emonard H, 2004, J BIOL CHEM, V279, P54944, DOI 10.1074/jbc.M406792200; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Gustafsdottir SM, 2007, P NATL ACAD SCI USA, V104, P3067, DOI 10.1073/pnas.0611229104; Hagedorn M, 2005, P NATL ACAD SCI USA, V102, P1643, DOI 10.1073/pnas.0408622102; Hahn-Dantona E, 2001, J BIOL CHEM, V276, P15498, DOI 10.1074/jbc.M100121200; He HL, 2009, CANCER RES, V69, P625, DOI 10.1158/0008-5472.CAN-08-1071; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI13992; Horlings HM, 2010, CLIN CANCER RES, V16, P651, DOI 10.1158/1078-0432.CCR-09-0709; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Knisely JM, 2007, EXP CELL RES, V313, P3298, DOI 10.1016/j.yexcr.2007.05.026; Kohno T, 2010, GENE CHROMOSOME CANC, V49, P342, DOI 10.1002/gcc.20746; Li YH, 2002, J BIOL CHEM, V277, P42366, DOI 10.1074/jbc.M207705200; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Liu CX, 2007, J BIOL CHEM, V282, P7504, DOI 10.1074/jbc.M608088200; Liu CX, 2000, GENOMICS, V69, P271, DOI 10.1006/geno.2000.6331; Liu CX, 2000, CANCER RES, V60, P1961; Liu CX, 2001, J BIOL CHEM, V276, P28889, DOI 10.1074/jbc.M102727200; Malchoff CD, 2000, J CLIN ENDOCR METAB, V85, P1758, DOI 10.1210/jc.85.5.1758; Malone CS, 2001, P NATL ACAD SCI USA, V98, P10404, DOI 10.1073/pnas.181206898; Marschang P, 2004, MOL CELL BIOL, V24, P3782, DOI 10.1128/MCB.24.9.3782-3793.2004; Mateus AR, 2009, EXP CELL RES, V315, P1393, DOI 10.1016/j.yexcr.2009.02.020; May P, 2007, ANN MED, V39, P219, DOI 10.1080/07853890701214881; McKay JD, 2001, AM J HUM GENET, V69, P440, DOI 10.1086/321979; Muraoka M, 1996, ONCOGENE, V12, P1565; Nagel R, 2008, CANCER RES, V68, P5795, DOI 10.1158/0008-5472.CAN-08-0951; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; Prazeres HJ, 2008, FAM CANCER, V7, P141, DOI 10.1007/s10689-007-9160-x; Ribeiro AS, 2010, ONCOGENE, V29, P392, DOI 10.1038/onc.2009.338; Ribeiro FR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-371; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; Roy R, 2009, J CLIN ONCOL, V27, P5287, DOI 10.1200/JCO.2009.23.5556; Schweppe RE, 2008, J CLIN ENDOCR METAB, V93, P4331, DOI 10.1210/jc.2008-1102; Shiroshima T, 2009, FEBS LETT, V583, P43, DOI 10.1016/j.febslet.2008.11.045; Song H, 2009, CANCER RES, V69, P879, DOI 10.1158/0008-5472.CAN-08-3379; Stankov K, 2004, INT J CANCER, V111, P463, DOI 10.1002/ijc.20259; Suh I, 2009, SURGERY, V146, P1073, DOI 10.1016/j.surg.2009.09.012; Tanaga K, 2004, ARTERIOSCL THROM VAS, V24, P1422, DOI 10.1161/01.ATV.0000133607.80554.09; TOTH M, 1990, J MOL BIOL, V214, P673, DOI 10.1016/0022-2836(90)90285-T; Ulisse S, 2009, CURR CANCER DRUG TAR, V9, P32, DOI 10.2174/156800909787314002; Walker LC, 2008, GENE CHROMOSOME CANC, V47, P405, DOI 10.1002/gcc.20545; Woodcock DM, 1997, J BIOL CHEM, V272, P7810, DOI 10.1074/jbc.272.12.7810; Yang ZT, 2001, J BIOL CHEM, V276, P8403, DOI 10.1074/jbc.M008925200	55	62	64	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	11					1302	1317		10.1038/onc.2010.512	http://dx.doi.org/10.1038/onc.2010.512			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	736JX	21057533	Green Published			2022-12-17	WOS:000288492100005
J	Yu, J; Cao, Q; Yu, J; Wu, L; Dallol, A; Li, J; Chen, G; Grasso, C; Cao, X; Lonigro, RJ; Varambally, S; Mehra, R; Palanisamy, N; Wu, JY; Latif, F; Chinnaiyan, AM				Yu, J.; Cao, Q.; Yu, J.; Wu, L.; Dallol, A.; Li, J.; Chen, G.; Grasso, C.; Cao, X.; Lonigro, R. J.; Varambally, S.; Mehra, R.; Palanisamy, N.; Wu, J. Y.; Latif, F.; Chinnaiyan, A. M.			The neuronal repellent SLIT2 is a target for repression by EZH2 in prostate cancer	ONCOGENE			English	Article						polycomb group proteins; EZH2; SLIT2; prostate cancer; epigenetic silencing; DNA hypermethylation	FREQUENT EPIGENETIC INACTIVATION; GROUP PROTEIN EZH2; CONTROL CELL FATE; EXPRESSION SIGNATURE; SQUAMOUS-CELL; BETA-CATENIN; E-CADHERIN; GENE; POLYCOMB; TUMOR	The neuronal repellent SLIT2 is repressed in a number of cancer types primarily through promoter hypermethylation. SLIT2, however, has not been studied in prostate cancer. Through genome-wide location analysis we identified SLIT2 as a target of polycomb group (PcG) protein EZH2. The EZH2-containing polycomb repressive complexes bound to the SLIT2 promoter inhibiting its expression. SLIT2 was downregulated in a majority of metastatic prostate tumors, showing a negative correlation with EZH2. This repressed expression could be restored by methylation inhibitors or EZH2-suppressing compounds. In addition, a low level of SLIT2 expression was associated with aggressive prostate, breast and lung cancers. Functional assays showed that SLIT2 inhibited prostate cancer cell proliferation and invasion. Thus, this study showed for the first time the epigenetic silencing of SLIT2 in prostate tumors, and supported SLIT2 as a potential biomarker for aggressive solid tumors. Importantly, PcG-mediated repression may serve as a precursor for the silencing of SLIT2 by DNA methylation in cancer. Oncogene (2010) 29, 5370-5380; doi: 10.1038/onc.2010.269; published online 12 July 2010	[Chinnaiyan, A. M.] Univ Michigan, Sch Med, Howard Hughes Med Inst, Dept Pathol & Urol, Ann Arbor, MI 48109 USA; [Yu, J.; Wu, L.; Wu, J. Y.] Northwestern Univ, Div Hematol Oncol, Dept Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; [Yu, J.; Cao, Q.; Yu, J.; Li, J.; Chen, G.; Grasso, C.; Cao, X.; Lonigro, R. J.; Varambally, S.; Mehra, R.; Palanisamy, N.; Chinnaiyan, A. M.] Univ Michigan, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA; [Yu, J.; Cao, Q.; Grasso, C.; Cao, X.; Varambally, S.; Mehra, R.; Palanisamy, N.; Chinnaiyan, A. M.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Yu, J.; Lonigro, R. J.; Chinnaiyan, A. M.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Dallol, A.; Latif, F.] Univ Birmingham, Inst Biomed Res, Dept Med & Mol Genet, Edgbaston, England; [Chinnaiyan, A. M.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA; [Wu, J. Y.] Northwestern Univ, Dept Neurol, Lurie Comprehens Canc Ctr, Ctr Genet Med, Chicago, IL 60611 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Birmingham; University of Michigan System; University of Michigan; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Chinnaiyan, AM (corresponding author), Univ Michigan, Sch Med, Howard Hughes Med Inst, Dept Pathol & Urol, 1500 E Med Ctr Dr,5410 CCGC, Ann Arbor, MI 48109 USA.	jindan-yu@northwestern.edu; arul@umich.edu	Dallol, Ashraf/H-8661-2012; Palanisamy, Nallasivam/ABC-8844-2020; Cao, Qi/A-5517-2010; WU, Longtao/G-6477-2014; Chen, Guoan/J-9140-2018	Dallol, Ashraf/0000-0002-8803-228X; Palanisamy, Nallasivam/0000-0002-0633-9772; Cao, Qi/0000-0002-5140-3681; WU, Longtao/0000-0003-3463-4127; Chen, Guoan/0000-0001-5608-6761; Varambally, Sooryanarayana/0000-0002-2277-1127	NIH [P50CA69568, P50CA090386, 1R01CA132874-01A1, CA114197, CA107193, K99CA129565-01A1]; Early Detection Research Network [UO1 111275]; US Department of Defense [PC051081, PC080665]; James S McDonnell Foundation; Searle Foundation; Doris Duke Charitable Foundation; Prostate Cancer Foundation; Howard Hughes Medical Institute; NATIONAL CANCER INSTITUTE [R00CA129565, P50CA069568, U01CA111275, R01CA107193, P50CA090386, R01CA132874, R01CA114197, K99CA129565] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Early Detection Research Network; US Department of Defense(United States Department of Defense); James S McDonnell Foundation; Searle Foundation; Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); Prostate Cancer Foundation; Howard Hughes Medical Institute(Howard Hughes Medical Institute); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported in part by the NIH Prostate Specialized Program of Research Excellence Grants P50CA69568 and P50CA090386, Early Detection Research Network Grant UO1 111275 (to AMC), the NIH 1R01CA132874-01A1 (to AMC), CA114197 and CA107193 (to JYW) and K99CA129565-01A1 (to JY), the US Department of Defense PC051081 (to AMC) and PC080665 (to JY), and the James S McDonnell Foundation Grant JSMF (to JYW) and Searle Foundation (to JYW). AMC is supported by a Burroughs Welcome Foundation Award in Clinical Translational Research, a Doris Duke Charitable Foundation Distinguished Clinical Investigator Award, the Prostate Cancer Foundation and the Howard Hughes Medical Institute. AMC is an American Cancer Society Research Professor.	Astuti D, 2004, BRIT J CANCER, V90, P515, DOI 10.1038/sj.bjc.6601447; Beke L, 2007, ONCOGENE, V26, P4590, DOI 10.1038/sj.onc.1210248; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200; Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687; Dallol A, 2003, CANCER RES, V63, P1054; Dallol A, 2002, CANCER RES, V62, P5874; Dammann R, 2005, EUR J CANCER, V41, P1223, DOI 10.1016/j.ejca.2005.02.020; Dammann R, 2005, HISTOL HISTOPATHOL, V20, P645, DOI 10.14670/HH-20.645; Dunwell TL, 2009, EPIGENETICS-US, V4, P265, DOI 10.4161/epi.9137; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Jin J, 2009, BIOCHEM BIOPH RES CO, V379, P86, DOI 10.1016/j.bbrc.2008.12.022; Kanno R, 2008, CANCER SCI, V99, P1077, DOI 10.1111/j.1349-7006.2008.00797.x; Kim HK, 2008, NEOPLASIA, V10, P1411, DOI 10.1593/neo.08804; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Liu SJ, 2005, CANCER RES, V65, P1277, DOI 10.1158/0008-5472.CAN-04-4532; Mathews LA, 2009, DIFFERENTIATION, V78, P1, DOI 10.1016/j.diff.2009.04.002; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Oh DS, 2006, J CLIN ONCOL, V24, P1656, DOI 10.1200/JCO.2005.03.2755; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Prasad A, 2004, J BIOL CHEM, V279, P9115, DOI 10.1074/jbc.M308083200; Prasad A, 2008, J BIOL CHEM, V283, P26624, DOI 10.1074/jbc.M800679200; Prasad A, 2007, J LEUKOCYTE BIOL, V82, P465, DOI 10.1189/jlb.1106678; Raponi M, 2006, CANCER RES, V66, P7466, DOI 10.1158/0008-5472.CAN-06-1191; ROTHBERG JM, 1988, CELL, V55, P1047, DOI 10.1016/0092-8674(88)90249-8; Sharma G, 2007, LIFE SCI, V80, P1873, DOI 10.1016/j.lfs.2007.02.026; Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Tseng RC, 2010, CANCER RES, V70, P543, DOI 10.1158/0008-5472.CAN-09-2084; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Werbowetski-Ogilvie TE, 2006, ONCOGENE, V25, P5103, DOI 10.1038/sj.onc.1209524; Wong K, 2002, CURR OPIN GENET DEV, V12, P583, DOI 10.1016/S0959-437X(02)00343-X; Wu JY, 2001, NATURE, V410, P948, DOI 10.1038/35073616; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158	46	62	67	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	39					5370	5380		10.1038/onc.2010.269	http://dx.doi.org/10.1038/onc.2010.269			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664EZ	20622896	Green Accepted			2022-12-17	WOS:000282944500004
J	Zeng, X; Shaikh, FY; Harrison, MK; Adon, AM; Trimboli, AJ; Carroll, KA; Sharma, N; Timmers, C; Chodosh, LA; Leone, G; Saavedra, HI				Zeng, X.; Shaikh, F. Y.; Harrison, M. K.; Adon, A. M.; Trimboli, A. J.; Carroll, K. A.; Sharma, N.; Timmers, C.; Chodosh, L. A.; Leone, G.; Saavedra, H. I.			The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2	ONCOGENE			English	Article						Ras; centrosome amplification; mammary cancers; cyclin D1; Cdk4; Nek2	IN-SITU HYBRIDIZATION; BREAST-CANCER; C-MYC; CHROMOSOME INSTABILITY; GENETIC INSTABILITY; TRANSGENIC MICE; MMTV-RAS; P21(WAF1/CIP1) DEFICIENCY; GENOMIC INSTABILITY; PROTEIN-KINASE	Centrosome amplification (CA) contributes to carcinogenesis by generating aneuploidy. Elevated frequencies of CA in most benign breast lesions and primary tumors suggest a causative role for CA in breast cancers. Clearly, identifying which and how altered signal transduction pathways contribute to CA is crucial to breast cancer control. Although a causative and cooperative role for c-Myc and Ras in mammary tumorigenesis is well documented, their ability to generate CA during mammary tumor initiation remains unexplored. To answer that question, K-Ras(G12D) and c-Myc were induced in mouse mammary glands. Although CA was observed in mammary tumors initiated by c-Myc or K-Ras(G12D), it was detected only in premalignant mammary lesions expressing K-Ras(G12D). CA, both in vivo and in vitro, was associated with increased expression of the centrosome-regulatory proteins, cyclin D1 and Nek2. Abolishing the expression of cyclin D1, Cdk4 or Nek2 in MCF10A human mammary epithelial cells expressing H-Ras(G12V) abrogated Ras-induced CA, whereas silencing cyclin E1 or B2 had no effect. Thus, we conclude that CA precedes mammary tumorigenesis, and interfering with centrosome-regulatory targets suppresses CA. Oncogene (2010) 29, 5103-5112; doi:10.1038/onc.2010.253; published online 28 June 2010	[Zeng, X.; Harrison, M. K.; Adon, A. M.; Saavedra, H. I.] Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA; [Zeng, X.; Harrison, M. K.; Adon, A. M.; Saavedra, H. I.] Emory Winship Canc Inst, Atlanta, GA USA; [Shaikh, F. Y.; Trimboli, A. J.; Sharma, N.; Timmers, C.; Leone, G.] Program Human Canc Genet, Dept Mol Virol Immunol & Med Genet, Columbus, OH USA; [Carroll, K. A.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Chodosh, L. A.] Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA; [Chodosh, L. A.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	Emory University; Emory University; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Saavedra, HI (corresponding author), Emory Univ, Sch Med, Dept Radiat Oncol, 1365C Clifton Rd,Room C3084, Atlanta, GA 30322 USA.	hsaaved@emory.edu			Georgia Cancer Coalition Distinguished Scholar Award;  [NIH R01CA98371];  [DOD BCRP W81XWH-05-1-0405];  [NIH U01 CA105490];  [R01CA85619];  [R01HD042619];  [R01CA121275];  [R01HD047470];  [P01CA097189];  [K01CA104079]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD042619, R01HD047470] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA085619, K01CA104079, R01CA098371, R01CA121275, U01CA105490, P01CA097189, R01CA151521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008490] Funding Source: NIH RePORTER	Georgia Cancer Coalition Distinguished Scholar Award; ; ; ; ; ; ; ; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Drs Rene Opavsky, Paul W Doetsch, Ya Wang and Hui Wang for manuscript discussions. We also thank Ms Carla G Saavedra and Meredith Roberts for editing; Dr Harold Varmus for providing tetO-K-Ras<SUP>G12D</SUP> mice; Dr J Brugge for nontransformed MCF10A cells; and Jana Opavska, Joi Carmichael and Stacy Sannem for technical assistance. We thank Dr Adam Marcus (from the Emory Imaging Core) and Mr Alan Bakaletz, for imaging advice. Lewis A Chodosh was funded by NIH R01CA98371, DOD BCRP W81XWH-05-1-0405 and NIH U01 CA105490, Gustavo Leone by R01CA85619, R01HD042619, R01CA121275, R01HD047470 and P01CA097189, Harold Saavedra by K01CA104079, and a Georgia Cancer Coalition Distinguished Scholar Award.	Adon AM, 2010, MOL CELL BIOL, V30, P694, DOI 10.1128/MCB.00253-09; BAILLY E, 1992, J CELL SCI, V101, P529; Basto R, 2008, CELL, V133, P1032, DOI 10.1016/j.cell.2008.05.039; Bearss DJ, 2002, CANCER RES, V62, P2077; Berman H, 2005, COLD SH Q B, V70, P317, DOI 10.1101/sqb.2005.70.051; BERNS EMJJ, 1992, J STEROID BIOCHEM, V43, P13, DOI 10.1016/0960-0760(92)90182-I; Blakely CM, 2005, DEVELOPMENT, V132, P1147, DOI 10.1242/dev.01655; Blancato J, 2004, BRIT J CANCER, V90, P1612, DOI 10.1038/sj.bjc.6601703; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Castellanos E, 2008, CURR BIOL, V18, P1209, DOI 10.1016/j.cub.2008.07.029; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; Chrzan P, 2001, CLIN BIOCHEM, V34, P557, DOI 10.1016/S0009-9120(01)00260-0; CLAIR T, 1987, CANCER RES, V47, P5290; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; Duensing A, 2006, CELL CYCLE, V5, P2899, DOI 10.4161/cc.5.24.3567; Duesberg P, 2000, CELL MOTIL CYTOSKEL, V47, P81; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Fisk HA, 2003, P NATL ACAD SCI USA, V100, P14875, DOI 10.1073/pnas.2434156100; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Fleisch MC, 2006, MICROSC RES TECHNIQ, V69, P964, DOI 10.1002/jemt.20372; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Goepfert TM, 2000, FASEB J, V14, P2221, DOI 10.1096/fj.00-0165com; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Guo HQ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1752; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Hanashiro K, 2008, ONCOGENE, V27, P5288, DOI 10.1038/onc.2008.161; Hayward DG, 2004, CANCER RES, V64, P7370, DOI 10.1158/0008-5472.CAN-04-0960; Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258; Hundley JE, 1997, MOL CELL BIOL, V17, P723, DOI 10.1128/MCB.17.2.723; Hundley JE, 1997, CANCER RES, V57, P600; Iovino F, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-38; JANES PW, 1994, ONCOGENE, V9, P3601; Kleylein-Sohn J, 2007, DEV CELL, V13, P190, DOI 10.1016/j.devcel.2007.07.002; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; MANGUES R, 1990, ONCOGENE, V5, P1491; McDermott KM, 2006, PLOS BIOL, V4, P350, DOI 10.1371/journal.pbio.0040051; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Miyakis S, 1998, BIOCHEM BIOPH RES CO, V251, P609, DOI 10.1006/bbrc.1998.9527; Nelsen CJ, 2005, J BIOL CHEM, V280, P768, DOI 10.1074/jbc.M407105200; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Oikawa T, 2005, MOL CELL BIOL, V25, P4046, DOI 10.1128/MCB.25.10.4046-4061.2005; Omer CA, 2000, CANCER RES, V60, P2680; Pihan GA, 1998, CANCER RES, V58, P3974; Podsypanina K, 2008, P NATL ACAD SCI USA, V105, P5242, DOI 10.1073/pnas.0801197105; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; Reddy HKDL, 2005, CANCER RES, V65, P10174, DOI 10.1158/0008-5472.CAN-05-2639; Rummukainen JK, 2001, MODERN PATHOL, V14, P1030, DOI 10.1038/modpathol.3880431; Saavedra HI, 2003, CANCER CELL, V3, P333, DOI 10.1016/S1535-6108(03)00083-7; Saavedra HI, 1999, J BIOL CHEM, V274, P38083, DOI 10.1074/jbc.274.53.38083; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Schliekelman M, 2009, CANCER RES, V69, P45, DOI 10.1158/0008-5472.CAN-07-6330; Schneeweiss A, 2003, INT J CANCER, V107, P346, DOI 10.1002/ijc.11408; Shackney SE, 2004, CLIN CANCER RES, V10, P3042, DOI 10.1158/1078-0432.CCR-0401-3; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Suizu F, 2006, MOL CELL BIOL, V26, P1463, DOI 10.1128/MCB.26.4.1463-1479.2006; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tsunoda N, 2009, CANCER SCI, V100, P111, DOI 10.1111/j.1349-7006.2008.01007.x; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Wang X, 2006, ONCOGENE, V25, P7148, DOI 10.1038/sj.onc.1209707; Weaver BAA, 2007, CANCER RES, V67, P10103, DOI 10.1158/0008-5472.CAN-07-2266; Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.0.CO;2-3; Wu GK, 2008, CANCER RES, V68, P8393, DOI 10.1158/0008-5472.CAN-08-1915; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	70	62	67	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2010	29	36					5103	5112		10.1038/onc.2010.253	http://dx.doi.org/10.1038/onc.2010.253			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	647LN	20581865	Green Accepted			2022-12-17	WOS:000281620100010
J	Sauer, L; Gitenay, D; Vo, C; Baron, VT				Sauer, L.; Gitenay, D.; Vo, C.; Baron, V. T.			Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells	ONCOGENE			English	Article						p53; Egr-1; prostate cancer; EGF receptor; SV40 large T-antigen	GROWTH-FACTOR-BETA; EGR1 TARGET GENES; LARGE T-ANTIGEN; TUMOR-SUPPRESSOR; CARCINOMA-CELLS; IMMUNE-RESPONSE; IN-VIVO; EXPRESSION; TRANSCRIPTION; LINE	Early growth response-1 (Egr-1) is overexpressed in human prostate tumors and contributes to cancer progression. On the other hand, mutation of p53 is associated with advanced prostate cancer, as well as with metastasis and hormone independence. This study shows that in prostate cell lines in culture, Egr-1 overexpression correlated with an alteration of p53 activity because of the expression of SV40 large Tantigen or because of a mutation in the TP53 gene. In cells containing altered p53 activity, Egr-1 expression was abolished by pharmacological inhibition or RNAi silencing of p53. Although forced expression of wild-type p53 was not sufficient to trigger Egr-1 transcription, four different mutants of p53 were shown to induce Egr-1. Direct binding of p53 to the EGR1 promoter could not be detected. Instead, Egr-1 transcription was driven by the ERK1/2 pathway, as it was abrogated by specific inhibitors of MEK. Egr-1 increased the transcription of HB-EGF (epidermal growth factor), amphiregulin and epiregulin, resulting in autocrine activation of the EGF receptor (EGFR) and downstream MEK/ERK cascade. Thus, mutant p53 initiates a feedback loop that involves ERK1/2-mediated transactivation of Egr-1, which in turn increases the secretion of EGFR ligands and stimulates the EGFR signaling pathway. Finally, p53 may further regulate this feedback loop by altering the level of EGFR expression. Oncogene (2010) 29, 2628-2637; doi:10.1038/onc.2010.24; published online 1 March 2010	[Sauer, L.; Gitenay, D.; Vo, C.; Baron, V. T.] VRISD, San Diego, CA 92121 USA		Baron, VT (corresponding author), VRISD, 10835 Rd Cure,Suite 150, San Diego, CA 92121 USA.	vbaron@sdibr.org		Gitenay, Delphine/0000-0002-6043-4519; Schenk, Lysann/0000-0002-5146-8485	NIH/NCI [RO1 CA102688]; NATIONAL CANCER INSTITUTE [R01CA102688] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Ruth Gjerset (Torrey Pines Institute for Molecular Studies, San Diego, CA) for comments and critical reading of the paper. We are grateful to Dr Eileen Adamson and Dr Dan Mercola (University of California, Irvine, CA) for their support and many suggestions. This work was supported by a Grant from NIH/NCI-RO1 CA102688 (V Baron).	Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Baron V, 2003, ONCOGENE, V22, P4194, DOI 10.1038/sj.onc.1206560; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Biswas S, 2006, CLIN CANCER RES, V12, P4142, DOI 10.1158/1078-0432.CCR-06-0952; Bocchetta M, 2008, CANCER RES, V68, P1022, DOI 10.1158/0008-5472.CAN-07-5203; CAO XM, 1993, J BIOL CHEM, V268, P16949; CONNOLLY JM, 1991, PROSTATE, V19, P173, DOI 10.1002/pros.2990190210; DEB SP, 1994, ONCOGENE, V9, P1341; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; Eid MA, 1998, CANCER RES, V58, P2461; Gitenay D, 2009, FUTURE ONCOL, V5, P993, DOI [10.2217/fon.09.67, 10.2217/FON.09.67]; Gurova KV, 2003, CANCER RES, V63, P2905; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; ISAACS WB, 1991, CANCER RES, V51, P4716; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; KAIGHN ME, 1979, INVEST UROL, V17, P16; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Lilyestrom W, 2006, GENE DEV, V20, P2373, DOI 10.1101/gad.1456306; LONG SB, 1995, ANTICANCER RES, V15, P1375; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Nishi H, 2002, CANCER RES, V62, P827; PARDA DS, 1993, PROSTATE, V23, P91, DOI 10.1002/pros.2990230202; Ramsamooj P, 1997, Radiat Oncol Investig, V5, P269, DOI 10.1002/(SICI)1520-6823(1997)5:6<269::AID-ROI2>3.0.CO;2-W; Shin SY, 2006, EMBO J, V25, P1093, DOI 10.1038/sj.emboj.7600987; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Teicher BA, 2007, CLIN CANCER RES, V13, P6247, DOI 10.1158/1078-0432.CCR-07-1654; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Thigpen AE, 1996, J UROLOGY, V155, P975, DOI 10.1016/S0022-5347(01)66361-4; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Virolle T, 2003, J BIOL CHEM, V278, P11802, DOI 10.1074/jbc.M210279200; Weisz L, 2004, CANCER RES, V64, P8318, DOI 10.1158/0008-5472.CAN-04-1145; Wrzesinski SH, 2007, CLIN CANCER RES, V13, P5262, DOI 10.1158/1078-0432.CCR-07-1157; Wu GS, 2004, CANCER BIOL THER, V3, P156, DOI 10.4161/cbt.3.2.614; Yang SZ, 2003, J BIOL CHEM, V278, P39906, DOI 10.1074/jbc.M307250200; Yu J, 2007, CELL DEATH DIFFER, V14, P436, DOI 10.1038/sj.cdd.4402029	40	62	64	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 6	2010	29	18					2628	2637		10.1038/onc.2010.24	http://dx.doi.org/10.1038/onc.2010.24			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592DC	20190820	Green Accepted			2022-12-17	WOS:000277354600003
J	Fernandez, AF; Esteller, M				Fernandez, A. F.; Esteller, M.			Viral epigenomes in human tumorigenesis	ONCOGENE			English	Review						epigenetics; DNA methylation; histone modification; virus; viral oncogenes; human cancer	EPSTEIN-BARR-VIRUS; SARCOMA-ASSOCIATED HERPESVIRUS; HEPATITIS-B-VIRUS; T-CELL LEUKEMIA; HUMAN-PAPILLOMAVIRUS TYPE-16; IMMEDIATE-EARLY PROMOTER; DNA METHYLTRANSFERASE DNMT3A; LATENT NUCLEAR ANTIGEN; HUMAN CANCER-CELLS; CPG METHYLATION	Viruses are associated with 15-20% of human cancers worldwide. In the last century, many studies were directed towards elucidating the molecular mechanisms and genetic alterations by which viruses cause cancer. The importance of epigenetics in the regulation of gene expression has prompted the investigation of virus and host interactions not only at the genetic level but also at the epigenetic level. In this study, we summarize the published epigenetic information relating to the genomes of viruses directly or indirectly associated with the establishment of tumorigenic processes. We also review aspects such as viral replication and latency associated with epigenetic changes and summarize what is known about epigenetic alterations in host genomes and the implications of these for the tumoral process. The advances made in characterizing epigenetic features in cancer-causing viruses have improved our understanding of their functional mechanisms. Knowledge of the epigenetic changes that occur in the genome of these viruses should provide us with markers for following cancer progression, as well as new tools for cancer therapy. Oncogene (2010) 29, 1405-1420; doi:10.1038/onc.2009.517; published online 25 January 2010	[Esteller, M.] Hosp Duran & Reynals, PEBC, Bellvitge Biomed Res Inst, IDIBELL, Barcelona 08907, Catalonia, Spain; [Esteller, M.] ICREA, Barcelona, Catalonia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; University of Barcelona; ICREA	Esteller, M (corresponding author), Hosp Duran & Reynals, PEBC, Bellvitge Biomed Res Inst, IDIBELL, 3rd Floor,Gran Via 199-203, Barcelona 08907, Catalonia, Spain.	mesteller@iconcologia.net	Esteller, Manel/L-5956-2014; Fernandez, Agustin F./N-7302-2014	Esteller, Manel/0000-0003-4490-6093; Fernandez, Agustin F./0000-0002-3792-4085	Spanish Association Against Cancer (AECC); Fundacion Mutua Madrilena; Swiss Bridge Award;  [MCYT08-03]; ICREA Funding Source: Custom	Spanish Association Against Cancer (AECC); Fundacion Mutua Madrilena(Instituto de Salud Carlos III); Swiss Bridge Award; ; ICREA(ICREA)	This study was supported by grants I+D+I MCYT08-03, Spanish Association Against Cancer (AECC), Fundacion Mutua Madrilena and the Swiss Bridge Award. ME is an ICREA (Institucio Catalana de Recerca i Estudis Avancats) Research Professor.	Ambinder RF, 1999, SEMIN CANCER BIOL, V9, P369, DOI 10.1006/scbi.1999.0137; Appleby P, 2000, JNCI-J NATL CANCER I, V92, P1823, DOI 10.1093/jnci/92.22.1823; Areste C, 2009, TRENDS MICROBIOL, V17, P119, DOI 10.1016/j.tim.2008.12.001; Avvakumov N, 2003, ONCOGENE, V22, P3833, DOI 10.1038/sj.onc.1206562; Badal S, 2004, VIROLOGY, V324, P483, DOI 10.1016/j.virol.2004.04.002; Badal V, 2003, J VIROL, V77, P6227, DOI 10.1128/JVI.77.11.6227-6234.2003; Ballestas ME, 1999, SCIENCE, V284, P641, DOI 10.1126/science.284.5414.641; Barozzi P, 2007, AUTOIMMUN REV, V7, P132, DOI 10.1016/j.autrev.2007.02.018; Beck J, 2007, WORLD J GASTROENTERO, V13, P48, DOI 10.3748/wjg.v13.i1.48; BEDNARIK DP, 1990, EMBO J, V9, P1157, DOI 10.1002/j.1460-2075.1990.tb08222.x; Bernat A, 2003, ONCOGENE, V22, P7871, DOI 10.1038/sj.onc.1206896; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033; Bhattacharjee B, 2006, VIROLOGY, V354, P280, DOI 10.1016/j.virol.2006.06.018; Bhende PM, 2005, J VIROL, V79, P7338, DOI 10.1128/JVI.79.12.7338-7348.2005; Bouvard V, 2009, LANCET ONCOL, V10, P321, DOI 10.1016/S1470-2045(09)70096-8; Brandsma JL, 2009, VIROLOGY, V389, P100, DOI 10.1016/j.virol.2009.03.029; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Breitbart M, 2005, TRENDS MICROBIOL, V13, P278, DOI 10.1016/j.tim.2005.04.003; Brooks AR, 2004, J GENE MED, V6, P395, DOI 10.1002/jgm.516; Bubman D, 2007, ONCOGENE, V26, P4979, DOI 10.1038/sj.onc.1210299; Burgers WA, 2007, ONCOGENE, V26, P1650, DOI 10.1038/sj.onc.1209950; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; Cai Xuezhong, 2006, PLoS Pathogens, V2, P236, DOI 10.1371/journal.ppat.0020023; Carbone A, 2007, INT J BIOL MARKER, V22, P161, DOI 10.1177/172460080702200211; Carbone A, 2005, BRIT J HAEMATOL, V130, P662, DOI 10.1111/j.1365-2141.2005.05613.x; Carbone A, 2009, CURR OPIN HIV AIDS, V4, P3, DOI 10.1097/COH.0b013e32831a722b; Chang Y, 2006, J VIROL, V80, P7748, DOI 10.1128/JVI.02608-05; Chen J, 2001, P NATL ACAD SCI USA, V98, P4119, DOI 10.1073/pnas.051004198; Chuang JC, 2007, PEDIATR RES, V61, p24R, DOI 10.1203/pdr.0b013e3180457684; Cinati J, 2004, TRENDS MOL MED, V10, P19, DOI 10.1016/j.molmed.2003.11.002; Cinatl J, 1996, INTERVIROLOGY, V39, P259, DOI 10.1159/000150527; Colot V, 1999, BIOESSAYS, V21, P402, DOI 10.1002/(SICI)1521-1878(199905)21:5<402::AID-BIES7>3.3.CO;2-2; Cotter MA, 1999, VIROLOGY, V264, P254, DOI 10.1006/viro.1999.9999; Cougot D, 2007, J BIOL CHEM, V282, P4277, DOI 10.1074/jbc.M606774200; Cougot D, 2005, J CLIN VIROL, V34, pS75, DOI 10.1016/S1386-6532(05)80014-9; Countryman JK, 2008, J VIROL, V82, P4706, DOI 10.1128/JVI.00116-08; Cuevas-Bennett C, 2008, J VIROL, V82, P9525, DOI 10.1128/JVI.00946-08; Cullen BR, 2009, NATURE, V457, P421, DOI 10.1038/nature07757; Damania B, 2007, TRENDS MICROBIOL, V15, P38, DOI 10.1016/j.tim.2006.11.002; DANOS O, 1980, EUR J BIOCHEM, V109, P457, DOI 10.1111/j.1432-1033.1980.tb04815.x; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033; DeCaprio JA, 2009, VIROLOGY, V384, P274, DOI 10.1016/j.virol.2008.12.010; Derse D, 2007, J VIROL, V81, P6731, DOI 10.1128/JVI.02752-06; Di Bartolo DL, 2008, BLOOD, V111, P4731, DOI 10.1182/blood-2007-09-110544; Dickerson SJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000356; Dolken L, 2009, VIRUS GENES, V38, P355, DOI 10.1007/s11262-009-0347-0; Doerfler W, 1996, BBA-REV CANCER, V1288, pF79, DOI 10.1016/0304-419X(96)00024-8; DOERFLER W, 1991, BIOL CHEM H-S, V372, P557; Doi K, 2005, BLOOD, V106, P1048, DOI 10.1182/blood-2004-11-4350; Dourmishev LA, 2003, MICROBIOL MOL BIOL R, V67, P175, DOI 10.1128/MMBR.67.2.175-212.2003; Duverger A, 2009, J VIROL, V83, P3078, DOI 10.1128/JVI.02058-08; DYSON PJ, 1985, J GEN VIROL, V66, P1931, DOI 10.1099/0022-1317-66-9-1931; de Oliveira DE, 2007, CANCER LETT, V247, P182, DOI 10.1016/j.canlet.2006.05.010; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Feinberg AP, 2002, SEMIN CANCER BIOL, V12, P389, DOI 10.1016/S1044-579X(02)00059-7; Fejer G, 2008, J GEN VIROL, V89, P1364, DOI 10.1099/vir.0.83594-0; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; Fernandez AF, 2009, GENOME RES, V19, P438, DOI 10.1101/gr.083550.108; Ferrari R, 2009, NAT REV GENET, V10, P290, DOI 10.1038/nrg2539; Flanagan JM, 2007, BRIT J CANCER, V96, P183, DOI 10.1038/sj.bjc.6603516; Fraga MF, 2005, CELL CYCLE, V4, P1377, DOI 10.4161/cc.4.10.2113; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Fujimuro M, 2003, NAT MED, V9, P300, DOI 10.1038/nm829; Fukayama M, 2008, CANCER SCI, V99, P1726, DOI 10.1111/j.1349-7006.2008.00888.x; GEORG WB, 2009, INT J CANCER, V124, P1745; Gerle B, 2007, J VIROL, V81, P13242, DOI 10.1128/JVI.01396-07; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; Goel A, 2006, GASTROENTEROLOGY, V130, P1950, DOI 10.1053/j.gastro.2006.02.061; Gottwein E, 2008, CELL HOST MICROBE, V3, P375, DOI 10.1016/j.chom.2008.05.002; Gray KS, 2009, J VIROL, V83, P314, DOI 10.1128/JVI.01444-08; Grey F, 2008, MED MICROBIOL IMMUN, V197, P261, DOI 10.1007/s00430-007-0070-1; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; Grundhoff A, 2006, RNA, V12, P733, DOI 10.1261/rna.2326106; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Guo YH, 2009, J MED VIROL, V81, P1177, DOI 10.1002/jmv.21525; Gurtsevitch VE, 2008, BIOCHEMISTRY-MOSCOW+, V73, P504, DOI 10.1134/S0006297908050039; Han YF, 2008, CELL HOST MICROBE, V4, P134, DOI 10.1016/j.chom.2008.06.008; HAUSEN HZ, 1977, CURR TOP MICROBIOL, P1; Heather J, 2009, J GEN VIROL, V90, P1450, DOI 10.1099/vir.0.007922-0; Herceg Z, 2009, J HEPATOL, V50, P252, DOI 10.1016/j.jhep.2008.11.013; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hino R, 2009, CANCER RES, V69, P2766, DOI 10.1158/0008-5472.CAN-08-3070; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; Horenstein MG, 2008, J CUTAN PATHOL, V35, P40, DOI 10.1111/j.1600-0560.2008.01118.x; Horikawa I, 2003, CARCINOGENESIS, V24, P1167, DOI 10.1093/carcin/bgg085; Howie HL, 2009, VIROLOGY, V384, P324, DOI 10.1016/j.virol.2008.11.017; Hublarova P, 2009, INT J GYNECOL CANCER, V19, P321, DOI 10.1111/IGC.0b013e31819d8a5c; Ioudinkova E, 2006, GENE, V384, P120, DOI 10.1016/j.gene.2006.07.021; Ishida T, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-69; Javier RT, 2008, CANCER RES, V68, P7693, DOI 10.1158/0008-5472.CAN-08-3301; Jenner RG, 2001, J VIROL, V75, P891, DOI 10.1128/JVI.75.2.891-902.2001; Jiang GC, 2007, J VIROL, V81, P10914, DOI 10.1128/JVI.01208-07; Jiang MX, 2009, VIROLOGY, V384, P266, DOI 10.1016/j.virol.2008.09.027; Jin WB, 2007, COMPUT BIOL CHEM, V31, P124, DOI 10.1016/j.compbiolchem.2007.01.005; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Jung JK, 2007, CANCER RES, V67, P5771, DOI 10.1158/0008-5472.CAN-07-0529; Kalantari M, 2004, J VIROL, V78, P12762, DOI 10.1128/JVI.78.23.12762-12772.2004; Kamoi K, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-5; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; Kim K, 2003, J VIROL, V77, P12450, DOI 10.1128/JVI.77.23.12450-12459.2003; Kinlen L, 2004, ONCOGENE, V23, P6341, DOI 10.1038/sj.onc.1207898; Klein E, 2007, ONCOGENE, V26, P1297, DOI 10.1038/sj.onc.1210240; Koiwa T, 2002, J VIROL, V76, P9389, DOI 10.1128/JVI.76.18.9389-9397.2002; Lai HC, 2008, INT J CANCER, V123, P161, DOI 10.1002/ijc.23519; Lee D, 2000, J BIOL CHEM, V275, P7045, DOI 10.1074/jbc.275.10.7045; Lenasi T, 2008, CELL HOST MICROBE, V4, P123, DOI 10.1016/j.chom.2008.05.016; Levine AJ, 2009, VIROLOGY, V384, P285, DOI 10.1016/j.virol.2008.09.034; Li H, 2003, ADV CANCER RES, V89, P133, DOI 10.1016/S0065-230X(03)01004-2; Li HP, 2005, CELL RES, V15, P262, DOI 10.1038/sj.cr.7290295; Li QH, 2008, VIROLOGY, V379, P234, DOI 10.1016/j.virol.2008.06.043; Lin ZH, 2009, CLIN CANCER RES, V15, P570, DOI 10.1158/1078-0432.CCR-08-1813; Liu Y, 2009, CHINESE MED J-PEKING, V122, P10, DOI 10.3760/cma.j.issn.0366-6999.2009.01.003; Lu F, 2006, J VIROL, V80, P5273, DOI 10.1128/JVI.02541-05; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Lupberger J, 2007, WORLD J GASTROENTERO, V13, P74, DOI 10.3748/wjg.v13.i1.74; Martinez I, 2008, ONCOGENE, V27, P2575, DOI 10.1038/sj.onc.1210919; Matsuoka M, 2007, NAT REV CANCER, V7, P270, DOI 10.1038/nrc2111; McCabe M, 2006, ONCOGENE, V25, P2727, DOI 10.1038/sj.onc.1209266; McCormick C, 2005, SCIENCE, V307, P739, DOI 10.1126/science.1105779; McLaughlin-Drubin ME, 2008, BBA-MOL BASIS DIS, V1782, P127, DOI 10.1016/j.bbadis.2007.12.005; McLaughlin-Drubin ME, 2009, VIROLOGY, V384, P335, DOI 10.1016/j.virol.2008.10.006; Mehta AK, 2009, GENE, V428, P20, DOI 10.1016/j.gene.2008.09.033; Michaelis M, 2009, NEOPLASIA, V11, P1, DOI 10.1593/neo.81178; MILLER RH, 1983, P NATL ACAD SCI-BIOL, V80, P2534, DOI 10.1073/pnas.80.9.2534; Minarovits J, 2006, CURR TOP MICROBIOL, V310, P61; Mok HP, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-228; Nair V, 2006, TRENDS MICROBIOL, V14, P169, DOI 10.1016/j.tim.2006.02.007; Niemhom S, 2008, CANCER DETECT PREV, V32, P127, DOI 10.1016/j.cdp.2008.05.005; Niller HH, 2008, AUTOIMMUNITY, V41, P298, DOI 10.1080/08916930802024772; Pantry SN, 2009, SEMIN CANCER BIOL, V19, P153, DOI 10.1016/j.semcancer.2009.02.010; Park IY, 2007, GASTROENTEROLOGY, V132, P1476, DOI 10.1053/j.gastro.2007.01.034; Park JH, 2007, BIOCHEM BIOPH RES CO, V358, P513, DOI 10.1016/j.bbrc.2007.04.169; Park JJ, 2007, J GEN VIROL, V88, P3214, DOI 10.1099/vir.0.83171-0; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Paulson EJ, 1999, J VIROL, V73, P9959, DOI 10.1128/JVI.73.12.9959-9968.1999; Payer B, 2008, ANNU REV GENET, V42, P733, DOI 10.1146/annurev.genet.42.110807.091711; Peng YC, 2000, J VIROL, V74, P5872, DOI 10.1128/JVI.74.13.5872-5879.2000; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Pollicino T, 2006, GASTROENTEROLOGY, V130, P823, DOI 10.1053/j.gastro.2006.01.001; Proietti FA, 2005, ONCOGENE, V24, P6058, DOI 10.1038/sj.onc.1208968; Prosch S, 1996, BIOL CHEM H-S, V377, P195, DOI 10.1515/bchm3.1996.377.3.195; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Reeves M, 2006, J VIROL, V80, P9998, DOI 10.1128/JVI.01297-06; Reshmi G, 2008, FEBS LETT, V582, P4113, DOI 10.1016/j.febslet.2008.11.011; Richman DD, 2009, SCIENCE, V323, P1304, DOI 10.1126/science.1165706; Robertson KD, 1997, BLOOD, V90, P4480, DOI 10.1182/blood.V90.11.4480.4480_4480_4484; Rollins RA, 2006, GENOME RES, V16, P157, DOI 10.1101/gr.4262006; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Sakakibara S, 2004, J VIROL, V78, P7299, DOI 10.1128/JVI.78.14.7299-7310.2004; Salamon D, 2001, J VIROL, V75, P2584, DOI 10.1128/JVI.75.6.2584-2596.2001; Samols MA, 2007, PLOS PATHOG, V3, P611, DOI 10.1371/journal.ppat.0030065; Scaria V, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-68; Seeger C, 2000, MICROBIOL MOL BIOL R, V64, P51, DOI 10.1128/MMBR.64.1.51-68.2000; Seo GJ, 2008, J VIROL, V82, P9823, DOI 10.1128/JVI.01144-08; Shamay M, 2006, P NATL ACAD SCI USA, V103, P14554, DOI 10.1073/pnas.0604469103; Sharara AI, 1996, ANN INTERN MED, V125, P658, DOI 10.7326/0003-4819-125-8-199610150-00006; SHAW JE, 1979, J VIROL, V29, P657, DOI 10.1128/JVI.29.2.657-665.1979; Shona JK, 2009, VIRUS RES, V139, P14, DOI 10.1016/j.virusres.2008.09.006; Soderberg-Naucler C, 2006, J INTERN MED, V259, P219, DOI 10.1111/j.1365-2796.2006.01618.x; Steenbergen RDM, 1996, ONCOGENE, V13, P1249; Stuber G, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-28; Sun R, 1998, P NATL ACAD SCI USA, V95, P10866, DOI 10.1073/pnas.95.18.10866; Takeda S, 2004, INT J CANCER, V109, P559, DOI 10.1002/ijc.20007; Taniguchi Y, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-64; Tao Q, 1998, J VIROL, V72, P7075, DOI 10.1128/JVI.72.9.7075-7083.1998; Tao Q, 2003, CLIN IMMUNOL, V109, P53, DOI 10.1016/S1521-6616(03)00198-0; Thain A, 1996, J VIROL, V70, P7233, DOI 10.1128/JVI.70.10.7233-7235.1996; Tischoff I, 2008, WORLD J GASTROENTERO, V14, P1741, DOI 10.3748/wjg.14.1741; Tsai CL, 2006, CANCER RES, V66, P11668, DOI 10.1158/0008-5472.CAN-06-2194; Turan T, 2007, VIROLOGY, V361, P185, DOI 10.1016/j.virol.2006.11.010; Turan T, 2006, VIROLOGY, V349, P175, DOI 10.1016/j.virol.2005.12.033; Verma SC, 2007, J VIROL, V81, P3402, DOI 10.1128/JVI.01607-06; Vivekanandan P, 2008, J VIRAL HEPATITIS, V15, P103, DOI 10.1111/j.1365-2893.2007.00905.x; Vivekanandan P, 2009, J INFECT DIS, V199, P1286, DOI 10.1086/597614; Wang X, 2009, RNA, V15, P637, DOI 10.1261/rna.1442309; Wang XH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002557; Wentzensen N, 2009, GYNECOL ONCOL, V112, P293, DOI 10.1016/j.ygyno.2008.10.012; Whitby D, 2009, NAT GENET, V41, P7, DOI 10.1038/ng0109-7; Whiteside MA, 2008, CANCER-AM CANCER SOC, V113, P2981, DOI 10.1002/cncr.23750; Wiencke JK, 2008, ONCOGENE, V27, P2412, DOI 10.1038/sj.onc.1210895; Williams H, 2006, BLOOD, V107, P862, DOI 10.1182/blood-2005-07-2702; Woodman CBJ, 2007, NAT REV CANCER, V7, P11, DOI 10.1038/nrc2050; Yasunaga JI, 2007, REV MED VIROL, V17, P301, DOI 10.1002/rmv.548; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Yokosuka O, 2006, MED MOL MORPHOL, V39, P113, DOI 10.1007/s00795-006-0328-5; Yoshioka M, 2003, J MED VIROL, V70, P410, DOI 10.1002/jmv.10411; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Zheng DL, 2009, J HEPATOL, V50, P377, DOI 10.1016/j.jhep.2008.10.019; Zheng ZM, 2006, FRONT BIOSCI-LANDMRK, V11, P2286, DOI 10.2741/1971; zur Hausen H., 2006, INFECT CAUSING HUMAN; zur Hausen H, 2009, VIROLOGY, V384, P260, DOI 10.1016/j.virol.2008.11.046	195	62	67	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1405	1420		10.1038/onc.2009.517	http://dx.doi.org/10.1038/onc.2009.517			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	20101211				2022-12-17	WOS:000275392400001
J	Bohm, M; Locke, WJ; Sutherland, RL; Kench, JG; Henshall, SM				Boehm, M.; Locke, W. J.; Sutherland, R. L.; Kench, J. G.; Henshall, S. M.			A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes	ONCOGENE			English	Article						AR; GATA-2; prostate cancer; progression	LIPID MOBILIZING FACTOR; TRANSCRIPTION FACTORS; RECEPTOR; EXPRESSION; CELLS; ADIPOCYTES; EVOLUTION; PATHWAY; MODEL	GATA-2, a member of the GATA family of transcription factors, is involved in androgen receptor (AR) signaling, however, little is known regarding its role in prostate cancer. Here, we report that GATA-2 is expressed in a substantial proportion of prostate cancers and that high expression of GATA-2 is associated with biochemical recurrence and distant metastatic progression in a validation set of 203 cancers. In vitro data show that GATA-2 is directly recruited to the promoter region of the AR upon androgen stimulation of LNCaP prostate cancer cells with 5 alpha-dihydroxytestosterone (DHT) for 24 h. Ectopic GATA-2 expression causes the induction of AR transcript levels under androgen-depleted conditions (P<0.05). The expression of the AR target gene, AZGP1, is induced upon androgen stimulation and this effect is repressed by GATA-2. In contrast, GATA-2 significantly increases transcript levels of KLK2, which increases further in a time-dependent manner on DHT treatment and in the presence of GATA-2. These results indicate that upregulation of GATA-2 may contribute to the progression to aggressive prostate cancer through modulation of expression of AR and key androgen-regulated genes, one of which, AZGP1, is associated with the progression to metastatic disease. Oncogene (2009) 28, 3847-3856; doi:10.1038/onc.2009.243; published online 17 August 2009	[Boehm, M.; Locke, W. J.; Sutherland, R. L.; Kench, J. G.; Henshall, S. M.] Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; [Kench, J. G.] Royal Prince Alfred Hosp, Dept Anat Pathol, Sydney, NSW, Australia	Garvan Institute of Medical Research; University of Sydney	Henshall, SM (corresponding author), Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	s.henshall@garvan.org.au	Locke, Warwick/G-3152-2017; Sutherland, Robert L/A-8378-2008	Locke, Warwick/0000-0002-9281-0363; Kench, James Geoffrey/0000-0001-8687-4988	Cancer Institute NSW; National Health and Medical Research Council; Prostate Cancer Foundation of Australia; RT Hall Trust	Cancer Institute NSW; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Prostate Cancer Foundation of Australia; RT Hall Trust	This work is supported by grants from the Cancer Institute NSW, the National Health and Medical Research Council, the Prostate Cancer Foundation of Australia and the RT Hall Trust. We thank Professor Liz Musgrove, Dr Ross Laybutt and Dr Liz Caldon for helpful discussion and critical reading of the paper. Furthermore, we thank Ruth PeBenito for technical support.	Bao Y, 2005, FEBS LETT, V579, P41, DOI 10.1016/j.febslet.2004.11.042; Bing C, 2004, P NATL ACAD SCI USA, V101, P2500, DOI 10.1073/pnas.0308647100; Borgono CA, 2004, MOL CANCER RES, V2, P257; COX DR, 1972, J R STAT SOC B, V187, P220; Dehm SM, 2006, J CELL BIOCHEM, V99, P333, DOI 10.1002/jcb.20794; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Hayakawa F, 2004, J LEUKOCYTE BIOL, V75, P529, DOI 10.1189/jlb.0603289; Heemers HV, 2009, MOL ENDOCRINOL, V23, P572, DOI 10.1210/me.2008-0363; Hendriksen PJM, 2006, CANCER RES, V66, P5012, DOI 10.1158/0008-5472.CAN-05-3082; Henshall SM, 2003, CANCER RES, V63, P4196; Henshall SM, 2006, J NATL CANCER I, V98, P1420, DOI 10.1093/jnci/djj378; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kato S, 2004, J STEROID BIOCHEM, V89-90, P627, DOI 10.1016/j.jsbmb.2004.03.099; Lin BY, 1999, CANCER RES, V59, P4180; Lowry JA, 2000, J MOL EVOL, V50, P103, DOI 10.1007/s002399910012; Magklara A, 2009, MOL ENDOCRINOL, V23, P61, DOI 10.1210/me.2008-0028; Masuda K, 2005, J MOL BIOL, V353, P763, DOI 10.1016/j.jmb.2005.09.009; Matsuyama M, 2008, PPAR RES, V2008, DOI 10.1155/2008/249849; Minegishi N, 2005, GENES CELLS, V10, P693, DOI 10.1111/j.1365-2443.2005.00864.x; Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Nemer G, 2003, DEV BIOL, V254, P131, DOI 10.1016/S0012-1606(02)00026-X; Oren Aharon, 2005, Saline Syst, V1, P2, DOI 10.1186/1746-1448-1-2; Perez-Stable CM, 2000, MOL CELL ENDOCRINOL, V167, P43, DOI 10.1016/S0303-7207(00)00300-2; Rasiah KK, 2006, CANCER EPIDEM BIOMAR, V15, P711, DOI 10.1158/1055-9965.EPI-05-0752; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; SIMON MC, 1995, NAT GENET, V11, P9, DOI 10.1038/ng0995-9; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; Usary J, 2004, ONCOGENE, V23, P7669, DOI 10.1038/sj.onc.1207966; Wang G, 2006, ONCOGENE, V25, P7311, DOI 10.1038/sj.onc.1209715; Wang HY, 2007, CANCER RES, V67, P528, DOI 10.1158/0008-5472.CAN-06-1672; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; WEISS MJ, 1995, EXP HEMATOL, V23, P99; Xu Y, 2003, J CELL PHYSIOL, V196, P131, DOI 10.1002/jcp.10281; YOUNG CYF, 1992, BIOCHEMISTRY-US, V31, P818, DOI 10.1021/bi00118a026	38	62	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	43					3847	3856		10.1038/onc.2009.243	http://dx.doi.org/10.1038/onc.2009.243			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512KT	19684615				2022-12-17	WOS:000271248400008
J	Pratt, MAC; Tibbo, E; Robertson, SJ; Jansson, D; Hurst, K; Perez-Iratxeta, C; Lau, R; Niu, MY				Pratt, M. A. C.; Tibbo, E.; Robertson, S. J.; Jansson, D.; Hurst, K.; Perez-Iratxeta, C.; Lau, R.; Niu, M. Y.			The canonical NF-kappa B pathway is required for formation of luminal mammary neoplasias and is activated in the mammary progenitor population	ONCOGENE			English	Article						NF-kappa B; transgenic mice; mammary cancer; luminal; basal; squamous	BREAST-CANCER; THERAPEUTIC TARGET; TRANSGENIC MICE; EXPRESSION; GROWTH; ALPHA; KINASE; GLAND; IKK; TRANSFORMATION	The role of the canonical NF-kappa B pathway in mammary tumorigenesis was investigated using a transgenic (TG) mouse expressing a dominant-negative inhibitor of kappa B (I kappa B alpha(SR(S32A/S36A))) in the mammary gland under the control of the mouse mammary tumor virus promoter ( MMTV). TG and control mice were subjected to a chemical carcinogenesis protocol. Hyperkeratinized squamous metaplasias ( cytokeratin -6+/p63+) sometimes with a basaloid island component, were found in both TG and control mice whereas luminal (cytokeratin-19+/ MUC1+) ErbB2+ papillary and adenomatous lesions developed almost exclusively in control mice. p65/RelA- and NF-kappa B DNA-binding activity were detected in mammary luminal lesions, but rarely in squamous metaplasias. Analysis of NF-kappa B family proteins and target genes using microarray data from a cohort of human mammary tumors revealed the expression of a canonical NF-kappa B pathway, but not non-canonical pathway proteins in HER2 | luminal cancers. HER2 | tumors also showed differential regulation of specific NF-kappa B target genes relative to basal and ER+ luminal cancers. Isolation of mammary cell populations enriched for stem and progenitor cell characteristics from an NF-kappa B-EGFP reporter mouse by fluorescence-activated cell sorting demonstrated that luminal progenitors contain activated NF-kappa B whereas the mammary stem cell-enriched population, does not. Together these data suggest that the canonical NF-kappa B pathway is active in normal luminal progenitor cells before transformation and is required for the formation of mammary luminal-type epithelial neoplasias. Oncogene (2009) 28, 2710-2722; doi:10.1038/onc.2009.131; published online 1 June 2009	[Pratt, M. A. C.; Tibbo, E.; Jansson, D.; Hurst, K.; Lau, R.; Niu, M. Y.] Univ Ottawa, Dept Cellular & Mol Med, Breast Canc Res Lab, Ottawa, ON K1H 8M5, Canada; [Robertson, S. J.] Ottawa Hosp, Dept Pathol & Lab Med, Ottawa, ON, Canada; [Perez-Iratxeta, C.] Sprott Ctr Stem Cell Res, Ottawa Hlth Res Inst, Ottawa, ON, Canada	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	Pratt, MAC (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, Breast Canc Res Lab, 451 Smyth Rd,RGN Hall, Ottawa, ON K1H 8M5, Canada.	cpratt@uottawa.ca		Jansson, Deidre/0000-0001-9757-8682; Bone, Kathleen Marie/0000-0002-2690-0934	Canadian Institutes of Health Research/Canadian Breast Cancer Research Alliance [FRN 79304]; Cancer Research Society Inc.	Canadian Institutes of Health Research/Canadian Breast Cancer Research Alliance(Canadian Institutes of Health Research (CIHR)); Cancer Research Society Inc.	Our thanks to Jun Wang, Jian Xuan and Jessica Sanguiliano for expert technical assistance. Supported by Grant no. FRN 79304 from the Canadian Institutes of Health Research/Canadian Breast Cancer Research Alliance and the Cancer Research Society Inc. to MACP.	Ackerman A.B., 1993, NEOPLASMS FOLLICULAR; Biswas DK, 2001, P NATL ACAD SCI USA, V98, P10386, DOI 10.1073/pnas.151257998; Calza S, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1517; Cao YX, 2007, P NATL ACAD SCI USA, V104, P15852, DOI 10.1073/pnas.0706728104; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Chen DY, 2003, ONCOGENE, V22, P4348, DOI 10.1038/sj.onc.1206532; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Demicco EG, 2005, MOL CELL BIOL, V25, P10136, DOI 10.1128/MCB.25.22.10136-10147.2005; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Grenier J, 2007, ANTICANCER RES, V27, P547; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Habib AA, 2001, J BIOL CHEM, V276, P8865, DOI 10.1074/jbc.M008458200; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang WC, 2007, MOL CELL, V26, P75, DOI 10.1016/j.molcel.2007.02.019; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528; Magness ST, 2004, J IMMUNOL, V173, P1561, DOI 10.4049/jimmunol.173.3.1561; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Pratt MAC, 2003, MOL CELL BIOL, V23, P6887, DOI 10.1128/MCB.23.19.6887-6900.2003; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Singh S, 2007, MOL CANCER THER, V6, P1973, DOI 10.1158/1535-7163.MCT-07-0063; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stingl J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2212; Tse GM, 2006, PATHOLOGY, V38, P16, DOI 10.1080/00313020500444625; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007; Wang XB, 2007, NAT CELL BIOL, V9, P470, DOI 10.1038/ncb1559; WIRAPATI P, 2008, BREAST CANCER RES, V10, P4; Zhou Y, 2005, ENDOCR-RELAT CANCER, V12, pS37, DOI 10.1677/erc.1.00977	37	62	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	30					2710	2722		10.1038/onc.2009.131	http://dx.doi.org/10.1038/onc.2009.131			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476OW	19483731				2022-12-17	WOS:000268452900002
J	Prasad, A; Park, IW; Allen, H; Zhang, X; Reddy, MVR; Boominathan, R; Reddy, EP; Groopman, JE				Prasad, A.; Park, I-W; Allen, H.; Zhang, X.; Reddy, M. V. R.; Boominathan, R.; Reddy, E. P.; Groopman, J. E.			Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells	ONCOGENE			English	Article						mantle cell lymphoma; cell cycle; cytotoxicity; apoptosis; sulfonyl compounds	INITIATION-FACTOR 4E; C-MYC; CASPASE-3 ACTIVATION; HUMAN CANCER; EXPRESSION; APOPTOSIS; PROTEIN; SURVIVAL; PATHWAY; DEATH	Mantle cell lymphoma (MCL) is characterized by the uncontrolled overexpression of cyclin D1. Styryl sulfonyl compounds have shown potent antitumor activity against MCL by inducing cell-cycle arrest and apoptosis. However, the exact molecular mechanism by which these compounds function is yet to be elucidated. Here, we show that the prototypical styryl sulfonyl compound ON 01910.Na decreased cyclin D1 and c-Myc protein levels in MCL cells, whereas mRNA levels of cyclin D1 were minimally affected. Notably, ON 01910.Na suppressed eukaryotic translation initiation factor 4E (eIF4E)-mediated cyclin D1 mRNA translation, decreased levels of phosphorylated Akt, mammalian target of Rapamycin (mTOR) and eIF4E-binding protein (eIF4E-BP), lowered the cap site binding activity of eIF4E and directly inhibited activity of phosphatidylinositol-3 kinase (PI-3K). Analysis of apoptotic signaling pathways revealed that ON 01910.Na induced the release of cytochrome c from mitochondria, altered expression of Bcl-2 family of proteins and stimulated activation of caspases. Taken together, styryl sulfonyls can cause a rapid decrease of cyclin D1 by blocking cyclin D1 mRNA translation through inhibition of the PI-3K/Akt/mTOR/eIF4E-BP signaling pathway and triggering a cytochrome c-dependent apoptotic pathway in MCL cells.	[Groopman, J. E.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Expt Med,Dept Med, Boston, MA 02215 USA; [Reddy, M. V. R.; Boominathan, R.; Reddy, E. P.] Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Biochem, Philadelphia, PA 19122 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Groopman, JE (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Expt Med,Dept Med, 330 Brookline Ave, Boston, MA 02215 USA.	jgroopma@bidmc.harvard.edu	Reddy, E. Premkumar/F-6233-2011		SBIR [1 R43 CA134108-01A1];  [CA109820]; NATIONAL CANCER INSTITUTE [R01CA109820, R43CA134108] Funding Source: NIH RePORTER	SBIR; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a charitable contribution from Mr and Mrs Henryk and Rochelle Schwarz and SBIR grant # 1 R43 CA134108-01A1. E Premkumar Reddy was supported by grant CA109820. Disclosure: Dr Groopman is a consultant to Onconova Therapeutics, Inc.	Adams JM, 2007, CURR OPIN IMMUNOL, V19, P488, DOI 10.1016/j.coi.2007.05.004; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Aoki M, 2004, P NATL ACAD SCI USA, V101, P13613, DOI 10.1073/pnas.0405454101; Armengol G, 2007, CANCER RES, V67, P7551, DOI 10.1158/0008-5472.CAN-07-0881; Bertoni F, 2006, HEMATOL ONCOL, V24, P22, DOI 10.1002/hon.767; Bertoni F, 2007, INT J BIOCHEM CELL B, V39, P1747, DOI 10.1016/j.biocel.2007.04.026; Brady SC, 2005, MOL CELL BIOL, V25, P10543, DOI 10.1128/MCB.25.23.10543-10555.2005; Brauns SC, 2005, ANTICANCER RES, V25, P4197; Campo E, 1999, SEMIN HEMATOL, V36, P115; de Leeuw RJ, 2004, HUM MOL GENET, V13, P1827, DOI 10.1093/hmg/ddh195; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Ely S, 2005, CANCER RES, V65, P11345, DOI 10.1158/0008-5472.CAN-05-2159; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; Kawamata N, 2007, BLOOD, V110, P2667, DOI 10.1182/blood-2005-11-026344; Kim R, 2005, CANCER-AM CANCER SOC, V103, P1551, DOI 10.1002/cncr.20947; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LEROUX D, 1991, BRIT J HAEMATOL, V77, P346, DOI 10.1111/j.1365-2141.1991.tb08582.x; Liao D. Joshua, 2007, Critical Reviews in Oncogenesis, V13, P93; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Martin SA, 2005, CANCER RES, V65, P10657, DOI 10.1158/0008-5472.CAN-05-2087; Mattoon DR, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-24; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Park IW, 2007, ONCOGENE, V26, P5635, DOI 10.1038/sj.onc.1210350; Prasad A, 2007, J LEUKOCYTE BIOL, V82, P465, DOI 10.1189/jlb.1106678; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Reddy MVR, 2008, J MED CHEM, V51, P86, DOI 10.1021/jm701077b; Rizzatti EG, 2005, BRIT J HAEMATOL, V130, P516, DOI 10.1111/j.1365-2141.2005.05630.x; Rosenwald A, 2003, CANCER CELL, V3, P185, DOI 10.1016/S1535-6108(03)00028-X; ROSENWALD IB, 1995, J BIOL CHEM, V270, P21176, DOI 10.1074/jbc.270.36.21176; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Vermeulen K, 2005, ANN HEMATOL, V84, P627, DOI 10.1007/s00277-005-1065-x; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Witzig TE, 2005, J CLIN ONCOL, V23, P6409, DOI 10.1200/JCO.2005.55.017; YODERHILL J, 1993, J BIOL CHEM, V268, P5566; ZUCCA E, 1995, ANN ONCOL, V6, P257, DOI 10.1093/oxfordjournals.annonc.a059155	41	62	64	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	12					1518	1528		10.1038/onc.2008.502	http://dx.doi.org/10.1038/onc.2008.502			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	424AH	19198627				2022-12-17	WOS:000264537400004
J	Bach, C; Mueller, D; Buhl, S; Garcia-Cuellar, MP; Slany, RK				Bach, C.; Mueller, D.; Buhl, S.; Garcia-Cuellar, M. P.; Slany, R. K.			Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2	ONCOGENE			English	Article						CxxC domain; MLL; MLL2; transformation	HISTONE METHYLTRANSFERASE COMPLEX; DROSOPHILA-TRITHORAX; REPRESSION DOMAIN; BINDING PROTEIN; HRX-ENL; MLL; GENE; DNA; TRANSFORMATION; MENIN	The mixed-lineage leukemia (MLL) family of histone methyltransferases has become notorious for the participation of the founding member, MLL, in fusion proteins that cause acute leukemia. Despite structural conservation, no other MLL homolog has so far been found in a similar arrangement. Here, we show that fusion proteins based on Mll2, the closest relative of MLL, are incapable of transforming hematopoietic cells. Elaborate swap experiments identified the small CxxC zinc-binding region of Mll2 and an adjacent 'post-CxxC' stretch of basic amino acids as the essential determinants for the observed difference. Gel shift experiments indicated that the combined CxxC and post-CxxC domains of MLL and Mll2 possess almost indistinguishable DNA-binding properties in vitro. Within the cellular environment, however, these motifs guided MLL and Mll2 to a largely nonoverlapping target gene repertoire, as evidenced by nuclear localization, reporter assays, and measurements of homeobox gene levels in primary cells expressing MLL and Mll2 fusion proteins. Therefore, the CxxC domain appears to be a promising target for therapies aimed at MLL fusion proteins without affecting the general function of other MLL family members.	[Bach, C.; Mueller, D.; Buhl, S.; Garcia-Cuellar, M. P.; Slany, R. K.] Univ Erlangen Nurnberg, Dept Genet, D-91058 Erlangen, Bavaria, Germany	University of Erlangen Nuremberg	Slany, RK (corresponding author), Univ Erlangen Nurnberg, Dept Genet, Staudtstr 5,Bldg A2, D-91058 Erlangen, Bavaria, Germany.	rslany@biologie.uni-erlangen.de		Bach, Christian/0000-0003-4675-7896	DFG [SL27/6-2, SFB473/D2]; Jose-Carerras-Stiftung; Curt-Bohnewald-Fond	DFG(German Research Foundation (DFG)); Jose-Carerras-Stiftung; Curt-Bohnewald-Fond	We thank Bernd Zeisig and Silvio Scheel for help in early stages of this work. Technical support of Renate Zimmermann and sharing of reagents by Francis Stewart, Boris Fehse and Carol Stocking is gratefully acknowledged. RKS was supported by DFG Grant SL27/6-2 and in part by SFB473/D2. Equipment funding came from Jose-Carerras-Stiftung and Curt-Bohnewald-Fond.	Allen MD, 2006, EMBO J, V25, P4503, DOI 10.1038/sj.emboj.7601340; Ayton PM, 2004, MOL CELL BIOL, V24, P10470, DOI 10.1128/MCB.24.23.10470-10478.2004; Birke M, 2002, NUCLEIC ACIDS RES, V30, P958, DOI 10.1093/nar/30.4.958; Caslini C, 2007, CANCER RES, V67, P7275, DOI 10.1158/0008-5472.CAN-06-2369; Chen W, 2008, CANCER CELL, V13, P432, DOI 10.1016/j.ccr.2008.03.005; Cheung N, 2007, NAT CELL BIOL, V9, P1208, DOI 10.1038/ncb1642; Demers C, 2007, MOL CELL, V27, P573, DOI 10.1016/j.molcel.2007.06.022; Dou YL, 2006, NAT STRUCT MOL BIOL, V13, P713, DOI 10.1038/nsmb1128; Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031; FitzGerald KT, 1999, GENOMICS, V59, P187, DOI 10.1006/geno.1999.5860; Glaser S, 2006, DEVELOPMENT, V133, P1423, DOI 10.1242/dev.02302; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Huntsman DG, 1999, ONCOGENE, V18, P7975, DOI 10.1038/sj.onc.1203291; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Lee JH, 2001, J BIOL CHEM, V276, P44669, DOI 10.1074/jbc.M107179200; Mueller D, 2007, BLOOD, V110, P4445, DOI 10.1182/blood-2007-05-090514; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Schreiner SA, 1999, LEUKEMIA, V13, P1525, DOI 10.1038/sj.leu.2401534; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Weber K, 2008, MOL THER, V16, P698, DOI 10.1038/mt.2008.6; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Xia ZB, 2003, P NATL ACAD SCI USA, V100, P8342, DOI 10.1073/pnas.1436338100; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Yokoyama A, 2005, CELL, V123, P207, DOI 10.1016/j.cell.2005.09.025; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; Zeisig BB, 2004, MOL CELL BIOL, V24, P617, DOI 10.1128/MCB.24.2.617-628.2004; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	29	62	62	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2009	28	6					815	823		10.1038/onc.2008.443	http://dx.doi.org/10.1038/onc.2008.443			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406UI	19060922				2022-12-17	WOS:000263320000004
J	Brooke, GN; Parker, MG; Bevan, CL				Brooke, G. N.; Parker, M. G.; Bevan, C. L.			Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression	ONCOGENE			English	Article						androgen receptor; prostate cancer; co-activators; anti-androgens; SARMs	LIGAND-BINDING DOMAIN; MOLECULAR-MECHANISMS; CELL-GROWTH; WILD-TYPE; COREGULATORS; RECOGNITION; COFACTORS; MUTATION; LNCAP; FXXLF	Prostate tumour growth depends on androgens; hence treatment includes androgen ablation and anti-androgens. Eventually tumours progress and in approximately 30% of patients this is associated with mutation of the androgen receptor. Several receptor variants associated with advanced disease show promiscuous activation by other hormones and anti-androgens. Such loss of speci.city could promote receptor activation, hence tumour growth, in the absence of conventional ligands, explaining therapy failure. We aimed to elucidate mechanisms by which alternative ligands promote receptor activation. The three most commonly identified variants in tumours (with amino-acid substitutions H874Y, T877A and T877S) and wild-type receptor showed differences in co-activator recruitment dependent upon ligand and the interaction motif utilized. Co-expression and knockdown of co-activators that bind via leucine or phenylalanine motifs, combined with chromatin immunoprecipitation and quantitative PCR, revealed these preferences extend to co-activator recruitment in vivo and affect receptor activity at the transcriptional level, with subsequent effects on target gene regulation. The findings suggest that mutant receptors, activated by alternative ligands, drive growth via different mechanisms to androgenactivated wild-type receptor. Tumours may hence behave differently dependent upon any androgen receptor mutation present and what ligand is driving growth, as distinct subsets of genes may be regulated.	[Brooke, G. N.; Bevan, C. L.] Univ London Imperial Coll Sci Technol & Med, Androgen Signalling Lab, Dept Oncol, London W12 0NN, England; [Parker, M. G.] Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, London W12 0NN, England	Imperial College London; Imperial College London	Bevan, CL (corresponding author), Univ London Imperial Coll Sci Technol & Med, Androgen Signalling Lab, Dept Oncol, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	charlotte.bevan@imperial.ac.uk	Brooke, Greg/C-9426-2013; Brooke, Greg/ABF-4859-2020; Bevan, Charlotte L/K-2276-2012; Bevan, Charlotte/T-7769-2019	Bevan, Charlotte L/0000-0002-7533-0552; Brooke, Greg/0000-0003-4501-4134	Medical Research Council Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Agoulnik IU, 2005, CANCER RES, V65, P7959, DOI 10.1158/0008-5472.CAN-04-3541; Askew EB, 2007, J BIOL CHEM, V282, P25801, DOI 10.1074/jbc.M703268200; BERREVOETS CA, 1993, J STEROID BIOCHEM, V46, P731, DOI 10.1016/0960-0760(93)90313-L; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Callewaert L, 2004, MOL ENDOCRINOL, V18, P1438, DOI 10.1210/me.2003-0313; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chmelar R, 2007, INT J CANCER, V120, P719, DOI 10.1002/ijc.22365; Dubbink HJ, 2004, MOL ENDOCRINOL, V18, P2132, DOI 10.1210/me.2003-0375; Duff J, 2005, MOL ENDOCRINOL, V19, P2943, DOI 10.1210/me.2005-0231; Estebanez-Perpina E, 2005, J BIOL CHEM, V280, P8060, DOI 10.1074/jbc.M407046200; Fujimoto N, 2001, UROLOGY, V58, P289, DOI 10.1016/S0090-4295(01)01117-7; Gamble SC, 2007, ONCOGENE, V26, P1757, DOI 10.1038/sj.onc.1209967; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Goktas S, 1999, SEMIN ONCOL, V26, P162; Gottlieb B, 2004, HUM MUTAT, V23, P527, DOI 10.1002/humu.20044; Gregory CW, 1998, CANCER RES, V58, P5718; Gregory CW, 2001, CANCER RES, V61, P4315; He B, 2002, J BIOL CHEM, V277, P25631, DOI 10.1074/jbc.M202809200; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; Hsu CL, 2003, J BIOL CHEM, V278, P23691, DOI 10.1074/jbc.M211908200; Hu YC, 2004, J BIOL CHEM, V279, P33438, DOI 10.1074/jbc.M401781200; Hur E, 2004, PLOS BIOL, V2, P1303, DOI 10.1371/journal.pbio.0020274; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Kazmin D, 2006, MOL ENDOCRINOL, V20, P1201, DOI 10.1210/me.2005-0309; Kemppainen JA, 1999, MOL ENDOCRINOL, V13, P440, DOI 10.1210/me.13.3.440; LI J, 2007, MOL ENDOCRINOL; Li P, 2002, AM J PATHOL, V161, P1467, DOI 10.1016/S0002-9440(10)64422-7; Li XT, 2003, MOL CELL BIOL, V23, P3763, DOI 10.1128/MCB.23.11.3763-3773.2003; Linja MJ, 2004, CLIN CANCER RES, V10, P1032, DOI 10.1158/1078-0432.CCR-0990-3; Linja MJ, 2001, CANCER RES, V61, P3550; Lu S, 1997, CANCER RES, V57, P4511; Maki HE, 2006, PROSTATE, V66, P1391, DOI 10.1002/pros.20427; Marcelli M, 2000, CANCER RES, V60, P944; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; McDonald S, 2000, CANCER RES, V60, P2317; McEwan IJ, 2004, ENDOCR-RELAT CANCER, V11, P281, DOI 10.1677/erc.0.0110281; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Mestayer C, 2003, PROSTATE, V56, P192, DOI 10.1002/pros.10229; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P7379, DOI 10.1073/pnas.95.13.7379; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Ozers MS, 2007, BIOCHEMISTRY-US, V46, P683, DOI 10.1021/bi061321b; Powell SM, 2004, ENDOCR-RELAT CANCER, V11, P117, DOI 10.1677/erc.0.0110117; Rogatsky I, 2001, EMBO J, V20, P6071, DOI 10.1093/emboj/20.21.6071; Segal S, 2006, EXPERT OPIN INV DRUG, V15, P377, DOI 10.1517/13543784.15.4.377; Steketee K, 2002, INT J CANCER, V100, P309, DOI 10.1002/ijc.10495; Taplin ME, 2007, NAT CLIN PRACT ONCOL, V4, P236, DOI 10.1038/ncponc0765; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Ulrix W, 1999, FEBS LETT, V455, P23, DOI 10.1016/S0014-5793(99)00845-5; van de Wijngaart DJ, 2006, J BIOL CHEM, V281, P19407, DOI 10.1074/jbc.M602567200; VELDSCHOLTE J, 1994, J STEROID BIOCHEM, V49, P341, DOI 10.1016/0960-0760(94)90277-1; Verrijdt G, 2003, MOL GENET METAB, V78, P175, DOI 10.1016/S1096-7192(03)00003-9; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922	55	62	64	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2008	27	21					2941	2950		10.1038/sj.onc.1210955	http://dx.doi.org/10.1038/sj.onc.1210955			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	298IP	18037956	Green Submitted			2022-12-17	WOS:000255681700001
J	Gallego, MA; Ballot, C; Kluza, J; Hajji, N; Martoriati, A; Castera, L; Cuevas, C; Formstecher, P; Joseph, B; Kroemer, G; Bailly, C; Marchetti, P				Gallego, M-A; Ballot, C.; Kluza, J.; Hajji, N.; Martoriati, A.; Castera, L.; Cuevas, C.; Formstecher, P.; Joseph, B.; Kroemer, G.; Bailly, C.; Marchetti, P.			Overcoming chemoresistance of non-small cell lung carcinoma through restoration of an AIF-dependent apoptotic pathway	ONCOGENE			English	Article						apoptosis; mitochondria; chemotherapy	CANCER-CELLS; MITOCHONDRIAL-DNA; LAMELLARIN-D; DEATH; INHIBITOR; CHEMOTHERAPY; TRANSLOCATION; COMBINATION; EXPRESSION; REDUCTION	Non-small cell lung carcinomas (NSCLCs) are typically resistant against apoptosis induced by standard chemotherapy. We evaluated the effects of the two potential antitumor agents of the lamellarin class on a highly apoptosis-resistant NSCLC cell line. Both the marine alkaloid lamellarin-D and its synthetic amino derivative PM031379 induced the activation of Bax, the mitochondrial release of cytochrome c and apoptosis-inducing factor (AIF), as well as the activation of caspase-3. However, only PM031379 triggered cell death and sign of nuclear apoptosis coupled to the nuclear translocation of AIF. Depletion of AIF with small interfering RNA or microinjection of a neutralizing anti-AIF antibody largely prevented PM031379-induced cytotoxicity, underscoring the essential contribution of AIF to NSCLC killing. Using NSCLC cells lacking mitochondrial DNA, we showed that the generation of mitochondrial reactive oxygen species (ROS) was crucial for the PM031379-induced translocation of AIF to the nucleus and subsequently cell death. Pretreatment of NSCLC cells with menadione, a mitochondrial ROS generator, was able to restore the deficient chemotherapy-induced apoptosis of NSCLC cells. Altogether, these data suggest that mitochondrial ROS generation is crucial for overriding the chemoresistance of NSCLC cells. Moreover, this study delineates the unique mechanism of action of lamellarins as potential anticancer agents.	[Gallego, M-A; Ballot, C.; Kluza, J.; Martoriati, A.; Castera, L.; Formstecher, P.; Bailly, C.; Marchetti, P.] Univ Lille 2, Fac Med, INSERM, Jean Pierre Aubert Res Ctr,U837, F-59045 Lille, France; [Hajji, N.; Joseph, B.] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Cuevas, C.] PharmaMar, E-28770 Madrid, Spain; [Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France	Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Karolinska Institutet; PharmaMar; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Marchetti, P (corresponding author), Univ Lille 2, Fac Med, INSERM, Jean Pierre Aubert Res Ctr,U837, 1 Pl Verdun, F-59045 Lille, France.	philippe.marchetti@lille.inserm.fr	hajji, nabil/AAV-1435-2020; Kroemer, Guido/AAY-9859-2020; BAILLY, Christian/AAK-2799-2021; KROEMER, Guido/B-4263-2013; Kluza, Jérome/B-6312-2012	BAILLY, Christian/0000-0002-2973-9357; KROEMER, Guido/0000-0002-9334-4405; Kluza, Jérome/0000-0002-7346-1305; MARCHETTI, Philippe/0000-0002-4663-6800; Castera, Laurent/0000-0002-0459-3400; Joseph, Bertrand/0000-0001-5655-9979; Martoriati, Alain/0000-0002-5684-1728				Anderson CP, 1997, EUR J CANCER, V33, P2016, DOI 10.1016/S0959-8049(97)00203-7; Armand R, 2004, TOXICOL APPL PHARM, V196, P68, DOI 10.1016/j.taap.2003.12.001; Bailly Christian, 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P363, DOI 10.2174/1568011043352939; Bartling B, 2004, EXP CELL RES, V298, P83, DOI 10.1016/j.yexcr.2004.04.007; BERGH J, 1985, ACTA PATH MICRO IM A, V93, P133; Broker LE, 2004, CANCER RES, V64, P27, DOI 10.1158/0008-5472.CAN-03-3060; Cande C, 2004, J CELL SCI, V117, P4461, DOI 10.1242/jcs.01356; Ekedahl J, 2003, CANCER BIOL THER, V2, P663; Engel RH, 2006, FRONT BIOSCI-LANDMRK, V11, P300, DOI 10.2741/1798; Facompre M, 2003, CANCER RES, V63, P7392; Fennell DA, 2005, CLIN CANCER RES, V11, P2097, DOI 10.1158/1078-0432.CCR-04-1482; Ferreira CG, 2001, ANN ONCOL, V12, P799, DOI 10.1023/A:1011167113067; Ferreira CG, 2001, CLIN CANCER RES, V7, P2468; Furre IE, 2005, CANCER RES, V65, P11051, DOI 10.1158/0008-5472.CAN-05-0510; Gabellini N, 2006, J CELL PHYSIOL, V207, P711, DOI 10.1002/jcp.20627; Gallego MA, 2004, ONCOGENE, V23, P6282, DOI 10.1038/sj.onc.1207835; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Joseph B, 2001, ONCOGENE, V20, P2877, DOI 10.1038/sj.onc.1204402; Kang YH, 2004, CANCER RES, V64, P8960, DOI 10.1158/0008-5472.CAN-04-1830; Kang YH, 2004, INT J CANCER, V112, P385, DOI 10.1002/ijc.20424; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; Kluza J, 2006, CANCER RES, V66, P3177, DOI 10.1158/0008-5472.CAN-05-1929; Krishnaiah P, 2004, J NAT PROD, V67, P1168, DOI 10.1021/np030503t; Marchetti P, 1996, CANCER RES, V56, P2033; Marchetti P., 1996, APOPTOSIS, V1, P119; Murahashi H, 2003, J LEUKOCYTE BIOL, V73, P399, DOI 10.1189/jlb.0702335; Nyman U, 2005, J BIOL CHEM, V280, P34159, DOI 10.1074/jbc.M500394200; O'Connor K, 2006, APOPTOSIS, V11, P1205, DOI 10.1007/s10495-006-6796-1; Okouoyo S, 2004, INT J CANCER, V108, P580, DOI 10.1002/ijc.11585; Park MT, 2005, BLOOD, V105, P1724, DOI 10.1182/blood-2004-07-2938; Park YC, 2005, LIFE SCI, V77, P2059, DOI 10.1016/j.lfs.2005.04.021; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Yang LL, 2003, CANCER RES, V63, P831; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhivotovsky B, 2003, SEMIN CANCER BIOL, V13, P125, DOI 10.1016/S1044-579X(02)00130-X	37	62	63	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 27	2008	27	14					1981	1992		10.1038/sj.onc.1210833	http://dx.doi.org/10.1038/sj.onc.1210833			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17906690				2022-12-17	WOS:000254359100003
J	Delys, L; Detours, V; Franc, B; Thomas, G; Bogdanova, T; Tronko, M; Libert, F; Dumont, JE; Maenhaut, C				Delys, L.; Detours, V.; Franc, B.; Thomas, G.; Bogdanova, T.; Tronko, M.; Libert, F.; Dumont, J. E.; Maenhaut, C.			Gene expression and the biological phenotype of papillary thyroid carcinomas	ONCOGENE			English	Article						cancer; thyroid; microarrays; molecular phenotype	GROWTH-FACTOR RECEPTOR; CANCER; INVASION; MECHANISMS; PROFILES; REVEALS; BRAF; OVEREXPRESSION; METASTASIS; MIGRATION	The purpose of this paper is to correlate the molecular phenotype of papillary thyroid carcinoma (PTC) to their biological pathology. We hybridized 26 PTC on microarrays and showed that nearly 44% of the transcriptome was regulated in these tumors. We then combined our data set with two published PTC microarray studies to produce a platform- and study-independent list of PTC-associated genes. We further confirmed the mRNA regulation of 15 genes from this list by quantitative reverse transcription PCR. Analysis of this list with statistical tools led to several conclusions: (1) there is a change in cell population with an increased expression of genes involved in the immune response, reflecting lymphocyte infiltration in the tumor compared to the normal tissue. (2) The c-jun N-terminal kinase pathway is activated by overexpression of its components. ( 3) The activation of ERKK1/2 by genetic alterations is supplemented by activation of the epidermal growth factor but not of the insulin-like growth factor signaling pathway. (4) There is a downregulation of immediate early genes. (5) We observed an overexpression of many proteases in accordance with tumor remodeling, and suggested a probable role of S100 proteins and annexin A2 in this process. (6) Numerous overexpressed genes favor the hypothesis of a collective migration mode of tumor cells.	[Delys, L.; Detours, V.; Libert, F.; Dumont, J. E.; Maenhaut, C.] Univ Libre Bruxelles, Inst Interdisciplinary Res, Sch Med, Brussels, Belgium; [Franc, B.] Univ Versailles St Quentin Yvelines, Serv Anat & Cytol Pathol, Fac Med Paris Ile France Ouest, Hop Ambroise Pare APHP, Boulogne, France; [Thomas, G.] Singleton Hosp, S W Wales Canc Inst, Swansea Clin Sch, Swansea SA2 8QA, W Glam, Wales; [Bogdanova, T.; Tronko, M.] Kiev Endocrinol & Metab Res Inst, Kiev, Ukraine	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Saclay; Singleton Hospital; National Academy of Medical Sciences of Ukraine; V. P. Komissarenko Institute of Endocrinology & Metabolism of the National Academy of Medical Science of Ukraine	Delys, L (corresponding author), Free Univ Brussels, Inst Interdisciplinary Res, Sch Med, Campus Erasme,Route Lennik 808, B-1070 Brussels, Belgium.	laurent.delys@ulb.ac.be; cmaenhau@ulb.ac.be	Tronko, Mykola/AAQ-3327-2021	Tronko, Mykola/0000-0001-7421-0981; Bogdanova, Tetiana/0000-0001-5119-0236				Albert L, 2003, J CELL PHYSIOL, V195, P168, DOI 10.1002/jcp.10252; Baris O, 2005, ONCOGENE, V24, P4155, DOI 10.1038/sj.onc.1208578; Borrello MG, 2005, P NATL ACAD SCI USA, V102, P14825, DOI 10.1073/pnas.0503039102; Ciampi R, 2005, ENDOCR PATHOL, V16, P163, DOI 10.1385/EP:16:3:163; Dano K, 2005, THROMB HAEMOSTASIS, V93, P676, DOI 10.1160/TH05-01-0054; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Detours V, 2005, BRIT J CANCER, V92, P1545, DOI 10.1038/sj.bjc.6602521; Farooq A, 2004, CELL SIGNAL, V16, P769, DOI 10.1016/j.cellsig.2003.12.008; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Fluge O, 2006, THYROID, V16, P161; Fluge O, 2000, INT J CANCER, V87, P763, DOI 10.1002/1097-0215(20000915)87:6<763::AID-IJC1>3.0.CO;2-T; Friedl P, 2004, CURR OPIN CELL BIOL, V16, P14, DOI 10.1016/j.ceb.2003.11.001; Gimm O, 2001, CANCER LETT, V163, P143, DOI 10.1016/S0304-3835(00)00697-2; Giordano TJ, 2005, ONCOGENE, V24, P6646, DOI 10.1038/sj.onc.1208822; Haugen DRF, 1996, CANCER RES, V56, P1184; Hawthorn L, 2004, HEAD NECK-J SCI SPEC, V26, P1069, DOI 10.1002/hed.20099; HOELTING T, 1994, J CLIN ENDOCR METAB, V79, P401, DOI 10.1210/jc.79.2.401; Hosack DA, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r70; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Jarzab B, 2005, CANCER RES, V65, P1587, DOI 10.1158/0008-5472.CAN-04-3078; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; LiVolsi VA, 2004, WHO CLASSIFICATION T, P57; Mandl M, 2005, MOL CELL BIOL, V25, P1830, DOI 10.1128/MCB.25.5.1830-1845.2005; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Mitsiades CS, 2006, J CLIN ENDOCR METAB, V91, P3662, DOI 10.1210/jc.2006-0055; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Pavlidis P, 2003, BIOINFORMATICS, V19, P1620, DOI 10.1093/bioinformatics/btg227; Powell DJ, 2003, J IMMUNOL, V170, P861, DOI 10.4049/jimmunol.170.2.861; Prasad ML, 2005, MODERN PATHOL, V18, P48, DOI 10.1038/modpathol.3800235; Semov A, 2005, J BIOL CHEM, V280, P20833, DOI 10.1074/jbc.M412653200; Shin E, 2004, YONSEI MED J, V45, P306, DOI 10.3349/ymj.2004.45.2.306; Sid B, 2006, INT J BIOCHEM CELL B, V38, P1729, DOI 10.1016/j.biocel.2006.04.005; Skrzydlewska E, 2005, WORLD J GASTROENTERO, V11, P1251, DOI 10.3748/wjg.v11.i9.1251; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vasko V, 2007, P NATL ACAD SCI USA, V104, P2803, DOI 10.1073/pnas.0610733104; Wattel S, 2005, ONCOGENE, V24, P6902, DOI 10.1038/sj.onc.1208849; Zou M, 2005, BRIT J CANCER, V93, P1277, DOI 10.1038/sj.bjc.6602856	42	62	68	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 13	2007	26	57					7894	7903		10.1038/sj.onc.1210588	http://dx.doi.org/10.1038/sj.onc.1210588			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248ON	17621275				2022-12-17	WOS:000252163500007
J	Li, J; Wood, WH; Becker, KG; Weeraratna, AT; Morin, PJ				Li, J.; Wood, W. H., III; Becker, K. G.; Weeraratna, A. T.; Morin, P. J.			Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells	ONCOGENE			English	Article						cisplatin; connexin; p53; microarrays; ovarian cancer; expression profling	P53 STATUS; INTERCELLULAR COMMUNICATION; REDUCED EXPRESSION; ANTICANCER AGENTS; CARCINOMA CELLS; LINES; IDENTIFICATION; APOPTOSIS; BCL-2; CHEMOTHERAPY	The molecular pathways activated in response to acute cisplatin exposure, as well as the mechanisms involved in the long-term development of cisplatin-resistant cancer cells remain unclear. Using whole genome oligonucleotide microarrays, we have examined the kinetics of gene expression changes in a cisplatin-sensitive cell line, A2780, and its cisplatin-resistant derivative, ACRP. Both sensitive and resistant cell lines exhibited a very similar response of p53-inducible genes as early as 16 h after treatment. This p53 response was further increased at the 24-h time point. These experiments identify p53 as the main pathway producing a large-scale transcriptional response after cisplatin treatment in these cells containing wild-type p53. Consistent with a role for the p53 response in cisplatin sensitivity, knock down of the p53 protein with small interfering RNA led to a twofold decrease in cell survival in the resistant cells. In addition, our analysis also allowed the identification of several genes that are differentially expressed between sensitive and resistant cells. These genes include GJA1 (encoding connexin 43 (Cx43)) and TWIST1, which are highly upregulated in cisplatin-resistant cells. The importance of Cx43 in drug resistance was demonstrated through functional analyses, although paradoxically, inhibition of Cx43 function in high expressing cells led to an increase in drug resistance. The pathways important in cisplatin response, as well as the genes found differentially expressed between cisplatin-resistant and -sensitive cells, may represent targets for therapy aimed at reversing drug resistance.	NIA, Gerontol Res Ctr, Cellular & Mol Biol Lab, Baltimore, MD 21224 USA; NIA, Gerontol Res Ctr, Resources Res Branch, Baltimore, MD 21224 USA; NIA, Gerontol Res Ctr, Immunol Lab, Baltimore, MD 21224 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University; Johns Hopkins Medicine	Morin, PJ (corresponding author), NIA, Gerontol Res Ctr, Cellular & Mol Biol Lab, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	morinp@grc.nia.nih.gov		Becker, Kevin/0000-0002-6794-6656	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE ON AGING [Z01AG000512] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akervall J, 2004, CLIN CANCER RES, V10, P8204, DOI 10.1158/1078-0432.CCR-04-0722; Amundson SA, 2005, ONCOGENE, V24, P4572, DOI 10.1038/sj.onc.1208653; Azzam EI, 2003, CANCER RES, V63, P7128; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Buttitta F, 1997, BRIT J CANCER, V75, P230, DOI 10.1038/bjc.1997.38; Cheng TC, 2006, CANCER CHEMOTH PHARM, V58, P384, DOI 10.1007/s00280-005-0171-8; Dalton WS, 1999, DRUG RESIST UPDATE, V2, P285, DOI 10.1054/drup.1999.0097; DeFeudis P, 1997, BRIT J CANCER, V76, P474, DOI 10.1038/bjc.1997.412; Dong Y, 1997, INT J CANCER, V74, P407, DOI 10.1002/(SICI)1097-0215(19970822)74:4<407::AID-IJC8>3.0.CO;2-Z; Einhorn LH, 2002, P NATL ACAD SCI USA, V99, P4592, DOI 10.1073/pnas.072067999; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; Fernstrom MJ, 2002, EXP MOL PATHOL, V73, P54, DOI 10.1006/exmp.2002.2436; Filmus J, 2001, GLYCOBIOLOGY, V11, p19R, DOI 10.1093/glycob/11.3.19R; Hawkins DS, 1996, CANCER RES, V56, P892; Herod JJO, 1996, CANCER RES, V56, P2178; Hough CD, 2001, CANCER RES, V61, P3869; Kang HC, 2004, CLIN CANCER RES, V10, P272, DOI 10.1158/1078-0432.CCR-1025-3; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; Kerley-Hamilton JS, 2005, ONCOGENE, V24, P6090, DOI 10.1038/sj.onc.1208755; Koivusalo R, 2002, CANCER RES, V62, P7364; KOPEMAIER P, 1992, CHEM-BIOL INTERACT, V82, P295; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lin HC, 1999, CANCER RES, V59, P807; Lin JHC, 2003, J NEUROSCI, V23, P430, DOI 10.1523/JNEUROSCI.23-02-00430.2003; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Moorehead RA, 2000, BIOCHEM PHARMACOL, V59, P337, DOI 10.1016/S0006-2952(99)00333-0; Morin PJ, 2003, DRUG RESIST UPDATE, V6, P169, DOI 10.1016/S1368-7646(03)00059-1; OConnor PM, 1997, CANCER RES, V57, P4285; OZOLS RF, 1984, SEMIN ONCOL, V11, P251; Pestell KE, 1998, INT J CANCER, V77, P913, DOI 10.1002/(SICI)1097-0215(19980911)77:6<913::AID-IJC19>3.0.CO;2-1; Pestell KE, 2000, MOL PHARMACOL, V57, P503, DOI 10.1124/mol.57.3.503; Reles A, 2001, CLIN CANCER RES, V7, P2984; Roberts D, 2005, BRIT J CANCER, V92, P1149, DOI 10.1038/sj.bjc.6602447; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Shen DW, 2004, MOL PHARMACOL, V66, P789, DOI 10.1124/mol.66.4.789; Sherman-Baust CA, 2003, CANCER CELL, V3, P377, DOI 10.1016/S1535-6108(03)00058-8; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Takata R, 2005, CLIN CANCER RES, V11, P2625, DOI 10.1158/1078-0432.CCR-04-1988; Tanaka T, 2001, MOL CARCINOGEN, V30, P176, DOI 10.1002/mc.1026; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Varma RR, 2005, ONCOL REP, V14, P925; Wang XH, 2004, ONCOGENE, V23, P474, DOI 10.1038/sj.onc.1207128; Wernyj RP, 2004, DRUG RESIST UPDATE, V7, P227, DOI 10.1016/j.drup.2004.08.002; Whiteside MA, 2004, ONCOGENE, V23, P744, DOI 10.1038/sj.onc.1207164; Wu GS, 1996, CLIN CANCER RES, V2, P623	51	62	66	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2860	2872		10.1038/sj.onc.1210086	http://dx.doi.org/10.1038/sj.onc.1210086			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17072341				2022-12-17	WOS:000246210800006
J	Mamidipudi, V; Dhillon, NK; Parman, T; Miller, LD; Lee, KC; Cartwright, CA				Mamidipudi, V.; Dhillon, N. K.; Parman, T.; Miller, L. D.; Lee, K. C.; Cartwright, C. A.			RACK1 inhibits colonic cell growth by regulating Src activity at cell cycle checkpoints	ONCOGENE			English	Article						RACK1; Src; colon cancer; cell cycle regulation	PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; TRANSFORMED-CELLS; FAMILY KINASES; SAM68; RNA; PROGRESSION; ACTIVATION; SUBSTRATE; MITOSIS	Previously, we showed that Src tyrosine kinases are activated early in the development of human colon cancer and are suppressed as intestinal cells differentiate. We identified RACK1 as an endogenous substrate, binding partner and inhibitor of Src. Here we show (by over-expressing RACK1, depleting Src or RACK1 and utilizing cell-permeable peptides that perturb RACK1's interaction with Src) that RACK1 regulates growth of colon cells by suppressing Src activity at G(1) and mitotic checkpoints, and consequently delaying cell cycle progression. Activated Src rescues RACK1-inhibited growth of HT-29 cells. Conversely, inhibiting Src abolishes growth promoted by RACK1 depletion in normal cells. Two potential mechanisms whereby RACK1 regulates mitotic exit are identified: suppression of Src-mediated Sam68 phosphorylation and maintenance of the cyclin-dependent kinase (CDK) 1-cyclin B complex in an active state. Our results reveal novel mechanisms of cell cycle control in G1 and mitosis of colon cells. The significance of this work lies in the discovery of a mechanism by which the growth of colon cancer cells can be slowed, by RACK1 suppression of an oncogenic kinase at critical cell cycle checkpoints. Small molecules that mimic RACK1 function may provide a powerful new approach to the treatment of colon cancer.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University	Cartwright, CA (corresponding author), Stanford Univ, Sch Med, Dept Med, M211 Alway Bldg,300 Pasteur Dr, Stanford, CA 94305 USA.	chris.cartwright@stanford.edu			NIDDK NIH HHS [DK43743, DK56339] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056339, R01DK043743, R29DK043743] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Cartwright C, 1998, GASTROENTEROLOGY, V114, P1335, DOI 10.1016/S0016-5085(98)70443-3; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2002, ONCOGENE, V21, P7619, DOI 10.1038/sj.onc.1206002; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Di Fruscio M, 1999, P NATL ACAD SCI USA, V96, P2710, DOI 10.1073/pnas.96.6.2710; Dorn GW, 2002, ANNU REV PHYSIOL, V64, P407, DOI 10.1146/annurev.physiol.64.081501.155903; Fleury S, 2000, P NATL ACAD SCI USA, V97, P5393, DOI 10.1073/pnas.97.10.5393; Haegebarth A, 2004, J BIOL CHEM, V279, P54398, DOI 10.1074/jbc.M409579200; Itoh M, 2002, NUCLEIC ACIDS RES, V30, P5452, DOI 10.1093/nar/gkf673; Liu K, 2000, J BIOL CHEM, V275, P40195, DOI 10.1074/jbc.M006194200; Lukong KE, 2005, J BIOL CHEM, V280, P38639, DOI 10.1074/jbc.M505802200; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Mamidipudi V, 2004, MOL CELL BIOL, V24, P6788, DOI 10.1128/MCB.24.15.6788-6798.2004; Mamidipudi V, 2004, FEBS LETT, V567, P321, DOI 10.1016/j.febslet.2004.03.125; Miller LD, 2004, ONCOGENE, V23, P5682, DOI 10.1038/sj.onc.1207735; Moasser MM, 1999, CANCER RES, V59, P6145; PARK J, 1995, MOL CELL BIOL, V15, P2374; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Pillay I, 1996, CELL GROWTH DIFFER, V7, P1487; Porter Lisa A, 2003, Prog Cell Cycle Res, V5, P335; Riley D, 2001, ONCOGENE, V20, P5941, DOI 10.1038/sj.onc.1204826; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Taylor SJ, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-5; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010	33	62	64	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2007	26	20					2914	2924		10.1038/sj.onc.1210091	http://dx.doi.org/10.1038/sj.onc.1210091			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17072338				2022-12-17	WOS:000246210800011
J	Pagano, L; Fianchi, L; Caira, M; Rutella, S; Leone, G				Pagano, L.; Fianchi, L.; Caira, M.; Rutella, S.; Leone, G.			The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients	ONCOGENE			English	Review						acute myeloid leukemia; elderly; mylotarg	ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; ANTIBODY-TARGETED CHEMOTHERAPY; ACUTE MYELOGENOUS LEUKEMIA; COLONY-STIMULATING FACTOR; PHASE-II; IN-VITRO; VENOOCCLUSIVE DISEASE; COMBINATION REGIMEN; MOLECULAR REMISSION	Gemtuzumab Ozogamicin (GO) is an antibody-targeted chemotherapy agent consisting of the humanized murine CD33 antibody (clone P67.6) to which the calicheamicin-g1 derivative is attached via a hydrolysable bifunctional linker. GO is able to induce apoptosis in vitro in CD33-expressing cells and it has been approved in USA and in Europe as monotherapy for the treatment of elderly patients (older than 60 years) with relapsed acute myeloid leukemia (AML). GO administered as a single agent has resulted in overall response rates of about 30% in previously relapsed adults AML patients (including also with incomplete platelet recovery). Preliminary data indicate a potential role for GO also as a component of induction or consolidation regimens in adults and children. As for adverse events, veno-occlusive syndrome characterizes its tolerability profile, but GO is comparatively well tolerated by most patients.	Univ Cattolica Sacro Cuore, Ist Ematol, I-00168 Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Pagano, L (corresponding author), Univ Cattolica Sacro Cuore, Ist Ematol, Largo Francesco Vito 1, I-00168 Rome, Italy.	lpagano@rm.unicatt.it	pagano, livio/J-3020-2018; Rutella, Sergio/AAF-9210-2020; Caira, Morena/A-3663-2009; Giuseppe Leone, Full Professor/I-9166-2019; Rutella, Sergio/AAF-9187-2020; pagano, livio/A-2024-2008	pagano, livio/0000-0001-8287-928X; Rutella, Sergio/0000-0003-1970-7375; Giuseppe Leone, Full Professor/0000-0002-7812-5300; Fianchi, Luana/0000-0002-7113-7202				Alvarado Y, 2003, CANCER CHEMOTH PHARM, V51, P87, DOI 10.1007/s00280-002-0546-z; Amadori S, 2005, LEUKEMIA, V19, P1768, DOI 10.1038/sj.leu.2403901; Amadori S, 2004, HAEMATOLOGICA, V89, P950; Amico D, 2003, BLOOD, V101, P4589, DOI 10.1182/blood-2002-07-2311; Apostolidou E, 2003, LEUKEMIA RES, V27, P887, DOI 10.1016/S0145-2126(03)00021-3; Arceci RJ, 2005, BLOOD, V106, P1183, DOI 10.1182/blood-2004-10-3821; Balaian L, 2003, EXP HEMATOL, V31, P363, DOI 10.1016/S0301-472X(03)00044-4; Bearman SI, 2000, CURR OPIN ONCOL, V12, P103, DOI 10.1097/00001622-200003000-00001; Chevallier P, 2005, LEUKEMIA RES, V29, P1003, DOI 10.1016/j.leukres.2005.02.005; Cohen AD, 2002, BONE MARROW TRANSPL, V30, P23, DOI 10.1038/sj.bmt.1703602; Cortes J, 2002, CANCER CHEMOTH PHARM, V50, P497, DOI 10.1007/s00280-002-0539-y; Crocker PR, 2002, CURR OPIN STRUC BIOL, V12, P609, DOI 10.1016/S0959-440X(02)00375-5; DEANGELO DJ, 2003, BLOOD, V102; DINNDORF PA, 1986, BLOOD, V67, P1048; Estey EH, 2000, LEUKEMIA, V14, P476, DOI 10.1038/sj.leu.2401568; Estey EH, 2002, BLOOD, V99, P4222, DOI 10.1182/blood-2001-12-0174; Estey EH, 2002, BLOOD, V99, P4343, DOI 10.1182/blood.V99.12.4343; FIANCHI L, 2006, HAEMATOL REP, V2, pA83; GILES FJ, 2001, CANCER, V2, P406; Guglielmi C, 1998, BRIT J HAEMATOL, V102, P1035, DOI 10.1046/j.1365-2141.1998.00871.x; IKEMOTO N, 1995, P NATL ACAD SCI USA, V92, P10506, DOI 10.1073/pnas.92.23.10506; Jedema I, 2004, LEUKEMIA, V18, P316, DOI 10.1038/sj.leu.2403205; Jurcic JG, 2000, CLIN CANCER RES, V6, P372; KEATING MJ, 1989, J CLIN ONCOL, V7, P1071, DOI 10.1200/JCO.1989.7.8.1071; Kell WJ, 2003, BLOOD, V102, P4277, DOI 10.1182/blood-2003-05-1620; Langston AA, 2004, BLOOD, V104, p502A, DOI 10.1182/blood.V104.11.1814.1814; Larson RA, 2005, CANCER, V104, P1442, DOI 10.1002/cncr.21326; Larson RA, 2002, LEUKEMIA, V16, P1627, DOI 10.1038/sj.leu.2402677; Legrand O, 2000, BLOOD, V96, P870, DOI 10.1182/blood.V96.3.870.015k16_870_877; Leone G, 2004, HAEMATOLOGICA, V89, P634; Leopold Lance H, 2003, Clin Adv Hematol Oncol, V1, P220; Lo-Coco F, 2004, BLOOD, V104, P1995, DOI 10.1182/blood-2004-04-1550; MCKOY JM, 2006, LEUK RES; Mingari MC, 2001, IMMUNOL REV, V181, P260, DOI 10.1034/j.1600-065X.2001.1810122.x; Montillo M, 1998, AM J HEMATOL, V58, P105, DOI 10.1002/(SICI)1096-8652(199806)58:2<105::AID-AJH3>3.0.CO;2-W; Moore J, 2006, LEUKEMIA RES, V30, P777, DOI 10.1016/j.leukres.2005.10.025; Nabhan C, 2005, LEUKEMIA RES, V29, P53, DOI 10.1016/j.leukres.2004.04.011; Nabhan C, 2004, ANN ONCOL, V15, P1231, DOI 10.1093/annonc/mdh324; *NCCN, 2002, NCCN PRACT GUID ONC; O'Donnel MR, 2004, CANC MANAGEMENT MULT, P747; Paietta E, 2003, BEST PRACT RES CL HA, V16, P369, DOI 10.1016/S1521-6926(03)00042-2; Pallis M, 2004, LEUKEMIA, V18, P1927, DOI 10.1038/sj.leu.2403511; Petti MC, 2001, BRIT J HAEMATOL, V115, P63, DOI 10.1046/j.1365-2141.2001.03091.x; Piccaluga PP, 2004, LEUKEMIA RES, V28, P987, DOI 10.1016/j.leukres.2004.01.009; Piccaluga PP, 2004, LEUKEMIA LYMPHOMA, V45, P1791, DOI 10.1080/1042819042000219485; RAO AV, 2005, BLOOD, V106; RAZA A, 2002, BLOOD, V100; Reinhardt D, 2004, ONKOLOGIE, V27, P269, DOI 10.1159/000075606; Rutella S, 2000, BLOOD, V95, P4015; Rutella S, 2006, EXP HEMATOL, V34, P54, DOI 10.1016/j.exphem.2005.10.003; Schwarz J, 2004, HEMATOL J, V5, P279, DOI 10.1038/sj.thj.6200367; SIEVERDING M, 2000, Z MED PSYCHOL, V1, P7; Sievers EL, 1999, BLOOD, V93, P3678, DOI 10.1182/blood.V93.11.3678; Sievers EL, 2001, J CLIN ONCOL, V19, P3244, DOI 10.1200/JCO.2001.19.13.3244; SIVARAMAN S, 2002, BLOOD, V100; STONE RM, 2004, BLOOD, V104; Takeshita A, 2005, INT J HEMATOL, V82, P445, DOI 10.1532/IJH97.05069; Taksin AL, 2007, LEUKEMIA, V21, P66, DOI 10.1038/sj.leu.2404434; Thalhammer F, 1996, ANN HEMATOL, V72, P216, DOI 10.1007/s002770050163; THOMAS X, 2005, BLOOD, V106; Tsimberidou A, 2003, LEUKEMIA RES, V27, P893, DOI 10.1016/S0145-2126(03)00022-5; Tsimberidou A, 2003, CANCER-AM CANCER SOC, V97, P1481, DOI 10.1002/cncr.11239; Tsimberidou AM, 2004, LEUKEMIA RES, V28, P991, DOI 10.1016/j.leukres.2004.01.004; van der Heiden PLJ, 2006, EUR J HAEMATOL, V76, P409, DOI 10.1111/j.1600-0609.2005.00623.x; van der Velden VHJ, 2001, BLOOD, V97, P3197, DOI 10.1182/blood.V97.10.3197; VENUGOPAL P, 2002, BLOOD, V100; VOGLER WR, 1994, LEUKEMIA, V8, P1847; Wadleigh M, 2003, BLOOD, V102, P1578, DOI 10.1182/blood-2003-01-0255; Walter RB, 2004, BLOOD, V103, P4276, DOI 10.1182/blood-2003-11-3825; ZEIN N, 1989, SCIENCE, V244, P697, DOI 10.1126/science.2717946; Zwaan CM, 2003, BLOOD, V101, P3868, DOI 10.1182/blood-2002-07-1947	71	62	65	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	25					3679	3690		10.1038/sj.onc.1210364	http://dx.doi.org/10.1038/sj.onc.1210364			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172PK	17530021				2022-12-17	WOS:000246816100010
J	Evans, MK; Yu, CR; Lohani, A; Mahdi, RM; Liu, X; Trzeciak, AR; Egwuagu, CE				Evans, M. K.; Yu, C-R; Lohani, A.; Mahdi, R. M.; Liu, X.; Trzeciak, A. R.; Egwuagu, C. E.			Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals	ONCOGENE			English	Article						breast-cancer cells; SOCS; breast cancer; STAT; BRCA1; DNA hypermethylation; interferon	ISLAND METHYLATOR PHENOTYPE; DNA-DAMAGE; IFN-GAMMA; BRCA1; TRANSCRIPTION; ACTIVATION; CARCINOMA; HYPERMETHYLATION; TUMORIGENESIS; COACTIVATOR	DNA-hypermethylation of SOCS genes in breast, ovarian, squamous cell and hepatocellular carcinoma has led to speculation that silencing of SOCS1 and SOCS3 genes might promote oncogenic transformation of epithelial tissues. To examine whether transcriptional silencing of SOCS genes is a common feature of human carcinoma, we have investigated regulation of SOCS genes expression by IFN gamma, IGF-1 and ionizing radiation, in a normal human mammary epithelial cell line (AG11134), two breast-cancer cell lines (MCF-7, HCC1937) and three prostate cancer cell lines. Compared to normal breast cells, we observe a high level constitutive expression of SOCS2, SOCS3, SOCS5, SOCS6, SOCS7, CIS and/or SOCS1 genes in the human cancer cells. In MCF-7 and HCC1937 breast-cancer cells, transcription of SOCS1 is dramatically up-regulated by IFN gamma and/or ionizing-radiation while SOCS3 is transiently down-regulated by IFN gamma and IGF-1, suggesting that SOCS genes are not silenced in these cells by the epigenetic mechanism of DNA-hypermethylation. We further show that the kinetics of SOCS1-mediated feedback inhibition of IFN gamma signaling is comparable to normal breast cells, indicating that the SOCS1 protein in breast-cancer cells is functional. We provide direct evidence that STAT3 pathways are constitutively activated in MCF-7 and HCC1937 cells and may drive the aberrant persistent activation of SOCS genes in breast-cancer cells. Our data therefore suggest that elevated expression of SOCS genes is a specific lesion of breast-cancer cells that may confer resistance to proinflammatory cytokines and trophic factors, by shutting down STAT1/STAT5 signaling that mediate essential functions in the mammary gland.	NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA; NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Evans, MK (corresponding author), NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA.	evansmi@grc.nia.nih.gov; egwuaguc@nei.nih.gov	Evans, Michele Kim/AAE-4776-2019	Evans, Michele/0000-0002-8546-2831; Yu, Cheng-Rong/0000-0001-7246-0362	NATIONAL EYE INSTITUTE [ZIAEY000372, Z01EY000372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000730] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Andrews HN, 2002, J BIOL CHEM, V277, P26225, DOI 10.1074/jbc.M201316200; Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brender C, 2005, LEUKEMIA, V19, P209, DOI 10.1038/sj.leu.2403610; Campbell IL, 2005, BRAIN RES REV, V48, P166, DOI 10.1016/j.brainresrev.2004.12.006; Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; Coccia EM, 1999, ONCOGENE, V18, P2129, DOI 10.1038/sj.onc.1202536; Cui JQ, 1998, ONCOL REP, V5, P591; Darnell JE, 2005, NAT MED, V11, P595, DOI 10.1038/nm0605-595; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752; Haura EB, 2005, NAT CLIN PRACT ONCOL, V2, P315, DOI 10.1038/ncponc0195; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Le Provost F, 2005, BIOCHEM BIOPH RES CO, V338, P1696, DOI 10.1016/j.bbrc.2005.10.138; Medina D, 2005, ENDOCR-RELAT CANCER, V12, P483, DOI 10.1677/erc.1.00804; Missiaglia E, 2005, ONCOGENE, V24, P199, DOI 10.1038/sj.onc.1208018; Niwa Y, 2005, ONCOGENE, V24, P6406, DOI 10.1038/sj.onc.1208788; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Raccurt M, 2003, BRIT J CANCER, V89, P524, DOI 10.1038/sj.bjc.6601115; Rottapel R, 2002, ONCOGENE, V21, P4351, DOI 10.1038/sj.onc.1205537; Saito H, 2000, J IMMUNOL, V164, P5833, DOI 10.4049/jimmunol.164.11.5833; Sultan AS, 2005, ONCOGENE, V24, P746, DOI 10.1038/sj.onc.1208203; Sutherland KD, 2004, ONCOGENE, V23, P7726, DOI 10.1038/sj.onc.1207787; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; Teodoridis JM, 2005, CANCER RES, V65, P8961, DOI 10.1158/0008-5472.CAN-05-1187; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Weber A, 2005, ONCOGENE, V24, P6699, DOI 10.1038/sj.onc.1208818; Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; Yu CR, 2004, J IMMUNOL, V173, P737, DOI 10.4049/jimmunol.173.2.737	33	62	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2007	26	13					1941	1948		10.1038/sj.onc.1209993	http://dx.doi.org/10.1038/sj.onc.1209993			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17001312				2022-12-17	WOS:000245117700011
J	Ayrault, O; Andrique, L; Fauvin, D; Eymin, B; Gazzeri, S; Seite, P				Ayrault, O.; Andrique, L.; Fauvin, D.; Eymin, B.; Gazzeri, S.; Seite, P.			Human tumor suppressor p14(ARF) negatively regulates rRNA transcription and inhibits UBF1 transcription factor phosphorylation	ONCOGENE			English	Article						p14(ARF); rRNA promoter; UBF	POLYMERASE-I TRANSCRIPTION; RDNA TRANSCRIPTION; CELL-PROLIFERATION; TOPOISOMERASE-I; PROTEIN; GENE; P19(ARF); P53; RB; BIOGENESIS	The nucleolar Arf protein has been shown to regulate cell cycle through both p53-dependent and -independent pathways. In addition to the well-characterized Arf-mdm2-p53 pathway, several partners of Arf have recently been described that could participate in alternative regulation process. Among those is the nucleolar protein B23/NPM, involved in the sequential maturation of rRNA. p19(ARF) can interact with B23/NPM in highmolecular complexes and partially inhibit the cleavage of the 32S rRNA, whereas the human p14(ARF) protein has been shown to participate in the degradation of NPM/B23 by the proteasome. These data led to define Arf as a negative regulator of ribosomal RNA maturation. Our recent finding that the human p14ARF protein was able to specifically interact with the rRNA promoter in a p53-independent context, led us to analyse in vitro and in vivo the consequences of this interaction. Luciferase assay and pulse-chase experiments demonstrated that the rRNA transcription was strongly reduced upon p14(ARF) overexpression. Investigations on potential interactions between p14(ARF) and the transcription machinery proteins demonstrated that the upstream binding factor (UBF), required for the initiation of the transcriptional complex, was a new partner of the p14(ARF) protein. We next examined the phosphorylation status of UBF as UBF phosphorylation is required to recruit on the promoter factors involved in the transcriptional complex. Upon p14(ARF) overexpression, UBF was found hypophosphorylated, thus unable to efficiently recruit the transcription complex. Taken together, these data de. ne a new p53-independent pathway that could regulate cell cycle through the negative control of rRNA transcription.	Lab Oncol Mol, EA 3805, F-86022 Poitiers, France; Inst Albert Bonniot, Grp Rech Canc Poumon, EA 2021, INSERM,Unite U578, La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Seite, P (corresponding author), Lab Oncol Mol, EA 3805, Pole Biol Sante 40,Ave Recteur Pineau, F-86022 Poitiers, France.	paule.seite@univ-poitiers.fr	Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/U-4669-2019; gazzeri, sylvie/M-1961-2013; eymin, beatrice/U-4670-2019	Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; gazzeri, sylvie/0000-0001-5817-1839; eymin, beatrice/0000-0002-7311-3810; Seite, Paule/0000-0002-7809-7610; Andrique, Laetitia/0000-0001-7840-8135				Andrique T, 2005, ONCOGENE, V24, P2580, DOI 10.1038/sj/onc.1208457; Ayrault O, 2004, ONCOGENE, V23, P8097, DOI 10.1038/sj.onc.1207968; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Ciarmatori S, 2001, MOL CELL BIOL, V21, P5806, DOI 10.1128/MCB.21.17.5806-5814.2001; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Drakas R, 2004, P NATL ACAD SCI USA, V101, P9272, DOI 10.1073/pnas.0403328101; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; GARG LC, 1987, P NATL ACAD SCI USA, V84, P3185, DOI 10.1073/pnas.84.10.3185; Ghoshal K, 2004, J BIOL CHEM, V279, P6783, DOI 10.1074/jbc.M309393200; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; Hannan KM, 2000, ONCOGENE, V19, P3487, DOI 10.1038/sj.onc.1203690; Hannan KM, 2000, ONCOGENE, V19, P4988, DOI 10.1038/sj.onc.1203875; Huang RM, 2002, FASEB J, V16, DOI 10.1096/fj.01-0687com; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Karayan L, 2001, ONCOGENE, V20, P836, DOI 10.1038/sj.onc.1204170; Klein J, 1999, P NATL ACAD SCI USA, V96, P6096, DOI 10.1073/pnas.96.11.6096; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Moss T, 2002, CELL, V109, P545, DOI 10.1016/S0092-8674(02)00761-4; Olivier A, 2003, ONCOGENE, V22, P1945, DOI 10.1038/sj.onc.1206214; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Voit R, 1999, EMBO J, V18, P1891, DOI 10.1093/emboj/18.7.1891; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; Voit R, 2001, P NATL ACAD SCI USA, V98, P13631, DOI 10.1073/pnas.231071698; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000	35	62	63	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7577	7586		10.1038/sj.onc.1209743	http://dx.doi.org/10.1038/sj.onc.1209743			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16924243				2022-12-17	WOS:000242655500003
J	Tsumura, H; Yoshida, T; Saito, H; Imanaka-Yoshida, K; Suzuki, N				Tsumura, H.; Yoshida, T.; Saito, H.; Imanaka-Yoshida, K.; Suzuki, N.			Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice	ONCOGENE			English	Article						pleomorphic rhabdomyosarcoma; K-ras; p53	SOFT-TISSUE SARCOMAS; N-RAS; SKELETAL-MUSCLE; H-RAS; P53-DEFICIENT MICE; POINT MUTATIONS; CRE RECOMBINASE; STEM-CELL; IN-VIVO; GENE	Human rhabdomyosarcomas (RMSs) frequently demonstrate genetic alterations in ras and p53. To investigate their possible involvement in the tumorigenesis, we generated a knock- in mouse line with oncogenic K- ras, conditionally expressed by Cre/ LoxP system on a background of p53 alteration. Electroporation of Cre expression vector in skeletal muscle tissues resulted in the generation of tumor in adults with tumor incidences of 100% at 10 weeks and 40% at 15 weeks, in p53(-/-) and p53(-/-) backgrounds, respectively. The tumor histology was pleomorphic RMS with characteristic bizarre giant cells, positive for desmin and alpha-sarcomeric actin and exhibiting remarkable increase in total and phosphorylated extracellular signal- regulated protein kinase (ERK) 1 and ERK2. Loss of the wild- type p53 was detected in K- rasG12V- expressed tumors of p53(-/+) mice. Early lesions 3 weeks after electroporation consisted of proliferating populations of myogenic progenitors, including stem cells positive for ScaI antigen, immature cells positive for desmin and neural cell adhesion molecule- positive myotubes. Thus, cooperation of oncogenic K- ras and p53 deficiency resulted in the development of pleomorphic RMS in adult mice, providing a useful mouse model for further detailed studies.	Mie Univ, Life Sci Res Ctr, Dept Anim Genom, Funct Genom Inst, Tsu, Mie 5148507, Japan; Mie Univ, Grad Sch Med, Tsu, Mie 5148507, Japan	Mie University; Mie University	Suzuki, N (corresponding author), Mie Univ, Life Sci Res Ctr, Dept Anim Genom, Funct Genom Inst, 2-174 Edobashi, Tsu, Mie 5148507, Japan.	nsuzuki@doc.medic.mie-u.ac.jp	Yoshida, Toshimichi/H-6204-2013	Yoshida, Toshimichi/0000-0001-8935-8217				BIRCH JM, 1990, CANCER-AM CANCER SOC, V66, P2239, DOI 10.1002/1097-0142(19901115)66:10<2239::AID-CNCR2820661034>3.0.CO;2-Q; Collins CA, 2005, CELL, V122, P289, DOI 10.1016/j.cell.2005.05.010; Durieux AC, 2004, J GENE MED, V6, P809, DOI 10.1002/jgm.534; Fedorov YV, 2002, MOL CELL BIOL, V22, P1140, DOI 10.1128/MCB.22.4.1140-1149.2002; FELIX CA, 1992, CANCER RES, V52, P2243; Fleischmann A, 2003, CANCER CELL, V4, P477, DOI 10.1016/S1535-6108(03)00280-0; Garcia JM, 2000, BRIT J CANCER, V82, P1183; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Hawkins WG, 2001, CANCER-AM CANCER SOC, V91, P794, DOI 10.1002/1097-0142(20010215)91:4<794::AID-CNCR1066>3.0.CO;2-Q; Hingorani SR, 2003, CURR OPIN GENET DEV, V13, P6, DOI 10.1016/S0959-437X(02)00017-5; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; KOYABU S, 1994, CELL MOTIL CYTOSKEL, V29, P259, DOI 10.1002/cm.970290309; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Linardic CM, 2005, CANCER RES, V65, P4490, DOI 10.1158/0008-5472.CAN-04-3194; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; Nanni P, 2003, CANCER RES, V63, P2728; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; Patel S R, 2000, Curr Treat Options Oncol, V1, P258, DOI 10.1007/s11864-000-0037-6; Saito H, 2005, BIOCHEM BIOPH RES CO, V331, P1216, DOI 10.1016/j.bbrc.2005.04.043; Sakai K, 1995, BIOCHEM BIOPH RES CO, V217, P393, DOI 10.1006/bbrc.1995.2789; Sharp R, 2002, NAT MED, V8, P1276, DOI 10.1038/nm787; STRATTON MR, 1989, CANCER RES, V49, P6324; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tiffin N, 2003, BRIT J CANCER, V89, P327, DOI 10.1038/sj.bjc.6601040; TSUKADA T, 1993, ONCOGENE, V8, P3313; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; WEXLER LH, 1994, CA-CANCER J CLIN, V44, P211, DOI 10.3322/canjclin.44.4.211; White JD, 2002, INT J DEV BIOL, V46, P577; WILKE W, 1993, MODERN PATHOL, V6, P129; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; Yoo J, 1999, CANCER, V86, P58, DOI 10.1002/(SICI)1097-0142(19990701)86:1<58::AID-CNCR10>3.3.CO;2-J	38	62	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2006	25	59					7673	7679		10.1038/sj.onc.1209749	http://dx.doi.org/10.1038/sj.onc.1209749			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16785989				2022-12-17	WOS:000242830800002
J	Sekine, Y; Tsuji, S; Ikeda, O; Sato, N; Aoki, N; Aoyama, K; Sugiyama, K; Matsuda, T				Sekine, Y.; Tsuji, S.; Ikeda, O.; Sato, N.; Aoki, N.; Aoyama, K.; Sugiyama, K.; Matsuda, T.			Regulation of STAT3-mediated signaling by LMW-DSP2	ONCOGENE			English	Article						IL-6; LIF; STAT3; phosphatase; transcriptional regulation	DUAL-SPECIFICITY PHOSPHATASE; PROTEIN-TYROSINE-PHOSPHATASE; CELL ANTIGEN RECEPTOR; FUNCTIONAL INTERACTIONS; NEGATIVE REGULATOR; STATS; TRANSDUCTION; ACTIVATION; PATHWAY; CLONING	Signal transducer and activator of transcription 3 (STAT3), which mediates biological actions in many physiological processes, is activated by cytokines and growth factors, and has been reported to be constitutively activated in numerous cancer cells. In this study, we examined whether low molecular weight-dual specificity phosphatase two (LMW-DSP2) is involved in the regulation of the interleukin 6 (IL-6)/leukemia inhibitory factor (LIF)/STAT3-mediated signaling pathway. IL-6/LIF-induced LMW-DSP2 expression in murine testicular or hepatoma cell lines, while LMW-DSP2 overexpression in 293T cells suppressed IL-6-induced phosphorylation and activation of STAT3. Furthermore, LMW-DSP2 suppressed the expression of IL-6-induced endogenous genes. In contrast, small-interfering RNA-mediated reduction of LMW-DSP2 expression enhanced IL-6-induced STAT3-dependent transcription. In fact, LMW-DSP2 interacted with STAT3 in vivo and endogenous LMW-DSP2 bound to STAT3 in murine testicular GC-1 cells. These results strongly suggest that LMW-DSP2 acts as a negative regulator of the IL-6/LIF/STAT3-mediated signaling pathway.	Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Sapporo, Hokkaido 0600812, Japan; Mie Univ, Dept Life Sci, Fac Bioresources, Lab Mol Food Chem & Biochem, Tsu, Mie 514, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Nagoya, Aichi, Japan; Nippon Boehringer Ingelheim Co Ltd, Kawanishi Pharma Res Inst, Kawanishi, Hyogo, Japan	Hokkaido University; Mie University; Nagoya University; Boehringer Ingelheim	Matsuda, T (corresponding author), Hokkaido Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.	tmatsuda@pharm.hokudai.ac.jp	Matsuda, Tadashi/A-3835-2012; Sekine, Yuichi/S-8813-2019	Matsuda, Tadashi/0000-0002-3089-3757; Sekine, Yuichi/0000-0002-2861-603X				Alonso A, 2004, TOP CURR GENET, V5, P333; Alonso A, 2002, J BIOL CHEM, V277, P5524, DOI 10.1074/jbc.M107653200; Alonso A, 2001, J BIOL CHEM, V276, P4766, DOI 10.1074/jbc.M006497200; Aoki N, 2002, MOL ENDOCRINOL, V16, P58, DOI 10.1210/me.16.1.58; Aoki N, 2001, J BIOCHEM, V130, P133, DOI 10.1093/oxfordjournals.jbchem.a002952; Aoyama K, 2001, J BIOL CHEM, V276, P27575, DOI 10.1074/jbc.M100408200; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Chen AJ, 2002, J BIOL CHEM, V277, P36592, DOI 10.1074/jbc.M200453200; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Imoto S, 2003, J BIOL CHEM, V278, P34253, DOI 10.1074/jbc.M304961200; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Muromoto R, 2004, J IMMUNOL, V172, P2985, DOI 10.4049/jimmunol.172.5.2985; Najarro P, 2001, J VIROL, V75, P3185, DOI 10.1128/JVI.75.7.3185-3196.2001; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Sekine Y, 2005, J BIOL CHEM, V280, P8188, DOI 10.1074/jbc.M411692200; Shen Y, 2001, P NATL ACAD SCI USA, V98, P13613, DOI 10.1073/pnas.231499098; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Simoncic PD, 2002, CURR BIOL, V12, P446, DOI 10.1016/S0960-9822(02)00697-8; Yamamoto T, 2002, BIOCHEM BIOPH RES CO, V297, P811, DOI 10.1016/S0006-291X(02)02291-X; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143	25	62	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5801	5806		10.1038/sj.onc.1209578	http://dx.doi.org/10.1038/sj.onc.1209578			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16636663	Green Submitted, Bronze			2022-12-17	WOS:000240765800010
J	Burek, M; Maddika, S; Burek, CJ; Daniel, PT; Schulze-Osthoff, K; Los, M				Burek, M; Maddika, S; Burek, CJ; Daniel, PT; Schulze-Osthoff, K; Los, M			Apoptin-induced cell death is modulated by Bcl-2 family members and is Apaf-1dependent	ONCOGENE			English	Article						Apaf-1; apoptin; apoptosis; caspases; Bcl-2; Bcl-xL	CHICKEN ANEMIA VIRUS; TUMOR-CELLS; INDUCED APOPTOSIS; PROTEIN APOPTIN; NUCLEAR-LOCALIZATION; CASPASE ACTIVATION; BH3-ONLY PROTEINS; CANCER; INDUCTION; SIGNAL	Apoptin, a chicken anemia virus-derived protein, selectively induces apoptosis in transformed but not in normal cells, thus making it a promising candidate as a novel anticancer therapeutic. The mechanism of apoptin-induced apoptosis is largely unknown. Here, we report that contrary to previous assumptions, Bcl-2 and Bcl-x(L) inhibit apoptin-induced cell death in several tumor cell lines. In contrast, deficiency of Bax conferred resistance, whereas Bax expression sensitized cells to apoptin-induced death. Cell death induction by apoptin was associated with cytochrome c release from mitochondria as well as with caspase-3 and -7 activation. Benzyloxy-carbonyl-Val-Ala-Asp-fluoromethyl ketone, a broad spectrum caspase inhibitor, was highly protective against apoptin-induced cell death. Apoptosis induced by apoptin required Apaf-1, as immortalized Apaf-1-deficient fibroblasts as well as tumor cells devoid of Apaf-1 were strongly protected. Thus, our data indicate that apoptin-induced apoptosis is not only Bcl-2- and caspase dependent, but also engages an Apaf-1 apoptosome-mediated mitochondrial death pathway.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; Univ Munster, Dept Immunol & Cell Biol, Munster, Germany; Charite, Dept Hematol Oncol & Tumor Immunol, Berlin, Germany; Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB, Canada	Heinrich Heine University Dusseldorf; University of Munster; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Manitoba	Schulze-Osthoff, K (corresponding author), Univ Dusseldorf, Inst Mol Med, Univ Str 1,Bldg 23-12, D-40225 Dusseldorf, Germany.	kso@uni-duesseldorf.de	Burek, Malgorzata/AAF-3283-2021; Schulze-Osthoff, Klaus/N-9025-2013	Burek, Malgorzata/0000-0001-6148-2195; Schulze-Osthoff, Klaus/0000-0003-1443-2720; Los, Marek/0000-0001-9518-1411	Canadian Institutes of Health Research [81237] Funding Source: Medline	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))		Adair BM, 2000, DEV COMP IMMUNOL, V24, P247, DOI 10.1016/S0145-305X(99)00076-2; ALMAZAN G, 1992, BRAIN RES, V579, P234, DOI 10.1016/0006-8993(92)90056-F; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Bitzer M, 2002, J BIOL CHEM, V277, P29817, DOI 10.1074/jbc.M111898200; Bouillet P, 2002, J CELL SCI, V115, P1567; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Danen-Van Oorschot AAAM, 1999, ADV EXP MED BIOL, V457, P245; Danen-van Oorschot AAAM, 2000, J VIROL, V74, P7072, DOI 10.1128/JVI.74.15.7072-7078.2000; Danen-van Oorschot AAAM, 2003, J BIOL CHEM, V278, P27729, DOI 10.1074/jbc.M303114200; DanenVanOorschot AAAM, 1997, P NATL ACAD SCI USA, V94, P5843; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; Essmann F, 2003, CELL DEATH DIFFER, V10, P1260, DOI 10.1038/sj.cdd.4401301; Everett H, 2001, VIROLOGY, V288, P1, DOI 10.1006/viro.2001.1081; Fischer U, 2005, PHARMACOL REV, V57, P187, DOI 10.1124/pr.57.2.6; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Ghavami S, 2004, J LEUKOCYTE BIOL, V76, P169, DOI 10.1189/jlb.0903435; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guelen L, 2004, ONCOGENE, V23, P1153, DOI 10.1038/sj.onc.1207224; Hamilton A, 2000, ANN ONCOL, V11, P647, DOI 10.1023/A:1008390429428; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; JAATTELA M, 1995, ONCOGENE, V10, P2297; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; LAMKANFI M, 2002, CASPASES THEIR ROLE; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Marsden VS, 2003, ANNU REV IMMUNOL, V21, P71, DOI 10.1146/annurev.immunol.21.120601.141029; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NOTEBORN MHM, 1994, J VIROL, V68, P346, DOI 10.1128/JVI.68.1.346-351.1994; Noteborn MHM, 1998, MUTAT RES-FUND MOL M, V400, P447, DOI 10.1016/S0027-5107(98)00016-5; Oro C, 2004, CURR DRUG TARGETS, V5, P179, DOI 10.2174/1389450043490631; Poon IKH, 2005, J VIROL, V79, P1339, DOI 10.1128/JVI.79.2.1339-1341.2005; Poppe M, 2001, J NEUROSCI, V21, P4551, DOI 10.1523/JNEUROSCI.21-13-04551.2001; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; Rohn JL, 2002, J BIOL CHEM, V277, P50820, DOI 10.1074/jbc.M208557200; Schoop RAL, 2004, INT J CANCER, V109, P38, DOI 10.1002/ijc.11675; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Schwerk C, 2005, MOL CELL, V19, P1, DOI 10.1016/j.molcel.2005.05.026; Somai S, 2003, INT J CANCER, V105, P607, DOI 10.1002/ijc.11147; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Stroh C, 1998, CELL DEATH DIFFER, V5, P997, DOI 10.1038/sj.cdd.4400451; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tavassoli M, 2005, APOPTOSIS, V10, P717, DOI 10.1007/s10495-005-0930-3; Teodoro JG, 2004, GENE DEV, V18, P1952, DOI 10.1101/gad.1198404; Thomson BJ, 2001, INT J EXP PATHOL, V82, P65, DOI 10.1111/j.1365-2613.2001.iep195.x; Wadia JS, 2004, J VIROL, V78, P6077, DOI 10.1128/JVI.78.11.6077-6078.2004; Zhang YH, 2003, EXP CELL RES, V289, P36, DOI 10.1016/S0014-4827(03)00188-5; Zheng TS, 2000, EXP CELL RES, V256, P67, DOI 10.1006/excr.2000.4841; Zhuang SM, 1995, CARCINOGENESIS, V16, P2939, DOI 10.1093/carcin/16.12.2939	52	62	73	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	15					2213	2222		10.1038/sj.onc.1209258	http://dx.doi.org/10.1038/sj.onc.1209258			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	029RD	16288204	Green Accepted, Green Published			2022-12-17	WOS:000236581200008
J	Wendt, J; Radetzki, S; von Haefen, C; Hemmati, PG; Guner, D; Schulze-Osthoff, K; Dorken, B; Daniel, PT				Wendt, J; Radetzki, S; von Haefen, C; Hemmati, PG; Guner, D; Schulze-Osthoff, K; Dorken, B; Daniel, PT			Induction of p21(CIP/WAF-1) and G2 arrest by ionizing irradiation impedes caspase-3-mediated apoptosis in human carcinoma cells	ONCOGENE			English	Article						ionizing irradiation; DNA damage; G2 cell cycle arrest; apoptosis; resistance	DRUG-INDUCED APOPTOSIS; CYCLE ARREST; MITOTIC CATASTROPHE; CD95/FAS RECEPTOR; MITOCHONDRIAL; BAX; DEATH; ACTIVATION; CANCER; P53	There is an ongoing controversy regarding the relevance of apoptosis induction by ionizing irradiation as compared with other end points including transient or permanent cell cycle arrest of damaged cells. Here, we show that such permanent cell cycle arrest and apoptosis represent two sides of the same coin. MCF-7 cells fail to express procaspase-3, which results in resistance to apoptosis induced by anticancer drugs. Conversely, restoration of procaspase-3 sensitizes MCF- 7 cells to chemotherapeutics including epirubicine, etoposide and taxol. In contrast, irradiation does not trigger apoptotic cell death but results in prolonged arrest in the G2 phase of the cell division cycle regardless of procaspase-3 expression. This suggested that the propensity of MCF-7 cells to arrest at the G2 checkpoint results in resistance to apoptosis upon gamma-irradiation. This G2 arrest was associated with upregulation of p21(CIP/WAF-1). Inhibition of DNA-damage-induced stress kinases and p21(CIP/WAF-1) expression by caffeine abrogated G2 arrest and induced apoptosis of the irradiated cells in a caspase-3-dependent manner. Inhibition of cell cycle progression by adenoviral expression of the cyclin dependent kinase inhibitor p21(CIP/WAF-1) prevented apoptosis upon caffeine treatment indicating that cell cycle progression, that is, G2-release, is required for induction of apoptosis. Likewise, cells homozygously deleted for p21(CIP/WAF-1) (HCT116 p21(-/-)) display enhanced irradiation-induced apoptosis via a caspase-3-dependent mechanism. These data indicate that the disruption of G2 checkpoint control overcomes cell cycle arrest and resistance to gamma-irradiation-induced cell death. Thus, DNA damage may trigger a permanent G2 arrest as an initial inactivation step of tumor cells where the phenomenon of apoptosis is hidden unless cell cycle arrest is overcome. The efficient induction of apoptosis upon G2 release thereby depends on the propensity to activate the key executioner caspase-3. This finding is of crucial importance for the understanding of molecular steps underlying the efficacy of ionizing radiation to delete tumor cells.	Humboldt Univ, Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Univ Dusseldorf, Inst Mol Med, D-4000 Dusseldorf, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Heinrich Heine University Dusseldorf	Daniel, PT (corresponding author), Humboldt Univ, Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Lindenberger Weg 80,Campus Berlin Buch, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de	Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720				Bhonde MR, 2005, ONCOGENE, V24, P148, DOI 10.1038/sj.onc.1207842; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Chu K, 2004, RADIAT RES, V162, P270, DOI 10.1667/RR3221; Daniel PT, 1999, ANAL BIOCHEM, V266, P110, DOI 10.1006/abio.1998.2929; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Guner Dilek, 2003, Curr Med Chem Anticancer Agents, V3, P319, DOI 10.2174/1568011033482369; Hasenjager A, 2004, ONCOGENE, V23, P4523, DOI 10.1038/sj.onc.1207594; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hemmati PG, 2005, ONCOGENE, V24, P4114, DOI 10.1038/sj.onc.1208579; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Janicke RU, 2001, ONCOGENE, V20, P5043, DOI 10.1038/sj.onc.1204659; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Javelaud D, 2002, J BIOL CHEM, V277, P37949, DOI 10.1074/jbc.M204497200; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Klopfer A, 2004, ONCOGENE, V23, P9408, DOI 10.1038/sj.onc.1207975; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Motwani M, 1999, CLIN CANCER RES, V5, P1876; Mrozek A, 2003, CELL DEATH DIFFER, V10, P461, DOI 10.1038/sj.cdd.4401193; Normand G, 2005, J BIOL CHEM, V280, P7118, DOI 10.1074/jbc.M412330200; Prokop A, 2003, ONCOGENE, V22, P9107, DOI 10.1038/sj.onc.1207196; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Rau B, 2003, J CLIN ONCOL, V21, P3391, DOI 10.1200/JCO.2003.07.077; Rudner J, 2001, J CELL SCI, V114, P4161; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Xaus J, 1999, IMMUNITY, V11, P103, DOI 10.1016/S1074-7613(00)80085-0; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	41	62	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					972	980		10.1038/sj.onc.1209031	http://dx.doi.org/10.1038/sj.onc.1209031			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16331277				2022-12-17	WOS:000235361000002
J	Hummerich, L; Muller, R; Hess, J; Kokocinski, F; Hahn, M; Furstenberger, G; Mauch, C; Lichter, P; Angel, P				Hummerich, L; Muller, R; Hess, J; Kokocinski, F; Hahn, M; Furstenberger, G; Mauch, C; Lichter, P; Angel, P			Cation of novel tumour-associated genes differentially expressed in the process of squamous cell cancer development	ONCOGENE			English	Article						multistage carcinogenesis; papilloma; squamous cell carcinoma; gene expression profiling; self-organizing maps	MALIGNANCY-ASSOCIATED REGIONS; TRANSCRIPTIONAL ACTIVATION; MATRIX METALLOPROTEINASES; DNA MICROARRAYS; CARCINOMA ESCC; HUMAN PROSTATE; CDNA; IDENTIFICATION; PROGRESSION; PROFILE	Chemically induced mouse skin carcinogenesis represents the most extensively utilized animal model to unravel the multistage nature of tumour development and to design novel therapeutic concepts of human epithelial neoplasia. We combined this tumour model with comprehensive gene expression analysis and could identify a large set of novel tumour-associated genes that have not been associated with epith elial skin cancer development yet. Expression data of selected genes were con. firmed by semiquantitative and quantitative RT-PCR as well as in situ hybridization and immuno. fluorescence analysis on mouse tumour sections. Enhanced expression of genes identified in our screen was also demonstrated in mouse keratinocyte cell lines that form tumours in vivo. Self-organizing map clustering was performed to identify different kinetics of gene expression and coregulation during skin cancer progression. Detailed analysis of differential expressed genes according to their functional annotation confirmed the involvement of several biological processes, such as regulation of cell cycle, apoptosis, extracellular proteolysis and cell adhesion, during skin malignancy. Finally, we detected high transcript levels of ANXA1, LCN2 and S100A8 as well as reduced levels for NDR2 protein in human skin tumour specimens demonstrating that tumour associated genes identified in the chemically induced tumour model might be of great relevance for the understanding of human epithelial malignancies as well.	Deutsch Krebsforschungszentrum, Div Mol Genet, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Signal Transduct & Growth Control, D-6900 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Biochem Tissue Specif Regulat, D-6900 Heidelberg, Germany; Univ Cologne, Dept Dermatol & Venerol, D-5000 Cologne 41, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Cologne	Lichter, P (corresponding author), Deutsch Krebsforschungszentrum, Div Mol Genet, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	m.macleod@dkfz.de	Piris, Miguel A/AAP-1445-2020; Hess, Jochen/ABE-1144-2021	Piris, Miguel A/0000-0001-5839-3634; Hess, Jochen/0000-0003-3493-1711; Kokocinski, Felix/0000-0002-8472-9207				Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Arias AM, 2001, CELL, V105, P425, DOI 10.1016/S0092-8674(01)00365-8; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Bowden GT, 2004, NAT REV CANCER, V4, P23, DOI 10.1038/nrc1253; Breitenbach U, 2001, J INVEST DERMATOL, V117, P634, DOI 10.1046/j.0022-202x.2001.01437.x; Cavallaro U, 2002, CANCER LETT, V176, P123, DOI 10.1016/S0304-3835(01)00759-5; Chen Y, 2003, CANCER RES, V63, P1927; Clarke PA, 2001, BIOCHEM PHARMACOL, V62, P1311, DOI 10.1016/S0006-2952(01)00785-7; Cromer A, 2004, ONCOGENE, V23, P2484, DOI 10.1038/sj.onc.1207345; DIAZGUERRA M, 1992, CANCER RES, V52, P680; Diehl F, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.7.e38; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Dooley TP, 2003, BIOCHEM BIOPH RES CO, V306, P1026, DOI 10.1016/S0006-291X(03)01099-4; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; FURSTENBERGER G, 1995, CARCINOGENESIS, V16, P61, DOI 10.1093/carcin/16.1.61; Gebhardt C, 2005, AM J PATHOL, V167, P243, DOI 10.1016/S0002-9440(10)62969-0; Gebhardt C, 2002, ONCOGENE, V21, P4266, DOI 10.1038/sj.onc.1205521; Glinsky GV, 2003, CANCER LETT, V201, P67, DOI 10.1016/S0304-3835(03)00419-1; Glinsky GV, 2003, NEOPLASIA, V5, P218, DOI 10.1016/S1476-5586(03)80054-4; Gogali A, 2004, EXP ONCOL, V26, P106; Hu YC, 2001, CLIN CANCER RES, V7, P2213; Hu YC, 2001, CLIN CANCER RES, V7, P3519; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Ishikawa N, 2004, CLIN CANCER RES, V10, P8363, DOI 10.1158/1078-0432.CCR-04-1436; Ito N, 1995, CRIT REV ONCOL HEMAT, V21, P105, DOI 10.1016/1040-8428(94)00169-3; Kargul GJ, 2001, NAT GENET, V28, P17, DOI 10.1038/ng0501-17; Kerkela E, 2003, EXP DERMATOL, V12, P109, DOI 10.1034/j.1600-0625.2003.120201.x; Kettunen E, 2004, CANCER GENET CYTOGEN, V149, P98, DOI 10.1016/s0165-4608(03)00300-5; Ko MSH, 2000, DEVELOPMENT, V127, P1737; KRIEG P, 1991, MOL CARCINOGEN, V4, P129, DOI 10.1002/mc.2940040208; Leethanakul C, 2000, ORAL ONCOL, V36, P474, DOI 10.1016/S1368-8375(00)00039-7; Li J, 2002, PHYSIOL GENOMICS, V9, P137, DOI 10.1152/physiolgenomics.00003.2002; Lu JY, 2001, INT J CANCER, V91, P288, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1063>3.0.CO;2-S; Luo AP, 2004, ONCOGENE, V23, P1291, DOI 10.1038/sj.onc.1207218; MARKS F, 1990, CARCINOGENESIS, V11, P2085, DOI 10.1093/carcin/11.12.2085; Mendez E, 2002, CANCER, V95, P1482, DOI 10.1002/cncr.10875; Nagata M, 2003, INT J CANCER, V106, P683, DOI 10.1002/ijc.11283; Nair KS, 2005, J CLIN PATHOL, V58, P343, DOI 10.1136/jcp.2004.018036; Patil MA, 2005, ONCOGENE, V24, P3737, DOI 10.1038/sj.onc.1208479; Petroziello J, 2004, ONCOGENE, V23, P7734, DOI 10.1038/sj.onc.1207921; Rennecke J, 1999, INT J CANCER, V80, P98, DOI 10.1002/(SICI)1097-0215(19990105)80:1<98::AID-IJC19>3.0.CO;2-D; Rundhaug JE, 1997, MOL CARCINOGEN, V20, P125, DOI 10.1002/(SICI)1098-2744(199709)20:1<125::AID-MC14>3.3.CO;2-A; Schlingemann J, 2003, INT J CANCER, V104, P699, DOI 10.1002/ijc.11008; Stern MC, 1997, MOL CARCINOGEN, V20, P137, DOI 10.1002/(SICI)1098-2744(199709)20:1<137::AID-MC15>3.0.CO;2-2; STRICKLAND JE, 1988, CANCER RES, V48, P165; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tanaka TS, 2000, P NATL ACAD SCI USA, V97, P9127, DOI 10.1073/pnas.97.16.9127; Tsai WC, 2004, ORAL ONCOL, V40, P418, DOI 10.1016/j.oraloncology.2003.09.015; Wrobel G, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng067; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6	52	62	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	1					111	121		10.1038/sj.onc.1209016	http://dx.doi.org/10.1038/sj.onc.1209016			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999QX	16247483				2022-12-17	WOS:000234406400012
J	Li, X; Luwor, R; Lu, Y; Liang, K; Fan, Z				Li, X; Luwor, R; Lu, Y; Liang, K; Fan, Z			Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells	ONCOGENE			English	Article						EGF receptor inhibitors; alkylphospholipids; PTEN; Akt; targeted therapy	GROWTH-FACTOR RECEPTOR; ACTIVATED PROTEIN-KINASE; TUMOR-SUPPRESSOR GENE; BREAST-CANCER; NEGATIVE REGULATION; PROSTATE-CANCER; SOLID TUMORS; PHASE-II; PATHWAY; MILTEFOSINE	Mutational inactivation or deletion of the phosphatase and tensin homologue deleted on chromosome 10 ( PTEN)/MMAC1/TEP gene in human cancer cells leads to a constitutively active status of the phosphatidylinositol 3-kinase/Akt pathway in the cells and has been linked to the lack of responses of the cells to the epidermal growth factor (EGF) receptor-targeted therapeutics. Akt is strongly inhibited by perifosine, an orally active alkyl-lysophospholipid currently being evaluated as an anticancer agent in phase 1 and 2 clinical trials. To determine whether perifosine may enhance the antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/ C225 in PTEN-deficient cancer cells, we exposed MDA468 breast cancer cells ( which contain mutated PTEN gene) and PC3 prostate cancer cells ( in which the PTEN gene is deleted) to perifosine and cetuximab, alone and in combination. Treatment of the cells with perifosine reduced baseline levels of phosphorylated Akt, phosphorylated p44/42 mitogen-activated protein kinase ( MAPK) and p38MAPK, and increased baseline levels of phosphorylated stress-activated protein kinase ( SAPK)/c-jun NH2-terminal kinase (JNK). A 72-h exposure of the MDA468 and PC3 cells to perifosine alone resulted in cell death in a dose-dependent manner, which was enhanced by cetuximab. Addition of subtoxic doses of perifosine to cetuximab treatment also enhanced the cetuximabinduced growth inhibition. The combination treatment enhanced the inhibition of phosphorylation of Akt, p44/ 42MAPK and p38MAPK, but offset the phosphorylation of SAPK/JNK that was activated by perifosine treatment alone. Taken together, the data showed that perifosine enhances the antitumor activity of cetuximab in PTEN deficient cancer cells. Further evaluation of the combination treatment in preclinical and clinical studies is warranted.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 036, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 036, 1515 Holcombe Blvd, Houston, TX 77030 USA.	zfan@mdanderson.org		Luwor, Rodney/0000-0002-3020-4245				Aikin R, 2004, ENDOCRINOLOGY, V145, P4522, DOI 10.1210/en.2004-0488; Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200; Bianco R, 2003, ONCOGENE, V22, P2812, DOI 10.1038/sj.onc.1206388; Clive S, 1997, LANCET, V349, P621, DOI 10.1016/S0140-6736(05)61570-X; Clive S, 1999, CANCER CHEMOTH PHARM, V44, pS29, DOI 10.1007/s002800051114; Crul M, 2002, EUR J CANCER, V38, P1615, DOI 10.1016/S0959-8049(02)00127-2; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; De Siervi A, 2004, CANCER RES, V64, P743, DOI 10.1158/0008-5472.CAN-03-2505; DUMMER R, 1992, PROG EXP TUMOR RES, V34, P160; Fry MJ, 2001, BREAST CANCER RES, V3, P304, DOI 10.1186/bcr312; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; Gonzalez I, 2004, MOL CELL BIOL, V24, P3607, DOI 10.1128/MCB.24.9.3607-3622.2004; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; HILGARD P, 1993, CANCER CHEMOTH PHARM, V32, P90, DOI 10.1007/BF00685608; Hilgard P, 1997, EUR J CANCER, V33, P442; Jin W, 2003, BRIT J CANCER, V89, P185, DOI 10.1038/sj.bjc.6601048; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Kondapaka SB, 2003, MOL CANCER THER, V2, P1093; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Liang K, 2003, MOL CANCER THER, V2, P1113; Liu B, 2000, BRIT J CANCER, V82, P1991; Lu Yiling, 2003, Rev Clin Exp Hematol, V7, P205; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Prewett M, 1996, J IMMUNOTHER, V19, P419, DOI 10.1097/00002371-199611000-00006; Ruiter GA, 2003, ANTI-CANCER DRUG, V14, P167, DOI 10.1097/00001813-200302000-00011; Ruiter GA, 2002, INT J CANCER, V102, P343, DOI 10.1002/ijc.10741; Ruiter GA, 1999, CANCER RES, V59, P2457; She QB, 2003, CLIN CANCER RES, V9, P4340; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Teng DHF, 1997, CANCER RES, V57, P5221; Terwogt JMM, 1999, BRIT J CANCER, V79, P1158, DOI 10.1038/sj.bjc.6690184; UNGER C, 1992, PROG EXP TUMOR RES, V34, P153; Van Ummersen L, 2004, CLIN CANCER RES, V10, P7450, DOI 10.1158/1078-0432.CCR-03-0406; VERWEIJ J, 1992, J CANCER RES CLIN, V118, P606, DOI 10.1007/BF01211805; VERWEIJ J, 1993, EUR J CANCER, V29A, P778, DOI 10.1016/S0959-8049(05)80369-7; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Zhou X, 1996, J CLIN INVEST, V98, P937, DOI 10.1172/JCI118877	48	62	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	4					525	535		10.1038/sj.onc.1209075	http://dx.doi.org/10.1038/sj.onc.1209075			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	006KW	16170346				2022-12-17	WOS:000234897400004
J	Dunn, KL; Davie, JR				Dunn, KL; Davie, JR			Stimulation of the Ras-MAPK pathway leads to independent phosphorylation of histone H3 on serine 10 and 28	ONCOGENE			English	Article						histone phosphorylation; H3 variants; Rasmitogen activated protein kinase signal transduction pathway	TRANSFORMED MOUSE FIBROBLASTS; EARLY GENE INDUCTION; H3 PHOSPHORYLATION; CHROMOSOME CONDENSATION; SER-10 PHOSPHORYLATION; ACTIVE CHROMATIN; TRANSCRIPTION; ACETYLATION; MEDIATE; KINASE	The Ras-mitogen activated protein kinase (Ras-MAPK) pathway plays an integral role in the formation of human malignancies. Stimulation of this pathway results in phosphorylation of histone H3 at serines 10 and 28 and expression of immediate-early genes. Phosphorylated (serine 10) H3, which is also acetylated on lysine 14, is associated with immediate-early genes. In this report, we investigated the relationship between these two H3 phosphorylation events in parental and ras-transformed fibroblasts. Immunoblot analyses of two-dimensional gel patterns demonstrated that all three H3 variants were phosphorylated after stimulation of the Ras-MAPK pathway and during mitosis. Following stimulation of the Ras-MAPK pathway, H3 phosphorylated on serines 10 and 28 was excluded from regions of highly condensed chromatin and was present in increased levels in ras-transformed cells. Although H3 phosphorylated at serine 10 or 28 was dynamically acetylated, H3 phosphorylated at serine 28 had a higher steady state of acetylation than that of H3 phosphorylated at serine 10. When visualized with indirect immunofluorescence, most foci of phosphorylated serine 28 H3 did not co-localize with foci of H3 phosphorylated on serine 10 or phosphoacetylated on serine 10 and lysine 14, suggesting that these two phosphorylation events act separately to promote gene expression.	Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada	University of Manitoba	Davie, JR (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.	davie@cc.umanitoba.ca		Davie, James/0000-0002-0420-6888				Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; CHADEE DN, 1995, J BIOL CHEM, V270, P20098, DOI 10.1074/jbc.270.34.20098; Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Clayton AL, 2000, EMBO J, V19, P3714, DOI 10.1093/emboj/19.14.3714; Clayton AL, 2003, FEBS LETT, V546, P51, DOI 10.1016/S0014-5793(03)00451-4; DAVIE JR, 2003, SCI STKE, V195, pPE33; Dimitrov SI, 1997, METHODS, V12, P57, DOI 10.1006/meth.1997.0447; Drobic B, 2004, CANCER RES, V64, P9076, DOI 10.1158/0008-5472.CAN-04-2369; Edmunds JW, 2004, J CELL SCI, V117, P3715, DOI 10.1242/jcs.01346; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; ESPINO P, 2005, IN PRESS J CELL BIOC; Fischer AH, 1998, J CELL BIOCHEM, V70, P130, DOI 10.1002/(SICI)1097-4644(19980701)70:1<130::AID-JCB13>3.3.CO;2-8; HENDZEL MJ, 1990, BIOCHEM J, V271, P67, DOI 10.1042/bj2710067; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Henikoff S, 2004, TRENDS GENET, V20, P320, DOI 10.1016/j.tig.2004.05.004; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; LAITINEN J, 1990, J CELL BIOL, V111, P9, DOI 10.1083/jcb.111.1.9; Lim JH, 2004, MOL CELL, V15, P573, DOI 10.1016/j.molcel.2004.08.006; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; McKittrick E, 2004, P NATL ACAD SCI USA, V101, P1525, DOI 10.1073/pnas.0308092100; Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007; RIDSDALE JA, 1987, NUCLEIC ACIDS RES, V15, P1081, DOI 10.1093/nar/15.3.1081; Samuel SK, 1997, CANCER RES, V57, P147; Schubeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Strelkov IS, 2002, CANCER RES, V62, P75; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Taylor WR, 1995, FEBS LETT, V377, P51, DOI 10.1016/0014-5793(95)01314-8; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; WATERBORG JH, 1993, J BIOL CHEM, V268, P4912; Workman JL, 2004, P NATL ACAD SCI USA, V101, P1429, DOI 10.1073/pnas.0308506101; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200; Zhong SP, 2001, J BIOL CHEM, V276, P12932, DOI 10.1074/jbc.M010931200; Zlatanova J, 1998, BIOPHYS J, V74, P2554, DOI 10.1016/S0006-3495(98)77963-9	41	62	68	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2005	24	21					3492	3502		10.1038/sj.onc.1208521	http://dx.doi.org/10.1038/sj.onc.1208521			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	925FT	15735677				2022-12-17	WOS:000229038800011
J	Zhang, BY; Srirangam, A; Potter, DA; Roman, A				Zhang, BY; Srirangam, A; Potter, DA; Roman, A			HPV16 E5 protein disrupts the c-Cbl-EGFR interaction and EGFR ubiquitination in human foreskin keratinocytes	ONCOGENE			English	Article						human papillomavirus; ubiquitination; epidermal growth factor receptor; c-Cbl; human foreskin keratinocytes	HUMAN-PAPILLOMAVIRUS TYPE-16; GROWTH-FACTOR RECEPTOR; TUMOR-SUPPRESSOR; E7; GENE; ONCOPROTEIN; ONCOGENE; E6; DEGRADATION; AUTOPHOSPHORYLATION	The E5 protein of human papillomavirus type 16 (HPV16) is a small hydrophobic protein, which localizes to the cell membrane, Golgi apparatus and endosomes. HPV16 E5 enhances the activation of the epidermal growth factor (EGFR). The activated EGFR is downregulated through the endocytic pathway, where E5 has been shown to inhibit endosomal acidification and trafficking. Ubiquitination of the activated EGFR plays a role in this downregulation. c-Cbl is a ubiquitin ligase that associates with the activated EGFR and targets it for degradation. Since E5 has been shown to form a complex with the EGFR, we tested the hypothesis that E5 affects the interaction of c-Cbl with the EGFR. We found a significant decrease of c-Cbl bound to the EGFR and of ubiquitinated EGFR in the presence of E5. E5 did not affect c-Cbl steady-state level, phosphorylation or translocation to the membrane. This novel result suggests that HPV16 E5 may, at least in part, upregulate EGFR-mediated signal transduction by inhibiting the interaction of c-Cbl with the EGFR, thereby decreasing c-Cbl-mediated degradation of the EGFR.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Med, Indianapolis, IN 46204 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46204 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46204 USA; Walther Canc Inst, Indianapolis, IN USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Roman, A (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, 635 Barnhill Dr,Med Sci Bldg,Room 420, Indianapolis, IN 46202 USA.	aroman@iupui.edu			NCI NIH HHS [R56 CA113570, R56 CA113570-01] Funding Source: Medline; NIGMS NIH HHS [1P20-GM66402, P20 GM066402] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM066402] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akerman GS, 2001, CANCER RES, V61, P3837; Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BOUVARD V, 1994, VIROLOGY, V203, P73, DOI 10.1006/viro.1994.1456; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Crusius K, 1998, EXP CELL RES, V241, P76, DOI 10.1006/excr.1998.4024; de Melker AA, 2001, J CELL SCI, V114, P2167; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; DiMaio D, 2001, ONCOGENE, V20, P7866, DOI 10.1038/sj.onc.1204915; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; Genther SM, 2003, J VIROL, V77, P2832, DOI 10.1128/JVI.77.5.2832-2842.2003; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Grant S, 2002, FRONT BIOSCI-LANDMRK, V7, pD376, DOI 10.2741/grant; GU ZM, 1995, J VIROL, V69, P8051, DOI 10.1128/JVI.69.12.8051-8056.1995; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Hubbard SR, 1999, PROG BIOPHYS MOL BIO, V71, P343, DOI 10.1016/S0079-6107(98)00047-9; HWANG ES, 1995, VIROLOGY, V211, P227, DOI 10.1006/viro.1995.1395; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kersemaekers AMF, 1999, CLIN CANCER RES, V5, P577; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1996, ONCOGENE, V12, P1117; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Mantovani F, 1999, SEMIN CANCER BIOL, V9, P387, DOI 10.1006/scbi.1999.0142; Mathur SP, 2001, AM J REPROD IMMUNOL, V46, P280, DOI 10.1034/j.1600-0897.2001.d01-14.x; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; MUNGER K, 1992, CANCER SURV, V12, P197; PIM D, 1992, ONCOGENE, V7, P27; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; Ravid T, 2004, J BIOL CHEM, V279, P37153, DOI 10.1074/jbc.M403210200; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SORKIN A, 1991, J BIOL CHEM, V266, P8355; Stoppler MC, 1996, VIROLOGY, V223, P251, DOI 10.1006/viro.1996.0475; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Thomsen P, 2000, ONCOGENE, V19, P6023, DOI 10.1038/sj.onc.1204010; VALLE GF, 1995, J GEN VIROL, V76, P1239, DOI 10.1099/0022-1317-76-5-1239; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zhang BY, 2002, J VIROL, V76, P220, DOI 10.1128/JVI.76.1.220-231.2002; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	46	62	67	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2005	24	15					2585	2588		10.1038/sj.onc.1208453	http://dx.doi.org/10.1038/sj.onc.1208453			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	913UV	15735736	Green Accepted			2022-12-17	WOS:000228180600017
J	Tuna, M; Chavez-Reyes, A; Tari, AM				Tuna, M; Chavez-Reyes, A; Tari, AM			HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells	ONCOGENE			English	Article						Wilms' tumor 1; HER2/neu; Akt; cyclin D1; Bcl-2; breast cancer	TUMOR SUPPRESSOR GENE; WILMS-TUMOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; CYCLIN D1; BCL-2; AKT; SURVIVAL; PHOSPHORYLATION; OVEREXPRESSION	High levels of the Wilms' Tumor 1 (WT1) protein and mRNA had been associated with aggressive phenotypes of breast tumors. Here we report that the HER2/neu oncogene increases WT1 expression. Approximately threefold higher levels of WT1 protein were observed in MCF-7 breast cancer cells transfected with the HER2/neu oncogene than in parental MCF-7 cells. Conversely, inhibition of HER2/neu with the anti-HER2/neu trastuzumab (Herceptint) antibody decreased WT1 protein levels in HER2/neu-overexpressing BT-474 and SKBr3 cells. We also found that HER2/neu engages Akt to regulate WT1 levels since inhibition of Akt reduced WT1 levels. Decreased expression of WT1 protein led to cell cycle arrest at the G1 phase and increased apoptosis in HER2/neu-overexpressing cells, which is correlated with decreased cyclin D1 and Bcl-2 levels. Our data indicate that HER2/neu engages Akt to increase WT1 expression, and that WT1 protein plays a vital role in regulating cell cycle progression and apoptosis in HER2/neu-overexpressing breast cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 422, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Tari, AM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 422, 1515 Holcombe Blvd, Houston, TX 77030 USA.	atari@mdanderson.org	Chavez-Reyes, Arturo/ABG-1231-2020	Chavez-Reyes, Arturo/0000-0002-6655-815X				ADNANE J, 1989, ONCOGENE, V4, P1389; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cheema SK, 2003, J BIOL CHEM, V278, P19995, DOI 10.1074/jbc.M205865200; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Gold MR, 1999, J IMMUNOL, V163, P1894; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HEWITT SM, 1995, CANCER RES, V55, P5386; Inoue K, 1997, BLOOD, V89, P1405, DOI 10.1182/blood.V89.4.1405; Karakas T, 2002, LEUKEMIA, V16, P846, DOI 10.1038/sj.leu.2402434; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lenferink AEG, 2001, CANCER RES, V61, P6583; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; Miyoshi Y, 2002, CLIN CANCER RES, V8, P1167; Oji Y, 2002, INT J CANCER, V100, P297, DOI 10.1002/ijc.10476; Silberstein GB, 1997, P NATL ACAD SCI USA, V94, P8132, DOI 10.1073/pnas.94.15.8132; Simeone AM, 2004, CANCER RES, V64, P1224, DOI 10.1158/0008-5472.CAN-03-2188; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Takata M, 1999, J BIOL CHEM, V274, P20611, DOI 10.1074/jbc.274.29.20611; Zapata-Benavides P, 2002, BIOCHEM BIOPH RES CO, V295, P784, DOI 10.1016/S0006-291X(02)00751-9; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	23	62	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1648	1652		10.1038/sj.onc.1208345	http://dx.doi.org/10.1038/sj.onc.1208345			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674342				2022-12-17	WOS:000227218200019
J	Suzuki, M; Toyooka, S; Shivapurkar, N; Shigematsu, H; Miyajima, K; Takahashi, T; Stastny, V; Zern, AL; Fujisawa, T; Pass, HI; Carbone, M; Gazdar, AF				Suzuki, M; Toyooka, S; Shivapurkar, N; Shigematsu, H; Miyajima, K; Takahashi, T; Stastny, V; Zern, AL; Fujisawa, T; Pass, HI; Carbone, M; Gazdar, AF			Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection	ONCOGENE			English	Article						methylation; malignant mesothelioma; SV40	TUMOR-SUPPRESSOR GENE; SIMIAN-VIRUS-40 DNA-SEQUENCES; NONSMALL CELL LUNG; PROMOTER METHYLATION; BREAST-CANCER; MULTIPLE GENES; EXPRESSION; HYPERMETHYLATION; HIC-1; METHYLTRANSFERASE	Malignant mesothelioma ( MM) is associated with asbestos exposure and the presence of SV40 viral sequences. Recently, we reported that SV40 infection of human mesothelial cells (HM) causes aberrant methylation of the tumor suppressor gene (TSG) RASSF1A. We investigated methylation of 12 genes by methylation-specific PCR in 63 MMs, six MM cell lines, and two foci of SV40-infected HM. Methylation percentages of the tested genes ranged from 3 to 65%. The frequencies of HPP1, RASSF1A, Cyclin D2, and RRAD methylation, and the value of the methylation index, were significantly higher in SV40 sequence-positive MMs than in SV40-negative MMs. Methylation of TMS1 and HIC-1 was associated with shortened survival. SV40-infected HM showed progressive aberrant methylation of seven genes ( RASSF1A, HPP1, DcR1, TMS1, CRBP1, HIC-1, and RRAD) during serial passage. Our results demonstrate a relationship between SV40 and methylation of multiple genes in MM, indicating that the virus plays a role in the pathogenesis of MM.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Chiba Univ, Grad Sch Med, Dept Thorac Surg, Chiba 2608670, Japan; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Karamanos Canc Ctr, Dept Thorac Surg, Detroit, MI 48201 USA; Loyola Univ, Cardinal Bernardin Canc Ctr, Dept Pathol, Maywood, IL 60153 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Chiba University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Loyola University Chicago	Gazdar, AF (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	adi.gazdar@utsouthwestern.edu		Pass, Harvey/0000-0003-3222-3471	NATIONAL CANCER INSTITUTE [R01CA092657, U01CA084971, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [R0-1 CA92657, P50CA70907, 5U01CA8497102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baas P, 2003, CURR OPIN ONCOL, V15, P127, DOI 10.1097/00001622-200303000-00002; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; CICALA C, 1993, AM J PATHOL, V142, P1524; Conway KE, 2000, CANCER RES, V60, P6236; Du Y, 2001, CANCER RES, V61, P8094; Edwards JG, 2003, BRIT J CANCER, V88, P1553, DOI 10.1038/sj.bjc.6600920; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 2002, CANCER RES, V62, P5902; Gazdar Adi F, 2003, Clin Lung Cancer, V5, P177, DOI 10.3816/CLC.2003.n.031; Gazdar AF, 2002, NAT REV CANCER, V2, P957, DOI 10.1038/nrc947; Gordon GJ, 2003, J NATL CANCER I, V95, P598, DOI 10.1093/jnci/95.8.598; Hayashi M, 2001, ANTICANCER RES, V21, P535; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Hirao T, 2002, CARCINOGENESIS, V23, P1127, DOI 10.1093/carcin/23.7.1127; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Kang GH, 2002, AM J PATHOL, V160, P787, DOI 10.1016/S0002-9440(10)64901-2; Nicoll G, 2001, BRIT J CANCER, V85, P1878, DOI 10.1054/bjoc.2001.2163; Padar A, 2003, CLIN CANCER RES, V9, P4730; PASS HI, 1995, ANN THORAC SURG, V59, P835, DOI 10.1016/0003-4975(95)00045-M; Phelps RM, 1996, J CELL BIOCHEM, P32; Powers A, 2002, CANCER BIOL THER, V1, P348; Rathi A, 2002, CLIN CANCER RES, V8, P3324; Rathi A, 2003, CLIN CANCER RES, V9, P3674; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Rizzo P, 2001, SEMIN CANCER BIOL, V11, P63, DOI 10.1006/scbi.2000.0347; Rood BR, 2002, CANCER RES, V62, P3794; Sandberg AA, 2001, CANCER GENET CYTOGEN, V127, P93, DOI 10.1016/S0165-4608(01)00432-0; Sato F, 2002, CANCER RES, V62, P6820; Shibata DM, 2002, CANCER RES, V62, P5637; Shivapurkar N, 2002, LANCET, V359, P851, DOI 10.1016/S0140-6736(02)07921-7; Shivapurkar N, 2004, CANCER RES, V64, P3757, DOI 10.1158/0008-5472.CAN-03-3307; Shivapurkar N, 2004, INT J CANCER, V109, P786, DOI 10.1002/ijc.20041; Shivapurkar N, 2000, J CELL BIOCHEM, V76, P181; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; Soejima K, 2003, ONCOGENE, V22, P4723, DOI 10.1038/sj.onc.1206510; Topol LZ, 2000, CYTOGENET CELL GENET, V89, P79, DOI 10.1159/000015568; Topol LZ, 1997, MOL CELL BIOL, V17, P4801, DOI 10.1128/MCB.17.8.4801; Toyooka S, 2002, ONCOGENE, V21, P4340, DOI 10.1038/sj.onc.1205381; Toyooka S, 2001, CANCER RES, V61, P5727; Tseng YH, 2001, CANCER RES, V61, P2071; van Noesel MM, 2002, CANCER RES, V62, P2157; Virmani A, 2003, INT J CANCER, V107, P341, DOI 10.1002/ijc.11393; Virmani A, 2003, INT J CANCER, V106, P198, DOI 10.1002/ijc.11206; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wong L, 2002, LUNG CANCER, V38, P131, DOI 10.1016/S0169-5002(02)00178-2; Yang B, 2003, AM J PATHOL, V163, P1101, DOI 10.1016/S0002-9440(10)63469-4; Zanella CL, 1996, CANCER RES, V56, P5334	48	62	64	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1302	1308		10.1038/sj.onc.1208263	http://dx.doi.org/10.1038/sj.onc.1208263			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15592515				2022-12-17	WOS:000226898700019
J	Lebedeva, IV; Su, ZZ; Sarkar, D; Gopalkrishnan, RV; Waxman, S; Yacoub, A; Dent, P; Fisher, PB				Lebedeva, IV; Su, ZZ; Sarkar, D; Gopalkrishnan, RV; Waxman, S; Yacoub, A; Dent, P; Fisher, PB			Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis	ONCOGENE			English	Article						mda-7/IL-24; ROS; pancreatic cancer; apoptosis	DIFFERENTIATION-ASSOCIATED GENE-7; PROSTATE-CANCER CELLS; HUMAN-MELANOMA CELLS; ARSENIC TRIOXIDE; GROWTH ARREST; MDA-7 IL-24; IN-VITRO; ENHANCES RADIOSENSITIVITY; TERMINAL DIFFERENTIATION; SELECTIVE APOPTOSIS	Pancreatic cancer is exceptionally aggressive with no long-term effective therapy. Current interventional approaches, including surgery, radiation and/or chemotherapy, have done little to quell the mortality associated with this malignancy. Subtraction hybridization identified a cancer-specific apoptosis-inducing cytokine gene, melanoma differentiation associated gene-7/interleukin-24 (mda-7/ IL-24), with a broad range of selective antitumor activity in diverse cancers both in vitro and in vivo in nude mice and recently in patients with advanced carcinomas and melanomas. Unlike most neoplasms, pancreatic cancers display innate resistance to mda-7/ IL-24-induced apoptosis, which correlates with a diminished capacity to convert mda-7/ IL-24 mRNA into protein. We presently demonstrate that this translational block can be reversed by treatment with agents that elevate reactive oxygen species (ROS). Induction of apoptosis in vitro and suppression of tumorigenesis in vivo in nude mice are induced in pancreatic cancers, irrespective of the status of their K-ras gene, only when tumor cells simultaneously express mda-7/ IL-24 and are treated with a ROS-inducer, such as arsenic trioxide (ARS), N-(4-hydroxyphenyl) retinamide (HPR) or dithiophene (NSC656240 (NSC)). In pancreatic cancer cells constitutively expressing mda-7/ IL-24 mRNA, a single treatment with arsenic trioxide, HPR or NSC656240 induces apoptosis, which correlates with production of MDA-7/IL-24 protein. The specificity of this action is documented by the ability of ROS inhibitors, including N-acetyl-L-cysteine and Tiron, to block this killing effect. Of potential clinical significance, similar treatment of normal cells does not elicit significant changes in growth nor does it induce apoptosis. Analysis of signal transduction changes in pancreatic carcinoma cells infected with Ad. mda-7 in combination with a ROS-inducer indicate that cell death correlates with modulation of discrete cassettes of multiple signaling pathways in a pancreatic cancer cell-specific manner, supporting global signaling dysregulation as a potential mediator of apoptosis induction. These findings suggest a promising combinatorial approach for safely promoting cell death in pancreatic tumors that provides a rational framework for developing a selective and effective therapy for this invariably fatal cancer.	Columbia Univ Coll Phys & Surg, Med Ctr, Dept Pathol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Columbia Univ Coll Phys & Surg, Med Ctr, Dept Urol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Med Ctr, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Icahn School of Medicine at Mount Sinai; Virginia Commonwealth University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Med Ctr, Dept Pathol, Herbert Irving Comprehens Canc Ctr, 630 W 168th St, New York, NY 10032 USA.	pbf1@columbia.edu	Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NATIONAL CANCER INSTITUTE [P01CA072955, R01CA088906, R01CA098712, R01CA097318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER; NCI NIH HHS [CA98712, CA97318, CA72955, CA88906] Funding Source: Medline; NIDDK NIH HHS [DK52825] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Dent P, 1998, LEUKEMIA, V12, P1843, DOI 10.1038/sj.leu.2401222; Fisher PB, 2003, CANCER BIOL THER, V2, pS23; Hail N, 2000, CANCER EPIDEM BIOMAR, V9, P1293; Huang F, 1999, GENE, V236, P125, DOI 10.1016/S0378-1119(99)00244-9; Huang F, 1999, ONCOGENE, V18, P3546, DOI 10.1038/sj.onc.1202715; Jaffee EM, 2002, CANCER CELL, V2, P25, DOI 10.1016/S1535-6108(02)00093-4; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang HP, 2000, P NATL ACAD SCI USA, V97, P12684, DOI 10.1073/pnas.220431297; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Kawabe S, 2002, MOL THER, V6, P637, DOI 10.1006/mthe.2002.0714; Kern SE, 2002, CANCER BIOL THER, V1, P607, DOI 10.4161/cbt.307; Kim DG, 2002, J BIOL CHEM, V277, P38930, DOI 10.1074/jbc.M205941200; Kulke Matthew H, 2002, Curr Treat Options Oncol, V3, P449, DOI 10.1007/s11864-002-0065-5; Lebedeva I, 2000, CANCER RES, V60, P6052; Lebedeva IV, 2003, CANCER RES, V63, P8138; Lebedeva IV, 2003, ONCOGENE, V22, P8758, DOI 10.1038/sj.onc.1206891; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; LEBEDEVA IV, 2004, IN PRESS MOL THER; Li XQ, 2003, PANCREAS, V27, P174, DOI 10.1097/00006676-200308000-00011; Madireddi MT, 2000, ADV EXP MED BIOL, V465, P239; McKenna S, 2003, ONCOLOGIST, V8, P149, DOI 10.1634/theoncologist.8-2-149; Mhashilkar AM, 2003, MOL THER, V8, P207, DOI 10.1016/S1525-0016(03)00170-9; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; Miller WH, 2002, CANCER RES, V62, P3893; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Sarkar D, 2002, BIOTECHNIQUES, P30; Sauane M, 2004, ONCOGENE, V23, P7679, DOI 10.1038/sj.onc.1207958; Sauane M, 2003, CYTOKINE GROWTH F R, V14, P35, DOI 10.1016/S1359-6101(02)00074-6; Simeone AM, 2002, MOL CANCER THER, V1, P1009; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Vuky J, 2002, INVEST NEW DRUG, V20, P327, DOI 10.1023/A:1016270206374; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; Xia Y, 2002, INT J CANCER, V102, P7, DOI 10.1002/ijc.10664; Yacoub A, 2004, CANCER BIOL THER, V3, P739, DOI 10.4161/cbt.3.8.968; Yacoub A, 2003, CANCER BIOL THER, V2, P347, DOI 10.4161/cbt.2.4.422; Yacoub A, 2003, CLIN CANCER RES, V9, P3272; Yacoub A, 2003, MOL CANCER THER, V2, P623; Zou CP, 2002, CANCER LETT, V180, P131, DOI 10.1016/S0304-3835(01)00864-3	50	62	77	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2005	24	4					585	596		10.1038/sj.onc.1208183	http://dx.doi.org/10.1038/sj.onc.1208183			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580305				2022-12-17	WOS:000226420400006
J	Swallow, CJ; Ko, MA; Siddiqui, NU; Hudson, JW; Dennis, JW				Swallow, CJ; Ko, MA; Siddiqui, NU; Hudson, JW; Dennis, JW			Sak/Plk4 and mitotic fidelity	ONCOGENE			English	Article						mitosis; Sak/Plk4; chromosomal instability; colorectal cancer; hepatoma	POLO-LIKE KINASE; ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; POSITIVE-FEEDBACK; TUMOR-DEVELOPMENT; SAK; CANCER; MICE; PLK	Sak/Plk4 differs from other polo-like kinases in having only a single polo box, which assumes a novel dimer fold that localizes to the nucleolus, centrosomes and the cleavage furrow. Sak expression increases gradually in S through M phase, and Sak is destroyed by APC/C dependent proteolysis. Sak-deficient mouse embryos arrest at E7.5 and display an increased incidence of apoptosis and anaphase arrest. Sak(+/-) mice are haploinsufficient for tumor suppression, with spontaneous tumors developing primarily in the liver with advanced age. During liver regeneration following partial hepatectomy, Sak(+/-) hepatocytes display a delay in reaching the first M phase, multipolar spindles, disorganized tissue morphology and loss of acuity for cyclin B1 expression. Similarly, Sak(+/-) MEF cells proliferate slowly, and show a high incidence of centrosome hyper-amplification. We suggest that Sak provides feedback to cell cycle regulators, and thereby precision to the switch-like transitions of centrosome duplication and exit-from-mitosis. Sak binds to p53, and studies are underway to provide a molecular context for the Sak-p53 interaction. Ani mal models of haploinsufficiency and more comprehensive models of cell cycle regulation should contribute to improvements in cancer risk assessment and novel therapies.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Microbiol & Med Genet, Toronto, ON, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; Univ Windsor, Dept Biol Sci, Windsor, ON N9B 3P4, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Windsor	Dennis, JW (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave,R988, Toronto, ON M5G 1X5, Canada.	dennis@mshri.on.ca	Dennis, James/E-7268-2013					Bai F, 2003, MOL CELL BIOL, V23, P1269, DOI 10.1128/MCB.23.4.1269-1277.2003; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bembenek J, 2001, J BIOL CHEM, V276, P48237, DOI 10.1074/jbc.M108126200; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Blagden SP, 2003, NAT CELL BIOL, V5, P505, DOI 10.1038/ncb0603-505; Brassac T, 2000, ONCOGENE, V19, P3782, DOI 10.1038/sj.onc.1203724; Budde PP, 2001, J CELL BIOL, V153, P149, DOI 10.1083/jcb.153.1.149; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; Dai W, 2000, GENE CHROMOSOME CANC, V27, P332, DOI 10.1002/(SICI)1098-2264(200003)27:3<332::AID-GCC15>3.0.CO;2-K; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fernebro E, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-25; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; FODE C, 1994, P NATL ACAD SCI USA, V91, P6388, DOI 10.1073/pnas.91.14.6388; Fode C, 1996, MOL CELL BIOL, V16, P4665; Hammond C, 1999, HEPATOLOGY, V29, P1479, DOI 10.1002/hep.510290513; HARTWELL LH, 1973, GENETICS, V74, P267; Hudson JW, 2000, GENE, V241, P65, DOI 10.1016/S0378-1119(99)00467-9; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; *INT SEQ AN CONS, 2000, NATURE, V408, P796; Jackson RJ, 2003, CANCER RES, V63, P3021; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Lucas JA, 2003, IMMUNOL REV, V191, P119, DOI 10.1034/j.1600-065X.2003.00029.x; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Macmillan JC, 2001, ANN SURG ONCOL, V8, P729, DOI 10.1245/aso.2001.8.9.729; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McNally KP, 2002, CELL MOTIL CYTOSKEL, V53, P337, DOI 10.1002/cm.10080; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; SHARON G, 1990, GENETICS, V125, P475; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Simizu S, 2000, NAT CELL BIOL, V2, P852, DOI 10.1038/35041102; Su TT, 1998, GENE DEV, V12, P1495, DOI 10.1101/gad.12.10.1495; Takahashi T, 2003, CANCER SCI, V94, P148, DOI 10.1111/j.1349-7006.2003.tb01411.x; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2002, CELL CYCLE, V1, P75, DOI 10.4161/cc.1.1.103; Tsai KY, 2002, P NATL ACAD SCI USA, V99, P16865, DOI 10.1073/pnas.262499599; Visintin R, 2003, MOL BIOL CELL, V14, P4486, DOI 10.1091/mbc.e03-02-0095; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Xiong W, 2003, NATURE, V426, P460, DOI 10.1038/nature02089; Yamashita Y, 2001, J BIOL CHEM, V276, P39012, DOI 10.1074/jbc.M106249200; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Zhang H, 2004, J BIOL CHEM, V279, P35726, DOI 10.1074/jbc.M403264200	51	62	67	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2005	24	2					306	312		10.1038/sj.onc.1208275	http://dx.doi.org/10.1038/sj.onc.1208275			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640847				2022-12-17	WOS:000226183100012
J	Epling-Burnett, PK; Bai, FQ; Wei, S; Chaurasia, P; Painter, JS; Olashaw, N; Hamilton, A; Sebti, S; Djeu, JY; Loughran, TP				Epling-Burnett, PK; Bai, FQ; Wei, S; Chaurasia, P; Painter, JS; Olashaw, N; Hamilton, A; Sebti, S; Djeu, JY; Loughran, TP			ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL)	ONCOGENE			English	Article						mitogen-activated protein kinase (MAPK); Ras; natural killer cells	NATURAL-KILLER-CELLS; GERANYLGERANYLTRANSFERASE-I; CHROMOSOMAL-ABNORMALITIES; PERIPHERAL-BLOOD; RECEPTOR; KINASE; PROTEIN; EXPRESSION; APOPTOSIS; LEUKEMIA	Chronic NK lymphoproliferative disease of large granular lymphocytes (LDGL) is characterized by the expansion of activated CD3(-), CD16(+) or CD56(+) lymphocytes. The mechanism of survival of NK cells from LDGL patients is unknown but may be related to antigenic stimulation. There is currently no standard effective therapy for LDGL, and the disease is characteristically resistant to standard forms of chemotherapy. We found evidence of constitutive activation of extracellular-regulated kinase (ERK) in NK cells from 13/13 patients with NK-LDGL (one patient with aggressive and 12 patients with chronic disease). Ablation of ERK activity by inhibitors or a dominant-negative form of MEK, the upstream activator of ERK, reduced the survival of patient NK cells. Ras was also constitutively active in patient NK cells, and exposure of cells to the Ras inhibitor FTI2153 or to dominant-negative-Ras resulted not only in ERK inhibition but also in enhanced apoptosis in both the presence and absence of anti-Fas. Therefore, we conclude that a constitutively active Ras/MEK/ERK pathway contributes to the accumulation of NK cells in patients with NK-LDGL. These findings suggest that strategies to inhibit this signaling pathway may be useful for the treatment of the NK type of LDGL.	James A Haley Vet Hosp, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr & Res Inst, Hematol Malignancies Program, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr & Res Inst, Program Immunol, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Dept Interdisciplinary Oncol, H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Penn State Coll Med, Penn State Canc Inst, Hershey, PA 17033 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Epling-Burnett, PK (corresponding author), James A Haley Vet Hosp, 13000 Bruce B Downs Blvd,Res Bldg 2,Room 115, Tampa, FL 33612 USA.	burnetpk@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [R01CA083146, R01CA098472, K24CA083947, R01CA090633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R43AI052613] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA098472, CA83947, CA90633, CA94872, CA83146] Funding Source: Medline; NIAID NIH HHS [AI052613] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; Djeu JY, 2002, CLIN CANCER RES, V8, P636; Epling-Burnette PK, 2004, BLOOD, V103, P3431, DOI 10.1182/blood-2003-02-0400; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Ferlazzo G, 2003, EUR J IMMUNOL, V33, P306, DOI 10.1002/immu.200310004; He T, 2002, J BIOL CHEM, V277, P10767, DOI 10.1074/jbc.M111436200; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Husain Z, 2002, IMMUNOLOGY, V106, P373, DOI 10.1046/j.1365-2567.2002.01444.x; Jiang K, 2000, NAT IMMUNOL, V1, P419, DOI 10.1038/80859; Lamy T, 1998, BLOOD, V92, P4771, DOI 10.1182/blood.V92.12.4771.424k32_4771_4777; LANIER LL, 1986, J EXP MED, V163, P209, DOI 10.1084/jem.163.1.209; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Lima M, 2002, BLOOD CELL MOL DIS, V28, P181, DOI 10.1006/bcmd.2002.0506; Loughran TP, 1997, BLOOD, V90, P1977, DOI 10.1182/blood.V90.5.1977; LOUGHRAN TP, 1994, LEUKEMIA RES, V18, P423, DOI 10.1016/0145-2126(94)90078-7; LOUGHRAN TP, 1985, ANN INTERN MED, V102, P169, DOI 10.7326/0003-4819-102-2-169; LOUGHRAN TP, 1993, BLOOD, V82, P1; MCVICAR DW, 2001, SCI STKE, pRE1, DOI DOI 10.1126/STKE.2001.75.RE1; MIYAWAKI T, 1992, J IMMUNOL, V149, P3753; MONTAGNA D, 1992, BIOL NEONATE, V62, P385; OHNO T, 1988, CANCER-AM CANCER SOC, V62, P1918, DOI 10.1002/1097-0142(19881101)62:9<1918::AID-CNCR2820620909>3.0.CO;2-8; ORTALDO JR, 1995, J EXP MED, V181, P339, DOI 10.1084/jem.181.1.339; Perzova RN, 2000, BRIT J HAEMATOL, V109, P64, DOI 10.1046/j.1365-2141.2000.01972.x; RITZ J, 1985, SCIENCE, V228, P1540, DOI 10.1126/science.2409597; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; SEMENZATO G, 1987, CANCER-AM CANCER SOC, V60, P2971, DOI 10.1002/1097-0142(19871215)60:12<2971::AID-CNCR2820601220>3.0.CO;2-O; Soderstrom TS, 2002, J IMMUNOL, V169, P2851, DOI 10.4049/jimmunol.169.6.2851; Sun JZ, 1999, CANCER RES, V59, P4919; Takahashi A, 2001, J IMMUNOL, V166, P6771, DOI 10.4049/jimmunol.166.11.6771; TANIWAKI M, 1990, AM J HEMATOL, V33, P32, DOI 10.1002/ajh.2830330107; TEFFERI A, 1994, BLOOD, V84, P2721; TIMONEN T, 1981, J EXP MED, V153, P569, DOI 10.1084/jem.153.3.569; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317; Wei S, 2000, J IMMUNOL, V165, P3811, DOI 10.4049/jimmunol.165.7.3811; Wei S, 1998, J EXP MED, V187, P1753, DOI 10.1084/jem.187.11.1753; Zingoni A, 2000, EUR J IMMUNOL, V30, P644, DOI 10.1002/1521-4141(200002)30:2<644::AID-IMMU644>3.0.CO;2-H	41	62	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9220	9229		10.1038/sj.onc.1208122	http://dx.doi.org/10.1038/sj.onc.1208122			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516985	Bronze			2022-12-17	WOS:000225638000007
J	Koutsodontis, G; Kardassis, D				Koutsodontis, G; Kardassis, D			Inhibition of p53-mediated transcriptional responses by mithramycin A	ONCOGENE			English	Article						p53; mithramycin A; 5-fluorouracil; genotoxic stress; p21(Cip1); PUMA; Sp1	COLORECTAL-CANCER CELLS; DEPENDENT KINASES; PAGETS-DISEASE; CDK INHIBITORS; FAMILY-MEMBERS; SMAD PROTEINS; IN-VIVO; P53; PROMOTER; SP1	In the present work, we show that mithramycin A, a drug that is currently used for the treatment of patients with Paget's disease of the bone as well as with several forms of cancer, is a strong activator of the tumor suppressor p53 protein in human hepatoma cells. The time course of p53 activation by mithramycin A was similar to the known chemotherapeutic compound 5-fluorouracil (5-FU). Both 5-FU and mithramycin A induced site-specific phosphorylation of p53 at serine 15. However, in contrast to 5-FU, mithramycin A failed to activate p53 target genes including the cell cycle inhibitor p21(Cip1) gene as well as the proapoptotic genes PUMA (p53-upregulated mediator of apotosis) and BAK (bcl2-homologous antagonist/killer) and blocked the induction of the above genes by 5-FU. Using transactivation assays in Sp1-deficient cells, we showed that mithramycin A inhibited the transcriptional activation of the p21(Cip1) and PUMA promoters by Sp1 and p53. Using chromatin immunoprecipitation assays and a novel protein-protein interaction assay based on biotinylation in vivo, we established that 5-FU enhanced the formation of p53-Sp1 complexes in solution and the subsequent recruitment of both factors to the p21(Cip1) promoter. Mithramycin A also enhanced the recruitment of p53 to the distal p21(Cip1) promoter but totally blocked the recruitment of Sp1 to the proximal p21(Cip1) promoter. Our findings suggest that inhibition of Sp1 binding to the promoters of several p53 target genes, such as the p21(Cip1) gene as well as certain proapoptotic genes, by mithramycin A, prevents the transcriptional induction of these genes by p53 and propose a mechanism that could account for some of the tumor suppressing and antiapoptotic effects of mithramycin A.	Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Iraklion, Greece; Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Greece	University of Crete; Foundation for Research & Technology - Hellas (FORTH)	Kardassis, D (corresponding author), Univ Crete, Sch Med, Dept Basic Sci, GR-71110 Iraklion, Greece.	kardasis@imbb.forth.gr						AICH P, 1995, BIOCHEMISTRY-US, V34, P1376, DOI 10.1021/bi00004a032; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BROWN JH, 1965, NEW ENGL J MED, V272, P111, DOI 10.1056/NEJM196501212720301; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Choi J, 1999, CELL MOL LIFE SCI, V55, P38, DOI 10.1007/s000180050268; de Boer E, 2003, P NATL ACAD SCI USA, V100, P7480, DOI 10.1073/pnas.1332608100; De Siervi A, 2004, CANCER RES, V64, P743, DOI 10.1158/0008-5472.CAN-03-2505; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; ELIAS EG, 1972, J BONE JOINT SURG AM, VA 54, P1730, DOI 10.2106/00004623-197254080-00013; Gartel AL, 2002, MOL CANCER THER, V1, P639; Hall PA, 2000, CARCINOGENESIS, V21, P153, DOI 10.1093/carcin/21.2.153; HALL TJ, 1993, BIOCHEM BIOPH RES CO, V195, P1245, DOI 10.1006/bbrc.1993.2178; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hatzis P, 2001, MOL CELL BIOL, V21, P7320, DOI 10.1128/MCB.21.21.7320-7330.2001; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Jayasuriya H, 2002, J NAT PROD, V65, P1091, DOI 10.1021/np010642f; Kardassis D, 2000, J BIOL CHEM, V275, P41405, DOI 10.1074/jbc.M007896200; Kardassis D, 2002, BIOCHEMISTRY-US, V41, P1217, DOI 10.1021/bi015618f; KARDASSIS D, 1992, J BIOL CHEM, V267, P2622; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Koutsodontis G, 2002, BIOCHEMISTRY-US, V41, P12771, DOI 10.1021/bi026141q; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Majee S, 1999, BIOCHEM PHARMACOL, V57, P981, DOI 10.1016/S0006-2952(98)00374-8; Majee S, 1999, EUR J BIOCHEM, V260, P619, DOI 10.1046/j.1432-1327.1999.00159.x; MILLER DM, 1987, AM J MED SCI, V294, P388, DOI 10.1097/00000441-198711000-00015; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; NEHLS MC, 1993, J CLIN INVEST, V92, P2916, DOI 10.1172/JCI116914; Orlando V, 2000, TRENDS BIOCHEM SCI, V25, P99, DOI 10.1016/S0968-0004(99)01535-2; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; RAY R, 1989, J CLIN INVEST, V83, P2003, DOI 10.1172/JCI114110; Remsing LL, 2003, BIOCHEMISTRY-US, V42, P8313, DOI 10.1021/bi034091z; RYAN WG, 1970, J AMER MED ASSOC, V213, P1153, DOI 10.1001/jama.213.7.1153; Schavinsky-Khrapunsky Y, 2003, ONCOGENE, V22, P5315, DOI 10.1038/sj.onc.1206782; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; SNYDER RC, 1991, BIOCHEMISTRY-US, V30, P4290, DOI 10.1021/bi00231a027; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; ZHANG H, 1994, COLD SPRING HARB SYM, V59, P21, DOI 10.1101/SQB.1994.059.01.005	47	62	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9190	9200		10.1038/sj.onc.1208141	http://dx.doi.org/10.1038/sj.onc.1208141			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15489892				2022-12-17	WOS:000225638000004
J	Chauchereau, A; Mathieu, M; de Saintignon, J; Ferreira, R; Pritchard, LL; Mishal, Z; Dejean, A; Harel-Bellan, A				Chauchereau, A; Mathieu, M; de Saintignon, J; Ferreira, R; Pritchard, LL; Mishal, Z; Dejean, A; Harel-Bellan, A			HDAC4 mediates transcriptional repression by the acute promyelocytic leukaemia-associated protein PLZF	ONCOGENE			English	Article						PLZF; HDAC; PLZF-RAR alpha	ACID RECEPTOR-ALPHA; II HISTONE DEACETYLASES; SERUM RESPONSE FACTOR; RAR-ALPHA; MUSCLE DIFFERENTIATION; NUCLEAR EXPORT; POZ DOMAIN; COREPRESSOR; COMPLEX; SMRT	PLZF, the promyelocytic leukaemia zinc-finger protein, is a transcriptional repressor essential to development. In some acute leukaemias, a chromosomal translocation fusing the PLZF gene to that encoding the retinoic acid receptor RARalpha gives rise to a fusion protein, PLZF RARa, thought to be responsible for constitutive repression of differentiation-associated genes in these cells. Repression by both PLZF and PLZF-RARalpha is sensitive to the histone deacetylase inhibitor TSA, and PLZF was previously shown to interact physically with HDAC1, a class I histone deacetylase. We here asked whether class II histone deacetylases, known to be generally involved in differentiation processes, participate in the repression mediated by PLZF and PLZF-RARalpha, and found that PLZF interacts with HDAC4 in both GST-pull-down and co-immunoprecipitation assays. Furthermore, HDAC4 is indeed involved in PLZF and PLZF-RARalpha-mediated repression, since an enzymatically dead mutant of HDAC4 released the repression, as did an siRNA that blocks HDAC4 expression. Taken together, our data indicate that recruitment of HDAC4 is necessary for PLZF-mediated repression in both normal and leukaemic cells.	Inst Andre Lwoff, CNRS, UPR 9079, F-94800 Villejuif, France; Inst Andre Lwoff, Lab Cytometrie, F-94800 Villejuif, France; Inst Pasteur, INSERM, U579, F-75015 Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Harel-Bellan, A (corresponding author), Inst Andre Lwoff, CNRS, UPR 9079, 7 Rue Guy Moquet, F-94800 Villejuif, France.	ahbellan@vjf.cnrs.fr	Chauchereau, Anne/N-8880-2016; Harel-Bellan, Annick/M-9795-2015; CHAUCHEREAU, Anne/B-1074-2009; Dejean, Anne/L-5145-2018	Chauchereau, Anne/0000-0001-9447-3797; Harel-Bellan, Annick/0000-0002-2339-153X; MATHIEU, Marion/0000-0002-1815-2112				AHMED N, 1993, BIOCHEM MOL BIOL INT, V29, P1055; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Borghi S, 2001, J CELL SCI, V114, P4477; Chan JKL, 2003, J BIOL CHEM, V278, P23515, DOI 10.1074/jbc.M301922200; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Davis FJ, 2003, J BIOL CHEM, V278, P20047, DOI 10.1074/jbc.M209998200; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Groisman R, 1996, J BIOL CHEM, V271, P5258; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Kao GD, 2003, J CELL BIOL, V160, P1017, DOI 10.1083/jcb.200209065; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Lemercier C, 2002, J BIOL CHEM, V277, P22045, DOI 10.1074/jbc.M201736200; Licht JD, 1996, ONCOGENE, V12, P323; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Miska EA, 2001, NUCLEIC ACIDS RES, V29, P3439, DOI 10.1093/nar/29.16.3439; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nanba D, 2003, J CELL BIOL, V163, P489, DOI 10.1083/jcb.200303017; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Senbonmatsu T, 2003, EMBO J, V22, P6471, DOI 10.1093/emboj/cdg637; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Verdel A, 1999, J BIOL CHEM, V274, P2440, DOI 10.1074/jbc.274.4.2440; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Watamoto K, 2003, ONCOGENE, V22, P9176, DOI 10.1038/sj.onc.1206902; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766	47	62	65	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8777	8784		10.1038/sj.onc.1208128	http://dx.doi.org/10.1038/sj.onc.1208128			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15467736				2022-12-17	WOS:000225165100007
J	Kawakubo, H; Carey, JL; Brachtel, E; Gupta, V; Green, JE; Walden, PD; Maheswaran, S				Kawakubo, H; Carey, JL; Brachtel, E; Gupta, V; Green, JE; Walden, PD; Maheswaran, S			Expression of the NF-kappa B-responsive gene BTG2 is aberrantly regulated in breast cancer	ONCOGENE			English	Article						BTG2; breast cancer; cell cycle; cyclin D1; NF-kappa B	MULLERIAN-INHIBITING SUBSTANCE; CYCLIN D1 TRANSCRIPTION; NERVE GROWTH-FACTOR; CELL-GROWTH; DOWN-REGULATION; TIS21 PROTEIN; DNA-DAMAGE; IN-VIVO; CARCINOMA; PC3	BTG2, a p53-inducible antiproliferative gene, is stimulated in breast cancer cells by activation of nuclear factor kappa B (NF-kappaB). In rat mammary glands, BTG2 is expressed in epithelial cells and levels decreased during pregnancy and lactation but recovered during involution. Estrogen and progestin suppress BTG2 expression, suggesting that these steroids, which stimulate proliferation and lobuloalveolar development of mammary epithelial cells, may downregulate BTG2 in the mammary gland during pregnancy. Consistent with the report that BTG2 inhibits cyclin D1 expression, suppression of BTG2 mRNA in the mammary gland during gestation, and by estrogen and progestin, correlated with stimulation of cyclin D1. Ectopic expression of BTG2 inhibited breast cancer cell growth by arresting cells in the G1 phase, an effect reversed by cyclin D1. BTG2 expression was very low or undetectable in human breast cancer cell lines compared with nontumorigenic mammary epithelial cells, and nuclear expression of BTG2 was absent in 65% of human breast tumors compared with adjacent matched normal glands. Spontaneous mammary tumors arising in a mouse model with targeted expression of the early region of the SV40 large tumor Ag demonstrated loss of BTG2 protein very early during the tumorigenic process. Thus deregulation of BTG2 may be an important step in the development of mammary tumors.	Massachusetts Gen Hosp, Dept Surg Oncol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; NIH, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; NYU Med Ctr, Dept Urol, New York, NY 10016 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; New York University	Maheswaran, S (corresponding author), Massachusetts Gen Hosp, Dept Surg Oncol, Jackson 904,55 Fruit St, Boston, MA 02114 USA.	maheswaran@helix.mgh.harvard.edu			NCI NIH HHS [CA84441, CA89138] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC005740, Z01BC005740, R01CA089138, R01CA084441] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; CMARIK JL, 1994, MOL CARCINOGEN, V11, P115, DOI 10.1002/mc.2940110209; Cortes U, 2000, MOL CARCINOGEN, V27, P57, DOI 10.1002/(SICI)1098-2744(200002)27:2<57::AID-MC1>3.3.CO;2-9; Desai KV, 2002, P NATL ACAD SCI USA, V99, P6967, DOI 10.1073/pnas.102172399; Duriez C, 2002, GENE, V282, P207, DOI 10.1016/S0378-1119(01)00825-3; Ficazzola MA, 2001, CARCINOGENESIS, V22, P1271, DOI 10.1093/carcin/22.8.1271; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Ha TU, 2000, J BIOL CHEM, V275, P37101, DOI 10.1074/jbc.M005701200; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Horwitz BH, 1997, IMMUNITY, V6, P765, DOI 10.1016/S1074-7613(00)80451-3; Hoshiya Y, 2003, MOL CELL ENDOCRINOL, V211, P43, DOI 10.1016/j.mce.2003.09.010; Iacopetti P, 1999, P NATL ACAD SCI USA, V96, P4639, DOI 10.1073/pnas.96.8.4639; Kaltschmidt B, 1999, ONCOGENE, V18, P3213, DOI 10.1038/sj.onc.1202657; Kuo ML, 2003, CANCER RES, V63, P1046; LIM IK, 1995, J CANCER RES CLIN, V121, P279, DOI 10.1007/BF01209594; Lim IK, 1998, BIOCHEM MOL BIOL INT, V45, P871; Lim IK, 1998, MOL CARCINOGEN, V23, P25, DOI 10.1002/(SICI)1098-2744(199809)23:1<25::AID-MC4>3.0.CO;2-G; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Matsuda S, 2001, FEBS LETT, V497, P67, DOI 10.1016/S0014-5793(01)02436-X; Melamed J, 2002, TISSUE CELL, V34, P28, DOI 10.1054/tice.2001.0220; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; Nakamura Y, 2002, MOL CELL BIOL, V22, P5563, DOI 10.1128/MCB.22.15.5563-5574.2002; NANDI S, 1958, J NATL CANCER I, V21, P1039; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Prevot D, 2000, J BIOL CHEM, V275, P147, DOI 10.1074/jbc.275.1.147; RAGIN RC, 1992, PROTEIN EXPRES PURIF, V3, P236, DOI 10.1016/1046-5928(92)90020-W; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Rouault JP, 1998, J BIOL CHEM, V273, P22563, DOI 10.1074/jbc.273.35.22563; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Sakaguchi T, 2001, MECH DEVELOP, V104, P113, DOI 10.1016/S0925-4773(01)00374-4; Segev DL, 2000, J BIOL CHEM, V275, P28371, DOI 10.1074/jbc.M004554200; Segev DL, 2002, P NATL ACAD SCI USA, V99, P239, DOI 10.1073/pnas.221599298; Segev DL, 2001, J BIOL CHEM, V276, P26799, DOI 10.1074/jbc.M103092200; Struckmann K, 2004, CANCER RES, V64, P1632, DOI 10.1158/0008-5472.CAN-03-1687; Tirone F, 2001, J CELL PHYSIOL, V187, P155, DOI 10.1002/jcp.1062; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; WOSIKOWSKI K, 1995, CELL GROWTH DIFFER, V6, P1395	44	62	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8310	8319		10.1038/sj.onc.1208008	http://dx.doi.org/10.1038/sj.onc.1208008			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378000				2022-12-17	WOS:000224749500013
J	Petroziello, J; Yamane, A; Westendorf, L; Thompson, M; McDonagh, C; Cerveny, C; Law, CL; Wahl, A; Carter, P				Petroziello, J; Yamane, A; Westendorf, L; Thompson, M; McDonagh, C; Cerveny, C; Law, CL; Wahl, A; Carter, P			Suppression subtractive hybridization and expression profiling identifies a unique set of genes overexpressed in non-small-cell lung cancer	ONCOGENE			English	Review						non-small-cell lung cancer; subtractive hybridization; expression profiling; quantitative PCR	TUMOR-TRANSFORMING GENE; RIBOSOMAL-PROTEIN; BINDING-PROTEIN; MOLECULAR-CLONING; BREAST-CANCER; HUMAN HOMOLOG; PULMONARY ADENOCARCINOMAS; THIOREDOXIN REDUCTASE; CDNA MICROARRAYS; HUMAN CARCINOMAS	Expression array data for >3000 individual clones from two suppression subtractive hybridization libraries revealed 147 genes overexpressed in non-small-cell lung cancer (NSCLC) cell lines. Of these 147 genes, 30 genes have previously unknown cancer association and 65 genes have been associated with cancers other than NSCLC. The identification of 52 genes previously associated with NSCLC by different methodologies supports the validity of the strategy used here. Of the 147 genes, 19 have no prior named Unigene cluster designation, and are designated herein as L1 to L19. Quantitative real-time PCR and cancer pro. ling arrays were used as independent validation tools to confirm tumor overexpression for five of the 'L' genes in tumor cell lines and patient samples from NSCLC and other cancers. Follow-up studies for candidate NSCLC-associated genes can be useful in providing valuable insight into the etiology of lung cancer as well as providing potentially interesting diagnostic or therapeutic targets for further investigation.	Seattle Genet Inc, Dept Antibody Technol, Bothell, WA 98021 USA; Seattle Genet Inc, Dept Biochem, Bothell, WA 98021 USA	Seattle Genetics; Seattle Genetics	Carter, P (corresponding author), Seattle Genet Inc, Dept Antibody Technol, 21823 30th St SE, Bothell, WA 98021 USA.	pcarter@seagen.com						Aarskog NK, 2000, HUM GENET, V107, P494, DOI 10.1007/s004390000399; Adam PJ, 2003, J BIOL CHEM, V278, P6482, DOI 10.1074/jbc.M210184200; Arenberg DA, 1998, J CLIN INVEST, V102, P465, DOI 10.1172/JCI3145; Balsara BR, 1997, CANCER RES, V57, P2116; Bangur CS, 2002, ONCOGENE, V21, P3814, DOI 10.1038/sj.onc.1205480; BARR LF, 1991, CANCER RES, V51, P5514; BATRA SK, 1991, J BIOL CHEM, V266, P6830; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bennett KL, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046925; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; BRINKMANN U, 1995, P NATL ACAD SCI USA, V92, P10427, DOI 10.1073/pnas.92.22.10427; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; Chambers AF, 1996, LUNG CANCER-J IASLC, V15, P311, DOI 10.1016/0169-5002(95)00595-1; Colleoni GWB, 2000, AM J PATHOL, V156, P781, DOI 10.1016/S0002-9440(10)64945-0; Cong F, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-10; CORSON JM, 1982, AM J PATHOL, V108, P80; Cribier B, 2001, BRIT J DERMATOL, V144, P977, DOI 10.1046/j.1365-2133.2001.04185.x; CROXTALL JD, 1992, P NATL ACAD SCI USA, V89, P3571, DOI 10.1073/pnas.89.8.3571; Dalerba P, 2001, INT J CANCER, V93, P85, DOI 10.1002/ijc.1307; DENIS MG, 1993, INT J CANCER, V55, P275, DOI 10.1002/ijc.2910550218; DeRisi J, 1996, NAT GENET, V14, P457; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Echchakir H, 2001, CANCER RES, V61, P4078; FAITH A, 1992, CLIN EXP IMMUNOL, V87, P272; FRIGERIO JM, 1995, BBA-GENE STRUCT EXPR, V1262, P64, DOI 10.1016/0167-4781(95)00045-I; Fujii T, 2002, CANCER RES, V62, P3340; GABIG TG, 1995, BLOOD, V85, P804, DOI 10.1182/blood.V85.3.804.bloodjournal853804; GALEOTTI T, 1970, European Journal of Biochemistry, V17, P485, DOI 10.1111/j.1432-1033.1970.tb01191.x; GANAPATHI R, 1988, BRIT J CANCER, V58, P335, DOI 10.1038/bjc.1988.214; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Garcia-Lora A, 2003, INT J CANCER, V106, P521, DOI 10.1002/ijc.11241; Geer LY, 2002, GENOME RES, V12, P1619, DOI 10.1101/gr.278202; Gil-Parrado S, 2002, J BIOL CHEM, V277, P27217, DOI 10.1074/jbc.M202945200; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Gorczyca W, 1997, MODERN PATHOL, V10, P457; Grinstein E, 2002, J EXP MED, V196, P1067, DOI 10.1084/jem.20011053; Halaban R, 2000, J EXP MED, V191, P1005, DOI 10.1084/jem.191.6.1005; Heighway J, 2002, ONCOGENE, V21, P7749, DOI 10.1038/sj.onc.1205979; HEINRICH PC, 1976, CANCER RES, V36, P3189; HENRY JL, 1993, CANCER RES, V53, P1403; Hibi K, 1999, AM J PATHOL, V155, P711, DOI 10.1016/S0002-9440(10)65169-3; Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147; Hufton SE, 1999, FEBS LETT, V463, P77, DOI 10.1016/S0014-5793(99)01578-1; Hukkanen J, 2000, AM J RESP CELL MOL, V22, P360, DOI 10.1165/ajrcmb.22.3.3845; Jaju RJ, 1999, BLOOD, V94, P773; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Ji SJ, 2003, NUCLEIC ACIDS RES, V31, P2534, DOI 10.1093/nar/gkg358; Jiang HP, 1997, ONCOGENE, V14, P473, DOI 10.1038/sj.onc.1200858; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KATAGIRI A, 1993, BRIT J CANCER, V68, P125, DOI 10.1038/bjc.1993.299; Kikuchi T, 2003, ONCOGENE, V22, P2192, DOI 10.1038/sj.onc.1206288; Koshikawa K, 2002, ONCOGENE, V21, P2822, DOI 10.1038/sj.onc.1205405; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kress S, 1998, J CANCER RES CLIN, V124, P315, DOI 10.1007/s004320050175; Lash AE, 2000, GENOME RES, V10, P1051, DOI 10.1101/gr.10.7.1051; Latif F, 1997, HUM GENET, V99, P334, DOI 10.1007/s004390050368; Le Roux LG, 2003, J VIROL, V77, P2330, DOI 10.1128/JVI.77.4.2330-2337.2003; Lewis BC, 2000, CANCER RES, V60, P6178; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Loging WT, 1999, CANCER EPIDEM BIOMAR, V8, P1011; LOY TS, 1994, AM J CLIN PATHOL, V102, P764, DOI 10.1093/ajcp/102.6.764; Maeda T, 2003, J HEPATOL, V38, P615, DOI 10.1016/S0168-8278(03)00052-7; Maekawa M, 2003, CLIN CHEM, V49, P1518, DOI 10.1373/49.9.1518; MARANGOS PJ, 1982, CANCER LETT, V15, P67, DOI 10.1016/0304-3835(82)90077-5; Matsuda S, 2000, CANCER RES, V60, P13; McDoniels-Silvers AL, 2002, CLIN CANCER RES, V8, P1127; Miyasaka Y, 2001, BRIT J CANCER, V85, P228, DOI 10.1054/bjoc.2001.1901; Mizunuma H, 2003, BRIT J CANCER, V88, P1543, DOI 10.1038/sj.bjc.6600952; Morino M, 1994, In Vivo, V8, P285; Nacht M, 2001, P NATL ACAD SCI USA, V98, P15203, DOI 10.1073/pnas.261414598; Niehans GA, 1996, AM J PATHOL, V149, P129; Oshita F, 2002, ANTICANCER RES, V22, P1065; Palackal NT, 2002, J BIOL CHEM, V277, P24799, DOI 10.1074/jbc.M112424200; Percy MJ, 2000, GENE CHROMOSOME CANC, V29, P356, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1044>3.0.CO;2-N; PEREZALVARADO GC, 1994, NAT STRUCT BIOL, V1, P388, DOI 10.1038/nsb0694-388; Pitterle DM, 1999, MAMM GENOME, V10, P916, DOI 10.1007/s003359901114; PONNAZHAGAN S, 1992, PIGM CELL RES, V5, P155, DOI 10.1111/j.1600-0749.1992.tb00453.x; Porkka KP, 2001, J PATHOL, V193, P73, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH751>3.0.CO;2-Y; Rao S, 2001, BIOCHEMISTRY-US, V40, P2096, DOI 10.1021/bi002323d; Rattner JB, 1997, CLIN INVEST MED, V20, P308; Redondo M, 1998, EUR J IMMUNOGENET, V25, P385, DOI 10.1046/j.1365-2370.1998.00116.x; RICHARD CW, 1991, AM J HUM GENET, V49, P1189; Rintoul RC, 2002, MOL BIOL CELL, V13, P2841, DOI 10.1091/mbc.01-11-0530; Robert C, 1999, CLIN CANCER RES, V5, P2094; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Salicioni AM, 2000, GENOMICS, V69, P54, DOI 10.1006/geno.2000.6315; Schnier JB, 1999, FEBS LETT, V454, P100, DOI 10.1016/S0014-5793(99)00773-5; Schraml P, 1997, CANCER RES, V57, P3669; Shibata Y, 2002, JPN J CLIN ONCOL, V32, P233, DOI 10.1093/jjco/hyf058; SILINI EM, 1994, VIRCHOWS ARCH, V424, P367; Simpson JC, 2000, EMBO REP, V1, P287, DOI 10.1093/embo-reports/kvd058; SMYTHE WR, 1995, CANCER METAST REV, V14, P229, DOI 10.1007/BF00690294; Soini Y, 2001, CLIN CANCER RES, V7, P1750; Soria JC, 2000, CANCER RES, V60, P4000; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Stassar MJJG, 2001, BRIT J CANCER, V85, P1372, DOI 10.1054/bjoc.2001.2074; Su AI, 2001, CANCER RES, V61, P7388; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P1764, DOI 10.1073/pnas.95.4.1764; Suzuki T, 1996, BIOCHEM BIOPH RES CO, V219, P708, DOI 10.1006/bbrc.1996.0299; Sykes DB, 2003, LEUKEMIA LYMPHOMA, V44, P1187, DOI 10.1080/1042819031000090273; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; TANAKA M, 1995, CANCER LETT, V89, P195, DOI 10.1016/0304-3835(94)03687-E; Tarantul VZ, 2000, AIDS RES HUM RETROV, V16, P173, DOI 10.1089/088922200309511; Tarazona R, 2000, J IMMUNOL, V165, P6776, DOI 10.4049/jimmunol.165.12.6776; Taxman DJ, 2003, CANCER RES, V63, P5095; Tong XJ, 2001, J BIOL CHEM, V276, P47709, DOI 10.1074/jbc.M107878200; TONIN PN, 1989, ONCOGENE, V4, P1117; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; TSYBIKOVA EB, 1996, VESTN ROS AKAD MED+, V12, P3; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WANG NS, 1992, ULTRASTRUCT PATHOL, V16, P439, DOI 10.3109/01913129209057829; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; YAMAUCHI M, 1990, EMBO J, V9, P2095, DOI 10.1002/j.1460-2075.1990.tb07377.x; Yan-Sanders Y, 2002, CANCER LETT, V183, P215, DOI 10.1016/S0304-3835(02)00168-4; Yang GP, 1999, NUCLEIC ACIDS RES, V27, P1517, DOI 10.1093/nar/27.6.1517; Yasuda M, 1999, CANCER RES, V59, P533; Yazawa T, 2003, PATHOL INT, V53, P58, DOI 10.1046/j.1440-1827.2003.01428.x; Yoshida Y, 2003, CANCER RES, V63, P3729; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Yu Q, 1997, BIOCHEMISTRY-US, V36, P5868, DOI 10.1021/bi962400y; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156	124	62	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 7	2004	23	46					7734	7745		10.1038/sj.onc.1207921	http://dx.doi.org/10.1038/sj.onc.1207921			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	859ZK	15334068				2022-12-17	WOS:000224306700015
J	Baldanzi, G; Mitola, S; Cutrupi, S; Filigheddu, N; van Blitterswijk, WJ; Sinigaglia, F; Bussolino, F; Graziani, A				Baldanzi, G; Mitola, S; Cutrupi, S; Filigheddu, N; van Blitterswijk, WJ; Sinigaglia, F; Bussolino, F; Graziani, A			Activation of diacylglycerol kinase alpha is required for VEGF-induced angiogenic signaling in vitro	ONCOGENE			English	Article						diacylglycerol kinase; VEGF; phosphatidic acid; Src; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; FOCAL ADHESION KINASE; PHOSPHATIDIC-ACID; PROCESSIVE PHOSPHORYLATION; PHOSPHOLIPASE-D; CELL MIGRATION; C-ALPHA; PHOSPHATIDYLINOSITOL; EXPRESSION; INHIBITOR	Vascular endothelial growth factor-A (VEGF-A) promotes angiogenesis by stimulating migration, proliferation and organization of endothelium, through the activation of signaling pathways involving Src tyrosine kinase. As we had previously shown that Src-mediated activation of diacylglycerol kinase-alpha (Dgk-alpha) is required for hepatocytes growth factor-stimulated cell migration, we asked whether Dgk-alpha is involved in the transduction of angiogenic signaling. In PAE-KDR cells, an endothelial-derived cell line expressing VEGFR-2, VEGF-A(165), stimulates the enzymatic activity of Dgk-alpha: activation is inhibited by R59949, an isoform-specific Dgk inhibitor, and is dependent on Src tyrosine kinase, with which Dgk-alpha forms a complex. Conversely in HUVEC, VEGF-A(165)-induced activation of Dgk is only partially sensitive to R59949, suggesting that also other isoforms may be activated, albeit still dependent on Src tyrosine kinase. Specific inhibition of Dgk-alpha, obtained in both cells by R59949 and in PAE-KDR by expression of Dgk-alpha dominant-negative mutant, imp airs VEGF-A(165)-dependent chemotaxis, proliferation and in vitro angiogenesis. In addition, in HUVEC, specific downregulation of Dgk-alpha by siRNA impairs in vitro angiogenesis on matrigel, further suggesting the requirement for Dgk-alpha in angiogenic signaling in HUVEC. Thus, we propose that activation of Dgk-alpha generates a signal essential for both proliferative and migratory response to VEGF-A(165), suggesting that it may constitute a novel pharmacological target for angiogenesis control.	Univ Amedeo Avogadro Piemonte Orientale, Dept Med Sci, I-28100 Novara, Italy; Univ Turin, Dept Oncol Sci, I-10124 Turin, Italy; Univ Turin, Inst Canc Res & Treatment IRCC, I-10124 Turin, Italy; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	University of Eastern Piedmont Amedeo Avogadro; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Netherlands Cancer Institute	Graziani, A (corresponding author), Univ Amedeo Avogadro Piemonte Orientale, Dept Med Sci, V Solaroli 17, I-28100 Novara, Italy.	graziani@med.unipmn.it	Bussolino, Federico/AES-3951-2022; Filigheddu, Nicoletta/N-7219-2015; graziani, andrea/B-2554-2009; Baldanzi, Gianluca/AAO-7673-2021; Graziani, Andrea/AAB-6301-2022; cutrupi, santina/AAC-4479-2022; Bussolino, Federico/K-2500-2016	Filigheddu, Nicoletta/0000-0002-3848-611X; graziani, andrea/0000-0002-6302-2317; Baldanzi, Gianluca/0000-0002-1370-9903; Graziani, Andrea/0000-0002-6302-2317; Bussolino, Federico/0000-0002-5348-1341; MITOLA, Stefania/0000-0002-5557-738X; CUTRUPI, SANTINA/0000-0002-2358-5852				Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Andresen BT, 2002, FEBS LETT, V531, P65, DOI 10.1016/S0014-5793(02)03483-X; Baldanzi G, 2002, J CELL BIOL, V159, P1029, DOI 10.1083/jcb.200207165; Benelli R, 1999, INT J BIOL MARKER, V14, P243, DOI 10.1177/172460089901400408; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cipres A, 2003, J BIOL CHEM, V278, P35629, DOI 10.1074/jbc.M305635200; Cutrupi S, 2000, EMBO J, V19, P4614, DOI 10.1093/emboj/19.17.4614; DAVIDSON L, 2004, IN PRESS J BIOL CHEM; DECOURCELLES DD, 1989, J BIOL CHEM, V264, P3274; Del Pozo MA, 2002, NAT CELL BIOL, V4, P232, DOI 10.1038/ncb759; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; Gomez-Cambronero J, 1998, CELL SIGNAL, V10, P387, DOI 10.1016/S0898-6568(97)00197-6; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jiang Y, 2000, BIOCHEM PHARMACOL, V59, P763, DOI 10.1016/S0006-2952(99)00395-0; Jones DR, 2002, FASEB J, V16, P595, DOI 10.1096/fj.01-0762fje; KAI M, 1994, J BIOL CHEM, V269, P18492; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Marconcini L, 1999, P NATL ACAD SCI USA, V96, P9671, DOI 10.1073/pnas.96.17.9671; Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; O'Luanaigh N, 2002, MOL BIOL CELL, V13, P3730, DOI 10.1091/mbc.E02-04-0213; PANETTI TS, 2002, BIOCHIM BIOPHYS ACTA, V23, P190; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; POOLE CA, 1993, J CELL SCI, V106, P685; SCHAAP D, 1993, BIOCHEM J, V289, P875, DOI 10.1042/bj2890875; SCHAAP D, 1990, FEBS LETT, V275, P151, DOI 10.1016/0014-5793(90)81461-V; Scott MP, 2000, BIOCHEMISTRY-US, V39, P14531, DOI 10.1021/bi001850u; Seibenhener M L, 1999, Mol Cell Biol Res Commun, V2, P28, DOI 10.1006/mcbr.1999.0140; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; SWIFT S, 1999, CURR PROTOCOLS IMMUN, DOI DOI 10.17.14-10.17.29; Thomas JW, 1998, J BIOL CHEM, V273, P577, DOI 10.1074/jbc.273.1.577; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; Waltenberger J, 1999, CIRC RES, V85, P12; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wang AH, 2002, CIRC RES, V90, P609, DOI 10.1161/01.RES.0000012503.30315.E8; Wellner M, 1999, ARTERIOSCL THROM VAS, V19, P178, DOI 10.1161/01.ATV.19.1.178; Xie YH, 2002, J BIOL CHEM, V277, P32516, DOI 10.1074/jbc.M203864200; Zeng HY, 2002, J BIOL CHEM, V277, P46791, DOI 10.1074/jbc.M206133200; Zhong XP, 2002, J BIOL CHEM, V277, P31089, DOI 10.1074/jbc.M203818200	50	62	62	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4828	4838		10.1038/sj.onc.1207633	http://dx.doi.org/10.1038/sj.onc.1207633			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15122338	Green Published			2022-12-17	WOS:000222104200003
J	Shigesada, K; van de Sluis, B; Liu, PP				Shigesada, K; van de Sluis, B; Liu, PP			Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11	ONCOGENE			English	Article						CBF beta-MYH11; CBF beta-SMMHC; inv(16); leukemia; hematopoiesis	ACUTE MYELOID-LEUKEMIA; MYOSIN HEAVY-CHAIN; SMOOTH-MUSCLE MYOSIN; CBF-BETA-SMMHC; ZINC-FINGER PROTEIN; TRANSCRIPTION FACTOR; FUSION GENE; DNA-BINDING; RUNT DOMAIN; MYELOGENOUS LEUKEMIA	Inv(16)(p13q22) is associated with acute myeloid leukemia subtype M4Eo that is characterized by the presence of myelomonocytic blasts and atypical eosinophils. This chromosomal rearrangement results in the fusion of CBFB and MYH11 genes. CBFbeta normally interacts with RUNX1 to form a transcriptionally active nuclear complex. The MYH11 gene encodes the smooth muscle myosin heavy chain. The CBFbeta-SMMHC fusion protein is capable of binding to RUNX1 and form dimers and multimers through its myosin tail. Previous results from transgenic mouse models show that Cbfb-MYH11 is able to inhibit dominantly Runx1 function in hematopoiesis, and is a key player in the pathogenesis of leukemia. In recent years, molecular and cellular biological studies have led to the proposal of several models to explain the function of CBFbeta-SMMHC. In this review, we will first focus our attention on the molecular mechanisms proposed in the recent publications. We will next examine recent gene expression pro. ling studies on inv(16) leukemia cells. Finally, we will describe a recent study from one of our labs on the identification of cooperating genes for leukemogenesis with CBFB-MYH11.	Kyoto Univ, Inst Virus Res, Dept Cell Biol, Kyoto 6068507, Japan; NHGRI, Oncogenesis & Dev Sect, NIH, Bethesda, MD 20892 USA	Kyoto University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Shigesada, K (corresponding author), Kyoto Univ, Inst Virus Res, Dept Cell Biol, Kyoto 6068507, Japan.	kshigesa@virus.kyoto-u.ac.jp; pliu@mail.nih.gov	Liu, Paul/A-7976-2012	Liu, Paul/0000-0002-6779-025X	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000030, ZIAHG000030] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Astrom AK, 1999, CANCER RES, V59, P918; Backstrom S, 2002, J MOL BIOL, V322, P259, DOI 10.1016/S0022-2836(02)00702-7; Bravo J, 2001, NAT STRUCT BIOL, V8, P371, DOI 10.1038/86264; Cameron ER, 2003, BLOOD CELL MOL DIS, V30, P194, DOI 10.1016/S1079-9796(03)00031-7; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Cao WS, 1998, J BIOL CHEM, V273, P31534, DOI 10.1074/jbc.273.47.31534; Care RS, 2003, BRIT J HAEMATOL, V121, P775, DOI 10.1046/j.1365-2141.2003.04362.x; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 2004, P NATL ACAD SCI USA, V101, P4924, DOI 10.1073/pnas.0400930101; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Chung CH, 2002, NAT GENET, V32, P533, DOI 10.1038/ng1038; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; Debernardi S, 2003, GENE CHROMOSOME CANC, V37, P149, DOI 10.1002/gcc.10198; Dunant NM, 2000, CELL SIGNAL, V12, P317, DOI 10.1016/S0898-6568(00)00073-5; Durst KL, 2003, MOL CELL BIOL, V23, P607, DOI 10.1128/MCB.23.2.607-619.2003; ERICKSON P, 1992, BLOOD, V80, P1825; Fortunel N, 2000, Hematol J, V1, P126, DOI 10.1038/sj.thj.6200021; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Gilliland DG, 2002, SEMIN HEMATOL, V39, P6, DOI 10.1053/shem.2002.36921; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Hanlon L, 2003, J VIROL, V77, P1059, DOI 10.1128/JVI.77.2.1059-1068.2003; Haviernik P, 2002, J GEN VIROL, V83, P819, DOI 10.1099/0022-1317-83-4-819; Hensen K, 2002, CANCER RES, V62, P1510; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Huang G, 2004, BLOOD, V104, p105A, DOI 10.1182/blood.V104.11.358.358; Huang SM, 2001, ONCOGENE, V20, P2134, DOI 10.1038/sj.onc.1204298; Ikebe M, 2001, J BIOL CHEM, V276, P30293, DOI 10.1074/jbc.M101969200; Imai Y, 2004, MOL CELL BIOL, V24, P1033, DOI 10.1128/MCB.24.3.1033-1043.2004; Inoue K, 2003, BLOOD CELL MOL DIS, V30, P157, DOI 10.1016/S1079-9796(03)00032-9; Kalev-Zylinska ML, 2003, DEV DYNAM, V228, P323, DOI 10.1002/dvdy.10388; Kanno Y, 1998, MOL CELL BIOL, V18, P4252, DOI 10.1128/MCB.18.7.4252; Kanto S, 2000, LEUKEMIA, V14, P1253, DOI 10.1038/sj.leu.2401821; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; Kogan SC, 1998, P NATL ACAD SCI USA, V95, P11863, DOI 10.1073/pnas.95.20.11863; Kohlmann A, 2003, GENE CHROMOSOME CANC, V37, P396, DOI 10.1002/gcc.10225; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kummalue T, 2002, MOL CELL BIOL, V22, P8278, DOI 10.1128/MCB.22.23.8278-8291.2002; Kundu M, 2002, BLOOD, V100, P2449, DOI 10.1182/blood-2002-04-1064; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; LIU P, 1994, COLD SPRING HARB SYM, V59, P547, DOI 10.1101/SQB.1994.059.01.061; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Liu PP, 1996, GENE CHROMOSOME CANC, V16, P77, DOI 10.1002/(SICI)1098-2264(199606)16:2<77::AID-GCC1>3.0.CO;2-#; LIU PP, 1995, BLOOD, V85, P2289, DOI 10.1182/blood.V85.9.2289.bloodjournal8592289; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; LU J, 1995, MOL CELL BIOL, V15, P1651; Lukasik SM, 2002, NAT STRUCT BIOL, V9, P674, DOI 10.1038/nsb831; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Miller JD, 2001, BLOOD, V97, P2248, DOI 10.1182/blood.V97.8.2248; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Otto F, 2003, LEUKEMIA, V17, P1677, DOI 10.1038/sj.leu.2403007; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Schnittger S, 2003, BLOOD, V102, P2746, DOI 10.1182/blood-2003-03-0880; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; Sohn RL, 1997, J MOL BIOL, V266, P317, DOI 10.1006/jmbi.1996.0790; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Tahirov TH, 2001, CELL, V104, P755, DOI 10.1016/S0092-8674(02)02053-6; Tang YY, 2000, J BIOL CHEM, V275, P39579, DOI 10.1074/jbc.M007350200; TRYBUS KM, 1984, J BIOL CHEM, V259, P8564; Trybus KM, 1997, P NATL ACAD SCI USA, V94, P48, DOI 10.1073/pnas.94.1.48; VIEILLEGROSJEAN I, 1995, J BIOL CHEM, V270, P4544, DOI 10.1074/jbc.270.9.4544; Voz ML, 2000, CANCER RES, V60, P106; Voz ML, 1998, ONCOGENE, V16, P1409, DOI 10.1038/sj.onc.1201660; WADA M, 2004, ONCOGENE, V26, P26; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Warren AJ, 2000, EMBO J, V19, P3004, DOI 10.1093/emboj/19.12.3004; Wijmenga C, 1996, P NATL ACAD SCI USA, V93, P1630, DOI 10.1073/pnas.93.4.1630; WISNIEWSKI D, 1994, LEUKEMIA, V8, P688; WOLFF L, 1991, J VIROL, V65, P3607, DOI 10.1128/JVI.65.7.3607-3616.1991; Wu XL, 2003, SCIENCE, V300, P1749, DOI 10.1126/science.1083413; Xu JQ, 1996, J CELL BIOL, V134, P53, DOI 10.1083/jcb.134.1.53; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303	81	62	65	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4297	4307		10.1038/sj.onc.1207748	http://dx.doi.org/10.1038/sj.onc.1207748			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156186				2022-12-17	WOS:000221586000015
J	Babic, I; Jakymiw, A; Fujita, DJ				Babic, I; Jakymiw, A; Fujita, DJ			The RNA binding protein Sam68 is acetylated in tumor cell lines, and its acetylation correlates with enhanced RNA binding activity	ONCOGENE			English	Article						acetylation; Sam68; RNA binding; breast cancer; gene expression	HUMAN-IMMUNODEFICIENCY-VIRUS; NUCLEAR-LOCALIZATION SIGNAL; KH-DOMAIN; POSTTRANSCRIPTIONAL REGULATION; TRANSCRIPTIONAL ACTIVITY; MAMMALIAN PROTEINS; CYCLE PROGRESSION; HIV REPLICATION; SRC SUBSTRATE; COFACTOR CBP	Sam68 ((S) under bar rc-(a) under bar ssociated in mitosis; 68 kDa) is a member of the STAR ((s) under bar ignal (t) under bar ransduction and (a) under bar ctivation of RNA) family of KH domain-containing RNA binding proteins. Accumulating evidence suggests that it plays an important role in cell cycle control. Tyrosine phosphorylation by Src family kinases and breast tumor kinase can negatively regulate its RNA binding activity. To date, there are no reports of a factor, such as a phosphatase, which can positively regulate Sam68 association with RNA. Acetylation is a reversible post-translational modification known to influence the activity of DNA binding proteins. However, acetylation of a cellular RNA binding protein as a mechanism for regulating its activity has not yet been reported. Here we demonstrate Sam68 to be acetylated in vivo. A screen of several human mammary epithelial cell lines revealed variations in Sam68 acetylation. Interestingly, the highest level of acetylation was found in tumorigenic breast cancer cell lines. The screen also showed a positive correlation between Sam68 acetylation and its ability to bind RNA. The acetyltransferase CBP was shown to acetylate Sam68 and enhance its binding to poly(U) RNA. These results suggest that Sam68 association with RNA substrates may be positively regulated by acetylation, and that enhanced acetylation and RNA binding activity of Sam68 may play a role in tumor cell proliferation.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada	University of Calgary	Fujita, DJ (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.	ibabic@ucalgary.ca; dfujita@ucalgary.ca		Jakymiw, Andrew/0000-0001-6431-8753				Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Arning S, 1996, RNA, V2, P794; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chen TP, 1998, MOL CELL BIOL, V18, P4863, DOI 10.1128/MCB.18.8.4863; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Coyle JH, 2003, MOL CELL BIOL, V23, P92, DOI 10.1128/MCB.23.1.92-103.2003; CRUZALVAREZ M, 1987, J BIOL CHEM, V262, P13377; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Di Fruscio M, 1999, P NATL ACAD SCI USA, V96, P2710, DOI 10.1073/pnas.96.6.2710; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Grossman JS, 1998, RNA, V4, P613, DOI 10.1017/S1355838298971448; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; Hong W, 2002, MOL CANCER RES, V1, P48; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; LHERNAULT SW, 1985, BIOCHEMISTRY-US, V24, P473, DOI 10.1021/bi00323a034; Li QH, 2002, FEBS LETT, V525, P145, DOI 10.1016/S0014-5793(02)03103-4; Lin Q, 1997, J BIOL CHEM, V272, P27274, DOI 10.1074/jbc.272.43.27274; Mandal M, 2001, J BIOL CHEM, V276, P9699, DOI 10.1074/jbc.M008514200; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Mueller F, 2003, BRIT J CANCER, V88, P699, DOI 10.1038/sj.bjc.6600790; Perrotti D, 2002, ONCOGENE, V21, P8577, DOI 10.1038/sj.onc.1206085; Reddy TR, 2000, ONCOGENE, V19, P3570, DOI 10.1038/sj.onc.1203676; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; Reddy TR, 2002, J BIOL CHEM, V277, P5778, DOI 10.1074/jbc.M106836200; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; Soros VB, 2001, J VIROL, V75, P8203, DOI 10.1128/JVI.75.17.8203-8215.2001; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Stoss O, 2001, J BIOL CHEM, V276, P8665, DOI 10.1074/jbc.M006851200; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; VOGEL LB, 1995, J BIOL CHEM, V270, P2506, DOI 10.1074/jbc.270.6.2506; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; Wu J, 1999, J BIOL CHEM, V274, P29202, DOI 10.1074/jbc.274.41.29202; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	46	62	65	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3781	3789		10.1038/sj.onc.1207484	http://dx.doi.org/10.1038/sj.onc.1207484			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021911				2022-12-17	WOS:000221242500005
J	Ordway, JM; Williams, K; Curran, T				Ordway, JM; Williams, K; Curran, T			Transcription repression in oncogenic transformation: common targets of epigenetic repression in cells transformed by Fos, Ras or Dnmt1	ONCOGENE			English	Article						methylation; silencing; cancer	TUMOR-SUPPRESSOR GENE; KINASE-C SUBSTRATE; HISTONE DEACETYLASE INHIBITION; MAMMARY EPITHELIAL-CELLS; CPG-BINDING PROTEIN; DNA-METHYLTRANSFERASE; MOLECULAR CLASSIFICATION; EXPRESSION PATTERNS; METHYLATED DNA; CANCER	Fos and Ras function in both dependent and independent signal transduction pathways, and sustained activity of either oncogene is sufficient to induce cell transformation and tumorigenesis. Increased DNA (cytosine-5) methyl-transferse (Dnmt1) activity is involved in the mechanism of transformation by both oncogenes, suggesting that inappropriate epigenetic transcription regulation may be a common route of oncogenesis, and that cell transformation may model aspects of the epigenetic deregulation that often occurs in tumors. Here, we have taken a microarray-based gene expression approach to identify differentially expressed genes in cells transformed by c-fos, v-fos, ras or Dnmt1. The cohort of genes differentially expressed in all four transformation systems includes an over-representation of repressed genes, many of which have been functionally implicated in the suppression of transformation or tumorigenesis. Furthermore, we identified four potential tumor suppressor genes subject to epigenetic transcriptional repression in transformed cells. The results emphasize the role of transcription repression in oncogenesis, and they provide insights into the potential common epigenetic mechanisms impacting cell transformation.	St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	St Jude Children's Research Hospital; University of Bath	Curran, T (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA.	fos1@aol.com	Curran, Tom/C-1164-2008; Curran, Tom/D-7515-2011; Curran, Thomas/AAE-7631-2019; Curran, Tom/F-5234-2018	Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551	NATIONAL CANCER INSTITUTE [T32CA009346, R01CA084139] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09346-20, R01 CA 84139] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollahi A, 1997, CANCER RES, V57, P2029; Abdollahi A, 1999, ONCOGENE, V18, P6477, DOI 10.1038/sj.onc.1203067; Abdollahi A, 2003, J BIOL CHEM, V278, P6041, DOI 10.1074/jbc.M210361200; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bilanges B, 2001, ONCOGENE, V20, P1246, DOI 10.1038/sj.onc.1204237; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399; CHOI YC, 1991, J BIOL CHEM, V266, P20504; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Dale L, 1999, BIOESSAYS, V21, P751, DOI 10.1002/(SICI)1521-1878(199909)21:9<751::AID-BIES6>3.0.CO;2-I; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; FEINBERG AP, 1988, CANCER RES, V48, P1159; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GRAFF JR, 1995, CANCER RES, V55, P5195; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Hedenfalk I, 2003, P NATL ACAD SCI USA, V100, P2532, DOI 10.1073/pnas.0533805100; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Henningfeld KA, 2000, J BIOL CHEM, V275, P21827, DOI 10.1074/jbc.M000978200; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; John RM, 1998, GENOME ANAL, V2, P217; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; KAUTIAINEN TL, 1986, J BIOL CHEM, V261, P1594; Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200; Kleeff J, 1999, GASTROENTEROLOGY, V116, P1202, DOI 10.1016/S0016-5085(99)70024-7; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; LABOW MA, 1990, MOL CELL BIOL, V10, P3343, DOI 10.1128/MCB.10.7.3343; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; LI L, 2003, CANC RES; Lin XY, 2000, MOL CELL BIOL, V20, P7259, DOI 10.1128/MCB.20.19.7259-7272.2000; Lin XY, 1997, CANCER RES, V57, P2304; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; LIN XY, 1995, MOL CELL BIOL, V15, P2754; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MILLER AD, 1985, J VIROL, V55, P521, DOI 10.1128/JVI.55.3.521-526.1985; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nutt CL, 2003, CANCER RES, V63, P1602; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Piras G, 2000, MOL CELL BIOL, V20, P3308, DOI 10.1128/MCB.20.9.3308-3315.2000; Raida M, 1999, INT J CANCER, V83, P38, DOI 10.1002/(SICI)1097-0215(19990924)83:1<38::AID-IJC8>3.3.CO;2-2; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Scandura JM, 2002, ONCOGENE, V21, P3422, DOI 10.1038/sj.onc.1205315; Shi Y, 2003, TRENDS GENET, V19, P9, DOI 10.1016/S0168-9525(02)00005-7; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Varrault A, 2001, J BIOL CHEM, V276, P18653, DOI 10.1074/jbc.C100095200; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Xia W, 2001, CANCER RES, V61, P5644; Yeoh EJ, 2002, CANCER CELL, V1, P133, DOI 10.1016/S1535-6108(02)00032-6; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; ZHANG M, 1995, CANCER RES, V55, P2537; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	76	62	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3737	3748		10.1038/sj.onc.1207483	http://dx.doi.org/10.1038/sj.onc.1207483			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	14990994				2022-12-17	WOS:000221242500001
J	Hui, LJ; Zhang, X; Wu, X; Lin, ZX; Wang, QK; Li, YX; Hu, GX				Hui, LJ; Zhang, X; Wu, X; Lin, ZX; Wang, QK; Li, YX; Hu, GX			Identification of alternatively spliced mRNA variants related to cancers by genome-wide ESTs alignment	ONCOGENE			English	Article						alternative splicing prediction; database; cancer; EST alignment	EXPRESSED SEQUENCE TAGS; COMPUTATIONAL ANALYSIS; GENE-EXPRESSION; DATABASE; PROTEIN; EXON	Several databases have been published to predict alternative splicing of mRNAs by analysing the exon linkage relationship by alignment of expressed sequence tags (ESTs) to the genome sequence; however, little effort has been made to investigate the relationship between cancers and alternative splicing. We developed a program, Alternative Splicing Assembler (ASA), to look for splicing variants of human gene transcripts by genome-wide ESTs alignment. Using ASA, we constructed the biosino alternative splicing database (BASD), which predicted splicing variants for reference sequences from the reference sequence database (RefSeq) and presented them in both graph and text formats. EST clusters that differ from the reference sequences in at least one splicing site were counted as splicing variants. Of 4322 genes screened, 3490 (81%) were observed with at least one alternative splicing variants. To discover the variants associated with cancers, tissue sources of EST sequences were extracted from the UniLib database and ESTs from the same tissue type were counted. These were regarded as the indicators for gene expression level. Using Fisher's exact test, alternative splicing variants, of which EST counts were significantly different between cancer tissues and their counterpart normal tissues, were identified. It was predicted that 2149 variants, or 383 variants after Bonferroni correction, of 26 812 variants were likely tumor-associated. By reverse transcription-PCR, 11 of 13 novel alternative splicing variants and eight of nine variants' tissue specificity were confirmed in hepatocelluar carcinoma and in lung cancer. The possible involvement of alternative splicing in cancer is discussed.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China; Shanghai Jiao Tong Univ, Inst Microelect, Shanghai 200030, Peoples R China; Zhongshan Hosp, Liver Canc Inst, Guangzhou, Peoples R China; Shanghai Jiao Tong Univ, Sch Life Sci, Shanghai 200030, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Bioinformat Ctr, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Li, YX (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Room 400,Cell Bldg,Yueyang Rd 320, Shanghai 200031, Peoples R China.	yxli@sibs.ac.cn; xbshu@sunm.shcnc.ac.cn	Wu, Xin/B-2244-2010					Ars E, 2000, NUCLEIC ACIDS RES, V28, P1307, DOI 10.1093/nar/28.6.1307; Baranova AV, 2001, FEBS LETT, V508, P143, DOI 10.1016/S0014-5793(01)03028-9; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Brett D, 2000, FEBS LETT, V474, P83, DOI 10.1016/S0014-5793(00)01581-7; Claverie JM, 2001, SCIENCE, V291, P1255, DOI 10.1126/science.1058969; Coward E, 2002, TRENDS GENET, V18, P53, DOI 10.1016/S0168-9525(01)02525-2; Dralyuk I, 2000, NUCLEIC ACIDS RES, V28, P296, DOI 10.1093/nar/28.1.296; Goodison S, 1999, J CLIN PATHOL-MOL PA, V52, P189; He JQ, 2001, J BIOL CHEM, V276, P26814, DOI 10.1074/jbc.M101820200; Hogenesch JB, 2001, CELL, V106, P413, DOI 10.1016/S0092-8674(01)00467-6; Huang RM, 2003, CANCER RES, V63, P3775; Huang YH, 2002, NUCLEIC ACIDS RES, V30, P186, DOI 10.1093/nar/30.1.186; Ji HK, 2001, NUCLEIC ACIDS RES, V29, P260, DOI 10.1093/nar/29.1.260; Kan ZY, 2002, GENOME RES, V12, P1837, DOI 10.1101/gr.764102; Kan ZY, 2001, GENOME RES, V11, P889, DOI 10.1101/gr.155001; Kaufmann D, 2002, CANCER RES, V62, P1503; Kawamoto S, 2000, GENOME RES, V10, P1817, DOI 10.1101/gr.151500; KRAWCZAK M, 1992, HUM GENET, V90, P41; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Matsui A, 2000, CANCER LETT, V150, P23, DOI 10.1016/S0304-3835(99)00368-7; McDoniels-Silvers AL, 2002, CLIN CANCER RES, V8, P1127; Mironov AA, 1999, GENOME RES, V9, P1288, DOI 10.1101/gr.9.12.1288; Modrek B, 2001, NUCLEIC ACIDS RES, V29, P2850, DOI 10.1093/nar/29.13.2850; Nash MA, 2002, CLIN CANCER RES, V8, P1754; Olopade OI, 1997, CANCER J SCI AM, V3, P230; Pruitt KD, 2001, NUCLEIC ACIDS RES, V29, P137, DOI 10.1093/nar/29.1.137; Reeve JG, 1996, BRIT J CANCER, V73, P1193, DOI 10.1038/bjc.1996.230; Scheurle D, 2000, CANCER RES, V60, P4037; Schuler GD, 1997, J MOL MED, V75, P694, DOI 10.1007/s001090050155; Stamm S, 2000, DNA CELL BIOL, V19, P739, DOI 10.1089/104454900750058107; Thompson TE, 2002, CANCER RES, V62, P3251; Valve EM, 2001, LAB INVEST, V81, P815, DOI 10.1038/labinvest.3780291; van der Spuy J, 2002, HUM MOL GENET, V11, P823, DOI 10.1093/hmg/11.7.823; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang ZN, 2003, CANCER RES, V63, P655; Wolfsberg TG, 1997, NUCLEIC ACIDS RES, V25, P1626, DOI 10.1093/nar/25.8.1626; Xie HQ, 2002, GENOMICS, V80, P326, DOI 10.1006/geno.2002.6841; Xu L, 2001, CANCER RES, V61, P3176; Xu Q, 2002, NUCLEIC ACIDS RES, V30, P3754, DOI 10.1093/nar/gkf492	39	62	64	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3013	3023		10.1038/sj.onc.1207362	http://dx.doi.org/10.1038/sj.onc.1207362			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	15048092				2022-12-17	WOS:000220845200005
J	Bahassi, ELM; Hennigan, RF; Myer, DL; Stambrook, PJ				Bahassi, ELM; Hennigan, RF; Myer, DL; Stambrook, PJ			Cdc25C phosphorylation on serine 191 by Plk3 promotes its nuclear translocation	ONCOGENE			English	Article						Cdc25C; Plk3; phosphorylation; nuclear exclusion	14-3-3 PROTEIN-BINDING; CELL-CYCLE REGULATION; G(2) CHECKPOINT; KINASE; PHOSPHATASE; LOCALIZATION; B1; AMPLIFICATION; ACTIVATION; INITIATION	Mitosis in human cells is initiated at the end of G2 by activation of the Cdc2/cyclin B complex. Activation occurs by dephosphorylation of the inhibitory residues, threonine 14 (T14) and tyrosine 15 (Y15), on Cdc2 by the Cdc25C phosphatase. Entry into mitosis is regulated by the subcellular relocalization of Cdc2/cyclin B, which is rapidly imported into the nucleus at the end of G2. Here, we show that polo-like kinase 3 (Plk3) is able to phosphorylate Cdc25C primarily on S191, and to a lesser extent on S198 in vitro, both of which are within a nuclear exclusion motif. Following transfection, the S191D Cdc25C mutant leads to an enhanced accumulation of Cdc25C in the nucleus, while the S191A mutant facilitated the Cdc25C nuclear exclusion. Furthermore, translocation of Cdc25C to the nucleus was accompanied by a decrease in Cdc2 phosphorylation on Y15. Plk3-WT overexpression led to a sharp increase in Cdc25C nuclear accumulation, while Plk3-KD overexpression failed to do so. The effect of Plk3 overexpression on Cdc25C was reversed by coexpression of a Plk3 siRNA. These results support a role for the polo kinases in coordinating the translocation and perhaps the timing of both Cdc25C and its target Cdc2/cyclin B to the nucleus upon entry into mitosis.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Stambrook, PJ (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, 3125 Eden Ave, Cincinnati, OH 45267 USA.	peter.stambrook@uc.edu			NCI NIH HHS [R01 CA90934] Funding Source: Medline; NIEHS NIH HHS [UO1 ES011038, T32 ES07250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007250, U01ES011038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abrieu A, 1998, J CELL SCI, V111, P1751; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Golsteyn R M, 1996, Prog Cell Cycle Res, V2, P107; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAGATA A, 1991, NEW BIOL, V3, P959; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Pines J, 1999, NATURE, V397, P104, DOI 10.1038/16344; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; TSVETKOV L, 2002, J BIOL CHEM     1218; Yang J, 2001, J BIOL CHEM, V276, P3604, DOI 10.1074/jbc.M008151200	32	62	64	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2658	2663		10.1038/sj.onc.1207425	http://dx.doi.org/10.1038/sj.onc.1207425			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	14968113				2022-12-17	WOS:000220714900007
J	Rodriguez, JA; Schuchner, S; Au, WWY; Fabbro, M; Henderson, BR				Rodriguez, JA; Schuchner, S; Au, WWY; Fabbro, M; Henderson, BR			Nuclear-cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is regulated by dimerization with BRCA1	ONCOGENE			English	Article						BARD1; BRCA1; nuclear export; cancer; apoptosis	CANCER-PREDISPOSING MUTATIONS; RING DOMAIN; TUMOR-SUPPRESSOR; CELL-CYCLE; IN-VIVO; GENE; PROTEIN; BREAST; IDENTIFICATION; BRCA1-BARD1	The breast cancer-associated protein, BARD1, colocalizes with BRCA1 in nuclear foci in the S phase and after DNA damage, and the two proteins form a stable heterodimer implicated in DNA repair, protein ubiquitination, and control of mRNA processing. BARD1 has a BRCA1-independent proapoptotic activity; however, little is known about its regulation. Here, we show that BARD1 localization and apoptotic activity are regulated by nuclear-cytoplasmic shuttling. We identified a functional CRM1-dependent nuclear export sequence (NES) near the N-terminal RING domain of BARD1. The NES forms part of the BRCA1 dimerization domain, and coexpression of BRCA1 resulted in masking of the NES and nuclear retention of BARD1. In transient expression assays, BARD1 apoptotic activity was stimulated by nuclear export, and both apoptotic function and nuclear export were markedly reduced by BRCA1. Similar findings were obtained for endogenous BARD1. Silencing BRCA1 expression by siRNA, or disrupting the endogenous BARD1/BRCA1 interaction by peptide competition caused a reduction in BARD1 nuclear localization and foci formation, and increased the level of cytoplasmic BARD1 correlating with increased apoptosis. Our findings suggest that BRCA1/BARD1 heterodimer formation is important for optimal nuclear targeting of BARD1 and its role in DNA repair and cell survival.	Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia	University of Sydney; Westmead Institute for Medical Research	Henderson, BR (corresponding author), Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Darcy Rd,POB 412, Westmead, NSW 2145, Australia.	beric_henderson@wmi.usyd.edu.au	Rodriguez, Jose Antonio/AAA-1125-2019	Rodriguez, Jose Antonio/0000-0002-2823-3733				Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Brzovic PS, 2001, J BIOL CHEM, V276, P41399, DOI 10.1074/jbc.M106551200; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chiba N, 2002, CANCER RES, V62, P4222; Chiba N, 2001, J BIOL CHEM, V276, P38549, DOI 10.1074/jbc.M105227200; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Ghimenti C, 2002, GENE CHROMOSOME CANC, V33, P235, DOI 10.1002/gcc.1223; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Irminger-Finger I, 2001, MOL CELL, V8, P1255, DOI 10.1016/S1097-2765(01)00406-3; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(01)00270-7; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Spahn L, 2002, CANCER RES, V62, P4583; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108	28	62	67	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1809	1820		10.1038/sj.onc.1207302	http://dx.doi.org/10.1038/sj.onc.1207302			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14647430				2022-12-17	WOS:000220129500002
J	Pfahl, M; Piedrafita, FJ				Pfahl, M; Piedrafita, FJ			Retinoid targets for apoptosis induction	ONCOGENE			English	Article						retinoids; apoptosis; MKP-1	CYTOCHROME-C RELEASE; PROTEIN-KINASE-C; KAPPA-B KINASE; CARBOXYLIC-ACID; N-(4-HYDROXYPHENYL)RETINAMIDE-INDUCED APOPTOSIS; POSTTRANSCRIPTIONAL REGULATION; RETRO-RETINOIDS; CARCINOMA CELLS; LEUKEMIA-CELLS; GROWTH ARREST	Certain synthetic retinoid-related molecules induce apoptosis in cancer cells through a novel mechanism of retinoid action that is independent of the nuclear retinoid receptors. These compounds target protein kinases and protein phosphatases to trigger signal transduction pathways that lead to apoptosis. Whereas retinoid agonists such as CD437 activate stress kinases via inhibition of the phosphatase MKP-1, the retinoid antagonist MX781 inhibits the survival kinase IKK. These retinoid-mediated signaling pathways converge at the mitochondria, where they cause the release of cytochrome c and subsequent Apaf-1-dependent activation of caspases. Identification of the retinoid targets that mediate their apoptotic activity will enhance our understanding of the mechanism of this novel retinoid action, to allow appropriate optimization of currently available compounds to advance into the clinic as novel anticancer agents.	Incyte San Diego Inc, San Diego, CA 92121 USA; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA	Incyte	Pfahl, M (corresponding author), Incyte San Diego Inc, 10835 Altman Row, San Diego, CA 92121 USA.	pfahl@incyte.com						Adachi H, 1998, CELL DEATH DIFFER, V5, P973, DOI 10.1038/sj.cdd.4400445; Bang YJ, 1998, BIOCHEM BIOPH RES CO, V250, P43, DOI 10.1006/bbrc.1998.9256; Bayon Y, 2003, MOL CELL BIOL, V23, P1061, DOI 10.1128/MCB.23.3.1061-1074.2003; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chen YQ, 1999, CANCER RES, V59, P3985; Degos L, 2001, ONCOGENE, V20, P7140, DOI 10.1038/sj.onc.1204763; DELIA D, 1993, CANCER RES, V53, P6036; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; Denkert C, 2002, INT J CANCER, V102, P507, DOI 10.1002/ijc.10746; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Erdreich-Epstein A, 2002, J BIOL CHEM, V277, P49531, DOI 10.1074/jbc.M209962200; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hail N, 2001, CANCER RES, V61, P6698; Hoyos B, 2002, J BIOL CHEM, V277, P23949, DOI 10.1074/jbc.M110750200; Hoyos B, 2000, J EXP MED, V192, P835, DOI 10.1084/jem.192.6.835; Hsieh TC, 1995, BIOCHEM MOL BIOL INT, V37, P499; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Imam A, 2001, FASEB J, V15, P28; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; KALEMKERIAN GP, 1995, J NATL CANCER I, V87, P1674, DOI 10.1093/jnci/87.22.1674; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Korichneva I, 1999, J CELL SCI, V112, P2521; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Lopez-Hernandez FJ, 2003, MOL CANCER THER, V2, P255; LOPEZHERNANDEZ FJ, 2003, IN PRESS CELL DEATH; Lu XP, 1997, NAT MED, V3, P686, DOI 10.1038/nm0697-686; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; Marchetti P, 1999, CANCER RES, V59, P6257; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Merritt G, 2001, CANCER LETT, V164, P15, DOI 10.1016/S0304-3835(00)00714-X; Mologni L, 1999, BLOOD, V93, P1045, DOI 10.1182/blood.V93.3.1045.403k22_1045_1061; OConnell MJ, 1996, J EXP MED, V184, P549, DOI 10.1084/jem.184.2.549; Oridate N, 1997, J NATL CANCER I, V89, P1191, DOI 10.1093/jnci/89.16.1191; Ortiz MA, 2001, CANCER RES, V61, P8504; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Ponzanelli I, 2000, BLOOD, V95, P2672; PONZONI M, 1995, CANCER RES, V55, P853; Rishi AK, 1999, NUCLEIC ACIDS RES, V27, P3111, DOI 10.1093/nar/27.15.3111; Sakaue M, 1999, MOL PHARMACOL, V55, P668; Simeone AM, 2002, MOL CANCER THER, V1, P1009; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sun SY, 2000, MOL PHARMACOL, V58, P508, DOI 10.1124/mol.58.3.508; Sun SY, 1999, ONCOGENE, V18, P3894, DOI 10.1038/sj.onc.1202771; Sun SY, 1999, CANCER RES, V59, P2829; Sun SY, 1999, CANCER RES, V59, P2493; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Vicent Silvestre, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P360; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang HT, 2001, CANCER RES, V61, P5102; Wang HY, 2003, CANCER LETT, V191, P229, DOI 10.1016/S0304-3835(02)00612-2; Wang TTY, 1996, CANCER LETT, V107, P65, DOI 10.1016/0304-3835(96)04344-3; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang JM, 2001, CANCER RES, V61, P4901; Zang Y, 2001, CELL DEATH DIFFER, V8, P477, DOI 10.1038/sj.cdd.4400843; Zhang YX, 1999, EXP CELL RES, V247, P233, DOI 10.1006/excr.1998.4350	64	62	65	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2003	22	56					9058	9062		10.1038/sj.onc.1207109	http://dx.doi.org/10.1038/sj.onc.1207109			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	751GC	14663484				2022-12-17	WOS:000187043600009
J	Pendaries, V; Verrecchia, F; Michel, S; Mauviel, A				Pendaries, V; Verrecchia, F; Michel, S; Mauviel, A			Retinoic acid receptors interfere with the TGF-beta/Smad signaling pathway in a ligand-specific manner	ONCOGENE			English	Article						transforming growth factor-beta; nuclear receptors; RAR; Smad; promoter region; gene expression	GROWTH-FACTOR-BETA; CANCER-CELL-LINES; TRANSCRIPTION FACTORS; HL-60 CELLS; PROMOTER; SMAD; GENE; DIFFERENTIATION; PROLIFERATION; ELEMENTS	Transforming growth factor-beta (TGF-beta) and retinoic acid (RA) are important regulators of cell growth and differentiation. The TGF-beta receptors utilize Smad proteins to transduce signals intracellularly and regulate transcription of target genes, either directly or in combination with other sequence-specific transcription factors. Two classes of nuclear receptors, the retinoic acid receptors (RARs) and the retinoic X receptors, are involved in mediating transcriptional responses to RA. Given the known interactions between the TGF-beta and RAR pathways, we have investigated the role played by RAR ligands in modulating functional interactions between Smad3 and RARs. Using transient cell transfection experiments with an artificial Smad3/Smad4-dependent reporter construct, we demonstrate that RAR overexpression enhances Smad-driven transactivation, an effect that requires both Smad3 and Smad4. We provide evidence that RAR effect on Smad3/Smad4-driven transcription is prevented by natural and synthetic RAR agonists, and potentiated by synthetic RAR antagonists. The activity of two TGF-beta-responsive human gene promoter constructs was regulated in a parallel fashion. Using both mammalian two-hybrid and immunoprecipitation/Western methods, we demonstrate a direct interaction between the region DEF of RARgamma and the MH2 domain of Smad3, inhibited by RAR agonists and enhanced by their antagonists. We propose that RARs may function as coactivators of the Smad pathway in the absence of RAR agonists or in the presence of their antagonists, a phenomenon that contrasts with their known role as agonist-activated transcriptional regulators of RA-dependent genes.	Univ Paris 07, Inst Rech Peau, Hop St Louis, INSERM,U532, F-75475 Paris 10, France; Galderma R&D, F-06902 Sophia Antipolis, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Galderma R&D SNC	Mauviel, A (corresponding author), Univ Paris 07, Inst Rech Peau, Hop St Louis, INSERM,U532, Pavillon Bazin,Ave Claude Vellefaux, F-75475 Paris 10, France.		MAUVIEL, Alain/F-6251-2013; Verrecchia, Franck/G-5535-2018	Verrecchia, Franck/0000-0003-4920-2554; Mauviel, Alain/0000-0002-0438-2793				Allenby G, 1995, Hum Exp Toxicol, V14, P226; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Borger DR, 2000, VIROLOGY, V270, P397, DOI 10.1006/viro.2000.0282; Cao ZH, 2003, BLOOD, V101, P498, DOI 10.1182/blood-2002-05-1549; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; CHIPUK JE, 2001, J BIOL CHEM, V13, P13; Datto M, 2000, CYTOKINE GROWTH F R, V11, P37, DOI 10.1016/S1359-6101(99)00027-1; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Defacque H, 1997, LEUKEMIA, V11, P221, DOI 10.1038/sj.leu.2400568; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Fink SP, 2003, ONCOGENE, V22, P1317, DOI 10.1038/sj.onc.1206128; Fu MG, 2001, J BIOL CHEM, V276, P45888, DOI 10.1074/jbc.M105490200; Germain S, 2000, GENE DEV, V14, P435; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Jetten AM, 2001, PROG NUCLEIC ACID RE, V69, P205, DOI 10.1016/S0079-6603(01)69048-2; Kumar R, 1999, STEROIDS, V64, P310, DOI 10.1016/S0039-128X(99)00014-8; La P, 2003, ONCOGENE, V22, P198, DOI 10.1038/sj.onc.1206100; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 1999, J BIOL CHEM, V274, P31229, DOI 10.1074/jbc.274.44.31229; Nunes I, 1996, CANCER RES, V56, P495; PEMRICK SM, 1994, LEUKEMIA, V8, P1797; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; ROBERTS AB, 1992, CANCER SURV, V14, P205; Rodeck U, 1999, CANCER RES, V59, P547; Schutte M, 1996, CANCER RES, V56, P2527; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; Toma S, 1998, INT J CANCER, V78, P86, DOI 10.1002/(SICI)1097-0215(19980925)78:1<86::AID-IJC14>3.0.CO;2-3; Verrecchia F, 2001, ONCOGENE, V20, P3332, DOI 10.1038/sj.onc.1204448; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317	42	62	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8212	8220		10.1038/sj.onc.1206913	http://dx.doi.org/10.1038/sj.onc.1206913			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603262				2022-12-17	WOS:000186403400016
J	Araki, K; Nakajima, Y; Eto, K; Ikeda, MA				Araki, K; Nakajima, Y; Eto, K; Ikeda, MA			Distinct recruitment of E2F family members to specific E2F-binding sites mediates activation and repression of the E2F1 promoter	ONCOGENE			English	Article						E2F1; cell cycle; transcription; E2F; corepressor	CELL-CYCLE REGULATION; TRANSCRIPTION FACTOR E2F; B-MYB TRANSCRIPTION; IN-VIVO; REGULATED TRANSCRIPTION; FUNCTIONAL INTERACTION; THYMIDINE KINASE; RESPONSIVE GENES; MAMMALIAN CDC6; S-PHASE	The activity of E2F transcription factors plays a crucial role in mammalian cell-cycle progression and is controlled by physical association with the pocket proteins (pRb and its related p107 and p130). The E2F1 promoter, which contains two overlapping E2F-binding sites, is activated at the G1/S transition in an E2F-dependent manner. Mutational experiments have shown that the distal E2F-binding site on the E2F1 promoter is required for transcriptional repression in the G0 phase, whereas the proximal E2F-binding site contributes to transcriptional activation at the G1/S boundary. Consistent with these results, chromatin immunoprecipitation assays have revealed that the E2F4/p130 repressor complex specifically binds to the distal E2F-binding site, whereas E2F1 and E2F3 activators preferentially bind to the proximal E2F-binding site. The assays also showed that the specific binding of E2F4/p130 complex to the distal site was dramatically impaired by a mutation introduced into the contiguous repression site ( cell Cycle gene Homology Region; CHR). Taken together, these findings indicate that the two E2F-binding sites play distinct roles in the regulation of E2F1 transcription by interacting with different sets of E2F members and cooperating with the contiguous repressor element.	Tokyo Med & Dent Univ, Grad Sch, Sect Mol Craniofacial Embryol, Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Grad Sch, Sect Oral Surg, Bunkyo Ku, Tokyo 1138549, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Ikeda, MA (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Sect Mol Embryol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.							Bennett JD, 1996, ONCOGENE, V13, P1073; Botz J, 1996, MOL CELL BIOL, V16, P3401; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Catchpole S, 2002, J BIOL CHEM, V277, P39015, DOI 10.1074/jbc.M202960200; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; Di Fiore B, 1999, J BIOL CHEM, V274, P10339, DOI 10.1074/jbc.274.15.10339; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Rotheneder H, 1999, J MOL BIOL, V293, P1005, DOI 10.1006/jmbi.1999.3213; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Takahashi Y, 2000, GENE DEV, V14, P804; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wu LL, 2000, MOL CELL BIOL, V20, P7059, DOI 10.1128/MCB.20.19.7059-7067.2000; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	42	62	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7632	7641		10.1038/sj.onc.1206840	http://dx.doi.org/10.1038/sj.onc.1206840			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576826				2022-12-17	WOS:000186113000011
J	Boon, K; Edwards, JB; Siu, IM; Olschner, D; Eberhart, CG; Marra, MA; Strausberg, RL; Riggins, GJ				Boon, K; Edwards, JB; Siu, IM; Olschner, D; Eberhart, CG; Marra, MA; Strausberg, RL; Riggins, GJ			Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes	ONCOGENE			English	Article						medulloblastoma; tumor-associated antigens; SAGE; bioinformatics	INDEPENDENT PROGNOSTIC MARKER; CENTRAL-NERVOUS-SYSTEM; PATIENT SURVIVAL; GLIOMA-CELLS; IN-VIVO; EXPRESSION; CANCER; CD24; ANTIGEN	Over 1.4 million transcript tags expressed in 20 different human medulloblastomas were counted using serial analysis of gene expression. Digital gene expression profiles in the medulloblastoma were compared to multiple regions of the normal human brain, revealing 30 transcripts with high expression in multiple tumors and little or no expression in the normal cerebellum and other adult and pediatric brain regions. Using independent medulloblastoma samples and normal tissue, real-time PCR verified eight of nine selected genes as candidate tumor-associated antigens. Differential protein expression for CD24, prolactin and Topo2A was further confirmed by immunohistochemical analysis using medulloblastoma and normal brain sections and a tissue microarray. The genes highly expressed in the medulloblastoma include PRAME, a cancer-testis antigen and potential targets for immunotherapy.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; BC Canc Agcy, Sequencing Ctr, Vancouver, BC, Canada; NCI, Off Canc Genom, Bethesda, MD 20892 USA	Duke University; Johns Hopkins University; British Columbia Cancer Agency; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Center for Cancer Genomics (CCG)	Riggins, GJ (corresponding author), Mason Lord Ctr Tower,5th Floor,Bhns Hopkins Beyvi, Baltimore, MD 21224 USA.		Marra, Marco A/B-5987-2008	Marra, Marco A/0000-0001-7146-7175	NATIONAL CANCER INSTITUTE [U01CA088128] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA88128] Funding Source: Medline; PHS HHS [S98-146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Anadon R, 2001, BRAIN RES, V894, P255, DOI 10.1016/S0006-8993(01)02024-8; Boon K, 2002, P NATL ACAD SCI USA, V99, P11287, DOI 10.1073/pnas.152324199; Bulfone A, 2000, HUM MOL GENET, V9, P1443, DOI 10.1093/hmg/9.9.1443; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fogel M, 1999, CANCER LETT, V143, P87, DOI 10.1016/S0304-3835(99)00195-0; GARSON JA, 1989, BRIT J CANCER, V59, P889, DOI 10.1038/bjc.1989.188; Gure AO, 2000, INT J CANCER, V85, P726, DOI 10.1002/(SICI)1097-0215(20000301)85:5<726::AID-IJC21>3.0.CO;2-F; Harries M, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090075; Holden JA, 1999, MODERN PATHOL, V12, P1094; Ikeda H, 1997, IMMUNITY, V6, P199, DOI 10.1016/S1074-7613(00)80426-4; Kanemura Y, 2001, DIFFERENTIATION, V68, P141, DOI 10.1046/j.1432-0436.2001.680208.x; Kirkin AF, 2002, CANCER INVEST, V20, P222, DOI 10.1081/CNV-120001150; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kristiansen G, 2003, BRIT J CANCER, V88, P231, DOI 10.1038/sj.bjc.6600702; Kristiansen G, 2002, AM J PATHOL, V161, P1215, DOI 10.1016/S0002-9440(10)64398-2; Lal A, 1999, CANCER RES, V59, P5403; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Senner V, 1999, J NEUROPATH EXP NEUR, V58, P795, DOI 10.1097/00005072-199908000-00002; Siu I.-Mei, 2001, Gene Expression Patterns, V1, P33, DOI 10.1016/S1567-133X(01)00006-0; St Croix B, 2000, SCIENCE, V289, P1197; Steinbach D, 2002, CANCER GENET CYTOGEN, V133, P118, DOI 10.1016/S0165-4608(01)00570-2; Vassal G, 2003, CANCER CHEMOTH PHARM, V51, P385, DOI 10.1007/s00280-003-0584-1; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484	25	62	71	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7687	7694		10.1038/sj.onc.1207043	http://dx.doi.org/10.1038/sj.onc.1207043			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576832				2022-12-17	WOS:000186113000017
J	Russell, JP; Shinohara, S; Melillo, RM; Castellone, MD; Santoro, M; Rothstein, JL				Russell, JP; Shinohara, S; Melillo, RM; Castellone, MD; Santoro, M; Rothstein, JL			Tyrosine kinase oncoprotein, RET/PTC3, induces the secretion of myeloid growth and chemotactic factors	ONCOGENE			English	Article						autoimmunity; inflammation; inflammatory cytokines; oncogene; RET/PTC; tumor antigen	PAPILLARY THYROID-CARCINOMA; NF-KAPPA-B; CHRONIC LYMPHOCYTIC THYROIDITIS; TUMOR-NECROSIS-FACTOR; CELL-LINE; IMMUNOCYTOCHEMICAL LOCALIZATION; TARGETED EXPRESSION; ONCOGENE ACTIVATION; RET PROTOONCOGENE; TRANSGENIC MICE	Differentiated thyroid carcinomas are the most frequent endocrine neoplasms, but account for few cancer-related deaths. Although the indolent growth of these cancers correlates well with longevity, the biological basis for this good prognosis is not known. In contrast, two of the most frequent autoimmune diseases involve the thyroid suggesting a high propensity for this organ to invoke destructive immunity. Unfortunately, the mechanism linking malignancy and autoimmunity is not clear, although the expression of the oncogenic fusion protein RET/PTC3 (RP3) in both of these disorders may provide a clue. Interestingly, the signaling caused by activated RET kinase involves overlapping pathways and some common to the inflammatory response. Accordingly, we analyzed the function of RP3 and a mutant RP3 molecule to induce proinflammatory pathways in thyroid epithelial cells. Indeed, we find that RP3 alone causes increases in nuclear NF-kappaB activity and secretion of MCP-1 and GM-CSF. Finally, transfer of RP3-expressing thyrocytes into mice in vivo attracted dense macrophage infiltrates, which lead to rapid thyroid cell death. Further, cytokine synthesis and inflammation was largely abrogated by mutation of RP3 Tyr(588); an important protein-binding site for downstream signaling. Together, these studies implicate oncogene-induced cytokine-signaling pathways in a new mechanism linking inflammation with cancer.	Thomas Jefferson Univ, Dept Microbiol & Immunol, Rothstein Kimmel Canc Inst, Philadelphia, PA 19107 USA; Univ Naples Federico II, Fac Med & Chirurg 2, Ctr Endocrinol & Oncol Sperimentale, CNR,Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy; Thomas Jefferson Univ, Dept Otolaryngol Head & Neck Surg, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Jefferson University; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Jefferson University	Rothstein, JL (corresponding author), Thomas Jefferson Univ, Dept Microbiol & Immunol, Rothstein Kimmel Canc Inst, 233 S 10th St,BLSB 909, Philadelphia, PA 19107 USA.	Jay.Rothstein@jefferson.edu	melillo, rosa marina/O-5255-2015; Shinohara, Shogo/H-8976-2019	Shinohara, Shogo/0000-0002-1794-2091; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037; MELILLO, Rosa Marina/0000-0002-9233-5275	NCI NIH HHS [T32-CA09678, CA-76259] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009678, P01CA076259] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asakawa H, 1999, ANTICANCER RES, V19, P761; Aust G, 1996, CLIN EXP IMMUNOL, V105, P148, DOI 10.1046/j.1365-2249.1996.d01-726.x; Aust G, 2001, J ENDOCRINOL, V170, P513, DOI 10.1677/joe.0.1700513; Basolo F, 1998, CLIN CANCER RES, V4, P381; Basolo F, 2002, INT J CANCER, V97, P608, DOI 10.1002/ijc.10116; Biswas SK, 2002, J INTERF CYTOK RES, V22, P527, DOI 10.1089/10799900252982007; Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; Borrello I, 2002, CYTOKINE GROWTH F R, V13, P185, DOI 10.1016/S1359-6101(01)00034-X; BRAVERMAN LE, 1995, THYROID FUNDAMENTAL; Chiariello M, 1998, ONCOGENE, V16, P2435, DOI 10.1038/sj.onc.1201778; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; CRILE G, 1953, CANCER-AM CANCER SOC, V6, P57, DOI 10.1002/1097-0142(195301)6:1<57::AID-CNCR2820060104>3.0.CO;2-D; DAILEY ME, 1955, ARCH SURG-CHICAGO, V70, P291, DOI 10.1001/archsurg.1955.01270080137023; Daniel D, 2003, J EXP MED, V197, P1017, DOI 10.1084/jem.20021047; Di Pasquale M, 2001, HUM PATHOL, V32, P24, DOI 10.1053/hupa.2001.21138; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ENOMOTO T, 1990, CANCER, V65, P1971, DOI 10.1002/1097-0142(19900501)65:9<1971::AID-CNCR2820650916>3.0.CO;2-V; Fiore L, 1997, J CLIN ENDOCR METAB, V82, P4094, DOI 10.1210/jc.82.12.4094; Fleischmann A, 1999, SCHWEIZ MED WSCHR, V129, P873; Foo SY, 1999, TRENDS GENET, V15, P229; Fusco A, 2002, AM J PATHOL, V160, P2157, DOI 10.1016/S0002-9440(10)61164-9; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Iwahashi N, 2002, BIOCHEM BIOPH RES CO, V294, P642, DOI 10.1016/S0006-291X(02)00528-4; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; KABEL PJ, 1987, ACTA ENDOCRINOL-COP, V115, P42; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kayser L, 1996, AUTOIMMUNITY, V23, P91, DOI 10.3109/08916939608995332; KAYSER L, 1995, AUTOIMMUNITY, V20, P75, DOI 10.3109/08916939509001930; Kebebew E, 2001, WORLD J SURG, V25, P632, DOI 10.1007/s002680020165; KENNEDY RL, 1992, J ENDOCRINOL, V133, P477, DOI 10.1677/joe.0.1330477; Kurebayashi J, 2000, J CLIN ENDOCR METAB, V85, P2889, DOI 10.1210/jc.85.8.2889; Loh KC, 1999, J CLIN ENDOCR METAB, V84, P458, DOI 10.1210/jc.84.2.458; Ludwig L, 2001, CANCER RES, V61, P4526; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; MATSUBAYASHI S, 1995, J CLIN ENDOCR METAB, V80, P3421, DOI 10.1210/jc.80.12.3421; Mechler C, 2001, BRIT J CANCER, V85, P1831, DOI 10.1054/bjoc.2001.2187; Nakada T, 1996, INTERNAL MED, V35, P815, DOI 10.2169/internalmedicine.35.815; Powell DJ, 2003, J IMMUNOL, V170, P861, DOI 10.4049/jimmunol.170.2.861; Powell DJ, 2001, ONCOGENE, V20, P3235, DOI 10.1038/sj.onc.1204425; Sagartz JE, 1997, LAB INVEST, V76, P307; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; SANTORO M, 1995, EUR J ENDOCRINOL, V133, P513, DOI 10.1530/eje.0.1330513; SANTORO M, 1994, ONCOGENE, V9, P509; Santoro M, 1996, ONCOGENE, V12, P1821; Scarpino S, 2000, AM J PATHOL, V156, P831, DOI 10.1016/S0002-9440(10)64951-6; Sheils OM, 2000, INT J SURG PATHOL, V8, P185, DOI 10.1177/106689690000800305; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; Tamimi DM, 2002, INT J SURG PATHOL, V10, P141, DOI 10.1177/106689690201000207; TOHYAMA K, 1992, JPN J CANCER RES, V83, P153, DOI 10.1111/j.1349-7006.1992.tb00080.x; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wang JM, 1998, J IMMUNOL METHODS, V220, P1, DOI 10.1016/S0022-1759(98)00128-8; Wirtschafter A, 1997, LARYNGOSCOPE, V107, P95, DOI 10.1097/00005537-199701000-00019; YOSHIDA A, 1994, J SURG ONCOL, V55, P104, DOI 10.1002/jso.2930550209; YOSHIDA M, 1992, CANCER RES, V52, P464	59	62	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2003	22	29					4569	4577		10.1038/sj.onc.1206759	http://dx.doi.org/10.1038/sj.onc.1206759			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	699JX	12881713				2022-12-17	WOS:000184054700012
J	Snijders, AM; Fridlyand, J; Mans, DA; Segraves, R; Jain, AN; Pinkel, D; Albertson, DG				Snijders, AM; Fridlyand, J; Mans, DA; Segraves, R; Jain, AN; Pinkel, D; Albertson, DG			Shaping of tumor and drug-resistant genomes by instability and selection	ONCOGENE			English	Article						genetic instability; amplification; array CGH; mismatch repair	DNA MISMATCH REPAIR; FOLYLPOLYGLUTAMATE SYNTHETASE GENE; FRAGILE SITES; DIHYDROFOLATE-REDUCTASE; IN-SITU; AMPLIFICATION; METHOTREXATE; CELLS; EXPRESSION; CANCER	Tumors with defects in mismatch repair (MMR) show fewer chromosomal changes by cytogenetic analyses than most solid tumors, suggesting that a greater proportion of the alterations required for malignancy occur in genes with nucleotide sequences susceptible to errors normally corrected by MMR. Here, we used genome-wide microarray comparative genomic hybridization to carry out a higher resolution evaluation of the effect of MMR competence on genomic alterations occurring in 20 cell lines and to determine if characteristic aberrations arise in MMR-proficient and -deficient HCT116 cells undergoing selection for methotrexate resistance. We observed different spectra of aberrations in MMR-proficient compared to -deficient cell lines, as well as among cell lines with different types of MMR-deficiency. We also observed different genetic routes to drug resistance. Resistant MMR-deficient cells most frequently displayed no copy number alterations (16/29 cell pools), whereas all MMR-proficient cells had unique abnormalities involving chromosome 5, including amplicons centered on the target gene, DHFR and/or a neighboring novel locus (7/13 pools). These observations support the concept that tumor genomes are shaped by selection for alterations that promote survival and growth advantage, as well as by the particular dysfunctions in genes responsible for maintenance of genetic integrity.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Albertson, DG (corresponding author), Univ Calif San Francisco, Canc Res Inst, Box 0808, San Francisco, CA 94143 USA.	albertson@cc.ucsf.edu			NATIONAL CANCER INSTITUTE [R01CA083040, R33CA094407] Funding Source: NIH RePORTER; NCI NIH HHS [CA83040, CA94407] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aebi S, 1996, CANCER RES, V56, P3087; Albertson DG, 2003, BREAST CANCER RES TR, V78, P289, DOI 10.1023/A:1023025506386; Banerjee D, 2002, BBA-MOL BASIS DIS, V1587, P164, DOI 10.1016/S0925-4439(02)00079-0; BOCKER T, 1999, BIOCHIM BIOPHYS ACTA, V1423, P1; Chen ZS, 2002, CANCER RES, V62, P3144; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; Cole PD, 2001, CANCER RES, V61, P4599; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Duval A, 2002, CANCER RES, V62, P2447; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8; Fink D, 1998, INT J CANCER, V77, P741, DOI 10.1002/(SICI)1097-0215(19980831)77:5<741::AID-IJC13>3.0.CO;2-4; Frouin I, 2001, EUR J CANCER, V37, P1173, DOI 10.1016/S0959-8049(01)00095-8; Guan XY, 1996, CANCER RES, V56, P3446; HAWN MT, 1995, CANCER RES, V55, P3721; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jain AN, 2002, GENOME RES, V12, P325, DOI 10.1101/gr.210902; KOI M, 1994, CANCER RES, V54, P4308; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; KUO MT, 1994, MOL CELL BIOL, V14, P5202, DOI 10.1128/MCB.14.8.5202; Lin CT, 2001, NUCLEIC ACIDS RES, V29, P3304, DOI 10.1093/nar/29.16.3304; Loeb LA, 2001, CANCER RES, V61, P3230; Matherly LH, 2001, PROG NUCLEIC ACID RE, V67, P131, DOI 10.1016/S0079-6603(01)67027-2; MULERIS M, 1995, GENE CHROMOSOME CANC, V14, P223, DOI 10.1002/gcc.2870140312; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; Paulson TG, 1998, MOL CELL BIOL, V18, P3089, DOI 10.1128/MCB.18.5.3089; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pipiras E, 1998, EMBO J, V17, P325, DOI 10.1093/emboj/17.1.325; RABINER LR, 1989, P IEEE, V77, P257, DOI 10.1109/5.18626; REMVIKOS Y, 1995, GENE CHROMOSOME CANC, V12, P272, DOI 10.1002/gcc.2870120406; Rots MG, 1999, BLOOD, V93, P1677, DOI 10.1182/blood.V93.5.1677.405a16_1677_1683; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Singer MJ, 2000, P NATL ACAD SCI USA, V97, P7921, DOI 10.1073/pnas.130194897; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Soulie P, 1999, CANCER GENET CYTOGEN, V115, P118, DOI 10.1016/S0165-4608(99)00073-4; Srimatkandada S, 2000, ONCOL RES, V12, P11; SUTHERLAND GR, 1991, GENET ANAL-BIOMOL E, V8, P161, DOI 10.1016/1050-3862(91)90056-W; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; SUTHERLAND GR, 1995, CURR OPIN GENET DEV, V5, P323, DOI 10.1016/0959-437X(95)80046-8; Takemura Y, 1999, ANTI-CANCER DRUG, V10, P677, DOI 10.1097/00001813-199908000-00008; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Turner FB, 2000, J BIOL CHEM, V275, P35960, DOI 10.1074/jbc.M005228200; Waldman FM, 2000, JNCI-J NATL CANCER I, V92, P313, DOI 10.1093/jnci/92.4.313; Zeng H, 2001, CANCER RES, V61, P7225; Zhang L, 2001, CANCER RES, V61, P3801; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5; Zimonjic D, 2001, CANCER RES, V61, P8838	50	62	64	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2003	22	28					4370	4379		10.1038/sj.onc.1206482	http://dx.doi.org/10.1038/sj.onc.1206482			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853973				2022-12-17	WOS:000183978900006
J	Narayan, G; Pulido, HA; Koul, S; Lu, XY; Harris, CP; Yeh, YA; Vargas, H; Posso, H; Terry, MB; Gissmann, L; Schneider, A; Mansukhani, M; Rao, PH; Murty, VVVS				Narayan, G; Pulido, HA; Koul, S; Lu, XY; Harris, CP; Yeh, YA; Vargas, H; Posso, H; Terry, MB; Gissmann, L; Schneider, A; Mansukhani, M; Rao, PH; Murty, VVVS			Genetic analysis identifies putative tumor suppressor sites at 2q35-q36.1 and 2q36.3-q37.1 involved in cervical cancer progression	ONCOGENE			English	Article						cervical carcinoma; chromosome 2; CGH; gene amplification; LOH; cervical intraepithelial neoplasia	SQUAMOUS-CELL CARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; UTERINE CERVIX; CHROMOSOMAL-ABERRATIONS; PRECANCEROUS LESIONS; INTRAEPITHELIAL NEOPLASIA; CHILDHOOD NEUROBLASTOMAS; RECURRENT PATTERN; E7 ONCOPROTEINS; OVARIAN-CANCER	We performed comparative genomic hybridization (CGH) and high-resolution deletion mapping of the long arm of chromosome 2 (2q) in invasive cervical carcinoma (CC). The CGH analyses on 52 CCs identified genetic losses at 2q33-q36, gain of 3q26-q29, and frequent chromosomal amplifications. Characterization of 2q deletions by loss of heterozygosity (LOH) in 60 primary tumors identified two sites of minimal deleted regions at 2q35-q36.1 and 2q36.3-q37.1. To delineate the stage at which these genetic alterations occur in CC progression, we analysed 33 cervical intraepithelial neoplasia (CIN) for LOH. We found that 89% of high-grade (CINII and CINIII) and 40% of low-grade (CINI) CINs exhibited LOH at 2q. To identify the target tumor suppressor gene (TSG), we performed an extensive genetic and epigenetic analyses of a number of candidate genes mapped to the deleted regions. We did not find inactivating mutations in CASP10, BARD1, XRCC5, or PPP1R7 genes mapped to the deleted regions. However, we did find evidence of downregulated gene expression in CFLAR, CASP10 and PPPIR7 in CC cell lines. We also found reactivated gene expression in CC cell lines in vitro after exposure to demethylating and histone deacetylase (HDAC) inhibiting agents. Thus, these data identify frequent chromosomal amplifications in CC, and sites of TSGs at 2q35-q36.1 and 2q36.3-q37.1 that are critical in CC development.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Inst Canc Genet, New York, NY 10032 USA; Inst Nacl Canerol, Dept Genet, Santa Fe De Bogota, Colombia; Inst Nacl Canerol, Dept Pathol, Santa Fe De Bogota, Colombia; Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA; Deutsch Krebsforschungszentrum, D-6900 Heidelberg, Germany; Univ Jena, Dept Obstet & Gynecol, D-6900 Jena, Germany	Columbia University; Columbia University; Baylor College of Medicine; Texas Children's Cancer Center; Columbia University; Helmholtz Association; German Cancer Research Center (DKFZ); Friedrich Schiller University of Jena	Murty, VVVS (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, 630 W 168th St, New York, NY 10032 USA.		Gissmann, Lutz/H-4688-2011; Arias-Pulido, Hugo/AEN-1741-2022	Arias-Pulido, Hugo/0000-0003-4941-1110; Terry, Mary Beth/0000-0002-4106-5033				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Chatterjee A, 2001, CANCER RES, V61, P2119; Dellas A, 1999, CANCER RES, V59, P3475; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Heselmeyer K, 1997, GENE CHROMOSOME CANC, V19, P233, DOI 10.1002/(SICI)1098-2264(199708)19:4<233::AID-GCC5>3.0.CO;2-Y; Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479; Hidalgo A, 2000, EUR J CANCER, V36, P542, DOI 10.1016/S0959-8049(99)00323-8; Hu N, 2000, GENE CHROMOSOME CANC, V27, P217, DOI 10.1002/(SICI)1098-2264(200003)27:3<217::AID-GCC1>3.0.CO;2-A; Kersemaekers AMF, 1999, GENE CHROMOSOME CANC, V26, P346, DOI 10.1002/(SICI)1098-2264(199912)26:4<346::AID-GCC9>3.0.CO;2-D; Kinoshita M, 1997, GENE DEV, V11, P1535, DOI 10.1101/gad.11.12.1535; Kirchhoff M, 1999, GENE CHROMOSOME CANC, V24, P144, DOI 10.1002/(SICI)1098-2264(199902)24:2<144::AID-GCC7>3.0.CO;2-9; Kubbutat MHG, 1996, SEMIN VIROL, V7, P295, DOI 10.1006/smvy.1996.0037; KURZROCK R, 1995, CANCER-AM CANCER SOC, V75, P584, DOI 10.1002/1097-0142(19950115)75:2<584::AID-CNCR2820750223>3.0.CO;2-P; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Lim DS, 2000, MOL CELL BIOL, V20, P3772, DOI 10.1128/MCB.20.11.3772-3780.2000; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; MITRA AB, 1994, CANCER RES, V54, P637; MITRA AB, 1995, J NATL CANCER I, V87, P742, DOI 10.1093/jnci/87.10.742; MUNGER K, 1992, CANCER SURV, V12, P197; MURTHY NS, 1990, BRIT J CANCER, V61, P732, DOI 10.1038/bjc.1990.164; OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; Otsuka T, 1996, GENE CHROMOSOME CANC, V16, P113, DOI 10.1002/(SICI)1098-2264(199606)16:2<113::AID-GCC5>3.0.CO;2-2; Pulido HA, 2000, CANCER RES, V60, P6677; Rader JS, 1998, GENE CHROMOSOME CANC, V22, P57, DOI 10.1002/(SICI)1098-2264(199805)22:1<57::AID-GCC8>3.0.CO;2-6; Ransom DT, 1998, HEAD NECK-J SCI SPEC, V20, P404; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; RENOUF S, 1995, FEBS LETT, V375, P75, DOI 10.1016/0014-5793(95)01180-M; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Schwab M, 1999, SEMIN CANCER BIOL, V9, P319, DOI 10.1006/scbi.1999.0126; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Singh B, 2001, CANCER RES, V61, P4506; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; Takita J, 2001, ONCOGENE, V20, P4424, DOI 10.1038/sj.onc.1204521; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Teitz T, 2001, J MOL MED, V79, P428, DOI 10.1007/s001090100233; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Tung WS, 1997, GENE CHROMOSOME CANC, V19, P43, DOI 10.1002/(SICI)1098-2264(199705)19:1<43::AID-GCC7>3.0.CO;2-0; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; Uejima H, 1998, MOL CARCINOGEN, V22, P34, DOI 10.1002/(SICI)1098-2744(199805)22:1<34::AID-MC5>3.0.CO;2-L; Umayahara K, 2002, GENE CHROMOSOME CANC, V33, P98, DOI 10.1002/gcc.1215; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970; ZURHAUSEN H, 1994, COLD SPRING HARB SYM, V59, P623, DOI 10.1101/SQB.1994.059.01.071; 1996, CERVICAL CANC, V14, P1	51	62	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3489	3499		10.1038/sj.onc.1206432	http://dx.doi.org/10.1038/sj.onc.1206432			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776201	Green Published			2022-12-17	WOS:000183128500016
J	Yamashita, H; Iwase, H; Toyama, T; Fujii, Y				Yamashita, H; Iwase, H; Toyama, T; Fujii, Y			Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells	ONCOGENE			English	Article						Stat5; estrogen receptor; signal transduction; recombinant adenovirus; breast cancer	MAMMARY-GLAND DEVELOPMENT; SIGNAL TRANSDUCER; SERINE PHOSPHORYLATION; CROSS-TALK; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOCORTICOID RECEPTOR; EPITHELIAL-CELLS; GENE-EXPRESSION; DNA-BINDING; ER-ALPHA	Signal transducer and activator of transcription (Stat) 5 regulates growth, differentiation, and survival of mammary and hematopoietic cells. The role of Stat5 in breast cancer has not been established, although Stat5 is critical for some hematopoietic malignancies. We detected for the first time that Stat5b is constitutively activated in human breast cancer cell lines, and analysed the role of Stat5 in estrogen receptor(ER)-positive breast cancer cell lines using dominant-negative variants of Stat5. Two distinct carboxyl-truncated Stat5a derivatives were generated. Stat5aDelta740 corresponded to a naturally occurring alternative splice variant, and Stat5aDelta713 was analogous to an 80 kDa Stat5a product of a nuclear protease. Stat5aDelta740 and Stat5aDelta713 displayed comparable dominant-negative properties and suppressed transcriptional activity of wildtype Stat5a and Stat5b equally well. Cotransfection experiments revealed that Stat5aDelta740 completely blocked transcriptional activity of endogenous estrogen receptor in T47D and MCF7 cells, and of both ERalpha and ERbeta in COS-7 cells. Stat5aDelta740 was selected for adenoviral delivery, and high-efficiency expression of tyrosine phosphorylated Stat5aDelta740 was achieved in infected cells. Adenoviral-mediated Stat5aDelta740 induced apoptosis in T47D cells but not in caspase-3-negative MCF7 cells. The present study indicates that overexpression of a dominant-negative variant of Stat5 suppresses ER transcriptional activity and induces apoptosis in estrogen-responsive breast cancer tissue culture cells.	Nagoya City Univ, Sch Med Sci, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 4678601, Japan	Nagoya City University	Yamashita, H (corresponding author), Nagoya City Univ, Sch Med Sci, Dept Surg 2, Mizuho Ku, Kawasumi 1, Nagoya, Aichi 4678601, Japan.		Yamashita, Hiroko/D-5102-2012	Yamashita, Hiroko/0000-0003-4281-8727; Toyama, Tatsuya/0000-0003-4713-7795				Beuvink I, 2000, J BIOL CHEM, V275, P10247, DOI 10.1074/jbc.275.14.10247; Bittorf T, 2000, CELL SIGNAL, V12, P23, DOI 10.1016/S0898-6568(99)00063-7; Bjornstrom L, 2001, J MOL ENDOCRINOL, V27, P93, DOI 10.1677/jme.0.0270093; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Buettner R, 2002, CLIN CANCER RES, V8, P945; Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; Dong F, 1998, J IMMUNOL, V161, P6503; Doppler W, 2001, MOL CELL BIOL, V21, P3266, DOI 10.1128/MCB.21.9.3266-3279.2001; Faulds MH, 2001, MOL ENDOCRINOL, V15, P1929, DOI 10.1210/me.15.11.1929; Favre-Young H, 2000, MOL ENDOCRINOL, V14, P1411, DOI 10.1210/me.14.9.1411; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; Frasor J, 2001, MOL ENDOCRINOL, V15, P2172, DOI 10.1210/me.15.12.2172; Grimley PM, 1999, CYTOKINE GROWTH F R, V10, P131, DOI 10.1016/S1359-6101(99)00011-8; Hennighausen L, 1997, J BIOL CHEM, V272, P7567, DOI 10.1074/jbc.272.12.7567; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; JONES N, 1979, CELL, V17, P683, DOI 10.1016/0092-8674(79)90275-7; KAZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598, DOI 10.1210/me.9.11.1598; Kirken RA, 1997, J BIOL CHEM, V272, P15459, DOI 10.1074/jbc.272.24.15459; Kirken RA, 1997, J BIOL CHEM, V272, P14098, DOI 10.1074/jbc.272.22.14098; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Park SH, 2001, MOL ENDOCRINOL, V15, P2157, DOI 10.1210/me.15.12.2157; Petersen H, 1998, EXP CELL RES, V243, P347, DOI 10.1006/excr.1998.4160; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; Schaber JD, 1998, CANCER RES, V58, P1914; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Sonoyama J, 2002, J BIOL CHEM, V277, P8076, DOI 10.1074/jbc.M111501200; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Stoecklin E, 1999, J STEROID BIOCHEM, V69, P195, DOI 10.1016/S0960-0760(99)00052-7; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; Watson CJ, 2001, J MAMMARY GLAND BIOL, V6, P115, DOI 10.1023/A:1009524817155; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; Yamashita H, 2001, MOL CELL ENDOCRINOL, V183, P151, DOI 10.1016/S0303-7207(01)00546-9	45	62	67	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1638	1652		10.1038/sj.onc.1206277	http://dx.doi.org/10.1038/sj.onc.1206277			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642867				2022-12-17	WOS:000181580500006
